PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	LI, CJ; WANG, CL; PARDEE, AB				LI, CJ; WANG, CL; PARDEE, AB			CAMPTOTHECIN INHIBITS TAT-MEDIATED TRANSACTIVATION OF TYPE-I HUMAN-IMMUNODEFICIENCY-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THYMIDINE KINASE PROMOTER; TRANS-ACTIVATOR GENE; KAPPA-B; T-CELLS; REPLICATION; TRANSCRIPTION; BINDING; EXPRESSION; RNA; INDUCTION	Transcription of type I human immunodeficiency virus (HIV-I) is governed by the viral long terminal repeat (LTR). By using HTV-1 LTR-directed reporter gene systems, we found that the DNA topoisomerase I inhibitor camptothecin inhibits Tat-mediated transactivation of HIV-1 LTR. The 293.27.2 cells that carry a stably transfected HIV-1 LTR-directed lacZ gene expression vector (pNAZ) were used. Inhibitions of LTR were observed at camptothecin concentrations (IC50 about 0.03 mu m, which was an order of magnitude lower than for Ro 24-7429), which had minor effects on cell survival, expression of the cellular gene gro, or Rous sarcoma virus-directed chloramphenicol acetyltransferase (CAT) gene expression. Inhibition was also seen with RPMI 8402, which is a human CD4-positive lymphocyte line transiently transfected with a HIV-1 LTR-directed (CAT) gene. Experiments with HIV-1 LTR mutants suggest that transactivation response sequence but not NF-kappa B is responsible for the inhibition by camptothecin. The target for camptothecin may be a cellular factor that is important for the activation of HIV-1 LTR by Tat and thus may offer a potential target for therapy of HIV-1 infection.			LI, CJ (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA050608] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50608] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANISOWICZ A, 1991, J IMMUNOL, V147, P520; BISWAS DK, 1993, P NATL ACAD SCI USA, V90, P11044, DOI 10.1073/pnas.90.23.11044; BISWAS DK, 1993, J ACQ IMMUN DEF SYND, V6, P778; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EGYHAZI E, 1987, MOL CELL BIOL, V6, P4221; FAZELY F, 1991, BLOOD, V77, P1653; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FRIDOVICHKEIL JL, 1991, CELL GROWTH DIFFER, V2, P67; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; HAN XM, 1992, J VIROL, V66, P4065, DOI 10.1128/JVI.66.7.4065-4072.1992; HASELTINE WA, 1991, FASEB J, V5, P2349, DOI 10.1096/fasebj.5.10.1829694; HSIANG YH, 1983, J BIOL CHEM, V260, P14873; HSU MC, 1991, SCIENCE, V254, P1799, DOI 10.1126/science.1763331; HSU MC, 1993, P NATL ACAD SCI USA, V90, P6395, DOI 10.1073/pnas.90.14.6395; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KARN J, 1992, TRENDS GENET, V8, P365, DOI 10.1016/0168-9525(92)90284-B; KEYOMARSI K, 1991, CANCER RES, V51, P3602; LI CJ, 1993, J BIOL CHEM, V268, P22463; LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839; LI CJ, 1994, IN PRESS TRENDS MICR; LIU JS, 1992, J VIROL, V66, P3883, DOI 10.1128/JVI.66.6.3883-3887.1992; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; SLICHENMYER WJ, 1993, JNCI-J NATL CANCER I, V85, P271, DOI 10.1093/jnci/85.4.271; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEWART AF, 1987, CELL, V50, P1109, DOI 10.1016/0092-8674(87)90177-2	36	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7051	7054						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125909				2022-12-25	WOS:A1994NA03200002
J	MUI, BLS; CULLIS, PR; PRITCHARD, H; MADDEN, TD				MUI, BLS; CULLIS, PR; PRITCHARD, H; MADDEN, TD			INFLUENCE OF PLASMA ON THE OSMOTIC SENSITIVITY OF LARGE UNILAMELLAR VESICLES PREPARED BY EXTRUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEINS; SERUM-INDUCED LEAKAGE; CHOLESTEROL CONTENT; BILAYER-MEMBRANES; RAT PLASMA; LIPOSOMES; RELEASE; SIZE; DISINTEGRATION; INVITRO	In the presence of plasma, the osmotic differential required to trigger lysis of large unilamellar vesicles is significantly decreased with the membrane tension at rupture being reduced from about 36 to about 12 dynes/cm for vesicles composed of palmitoyloleoylphosphatidylcholine: cholesterol (55:45). Despite increasing vesicle sensitivity, however, plasma does not alter the characteristics of osmotically induced lysis. As in the absence of plasma, lysis is not an all or nothing event but instead results in only partial loss of intravesicular solute, so that following membrane resealing the vesicle interior remains hyperosmotic with respect to the external medium. To identify the component responsible for the observed increase in vesicle osmotic sensitivity, plasma was fractionated by density centrifugation. Albumin and other soluble plasma proteins, including those associated with the complement system, were found to exert only a modest influence on vesicle osmotic behavior. In contrast all of the lipoprotein fractions lowered vesicle tolerance to osmotic pressure, with high density lipoprotein exerting an effect comparable to whole plasma.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PATHOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PHARMACOL & THERAPEUT,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia								ALLEN TM, 1992, CANCER RES, V52, P2431; ALLEN TM, 1985, BIOCHIM BIOPHYS ACTA, V818, P205, DOI 10.1016/0005-2736(85)90571-1; ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; ALLEN TM, 1983, J PHARMACOL EXP THER, V226, P539; COMISKEY SJ, 1990, BIOCHEMISTRY-US, V29, P3626, DOI 10.1021/bi00467a006; COOPER RA, 1975, J CLIN INVEST, V55, P115, DOI 10.1172/JCI107901; DAMEN J, 1981, BIOCHIM BIOPHYS ACTA, V665, P538, DOI 10.1016/0005-2760(81)90268-X; EPAND RM, 1989, J BIOL CHEM, V264, P4628; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; Fiske CH, 1925, J BIOL CHEM, V66, P375; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KANELLIS P, 1980, J BIOL CHEM, V255, P1464; KIRBY C, 1980, BIOCHEM J, V186, P591, DOI 10.1042/bj1860591; KLAUSNER RD, 1985, J BIOL CHEM, V260, P3719; LELKES PI, 1982, BIOCHIM BIOPHYS ACTA, V716, P410, DOI 10.1016/0304-4165(82)90034-4; MADDEN TD, 1990, CHEM PHYS LIPIDS, V53, P37, DOI 10.1016/0009-3084(90)90131-A; MAYER LD, 1985, BIOCHIM BIOPHYS ACTA, V817, P193, DOI 10.1016/0005-2736(85)90084-7; MUI BLS, 1993, BIOPHYS J, V64, P443, DOI 10.1016/S0006-3495(93)81385-7; NAKA K, 1992, J AM CHEM SOC, V114, P4011, DOI 10.1021/ja00036a080; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; OSTRO MJ, 1989, AM J HOSP PHARM, V46, P1576, DOI 10.1093/ajhp/46.8.1576; POWNALL HJ, 1979, BIOCHEMISTRY-US, V18, P574, DOI 10.1021/bi00571a004; RAHMAN A, 1980, CANCER RES, V40, P1532; SCHERPHOF G, 1984, BIOCHEM J, V221, P423, DOI 10.1042/bj2210423; SCHERPHOF G, 1978, BIOCHIM BIOPHYS ACTA, V542, P296, DOI 10.1016/0304-4165(78)90025-9; SCHERPHOF GL, 1984, LIPOSOME TECHNOLOGY, V3, P205; WEINSTEIN JN, 1981, BIOCHIM BIOPHYS ACTA, V647, P270, DOI 10.1016/0005-2736(81)90255-8; Weinstein JN, 1984, LIPOSOME TECHNOLOGY, VIII, P183; Whaley K, 1985, METHODS COMPLEMENT C, P77; WILLS GL, 1984, GUIDEBOOK LIPOPROTEI, V14, P18	30	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7364	7370						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125954				2022-12-25	WOS:A1994NA03200053
J	PETER, D; JIMENEZ, J; LIU, YJ; KIM, J; EDWARDS, RH				PETER, D; JIMENEZ, J; LIU, YJ; KIM, J; EDWARDS, RH			THE CHROMAFFIN GRANULE AND SYNAPTIC VESICLE AMINE TRANSPORTERS DIFFER IN SUBSTRATE RECOGNITION AND SENSITIVITY TO INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR MONOAMINE TRANSPORTER; FREELY MOVING RATS; RESERPINE BINDING; DIHYDROTETRABENAZINE BINDING; DOPAMINE CONCENTRATIONS; SEROTONIN TRANSPORTERS; STORAGE-VESICLES; MECHANISM; N-METHYL-4-PHENYLPYRIDINIUM; NEUROTRANSMITTERS	Classical studies using bovine chromaffin granules have defined the physiologic and pharmacologic properties of the vesicular amine transporter that packages monoamine transmitters into intracellular vesicles for subsequent regulated release. The recent isolation of two distinct but closely related cDNA clones encoding vesicular amine transport suggests that the activity expressed in the brain (synaptic vesicle amine transporter or SVAT) may differ significantly from the previously described adrenal gland activity (chromaffin granule amine transporter or CGAT). A direct comparison of the two transporters now shows that SVAT has a higher affinity than CGAT for monoamine substrates, in particular for histamine. In addition, SVAT shows approximately 10-fold greater sensitivity to tetrabenazine than CGAT. [H-3]Dihydrotetrabenazine shows no detectable binding to CGAT but does bind to SVAT, accounting for the differential sensitivity. Furthermore, methamphetamine preferentially inhibits transport by SVAT relative to CGAT, apparently by competing at the site of amine recognition rather than by disrupting the vesicular pH gradient. These previously unsuspected differences in the storage of monoamine transmitter in the central nervous system and the adrenal gland may help to account for several classic pharmacological observations.	UNIV CALIF LOS ANGELES, SCH MED, DEPT NEUROL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	PETER, D (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA.		Liu, Yongjian/J-7852-2018					AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; CARBONI E, 1989, NEUROSCIENCE, V28, P653, DOI 10.1016/0306-4522(89)90012-2; Carlsson A, 1965, HDB EXP PHARMAKOL, V19, P529; DARCHEN F, 1989, BIOCHEMISTRY-US, V28, P1692, DOI 10.1021/bi00430a040; DARCHEN F, 1988, MOL PHARMACOL, V33, P672; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DESNOS C, 1990, DEV BRAIN RES, V52, P161, DOI 10.1016/0165-3806(90)90231-M; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; Edwards R H, 1992, Curr Opin Neurobiol, V2, P586, DOI 10.1016/0959-4388(92)90023-E; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Frize E.D., 1954, NEW ENGL J MED, V251, P1006; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENRY JP, 1989, BIOCHEM PHARMACOL, V38, P2395, DOI 10.1016/0006-2952(89)90082-8; INNES IR, 1975, PHARMACOL BASIS, P477; JEVITCH J, 1985, P NATL ACAD SCI USA, V82, P2173; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KRUEGER MJ, 1990, BIOCHEM BIOPH RES CO, V169, P123, DOI 10.1016/0006-291X(90)91442-U; LIU Y, 1992, P NATL ACAD SCI USA, V89, P9074, DOI 10.1073/pnas.89.19.9074; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; PLETSCHER A, 1977, BRIT J PHARMACOL, V59, P419, DOI 10.1111/j.1476-5381.1977.tb08395.x; RAMSAY RR, 1986, J BIOL CHEM, V261, P7585; RUDNICK G, 1992, BIOCHEMISTRY-US, V31, P6710, DOI 10.1021/bi00144a010; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; RUDNICK G, 1993, MOL PHARMACOL, V43, P271; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; SCHERMAN D, 1988, NEUROSCIENCE, V27, P1029, DOI 10.1016/0306-4522(88)90207-2; SCHERMAN D, 1986, J NEUROCHEM, V47, P331; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; SNYDER SH, 1986, MPTP NEUROTOXIN PROD, P191; STERNBACH Y, 1990, J BIOL CHEM, V265, P3961; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521	37	178	184	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7231	7237						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125935				2022-12-25	WOS:A1994NA03200032
J	FINDLAY, WA; SONNICHSEN, FD; SYKES, BD				FINDLAY, WA; SONNICHSEN, FD; SYKES, BD			SOLUTION STRUCTURE OF THE TR(1)C FRAGMENT OF SKELETAL-MUSCLE TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CALCIUM-BINDING PROTEINS; DISTANCE CONSTRAINTS; BACKBONE DYNAMICS; REFINED STRUCTURE; NMR-SPECTROSCOPY; CALBINDIN-D9K; RESOLUTION; H-1-NMR; DOMAIN	Residues 12-87 (TR(1)C fragment) of turkey skeletal muscle troponin-C comprises two helix-loop-helix calcium-binding motifs which are the regulatory calcium binding sites in the N-terminal domain of the protein. We have used the combined distance geometry-simu lated annealing protocol DGII (Havel, T F. (1991) Prog. Biophys, Mel. Biol. 56, 43-78) to determine the structure of this 76-residue polypeptide in solution from 475 H-1 NMR-derived distance restraints. The nuclear Overhauser enhancement-derived distance constraints used in the DGII protocol were supplemented by introducing generic hydrogen bond distance restraints for slowly exchanging amide hydrogens in regular secondary structure elements, by restricting the available phi angle space to -180 degrees to 0 degrees for all residues except glycines, and by tailoring the distance boundaries used for quantitating the nuclear Overhauser enhancement intensities to correspond to characteristic distances found in helices. This improved the geometry of the four helices in the resulting structures. The relative positions of helices A and B which flank calcium-binding loop 1, helix D which follows calcium-binding loop 2, and the beta-sheet between the two calcium binding loops were well defined and had an overall root-mean-square deviation for 20 converged structures of 1.4 +/- 0.2 A for backbone atoms. The structure and relative orientations of these regions are very similar to these of the corresponding regions of the protein in the crystal structure of intact turkey skeletal troponin C (Herzberg, O., and James, M, N. G. (1988) Nature 313, 653-659). The structure of helix C was well defined, but its relative position to the other helices was not defined. It occupied a range of positions in the set of 20 DGII structures, the average of which was quite similar to the orientation of helix C in the x-ray structure. The overall structure of the apo regulatory domain of troponin-C is therefore not affected by the loss of the N-helix, or the low pH conditions used for the x-ray structure, but may be more flexible in regions known to be involved in contacts with other skeletal muscle regulatory proteins.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA; UNIV ALBERTA,MRC,PROT STRUCT & FUNCT,EDMONTON T6G 2H7,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,PROT ENGN NETWORK CTR EXCELLANCE,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta; University of Alberta			Sönnichsen, Frank D/D-8408-2011	Sönnichsen, Frank D/0000-0002-4539-3755				AKKE M, 1992, BIOCHEMISTRY-US, V31, P1011, DOI 10.1021/bi00119a009; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; BRUNGER AT, 1993, SCIENCE, V261, P328, DOI 10.1126/science.8332897; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; FINDLAY WA, 1993, BIOCHEMISTRY-US, V32, P3461, DOI 10.1021/bi00064a033; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1981, BIOCHIM BIOPHYS ACTA, V671, P227, DOI 10.1016/0005-2795(81)90138-0; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HINCKE MT, 1978, CAN J BIOCHEM CELL B, V56, P384, DOI 10.1139/o78-061; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KAY LE, 1991, BIOCHEMISTRY-US, V30, P4323, DOI 10.1021/bi00231a031; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KORDEL J, 1992, BIOCHEMISTRY-US, V31, P4856; LINSE S, 1990, BIOCHEMISTRY-US, V29, P5925, DOI 10.1021/bi00477a007; POTTER JD, 1975, J BIOL CHEM, V250, P4628; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHAW GS, 1992, BIOCHEMISTRY-US, V31, P9572, DOI 10.1021/bi00155a009; SKELTON NJ, 1990, J MOL BIOL, V213, P593, DOI 10.1016/S0022-2836(05)80244-X; SKELTON NJ, 1990, BIOCHEMISTRY-US, V29, P5752, DOI 10.1021/bi00476a016; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; TSALKOVA TN, 1985, J MOL BIOL, V181, P533, DOI 10.1016/0022-2836(85)90425-5; WANG CK, 1989, PROTEINS, V6, P424, DOI 10.1002/prot.340060409; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	31	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6773	6778						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120037				2022-12-25	WOS:A1994MZ50300081
J	MORO, O; SHOCKLEY, MS; LAMEH, J; SADEE, W				MORO, O; SHOCKLEY, MS; LAMEH, J; SADEE, W			OVERLAPPING MULTISITE DOMAINS OF THE MUSCARINIC CHOLINERGIC HM1 RECEPTOR INVOLVED IN SIGNAL-TRANSDUCTION AND SEQUESTRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; 3RD CYTOPLASMIC LOOP; BETA-2-ADRENERGIC RECEPTOR; ACETYLCHOLINE-RECEPTORS; DOWN-REGULATION; G-PROTEIN; INTERNALIZATION; BINDING; CELLS	Alanine mutagenesis scanning of the intracellular portion of the human muscarinic cholinergic Hm1 receptor was performed to identify domains mediating agonist induced receptor sequestration. Using these multiple alanine point mutants of Hm1, we had previously identified several receptor domains in the intracellular loops i1-3 that play a role in coupling to phosphatidyl inositol turnover, most notably, a lipophilic residue, Leu-131, in the conserved i2 loop domain DRYXXVXXPL (Moro, O., Lameh, J., Hogger, P, and Sadee, W. (1993) J. Biol. Chem. 268, 6862-6865). We now demonstrate that; alanine substitutions in three of these domains, i.e. middle of the i2 loop and both junctions of the i3 loop, also result in defective sequestration (loss of surface receptor sites accessible to a polar tracer) in transfected human kidney U293 cells. The i2 loop was studied further by single point mutations. The strongest impairment of sequestration occurred with mutant L131A which was also highly defective in phosphatidyl inositol (PI) coupling. Substitution of Leu-131 with several distinct amino acids indicated that a bulky lipophilic residue is required for sequestration in this position, as shown for coupling to PI turnover. Further, the double point mutation, V127A/L131A, almost completely suppressed both sequestration and coupling of Hm1, In the beta(2) adrenoceptor, alanine substitution of the i2 residue Phe-139, equivalent to Leu-131 in Hm1, also resulted in impaired coupling to adenylyl cyclase and sequestration, indicating a general role for this conserved i2 loop residue in both processes. The combined results show that the multi-site domain involved in signal transduction of Hm1 is similar to and overlaps with that involved in sequestration. However, three Hm1 mutants that were moderately deficient in stimulating PI turnover displayed normal sequestration, suggesting distinct mechanisms. We propose that cellular mediators of receptor sequestration are structurally similar or identical to the heterotrimeric G proteins.	UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM 43102] Funding Source: Medline; NIMH NIH HHS [K21 MH 00996] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000996] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN JM, 1989, MOL PHARMACOL, V36, P248; ARDEN JR, 1990, FEBS LETT, V269, P386; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FRASER CM, 1989, MOL PHARMACOL, V36, P840; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HERTEL C, 1990, J BIOL CHEM, V265, P17988; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAMEH J, 1992, J BIOL CHEM, V267, P13406; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; MORO O, 1993, J BIOL CHEM, V268, P6862; MORO O, 1993, J BIOL CHEM, V268, P22273; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TRAUB LM, 1991, J BIOL CHEM, V266, P24642	23	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6651	6655						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120019				2022-12-25	WOS:A1994MZ50300062
J	PREMONT, RT; KOCH, WJ; INGLESE, J; LEFKOWITZ, RJ				PREMONT, RT; KOCH, WJ; INGLESE, J; LEFKOWITZ, RJ			IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF GRK5, A MEMBER OF THE FAMILY OF G-PROTEIN-COUPLED RECEPTOR KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; BETA-GAMMA-SUBUNITS; ROD OUTER SEGMENTS; RHODOPSIN KINASE; BETA-2-ADRENERGIC RECEPTOR; DESENSITIZATION; SITES; ISOPRENYLATION; LOCALIZATION; TRANSDUCTION	A novel member of the family of G protein-coupled receptor kinases (GRKs), named GRK5, has been cloned from bovine taste epithelium. The cDNA sequence predicts a 590-amino acid protein with high overall similarity to rhodopsin kinase. GRK5 mRNA is found most abundantly in lung, heart, retina, and lingual epithelium hum, but is expressed very little in brain, liver, kidney, or testis. GRK5 expressed in Sf9 cells was purified to apparent homogeneity. GRK5 major autophosphorylation sites were mapped to Ser(484) and Thr(485). Purified GRK5 phosphorylates rhodopsin in a light-dependent manner and beta(2)-adrenergic receptor in an agonist-dependent manner and phosphorylates the C-terminal tail regions of both receptor proteins. GRK5 possesses neither a CAAX motif specifying protein prenylation like rhodopsin kinase nor similarity to the G protein beta gamma-subunit binding domain of beta-adrenergic receptor kinases. GRK5 phosphorylation of rhodopsin or beta(2)-adrenergic receptor is not stimulated by G protein beta gamma-subunits. The GRK5 protein does not undergo agonist-dependent translocation from cytosol to membranes as do beta-adrenergic receptor kinase and rhodopsin kinase, but rather appears to associate with membranes constitutively. GRK5 thus appears functionally similar to other characterized GRKs, but has distinct regulatory properties which may be important for its cellular function.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University			Lefkowitz, Robert/AAW-2649-2021	Premont, Richard/0000-0002-8053-5026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SOHLEMANN P, 1993, FEBS LETT, V324, P59, DOI 10.1016/0014-5793(93)81532-5; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	48	177	184	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6832	6841						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120045				2022-12-25	WOS:A1994MZ50300090
J	ZHOU, GC; SMITH, JL; ZALKIN, H				ZHOU, GC; SMITH, JL; ZALKIN, H			BINDING OF PURINE NUCLEOTIDES TO 2 REGULATORY SITES RESULTS IN SYNERGISTIC FEEDBACK INHIBITION OF GLUTAMINE 5-PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; GENE; PURIFICATION; SYNTHETASE; SEQUENCE; CLONING; ENZYME; PURF	Glutamine 5-phosphoribosylpyrophosphate amidotransferase from Escherichia coli is subject to synergistic feedback regulation by adenine and guanine nucleo tides. Inhibition assays and equilibrium binding measurements have established that synergistic inhibition by AMP and GRIP results from synergistic binding to two sites/enzyme subunit in the homotetramer. Although each nucleotide can bind to both sites, analyses of the wild type and mutant enzymes indicate that binding of GRIP to an A (allosteric) site and AMP to a proximal C (catalytic) site are necessary for synergistic inhibition. K326Q and P410W amino acid replacements result in decreased binding affinity for GRIP and AMP and lead to corresponding reductions in feedback inhibition. The K326Q A site mutation results not only in decreased affinity of GRIP for the mutant A site but also has an adverse effect on AMP affinity for the C site. Similarly, the P410W C site mutation has a detrimental effect on binding of AMP to the mutant C site and also on affinity of GRIP to the A site. The fact that a mutation in one site affects binding of nucleotides to both sites provides further evidence for synergistic binding of nucleotides.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIDDK NIH HHS [DK42303, R37 DK042303] Funding Source: Medline; NIGMS NIH HHS [GM24658] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042303, R01DK042303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024658, R01GM024658] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		HOULBERG U, 1983, J BACTERIOL, V153, P837, DOI 10.1128/JB.153.2.837-845.1983; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; MAKAROFF CA, 1983, J BIOL CHEM, V258, P586; MEI B, 1989, J BIOL CHEM, V264, P16613; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; MEYER E, 1979, J BIOL CHEM, V254, P5397; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; ROLFES RJ, 1990, J BACTERIOL, V172, P5637, DOI 10.1128/jb.172.10.5637-5642.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; TSO JY, 1982, J BIOL CHEM, V257, P3525; WONG JY, 1981, BIOCHEMISTRY-US, V20, P5669, DOI 10.1021/bi00523a005; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4; ZHOU GC, 1993, J BIOL CHEM, V268, P10471	18	34	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6784	6789						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120039				2022-12-25	WOS:A1994MZ50300083
J	BROWN, PH; CHEN, TK; BIRRER, MJ				BROWN, PH; CHEN, TK; BIRRER, MJ			MECHANISM OF ACTION OF A DOMINANT-NEGATIVE MUTANT OF C-JUN	ONCOGENE			English	Article							TRANSCRIPTIONAL ACTIVATION; MAMMALIAN-CELLS; PROTO-ONCOGENE; LEUCINE ZIPPER; FOS; PROTEINS; AP-1; TRANSFORMATION; DOMAIN; ONCOPROTEIN	The AP-1 transcriptional activating complex, made up of Jun and Fos proteins, is involved in controlling many cellular processes such as cell proliferation, differentiation and transformation. We have previously characterized a dominant-negative mutant of c-Jun called TAM-67 which forms dimers with c-Jun and c-Fos, and binds DNA as a homodimer or heterodimer with c-Jun or c-Fos. This dominant-negative mutant is a potent inhibitor of AP-1 mediated transactivation, as well as c-jun/ras and TPA/ras-induced transformation. The present report describes experiments designed to elucidate the exact molecular mechanism of this dominant-negative inhibitor. The DNA binding kinetics of both TAM-67:TAM-67 homodimers as well as TAM-67:Fos heterodimers were studied and compared to those of c-Jun and other transactivation-deficient mutants of c-Jun. These studies demonstrated that the TAM-67 proteins have similar DNA binding kinetics to c-Jun and other Jun mutant proteins. Thus, the deletion of the amino-terminal end of the Jun protein does not significantly alter the protein's affinity for DNA. In addition, to determine whether TAM-67 functions through the formation of homodimers, or through interactions with endogenous c-Jun or c-Fos, we constructed a pair of chimeric proteins made by replacing the leucine zipper of TAM-67 with the leucine zippers of GCN4 and c-Fos. These chimeric proteins, termed TAM/GCN4 and TAM/Fos, were then tested for their ability to bind DNA, inhibit c-Jun-induced transactivation, and inhibit TPA/ras-mediated transformation. The results of these studies show that while both chimeric proteins bind equally well to DNA, only the TAM/Fos protein, and not the TAM/GCN4 protein, inhibits AP-1-induced transactivation and TPA/ras-induced transformation. When compared to the TAM-67 protein, the TAM/Fos protein is an equally potent inhibitor of transactivation and transformation. These results suggest that TAM-67 inhibits AP-1-mediated processes through a 'quenching' mechanism by inhibiting the function of endogenous Jun and/or Fos proteins. The implications of these mechanistic findings on the development of potent inhibitors of signal transduction pathways are discussed.	NCI, DIV CANC PREVENT & CONTROL, BIOMARKERS & PREVENT RES BRANCH, ROCKVILLE, MD 20850 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA				Brown, Powel/0000-0002-3398-163X				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BROWN PH, 1993, ONCOGENE, V8, P877; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HIRAI SI, 1990, ONCOGENE, V5, P39; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN IM, 1992, ONCOGENE, V7, P1119; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2	30	212	217	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					791	799						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108121				2022-12-25	WOS:A1994MW55100014
J	FEO, S; DILIEGRO, C; JONES, T; READ, M; FRIED, M				FEO, S; DILIEGRO, C; JONES, T; READ, M; FRIED, M			THE DNA REGION AROUND THE C-MYC GENE AND ITS AMPLIFICATION IN HUMAN TUMOR-CELL LINES	ONCOGENE			English	Note							HUMAN-BREAST CARCINOMA; BURKITT-LYMPHOMA; CHROMOSOMAL TRANSLOCATIONS; N-MYC; ONCOGENE; EXPRESSION; SEQUENCES; CANCER; LOCUS; REARRANGEMENT	In order to study amplicons containing the c-myc locus in human tumour cells we have analysed the region around the human c-myc gene. Using pulsed field gel electrophoresis we have constructed a 1.8 Mb map of the c-myc locus using six rare-cutting endonucleases. In addition we have cloned 130 kb of continuous DNA around the c-myc gene which includes 65 kb of 5' sequence and 65 kb of 3' sequence. The first exon of the pvt-1 gene was located 59 kb 3' of the c-myc gene. Using nine neighbouring probes, covering a region of about 395 kb around the c-myc gene, we were able to determine the extent and composition of c-myc amplicons in the HL60, NCI-N417, Colo320HSR, SkBr3 and the Sk-N-MC human tumour cell lines. Furthermore we analysed the chromosomal location of amplified c-myc DNA in NCI-N417 and SkBr3 cells. Similarities and differences between the amplified DNA in the different cell lines are discussed.	IMPERIAL CANC RES FUND,EUKARYOT GENE ORG & EXPRESS LAB,LONDON WC2A 3PX,ENGLAND; CNR,IST BIOL SVILUPPO,I-90123 PALERMO,ITALY; DIPARTIMENTO BIOL CELLULARE & SVILUPPO,I-90123 PALERMO,ITALY; IMPERIAL CANC RES FUND,HUMAN CYTOGENET LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Consiglio Nazionale delle Ricerche (CNR); Cancer Research UK			Corbett-Jones, Tania A/E-4891-2013; Feo, Salvatore/C-1333-2012; Jones, Tania/C-8912-2011	Corbett-Jones, Tania A/0000-0002-0067-3382; Feo, Salvatore/0000-0003-3877-2906; Jones, Tania/0000-0002-0067-3382; Di Liegro, Carlo Maria/0000-0001-7362-7814				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FEO S, 1990, NUCLEIC ACIDS RES, V18, P4949, DOI 10.1093/nar/18.16.4949; FEO S, 1990, GENOMICS, V6, P192, DOI 10.1016/0888-7543(90)90467-9; FUKUMOTO M, 1993, SOMAT CELL MOLEC GEN, V19, P21, DOI 10.1007/BF01233951; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HEARD E, 1991, P NATL ACAD SCI USA, V88, P8242, DOI 10.1073/pnas.88.18.8242; JOOS S, 1992, CANCER RES, V52, P6547; KOZBOR D, 1984, CANCER RES, V44, P438; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LEHRACH H., 1990, GENOME ANAL, P39; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LITT M, 1985, P NATL ACAD SCI USA, V82, P6206, DOI 10.1073/pnas.82.18.6206; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; THEILLET C, 1989, ONCOGENE, V4, P915; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; WHANGPENG J, 1982, GENE AMPLIFICATION, P107; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	38	26	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					955	961						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108141				2022-12-25	WOS:A1994MW55100034
J	OHASHI, K; MIZUNO, K; KUMA, K; MIYATA, T; NAKAMURA, T				OHASHI, K; MIZUNO, K; KUMA, K; MIYATA, T; NAKAMURA, T			CLONING OF THE CDNA FOR A NOVEL RECEPTOR TYROSINE KINASE, SKY, PREDOMINANTLY EXPRESSED IN BRAIN	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; C-MET PROTOONCOGENE; SIGNAL TRANSDUCTION; LEUKEMIA-CELLS; PROTEIN; FAMILY; ONCOGENES; DOMAINS; GENE; PRODUCT	Based on homology to the tyrosine kinase domain of the chick erythroblastosis virus oncogene v-sea, we cloned a cDNA encoding a novel receptor tyrosine kinase from a human hepatoma HepG2 cDNA library. The encoded protein, which we termed 'Sky', contains an intracellular tyrosine kinase domain and a unique extracellular domain with two immunoglobulin (Ig)-like domains and two fibronectin type III (FN III) domains; The overall structure of Sky is homologous to the reported sequence of the oncogenic Axl/Ufo receptor tyrosine kinase. Phylogenetic analysis in the tyrosine kinase domain shows that Sky, Axl/Ufo, Ark, and v-Ryk form a subfamily distinct from other tyrosine kinases. Northern blot analysis revealed that sky mRNA is expressed predominantly in brain and faintly in tissues of other organs. As the combination of Ig-like and FN III domains is often observed in neural cell adhesion molecules and receptor protein tyrosine phosphatases, Sky may be involved in cell adhesion processes, particularly in the central nervous system.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,OSAKA 565,JAPAN	Kyushu University; Kyoto University; Osaka University			Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X				BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; FAUST M, 1992, ONCOGENE, V7, P1287; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMA K, 1993, MOL BIOL EVOL, V10, P539; Kuma K, 1991, CURR OPIN STRUC BIOL, V1, P384, DOI 10.1016/0959-440X(91)90036-S; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MIZUNO K, 1993, HEPATOCYTE GROWTH FA, P1; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	36	123	137	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					699	705						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108112				2022-12-25	WOS:A1994MW55100004
J	CURTIS, JE; HELGERSON, SL; PARKER, ET; LOLLAR, P				CURTIS, JE; HELGERSON, SL; PARKER, ET; LOLLAR, P			ISOLATION AND CHARACTERIZATION OF THROMBIN-ACTIVATED HUMAN FACTOR-VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; FACTOR-IXA; A1/A3-C1-C2 DIMER; PHOSPHOLIPID-VESICLES; PROCOAGULANT ACTIVITY; SUBUNIT STRUCTURE; A2 SUBUNIT; FACTOR-XA; PROTEINS; RECONSTITUTION	Recombinant human factor VIII (fVIII) was activated by thrombin at pH 7.4, followed by CM-Sepharose chromatography at pH values ranging from 3.5 to 7.4. Optimal coagulant activity was recovered at pH 5.5 and was associated with the isolation of an A1/A2/A3-C1-C2 heterotrimer. The activity was stable at -80 degrees C, but decayed slowly (t(1/2) approximate to 1 week) and nonproteolytically at room temperature or 4 degrees C. The coagulant activity of the pH 5.5 fVIIIa preparation assayed in human hemophilia A plasma was only 20% that of porcine factor VIIIa. However, its activity was approximately 75% that of porcine fVIIIa in a plasma-free assay, indicating that human fVIIIa is unstable relative to porcine fVIIIa during the coagulation assay. The first-order rate constant for spontaneous, nonproteolytic loss of activity of human fVIIIa at pH 7.4 was decreased 8-fold by fIXa and phospholipid, indicating that human fVIIIa is stabilized when incorporated into the intrinsic pathway factor X activation complex.	EMORY UNIV,DEPT MED,ATLANTA,GA 30322; BAXTER HEALTHCARE CORP,BAXTER BIOTECH GRP,DUARTE,CA 91010	Emory University; Baxter International Inc					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046215] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46215] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; COOPER HA, 1975, J CLIN INVEST, V56, P751, DOI 10.1172/JCI108146; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1987, BIOCHIM BIOPHYS ACTA, V952, P181; HULTIN MB, 1981, BLOOD, V57, P476; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LOLLAR P, 1992, METHOD ENZYMOL, V222, P128; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; PIETERS J, 1989, BLOOD, V74, P1021; PITTMAN DD, 1992, BLOOD, V79, P389; PITTMAN DD, 1993, BLOOD, V81, P2925; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612	27	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6246	6251						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119969				2022-12-25	WOS:A1994MY84000113
J	GIANNONI, F; BONEN, DK; FUNAHASHI, T; BURANT, CF; DAVIDSON, NO; HADJIAGAPIOU, C				GIANNONI, F; BONEN, DK; FUNAHASHI, T; BURANT, CF; DAVIDSON, NO; HADJIAGAPIOU, C			COMPLEMENTATION OF APOLIPOPROTEIN-B MESSENGER-RNA EDITING BY HUMAN LIVER ACCOMPANIED BY SECRETION OF APOLIPOPROTEIN B48	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RAT-LIVER; INTESTINE	Mammalian small intestine secretes a truncated apolipoprotein B (apoB48) species as a result of tissue-specific post-transcriptional RNA editing. The human liver, by contrast, contains only unedited apoB mRNA and secretes only apoB100. We have recently isolated a cDNA clone from rat small intestine which encodes an apoB mRNA editing protein, REPR (Teng, B., Burant, C. F., and Davidson, N. O. (1993) Science 260, 1816-1819). The current study demonstrates that homogenates of Xenopus oocytes expressing REPR confer editing ability upon S100 extracts prepared from human liver when tested on a synthetic apoB RNA template in vitro. Transfection of REPR into HepG2 cells resulted in editing of endogenous apoB mRNA and the appearance of an apoB48-like protein in the media. Extracts prepared hom these transfected cells edit mammalian apoB RNA templates when incubated alone and with enhanced efficiency in the presence of chicken intestinal S100 extracts. The results suggest that human liver expresses factor(s) which are critical to apoB mRNA editing and which allow functional complementation of REPR in vivo.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago			Giannoni, Federico/A-6577-2013; Burant, Charles/GPC-5690-2022	Giannoni, Federico/0000-0001-5521-512X; Burant, Charles/0000-0001-9189-5003	NHLBI NIH HHS [HL-38180, HL-02166] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002166, R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAUM CL, 1990, J BIOL CHEM, V265, P19263; BOSTROM K, 1989, J BIOL CHEM, V264, P15701; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHHEN SH, 1991, SCIENCE, V238, P363; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; GIANNONI F, 1994, IN PRESS J LIPID RES; GREEVE J, 1993, J LIPID RES, V34, P1367; HIGUCHI K, 1992, J LIPID RES, V33, P1753; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SEISHIMA M, 1991, J LIPID RES, V32, P941; SPRING DJ, 1992, J LIPID RES, V33, P233; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; WU JH, 1990, J BIOL CHEM, V265, P12312	20	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5932	5936						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119937				2022-12-25	WOS:A1994MY84000070
J	GROSKREUTZ, DJ; SLIWKOWSKI, MX; GORMAN, CM				GROSKREUTZ, DJ; SLIWKOWSKI, MX; GORMAN, CM			GENETICALLY-ENGINEERED PROINSULIN CONSTITUTIVELY PROCESSED AND SECRETED AS MATURE, ACTIVE INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN-LIKE PROTEASE; STIMULATES TYROSINE PHOSPHORYLATION; MONOMERIC INSULINS; INTACT-CELLS; CLEAVAGE; FAMILY; DNA; IDENTIFICATION; EXPRESSION; MEMBER	The conversion of human proinsulin to insulin occurs only in specialized cells which contain the appropriate processing enzymes. To allow proinsulin processing to occur in a wide variety of cell types, we engineered human proinsulin to be cleaved in the constitutive secretory pathway. Using site directed mutagenesis, we have introduced furin consensus cleavage sequences (Arg-X-Lys-Arg) into the human proinsulin cDNA. These mutations allowed for efficient proteolytic maturation of human proinsulin to insulin within cells containing only a constitutive pathway of secretion. Additionally, a naturally occurring mutation (histidine B10 to aspartic acid) yields a form of human insulin which accumulates 10- to over 100-fold more mature insulin when compared to the mutants lacking this change. Engineering furin-specific cleavage sites into each junction of the human proinsulin cDNA results in the secretion of peptides that display the expected molecular weights for the A and B chains of insulin. The accumulation of mature, processed, human insulin was measured in the supernatants by radioimmunoassay, and the bioactivity of this molecule was measured by its ability to stimulate autophosphorylation of the insulin receptor. Our results suggest that any cell type might be engineered to produce mature, active, and stable insulin in the constitutive pathway of secretion.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech								AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; BRANGE J, 1990, DIABETES CARE, V13, P923, DOI 10.2337/diacare.13.9.923; BREMS DN, 1992, PROTEIN ENG, V5, P519, DOI 10.1093/protein/5.6.519; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAN SJ, 1987, P NATL ACAD SCI USA, V84, P2194, DOI 10.1073/pnas.84.8.2194; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; KUNKEL TA, 1987, NUCLEIC ACIDS MOL BI, pR20; MARRIOTT D, 1992, MOL ENDOCRINOL, V6, P1441, DOI 10.1210/me.6.9.1441; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHWARTZ GP, 1987, P NATL ACAD SCI USA, V84, P6408, DOI 10.1073/pnas.84.18.6408; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1979, ENDOCRINOLOGY, P921; SURES I, 1980, SCIENCE, V208, P57, DOI 10.1126/science.6927840; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VOLLENWEIDER F, 1992, J BIOL CHEM, V267, P14629; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; YANAGITA M, 1992, FEBS LETT, V311, P55, DOI 10.1016/0014-5793(92)81366-T; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	37	113	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6241	6245						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119968				2022-12-25	WOS:A1994MY84000112
J	QU, ZQ; FUJIMOTO, S; TANIGUCHI, T				QU, ZQ; FUJIMOTO, S; TANIGUCHI, T			ENHANCEMENT OF INTERFERON-GAMMA-INDUCED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II GENE-EXPRESSION BY EXPRESSING AN ANTISENSE RNA OF POLY(ADP-RIBOSE) SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE DIPHOSPHORIBOSYL TRANSFERASE; INDUCED ACTIVATION PROCESS; MACROPHAGE TUMOR-CELLS; C-INDEPENDENT PATHWAY; NECROSIS-FACTOR; CDNA SEQUENCE; HLA-DR; DNA; POLYMERASE; KINASE	We studied the effect of poly(ADP-ribose) synthetase on the interferon-gamma (IFN-gamma)-inducible expression of major histocompatibility complex (MHC) class II molecules by expressing an antisense RNA of poly(ADP-ribose) synthetase. We constructed two expression plasmids capable of expressing an antisense RNA for poly(ADP-ribose) synthetase, carrying 0.7-kilobase long fragment of 5'-coding region (pAS-5') and full-length cDNA (pAS-FL) of poly(ADP-ribose) synthetase in an antisense orientation under control of metallothionein I promoter. We transfected the plasmid into human leukemia THP-1 cells and isolated transformants. Metal-inducible reduction in poly(ADP-ribose) synthetase activity wars observed in two pAS-5'-transfected clones out of 72 neo-resistant clones examined, and metal-independent reduction in the activity was exhibited in pAS-FL-transfected clones. The antisense RNA was induced in a metal-dependent manner in the clones transfected with pAS-5', as judged by hybridizing with a sense riboprobe of the synthetase gene. The mRNA of the synthetase decreased 1 day after an addition of metal ions, and the synthetase activity of the transformants decreased by more than 90% 3 days after an addition of metal ions. Thus, we incubated the transformant clones in the presence of metal ions for 3 days and then treated them with IFN-gamma. The IFN-gamma-inducible expression of MHC class II molecules was amplified in the transformant clones, as judged by RNA blot analysis and flow cytometry. These results indicate that the decrease in poly(ADP-ribose) synthetase makes THP-1 cells favorable to induce MHC class II molecules by IFN-gamma.	KOCHI MED SCH,MED RES LAB,KOCHI 783,JAPAN; KOCHI MED SCH,DEPT IMMUNOL,KOCHI 783,JAPAN	Kochi University; Kochi University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; BUKI KG, 1991, BIOCHEM BIOPH RES CO, V180, P496, DOI 10.1016/S0006-291X(05)81092-7; CELADA A, 1991, J IMMUNOL, V146, P114; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; COROMINAS M, 1985, J BIOL CHEM, V260, P6269; DING RC, 1992, J BIOL CHEM, V267, P12804; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; EKI T, 1991, J BIOL CHEM, V266, P3087; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HAMILTON TA, 1985, J BIOL CHEM, V260, P1378; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KLEIN JB, 1987, BIOCHEM BIOPH RES CO, V145, P1295, DOI 10.1016/0006-291X(87)91578-6; KOIDE Y, 1988, P NATL ACAD SCI USA, V85, P3120, DOI 10.1073/pnas.85.9.3120; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; MANDEL P, 1982, PROG NUCLEIC ACID RE, V27, P1, DOI 10.1016/S0079-6603(08)60596-6; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NOMURA I, 1991, BIOCHEM BIOPH RES CO, V175, P685, DOI 10.1016/0006-291X(91)91620-R; OHASHI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7132, DOI 10.1073/pnas.81.22.7132; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OSTROWSKI J, 1988, J BIOL CHEM, V263, P13786; PETERLIN BM, 1987, MOL CELL BIOL, V7, P1967, DOI 10.1128/MCB.7.5.1967; Purnell MR, 1980, BIOCHEM SOC T, V8, P215, DOI 10.1042/bst0080215; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SULLIVAN KE, 1987, IMMUNOL TODAY, V8, P289, DOI 10.1016/0167-5699(87)90013-2; TANIGUCHI T, 1988, BIOCHEM BIOPH RES CO, V154, P1034, DOI 10.1016/0006-291X(88)90244-6; TANIGUCHI T, 1988, EUR J BIOCHEM, V171, P571, DOI 10.1111/j.1432-1033.1988.tb13826.x; TANIGUCHI T, 1991, EUR J BIOCHEM, V195, P557, DOI 10.1111/j.1432-1033.1991.tb15737.x; TOMODA T, 1992, BIOCHIM BIOPHYS ACTA, V1135, P79, DOI 10.1016/0167-4889(92)90169-C; TOMODA T, 1991, BIOCHIM BIOPHYS ACTA, V1088, P359, DOI 10.1016/0167-4781(91)90125-6; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522	41	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5543	5547						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119888				2022-12-25	WOS:A1994MY84000014
J	KAETZEL, MA; CHAN, HC; DUBINSKY, WP; DEDMAN, JR; NELSON, DJ				KAETZEL, MA; CHAN, HC; DUBINSKY, WP; DEDMAN, JR; NELSON, DJ			A ROLE FOR ANNEXIN-IV IN EPITHELIAL-CELL FUNCTION - INHIBITION OF CALCIUM-ACTIVATED CHLORIDE CONDUCTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPID-BINDING-PROTEIN; CYSTIC-FIBROSIS; ANTICOAGULANT PROTEIN; LIPID MONOLAYERS; LINE T84; CHANNELS; EXPRESSION; CRYSTALLIZATION; PURIFICATION	The cellular function of annexin IV was evaluated by correlating tissue expression, cellular localization, and whole-cell electrophysiology. Immunolocalization and biochemical data demonstrate that annexin IV is concentrated along the apical membranes of many epithelia. Introduction of purified exogenous annexin IV into colonic T84 cells through a patch pipette specifically prevented Ca2+-dependent Cl- current activation. Affinity-purified antibody against annexin IV applied in the same manner enhanced the activation. Reduction of the endogenous level of annexin IV with a derivatized oligodeoxynucleotide antisense to annexin IV mRNA lowered the threshold for the Ca2+-induced current response, mimicking the enhancement of current activation exerted by anti-annexin TV antibody. The inhibitory effect of annexin IV on Ca2+-dependent Cl- conductance represents a novel mechanism by which Ca2+-binding proteins modulate membrane channel activity.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637; UNIV TEXAS,SCH MED,DEPT PHYSIOL & CELL BIOL,HOUSTON,TX 77235	University of Chicago; University of Chicago; University of Texas System	KAETZEL, MA (corresponding author), UNIV CINCINNATI,COLL MED,DEPT PHYSIOL & BIOPHYS,231 BETHESDA AVE,CINCINNATI,OH 45267, USA.		Chan, Hsiao Chang/E-1507-2016					ANDREE HAM, 1992, J BIOL CHEM, V267, P17907; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHAN HC, 1992, J BIOL CHEM, V262, pC1273; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CONCHA NO, 1992, FEBS LETT, V314, P159, DOI 10.1016/0014-5793(92)80964-I; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DEDMAN JR, 1978, J BIOL CHEM, V253, P7515; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; DISANTAGNESE PA, 1953, PEDIATRICS, V12, P549; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; JUNKER M, 1993, BIOCHEMISTRY-US, V32, P9968, DOI 10.1021/bi00089a012; KACHINTORN U, 1992, AM J PHYSIOL, V262, pC15, DOI 10.1152/ajpcell.1992.262.1.C15; KAETZEL MA, 1990, BIOCHEM SOC T, V18, P1108, DOI 10.1042/bst0181108; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KAPLAN R, 1988, J BIOL CHEM, V263, P8037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; LOTAN I, 1988, NEURON, V1, P963, DOI 10.1016/0896-6273(88)90153-5; MASSEY D, 1992, BIOL CELL, V73, P151; Moss S. E, 1992, ANNEXINS; MOSSER G, 1991, J MOL BIOL, V217, P241, DOI 10.1016/0022-2836(91)90538-H; NEWMAN R, 1989, J MOL BIOL, V206, P213, DOI 10.1016/0022-2836(89)90534-2; NEWMAN RH, 1991, FEBS LETT, V279, P21, DOI 10.1016/0014-5793(91)80240-4; POLLARD HB, 1992, BIOPHYS J, V62, P15, DOI 10.1016/S0006-3495(92)81764-2; PRESTON CL, 1992, AM J PHYSIOL, V263, pC879, DOI 10.1152/ajpcell.1992.263.4.C879; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; SCHLAEPFER DD, 1992, BIOCHEMISTRY-US, V31, P1886, DOI 10.1021/bi00121a043; SCHOPPA N, 1989, J MEMBRANE BIOL, V108, P73, DOI 10.1007/BF01870427; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SEATON BA, 1990, J BIOL CHEM, V265, P4567; SOBOTA A, 1993, FEBS LETT, V315, P178, DOI 10.1016/0014-5793(93)81158-V; SORSCHER EJ, 1991, P NATL ACAD SCI USA, V88, P7759, DOI 10.1073/pnas.88.17.7759; SUN J, 1993, THROMB RES, V69, P289, DOI 10.1016/0049-3848(93)90026-K; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	47	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5297	5302						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106514				2022-12-25	WOS:A1994MX57100091
J	MIYAZAKI, A; SAKAI, M; SUGINOHARA, Y; HAKAMATA, H; SAKAMOTO, YI; MORIKAWA, W; HORIUCHI, S				MIYAZAKI, A; SAKAI, M; SUGINOHARA, Y; HAKAMATA, H; SAKAMOTO, YI; MORIKAWA, W; HORIUCHI, S			ACETYLATED LOW-DENSITY-LIPOPROTEIN REDUCES ITS LIGAND ACTIVITY FOR THE SCAVENGER RECEPTOR AFTER INTERACTION WITH RECONSTITUTED HIGH-DENSITY-LIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; CYTOPLASMIC CHOLESTERYL ESTERS; CULTURED-CELLS; ATHEROSCLEROTIC LESIONS; PERITONEAL-MACROPHAGES; MEDIATED ENDOCYTOSIS; PLASMA-LIPOPROTEINS; CROSS-LINKING; ADIPOSE-CELLS; LDL	Complexes of apolipoprotein A-I (apoA-I) with phospholipids are known to induce cholesterol efflux from cells. In a cholesteryl ester accumulation system in which rat peritoneal macrophages were incubated with acetylated low density lipoprotein (acetyl-LDL) and either dimyristoylphosphatidylcholine complexes (DMPC/apoA-I) or native high density lipoprotein (HDL), DMPC/apoA-I exhibited a much stronger effect than native HDL in preventing cholesteryl ester accumulation. The mechanism for this phenomenon was investigated in the present study. After 18 h incubation with DMPC/apoA-I in a cell-free system, acetyl-LDL was re-isolated from DMPC/apoA-I by Sephacryl S-300 gel filtration chromatography, Re-isolated acetyl-LDL exhibited an increase in its phospholipid content by 86% as well as a reduction in the electrophoretic mobility. Its endocytic degradation by macrophages was reduced by 60% when compared with control acetyl-LDL, suggesting a significant reduction in the ligand activity for the macrophage scavenger receptor. Transfer of apolipoproteins between acetyl-LDL and DMPC/apoA-I did not occur. These results indicate that transfer of DMPC from DMPC/apoA-I to acetyl-LDL weakens the ligand activity for the scavenger receptor due probably to a decrease in net negative charge, This study demonstrated for the first time that lipid modification (change in the lipid moiety) of acetyl-LDL can induce alteration in its apolipoprotein moiety, leading to a significant loss of its biological activity. Because discoidal HDLs are known to occur in vivo, this phenomenon may explain one of the anti-atherogenic functions of HDL in vivo.	KUMAMOTO UNIV, SCH MED, DEPT BIOCHEM, KUMAMOTO 860, JAPAN; CHEMO-SERO-THERAPEUT RES INST, KUMAMOTO 860, JAPAN	Kumamoto University								ALLAIN CC, 1974, CLIN CHEM, V20, P470; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; AVIRAM M, 1991, J BIOL CHEM, V266, P11567; BARBARAS R, 1986, BIOCHIM BIOPHYS ACTA, V888, P143, DOI 10.1016/0167-4889(86)90015-7; BOYD HC, 1989, AM J PATHOL, V135, P815; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GUPTA AK, 1992, J LIPID RES, V33, P1741; HARA H, 1991, J BIOL CHEM, V266, P3080; HIGGS DW, 1984, ARTERIOSCLEROSIS, V4, P208, DOI 10.1161/01.ATV.4.3.208; HO YK, 1980, J LIPID RES, V21, P391; HUNTER JA, 1982, BIOCHEM BIOPH RES CO, V105, P828, DOI 10.1016/0006-291X(82)91044-0; INNERARITY TL, 1982, ARTERIOSCLEROSIS, V2, P114, DOI 10.1161/01.ATV.2.2.114; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1988, J LIPID RES, V29, P1349; JONAS A, 1986, METHOD ENZYMOL, V128, P553; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1085, P71, DOI 10.1016/0005-2760(91)90233-8; KUNITAKE ST, 1992, P NATL ACAD SCI USA, V89, P6993, DOI 10.1073/pnas.89.15.6993; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MCCALL MR, 1988, J LIPID RES, V29, P1127; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MIYAZAKI A, 1992, BIOCHIM BIOPHYS ACTA, V1126, P73, DOI 10.1016/0005-2760(92)90219-L; MIYAZAKI A, 1990, ARTERIOSCLEROSIS, V10, pA793; MIYAZAKI A, 1991, BIOCHIM BIOPHYS ACTA, V1082, P143; MURAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P729, DOI 10.1093/jb/101.3.729; MUSLINER TA, 1991, J LIPID RES, V32, P917; NICHOLS AV, 1980, BIOCHIM BIOPHYS ACTA, V617, P480, DOI 10.1016/0005-2760(80)90014-4; OHTA T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P119, DOI 10.1016/0005-2760(92)90083-8; OHTA T, 1989, FEBS LETT, V257, P435, DOI 10.1016/0014-5793(89)81590-X; PARKS JS, 1985, J BIOL CHEM, V260, P3155; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; ROBERTS DCK, 1985, BIOCHEM J, V226, P319, DOI 10.1042/bj2260319; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SAKAI M, 1992, FEBS LETT, V314, P199, DOI 10.1016/0014-5793(92)80974-L; SLOOP CH, 1987, J LIPID RES, V28, P225; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; SPAYD RW, 1978, CLIN CHEM, V24, P1343; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V984, P273, DOI 10.1016/0005-2736(89)90293-9; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	50	62	65	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5264	5269						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106510				2022-12-25	WOS:A1994MX57100087
J	REID, RJD; BODLEY, JW; ANDERSON, D				REID, RJD; BODLEY, JW; ANDERSON, D			CHARACTERIZATION OF THE PROHEAD-PRNA INTERACTION OF BACTERIOPHAGE-PHI-29	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; T7 RNA-POLYMERASE; RESTRICTION FRAGMENTS; PHENOTYPIC SELECTION; DNA; SEQUENCE; PROTEIN; DNA-GP3; ATPASE; SIZE	The small prohead RNA(pRNA) of the Bacillus subtilis bacteriophage phi 29 is essential for ATP dependent packaging of viral DNA. The 174-, 124-, and 120-residue forms of pRNA produced in vitro using T7 RNA polymerase were equivalent in prohead binding and DNA packaging activity to pRNAs produced in phi 29-infected cells. pRNA binding to proheads, characterized by the use of Northern hybridization and filter binding assays, was specific, rapid, and irreversible in the presence of 10 mM Mg2+. Proheads produced in phage-infected cells carried 5.8 +/- 2.7 copies of pRNA, and proheads assembled in Escherichia coli in the absence of pRNA bound 6.0 +/- 3.5 copies of pRNA. Footprints of proheads on pRNA generated with the ribonucleases A, T1, and V1 showed that nucleotides 22-84, 5' to 3', were protected from ribonuclease attack. Enhanced cleavage at nucleotides 37-40 with ribonuclease V1 suggested a conformational change of pRNA upon prohead binding.	UNIV MINNESOTA, DEPT GENET & CELL BIOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT MICROBIOL & ORAL SCI, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Reid, Robert/AAR-1560-2020	Reid, Robert/0000-0002-7424-3537				BAILEY S, 1990, J BIOL CHEM, V265, P22365; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CHAPMAN KA, 1987, NUCLEIC ACIDS RES, V15, P5413, DOI 10.1093/nar/15.13.5413; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CUNNINGHAM PR, 1990, BIOTECHNIQUES, V9, P713; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; GRIMES S, 1989, J MOL BIOL, V209, P101, DOI 10.1016/0022-2836(89)90173-3; GRIMES S, 1989, J MOL BIOL, V209, P91, DOI 10.1016/0022-2836(89)90172-1; GUO PX, 1987, NUCLEIC ACIDS RES, V15, P7081, DOI 10.1093/nar/15.17.7081; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1991, VIROLOGY, V185, P395, DOI 10.1016/0042-6822(91)90787-C; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; GUO PX, 1991, VIROLOGY, V183, P366, DOI 10.1016/0042-6822(91)90149-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWARY P, 1986, STRUCTURE DYNAMICS R, P69; Maniatis T., 1982, MOL CLONING; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WICHITWECHKARN J, 1989, NUCLEIC ACIDS RES, V17, P3459, DOI 10.1093/nar/17.9.3459; WICHITWECHKARN J, 1992, J MOL BIOL, V223, P991, DOI 10.1016/0022-2836(92)90257-K; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	23	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5157	5162						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106496				2022-12-25	WOS:A1994MX57100073
J	ZHANG, MJ; HUQUE, E; VOGEL, HJ				ZHANG, MJ; HUQUE, E; VOGEL, HJ			CHARACTERIZATION OF TRIMETHYLLYSINE-115 IN CALMODULIN BY N-14 AND C-13 NMR-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SITE-SPECIFIC MUTAGENESIS; AMINO-ACID SEQUENCE; LIGHT CHAIN KINASE; DICTYOSTELIUM-DISCOIDEUM; PROTEOLYTIC FRAGMENTS; PROTEIN-DEGRADATION; N-METHYLTRANSFERASE; ESCHERICHIA-COLI; METHYLATION	In this paper we describe three approaches to study the single trimethyllysine 115 in calmodulin. First, N-14 NMR spectroscopy has been used as a novel spectroscopic tool. Because of the unique symmetrical tetrahedral substitution of its side chain, the trimethyllysine residue gives rise to a sharp N-14 NMR resonance; hence, this has allowed the detection and quantitation of the level of trimethylation. Trimethyllysine side chains of bovine testis calmodulin and yeast cytochrome c were shown to have a high mobility in aqueous solution as determined by N-14 NMR relaxation measurements. Second, we have purified mammalian calmodulin from an overproducing Escherichia coli strain. By comparison of the H-1-C-13 heteronuclear multiple quantum coherence spectra of C-13-dimethylated calmodulin samples from bovine testis and E. coli, the resonance for Lys-115 in bacterially expressed calmodulin could be identified. pH titration experiments showed that the epsilon-NH2 group of Lys-115 has a normal pK alpha value both in the apo and Ca2+ forms of the protein and in a complex of calmodulin with a 22-residue calmodulin-binding peptide derived from myosin light chain kinase. Third, we have shown that mutation of Lys-115 to the uncharged Gln residue does not alter the ability of the protein to stimulate the enzymes cyclic nucleotide phosphodiesterase and myosin light chain kinase. These results show that the trimethylation of Lys-115 is not caused by an unusual pK alpha and reactivity of its epsilon-NH2 group and that its side chain remains flexible. Moreover, our data suggest that the introduction of a permanent positive charge on Lys-115 by trimethylation is also not the major reason for this specific post-translational modification.	UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,AB,CANADA	University of Calgary				Zhang, Mingjie/0000-0001-9404-0190				ANDERSSON A, 1983, BIOCHEMISTRY-US, V22, P2309, DOI 10.1021/bi00279a001; ARAI K, 1980, P NATL ACAD SCI-BIOL, V77, P1326, DOI 10.1073/pnas.77.3.1326; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BLOMBERG F, 1976, P NATL ACAD SCI USA, V73, P1409, DOI 10.1073/pnas.73.5.1409; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BRODIN P, 1989, PROTEIN ENG, V2, P353, DOI 10.1093/protein/2.5.353; BRODIN P, 1986, BIOCHEMISTRY-US, V25, P5371, DOI 10.1021/bi00367a004; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; COHEN EA, 1975, ORG MAGN RESONANCE, V7, P605, DOI 10.1002/mrc.1270071210; DELANGE RJ, 1970, J BIOL CHEM, V245, P3325; GEROTHANASSIS IP, 1987, J MAGN RESON, V75, P513, DOI 10.1016/0022-2364(87)90107-7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREGORI L, 1987, J BIOL CHEM, V262, P2562; GREGORI L, 1985, J BIOL CHEM, V260, P5232; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HUQUE ME, 1989, THESIS U CALGARY; HUQUE ME, 1993, J PROTEIN CHEM, V12, P693; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JENNISSEN HP, 1992, FEBS LETT, V296, P51, DOI 10.1016/0014-5793(92)80401-2; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KEIM P, 1974, J BIOL CHEM, V249, P4149; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LING KY, 1992, PROTEINS, V12, P365, DOI 10.1002/prot.340120408; LUKAS TJ, 1985, PLANT PHYSIOL, V78, P477, DOI 10.1104/pp.78.3.477; LUKAS TJ, 1989, P NATL ACAD SCI USA, V86, P7331, DOI 10.1073/pnas.86.19.7331; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARSHAK DR, 1984, BIOCHEMISTRY-US, V23, P2891, DOI 10.1021/bi00308a007; MCINTYRE DD, 1989, J MAGN RESON, V83, P377, DOI 10.1016/0022-2364(89)90199-6; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MOLLA A, 1981, J BIOL CHEM, V256, P15; MORINO H, 1987, J NEUROCHEM, V48, P1201, DOI 10.1111/j.1471-4159.1987.tb05647.x; OH SH, 1990, PLANT PHYSIOL, V93, P880, DOI 10.1104/pp.93.3.880; OH SH, 1992, ARCH BIOCHEM BIOPHYS, V297, P28, DOI 10.1016/0003-9861(92)90636-B; PAIK WK, 1989, BIOCHEM CELL BIOL, V67, P602; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; PUTKEY JA, 1986, J BIOL CHEM, V261, P9896; RAO ST, 1993, PROTEIN SCI, V2, P436; RICHARDS RE, 1974, J CHEM SOC P1, V2, P368; ROBERTS DM, 1986, J BIOL CHEM, V261, P1491; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; ROBERTS DM, 1992, P NATL ACAD SCI USA, V89, P8394, DOI 10.1073/pnas.89.17.8394; ROWE PM, 1986, J BIOL CHEM, V261, P7060; Ruben L., 1984, Molecular biology of host-parasite interactions. Proc. UCLA Symp., Park City, Utah, USA, 30 Jan.-4 Feb. 1983. (UCLA Symposia on Molecular and Cellular Biology New Series, Vol. 13)., P267; SAUTER A, 1993, COMP BIOCH PHYSL B, V114, P119; SCHAEFER WH, 1987, J BIOL CHEM, V262, P1025; Sharma R K, 1979, Adv Cyclic Nucleotide Res, V10, P187; TZALMONA A, 1974, J CHEM PHYS, V61, P2637, DOI 10.1063/1.1682391; VOGEL HJ, 1983, FEBS LETT, V157, P241, DOI 10.1016/0014-5793(83)80554-7; VOGEL HJ, 1987, CALCIUM DRUG ACTIONS, P57; ZHANG MJ, 1993, J BIOL CHEM, V268, P22420; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114; [No title captured]	56	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5099	5105						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106489				2022-12-25	WOS:A1994MX57100064
J	LANGE, Y				LANGE, Y			CHOLESTEROL MOVEMENT FROM PLASMA-MEMBRANE TO ROUGH ENDOPLASMIC-RETICULUM - INHIBITION BY PROGESTERONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDIG TUMOR-CELLS; TRANSPORT; OXIDASE	The effect of progesterone on the movement of sterols from the cell surface to the rough endoplasmic reticulum (ER) was examined in rat hepatoma cells. Plasma membranes were labeled exogenously with [H-3]cholesterol or [H-3]zymosterol. Translocation of the labeled sterols to the rough ER was inferred from their conversion to [H-3]cholesteryl esters and [H-3]cholesterol, respectively. Progesterone inhibited both of these reactions by more than 90%. The concentration for half-maximal inhibition was 0.7 mug/ml. Progesterone did not inhibit acyl-/CoA:cholesterol acyltransferase activity itself, since the steroid had no effect on the esterification of [H-3]cholesterol synthesized in vitro in the rough ER from [H-3]zymosterol. Moreover, the small amount of [H-3]cholesterol synthesized from plasma membrane [H-3]zymosterol in progesterone-treated intact cells was esterified at the same fractional rate as cholesterol in control cells. Subcellular fractionation of cells pulse-labeled with [H-3]cholesterol and treated with progesterone suggested that the block in plasma membrane cholesterol transfer to the rough ER occurred at the level of the plasma membrane.			LANGE, Y (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PATHOL,CHICAGO,IL 60612, USA.		Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028448, R55HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LISCUM L, 1992, J LIPID RES, V33, P1239; NAGY L, 1990, ENDOCRINOLOGY, V126, P2267, DOI 10.1210/endo-126-5-2267; NAGY L, 1990, BIOCHEM J, V271, P809, DOI 10.1042/bj2710809; QIAN XD, 1990, J BIOL CHEM, V265, P18753; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; SUCKLING KE, 1985, J LIPID RES, V26, P647; TABAS I, 1988, J BIOL CHEM, V263, P1266	15	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3411	3414						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106380				2022-12-25	WOS:A1994MV63100044
J	WU, QY; PICARD, V; AIACH, M; SADLER, JE				WU, QY; PICARD, V; AIACH, M; SADLER, JE			ACTIVATION-INDUCED EXPOSURE OF THE THROMBIN ANION-BINDING EXOSITE - INTERACTIONS OF RECOMBINANT MUTANT PROTHROMBINS WITH THROMBOMODULIN AND A THROMBIN EXOSITE-SPECIFIC ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; FACTOR-XA; EQUILIBRIUM BINDING; BOVINE PROTHROMBIN; CRYSTAL-STRUCTURE; MAJOR PRODUCT; FACTOR-VA; MEIZOTHROMBIN; HIRUDIN; PLASMA	The activation of serine protease zymogens involves conformational changes that increase the affinity of substrate binding and the activity of the catalytic center. The activation of prothrombin is particularly complex and requires several cleavages in the proenzyme region in addition to the conserved activation cleavage after Arg320. To understand how these cleavages lead to the exposure of the thrombin anion-binding exosite, a major macromolecular recognition site, interactions of recombinant human prothrombin derivatives with thrombomodulin, and an exosite-specific antibody were studied by competition binding and immunoprecipitation. By either method, the anion-binding exosite is not functional on prethrombin 2, which is cleaved after Arg271 and lacks fragment 1.2, nor on meizothrombin, which is cleaved only after Arg320. In contrast, the exosite is fully exposed on meizothrombin des-Fl, which is cleaved after both Arg320 and Arg155 and therefore lacks amino-terminal fragment 1 (Fl). Thus, two events are required to create the exosite. First, cleavage after Arg320 causes conformational changes that are much more extensive than those accompanying the activation of trypsinogen. Second, removal of amino-terminal Fl is necessary, perhaps to relieve steric hindrance. These results indicate that the F1 fragment regulates access to the thrombin exosite. The properties of meizothrombin des-Fl suggest that this prothrombin derivative could have a biological function.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,HOWARD HUGHES MED INST,660 S EUCLID,POB 8022,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MOLEC BIOPHYS,ST LOUIS,MO 63110; HOP BROUSSAIS,INSERM,UFR SCI PHARMACEUT & BIOL,F-75674 PARIS 14,FRANCE	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Sadler, Evan/D-8556-2011	Wu, Qingyu/0000-0003-0561-9315; Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNAUD E, 1993, THROMB HAEMOSTASIS, V69, P555; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; COSTA JM, 1992, THROMB HAEMOSTASIS, V67, P193; DEGEN SJF, 1990, DNA CELL BIOL, V9, P487, DOI 10.1089/dna.1990.9.487; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DIHANICH M, 1990, NUCLEIC ACIDS RES, V18, P4251, DOI 10.1093/nar/18.14.4251; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON NL, 1988, CIRCULATION, V78, P317; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P486; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LENTZ SR, 1991, BLOOD, V77, P542; LIU LW, 1991, J BIOL CHEM, V266, P23632; MACGILLIVRAY RTA, 1984, BIOCHEMISTRY-US, V23, P1626, DOI 10.1021/bi00303a007; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1990, BLOOD, V76, P1; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MORITA T, 1981, METHOD ENZYMOL, V80, P303; NESHEIM ME, 1988, J BIOL CHEM, V263, P1037; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NGAI PK, 1991, BIOCHEM J, V280, P805, DOI 10.1042/bj2800805; RABIET MJ, 1986, J BIOL CHEM, V261, P3210; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SADLER JE, 1993, HAEMOSTASIS, V23, P183; SHUMAN MA, 1976, J CLIN INVEST, V58, P1249, DOI 10.1172/JCI108579; STEVENS WK, 1993, BIOCHEMISTRY-US, V32, P2787, DOI 10.1021/bi00062a008; TANS G, 1991, J BIOL CHEM, V266, P21864; TSIANG M, 1992, J BIOL CHEM, V267, P6164; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WU Q, 1991, P NATL ACAD SCI USA, V8, P6775; WU QY, 1992, J BIOL CHEM, V267, P24408; WU QY, 1992, J BIOL CHEM, V267, P7083	44	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3725	3730						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106418				2022-12-25	WOS:A1994MV63100087
J	YANG, W; BOSS, WF				YANG, W; BOSS, WF			REGULATION OF PHOSPHATIDYLINOSITOL 4-KINASE BY THE PROTEIN ACTIVATOR PIK-A49 - ACTIVATION REQUIRES PHOSPHORYLATION OF PIK-A49	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-I; SEA-URCHIN EGGS; PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE-C; PHOSPHOINOSITIDE KINASES; DIACYLGLYCEROL KINASE; BINDING PROTEIN; F-ACTIN; CALCIUM	PIK-A49 is a 49-kDa soluble protein that was isolated as an activator of the plasma membrane phosphatidylinositol (PI) 4-kinase from carrot cells (Yang, W., Burkhart, W., Cavallius, J., Merrick, W. C., and Boss, W. F. (1993) J. Biol. Chem. 268, 392-398). PIK-A49 is a multifunctional protein that binds and bundles F-actin and has translational elongation factor-1alpha activity. In this paper, we have investigated the mechanism of activation of PI 4-kinase by PIK-A49. PIK-A49 decreased the K(m) of PI 4-kinase for ATP from 0.40 to 0.19 mm. GTP and GDP, which affect the elongation factor-1alpha function of the protein, inhibited the activation of PI 4-kinase by PIK-A49. Phosphorylation of purified PIK-A49 by a calcium-dependent protein kinase enhanced activation of PI 4-kinase. When dephosphorylated by alkaline phosphatase PIK-A49 no longer activated PI 4-kinase; however, rephosphorylation of PIK-A49 by calcium-dependent protein kinase fully restored activation. Western blots using anti-PIK-A49 serum showed that PIK-A49 was associated with the plasma membrane and the F-actin fraction isolated from plasma membranes, indicating that PIK-A49 would be in a position to regulate plasma membrane PI 4-kinase. Based on these data, we propose a mechanism for feed-forward regulation of polyphosphoinositide biosynthesis in response to increases in cytosolic calcium.	N CAROLINA STATE UNIV, DEPT BOT, BOX 7612, RALEIGH, NC 27695 USA	University of North Carolina; North Carolina State University								BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHAUHAN A, 1989, BIOCHEMISTRY-US, V28, P4952, DOI 10.1021/bi00438a007; CHEN QY, 1990, PLANT PHYSIOL, V94, P1820, DOI 10.1104/pp.94.4.1820; CHEN QY, 1991, PLANT PHYSIOL, V96, P340, DOI 10.1104/pp.96.1.340; CHO MH, 1992, LC GC-MAG SEP SCI, V10, P464; CHO MH, 1993, PLANT PHYSIOL, V103, P637, DOI 10.1104/pp.103.2.637; COTE GG, 1993, ANNU REV PLANT PHYS, V44, P333, DOI 10.1146/annurev.pp.44.060193.002001; DHARMAWARDHANE S, 1991, CELL MOTIL CYTOSKEL, V20, P279, DOI 10.1002/cm.970200404; DIDICHENKO SA, 1991, EUR J BIOCHEM, V198, P705, DOI 10.1111/j.1432-1033.1991.tb16070.x; DROBAK BK, 1993, PLANT PHYSIOL, V102, P705, DOI 10.1104/pp.102.3.705; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Gross W., 1993, Control of plant gene expression., P17; GROSS W, 1992, BIOCHIM BIOPHYS ACTA, V1134, P73, DOI 10.1016/0167-4889(92)90029-B; HOLLAND KM, 1988, J BACTERIOL, V170, P828, DOI 10.1128/jb.170.2.828-833.1988; HUBER JLA, 1992, BIOCHEM J, V283, P877, DOI 10.1042/bj2830877; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KATO H, 1989, J BIOL CHEM, V264, P3116; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KURIYAMA R, 1990, J CELL SCI, V95, P231; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MEMON AR, 1990, J BIOL CHEM, V265, P14817; MISSIAEN L, 1989, BIOCHEM J, V261, P1055, DOI 10.1042/bj2611055; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHTA K, 1990, J BIOL CHEM, V265, P3240; PALEN E, 1990, FEBS LETT, V274, P12, DOI 10.1016/0014-5793(90)81317-H; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; PUTNAMEVANS C, 1989, CELL MOTIL CYTOSKEL, V12, P12, DOI 10.1002/cm.970120103; PUTNAMEVANS CL, 1990, BIOCHEMISTRY-US, V29, P2488, DOI 10.1021/bi00462a008; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; RINCON M, 1990, PLANT BIOL, V9, P173; Roberts DM, 1993, CURR OPIN CELL BIOL, V5, P242, DOI 10.1016/0955-0674(93)90110-C; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SAHYOUN NE, 1989, J BIOL CHEM, V264, P1062; SCHALLER GE, 1992, BIOCHEMISTRY-US, V31, P1721, DOI 10.1021/bi00121a020; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; TAN Z, 1992, PLANT PHYSIOL, V100, P2116, DOI 10.1104/pp.100.4.2116; TAYLOR MV, 1984, NATURE, V312, P462, DOI 10.1038/312462a0; VANDONGEN CJ, 1985, BIOCHEM BIOPH RES CO, V128, P1219, DOI 10.1016/0006-291X(85)91070-8; VENEMA RC, 1991, J BIOL CHEM, V266, P11993; VOGEL S, 1986, EUR J BIOCHEM, V154, P253, DOI 10.1111/j.1432-1033.1986.tb09390.x; WALKER DH, 1990, BIOCHIM BIOPHYS ACTA, V1055, P295, DOI 10.1016/0167-4889(90)90046-G; WHEELER JJ, 1987, PLANT PHYSIOL, V85, P389, DOI 10.1104/pp.85.2.389; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YANG WN, 1993, J BIOL CHEM, V268, P392; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	54	62	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3852	3857						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106430				2022-12-25	WOS:A1994MV63100105
J	DEVAJYOTHI, C; KALVAKOLANU, I; BABCOCK, GT; VASAVADA, HA; HOWE, PH; RANSOHOFF, RM				DEVAJYOTHI, C; KALVAKOLANU, I; BABCOCK, GT; VASAVADA, HA; HOWE, PH; RANSOHOFF, RM			INHIBITION OF INTERFERON-GAMMA-INDUCED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II GENE-TRANSCRIPTION BY INTERFERON-BETA AND TYPE-BETA-1 TRANSFORMING GROWTH-FACTOR IN HUMAN ASTROCYTOMA-CELLS - DEFINITION OF CIS-ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DR ANTIGEN EXPRESSION; X-BOX-BINDING; DOWN-REGULATION; IA-ANTIGEN; HLA-DR; MESSENGER-RNA; DAUDI CELLS; RIFN-GAMMA; ALPHA-BETA; PROMOTER	To address mechanisms by which cytokines inhibit interferon-gamma (IFNgamma)-induced gene expression in astrocytic cells, we have been studying effects of type beta1 transforming growth factor (TGFbeta1) and interferon-beta (IFNbeta) on IFNgamma-induced expression of the well-characterized human major histocompatibility complex (MHC) class II gene DRA. This investigation was motivated by the observations that IFNgamma-induced expression of MHC class II antigen expression on astrocytic cells can be blocked in a tissue-specific fashion by several cytokines and neurotransmitters in tissue culture and that astrocyte expression of MHC class II is severely restricted in vivo. We previously showed that IFNbeta inhibited IFNgamma-induced DRA expression at the transcriptional level. This inhibition was not global, since IFNgamma-induction of intercellular adhesion molecule-1 was not affected. Here, TGFbeta1-mediated inhibition of DRA is shown to exhibit similar characteristics. To address the mechanism of this inhibition, sequence requirements for IFNbeta and TGFbeta1 to suppress IFNgamma-induced transcription of DRA were determined. A 135-base pair DRA sequence element containing the IFNgamma-responsive region and transcriptional start site was sufficient to direct IFNbeta- or TGFbeta1-mediated suppression of a reporter gene. These experiments suggested that either IFNbeta or TGFbeta1 could repress IFNgamma-induced DRA transcription directly, without requiring a cis-element extrinsic to the IFNgamma-inducible DRA sequences. Consistently similar effects of IFNbeta and TGFbeta1 observed in these experiments prompted comparison of other gene regulatory effects of the two cytokines. TGFbeta1, unlike IFNbeta, induced gene expression directed by upstream elements of the gene encoding plasminogen activator inhibitor type-1. IFNbeta, unlike TGFbeta1, enhanced levels of 2'-5'-oligoadenylate synthetase activity. Additionally, direct assay of TGFbeta1 and monoclonal anti-TGFbeta antibody blocking experiments were used to determine that cells treated with IFNbeta did not produce increased amounts of active or latent TGFbeta. These data argued that IFNbeta and TGFbeta1 utilized distinct pathways to mediate the inhibition of IFNgamma-induced DRA transcription.	CLEVELAND CLIN FDN,RES INST,MELLEN CTR MULTIPLE SCLEROSIS TREATMENT & RES,CLEVELAND,OH 44195; MILES RES CTR,INST ARTHRITIS & AUTOIMMUN,W HAVEN,CT 06516	Cleveland Clinic Foundation					NINDS NIH HHS [NS-KO8-01265] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001265] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLDRIDGE LC, 1991, EXP CELL RES, V195, P546, DOI 10.1016/0014-4827(91)90410-V; BARNA BP, 1989, J NEUROIMMUNOL, V23, P45, DOI 10.1016/0165-5728(89)90072-6; BASTA PV, 1988, P NATL ACAD SCI USA, V85, P8618, DOI 10.1073/pnas.85.22.8618; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; DAS HK, 1983, P NATL ACAD SCI-BIOL, V80, P3543, DOI 10.1073/pnas.80.12.3543; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ESTES ML, 1990, J NEUROSCI RES, V27, P697, DOI 10.1002/jnr.490270430; FERTSCH D, 1987, J IMMUNOL, V139, P244; FERTSCHRUGGIO D, 1988, J IMMUNOL, V141, P1582; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOWE PH, 1990, BIOCHEM J, V266, P537, DOI 10.1042/bj2660537; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; INABA K, 1986, J EXP MED, V163, P1030, DOI 10.1084/jem.163.4.1030; JOHNS LD, 1992, BRAIN RES, V585, P229, DOI 10.1016/0006-8993(92)91211-V; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P16999; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; LING PD, 1985, J IMMUNOL, V135, P1857; LOH JE, 1992, EMBO J, V11, P1351, DOI 10.1002/j.1460-2075.1992.tb05180.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; MOSES H, 1992, J IMMUNOL, V148, P3643; MOSES H, 1991, J NEUROIMMUNOL, V35, P273; OLIVEIRA IC, 1992, P NATL ACAD SCI USA, V89, P9049, DOI 10.1073/pnas.89.19.9049; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RANSOHOFF RM, 1991, J NEUROIMMUNOL, V33, P103, DOI 10.1016/0165-5728(91)90054-B; RANSOHOFF RM, UNPUB; ROY C, 1990, NUCLEIC ACIDS RES, V18, P2125, DOI 10.1093/nar/18.8.2125; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SHAN B, 1990, EMBO J, V9, P4307, DOI 10.1002/j.1460-2075.1990.tb07879.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TWARDZIK DR, 1990, ANN NY ACAD SCI, V593, P276, DOI 10.1111/j.1749-6632.1990.tb16119.x; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; ZUBER P, 1988, EUR J IMMUNOL, V18, P1623, DOI 10.1002/eji.1830181023	44	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18794	18800						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103050				2022-12-25	WOS:A1993LV65900065
J	PARKS, GD; LAMB, RA				PARKS, GD; LAMB, RA			ROLE OF NH2-TERMINAL POSITIVELY CHARGED RESIDUES IN ESTABLISHING MEMBRANE-PROTEIN TOPOLOGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL SIGNAL SEQUENCE; ENDOPLASMIC-RETICULUM MEMBRANE; INFLUENZA-B VIRUS; HEMAGGLUTININ-NEURAMINIDASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; AMINO-ACIDS; DIRECTED MUTAGENESIS; INVARIANT CHAIN; SIMIAN VIRUS-5	The paramyxovirus HN polypeptide is a model type II membrane protein, containing an internal uncleaved signal/anchor (S/A) and is oriented in the membrane with an NH2-terminal cytoplasmic domain and COOH-terminal ectodomain (N(cyt) topology). To test the role of NH2-terminal positively charged residues in directing the HN membrane topology, the 3 arginine (Arg) residues within the 17-amino-acid NH2-terminal domain were systematically converted to a glutamine or glutamate, and the topology of the mutant proteins was examined after expression in CV-1 cells. The data indicate that: (i) each of the NH2-terminal Arg residues contributes to the signal directing proper HN topology, since substitutions in any of the three positions resulted in approximately 13-23% inversion into the N(exo) form; (ii) substitutions in the Arg directly flanking the signal/anchor domain resulted in slightly more inversion than those which were located more distally; and (iii) substitution with a negatively charged glutamate led to more inversion than did replacement with an uncharged glutamine. The effect of a single Arg to Glu substitution on the HN topology was enhanced when present in the context of a truncated NH2-terminal cytoplasmic tail (3 residues). A comparison of the sequences flanking the signal/anchor of well documented type III proteins showed that the majority of three proteins contain a negatively charged residue flanking the NH2-terminal side. An exception to this rule is the NB protein which contains a single positively charged Arg residue in this position. A chimeric protein containing the NB ectodomain and the HN S/A and HN ectodomain lead to a significant fraction (70%) of the chimeric protein adopting type II topology suggesting that the positive charge flanking the S/A domain is important for establishing type II topology. These data are discussed in the context of the loop model for the biogenesis of integral membrane proteins and the possible signals necessary for establishing differing orientations.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,2153 SHERIDAN RD,EVANSTON,IL 60208; NORTHWESTERN UNIV,HOWARD HUGHES MED INST,EVANSTON,IL 60208	Northwestern University; Howard Hughes Medical Institute; Northwestern University								ADAMS GA, 1985, MOL CELL BIOL, V5, P1442, DOI 10.1128/MCB.5.6.1442; AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BERGMANN C, 1989, EMBO J, V5, P1543; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ERICKSON AH, 1979, J BIOL CHEM, V254, P1771; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIEBERT SW, 1985, J VIROL, V54, P1; HIGH S, 1987, BIOCHEM J, V243, P277, DOI 10.1042/bj2430277; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LAMB RA, 1982, VIROLOGY, V123, P237, DOI 10.1016/0042-6822(82)90258-6; LAMB RA, 1976, VIROLOGY, V74, P504, DOI 10.1016/0042-6822(76)90356-1; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; PARKS GD, 1990, J VIROL, V64, P3605, DOI 10.1128/JVI.64.8.3605-3616.1990; PARKS GD, 1989, J CELL BIOL, V109, P2023, DOI 10.1083/jcb.109.5.2023; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PATERSON RG, 1990, J CELL BIOL, V110, P999, DOI 10.1083/jcb.110.4.999; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHOFIELD PR, 1987, NUCLEIC ACIDS RES, V15, P3636, DOI 10.1093/nar/15.8.3636; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SHAW MW, 1982, P NATL ACAD SCI-BIOL, V79, P6817, DOI 10.1073/pnas.79.22.6817; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P6711; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WILLIAMS MA, 1986, MOL CELL BIOL, V6, P4317, DOI 10.1128/MCB.6.12.4317; WILSON C, 1990, MOL CELL BIOL, V10, P449, DOI 10.1128/MCB.10.2.449; ZERIAL M, 1987, CELL, V48, P147, DOI 10.1016/0092-8674(87)90365-5	65	54	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19101	19109						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103052				2022-12-25	WOS:A1993LV65900107
J	ARRIZA, JL; KAVANAUGH, MP; FAIRMAN, WA; WU, YN; MURDOCH, GH; NORTH, RA; AMARA, SG				ARRIZA, JL; KAVANAUGH, MP; FAIRMAN, WA; WU, YN; MURDOCH, GH; NORTH, RA; AMARA, SG			CLONING AND EXPRESSION OF A HUMAN NEUTRAL AMINO-ACID TRANSPORTER WITH STRUCTURAL SIMILARITY TO THE GLUTAMATE TRANSPORTER GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-BRAIN; GLYCINE TRANSPORTER; CARRIER; IDENTIFICATION; RECEPTOR	A cDNA was isolated from human brain that encodes an amino acid sequence 34-39% identical to previously published glutamate transporter sequences. Injection of RNA transcribed from this cDNA into Xenopus oocytes resulted in expression of a transport activity with the properties of the neutral amino acid uptake system ASC. Superfusion of alanine, serine, and cysteine evoked sodium-dependent inward currents in voltage-clamped oocytes expressing the transporter. These currents were dose-dependent, stereospecific, and saturable, with K(m) values ranging from 29 to 88 muM. Northern blot analyses revealed ubiquitous expression of this gene, termed ASCT1, consistent with the general metabolic role ascribed to system ASC.			ARRIZA, JL (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES L-474,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.		North, Richard/GQA-6156-2022	Amara, Susan/0000-0001-8914-1106	NATIONAL INSTITUTE ON DRUG ABUSE [R37DA007595, R37DA003160, R01DA003160, R01DA007595] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07595, DA03160] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BUSSOLATI O, 1992, J BIOL CHEM, V267, P8330; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CHRISTENSEN HN, 1967, J BIOL CHEM, V242, P5237; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; ENGELKE T, 1989, J BACTERIOL, V171, P5551, DOI 10.1128/jb.171.10.5551-5560.1989; ERICINSKA M, 1983, J BIOL CHEM, V258, P9069; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KONG CT, 1993, J BIOL CHEM, V268, P1509; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; LUI QR, 1992, FEBS LETT, V305, P110; MAENZ DD, 1992, J BIOL CHEM, V267, P1510; MAKOWSKE M, 1982, J BIOL CHEM, V257, P4635; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; OLNEY JW, 1990, SCIENCE, V248, P596, DOI 10.1126/science.2185543; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STEIN WD, 1986, TRANSPORT DIFFUSION, P467; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; WALLACE B, 1990, J BACTERIOL, V172, P3214, DOI 10.1128/jb.172.6.3214-3220.1990; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0	27	329	334	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15329	15332						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101838				2022-12-25	WOS:A1993LN30500002
J	CONRAD, ME; UMBREIT, JN; MOORE, EG; UZEL, C; BERRY, MR				CONRAD, ME; UMBREIT, JN; MOORE, EG; UZEL, C; BERRY, MR			ALTERNATE IRON TRANSPORT PATHWAY - MOBILFERRIN AND INTEGRIN IN K562 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN-BOUND IRON; RECEPTOR-MEDIATED ENDOCYTOSIS; RAT-LIVER; BINDING PROTEIN; DUODENAL MUCOSA; MEMBRANE; CALRETICULIN; CLEARANCE; SYSTEM	A transferrin-independent iron transport system in cells containing transferrin receptors was described previously by several investigators. Prior studies did not identify the proteins involved in this alternate iron transport pathway. Using a human-derived erythroleukemia tissue culture line, iron-binding proteins were isolated from cytosol and cell membranes. The cytosol protein was soluble in 60% ammonium sulfate, had a molecular mass similar to mobilferrin (56 kDa), and reacted with anti-mobilferrin antibodies. The water-in soluble radiolabeled protein was solubilized with Nonidet P-40 and immunoprecipitated with monoclonal antibody against beta 3 human integrin. Pulse-chase studies suggested sequential passage of iron to integrin, mobilferrin, and ferritin, respectively. Thus, the alternate iron transport pathway contained proteins similar to those observed in intestinal cells which did not possess transferrin receptors on their absorptive surface. The alternate iron transport pathway is only partially shared with zinc and cadmium. Mobilferrin bound zinc and iron competitively, but the two metals were not transported competitively into K562 cells. Immunoprecipitates of integrin containing radiozinc were obtained with a monoclonal antibody against beta 1 human integrin. This suggested iron and zinc may utilize different integrins to passage the cell membrane.	UNIV SO ALABAMA,DEPT PATHOL,MOBILE,AL 36688; UNIV SO ALABAMA,DEPT BIOCHEM,MOBILE,AL 36688	University of South Alabama; University of South Alabama	CONRAD, ME (corresponding author), UNIV SO ALABAMA,USA CANC CTR,DEPT MED,MOBILE,AL 36688, USA.				NIDDK NIH HHS [2R01 DK36112] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036112] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANERJEE D, 1986, GASTROENTEROLOGY, V91, P861, DOI 10.1016/0016-5085(86)90687-6; BRISSOT P, 1985, J CLIN INVEST, V76, P1463, DOI 10.1172/JCI112125; CONRAD ME, 1993, GASTROENTEROLOGY, V104, P1700, DOI 10.1016/0016-5085(93)90648-V; CONRAD ME, 1993, J AM COLL NUTR, V12, P720; CONRAD ME, 1991, GASTROENTEROLOGY, V100, P129, DOI 10.1016/0016-5085(91)90592-9; CONRAD ME, 1992, BLOOD, V79, P244, DOI 10.1182/blood.V79.1.244.bloodjournal791244; CONRAD ME, 1990, J BIOL CHEM, V265, P5273; CONRAD ME, 1993, AM J HEMATOL, V42, P67, DOI 10.1002/ajh.2830420114; CONRAD ME, 1993, AM J HEMATOL, V43, P234, DOI 10.1002/ajh.2830430315; CONRAD ME, 1993, BLOOD, V81, P517; CONRAD ME, 1987, PHYSL GASTROINTESTIN, P1437; CRAVEN CM, 1987, P NATL ACAD SCI USA, V84, P3457, DOI 10.1073/pnas.84.10.3457; EGYED A, 1988, BRIT J HAEMATOL, V68, P483, DOI 10.1111/j.1365-2141.1988.tb04241.x; GUAN SH, 1991, BIOCHEMISTRY-US, V30, P9892, DOI 10.1021/bi00105a012; INMAN RS, 1993, J BIOL CHEM, V268, P8521; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; KARIN M, 1981, J BIOL CHEM, V256, P3245; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; LAUFFER RB, 1992, IRON HUMAN DISEASE; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; MUIR WA, 1984, J BIOL CHEM, V259, P4896; NUNEZ MT, 1992, J BIOL CHEM, V267, P11490; OCTAVE JN, 1981, EUR J BIOCHEM, V115, P611; PARMLEY RT, 1985, BRIT J HAEMATOL, V60, P81, DOI 10.1111/j.1365-2141.1985.tb07388.x; POLLACK S, 1965, J CLIN INVEST, V44, P1470, DOI 10.1172/JCI105253; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SELIGMAN PA, 1991, BLOOD, V78, P1526; STURROCK A, 1990, J BIOL CHEM, V265, P3139; VANBOCKXMEER FM, 1977, BIOCHIM BIOPHYS ACTA, V468, P437, DOI 10.1016/0005-2736(77)90293-0; WRIGHT TL, 1986, J BIOL CHEM, V261, P909; WRIGHT TL, 1988, J BIOL CHEM, V263, P1842	31	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7169	7173						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125927				2022-12-25	WOS:A1994NA03200023
J	RAO, GN; GRIENDLING, KK; FREDERICKSON, RM; SONENBERG, N; ALEXANDER, RW				RAO, GN; GRIENDLING, KK; FREDERICKSON, RM; SONENBERG, N; ALEXANDER, RW			ANGIOTENSIN-II INDUCES PHOSPHORYLATION OF EUKARYOTIC PROTEIN-SYNTHESIS INITIATION-FACTOR 4E IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; RNA 5' CAP; MESSENGER-RNA; GROWTH-FACTOR; KINASE-C; RIBOSOMAL PROTEIN-S6; HYPERTENSIVE RAT; PHORBOL ESTERS; FACTORS EIF-4F; TRANSLATION	Angiotensin II has been shown to induce hypertrophy of cultured vascular smooth muscle cells (VSMC). To understand the mechanisms of induction of the hypertrophy, we studied its effect on the phosphorylation state of eIF-4E, a rate limiting eukaryotic protein synthesis initiation factor whose activity has been shown to be regulated by phosphorylation. Angiotensin II induced a 2-3-fold increase in the phosphorylation of eIF-4E in VSMC. The stimulation of phosphorylation was apparent at 20 min and persisted for at least 12 h. Phosphoamino acid analysis revealed that serine is the major residue of eIF-4E phosphorylated by angiotensin II. Staurosporine and calphostin C, two potent inhibitors of the serine/threonine protein kinase, protein kinase C, significantly attenuated the angiotensin II-induced eIF-4E phosphorylation. Staurosporine and calphostin C also blunted the angiotensin II-stimulated protein synthesis. Together, these observations indicate that angiotensin II induces phosphorylation of eIF-4E in a protein kinase C-dependent manner and suggest that this pathway may play an important role in the mechanism by which angiotensin II causes hypertrophy of VSMC.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, PQ, CANADA	McGill University	RAO, GN (corresponding author), EMORY UNIV, SCH MED, DIV CARDIOL, PO DRAWER LL, ATLANTA, GA 30322 USA.			Griendling, Kathy/0000-0002-9456-8582	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038206, R29HL038206, R37HL038206] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38206] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMICK GD, 1992, BIOCHEM BIOPH RES CO, V183, P431, DOI 10.1016/0006-291X(92)90499-B; BERK BC, 1993, J CELL PHYSIOL, V154, P368, DOI 10.1002/jcp.1041540221; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DZAU VJ, 1988, AM J CARDIOL, V62, pG30; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRIENDLING KK, 1989, J CARDIOVASC PHARM, V14, pS27, DOI 10.1097/00005344-198906146-00008; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON TG, 1986, J BIOL CHEM, V261, P13979; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; OSTERRIEDER W, 1991, HYPERTENSION, V18, P60; OWENS GK, 1983, CIRC RES, V53, P491, DOI 10.1161/01.RES.53.4.491; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; RAY BK, 1985, J BIOL CHEM, V260, P7651; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SCOTTBURDEN T, 1988, BIOCHEM BIOPH RES CO, V151, P583, DOI 10.1016/0006-291X(88)90634-1; SHIMAMOTO Y, 1993, AM J PHYSIOL, V264, pH1300, DOI 10.1152/ajpheart.1993.264.4.H1300; SMITH M R, 1990, New Biologist, V2, P648; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVO P, 1980, BLOOD VESSELS, V17, P110; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; WEBB NR, 1984, BIOCHEMISTRY-US, V23, P177, DOI 10.1021/bi00297a001	54	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7180	7184						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125929				2022-12-25	WOS:A1994NA03200025
J	CHEN, JM; ZONG, CS; WANG, LH				CHEN, JM; ZONG, CS; WANG, LH			TISSUE AND EPITHELIAL CELL-SPECIFIC EXPRESSION OF CHICKEN PROTOONCOGENE C-ROS IN SEVERAL ORGANS SUGGESTS THAT IT MAY PLAY ROLES IN THEIR DEVELOPMENT AND MATURE FUNCTIONS	ONCOGENE			English	Article							TYROSINE-KINASE RECEPTOR; HUMAN INSULIN-RECEPTOR; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; SEVENLESS PROTEIN; GENE; FAMILY; PROTOONCOGENE; PRODUCTS; MEMBERS	Proto-oncogene c-ros codes for a receptor-type protein tyrosine kinase (PTK) sharing high homology with the Drosophila sevenless protein. Recent studies of c-ros expression in mouse by in situ hybridization showed that c-ros was expressed specifically and transiently in the epithelial cells of late embryonic kidney collecting duct and intestine villi. Those investigators suggested that c-ros may play a role in the development of those organelles. In the present study, we have examined the expression profile of c-ros in chicken by RNAase protection and in situ hybridization with riboprobes. Our results showed that in addition to kidney and intestine, low levels of c-ros mRNA could also be detected in lung, testis, thymus and bursa. Expression of c-ros commences during middle to late embryonic stages in those organs and persists into the adult life. In situ hybridization revealed that expression of c-ros was restricted to the epithelial cells of all the tissues examined including kidney, intestine, bursa, thymus and testis. In kidney c-ros was detected in all the epithelial cells of the collecting ducts, in intestine it was detected in the epithelial cells of villi and the underneath crypts. Our finding of c-ros expression in chicken differs from those in mouse in (1) instead of transient expression during the embryonic stage, expression of c-ros in chicken kidney and intestine persists into the adult life and (2) expression of c-ros in renal collecting ducts is not restricted to its growing tips, instead it is expressed in the entire epithelial layer of the ducts. Our results suggest that c-ros may play a role not only in the initial induction events in the organogenesis, but also in the mature function of those organs.	MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA 29339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN GA, 1959, AM J ANAT, V104, P163, DOI 10.1002/aja.1001040202; BASLER K, 1988, CELL, V54, P299; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P1122; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; CHEN JM, 1991, ONCOGENE, V6, P257; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GILBERT SF, 1991, DEV BIOL, P582; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HART AC, 1993, NATURE, V361, P732, DOI 10.1038/361732a0; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Kratochwil K., 1983, P99; KRESS C, 1990, DEVELOPMENT, V109, P775; LEDOUARIN N, 1968, ANN EMBRYOL MORPHOG, V1, P29; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NORTON PA, 1990, CELL, V61, P15, DOI 10.1016/0092-8674(90)90209-W; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Rolnik V.V., 1970, BIRD EMBRYOLOGY; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; Sambrook J., 1989, MOL CLONING; SHARMA S, 1989, ONCOGENE RES, V5, P91; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; TIEDGE H, 1991, DNA CELL BIOL, V10, P143, DOI 10.1089/dna.1991.10.143; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LH, 1974, J VIROL, V14, P1515, DOI 10.1128/JVI.14.6.1515-1529.1974; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982	35	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					773	780						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108119				2022-12-25	WOS:A1994MW55100012
J	JIANG, Y; TRIEZENBERG, SJ; GRALLA, JD				JIANG, Y; TRIEZENBERG, SJ; GRALLA, JD			DEFECTIVE TRANSCRIPTIONAL ACTIVATION BY DIVERSE VP16 MUTANTS ASSOCIATED WITH A COMMON INABILITY TO FORM OPEN PROMOTER COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA POLYMERASE-II; EARLY GENE-EXPRESSION; TATA-BINDING PROTEIN; TERMINAL DOMAIN; NONPHOSPHORYLATED FORM; CELLULAR PROTEINS; GAL4 DERIVATIVES; DNA-SEQUENCE; MECHANISM; ELONGATION	Three different types of VP16 mutants were assayed in vitro. These included deletion of the C-terminal activation subdomain and alterations in either the acidic or non-acidic components of the minimal activation domain. The mutant GAL4-VP16 proteins were found to be transcriptionally defective using a HeLa cell nuclear extract. In all three cases the loss of transcription activity was accompanied by a commensurate loss in ability to form open transcription complexes. The comparison implies that the diverse components of GAL4-VP16 activate transcription by the common facilitation of steps required for open complex formation. The results further imply that open complex formation may be a common target for mammalian transcriptional activation, as known previously to be the case in bacterial systems.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA; MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	University of California System; University of California Los Angeles; Michigan State University				Triezenberg, Steven/0000-0003-4184-5221	NIAID NIH HHS [AI 27323] Funding Source: Medline; NIGMS NIH HHS [GM49048] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027323, R21AI027323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049048] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRALLA JD, 1990, METHOD ENZYMOL, V185, P37; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JIANG Y, 1993, J BIOL CHEM, V268, P6535; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LI Z, 1989, GENE DEV, V3, P1814, DOI 10.1101/gad.3.11.1814; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	45	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5505	5508						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119881				2022-12-25	WOS:A1994MY84000007
J	MARECHAL, E; BLOCK, MA; JOYARD, J; DOUCE, R				MARECHAL, E; BLOCK, MA; JOYARD, J; DOUCE, R			KINETIC-PROPERTIES OF MONOGALACTOSYLDIACYLGLYCEROL SYNTHASE FROM SPINACH CHLOROPLAST ENVELOPE MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL GALACTOSYLTRANSFERASE ACTIVITY; MIXED MICELLES; UDP-GALACTOSE; PHOSPHATIDATE PHOSPHATASE; OUTER-MEMBRANE; SOLUBILIZATION; PURIFICATION; PHOSPHATIDYLCHOLINE; THYLAKOIDS; METABOLISM	We have investigated the functioning of monogalactosyldiacylglycerol (MGDG) synthase activity partially purified from spinach chloroplast envelope membranes, using mixed micelles containing diacylglycerol (the substrate for MGDG synthase), CHAPS (3-[(cholamidopropyl)dimethylammonio]-1-propanesulfonic acid), and phosphatidylglycerol. The presence of this anionic phospholipid was essential for optimal MGDG synthase activity because it strongly improves diacylglycerol solubilization by CHAPS. We have demonstrated that the ''surface dilution'' kinetic model proposed by Deems ct al. (Deems, R. A., Eaten, B. R., and Dennis, E.A. (1975) J. Biol. Chem. 250, 9013-9020) is valid for MGDG synthase assayed in mixed micelles within a narrow range of CHAPS concentration. However, the experimental conditions we have set up in this study led to the description of defined equilibrium and kinetic parameters of the interaction of the envelope MGDG synthase with diacylglycerol. Two-substrate kinetic studies were performed with varied UDP-galactose molar concentrations and varied dioleoylglycerol surface concentrations. The families of reciprocal plots obtained were shown to intersect at a single point of the 1/[substrate] axis thus demonstrating that MGDG synthase is a sequential, either random or ordered, bireactant system. Therefore, MGDG synthase possesses two distinct and independent substrate-binding sites, a hydrophilic one for UDP-galactose and a hydrophobic one for diacylglycerol. The dependence of kinetic parameters on the diacylglycerol mel fraction allows a comparison of the affinity of the enzyme for a wide range of diacylglycerol molecular species. The K-m values obtained were ranging between 0.0089 mol fraction (52 mu M) for dilinoleoylglycerol (18:2/18:2) to 0.0666 mol fraction (416 mu M for distearoylglycerol (18:0/18:0), but the differences observed were not really related to the unsaturation of the molecule since the K-m value for dilinoleoylglycerol was much lower than that (0.040 mol fraction) for dilinoleoylglycerol (18:3/18:3). The K-m values for dioleoylglycerol (18:1/18:1) and for the diacylglycerol molecular species synthesized within chloroplasts, i.e. containing 18:1/ 16:0, were in the average range, i.e. lower than 0.030 mol fraction (around 170 mu M).	UNIV JOSEPH FOURIER,F-38054 GRENOBLE 9,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	MARECHAL, E (corresponding author), CEN GRENOBLE,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,CNRS,UA 576,F-38054 GRENOBLE 9,FRANCE.							[Anonymous], METHODS CHLOROPLAST; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BENSON AA, 1964, ANN REV PLANT PHYSIO, V15, P1, DOI 10.1146/annurev.pp.15.060164.000245; BLIGNY R, 1990, J BIOL CHEM, V265, P1319; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; COVES J, 1986, FEBS LETT, V208, P401, DOI 10.1016/0014-5793(86)81057-2; COVES J, 1988, P NATL ACAD SCI USA, V85, P4966, DOI 10.1073/pnas.85.14.4966; COVES J, 1987, PLANT MEMBRANES STRU, P103; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DENNIS E A, 1974, Journal of Supramolecular Structure, V2, P682, DOI 10.1002/jss.400020513; DENNIS EA, 1983, ENZYMES, V16, P308; DORNE AJ, 1990, P NATL ACAD SCI USA, V87, P71, DOI 10.1073/pnas.87.1.71; DORNE AJ, 1985, J CELL BIOL, V100, P1690, DOI 10.1083/jcb.100.5.1690; DORNE AJ, 1982, FEBS LETT, V145, P30, DOI 10.1016/0014-5793(82)81200-3; Douce, 1987, BIOCH PLANTS, P215, DOI 10.1016/B978-0-12-675409-4.50015-0; DOUCE R, 1974, SCIENCE, V183, P852, DOI 10.1126/science.183.4127.852; Douce R., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P321; DOUCE R, 1990, METHODS PLANT BIOCH, V4, P71; FERRARI RA, 1961, ARCH BIOCHEM BIOPHYS, V93, P185, DOI 10.1016/0003-9861(61)90248-X; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; FRENTZEN M, 1983, EUR J BIOCHEM, V129, P629; HAJRA AK, 1974, LIPIDS, V9, P502, DOI 10.1007/BF02532495; HEBER U, 1981, ANNU REV PLANT PHYS, V32, P139, DOI 10.1146/annurev.pp.32.060181.001035; HEEMSKERK JWM, 1987, BIOCHIM BIOPHYS ACTA, V918, P189, DOI 10.1016/0005-2760(87)90194-9; Heinz E., 1977, Lipids and lipid polymers in higher plants., P102; HEIRWEGH KPM, 1988, BIOCHEM J, V254, P101, DOI 10.1042/bj2540101; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; JOYARD J, 1986, BIOCHIM BIOPHYS ACTA, V879, P78, DOI 10.1016/0005-2760(86)90269-9; JOYARD J, 1976, BIOCHIM BIOPHYS ACTA, V424, P125, DOI 10.1016/0005-2760(76)90057-6; KUCERA GL, 1988, J BIOL CHEM, V263, P1920; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIN YP, 1990, J BIOL CHEM, V265, P166; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALHERBE A, 1992, J BIOL CHEM, V267, P23546; MANTEL CR, 1993, BIOCHEM J, V289, P815, DOI 10.1042/bj2890815; MARECHAL E, 1991, CR ACAD SCI III-VIE, V313, P521; MILLER JC, 1981, J BIOL CHEM, V256, P2662; MUDD JB, 1969, J LIPID RES, V10, P623; NEUFELD EF, 1964, BIOCHEM BIOPH RES CO, V14, P503, DOI 10.1016/0006-291X(64)90259-1; ROUGHAN PG, 1982, ANNU REV PLANT PHYS, V33, P97, DOI 10.1146/annurev.pp.33.060182.000525; SAKAKI T, 1990, PLANT PHYSIOL, V94, P773, DOI 10.1104/pp.94.2.773; SCHMIDT H, 1990, P NATL ACAD SCI USA, V87, P9477, DOI 10.1073/pnas.87.23.9477; Segel I.H., 1975, ENZYME KINETICS; SEIFERT U, 1992, BOT ACTA, V105, P197, DOI 10.1111/j.1438-8677.1992.tb00287.x; SIEBERTZ HP, 1980, EUR J BIOCHEM, V108, P177, DOI 10.1111/j.1432-1033.1980.tb04710.x; SIEBERTZ HP, 1979, EUR J BIOCHEM, V101, P429, DOI 10.1111/j.1432-1033.1979.tb19736.x; TEUCHER T, 1991, PLANTA, V184, P319, DOI 10.1007/BF00195332; URBANEJA MA, 1990, BIOCHEM J, V270, P305, DOI 10.1042/bj2700305; VANBESOUW A, 1979, FEBS LETT, V102, P33; VANBESOUW A, 1978, BIOCHIM BIOPHYS ACTA, V529, P44, DOI 10.1016/0005-2760(78)90102-9; WARNER TG, 1975, J BIOL CHEM, V250, P8004; WELSH GR, 1988, J THEOR BIOL, V130, P407; WILCOX RW, 1991, LIPIDS, V26, P283, DOI 10.1007/BF02537138	54	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5788	5798						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119920				2022-12-25	WOS:A1994MY84000050
J	MASTICK, CC; AEBERSOLD, R; LIENHARD, GE				MASTICK, CC; AEBERSOLD, R; LIENHARD, GE			CHARACTERIZATION OF A MAJOR PROTEIN IN GLUT4 VESICLES - CONCENTRATION IN THE VESICLES AND INSULIN-STIMULATED TRANSLOCATION TO THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR GLUCOSE TRANSPORTERS; 3T3-L1 ADIPOCYTES; RAT ADIPOCYTES; LOCALIZATION	GLUT4-enriched vesicles from fat and muscle cells contain a major protein of 165 kDa. In the present study we have prepared GLUT4 vesicles from a large number of rat adipocytes, isolated the 165-kDa protein by SDS-gel electrophoresis, and obtained the sequences of four tryptic peptides. Comparison of the sequences with those in protein data banks showed that the 165-kDa protein had not previously been sequenced. An antibody preparation against one of the peptides immunoblotted the 165-kDa protein. By this means it was found that the 165-kDa protein was concentrated in GLUT4 vesicles, and that insulin treatment of rat adipocytes caused a translocation of the protein to the plasma membrane that paralleled the translocation of GLUT4	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER V6T 1W5,BC,CANADA	Dartmouth College; University of British Columbia; University of British Columbia			Mastick, Cynthia/G-9841-2017	Mastick, Cynthia/0000-0003-4769-5412	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025336, R55DK025336] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25336] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; BROWN SJ, 1988, BIOCHIM BIOPHYS ACTA, V971, P339, DOI 10.1016/S0005-2728(88)80049-5; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; KELLER SR, 1991, J BIOL CHEM, V266, P12817; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; LEINHARD GE, 1982, BIOCHEM BIOPH RES CO, V105, P1150; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; WEBER TM, 1988, RECEPTOR BIOCH METHO, P171; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	22	114	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6089	6092						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119954				2022-12-25	WOS:A1994MY84000092
J	TANTI, JF; GREMEAUX, T; VANOBBERGHEN, E; LEMARCHANDBRUSTEL, Y				TANTI, JF; GREMEAUX, T; VANOBBERGHEN, E; LEMARCHANDBRUSTEL, Y			SERINE/THREONINE PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1 MODULATES INSULIN-RECEPTOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; OKADAIC ACID; RAT ADIPOCYTES; PROTEIN-KINASE; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; CONFORMATIONAL-CHANGES; PHOSPHATASE INHIBITOR; SKELETAL-MUSCLE; HEPATOMA-CELLS	Treatment of cells with okadaic acid, a protein phosphatase inhibitor, leads to an insulin-resistant state without modification in the tyrosine kinase activity of the receptor toward exogenous substrates. In 3T3-L1 adipocytes, okadaic acid induced a similar dose dependent inhibition of the insulin effect on deoxyglucose uptake, phosphatidylinositol 3-kinase (PI 3-kinase) activation, and insulin receptor substrate (IRS) 1 tyrosine phosphorylation. Simultaneously, in okadaic acid-treated 3T3-L1 adipocytes, the reduced IRS 1 tyrosine phosphorylation was linked to a decrease in its electrophoretic mobility due to phosphorylation on serine/threonine residues. This phosphorylation appeared to result from the activation of cytosolic kinase(s). Furthermore, using in vitro reconstitution, we show that, compared to IRS 1 immunopurified from untreated cells, the IRS 1 obtained from okadaic acid-treated cells had a reduced capacity to be phosphorylated by insulin receptors and, concomitantly, to bind PI and kinase, Taken together these data suggest that serine/threonine phosphorylation of IRS 1 induced by okadaic acid reduces the ability of the insulin receptor to phosphorylate IRS 1 and to dock one of its interacting molecules, i.e. PI 3-kinase. Finally, the inhibitory effect of okadaic acid on the stimulatory action of insulin on glucose transport suggests that the serine/threonine phosphorylation of IRS 1 might represent a key regulatory mechanism of insulin action.			TANTI, JF (corresponding author), FAC MED NICE,INST NATL SANT & RECH MED,U 145,AVE VALOMBROSE,F-06107 NICE 02,FRANCE.			Tanti, Jean-Francois/0000-0003-1782-1318				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARON V, 1992, J BIOL CHEM, V267, P23290; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BROWN NA, 1993, BIOCHEMISTRY-US, V32, P4659, DOI 10.1021/bi00068a025; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CORVERA S, 1991, J BIOL CHEM, V266, P9271; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; EGAN SE, 1993, SCIENCE, V363, P45; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; GIORGINO F, 1993, J CLIN INVEST, V91, P2020, DOI 10.1172/JCI116424; HARING H, 1986, BIOCHEM J, V234, P59; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SHISHEVA A, 1991, ENDOCRINOLOGY, V129, P2279; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1991, J BIOL CHEM, V266, P2099; TANTI JF, 1987, BIOCHEM J, V245, P19, DOI 10.1042/bj2450019; TANTI JF, 1993, AM J PHYSIOL, V265, pE868; WHITE MF, 1987, J BIOL CHEM, V262, P9769; YU KT, 1987, J BIOL CHEM, V262, P16677	51	262	273	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6051	6057						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119950				2022-12-25	WOS:A1994MY84000087
J	WITTUNG, P; NORDEN, B; KIM, SK; TAKAHASHI, M				WITTUNG, P; NORDEN, B; KIM, SK; TAKAHASHI, M			INTERACTIONS BETWEEN DNA-MOLECULES BOUND TO RECA FILAMENT - EFFECTS OF BASE COMPLEMENTARITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LINEAR DICHROISM; STRAND EXCHANGE; GENETIC-RECOMBINATION; ELECTRON-MICROSCOPY; PROTEIN-BINDING; DUPLEX DNA; COMPLEXES; STOICHIOMETRY; ACCESSIBILITY	To gain information about the mechanism of RecA-promoted strand exchange reactions in genetic recombination, we have investigated the environment of and interactions between DNA strands accommodated in complexes with Beck protein. DNA bound in different sites in the Reck filament was tested by adding stoichiometric amounts of DNAs of variable base compositions. For this purpose, poly(dA) labeled by fluorescent benzo(a)pyrenediol epoxide (BPDE), which binds covalently to N-6 of adenine, was used. The fluorescence intensity, anisotropy, and quenching by acrylamide provide information about the DNA environment in the complexes with Reck In the absence of extra DNA, binding of Reck to BPDE-poly(dA) only slightly affects both the intensity of the BPDE fluorescence and the accessibility of BPDE to acrylamide. However, a strongly increased fluorescence anisotropy shows that the mobility of the BPDE fluorophore is restricted in the Reck complex. Binding of a second and third single-stranded DNA to the RecA.BPDE-poly(dA) complex reduces the fluorescence intensity in a manner that depends on base complementarity. The change is large when the second and third DNAs are poly(dT), i.e. complementary to the already bound poly(dA) strand. In such a complex, the accessibility of BPDE to quencher is also reduced. When BPDE-poly(dA) was added as the second or third DNA in the Reck filament, the fluorescence intensity became smaller when the earlier bound DNA was complementary to the added DNA. These results indicate that all three DNA strands are interacting with each other in the Beck filament. BPDE-modified poly(dA) forms a duplex with poly(dT), whereupon the fluorescence of BPDE is strongly decreased. Binding of Reck to this duplex DNA increases the BPDE fluorescence, suggesting a destabilization of the duplex. Finally, we also find indications of base complementary interactions between single-stranded and double-stranded DNAs bound to the Beck filament.	YEUNGNAM UNIV,DEPT CHEM,KYOUNG BUK 712749,SOUTH KOREA; UNIV PARIS 11,INST CURIE,ETUD MUTAGENESE & CANCEROGENESE GRP,CNRS,URA 1342,F-91405 ORSAY,FRANCE	Yeungnam University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	WITTUNG, P (corresponding author), CHALMERS UNIV TECHNOL,DEPT PHYS CHEM,S-41296 GOTHENBURG,SWEDEN.		Norden, Bengt/ABE-3675-2020; wittung-stafshede, pernilla/AAV-4392-2021	Norden, Bengt/0000-0002-7946-200X; wittung-stafshede, pernilla/0000-0003-1058-1964				Cantor C.R., 1980, BIOPHYS CHEM; CHABBERT M, 1991, J BIOL CHEM, V266, P5395; CHOW SA, 1988, J BIOL CHEM, V263, P3335; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; GEACINTOV NE, 1990, MOL BASIS SPECIFICIT, P433; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; KIM SK, 1988, BASIC LIFE SCI, V51, P187; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NORDEN B, 1992, J MOL BIOL, V226, P1175, DOI 10.1016/0022-2836(92)91060-3; OGAWA T, 1993, SCIENCE, V259, P1892; PUGH BF, 1989, J MOL BIOL, V205, P487, DOI 10.1016/0022-2836(89)90219-2; PUGH BF, 1987, J BIOL CHEM, V262, P1337; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; TAKAHASHI M, 1991, FEBS LETT, V279, P270, DOI 10.1016/0014-5793(91)80165-Y; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; TAKAHASHI M, 1989, J BIOL CHEM, V264, P288; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9	33	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5799	5803						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119921				2022-12-25	WOS:A1994MY84000051
J	ARGAET, VP; WILSON, T; DAVIDSON, BE				ARGAET, VP; WILSON, T; DAVIDSON, BE			PURIFICATION OF THE ESCHERICHIA-COLI REGULATORY PROTEIN TYRR AND ANALYSIS OF ITS INTERACTIONS WITH ATP, TYROSINE, PHENYLALANINE, AND TRYPTOPHAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T7 RNA-POLYMERASE; NUCLEOTIDE-SEQUENCE; BINDING-PROTEIN; TRANSCRIPTION; GENE; K-12; REPRESSOR; EXPRESSION; OPERATOR; CHROMATOGRAPHY	A plasmid that directs the overexpression of the Escherichia coli regulatory protein TyrR was constructed. Cell extracts of an E. coli strain harboring the plasmid were used to develop a two-step procedure for purifying homogenous TyrR. The weight-average molecular weight of the pure protein was determined by sedimentation equilibrium analyses to be 110,000 +/- 5,000, indicating that native TyrR is a homodimer. The binding of ligands to TyrR was investigated by the techniques of sedimentation velocity meniscus depletion and steady state dialysis. One mol of ATP bound per mol of TyrR subunit with half-maximal saturation at 5-7 mu M ATP. ATP binding curves exhibited positive cooperativity, with a value of 1.3 for the Hill constant, n(H). The binding was not significantly affected by the presence of either 500 mu M tyrosine or 2 mM phenylalanine. Binding of tyrosine to TyrR (40 mu M subunit) could not be detected in the absence of ATP, indicating that the TyrR-tyrosine complex has a dissociation constant (K-d) in excess of 180 mu M. However, binding was observed in the presence of saturating ATP (200 mu M), where 1 mol of tyrosine bound per mol of TyrR subunit with half-maximal saturation at 50 mu M tyrosine. The binding exhibited positive cooperativity (n(H) of 1.2). There was no detectable binding of either phenylalanine or tryptophan to TyrR (40 mu M) in the absence or presence of 200 mu M ATP, indicating that any binding of these amino acids to TyrR or TyrR.ATP also has a Rd in excess of 180 mu M. Each of these amino acids was found to inhibit the binding of tyrosine by TyrR.ATP when present in large molar excess (20 mu M tyrosine and 2 or 10 mM phenylalanine or tryptophan), indicating that TyrR binds each of these amino acids, albeit more weakly than it binds tyrosine.	UNIV MELBOURNE,RUSSELL GRIMWADE SCH BIOCHEM,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne								ANDERSON WF, 1981, NATURE, V290, P754, DOI 10.1038/290754a0; ARGYROPOULOS VP, 1989, THESIS U MELBOURNE; ARGYROPOULOS VP, 1988, P AUST BIOCHEM SOC, V20, pSP34; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BALDWIN GS, 1981, ARCH BIOCHEM BIOPHYS, V211, P76, DOI 10.1016/0003-9861(81)90431-8; BASEGGIO N, 1990, J BACTERIOL, V172, P2547, DOI 10.1128/jb.172.5.2547-2557.1990; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BORCK K, 1976, MOL GEN GENET, V146, P199, DOI 10.1007/BF00268089; BROWN KD, 1968, GENETICS, V60, P31; BROWN KD, 1970, J BACTERIOL, V104, P177, DOI 10.1128/JB.104.1.177-188.1970; CAMAKARIS H, 1982, J BACTERIOL, V150, P70, DOI 10.1128/JB.150.1.70-75.1982; CAMAKARIS J, 1974, J BACTERIOL, V120, P590, DOI 10.1128/JB.120.2.590-597.1974; CAMPBELL JL, 1978, P NATL ACAD SCI USA, V75, P2276, DOI 10.1073/pnas.75.5.2276; CHYE ML, 1987, J BACTERIOL, V169, P386, DOI 10.1128/jb.169.1.386-393.1987; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; CORNISH EC, 1982, J BACTERIOL, V152, P1276; CORNISH EC, 1986, J BIOL CHEM, V261, P403; CUI JS, 1993, J BIOL CHEM, V268, P13023; CUI JS, 1993, J BIOL CHEM, V268, P5040; DUDZINSKI PK, 1976, PREP BIOCHEM, V6, P113, DOI 10.1080/00327487608061606; DUSHA I, 1976, BIOCHIM BIOPHYS ACTA, V438, P563, DOI 10.1016/0005-2744(76)90272-2; FOLKMANIS A, 1976, P NATL ACAD SCI USA, V73, P2249, DOI 10.1073/pnas.73.7.2249; GARNER CC, 1985, J BIOL CHEM, V260, P3820; GAVINI N, 1991, J BIOL CHEM, V266, P7750; GETHING MJ, 1978, EUR J BIOCHEM, V86, P165, DOI 10.1111/j.1432-1033.1978.tb12296.x; GETHING MJH, 1976, EUR J BIOCHEM, V71, P317, DOI 10.1111/j.1432-1033.1976.tb11118.x; GIBSON F, 1968, BIOCHEM PREP, V12, P94; GREGO B, 1985, EUR J BIOCHEM, V148, P485, DOI 10.1111/j.1432-1033.1985.tb08865.x; HEATWOLE VM, 1991, J BACTERIOL, V173, P108, DOI 10.1128/jb.173.1.108-115.1991; HENIKOFF S, 1988, NUCLEIC ACIDS RES, V16, P6191, DOI 10.1093/nar/16.13.6191; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HOWLETT GJ, 1978, ARCH BIOCHEM BIOPHYS, V190, P809, DOI 10.1016/0003-9861(78)90341-7; HUDSON GS, 1983, J BIOL CHEM, V258, P3114; HUDSON GS, 1984, J MOL BIOL, V180, P1023, DOI 10.1016/0022-2836(84)90269-9; ITO J, 1969, J BACTERIOL, V97, P734, DOI 10.1128/JB.97.2.734-742.1969; JOACHIMIAK A, 1983, P NATL ACAD SCI-BIOL, V80, P668, DOI 10.1073/pnas.80.3.668; KASIAN PA, 1986, J BACTERIOL, V167, P556, DOI 10.1128/jb.167.2.556-561.1986; KASIAN PA, 1987, THESIS U MELBOURNE V; Miller J.H., 1972, EXPT MOL GENETICS; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MUDAY GK, 1991, J BACTERIOL, V173, P3930, DOI 10.1128/JB.173.12.3930-3932.1991; PITTARD AJ, 1991, MOL MICROBIOL, V5, P1585, DOI 10.1111/j.1365-2958.1991.tb01904.x; PITTARD AJ, 1987, ESCHERICHIA COLI SAL, P368; RANDERATH K, 1966, J CHROMATOGR, V22, P110, DOI 10.1016/S0021-9673(01)97076-1; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RODRIGUEZ R, 1976, MOL MECHANISMS CONTR; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SARSERO JP, 1991, J BACTERIOL, V1734, P133; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMPSON RJ, 1971, J BACTERIOL, V107, P798, DOI 10.1128/JB.107.3.798-805.1971; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VIDALINGIGLIARDI D, 1985, NUCLEIC ACIDS RES, V13, P5919, DOI 10.1093/nar/13.16.5919; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WHIPP MJ, 1977, J BACTERIOL, V132, P453, DOI 10.1128/JB.132.2.453-461.1977; YANG J, 1993, J BACTERIOL, V175, P1767, DOI 10.1128/JB.175.6.1767-1776.1993; YANOFSKY C, 1984, J BACTERIOL, V158, P1018, DOI 10.1128/JB.158.3.1018-1024.1984; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZAMYATNIN AA, 1972, PROG BIOPHYS MOL BIO, V24, P109	62	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5171	5178						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106498				2022-12-25	WOS:A1994MX57100075
J	LEHEL, C; OLAH, Z; MISCHAK, H; MUSHINSKI, JF; ANDERSON, WB				LEHEL, C; OLAH, Z; MISCHAK, H; MUSHINSKI, JF; ANDERSON, WB			OVEREXPRESSED PROTEIN-KINASE C-DELTA AND C-EPSILON SUBTYPES IN NIH 3T3 CELLS EXHIBIT DIFFERENTIAL SUBCELLULAR-LOCALIZATION AND DIFFERENTIAL REGULATION OF SODIUM-DEPENDENT PHOSPHATE-UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LLC-PK1 CELLS; PKC-EPSILON; RAT-BRAIN; EXPRESSION; COTRANSPORT; ACTIVATION; CDNA; SPECIFICITY; STIMULATION; MECHANISMS	To examine the biological properties of protein kinase C (PHC)-delta and -epsilon NIH 3T3 cells were stably transfected with metallothionein-based expression vectors that overexpressed these isoforms. In addition to their inducibility by Zn2+, the protein levels of these two PKC subtypes, but not that of endogenous PKC-alpha, increased with increasing cell density. An unexpected role for Mg2+ in the subcellular localization of PKC-delta was found. This isoenzyme was predominantly membrane-associated when cell fractionation was carried out in the absence of Mg2+ but cytosolic when the fractionation was performed in the presence of 10 mM Mg2+. In contrast, the predominant localization of cytosolic PKC-alpha and of membrane-associated PKC-epsilon was not influenced by Mg2+. In vivo and in vitro studies of [H-3]phorbol 12,13-dibutyrate binding in the overexpressing cell lines confirmed the cytosolic localization of PHC-alpha, the membrane-associated state of PHC-epsilon, and the presence of PKC-delta at both locations. Readdition of serum for 5 min to serum-starved, quiescent cell lines initiated the redistribution of PKC-alpha to the particulate fraction, while the location of PKC-delta and PKC-epsilon was not affected. Zn2+-induced overexpression of PKC-delta- and PKC-epsilon-stimulated sodium dependent phosphate uptake. Overexpression of PKC-delta caused an increase in the V-max of Na+/P-i uptake, while overexpression of PKC-epsilon resulted in a decrease in K-m, for orthophosphate. A further stimulation of Na+/P-i uptake in the overexpressing cells could be achieved by phorbol ester activation of endogenous PKC-alpha. These results suggest that each of the three PKC isotypes contribute to the regulation of sodium-dependent phosphate uptake, but through distinct mechanisms.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NCI,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011	Mischak, Harald/0000-0003-0323-0306				BAXTER G, 1992, J BIOL CHEM, V267, P1910; EXTON JH, 1990, J BIOL CHEM, V265, P1; GROSS JL, 1991, ANAL BIOCHEM, V193, P149, DOI 10.1016/0003-2697(91)90055-X; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HILBORN DA, 1975, J CELL PHYSL, V87, P111; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; HUANG K-P, 1990, Biofactors, V2, P171; HUBBARD SR, 1991, SCIENCE, V254, P1776; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KINOSHITA Y, 1987, BIOCHEM BIOPH RES CO, V144, P741, DOI 10.1016/S0006-291X(87)80027-X; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; MOHRMANN I, 1986, BIOCHIM BIOPHYS ACTA, V860, P35, DOI 10.1016/0005-2736(86)90495-5; MURER H, 1991, AM J PHYSIOL, V260, pC885, DOI 10.1152/ajpcell.1991.260.5.C885; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OLAH Z, 1993, BIOCHIM BIOPHYS ACTA, V1176, P333, DOI 10.1016/0167-4889(93)90063-U; OLAH Z, 1990, NEUROCHEM RES, V15, P515, DOI 10.1007/BF00966209; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; QUAMME G, 1989, AM J PHYSIOL, V257, pF967, DOI 10.1152/ajprenal.1989.257.6.F967; RAYMOND JR, 1989, J BIOL CHEM, V264, P21943; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SHARMA P, 1991, BIOCHEM BIOPH RES CO, V177, P1033, DOI 10.1016/0006-291X(91)90642-K; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608	36	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4761	4766						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106444				2022-12-25	WOS:A1994MX57100013
J	KIM, KS; LEE, MK; CARROLL, J; JOH, TH				KIM, KS; LEE, MK; CARROLL, J; JOH, TH			BOTH THE BASAL AND INDUCIBLE TRANSCRIPTION OF THE TYROSINE-HYDROXYLASE GENE ARE DEPENDENT UPON A CAMP RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; RAT SOMATOSTATIN GENE; NERVE GROWTH-FACTOR; NUCLEAR FACTOR CREB; CYCLIC-AMP; REGULATORY ELEMENTS; FUNCTIONAL-ANALYSIS; ALPHA-SUBUNIT; C-FOS	The cAMP response element (CRE) mediates cAMP responsiveness in many eukaryotic genes (Roesler, W. J., Vandenbark, G. R., and Hansen, R. W. (1988) J. Biol. Chem. 263, 9063-9066). The tyrosine hydroxylase gene (TH) contains a single copy of a consensus CRE at -45 to -38 base pair (bp) upstream of the transcription initiation site. Deletional and mutational analyses of the upstream 2400-base pair region of the rat TH gene using transient transfection assay demonstrated that the CRE was essential for both cAMP-mediated induction and basal transcription of the TH gene. Another domain between -365 and -151 bp, containing the AP1 site, contributed to transcription to a smaller degree. Thus, the CRE appears to play an important dual role as a basal promoter element and an inducible enhancer for TH transcription. Interactions between the DNA binding factors in nuclear extract and CRE-containing oligonucleotides were investigated by gel retardation and competition assays. Oligonucleotides corresponding to the CRE regions of the TH or somatostatin gene gave rise to a pair of distinct protein-DNA complexes with identical mobilities in the gel retardation assay, suggesting that similar nuclear factor(s) might bind to the CREs of the TH and somatostatin genes. This study emphasizes a fundamental role of the CRE in transcriptional activation of the TH gene in catecholaminergic cells.	CORNELL UNIV,COLL MED,BURKE MED RES INST,MOLEC NEUROBIOL LAB,785 MAMARONECK AVE,WHITE PLAINS,NY 10605	Cornell University					NIMH NIH HHS [MH 48866, MH 24285] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH048866, R01MH048866, R37MH024285, R01MH024285] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BLACK IB, 1987, SCIENCE, V236, P1263, DOI 10.1126/science.2884727; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CARROLL JM, 1991, J MOL NEUROSCI, V3, P65, DOI 10.1007/BF02885527; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FADER D, 1990, MOL BRAIN RES, V8, P25, DOI 10.1016/0169-328X(90)90005-X; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GANDELMAN KY, 1990, J NEUROCHEM, V55, P2149, DOI 10.1111/j.1471-4159.1990.tb05811.x; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARRINGTON CA, 1987, NUCLEIC ACIDS RES, V15, P2363, DOI 10.1093/nar/15.5.2363; HAWLEY RJ, 1992, J NEUROSCI, V12, P2573; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HUANG ZM, 1991, MOL BRAIN RES, V11, P309, DOI 10.1016/0169-328X(91)90040-5; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; ISHIGURO H, 1993, IN PRESS J BIOL CHEM; JOH TH, 1978, P NATL ACAD SCI USA, V75, P4744, DOI 10.1073/pnas.75.10.4744; KANEDA N, 1991, NEURON, V6, P583, DOI 10.1016/0896-6273(91)90061-4; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSS RA, 1981, CELL MOL NEUROBIOL, V1, P301, DOI 10.1007/BF00710685; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SHORT S, 1991, J BIOL CHEM, V266, P22164; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; THOENEN H, 1969, J PHARMACOL EXP THER, V169, P249; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	53	206	208	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15689	15695						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101843				2022-12-25	WOS:A1993LN30500056
J	BROMBERG, Y; SHANI, E; JOSEPH, G; GORZALCZANY, Y; SPERLING, O; PICK, E				BROMBERG, Y; SHANI, E; JOSEPH, G; GORZALCZANY, Y; SPERLING, O; PICK, E			THE GDP-BOUND FORM OF THE SMALL G-PROTEIN RAC1 P21 IS A POTENT ACTIVATOR OF THE SUPEROXIDE-FORMING NADPH OXIDASE OF MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-FREE SYSTEM; GTP-BINDING PROTEIN; SODIUM DODECYL-SULFATE; CHRONIC GRANULOMATOUS-DISEASE; HUMAN-NEUTROPHILS; GUANINE-NUCLEOTIDES; REGULATORY PROTEIN; EXCHANGE PROTEINS; ARACHIDONIC-ACID; CYTOSOLIC FACTOR	Phagocytes produce superoxide by the assembly of a multicomponent complex that utilizes NADPH for the reduction of molecular oxygen (NADPH oxidase). The components participating in the assembly are a membrane-bound flavocytochrome and three cytosolic proteins, one of which was shown to be a dimer of the small GTP-binding protein (G protein) Rac1 p21 or Rac2 p21 with GDP dissociation inhibitor for Rho (Rho GDI). We determined the identity and quantity of the nucleotide bound to Rac1 p21 by high performance anion exchange chromatography of extracts prepared from highly purified Rac1 p21-Rho GDI, isolated from guinea pig macrophage cytosol. Rac1 p21 contained only GDP at a ratio of close to 1 mol of GDP per mol of G protein. The GDP-bound form of Rac1 p21 complexed to Rho GDI functioned as a potent activator of NADPB oxidase in a cell-free system that contained no free GTP or ATP. We propose that the GDP-bound form of Rac1 p21 might be the physiological activator of NADPH oxidase in macrophages, following its dissociation from Rho GDI, and that nucleotide exchange or conversion to GTP is not necessarily involved.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IMMUNOPHARMACOL LAB,IL-69978 TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,DEPT CHEM PATHOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine			Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233				ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AHARONI I, 1990, J LEUKOCYTE BIOL, V48, P107, DOI 10.1002/jlb.48.2.107; ANDO S, 1992, J BIOL CHEM, V267, P25709; BOLSCHER BGJM, 1989, J CLIN INVEST, V83, P757, DOI 10.1172/JCI113954; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHANG TH, 1993, J BIOL CHEM, V268, P775; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DAVYDOVA EK, 1993, EUR J BIOCHEM, V215, P291, DOI 10.1111/j.1432-1033.1993.tb18034.x; DOUSSIERE J, 1988, BIOCHEM BIOPH RES CO, V152, P993, DOI 10.1016/S0006-291X(88)80382-6; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GABIG TG, 1990, J IMMUNOL, V145, P945; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HARTWICK RA, 1975, J CHROMATOGR, V112, P651, DOI 10.1016/S0021-9673(00)99994-1; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; ISOMURA M, 1991, ONCOGENE, V6, P119; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PERRETT D, 1987, HPLC SMALL MOL PRACT, P221; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; PICK E, 1989, J IMMUNOL, V143, P4180; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1992, INFLAMMATION BASIC P, P589; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEIFERT R, 1986, FEBS LETT, V205, P161, DOI 10.1016/0014-5793(86)80886-9; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; UEDA T, 1990, J BIOL CHEM, V265, P9373; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WEISS O, 1989, J BIOL CHEM, V264, P21066	47	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7055	7058						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125910				2022-12-25	WOS:A1994NA03200003
J	NEBL, G; MERMOD, N; CATO, ACB				NEBL, G; MERMOD, N; CATO, ACB			POSTTRANSCRIPTIONAL DOWN-REGULATION OF EXPRESSION OF TRANSCRIPTION FACTOR NF1 BY HA-RAS ONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; NUCLEAR FACTOR-I; DNA-BINDING PROTEIN; LONG TERMINAL REPEAT; GROWTH FACTOR-BETA; MESSENGER-RNA; ADENOVIRUS DNA; DEPENDENT TRANSCRIPTION; GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION	NF1 is a family of polypeptides that binds to discrete DNA motifs and plays varying roles in the regulation of gene expression. These polypeptides are also thought to mediate the expression of differentiation-specific markers such as adipocyte and mammary cell type-specific genes. The expression of a number of cellular differentiation-specific markers is down-regulated during neoplastic transformation. We therefore investigated whether oncogenic transformation interferes with the action of NF1. Stable transfection of activated Ha-ras into a number of murine cells correlated with a down-regulation of the expression of the NF1 genes NF1/CTF and NF1/X The down-regulation was not at the transcriptional level but at the level of stability of the NF1 mRNAs. The level of the DNA binding activity of the NF1 proteins was also reduced in Ha-v-ras-transformed cells, and the expression of a gene that depends on this family of transcription factors was specifically repressed. These results demonstrate that an activated Ha-ras-induced pathway destabilizes the half-life of mRNAs encoding specific members in the NF1 family of transcription factors, which leads to a decrease in NF1-dependent gene expression.	KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET,D-76021 KARLSRUHE,GERMANY; UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND	Helmholtz Association; Karlsruhe Institute of Technology; University of Lausanne			Cato, Andrew C. B./H-2071-2013	Cato, Andrew C. B./0000-0001-8508-3834				ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AVVEDIMENTO VE, 1988, P NATL ACAD SCI USA, V85, P1744, DOI 10.1073/pnas.85.6.1744; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CATO ACB, 1990, ONCOGENE, V5, P103; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; HARTIG E, 1993, J VIROL, V67, P813; HARTIG E, 1993, MOL BIOL, V12, P37; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; HYNES NE, 1987, CELLULAR MOL BIOL MA, P321; INOUE T, 1990, J BIOL CHEM, V265, P19065; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUMAR CC, 1992, CANCER RES, V52, P6877; KUMAR CC, 1992, CELL GROWTH DIFFER, V3, P1; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LUBON H, 1988, BIOCHEM J, V256, P391, DOI 10.1042/bj2560391; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MIURA M, 1989, GENE, V75, P31; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; OWEN RD, 1987, MOL CELL BIOL, V7, P2512, DOI 10.1128/MCB.7.7.2512; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; VACCA A, 1989, MOL ENDOCRINOL, V3, P1659, DOI 10.1210/mend-3-10-1659; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	55	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7371	7378						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125955				2022-12-25	WOS:A1994NA03200054
J	SEKIMOTO, T; FUKUI, T; TANIZAWA, K				SEKIMOTO, T; FUKUI, T; TANIZAWA, K			INVOLVEMENT OF CONSERVED LYSINE-68 OF BACILLUS-STEAROTHERMOPHILUS LEUCINE DEHYDROGENASE IN SUBSTRATE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DEPENDENT GLUTAMATE-DEHYDROGENASE; COMPLETE NUCLEOTIDE-SEQUENCE; NAD(P)+-DEPENDENT DEHYDROGENASES; PHENYLALANINE DEHYDROGENASE; BOVINE ENZYME; GENE; CLONING; PHOSPHATE; LIVER	Lysine 68 of Bacillus stearothermophilus leucine dehydrogenase is highly conserved in the corresponding regions of NAD(P)(+) dependent amino acid dehydrogenase sequences. To elucidate its functional role, the lysyl residue of the recombinant enzyme has been replaced with alanine or arginine by site directed mutagenesis. Either mutation resulted in nearly complete loss of activity in the oxidative deamination, whereas only the mutation to alanine led to a marked increase in Michaelis constants for both amino and keto acid substrates. On the other hand, an ionizable group in the wild-type enzyme with a pK(a) value of 10.1-10.7, which must be protonated for binding of substrate and competitive inhibitor with an alpha-carboxyl group, was unobservable in both mutant enzymes. These results altogether led to the conclusion that Lys 68 is located at the active site of the enzyme and involved in binding of the alpha-carboxyl group of substrate through an ionic interaction. In addition, the alanine mutant enzyme that is almost inactive in the deamination but significantly active in the amination was greatly stimulated by exogenously added ammonia, suggesting that proper binding of the substrate alpha-carboxyl group at Lys-68 is essential for catalysis.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN	Osaka University								BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BIRKTOFT JJ, 1984, PEPT PROTEIN REV, V4, P1; BLUMENTHAL KM, 1975, J BIOL CHEM, V250, P3644; Cleland W W, 1979, Methods Enzymol, V63, P103; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; HABERLAND ME, 1980, J BIOL CHEM, V255, P7984; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; JULLIARD JH, 1979, J BIOL CHEM, V254, P3427; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURODA SI, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00456a025; LILLEY KS, 1991, BIOCHIM BIOPHYS ACTA, V1080, P191, DOI 10.1016/0167-4838(91)90001-G; MATSUYAMA T, 1992, J BIOCHEM-TOKYO, V112, P258, DOI 10.1093/oxfordjournals.jbchem.a123887; MCPHERSON MJ, 1983, NUCLEIC ACIDS RES, V11, P5257, DOI 10.1093/nar/11.15.5257; MOON K, 1973, J BIOL CHEM, V248, P3082; MOON K, 1972, P NATL ACAD SCI USA, V69, P1380, DOI 10.1073/pnas.69.6.1380; MOYE WS, 1985, J BIOL CHEM, V260, P8502; NAGATA S, 1988, BIOCHEMISTRY-US, V27, P9056, DOI 10.1021/bi00425a026; OKAZAKI N, 1988, GENE, V63, P337, DOI 10.1016/0378-1119(88)90537-9; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SEKIMOTO T, 1993, J BIOL CHEM, V268, P27039; SINGH N, 1993, J BIOL CHEM, V268, P21; TAKADA H, 1991, J BIOCHEM-TOKYO, V109, P371, DOI 10.1093/oxfordjournals.jbchem.a123388; VALLE F, 1984, GENE, V27, P193, DOI 10.1016/0378-1119(84)90140-9; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WOOTTON JC, 1974, P NATL ACAD SCI USA, V71, P4361, DOI 10.1073/pnas.71.11.4361	26	16	17	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7262	7266						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125938				2022-12-25	WOS:A1994NA03200037
J	JOHANNES, FJ; PRESTLE, J; EIS, S; OBERHAGEMANN, P; PFIZENMAIER, K				JOHANNES, FJ; PRESTLE, J; EIS, S; OBERHAGEMANN, P; PFIZENMAIER, K			PKCU IS A NOVEL, ATYPICAL MEMBER OF THE PROTEIN-KINASE-C FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; NPKC; PHOSPHORYLATION; ACTIVATION; THREONINE; MESSENGER; DNA	We have isolated the full-length cDNA of a novel human serine/threonine protein kinase gene. The deduced protein sequence shows strong homology to conserved domains of members of the protein kinase C (PRC) subfamily. Homologies reside in the duplex zinc-finger-like cysteine-rich motif and in the protein kinase domain. The lack of the C-2 domain of the Ca2(+)-dependent PKCs and the presence of a unique NH2-terminal sequence with a potential signal peptide and a transmembrane domain suggest that PKC mu is a novel member of the subgroup of atypical PKCs. An open reading frame coding for 912 amino acids directs an in vitro translation product with an apparent M(r) of 115,000. In vitro phorbol ester binding studies and kinase assays with lysates of cells overexpressing PKC mu showed phorbol ester-independent kinase activity, autophosphorylation, and, in normal rat kidney (NRK) cells, predominant phosphorylation of a 30-kDa protein at serine residues. Southern analysis revealed that PKC mu is a single copy gene located on human chromosome 21. There is constitutive low level expression of the human PKC mu gene in normal tissues with a single transcript of 3.8 kilobases and elevated expression levels in selected tumor cell lines. These data suggest a role of PKC mu in signal transduction pathways related to growth control.	UNIV STUTTGART,INST CELL BIOL & IMMUNOL,D-70569 STUTTGART,GERMANY	University of Stuttgart								ADEN DP, 1978, NATURE, V271, P375, DOI 10.1038/271375a0; AKITA Y, 1990, J BIOL CHEM, V265, P354; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P59; BLOCK C, 1992, J BIOL CHEM, V267, P19824; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Devereux J., 1984, NUCLEIC ACIDS RES, V12, P287; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FISCHER T, 1990, Cytokine, V2, P157, DOI 10.1016/1043-4666(90)90010-Q; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JOHANNES FJ, 1992, TRENDS GENET, V8, P48; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIGUCHI M, 1985, BIOMED PHARMACOTHER, V39, P372; TOKUNAGA KY, 1982, CANCER RES, V47, P5616; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATANABE S, 1991, CURR OPIN BIOTECH, V2, P227, DOI 10.1016/0958-1669(91)90015-W; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	38	517	526	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6140	6148						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119958				2022-12-25	WOS:A1994MY84000099
J	KOCH, WJ; HAWES, BE; INGLESE, J; LUTTRELL, LM; LEFKOWITZ, RJ				KOCH, WJ; HAWES, BE; INGLESE, J; LUTTRELL, LM; LEFKOWITZ, RJ			CELLULAR EXPRESSION OF THE CARBOXYL-TERMINUS OF A G-PROTEIN-COUPLED RECEPTOR KINASE ATTENUATES G(BETA-GAMMA)-MEDIATED SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; MUSCARINIC ACETYLCHOLINE-RECEPTORS; PHOSPHOLIPASE-C; ADENYLYL CYCLASE; DEPENDENT PHOSPHORYLATION; STIMULATION; ACTIVATION; TRANSDUCTION; HYDROLYSIS	The beta gamma subunits (G(beta gamma)) of heterotrimeric G proteins modulate the activity of several signal-transducing effector molecules including G protein-coupled receptor kinases. G(beta gamma) binds to the carboxyl terminus of the beta-adrenergic receptor kinase (beta ARK) and regulates its activity. To investigate the effect of such a G(beta gamma)-binding domain on heterologous G(beta gamma) interactions, various receptors that can stimulate phospholipase C and/or type II adenylate cyclase were coexpressed in COS-7 cells with the carboxyl terminus of beta ARK1. Phosphoinositol hydrolysis in response to activation of receptors that stimulate phospholipase C via G(i beta gamma) (alpha(2)-adrenergic and M2-muscarinic cholinergic receptors) was markedly inhibited by the coexpressed beta ARK1 polypeptide, whereas that mediated by G(q alpha) subunits (alpha(1)-adrenergic and M1-muscarinic cholinergic receptors) was unaffected. Increased cellular cAMP levels due to stimulation of receptors and coexpressed adenylate cyclase II displayed marked inhibition in the presence of the beta ARK1 polypeptide. Moreover, inhibition of adenylate cyclase produced by alpha(2)-adrenergic receptor stimulation (a G(i alpha)-mediated process) was unaffected, indicating that the beta ARK1 polypeptide provides a useful tool for distinguishing between G(alpha) and G(beta gamma) pathways.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLANK JL, 1992, J BIOL CHEM, V267, P23069; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; COROZZI A, 1993, FEBS LETT, V315, P340; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; EASON MG, 1992, J BIOL CHEM, V267; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; PARK DG, 1993, J BIOL CHEM, V268, P4573; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1992, J BIOL CHEM, V267, P25798	35	377	381	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6193	6197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119963				2022-12-25	WOS:A1994MY84000106
J	MCCORMACK, FX; CALVERT, HM; WATSON, PA; SMITH, DL; MASON, RJ; VOELKER, DR				MCCORMACK, FX; CALVERT, HM; WATSON, PA; SMITH, DL; MASON, RJ; VOELKER, DR			THE STRUCTURE AND FUNCTION OF SURFACTANT PROTEIN-A - HYDROXYPROLINE-DEFICIENT AND CARBOHYDRATE-DEFICIENT MUTANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT; II CELLS; SP-A; HIGH-AFFINITY; PHOSPHOLIPID SECRETION; RECOGNITION DOMAINS; COLLAGENOUS DOMAIN; CALCIUM-IONS; LUNG; RAT	Pulmonary surfactant protein A (SP-A) regulates the uptake and secretion of phospholipid by alveolar type II cells and is an important component of surfactant lipid aggregates. In an attempt to understand how specific structural domains of SP-A relate to the function of the protein, we used site-directed mutagenesis of the cDNA for SP-A and heterologous expression with baculovirus vectors. Synthesis of the wild type SP-A in insect cells resulted in a form of the protein in which proline residues were not hydroxylated and that is denoted Sp-A(hyp). Three mutant SP-As with substitutions in the consensus sequences for glycosylation (Sp-A(hyp,glc)) to prevent N-linked oligosaccharide attachment at Asn(1) and Asn(187) were produced, individually and in tandem. The Sp-A(hyp) was glycosylated at both the Asn(1) and Asn(187) positions, demonstrated partial sulfhydryl-dependent oligomerization, and formed incomplete oligomers in solution. The Sp-A(hyp) and Sp-A(hyp,glc) bound to immobilized carbohydrate and to phospholipid liposomes and partially competed for occupancy of a plasma membrane receptor for SP-A. The SP-A(hyp) and the Sp-A(hyp,glc) were equally effective inhibitors of the secretion of surfactant lipids from isolated type II cells (IC50 = 0.5 mu g/ml) and aggregated phospholipid liposomes at 20 degrees C. All of the recombinant SP As demonstrated markedly reduced aggregation of lipid at 37 degrees C. We conclude that the hydroxylation of proline residues is required for perfect oligomerization of SP-A and for thermal stability in the interaction with lipid. Furthermore, recombinant SP-A is able to inhibit the secretion of phospholipid from isolated type II cells and to aggregate lipid vesicles independent of the presence of N-linked carbohydrate or the site of glycosylation.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80206	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	MCCORMACK, FX (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,LORD & TAYLOR LAB LUNG BIOCHEM,K-601,1400 JACKSON ST,DENVER,CO 80206, USA.		McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045286] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02423, HL-45286] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS E, 1978, SCIENCE, V202, P591, DOI 10.1126/science.212833; AKINO T, 1990, American Review of Respiratory Disease, V141, pA698; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BENSON BJ, 1984, BIOCHIM BIOPHYS ACTA, V793, P18, DOI 10.1016/0005-2760(84)90048-1; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAAGSMAN HP, 1991, BIOCHEM J, V275, P273, DOI 10.1042/bj2750273; HAWGOOD S, 1985, BIOCHEM SOC T, V13, P1092, DOI 10.1042/bst0131092; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAWADA H, 1989, AM REV RESPIR DIS, V140, P460, DOI 10.1164/ajrccm/140.2.460; KING RJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P294, DOI 10.1016/0005-2760(89)90114-8; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; KIVIRIKKO KI, 1986, ANN NY ACAD SCI, V460, P187; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KUROKI Y, 1991, BIOCHEM INT, V24, P225; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MCCORMACK FX, 1990, BIOCHIM BIOPHYS ACTA, V1087, P190, DOI 10.1016/0167-4781(90)90204-F; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V969, P176, DOI 10.1016/0167-4889(88)90073-0; PROCKOP DJ, 1976, BIOCH COLLAGEN, P161; RICE WR, 1988, BIOCHIM BIOPHYS ACTA, V958, P205, DOI 10.1016/0005-2760(88)90178-6; ROSS GF, 1986, J BIOL CHEM, V261, P14283; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SEE PM, 1988, PROTEIN STRUCTURE PR, P1; SUMMERS MD, 1988, MANUAL BACULOVIRUS V; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; VANNESS KP, 1988, COMP BIOCHEM PHYS B, V91, P531, DOI 10.1016/0305-0491(88)90017-X; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1986, J APPL PHYSIOL, V60, P817, DOI 10.1152/jappl.1986.60.3.817; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410	46	72	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5833	5841						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119925				2022-12-25	WOS:A1994MY84000056
J	MIKI, H; MIURA, K; MATUOKA, K; NAKATA, T; HIROKAWA, N; ORITA, S; KAIBUCHI, R; TAKAI, Y; TAKENAWA, T				MIKI, H; MIURA, K; MATUOKA, K; NAKATA, T; HIROKAWA, N; ORITA, S; KAIBUCHI, R; TAKAI, Y; TAKENAWA, T			ASSOCIATION OF ASH/GRB-2 WITH DYNAMIN THROUGH THE SRC HOMOLOGY-3 DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE KINASES; SH3 DOMAINS; PROTEIN; MICROTUBULES; SHIBIRE	Ash/Grb-2 is an adaptor protein composed only of Src homology (SH) 2 and SH3 domains that is considered to be essential for Res activation. To clarify the downstream of Ash signaling, we investigated Ash-bound proteins. Ash-glutathione S-transferase (GST) fusion proteins were used to affinity-purify proteins bound to Ash. We found 180-, 150-, 100, and 70-kDa proteins bound to GST-Ash, among which the 100 kDa protein was found to be dynamin by amino acid sequencing and Western blot with anti-dynamin antibody. Next, the in vitro and in vivo associations between Ash and dynamin were examined using PC12 cells. Dynamin in PC12 cell lysates bound to GST-Ash independent of NGF treatment. Also, Ash and dynamin co-precipitated when cell lysates of PC12 were immunoprecipitated with anti-Ash antibody or anti-dynamin antibody, Using various GST-Ash constructs, we studied the importance of the individual domains in binding and found that the SH3 domain is necessary for binding, This binding was inhibited by a synthetic peptide (GPPPQVPSRPNRC, amino acids 827-838 in dynamin). These data show that Ash SH3 domains bind to the proline-rich region of dynamin. Considering the function of dynamin in membrane trafficking, Ash may regulate endocytosis in addition to Res activation.	UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,MINATO KU,TOKYO,TOKYO 108,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO,TOKYO 173,JAPAN; UNIV TOKYO,SCH MED,DEPT ANAT & CELL BIOL,BUNKYO KU,TOKYO,TOKYO 113,JAPAN; UNIV KOBE,SCH MED,DEPT BIOCHEM,KOBE,HYOGO 650,JAPAN	University of Tokyo; Tokyo Metropolitan Institute of Gerontology; University of Tokyo; Kobe University								BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; NAKATA Y, 1994, IN PRESS BIOPHYS J; NODA Y, 1993, NEUROSCIENCE, V55, P113, DOI 10.1016/0306-4522(93)90459-S; OLIVIER JP, 1993, CELL, V73, P169; ROBINSON DJ, 1993, NATURE, V365, P163; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHOLNIK EY, 1993, EMBO J, V12, P1929; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; TOBE K, 1993, J BIOL CHEM, V268; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0	25	125	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5489	5492						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119878				2022-12-25	WOS:A1994MY84000003
J	MORINELLI, TA; ZHANG, LM; NEWMAN, WH; MEIER, KE				MORINELLI, TA; ZHANG, LM; NEWMAN, WH; MEIER, KE			THROMBOXANE A(2) PROSTAGLANDIN H-2-STIMULATED MITOGENESIS OF CORONARY-ARTERY SMOOTH-MUSCLE CELLS INVOLVES ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE AND S6 KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATES DNA-SYNTHESIS; GROWTH-FACTOR; SIGNALING PATHWAYS; EPITHELIAL-CELLS; RECEPTORS; PLATELET; CALCIUM; RAT; PROLIFERATION; INHIBITION	Prostaglandin H-2 (PGH(2)) and thromboxane A(2) (TXA(2)) are potent activators of platelets and vascular smooth muscle whose responses are mediated through a common G protein coupled receptor (TXA(2)/PGH(2) receptor). Despite the many studies describing their ability to aggregate platelets and contract vascular smooth muscle, little is known concerning the potential mitogenic capabilities of these autocoids. Mitogen-activated protein kinases (MAP kinases) and ribosomal S6 kinases are well characterized intracelluIar mediators involved in proliferation of cells. The present study was designed to examine the activation of MAP kinase and S6 kinase in guinea pig coronary artery smooth muscle cells (CASMC) in response to stimulation by a TXA(2)/PGH(2) mimetic, I-BOP ([1S-(1 alpha,2 beta(5Z),3 alpha(1E,3R*),4 alpha)]-7-[3-(3-hydroxy- 4-(4'-iodophenoxy)-1-butenyl)-7-oxabicyclo[2.2.1]heptan-2-yl]-5-heptenoic acid), Equilibrium radioligand binding assays using [I-125]BOP defined a single class of high affinity TXA(2)/PGH(2), receptors on monolayers of guinea pig CASMC (K-d = 0.18 +/- 0.03 nM; 26,476 +/- 3,600 sites/cell; 0.08 +/- 0.01 pmol/mg of protein; n = 12). I-BOP produced a concentration-dependent increase in [H-3]thymidine incorporation in these cells (EC(50) = 0.3 nM) which was inhibited by a series of TXA(2)/PGH(2) recep tor antagonists as well as by verapamil and staurosporine. I-BOP also produced a time-dependent increase in the activation of kinases phosphorylating myelin basic protein (MBP; a substrate for MAP kinase) and RRLSSLRA (S6 peptide; a substrate for pp85(rsk) kinase), reaching a peak activation between 5 and 10 min. Stimulated MBP kinases were identified as ERK1 and ERK2. The activation of these kinases by I-BOP was inhibited by the TXA(2)/PGH(2) receptor antagonist SQ29548 and also by staurosporine. These results indicate that I-BOP, a TXA(2)/PGH(2) mimetic, produces growth of coronary artery vascular smooth muscle cells, which is preceded by activation of MAP kinase and S6 kinase.	MED UNIV S CAROLINA,DEPT CELL & MOLEC PHARMACOL & EXPTL THERAPEUT,CHARLESTON,SC 29425; MED CTR CENT GEORGIA,MACON,GA 31201; MERCER UNIV,SCH MED,DEPT ANESTHESIOL,MACON,GA 31201	Medical University of South Carolina; Mercer University	MORINELLI, TA (corresponding author), MED UNIV S CAROLINA,DEPT MED,DIV CLIN PHARM,CHARLESTON,SC 29425, USA.							COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DORN GW, 1992, J BIOL CHEM, V267, P24897; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GILLARD JW, 1989, PROSTAGLANDINS CLIN, P579; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; HALUSHKA PV, 1989, ANN REV PHARM TOXICO, V10, P213; HANASAKI K, 1990, BIOCHEM PHARMACOL, V40, P2535, DOI 10.1016/0006-2952(90)90096-4; HANASAKI K, 1988, BIOCHEM BIOPH RES CO, V150, P1170, DOI 10.1016/0006-291X(88)90752-8; HANSSON A, 1991, CELL SIGNAL, V3, P293, DOI 10.1016/0898-6568(91)90057-2; HE CJ, 1992, J CELL PHYSIOL, V150, P475, DOI 10.1002/jcp.1041500307; HEBDERG A, 1988, J PHARMACOL EXP THER, V245, P786; HIDAKA J, 1992, ANN REV PHARM TOXICO, V32, P377; ISHIMITSU T, 1988, HYPERTENSION, V12, P46, DOI 10.1161/01.HYP.12.1.46; ISSANDOU M, 1991, J BIOL CHEM, V266, P21037; KENT TA, 1992, J CEREBR BLOOD F MET, V12, P139, DOI 10.1038/jcbfm.1992.17; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LUMLEY P, 1989, BRIT J PHARMACOL, V97, P783, DOI 10.1111/j.1476-5381.1989.tb12017.x; MARTINPERE J, 1983, P NATL ACAD SCI USA, V80, P929; MASUDA A, 1991, CIRC RES, V69, P638, DOI 10.1161/01.RES.69.3.638; MASUDA A, 1991, BIOCHEM PHARMACOL, V42, P537, DOI 10.1016/0006-2952(91)90316-W; MEIER KE, 1990, J BIOL CHEM, V265, P4635; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MIHARA S, 1989, EUR J PHARMACOL, V160, P313, DOI 10.1016/0014-2999(89)90086-1; MIKI I, 1992, THROMB HAEMOSTASIS, V67, P582; MORINELLI TA, 1989, J PHARMACOL EXP THER, V251, P557; MORINELLI TA, 1990, LIFE SCI, V46, P1765, DOI 10.1016/0024-3205(90)90140-M; NAGATA T, 1992, AM J PHYSIOL, V263, pH1331, DOI 10.1152/ajpheart.1992.263.5.H1331; PARIS S, 1991, ANN NY ACAD SCI, V638, P139, DOI 10.1111/j.1749-6632.1991.tb49024.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; ROE MW, 1989, J CELL PHYSIOL, V139, P100, DOI 10.1002/jcp.1041390115; SAURO MD, 1991, J CELL PHYSIOL, V148, P133, DOI 10.1002/jcp.1041480116; SMITH CD, 1988, BIOCHEM BIOPH RES CO, V156, P1250, DOI 10.1016/S0006-291X(88)80767-8; SPERTI G, 1991, EUR J PHARM-MOLEC PH, V206, P279, DOI 10.1016/0922-4106(91)90110-4; SUSA M, 1992, J BIOL CHEM, V267, P6905; TAKUWA N, 1991, J BIOL CHEM, V266, P1403; THYBERG J, 1987, BIOL CELL, V60, P125, DOI 10.1111/j.1768-322X.1987.tb00552.x; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; UEHARA Y, 1988, PROSTAGLANDINS, V36, P847, DOI 10.1016/0090-6980(88)90061-5	41	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5693	5698						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119906				2022-12-25	WOS:A1994MY84000035
J	SEELIG, GF; PROSISE, WW; SCHEFFLER, JE				SEELIG, GF; PROSISE, WW; SCHEFFLER, JE			A ROLE FOR THE CARBOXYL-TERMINUS OF HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN THE BINDING OF LIGAND TO THE ALPHA-SUBUNIT OF THE HIGH-AFFINITY RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN CELL-LINE; GM-CSF; RADIOACTIVITIES; RECONSTITUTION; ESTABLISHMENT; EXPRESSION; LEUKEMIA; CLONING; IL-3	A synthetic segment (110-127) of the carboxyl terminus of recombinant human granulocyte-macrophage colony-stimulating factor (rh-GM-CSF) was used to generate a rabbit polyclonal antibody (345-6), which recognized both peptide and full-length Escherichia coli-derived rh-GM-CSF in a direct enzyme-linked immunosorbent assay. Antibody 345-6 was shown to antagonize the binding of I-125-labeled rh-GM-CSF to its receptor on the KG-1 cell line and to inhibit human GM-CSF-dependent proliferation of the AML-193 cell line. The purified IgG fraction of neutralizing antibody 345-6 was used as immunogen to obtain sheep antiserum 1418. Antibody 1418 recognized antibody 345-6 on direct enzyme-linked immunosorbent assay but did not recognize rh-GM-CSF or the peptide 110-127 to which antibody 345-6 was raised. Antiserum 1418, as well as a purified IgG fraction of this serum, inhibited both rh-GM-CSF-stimulated cell proliferation and I-126-labeled rh-GM-CSF receptor binding but not I-125- labeled recombinant human interleukin-4 receptor binding. The anti-idiotypic antibody response derived from the anti-(110-127) antibody strongly suggests that the carboxyl-terminal region of rh-GM-CSF may be directly involved in the receptor-ligand interaction of this protein. The high affinity receptor consists of two different components (GM-R alpha beta) a cytokine-specific alpha-subunit and a beta-subunit that is shared by human GM-CSF, interleukin-3, and interleukin-5. In an effort to localize the epitope of antibody 1418 to either GMR alpha or GMRB beta several cell lines containing high, low, or both high and low affinity receptors were examined. Each was specifically and completely inhibited by antibody 1418. Interleukin-3-dependent cell proliferation of the AML-193 cell line was found to be unaffected by the antibody 1418. Thus, the carboxyl-terminal region of rh-GM-CSF is likely to be involved in the interaction of the ligand with the a-subunit of the high affinity receptor.			SEELIG, GF (corresponding author), SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033, USA.							BALDWIN GC, 1988, P NATL ACAD SCI USA, V85, P2763, DOI 10.1073/pnas.85.8.2763; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, J MOL BIOL, V221, P55, DOI 10.1016/0022-2836(91)90803-E; DISPERSIO J, 1988, J BIOL CHEM, V263, P1834; GASSON JC, 1986, P NATL ACAD SCI USA, V83, P669, DOI 10.1073/pnas.83.3.669; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GREENBERG R, 1988, CURR MICROBIOL, V17, P321, DOI 10.1007/BF01570872; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; LANGE B, 1987, BLOOD, V70, P192; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSIS AJ, 1980, P NATL ACAD SCI-BIOL, V77, P5346, DOI 10.1073/pnas.77.9.5346; MADJIC O, 1984, INT J CANCER, V33, P617; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; METCALF D, 1986, BLOOD, V67, P257; MONROY RL, 1987, BLOOD, V70, P1096; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SHANAFELT AB, 1991, J BIOL CHEM, V266, P13804; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; TROTTA P, 1987, Patent No. 883064214; TROTTA PP, 1989, 9TH P SAT S EUR C CL, P6; VANDHANRAJ S, 1987, NEW ENGL J MED, V317, P1545; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5	31	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5548	5553						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119889				2022-12-25	WOS:A1994MY84000015
J	YANG, B; IBRAGHIMOVBESKROVNAYA, O; MOOMAW, CR; SLAUGHTER, CA; CAMPBELL, KP				YANG, B; IBRAGHIMOVBESKROVNAYA, O; MOOMAW, CR; SLAUGHTER, CA; CAMPBELL, KP			HETEROGENEITY OF THE 59-KDA DYSTROPHIN-ASSOCIATED PROTEIN REVEALED BY CDNA CLONING AND EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLE; PURIFICATION	The 59-kDa dystrophin-associated protein triplet (59-DAP) is a component of the dystrophin-glycoprotein complex which may directly associate with dystrophin. The cDNA encoding one component (59-1 DAP) of the 59-DAP triplet has now been cloned from rabbit skeletal muscle. The deduced amino acid sequence of 59-1 DAP predicts a 505-amino acid polypeptide containing nine potential phosphorylation sites and no predicted transmembrane domains. This is consistent with the 59-1 DAP being a peripheral membrane protein associated with the cytoplasmic face of the dystrophin-glycoprotein complex. Affinity-purified antibodies against rabbit 59-1 DAP fusion proteins only recognize the lowest band of the 59-DAP triplet in skeletal muscle sarcolemma and isolated dystrophin-glycopratein complex. The tissue-specific expression of 59-1 DAP mRNA, which is most prominent in skeletal and cardiac muscle and is also detected in brain, parallels that of dystrophin but not of utrophin. Levels of 59-1 DAP mRNA are unaffected in mdx mouse skeletal and cardiac muscles, although all dystrophin-associated proteins, including 59-DAP, are greatly reduced in mdx mouse skeletal muscle. However, in mdx mouse cardiac muscle, the up-regulation of utrophin preserves all dystrophin-associated proteins except 59-DAP. Our results suggest that the 59-DAP triplet may contain different protein species and that the 59-1 DAP may associate more specifically with dystrophin than with utrophin.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,BIOPOLYMER FACIL,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Campbell, Kevin/0000-0003-2066-5889				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CARTAUD A, 1993, J BIOL CHEM, V268, P13019; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; KOZAK M, 1991, J BIOL CHEM, V266, P19867; MATSUMURA K, 1993, FEBS LETT, V320, P276, DOI 10.1016/0014-5793(93)80602-Q; MATSUMURA K, 1993, J CLIN INVEST, V92, P866, DOI 10.1172/JCI116661; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; YAMAMOTO H, 1993, J BIOCHEM-TOKYO, V114, P132, DOI 10.1093/oxfordjournals.jbchem.a124128; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	25	112	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6040	6044						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119949				2022-12-25	WOS:A1994MY84000085
J	ROFFEY, RA; VANWIJK, KJ; SAYRE, RT; STYRING, S				ROFFEY, RA; VANWIJK, KJ; SAYRE, RT; STYRING, S			SPECTROSCOPIC CHARACTERIZATION OF TYROSINE-Z IN HISTIDINE-190 MUTANTS OF THE D1 PROTEIN IN PHOTOSYSTEM-II (PSII) IN CHLAMYDOMONAS-REINHARDTII - IMPLICATIONS FOR THE STRUCTURAL MODEL OF THE DONOR SIDE OF PSII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; RIBONUCLEOTIDE REDUCTASE; RESONANCE SPECTROSCOPY; DIRECTED MUTAGENESIS; CHARGE ACCUMULATION; THYLAKOID MEMBRANE; MANGANESE CLUSTER; COMPLEX; PHOTOINHIBITION; CHLOROPLASTS	EPR spectra attributed to the redox active tyrosine residues on the oxidizing side of photosystem II (Tyr(Z) and Tyr(D)) have almost identical line shapes, although the tyrosyl radicals differ in stability and redox characteristics. Strongly modified spectra of oxidized Tyr(D) in site-directed mutants in a histidine residue, H189 on the D2 reaction center protein in the cyanobacterium Synechocystis 6803, support a structural model where H189 interacts closely, probably via a hydrogen bond, to Tyr(D) (Tommos, C., Davidsson, L., Svensson, B., Madsen, C., Vermaas, W., and Styring, S. (1993) Biochemistry 32, 5436-5441). To determine whether Tyr(Z) and the corresponding histidine on the D1 protein (D1-H190) interacts similarly, we have generated His-Phe (H190F) and His-Tyr (H190Y) mutations in the C2 symmetry related H190 residue on the D1 reaction center protein by site-directed mutagenesis in Chlamydomonas reinhardtii. The H190F and H190Y mutants assemble photosystem II reaction centers capable of primary photochemistry but unable to oxidize water. We have obtained kinetic spectra of a flash-induced transient EPR signal that we assign to oxidized Tyr(Z) in the D1-H190 mutants. The spectra are identical in line width (18-20 G) and hyperfine structure to the wild-type spectrum from oxidized Tyr(Z) and exhibit decay kinetics (t(1/2) approximate to 500 ms) typical for the Tyr(Z) radical in managenese-depleted photosystem II membranes, However, both Tyr(Z) and Tyr(D) were oxidized with reduced (10-15%) quantum yield in these mutants, indicating that the kinetics of electron donation to P-680(+), were significantly modified as a result of the mutation. Thus, the altered kinetics of Tyr(Z) in the mutants suggest that there is an interaction between TyrZ and His-190 on the D1 protein. However, unlike the situation on the D2 side, the presence of a hydrogen bond between Tyr(Z) and H190 on the D1 protein is improbable.	STOCKHOLM UNIV, ARRHENIUS LABS NAT SCI, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN; OHIO STATE UNIV, DEPT PLANT BIOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA	Stockholm University; Ohio State University; Ohio State University			Styring, Stenbjörn/L-8414-2016	Styring, Stenbjörn/0000-0002-2803-9244; Sayre, Richard/0000-0002-3153-7084				ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; BABCOCK GT, 1973, BIOCHIM BIOPHYS ACTA, V325, P483, DOI 10.1016/0005-2728(73)90209-0; BABCOCK GT, 1976, FEBS LETT, V61, P286; BABCOCK GT, 1989, BIOCHEMISTRY-US, V28, P9557, DOI 10.1021/bi00451a001; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P709; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BLUBAUGH DJ, 1991, BIOCHEMISTRY-US, V30, P7586, DOI 10.1021/bi00244a030; BOERNER RJ, 1992, BIOCHEMISTRY-US, V31, P6660, DOI 10.1021/bi00144a005; BRETTEL K, 1984, BIOCHIM BIOPHYS ACTA, V766, P403, DOI 10.1016/0005-2728(84)90256-1; CALLAHAN FE, 1986, PLANT PHYSIOL, V82, P261, DOI 10.1104/pp.82.1.261; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; JEGERSCHOLD C, 1990, BIOCHEMISTRY-US, V29, P6179, DOI 10.1021/bi00478a010; LJUNGBERG U, 1986, EUR J BIOCHEM, V158, P477, DOI 10.1111/j.1432-1033.1986.tb09779.x; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; NIXON PJ, 1992, PLANT PROTEIN ENG, P93; ROFFEY RA, 1991, P NATL ACAD SCI USA, V88, P9122, DOI 10.1073/pnas.88.20.9122; RUFFLE SV, 1992, PHOTOSYNTH RES, V34, P287, DOI 10.1007/BF00033446; Rutherford A.W., 1992, PHOTOSYSTEMS STRUCTU, P179; RUTHERFORD AW, 1986, PROGR PHOTOSYNTHESIS, V1, P277; SAYRE RT, 1986, CELL, V47, P601, DOI 10.1016/0092-8674(86)90624-0; SHIM HS, 1990, PHOTOSYNTH RES, V26, P223, DOI 10.1007/BF00033135; STYRING S, 1993, PHOTOSYNTHETICA, V28, P225; SVENSSON B, 1990, EMBO J, V9, P2051, DOI 10.1002/j.1460-2075.1990.tb07372.x; SVENSSON B, 1991, Z NATURFORSCH C, V46, P767; SVENSSON B, 1992, RES PHOTOSYNTHESIS, V2, P147; THEG SM, 1986, BIOCHIM BIOPHYS ACTA, V849, P104, DOI 10.1016/0005-2728(86)90101-5; TOMMOS C, 1993, BIOCHEMISTRY-US, V32, P5436, DOI 10.1021/bi00071a020; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREBST A, 1986, Z NATURFORSCH C, V41, P240; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; VERMAAS WFJ, 1988, P NATL ACAD SCI USA, V85, P8477, DOI 10.1073/pnas.85.22.8477; VERMAAS WFJ, 1991, CELL CULTURE SOMAT B, V7, P25; VIRGIN I, 1988, FEBS LETT, V233, P408, DOI 10.1016/0014-5793(88)80472-1; YARKES CT, 1980, BIOCHIM BIOPHYS ACTA, V590, P360; [No title captured]	45	69	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5115	5121						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106491				2022-12-25	WOS:A1994MX57100066
J	WALL, D; ZYLICZ, M; GEORGOPOULOS, C				WALL, D; ZYLICZ, M; GEORGOPOULOS, C			THE NH2-TERMINAL 108 AMINO-ACIDS OF THE ESCHERICHIA-COLI DNAJ PROTEIN STIMULATE THE ATPASE ACTIVITY OF DNAK AND ARE SUFFICIENT FOR LAMBDA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; BACTERIOPHAGE-LAMBDA; CHAPERONE; GRPE; PURIFICATION; INITIATION; BINDING; GENE; SEQUENCE; MUTANTS	The Escherichia coli heat shock proteins DnaK and DnaJ function cooperatively as molecular chaperones. Central to their biochemical functions is the ability of DnaJ to interact with DnaK and to stimulate its ATPase activity. Here, we report the genetic isolation of dnaJ12, which has a nonsense mutation at codon 109, yet was able to support lambda growth at 30 degrees C. The 12-kDa DnaJ12 protein was purified to homogeneity and shown to be active in an in vitro lambda-DNA replication system and to be capable of stimulating DnaK's ATPase activity, specifically at the step of ATP hydrolysis. The previously web studied and characterized dnaJ259 mutation was also cloned and sequenced, revealing a single His --> Gln amino acid change at codon 33. The purified DnaJ259 protein was inactive in an in vitro lambda-DNA replication system and was unable to stimulate DnaK's ATPase activity. Consistent with this, an NH2-terminal deletion of the first 34 amino acids or an Asp insertion at residue 35 of DnaJ resulted in a protein that completely lacked DnaJ activity. Collectively, these results demonstrate that the highly conserved NH2-terminal region of DnaJ, the so-called J region, is necessary and sufficient for stimulating both DnaK's ATPase activity and lambda-DNA replication. These results may be applicable to other eukaryotic proteins that contain this conserved J domain as proteins that interact and stimulate the hydrolysis of ATP by their cognate HSP70 proteins.	CTR MED UNIV GENEVA, DEPT BIOCHIM MED, CH-1211 GENEVA 4, SWITZERLAND; UNIV GDANSK, DIV BIOPHYS, DEPT MOLEC BIOL, PL-80822 GDANSK, POLAND	University of Geneva; Fahrenheit Universities; University of Gdansk	WALL, D (corresponding author), UNIV UTAH, MED CTR, DEPT CELLULAR VIRAL & MOLEC BIOL, SALT LAKE CITY, UT 84132 USA.			Wall, Daniel/0000-0002-0273-1371	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023917, R01GM023917] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23917] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ANG D, 1991, J BIOL CHEM, V266, P24233; BORK P, 1992, TRENDS BIOCHEM SCI, V17, P129, DOI 10.1016/0968-0004(92)90319-5; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CRAIG EA, 1990, STRESS PROTEINS BIOL, P279; CYR DM, 1992, J BIOL CHEM, V267, P20927; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; KURIHARA T, 1992, MEMBRANE BIOGENESIS, P309; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Miller J.H., 1972, EXPT MOL GENETICS; OHKI M, 1986, J BIOL CHEM, V261, P1778; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; Sambrook J, 1989, MOL CLONING LABORATO; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; SELL SM, 1987, THESIS U UTAH; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SUNSHINE M, 1977, MOL GEN GENET, V151, P27, DOI 10.1007/BF00446909; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	40	250	255	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5446	5451						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106526				2022-12-25	WOS:A1994MX57100110
J	DAVIS, JT; HIRANI, S; BARTLETT, C; REID, BR				DAVIS, JT; HIRANI, S; BARTLETT, C; REID, BR			H-1-NMR STUDIES ON AN ASN-LINKED GLYCOPEPTIDE - GLCNAC-1 C2-N2 BOND IS RIGID IN H2O	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL ENERGY CALCULATIONS; MAGNETIC-RESONANCE SPECTROSCOPY; TWO-DIMENSIONAL NMR; N-TERMINAL PORTION; CIRCULAR-DICHROISM; OLIGOSACCHARIDES; GLYCOSYLATION; GLYCOPROTEINS; COMPLEX; H-1-NMR	The conformation of an Asn-linked glycopeptide in H2O was studied by two-dimensional H-1 NMR. Nonexchangeable proton and exchangeable amide (NH) proton resonances were assigned for the hen ovomucoid glycopeptide 1, Ser-Ile-Glu-Phe-Gly-Thr-Asn*Ile-Ser-Lys, with pentasaccharide Manalpha1-3 (Manalpha1-6)Manbeta1-4GIcNAcbeta1-4GlcNAcbeta1-NH attached to the Asn7 gamma-carboxamide. The pentasaccharide increases the local correlation times of amino acid residues near the N-glycosylation site. Nuclear Overhauser effect (NOE) measurements on 1 and the corresponding Man3GlcNAc2 pentasaccharide 3 show that the attached peptide does not perturb 0-glycoside conformation. Sequential d(NN) (i, i+l) NOEs in the Thr6-Ser9 region indicate populations of folded structure near the N-glycosylation site of both glycopeptide 1 and aglycosyl peptide 2. However, the Man3GlcNAC2 pentasaccharide does not dramatically affect the average conformation of either the peptide backbone or the Asn7 side chain. GlcNAc NH protons were studied at pH 3.0; and NOE and 3J(NH) data were used to constrain the glycopeptide' s GlcNAc-I side chain dihedral angle (tau) (Cl-C2-N2-C7(Ac)). The glycopeptide's core GlcNAc-1 C2-N2 side chain bond is not flexible in H2O. A strong GlcNAc-1 NH2-H3 NOE, a medium strength NH2-Hl NOE, and a weak NH2-H2 interaction suggest that GlcNAc-I has a rigid C2-N2 bond, with tau between 95 and 115-degrees. No evidence was found for intramolecular hydrogen bonds restricting this C2 side chain torsion. It may be that GlcNAc-l's rigid planar N-glycosidic linkage limits the conformational space available to the adjacent C2 acetamido side chain.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; GENZYME CORP,CAMBRIDGE,MA 02139; UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Sanofi-Aventis; Genzyme Corporation; University of Washington; University of Washington Seattle	DAVIS, JT (corresponding author), UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLL PK,MD 20742, USA.				NIGMS NIH HHS [R44 GM39656-02, F32 GM14340-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014340, R44GM039656] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBADI A, 1986, INT J BIOL MACROMOL, V8, P252, DOI 10.1016/0141-8130(86)90036-X; ANDREOTTI AH, 1993, J AM CHEM SOC, V115, P3352, DOI 10.1021/ja00061a053; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BAX A, 1981, J MAGN RESON, V44, P542, DOI 10.1016/0022-2364(81)90287-0; BEELEY JG, 1976, BIOCHEM J, V159, P335, DOI 10.1042/bj1590335; BEINTEMA JJ, 1986, BIOSCIENCE REP, V6, P709, DOI 10.1007/BF01116537; BERMAN E, 1988, CARBOHYD RES, V176, P1, DOI 10.1016/0008-6215(88)84053-9; BERMAN E, 1981, J BIOL CHEM, V256, P3853; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3671, DOI 10.1021/bi00284a021; BROCKBANK RL, 1990, BIOCHEMISTRY-US, V29, P5574, DOI 10.1021/bi00475a023; BUSH CA, 1980, BIOCHEMISTRY-US, V19, P501, DOI 10.1021/bi00544a017; BUSH CA, 1982, BIOPOLYMERS, V21, P535, DOI 10.1002/bip.360210305; BUSH CA, 1982, J BIOL CHEM, V257, P8199; CAGAS P, 1991, J AM CHEM SOC, V113, P6815, DOI 10.1021/ja00018a016; CUNG MT, 1982, BIOPOLYMERS, V21, P953, DOI 10.1002/bip.360210508; DABROWSKI J, 1989, J AM CHEM SOC, V111, P1510, DOI 10.1021/ja00186a063; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DILL K, 1990, J PROTEIN CHEM, V9, P129, DOI 10.1007/BF01025303; DILL K, 1986, PROG NUCL MAG RES SP, V18, P307, DOI 10.1016/0079-6565(86)80002-4; DROBNY G, 1979, FARADAY DIV CHEM SOC, V13, P49; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HIRANI S, 1987, ANAL BIOCHEM, V162, P485, DOI 10.1016/0003-2697(87)90424-6; HOMANS SW, 1986, BIOCHEMISTRY-US, V25, P6342, DOI 10.1021/bi00368a076; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6553, DOI 10.1021/bi00394a040; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6549; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7942, DOI 10.1021/ja00046a068; ISHII H, 1985, POLYM J, V17, P693, DOI 10.1295/polymj.17.693; JAO HC, 1992, FEBS LETT, V7, P343; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P4212, DOI 10.1021/ja00221a020; KESSLER H, 1991, J AM CHEM SOC, V113, P7550, DOI 10.1021/ja00020a016; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; MAEJI NJ, 1987, BIOPOLYMERS, V26, P1753, DOI 10.1002/bip.360261008; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; OHANESSIAN J, 1980, CARBOHYD RES, V80, P1, DOI 10.1016/S0008-6215(00)85309-4; PERCZEL A, 1991, J AM CHEM SOC, V113, P9772, DOI 10.1021/ja00026a010; PINCUS MR, 1976, BIOPOLYMERS, V15, P2485, DOI 10.1002/bip.1976.360151212; POPPE L, 1990, J AM CHEM SOC, V112, P7762, DOI 10.1021/ja00177a042; ROBERTSON AD, 1991, BIOCHEMISTRY-US, V30, P9907, DOI 10.1021/bi00105a014; SAVVIDOU G, 1984, BIOCHEMISTRY-US, V23, P3736, DOI 10.1021/bi00311a026; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STUIKEPRILL R, 1990, EUR J BIOCHEM, V194, P903, DOI 10.1111/j.1432-1033.1990.tb19485.x; VLIEGENTHART JFG, 1983, ADV CARBOHYDR CHEM B, V41, P279; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P169; YET MG, 1988, J BIOL CHEM, V263, P111	52	65	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3331	3338						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106372				2022-12-25	WOS:A1994MV63100034
J	MA, CP; VU, JH; PROSKE, RJ; SLAUGHTER, CA; DEMARTINO, GN				MA, CP; VU, JH; PROSKE, RJ; SLAUGHTER, CA; DEMARTINO, GN			IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF A HIGH-MOLECULAR-WEIGHT, ATP-DEPENDENT ACTIVATOR (PA700) OF THE 20-S PROTEASOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; RABBIT RETICULOCYTE LYSATE; ENDOGENOUS INHIBITOR; SOLUBLE EXTRACTS; LATENT FORM; MACROPAIN; UBIQUITIN; PROTEOLYSIS; DEGRADATION; FIBROBLASTS	In order to identify protein complexes consisting of the proteasome and specific proteasome regulators, crude soluble lysates of red blood cells were fractionated by gel filtration chromatography and by velocity sedimentation centrifugation. The fractionated lysates were then tested for the relative distribution of proteasome activity, proteasome protein, and protein of a known proteasome activator, PA28. At least two proteasome complexes containing PA28 were identified. One of these complexes had an apparent molecular weight of approximately 1,750,000, and appeared to have much more proteasome activity than could be accounted for by its relative concentrations of proteasome and PA28 protein. We hypothesized that this complex contained another activator of the proteasome, and we sought to purify this activator from extracts of red blood cells. A proteasome activator with an apparent molecular weight of approximately 700,000 was identified, purified, and characterized. This activator, termed PA700, greatly stimulated the peptidase activities of the proteasome in an ATP-dependent fashion. PA700 was composed of about 16 polypeptides ranging in molecular weight from 20,000 to 100,000. The ATP-dependent activation of the proteasome by PA700 was closely linked to the formation of a high molecular weight complex that required no additional ATP for activated proteolysis. These results indicate that PA700 is a regulatory protein of the proteasome and is a component of at least one high molecular weight proteasome-containing complex occurring in cell extracts.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED CTR,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1073, P299, DOI 10.1016/0304-4165(91)90135-4; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GRAY CB, 1994, IN PRESS J MOL BIOL; HERESHKO A, 1992, ANN REV BIOCH, V61, P761; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1987, J BIOL CHEM, V262, P8303; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MA CP, 1992, J BIOL CHEM, V267, P10515; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCGUIRE MJ, 1989, BIOCHEM BIOPH RES CO, V160, P911, DOI 10.1016/0006-291X(89)92521-7; MCGUIRE MJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P273, DOI 10.1016/0003-9861(88)90189-0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; TANAKA K, 1990, CELL STRUCT FUNCT, V15, P127, DOI 10.1247/csf.15.127; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; WAXMAN L, 1987, J BIOL CHEM, V262, P2451	28	227	230	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3539	3547						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106396				2022-12-25	WOS:A1994MV63100064
J	ZHU, Y; CONNER, GE				ZHU, Y; CONNER, GE			INTERMOLECULAR ASSOCIATION OF LYSOSOMAL PROTEIN PRECURSORS DURING BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYL PHOSPHODIESTERASE; I-CELL DISEASE; CATHEPSIN-D; ENDOPLASMIC-RETICULUM; MEMBRANE ASSOCIATION; PARTIAL-PURIFICATION; HEPG2 CELLS; ACTIVATOR; ENZYMES; FIBROBLASTS	To study the mechanism involved in mannose-6-phosphate (Man-6-P) independent lysosomal proenzyme membrane association, we used a reversible cross-linker to probe radiolabeled human HepG2 cells permeabilized with saponin in the presence of Man-6-P. After immunoprecipitation of the extracted and cross-linked cells with anti-cathepsin D antibody, followed by complete reduction of the immunoprecipitates and SDS-polyacrylamide gel electrophoresis analysis, we found that procathepsin D was specifically and transiently associated, independent of Man-6-P, with two co-synthesized glycoproteins having molecular masses of 68 and 72 kDa. Pulse-chase and cell fractionation experiments showed that the Man-6-P independent association of procathepsin D with the 68-kDa protein started in the rough endoplasmic reticulum, continued in the Golgi, but had no association with either membrane. The Man-6-P independent association of procathepsin D with the 72-kDa protein and the membrane was found in compartments all the way from the Golgi to the dense lysosome, where processing of procathepsin D is believed to occur and where procathepsin D dissociated from the 72-kDa protein and the membrane. Endo H digestion of the 72-kDa protein showed that this protein was partially resistant to Endo H, suggesting that membrane association of the procathepsin D-72.kDa protein complex probably began in a late Golgi compartment. Endo F digestion of the proteins showed both have the same molecular mass around 58 kDa. Using antiserum against human saposin C, we identified the two glycoproteins as forms of prosaposin with different glycosylation. The transient, Man-6-P independent, membrane association of the procathepsin D-prosaposin complex and the presence of this complex in heavy lysosomes indicated that the proteins were transported to the lysosome as a complex. The association of two lysosomal proteins in the endoplasmic reticulum early after synthesis suggested that preassembly of some lysosomal components occurs before the earliest previously identified steps in the sorting pathway.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami			Conner, Gregory/AAI-1285-2021	Conner, Gregory/0000-0003-2217-2252				BRETZ R, 1977, EUR J BIOCHEM, V77, P187; BURGE V, 1991, BIOCHEM J, V275, P797, DOI 10.1042/bj2750797; CONNER GE, 1989, BIOCHEMISTRY-US, V28, P3530, DOI 10.1021/bi00434a057; CONNER GE, 1992, J BIOL CHEM, V267, P2738; DIMENT S, 1988, J BIOL CHEM, V263, P6901; FISHER PA, 1982, J CELL BIOL, V92, P674, DOI 10.1083/jcb.92.3.674; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; GRASSEL S, 1992, BIOCHEM BIOPH RES CO, V182, P276, DOI 10.1016/S0006-291X(05)80141-X; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; JINSEL LA, 1991, CELL BIOL INT REP, V15, P1167; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEROY JG, 1972, PEDIATR RES, V6, P752, DOI 10.1203/00006450-197210000-00002; LITTLE L, 1987, BIOCHEM J, V248, P151, DOI 10.1042/bj2480151; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; MORREAU H, 1992, J BIOL CHEM, V267, P17949; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; NEUFELD EF, 1983, METABOLIC BASIS INHE, P787; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; OWADA M, 1982, BIOCHEM BIOPH RES CO, V105, P814, DOI 10.1016/0006-291X(82)91042-7; PATTHY L, 1991, J BIOL CHEM, V266, P6035; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; SOEDA S, 1993, J BIOL CHEM, V268, P18519; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; TONDEUR M, 1971, J PEDIATR-US, V79, P366, DOI 10.1016/S0022-3476(71)80143-9; TONG PY, 1989, J BIOL CHEM, V264, P7970; TSUJI A, 1987, BIOCHEM INT, V15, P945; VANWEELY S, 1990, EUR J BIOCHEM, V191, P669; VARKI A, 1981, J BIOL CHEM, V256, P9937; VONFIGURA K, 1977, EUR J BIOCHEM, V80, P525; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717; WYNN CH, 1986, BIOCHEM J, V240, P921, DOI 10.1042/bj2400921	43	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3846	3851						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106429				2022-12-25	WOS:A1994MV63100104
J	LIAO, JK; HOMCY, CJ				LIAO, JK; HOMCY, CJ			THE RELEASE OF ENDOTHELIUM-DERIVED RELAXING FACTOR VIA ALPHA(2)-ADRENERGIC RECEPTOR ACTIVATION IS SPECIFICALLY MEDIATED BY G(I-ALPHA-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; NUCLEOTIDE-BINDING PROTEINS; PERTUSSIS-TOXIN; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; REGULATORY PROTEINS; ADRENERGIC-RECEPTOR; GTPASE ACTIVITY; ANTIBODIES; GI2	The purpose of this study is to determine which pertussis toxin-sensitive guanine nucleotide-binding protein (G(i)) mediates alpha2-adrenergic receptor stimulation of endothelium-derived relaxing factor (EDRF) release. Bovine aortic endothelial cells were treated with pertussis toxin (0-100 ng/ml) for 16 h and stimulated with an alpha2-adrenergic receptor agonist, UK14304, to release EDRF in a bioassay system. Pertussis toxin produced a concentration-dependent decrease in EDRF release with maximal inhibition (80%) occurring at 5 ng/ml. This correlated with a decrease in receptor-G protein coupling as measured by 87% loss of high affinity agonist binding sites and 94% decrease in agonist-stimulated GTPase activity. Immunoprecipitation of [P-32]NAD-ribosylated membranes using specific G(i) protein antisera demonstrated that complete ADP-ribosylation of G(ialpha2) occurred at 5 ng/ml compared to 30 ng/ml for G(ialpha3). When bovine aortic endothelial cell membranes were treated with carboxyl terminus-directed antisera to G(ialpha2) (P4) and G(ialpha3) (EC), the P4 antisera abolished 86% of the high affinity agonist binding sites and 93% decrease in agonist-stimulated GTPase activity, while the EC antisera had minimal effect (12%). These results indicate that G(ialpha2) mediates most of the EDRF released via the alpha2-adrenergic receptor.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,PEARL RIVER,NY 10965	Harvard University; Harvard Medical School; Columbia University	LIAO, JK (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,221 LONGWOOD AVE,LMRC-307,BOSTON,MA 02115, USA.				NHLBI NIH HHS [HL02508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HUFF RM, 1986, J BIOL CHEM, V261, P1105; KATADA T, 1986, J BIOL CHEM, V261, P8182; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; KIM SY, 1987, P NATL ACAD SCI USA, V85, P4153; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEER EJ, 1984, J BIOL CHEM, V259, P4222; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RIBEIRONETO FAP, 1985, METHOD ENZYMOL, V109, P566; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809	27	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19528	19533						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103519				2022-12-25	WOS:A1993LW81900059
J	SHENG, S; MORAGAAMADOR, DA; VANHEEKE, G; ALLISON, RD; RICHARDS, NGJ; SCHUSTER, SM				SHENG, S; MORAGAAMADOR, DA; VANHEEKE, G; ALLISON, RD; RICHARDS, NGJ; SCHUSTER, SM			GLUTAMINE INHIBITS THE AMMONIA-DEPENDENT ACTIVITIES OF 2 CYS-1 MUTANTS OF HUMAN ASPARAGINE SYNTHETASE THROUGH THE FORMATION OF AN ABORTIVE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMIDE TRANSFER-FUNCTION; ESCHERICHIA-COLI; PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; METHIONINE AMINOPEPTIDASE; MONOCLONAL-ANTIBODIES; LINKED GLYCOSYLATION; CARBAMYL-PHOSPHATE; EXPRESSION; CYSTEINE	Cys-1 mutants of recombinant human asparagine synthetase were constructed and their ability to catalyze the glutamine-dependent nitrogen transfer reaction required for asparagine biosynthesis was determined. In agreement with previous work, altering Cys-1 to either Ala or Ser eliminated the glutamine-dependent activity while only minimally affecting the kinetic properties of the ammonia-dependent reaction. A lack of glutaminase activity in these mutants also allowed examination of glutamine binding in studies of the ability of glutamine to inhibit the ammonia-dependent production of asparagine. In both mutants, analysis of the observed kinetics indicated that glutamine inhibited ammonia-dependent asparagine synthesis through the formation of an abortive complex. This unanticipated observation suggests that the commonly accepted mechanism for nitrogen transfer from the primary amide of glutamine to aspartic acid in asparagine synthetase may have to be re-examined. A novel mechanistic proposal which is consistent with the formation of an abortive complex in the two Cys-1 mutants is presented.	UNIV FLORIDA, ICBR, BOX 110580, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, SCH MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, DEPT CHEM, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida			van Opstal, John/D-1907-2010		NATIONAL CANCER INSTITUTE [R01CA028725] Funding Source: NIH RePORTER; NCI NIH HHS [CA28725] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON RD, 1977, J BIOL CHEM, V252, P6046; AMURO N, 1985, J BIOL CHEM, V260, P4844; ANDRULIS IL, 1987, MOL CELL BIOL, V7, P2435, DOI 10.1128/MCB.7.7.2435; BAKER EN, 1976, J MOL BIOL, V101, P185, DOI 10.1016/0022-2836(76)90371-5; BARTLETT PA, 1983, BIOCHEMISTRY-US, V22, P4618, DOI 10.1021/bi00289a002; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEDAR H, 1969, J BIOL CHEM, V244, P4122; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLLETTA G, 1992, BIOCHEM BIOPH RES CO, V183, P265, DOI 10.1016/0006-291X(92)91638-7; COONEY DA, 1980, INT J BIOCHEM, V11, P519, DOI 10.1016/0020-711X(80)90261-X; COONEY DA, 1976, CANCER TREAT REP, V60, P1493; DRENNTH J, 1971, ENZYMES, P609; DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIBBS RA, 1992, SCIENCE, V258, P803, DOI 10.1126/science.1439788; GONG SS, 1990, NUCLEIC ACIDS RES, V18, P3509, DOI 10.1093/nar/18.12.3509; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HONGO S, 1989, BIOCHEM INT, V18, P661; HONGO S, 1990, LEUKEMIA, V4, P708; HUANG CY, 1978, FED PROC, V37, P1423; HUANG YZ, 1975, ENZYME, V19, P314, DOI 10.1159/000459006; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7944, DOI 10.1021/ja00046a069; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7942, DOI 10.1021/ja00046a068; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LUEHR CA, 1985, ARCH BIOCHEM BIOPHYS, V237, P335, DOI 10.1016/0003-9861(85)90285-1; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; MANTSALA P, 1984, J BIOL CHEM, V259, P4230; MEHLHAFF PM, 1985, BIOCHEMISTRY-US, V24, P1104, DOI 10.1021/bi00326a006; MEI B, 1989, J BIOL CHEM, V264, P16613; MILMAN HA, 1979, BIOCHEM J, V181, P51, DOI 10.1042/bj1810051; NAKAGAWA S, 1989, ANAL BIOCHEM, V181, P75, DOI 10.1016/0003-2697(89)90395-3; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; PFEIFFER NE, 1987, J BIOL CHEM, V262, P11565; RICHARDS NGJ, 1992, FEBS LETT, V313, P98, DOI 10.1016/0014-5793(92)81421-H; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; Sambrook J, 1989, MOL CLONING LABORATO; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SHENG SJ, 1992, PROTEIN EXPRES PURIF, V3, P337, DOI 10.1016/1046-5928(92)90010-T; TRECO DA, 1987, CURRENT PROTOCOLS MO; TSO JY, 1982, J BIOL CHEM, V257, P3525; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; UNNITHAN S, 1984, ANAL BIOCHEM, V136, P195, DOI 10.1016/0003-2697(84)90325-7; UREN JR, 1977, BIOCHEM PHARMACOL, V26, P1405, DOI 10.1016/0006-2952(77)90365-3; VANHEEKE G, 1989, J BIOL CHEM, V264, P19475; VANHEEKE G, 1989, J BIOL CHEM, V264, P5503; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WALSH C, 1979, ENZYMATIC REACTION M, P170; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; WINTERBU.PJ, 1971, BIOCHEM J, V121, P701, DOI 10.1042/bj1210701; ZAHN H, 1969, CHEM BER-RECL, V102, P2158, DOI 10.1002/cber.19691020645; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203	55	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16771	16780						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8102140				2022-12-25	WOS:A1993LQ33600097
J	SKERJANC, IS; TOYOFUKU, T; RICHARDSON, C; MACLENNAN, DH				SKERJANC, IS; TOYOFUKU, T; RICHARDSON, C; MACLENNAN, DH			MUTATION OF GLUTAMATE-309 TO GLUTAMINE ALTERS ONE CA2+-BINDING SITE IN THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM EXPRESSED IN SF9 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAIN; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; TRANSMEMBRANE DOMAIN; ADENOSINE-TRIPHOSPHATASE; CA-2+-ATPASE; ATPASE; CALCIUM; MUSCLE; ANTIBODIES	Sf9 cells infected with a baculovirus vector containing SERCA1 cDNA expressed immunoreactive rabbit fast-twitch muscle Ca2+-ATPase at levels up to 3 mg/liter. The microsomal fraction isolated from infected Sf9 cells catalyzed Ca2+ transport at rates 6-fold above control values. To obtain direct evidence for the postulate (Clarke, D. M., Loo, T. W., Inesi, G., and MacLennan, D. H., et al. (1989) Nature 339, 476-478) that Glu309 contributes to a Ca2+-binding site in the transmembrane sector of the Ca2+-ATPase, Ca2+ binding to wild type and mutant (Glu309 to Gln) Ca2+-ATPases was measured. The wild type Ca2+-ATPase, expressed in Sf9 cells and purified using a monoclonal antibody bound to Sepharose beads, bound approximately 1.6-1.7 mol Ca2+/mol of enzyme at 2 muM Ca2+ in a buffer favoring the E1 conformation of the enzyme and at 10 muM Ca2+ in a buffer favoring the E2 conformation. Under identical conditions, the mutant Ca2+-ATPase bound less than 0.1 mol of Ca2+/mol of enzyme in E1 buffer, but 0.8 mol Ca2+/mol in the E2 buffer. In spite of the ability of the Glu309 to Gln mutant enzyme to bind about 1 mol of Ca2+/mol of enzyme, E2P formation was not inhibited by up to 100 muM Ca2+, and E1P formation from ATP and Ca2+ was not observed with up to 100 muM Ca2+ in intact microsomal vesicles from Sf9 cells. Nevertheless, with detergent-solubilized and purified mutant Ca2+-ATPases, E2P formation was inhibited with a K0.5 of 2 muM Ca2+. These observations are consistent with the view that a single intact Ca2+-binding site is present in the mutant Ca2+-ATPase, which is accessible to Ca2+ only from the lumenal side and only in the E2 conformation. Transition from E2 to E1-Ca2+ may occur during or following Ca2+ binding, accounting for the relatively high Ca2+ affinity and inhibition by Ca2+ of phosphorylation from P(i).	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ONTARIO, CANADA; NATL RES COUNCIL CANADA, INST BIOTECHNOL RES, MONTREAL H4P 2R2, PQ, CANADA	University of Toronto; National Research Council Canada			Skerjanc, Ilona/AAN-3318-2020					ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HANEL AM, 1991, BIOCHEMISTRY-US, V30, P11320, DOI 10.1021/bi00111a019; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1985, ANNU REV PHYSIOL, V45, P574; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MACLENNAN DH, 1991, 1991 HASSL S ION PUM, P54; MACLENNAN DH, 1985, STRUCTURE FUNCTION S, P91; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MOLNAR E, 1990, BIOCHIM BIOPHYS ACTA, V1023, P147, DOI 10.1016/0005-2736(90)90410-P; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; RICHARDSON C, 1992, BACULOVIRUS RECOMBIN, P67; ROSSI B, 1979, J BIOL CHEM, V254, P2302; SKERJANC IS, 1991, MOL BIOL MUSCLE; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	35	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15944	15950						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101845				2022-12-25	WOS:A1993LN30500088
J	BRANDSCH, R; BICHLER, V; MAUCH, L; DECKER, K				BRANDSCH, R; BICHLER, V; MAUCH, L; DECKER, K			CYSTEINE TO SERINE REPLACEMENTS IN 6-HYDROXY-D-NICOTINE OXIDASE - CONSEQUENCES FOR ENZYME-ACTIVITY, COFACTOR INCORPORATION, AND FORMATION OF HIGH-MOLECULAR-WEIGHT PROTEIN COMPLEXES WITH MOLECULAR CHAPERONES (GROEL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND FLAVIN; BINDING; IDENTIFICATION; SITE; FAD	6-Hydroxy-D-nicotine oxidase, an enzyme with FAD covalently attached to the protein, contains 6 cysteine residues in positions 45 (Cys1), 59 (Cys2), 136 (Cys3), 173 (Cys4), 260 (Cys5) and 433 (Cys6). Cys2, 3, 5, and 6 were replaced with serine by site-directed mutagenesis. The effects of these exchanges on enzyme activity, the autocatalytic incorporation of the cofactor, and the interaction of the mutant proteins with molecular chaperones were analyzed. The flavinylation of 6-hydroxy-D-nicotine oxidase is dependent on the presence of allosteric effectors, e.g. glycerol 3-phosphate or other phosphorylated tricarbon compounds. Replacement of Cys2 or Cys5 abolished this dependence. Covalent incorporation of FAD was reduced to an undetectable level in the Cys3 and Cys5 mutants. Replacement of Cys6 by Ser had no significant effect on enzyme activity and cofactor attachment. Deletion of two amino acids, Phe and Arg, situated 12 and 11 amino acid residues, respectively, from the carboxyl terminus of the protein, resulted in an inactive enzyme with no covalently bound FAD. This result indicates that almost the entire protein chain has to be synthesized before the cofactor can be incorporated, making a cotranslational flavinylation step rather unlikely. The distribution of the 6-hydroxy-D-nicotine oxidase polypeptide between the high molecular weight complexes and the free soluble form was analyzed by gel filtration on Sephacryl S-200. The wild-type holoenzyme as well as the wild-type apoenzyme were recovered in the eluent fraction of the column while the mutant proteins were retained in high molecular weight complexes, predominantly in those associated with GroEL, as revealed by immunoprecipitation. The extent of complex formation with this molecular chaperone depended on the position of the mutated Cys residue within the protein. Complex formation was highest with protein from the mutants Cys2 and Cys3, less with the Cys5, and absent with the Cys6 mutant protein. Thus, alterations in the amino-terminal part of the 6-hydroxy-D-nicotine oxidase appear more important for the interaction with molecular chaperones than alterations situated in the carboxyl-terminal part of the protein.			BRANDSCH, R (corresponding author), UNIV FREIBURG,INST BIOCHEM,HERMANN HERDER STR 7,W-7800 FREIBURG,GERMANY.							Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BRANDSCH R, 1989, EUR J BIOCHEM, V182, P125, DOI 10.1111/j.1432-1033.1989.tb14808.x; DECKER K, 1991, BIOFACTORS, V3, P669; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; HEDERSTEDT L, 1989, BIOCHEM J, V260, P491, DOI 10.1042/bj2600491; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MAGUIRE JJ, 1986, BIOCHEMISTRY-US, V25, P5202, DOI 10.1021/bi00366a033; Maniatis T., 1982, MOL CLONING; MAUCH L, 1989, FEBS LETT, V257, P86, DOI 10.1016/0014-5793(89)81792-2; MAUCH L, 1990, THESIS U FREIBURG FR; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MOHLER H, 1972, EUR J BIOCHEM, V29, P152, DOI 10.1111/j.1432-1033.1972.tb01969.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6	18	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12724	12729						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8099585				2022-12-25	WOS:A1993LG65800074
J	CARROLL, K; ELROYSTEIN, O; MOSS, B; JAGUS, R				CARROLL, K; ELROYSTEIN, O; MOSS, B; JAGUS, R			RECOMBINANT VACCINIA VIRUS K3L GENE-PRODUCT PREVENTS ACTIVATION OF DOUBLE-STRANDED RNA-DEPENDENT, INITIATION FACTOR-2-ALPHA-SPECIFIC PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON; TRANSLATION; EIF-2-ALPHA; INHIBITION; BINDING; CELLS; DNA; AUTOPHOSPHORYLATION; PHOSPHORYLATION; PURIFICATION	Deletion of the vaccinia virus K3L gene, a homologue of the alpha subunit of protein synthesis initiation factor 2, has been reported to reduce the ability of the virus to grow in interferon-treated cells (Beattie, E., Tattaglia, J., and Paoletti, E. (1991) Virology 183, 419-422). Purified recombinant K3L gene product, pK3r, has potent effects on activation of double-stranded (ds) RNA-dependent, initiation factor-2alpha (eIF-2alpha)-specific protein kinase (PKR) in in vitro reactions. Recombinant pK3 prevents the inhibition of protein synthesis by dsRNA in a cell-free translation system from rabbit reticulocytes at levels equal to, or lower than, the level of endogenous eIF-2alpha. In the cell-free translation system, pK3r exerts its effects at all dsRNA concentrations tested, by preventing phosphorylation of eIF-2alpha. In addition, pK3r reduces the autophosphorylation of immunopurified PKR, as well as its ability to phosphorylate the alpha subunit of purified eIF-2. At 400 mM NaCl, in vitro translated [S-35]methionine-radiolabeled pK3 can be co-immunoprecipitated with human PKR, using a monoclonal antibody to PKR. This tight binding is consistent with a role for pK3 as a pseudosubstrate for the kinase, and identifies the amino-terminal 30% of eIF-2alpha as the domain recognized by the eIF-2alpha-specific protein kinases. In addition, the tight binding opens up the possibility of using binding assays to identify functional domains within the kinase and pK3. Recombinant pK3 also prevents activation of the heme-sensitive eIF-2alpha-specific protein kinase, eIF-2alpha-PK(h), in both cell-free translation systems as well as in partially purified preparations. This suggests some similarity between the eIF-2alpha binding domains of the two eIF-2alpha specific protein kinases.	CTR MARINE BIOTECHNOL,600 E LOMBARD ST,BALTIMORE,MD 21202; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Elroy-Stein, Orna/0000-0002-3716-1540; Moss, Bernard/0000-0002-2154-8564				AKKARAJU GR, 1989, J BIOL CHEM, V264, P10321; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; BOURSNELL MEG, 1988, J GEN VIROL, V69, P2995, DOI 10.1099/0022-1317-69-12-2995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CLEMENS M, 1992, NATURE, V360, P210, DOI 10.1038/360210a0; CLEMENS MJ, 1993, IN PRESS J INTERFERO; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DESTEFANO J, 1990, J VIROL, V64, P4445, DOI 10.1128/JVI.64.9.4445-4453.1990; ESPOSITO J, 1981, J VIROL METHODS, V2, P175, DOI 10.1016/0166-0934(81)90036-7; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GUPTA SL, 1982, VIROLOGY, V120, P495, DOI 10.1016/0042-6822(82)90051-4; HINNEBUSCH AG, 1993, TRANSLATIONAL REGULA, P87; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; JAGUS R, 1987, METHOD ENZYMOL, V152, P296; JAGUS R, 1987, METHOD ENZYMOL, V152, P267; JAGUS R, 1983, POSTTRANSLATIONAL CO, P159; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LEE TG, 1992, J BIOL CHEM, V267, P14238; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NILSEN TW, 1982, J BIOL CHEM, V257, P4593; ONIELL RE, 1989, J VIROL, V63, P5069; RICE AP, 1985, J VIROL, V54, P894, DOI 10.1128/JVI.54.3.894-898.1985; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SAFER B, 1990, EUR J BIOCHEM, V89, P696; SAMUEL CE, 1988, PROG NUCLEIC ACID RE, V35, P27, DOI 10.1016/S0079-6603(08)60609-1; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1984, J BIOL CHEM, V259, P3451; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SONENBERG N, 1990, New Biologist, V2, P402; STUDIER FW, 1990, METHOD ENZYMOL, V185, P49; WATSON JC, 1991, VIROLOGY, V185, P206, DOI 10.1016/0042-6822(91)90768-7; WHITAKERDOWLING P, 1983, VIROLOGY, V131, P128, DOI 10.1016/0042-6822(83)90539-1; WHITAKERDOWLING P, 1984, VIROLOGY, V137, P171, DOI 10.1016/0042-6822(84)90020-5	52	158	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12837	12842						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8099586				2022-12-25	WOS:A1993LG65800089
J	BERTHIAUME, L; DEICHAITE, I; PESECKIS, S; RESH, MD				BERTHIAUME, L; DEICHAITE, I; PESECKIS, S; RESH, MD			REGULATION OF ENZYMATIC-ACTIVITY BY ACTIVE-SITE FATTY ACYLATION - A NEW ROLE FOR LONG-CHAIN FATTY-ACID ACYLATION OF PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONATE-SEMIALDEHYDE DEHYDROGENASE; ISOLATED RAT HEPATOCYTES; PALMITOYL COENZYME-A; PROPIONIC-ACID; METABOLISM; LIVER; INHIBITION; OXIDATION; CARNITINE; COA	Methylmalonate semialdehyde dehydrogenase (MMSDH) is a mitochondrial enzyme which can be acylated by myristoyl-CoA analogs (Deichaite, I., Berthiaume, L., Peseckis, S. M., Patton, W. F., and Resh, M. D. (1993) J. Biol. Chem. 268, 13788-13747). Here we describe the mechanisms which mediate regulation of the enzymatic activity of bovine MMSDH by long chain fatty acylation. The substrate specificity of the acylation reaction was measured in vitro using purified MMSDH and the coenzyme A derivative of an I-125-labeled long chain fatty acid (13-iodotridecanoate), an analog of myristoyl-CoA. Long chain fatty acyl CoAs (>8 carbons) were able to inhibit radiolabeling of MMSDH. In order to study the physiological role of the acylation process in vivo, a system using highly purified mitochondria from COS-1 cells overexpressing MMSDH was exploited. MMSDH was shown to be processed properly, targeted to the mitochondrial fraction, and enzymatically active. The extent of fatty acylation of MMSDH as well as of other mitochondrial proteins was correlated with the mitochondrial energy level. Biochemical evidence as well as site-specific mutagenesis of cysteine 319 revealed that this highly conserved active site cysteine of MMSDH was the target of the fatty acylation. Another member of the aldehyde dehydrogenase family, yeast aldehyde dehydrogenase was also covalently modified by [I-125]13-iodotridecanoyl-CoA and thereby inactivated. Furthermore, we demonstrate that glutamate dehydrogenase, an enzyme that has been previously shown to be strongly inhibited by palmitoyl-CoA, is fatty acylated by the I-125-labeled myristoyl-CoA analog. Our data suggest that attachment of long chain fatty acids to proteins is a new and potentially widespread type of enzyme regulation mechanism that we denote active site fatty acylation.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Deichaite, Ida/0000-0001-8839-0573; Berthiaume, Luc/0000-0003-0926-059X; Resh, Marilyn/0000-0001-6118-9466	NATIONAL CANCER INSTITUTE [P30CA008748, R01CA052405] Funding Source: NIH RePORTER; NCI NIH HHS [CA52405, NCI-P30-CA 08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BRASS EP, 1986, BIOCHIM BIOPHYS ACTA, V888, P18, DOI 10.1016/0167-4889(86)90065-0; BRASS EP, 1986, BIOCHEM J, V236, P131, DOI 10.1042/bj2360131; BRASS EP, 1988, BIOCHEM J, V250, P819, DOI 10.1042/bj2500819; BREMER J, 1978, BIOCHIM BIOPHYS ACTA, V528, P269, DOI 10.1016/0005-2760(78)90016-4; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; BRYLA J, 1967, BIOCHIM BIOPHYS ACTA, V143, P285, DOI 10.1016/0005-2728(67)90082-5; BUFFINGTON CK, 1979, J BIOL CHEM, V254, P453; DEICHAITE I, 1993, J BIOL CHEM, V268, P1378; Deschenes RJ, 1990, CURR OPIN CELL BIOL, V2, P1108, DOI 10.1016/0955-0674(90)90164-A; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; GLASGOW AM, 1976, PEDIATR RES, V10, P683, DOI 10.1203/00006450-197610070-00010; GOLDBERG AL, 1978, FED PROC, V37, P2301; GOODWIN GW, 1989, J BIOL CHEM, V264, P14965; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HOCHACHKA PW, 1977, FED PROC, V36, P2009; JAKOBY WB, 1963, ENZYMES, V7, P203; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSON WA, 1972, BIOCHEMISTRY-US, V11, P1967, DOI 10.1021/bi00760a036; KASINATHAN C, 1990, J BIOL CHEM, V265, P5139; KAWAGUCHI A, 1974, J BIOL CHEM, V249, P5793; KAWAGUCHI A, 1976, J BIOL CHEM, V251, P1406; KEDISHVILI NY, 1992, J BIOL CHEM, V267, P19724; LATIPAA PM, 1986, BIOCHIM BIOPHYS ACTA, V875, P293, DOI 10.1016/0005-2760(86)90179-7; MOREL F, 1974, FEBS LETT, V39, P133, DOI 10.1016/0014-5793(74)80035-9; OLOWE Y, 1980, EUR J BIOCHEM, V109, P425, DOI 10.1111/j.1432-1033.1980.tb04811.x; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RYDSTROM J, 1972, EUR J BIOCHEM, V31, P496, DOI 10.1111/j.1432-1033.1972.tb02557.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHULZ H, 1985, BIOCH LIPIDS MEMBRAN, P118; SCHWARZ H, 1992, BIOTECHNIQUES, V13, P205; SOBOLL S, 1985, BIOCHIM BIOPHYS ACTA, V807, P245, DOI 10.1016/0005-2728(85)90255-5; STORRIE B, 1990, METHOD ENZYMOL, V182, P214; STUCKI JW, 1989, J BIOL CHEM, V264, P6376; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WHITMER JT, 1978, J BIOL CHEM, V253, P4305; WILLIAMSON JR, 1979, J BIOL CHEM, V254, P1511; WOJTCZAK L, 1976, J BIOENERG BIOMEMBR, V8, P293	44	59	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6498	6505						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120000				2022-12-25	WOS:A1994MZ50300038
J	PERTOVAARA, L; KAIPAINEN, A; MUSTONEN, T; ORPANA, A; FERRARA, N; SAKSELA, O; ALITALO, K				PERTOVAARA, L; KAIPAINEN, A; MUSTONEN, T; ORPANA, A; FERRARA, N; SAKSELA, O; ALITALO, K			VASCULAR ENDOTHELIAL GROWTH-FACTOR IS INDUCED IN RESPONSE TO TRANSFORMING GROWTH-FACTOR-BETA IN FIBROBLASTIC AND EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PERMEABILITY FACTOR; TYROSINE KINASE; MESSENGER-RNA; FACTOR FAMILY; C-FOS; DIFFERENTIATION; ANGIOGENESIS; MITOGEN; PROTEIN; STIMULATION	Transforming growth factor beta (TGF-beta) is a multifunctional polypeptide that regulates the proliferation and differentiation of various cells and has an angiogenic effect in vivo although it inhibits the growth of cultured endothelial cells. We report here that TGF-beta treatment of quiescent cultures of mouse embryo-derived AKR-2B cells, which are growth-stimulated by TGF-beta, and human lung adenocarcinoma A549 cells, which are growth-inhibited by TGF-beta, results in the induction of vascular endothelial growth factor (VEGF) mRNA and protein. Maximal VEGF mRNA levels occurred 4-8 h after stimulation with a decline to background levels in 24 h. In contrast, the related placenta growth factor mRNA was not induced by TGF-beta in these cells. No VEGF receptor mRNA was seen in AKR SB cells. Also, TGF-beta treatment of endothelial cells, which express the FLT1 and KDR/FLK-1 receptors for VEGF, did not cause VEGF induction. Because VEGF is known to be a strong angiogenic factor for endothelial cells, the results suggest that the angiogenic effect of TGF-beta on endothelial cells in blood vessels may be mediated at least partly by a paracrine induction of VEGF in other surrounding cell types.	UNIV HELSINKI,DEPT PATHOL,MOLEC CANC BIOL LAB,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT VIROL,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT OBSTET & GYNECOL,SF-00290 HELSINKI 29,FINLAND; GENENTECH INC,S SAN FRANCISCO,CA 94080	University of Helsinki; University of Helsinki; University of Helsinki; Roche Holding; Genentech			Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Mustonen, Tuija/0000-0002-2429-5064				ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BREIER G, 1992, DEVELOPMENT, V114, P521; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KLAGSBRUN M, 1991, PEPTIDE GROWTH FACTO, P549; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MILLAUER B, 1993, CELL, V72, P1; MOSES HL, 1985, CANCER CELL, V3, P65; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PERTOVAARA L, 1993, GROWTH FACTORS, V9, P81, DOI 10.3109/08977199308991584; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Sambrook J, 1989, MOL CLONING LABORATO; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0	38	609	637	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6271	6274						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119973				2022-12-25	WOS:A1994MZ50300004
J	WERNER, A; KEMPSON, SA; BIBER, J; MURER, H				WERNER, A; KEMPSON, SA; BIBER, J; MURER, H			INCREASE OF NA/P-I-COTRANSPORT ENCODING MESSENGER-RNA IN RESPONSE TO LOW P-I DIET IN RAT-KIDNEY CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; BRUSH-BORDER MEMBRANE; EXPRESSION; TRANSPORT; PHOSPHATE; FLUIDITY; SYSTEM	Renal proximal Na/P-i-cotransport is increased in response to low dietary P-i intake. Recently, a cDNA (NaPi-2) related to the rat renal brush membrane Na/P-i-cotransporter has been cloned. In the present study, we used rats fed for 6 days with either a low P-i diet (LPD) or a high P-i diet (HPD), respectively. In parallel to an increased renal brush-border membrane Na/P-i-cotransport in LPD rats, there was also an increased content of NaPi-2 mRNA in renal cortex. After injection into Xenopus laevis oocytes, mRNA isolated from LPD rats induced a greater increase in Na/P-i-cotransport compared to mRNA from HPD rats. Hybrid depletion experiments suggested that mRNA induced Na/P-i-cotransport is related to NaPi-2. We conclude that chronic P-i deprivation leads to an increased brush border membrane Na/P-i-cotransport via an increase in the level of (NaPi-2) mRNA.	INDIANA UNIV,MED CTR,DEPT PHYSIOL & BIOPHYS,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis	WERNER, A (corresponding author), UNIV ZURICH,DEPT PHYSIOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.				NIDDK NIH HHS [DK 32148] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032148] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; Berndt T. J., 1992, KIDNEY PHYSL PATHOPH, P2511; BIBER J, 1981, BIOCHIM BIOPHYS ACTA, V647, P169, DOI 10.1016/0005-2736(81)90243-1; DENNIS VW, 1992, RENAL PHYSL, P1785; LEVI M, 1989, AM J PHYSIOL, V256, pF85, DOI 10.1152/ajprenal.1989.256.1.F85; LEVINE BS, 1991, AM J PHYSIOL, V260, pF613, DOI 10.1152/ajprenal.1991.260.5.F613; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MEYERHOF W, 1990, FEBS LETT, V266, P192, DOI 10.1016/0014-5793(90)81537-X; MURER H, 1992, HDB PHYSL 8, V2, P2165; MURER H, 1992, KIDNEY PHYSL PATHOPH, P2481; SHATZ SV, 1979, J CLIN INVEST, V64, P955; WERNER A, 1990, J BIOL CHEM, V265, P12331; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; YUSUFI ANK, 1989, AM J PHYSIOL, V256, pF852, DOI 10.1152/ajprenal.1989.256.5.F852	15	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6637	6639						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120016				2022-12-25	WOS:A1994MZ50300059
J	KIESER, A; WELCH, HA; BRANDNER, G; MARME, D; KOLCH, W				KIESER, A; WELCH, HA; BRANDNER, G; MARME, D; KOLCH, W			MUTANT P53 POTENTIATES PROTEIN-KINASE-C INDUCTION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR EXPRESSION	ONCOGENE			English	Note							SWISS 3T3 CELLS; FACTOR GENE; TRANSFORMATION; INHIBITION; MUTATIONS; ONCOGENE; TUMORS; RAS; ANGIOGENESIS; MODULATION	Many tumor cells produce vascular endothelial growth factor (VEGF), which is thought to be a pivotal mediator of tumor neoangiogenesis. Expression of the VEGF gene can be induced by tumor promoting phorbol esters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA), which activate protein kinase C (PKC). Here we show that in transient transfection assays a mutated form of the murine p53 tumor suppressor gene (ala135-->val) induces expression of VEGF mRNA and potentiates TPA stimulated VEGF mRNA expression. In NM 3T3 cells which stably overexpress the temperature sensitive p53 (ala135-->val), displaying mutant phenotype at 37 degrees C and wildtype phenotype at 32.5 degrees C, induction of VEGF mRNA and protein by activated PKC is strongly synergistic with mutant, but not wildtype p53. Mutant p53 specifically increases TPA induction of VEGF without affecting the expression of other TPA inducible genes. TPA dependent VEGF expression is also enhanced by human p53 mutated at amino acid 175. Thus, our data link PKC and p53, the gene most frequently altered in human tumors, with the regulation of tumor angiogenesis.	GODECKE AG,UNIV FREIBURG,INST MOLEK ZELLBIOL,W-7800 FREIBURG,GERMANY; UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,W-7800 FREIBURG,GERMANY; GODECKE AG,BIOL RES & DEV,W-7800 FREIBURG,GERMANY	University of Freiburg; University of Freiburg			Kolch, Walter/ABF-2102-2021; Kieser, Arnd/M-4616-2014	Kieser, Arnd/0000-0003-0783-1950; Kolch, Walter/0000-0001-5777-5016				AKINAGA S, 1991, CANCER RES, V51, P4888; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; Folkman J, 1992, Semin Cancer Biol, V3, P65; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIM RW, 1987, ONCOGENE, V1, P263; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER CW, 1993, ONCOGENE, V8, P1815; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; WEINSTEIN IB, 1990, ADV 2ND MESSENGER PH, V26, P307; ZARLING JM, 1973, J NATL CANCER I, V50, P137, DOI 10.1093/jnci/50.1.137; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	39	410	428	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					963	969						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108142				2022-12-25	WOS:A1994MW55100035
J	CLEVENGER, CV; TORIGOE, T; REED, JC				CLEVENGER, CV; TORIGOE, T; REED, JC			PROLACTIN INDUCES RAPID PHOSPHORYLATION AND ACTIVATION OF PROLACTIN RECEPTOR-ASSOCIATED RAF-1 KINASE IN A T-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SERINE-THREONINE KINASE; PROTEIN-TYROSINE KINASE; CLONED LYMPHOCYTES-T; RAT LYMPHOMA-CELLS; MONOCLONAL-ANTIBODIES; HYPOPHYSECTOMIZED RATS; SIGNAL TRANSDUCTION; NB2 LYMPHOMA; C-RAF	The receptor for prolactin (PRL) is a member of the hematopoietic receptor family that also includes the receptors for interleukins 2-7. PRL is synthesized and is secreted by human T lymphocytes and acts as a lymphokine necessary, but not sufficient, for T lymphocyte progression through the G(1) phase of the cell cycle. Although data now indicate that PRL serves an immunomodulatory role in vitro and in vivo, the mechanisms. of PRL receptor signal transduction in T cells have not been defined. We demonstrate here that PRL induced the phosphorylation of the p72-74 serine/threonine kinase c-Raf-1 in the PRL-dependent rat T-cell line Nb2. Associated with this inducible phosphorylation of Raf-1 was a concentration- and time-dependent activation of in vitro Raf-1 autokinase and substrate kinase activities, which correlated with the PRL-induced proliferation of Nb2 cells. Co-immunoprecipitation studies revealed association of Raf-1 with PRL receptors in Nb2 cells. These results revealed that all isoforms of the PRL receptor (short, intermediate, and long) are expressed in Nb2 cells and associate with Raf-1. In contrast to the PRL-dependent Nb2 cells, phosphorylation and activation of Raf-1 were constitutive in the Nb2-derived, PRL-independent, T-cell line Sp. These studies demonstrate for the first time an association between the PRL receptor and a serine/threonine kinase affiliated with signal transduction.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	University of Pennsylvania; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA054957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033510] Funding Source: NIH RePORTER; NCI NIH HHS [CA-54957] Funding Source: Medline; NIAID NIH HHS [AI-33510] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI S, 1991, J BIOL CHEM, V266, P20110; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BANARJEE R, 1992, MOL CELL ENDOCRINOL, V90, P61; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNTON EW, 1988, SCIENCE, V239, P401, DOI 10.1126/science.3122324; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLEVENGER CV, 1990, ENDOCRINOLOGY, V127, P3151, DOI 10.1210/endo-127-6-3151; CLEVENGER CV, 1991, SCIENCE, V253, P77, DOI 10.1126/science.2063207; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; CLEVENGER CV, 1992, ENDOCRINOLOGY, V130, P3216, DOI 10.1210/en.130.6.3216; CLEVENGER CV, 1987, J CELL PHYSIOL, V130, P336, DOI 10.1002/jcp.1041300305; ELBERG G, 1990, J BIOL CHEM, V265, P14770; GOUT PW, 1980, CANCER RES, V40, P2433; HARTMANN DP, 1989, FASEB J, V3, P2194, DOI 10.1096/fasebj.3.10.2787766; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KANAKURA Y, 1991, BLOOD, V77, P243; KATOH M, 1987, ENDOCRINOLOGY, V120, P739, DOI 10.1210/endo-120-2-739; KAVACINA KS, 1990, J BIOL CHEM, V265, P12115; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NAGY E, 1978, ACTA ENDOCRINOL-COP, V89, P530; NAGY E, 1983, IMMUNOPHARMACOLOGY, V6, P231, DOI 10.1016/0162-3109(83)90023-1; NAGY E, 1991, ENDOCRINOLOGY, V128, P2776, DOI 10.1210/endo-128-6-2776; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; RAYHEL EJ, 1990, J CELL BIOCHEM, V43, P327, DOI 10.1002/jcb.240430405; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; RILLEMA JA, 1989, BIOCHIM BIOPHYS ACTA, V1014, P78, DOI 10.1016/0167-4889(89)90243-7; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RUI H, 1992, J BIOL CHEM, V267, P24076; SISSOM JF, 1988, AM J PATHOL, V133, P589; SOZERI O, 1992, ONCOGENE, V7, P2259; TAKACS L, 1985, CLIN EXP IMMUNOL, V59, P37; TAMAKI T, 1992, CANCER RES, V52, P566; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TOO CKL, 1989, ENDOCRINOLOGY, V124, P2185, DOI 10.1210/endo-124-5-2185; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WILLIAMS LT, 1991, COLD SH Q B, V56, P243; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	48	119	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5559	5565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119890				2022-12-25	WOS:A1994MY84000017
J	DECHERT, U; ADAM, M; HARDER, KW; CLARKLEWIS, I; JIRIK, F				DECHERT, U; ADAM, M; HARDER, KW; CLARKLEWIS, I; JIRIK, F			CHARACTERIZATION OF PROTEIN-TYROSINE-PHOSPHATASE SH-PTP2 - STUDY OF PHOSPHOPEPTIDE SUBSTRATES AND POSSIBLE REGULATORY ROLE OF SH2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; STIMULATING FACTOR-I; KINASE INSERT; SEQUENCE SIMILARITY; CSF-1 RECEPTOR; HUMAN-PLACENTA; PDGF RECEPTOR; PURIFICATION; AUTOPHOSPHORYLATION; PHOSPHORYLATION	The src homology 2 (SH2) domain containing protein-tyrosine-phosphatase SH-PTP2, was over-expressed in Escherichia coli for a kinetic study employing a set of synthetic 13- to 14-mer phosphopeptide substrates. The full-length SH-PTP2 protein, as well as a truncated form, lacking the two amino terminus SH2 domains (SH-PTP2(Delta SH2)), exhibited Michaelis-Menten kinetics, and demonstrated striking substrate preferences on phosphopeptides having sequences based on sites of intracellular protein tyrosine phosphorylation. For example, while a K-M of 59 mu M and k(cat)/K-M of 1.1 x 10(5) were obtained using SH-PTP2(Delta SH2) and PDGFR(Y1021), a phosphorylation site within the platelet-derived growth factor receptor, other peptides revealed no detectable phosphate release. PDGFR(Y1009), modeled after a sequence identified as an in vivo binding site for SH-PTP2, was also a good substrate for this enzyme. The truncated form, lacking the SH2 domains demonstrated higher catalytic efficiency than the full-length enzyme. Interestingly, soluble SH2 domains were found to inhibit the catalytic activity of SH-PTP2 in a concentration-dependent manner. There was also evidence of a non-phosphotyrosine-mediated association between the two domains, These observations suggested that the SH2 domains have a direct role in regulating the catalytic activity of SH(-)PTP2.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA; MERCK FROSST CTR THERAPEUT RES, POINTE CLAIRE H9R 4P8, PQ, CANADA	University of British Columbia; University of British Columbia; Merck & Company								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BASTIEN L, 1993, BIOCHEM BIOPH RES CO, V196, P124, DOI 10.1006/bbrc.1993.2224; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FENG GS, 1993, NATURE, V259, P1607; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GILBERT DG, 1982, ENZYME KINETICS; HASEGAWA H, 1982, ANAL BIOCHEM, V120, P360, DOI 10.1016/0003-2697(82)90358-X; HIRAGA A, 1992, EUR J BIOCHEM, V209, P195, DOI 10.1111/j.1432-1033.1992.tb17277.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; ITOH M, 1992, J BIOL CHEM, V267, P12356; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LEE AWM, 1992, CURR TOP CELL REGUL, V32, P73; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VOGEL W, 1993, NATURE, V259, P1611; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5602	5611						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119896				2022-12-25	WOS:A1994MY84000023
J	SCHNITZER, JE; OH, P				SCHNITZER, JE; OH, P			ALBONDIN-MEDIATED CAPILLARY-PERMEABILITY TO ALBUMIN - DIFFERENTIAL ROLE OF RECEPTORS IN ENDOTHELIAL TRANSCYTOSIS AND ENDOCYTOSIS OF NATIVE AND MODIFIED ALBUMINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; BLOOD-BRAIN-BARRIER; PERFUSED RAT LUNGS; SERUM-ALBUMIN; MICROVASCULAR ENDOTHELIUM; BINDING-PROTEINS; FATTY-ACIDS; TRANSENDOTHELIAL TRANSPORT; GLYCOSYLATED ALBUMIN; CELL-SURFACE	Specific albumin binding to the surface of endothelium initiates its transcytosis across continuous endothelium via noncoated plasmalemmal vesicles. Past work has identified several putative albumin-binding proteins (SPARC, gp60, gp30, and gp18). In this study, we examined the specific role of these proteins in the binding of bovine serum albumin (BSA) to endothelium. The 60-kDa albumin-binding protein (gp60, now called albondin) was purified from cultured rat microvascular endothelial cells for antibody production. Anti-albondin antibodies (alpha gp60) specifically recognized albondin expressed by rat, bovine, and human endothelial cells (EC). alpha gp60 and unlabeled native BSA inhibited I-125-BSA binding to confluent EC monolayers and to both albondin and SPARC extracts immobilized on filters. Modification of BSA by maleic anhydride treatment (Mal-BSA) or by surface adsorption to colloidal gold particles (A-Au) renders the Ligand specific for gp30 and gp18 while eliminating its ability to inhibit I-125-BSA binding to EC and to both albondin and SPARC extracts. Mal-BSA and A-Au interacted with EC via distinct binding sites not recognizing native BSA EC internalization of I-125-BSA is inhibited by unlabeled BSA and alpha gp60 IgG but not nonimmune IgG, Mal-BSA, or A-Au. Conversely internalization of modified BSA is inhibited by unlabeled modified BSA but not BSA or alpha gp60 IgG. Specific (125)Ig-BSA transendothelial transport in rat lungs perfused in situ and for EC monolayers in vitro is inhibited (greater than or equal to 90%) by unlabeled BSA and alpha gp60 IgG but not nonimmune IgG and Mal-BSA. No specific transport of I-125-Mal-BSA is detected across bovine lung microvascular endothelial cell monolayers, only paracellular and/or fluid-phase transport. Low temperatures reduce BSA transport by 5-fold and Mal-BSA by 2-fold. Interestingly, 3-fold more native BSA is transported than Mal-BSA at 37 degrees C, whereas at 8-10 degrees C they are nearly equal, suggesting facilitation of BSA transport. Cumulatively, it appears that gp30 and gp18 mediate the binding, endocytosis, and degradation of modified albumins, whereas albondin mediates native albumin binding which significantly enhances its transcytosis and capillary permeability.	UNIV CALIF SAN DIEGO,SCH MED,INST BIOMED ENGN,DEPT MED & PATHOL,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego	SCHNITZER, JE (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,RES N,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043278] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43278] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUMBASIREVIC V, 1990, J SUBMICR CYTOL PATH, V22, P135; CURRY FRE, 1985, FED PROC, V44, P2610; CZARTOLOMNA J, 1991, J APPL PHYSIOL, V70, P1854, DOI 10.1152/jappl.1991.70.4.1854; DRINKER CK, 1927, J PHYSIOL-LONDON, V98, P109; FARRELL CL, 1991, P NATL ACAD SCI USA, V88, P5779, DOI 10.1073/pnas.88.13.5779; FRIDEN PM, 1991, P NATL ACAD SCI USA, V88, P4771, DOI 10.1073/pnas.88.11.4771; GALIS Z, 1988, EUR J CELL BIOL, V47, P358; GAMBLE J, 1983, J PHYSIOL-LONDON, V387, P69; GEOFFROY JS, 1984, J ULTRA MOL STRUCT R, V89, P223, DOI 10.1016/S0022-5320(84)80039-8; GHINEA N, 1989, J BIOL CHEM, V264, P4755; GHINEA N, 1988, J CELL BIOL, V107, P231, DOI 10.1083/jcb.107.1.231; GHITESCU L, 1992, J CELL BIOL, V117, P745, DOI 10.1083/jcb.117.4.745; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HARALDSSON B, 1987, ACTA PHYSIOL SCAND, V129, P127, DOI 10.1111/j.1748-1716.1987.tb08047.x; HE P, 1993, AM J PHYSIOL, V265, pH74, DOI 10.1152/ajpheart.1993.265.1.H74; HUTTER JF, 1984, BASIC RES CARDIOL, V79, P274; HUXLEY VH, 1991, AM J PHYSIOL, V260, pH1645, DOI 10.1152/ajpheart.1991.260.5.H1645; HUXLEY VH, 1985, AM J PHYSIOL, V248, pH264, DOI 10.1152/ajpheart.1985.248.2.H264; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; KERN DF, 1983, AM J PHYSIOL, V245, pH229, DOI 10.1152/ajpheart.1983.245.2.H229; KING GL, 1985, SCIENCE, V227, P1583, DOI 10.1126/science.3883490; LEVICK JR, 1973, Q J EXP PHYSIOL CMS, V58, P87, DOI 10.1113/expphysiol.1973.sp002194; MANN GE, 1981, J PHYSIOL-LONDON, V319, P311, DOI 10.1113/jphysiol.1981.sp013910; MELSERT R, 1991, MOL CELL ENDOCRINOL, V82, P23, DOI 10.1016/0303-7207(91)90005-D; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; Palade GE, 1988, ENDOTHELIAL CELL BIO, P3; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PREDESCU D, 1988, J CELL BIOL, V107, P1729, DOI 10.1083/jcb.107.5.1729; RENKIN EM, 1985, J APPL PHYSIOL, V134, P375; SAGE H, 1984, J BIOL CHEM, V259, P3993; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SCHAEFFER RC, 1992, AM J PHYSIOL, V263, pL27, DOI 10.1152/ajplung.1992.263.1.L27; SCHNEEBERGER EE, 1984, AM J PHYSIOL, V247, pH206, DOI 10.1152/ajpheart.1984.247.2.H206; SCHNITZER JE, 1990, EUR J CELL BIOL, V52, P241; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; SCHNITZER JE, 1990, P NATL ACAD SCI USA, V87, P6843, DOI 10.1073/pnas.87.17.6843; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SCHNITZER JE, 1988, AM J PHYSIOL, V254, pH425, DOI 10.1152/ajpheart.1988.254.3.H425; SCHNITZER JE, 1992, AM J PHYSIOL, V263, pH1872, DOI 10.1152/ajpheart.1992.263.6.H1872; SCHNITZER JE, 1992, AM J PHYSIOL, V262, pH246, DOI 10.1152/ajpheart.1992.262.1.H246; SCHNITZER JE, 1992, AM J PHYSIOL, V263, pH48, DOI 10.1152/ajpheart.1992.263.1.H48; SCHNITZER JE, 1992, MOL BIOL CELL, V3, P59; Sober HA, 1970, HDB BIOCH; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; TAVASSOLI M, 1986, J CELL BIOL, V102, P1298, DOI 10.1083/jcb.102.4.1298; TAYLOR AE, 1984, HDB PHYSL 2, P467; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; VILLASCHI S, 1986, MICROVASC RES, V32, P190, DOI 10.1016/0026-2862(86)90053-1; WAGNER RC, 1983, MICROVASC RES, V25, P387, DOI 10.1016/0026-2862(83)90028-6; WEISIGER R, 1981, SCIENCE, V211, P1048, DOI 10.1126/science.6258226; WILLIAMS SK, 1981, P NATL ACAD SCI-BIOL, V78, P2393, DOI 10.1073/pnas.78.4.2393; YOKOTA S, 1983, BIOMED RES-TOKYO, V4, P577, DOI 10.2220/biomedres.4.577	56	262	278	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6072	6082						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119952				2022-12-25	WOS:A1994MY84000090
J	TAUSSIG, R; TANG, WJ; HEPLER, JR; GILMAN, AG				TAUSSIG, R; TANG, WJ; HEPLER, JR; GILMAN, AG			DISTINCT PATTERNS OF BIDIRECTIONAL REGULATION OF MAMMALIAN ADENYLYL CYCLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ISLET-ACTIVATING PROTEIN; AMINO-TERMINAL REGION; GS-ALPHA; EXPRESSION; CLONING; CELLS; CALMODULIN; BRAIN; IDENTIFICATION	The capacities of the cu subunits of pertussis toxin-sensitive guanine nucleotide-binding regulatory proteins (G proteins) to inhibit different isoforms of mammalian adenylyl cyclases were assessed. Membranes from Sf9 cells infected with recombinant baculoviruses encoding either type I, II, V, or VI adenylyI cyclase were reconstituted with purified G protein subunits. Types V and VI adenylyl cyclase are most sensitive to inhibition by G(i alpha 1) G(i alpha 2) and G(i alpha 3); type I adenylyl cyclase can be inhibited by these three G(i alpha) proteins and by G(o alpha) as well. Type II adenylyl cyclase appears to be immune to inhibition by these proteins. Examination of the effects of native and mutant G(i alpha) proteins, as well as analysis of competition for binding of G(s alpha) to adenylyl cyclases, indicate that at least certain adenylyl cyclases have independent sites for interaction with G(s alpha) (site 1, stimulatory) and G(i alpha) (site 2, inhibitory). High concentrations of G(i alpha) can interact with site 1 on types I and II adenylyl cyclase and activate the enzymes. Types I and II adenylyl cyclase also appear to have independent sites for interaction with G protein beta gamma subunits. The type I enzyme is strongly inhibited, while type II adenyIyI cyclase is activated if G(s alpha) is also present.			TAUSSIG, R (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.			Tang, Wei-Jen/0000-0002-8267-8995	NIGMS NIH HHS [GM13569, GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497, F32GM013569] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEBERNARDI MA, 1993, MOL PHARMACOL, V43, P451; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAZEKI O, 1981, J BIOL CHEM, V256, P2856; HELLEVUO K, 1993, BIOCHEM BIOPH RES CO, V192, P311, DOI 10.1006/bbrc.1993.1415; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; ITOH H, 1991, J BIOL CHEM, V266, P16226; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KATADA T, 1982, J BIOL CHEM, V257, P3739; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEE E, 1993, IN PRESS METHODS ENZ; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; NAVON SE, 1987, J BIOL CHEM, V262, P15746; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Summers MD, 1987, MANUAL METHODS BACUL; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; UEDA N, 1994, J BIOL CHEM, V269, P4388; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	50	285	292	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6093	6100						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119955				2022-12-25	WOS:A1994MY84000093
J	IBRAHIM, HR; YAMADA, M; MATSUSHITA, K; KOBAYASHI, R; KATO, A				IBRAHIM, HR; YAMADA, M; MATSUSHITA, K; KOBAYASHI, R; KATO, A			ENHANCED BACTERICIDAL ACTION OF LYSOZYME TO ESCHERICHIA-COLI BY INSERTING A HYDROPHOBIC PENTAPEPTIDE INTO ITS C-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; EGG-WHITE LYSOZYME; SACCHAROMYCES-CEREVISIAE; MEMBRANE; PROTEIN; CONVERSION; BINDING; MODEL; ACID	The mechanism of the enhanced bactericidal action to Escherichia coli of the lysozyme having a hydrophobic pentapeptide (Phe-Phe-Val-Ala-Pro) at its C terminus was investigated. The modified lysozyme, hydrophobic pentapeptide-fused lysozyme (HLz), was secreted in the culture medium from yeast harboring the expression plasmid, in which a synthetic DNA fragment encoding a hydrophobic pentapeptide was introduced to the 3'-end of the coding region of the lysozyme cDNA. Although CD analysis showed that HLz was considerably different from wild-type lysozyme (WLz) in the secondary and tertiary structures, it retained 76% of the lytic activity of WLz. When E. coli cells were exposed to the WLz or HLz, the survival cells were significantly reduced only in the case of HLz. Periplasmic proteins from the HLz-treated cells were released to an extent similar to that from the WLz-treated cells, indicating that HLz has nearly the same action as WLz with respect to the disruption of the outer membrane and peptidoglycan. Experiments with E. coli phospholipid liposomes revealed that HLz dissipated the valinomycin-induced transmembrane electrochemical potential, but WLz did not. These results suggest that the enhanced bactericidal action of HLz to E. coli is due to disruption of the electrochemical potential of the inner membrane in cooperation with the inherent function of the lysozyme to the outer membrane and peptidoglycan.	YAMAGUCHI UNIV,FAC AGR,DEPT BIOL CHEM,YAMAGUCHI 753,JAPAN	Yamaguchi University			Ibrahim, Hisham/AAB-3945-2021	Ibrahim, Hisham/0000-0002-7809-900X; Yamada, Mamoru/0000-0003-4354-7324				ALDERTON G, 1946, J BIOL CHEM, V164, P1; CITTI JE, 1965, J BACTERIOL, V89, P937, DOI 10.1128/JB.89.4.937-942.1965; DEPETRIS S, 1967, J ULTRA MOL STRUCT R, V19, P45, DOI 10.1016/S0022-5320(67)80059-5; HOVDE CJ, 1986, INFECT IMMUN, V52, P90, DOI 10.1128/IAI.52.1.90-95.1986; IBRAHIM HR, 1991, J AGR FOOD CHEM, V39, P2077, DOI 10.1021/jf00011a039; IBRAHIM HR, 1992, BIOSCI BIOTECH BIOCH, V56, P1361, DOI 10.1271/bbb.56.1361; INOUYE M, 1974, P NATL ACAD SCI USA, V71, P2396, DOI 10.1073/pnas.71.6.2396; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOLLES P, 1984, MOL CELL BIOCHEM, V63, P165; KITA K, 1982, J BIOL CHEM, V257, P7933; KONINGS WN, 1973, P NATL ACAD SCI USA, V70, P3376, DOI 10.1073/pnas.70.12.3376; KUMAGAI I, 1989, J BIOCHEM-TOKYO, V105, P946, DOI 10.1093/oxfordjournals.jbchem.a122784; KUMAGAI I, 1987, J BIOCHEM-TOKYO, V102, P733, DOI 10.1093/oxfordjournals.jbchem.a122111; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LEIVE L, 1974, ANN NY ACAD SCI, V235, P109, DOI 10.1111/j.1749-6632.1974.tb43261.x; Malymy M., 1966, METHODS ENZYMOLOGY, V9, P639, DOI [10.1016/0076-6879(66)09129-8, DOI 10.1016/0076-6879(66)09129-8]; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; MIYANOHARA A, 1986, J VIROL, V59, P176, DOI 10.1128/JVI.59.1.176-180.1986; MURRAY RGE, 1965, CAN J MICROBIOL, V11, P547, DOI 10.1139/m65-072; OHNO N, 1989, J BIOL CHEM, V264, P4434; OSTERMAN DG, 1985, J CELL BIOCHEM, V29, P57, DOI 10.1002/jcb.240290202; SHAFER WM, 1991, J BIOL CHEM, V266, P112; SHAFER WM, 1990, MOL MICROBIOL, V4, P1269, DOI 10.1111/j.1365-2958.1990.tb00706.x; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILKINSON RG, 1972, J GEN MICROBIOL, V70, P527, DOI 10.1099/00221287-70-3-527; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0	27	98	110	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5059	5063						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106483				2022-12-25	WOS:A1994MX57100058
J	MASUDA, S; STRUGNELL, S; CALVERLEY, MJ; MAKIN, HLJ; KREMER, R; JONES, G				MASUDA, S; STRUGNELL, S; CALVERLEY, MJ; MAKIN, HLJ; KREMER, R; JONES, G			IN-VITRO METABOLISM OF THE ANTIPSORIATIC VITAMIN-D ANALOG, CALCIPOTRIOL, IN 2 CULTURED HUMAN KERATINOCYTE MODELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOSARCOMA CELLS; TUMOR PROGRESSION; MC-903; 1,25-DIHYDROXYVITAMIN-D3; INVITRO; OSTEOCALCIN; RECEPTOR; PROTEIN; AFFINITY; BINDING	Calcipotriol (MC903) is a side chain analog of the vitamin D hormone calcitriol, containing a 22-23 double bond, a 24(S)-hydroxyl function, and carbons 25, 26, and 27 incorporated into a cyclopropane ring which has been developed for treating psoriasis. The in vitro metabolism of calcipotriol was studied in two keratinocyte cell models, HPK1A and HPK1A-ras. Calcipotriol was initially converted into the 24-ketone (MC1046) and its 22,23-hydrogenated derivative (MC1080), metabolites observed in osteosarcoma, kidney, and hepatoma cell lines. We also observed the formation of further metabolites, identified as the two 23-hydroxylated derivatives of MC1080 (MC1439 and MC1441), the two 23,24-dihydroxylated compounds (MC1575 and 1577), and the side chain-cleaved compounds, tetranor-1,23-(OH)(2)D-3 and calcitroic acid, the end products of catabolism of calcitriol. These findings suggest that calcitriol and calcipotriol may share catabolic enzymes. The biological activity of each of the principal metabolites of calcipotriol, assessed using a growth hormone reporter gene transcriptional activation system and a vitamin D receptor assay, was found to be lower than that of calcipotriol. If the extensive in vitro metabolism of calcipotriol is also found in normal and psoriatic keratinocytes in vivo, then this may explain the lack of systemic calcemic activity of topically applied drug.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ON,CANADA; QUEENS UNIV,DEPT MED,KINGSTON K7L 3N6,ON,CANADA; LEO PHARMACEUT PROD LTD,CHEM RES DEPT,DK-2750 BALLERUP,DENMARK; UNIV LONDON LONDON HOSP,COLL MED,DEPT CHEM PATHOL,LONDON E1 2AD,ENGLAND; MCGILL UNIV,DEPT MED,MONTREAL H3A 1A1,PQ,CANADA	Queens University - Canada; Queens University - Canada; University of London; University College London; McGill University				Kremer, Richard/0000-0002-7053-2139				BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; BINDERUP L, 1988, BIOCHEM PHARMACOL, V37, P889, DOI 10.1016/0006-2952(88)90177-3; BINDERUP L, 1992, REV CONTEMP PHARMACO, V3, P357; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUILLON R, 1991, J BONE MINER RES, V6, P1051; BOWER M, 1991, LANCET, V337, P701, DOI 10.1016/0140-6736(91)90280-3; Calverley M. J., 1992, ANTITUMOR STEROIDS, P193; CALVERLEY MJ, 1987, TETRAHEDRON, V43, P4609, DOI 10.1016/S0040-4020(01)86903-9; CALVERLEY RKS, 1990, METHODS NEUROSCIENCE, V3, P155; EVANS DB, 1991, J BONE MINER RES, V6, P1307; HENDERSON J, 1991, CANCER RES, V51, P6521; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; JONES G, 1991, J BONE MINER RES, V6, pS123; KISSMEYER AM, 1991, BIOCHEM PHARMACOL, V41, P1601, DOI 10.1016/0006-2952(91)90160-7; KRAGBALLE K, 1991, LANCET, V337, P193, DOI 10.1016/0140-6736(91)92157-W; LOHNES D, 1987, J BIOL CHEM, V262, P14394; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; MARIE PJ, 1990, BONE, V11, P171, DOI 10.1016/8756-3282(90)90211-G; MILLER BE, 1990, J BONE MINER RES, V5, P597; MORRISON NA, 1991, J BONE MINER RES, V6, P893; NAPOLI JL, 1983, BIOCHEMISTRY-US, V22, P5843; POLS HAP, 1991, BONE MINER, V14, P103, DOI 10.1016/0169-6009(91)90087-G; QAW F, 1993, J BIOL CHEM, V268, P282; Sambrook J, 1989, MOL CLONING LABORATO; SEBAG M, 1992, J BIOL CHEM, V267, P12162; SORENSEN H, 1990, BIOCHEM PHARMACOL, V39, P391, DOI 10.1016/0006-2952(90)90039-N; STRUGNELL S, 1990, BIOCHEM PHARMACOL, V40, P333, DOI 10.1016/0006-2952(90)90696-I; SUDA T, 1990, ANNU REV NUTR, V10, P195, DOI 10.1146/annurev.nu.10.070190.001211; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; TOMON M, 1990, AM J PHYSIOL, V358, pG557; VALAJA T, 1990, BIOCHEM PHARMACOL, V40, P1827, DOI 10.1016/0006-2952(90)90363-P	31	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4794	4803						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106449				2022-12-25	WOS:A1994MX57100018
J	MINOGUCHI, K; SWAIM, WD; BERENSTEIN, EH; SIRAGANIAN, RP				MINOGUCHI, K; SWAIM, WD; BERENSTEIN, EH; SIRAGANIAN, RP			SRC FAMILY TYROSINE KINASE P53/56(LYN), A SERINE KINASE AND FC-EPSILON-RI ASSOCIATE WITH ALPHA-GALACTOSYL DERIVATIVES OF GANGLIOSIDE GD(1B) IN RAT BASOPHILIC LEUKEMIA RBL-2H3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; MAST-CELLS; PROTEIN; PHOSPHORYLATION; SURFACE	The monoclonal antibody (mAb) AA4 recognizes two alpha-galactosyl derivatives of the GD(1b) ganglioside on rat mast cells and on the rat basophilic leukemia RBL-2H3 cultured cell line. Here we demonstrate that mAb AA4 coprecipitated both protein tyrosine and serine kinases. In contrast, a monoclonal antibody to the GD(3) ganglioside did not coprecipitate any kinase activity. In kinase assays of mAb AA4 immunoprecipitates there were phosphorylated proteins of 71-80, 53/56, and 41/42 kDa. All proteins were phosphorylated on tyrosine, whereas the 71-80- and 41/42-kDa proteins were also phosphorylated on serine residues. The precipitation of these proteins by mAb AA4 correlated with the presence of the alpha-galactosyl derivatives of GD(1b). The 53/56-kDa proteins were identified as the Src-related tyrosine kinase p53/56(lyn). The presence of p53/56(lyn) in the mAb AA4 immunoprecipitates was specific and was observed when several different detergents were used. The same 71-80-kDa tyrosine-phosphorylated proteins were immunoprecipitated by mAb AA4 and anti-Lyn antibodies and may play a role in the interaction of p53/56(lyn) with the gangliosides. Although there is a weak association of the high affinity IgE receptor with these gangliosides, the coprecipitation of p53/56(lyn) with mAb AA4 was not secondary to the association of this kinase with receptor. These complexes of gangliosides and several proteins that include p53/56(lyn), a serine kinase, and the high affinity IgE receptor could play an important role in receptor-mediated signal transduction.			MINOGUCHI, K (corresponding author), NIDR, IMMUNOL LAB, BLDG 10-1N-106, BETHESDA, MD 20892 USA.							BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BOHUSLAV J, 1993, EUR J IMMUNOL, V23, P825, DOI 10.1002/eji.1830230409; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CMEK T, 1992, J IMMUNOL, V149, P2262; DIPPOLD WG, 1980, P NATL ACAD SCI-BIOL, V77, P6114, DOI 10.1073/pnas.77.10.6114; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; DRABEROVA L, 1989, EUR J IMMUNOL, V19, P1715, DOI 10.1002/eji.1830190928; EISEMAN E, 1992, NATURE, V355, P78; ESTES KAS, 1988, THESIS CORNELL U ITH; GUO N, 1989, J BIOL CHEM, V264, P13267; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1992, J IMMUNOL, V148, P524; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HANAI N, 1988, J BIOL CHEM, V263, P10915; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HOOK WA, 1991, J IMMUNOL, V147, P2670; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IGARASHI Y, 1989, METHOD ENZYMOL, V179, P521; KINET JP, 1985, BIOCHEMISTRY-US, V24, P7342, DOI 10.1021/bi00346a048; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KITANI S, 1991, J BIOL CHEM, V266, P1903; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLIVER C, 1992, J CELL BIOL, V116, P635, DOI 10.1083/jcb.116.3.635; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; STEFANOVA I, 1991, J IMMUNOL, V147, P1587; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STEPHAN V, 1991, J IMMUNOL, V146, P4271; STRACKE ML, 1987, MOL IMMUNOL, V24, P347, DOI 10.1016/0161-5890(87)90176-3; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YATES AJ, 1993, EXP CELL RES, V204, P38, DOI 10.1006/excr.1993.1006; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341	47	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5249	5254						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106508				2022-12-25	WOS:A1994MX57100085
J	SHORE, SK; LACAVA, M; YENDAPALLI, S; REDDY, EP				SHORE, SK; LACAVA, M; YENDAPALLI, S; REDDY, EP			STRUCTURAL ALTERATIONS IN THE CARBOXYL-TERMINAL DOMAIN OF THE BCRABL GENE-PRODUCT ACTIVATE ITS FIBROBLASTIC TRANSFORMING POTENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; OSTEO-SARCOMA VIRUS; C-ABL; PHILADELPHIA CHROMOSOME; NUCLEOTIDE-SEQUENCE; NUCLEIC-ACID; PROVIRAL DNA; V-ABL; PROTEIN; ONCOGENE	Activation of the c-abl protooncogene occurs in Abelson murine leukemia virus, Hardy-Zuckerman-2 feline sarcoma virus, and during the chromosomal translocation that generates the BCRABL fusion gene. The three genes exhibit varying degrees of transforming activity; the two viral genes transform NIH-3T3 cells in vitro, whereas the BCRABL gene is incapable of transforming these cells. To determine whether genetic alterations can enhance the transforming potential of the BCRABL gene, we employed genetic selection techniques which led to the isolation of a mutant form of the BCRABL gene with high levels of fibroblastic transforming activity. Molecular analysis of this clone shows that it suffered a deletion of 3' ABL sequences and their replacement with a cellular sequence of unknown origin, termed X. This tripartite gene is capable of inducing 35 foci/10 ng of DNA. Deletion of 3' ABL sequences analogous to that seen in the activated BCRABL protein without the addition of X yields 5 foci/100 ng of DNA. These results suggest that carboxyl-terminal truncations unmask the fibroblastic transforming activity of the BCRABL gene product and the addition of X sequences dramatically enhances this transforming potential, indicating a dominant contribution by the X reading frame.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	SHORE, SK (corresponding author), TEMPLE UNIV,SCH MED,FELS INST MOLEC BIOL & CANC RES,PHILADELPHIA,PA 19140, USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P30CA012227, R01CA047937] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47937-01, CA-12227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARLINGHAUS RB, 1991, CHRONIC MYELOGENOUS, P283; BERGOLD PJ, 1987, J VIROL, V61, P1193, DOI 10.1128/JVI.61.4.1193-1202.1987; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DHUT S, 1991, ONCOGENE, V6, P1459; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GROFFEN J, 1991, CHRONIC MYELOGENOUS, P181; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; Kuzrock R, 1988, NEW ENGL J MED, V319, P990; LI WJ, 1989, ONCOGENE, V4, P127; LIU J, 1992, ONCOGENE, V8, P101; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MCWHIRTER JR, 1993, MOL CELL BIOL, V12, P1533; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REDDY EPA, 1988, ONCOGENE HDB; Sambrook J, 1989, MOL CLONING LABORATO; SCHER CD, 1975, NATURE, V253, P792; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHORE SK, 1989, ONCOGENE, V4, P1411; SHORE SK, 1991, CHRONIC MYELOGENOUS, P153; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	45	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5413	5419						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106523				2022-12-25	WOS:A1994MX57100106
J	BENDIXEN, E; BORTH, W; HARPEL, PC				BENDIXEN, E; BORTH, W; HARPEL, PC			TRANSGLUTAMINASES CATALYZE CROSS-LINKING OF PLASMINOGEN TO FIBRONECTIN AND HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIN-STABILIZING FACTOR; ALPHA-2-PLASMIN INHIBITOR; CELLULAR TRANSGLUTAMINASE; TISSUE TRANSGLUTAMINASE; EXTRACELLULAR-MATRIX; POTENTIAL ROLE; LIPOPROTEIN(A); BINDING; ACTIVATOR; COMPLEXES	We have previously reported that apolipoprotein (a) is a substrate for transglutaminases. We now demonstrate that plasminogen which is homologous to apolipoprotein (a), is also modified by these enzymes. Transglutaminases from different sources mediated the incorporation of monodansyl-cadaverine into plasminogen, indicating the presence of reactive glutamine(s) in plasminogen. Reactive lysines were also identified using the lysine-decorating peptide dansyl-PGGQQIV. In addition, transglutaminases catalyzed the formation of plasminogen homopolymers and plasminogen-fibronectin heteropolymers. Human umbilical vein endothelial cells cross-linked plasminogen into high molecular mass aggregates. Cross-linked plasminogen was cell associated, and no cross-linking of plasminogen was seen in the fluid-phase. Large molecular mass plasminogen generated on the human umbilical vein endothelial cell (HUVEC) surface could not be eluted with epsilon-aminocapoic acid and was activatable by tissue plasminogen activator. These results suggest that, following non-covalent association of plasminogen with the HUVEC surface, cell surface-associated transglutaminase catalyzes cross-linking of plasminogen into large molecular mass aggregates that can be converted into functional plasmin. It is proposed that transglutaminases may function to localize plasminogen to cell surfaces and matrices of tissues.	CUNY MT SINAI SCH MED,DEPT MED,DIV HEMATOL,BOX 1079,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; BORTH W, 1991, J BIOL CHEM, V266, P18149; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; COCUZZI ET, 1986, J BIOL CHEM, V261, P8122; DANO K, 1985, ADV CANCER RES, V44, P146; DAVIDSON JF, 1978, PROGR CHEM FIBRINOLY, V3; GENTILE V, 1991, J BIOL CHEM, V266, P478; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HALL SW, 1991, J BIOL CHEM, V266, P12319; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; HARPEL PC, 1981, J CLIN INVEST, V68, P46, DOI 10.1172/JCI110253; HARPEL PC, 1991, J BIOL CHEM, V264, P616; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KINSELLA MG, 1990, J BIOL CHEM, V265, P17891; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; LAKI K, 1972, ANN NY ACAD SCI, V202, P235, DOI 10.1111/j.1749-6632.1972.tb16337.x; LAWN RM, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0692-54; LEMOSY EK, 1992, J BIOL CHEM, V267, P7880; LORAND L, 1991, P NATL ACAD SCI USA, V88, P82, DOI 10.1073/pnas.88.1.82; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; LORAND L, 1981, METHOD ENZYMOL, V80, P33; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MARTINEZ J, 1989, J BIOL CHEM, V264, P20502; MCFARLANE AS, 1956, BIOCHEM J, V62, P135, DOI 10.1042/bj0620135; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MOSHER DF, 1976, J BIOL CHEM, V251, P1639; MOSHER DF, 1984, MOL CELL BIOCHEM, V58, P63, DOI 10.1007/BF00240605; NACHMAN RL, 1992, BLOOD, V79, P1897, DOI 10.1182/blood.V79.8.1897.bloodjournal7981897; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; ROUY D, 1991, ARTERIOSCLER THROMB, V11, P629, DOI 10.1161/01.ATV.11.3.629; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SANE DC, 1991, BIOCHEM BIOPH RES CO, V174, P465, DOI 10.1016/0006-291X(91)91439-J; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; TYRELL DJ, 1988, J BIOL CHEM, V263, P8464; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WIEBE RI, 1991, BIOCHEM CELL BIOL, V69, P821, DOI 10.1139/o91-122; WU CY, 1991, J BIOL CHEM, V266, P18802	52	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21962	21967						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104945				2022-12-25	WOS:A1993MC80900079
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			FUNCTIONAL CONSEQUENCES OF PHENYLALANINE MUTATIONS IN THE PREDICTED TRANSMEMBRANE DOMAIN OF P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; ENDOPLASMIC-RETICULUM; SARCOPLASMIC-RETICULUM; DEPENDENT TRANSPORT; PHOTOACTIVE ANALOGS; PLASMA-MEMBRANE; ATP HYDROLYSIS; TUMOR-CELLS; BINDING; PROTEINS	Site-directed mutagenesis was used to investigate whether phenylalanine residues in predicted transmembrane sequences play essential roles in the function of human P-glycoprotein. Mutant cDNAs, in which codons for each of the 31 phenylalanine residues were changed to alanine, were expressed in mouse NIH 3T3 cells and analyzed with respect to their ability to confer resistance to various drugs. Mutation of either Phe-335 to Ala in transmembrane segment 6, or Phe-978 to Ala in transmembrane segment 12, drastically altered the drug resistance profile conferred by the mutant P-glycoprotein in transfected cells. Mutant Phe-335 --> Ala conferred little resistance to vinblastine or actinomycin D but retained the ability to confer resistance to colchicine and adriamycin. The mutant also showed increased binding of azidopine, which could be inhibited by lower levels of vinblastine, relative to the wild-type enzyme. By contrast, mutant Phe-978 --> Ala conferred little or no resistance to colchicine or adriamycin, while its ability to confer resistance to vinblastine or actinomycin D was retained. These results suggest that Phe-335 and Phe-978 play important roles in the recognition and transport of specific substrates by P-glycoprotein. Mutation of Phe-777 to Ala affected the biosynthesis of the transporter. Mutation of the other 28 phenylalanine residues yielded protein products with structural and functional characteristics that were indistinguishable froin the wild-type enzyme.	UNIV TORONTO,DEPT MED,1 KINGS COLL CIRCLE,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALLEY MC, 1988, CANCER RES, V48, P589; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BRUGGEMAN EP, 1992, J BIOL CHEM, V264, P21020; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CURRIER SJ, 1989, J BIOL CHEM, V264, P15483; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGGINS CF, 1990, PHILOS T R SOC B, V326, P353, DOI 10.1098/rstb.1990.0017; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P553; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOO TW, 1993, J BIOL CHEM, V268, P3143; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; NAITO M, 1988, J BIOL CHEM, V263, P11887; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; QIAN XD, 1990, CANCER RES, V50, P1132; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; ROBINSON IB, 1991, MOL CELLULAR BIOL MU; SAFA AR, 1989, BIOCHEM BIOPH RES CO, V162, P1402, DOI 10.1016/0006-291X(89)90830-9; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG CPH, 1988, BIOCHEM PHARMACOL, V37, P1417; YUSA K, 1989, CANCER RES, V49, P5002; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	48	147	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19965	19972						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104183				2022-12-25	WOS:A1993LY01900011
J	MATSUSHITA, T; KOJIMA, T; EMI, N; TAKAHASHI, I; SAITO, H				MATSUSHITA, T; KOJIMA, T; EMI, N; TAKAHASHI, I; SAITO, H			IMPAIRED HUMAN TISSUE FACTOR-MEDIATED ACTIVITY IN BLOOD-CLOTTING FACTOR-VII(NAGOYA) (ARG(304)-]TRP) - EVIDENCE THAT A REGION IN THE CATALYTIC DOMAIN OF FACTOR-VII IS IMPORTANT FOR THE ASSOCIATION WITH TISSUE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; BOVINE FACTOR-VII; FACTOR-IX; FACTOR-X; ENZYMATIC AMPLIFICATION; HAGEMAN-FACTOR; FACTOR PATHWAY; ACTIVATION; DEFICIENCY; PROTEIN	A 37-year-old man was found to have an inherited abnormal factor VII (FVII) (designated FVIINagoya) that has a lower FVII procoagulant activity when tested in a one-stage assay using rabbit, simian, or human tissue factor (TF), but surprisingly has a nearly normal activity using bovine TF. DNA sequence analysis of the propositus' FVII gene revealed a C to T mutation that results in a novel amino acid substitution of Arg(304) to Trp. Restriction enzyme analysis of the amplified fragment obtained from each family member demonstrated that the patient is homozygous for the point mutation, and the mother and sister of the patient are heterozygous for this mutation. To elucidate the abnormality in FVIINagoya, we compared the recombinant mutant FVII with normal FVII. In the presence of human TF, kinetic analyses demonstrated that the apparent K-m values of FVIINagoya for factor Xa-mediated FVII activation and for FVIIa-mediated factor X (FX) activation were 3.6- and 4.5-fold higher than those of normal FVII, respectively. The ligand binding assay to human TF also showed that FVIINagoya had a 5.2-fold larger apparent K-d than normal. In the presence of bovine TF, however, these values showed no difference between normal and mutant FVII. These findings indicate that the major abnormality in FVIINagoya is not a catalytic dysfunction but an impaired complex-formation of human TF.FVII.FX, suggesting the importance of Arg(304) in the interaction with human TF.	NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 1, SHOWA KU, NAGOYA, AICHI 466, JAPAN; JAPANESE RED CROSS, AICHI BLOOD CTR, SETO, AICHI 489, JAPAN; AICHI JURID FDN BLOOD DIS RES, NAGOYA, AICHI 463, JAPAN	Nagoya University; Japanese Red Cross Medical Center			Matsushita, Tadadshi/I-7349-2014; Kojima, Tetsuhito/I-6271-2014	Kojima, Tetsuhito/0000-0002-1905-1065				AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; ARDREWS BS, 1991, TRENDS BIOCHEM SCI, V16, P31; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; CARSON SD, 1980, THROMB HAEMOSTASIS, V44, P12; CHAING SH, 1990, BLOOD, V76, pA417; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; GIROLAMI A, 1977, BLOOD, V50, P603; GIROLAMI A, 1978, J LAB CLIN MED, V91, P387; GIROLAMI A, 1979, BLOOD, V54, P46; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; JAMES HL, 1991, BLOOD, V77, P317; JAMES HL, 1991, THROMB HAEMOSTASIS, V65, P937; JANSON TL, 1984, HAEMOSTASIS, V14, P440; KAMIYA T, 1986, BLOOD, V67, P406; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P4189, DOI 10.1021/bi00638a009; KISIEL W, 1981, THROMB RES, V22, P375, DOI 10.1016/0049-3848(81)90130-4; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHITA T, 1990, J LAB CLIN MED, V116, P492; MATSUSHITA T, 1991, BLOOD S, V78, pA181; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NAKAGAKI T, 1992, THROMB RES, V65, P105, DOI 10.1016/0049-3848(92)90230-8; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEMERSON Y, 1988, BLOOD, V71, P1; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; OBRIEN DP, 1991, BLOOD, V78, P132; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; RADCLIFFE R, 1977, BLOOD, V50, P611; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; RADCLIFFE R, 1975, J BIOL CHEM, V250, P388; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1985, BLOOD, V65, P218; RAPAPORT SI, 1991, ANN NY ACAD SCI, V614, P51, DOI 10.1111/j.1749-6632.1991.tb43691.x; RUF W, 1991, J BIOL CHEM, V266, P15719; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SUGIURA M, 1982, JPN J CLIN CHEM, V11, P83; TAKAHASHI I, 1991, J LAB CLIN MED, V118, P317; TAKAMIYA O, 1988, CLIN LAB HAEMATOL, V10, P159; TAKAYENOKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1145, DOI 10.1016/0006-291X(91)92058-R; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TRIPLETT DA, 1985, BLOOD, V66, P1284; WILDGOOSE P, 1989, BLOOD, V73, P1888; YAMAMOTO K, 1992, J CLIN INVEST, V90, P2439, DOI 10.1172/JCI116135; YAMAMOTO M, 1992, J BIOL CHEM, V267, P19089	54	64	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7355	7363						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125953				2022-12-25	WOS:A1994NA03200052
J	PICKART, CM; KASPEREK, EM; BEAL, R; KIM, A				PICKART, CM; KASPEREK, EM; BEAL, R; KIM, A			SUBSTRATE PROPERTIES OF SITE-SPECIFIC MUTANT UBIQUITIN PROTEIN (G76A) REVEAL UNEXPECTED MECHANISTIC FEATURES OF UBIQUITIN-ACTIVATING ENZYME (E1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE Y-CHROMOSOME; AFFINITY PURIFICATION; MOLECULAR-CLONING; CARRIER PROTEINS; GENE; EXPRESSION; SYSTEM; DEGRADATION	Ubiquitin-mediated proteolysis proceeds via the formation and degradation of ubiquitin-protein conjugates. Ubiquitin (Ub)-activating enzyme (E1) catalyzes the first, MgATP-dependent step in the conjugative reaction sequence. With wild type ubiquitin, the product of the E1 reaction is a ternary complex (E1-Ub.AMP-Ub) containing one thiol-linked ubiquitin (via the Uh COOH terminus, Gly-76) and one tightly bound ubiquitin adenylate. The thiol-linked ubiquitin is subsequently transferred to the thiol of a ubiquitin-conjugating enzyme (E2 protein); the latter adduct is the proximal donor of ubiquitin to the target protein. A mutant ubiquitin, bearing a Gly to Ala substitution at the COOH terminus (G76A-ubiquitin), was characterized as a substrate for E1. G76A-ubiquitin 1) supported PP1-ATP exchange poorly (500-fold decrease in k(cat)/K-m); 2) did not produce detectable AMP-Ub with native E1; 3) produced stoichiometric AMP-Ub with thiol-blocked E1; 4) gave a stoichiometric burst of ATP consumption (1 mol/mol E1) with either native or thiol-blocked E1; 5) supported E1-ubiquitin thiol ester formation with native E1; 6) supported several downstream reactions of the proteolytic pathway at similar to 20% of the rate of wild type ubiquitin. These results indicate that G76A-ubiquitin gives a binary E1 thiol ester complex with native E1, due to the failure of the E1-ubiquitin thiol ester to undergo another round of adenylate synthesis; thus AMP-Ub is detected only if adenylate to thiol transfer is prevented by alkylating E1. The inability of G76A-ubiquitin to support ternary complex formation has implications for E1 active site structure. In other experiments, occupancy of the nucleotide/adenylate site of E1, by either MgATP or AMP-Ub, was found to stimulate ubiquitin transthiolation between E1 and E2 proteins. The intermediacy of ubiquitin adenylate thus provides a previously unrecognized catalytic advantage in the E1 mechanism.			PICKART, CM (corresponding author), SUNY BUFFALO, DEPT BIOCHEM, 140 FARBER HALL, BUFFALO, NY 14214 USA.				NIDDK NIH HHS [DK43769] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043769] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERLETH ES, 1992, J BIOL CHEM, V267, P16403; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; COOK JC, 1992, J BIOL CHEM, V267, P24315; COX MJ, 1986, ANAL BIOCHEM, V154, P345, DOI 10.1016/0003-2697(86)90535-X; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1983, BIOCHEMISTRY-US, V22, P4388, DOI 10.1021/bi00288a007; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1985, PREP BIOCHEM, V15, P49; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; JONNALAGADDA S, 1988, J BIOL CHEM, V263, P5016; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1992, J BIOL CHEM, V267, P14418; PICKART CM, 1988, J BIOL CHEM, V263, P12028; ROSE IA, 1987, P NATL ACAD SCI USA, V84, P1477, DOI 10.1073/pnas.84.6.1477; ROSE IA, 1983, BIOCHEMISTRY-US, V22, P4234, DOI 10.1021/bi00287a012; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; TADARI T, 1992, J BIOL CHEM, V267, P719; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	33	74	77	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7115	7123						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125920				2022-12-25	WOS:A1994NA03200015
J	TAKEI, H; GAT, Y; ROTHMAN, Z; LEWIS, A; SHEVES, M				TAKEI, H; GAT, Y; ROTHMAN, Z; LEWIS, A; SHEVES, M			ACTIVE-SITE LYSINE BACKBONE UNDERGOES CONFORMATIONAL-CHANGES IN THE BACTERIORHODOPSIN PHOTOCYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; N INTERMEDIATE; BINDING-SITE; PROTEIN; RHODOPSIN; MEMBRANE; SPECTRA; MODEL	Results are presented demonstrating that the backbone of the active site lysine of bacteriorhodopsin undergoes light-induced structural alterations during bacteriorhodopsin-mediated light-induced proton pumping. This conclusion is based on difference Fourier transform infrared spectroscopy of isotopically labeled bacteriorhodopsin. The data demonstrate that the backbone carbonyl of lysine achieves an extremely low vibrational frequency during M(412) intermediate formation. This is preceded by a structural transition in the lysine backbone that leads to an active site lysine carbonyl with the observed low vibrational frequency, probably due to a high degree of solvation.	CORNELL UNIV,DEPT APPL PHYS,ITHACA,NY 14853; WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV HOSP,HADASSAH LASER CTR,DEPT OPHTHALMOL,EIN KEREM,ISRAEL	Cornell University; Weizmann Institute of Science								ARGADE PV, 1981, P NATL ACAD SCI-BIOL, V78, P1643, DOI 10.1073/pnas.78.3.1643; BALASHOV SP, 1981, BIOPHYSICS-USSR, V26, P566; BIRGE RR, 1990, BIOCHIM BIOPHYS ACTA, V1016, P293, DOI 10.1016/0005-2728(90)90163-X; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; DICAPUA FM, 1991, J AM CHEM SOC, V113, P6145, DOI 10.1021/ja00016a034; FODOR SPA, 1988, BIOCHEMISTRY-US, V27, P7097, DOI 10.1021/bi00418a064; GAT Y, 1992, P NATL ACAD SCI USA, V89, P2434, DOI 10.1073/pnas.89.6.2434; GERWERT K, 1990, FEBS LETT, V261, P449, DOI 10.1016/0014-5793(90)80613-N; KATRE NV, 1981, P NATL ACAD SCI-BIOL, V78, P4068, DOI 10.1073/pnas.78.7.4068; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LEMKE HD, 1981, FEBS LETT, V128, P255, DOI 10.1016/0014-5793(81)80093-2; LEWIS A, 1974, P NATL ACAD SCI USA, V71, P4462, DOI 10.1073/pnas.71.11.4462; LEWIS A, 1973, J CHEM PHYS, V58, P3661, DOI 10.1063/1.1679716; LEWIS A, 1971, MACROMOLECULES, V4, P539, DOI 10.1021/ma60023a003; MAEDA A, 1991, PHOTOCHEM PHOTOBIOL, V54, P911, DOI 10.1111/j.1751-1097.1991.tb02111.x; MATHIES R, 1990, BIOL APPLICATIONS RA, V2, P59; MCMASTER E, 1988, BIOCHEM BIOPH RES CO, V156, P86, DOI 10.1016/S0006-291X(88)80808-8; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; OTTOLENGHI M, 1989, J MEMBRANE BIOL, V112, P193, DOI 10.1007/BF01870951; PAPADOPOULOS G, 1990, J MOL BIOL, V214, P15, DOI 10.1016/0022-2836(90)90140-H; PFEFFERLE JM, 1991, BIOCHEMISTRY-US, V30, P6548, DOI 10.1021/bi00240a027; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; SUBRAMANIAM S, 1993, EMBO J, V12, P1; SUNDARALINGAM M, 1989, SCIENCE, V244, P1333, DOI 10.1126/science.2734612; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; TAKEI H, 1992, BIOPHYS J, V63, P1643, DOI 10.1016/S0006-3495(92)81757-5; UNWIN P, 1975, NATURE, V257, P28	28	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7387	7389						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125956				2022-12-25	WOS:A1994NA03200056
J	TILL, JH; ANNAN, RS; CARR, SA; MILLER, WT				TILL, JH; ANNAN, RS; CARR, SA; MILLER, WT			USE OF SYNTHETIC PEPTIDE LIBRARIES AND PHOSPHOPEPTIDE-SELECTIVE MASS-SPECTROMETRY TO PROBE PROTEIN-KINASE SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; BASIC RESIDUES; PP60V-SRC; MIXTURES; SEQUENCE; LIGANDS; MOTIFS; SITES; VIRUS	To search for peptides which serve as substrates for protein kinases, an approach based on peptide libraries has been developed. These peptide libraries are chemically synthesized by a modified ''divide-couple-recombine'' strategy. After reaction with the kinase of interest, the most highly phosphorylated substrate (selected from the library) is identified using on-line liquid chromatography-electrospray mass spectrometry (LC-ESMS). Negative ion LC-ESMS with stepped collision energy is used to identify phosphorylated peptides in the enzyme reactions. As predicted, the cAMP-dependent protein kinase is shown to preferentially phosphorylate Kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly) in a library consisting of 19 variants of Kemptide substituted at position 2. Additional experiments have been carried out on the nonreceptor tyrosine kinase v-Abl using a peptide library based on the v-Src autophosphorylation site (Arg-Arg-Leu-Ile-Glu-Asp-Ala-Glu-Tyr-Ala-Ala-Arg-Gly). These results indicate that Ile is the optimal residue at the position N-terminal to tyrosine. Individual peptides containing the Glu-Asp-Ala-Ile-Tyr motif have V-max/K-m values 6-fold higher than the peptide based on the autophosphorylation site itself, confirming the results of the library experiments. This motif has been identified in several tyrosine kinases at a position in the sequence not previously reported to serve as a phosphorylation or autophosphorylation site.	SUNY STONY BROOK, SCH MED, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA; SMITHKLINE BEECHAM PHARMACEUT INC, DEPT PHYS & STRUCT CHEM, KING OF PRUSSIA, PA USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; GlaxoSmithKline			Carr, Steven A./AAH-8366-2019					Barany G, 1979, PEPTIDES           A, V2, P1; BERMAN J, 1992, J BIOL CHEM, V267, P1434; BIRKETT AJ, 1991, ANAL BIOCHEM, V196, P137, DOI 10.1016/0003-2697(91)90129-H; CARR SA, 1993, PROTEIN SCI, V2, P183; CASNELLIE JE, 1984, ADV ENZYME REGUL, V22, P501, DOI 10.1016/0065-2571(84)90028-1; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Fersht AR., 1977, ENZYME STRUCTURE MEC; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GARCIA P, 1993, J BIOL CHEM, V268, P25146; GEAHLEN RL, 1990, PEPT PROT PHOSPH, P239; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HUDDLESTON MJ, 1993, J AM SOC MASS SPECTR, V4, P710, DOI 10.1016/1044-0305(93)80049-5; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KEMP BE, 1977, J BIOL CHEM, V252, P4888; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETITHORY JR, 1991, P NATL ACAD SCI USA, V88, P11510, DOI 10.1073/pnas.88.24.11510; PIKE LJ, 1982, P NATL ACAD SCI-BIOL, V79, P1443, DOI 10.1073/pnas.79.5.1443; RADZIEJEWSKI C, 1989, BIOCHEMISTRY-US, V28, P9047, DOI 10.1021/bi00449a013; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4344, DOI 10.1021/bi00067a025; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; Stewart JM, 1984, SOLID PHASE PEPTIDE; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TINKER DA, 1988, J BIOL CHEM, V263, P5024; TJOENG FS, 1990, INT J PEPT PROT RES, V35, P141; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581; ZETTERQVIST O, 1976, BIOCHEM BIOPH RES CO, V70, P696, DOI 10.1016/0006-291X(76)90648-3; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZUCKERMANN RN, 1992, P NATL ACAD SCI USA, V89, P4505, DOI 10.1073/pnas.89.10.4505	34	86	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7423	7428						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125961				2022-12-25	WOS:A1994NA03200062
J	EYERS, SAC; RIDGWELL, K; MAWBY, WJ; TANNER, MJA				EYERS, SAC; RIDGWELL, K; MAWBY, WJ; TANNER, MJA			TOPOLOGY AND ORGANIZATION OF HUMAN RH (RHESUS) BLOOD GROUP-RELATED POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; RED-CELL MEMBRANE; RH(D) POLYPEPTIDE; MOLECULAR-CLONING; PROTEINS; IDENTIFICATION; ANTIGENS; SEQUENCE; LOCALIZATION; GLYCOPROTEIN	The Rh blood group antigens are associated with nonglycosylated human erythrocyte membrane proteins of molecular mass 30 kDa (the Rh-30 polypeptides) and a glycoprotein of 40-100 kDa (the Rh glycoprotein). We have studied the topology of this family of proteins in the erythrocyte membrane. We confirmed the predicted cytosolic localization of the C and N termini of the Rh protein family. We located Lys-196 and Arg-323 of the Rh glycoprotein to the cytosol, and Glu-34 to the extracellular side of the plasma membrane in erythrocytes, by N-terminal sequencing of Rh glycoprotein peptides produced by proteolysis at the cytoplasmic or extracellular side of the membrane. We also show that a glycan chain is present on only one (Asn-37) of the three potential N-glycan addition sites in the Rh glycoprotein. Studies of the Rh glycoprotein fragments that co-immunoprecipitated with the Rh-30 polypeptides suggest there is an interaction between the Rh-30 polypeptides and amino acids 35-196 of the Rh glycoprotein. A model for the organization of the components of the Rh complex in the red cell membrane is proposed.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND	University of Bristol								AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; ALEXANDER S, 1982, METHOD ENZYMOL, V79, P505; ANSTEE DJ, 1993, BAILLIERE CLIN HAEM, V6, P401, DOI 10.1016/S0950-3536(05)80152-0; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; AVENT ND, 1992, J BIOL CHEM, V267, P15134; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BARKER RN, 1992, BRIT J HAEMATOL, V82, P126, DOI 10.1111/j.1365-2141.1992.tb04604.x; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BLOY C, 1990, J BIOL CHEM, V265, P21482; BLOY C, 1988, BLOOD, V72, P661; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GAHMBERG CG, 1982, FEBS LETT, V140, P93, DOI 10.1016/0014-5793(82)80528-0; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HADLEY AG, 1993, BAILLIERE CLIN HAEM, V6, P423, DOI 10.1016/S0950-3536(05)80153-2; HARTELSCHENK S, 1992, J BIOL CHEM, V267, P5569; KAJII E, 1993, HUM GENET, V91, P157; KAJII E, 1992, P JPN ACAD B-PHYS, V68, P51, DOI 10.2183/pjab.68.51; KRAHMER M, 1987, FEBS LETT, V226, P105, DOI 10.1016/0014-5793(87)80560-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; LEVANKIM C, 1992, BLOOD, V80, P1074; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; Race R. R, 1968, BLOOD GROUPS MAN; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; RIDGWELL K, 1994, J BIOL CHEM, V269, P6410; RIDGWELL K, 1983, BIOCHEM J, V213, P267, DOI 10.1042/bj2130267; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUYAMA K, 1992, BLOOD, V79, P808; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x	35	91	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6417	6423						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119991				2022-12-25	WOS:A1994MZ50300027
J	HUBER, HE; GOODHART, PJ; HUANG, PS				HUBER, HE; GOODHART, PJ; HUANG, PS			RETINOBLASTOMA PROTEIN REVERSES DNA BENDING BY TRANSCRIPTION FACTOR E2F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MYC PROMOTER; GENE-PRODUCT; BINDING PROTEIN; C-MYC; OPPOSITE ORIENTATIONS; TRANS-ACTIVATION; ESCHERICHIA-COLI; COMPLEX; SITE; RB	E2F is a mammalian transcription factor involved in cell cycle regulation. The retinoblastoma gene product, pRB, binds to E2F in a cell cycle-dependent manner and appears to turn E2F from a transcriptional activator into a repressor. We show here that in vitro binding of pRB has three major effects on the DNA binding properties of E2F affinity-purified from HeLa cells; pRB binding increases the half-life of E2F.DNA complexes 10-15-fold, it reduces E2F specific DNA binding in the presence of nonspecific DNA by sequestering E2F, and it partially reverses the DNA bending induced by E2F, Upon specific DNA binding, E2F induces a DNA bend with a flexure angle of 125 degrees. Both full-length pRB105 and the N-terminally truncated pRB60 bind to the E2F DNA complex with a K-d,K-app of 150 pM and reduce the apparent DNA bending to less than 80 degrees. DNA footprinting analysis indicates that the nonspecific DNA binding activity of pRB is not involved in this effect. Our biochemical data suggest that transcriptional activation by E2F may involve DNA bending and that the reversal of bending upon binding of pRB may turn E2F into a repressor.			HUBER, HE (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,DEPT CANC RES,BLDG WP16-3,W POINT,PA 19486, USA.							ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENOWITZ M, 1988, CURRENT PROTOCOLS MO, V2; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EDWARDS GM, 1992, J BIOL CHEM, V267, P7971; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KING IN, 1993, J BIOL CHEM, V268, P495; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; NEVINS JR, 1992, SCIENCE, V258, P424; NEVINS JR, 1994, IN PRESS CELL; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PEREZMARTIN J, 1993, SCIENCE, V260, P805, DOI 10.1126/science.8387228; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAY SK, 1992, MOL CELL BIOL, V12, P4327, DOI 10.1128/MCB.12.10.4327; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STAMMERS DK, 1991, FEBS LETT, V283, P298, DOI 10.1016/0014-5793(91)80613-8; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; STIRDIVANT SM, 1992, J BIOL CHEM, V267, P14846; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	61	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6999	7005						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120063				2022-12-25	WOS:A1994MZ50300112
J	LI, X; DRUCKER, DJ				LI, X; DRUCKER, DJ			PARATHYROID HORMONE-RELATED PEPTIDE IS A DOWNSTREAM TARGET FOR RAS AND SRC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ISLET CELL-LINE; GENE-EXPRESSION; GROWTH-FACTORS; HUMORAL HYPERCALCEMIA; HUMAN KERATINOCYTES; RAPID INDUCTION; SODIUM-BUTYRATE; HUMAN-TUMOR; PROTEIN; RNA	Neoplastic transformation may be associated with the development of paraneoplastic syndromes that complicate the management of patients with malignant disease. One of these syndromes, humoral hypercalcemia of malignancy, has been shown to be attributable to increased secretion of a parathyroid hormone-related peptide (PTHrP). The gene encoding PTHrP is expressed at low levels in a growth factor dependent manner in normal tissues, and the mechanisms underlying selective tumor-associated induction of PTHrP gene expression remain unclear. Here we show that cellular transformation by the EJ-Ha-ras and v-src oncogenes is associated with a marked increase in PTHrP gene expression. Ha-ras and v-src-transfected NRK 49F cells and ras-transfected RCB 2.2 cell lines secreted increased amounts of immunoreactive PTHrP. Northern blot analysis also demonstrated increased levels of PTHrP mRNA transcripts in oncogene-transfected stable cell lines. No significant change in the half-life of PTHrP mRNA transcripts was detected in Ha-ras and v-src-transformed cells. In contrast, nuclear run-on assays demonstrated an increased rate of PTHrP gene transcription in oncogene-transformed cells. These observations demonstrate that the gene encoding PTHrP is a downstream target for ras and src, potentially providing a molecular basis for understanding the activation of PTHrP gene expression in malignancy-associated hypercalcemia.	UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO M5G 2C4, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET & MED, TORONTO M5G 2C4, ON, CANADA	University of Toronto; University of Toronto			Drucker, Daniel J/A-4092-2010					ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ADACHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1088, DOI 10.1016/0006-291X(90)90978-V; ALLINSON ET, 1992, CANCER RES, V52, P3103; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; AUBIN JE, 1988, J BONE MINER RES, V3, P333; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BURTON PBJ, 1992, FEBS LETT, V305, P228, DOI 10.1016/0014-5793(92)80674-6; BURTON PBJ, 1990, BIOCHEM BIOPH RES CO, V167, P1134, DOI 10.1016/0006-291X(90)90641-Y; CAMPOS RV, 1992, MOL ENDOCRINOL, V6, P1642, DOI 10.1210/me.6.10.1642; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEMETRI GD, 1990, J CLIN INVEST, V86, P1261, DOI 10.1172/JCI114833; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; EJIMA E, 1993, BLOOD, V81, P1017; ENOMOTO H, 1993, BIOCHEM BIOPH RES CO, V191, P1261, DOI 10.1006/bbrc.1993.1353; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; HORIUCHI N, 1987, SCIENCE, V238, P1566, DOI 10.1126/science.3685994; IKEDA K, 1990, J BIOL CHEM, V265, P5398; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KEMP BE, 1987, SCIENCE, V238, P1568, DOI 10.1126/science.3685995; KIRIYAMA T, 1993, MOL CELL ENDOCRINOL, V92, P55, DOI 10.1016/0303-7207(93)90074-T; KREIDER BL, 1992, ONCOGENE, V7, P135; KREMER R, 1991, J CLIN INVEST, V87, P884, DOI 10.1172/JCI115094; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LI X, 1993, CANCER RES, V53, P2980; LIAPIS H, 1993, AM J PATHOL, V143, P1169; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MANGIN M, 1990, MOL ENDOCRINOL, V4, P851, DOI 10.1210/mend-4-6-851; MERENDINO JJ, 1986, SCIENCE, V231, P388, DOI 10.1126/science.2417317; MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048; PHILIPPE J, 1987, MOL CELL BIOL, V7, P560, DOI 10.1128/MCB.7.1.560; RABBANI SA, 1988, ENDOCRINOLOGY, V123, P2709; RODAN SB, 1988, J CLIN INVEST, V81, P924, DOI 10.1172/JCI113404; RODAN SB, 1989, J ENDOCRINOL, V122, P219, DOI 10.1677/joe.0.1220219; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STEWART AF, 1988, J CLIN INVEST, V81, P596, DOI 10.1172/JCI113358; STREUTKER C, 1991, MOL ENDOCRINOL, V5, P703, DOI 10.1210/mend-5-5-703; STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P4605, DOI 10.1073/pnas.85.13.4605; THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653; VASAVADA RC, 1993, MOL ENDOCRINOL, V7, P273, DOI 10.1210/me.7.2.273; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; YASUDA T, 1989, MOL ENDOCRINOL, V3, P518, DOI 10.1210/mend-3-3-518	50	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6263	6266						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119972				2022-12-25	WOS:A1994MZ50300002
J	LI, Z; MEIGHEN, EA				LI, Z; MEIGHEN, EA			THE TURNOVER OF BACTERIAL LUCIFERASE IS LIMITED BY A SLOW DECOMPOSITION OF THE TERNARY ENZYME-PRODUCT COMPLEX OF LUCIFERASE, FMN, AND FATTY-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; VIBRIO-HARVEYI; SUBUNIT; GENE	Bacterial luciferase catalyzes the conversion of reduced flavin mononucleotide, O-2, and fatty aldehyde to FMN, H2O, and fatty acid with light being emitted at a very low rate characterized by the decay of luminescence in single turnover flash assays, The present studies have now revealed that the decomposition of the ternary complex of luciferase with FMN and myristic acid occurs at a rate 10-15 times slower than the decay of luminescence and that functional luciferase is only regenerated after the release of flavin. In contrast, the rate of FMN dissociation and recovery of activity observed with a binary luciferase-FMN complex was more rapid indicating that release of fatty acid played the critical role in determining the rate of FMN dissociation from the ternary complex. Decomposition of the ternary complex was shown to occur by an ordered process involving the slow release of fatty acid followed by the more rapid release of flavin. The present results suggest that the rate-limiting step for the turnover of luciferase occurs subsequent to emission of light and would be the controlling step under conditions (e.g. in cells) with continuous light emission.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA	McGill University								ABOUKHAIR NK, 1985, BIOCHEMISTRY-US, V24, P3942, DOI 10.1021/bi00336a021; BALDWIN TO, 1975, J BIOL CHEM, V250, P2763; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, V3; COHN DH, 1985, J BIOL CHEM, V260, P6139; GUNSALUSMIGUEL A, 1972, J BIOL CHEM, V247, P398; HASTINGS JW, 1963, J OPT SOC AM, V53, P1410, DOI 10.1364/JOSA.53.001410; HASTINGS JW, 1963, J BIOL CHEM, V238, P2537; HASTINGS JW, 1973, P NATL ACAD SCI USA, V70, P3468, DOI 10.1073/pnas.70.12.3468; HASTINGS JW, 1966, IBOLUMINESCENCE PROG, P151; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; LEE J, 1988, BIOCHEMISTRY-US, V27, P4862, DOI 10.1021/bi00413a042; LI Z, 1992, BIOCHEM BIOPH RES CO, V188, P498; MEIGHEN EA, 1971, J BIOL CHEM, V246, P7666; MEIGHEN EA, 1993, ADV MICROB PHYSIOL, V34, P1, DOI 10.1016/S0065-2911(08)60027-2; MITCHELL GW, 1971, ANAL BIOCHEM, V39, P243, DOI 10.1016/0003-2697(71)90481-7; SZITTNER R, 1990, J BIOL CHEM, V265, P16581; ULITZUR S, 1978, P NATL ACAD SCI USA, V75, P266, DOI 10.1073/pnas.75.1.266; ZIEGLERNICOLI M, 1974, J BIOL CHEM, V249, P2385	18	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6640	6644						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120017				2022-12-25	WOS:A1994MZ50300060
J	TRAN, CM; HUSTON, EE; FARLEY, RA				TRAN, CM; HUSTON, EE; FARLEY, RA			PHOTOCHEMICAL LABELING AND INHIBITION OF NA,K-ATPASE BY 2-AZIDO-ATP - IDENTIFICATION OF AN AMINO-ACID LOCATED WITHIN THE ATP BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; ESSENTIAL RESIDUE; SEQUENCE; KIDNEY; (NA++K+)-ATPASE; (NA,K)-ATPASE; LYSINE-480; PROTEINS	2-Azido-ATP (2-N-3-ATP) was investigated as a reagent for the identification of amino acids located within the catalytic ATP binding site of Na,K-ATPase. The enzymatic activity of Na,K-ATPase was inhibited up to 50% by 2-N-3-ATP (K-0.5 = 5-10 mu M) after irradiation with ultraviolet light, and inhibition was prevented by 0.2 mM ATP. The binding of ATP to Na,K-ATPase (K-D = 0.1 mu M) was inhibited competitively by 2-N-3-ATP. [alpha-P-32]2-N-3-ATP labels the alpha subunit of Na,K-ATPase, and the stoichiometry of covalent ATP-protectable incorporation of the probe into the protein is approximately equal to the stoichiometry of high-affinity binding of ATP to the Na,K-ATPase. 2-N-3-ATP is also hydrolyzed by Na,K-ATPase as a substrate. From these data, it is concluded that 2-N-3-ATP photochemically labels the Na,K-ATPase from within the catalytic ATP site on the protein. Trypsin digestion of Na,K-ATPase after photochemical labeling with [alpha-P-32]2-N-3-ATP generated a large 30-kDa fragment containing the radiolabeled nucleotide. This fragment was resistant to further cleavage by trypsin, but it could be digested further after denaturation in urea. High pressure liquid chromatography separation of tryptic peptides from the 30-kDa fragment and subsequent amino acid sequence analysis of the radiolabeled peptides identified the region between His(496) and Arg(510) of the Na,K-ATPase alpha subunit as the region labeled by [alpha(32)P]2-N-3-ATP. Gly(502) was absent from all sequences of the radiolabeled peptides from this region, consistent with the derivatization of this amino acid by 2-N-3-ATP and localization of Gly(502) within the ATP binding site.	UNIV SO CALIF, SCH MED, DEPT PHYSIOL & BIOPHYS, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028673] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28673] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULAY F, 1985, BIOCHEMISTRY-US, V24, P7372, DOI 10.1021/bi00346a052; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DAVIS CB, 1990, J BIOL CHEM, V265, P1300; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; Fiske CH, 1925, J BIOL CHEM, V66, P375; HINZ HR, 1990, J BIOL CHEM, V265, P10260; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MELESE T, 1985, J BIOL CHEM, V260, P5398; MICHELSON AM, 1964, BIOCHIM BIOPHYS ACTA, V91, P1, DOI 10.1016/0926-6550(64)90164-1; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PEDEMONTE CH, 1992, FEBS LETT, V314, P97, DOI 10.1016/0014-5793(92)81470-7; RUSH J, 1990, J BIOL CHEM, V265, P4821; SCHAEFFER HJ, 1958, J AM CHEM SOC, V80, P3738, DOI 10.1021/ja01547a068; SCHEINERBOBIS G, 1985, EUR J BIOCHEM, V152, P739, DOI 10.1111/j.1432-1033.1985.tb09255.x; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SYMONS RH, 1968, BIOCHIM BIOPHYS ACTA, V155, P609, DOI 10.1016/0005-2787(68)90205-0; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TOMASZ J, 1978, NUCLEIC ACID CHEM, V3, P765; TRAN CM, 1988, BIOPHYS J, V53, pA343; WANG K, 1992, J BIOL CHEM, V267, P3577; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; YOSHIKAWA M, 1967, TETRAHEDRON LETT, P5065	29	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6558	6565						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120008				2022-12-25	WOS:A1994MZ50300047
J	YAMAMOTO, T; ROBY, KF; KWOK, SCM; SOARES, MJ				YAMAMOTO, T; ROBY, KF; KWOK, SCM; SOARES, MJ			TRANSCRIPTIONAL ACTIVATION OF CYTOCHROME-P450 SIDE-CHAIN CLEAVAGE ENZYME EXPRESSION DURING TROPHOBLAST CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; HUMAN GROWTH-HORMONE; PLACENTAL-LACTOGEN; GENE-EXPRESSION; PROLACTIN FAMILY; RAT; PROTEIN; STEROIDOGENESIS; IDENTIFICATION; ESTABLISHMENT	The purpose of this study was to investigate P450scc expression during trophoblast differentiation. Biochemical characteristics of P450scc protein and mRNA identified in rat trophoblast tissues were similar to those identified in the rat adrenal gland. Furthermore, P450scc was localized to trophoblast giant cells. This observation prompted an examination of progesterone biosynthesis and P450scc expression in Rcho-1 cells. Rcho-1 cells were derived from a transplantable rat choriocarcinoma, their differentiation can be regulated, and they have the capacity to express the trophoblast giant cell phenotype. Progesterone was produced by Rcho-1 cells and increased approximately 100-fold as the cells progressed from proliferation to differentiation. P450scc protein and mRNA accumulation also increased during trophoblast differentiation. P450scc expression within the Rcho-1 cell line was restricted to trophoblast giant cells. To further investigate the regulation of P450scc expression during trophoblast differentiation, we examined a plasmid construct, containing 894 base pairs of DNA 5' upstream from the P450scc transcriptional start site linked to a human growth hormone reporter gene, following stable transfection into Rcho-1 cells. The transfected P450scc regulatory DNA permitted the expression of human growth hormone which paralleled expression of the endogenous P450scc gene, In conclusion, transcriptional activation of the P450scc gene accompanies trophoblast giant cell differentiation.	UNIV KANSAS, MED CTR, DEPT PHYSIOL, KANSAS CITY, KS 66160 USA; ALBERT EINSTEIN MED CTR, DEPT OBSTET & GYNECOL, PHILADELPHIA, PA 19141 USA	University of Kansas; University of Kansas Medical Center; Yeshiva University				Kwok, Simon/0000-0001-6003-5350	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD020676] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029036] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-20676, HD29036, HD 07502] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOTTE V, 1966, J ENDOCRINOL, V34, P179, DOI 10.1677/joe.0.0340179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL WJ, 1989, ENDOCRINOLOGY, V125, P1565, DOI 10.1210/endo-125-3-1565; CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; DEANE HW, 1962, ENDOCRINOLOGY, V70, P407, DOI 10.1210/endo-70-3-407; DURKEE TJ, 1992, ENDOCRINOLOGY, V130, P1309, DOI 10.1210/en.130.3.1309; FARIA TN, 1991, ENDOCRINOLOGY, V129, P2895, DOI 10.1210/endo-129-6-2895; FARIA TN, 1990, ENDOCRINOLOGY, V127, P3131, DOI 10.1210/endo-127-6-3131; GIBORI G, 1988, RECENT PROG HORM RES, V44, P377; GOLDRING NB, 1987, ENDOCRINOLOGY, V120, P1942, DOI 10.1210/endo-120-5-1942; HUM DW, 1993, CLIN CHEM, V39, P333; JAMESON JL, 1993, ENDOCR REV, V14, P203, DOI 10.1210/er.14.2.203; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; MCMASTERS KM, 1987, GENE, V57, P1, DOI 10.1016/0378-1119(87)90170-3; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; NILSON JH, 1991, BIOL REPROD, V44, P231, DOI 10.1095/biolreprod44.2.231; OONK RB, 1990, J BIOL CHEM, V265, P22392; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; RINGER GE, 1990, ENDOCR REV, V111, P105; ROBY KF, 1991, MOL CELL ENDOCRINOL, V79, P13, DOI 10.1016/0303-7207(91)90090-F; SCHIFF R, 1993, ENDOCRINOLOGY, V133, P529, DOI 10.1210/en.133.2.529; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHALEM Z, 1988, J STEROID BIOCHEM, V31, P835, DOI 10.1016/0022-4731(88)90293-2; SHEMESH M, 1988, J STEROID BIOCHEM, V29, P21, DOI 10.1016/0022-4731(88)90371-8; SHEMESH M, 1984, P NATL ACAD SCI-BIOL, V81, P6403, DOI 10.1073/pnas.81.20.6403; SHERMAN M, 1993, BIOL TROPHOBLAST, P401; SHIDA MM, 1993, MOL ENDOCRINOL, V7, P181, DOI 10.1210/me.7.2.181; SOARES MJ, 1988, J ENDOCRINOL, V116, P101, DOI 10.1677/joe.0.1160101; SOARES MJ, 1987, J REPROD FERTIL, V79, P93; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; SOARES MJ, 1985, DEV BIOL, V107, P520, DOI 10.1016/0012-1606(85)90332-X; SOARES MJ, 1987, DEV BIOL, V124, P134, DOI 10.1016/0012-1606(87)90466-0; STRAUSS JF, 1992, PLACENTA, V13, P389, DOI 10.1016/0143-4004(92)90047-W; TESHIMA S, 1983, JPN J CANCER RES, V74, P205; VALENZUELA P, 1981, NATURE, V289, P650, DOI 10.1038/289650a0; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533	37	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6517	6523						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120003				2022-12-25	WOS:A1994MZ50300041
J	FUJIMOTO, J; YAMAMOTO, T				FUJIMOTO, J; YAMAMOTO, T			BRT, A MOUSE GENE ENCODING A NOVEL RECEPTOR-TYPE PROTEIN-TYROSINE KINASE, IS PREFERENTIALLY EXPRESSED IN THE BRAIN	ONCOGENE			English	Article							MOLECULAR-CLONING; LEUKEMIA-CELLS; W-LOCUS; FAMILY; DOMAINS; ONCOGENE; SEQUENCE	Using polymerase chain reaction (PCI)-mediated cloning procedure, we have isolated a novel gene encoding protein-tyrosine kinase from fetal mouse brain. This gene, named brt (from brain tyrosine kinase), had an open reading frame that encoded 856 amino acids. The deduced amino acid sequence revealed that the gene product had all the hallmarks of a receptor-type protein-tyrosine kinase. The brt protein showed significant homology to the axl/ufo protein that has an oncogenic potential. Northern blot analysis showed that but was expressed preferentially in the brain of both embryo and adult. Thus, brt is a new member of the subfamily of receptor-type protein-tyrosine kinases and is suggested to play important roles in development and functions in the central nervous system.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,TOKYO 108,JAPAN	University of Tokyo								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BASLER K, 1988, TRENDS GENET, V4, P74, DOI 10.1016/0168-9525(88)90044-3; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAUST M, 1992, ONCOGENE, V7, P1287; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KELMANZ, 1993, ONCOGENE, V8, P37; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MARCELLE C, 1992, ONCOGENE, V7, P2479; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ AS, 1993, ONCOGENE, V8, P509; SHIBUYA M, 1990, ONCOGENE, V5, P519; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SUDOL M, 1993, ONCOGENE, V8, P823; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237	32	69	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					693	698						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108111				2022-12-25	WOS:A1994MW55100003
J	SCHWARTEWALDHOFF, I; MARTIN, W; WILLECKE, K; SCHAFER, R				SCHWARTEWALDHOFF, I; MARTIN, W; WILLECKE, K; SCHAFER, R			FUNCTIONAL IDENTIFICATION AND MOLECULAR-CLONING OF A RAT GENE MEDIATING GROWTH-INHIBITION AND PROGRAMMED CELL-DEATH IN NORMAL AND TRANSFORMED RAT-CELL LINES	ONCOGENE			English	Article							WILD-TYPE P53; TUMOR SUPPRESSOR GENES; HIGHER EUKARYOTIC CELLS; C-MYC EXPRESSION; RB GENE; EMBRYONIC FIBROBLASTS; ONCOGENE EXPRESSION; EPITHELIAL-CELLS; CARCINOMA-CELLS; HAMSTER-CELLS	We wished to identify DNA sequences conferring suppression of proliferation and transformed phenotypes. Thus, we have transfected DNA from normal rat cells, covalently linked to neo DNA coding for neomycin resistance into a tumorigenic, HRAS transformed rat cell line. Phenotypic revertants were selected after the first cycle of transfection by enrichment procedures that served to eliminate transformed cells. The revertant clones continued to express the HRAS oncogene, but exhibited a lower tumorigenicity, loss of anchorage-independent proliferation, flat morphology, and retardation of growth in monolayer culture. The reverted phenotype could be transferred in a second cycle of transfection into the HRAS transformed rat cells. Neo DNA ligated to genomic donor DNA was used as a tagging sequence to molecularly clone the transferred DNA sequence in a recombinant phage. Fragments of the cloned DNA detect a 2.5 kb transcript in parental cells and revertants. Thus, the recombinant phage harbors a putative growth inhibitory gene, designated trg, that is expressed at a higher level in rat embryo fibroblasts and in the REF52 cell line. Introduction of recombinant phage DNA into established 208F and Rat-2 cells and into HRAS-, v-fgr-, v-fms- and v-raf-transformed rat cell lines resulted in inhibition of growth and induction of programmed cell death.	UNIV ZURICH,DEPT PATHOL,DIV CANC RES,CH-8091 ZURICH,SWITZERLAND	University of Zurich	SCHWARTEWALDHOFF, I (corresponding author), UNIV BONN,INST GENET,DIV MOLEC GENET,MOLEK GENET ABT,ROMERSTR 164,D-53117 BONN,GERMANY.		Schäfer, Reinhold/AAB-5110-2021					ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKER RF, 1983, P NATL ACAD SCI-BIOL, V80, P1174, DOI 10.1073/pnas.80.5.1174; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BASSIN RH, 1984, CANCER CELL, V2, P463; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADY G, 1985, EMBO J, V4, P2583, DOI 10.1002/j.1460-2075.1985.tb03974.x; BRADY G, 1984, GENE, V27, P223, DOI 10.1016/0378-1119(84)90143-4; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EIDEN MV, 1991, MOL CELL BIOL, V11, P5321, DOI 10.1128/MCB.11.10.5321; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GEISER A G, 1989, Critical Reviews in Oncogenesis, V1, P261; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HARRIS H, 1988, CANCER RES, V48, P3302; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KLINGER HP, 1983, JNCI-J NATL CANCER I, V71, P559; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTIN W, 1992, EXP CELL RES, V200, P41, DOI 10.1016/S0014-4827(05)80069-2; MERCER WE, 1990, ONCOGENE, V5, P973; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; NAGY A, 1987, J CELL SCI, V87, P651; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PADMANABHAN R, 1987, MOL CELL BIOL, V7, P1894, DOI 10.1128/MCB.7.5.1894; PHILIPSON L, 1991, J CELL BIOCHEM, V46, P95, DOI 10.1002/jcb.240460202; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAGER R, 1986, CANCER RES, V46, P1573; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1983, CANCER RES, V43, P2240; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; Smith J R, 1990, Adv Cancer Res, V54, P63, DOI 10.1016/S0065-230X(08)60808-8; SORRENTINO V, 1989, ANTICANCER RES, V9, P1925; SORRENTINO V, 1989, ONCOGENE, V4, P569; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEINBERG B, 1978, CELL, V13, P300; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	78	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					899	909						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108134				2022-12-25	WOS:A1994MW55100027
J	KOVACS, T; CORVAZIER, E; PAPP, B; MAGNIER, C; BREDOUX, R; ENYEDI, A; SARKADI, B; ENOUF, J				KOVACS, T; CORVAZIER, E; PAPP, B; MAGNIER, C; BREDOUX, R; ENYEDI, A; SARKADI, B; ENOUF, J			CONTROLLED PROTEOLYSIS OF CA2+-ATPASES IN HUMAN PLATELET AND NONMUSCLE CELL-MEMBRANE VESICLES - EVIDENCE FOR A MULTI-SARCO/ENDOPLASMIC RETICULUM CA2+-ATPASE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; PLASMA-MEMBRANE; CA-2+ PUMP; CA-2+-TRANSPORT ATPASE; CA-2+-ATPASE GENE; SKELETAL-MUSCLE; MESSENGER-RNA; SMOOTH-MUSCLE; EXPRESSION	Two sarco/endoplasmic reticulum Ca2+-ATPases (SERCAs) have been previously identified in platelets: the 100-kDa SERCA(2b), and the 97-kDa SERCA(3) isoforms. Analysis of the acylphosphate intermediate (E similar to P) formation and the immunoreactivity of the platelet Ca2+-ATPases and their proteolytic fragments upon controlled trypsinolysis revealed the presence of an additional 97-kDa Ca2+-ATPase that comigrates with SERCA(3) on SDS-polyacrylamide gels. At a trypsin/membrane protein ratio of 0.025 at 4 degrees C, tryptic fragments of 73-, 68- and 40-kDa, previously unknown in the SERCA family, could be detected by using the PL/IM 430 anti-Ca2+-ATPase antibody that had been shown to recognize a 97-kDa Ca2+-ATPase. The 73- and 68-kDa fragments were precursors of the 40-kDa one. Ca2+-dependent phospholabeling of the 73-kDa fragment and immunostaining of all these proteolytic products by another antibody raised against SERCA(1) established the SERCA nature of the 97-kDa parent enzyme. The SERCA(3)-related E similar to P-forming 80-kDa tryptic fragment appeared during trypsinolysis with a different time course from that of the 73-, 68-, and 40-kDa ones. At a trypsin/membrane protein ratio of 0.125 at 37 degrees C, it reached its maximum level at 5 min of digestion, while the 73-, 68-, and 40-kDa fragments were fully degraded at 2 min of trypsinization. This 80-kDa species was immunostained neither with the PL/IM 430, nor with the anti-SERCA(1) antibodies. Similar results were found in some megakaryoblastoid and lymphoblastoid cell lines. All these data indicate the presence of two distinct tryptic fragmentation patterns attributed to two 97-kDa SERCA isoforms and point to the existence of a multi-SERCA system in different human non-muscle cells.	NATL INST HAEMATOL & BLOOD TRANSFUS,H-1113 BUDAPEST,HUNGARY		KOVACS, T (corresponding author), HOP LARIBOISIERE,INSERM,U348,8 RUE GUY PATIN,F-75475 PARIS 10,FRANCE.		Kovács, Tünde/O-6020-2017; Enyedi, Agnes/N-9742-2013; Sarkadi, Balazs/I-5024-2013	Kovács, Tünde/0000-0003-1064-2616; Enyedi, Agnes/0000-0002-7366-9376; Papp, Bela/0000-0002-5025-3087				BOBE R, 1994, J BIOL CHEM, V269, P1417; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; DEAN WL, 1984, J BIOL CHEM, V259, P7343; DEAN WL, 1989, CELL CALCIUM, V10, P289, DOI 10.1016/0143-4160(89)90055-9; DEAN WL, 1982, J BIOL CHEM, V257, P4390; DUX L, 1983, J BIOL CHEM, V258, P111; EGGERMONT JA, 1989, BIOCHEM J, V260, P757, DOI 10.1042/bj2600757; ENOUF J, 1988, J BIOL CHEM, V263, P13922; ENOUF J, 1992, BIOCHEM J, V286, P135, DOI 10.1042/bj2860135; ENOUF J, 1987, J BIOL CHEM, V262, P9293; ENYEDI A, 1986, J BIOL CHEM, V261, P9558; FISCHER TH, 1985, J BIOL CHEM, V260, P8996; GREENBERG SM, 1988, BLOOD, V72, P1968; HACK N, 1988, BIOSCIENCE REP, V8, P379, DOI 10.1007/BF01115229; HACK N, 1988, BIOCHEM J, V250, P355, DOI 10.1042/bj2500355; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; JAVORS MA, 1982, BIOCHIM BIOPHYS ACTA, V691, P220, DOI 10.1016/0005-2736(82)90410-2; JENCKS WP, 1992, ANN NY ACAD SCI, V671, P49, DOI 10.1111/j.1749-6632.1992.tb43783.x; KASERGLANZMANN R, 1977, BIOCHIM BIOPHYS ACTA, V466, P429, DOI 10.1016/0005-2736(77)90336-4; KASERGLANZMANN R, 1978, BIOCHIM BIOPHYS ACTA, V512, P1, DOI 10.1016/0005-2736(78)90213-4; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LEVITSKY DO, 1993, J BIOL CHEM, V268, P8325; LOMPRE AM, 1989, FEBS LETT, V249, P35, DOI 10.1016/0014-5793(89)80010-9; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MENASHI S, 1984, BIOCHEM J, V222, P413, DOI 10.1042/bj2220413; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; PAPP B, 1993, CELL CALCIUM, V14, P531, DOI 10.1016/0143-4160(93)90074-G; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; PAPP B, 1989, J BIOL CHEM, V264, P4577; PAPP B, 1993, BIOCHEM J, V295, P685, DOI 10.1042/bj2950685; PAPP B, 1991, J BIOL CHEM, V266, P14592; ROBBLEE LS, 1973, J GEN PHYSIOL, V61, P462, DOI 10.1085/jgp.61.4.462; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SARKADI B, 1988, BIOCHIM BIOPHYS ACTA, V939, P40, DOI 10.1016/0005-2736(88)90044-2; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; WUYTACK F, 1992, J BIOENERG BIOMEMBR, V24, P285; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670; [No title captured]	48	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6177	6184						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119962				2022-12-25	WOS:A1994MY84000104
J	LUESCHER, IF; CEROTTINI, JC; ROMERO, P				LUESCHER, IF; CEROTTINI, JC; ROMERO, P			PHOTOAFFINITY-LABELING OF THE T-CELL RECEPTOR ON CLONED CYTOTOXIC T-LYMPHOCYTES BY COVALENT PHOTOREACTIVE LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; HISTOCOMPATIBILITY COMPLEX-MOLECULES; MONOCLONAL-ANTIBODIES; ANTIGENIC PEPTIDES; LIVING CELLS; HEAVY-CHAINS; MHC; CD8; BINDING; SURFACE	The interaction of the T cell antigen receptor with a photoreactive antigenic peptide derivative bound covalently to the H-2K(d) (K-d) molecule was studied by photoaffinity labeling on cloned, CD8 positive cytotoxic T lymphocytes. The K-d-restricted Plasmodium berghei circumsporozoite peptide 253-260 (YIPS-AEKI) was conjugated with iodo-4-azidosalicylic acid at the N terminus and with 4-azidobenzoic acid at the T cell receptor residue Lys-259. Cell-associated or soluble K-d molecules were photoaffinity-labeled with the peptide derivative by selective photoactivation of the N-terminal photoreactive group. Incubation of cell-associated or soluble covalent K-d-peptide derivative complexes (ligands) with cytotoxic T lymphocytes that recognized this peptide derivative and activation of the orthogonal photoreactive group resulted in specific photoaffinity labeling of the T cell receptor. The labeling was inhibitable by an anti-K-d antibody and was absent on K-d-restricted cytotoxic T lymphocytes of different specificity. The binding of the soluble ligand reached a maximum after 2-4 min at 37 degrees C, after 30 min at 18 degrees C, and after 3 h at 4 degrees C. In contrast, binding of the cell-associated ligand reached a transient maxima after 50 and 110 min at 37 and 18 degrees C, respectively. The degree of binding at 37 degrees C was approximately 30% lower than that at 18 degrees C. No binding took place at 4 degrees C. Inhibition studies with antibodies and drugs indicated that the binding of the cell-associated, but not the soluble ligand, was highly dependent on T cell-target cell conjugate formation, whereas the binding of the soluble ligand was greatly dependent on CD8.			LUESCHER, IF (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CHEMIN BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.							BALEY H, 1984, AZIDES NITRENES REAC, P434; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; CEROTTINI JC, 1972, NATURE-NEW BIOL, V237, P272, DOI 10.1038/newbio237272a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P2085, DOI 10.1002/eji.1830220819; GLASEBROOK AL, 1978, J IMMUNOL, V121, P1870; GODEAU F, 1992, INT IMMUNOL, V4, P265, DOI 10.1093/intimm/4.2.265; GOLSTEIN P, 1982, IMMUNOL REV, V68, P5, DOI 10.1111/j.1600-065X.1982.tb01058.x; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; ISAKOV N, 1993, MOL IMMUNOL, V30, P197, DOI 10.1016/0161-5890(93)90092-P; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; LUESCHER IF, 1987, ELECTROPHORESIS, V8, P508, DOI 10.1002/elps.1150081103; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; LUESCHER IF, 1992, J IMMUNOL, V148, P1003; MALEFYT RD, 1993, EUR J IMMUNOL, V23, P418; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; NEEFJES JJ, 1993, EUR J IMMUNOL, V23, P840, DOI 10.1002/eji.1830230411; OJCIUS DM, 1993, EUR J IMMUNOL, V23, P1118, DOI 10.1002/eji.1830230521; OROURKE AM, 1991, J EXP MED, V173, P241, DOI 10.1084/jem.173.1.241; OROURKE AM, 1993, IMMUNOL TODAY, V14, P183; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; RATNOFSKY SE, 1987, J EXP MED, V166, P1747, DOI 10.1084/jem.166.6.1747; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROMERO P, 1992, J IMMUNOL, V148, P1871; ROMERO P, 1993, J EXP MED, V177, P1247, DOI 10.1084/jem.177.5.1247; ROMERO P, 1993, J IMMUNOL, V150, P3825; ROURKE AM, 1992, NATURE, V358, P253; SAMELSON LE, 1985, J IMMUNOL, V134, P2529; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SMITH JD, 1992, P NATL ACAD SCI USA, V89, P7767, DOI 10.1073/pnas.89.16.7767; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VANSNICK J, 1982, EUR J IMMUNOL, V12, P905, DOI 10.1002/eji.1830121102; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0	40	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5574	5582						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119892				2022-12-25	WOS:A1994MY84000019
J	PATEL, YM; YUN, JS; LIU, JS; MCGRANE, MM; HANSON, RW				PATEL, YM; YUN, JS; LIU, JS; MCGRANE, MM; HANSON, RW			AN ANALYSIS OF REGULATORY ELEMENTS IN THE PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) GENE WHICH ARE RESPONSIBLE FOR ITS TISSUE-SPECIFIC EXPRESSION AND METABOLIC CONTROL IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE GENE; ENRICHED TRANSCRIPTIONAL ACTIVATOR; ENHANCER-BINDING-PROTEIN; RAT-LIVER; CYCLIC-AMP; PYRUVATE-CARBOXYLASE; DIETARY-REGULATION; THYROID-HORMONE; MESSENGER-RNA; IDENTIFICATION	Sequences in the gene for P-enolpyruvate carboxykinase (PEPCK) which are responsible for its complex pattern of transcriptional control were determined using transgenic mice containing a chimeric PEPCK-bovine growth hormone (bGH) gene consisting of a segment of the PEPCK promoter from -460 to +73, with mutations in specific regulatory domains. A mutation in the cAMP response element (CRE) (-87 to -74), which binds CCATT/enhancer-binding protein beta (C/EBP beta) and/or cAMP response element-binding protein (CREE), resulted in a 4- and 20-fold elevation in the level of bGH mRNA in the liver and kidney of transgenic mice, respectively. Expression of the PEPCK bGH gene in the liver was reduced 60% by a mutation in the P3 (I) region (-248 to -230), whereas expression in the kidney was increased 10-fold by the same mutation. A mutation in the P2 region (-200 to -164) greatly reduced expression of the PEPCK-bGH gene in the kidney but not in the liver Induction of hepatic PEPCK-bGH gene expression by Bt(2)cAMP was eliminated by mutations in the CRE, P1, P3(I), or by a double mutation of the CRE and P3(I). Mutations in the CRE or P3(I) regions of the PEPCK promoter did not interfere with the expected induction of the PEPCK-bGH gene in the liver at birth. None of the mutations in the PEPCK promoter interfered with the induction of transcription of the PEPCK-bGH gene in the liver when mice were fed a carbohydrate free diet or the deinduction of transcription from the PEPCK promoter caused by a diet high in carbohydrate, whereas a mutation in P2 (an HNF-1 binding domain) eliminated dietary regulation of transcription of the transgene in the kidney. A model to explain the role of the various elements in the PEPCK promoter on the control of PEPCK gene transcription in the liver and kidney is presented.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT NUTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,PEW CTR MOLEC NUTR,CLEVELAND,OH 44106; OHIO UNIV,EDISON ANIM BIOTECHNOL CTR,ATHENS,OH 45107	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Ohio University					NIDDK NIH HHS [DK-24451, DK-07319, DK-21859] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021859, R01DK021859] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JW, 1970, BIOCHIM BIOPHYS ACTA, V208, P165, DOI 10.1016/0304-4165(70)90066-8; BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTCHER FR, 1972, CANCER RES, V32, P2141; CHEE PP, 1991, PLANT MOL BIOL MANUA, P19; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davis R W, 1980, Methods Enzymol, V65, P404; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; FABER S, 1993, J BIOL CHEM, V268, P24976; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; GARCIARUIZ JP, 1983, ENZYME, V30, P265; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GIRARD JR, 1973, J CLIN INVEST, V52, P3190, DOI 10.1172/JCI107519; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HANSON RW, 1972, AM J CLIN NUTR, V25, P1010; HENNING HV, 1966, BIOCHEM Z, V344, P274; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IYNEDJIAN PB, 1975, J BIOL CHEM, V250, P5596; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAISER S, 1991, J BIOL CHEM, V266, P9397; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; LOOSE DS, 1985, BIOCHEMISTRY-US, V24, P4509, DOI 10.1021/bi00338a004; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NECHUSHTAN H, 1987, NUCLEIC ACIDS RES, V15, P6405, DOI 10.1093/nar/15.16.6405; NORDLIE RC, 1963, J BIOL CHEM, V238, P2259; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PERET J, 1976, J NUTR, V106, P103, DOI 10.1093/jn/106.1.103; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SALAVERT A, 1982, J BIOL CHEM, V257, P13404; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; WAGNER TE, 1981, P NATL ACAD SCI-BIOL, V78, P6376, DOI 10.1073/pnas.78.10.6376; WOYCHIK RP, 1982, NUCLEIC ACIDS RES, V10, P7197, DOI 10.1093/nar/10.22.7197	50	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5619	5628						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119898				2022-12-25	WOS:A1994MY84000025
J	QUEMENEUR, E; GUTHAPFEL, R; GUEGUEN, P				QUEMENEUR, E; GUTHAPFEL, R; GUEGUEN, P			A MAJOR PHOSPHOPROTEIN OF THE ENDOPLASMIC-RETICULUM IS PROTEIN DISULFIDE-ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THIN-LAYER CHROMATOGRAPHY; HORMONE BINDING-PROTEIN; ESCHERICHIA-COLI; HEAT-SHOCK; MEMBRANE; LIVER; LUMEN; SITE; ATP; PHOSPHORYLATION	One of the effects of ATP in the endoplasmic reticulum is to induce the phosphorylation of several proteins among which a 57-kDa protein (pp57) prevails in our labeling conditions. We provide evidence that pp57 is protein disulfide isomerase (PDI), an abundant ubiquitous protein of the endoplasmic reticulum involved in various important cellular functions. This phosphorylation does not result from the activity of a microsomal protein kinase but from an autophosphorylation as described for other microsomal proteins such as chaperones. Phosphoamino acid analysis and cyanogen bromide cleavage indicate that the modification site lies on a threonine residue within the central region of the protein outside the thioredoxin-like domains. For the pure PDI, only the dimer is able to phosphorylate, while some experiments suggest that within the endoplasmic reticulum the phosphorylated form of PDI is mainly mobilized in larger size oligomers. Thus a possible role for this phosphorylation may be to modulate the association of PDI with its different partners.			QUEMENEUR, E (corresponding author), CTR ETUD SACLAY, CEA, DEPT INGN & ETUD PROT, BATIMENT 152, F-91191 GIF SUR YVETTE, FRANCE.							AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BEHARBANNELIER M, 1980, BIOCHEM J, V187, P147, DOI 10.1042/bj1870147; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Freedman R. B., 1992, PROTEIN FOLDING, P457; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HARLOW E, 1988, ANTIBODIES LABORATOR; HASUMURA S, 1986, BIOCHEMISTRY-US, V25, P7881, DOI 10.1021/bi00372a014; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; LAMBERT N, 1989, PROTEIN PURIFICATION, P101; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MILLS ENC, 1983, BIOCHEM J, V213, P245, DOI 10.1042/bj2130245; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PIGIET V, 1978, J BIOL CHEM, V253, P1910; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; TSIBRIS JCM, 1989, J BIOL CHEM, V264, P13967; VUORI K, 1992, J BIOL CHEM, V267, P7211; WADA I, 1991, J BIOL CHEM, V266, P19599; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; YAMAUCHI K, 1987, BIOCHEM BIOPH RES CO, V146, P1485, DOI 10.1016/0006-291X(87)90817-5	32	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5485	5488						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119877				2022-12-25	WOS:A1994MY84000002
J	TSAI, MY; WANG, C				TSAI, MY; WANG, C			UNCOUPLING OF PEPTIDE-STIMULATED ATPASE AND CLATHRIN-UNCOATING ACTIVITY IN DELETION MUTANT OF HSC70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; STRESS PROTEINS; COATED VESICLES; DNAJ; HOMOLOG	The recombinant 60-kDa fragment of rat hsc70 has been overexpressed in Escherichia coli. The recombinant protein is not capable of disassembling clathrin from coated vesicles. However, the affinity for peptides and the peptide-stimulated ATPase activity of the intact protein are retained in the 60-kDa fragment. The dissociation constants of peptide P3a (the recognition sequence of clathrin light chain LCa by hsc70) and S peptide of ribonuclease for 60-kDa protein are 13 and 7 mu M, respectively. The maximal velocities of stimulated ATPase activity by peptides P3a and GT4 are 0.25 and 0.31 nmol/h/mu g of protein, respectively, and the EC(50) values (the concentration of peptides that brought about half-maximum hydrolysis) for peptides P3a and GT4 are 0.56 and 0.30 mM, respectively. These results indicate that peptide-stimulated ATPase activity of hsc70 is not sufficient for clathrin uncoating. We suggest that other activities or cellular components as yet unidentified associated with the C-terminal 10-kDa fragment of hsc70 are required for clathrin uncoating.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan								CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CYR DM, 1992, J BIOL CHEM, V267, P20927; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; HUANG SP, 1993, J BIOL CHEM, V268, P2063; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; ZHU JK, 1993, PLANT CELL, V5, P341, DOI 10.1105/tpc.5.3.341	21	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5958	5962						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119940				2022-12-25	WOS:A1994MY84000074
J	HYDE, H; DAVIES, AA; BENSON, FE; WEST, SC				HYDE, H; DAVIES, AA; BENSON, FE; WEST, SC			RESOLUTION OF RECOMBINATION INTERMEDIATES BY A MAMMALIAN ACTIVITY FUNCTIONALLY ANALOGOUS TO ESCHERICHIA-COLI RUVC RESOLVASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 ENDONUCLEASE-I; HOLLIDAY JUNCTIONS INVITRO; DNA-REPAIR GENE; SACCHAROMYCES-CEREVISIAE; RECA PROTEIN; SCID MUTATION; MUTANTS; IDENTIFICATION; PURIFICATION; CLEAVAGE	A mammalian endonuclease that resolves Holliday junctions has been partially purified from extracts of calf thymus and Chinese hamster ovary cells. The activity acts upon (i) synthetic Holliday junctions and (ii) recombination intermediates made by the Escherichia coli RecA protein and appears to be functionally analogous to the E. coli RuvC protein. Cleavage occurs by the introduction of symmetrically related nicks in strands of like polarity to produce nicked duplex DNA products. The nicks can be repaired by DNA ligase. The resolvase is specific for Holliday junctions and does not act upon Y junctions, G/A mismatches, or heterologous loops. The substrate specificity is therefore similar to that of E. coli RuvC protein and contrasts with the broad range specificity of other junction resolvases such as T4 endonuclease VII. The mammalian resolvase activity has been observed at normal levels in extracts prepared from a series of DNA repair-defective cells. These include the x-ray or UV-sensitive hamster lines xrs-5, xrs-6, and Chinese hamster ovary 43-3B (defective in ERCC-1), and murine cells that are severely immunodeficient and defective in both V(D)J rejoining and DNA repair.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND					Benson, Fiona Elizabeth/0000-0002-3918-7015				BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1994, J BIOL CHEM, V269, P5195; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; COUTURE C, 1992, NUCLEIC ACIDS RES, V20, P4355, DOI 10.1093/nar/20.16.4355; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DICKIE P, 1987, J BIOL CHEM, V262, P14826; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; EVANS DH, 1988, J MOL BIOL, V201, P69, DOI 10.1016/0022-2836(88)90439-1; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JAYASEELAN R, 1988, BIOCHEM BIOPH RES CO, V156, P1054; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; JENSCH F, 1986, EMBO J, V5, P181, DOI 10.1002/j.1460-2075.1986.tb04194.x; KEMPER B, 1976, J VIROL, V18, P992, DOI 10.1128/JVI.18.3.992-999.1976; KEMPER B, 1990, STRUCTURE METHODS, V1, P215; KLEFF S, 1988, EMBO J, V7, P1527, DOI 10.1002/j.1460-2075.1988.tb02972.x; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Maxam A M, 1980, Methods Enzymol, V65, P499; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MOSIG G, 1987, ANNU REV GENET, V21, P347, DOI 10.1146/annurev.ge.21.120187.002023; MULLER B, 1990, NUCLEIC ACIDS RES, V18, P5633, DOI 10.1093/nar/18.19.5633; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; MURCHIE AIH, 1993, J MOL BIOL, V233, P77, DOI 10.1006/jmbi.1993.1486; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SAMBROOK E, 1989, MOL CLONING LABORATO; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; WALDMAN AS, 1988, NUCLEIC ACIDS RES, V16, P10249, DOI 10.1093/nar/16.21.10249; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; WEST SC, 1982, MOL GEN GENET, V186, P333, DOI 10.1007/BF00729451; WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0; WOOD RD, 1982, MUTAT RES, V95, P505, DOI 10.1016/0027-5107(82)90281-0	56	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5202	5209						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106502				2022-12-25	WOS:A1994MX57100079
J	LI, Q; GARDNER, DG				LI, Q; GARDNER, DG			NEGATIVE REGULATION OF THE HUMAN ATRIAL-NATRIURETIC-PEPTIDE GENE BY 1,25-DIHYDROXYVITAMIN D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D RECEPTOR; PARATHYROID-HORMONE GENE; HUMAN OSTEOCALCIN GENE; RETINOID X-RECEPTOR; THYROID-HORMONE; MUSCLE CELLS; CHLORAMPHENICOL ACETYLTRANSFERASE; CARDIOVASCULAR FUNCTION; RESPONSE ELEMENTS; CARDIAC-MUSCLE	We have examined the effect of 1,25 dihydroxyvitamin D-3 on the promoter activity of the atrial natriuretic peptide (ANP) gene in cultured neonatal rat atrial myocytes. In acute transfection studies 1,25-dihydroxyvitamin D-3 inhibited the expression of a human ANP (hANP) promoter-driven chloramphenicol acetyltransferase reporter (-1150 hANP CAT) in a dose-dependent fashion (10-(10)-10-(8) M). When an expression vector for the vitamin D receptor (VDR) (pSVL-VDR) was introduced together with the reporter plasmid, there was a significant ligand-dependent amplification of the vitamin D-dependent inhibition. Deletion analysis of the 5'-flanking sequence localized the suppressible promoter sequence to within 104 base pairs of the transcription start site of the hANP gene. Thyroid hormone, glucocorticoid, estrogen, and retinoic acid receptor were incapable of mimicking the VDR-dependent inhibition. Retinoid X receptor, on the other hand, effected a significant reduction in hANP promoter activity which was at least additive with that produced by the liganded VDR The VDR-dependent inhibition displayed promoter selectivity. Both the SV40 promoter and a conventional vitamin D response element linked to a truncated SV40 promoter were activated by the liganded vitamin D receptor, whereas the Rous sarcoma virus promoter was unaffected. On the other hand, the cardiac-specific troponin T promoter was suppressed in a fashion similar to ANP. These findings imply a potentially important role for vitamin D-3 in the regulation of gene transcription in myocardial cells.	UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [R01 HL 35753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BAUER RF, 1976, IN VITRO CELL DEV B, V12, P558; BIDMON HJ, 1991, EXPERIENTIA, V47, P958, DOI 10.1007/BF01929891; BORTELL R, 1992, P NATL ACAD SCI USA, V89, P6119, DOI 10.1073/pnas.89.13.6119; BUGAISKY LB, 1991, HEART CARDIOVASCULAR, P1621; DELUCA HF, 1992, ANN NY ACAD SCI, V669, P59; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; ENOMOTO H, 1992, ENDOCRINOLOGY, V130, P3467, DOI 10.1210/en.130.6.3467; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRAMPTON RJ, 1983, CANCER RES, V43, P4443; GARDNER DG, 1990, J CLIN INVEST, V86, P52, DOI 10.1172/JCI114714; GARDNER DG, 1987, MOL ENDOCRINOL, V1, P260, DOI 10.1210/mend-1-3-260; GARDNER DG, 1988, J CLIN INVEST, V82, P1275, DOI 10.1172/JCI113726; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; LAPOINTE MC, 1988, J BIOL CHEM, V263, P9075; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MERKE J, 1989, J CLIN INVEST, V83, P1903, DOI 10.1172/JCI114097; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; MITSUHASHI T, 1991, J CLIN INVEST, V87, P1889, DOI 10.1172/JCI115213; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OKAZAKI T, 1991, J BIOL CHEM, V266, P21903; OKAZAKI T, 1988, J BIOL CHEM, V263, P2203; OSMUNDSEN BC, 1989, J STEROID BIOCHEM, V34, P339, DOI 10.1016/0022-4731(89)90105-2; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SONE T, 1991, J BIOL CHEM, V266, P23296; STUMPF WE, 1979, SCIENCE, V206, P1188, DOI 10.1126/science.505004; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WALTERS MR, 1987, J BIOL CHEM, V262, P2536; WALTERS MR, 1986, J MOL CELL CARDIOL, V18, P67, DOI 10.1016/S0022-2828(86)80983-X; WALTERS MR, 1987, EXCERPTA MED INT C S, V735, P479; WEISHAAR RE, 1990, AM J PHYSIOL, V258, pE134, DOI 10.1152/ajpendo.1990.258.1.E134; WEISHAAR RE, 1987, J CLIN INVEST, V79, P1706, DOI 10.1172/JCI113010; WU JP, 1991, MOL ENDOCRINOL, V5, P1311, DOI 10.1210/mend-5-9-1311; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4934	4939						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106467				2022-12-25	WOS:A1994MX57100039
J	MINTZ, KP; FISHER, LW; GRZESIK, WJ; HASCALL, VC; MIDURA, RJ				MINTZ, KP; FISHER, LW; GRZESIK, WJ; HASCALL, VC; MIDURA, RJ			CHLORATE-INDUCED INHIBITION OF TYROSINE SULFATION ON BONE SIALOPROTEIN SYNTHESIZED BY A RAT OSTEOBLAST-LIKE CELL-LINE (UMR 106-01 BSP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSYLPROTEIN SULFOTRANSFERASE; BALANCE-SHEET; PROTEINS; PROTEOGLYCANS; INVITRO; SECRETION; RESIDUES; PURIFICATION; SUBSTRATE; CULTURES	Bone sialoprotein (BSP) is a major noncollagenous, RGD-containing glycoprotein found in the extracellular matrix of bone. The RGD sequence is flanked by two tyrosine-rich regions, which fit the established consensus requirements for tyrosine sulfation. Tyrosine sulfation is suggested to be important in the regulation of protein secretion and function. The role of this posttranslational modification on the cell attachment activity and secretion of a highly sulfated form of BSP isolated from a rat osteoblast-like cell line (UMR 106-01 BSP) was investigated by inhibiting sulfation with chlorate. [S-35]Sulfate, [H-3]glucosamine, and [H-3]tyrosine were used as metabolic precursors to monitor biosynthetic products. Chlorate was effective in inhibiting to tal [S-35]sulfate incorporation by 90% without altering overall protein synthesis and secretion in cultures up to 72 h under serum-free conditions. Isolated proteoglycans and purified BSP were analyzed for sulfate incorporation. Proteoglycans isolated from the medium of cells treated with chlorate displayed a difference in the hydrodynamic properties of the molecules as compared with control cultures. An increase in the specific activity of proteoglycans labeled with [H-3]glucosamine isolated from chlorate-treated cells was also observed suggesting a change in hexosamine metabolism induced by chlorate. BSP purified from the medium of chlorate-treated cells contained similar to 7% of the S-35 incorporation as compared with nontreated control cultures. Quantification of sulfate incorporation into glycoconjugates versus tyrosine sulfate of BSP indicates that the amount of sulfate associated with N- and O-linked oligosaccharides was reduced by similar to 97%, while that on tyrosine residues was reduced by similar to 90%. Using normal human bone cells, the cell attachment activity of the reduced sulfate form of BSP was nearly equivalent to that of the fully sulfated product.	NIDR, BONE RES BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DECHERNEY GS, 1989, BIOCHEM BIOPH RES CO, V159, P755, DOI 10.1016/0006-291X(89)90059-4; ECAROTCHARRIER B, 1989, J BIOL CHEM, V264, P20049; FISHER LW, 1983, J BIOL CHEM, V258, P2723; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FRIEDERICH E, 1988, J CELL BIOL, V107, P1655, DOI 10.1083/jcb.107.5.1655; GRZESIK WJ, 1994, IN PRESS J BONE MINE; HILLE A, 1984, FEBS LETT, V177, P129, DOI 10.1016/0014-5793(84)80996-5; HILLE A, 1990, EUR J BIOCHEM, V188, P577, DOI 10.1111/j.1432-1033.1990.tb15438.x; HILLE A, 1990, EUR J BIOCHEM, V188, P587, DOI 10.1111/j.1432-1033.1990.tb15439.x; HIROSE S, 1988, J BIOL CHEM, V263, P7426; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V150, P342, DOI 10.1016/0006-291X(88)90526-8; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V151, P417, DOI 10.1016/0006-291X(88)90609-2; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; HUTTNER WB, 1982, NATURE, V299, P273, DOI 10.1038/299273a0; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JUKKOLA A, 1990, BIOCHEM BIOPH RES CO, V170, P264, DOI 10.1016/0006-291X(90)91269-X; KUMARASAMY R, 1986, J BIOL CHEM, V261, P6473; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LEE RWH, 1983, J BIOL CHEM, V258, P1326; LEYTE A, 1991, J BIOL CHEM, V266, P740; LIU N, 1986, J BIOL CHEM, V261, P856; MCQUILLAN DJ, 1991, BIOCHEM J, V277, P199, DOI 10.1042/bj2770199; MCQUILLAN DJ, 1992, BIOCHEM J, V285, P25, DOI 10.1042/bj2850025; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; MINTZ KP, 1993, J BONE MINER RES, V8, P985; NAGATA T, 1991, MATRIX, V11, P86, DOI 10.1016/S0934-8832(11)80212-X; NIEHRS C, 1990, J BIOL CHEM, V265, P9314; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; ROBEY PG, 1989, ENDOCRIN METAB CLIN, V18, P859, DOI 10.1016/S0889-8529(18)30347-5; SOMERMAN MJ, 1988, CALCIFIED TISSUE INT, V43, P50, DOI 10.1007/BF02555169; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279	41	20	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4845	4852						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106456				2022-12-25	WOS:A1994MX57100025
J	CARLIER, MF; DIDRY, D; ERK, I; LEPAULT, J; PANTALONI, D				CARLIER, MF; DIDRY, D; ERK, I; LEPAULT, J; PANTALONI, D			MYOSIN SUBFRAGMENT-1-INDUCED POLYMERIZATION OF G-ACTIN - FORMATION OF PARTIALLY DECORATED FILAMENTS AT HIGH ACTIN-S(1) RATIOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; F-ACTIN; BINDING; ATP; TROPOMYOSIN; INTERACTS; PROTEINS; KINETICS	Myosin subfragment-1-induced polymerization of G-actin into arrowhead-decorated F-actin-myosin subfragment-1 (S1) filaments has been studied at low ionic strength and in the absence of ATP, using a combination of light scattering, fluorescence of 4-nitrobenz-2-oxa-1,3-diazol-7-yl- or pyrenyl-labeled actin, sedimentation, and electron microscopy techniques. When G-actin is in excess over myosin subfragment-1, the initial formation of fully decorated F-actin-S1 filaments, in which the actin:S1 molar ratio is 1:1, is followed by further incorporation of G-actin subunits in the polymer concomitant with the redistribution of the myosin heads along the polymer, leading to partially decorated filaments containing less than one S1/actin, in equilibrium with G-actin. This process leads to an overshoot in the light-scattering polymerization curves at high actin:S1 ratios. The concentration of G-actin at equilibrium with partially decorated filaments is a nonlinear function of the molar fraction of S1 in the polymer, indicating that actin-actin-S1 interactions are energetically more favorable than actin-actin or actin-S1-actin-S1 interactions.	CNRS,CTR GENET MOLEC,F-91128 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	CARLIER, MF (corresponding author), CNRS,ENZYMOL LAB,F-91128 GIF SUR YVETTE,FRANCE.		Lepault, Jean/AAN-8859-2020					CARLIER MF, 1984, J BIOL CHEM, V259, P9983; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; DEROSIER DJ, 1970, J MOL BIOL, V52, P255; DETMERS P, 1981, J BIOL CHEM, V256, P99; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; GERGELY J, 1957, C CHEM MUSCLE CONTRA; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; GRAZI E, 1909, EUR J BIOCHEM, V182, P277; GRAZI E, 1990, FEBS LETT, V112, P67; HILL TL, 1987, LINEAR AGGREGATION 1, P110; KEANE AM, 1990, NATURE, V344, P265, DOI 10.1038/344265a0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOSCALZO J, 1975, P NATL ACAD SCI USA, V72, P3412, DOI 10.1073/pnas.72.9.3412; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MILLER L, 1988, J BIOL CHEM, V263, P1996; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TESI C, 1990, BIOCHEMISTRY-US, V29, P1846, DOI 10.1021/bi00459a026; VALENTINRANC C, 1992, J BIOL CHEM, V267, P21543; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8	27	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3829	3837						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106427				2022-12-25	WOS:A1994MV63100102
J	LEE, RJ; LOW, PS				LEE, RJ; LOW, PS			DELIVERY OF LIPOSOMES INTO CULTURED KB CELLS VIA FOLATE RECEPTOR-MEDIATED ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; LINES; SIZE	Folic acid was covalently conjugated to 66-nm liposomes via spacers of various lengths in an attempt to target the liposomes to KB cells expressing folate receptors. Spacers of short and intermediate lengths were unable to mediate association of folate-conjugated liposomes with receptor-bearing cells, however, use of a 250 angstrom polyethyleneglycol spacer (PEG, M(r) approximately 3350) permitted avid uptake of the liposomes at approximately 2.5 x 10(5) sites/cell. The binding of folate-PEG liposomes to KB cells could be competitively inhibited by excess free folate or by antiserum against the folate receptor, demonstrating the interaction is mediated by the cell surface folate-binding protein. Following binding, cell-associated folate-PEG liposomes were internalized by folate-receptor-mediated endocytosis at 37-degrees-C but not at 4-degrees-C. These folate-PEG liposomes show potential for delivering large quantities of low molecular weight compounds non-destructively into folate receptor-bearing cells.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528				ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BERINSTEIN N, 1987, CANCER RES, V47, P5954; BOLHUIS RLH, 1992, INT J CANCER, P78; CANEVARI S, 1992, INT J CANCER, P42; GARELLI N, 1992, BIOCHIM BIOPHYS ACTA, V1127, P41, DOI 10.1016/0005-2760(92)90199-6; ITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P201; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KANE MA, 1986, J BIOL CHEM, V261, P44; KLIBANOV AL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P142, DOI 10.1016/0005-2736(91)90385-L; LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572; LEAMON CP, 1993, BIOCHEM J, V291, P855, DOI 10.1042/bj2910855; LEAMON CP, 1992, J BIOL CHEM, V267, P24966; LESERMAN LD, 1980, P NATL ACAD SCI-BIOL, V77, P4089, DOI 10.1073/pnas.77.7.4089; LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1104, P179, DOI 10.1016/0005-2736(92)90148-F; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAYER LD, 1989, CANCER RES, V49, P5922; MILHAUD PG, 1989, BIOCHIM BIOPHYS ACTA, V987, P15, DOI 10.1016/0005-2736(89)90449-5; MOGHIMI SM, 1992, BIOCHIM BIOPHYS ACTA, V1135, P269; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PHILLIPS NC, 1991, IMMUNOL LETT, V30, P291, DOI 10.1016/0165-2478(91)90040-H; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; STEWART JC, 1980, ANAL BIOCHEM, V104, P486; TUREK JJ, 1993, J CELL SCI, V106, P423; WEITMAN SD, 1992, CANCER RES, V52, P3396; [No title captured]	26	631	708	0	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3198	3204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106354				2022-12-25	WOS:A1994MV63100015
J	MOL, CD; MUIR, AKS; CYGLER, M; LEE, JS; ANDERSON, WF				MOL, CD; MUIR, AKS; CYGLER, M; LEE, JS; ANDERSON, WF			STRUCTURE OF AN IMMUNOGLOBULIN FAB FRAGMENT SPECIFIC FOR TRIPLE-STRANDED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; MULTIWIRE AREA DETECTOR; HELIX FORMATION; NEUTRAL PH; FORM; RESOLUTION; CHROMATIN; COMPLEXES; CRYSTALLIZATION; DIFFRACTOMETER	Triple-stranded DNA of the form poly(Pyr).poly(Pur).poly(Pyr) (where Pyr represents a pyrimidine, and Pur represents a purine) has become the subject of intense research because of its potential use in the control of gene expression and in the development of sequence-specific reagents for cleaving DNA. In a triplex of this type, the second pyrimidine strand is in a parallel orientation to the purine strand and forms Hoogsteen base pairs with it via the major groove. We describe here the three-dimensional crystal structure determination of the antigen-binding fragment (Fab) from the murine monoclonal antibody Jel 318. Jel 318 is specific for triple-stranded DNA, with a preference for the sequence poly[d(T.m5C)].poly[d(G.A)].poly[(d(m5C+.T)]. The structure has been solved by the molecular replacement method and refined by molecular. dynamics to an R value of 0.20 at a resolution of 2.8 angstrom. The crystals have cell dimensions that are very similar to those of the previously determined structure of Fab Kol, but the Fab fragments pack within the unit cell in a completely different manner. The protein is in an extended conformation, with an elbow angle of 154-degrees. The shape and electrostatic surface potential of the antibody combining site suggest a possible model for the recognition of triplex DNA in which residues of CDR-H2 (where CDR represents complementarity-determining region) make specific contact with the DNA bases in the minor groove of the triplex.	VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; NATL RES COUNCIL CANADA,DIV BIOL SCI,OTTAWA K1A 0R6,ONTARIO,CANADA; UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL H4P 2R2,PQ,CANADA	Vanderbilt University; National Research Council Canada; University of Saskatchewan; National Research Council Canada					NIDDK NIH HHS [DK42502] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; ARNOTT S, 1976, NUCLEIC ACIDS RES, V11, P4141; ARTYMIUK PJ, 1982, ACTA CRYSTALLOGR B, V38, P778, DOI 10.1107/S0567740882004075; BARRY MM, 1994, J BIOL CHEM, V269, P3623; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; BIRG F, 1990, NUCLEIC ACIDS RES, V18, P2901, DOI 10.1093/nar/18.10.2901; BIRNBOIM HC, 1979, EUR J BIOCHEM, V98, P301, DOI 10.1111/j.1432-1033.1979.tb13189.x; BOODHOO A, 1988, J BIOL CHEM, V263, P18578; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURKHOLDER GD, 1991, CHROMOSOMA, V101, P11, DOI 10.1007/BF00360681; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; CYGLER M, 1989, ACTA CRYSTALLOGR A, V45, P563, DOI 10.1107/S0108767389003818; CYGLER M, 1987, J BIOL CHEM, V262, P643; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIES DR, 1971, METHOD ENZYMOL, V22, P266, DOI DOI 10.1016/0076-6879(71)22027-9; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; ELGIN SCR, 1982, NATURE, V300, P402, DOI 10.1038/300402a0; FELSENFE.G, 1967, ANNU REV BIOCHEM, V36, P407, DOI 10.1146/annurev.bi.36.070167.002203; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; GLOVER JNM, 1990, J MOL BIOL, V215, P653, DOI 10.1016/S0022-2836(05)80175-5; HAMPEL KJ, 1991, BIOCHEMISTRY-US, V30, P4455, DOI 10.1021/bi00232a012; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HOWARD FB, 1964, BIOCHEM BIOPH RES CO, V17, P93, DOI 10.1016/0006-291X(64)90306-7; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE JS, 1979, NUCLEIC ACIDS RES, V6, P3073, DOI 10.1093/nar/6.9.3073; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MATSUSHIMA M, 1978, J MOL BIOL, V121, P441, DOI 10.1016/0022-2836(78)90393-5; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOL CD, 1994, J BIOL CHEM, V269, P3605; MOOREN MMW, 1990, NUCLEIC ACIDS RES, V18, P6523, DOI 10.1093/nar/18.22.6523; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; POVSIC TJ, 1990, J AM CHEM SOC, V112, P9428, DOI 10.1021/ja00181a075; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; SAUL FA, 1992, PROTEINS, V14, P363, DOI 10.1002/prot.340140305; SCHON E, 1983, CELL, V35, P837, DOI 10.1016/0092-8674(83)90116-2; STEIPE B, 1992, J MOL BIOL, V225, P739, DOI 10.1016/0022-2836(92)90398-4; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; TORMO J, 1992, PROTEIN SCI, V1, P1174; TULIP WR, 1992, J MOL BIOL, V227, P122, DOI 10.1016/0022-2836(92)90687-F; WEINER SJ, 1984, J AM CHEM SOC, V106, P6243, DOI 10.1021/ja00333a021; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105	64	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3615	3622						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106406				2022-12-25	WOS:A1994MV63100074
J	MURAMOTO, K; SUGIYAMA, S; CRAGOE, EJ; IMAE, Y				MURAMOTO, K; SUGIYAMA, S; CRAGOE, EJ; IMAE, Y			SUCCESSIVE INACTIVATION OF THE FORCE-GENERATING UNITS OF SODIUM-DRIVEN BACTERIAL FLAGELLAR MOTORS BY A PHOTOREACTIVE AMILORIDE ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALOPHILIC BACILLUS; PROTEIN; TRANSPORT; MOTILITY; SUBTILIS; STRAIN	Like amiloride, 6-iodoamiloride (6-IA) competitively and reversibly inhibits rotation of the Na+-driven flagellar motors of alkalophilic Bacillus cells. However, when 6-IA-treated cells are irradiated with UV light, motility is irreversibly inhibited. This treatment does not alter the membrane potential or affect Na+-coupled alpha-aminoisobutyrate transport. An increase in the Na+ concentration during UV irradiation substantially protects the motors from irreversible inhibition. Thus, photoactivated 6-IA seems to bind specifically and covalently at or around the Na-interaction site of the force-generating units of the motors to inhibit motor rotation irreversibly. Rotation of each motor, which is monitored using tethered alkalophilic Bacillus cells, is also inhibited by photoactivated 6-IA. In this case, however, the rotation rate during UV irradiation decreases stepwise, suggesting the presence of several independently functioning force-generating units in a motor. From the data of 14 tethered cells, the number of units/motor is estimated to be 5-9.			MURAMOTO, K (corresponding author), NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN.							ATSUMI T, 1990, J BACTERIOL, V172, P1634, DOI 10.1128/jb.172.3.1634-1639.1990; BENOS DJ, 1978, SCIENCE, V199, P1205, DOI 10.1126/science.305114; Blair D F, 1990, Semin Cell Biol, V1, P75; BLAIR DF, 1990, CELL, V60, P439, DOI 10.1016/0092-8674(90)90595-6; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; BLOCK SM, 1984, NATURE, V309, P470, DOI 10.1038/309470a0; COBB MH, 1981, EXPERIENTIA, V37, P68, DOI 10.1007/BF01965574; CRAGOE EJ, 1967, J MED CHEM, V10, P66, DOI 10.1021/jm00313a014; FRANCIS NR, 1992, P NATL ACAD SCI USA, V89, P6304, DOI 10.1073/pnas.89.14.6304; HIROTA N, 1983, J BIOL CHEM, V258, P577; IMAE Y, 1986, METHOD ENZYMOL, V125, P582; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; IWAZAWA J, 1993, BIOPHYS J, V64, P925, DOI 10.1016/S0006-3495(93)81454-1; KHAN S, 1988, J MOL BIOL, V202, P575, DOI 10.1016/0022-2836(88)90287-2; KHAN S, 1992, J BACTERIOL, V174, P5123, DOI 10.1128/JB.174.15.5123-5126.1992; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KRULWICH TA, 1982, J BIOL CHEM, V257, P1885; MATSUURA S, 1977, FEBS LETT, V82, P187, DOI 10.1016/0014-5793(77)80581-4; NAKAMURA N, 1975, BIOCHIM BIOPHYS ACTA, V397, P188, DOI 10.1016/0005-2744(75)90192-8; OH Y, 1992, J BIOL CHEM, V267, P18498; SHIOI J, 1980, J BACTERIOL, V144, P891, DOI 10.1128/JB.144.3.891-897.1980; SUGIYAMA S, 1988, J BIOL CHEM, V263, P8215; UOZUMI T, 1977, MOL GEN GENET, V152, P65, DOI 10.1007/BF00264941	24	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3374	3380						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106377				2022-12-25	WOS:A1994MV63100039
J	WOLF, FW; SARMA, V; SELDIN, M; DRAKE, S; SUCHARD, SJ; SHAO, H; OSHEA, KS; DIXIT, VM				WOLF, FW; SARMA, V; SELDIN, M; DRAKE, S; SUCHARD, SJ; SHAO, H; OSHEA, KS; DIXIT, VM			B94, A PRIMARY RESPONSE GENE INDUCIBLE BY TUMOR-NECROSIS-FACTOR-ALPHA, IS EXPRESSED IN DEVELOPING HEMATOPOIETIC TISSUES AND THE SPERM ACROSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DEVELOPING RAT; RECEPTOR; CELLS; FERTILIZATION; PRODUCTS; THYMUS; LIGAND; EMBRYO; KINASE	B94 was originally described as a novel tumor necrosis factor-alpha-inducible primary response gene in endothelial cells which was also induced in an in vitro model of angiogenesis. To further characterize its expression, we cloned the mouse homologue and mapped its developmental and tissue specific expression. The predicted amino acid sequence of mouse B94 was found to be 83% similar to its human homologue. The gene was localized to mouse chromosome 12 just centromeric to the immunoglobulin heavy chain locus, in a region that is often rearranged in T-cell neoplasms. To explore the possibility that B94 is expressed during vasculogenesis and other developmental processes, the expression of its transcript was determined during mouse development by in situ hybridization. In 10-day embryos B94 was expressed prominently in the myocardium and in the aortic arch. By the 15th day of gestation, expression was restricted largely to the liver, the bone forming regions of the jaw, the aortic endothelium, and the nasopharynx: a pattern that was maintained until just prior to birth. Postnatally, expression shifted to the red pulp of the spleen and the thymic medulla. B94 expression was extinguished in most adult tissues but was detectable in lymphopoietic tissues including the spleen, tonsil, and lymphatic aggregates in the gut. Consistent with this was the finding that mononuclear progenitor cells in bone marrow and mature peripheral blood monocytes expressed B94. A truncated testis-specific transcript previously identified by Northern blot analysis was determined to result from the use of an alternate polyadenylation signal which was surprisingly located within the open reading frame. This shorter transcript was expressed at high levels exclusively in late stage spermatids. Immuno-staining with an affinity-purified polyclonal antiserum revealed B94 to be localized to the acrosomal compartment of mature sperm. These studies demonstrate that B94 expression is tightly regulated during development and suggests distinct roles for B94 in myelopoiesis and spermatogenesis.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, 1301 CATHERINE ST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PEDIAT, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, PROGRAM CELLULAR & MOLEC BIOL, ANN ARBOR, MI 48109 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Duke University; Duke University			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NHLBI NIH HHS [HL45351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BEUTLER B, 1988, ADV IMMUNOL, V42, P213, DOI 10.1016/S0065-2776(08)60846-9; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; DEKOSSODO S, 1992, J EXP MED, V176, P1259, DOI 10.1084/jem.176.5.1259; Deman J, 1992, Dev Immunol, V2, P103, DOI 10.1155/1992/48713; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FU YM, 1991, J CELL BIOL, V114, P1261, DOI 10.1083/jcb.114.6.1261; GIROIR BP, 1992, P NATL ACAD SCI USA, V89, P4864, DOI 10.1073/pnas.89.11.4864; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KEW D, 1990, P NATL ACAD SCI USA, V87, P9143, DOI 10.1073/pnas.87.23.9143; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; MACGROGAN D, 1992, J NEUROCHEM, V59, P1381, DOI 10.1111/j.1471-4159.1992.tb08451.x; MANTHORPE M, 1989, DISSECTION TISSUE CU; Mundy G R, 1992, Immunol Ser, V56, P483; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; OZAWA K, 1992, GENOMICS, V12, P214, DOI 10.1016/0888-7543(92)90368-3; PALMITER RD, 1984, CELL, V36, P869, DOI 10.1016/0092-8674(84)90036-9; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; PERSSON H, 1989, P NATL ACAD SCI USA, V86, P6166, DOI 10.1073/pnas.86.16.6166; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; Sambrook J, 1989, MOL CLONING LABORATO; SARMA V, 1992, J IMMUNOL, V148, P3302; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; STOREY BT, 1991, ANN NY ACAD SCI, V637, P459, DOI 10.1111/j.1749-6632.1991.tb27330.x; TAVASSOLI M, 1991, BLOOD CELLS, V17, P269; Trinchieri G, 1992, Immunol Ser, V56, P289; Vilcek J, 1992, Immunol Ser, V56, P269; WATSON MA, 1990, DEVELOPMENT, V110, P173; Weiss L., 1983, HISTOLOGY CELL TISSU	38	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3633	3640						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106408				2022-12-25	WOS:A1994MV63100076
J	VAANDRAGER, AB; VANDERWIEL, E; DEJONGE, HR				VAANDRAGER, AB; VANDERWIEL, E; DEJONGE, HR			HEAT-STABLE ENTEROTOXIN ACTIVATION OF IMMUNOPURIFIED GUANYLYL CYCLASE-C - MODULATION BY ADENINE-NUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL ELECTROLYTE TRANSPORT; PROTEIN-KINASE; DIARRHEAL DISEASE; HUMAN RECEPTOR; EXPRESSION; MEMBRANES; BINDING; DOMAIN	We studied the activation and inactivation of recombinant guanylyl cyclase (GC) C stably expressed in human kidney 293 cells. Activation of GC-C by heat-stable enterotoxin (STa), Cd2+, hemin, or the detergent Triton X-100 was followed by a rapid inactivation of the enzyme. Adenine nucleotides were found to prevent the inactivation process in native membranes, as well as following enzyme solubilization and immunopurification. Inactivation of GC-C was not associated with dephosphorylation. However, the phosphorylation of GC-C was promoted by phorbol esters, known activators of protein kinase C. The activation of purified GC-C by STa required the presence of a nonspecific factor as exemplified by bovine serum albumin. When immunopurified GC-C, stabilized by ATP and bovine serum albumin, was analyzed by SDS-polyacrylamide gel electrophoresis under nonreducing conditions, proteins with almost twice the molecular mass (220 and 245 kDa) of the monomer were observed. The mobility of these high M(r) GC-C forms was reduced by STa, suggesting that STa induces a conformation change in a preexisting GC-C dimer. These results indicate that ATP interacts directly with GC-C, stabilizing its active conformation and that the activation of GC-C may occur in the absence of other specific regulatory factors.			VAANDRAGER, AB (corresponding author), ERASMUS UNIV ROTTERDAM,FAC MED,DEPT BIOCHEM,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.			Vaandrager, Arie/0000-0001-9394-9239				BENTLY KJ, 1986, J BIOL CHEM, V261, P14859; BRASITUS TA, 1980, BIOCHIM BIOPHYS ACTA, V630, P152, DOI 10.1016/0304-4165(80)90147-6; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CRANE JK, 1992, INFECT IMMUN, V60, P5004, DOI 10.1128/IAI.60.12.5004-5012.1992; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DEJONGE HR, 1984, BIOCHEM SOC T, V12, P180, DOI 10.1042/bst0120180; DEJONGE HR, 1990, TXB SECRETORY DIARRH, P190; DEJONGE HR, 1986, ZENTRALBL BAKTERIO S, V15, P335; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; DUDA T, 1993, FEBS LETT, V315, P143, DOI 10.1016/0014-5793(93)81151-O; ELDEIB MMR, 1987, BIOCHIM BIOPHYS ACTA, V928, P83, DOI 10.1016/0167-4889(87)90088-7; FIELD M, 1989, NEW ENGL J MED, V321, P879; FIELD M, 1989, NEW ENGL J MED, V321, P800; GAZZANO H, 1991, INFECT IMMUN, V59, P1552, DOI 10.1128/IAI.59.4.1552-1557.1991; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; JEWITT JRS, 1993, EMBO J, V12, P769; KATWA LC, 1992, BIOCHEM J, V283, P727, DOI 10.1042/bj2830727; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; POTTER LR, 1992, J BIOL CHEM, V267, P14531; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1992, GASTROENTEROLOGY, V102, P1161; VAANDRAGER AB, 1993, CYCLIC GMP SYNTHESIS; WILSON SP, 1988, SEC MESS PHOSPHOPROT, V12, P1; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862	34	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19598	19603						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103520				2022-12-25	WOS:A1993LW81900070
J	PADMANABHAN, K; PADMANABHAN, KP; FERRARA, JD; SADLER, JE; TULINSKY, A				PADMANABHAN, K; PADMANABHAN, KP; FERRARA, JD; SADLER, JE; TULINSKY, A			THE STRUCTURE OF ALPHA-THROMBIN INHIBITED BY A 15-MER SINGLE-STRANDED-DNA APTAMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CRYSTALLOGRAPHIC REFINEMENT; CRYSTAL-STRUCTURE; TELOMERIC DNA; SPECIFICITY; COMPLEXES; RESIDUES; SITE; FORM	The structure of a complex between human alpha-thrombin and a GGTTGGTGTGGTTGG 15-nucleotide consensus sequence has been solved by x-ray crystallography and refined at 2.9-angstrom resolution to an R value of 0.159. As in solution, in the complex the single-stranded DNA folds into a structure with two G-quartets. The DNA is sandwiched between two different positively charged regions of two symmetry-related thrombin molecules in the crystal structure making ionic and hydrophobic interactions. One region is the fibrinogen recognition exosite and the other, the putative heparin binding site. The lack of inhibition of fibrinogen clotting and platelet activation by the DNA 15-mer with the Arg75 --> Glu mutant of thrombin is consistent with the several salt bridges of the DNA in the fibrinogen exosite. The association of DNA with the heparin site of a neighboring molecule appears to simply compensate residual charge. Differences in the 15-mer loop conformations between the complex and NMR solution structures can be attributed to conformational changes upon thrombin binding. Although G-quadruplexes are favored in the presence of monovalent cations, there is no evidence of the latter in the thrombin complex.	MICHIGAN STATE UNIV, DEPT CHEM, E LANSING, MI 48824 USA; MOLEC STRUCT CORP, THE WOODLANDS, TX USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MED & BIOCHEM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Michigan State University; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)			Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043229, P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43229, HL14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODE W, 1992, PROTEIN SCI, V1, P426; BRUNGER A, 1992, X PLOR MANUAL; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; HARDIN CC, 1992, BIOCHEMISTRY-US, V31, P833, DOI 10.1021/bi00118a028; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HIGASHI T, 1990, J APPL CRYSTALLOGR, V23, P253, DOI 10.1107/S0021889890002461; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; WU QY, 1992, J BIOL CHEM, V267, P24408; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	30	439	483	2	82	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17651	17654						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8102368				2022-12-25	WOS:A1993LT74300001
J	BROWSE, J; MCCONN, M; JAMES, D; MIQUEL, M				BROWSE, J; MCCONN, M; JAMES, D; MIQUEL, M			MUTANTS OF ARABIDOPSIS DEFICIENT IN THE SYNTHESIS OF ALPHA-LINOLENATE - BIOCHEMICAL AND GENETIC-CHARACTERIZATION OF THE ENDOPLASMIC-RETICULUM LINOLEOYL DESATURASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER-PROTEIN DESATURASE; FATTY-ACID COMPOSITION; CARTHAMUS-TINCTORIUS L; OLEOYL-PHOSPHATIDYLCHOLINE; LIPID-SYNTHESIS; RAT-LIVER; SAFFLOWER; CHLOROPLASTS; COTYLEDONS; MEMBRANES	The overall fatty compositions of leaf and root lipids from a mutant of Arabidopsis thaliana were characterized by reduced levels of linolenate (18:3) and correspondingly elevated levels of linoleate (18:2) as a consequence of a single nuclear mutation at the fad3 locus. Comparison of the fatty acid compositions of individual lipids from wild type and mutant plants showed that chloroplast lipids were largely unaffected by the mutation, whereas each of the phospholipids synthesized on the endoplasmic reticulum in the mutant exhibited a marked reduction in the proportion of 18:3 relative to wild type. These and other results indicate that the fad3 mutants are deficient in the activity of an endoplasmic reticulum 18:2 desaturase. In root tissues, this enzyme appears to account for over 80% of the 18:3 present. However, in young leaves of the mutant, phosphatidylcholine (the major phospholipid) contains 16% 18:3 compared with 29% in the wild type, and the proportion of 18:3 in this lipid increases with plant age in both wild type and mutant plants. These results reflect an exchange of lipid between the chloroplast and endoplasmic reticulum that allows the chloroplast desaturases to provide highly unsaturated lipids to the extrachloroplast membranes of leaf cells.	DNA PLANT TECHNOL CORP,OAKLAND,CA 94608		BROWSE, J (corresponding author), WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164, USA.			Browse, John/0000-0002-2554-2821				ARONDEL V, 1992, SCIENCE, V258, P1353, DOI 10.1126/science.1455229; BROWSE J, 1989, PLANT PHYSIOL, V90, P522, DOI 10.1104/pp.90.2.522; BROWSE J, 1986, PLANT PHYSIOL, V81, P859, DOI 10.1104/pp.81.3.859; BROWSE J, 1985, SCIENCE, V227, P763, DOI 10.1126/science.227.4688.763; BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; Browse J, 1989, BIOL ROLE PLANT LIPI, P335; BROWSE JA, 1981, FEBS LETT, V1321, P111; FELDMANN KA, 1987, MOL GEN GENET, V208, P1, DOI 10.1007/BF00330414; FUJIWARA Y, 1984, ARCH BIOCHEM BIOPHYS, V233, P402, DOI 10.1016/0003-9861(84)90461-2; Harwood J. L., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P1; HARWOOD JL, 1986, LIPID HDB, P527; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JAMES DW, 1990, THEOR APPL GENET, V80, P241, DOI 10.1007/BF00224393; KEARNS EV, 1991, ARCH BIOCHEM BIOPHYS, V284, P431, DOI 10.1016/0003-9861(91)90319-E; KUNST L, 1989, PLANT PHYSIOL, V91, P401, DOI 10.1104/pp.91.1.401; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; Marsh D., 2013, HDB LIPID BILAYERS; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; MIQUEL M, 1992, J BIOL CHEM, V267, P1502; ROUGHAN PG, 1980, BIOCHEM J, V188, P17, DOI 10.1042/bj1880017; ROUGHAN PG, 1982, ANNU REV PLANT PHYS, V33, P97, DOI 10.1146/annurev.pp.33.060182.000525; ROUGHAN PG, 1979, BIOCHEM J, V184, P571, DOI 10.1042/bj1840571; SCHMIDT H, 1990, P NATL ACAD SCI USA, V87, P9477, DOI 10.1073/pnas.87.23.9477; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; SHIMAKATA T, 1982, P NATL ACAD SCI-BIOL, V79, P5808, DOI 10.1073/pnas.79.19.5808; SLACK CR, 1978, BIOCHEM J, V170, P421, DOI 10.1042/bj1700421; SMITH MA, 1990, BIOCHEM J, V272, P23, DOI 10.1042/bj2720023; SOMERVILLE C, 1991, SCIENCE, V252, P80, DOI 10.1126/science.252.5002.80; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; STYMNE S, 1980, PLANT SCI LETT, V17, P287, DOI 10.1016/0304-4211(80)90159-5; STYMNE S, 1978, EUR J BIOCHEM, V90, P223, DOI 10.1111/j.1432-1033.1978.tb12594.x; STYMNE S, 1992, ARCH BIOCHEM BIOPHYS, V296, P557; WADA H, 1990, NATURE, V347, P200, DOI 10.1038/347200a0	34	177	197	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16345	16351						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8102138				2022-12-25	WOS:A1993LQ33600041
J	CALLAGHAN, R; RIORDAN, JR				CALLAGHAN, R; RIORDAN, JR			SYNTHETIC AND NATURAL OPIATES INTERACT WITH P-GLYCOPROTEIN IN MULTIDRUG-RESISTANT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL BLOCKERS; MEMBRANE GLYCOPROTEIN; BIOCHEMICAL-CHARACTERIZATION; BINDING; VINBLASTINE; VESICLES; MORPHINE; TISSUES; LINES; RAT	The ability of P-glycoprotein (P-gp) to transport naturally occurring and synthetic opiate analgesics was investigated. Multidrug-resistant Chinese hamster ovary cells (B30) were found to accumulate significantly lower amounts of morphine than their drug-sensitive counterparts (B1). This decreased accumulation was reversed upon depletion of cellular stores of ATP. In addition, morphine bound to plasma membranes from B30 cells in a specific, saturable fashion. Verapamil and vinblastine, compounds transported by P-gp, were able to increase accumulation and displace the binding of morphine in B30 cells. In turn, the synthetic opiates meperidine, pentazocine, and methadone were able to increase the accumulation of vinblastine in resistant cells. These compounds were also able to displace the specific binding of vinblastine and the photoaffinity labeling of P-gp in plasma membranes by the radioiodinated anthracycline, iodomycin. The implications of these findings in relation to the distribution, tolerance, and gastrointestinal side effects of opiates are discussed.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT BIOCHEM,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT CLIN BIOCHEM,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Callaghan, Richard/ABG-1638-2020; Callaghan, Richard/B-7032-2012	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532				BECK WT, 1984, ADV ENZYME REGUL, V22, P207, DOI 10.1016/0065-2571(84)90015-3; BOWMAN WC, 1984, TXB PHARM; BUSCHE R, 1989, MOL PHARMACOL, V35, P414; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V36, P2115, DOI 10.1016/0006-2952(87)90139-0; CHARUK JHM, 1992, BIOCHEM BIOPH RES CO, V186, P796, DOI 10.1016/0006-291X(92)90816-4; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; ENDICOTT JA, 1989, ANN REV BIOCH, V58, P367; FORD JM, 1990, CANCER RES, V50, P1748; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIAT WN, 1992, BIOCHEM PHARMACOL, V43, P103; HORN AS, 1977, J PHARM PHARMACOL, V29, P257, DOI 10.1111/j.2042-7158.1977.tb11308.x; ICHIKAWA M, 1990, BIOCHEM BIOPH RES CO, V166, P74, DOI 10.1016/0006-291X(90)91913-D; INABA M, 1979, CANCER RES, V39, P2200; IWAMOTO K, 1977, J PHARMACOL EXP THER, V200, P236; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; LING V, 1983, CANCER TREAT REP, V67, P869; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SAFA AR, 1987, J BIOL CHEM, V262, P1261; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SNYDER SH, 1977, SCI AM, V236, P44, DOI 10.1038/scientificamerican0377-44; SUZUKI S, 1990, J PHYSIOL-LONDON, V421, P645, DOI 10.1113/jphysiol.1990.sp017967; TAMAI I, 1991, J BIOL CHEM, V266, P16796; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALSH CT, 1975, J PHARMACOL EXP THER, V195, P303; ZAMORA JM, 1988, MOL PHARMACOL, V33, P454	31	126	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16059	16064						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101846				2022-12-25	WOS:A1993LN30500102
J	KOHNO, T; TAKAYAMA, H; HAMAGUCHI, M; TAKANO, H; YAMAGUCHI, N; TSUDA, H; HIROHASHI, S; VISSING, H; SHIMIZU, M; OSHIMURA, M; YOKOTA, J				KOHNO, T; TAKAYAMA, H; HAMAGUCHI, M; TAKANO, H; YAMAGUCHI, N; TSUDA, H; HIROHASHI, S; VISSING, H; SHIMIZU, M; OSHIMURA, M; YOKOTA, J			DELETION MAPPING OF CHROMOSOME-3P IN HUMAN UTERINE CERVICAL-CANCER	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; VONHIPPEL-LINDAU DISEASE; HUMAN-BREAST CARCINOMA; LUNG-CANCER; SHORT ARM; SMALL REGION; HETEROZYGOSITY; GENE; RECEPTOR; ALLELES	Deletion mapping of chromosome 3p was performed on 47 cases of human uterine cervical cancer using 24 polymorphic DNA markers including five inter-Alu DNA markers and two NotI-boundary cosmid markers obtained in our laboratory. The most likely order of these 24 polymorphic DNA markers was determined as being cen-[D3S4, H8]-D3S693-D3S659-D3S30-D3S687-[D3S2, UR9, UR47]-J36-J17-GNA12B-D3F15S2-D3S643-D3S32-D3S23-D3S686-H35-UR189-D3S685-D3S11-D3S12-THRB-D3S22-pter, based on the data from radiation hybrid mapping, genetic linkage analysis and in situ hybridization. Loss of heterozygosity (LOH) at one or more loci on chromosome 3p was detected in 21 of 47 cases (45%). Four tumors showed partial or interstitial deletions, and the common region of LOH in these tumors was 3p13-p21.1 between the D3S30 marker and the D3S2 marker. Candidates for tumor-suppressor genes, APEH, D8, GNAI2B, ZNF35, RARB, THRB and RAFI, were all mapped outside of the common region in uterine cervical cancer. However, this region is commonly deleted in carcinoma of the lung, breast and kidney, and encompasses the breakpoint of the (3;8) translocation in hereditary renal cell carcinoma. This result indicates the presence of a novel tumor-suppressor gene in the region of 3p13-p21.1, which is involved in the development of several human cancers.	NATL CANC CTR,RES INST,1-1 TSUKIJI 5-CHOME,CHUO KU,TOKYO 104,JAPAN; HAGEDORN RES INST,DEPT MOLEC ENDOCRINOL,DK-2820 GENTOFTE,DENMARK; TOTTORI UNIV,SCH LIFE SCI,YONAGO,TOTTORI 683,JAPAN	National Cancer Center - Japan; Novo Nordisk; Hagedorn Research Institute; Tottori University				takano, hirokuni/0000-0002-6465-7883				ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; CARRITT B, 1992, CANCER RES, V52, P1536; COTTER FE, 1990, GENOMICS, V7, P257, DOI 10.1016/0888-7543(90)90548-9; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DIDSBURY JR, 1987, FEBS LETT, V211, P160, DOI 10.1016/0014-5793(87)81428-X; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EHREN T, 1990, ONCOGENE, V5, P219; ERLANDSSON R, 1991, ONCOGENE, V6, P1293; FALK CT, 1991, GENOMICS, V9, P120, DOI 10.1016/0888-7543(91)90228-7; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; GEBERT JF, 1991, ONCOGENE, V6, P1859; GINZINGER DG, 1992, AM J HUM GENET, V50, P826; GORADIA TM, 1991, GENOMICS, V10, P748, DOI 10.1016/0888-7543(91)90459-R; GROSVELD FG, 1982, NUCLEIC ACIDS RES, V10, P6715, DOI 10.1093/nar/10.21.6715; GROVER T, 1984, HUM GENET, V67, P136; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HARMER MH, 1978, TNM CLASSIFICATION M; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HIBI K, 1992, ONCOGENE, V7, P445; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LANFRANCONE L, 1992, GENOMICS, V12, P720, DOI 10.1016/0888-7543(92)90301-8; LEDUC F, 1989, AM J HUM GENET, V44, P282; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MAGOVCEVIC I, 1992, GENOMICS, V12, P125, DOI 10.1016/0888-7543(92)90414-N; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; MORI N, 1989, CANCER RES, V49, P5130; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; POULSEN HE, 1975, INT HISTOLOGICAL CLA, V13; RAPP UR, 1988, LUNG CANCER, V4, P162; SATO T, 1991, CANCER RES, V51, P5794; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SHIMIZU M, 1990, ONCOGENE, V5, P185; SITHANANDAM G, 1989, ONCOGENE, V4, P451; TAMARI M, 1992, GENOMICS, V13, P705, DOI 10.1016/0888-7543(92)90145-I; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; 1991, CYTOGENET CELL GENET, V58, P1	51	100	100	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1825	1832						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8099726				2022-12-25	WOS:A1993LG68200014
J	NG, L; MCCONNELL, M; TAN, CK; DOWNEY, KM; FISHER, PA				NG, L; MCCONNELL, M; TAN, CK; DOWNEY, KM; FISHER, PA			INTERACTION OF DNA POLYMERASE-DELTA, PROLIFERATING CELL NUCLEAR ANTIGEN, AND SYNTHETIC OLIGONUCLEOTIDE TEMPLATE-PRIMERS - ANALYSIS BY POLYACRYLAMIDE-GEL ELECTROPHORESIS-BAND MOBILITY SHIFT ASSAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMOLOGICAL CHARACTERIZATION; AUXILIARY PROTEIN; CALF THYMUS; REPLICATION INVITRO; MOLECULAR-CLONING; ABASIC SITES; PCNA CYCLIN; KB-CELLS; BINDING; RECOGNITION	A polyacrylamide gel electrophoresis band-mobility shift assay was developed to study the binding of synthetic oligonucleotides by DNA polymerase delta (pol delta) and proliferating cell nuclear antigen (PCNA). As measured by this assay, neither calf thymus pol delta core enzyme nor PCNA alone bind DNA stably. However, mammalian PCNA but not Drosophila PCNA promotes the formation of a distinct pol delta.PCNA.template-primer complex. Appearance of this complex is primer-dependent but does not require Mg2+. Complex stability is also influenced by the presence or absence of individual dNTPs. A model for the ordered sequential interaction of pol delta, PCNA, and DNA template-primers is proposed.	SUNY, HLTH SCI CTR, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA; UNIV MIAMI, SCH MED, DEPT MED, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT BIOCHEM, MIAMI, FL 33101 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; University of Miami; University of Miami					NIDDK NIH HHS [DK-26206] Funding Source: Medline; NIEHS NIH HHS [ES-04068] Funding Source: Medline; NIGMS NIH HHS [GM-35943] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035943] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; DOWNEY KM, 1988, CANCER CELLS EUKARYO, V6, P403; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4570, DOI 10.1021/bi00519a009; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; FISHER PA, 1979, J BIOL CHEM, V254, P6128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEIBOVICI M, 1990, DEV BIOL, V141, P183, DOI 10.1016/0012-1606(90)90113-W; MATSUMOTO K, 1987, EMBO J, V6, P637, DOI 10.1002/j.1460-2075.1987.tb04802.x; NG L, 1989, J BIOL CHEM, V264, P13018; NG L, 1991, J BIOL CHEM, V266, P11699; NG L, 1990, J BIOL CHEM, V265, P11948; OGATA K, 1987, EXP CELL RES, V168, P475, DOI 10.1016/0014-4827(87)90020-6; OLINS DE, 1989, J CELL BIOL, V109, P1399, DOI 10.1083/jcb.109.4.1399; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SUZUKA I, 1989, P NATL ACAD SCI USA, V86, P3189, DOI 10.1073/pnas.86.9.3189; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WONG SW, 1986, J BIOL CHEM, V261, P7958; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; ZUBER M, 1989, EXP CELL RES, V182, P384, DOI 10.1016/0014-4827(89)90243-7	27	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13571	13576						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8099910				2022-12-25	WOS:A1993LH55300079
J	HASELBECK, RJ; MCALISTERHENN, L				HASELBECK, RJ; MCALISTERHENN, L			FUNCTION AND EXPRESSION OF YEAST MITOCHONDRIAL NAD-SPECIFIC AND NADP-SPECIFIC ISOCITRATE DEHYDROGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; STRUCTURAL GENE; DISRUPTION; CLONING; TRANSFORMATION; PROTEINS	The three isozymes of isocitrate dehydrogenase in Saccharomyces cerevisiae differ in subunit structure, subcellular location, and cofactor specificity. The two mitochondrial isozymes, IDH and IDP1, are NAD- and NADP-specific, respectively. Several lines of evidence presented here confirm the importance of IDH to respiratory processes. Expression of IDH RNA and protein is low with growth on glucose and is elevated with growth on non-fermentable carbon sources, a pattern of expression similar to that seen for other tricarboxylic acid cycle enzymes. In addition, a disruption mutant lacking IDH activity exhibits reduced growth rates on non-fermentable carbon sources, and mitochondria isolated from this mutant are incapable of respiration with added citrate. In contrast, IDP1 expression levels appear to be unresponsive to carbon source, and an IDP1 disruption mutant is not significantly impaired for growth or mitochondrial respiration. These results strongly suggest that IDP1 is incapable of participating in tricarboxylic acid cycle-based respiration despite its mitochondrial location. Analysis of the IDP1 and IDH disruption mutants for glutamate auxotrophy showed that either enzyme can contribute alpha-ketoglutarate for endogenous glutamate synthesis. IDH expression levels were found to be repressed in response to added glutamate during growth on glucose, while IDP1 expression levels remained unchanged. A double mutant lacking both IDP1 and IDH activities proved to be auxotrophic for glutamate during growth on glucose, but was capable of growth independent of added glutamate on non-fermentable carbon sources. These results suggest that the cytosolic NADP-specific IDP2 isozyme may provide alpha-ketoglutarate both for tricarboxylic acid cycle carbon flux and for cytosolic glutamate synthesis during growth on non-fermentable carbon sources in the absence of mitochondrial isocitrate dehydrogenase activity.	UNIV CALIF IRVINE,SCH MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BOTSTEIN D, 1979, GENE, V8, P12; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAUM G, 1982, J BIOL CHEM, V257, P3028; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORSBACH V, 1989, MOL GEN GENET, V218, P57, DOI 10.1007/BF00330565; GANGLOFF SP, 1990, MOL CELL BIOL, V10, P3351; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KEYS DA, 1990, THESIS U CALIFORNIA; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KORNBERG A, 1951, J BIOL CHEM, V189, P123; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; MCALISTER L, 1982, J BIOL CHEM, V257, P7181; MCALISTER L, 1980, J BACTERIOL, V143, P603, DOI 10.1128/JB.143.2.603-612.1980; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; OHNISHI T, 1966, J BIOL CHEM, V241, P1797; RALEIGH EA, 1988, NUCLEIC ACIDS RES, V16, P1563, DOI 10.1093/nar/16.4.1563; REPETTO B, 1989, MOL CELL BIOL, V9, P2695, DOI 10.1128/MCB.9.6.2695; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RydstroM J., 1976, ENZYME, V13, P51; Sherman F, 1979, METHODS YEAST GENETI; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183; WRIGHT RM, 1989, NUCLEIC ACIDS RES, V17, P1103, DOI 10.1093/nar/17.3.1103	34	129	131	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12116	12122						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8099357				2022-12-25	WOS:A1993LF28400097
J	KAYA, SJ; TSUDA, T; HAGIWARA, K; FUKUI, T; TANIGUCHI, K				KAYA, SJ; TSUDA, T; HAGIWARA, K; FUKUI, T; TANIGUCHI, K			PYRIDOXAL 5'-PHOSPHATE PROBES AT LYS-480 CAN SENSE THE BINDING OF ATP AND THE FORMATION OF PHOSPHOENZYMES IN NA+,K+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; AMINO-ACID-SEQUENCE; CONFORMATIONAL CHANGE; CA-2+-TRANSPORTING ATPASE; SARCOPLASMIC-RETICULUM; INORGANIC-PHOSPHATE; ESSENTIAL RESIDUE; ACTIVE-SITE; NA+; K+	The Lys-480 in the alpha-subunits of Na+,K+-ATPase from pig kidneys was specifically modified with pyridoxal 5'-phosphate (PLP) or pyridoxal 5'-diphospho-5'-adenosine (AP(2)PL) probes in the presence of NaCl. The site was shown to be the same as the ATP-protectable binding of these probes (Hint, H. R., and Kirley, T. L. (1990) J. Biol. Chem. 265, 10260-10265). Modifications strongly reduced both Na+,K+-ATPase activity and the amount of Na+-dependent phosphoenzyme from [P-32]ATP but not from [P-32]acetyl-phosphate (AcP). Addition of AcP to the enzyme induced a slight decrease in the fluorescence of the PLP probe in the presence of 2 M NaCl and 4 mM MgCl2 but a single exponential increase in the presence of 16 mM NaCl and 4 mM MgCl2. The addition of ATP induced single exponential fluorescence increases at both Na+ concentrations. The data show that these probes can sense molecular events related to the formation of phosphoenzymes induced by AcP and presumably to the formation of Mg-Na-ATP-enzyme complex. The data also suggest that PLP or AP(2)PL probes at Lys-480 in the presence of Na+ and Mg2+ do not affect the transphosphorylation from AcP to Asp-369 to form phosphoenzymes but that they inhibit the transphosphorylation from the gamma-phosphoryl group of ATP and also ATP binding in the absence of Mg2+.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN	Osaka University	KAYA, SJ (corresponding author), HOKKAIDO UNIV,FAC SCI,DEPT CHEM,SAPPORO,HOKKAIDO 060,JAPAN.							ABBOTT AJ, 1991, BIOCHEMISTRY-US, V30, P1692, DOI 10.1021/bi00220a035; ALBERS RW, 1976, ENZYMES BIOLOGICAL M, V3, P283; BERBERIAN G, 1991, BIOCHIM BIOPHYS ACTA, V1063, P217, DOI 10.1016/0005-2736(91)90374-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVID P, 1991, J BIOL CHEM, V266, P14896; ELISDAVIES GCR, 1993, J BIOL CHEM, V268, P11622; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; Fiske CH, 1925, J BIOL CHEM, V66, P375; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; HEGYVARY C, 1981, J BIOL CHEM, V256, P6296; HINZ HR, 1990, J BIOL CHEM, V265, P10260; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; MAEDA M, 1988, J BIOL CHEM, V263, P3652; NAGAI M, 1986, J BIOL CHEM, V261, P3197; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; REPKE KRH, 1992, BIOL REV, V67, P31; ROBINSON JD, 1993, BIOCHIM BIOPHYS ACTA, V1154, P83, DOI 10.1016/0304-4157(93)90018-J; SCHULL GE, 1985, NATURE, V316, P691; SKOU JC, 1982, BIOCHIM BIOPHYS ACTA, V688, P369, DOI 10.1016/0005-2736(82)90348-0; STEINBERG M, 1989, J BIOL CHEM, V264, P2726; SUZUKI K, 1987, J BIOL CHEM, V262, P11752; TAGAYA M, 1986, BIOCHEMISTRY-US, V25, P2958, DOI 10.1021/bi00358a034; TANIGUCHI K, 1975, J BIOL CHEM, V250, P3010; TANIGUCHI K, 1991, J BIOCHEM-TOKYO, V109, P299; TANIGUCHI K, 1986, J BIOL CHEM, V261, P3272; TANIGUCHI K, 1993, J BIOL CHEM, V268, P15588; TANIGUCHI K, 1984, J BIOL CHEM, V259, P5228; TANIGUCHI K, 1982, J BIOL CHEM, V257, P659; TANIGUCHI K, 1988, J BIOL CHEM, V263, P12943; Taniguchi K, 1988, Prog Clin Biol Res, V268A, P369; TANIGUCHI K, 1980, J BIOCHEM-TOKYO, V88, P609, DOI 10.1093/oxfordjournals.jbchem.a133010; WANG K, 1992, J BIOL CHEM, V267, P3577; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976	38	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7419	7422						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125960				2022-12-25	WOS:A1994NA03200061
J	RAO, SI; WILKS, A; HAMBERG, M; DEMONTELLANO, PRO				RAO, SI; WILKS, A; HAMBERG, M; DEMONTELLANO, PRO			THE LIPOXYGENASE ACTIVITY OF MYOGLOBIN - OXIDATION OF LINOLEIC-ACID BY THE FERRYL OXYGEN RATHER THAN PROTEIN RADICAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE; SPERM WHALE MYOGLOBIN; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; FATTY-ACIDS; METMYOGLOBIN; IDENTIFICATION; HYDROPEROXIDE; SPECTROSCOPY; BIOSYNTHESIS	Linoleic (9(Z),12(Z)-octadecadienoic) acid is oxidized by sperm whale myoglobin and H2O2 to an 84:16 (9S):(9R) enantiomer mixture of 9-hydroperoxy-10(E),12(Z)-octadecadienoic acid. Neither the 9,10- nor 12,13-epoxide of linoleic acid, nor 9-hydroxy-10(E),12(Z)-octadecadienoic nor 13-hydroperoxy-9(Z),11(E)-octadeca-dienoic acids, is detectably formed. Incubations with [(11R)-H-2]- and [(11S)-H-2]linoleic acids indicate that the pro-R hydrogen is abstracted 76% of the time. An H64V mutant in which access to the heme crevice is increased oxidizes linoleic acid exclusively by abstraction of the pro-R hydrogen to give the (9S)-hydroperoxide. Spectroscopic studies show that the K-d value for binding of linoleic acid to myoglobin is similar to the K-m value for its oxidation and indicate that linoleic acid reduces the ferryl species to the ferric state. The stereochemical results, supported by O-18-labeling studies, definitively rule out a significant role for singlet oxygen in the myoglobin-catalyzed, H2O2-dependent oxidation of linoleic acid. The myoglobin protein radical formed with H2O2 also plays no part in the reaction because the K-m and V-max values for the oxidation of linoleic acid are similar for native myoglobin and two mutants (K102Q/ Y103F/Y146F/Y151F and H64V/K102Q/Y103F/Y146F/ Y151F) with no tyrosine residues. Furthermore, the rate of formation of the 9-hydroperoxide is not changed if the protein radical is allowed to decay before linoleic acid is added. The results establish that linoleic acid is oxidized within the heme crevice by reaction with the ferryl oxygen rather than a protein radical. They indicate, furthermore, that hydrogen abstraction and oxygen addition occur in an antarafacial manner and suggest a specific model for binding of linoleic acid within the myoglobin active site.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; KAROLINSKA INST, DEPT PHYSIOL CHEM, S-10401 STOCKHOLM, SWEDEN	University of California System; University of California San Francisco; Karolinska Institutet					NCRR NIH HHS [RR01614] Funding Source: Medline; NIDDK NIH HHS [DK30297, P-50 DK26743] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, R01DK030297] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ JC, 1992, BIOCHEMISTRY-US, V31, P8315, DOI 10.1021/bi00150a027; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CATALANO CE, 1987, BIOCHEMISTRY-US, V26, P8373, DOI 10.1021/bi00399a052; CHANCE M, 1986, BIOCHEMISTRY-US, V25, P1259, DOI 10.1021/bi00354a010; DAVIES MJ, 1990, FREE RADICAL RES COM, V10, P361, DOI 10.3109/10715769009149905; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DIX TA, 1985, J BIOL CHEM, V260, P5351; EGGER KW, 1973, HELV CHIM ACTA, V56, P1516, DOI 10.1002/hlca.19730560509; FANTONE J, 1989, J BIOL CHEM, V264, P9408; FUNK MO, 1976, LIPIDS, V11, P113, DOI 10.1007/BF02532660; GALARIS D, 1990, ARCH BIOCHEM BIOPHYS, V281, P163, DOI 10.1016/0003-9861(90)90427-Z; GALARIS D, 1989, ARCH BIOCHEM BIOPHYS, V273, P497, DOI 10.1016/0003-9861(89)90509-2; GALARIS D, 1988, ARCH BIOCHEM BIOPHYS, V262, P221, DOI 10.1016/0003-9861(88)90184-1; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; HSUANYU YC, 1992, J BIOL CHEM, V267, P17649; HUBBARD WC, 1980, PROSTAGLANDINS, V20, P431; KANNER J, 1985, ARCH BIOCHEM BIOPHYS, V237, P314, DOI 10.1016/0003-9861(85)90282-6; KELMAN DJ, 1992, FREE RADICAL RES COM, V16, P27, DOI 10.3109/10715769209049156; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; KUHN H, 1987, ANAL BIOCHEM, V160, P24, DOI 10.1016/0003-2697(87)90609-9; KUHN H, 1981, EUR J BIOCHEM, V120, P161, DOI 10.1111/j.1432-1033.1981.tb05684.x; KUHN H, 1993, BIOCHIM BIOPHYS ACTA, V1169, P80, DOI 10.1016/0005-2760(93)90085-N; LAMAR GN, 1983, J AM CHEM SOC, V105, P782, DOI 10.1021/ja00342a022; MIEYAL JJ, 1985, REV BIOCHEM TOXICOL, V7, P1; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; MITSOS SE, 1988, LAB INVEST, V59, P824; NEWMAN ESR, 1991, BIOCHEM BIOPH RES CO, V179, P1414, DOI 10.1016/0006-291X(91)91730-Z; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V300, P434, DOI 10.1006/abbi.1993.1059; OZAWA T, 1986, BIOCHEM BIOPH RES CO, V134, P1071, DOI 10.1016/0006-291X(86)90360-8; RAO SI, 1993, J BIOL CHEM, V268, P803; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; SHINAR E, 1990, SEMIN HEMATOL, V27, P70; SITTER AJ, 1985, BIOCHIM BIOPHYS ACTA, V828, P229, DOI 10.1016/0167-4838(85)90301-2; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; STARKE DW, 1989, BIOCHEM PHARMACOL, V38, P201, DOI 10.1016/0006-2952(89)90169-X; TEW D, 1988, J BIOL CHEM, V263, P17880; WILKS A, 1992, J BIOL CHEM, V267, P8827; YONETANI T, 1967, J BIOL CHEM, V242, P1974	42	104	104	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7210	7216						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125933				2022-12-25	WOS:A1994NA03200029
J	YANG, LJ; RHEE, SG; WILLIAMSON, JR				YANG, LJ; RHEE, SG; WILLIAMSON, JR			EPIDERMAL GROWTH FACTOR-INDUCED ACTIVATION AND TRANSLOCATION OF PHOSPHOLIPASE C-GAMMA-1 TO THE CYTOSKELETON IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PERTUSSIS TOXIN; C-GAMMA; SIGNAL TRANSDUCTION; CALCIUM RELEASE; DNA-SYNTHESIS; EGF RECEPTOR; SH3 DOMAINS	In this study, we have examined the relationship between epidermal growth factor (EGF)-induced tyrosine phosphorylation of phospholipase C-gamma 1 (PLC-gamma 1) and its translocation from the cytosol to the Triton X-100-insoluble cytoskeleton fraction in rat hepatocytes. The translocation of PLC-gamma 1 was specific for EGF stimulation, because a similar effect was not observed with insulin or vasopressin. EGF caused a transient increase of PLC activity in the cytoskeleton fraction which could be abolished by immunoprecipitating PLC-gamma 1. Tyrosine phosphorylated PLC-gamma 1 was seen only in the cytoskeleton fraction, suggesting that tyrosine phosphorylation is required for PLC-gamma 1 translocation to the cytoskeleton. This process may involve binding of PLC-gamma 1 to actin filaments, since actin was immunoprecipitated together with PLC-gamma 1 in the cytoskeleton after EGF treatment. EGF-induced translocation of PLC-gamma 1 to the cytoskeleton was not inhibited by pertussis toxin, but Gi alpha was translocated in an EGF dependent manner, suggesting that the interaction of PLC-gamma 1 with its activated Gi-protein is downstream from both PLC-gamma 1 tyrosine phosphorylation and its translocation to the cytoskeleton. Taken together, the present studies indicate that EGF-induced tyrosine phosphorylation of PLC-gamma 1, its association with the cytoskeleton, and its interaction with activated Gi alpha protein are all obligatory for PLC-gamma 1 activation in hepatocytes.	NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	YANG, LJ (corresponding author), UNIV PENN, DEPT BIOCHEM & BIOPHYS, 37TH & HAMILTON WALK, PHILADELPHIA, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015120, P30DK019525] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19525, DK-07314, DK-15120] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAFFY G, 1992, J CELL PHYSIOL, V153, P332, DOI 10.1002/jcp.1041530213; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BELL RM, 1991, J BIOL CHEM, V266, P4661; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG CP, 1991, J BIOL CHEM, V266, P23467; COCKCROFT S, 1992, BIOCHEM J, V288, P1; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; ENHENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; ENHENEGOUWEN PMPV, 1992, EXP CELL RES, V199, P90, DOI 10.1016/0014-4827(92)90465-K; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HANSEN CA, 1991, J BIOL CHEM, V266, P18573; HEPLER JR, 1990, BIOCHEM J, V270, P337, DOI 10.1042/bj2700337; HERNANDEZSOTOMAYOR SMT, 1993, BIOCHEM J, V293, P507, DOI 10.1042/bj2930507; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUANG CL, 1989, J BIOL CHEM, V264, P4391; JONES GA, 1993, J BIOL CHEM, V268, P20845; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANDRETH GE, 1985, J CELL BIOL, V101, P1341, DOI 10.1083/jcb.101.4.1341; LI W, 1991, CELL REGUL, V2, P641, DOI 10.1091/mbc.2.8.641; LIANG M, 1992, MOL PHARMACOL, V42, P743; LIANG M, 1991, J BIOL CHEM, V266, P13342; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MOZHAYEVA GN, 1990, FEBS LETT, V277, P233, DOI 10.1016/0014-5793(90)80853-B; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; SHI YE, 1989, CANCER RES, V49, P3574; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR CW, 1988, BIOCHEM J, V249, P917, DOI 10.1042/bj2490917; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WHITMAN M, 1989, BIOCHIM BIOPHYS ACTA, V948, P327, DOI 10.1016/0304-419X(89)90005-X; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YANG LJ, 1993, J BIOL CHEM, V268, P3739; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	109	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7156	7162						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125925				2022-12-25	WOS:A1994NA03200021
J	HAUSER, JML; BUEHRER, BM; BELL, RM				HAUSER, JML; BUEHRER, BM; BELL, RM			ROLE OF CERAMIDE IN MITOGENESIS INDUCED BY EXOGENOUS SPHINGOID BASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NECROSIS-FACTOR-ALPHA; CELLULAR PROLIFERATION; SIGNAL TRANSDUCTION; MONOCYTIC DIFFERENTIATION; HL-60 CELLS; SPHINGOMYELIN TURNOVER; ENDOGENOUS GANGLIOSIDE; PHOSPHATIDIC-ACID; A431 CELLS	Dihydrosphingosine, an intermediate in the de novo synthesis of ceramide, induced proliferation of Swiss 3T3 cells. The proliferative effects of this lipid were much more potent than those of sphingosine, a breakdown product of ceramide. The maximal proliferative response to dihydrosphingosine occurred at relatively low concentrations (1 mu M), while sphingosine produced its maximal effect at much higher concentrations (15 mu M), The cell-permeable ceramide, N-hexanoylsphingosine (C-6-ceramide), which was also a mitogen in these cells (at 1 mu M), caused a striking morphological change when added to the cells at concentrations of 5-10 mu M. This shape change was reversible with the removal of ceramide. Exogenous dihydrosphingosines and sphingosines have at least two metabolic fates in Swiss 3T3 cells, conversion to ceramide or to sphingosine 1-phosphate, Surprisingly, both the synthetic threo- isomer and the naturally occurring erythro- isomer of dihydrosphingosine and sphingosine (D-erythro-sphingosine, L-threo-sphingosine, DL-threo-dihydrosphingosine, and DL-erythro-dihydrosphingosine) were readily phosphorylated in in tact Swiss 3T3 cells. This substrate specificity may be an indication of a sphingosine kinase activity which is distinct from that of platelets or rat brain. Although sphingosine 1-phosphate and ceramide were both produced upon the addition of sphingosine and dihydrosphingosine, no sphingosine 1-phosphate was produced when Swiss 3T3 cells were treated with mitogenic concentrations of C-6-ceramide. These data are consistent with the formation of ceramide and not sphingosine 1-phosphate being required for the mitogenesis produced by exogenous sphingoid bases.	DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University				Buehrer, Benjamin/0000-0001-6654-4367	NIDDK NIH HHS [DK 20205] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020205, R01DK020205] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1960, J BIOL CHEM, V235, P769; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BARBOUR S, 1992, J CELL PHYSIOL, V150, P610, DOI 10.1002/jcp.1041500322; BELL RM, 1988, COLD SPRING HARB SYM, V53, P103, DOI 10.1101/SQB.1988.053.01.016; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRESTSCHER A, 1991, ANN REV CELL BIOL, V7, P337; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DESAI NN, 1992, J BIOL CHEM, V267, P26121; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; GHIDONI R, 1986, BIOCHEM J, V237, P147, DOI 10.1042/bj2370147; GHIDONI R, 1983, BIOCHEM J, V213, P321, DOI 10.1042/bj2130321; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HAKOMORI S, 1983, SPHINGOLIPID BIOCH, P327; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1989, CLIN CHIM ACTA, V185, P333, DOI 10.1016/0009-8981(89)90224-6; HARTWIG JH, 1989, J CELL BIOL, V109, P1571, DOI 10.1083/jcb.109.4.1571; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MEDLOCK KA, 1988, BIOCHEM BIOPH RES CO, V157, P232, DOI 10.1016/S0006-291X(88)80037-8; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; OKADA Y, 1988, FEBS LETT, V235, P25, DOI 10.1016/0014-5793(88)81227-4; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PREISS J, 1986, J BIOL CHEM, V261, P8597; RADIN NS, 1991, TRENDS GLYCOSCI GLYC, V3, P200; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITO M, 1985, BIOCHEM BIOPH RES CO, V132, P223, DOI 10.1016/0006-291X(85)91011-3; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; SHUKLA GS, 1991, BIOCHIM BIOPHYS ACTA, V1083, P101, DOI 10.1016/0005-2760(91)90130-A; SPIEGEL S, 1989, J BIOL CHEM, V264, P16512; SPIEGEL S, 1987, P NATL ACAD SCI USA, V84, P141, DOI 10.1073/pnas.84.1.141; SPIEGEL S, 1988, EXP CELL RES, V177, P414, DOI 10.1016/0014-4827(88)90474-0; STEVENS VL, 1989, CANCER RES, V49, P3229; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TRINCHERA M, 1988, BIOCHEM J, V252, P375, DOI 10.1042/bj2520375; TRINCHERA M, 1990, BIOCHEM J, V270, P815, DOI 10.1042/bj2700815; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; WANG E, 1991, J BIOL CHEM, V266, P14486; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	60	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6803	6809						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120042				2022-12-25	WOS:A1994MZ50300086
J	KNORR, BA; LIPKOWITZ, MS; POTTER, BJ; MASUR, SK; ABRAMSON, RG				KNORR, BA; LIPKOWITZ, MS; POTTER, BJ; MASUR, SK; ABRAMSON, RG			ISOLATION AND IMMUNOLOCALIZATION OF A RAT RENAL CORTICAL MEMBRANE URATE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-SPECIFIC EXPRESSION; URICASE; ANTIBODIES; VESICLES; OXIDASE	Two modalities of urate transport have been reported in rat kidney, a urate/anion exchanger and a potential sensitive, uricase-like uniporter. As an initial attempt to isolate and characterize the responsible transport protein(s), rat renal cortical membranes were harvested, solubilized, and subjected to affinity chromatography with urate or xanthine as the affinity ligand. Pig liver peroxisomal uricase was purified with the same system, and the enzymatically active protein was used to generate polyclonal antibodies in rabbit, Silver stain of SDS-polyacrylamide gel electrophoresis gels of the eluted fraction containing the affinity-purified renal membrane protein(s) demonstrated bands at 25, 32, 36, and 41 kDa. On Western blot, two of these bands (32 and 36 kDa) were immunoreactive to the polyclonal antibody to pig liver uricase. In 6 of 10 studies, the affinity-purified renal membrane protein(s) also oxidized urate. Anti-pig liver uricase produced a selective and dose-dependent inhibition of the uricase like urate uniporter in renal membrane vesicles, but did not affect the urate/anion exchanger or the sodium-dependent glucose transporter. Immunocytochemical studies of rat renal cortex with the same antibody indicated that the immunoreactivity was localized to proximal tubules. These studies demonstrate that the renal cortical plasma membranes contain urate-binding proteins, which have some func tional and immunological homology to the hepatic per oxisomal core protein, uricase. Within the renal cortex, these proteins are localized to proximal tubules, the site of urate transport. Since the antibody that reacts with the affinity-purified urate-binding proteins on Western blot selectively inhibits urate transport in intact membrane vesicles, it is concluded that at least one of the affinity-purified urate-binding proteins is a uricase like urate transporter.	MT SINAI SCH MED,DEPT OPTHALMOL,NEW YORK,NY 10029; MT SINAI SCH MED,DEPT OPHTHALMOL,NEW YORK,NY 10029; LOUISIANA STATE UNIV,MED CTR,DEPT PHYSIOL,NEW ORLEANS,LA 70112	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Louisiana State University System					NATIONAL EYE INSTITUTE [R03EY009244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008419, R01DK037315] Funding Source: NIH RePORTER; NEI NIH HHS [EY09244] Funding Source: Medline; NIDDK NIH HHS [DK08419, DK37315] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMSON RG, 1982, AM J PHYSIOL, V242, pF158, DOI 10.1152/ajprenal.1982.242.2.F158; ABRAMSON RG, 1974, J APPL PHYSIOL, V36, P500, DOI 10.1152/jappl.1974.36.4.500; ABRAMSON RG, 1990, EVOLUTION URIC ACID, P115; ABRAMSON RG, 1985, AM J PHYSIOL, V17, pF574; AHMED K, 1964, BIOCHIM BIOPHYS ACTA, V93, P603, DOI 10.1016/0304-4165(64)90343-5; BATISTAVIERA F, 1977, PREP BIOCHEM, V7, P103, DOI 10.1080/00327487708061629; BAUDHUIN P, 1965, BIOCHEM BIOPH RES CO, V20, P53, DOI 10.1016/0006-291X(65)90949-6; BEARD ME, 1968, J EXP ZOOL, V168, P477, DOI 10.1002/jez.1401680408; BURRIDGE K, 1976, P NATL ACAD SCI USA, V73, P4457, DOI 10.1073/pnas.73.12.4457; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; FRIDOVIC.I, 1965, J BIOL CHEM, V240, P2491; GREGER R, 1974, PFLUG ARCH EUR J PHY, V352, P115, DOI 10.1007/BF00587510; HEIDRICH HG, 1980, J CELL BIOL, V54, P232; Hruban Z, 1969, MICROBODIES RELATED; HTAY HH, 1989, COMP BIOCHEM PHYS B, V92, P583, DOI 10.1016/0305-0491(89)90135-1; KAHN AM, 1983, AM J PHYSIOL, V245, pF151, DOI 10.1152/ajprenal.1983.245.2.F151; KAHN AM, 1985, AM J PHYSIOL, V249, pF684; KINNE R, 1982, AM J PHYSIOL, V242, pF158; KRAMP RA, 1975, AM J PHYSIOL, V288, P875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLER HR, 1956, SCIENCE, V124, P705, DOI 10.1126/science.124.3225.705; MOTOJIMA K, 1990, BIOCHIM BIOPHYS ACTA, V1087, P316, DOI 10.1016/0167-4781(90)90005-M; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PORDY WT, 1987, AM J PHYSIOL, V253, pF702, DOI 10.1152/ajprenal.1987.253.4.F702; REDDY PG, 1988, P NATL ACAD SCI USA, V85, P9081, DOI 10.1073/pnas.85.23.9081; USADA N, 1988, LAB INVEST, V58, P100; VOLKL A, 1988, J HISTOCHEM CYTOCHEM, V36, P329, DOI 10.1177/36.4.3346536; WADE JB, 1986, AM J PHYSIOL, V251, pC380, DOI 10.1152/ajpcell.1986.251.3.C380; WATANABE T, 1978, ANAL BIOCHEM, V86, P357, DOI 10.1016/0003-2697(78)90758-3	30	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6759	6764						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120036				2022-12-25	WOS:A1994MZ50300079
J	OSIFCHIN, NE; JIANG, D; OHTANIFUJITA, N; FUJITA, T; CARROZA, M; KIM, SJ; SAKAI, T; ROBBINS, PD				OSIFCHIN, NE; JIANG, D; OHTANIFUJITA, N; FUJITA, T; CARROZA, M; KIM, SJ; SAKAI, T; ROBBINS, PD			IDENTIFICATION OF A P53 BINDING-SITE IN THE HUMAN RETINOBLASTOMA SUSCEPTIBILITY GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; LARGE T-ANTIGEN; CELL-CYCLE; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; PROTEINS BIND; DNA-SEQUENCE; SV40 ORIGIN; RB GENE; PRODUCT	p53 is a tumor suppressor gene-found to be mutated in a wide variety of tumors. The encoded p53 protein has properties of a classical transcription factor, but the promoter targets for its regulation are largely unknown. We have investigated the ability of p53 to regulate activity of the human retinoblastoma susceptibility gene (Rb) promoter using a cotransfection assay in CCL-64 and Saos-2 cells, p53 was able to stimulate transcription from the Rb promoter at low input doses of p53 expression plasmid, whereas transcription was repressed at high input doses. The stimulatory effect of p53 on Rb promoter activity mapped to a region between 4 and 92 base pairs upstream from the start site of translation, whereas the region controlling repression by p53 mapped to the basal transcriptional control region of the promoter between -207 and -185. Moreover, an oligonucleotide containing Rb promoter sequences between -63 and -88 was sufficient to confer stimulation by p53 when inserted upstream from a minimal heterologous promoter. Gel mobility shift analysis was used to demonstrate that p53 can bind to a sequence within the -63 to -88 oligonucleotide with homology to a p53 binding site. The presence of a functional p53 binding site in the human retinoblastoma tumor suppressor gene promoter suggests that p53 can regulate Rb promoter activity.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15261; KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; NATL CANC INST,CHEMOPREVENT LAB,BETHESDA,MD 20892	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kyoto Prefectural University of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007458] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55227] Funding Source: Medline; NIDDK NIH HHS [5 T32 DK07458] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6789; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; AUSUBEL FM, CURRENT PROTOCOL MOL; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DUTTA Z, 1993, NATURE, V365, P79; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JIANG D, 1993, ONCOGENE, V8, P2805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	54	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6383	6389						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119988				2022-12-25	WOS:A1994MZ50300022
J	RAMOS, C; WINTHER, JR; KIELLANDBRANDT, MC				RAMOS, C; WINTHER, JR; KIELLANDBRANDT, MC			REQUIREMENT OF THE PROPEPTIDE FOR IN-VIVO FORMATION OF ACTIVE YEAST CARBOXYPEPTIDASE-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN CONFORMATION; SECRETORY PATHWAY; ESCHERICHIA-COLI; PRO-SEQUENCE; TRANSPORT; VACUOLE; GENE; SUBTILISIN; PRECURSOR	Deletions have been constructed in the region encoding the 91-amino acid propeptide of the vacuolar enzyme carboxypeptidase Y of Saccharomyces cerevisiae, and in vivo effects of these mutations on the intracellular transport of the mutant proenzymes have been examined. Deletions did not include the vacuolar targeting signal, and none of the mutated forms of procarboxypeptidase Y was found to be secreted. All deletions, however, re suited in a decreased rate of transport of the truncated proenzymes from the endoplasmic reticulum to the Golgi apparatus. Up to 29 residues close to the N terminus can be removed without completely eliminating transport of the mutated proenzymes to the vacuole. However, the C-terminal part of the propeptide contains elements which are essential, since two small deletions, of 9 and 15 residues, respectively, within this area re suited in loss of carboxypeptidase Y activity. This region is, however, not sufficient for efficient formation of active carboxypeptidase Y, since truncated precursors in which the vacuolar targeting signal was fused to the C-terminal part of the proregion did not give rise to active enzyme. Based on the results, we propose that the carboxypeptidase Y propeptide plays an essential role in guiding the proper folding of the protein in vivo and that many parts of the propeptide contribute, in an additive way, to this function.	CARLSBERG LAB, DEPT YEAST GENET, DK-2500 COPENHAGEN, DENMARK				Winther, Jakob R./K-4451-2014; Kielland-Brandt, Morten C./D-2563-2015; RAMOS, CAYO/G-3818-2011	Winther, Jakob R./0000-0001-6995-9154; RAMOS, CAYO/0000-0002-2362-5041; Kielland-Brandt, Morten/0000-0002-1272-3877				AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BIELEFELD M, 1989, MOL GEN GENET, V215, P401, DOI 10.1007/BF00427036; BLACHLYDYSON E, 1987, J CELL BIOL, V104, P1183, DOI 10.1083/jcb.104.5.1183; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; FABRE E, 1991, J BIOL CHEM, V266, P3782; FEDER J, 1970, BIOCHEMISTRY-US, V9, P2784, DOI 10.1021/bi00816a005; FUJISHIGE A, 1992, J CELL BIOL, V118, P33, DOI 10.1083/jcb.118.1.33; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HASILIK A, 1978, EUR J BIOCHEM, V85, P599, DOI 10.1111/j.1432-1033.1978.tb12275.x; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MK, 1990, NUCLEIC ACIDS RES, V18, P3439, DOI 10.1093/nar/18.12.3439; MUKHTAR M, 1992, GENE, V121, P173, DOI 10.1016/0378-1119(92)90178-R; NEBES VL, 1991, J BIOL CHEM, V266, P22851; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NIELSEN TL, 1990, APPL MICROBIOL BIOT, V33, P307, DOI 10.1007/BF00164527; OLESEN K, 1993, PROTEIN ENG, V6, P409, DOI 10.1093/protein/6.4.409; PAYNE GS, 1988, J CELL BIOL, V106, P1453, DOI 10.1083/jcb.106.5.1453; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; Sambrook J, 1989, MOL CLONING LABORATO; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SORENSEN SO, 1994, IN PRESS EUR J BIOCH; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; TRIMBLE RB, 1983, J BIOL CHEM, V258, P2562; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	45	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					7006	7012						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120064				2022-12-25	WOS:A1994MZ50300113
J	SANG, BC; CHEN, JY; MINNA, J; BARBOSA, MS				SANG, BC; CHEN, JY; MINNA, J; BARBOSA, MS			DISTINCT REGIONS OF P53 HAVE A DIFFERENTIAL ROLE IN TRANSCRIPTIONAL ACTIVATION AND REPRESSION FUNCTIONS	ONCOGENE			English	Article							WILD-TYPE P53; CELL LUNG-CANCER; DNA-BINDING; T-ANTIGEN; GENE-EXPRESSION; PROTEINS BIND; MUTANT P53; SEQUENCE; MUTATIONS; INVITRO	The wild type p53 tumor suppressor protein transactivates genes carrying p53 responsive elements and represses several TATA containing promoters. We report in vivo gene regulation assays where deletion of the N-terminal 75 residues (Delta N75) results in loss of transactivation of p53CON and repression of an HPV 6 reporter. In contrast, removal of the C-terminal 75 (Delta C75) amino acids resulted in a truncated protein capable of trans-activating p53CON but not able to repress the HPV 6 reporter. In vitro protein association assays revealed that the Delta N75 protein, but not the Delta C75 truncated protein, could oligomerize with the wild type p53 protein. Co-transfection assays with wild type p53 showed that the Delta N75 mutant protein has a dominant negative effect on trans-activation function. However, it does not affect the ability of wild type p53 to repress transcription from the HPV 6 reporter. The Delta C75 protein had no effect on the ability of the wild type p53 to activate p53CON or repress the HPV 6 reporter. These results suggest that distinct regions of p53 have a differential role in transcriptional activation and repression functions.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Chen, Joanne Jeou-Yuan/S-7022-2018		NCI NIH HHS [CA55703, CA58220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055703, P20CA058220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWER M, 1986, CANCER RES, V46, P798; CHEN JY, 1993, ONCOGENE, V8, P2159; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MITSUDOMI T, 1992, ONCOGENE, V7, P171; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1992, ONCOGENE, V7, P1153; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	49	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					853	859						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108128				2022-12-25	WOS:A1994MW55100021
J	JOUVIN, MHE; ADAMCZEWSKI, M; NUMEROF, R; LETOURNEUR, O; VALLE, A; KINET, JP				JOUVIN, MHE; ADAMCZEWSKI, M; NUMEROF, R; LETOURNEUR, O; VALLE, A; KINET, JP			DIFFERENTIAL CONTROL OF THE TYROSINE KINASES LYN AND SYK BY THE 2 SIGNALING CHAINS OF THE HIGH-AFFINITY IMMUNOGLOBULIN-E RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; T-CELL; ANTIGEN RECEPTOR; IGE RECEPTOR; ZETA-CHAIN; PHOSPHOLIPASE C-GAMMA-1; CYTOPLASMIC DOMAINS; MONOCLONAL-ANTIBODY; TRANSFECTED CELLS; MOLECULAR-CLONING	Nonreceptor tyrosine kinases such as the newly described 70-kDa (ZAP-70/Syk) and Src-related tyrosine kinases are coupled to a variety of receptors, including the antigen receptors on B- and T-cells and the Fc receptors for IgE (Fc epsilon RI) and IgG (Fc gamma RI, Fc gamma RIII/CD16). Various subunits of these receptors contain homologous activation motifs which appear capable of autonomously triggering cell activation. Two forms of this motif are present in the Fc epsilon RI multimeric complex: one in the beta chain and one in the gamma chain. Here we show that each of the two tyrosine kinases known to be involved in Fc epsilon RI signaling is controlled by a distinct motif-containing chain. Lyn associates with the nonactivated beta chain, whereas gamma promotes the activation of Syk. We also show that neither the beta nor the gamma motif alone can account for the full signaling capacity of the entire receptor. We propose that, upon triggering of the tetrameric receptor, Lyn already bound to beta becomes activated and phosphorylates beta and gamma; the phosphorylation of gamma induces the association of Syk with gamma and also the activation of Syk, resulting in the phosphorylation and activation of phospholipase C gamma(1). Cooperative recruitment of specific kinases by the various signaling chains found in this family of antigen receptors could represent a way to achieve the full signaling capacity of the multimeric complexes.	NIAID, MOLEC ALLERGY & IMMUNOL SECT, ROCKVILLE, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Valle, Angel/L-3194-2019					ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; ALBER G, 1991, J BIOL CHEM, V266, P22613; AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HEMLER ME, 1983, HUM IMMUNOL, V8, P153, DOI 10.1016/0198-8859(83)90010-1; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KINET JP, 1988, P NATL ACAD SCI USA, V85, P6483, DOI 10.1073/pnas.85.17.6483; KINET JP, 1987, BIOCHEMISTRY-US, V26, P4605, DOI 10.1021/bi00389a002; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SALCEDO TW, 1993, J EXP MED, V177, P1475, DOI 10.1084/jem.177.5.1475; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YU KT, 1991, J BIOL CHEM, V266, P22564; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	348	351	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5918	5925						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119935				2022-12-25	WOS:A1994MY84000068
J	LADIAS, JAA				LADIAS, JAA			CONVERGENCE OF MULTIPLE NUCLEAR RECEPTOR SIGNALING PATHWAYS ONTO THE LONG TERMINAL REPEAT OF HUMAN IMMUNODEFICIENCY VIRUS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							9-CIS RETINOIC ACID; THYROID-HORMONE; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; X-RECEPTOR; GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION; MEMBRANE DEPOLARIZATION; RESPONSE ELEMENTS; GROWTH-FACTORS	A composite element that interacts with multiple nuclear receptors has been identified in the long terminal repeat (LTR) of the human immunodeficiency virus-1 (HIV-1). This element, designated nuclear receptor-responsive element (NRRE), spans the -356 to -320 LTR region and contains tightly clustered binding sites for the retinoid X receptor-alpha (RXR alpha) and for five nuclear receptors with unknown ligands, apolipoprotein AT regulatory protein-1 (ARP-1), v-erbA-related proteins-2 and -3 (EAR-2 and EAR-3), hepatocyte nuclear factor-4 (HNF-4), and nerve growth factor-inducible protein-B (NGFI-B). The NRRE also interacts with heterodimers formed between RXR alpha and either ARP-1, EAR-2, EAR-3, the retinoic acid receptor-alpha (RAR alpha), or the peroxisome proliferator-activated receptor (PPAR). Remarkably, nuclear receptor binding is conserved in the LTRs of recently evolved HIV-1 strains but it is absent in the oldest and most divergent viral isolates, raising the intriguing possibility that the NRRE has been evolved recently in the viral genome. Cotransfection experiments in human choriocarcinoma JEG-3 cells have shown that the HIV-1 LTR-driven transcription is activated by RXR alpha and RAR alpha in the presence of 9-cis- and all-trans-retinoic acid, by PPAR and RXR alpha in the presence of clofibric acid and 9-cis-retinoic acid, and by the ''orphan'' receptors HNF-4 and NGFI-B. These findings suggest that a complex network of nuclear receptor signaling pathways, that include 9-cis- and all-trans-retinoic acid, fatty acids, peroxisome proliferators, growth factors, membrane depolarization, and possibly other signals, converge onto the HIV-1 NRRE and may participate in modulation of viral gene expression.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02215	Harvard University; Harvard Medical School	LADIAS, JAA (corresponding author), HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,RM 503A,BOSTON,MA 02215, USA.				NIAID NIH HHS [1R29AI34270-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; CHENG-MAYER C, 1990, AIDS (London), V4, pS49; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; COONEY AJ, 1991, J VIROL, V65, P2853, DOI 10.1128/JVI.65.6.2853-2860.1991; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; CORBOY JR, 1992, SCIENCE, V258, P1804, DOI 10.1126/science.1465618; DE LUCA LM, 1991, FASEB J, V5, P2924; DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI WH, 1988, MOL BIOL EVOL, V5, P313; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MYERS G, 1991, DATABASE HUMAN RETRO; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ORAM JD, 1990, AIDS RES HUM RETROV, V6, P1073, DOI 10.1089/aid.1990.6.1073; ORCHARD K, 1993, J ACQ IMMUN DEF SYND, V6, P440; ORCHARD K, 1990, J VIROL, V64, P3234, DOI 10.1128/JVI.64.7.3234-3239.1990; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POLI G, 1992, P NATL ACAD SCI USA, V89, P2689, DOI 10.1073/pnas.89.7.2689; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SRINIVASAN A, 1989, AIDS RES HUM RETROV, V5, P121, DOI 10.1089/aid.1989.5.121; TURPIN JA, 1992, J IMMUNOL, V148, P2539; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YANG ZY, 1993, NUCLEIC ACIDS RES, V21, P2831, DOI 10.1093/nar/21.12.2831; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	54	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5944	5951						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119938				2022-12-25	WOS:A1994MY84000072
J	BRAUN, JEA; FRITZ, BA; WONG, SME; LOWE, AW				BRAUN, JEA; FRITZ, BA; WONG, SME; LOWE, AW			IDENTIFICATION OF A VESICLE-ASSOCIATED MEMBRANE-PROTEIN (VAMP)-LIKE MEMBRANE-PROTEIN IN ZYMOGEN GRANULES OF THE RAT EXOCRINE PANCREAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED CHROMAFFIN CELLS; BOTULINUM-A TOXIN; SYNAPTIC VESICLES; TETANUS TOXIN; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; STREPTOLYSIN-O; ACINAR-CELLS; LIGHT CHAIN; GENES	Zymogen granules of the exocrine pancreas are the secretory organelles responsible for the regulated secretion of digestive enzymes. Several proteins are associated with or are integral components of the lipid bilayer that forms the zymogen granule membrane. These proteins likely represent important components in the regulated secretion of digestive enzymes. VAMPs (vesicle-associated membrane proteins)/synaptobrevins are a family of 18-kDa integral membrane proteins originally characterized in synaptic vesicles. Polyclonal antisera raised against either a VAMP/glutathione S-transferase (GST) fusion protein or rat brain synaptic vesicles, defected an 18-kDa immunoreactive protein in zymogen granule membranes that co-migrates electrophoretically with rat brain synaptic vesicle VAMP. Rat brain synaptic vesicle VAMP was detected by both antisera. Botulinum-B toxin treatment of zymogen granule membranes did not result in cleavage of zymogen granule membrane VAMP, indicating that exocrine pancreatic VAMP is either VAMP1 or a novel VAMP-isoform Immunofluorescent studies demonstrated that exocrine pancreatic VAMP localized with GP2, a zymogen granule membrane protein, to the apical region of pancreatic acinar cells. No significant labeling was observed in basolateral regions of pancreatic acinar cells. These results establish the presence of a VAMP protein in the zymogen granule of the rat pancreas and suggest that VAMPs have a role in exocrine secretion.	STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA; STANFORD UNIV, CTR DIGEST DIS, STANFORD, CA 94305 USA	Stanford University; Stanford University					NIDDK NIH HHS [DK38707, DK43294-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R01DK043294, R29DK043294] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BEAUDOIN AR, 1993, J HISTOCHEM CYTOCHEM, V41, P225, DOI 10.1177/41.2.7678269; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BERGEY GK, 1987, J NEUROPHYSIOL, V57, P121, DOI 10.1152/jn.1987.57.1.121; BIGALKE H, 1981, N-S ARCH PHARMACOL, V316, P244, DOI 10.1007/BF00505657; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BITTNER MA, 1988, J NEUROCHEM, V51, P451, DOI 10.1111/j.1471-4159.1988.tb01059.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAND SH, 1991, J BIOL CHEM, V266, P18949; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; CHIN AC, 1993, GENE, V131, P175, DOI 10.1016/0378-1119(93)90291-A; CHIN GJ, 1992, BRAIN RES, V571, P89, DOI 10.1016/0006-8993(92)90512-8; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DRENCKHAHN D, 1983, EUR J CELL BIOL, V30, P167; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GREENBERG HB, 1983, J VIROL, V47, P267, DOI 10.1128/JVI.47.2.267-275.1983; HAVINGA JR, 1985, EUR J CELL BIOL, V39, P70; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1992, EUR J CELL BIOL, V58, P12; LAURIE SM, 1992, J HISTOCHEM CYTOCHEM, V40, P1827, DOI 10.1177/40.12.1453001; LEBEL D, 1988, BIOCHEM BIOPH RES CO, V154, P818, DOI 10.1016/0006-291X(88)90213-6; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LINK E, 1993, J BIOL CHEM, V268, P18423; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MACDONAL.RJ, 1972, BIOCHEM BIOPH RES CO, V49, P377, DOI 10.1016/0006-291X(72)90421-4; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MELDOLESI J, 1971, J CELL BIOL, V49, P109, DOI 10.1083/jcb.49.1.109; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; RONZIO RA, 1978, BIOCHIM BIOPHYS ACTA, V508, P65, DOI 10.1016/0005-2736(78)90189-X; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHEFFER RCT, 1980, EUR J CELL BIOL, V23, P122; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STECHER B, 1989, FEBS LETT, V255, P391, DOI 10.1016/0014-5793(89)81129-9; STECHER B, 1992, BIOCHEM J, V283, P899, DOI 10.1042/bj2830899; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WISHART MJ, 1993, J BIOL CHEM, V268, P10303	55	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5328	5335						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106518				2022-12-25	WOS:A1994MX57100095
J	BREITTMAYER, JP; BERNARD, A; AUSSEL, C				BREITTMAYER, JP; BERNARD, A; AUSSEL, C			REGULATION BY SPHINGOMYELINASE AND SPHINGOSINE OF CA2+ SIGNALS ELICITED BY CD3 MONOCLONAL-ANTIBODY, THAPSIGARGIN, OR IONOMYCIN IN THE JURKAT T-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM RELEASE; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-D; INHIBITION; ACTIVATION; INFLUX; STORES; SPHINGOSINE-1-PHOSPHATE; SPHINGOLIPIDS; PROLIFERATION	Sphingomyelinase induces a marked rapid decrease of cytosolic Ca2+ concentration in Jurkat T cells treated with either CD3 monoclonal antibody; the Ca2+-ATPase inhibitor, thapsigargin; or the Ca2+ ionophore, ionomycin. Sphingomyelinase treatment of Jurkat cells results in a net decrease of cellular sphingomyelin content. Among the products generated by the catabolism of sphingomyelin, sphingosine displayed exactly the same effect as sphingomyelinase. Sphingosine decreases the cytosolic Ca2+ concentration in cells treated with CD3, thapsigargin, or ionomycin. Studying the effect of sphingosine in CD3-activated cells showed that this compound does not modify Ca2+ mobilization from intracellular stores but strongly inhibited the Ca2+ influx induced by the monoclonal antibody. The fact that sphingosine inhibits Ca2+ influx generated by thapsigargin and ionomycin supports the hypothesis that the drug activates the Ca2+ extrusion process. Derivatives of sphingosine such as erythrosphinganine and threosphinganine share the same inhibitory properties,	FAC MED NICE,INSERM,U343,INTERACT CELLULAIRES & MOLEC IMMUNOL LAB,F-06107 NICE,FRANCE; HOP ARCHET,LAB CENT IMMUNOL,F-06012 NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Cote d'Azur; CHU Nice								ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; AUSSEL C, 1991, J LIPID MEDIATOR, V3, P267; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREITTMAYER JP, 1993, J BIOL CHEM, V268, P20812; BREITTMAYER JP, 1991, IMMUNOLOGY, V73, P134; CHOW SC, 1990, BIOCHEM J, V267, P727, DOI 10.1042/bj2670727; CZARNY M, 1992, BIOCHEM BIOPH RES CO, V186, P1582, DOI 10.1016/S0006-291X(05)81588-8; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DORNAND J, 1987, IMMUNOL LETT, V16, P101, DOI 10.1016/0165-2478(87)90115-5; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JALINK K, 1990, J BIOL CHEM, V265, P12232; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KUBBIES M, 1989, EUR J IMMUNOL, V19, P1393, DOI 10.1002/eji.1830190807; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NORDSTROM T, 1991, CELL CALCIUM, V12, P449, DOI 10.1016/0143-4160(91)90027-C; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PELASSY C, 1991, J LIPID MEDIATOR, V4, P199; PELASSY C, 1992, BIOCHEM J, V288, P785, DOI 10.1042/bj2880785; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; PUTNEY JW, 1986, CELL CALCIUM, V7, P11; RANDRIAMAMPITA C, 1990, J BIOL CHEM, V265, P18059; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SARKADI B, 1991, J MEMBRANE BIOL, V123, P9, DOI 10.1007/BF01993958; SPENCE MW, 1989, PHOSPHATIDYLCHOLINE, P185; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; TORDAI A, 1989, IMMUNOL LETT, V20, P47, DOI 10.1016/0165-2478(89)90067-9; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	37	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5054	5058						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106482				2022-12-25	WOS:A1994MX57100057
J	SKIBA, MC; KNIGHT, KL				SKIBA, MC; KNIGHT, KL			FUNCTIONALLY IMPORTANT RESIDUES AT A SUBUNIT INTERFACE SITE IN THE RECA PROTEIN FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENTS; DNA	Assembly of RecA subunits into long, helical oligomers is required for its roles in recombinational DNA repair and homologous genetic recombination. The crystal structure of RecA reveals an extensive network of amino acid residues that lie at the subunit boundaries. We have introduced a large set of substitutions at 5 clustered residues, which are shown in the crystal structure to make specific contacts with positions in the neighboring monomer. We find that 3 of the 5 residues are important for RecA function (Lys216, Phe217, and Arg222), whereas the other 2 (Asn213 and Tyr218) are not. The patterns of functionally allowed substitutions provide insight into the chemical and steric constraints required at these positions.			SKIBA, MC (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655, USA.				NIGMS NIH HHS [GM 44772] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044772] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COX MM, 1991, MOL MICROBIOL, V5, P1295, DOI 10.1111/j.1365-2958.1991.tb00775.x; DUTREIX M, 1992, MOL GEN GENET, V232, P489, DOI 10.1007/BF00266254; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; NGUYEN TT, 1993, J BIOL CHEM, V268, P3107; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; REIDHAAROLSON JF, 1991, METHOD ENZYMOL, V208, P564; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; STEVENS RC, 1991, PROTEIN ENG, V4, P391, DOI 10.1093/protein/4.4.391; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L	20	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3823	3828						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106426				2022-12-25	WOS:A1994MV63100101
J	XU, Y; OOMEN, R; KLEIN, MH				XU, Y; OOMEN, R; KLEIN, MH			RESIDUE AT POSITION-331 IN THE IGG1 AND IGG4 CH2 DOMAINS CONTRIBUTES TO THEIR DIFFERENTIAL ABILITY TO BIND AND ACTIVATE COMPLEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EFFECTOR FUNCTIONS; IMMUNOGLOBULIN-G; HINGE REGION; C1Q BINDING; SEGMENTAL FLEXIBILITY; CHIMERIC HUMAN; ANTIBODIES; RABBIT; CARBOHYDRATE; EXPRESSION	A conserved proline residue is found at position 331 in the C(H)2 domains of human IgG subclasses which fix complement. This residue is replaced by a serine in IgG4 which is inactive. To determine the role of residue 331 in the differential ability of human IgGs to activate the complement cascade, a pair of genetically engineered anti-dinitrophenol IgG1 and IgG4 antibodies with reciprocal mutations at position 331 were tested for their hemolytic activity as well as for their ability to bind C1q, activate C1 and cleave C4. The IgG1 Ser331 mutant was virtually unable to mediate the lysis of trinitrobenzene-sulfonic acid-derivatized sheep red blood cells as a result of a marked defect in Clq binding activity. In contrast, the substitution of Pro for Ser331 in IgG4 bestowed partial hemolytic activity (40%) to the IgG4 Pro331 variant. Under low ionic strength conditions, this mutant was found to be approximately 50 and 75% as active as wild-type IgG1 in the Clq binding and C4b deposition assays, respectively. These results indicate that residue Pro''', which folds into close proximity to a previously identified Clq binding motif (Duncan, A. R., and Winter, G. (1988) Nature 332, 738-740), contributes to the architecture of the IgG1 Clq binding site and that its replacement by a serine residue in IgG4 is largely responsible for the functional inactivity of this isotype.	UNIV TORONTO,DEPT IMMUNOL,MED SCI BLDG,TORONTO M5S 1A8,ONTARIO,CANADA; CONNAUGHT CTR BIOTECHNOL RES,N YORK M2R 3T4,ON,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto								BINDON CI, 1990, EUR J IMMUNOL, V20, P277, DOI 10.1002/eji.1830200208; BINDON CI, 1988, J EXP MED, V168, P127, DOI 10.1084/jem.168.1.127; BREKKE OH, 1993, NATURE, V363, P628, DOI 10.1038/363628a0; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; BURTON DR, 1980, NATURE, V288, P338, DOI 10.1038/288338a0; CAMPBELL RD, 1980, BIOCHEM J, V189, P67, DOI 10.1042/bj1890067; CLARK M, 1989, EUR J IMMUNOL, V19, P381, DOI 10.1002/eji.1830190224; COLOMB M, 1975, BIOCHEM J, V145, P177, DOI 10.1042/bj1450177; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; HUGHESJONES NC, 1977, IMMUNOLOGY, V32, P191; ISENMAN DE, 1975, J IMMUNOL, V114, P1726; KLEIN M, 1981, P NATL ACAD SCI-BIOL, V78, P524, DOI 10.1073/pnas.78.1.524; LAW SKA, 1988, COMPLEMENT; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; MATSUDA H, 1990, MOL IMMUNOL, V27, P51; MICHAELSEN TE, 1990, SCAND J IMMUNOL, V32, P517, DOI 10.1111/j.1365-3083.1990.tb03192.x; NORDERHAUG L, 1991, EUR J IMMUNOL, V21, P2379, DOI 10.1002/eji.1830211013; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; PERKINS SJ, 1991, J MOL BIOL, V221, P1345; POON PH, 1985, J BIOL CHEM, V260, P9357; RINFRET A, 1990, J IMMUNOL, V145, P925; RITTENBERG MB, 1969, P SOC EXP BIOL MED, V132, P575; SAMBROOK RJ, 1989, MOL CLONING LABORATO; SANDLIE I, 1989, EUR J IMMUNOL, V19, P1599, DOI 10.1002/eji.1830190912; SCHUMAKER VN, 1976, BIOCHEMISTRY-US, V15, P5175, DOI 10.1021/bi00668a035; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162; TAO MH, 1989, J IMMUNOL, V143, P2595; TAO MH, 1991, J EXP MED, V173, P1025, DOI 10.1084/jem.173.4.1025; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TENNER AJ, 1981, J IMMUNOL, V127, P648; UTSUMI S, 1985, MOL IMMUNOL, V22, P811, DOI 10.1016/0161-5890(85)90147-6; WRIGHT JF, 1988, J BIOL CHEM, V263, P11221; YASMEEN D, 1976, J IMMUNOL, V116, P518	38	56	167	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3469	3474						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106388				2022-12-25	WOS:A1994MV63100053
J	PERLMAN, RK; GEHM, BD; KUO, WL; ROSNER, MR				PERLMAN, RK; GEHM, BD; KUO, WL; ROSNER, MR			FUNCTIONAL-ANALYSIS OF CONSERVED RESIDUES IN THE ACTIVE-SITE OF INSULIN-DEGRADING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; METALLOENDOPROTEASE INHIBITORS; DROSOPHILA-MELANOGASTER; DEGRADATION PRODUCTS; PROTEASE-III; FACTOR-ALPHA; RAT-LIVER; CELLS; PURIFICATION; THERMOLYSIN	Insulin-degrading enzyme (IDE), a nonlysosomal metalloprotease involved in metabolizing internalized insulin, has catalytic properties that have been strongly conserved through evolution. Two major properties distinguish IDE from the prototypic metalloprotease thermolysin. 1) It is inhibited by cysteine protease inhibitors as well as metalloprotease inhibitors; 2) it contains an inversion of the HEXXH active site motif of thermolysin, where the histidines coordinate zinc and the glutamate participates in catalysis. Furthermore, cysteine is adjacent to the glutamate residue (HXCEH) in human, rat, and Drosophila IDE, although it is not conserved in their close homologue, Escherichia coli protease III. This cysteine has been postulated to mediate the differential sensitivity of IDE and protease III to cysteine protease inhibitors and chelators. The role of the cysteine in IDE catalysis and inhibitor sensitivity was examined by mutating Cys110 to glycine or serine. To determine whether glutamate in this unusual motif participates in catalysis, we mutated Glu111 to aspartate, valine, or glutamine. Vectors containing wild type or mutant enzymes were transfected into COS cells, and expression was confirmed by Western blotting. Although the glutamate mutants were devoid of insulin degrading activity, the cysteine mutants were indistinguishable from wild type enzyme in both catalytic activity and sensitivity to inhibitors. The loss of activity in the glutamate mutants was not due to gross alterations in tertiary structure, as shown by retention of the ability to bind substrate and by conservative and nonconservative mutation of a neighboring residue with no apparent effect on catalysis. These results demonstrate that the conserved glutamate in the zinc-binding site of human insulin-degrading enzyme is a major catalytic residue, while a conserved cysteine in this region is not essential for catalysis or inhibitor sensitivity.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago	PERLMAN, RK (corresponding author), UNIV CHICAGO, BEN MAY INST, CHICAGO, IL 60637 USA.				NIGMS NIH HHS [2T32 GM07151-17] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007151] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFHOLTER JA, 1990, MOL ENDOCRINOL, V4, P1125, DOI 10.1210/mend-4-8-1125; AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; AFFHOLTER JA, 1990, BIOCHEMISTRY-US, V29, P7727, DOI 10.1021/bi00485a022; BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BIGNER SH, 1990, CANCER RES, V50, P8017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUSH JS, 1971, DIABETES, V20, P140, DOI 10.2337/diab.20.3.140; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DUCKWORTH WC, 1988, J BIOL CHEM, V263, P1826; DUCKWORTH WC, 1988, ENDOCR REV, V9, P319, DOI 10.1210/edrv-9-3-319; Dunn BM., 1989, PROTEOLYTIC ENZYMES, P57; FAGAN JM, 1991, BIOCHEM J, V277, P779, DOI 10.1042/bj2770779; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P7695, DOI 10.1093/nar/14.19.7695; GARCIA JV, 1987, J CELL BIOL, V105, P449, DOI 10.1083/jcb.105.1.449; GARCIA JV, 1988, BIOCHEMISTRY-US, V27, P4237, DOI 10.1021/bi00412a006; GARCIA JV, 1989, J CELL BIOL, V109, P1301, DOI 10.1083/jcb.109.3.1301; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEHM BD, 1991, ENDOCRINOLOGY, V128, P1603, DOI 10.1210/endo-128-3-1603; GEHM BD, 1993, J BIOL CHEM, V268, P7943; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; HOLDEN HM, 1988, J BIOL CHEM, V263, P3256; KAYALAR C, 1989, J BIOL CHEM, V264, P8928; KAYALAR C, 1990, J CELL BIOCHEM, V44, P137, DOI 10.1002/jcb.240440303; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KOLE HK, 1992, ARCH BIOCHEM BIOPHYS, V297, P199, DOI 10.1016/0003-9861(92)90662-G; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; KUO WL, 1991, MOL ENDOCRINOL, V5, P1467, DOI 10.1210/mend-5-10-1467; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI D, 1992, J BIOL CHEM, V267, P2414; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P41, DOI 10.1038/newbio238041a0; MULLER D, 1992, BIOCHEMISTRY-US, V31, P11138; NEURATH H, 1989, PROTEOLYTIC ENZYMES, P1; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; RAWLINGS ND, 1991, BIOCHEM SOC T, V19, pS289, DOI 10.1042/bst019289s; ROTH RA, 1984, ENDOCR RES, V10, P101, DOI 10.3109/07435808409035411; Sambrook J, 1989, MOL CLONING LABORATO; SEMPLE JW, 1992, INT IMMUNOL, V4, P1161, DOI 10.1093/intimm/4.10.1161; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; STOPPELLI MP, 1988, P NATL ACAD SCI USA, V85, P3469, DOI 10.1073/pnas.85.10.3469; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001	46	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21538	21544						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104941				2022-12-25	WOS:A1993MC80900020
J	YAMAGUCHI, M; HATEFI, Y				YAMAGUCHI, M; HATEFI, Y			ENERGY-TRANSDUCING NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE - NUCLEOTIDE-BINDING PROPERTIES OF THE PURIFIED ENZYME AND PROTEOLYTIC FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; ESCHERICHIA-COLI; MITOCHONDRIAL TRANSHYDROGENASE; BEEF-HEART; N,N'-DICYCLOHEXYLCARBODIIMIDE; DICYCLOHEXYLCARBODIIMIDE; SITE; N-(ETHOXYCARBONYL)-2-ETHOXY-1,2-DIHYDROQUINOLINE; PURIFICATION; PROTEINS	The mitochondrial energy-transducing nicotinamide nucleotide transhydrogenase is a homodimer of monomer M(r) = 109,065. It is composed of a 430-residue-long N-terminal hydrophilic domain, a 400-residue-long central hydrophobic domain, and a 200-residue-long C-terminal hydrophilic domain. The N- and the C-terminal hydrophilic domains extend into the mitochondrial matrix, and the central hydrophobic domain intercalates into the inner membrane. Equilibrium binding of [C-14]NADH and [C-14]NADPH was carried out to the purified transhydrogenase, transhydrogenase modified with N,N'-dicyclohexylcarbodiimide (DCCD) at the NADH-protectable Glu257, and to proteolytic fragments corresponding to dimers of the N-terminal and the C-terminal hydrophilic domains. The intact enzyme bound 1 mol of [C-14]NADH or [C-14] NADPH per dimer with K(d) values of 9.5 and 5.7 muM, respectively. The 90% DCCD-inhibited enzyme bound [C-14]NADPH with undiminished capacity and [C-14] NADH with 10% capacity as compared with unmodified enzyme. The K(d) values were unaltered. The N-terminal fragment bound [C-14]NADH at 0.76 mol/dimer with unaltered K(d) but did not bind [C-14]NADPH. The C-terminal fragment bound 0.32 mol of [C-14] NADPH/dimer with unaltered K(d) but did not bind [C-14] NADH. These results are consistent with our previous assignment of the NAD(H) and the NADP(H) binding sites to the N- and the C-terminal hydrophilic domains, respectively. The binding stoichiometries of 1 mol each of [C-14]NADH and [C-14]NADPH/dimeric transhydrogenase suggest half-of-the-sites reactivity, which is consistent with our previous findings that 100% inhibition by either p-[H-3]fluorosulfonylbenzoyl-5'-adenosine or [C-14]DCCD involved the incorporation of 1 mol of inhibitor/dimeric enzyme. We had shown earlier that N-(ethoxycarbonyl)2-ethoxy-1,2-dihydroquinoline (EEDQ) inhibits the transhydrogenase, apparently at the NAD binding site, but differently from DCCD. The enzyme was protected by 5'-AMP strongly against DCCD and weakly against EEDQ, whereas it was protected by NMNH strongly against EEDQ and not at all against DCCD. We have now determined the EEDQ binding sites to be Glu232 and Glu880. The different mononucleotide protections against DCCD and EEDQ suggest that the AMP moiety of NAD binds near Glu257 and its NMN portion near Glu232. They also suggest that the NMN moiety of NADP may bind near Glu880.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024887] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24887] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1992, EUR J BIOCHEM, V207, P733, DOI 10.1111/j.1432-1033.1992.tb17103.x; BLAZYK JF, 1975, FEBS LETT, V50, P227, DOI 10.1016/0014-5793(75)80494-7; CLARKE DM, 1985, EUR J BIOCHEM, V149, P517, DOI 10.1111/j.1432-1033.1985.tb08955.x; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P332, DOI 10.1016/0167-4838(92)90490-5; FISHER R. R., 1982, PYRIDINE NUCLEOTIDE, P279; HANSON RL, 1979, J BIOL CHEM, V254, P888; HATEFI Y, 1980, J BIOL CHEM, V255, P9526; HATEFI Y, 1992, MOL MECHANISMS BIOEN, P265; HOU C, 1990, BIOCHIM BIOPHYS ACTA, V1018, P61, DOI 10.1016/0005-2728(90)90110-P; HOWLETT GJ, 1978, ARCH BIOCHEM BIOPHYS, V190, P809, DOI 10.1016/0003-9861(78)90341-7; HU PS, 1992, BIOCHIM BIOPHYS ACTA, V1102, P19, DOI 10.1016/0167-4838(92)90494-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIKIND PK, 1985, ARCH BIOCHEM BIOPHYS, V240, P904, DOI 10.1016/0003-9861(85)90100-6; LEE CP, 1989, BIOCHIM BIOPHYS ACTA, V1000, P371, DOI 10.1016/S0006-3002(89)80032-0; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; OLAUSSON T, 1992, ACTA PHYSIOL SCAND, V146, P13; PENNINGTON RM, 1981, J BIOL CHEM, V256, P8963; PERSSON B, 1984, J BIOL CHEM, V259, P8626; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P6340, DOI 10.1021/bi00321a008; PHELPS DC, 1981, J BIOL CHEM, V256, P8217; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; PHELPS DC, 1985, BIOCHEMISTRY-US, V24, P3503, DOI 10.1021/bi00335a017; PHELPS DC, 1985, ARCH BIOCHEM BIOPHYS, V243, P298, DOI 10.1016/0003-9861(85)90799-4; RAFTER GW, 1957, METHOD ENZYMOL, V3, P887, DOI 10.1016/S0076-6879(57)03471-0; RYDSTROM J, 1977, BIOCHIM BIOPHYS ACTA, V463, P155, DOI 10.1016/0304-4173(77)90007-6; RYDSTROM J, 1987, PYRIDINE NUCLEOTID B, V2, P433; SEGEL IH, 1975, ENZYME KINETICS BEHA, P218; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P915; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P667; WANG TP, 1954, J BIOL CHEM, V211, P465; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P5728; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; YAMAGUCHI M, 1986, BIOCHEMISTRY-US, V25, P4864, DOI 10.1021/bi00365a021	37	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17871	17877						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8102370				2022-12-25	WOS:A1993LT74300037
J	CORNWELL, MM; SMITH, DE				CORNWELL, MM; SMITH, DE			A SIGNAL-TRANSDUCTION PATHWAY FOR ACTIVATION OF THE MDR1 PROMOTER INVOLVES THE PROTOONCOGENE C-RAF KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EGR-1 PROMOTER; V-RAF; RESISTANCE; GROWTH; EXPRESSION; CELLS; GENE; SITE	To investigate the regulation of expression of the human mdr1 gene, the response of the mdr1 promoter to signals involved in cell proliferation was examined. The activity of the mdr1 promoter was measured in transiently transfected NIH 3T3 cells, which were stimulated to enter the cell cycle by addition of serum, platelet-derived growth factor, or transforming growth factor alpha. Addition of serum to quiescent NIH 3T3 cells resulted in a 6-8-fold activation of mdr1 promoter activity, which peaked at 10 h, just prior to S-phase. Treatment of serum-starved cells with the serum mitogens platelet-derived growth factor and transforming growth factor alpha also activated the mdr1 promoter. To define components of the signal cascade resulting in mdr1 promoter activation, the role of c-Raf kinase, a serine/threonine kinase important in mitogen-activated signal transduction, was examined. We measured the effects of a constitutively activated Raf kinase, v-raf, and a dominant negative Raf mutant, c-Raf-C4, on mdr1 promoter activity in NIH 3T3 and HepG2 cells. In serum-starved NIH 3T3 cells, v-raf increased mdr1 promoter activity approximately 10-fold compared to a v-raf frame-shift control. Raf responsiveness of the mdr1 promoter was localized to sequences between -69 and -41, relative to the initiation site. Serum stimulation of the mdr1 promoter was blocked by co-transfection of NIH 3T3 cells with the dominant negative Raf mutant c-Raf-C4. In the human hepatoma cell line HepG2, which has high endogenous Raf kinase activity (Bruder, J. T., Heidecker, G., and Rapp, U. R. (1992) Genes & Dev. 6, 545-556), co-transfection with c-Raf-C4 decreased mdr1 promoter activity 20-fold. Taken together, these data suggest that the mdr1 gene is transcriptionally regulated by normal cellular signaling events involving activation of c-Raf kinase.			CORNWELL, MM (corresponding author), FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA.				NCI NIH HHS [CA51728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051728, R01CA051728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHIN KV, 1993, ADV CANCER RES, V60, P157; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MILTENBERGER R, 1993, IN PRESS J BIOL CHEM, V268; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1991, ONCOGENE, V6, P995; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RIM M, 1992, ONCOGENE, V7, P2065; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; RONINSON IB, 1992, BIOCHEM PHARMACOL, V43, P95, DOI 10.1016/0006-2952(92)90666-7	23	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15347	15350						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101839				2022-12-25	WOS:A1993LN30500007
J	HUANG, HM; GIBSON, GE				HUANG, HM; GIBSON, GE			ALTERED BETA-ADRENERGIC RECEPTOR-STIMULATED CAMP FORMATION IN CULTURED SKIN FIBROBLASTS FROM ALZHEIMER DONORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYTOSOLIC FREE CALCIUM; ADENYLATE-CYCLASE; MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTOR; DISEASE FIBROBLASTS; DOWN-REGULATION; NERVOUS-SYSTEM; PHOSPHORYLATION; BINDING	An alteration in signal transduction systems in Alzheimer's disease would likely be of pathophysiological significance, because these steps are critical to normal brain function. Since dynamic processes are difficult to study in autopsied brain, the current studies utilized cultured skin fibroblasts. The beta-adrenergic-stimulated increase in cAMP was reduced approximately 80% in fibroblasts from Alzheimer's disease compared with age-matched controls. The deficit in Alzheimer fibroblasts in response to various adrenergic agonists paralleled their beta-adrenergic potency, and enhancement of cAMP accumulation by a non-adrenergic agonist, such as prostaglandin E1, was similar in Alzheimer and control fibroblasts. Diminished adenylate cyclase activity did not underlie these abnormalities, since direct stimulation of adenylate cyclase by forskolin elevated cAMP production equally in Alzheimer and control fibroblasts. Cholera toxin equally stimulated cAMP formation in Alzheimer and control fibroblasts. Moreover, cholera toxin partially reduced isoproterenol-induced cAMP deficit in Alzheimer fibroblasts. Pertussis toxin, on the other hand, did not alter the Alzheimer deficits. The results suggest either that the coupling of the GTP-binding protein(s) to the beta-adrenergic receptor is abnormal or that the sensitivity of receptor is altered with Alzheimer's disease. Further, any hypothesis about Alzheimer's disease must explain why a reduced beta-adrenergic-stimulated cAMP formation persists in tissue culture.			HUANG, HM (corresponding author), CORNELL UNIV,COLL MED,BURKE MED RES INST,WHITE PLAINS,NY 10605, USA.				NIA NIH HHS [AG09014, AG03853] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG003853, R35AG009014] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; BAUZBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BLASS JP, 1991, REV NEUROL, V147, P513; BLASS JP, 1988, REV NEUROL, V144, P543; BORDEN LA, 1992, NEUROBIOL AGING, V13, P33, DOI 10.1016/0197-4580(92)90005-I; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEDID M, 1989, J IMMUNOL, V142, P4301; CLARK EA, 1991, LAB INVEST, V64, P35; COWBURN R F, 1992, Neurobiology of Aging, V13, pS60; Cristofalo VJ, 1980, J TISSUE CULTURE MET, V6, P117; DANIELSSON E, 1988, NEUROBIOL AGING, V9, P153, DOI 10.1016/S0197-4580(88)80045-9; DEKEYSER J, 1990, ARCH NEUROL-CHICAGO, V47, P761, DOI 10.1001/archneur.1990.00530070055011; DESHMUKH VD, 1990, MED HYPOTHESES, V32, P293, DOI 10.1016/0306-9877(90)90109-R; EBSTEIN RP, 1984, LIFE SCI, V34, P2239, DOI 10.1016/0024-3205(84)90211-X; FISHMAN PH, 1987, BIOCHEM BIOPH RES CO, V144, P620, DOI 10.1016/S0006-291X(87)80011-6; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GANDY SE, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P155; GIBSON G, 1987, BANBURY REPORTS, V27, P85; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HARRISON PJ, 1991, MOL BRAIN RES, V10, P71, DOI 10.1016/0169-328X(91)90058-6; HORSBURGH K, 1991, J NEUROCHEM, V56, P1121, DOI 10.1111/j.1471-4159.1991.tb11401.x; HUANG H-M, 1991, Journal of Cell Biology, V115, p16A; HUANG HM, 1991, NEUROBIOL AGING, V12, P469, DOI 10.1016/0197-4580(91)90075-U; HUANG HM, 1992, T AM SOC NEUROCHEM, V23, P105; KALARIA RN, 1989, NEUROSCI LETT, V106, P233, DOI 10.1016/0304-3940(89)90231-0; KALARIA RN, 1989, J NEUROCHEM, V53, P1772, DOI 10.1111/j.1471-4159.1989.tb09242.x; KOSIK KS, 1989, J GERONTOL, V44, P855; LI JC, 1985, BIOCHEM BIOPH RES CO, V129, P733, DOI 10.1016/0006-291X(85)91953-9; LIEBMANN C, 1991, PEPTIDES, V12, P265, DOI 10.1016/0196-9781(91)90009-E; Maguire M E, 1977, Adv Cyclic Nucleotide Res, V8, P1; MALOW BA, 1989, ARCH NEUROL-CHICAGO, V46, P1201, DOI 10.1001/archneur.1989.00520470057027; MASLIAH E, 1991, J NEUROSCI, V11, P2759; MCCOY K R, 1991, Journal of Cell Biology, V115, p8A; MCDONALD WM, 1991, PSYCHIAT CLIN N AM, V14, P421; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NAKADA MT, 1990, J PHARMACOL EXP THER, V253, P221; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PAPASOZOMENOS SC, 1991, P NATL ACAD SCI USA, V88, P4543, DOI 10.1073/pnas.88.10.4543; PETERSON C, 1986, P NATL ACAD SCI USA, V83, P7999, DOI 10.1073/pnas.83.20.7999; PETERSON C, 1986, P NATL ACAD SCI USA, V83, P2758, DOI 10.1073/pnas.83.8.2758; PETERSON C, 1985, NEW ENGL J MED, V312, P1063; PETERSON C, 1988, NEUROBIOL AGING, V9, P261, DOI 10.1016/S0197-4580(88)80063-0; REINIKAINEN KJ, 1990, J NEUROSCI RES, V27, P576, DOI 10.1002/jnr.490270419; ROPPER AH, 1980, NEUROLOGY, V30, P639, DOI 10.1212/WNL.30.6.639; Saitoh T, 1990, Adv Exp Med Biol, V265, P301; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SHAPIRO IP, 1991, J NEUROCHEM, V56, P1154, DOI 10.1111/j.1471-4159.1991.tb11405.x; SHEU KFR, 1985, ANN NEUROL, V17, P444; SHIMOHAMA S, 1987, J NEUROCHEM, V48, P1215, DOI 10.1111/j.1471-4159.1987.tb05649.x; SIMS NR, 1987, ANN NEUROL, V21, P451, DOI 10.1002/ana.410210507; SISKEN J E, 1989, Journal of Cell Biology, V109, p301A; SMITH CJ, 1987, NEUROSCI LETT, V82, P227, DOI 10.1016/0304-3940(87)90135-2; VANHUYNH T, 1989, ARCH NEUROL-CHICAGO, V46, P1195, DOI 10.1001/archneur.1989.00520470049026; VOLICER L, 1985, NEUROBIOL AGING, V6, P35, DOI 10.1016/0197-4580(85)90069-7; WARPMAN U, 1992, Neurobiology of Aging, V13, pS61, DOI 10.1016/0197-4580(92)90368-8; WEINER N, 1985, PHARMACOL BASIS THER, P145	61	68	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14616	14621						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8100816				2022-12-25	WOS:A1993LL75900016
J	ETIEMBLE, J; DEGOTT, C; RENARD, CA; FOUREL, G; SHAMOON, B; VITVITSKITREPO, L; HSU, TY; TIOLLAIS, P; BABINET, C; BUENDIA, MA				ETIEMBLE, J; DEGOTT, C; RENARD, CA; FOUREL, G; SHAMOON, B; VITVITSKITREPO, L; HSU, TY; TIOLLAIS, P; BABINET, C; BUENDIA, MA			LIVER-SPECIFIC EXPRESSION AND HIGH ONCOGENIC EFFICIENCY OF A C-MYC TRANSGENE ACTIVATED BY WOODCHUCK HEPATITIS-VIRUS INSERTION	ONCOGENE			English	Article							SURFACE-ANTIGEN GENE; B VIRUS; HEPATOCELLULAR-CARCINOMA; N-MYC; INFECTED WOODCHUCKS; RAT-LIVER; MICE; ENHANCER; TUMORS; DNA	The high oncogenic efficiency of woodchuck hepatitis virus (WHV) has been correlated with the ability of this virus to provoke insertional activation of mye family genes. To assess the impact of viral integration on liver cell transformation, we have generated transgenic mice carrying the mutated c-mye gene and adjacent viral DNA from a woodchuck tumor, in original configuration. Virtually all mice from two different strains developed hepatocellular carcinoma with a mean latency period of 8-12 months. The c-mye transgene was expressed transiently in neonatal livers, and re-expressed at preneoplastic and neoplastic stages in adult livers. Woodchuck c-mye mRNA driven by the normal P1 and P2 promoters and WHV-specific transcripts encoding viral surface antigens were produced in a strictly co-regulated fashion during development and tumorigenesis, indicating a predominant regulatory influence of the viral enhancer. Furthermore, the activity of the viral enhancer in response to various biological stimuli was apparently modulated by glucose uptake and glucogon/insulin balance in differentiated hepatocytes. In this model, a viral integration event selected from a naturally occurring tumor proved to be determinant for induction of hepatocarcinogenesis, although enforced, liver-specific expression of c-mye was limited to a particular developmental stage.	INST PASTEUR, INSERM, U163, UNITE RECOMBINAISON & EXPRESS GENET, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE; HOP BEAUJON, ANATOMOPATHOL LAB, CLICHY, FRANCE; HOP ST LOUIS, UNITE RECOMBINAISON GENET, CNRS, UPR 41, PARIS, FRANCE; INSERM, U271, UNITE RECH HEPATITES, LYON, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)								ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; BABINET C, 1985, SCIENCE, V230, P1160, DOI 10.1126/science.3865370; BEASLEY RP, 1981, LANCET, V2, P1129; BULLA GA, 1988, J VIROL, V62, P1437, DOI 10.1128/JVI.62.4.1437-1441.1988; CARTIER N, 1992, ONCOGENE, V7, P1413; CHANDAR N, 1989, P NATL ACAD SCI USA, V86, P2703, DOI 10.1073/pnas.86.8.2703; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DELOIA JA, 1989, J VIROL, V63, P4069, DOI 10.1128/JVI.63.9.4069-4073.1989; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FARZA H, 1988, J VIROL, V62, P4144, DOI 10.1128/JVI.62.11.4144-4152.1988; FARZA H, 1987, P NATL ACAD SCI USA, V84, P1187, DOI 10.1073/pnas.84.5.1187; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GARCIARUIZ JP, 1978, P NATL ACAD SCI USA, V75, P4189; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KORBA BE, 1987, J VIROL, V61, P1318, DOI 10.1128/JVI.61.5.1318-1324.1987; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; MAKINO R, 1984, BIOCHEM BIOPH RES CO, V119, P1096, DOI 10.1016/0006-291X(84)90887-8; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MCGRANE MM, 1992, TRENDS BIOCHEM SCI, V17, P40, DOI 10.1016/0968-0004(92)90426-A; MORIYAMA T, 1990, SCIENCE, V248, P361, DOI 10.1126/science.1691527; MOROY T, 1985, EMBO J, V4, P1507, DOI 10.1002/j.1460-2075.1985.tb03810.x; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MURAKAMI H, 1993, CANCER RES, V53, P1719; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; RUTHER U, 1993, ONCOGENE, V8, P87; SANDGREN EP, 1989, ONCOGENE, V4, P715; SEEGER C, 1991, J VIROL, V65, P1673, DOI 10.1128/JVI.65.4.1673-1679.1991; SHAMOON BM, 1991, J GEN VIROL, V72, P421, DOI 10.1099/0022-1317-72-2-421; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; SZUMUNESS W, 1978, PROG MED VIROL, V24, P40; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANNICE JL, 1988, J VIROL, V62, P1305, DOI 10.1128/JVI.62.4.1305-1313.1988; VITVITSKI L, 1988, VIRAL HEPATITIS LIVE, P341; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545	53	54	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					727	737						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108115				2022-12-25	WOS:A1994MW55100007
J	COLAMONICI, OR; DOMANSKI, P; KROLEWSKI, JJ; FU, XY; REICH, NC; PFEFFER, LM; SWEET, ME; PLATANIAS, LC				COLAMONICI, OR; DOMANSKI, P; KROLEWSKI, JJ; FU, XY; REICH, NC; PFEFFER, LM; SWEET, ME; PLATANIAS, LC			INTERFERON-ALPHA (IFN-ALPHA) SIGNALING IN CELLS EXPRESSING THE VARIANT FORM OF THE TYPE-I IFN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; ESTABLISHMENT; DOMAINS; SYSTEM; GENES	Two different type I interferon receptors (IFN-R) have been described: the normal and the variant receptors. The a subunit of the Type I IFN-R has a molecular mass of 110 kDa in cells expressing normal and variant receptors. The beta subunit has a molecular mass of approximately 100 kDa in cells that express normal receptors and 55 kDa in cells expressing the variant form of the receptor. The IFN alpha-resistant U-937 cell line expresses variant receptors and fails to down-regulate and phosphorylate the alpha subunit on tyrosine residues. We report that two other myelomonocytic cell lines, YK-M2 and ML-2, also expressing the variant form of the receptor, fail to down-regulate and phosphorylate the a subunit on tyrosine residues. However, YK-M2 and ML-2 cells are sensitive to the antiproliferative and antiviral effects of IFN alpha 2, indicating that phosphorylation of the a subunit is not necessary to elicit an IFN alpha response and that expression of variant receptors is not a source of IFN alpha resistance. We also determined if other proteins involved in the IFN alpha signal transduction pathway had a different phosphorylation pattern. Treatment of cells expressing variant receptors induced tyrosine phosphorylation of the p135(tyk2) tyrosine kinase, and the three interferon-stimulated gene factor 3 alpha (ISGFS3 alpha) polypeptides (p113, p91, and p84), albeit at lower levels. These results indicate that cells expressing either form of the Type I IFN-R phosphorylate a similar set of proteins, with the exception of the alpha subunit.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032; MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; LOYOLA UNIV,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; EDWARD HINES JR VET ADM MED CTR,MAYWOOD,IL 60153	Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	COLAMONICI, OR (corresponding author), UNIV TENNESSEE,DEPT PATHOL,800 MADISON AVE,MEMPHIS,TN 38163, USA.			Pfeffer, Lawrence/0000-0003-2809-1234	NIGMS NIH HHS [GM36716] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036716] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUET M, 1980, NATURE, V284, P459, DOI 10.1038/284459a0; BENOIT P, 1993, J IMMUNOL, V150, P707; BERNARDS A, 1991, ONCOGENE, V6, P1185; BRANCA AA, 1988, IN VITRO CELL DEV B, V24, P155; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GAZDAR AF, 1986, BLOOD, V67, P1542; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; KRAFT IF, 1990, ONCOGENE, V5, P1329; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEVY DE, 1989, GENE DEV, V3, P1203; OHNO H, 1986, CANCER RES, V46, P6400; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1991, PHARMACOL THERAPEUT, V52, P149, DOI 10.1016/0163-7258(91)90005-7; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1992, J BIOL CHEM, V267, P5017; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	30	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5660	5665						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119902				2022-12-25	WOS:A1994MY84000030
J	MITSUI, T; KITAZAWA, T; IKEBE, M				MITSUI, T; KITAZAWA, T; IKEBE, M			CORRELATION BETWEEN HIGH-TEMPERATURE DEPENDENCE OF SMOOTH-MUSCLE MYOSIN LIGHT-CHAIN PHOSPHATASE-ACTIVITY AND MUSCLE-RELAXATION RATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; SKELETAL-MUSCLE; KINASE; PHOSPHORYLATION; PURIFICATION; CONTRACTION	Q(10) values of the protein phosphatases that can dephosphorylate the regulatory light chain of smooth muscle myosin were determined. Six phosphatases were examined, i.e. skeletal muscle protein phosphatase 1c; protein phosphatase 2Ac; smooth muscle phosphatases (SMP) I, II, and IV; and myosin-associated protein phosphatase (MAP phosphatase). Among them, SMP-IV and MAP phosphatase, which can dephosphorylate intact smooth muscle myosin, showed extremely high Q(10) values (5.3 and 5.2, respectively). On the other hand, the Q(10) values of other tested phosphatases were within the range of the normal enzyme reaction (Q(10) = 2.0). The rate of dephosphorylation of the myosin light chain in alpha-toxin-skinned strips was measured at different temperatures. The results provided a Q(10) of 5.1, which was quite similar to those values obtained for SMP-IV and MAP phosphatase. These results suggest that the physiological myosin light chain phosphatases are SMP-IV and/or MAP phosphatase, i.e. type 1 protein phosphatases. The temperature dependence of maximum force, the steady-state extent of myosin light chain phosphorylation, and the relaxation rate of alpha-toxin-permeabilized rabbit postal vein smooth muscle strips were measured. Both maximum force and the extent of myosin light chain phosphorylation were significantly higher at lower temperature (15 degrees C) than at higher temperature (25 degrees C) under all pCa conditions tested, i.e. >8, 6.3, and 5. The temperature dependence of the relaxation rate was much steeper (decreased 4 times by lowering the temperature from 25 to 15 degrees C) than that of the initial rate of increase in force development (decreased 1.4 times by lowering the temperature from 25 to 15 degrees C). These results are consistent with the and to values of myosin light chain phosphatases (Q(10) = 5) and myosin light chain kinase (Q(10) = 1.7) and further show that the smooth muscle type 1 phosphatases are responsible for the dephosphorylation of smooth muscle myosin in situ.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; UNIV VIRGINIA, SCH MED, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA	Case Western Reserve University; University of Virginia			Mitsui, Toshiaki/N-9773-2017	Mitsui, Toshiaki/0000-0002-9165-8830	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, R01AR038888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37117] Funding Source: Medline; NIAMS NIH HHS [AR38888, AR41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CSABINA S, 1986, BIOCHIM BIOPHYS ACTA, V871, P311, DOI 10.1016/0167-4838(86)90213-X; DRISKA SP, 1981, AM J PHYSIOL, V240, pC222, DOI 10.1152/ajpcell.1981.240.5.C222; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; IKEBE M, 1987, J BIOL CHEM, V262, P9569; ISHIHARA H, 1989, BIOPHYS J, V55, P475; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KLEMT P, 1978, PFLUG ARCH EUR J PHY, V378, P31, DOI 10.1007/BF00581955; MIRSUI T, 1992, J BIOL CHEM, V267, P16727; PATO MD, 1985, J BIOL CHEM, V260, P2359; PATO MD, 1983, EUR J BIOCHEM, V132, P283, DOI 10.1111/j.1432-1033.1983.tb07360.x; PATO MD, 1983, J BIOL CHEM, V258, P7047; PATO MD, 1983, J BIOL CHEM, V258, P7055; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; Smith R. M., 1977, CRITICAL STABILITY C, V1-4; TAKAI A, 1989, BIOCHEM J, V262, P617, DOI 10.1042/bj2620617; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; WALSH MP, 1983, METHOD ENZYMOL, V99, P279	25	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5842	5848						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119926				2022-12-25	WOS:A1994MY84000057
J	STURGES, MR; PECK, LJ				STURGES, MR; PECK, LJ			CALCIUM-DEPENDENT INACTIVATION OF RNA-POLYMERASE-III TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR DEVELOPMENTAL TRANSITION; ALU REPEATED SEQUENCES; EARLY XENOPUS-EMBRYOS; SACCHAROMYCES-CEREVISIAE; INVITRO TRANSCRIPTION; MULTIPLE FACTORS; GENE-PRODUCT; ACTIVE FORM; CALPAIN; ADENOVIRUS	Extracts from whole oocytes of Xenopus laevis are widely used as an efficient in vitro system for the transcription of cloned genes by RNA polymerase m. We have found that these extracts no longer support RNA polymerase III transcription in response to a brief incubation in the presence of Ca2+. However, when transcription complexes were first formed on the genes, a subsequent incubation in the presence of Ca2+ had little effect. Fractionation of extracts was used to show that transcription factors (TF) IIIC and, to a lesser extent, TFIIIB, but not RNA polymerase III, were targets of the Ca2+ dependent inactivation process. An additional component (not present in fractionated TFIIIC or TFIIIB) was required far the Ca2+-dependent destruction of transcription factor activity. The Ca2+-dependent inactivation process was blocked by protease inhibitors that inhibit known Ca2+-dependent proteases called calpains. These results suggest that TFIIIC and TFIIIB are inactivated by an endogenous calpain. The common use of Ca2+ as a second messenger and the widespread distribution of calpains suggest that the proteolytic degradation of transcription factors may be a general mechanism for the regulation of gene expression.	UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz					NIGMS NIH HHS [GM46232] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046232] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; CLARK ME, 1991, EMBO J, V10, P2941, DOI 10.1002/j.1460-2075.1991.tb07844.x; CLARK ME, 1990, MOL CELL BIOL, V10, P5106, DOI 10.1128/MCB.10.10.5106; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DATTA S, 1991, J VIROL, V65, P5297, DOI 10.1128/JVI.65.10.5297-5304.1991; DIECI G, 1993, J BIOL CHEM, V268, P11199; FOLK WR, 1983, CELL, V33, P585, DOI 10.1016/0092-8674(83)90439-7; FRADKIN LG, 1987, MOL CELL BIOL, V7, P3880, DOI 10.1128/MCB.7.11.3880; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GAYNOR RB, 1985, SCIENCE, V230, P447, DOI 10.1126/science.2996135; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, TRANSCRIPTIONAL REGU, V1, P247; GIARDINA CA, 1990, J BIOL CHEM, V265, P9121; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; JAMES CBL, 1992, J GEN VIROL, V73, P3133, DOI 10.1099/0022-1317-73-12-3133; JANG KL, 1992, BIOCHEM J, V284, P667, DOI 10.1042/bj2840667; JANG KL, 1992, J ACQ IMMUN DEF SYND, V5, P1142; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; LUND E, 1992, GENE DEV, V6, P1097, DOI 10.1101/gad.6.6.1097; MAKI M, 1989, J BIOL CHEM, V264, P18866; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; PARSONS MC, 1992, J BIOL CHEM, V267, P2894; PECK LJ, 1987, MOL CELL BIOL, V7, P3503, DOI 10.1128/MCB.7.10.3503; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROEDER RG, 1974, J BIOL CHEM, V249, P241; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SEIDEL CW, 1992, J MOL BIOL, V227, P1009, DOI 10.1016/0022-2836(92)90517-N; SHASTRY BS, 1982, J BIOL CHEM, V257, P2979; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; WALDSCHMIDT R, 1992, J BIOL CHEM, V267, P16359; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726; YOUNG LS, 1991, SCIENCE, V252, P542, DOI 10.1126/science.1708526	52	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5712	5719						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119909				2022-12-25	WOS:A1994MY84000038
J	ZHU, XY; SUEN, KL; BARBACID, M; BOLEN, JB; FARGNOLI, J				ZHU, XY; SUEN, KL; BARBACID, M; BOLEN, JB; FARGNOLI, J			INTERLEUKIN-2-INDUCED TYROSINE PHOSPHORYLATION OF SHC PROTEINS CORRELATES WITH FACTOR-DEPENDENT T-CELL PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-CHAIN; HUMAN IL-2 RECEPTOR; COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; LYMPHOCYTES-T; GROWTH-FACTOR; GAMMA-CHAIN; KINASES; ACTIVATION; SRC	Interleukin-2 (IL-2) is a growth factor involved in the clonal expansion of antigen-activated T lymphocytes. Interaction of IL-2 with its receptor triggers tyrosine phosphorylation of a series of proteins and results in the activation of p21(ras). We report here that Shc, an SH2-containing adaptor protein, is tyrosine-phosphorylated following IL-2 stimulation, IL-2-induced tyrosine phosphorylation of She was detectable within seconds following IL-2 addition, reaching its highest level by 15 min. Tyrosine phosphorylation of Shc was induced in multiple IL-2-dependent T cell lines and was found to correlate with IL-2-dependent cell proliferation. Tyrosine-phosphorylated She was found to be capable of associating with the SE2 domain of Grb2 following IL-2 stimulation. These results indicate that tyrosine phosphorylation of She and its association with Grb2 may be important events in IL-2-initiated signal transduction events in T cells.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FUNG MR, 1991, J IMMUNOL, V147, P1253; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARCIA GG, 1992, BIOCHEM J, V285, P851, DOI 10.1042/bj2850851; GILLIS S, 1978, J IMMUNOL, V120, P2027; GRAVES JD, 1992, J IMMUNOL, V148, P2417; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IZQUIERDO M, 1993, EUR J IMMUNOL, V23, P131, DOI 10.1002/eji.1830230121; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLS GB, 1992, INT IMMUNOL, V4, P1233, DOI 10.1093/intimm/4.11.1233; MINAMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1114, P163, DOI 10.1016/0304-419X(92)90013-O; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHMANDT R, 1992, BAILLIERE CLIN HAEM, V5, P551, DOI 10.1016/S0950-3536(11)80007-7; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; SILICIANO J, 1992, P NATL ACAD SCI USA, V89, P1114; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681	45	46	46	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5518	5522						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119884				2022-12-25	WOS:A1994MY84000010
J	JOHNSON, AW; KOLODNER, RD				JOHNSON, AW; KOLODNER, RD			CHARACTERIZATION OF THE INTERACTION OF SACCHAROMYCES-CEREVISIAE STRAND EXCHANGE PROTEIN-1 WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA-PROTEIN; ESCHERICHIA-COLI; BINDING; RECOMBINATION; PURIFICATION; MOLECULES; SYNAPSIS; JOINTS	We have analyzed in greater detail the interaction of strand exchange protein 1 (Sep1) from Saccharomyces cerevisiae with DNA. The binding site size of Sep1 on single-stranded DNA (ssDNA) was determined to be 70 nucleotides per protein monomer using a fluorescence assay and 100 nucleotides using an exonuclease titration technique. The amount of Sep1 required for maximum aggregation of ssDNA was the amount needed to saturate the DNA. When double-stranded DNA (dsDNA) and ssDNA were both present, the duplex DNA was efficiently aggregated only at protein concentrations above that required for saturation of ssDNA. Strand exchange reactions with blunt-ended linear dsDNA and homologous ssDNA substrates required saturation of the ssDNA with Sep1 since free Sep1 is needed for exonuclease activity to initiate pairing with the dsDNA substrate. Preincubation of Sep1 with resected duplex DNA before adding ssDNA allowed joint molecule formation to occur at protein concentrations at least 10-fold below that required for saturation of the ssDNA. However, preincubation of Sep1 with ssDNA before the addition of resected duplex DNA required saturating amounts of Sep1 for joint molecule formation to occur. These results suggest that pairing requires Sep1 on both the ssDNA and the resected ends of the dsDNA.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Johnson, Arlen/0000-0002-4742-085X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029383, F32GM013594] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13594, GM29383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; HALL SD, 1993, IN PRESS P NATL ACAD; HEYER WD, 1988, J BIOL CHEM, V263, P15189; JOHNSON AW, 1994, J BIOL CHEM, V269, P3664; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1981, ENZYMES, P373; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7911, DOI 10.1021/bi00486a019; RADDING CM, 1991, J BIOL CHEM, V266, P5355; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; RIDDLES PW, 1985, J BIOL CHEM, V260, P165; ROSELLI W, 1990, J MOL BIOL, V216, P335; SANDER M, 1993, J BIOL CHEM, V268, P2075; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STEENSGAARD J, 1992, PREPARATIVE CENTRIFU, P208; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; [No title captured]	32	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3673	3681						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106412				2022-12-25	WOS:A1994MV63100080
J	MAHRENHOLZ, AM; YEH, CH; SHIVELY, JE; HEFTA, SA				MAHRENHOLZ, AM; YEH, CH; SHIVELY, JE; HEFTA, SA			MICROSEQUENCE AND MASS-SPECTRAL ANALYSIS OF NONSPECIFIC CROSS-REACTING ANTIGEN-160, A CD15-POSITIVE NEUTROPHIL MEMBRANE GLYCOPROTEIN - DEMONSTRATION OF IDENTITY WITH BILIARY GLYCOPROTEIN-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARCINOEMBRYONIC ANTIGEN; MONOCLONAL-ANTIBODIES; CROSSREACTING ANTIGEN; ADHESION MOLECULES; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; GENE FAMILY; CDNA CLONE; CEA; PROTEINS	Sequence information was obtained from low picomole amounts of nonspecific cross-reacting antigen (NCA) 160 (M(r) 160,000), a granulocyte membrane glycoprotein. Following affinity purification and SDS-polyacrylamide gel electrophoresis, the protein was electrotransferred to nitrocellulose, digested with trypsin, and the peptides were isolated using capillary reversed-phase liquid chromatography. Analysis of these peptides by Edman microsequencing and mass spectrometry established that NCA-160 was identical to biliary glycoprotein I, a protein that we previously cloned from a human colon library (1). NCA-160 from human granulocytes is a CD15-positive glycoprotein belonging to the carcinoembryonic antigen family and possesses putative transmembrane and cytoplasmic domains. Previous efforts to characterize this antigen at the protein level were hampered by a blocked NH2 terminus. In this study, we confirmed 20% of the deduced amino acid sequence starting with approximately 50 pmol of sample. Carbohydrate structural data is also presented on a single N-linked oligosaccharide moiety located in the A' domain. The capillary high performance liquid chromatography techniques used here, as well as mass spectrometry, were essential for high sensitivity analysis of the blotted, digested glycoprotein.	CITY HOPE NATL MED CTR, BECKMAN RES INT, DIV IMMUNOL, 1450 E DUARTE RD, DUARTE, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope					NATIONAL CANCER INSTITUTE [P30CA033572, R01CA037808] Funding Source: NIH RePORTER; NCI NIH HHS [CA37808, CA33572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARAKAWA F, 1990, BIOCHEM BIOPH RES CO, V166, P1063, DOI 10.1016/0006-291X(90)90975-S; AUDETTE M, 1987, MOL IMMUNOL, V24, P1177, DOI 10.1016/0161-5890(87)90164-7; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BERLING B, 1990, CANCER RES, V50, P6534; BUCHEGGER F, 1984, INT J CANCER, V33, P643, DOI 10.1002/ijc.2910330515; BURLINGAME AL, 1992, ANAL CHEM, V64, pR467, DOI 10.1021/ac00036a025; BURTIN P, 1975, NATURE, V255, P714, DOI 10.1038/255714a0; DAVIS MT, 1992, PROTEIN SCI, V1, P935, DOI 10.1002/pro.5560010712; FORSYTH KD, 1989, EUR J IMMUNOL, V19, P1331, DOI 10.1002/eji.1830190727; HAWKE DH, 1985, ANAL BIOCHEM, V147, P315, DOI 10.1016/0003-2697(85)90278-7; HEFTA SA, 1990, J BIOL CHEM, V265, P8618; HINODA Y, 1989, P NATL ACAD SCI USA, V86, P1668; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; KUROKI M, 1989, INT J CANCER, V44, P208, DOI 10.1002/ijc.2910440204; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUSCH HG, 1990, FEBS LETT, V261, P405, DOI 10.1016/0014-5793(90)80603-G; MELNICK DA, 1985, J IMMUNOL, V134, P3346; NEUMAIER M, 1985, J IMMUNOL, V135, P3604; NEUMAIER M, 1988, J BIOL CHEM, V263, P3202; SAUTER SL, 1991, INFECT IMMUN, V59, P2485, DOI 10.1128/IAI.59.7.2485-2493.1991; SKUBITZ KM, 1987, J IMMUNOL, V139, P1631; STOCKS SC, 1990, BIOCHEM J, V268, P275, DOI 10.1042/bj2680275; SVENBERG T, 1976, INT J CANCER, V17, P588, DOI 10.1002/ijc.2910170506; von Kleist S, 1972, Proc Natl Acad Sci U S A, V69, P2492; WATT SM, 1991, BLOOD, V78, P63; WEBB JW, 1988, ANAL BIOCHEM, V169, P337, DOI 10.1016/0003-2697(88)90293-X; XU QY, 1988, ANAL BIOCHEM, V170, P19, DOI 10.1016/0003-2697(88)90084-X	28	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13015	13018						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8099907				2022-12-25	WOS:A1993LH55300002
J	LIEBERHERR, M; GROSSE, B				LIEBERHERR, M; GROSSE, B			ANDROGENS INCREASE INTRACELLULAR CALCIUM-CONCENTRATION AND INOSITOL 1,4,5-TRISPHOSPHATE AND DIACYLGLYCEROL FORMATION VIA A PERTUSSIS-TOXIN-SENSITIVE G-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE CA-2+ CONCENTRATIONS; CYTOPLASMIC FREE CA-2+; HORMONE-INDUCED SPIKE; C-DEPENDENT PROCESSES; SIGNAL TRANSDUCTION; TUMOR PROMOTER; CELLS; PHOSPHATES; BONE; PROGESTERONE	Bone is a target tissue of androgens, but the mechanisms by which they act on bone are still unclear. This study examines the early (5-60 s) effects of 1 pM to 1 mu M testosterone on cytosolic free Ca2+ concentration ([Ca2+](i)) and inositol 1,4,5-trisphosphate (InsP(3)) and diacylglycerol (DAG) formation in confluent male rat osteoblasts. 10 pM to 10 nM testosterone increased [Ca2+](i) within 5 s via Ca2+ influx as shown by the effects of EGTA and the Ca2+ channel blockers nifedipine and verapamil and via Ca2+ mobilization from the endoplasmic reticulum as shown by the effects of thapsigargin and neomycin. 10 pM to 10 nM testosterone increased InsP(3) and DAG formation within 10 s. Testosterone immobilized on bovine serum albumin (testosterone (O-carboxymethyl)oxime/bovine serum albumin) and its derivative, (O-carboxymethyl)oxime, rapidly increased [Ca2+](i) and InsP(3) and DAG formation and were full agonists, although they were less potent than the free steroid. Cyproterone acetate, a nuclear antagonist, did not block the increase in [Ca2+](i) and InsP(3) and DAG formation induced by testosterone. Finally, neomycin and pertussis toxin totally abolished the effects of testosterone on InsP(3) and DAG. These results suggest that male rat osteoblasts bear nongenomic unconventional cell-surface receptors for testosterone that belong to the class of the membrane receptors coupled to a phospholipase C via a pertussis toxin-sensitive G-protein.	UNIV PARIS 05, CNRS, URA 583, F-75015 PARIS, FRANCE; GRP HOSP NECKER ENFANTS MALADES, F-75015 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite								ALBERT PR, 1984, J BIOL CHEM, V259, P5350; ALBERT PR, 1984, J BIOL CHEM, V259, P5827; BARAN DT, 1978, CALC TISS RES, V26, P103, DOI 10.1007/BF02013243; BATRA S, 1987, BRIT J PHARMACOL, V92, P389, DOI 10.1111/j.1476-5381.1987.tb11335.x; BAULIEU EE, 1978, NATURE, V275, P593, DOI 10.1038/275593a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHESNOYMARCHAIS D, 1988, J PHYSIOL-LONDON, V398, P291, DOI 10.1113/jphysiol.1988.sp017043; COLVARD DS, 1989, P NATL ACAD SCI USA, V86, P854, DOI 10.1073/pnas.86.3.854; CRILLY RG, 1981, CLIN ENDOCRINOL META, V10, P115, DOI 10.1016/S0300-595X(81)80041-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JOSEPH SK, 1989, ARCH BIOCHEM BIOPHYS, V273, P1, DOI 10.1016/0003-9861(89)90156-2; KERRIGAN JR, 1992, ENDOCR REV, V13, P281, DOI 10.1210/er.13.2.281; KORTE K, 1982, J CHROMATOGR, V232, P47, DOI 10.1016/S0378-4347(00)86006-5; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; PRENTKI M, 1986, FEBS LETT, V197, P285, DOI 10.1016/0014-5793(86)80343-X; SADLER SE, 1982, P NATL ACAD SCI USA, V77, P1534; SANCHEZBUENO A, 1991, BIOCHEM J, V280, P273, DOI 10.1042/bj2800273; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; STEINSAPIR J, 1991, BIOCHEM BIOPH RES CO, V179, P90, DOI 10.1016/0006-291X(91)91338-D; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VITIELLO F, 1978, J CHROMATOGR, V166, P637, DOI 10.1016/S0021-9673(00)95654-1; WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567; WONG G, 1974, NATURE, V252, P713, DOI 10.1038/252713a0	34	236	247	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7217	7223						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125934				2022-12-25	WOS:A1994NA03200030
J	MISHRA, VK; PALGUNACHARI, MN; SEGREST, JP; ANANTHARAMAIAH, GM				MISHRA, VK; PALGUNACHARI, MN; SEGREST, JP; ANANTHARAMAIAH, GM			INTERACTIONS OF SYNTHETIC PEPTIDE ANALOGS OF THE CLASS A AMPHIPATHIC HELIX WITH LIPIDS - EVIDENCE FOR THE SNORKEL HYPOTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; CHOLESTEROL ACYLTRANSFERASE; SECONDARY STRUCTURE; PROTEIN INTERACTIONS; PLASMA LIPOPROTEINS; PHOSPHATIDYLCHOLINE; FLUORESCENCE; ACTIVATION; COMPLEXES; LECITHIN	Class A amphipathic helixes present in exchangeable plasma apolipoproteins are characterized by the location of positively charged amino acid residues at the non-polar-polar interface and negatively charged amino acid residues at the center of the polar face. The objectives of the present study were: (i) to investigate the role of hydrocarbon side chain length of the interfacial positively charged amino acid residues in the lipid affinity of class A amphipathic helixes, and (ii) to investigate the importance of the nature of interfacial charge in the lipid affinity of class A amphipathic helixes. Toward this end, lipid interactions of the following two analogs of the class A amphipathic helix, Ac-18A-NH2 (acetyl-Asp-Trp-Leu-Lys-Ala-Phe-Tyr-Asp-Lys-Val-Ala-Glu-Lys-Leu-Lys-Glu-Ala-Phe-NH2), and Ac-18A(Lys>Haa)-NH2 (acetyl-Asp-Trp-Leu-Haa-Ala-Phe-Tyr-Asp-Haa-Val-Ala- Glu-Haa-Leu-Haa-Glu-Ala-Phe-NH2) (Haa = homoaminoalanine), were studied. The side chain of Has has two CH2 groups less than that of lysine. The lipid affinities of these two peptide analogs were compared with that of Ac-18R-NH2, an analog of Ac-18A-NH2 with positions of the charged amino acid residues reversed. The techniques used in these studies were circular dichroism, fluorescence spectroscopy, right-angle light scattering measurements, and differential scanning calorimetry. The results of these studies indicated the following rank order of lipid affinity: Ac-18A-NH2 > Ac-18A(Lys>Haa)NH2 > Ac-18R-NH2. These results are in agreement with the ''snorkel' model proposed earlier to explain the higher lipid affinity of class A amphipathic helixes (Segrest, J. P., Loof, H. D., Dohlman, J. G., Brouillette, C. G., and Anantharamaiah, G. M. (1990) Proteins Struct. Funct. Genetics 8, 103-117). In addition, it was observed from the differential scanning calorimetry studies that Ac-18A-NH2 and Ac-18A(Lys>Haa)-NH2 interact more strongly than Ac-18R-NH2 with negatively charged dimyristoyl phosphatidylglycerol. The weaker interaction of Ac-18R-NH2 with dimyristoyl phosphatidylglycerol is suggested to be due to electrostatic repulsion between the negatively charged lipid and the interfacial negative charges of the peptide.	UNIV ALABAMA,MED CTR,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,MED CTR,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,MED CTR,ATHEROSCLEROSIS RES UNIT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Mishra, Vinod/0000-0002-4527-1512	NHLBI NIH HHS [HL34343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; ANANTHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P109; ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P626; BLACKBURN WD, 1991, J LIPID RES, V32, P1911; CALHOUN DB, 1983, BIOCHEMISTRY-US, V22, P1533, DOI 10.1021/bi00276a003; CHUNG BH, 1985, J BIOL CHEM, V260, P256; EFTINK MR, 1993, BIOCHEMISTRY-US, V32, P9189, DOI 10.1021/bi00086a026; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EPAND RM, 1990, J BIOL CHEM, V265, P20829; EPAND RM, 1987, J BIOL CHEM, V262, P9389; EPAND RM, 1989, J BIOL CHEM, V264, P4628; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KANELIS P, 1980, J BIOL CHEM, V260, P10248; KROON AIP, 1990, BIOCHEMISTRY-US, V29, P8229; KURZBAN GP, 1989, BIOCHEMISTRY-US, V28, P8537, DOI 10.1021/bi00447a040; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEDGER R, 1965, AUST J CHEM, V18, P933, DOI 10.1071/CH9650933; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LIE D, 1990, BIOCHEMISTRY-US, V29, P3637; MAO SJT, 1977, BIOCHEMISTRY-US, V16, P4150, DOI 10.1021/bi00638a003; Marsh D., 2013, HDB LIPID BILAYERS; MCLEAN LR, 1991, BIOCHEMISTRY-US, V30, P31, DOI 10.1021/bi00215a005; MEL SF, 1993, BIOCHEMISTRY-US, V32, P2082, DOI 10.1021/bi00059a028; MORRISET.JD, 1973, BIOCHEMISTRY-US, V12, P1290, DOI 10.1021/bi00731a008; MORRISETT JD, 1977, BIOCHIM BIOPHYS ACTA, V472, P93, DOI 10.1016/0304-4157(77)90015-6; OWENS RJ, 1990, J CLIN INVEST, V86, P1142, DOI 10.1172/JCI114819; PONSIN G, 1984, BIOCHEMISTRY-US, V23, P5337, DOI 10.1021/bi00317a036; PONSIN G, 1986, J BIOL CHEM, V261, P9202; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1992, J LIPID RES, V33, P141; SEGREST JP, 1991, MOL CONFORMATION BIO, P597; SISSEL LK, 1990, J BIOL CHEM, V265, P12217; SMALL DM, 1992, PLASMA LIPOPROTEINS, P57; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; SPARROW JT, 1981, PEPTIDES, P253; SUREWICZ WK, 1986, J BIOL CHEM, V261, P6191; TYTLER EM, 1993, J BIOL CHEM, V268, P22112; VENKATACHALAPAT.YV, 1991, MOL CONFORMATION BIO, P585; VENKATACHALAPATHI YV, 1993, PROTEINS, V15, P349, DOI 10.1002/prot.340150403; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P3942, DOI 10.1021/bi00066a014	45	164	171	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7185	7191						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125930				2022-12-25	WOS:A1994NA03200026
J	NIKOLOFF, DM; HENRY, SA				NIKOLOFF, DM; HENRY, SA			FUNCTIONAL-CHARACTERIZATION OF THE INO2 GENE OF SACCHAROMYCES-CEREVISIAE - A POSITIVE REGULATOR OF PHOSPHOLIPID BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; POLYMERASE CHAIN-REACTION; DNA-BINDING; SUBSTRATE-SPECIFICITY; SYNTHETIC PEPTIDES; ESCHERICHIA-COLI; YEAST; TRANSFORMATION; MUTAGENESIS; EXPRESSION	The INO2 locus encodes a novel product showing structural similarity to the basic helix-loop-helix (b-HLH) family of regulatory proteins (Nikoloff, D. M., McGraw, P., and Henry, S. A. (1992) Nucleic Acids Res. 20, 3253). The ino2 mutants exhibit pleiotropic defects in phospholipid metabolism including inability to derepress the biosynthetic enzyme inositol-1-phosphate synthase. Localization of mutations in ino2 strains has demonstrated that the b-HLH domain is required for biological activity and is sensitive to perturbation, thereby establishing a correlation between the structure and function of Ino2p. Defects in the b-HLH domain of Ino2p resulted in reduced DNA binding activity. In addition, the absence of a specific DNA-protein complex correlated with a reduction or loss of INO1 transcription. Studies using Ino2p-specific antibody revealed that Ino2p participates in the formation of specific DNA-protein complexes. Ino2p-dependent binding activity overlapped with a region of the INO1 promoter that contains two potential HLH consensus binding sites. Furthermore, Ino2p showed single base pair discrimination in a putative binding site, establishing a relationship between Ino2p and its target binding site.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University			Henry, Susan/K-5464-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019629, R01GM019629] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-19629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CAI MJ, 1989, MOL CELL BIOL, V9, P2544, DOI 10.1128/MCB.9.6.2544; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; COMPANY M, 1988, MOL CELL BIOL, V8, P2545, DOI 10.1128/MCB.8.6.2545; CULBERTSON MR, 1975, GENETICS, V80, P23; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; DONAHUE TF, 1981, GENETICS, V98, P491; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; GREENBERG ML, 1982, GENETICS, V100, P19; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HAYASHI N, 1991, MOL CELL BIOL, V11, P785, DOI 10.1128/MCB.11.2.785; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HOROWICZ, 1981, NUCLEIC ACIDS RES, V9, P2989; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MCGRAW P, 1989, GENETICS, V122, P317; MELLOR J, 1991, NUCLEIC ACIDS RES, V19, P2961, DOI 10.1093/nar/19.11.2961; Miller J.H., 1972, EXPT MOL GENETICS; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1978, METHODS YEAST GENETI; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WINTER B, 1992, EMBO J, V11, P1843, DOI 10.1002/j.1460-2075.1992.tb05236.x; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	48	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7402	7411						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125958				2022-12-25	WOS:A1994NA03200059
J	DIRKSEN, WP; HAMPSON, RK; SUN, Q; ROTTMAN, FM				DIRKSEN, WP; HAMPSON, RK; SUN, Q; ROTTMAN, FM			A PURINE-RICH EXON SEQUENCE ENHANCES ALTERNATIVE SPLICING OF BOVINE GROWTH-HORMONE PRE-MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GENE-EXPRESSION; VARIANT; PLACENTA	A previous study has demonstrated that deletion of a region within the last exon of bovine growth hormone (bGH) pre-mRNA results in almost complete retention of the upstream intron (Hampson, R. K., LaFollette, L., and Rottman, F. M. (1989) Mol. Cell Biol. 9, 1604-1610), We now demonstrate that insertion of a simple purine-rich element (GGAAG), which is present within the deleted region, activates intron splicing upon expression in transfected cells. Moreover, several repeats of the GGAA(G) sequence restore splicing to near wild-type levels and direct the binding of a factor present in HeLa cell nuclear extracts. Mutation of the 5'-splice site toward U1 small nuclear RNA complementarity eliminates dependence on the downstream exon sequence for splicing. These results support a model for alternative intron retention in which purine-rich sequences function as part of an ''exonic splicing enhancer'' to complement a weak 5'-splice site and thereby facilitate intron removal. As a result, the majority of bGH mRNA is processed to remove intron D while still allowing a fraction of bGH mRNA containing the intact intron to reach the cytoplasm.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032770] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32770] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; COOKE NE, 1988, J BIOL CHEM, V263, P9001; CRABTREE GR, 1982, CELL, V31, P159, DOI 10.1016/0092-8674(82)90415-9; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAMPSON RK, 1987, P NATL ACAD SCI USA, V84, P2673, DOI 10.1073/pnas.84.9.2673; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; KAKIZUKA A, 1990, J BIOL CHEM, V265, P10102; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LIEBHABER SA, 1989, J CLIN INVEST, V83, P1985, DOI 10.1172/JCI114108; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; McKeown M, 1990, Genet Eng (N Y), V12, P139; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STERNER DA, 1993, MOL CELL BIOL, V13, P2677, DOI 10.1128/MCB.13.5.2677; SUN Q, 1993, J BIOL CHEM, V268, P15659; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	25	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6431	6436						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119993				2022-12-25	WOS:A1994MZ50300029
J	DONG, AC; CAUGHEY, WS; DUCLOS, TW				DONG, AC; CAUGHEY, WS; DUCLOS, TW			EFFECTS OF CALCIUM, MAGNESIUM, AND PHOSPHORYLCHOLINE ON SECONDARY STRUCTURES OF HUMAN C-REACTIVE PROTEIN AND SERUM AMYLOID-P COMPONENT OBSERVED BY INFRARED-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER FEMALE PROTEIN; SYRIAN-HAMSTER; AMIDE-I; BINDING-PROTEIN; PURPLE MEMBRANE; SPECTRA; WATER; RESOLUTION; PENTRAXIN; HISTONES	The secondary structures of human C-reactive protein (CRP) and serum amyloid P component (SAP) in D2O-based solutions in the presence or absence of calcium, magnesium, and phosphorylcholine have been investigated using Fourier transform infrared spectroscopy. Quantitative analysis provided estimations of about 50% beta-sheet, 12% alpha-helix, 24% beta-turn, and 14% unordered structure for CRP and about 54% beta-sheet, 12% alpha-helix, 25% beta-turn, and 9% unordered structure for SAP. With both proteins significant calcium dependent changes were observed in conformation-sensitive amide I regions assigned to each type of structure. The CRP spectrum was also affected by magnesium, but the changes differed from those induced by calcium. The SAP spectrum was not affected by magnesium. Phosphorylcholine in the presence of calcium also affected the spectrum of CRP but not the spectrum of SAP, Our present study provides the first direct comparison of the secondary structures of the pentraxins human CRP and SAP and hamster female protein (Dong, A., Caughey, B., Caughey, W. S., Bhat, K. S., and Coe, J. E. (1992) Biochemistry 32, 9364-9370), These findings suggest that the three pentraxins have similar secondary structure compositions and calcium dependent conformational changes, but differ significantly in their responses to phosphorylcholine and magnesium. Such properties are expected to be relevant to the incompletely understood roles of these highly conserved proteins including binding to nuclear proteins, complement activation, and association with amyloids,	COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523; VET ADM MED CTR,DEPT MED,ALBUQUERQUE,NM 87108; UNIV NEW MEXICO,ALBUQUERQUE,NM 87108	Colorado State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico					PHS HHS [A128358] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARRONDO JLR, 1988, BIOCHIM BIOPHYS ACTA, V952, P261, DOI 10.1016/0167-4838(88)90125-2; BANDEKAR J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P123, DOI 10.1016/0167-4838(92)90261-B; BLADEN HA, 1966, J ULTRA MOL STRUCT R, V14, P449, DOI 10.1016/S0022-5320(66)80075-8; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CASAL HL, 1988, BIOCHIM BIOPHYS ACTA, V957, P11, DOI 10.1016/0167-4838(88)90152-5; CATHCART ES, 1965, NEW ENGL J MED, V273, P143, DOI 10.1056/NEJM196507152730306; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P607, DOI 10.1002/bip.1976.360150402; COE JE, 1983, CONTEMP TOP MOLEC IM, V9, P211; COE JE, 1990, J EXP MED, V171, P1257, DOI 10.1084/jem.171.4.1257; COE JE, 1985, J CLIN INVEST, V76, P66, DOI 10.1172/JCI111978; COE JE, 1983, J EXP MED, V157, P1421, DOI 10.1084/jem.157.5.1421; COE JE, 1981, J EXP MED, V153, P977, DOI 10.1084/jem.153.4.977; DONG A, 1992, BIOCHEMISTRY-US, V31, P182, DOI 10.1021/bi00116a027; DONG A, 1992, BIOCHEMISTRY-US, V31, P9364, DOI 10.1021/bi00154a006; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DOUSSEAU F, 1990, BIOCHEMISTRY-US, V29, P8771, DOI 10.1021/bi00489a038; DOWTON SB, 1991, BIOCHEMISTRY-US, V30, P9531, DOI 10.1021/bi00103a021; DUCLOS TW, 1988, J IMMUNOL, V141, P4266; DUCLOS TW, 1991, J BIOL CHEM, V266, P2167; DUCLOS TW, 1989, J IMMUNOL, V143, P2553; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; ETLINGER HM, 1986, INT ARCH ALLER A IMM, V81, P189, DOI 10.1159/000234132; GOTSCHLICH EC, 1967, P NATL ACAD SCI USA, V57, P706, DOI 10.1073/pnas.57.3.706; HARIS PI, 1988, BIOCHIM BIOPHYS ACTA, V943, P375, DOI 10.1016/0005-2736(88)90571-8; HICKS PS, 1992, J IMMUNOL, V149, P3689; HOLLOWAY PW, 1989, BIOCHEMISTRY-US, V28, P931, DOI 10.1021/bi00429a002; HOOKER TM, 1970, BIOPOLYMERS, V9, P1319, DOI 10.1002/bip.1970.360091104; KALB AJ, 1968, BIOCHEM J, V109, P669, DOI 10.1042/bj1090669; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; KENNEDY DF, 1991, BIOCHEMISTRY-US, V30, P6541, DOI 10.1021/bi00240a026; KILPATRICK JM, 1982, MOL IMMUNOL, V19, P1159, DOI 10.1016/0161-5890(82)90326-1; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; KINOSHITA CM, 1989, BIOCHEMISTRY-US, V28, P9840, DOI 10.1021/bi00451a044; KOENIG JL, 1980, NATO ADV STUDY I C, V57, P241; Kretsinger R.H., 1991, NOVEL CALCIUM BINDIN, P17; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; LEE DC, 1990, BIOCHEMISTRY-US, V29, P9185, DOI 10.1021/bi00491a012; LIU TY, 1982, ANN NY ACAD SCI, V389, P151, DOI 10.1111/j.1749-6632.1982.tb22133.x; MANNING MC, 1989, BIOCHEMISTRY-US, V28, P8609, DOI 10.1021/bi00447a051; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MIYAZAWA T, 1961, J AM CHEM SOC, V83, P712, DOI 10.1021/ja01464a042; Moore C., 1993, CHEMTRACTS BIOCH MOL, V4, P67; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; NGUYEN NY, 1986, J BIOL CHEM, V261, P450; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; PAINTER RH, 1982, ANN NY ACAD SCI, V389, P199, DOI 10.1111/j.1749-6632.1982.tb22138.x; PARKER FS, 1983, APPLICATIONS INFRARE; PEPYS MB, 1977, LANCET, V1, P1029; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1993, 7TH INT S AM; PRESTRELSKI SJ, 1991, BIOCHEMISTRY-US, V30, P133, DOI 10.1021/bi00215a020; ROBEY FA, 1984, J BIOL CHEM, V259, P7311; ROTHSCHILD KJ, 1979, BIOPHYS J, V25, P473, DOI 10.1016/S0006-3495(79)85317-5; SARVER RW, 1991, ANAL BIOCHEM, V194, P89, DOI 10.1016/0003-2697(91)90155-M; SAVITZKY A, 1964, ANAL CHEM, V36, P1628; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; SUSI H, 1986, METHOD ENZYMOL, V130, P290; SUSI H, 1987, ARCH BIOCHEM BIOPHYS, V258, P465, DOI 10.1016/0003-9861(87)90367-5; VOLANAKIS JE, 1981, J EXP MED, V153, P1604, DOI 10.1084/jem.153.6.1604; WHITEHEAD AS, 1990, BIOCHEM J, V266, P283, DOI 10.1042/bj2660283; WOO P, 1985, J BIOL CHEM, V260, P3384; YOUNG NM, 1978, J IMMUNOL, V121, P1893	67	35	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6424	6430						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119992				2022-12-25	WOS:A1994MZ50300028
J	LANOIX, J; LACOSTE, J; PEPIN, N; RICE, N; HISCOTT, J				LANOIX, J; LACOSTE, J; PEPIN, N; RICE, N; HISCOTT, J			OVERPRODUCTION OF NFKB2(LYT-1O) AND C-REL - A MECHANISM FOR HTLV-I TAX-MEDIATED TRANSACTIVATION VIA THE NF-KAPPA-B SIGNALING PATHWAY	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; CANDIDATE PROTOONCOGENE BCL-3; ENHANCER-BINDING PROTEINS; LONG TERMINAL REPEAT; HUMAN T-CELLS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; GENE-EXPRESSION; PROTO-ONCOGENE	Molecular, biochemical and epidemiological evidence implicate HTLV-I as an etiologic agent of adult T cell leukemia (ATL). The Tax protein of HTLV-I, a positive transcriptional activator of HTLV-I gene expression, is a viral oncogene that also increases transcription of cellular genes including GM-CSF, IL-2R alpha and IL-2. One of the cellular targets of the trans-activating effects of Tax is the NF-kappa B/Rel family of transcription factors, pleiotropic regulators of immunoregulatory, cytokine and viral gene expression. In this report, we demonstrate that NFKB2, (lyt-10) and c-Rel are overexpressed in HTLV-I infected and Tax-expressing cells and, together, account for the majority of the constitutive NF-kappa-B binding activity in these cells before and after PMA stimulation. Most importantly, we show a Tax-dependent correlation between expression of NFKB2(p100) and processing to the DNA binding NFKB2(p52) form, induction of c-Rel, and trans-activation of NF-kappa B-mediated gene expression. Furthermore, the NFKB2 precursor is physically associated with c-Rel and with Tax in HTLV-I infected cells. We propose that NFKB2 synthesis and processing allows continuous nuclear expression of an otherwise cytoplasmic protein and, in conjunction with overexpression of c-Rel, NFKB2 alters the NF-kappa B signalling pathway and contributes to leukemic transformation of T cells by HTLV-I.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,ABE STERN CANC RES LAB,MONTREAL H3T 1E2,PQ,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ,CANADA; FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ABL,MOLEC VIROL & CARCINOGENESIS LAB,FREDERICK,MD	Lady Davis Institute; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; COHEN L, 1992, J CELL PHYSIOL, V152, P10, DOI 10.1002/jcp.1041520103; CRENON L, 1993, ONCOGENE, V8, P867; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAERTLE T, 1988, J BIOL CHEM, V263, P5870; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HANNINK M, 1990, ONCOGENE, V5, P1843; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LACOSTE J, 1990, J VIROL, V64, P4726, DOI 10.1128/JVI.64.10.4726-4734.1990; LACOSTE J, 1991, VIROLOGY, V184, P553, DOI 10.1016/0042-6822(91)90425-B; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIWA M, 1984, GANN, V75, P752; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKEUCHI K, 1985, J GEN VIROL, V66, P1825, DOI 10.1099/0022-1317-66-8-1825; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	73	75	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					841	852						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108127				2022-12-25	WOS:A1994MW55100020
J	NG, IOL; CHUNG, LP; TSANG, SWY; LAM, CL; LAI, ECS; FAN, ST; NG, M				NG, IOL; CHUNG, LP; TSANG, SWY; LAM, CL; LAI, ECS; FAN, ST; NG, M			P53 GENE MUTATION SPECTRUM IN HEPATOCELLULAR CARCINOMAS IN HONG-KONG CHINESE	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; CELL-LINES; CANCER; EXPRESSION; OVEREXPRESSION; AFLATOXIN; INVITRO	To examine the significance of mutation of the p53 tumour suppressor gene in the development of human hepatocellular carcinoma in a high-prevalence area for hepatitis B viral infection but a low-exposure area for aflatoxin B1, the spectrum of p53 gene mutations was examined in 21 tumour samples from Hong Kong Chinese patients, all of whom were HBsAg positive. DNA sequencing covering exons 5 to 9 of the p53 gene and Hae III restriction enzyme digestion for preliminary assessment of mutation at codon 249 were performed. Immunohistochemical staining with anti-p53 monoclonal antibodies was done on both tumour and nontumour liver tissues. Six tumours (28.6%) showed a p53 mutation and all were point mutations. Of the six point mutations, two (9.5%) were at codon 249 and both were G to T transversions (AGG-->ATG and AGG-->AGT transversions). The remaining point mutations were transversions scattered at codon 172 (exon 5), 214 (exon 6), 273 (exon 8) and 330 (exon 9). Mutated p53 protein was detected in five of these six cases with demonstrable point mutations by DNA sequencing, in contrast to none detected in all of the 15 cases without demonstrable point mutations. The presence of p53 mutations, including those at codon 249, did not show a significant association with tumour size, sex, age, tumour invasiveness in terms of liver invasion, microsatellites and venous permeation, cirrhosis and encapsulation, but tumours with low cellular differentiation tended to have a higher incidence (71%) of point mutations than those with high cellular differentiation (8%). In conclusion, both the overall p53 mutation rate and that at codon 249 in HCC in Hong Kong Chinese are lower than those reported in tumours from China and sub-Saharan Africa. The low mutation rate at codon 249 is compatible with a low aflatoxin exposure. A special type of p53 mutation has not been found to be associated with hepatitis B viral infection. Mutations of p53 gene tends to occur in tumours with low cellular differentiation, suggesting a late occurrence in the event of tumour progression.	UNIV HONG KONG,QUEEN MARY HOSP,DEPT SURG,HONG KONG,HONG KONG; UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG	University of Hong Kong; University of Hong Kong	NG, IOL (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT PATHOL,HONG KONG,HONG KONG.		Fan, Sheung Tat/C-4138-2009	Ng, Irene Oi-lin/0000-0001-7532-2029				BAKER SJ, 1990, CANCER RES, V50, P7717; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; CAAMANO J, 1991, AM J PATHOL, V139, P839; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHALLEN C, 1992, HEPATOLOGY, V16, P1362, DOI 10.1002/hep.1840160610; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; HARRIS AL, 1991, NATURE, V350, P377, DOI 10.1038/350377a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KASTAN MB, 1991, CANCER RES, V51, P4279; KOHLER MF, 1992, CANCER RES, V52, P1622; LAURENTPUIG P, 1992, HEPATOLOGY, V16, P1171, DOI 10.1016/0270-9139(92)90010-7; LEUNG NWY, 1992, CANCER, V70, P40, DOI 10.1002/1097-0142(19920701)70:1<40::AID-CNCR2820700107>3.0.CO;2-P; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINSELL CA, 1977, T ROY SOC TROP MED H, V71, P471, DOI 10.1016/0035-9203(77)90136-5; LOK ASF, 1990, HEPATOLOGY, V12, P582, DOI 10.1002/hep.1840120322; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NIGRO JM, 1989, NATURE, V342, P505; ODA T, 1992, CANCER RES, V52, P6358; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; SCORSONE KA, 1992, CANCER RES, V52, P1635; SHANK RC, 1972, FOOD COSMET TOXICOL, V10, P51, DOI 10.1016/S0015-6264(72)80046-4; SHANK RC, 1972, FOOD COSMET TOXICOL, V10, P61, DOI 10.1016/S0015-6264(72)80047-6; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; WALKER GJ, 1991, CANCER RES, V51, P4367; 1983, WHO TECH REP SER, V691, P7; 1991, HONG KONG ANN DEP RE; 1992, DATA DEPT HLTH	33	53	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					985	990						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108145				2022-12-25	WOS:A1994MW55100039
J	WIMMEL, A; LUCIBELLO, FC; SEWING, A; ADOLPH, S; MULLER, R				WIMMEL, A; LUCIBELLO, FC; SEWING, A; ADOLPH, S; MULLER, R			INDUCIBLE ACCELERATION OF G(1) PROGRESSION THROUGH TETRACYCLINE-REGULATED EXPRESSION OF HUMAN CYCLIN-E	ONCOGENE			English	Note							CELL-CYCLE; PHASE	Cyclin E is a cell cycle-regulated protein that activates the cdc2-related protein kinases cdk2 shortly before S-phase entry. In order to analyse the biological role of cyclin E, we have generated HeLa cells that allow the conditional expression of ectopic human cyclin E. In these cells, a cyclin E cDNA is under the control of a bacterial tetracycline repressor-VP16 activator hybrid protein. In the absence of tetracycline, the endogenous gene becomes activated and leads to the synthesis of elevated levels of cyclin E. Concomitant with this increase in cyclin E expression we show by a combined time-lapse video recording/5-bromo-deoxyuridine labelling procedure a significant acceleration of G(1) transition by approximately 1.5 hours. This observation is consistent with the idea that cyclin E is a rate-limiting factor with respect to the control of G(1)-->S transition. The experimental system described here should also prove useful to address the function of cyclin E in further detail.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADOLPH S, 1993, J CELL SCI, V105, P113; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; TSAI LH, 1993, ONCOGENE, V8, P1593; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	19	138	150	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					995	997						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108147				2022-12-25	WOS:A1994MW55100041
J	CASTELLO, A; RODRIQUEZMANZANEQUE, JC; CAMPS, M; PEREZCASTILLO, A; TESTAR, X; PALACIN, M; SANTOS, A; ZORZANO, A				CASTELLO, A; RODRIQUEZMANZANEQUE, JC; CAMPS, M; PEREZCASTILLO, A; TESTAR, X; PALACIN, M; SANTOS, A; ZORZANO, A			PERINATAL HYPOTHYROIDISM IMPAIRS THE NORMAL TRANSITION OF GLUT4 AND GLUT1 GLUCOSE TRANSPORTERS FROM FETAL TO NEONATAL LEVELS IN HEART AND BROWN ADIPOSE-TISSUE - EVIDENCE FOR TISSUE-SPECIFIC REGULATION OF GLUT4 EXPRESSION BY THYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-INDUCED TRANSLOCATION; MESSENGER-RIBONUCLEIC-ACID; RAT SKELETAL-MUSCLE; RETINOIC ACID; GENE-EXPRESSION; SOLEUS MUSCLE; DEVELOPMENTAL REGULATION; MATERNAL HYPOTHYROIDISM; NUCLEAR RECEPTORS; WHITE MUSCLE	GLUT1 and GLUT4 glucose transporter expression is highly regulated in muscle and adipose tissue during perinatal life. Here we have investigated the role of thyroid hormones in the regulation of GLUT4 induction and GLUT1 repression associated to neonatal development. Perinatal hypothyroidism markedly impaired GLUT4 protein induction in heart. This effect was heart specific, and a greater expression of GLUT4 was detected in brown adipose tissue from neonatal hypothyroid rats compared with controls. These changes in GLUT4 protein expression were not detected in brown adipose tissue or heart when hypothyroidism was induced in adult rats. These results indicate that GLUT4 induction during perinatal life is highly sensitive to thyroid hormones in both heart and adipose tissue. Perinatal hypothyroidism was characterized by decreased cardiac GLUT4 mRNA concentrations. T-3 injection caused a marked increase in cardiac levels of GLUT4 mRNA in hypothyroid neonates. Thus, in 18-day-old hypothyroid rats, GLUT4 mRNA levels increased 3-fold 1 h after T-3 injection. Under these conditions, retinoic acid also caused a rapid increase in cardiac GLUT4 mRNA levels from hypothyroid neonates. In addition, cardiac levels of GLUT4 protein markedly increased in fetuses and in neonates 24 h after T-3 injection. These findings suggest that a direct effect of thyroid hormones is the promotion of cardiac GLUT4 gene expression. GLUT1 protein expression was markedly enhanced in brown adipose tissue and heart during neonatal hypothyroidism as well, as in hypothyroidism induced in adult rats. This was concomitant to greater levels of GLUT1 mRNA in hearts from hypothyroid neonates, Immunofluorescence analysis indicated that cardiomyocytes from hypothyroid pups contained an enhanced level of GLUT1 protein. Furthermore, T-3 injection caused a decrease in cardiac levels of GLUT1 mRNA in hypothyroid neonates. These results indicate that thyroid hormone manipulation leads to inverse regulation of GLUT1 and GLUT4 glucose transporter gene expression in the neonatal heart. We conclude that thyroid hormones play a pivotal role controlling the transition of glucose transporter carriers from fetal to neonatal levels in heart and brown adipose tissue.	UNIV BARCELONA, FAC BIOL, DEPT BIOQUIM & FISIOL, E-08028 BARCELONA, SPAIN; UNIV COMPLUTENSE MADRID, FAC MED, DEPT BIOQUIM & BIOL MOLEC, E-28040 MADRID, SPAIN; CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN	University of Barcelona; Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015; Rodriguez-Manzaneque, Juan Carlos/F-3899-2012; Farré, Anna Castelló/K-9637-2015; Perez-Castillo, Ana/A-9505-2015; Santos, Angel/K-3744-2014	Rodriguez-Manzaneque, Juan Carlos/0000-0001-5951-7029; Farré, Anna Castelló/0000-0001-8497-6251; Palacin, Manuel/0000-0002-8670-293X; Perez-Castillo, Ana/0000-0002-2632-5853; Santos, Angel/0000-0002-7551-8483				ARGENTIN S, 1987, BIOCHEM BIOPH RES CO, V146, P1336, DOI 10.1016/0006-291X(87)90796-0; BALDWIN KM, 1978, AM J PHYSIOL, V235, pC97, DOI 10.1152/ajpcell.1978.235.3.C97; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BLOCK NE, 1991, J CLIN INVEST, V88, P1546, DOI 10.1172/JCI115465; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CAMPS L, 1991, J LIPID RES, V32, P1877; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CASLA A, 1990, BIOCHEM BIOPH RES CO, V171, P182, DOI 10.1016/0006-291X(90)91374-2; CASTELLO A, 1993, J BIOL CHEM, V268, P14998; CHIZZONITE RA, 1984, J BIOL CHEM, V259, P2628; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK CM, 1971, AM J PHYSIOL, V220, P583; CODERRE L, 1992, ENDOCRINOLOGY, V131, P1821, DOI 10.1210/en.131.4.1821; DEESCOBAR GM, 1985, ENDOCRINOLOGY, V117, P1890, DOI 10.1210/endo-117-5-1890; DEONA CR, 1991, ENDOCRINOLOGY, V128, P422, DOI 10.1210/endo-128-1-422; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FLIER JS, 1987, J CLIN INVEST, V79, P657, DOI 10.1172/JCI112864; FREAKE HC, 1987, P NATL ACAD SCI USA, V84, P3070, DOI 10.1073/pnas.84.9.3070; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GUMA A, 1992, FEBS LETT, V310, P51, DOI 10.1016/0014-5793(92)81144-B; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KLIP A, 1992, J CELL BIOCHEM, V48, P51, DOI 10.1002/jcb.240480109; KURUVILLA AK, 1991, BIOCHIM BIOPHYS ACTA, V1094, P300, DOI 10.1016/0167-4889(91)90090-K; LADENSON PW, 1988, ENDOCRINOLOGY, V123, P652, DOI 10.1210/endo-123-1-652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; NATAF B, 1961, CR SOC BIOL, V155, P1235; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; ONTELL M, 1988, AM J ANAT, V181, P279, DOI 10.1002/aja.1001810306; PEREZCASTILLO A, 1985, ENDOCRINOLOGY, V117, P2457, DOI 10.1210/endo-117-6-2457; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIPAON C, 1992, J BIOL CHEM, V267, P21, DOI 10.1016/S0021-9258(18)48449-9; PRACYK JB, 1992, J PHARMACOL EXP THER, V261, P951; ROHRER D, 1988, J BIOL CHEM, V263, P6941; Rosen K., 1990, FOCUS, V12, P23; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SUGIE H, 1985, MUSCLE NERVE, V8, P654, DOI 10.1002/mus.880080805; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WANG C, 1985, P NATL ACAD SCI USA, V82, P3621, DOI 10.1073/pnas.82.11.3621; WEINSTEIN SP, 1992, BIOCHIM BIOPHYS ACTA, V1136, P302, DOI 10.1016/0167-4889(92)90121-Q; WEINSTEIN SP, 1991, ENDOCRINOLOGY, V129, P455, DOI 10.1210/endo-129-1-455; WEINSTEIN SP, 1990, ENDOCRINOLOGY, V126, P1421, DOI 10.1210/endo-126-3-1421; WERNER H, 1989, MOL ENDOCRINOL, V3, P273, DOI 10.1210/mend-3-2-273; WRUTNIAK C, 1983, J ENDOCRINOL, V99, P233, DOI 10.1677/joe.0.0990233; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	59	98	98	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5905	5912						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119934				2022-12-25	WOS:A1994MY84000066
J	CHAN, YL; OLVERA, J; GLUCK, A; WOOL, IG				CHAN, YL; OLVERA, J; GLUCK, A; WOOL, IG			A LEUCINE ZIPPER-LIKE MOTIF AND A BASIC REGION-LEUCINE ZIPPER-LIKE ELEMENT IN RAT RIBOSOMAL-PROTEIN L13A - IDENTIFICATION OF THE TUM(-) TRANSPLANTATION ANTIGEN P198	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAINS; SACCHAROMYCES-CEREVISIAE; HYPOTHETICAL STRUCTURE; AMINO-ACIDS; SEQUENCE; FAMILY; RNA; RECOGNITION; REPEATS; MODEL	The amino acid sequence of the rat 60 S ribosomal subunit protein L13a was deduced from the sequence of nucleotides in two recombinant cDNAs. Mature ribosomal protein L13a has 202 amino acids (the NH2-terminal methionine is removed after translation of the mRNA) and a M(r) of 23,330. Hybridization of the L13a cDNA to digests of nuclear DNA suggests that there are 9-11 copies of the L13a gene. The mRNA for the protein is similar to 800 nucleotides in length. Rat L13a is related to the Saccharomyces cerevisiae ribosomal proteins that have been provisionally designated rp22 and rp23 and to the eubacterial and archaebacterial family of L13 ribosomal proteins. The mouse tum(-) transplantation antigen P198 is a mutant of the mouse homolog of rat ribosomal protein L13a. Rat ribosomal protein L7 has, at its NH2 terminus, five tandem repeats of a similar sequence of 12 amino acids (Lin, A., Chan, Y. L., McNally, J., Peleg, D., Meyuhas, O., and Wool, I. G. (1987) J. Biol. Chem. 262, 12665-12671); L13a has, in its carboxyl-terminal region, amino acid sequences with significant identity to L7 repeats 1, 3, and 5. L13a also has a number of short amino acid sequences that are repeated, a leucine zipper-like moth at its NH2 terminus, and a potential basic region-leucine zipper element in its carboxyl-terminal region.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago					NIGMS NIH HHS [GM-21769] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021769] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHAN YL, 1987, J BIOL CHEM, V262, P12879; CHAN YL, 1990, ARCH BIOCHEM BIOPHYS, V283, P546, DOI 10.1016/0003-9861(90)90682-O; CHAN YL, 1993, NUCLEIC ACIDS RES, V21, P649, DOI 10.1093/nar/21.3.649; CHAN YL, 1988, J BIOL CHEM, V263, P2891; COLLATZ E, 1976, J BIOL CHEM, V251, P1808; DAYHOFF MO, 1978, ATLAS PROTEIN SEQUEN, V5, P1; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLUCK A, 1989, EUR J BIOCHEM, V182, P105, DOI 10.1111/j.1432-1033.1989.tb14805.x; GONGADZE GM, 1986, FEBS LETT, V197, P74, DOI 10.1016/0014-5793(86)80301-5; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEMMERICH P, 1993, NUCLEIC ACIDS RES, V21, P223, DOI 10.1093/nar/21.2.223; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KROMER WJ, 1991, J BIOL CHEM, V266, P24573; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN A, 1987, J BIOL CHEM, V262, P12665; MATHESON AT, 1990, RIBOSOME, P617; MEYUHAS O, 1990, J BIOL CHEM, V265, P11465; MIZUTA K, 1992, NUCLEIC ACIDS RES, V20, P1011, DOI 10.1093/nar/20.5.1011; NIERHAUS KH, 1980, RIBOSOMES STRUCTURE, P267; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RICE PA, 1989, NUCLEIC ACIDS RES, V17, P3757, DOI 10.1093/nar/17.10.3757; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; SUZUKI K, 1993, J BIOL CHEM, V268, P2755; SZYMKOWSKI DE, 1989, NUCLEIC ACIDS RES, V17, P5393, DOI 10.1093/nar/17.13.5393; TAKAKURA H, 1992, J BIOL CHEM, V267, P5442; TSURUGI K, 1978, J BIOL CHEM, V253, P946; TSURUGI K, 1991, BIOCHEM BIOPH RES CO, V174, P1318, DOI 10.1016/0006-291X(91)91566-U; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1992, NEW BIOL, V4, P396; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WITTMANNLIEBOLD B, 1984, MOL GEN GENET, V196, P439, DOI 10.1007/BF00436191; WITTMANNLIEBOLD B, 1984, ADV PROTEIN CHEM, V36, P56; WOOL IG, 1993, TRANSLATIONAL APPARATUS, P727; WOOL IG, 1990, RIBOSOME, P203; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587	48	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5589	5594						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119894				2022-12-25	WOS:A1994MY84000021
J	ERNST, TJ; SLATTERY, KE; GRIFFIN, JD				ERNST, TJ; SLATTERY, KE; GRIFFIN, JD			P210(BCR/ABL) AND P160(V-ABL) INDUCE AN INCREASE IN THE TYROSINE PHOSPHORYLATION OF P93(C-FES)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; FUJINAMI SARCOMA-VIRUS; V-ABL; C-FPS; PROTEIN-KINASE; CELL-LINE; ONCOGENE PRODUCTS; TRANSGENIC MICE; FES LOCUS; EXPRESSION	Chronic myelogenous leukemia is caused by a reciprocal chromosomal translocation of human chromosomes 9 and 22. The resulting fusion protein, p210(Bcr/Abl), has enhanced tyrosine kinase activity compared with the normal cellular homologue, p145(c-Abl). Expression of this chimeric protein in hematopoietic cell lines results in a rapid progression to growth factor independence and increased tyrosine phosphorylation of a number of unidentified cellular proteins. In this study, we show that the phosphorylation state of the hematopoietically restricted tyrosine kinase, p93(c-Fes), is increased. Increased phosphorylation of p93(c-Fes) was detected in p210(Bcr/Abl)(+) human leukemic cell lines, in primary leukemic cells from patients with chronic myelogenous leukemia, and in myeloid cell lines expressing p210(Bcr/Abl) after transfection. Furthermore, p93(c-Fes) phosphorylation was increased by p210(Bcr/Abl) even when coexpressed in NIH 3T3 fibroblasts. v-abl expression was also found to increase the tyrosine phosphorylation of p93(c-Fes) This increased phosphorylation was found to be accompanied by an increase in the ability of p93(c-Fes) to phosphorylate exogenous substrates. p93(c-Fes) could contribute to the transforming activity of the abl oncogenes.			ERNST, TJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [P01CA034183] Funding Source: NIH RePORTER; NCI NIH HHS [CA34183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; CANNISTRA SA, 1985, BLOOD, V65, P414; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DRUKER B, 1992, BLOOD, V79, P2215; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FRANCHINI G, 1981, NATURE, V290, P154, DOI 10.1038/290154a0; FUKUI Y, 1989, ONCOGENE RES, V4, P283; Gishizky M L, 1992, Curr Top Microbiol Immunol, V182, P65; Goldman J M, 1990, Curr Opin Oncol, V2, P49; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GROFFEN J, 1983, VIROLOGY, V125, P480, DOI 10.1016/0042-6822(83)90219-2; HAMMOND CI, 1985, VIROLOGY, V143, P300, DOI 10.1016/0042-6822(85)90117-5; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MECKLING GK, 1992, BIOCHIM BIOPHYS ACTA, V1137, P65; MOSS P, 1984, J VIROL, V52, P557, DOI 10.1128/JVI.52.2.557-565.1984; OKUDA K, 1992, BLOOD, V79, P2880; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PIKE LJ, 1982, P NATL ACAD SCI-BIOL, V79, P1443, DOI 10.1073/pnas.79.5.1443; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WOOLFORD J, 1984, VIROLOGY, V135, P168, DOI 10.1016/0042-6822(84)90127-2; YEE SP, 1989, MOL CELL BIOL, V9, P5491, DOI 10.1128/MCB.9.12.5491; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	48	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5764	5769						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119916				2022-12-25	WOS:A1994MY84000046
J	JHUN, BH; MEINKOTH, JL; LEITNER, JW; DRAZNIN, B; OLEFSKY, JM				JHUN, BH; MEINKOTH, JL; LEITNER, JW; DRAZNIN, B; OLEFSKY, JM			INSULIN AND INSULIN-LIKE GROWTH FACTOR-I SIGNAL-TRANSDUCTION REQUIRES P21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; MAP KINASE; GENE-EXPRESSION; PC12 CELLS; H-RAS; PROTEIN; RECEPTOR; MICROINJECTION; STIMULATION; ACTIVATION	We have investigated the role of cellular p21(ras) protein in insulin and insulin-like growth factor-I (IGF-I) signaling pathways. Insulin stimulation increased Ras-GTP formation in Rat-1 fibroblasts overexpressing normal human insulin receptors (HIRc-B), far greater than in parental Rat-1 fibroblasts, indicating that competent insulin receptors mediate this response, Cellular microinjection of a dominant-negative mutant p21(ras) protein (N17 ras) or anti-pa21(ras) monoclonal antibody (Y13-259) into HIRc-B cells reduced insulin- and IGF-I-stimulated DNA synthesis by 75-90%. Insulin-induced c-fos protein expression was also inhibited by 74%. Microinjection of oncogenic p2l(ras) (T-24 ras) into HIRc-B cells activated the mitogenic pathway, and coinjection of N17 ras and T-24 ras showed that oncogenic p21(ras) rescued the cells from the N17 ras blockade. This later finding indicates that T-24 ras acts downstream of N17 ras. In conclusion, 1) microinjection of a dominant interferring ras mutant into quiescent cells abrogated subsequent insulin and IGF-I mitogenic signaling; 2) oncogenic ras protein rescued cells from the N17 ras blockade, indicating that T24 ras action is downstream of the site of N17 inhibition; and 3) p21(ras) is an intermediate signaling molecule in the insulin/IGF-I signal transduction pathway and is required for gene expression and DNA synthesis.	UNIV CALIF SAN DIEGO,CTR CANC,DEPT MED 9111G,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,SAN DIEGO,CA 92161; VET ADM MED CTR,DEPT MED,DENVER,CO 80220	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)			Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEIG LA, 1988, MOL CELL BIOL, V8, P3255; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FERAMISCO JR, 1979, P NATL ACAD SCI USA, V76, P3967, DOI 10.1073/pnas.76.8.3967; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MAASSEN JA, 1992, HORM METAB RES, V24, P214, DOI 10.1055/s-2007-1003296; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; PORRAS A, 1992, J BIOL CHEM, V267, P21124; RAPP UR, 1991, ONCOGENE, V6, P495; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	39	68	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5699	5704						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119907				2022-12-25	WOS:A1994MY84000036
J	POLANS, AS; PALCZEWSKI, K; ASSONBATRES, MA; OHGURO, H; WITKOWSKA, D; HALEY, TL; BAIZER, L; CRABB, JW				POLANS, AS; PALCZEWSKI, K; ASSONBATRES, MA; OHGURO, H; WITKOWSKA, D; HALEY, TL; BAIZER, L; CRABB, JW			PURIFICATION AND PRIMARY STRUCTURE OF CAPL, AN S-100-RELATED CALCIUM-BINDING PROTEIN ISOLATED FROM BOVINE RETINA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MOUSE CELLS; MESSENGER-RNA; GROWTH-FACTOR; MOLECULAR-CLONING; NEURITE EXTENSION; EPITHELIAL-CELLS; CYCLIC-GMP; BRAIN; GENE; EXPRESSION	Calcium protein placental homolog (Capl) is an S-100-related calcium-binding protein selectively expressed in cell lines that have been induced to grow or differentiate. In addition, the expression of Capl correlates with the induction of the metastatic phenotype in tumor cell lines and the transformation of normal cells by activated oncogenes or chemical carcinogens. Although not previously associated with the nervous system, in this study, Capl was purified from bovine neural retina by a combination of phenyl-Sepharose and organomercurial chromatography. The complete amino acid sequence of bovine Capl was established primarily by Edman degradation of peptides generated by cleavage of methionyl, lysyl, glutamyl, and aspartyl bonds. NH2-terminal methionyl and aspartyl peptides were analyzed by tandem mass spectrometry, which provided the sequence of the first 8 residues and identified the NH2-terminal blocking group as an acetyl moiety. The molecular mass of the intact protein determined by electrospray mass spectrometry (M(r) = 11,716.75 +/- 0.42) and the calculated molecular mass deduced from the amino acid composition (M(r) = 11,718) were in agreement, thus supporting the accuracy of the sequence assignment. Capl isolated from the retina was shown to be indistinguishable by mass and immunochemical. properties from its counterpart in the bovine aorta, which previously was the only source of purified Capl, Northern analysis using cloned Capl cDNA revealed that Capl mRNA is present not only in the retina but the choroid as well. Further support for choroidal localization came from immunohistochemical experiments using specific anti-Capl antibodies. The physiological significance of Capl in ocular tissues and the aorta is discussed.	GOOD SAMARITAN HOSP,DEPT OPHTHALMOL,PORTLAND,OR 97209; UNIV WASHINGTON,DEPT OPHTHALMOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	POLANS, AS (corresponding author), GOOD SAMARITAN HOSP,RS DOW NEUROL SCI INST,1120 NW 20TH AVE,PORTLAND,OR 97209, USA.		Witkowska, Danuta/O-3951-2019	Witkowska, Danuta/0000-0003-3494-8724	NATIONAL EYE INSTITUTE [R29EY007089, R01EY007089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038639] Funding Source: NIH RePORTER; NEI NIH HHS [EY07089, EY06603] Funding Source: Medline; NIDDK NIH HHS [DK38639] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BARRACLOUGH R, 1982, EUR J BIOCHEM, V129, P335, DOI 10.1111/j.1432-1033.1982.tb07056.x; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BRUNS GAP, 1989, CYTOGENET CELL GENET, V51, P67, DOI 10.1159/000132781; CAI L, 1990, J PROTEIN CHEM, V9, P623, DOI 10.1007/BF01025016; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; CRABB JW, 1988, J BIOL CHEM, V263, P16674; DAVIES BR, 1993, ONCOGENE, V8, P999; DAYHOFF MO, 1969, ATLAS PROTEIN SEQUEN, P75; DEVOUGE MW, 1992, ONCOGENE, V7, P109; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DORIN JR, 1990, GENOMICS, V8, P420, DOI 10.1016/0888-7543(90)90027-R; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; GERKE V, 1991, NOVEL CALCIUM BINDIN, P139; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GHOSE T, 1990, CANCER RES, V50, P3737; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KINCAID RL, 1987, METHOD ENZYMOL, V139, P3, DOI 10.1016/0076-6879(87)39070-6; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; KORETSUNE Y, 1990, CIRCULATION, V82, P528, DOI 10.1161/01.CIR.82.2.528; Kretsinger R.H., 1991, NOVEL CALCIUM BINDIN, P17; Kretsinger RH, 1975, CALCIUM TRANSPORT CO, P469; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; NAGAO S, 1987, BIOCHEMISTRY-US, V26, P1659, DOI 10.1021/bi00380a026; NAKANO A, 1992, BIOCHEM BIOPH RES CO, V186, P1207, DOI 10.1016/S0006-291X(05)81534-7; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1991, J BIOL CHEM, V266; PASTEELS B, 1990, VISUAL NEUROSCI, V5, P1, DOI 10.1017/S0952523800000031; POCHET R, 1991, J COMP NEUROL, V314, P750, DOI 10.1002/cne.903140408; POLANS AS, 1988, INVEST OPHTH VIS SCI, V29, P1523; POLANS AS, 1993, INVEST OPHTH VIS SCI, V34, P81; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; POLANS AS, 1993, METH NEUROSCI, V15, P248; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; SANNA PP, 1990, NEUROSCI LETT, V118, P136, DOI 10.1016/0304-3940(90)90267-D; SANO T, 1991, CANCER RES, V51, P2926; SZENBENYI DME, 1981, NATURE, V294, P327; TAKAMATSU K, 1992, BRAIN RES, V571, P350, DOI 10.1016/0006-8993(92)90676-Z; TULCHINSKY EM, 1990, GENE, V87, P219, DOI 10.1016/0378-1119(90)90305-B; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WATANABE Y, 1992, J BIOL CHEM, V267, P17136; WATANABE Y, 1992, ARCH BIOCHEM BIOPHYS, V292, P563, DOI 10.1016/0003-9861(92)90031-Q; WEST KA, 1992, TECHNIQUES PROTEIN C, V2, P233; WILKINSON M, 1991, ESSENTIAL MOL BIOL P, P69; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; WOLMAN SR, 1992, CANCER, V70, P1765, DOI 10.1002/1097-0142(19920915)70:4+<1765::AID-CNCR2820701618>3.0.CO;2-C; YAMAGATA K, 1990, NEURON, V2, P469	59	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6233	6240						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119967				2022-12-25	WOS:A1994MY84000111
J	ARRETZ, M; SCHNEIDER, H; GUIARD, B; BRUNNER, M; NEUPERT, W				ARRETZ, M; SCHNEIDER, H; GUIARD, B; BRUNNER, M; NEUPERT, W			CHARACTERIZATION OF THE MITOCHONDRIAL PROCESSING PEPTIDASE OF NEUROSPORA-CRASSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; YEAST MITOCHONDRIA; INTERMEMBRANE SPACE; PROTEIN IMPORT; ORNITHINE TRANSCARBAMYLASE; PROTEOLYTIC CLEAVAGE; PRECURSOR PROTEINS; TRANSLATION SYSTEM; TARGETING PEPTIDES; SENSITIVE METHOD	The mitochondrial processing peptidase (MPP) of Neurospora crassa is constituted by an alpha- and a beta-subunit. We have purified alpha-MPP after expression in Escherichia coli while beta-MPP was purified from mitochondria. A fusion protein between precytochrome b(2) and mouse dihydrofolate reductase was expressed in E. coli, and the purified protein was used as substrate for MPP. Both subunits of MPP are required for processing. MPP removes the matrix targeting signal of cytochrome b(2) by a single cut, and the resulting presequence peptide is 31 amino acid residues in length. It acts as a competitive inhibitor of processing but has a similar to 30-fold lower affinity for MPP than the preprotein. Competition assays show that MPP recognizes the COOH-terminal portion of the presequence of cytochrome b(2) rather than the NH2-terminal part which has the potential to form an amphiphilic helix. Substitution of arginine in position -2 of the matrix targeting sequence of cytochrome b(2) prevents processing but not import of a chimeric precursor. Substitution of the tyrosyl residue in position +1 also prevents processing, indicating that MPP interacts with sequences COOH-terminal to the cleavage site. Noncleavable preprotein is still recognized by MPP. Our data suggest that processing peptidase and import machinery recognize distinct structural elements in preproteins which, however, can be overlapping.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY; UNIV PIERRE & MARIE CURIE,CNRS,CTR GENET MOLEC,F-91190 GIF SUR YVETTE,FRANCE	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay				Brunner, Michael/0000-0001-9798-3047				ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DAUM G, 1982, J BIOL CHEM, V257, P3028; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GELI V, 1990, J BIOL CHEM, V265, P19216; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HORWICH AL, 1987, J CELL BIOL, V105, P669, DOI 10.1083/jcb.105.2.669; HURT EC, 1987, J BIOL CHEM, V262, P1420; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KALOUSEK F, 1993, TRENDS BIOCHEM SCI, V18, P249, DOI 10.1016/0968-0004(93)90174-L; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; NICHOLSON DW, 1988, PROTEIN TRANSFER ORG, P677; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; Sebald W, 1979, Methods Enzymol, V55, P144; STUBER D, 1984, EMBO J, V3, P3143; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	41	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4959	4967						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106471				2022-12-25	WOS:A1994MX57100043
J	DUNDERDALE, HJ; SHARPLES, GJ; LLOYD, RG; WEST, SC				DUNDERDALE, HJ; SHARPLES, GJ; LLOYD, RG; WEST, SC			CLONING, OVEREXPRESSION, PURIFICATION, AND CHARACTERIZATION OF THE ESCHERICHIA-COLI RUVC HOLLIDAY JUNCTION RESOLVASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; CONJUGATIONAL RECOMBINATION; RECA PROTEIN; GENE-PRODUCT; K-12 REVEALS; ENDONUCLEASE; RESOLUTION; MUTANTS; EXPRESSION; DEFICIENT	The ruv(C) gene has been cloned into the plasmid pT7-7 under the control of the T7 phi 10 promoter. Following induction with isopropyl-1-thio-beta-D-galactopyranoside, the l9-kDa RuvC protein was overexpressed to 20-30% of total cell protein. RuvC has been purified to homogeneity by a simple procedure involving precipitation from the crude lysate, followed by three chromatographic steps. The purified protein resolves synthetic Holliday junctions (60 nucleotides in length) by cleavage at the 3'-side of a phosphate group, to produce nicked duplex DNA Under the same conditions no cleavage of linear duplex or single-stranded DNA was detected. However, low levels of cleavage were observed with supercoiled form I and single-stranded circular DNA substrates, consistent with the interaction of RuvC with secondary structures. Using synthetic Holliday junctions, we show that RuvC-mediated resolution requires Mg2+ (10 mM) and exhibits an alkaline pH optimum (pH 9.0). No energy cofactors are needed. When RuvC was analyzed by gel filtration and polyacrylamide gel electrophoresis, monomeric and dimeric forms of the protein were observed.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV NOTTINGHAM,QUEENS MED CTR,DEPT GENET,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham			Sharples, Gary/B-8638-2016	Sharples, Gary/0000-0003-2495-0062; West, Stephen/0000-0001-8848-9418				BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1994, J BIOL CHEM, V269, P5195; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; IWASAKI H, 1989, MOL GEN GENET, V219, P328, DOI 10.1007/BF00261196; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KOSAK HG, 1990, EUR J BIOCHEM, V194, P779, DOI 10.1111/j.1432-1033.1990.tb19469.x; LILLY DMJ, 1981, NUCLEIC ACIDS RES, V9, P1271, DOI 10.1093/nar/9.6.1271; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LUISIDELUCA C, 1989, GENETICS, V122, P269; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; SAMBROOK E, 1989, MOL CLONING LABORATO; SARGENTINI NJ, 1989, MUTAT RES, V215, P115, DOI 10.1016/0027-5107(89)90224-8; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHURVINTON CE, 1982, MOL GEN GENET, V185, P352, DOI 10.1007/BF00330811; STACEY KA, 1976, MOL GEN GENET, V143, P223, DOI 10.1007/BF00266925; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEST SC, 1980, P NATL ACAD SCI-BIOL, V77, P2569, DOI 10.1073/pnas.77.5.2569	37	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5187	5194						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106500				2022-12-25	WOS:A1994MX57100077
J	FARAH, CS; MIYAMOTO, CA; RAMOS, CHI; DASILVA, ACR; QUAGGIO, RB; FUJIMORI, K; SMILLIE, LB; REINACH, FC				FARAH, CS; MIYAMOTO, CA; RAMOS, CHI; DASILVA, ACR; QUAGGIO, RB; FUJIMORI, K; SMILLIE, LB; REINACH, FC			STRUCTURAL AND REGULATORY FUNCTIONS OF THE NH2- AND COOH-TERMINAL REGIONS OF SKELETAL-MUSCLE TROPONIN-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PROTON-MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; BIOLOGICAL-ACTIVITY; INHIBITORY REGION; BINDING-SITES; CROSS-LINKING; CONFORMATIONAL TRANSITION; PROTEOLYTIC FRAGMENTS; SYNTHETIC PEPTIDES	Calcium binding to regulatory sites located in the NH2-terminal domain of troponin C (TnC) induces a conformational change that blocks the inhibitory action of troponin I (TnI) and triggers muscle contraction. We used deletion mutants of TnI in conjunction with a series of TnC mutants to understand the structural and functional relationship between different TnI regions and TnC domains. Our results indicate that TnI is organized into structural and regulatory regions which interact in an antiparallel fashion with the corresponding structural and regulatory regions of TnC. Functional studies show that the COOH-terminal region of TnI, when linked to the inhibitory region (TnI(103-182)) can regulate actomyosin ATPase. A TnI lacking the first 57 amino acids (TnI(d57)) has been shown to have similar properties (Sheng, Z., Pan, B.-S., Miller, T.E., and Potter, J. D. (1992) J. Biol. Chem. 267, 25407-25413). Regulation was not observed with the COOH-terminal region alone (TnI(120-182)), with the NH2-terminal region alone (TnI(1-98)), or with the NH2-terminal linked to the inhibitory region (TnI(1-116)). Binding studies show that the NH2-terminal region of TnI interacts with the COOH-terminal domain of TnC in the presence of Ca2+ or Mg2+ and that the inhibitory plus COOH-terminal region of TnI (TnI(103-182)) interacts with the NH2-terminal domain of TnC in a Ca2+-dependent manner. Based on these results we propose a model for the Ca2+-induced conformational change. In our model the NH2-terminal domain of TnI is anchored strongly to the COOH-terminal domain of TnC in the absence and presence of Ca2+ while the inhibitory and COOH-terminal regions of TnI switch between actin-tropomyosin in the absence of Ca2+ to binding sites in bath NH2- and COOH-terminal domains of TnC in the presence of Ca2+.	UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,BR-01498 SAO PAULO,SP,BRAZIL; UNIV ALBERTA,MED RES COUNCIL GRP PROT STRUCT & FUNCT,EDMONTON T6G 2H7,AB,CANADA	Universidade de Sao Paulo; University of Alberta			Farah, Chuck Shaker/G-5565-2012; Ramos, CH/C-1571-2012	Farah, Chuck Shaker/0000-0003-3110-6302; Ramos, CH/0000-0002-7246-9081				BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; BEALL CJ, 1991, J CELL BIOL, V114, P941, DOI 10.1083/jcb.114.5.941; CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CHEUNG HC, 1987, BIOCHEMISTRY-US, V26, P5904, DOI 10.1021/bi00392a049; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; DOBROVOLSKY AB, 1984, BIOCHIM BIOPHYS ACTA, V789, P144, DOI 10.1016/0167-4838(84)90198-5; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; GRAND RJA, 1982, BIOCHEM J, V203, P61, DOI 10.1042/bj2030061; GREASER ML, 1971, J BIOL CHEM, V246, P4226; GREASER ML, 1973, J BIOL CHEM, V248, P2125; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HILL LE, 1992, J BIOL CHEM, V267, P16106; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P7372; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KATAYAMA E, 1982, J BIOCHEM-TOKYO, V91, P1449, DOI 10.1093/oxfordjournals.jbchem.a133835; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KOBAYASHI T, 1989, J BIOL CHEM, V264, P1551; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN JQ, 1989, BIOCHEMISTRY-US, V28, P7380, DOI 10.1021/bi00444a035; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P2821, DOI 10.1021/bi00408a024; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; NEGELE JC, 1992, J BIOL CHEM, V267, P825; NGAI SM, 1992, J BIOL CHEM, V267, P15715; NOZAKI S, 1980, CHEM LETT, P345, DOI 10.1246/cl.1980.345; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; PAN BS, 1992, J BIOL CHEM, V267, P23052; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; PERRY SV, 1972, COLD SPRING HARB SYM, V37, P251; POTTER JD, 1975, J BIOL CHEM, V250, P4628; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; REINACH FC, 1988, J BIOL CHEM, V263, P2371; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SILVA A C R D, 1991, Trends in Biochemical Sciences, V16, P53; SILVA ACR, 1993, EUR J BIOCHEM, V213, P599; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1989, BIOCHEMISTRY-US, V28, P5902, DOI 10.1021/bi00440a029; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TSUDA S, 1992, J BIOCHEM-TOKYO, V112, P665, DOI 10.1093/oxfordjournals.jbchem.a123956; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WADE R, 1990, GENOMICS, V7, P346, DOI 10.1016/0888-7543(90)90168-T; WANG CK, 1984, J MOL BIOL, V190, P509; WEEKS RA, 1978, BIOCHEM J, V173, P449, DOI 10.1042/bj1730449; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	69	196	201	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5230	5240						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106506				2022-12-25	WOS:A1994MX57100083
J	BIGNON, C; SAKAL, E; BELAIR, L; CHAPNIKCOHEN, N; DJIANE, J; GERTLER, A				BIGNON, C; SAKAL, E; BELAIR, L; CHAPNIKCOHEN, N; DJIANE, J; GERTLER, A			PREPARATION OF THE EXTRACELLULAR DOMAIN OF THE RABBIT PROLACTIN RECEPTOR EXPRESSED IN ESCHERICHIA-COLI AND ITS INTERACTION WITH LACTOGENIC HORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; MAMMARY-GLAND; BIOLOGICAL-ACTIVITIES; MONOCLONAL-ANTIBODIES; BINDING-PROPERTIES; MOLECULAR-CLONING; PURIFICATION; FRAGMENTS; TERMINUS; FAMILY	The cDNA of the extracellular domain of the rabbit prolactin receptor (rbPRLR-ECD) was cloned in the prokaryotic expression vector pTrc99A to enable its expression in Escherichia coli after induction with isopropyl-1-thio-beta-D-galactopyranoside. The bacterially expressed rbPRLR-ECD protein, contained within the refractile body pellet, was solubilized in 4.5 m urea, refolded, and purified on a Q-Sepharose column by stepwise elution with NaCl. The bioactive monomeric fraction was eluted in 0.05 m NaCl, yielding 15-20 mg/8 liters of induced culture. The purified protein was >98% homogeneous, as shown by SDS-polyacrylamide gel electrophoresis in the presence or absence of reducing agent and by chromatography on a Superdex column. Its molecular mass was 25 kDa as determined by SDS-polyacrylamide gel electrophoresis in the absence of reducing agent and 22 kDa as determined by gel filtration. Binding experiments revealed remarkable differences between rabbit and porcine prolactins (PRLs) and the other tested lactogenic hormones. Gel filtration was used to determine the stoichiometry of the rbPRLR-ECD interaction with ovine, rabbit, and porcine PRLs, with human growth hormone and its truncated des-7 analogue, and with bovine placental lactogen (bPL) and des-13-bPL. The formation of only 1:1 complexes was indicated, except with bPL, for which a 2:1 complex was detected. Identical stoichiometry was also obtained using excess radiolabeled rbPRLR-ECD in gel filtration experiments. Interaction of I-125-labeled ovine PRL with rbPRLR-ECD secreted into conditioned medium by rbPRLR-ECD cDNA-transfected COS 7 cells also indicated formation of 1:1 molar complexes. Despite the differences in binding potency and stoichiometries of the interaction with rbPRLR-ECD, all seven tested hormones were biologically active in inducing PRL receptor-mediated casein synthesis in explants of rabbit mammary gland. We therefore propose that the formation of the 1:2 complexes with soluble rbPRLR-ECD is not predictive of biological activity of the different lactogenic hormones.	HEBREW UNIV JERUSALEM,FAC AGR,DEPT BIOCHEM FOOD SCI & NUTR,POB 12,IL-76100 REHOVOT,ISRAEL; INRA,ENDOCRINOL MOLEC UNITE,F-78352 JOUY EN JOSAS,FRANCE	Hebrew University of Jerusalem; INRAE; UDICE-French Research Universities; Universite Paris Saclay								ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V86, P2112; AMMAN E, 1988, GENE, V69, P301; BINDER L, 1990, MOL ENDOCRINOL, V4, P1060, DOI 10.1210/mend-4-7-1060; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BYATT JC, 1992, J ANIM SCI, V70, P2911, DOI 10.2527/1992.7092911x; CAHOREAU C, 1992, BIOCHIMIE, V74, P1053, DOI 10.1016/0300-9084(92)90003-W; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DJIANE J, 1985, J BIOL CHEM, V260, P1430; DUSANTERFOURT I, 1984, ENDOCRINOLOGY, V114, P1021, DOI 10.1210/endo-114-3-1021; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FRITZ H, 1965, Z PHYSL CHEM, V342, P253; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GERTLER A, 1984, MOL CELL ENDOCRINOL, V34, P51, DOI 10.1016/0303-7207(84)90158-8; GERTLER A, 1992, J BIOL CHEM, V267, P12655; GERTLER A, 1993, FEBS LETT, V319, P277, DOI 10.1016/0014-5793(93)80562-9; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JAHN G, 1987, P SOC EXP BIOL MED, V184, P19, DOI 10.3181/00379727-184-42440; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martson F.A.O., 1986, BIOCHEM J, V240, P1; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT P, 1992, MOL CELL ENDOCRINOL, V89, P47, DOI 10.1016/0303-7207(92)90210-W; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; TCHELET A, 1993, ADOLESC PEDIATR ENDO, V24, P114; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; TOWNS R, 1992, ENDOCRINOLOGY, V130, P1225, DOI 10.1210/en.130.3.1225; WATERS MJ, 1990, INT J BIOCHEM, V10, P1089	32	52	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3318	3324						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106371				2022-12-25	WOS:A1994MV63100032
J	GRAF, R; LEPIER, A; HARVEY, WR; WIECZOREK, H				GRAF, R; LEPIER, A; HARVEY, WR; WIECZOREK, H			A NOVEL 14-KDA V-ATPASE SUBUNIT IN THE TOBACCO HORNWORM MIDGUT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; TRANSPORTING PLASMA-MEMBRANES; PROTON PUMP; RECONSTITUTION; PURIFICATION; EXPRESSION; KIDNEY; DNA	A cDNA clone encoding a hydrophilic protein with a calculated molecular mass of 13,839 Da was isolated by shotgun screening with an anti-V-ATPase holoenzyme serum. The deduced amino acid sequence showed no significant homology to any other known protein. Southern blots revealed the existence of only one gene encoding the 14-kDa protein. Monospecific antibodies purified by affinity to the recombinant protein demonstrated the presence of a 14-kDa protein in the highly purified goblet cell apical membrane and inhibited ATP-dependent proton transport as well as V-ATPase activity to the same extent. Thus, the 14-kDa protein was shown to be a part of the V-ATPase holoenzyme. Binding of the monospecific antibodies to the ATPase seemed to require an ATP-dependent conformational change of the enzyme, since inhibition only occurred when ATP was present during the antibody binding step. The 14-kDa subunit could be stripped from the membrane by treatment with the chaotropic agent KI, confirming it to be part of the soluble complex of the V-ATPase. In immunoblots, the 14-kDa-specific antibodies showed no cross-reaction with several xenic V-ATPases.	UNIV MUNICH,INST ZOOL,D-80021 MUNICH,GERMANY	University of Munich			/AAU-6215-2020		NIAID NIH HHS [AI22444] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022444] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI I, 1990, J BIOL CHEM, V265, P960; ANRAKU Y, 1992, J EXP BIOL, V172, P67; BACHHAWAT AK, 1993, YEAST, V9, P175, DOI 10.1002/yea.320090208; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROWN D, 1992, J EXP BIOL, V172, P231; BROWN TA, 1991, ESSENTIAL MOL BIOL, V1; CHATTERJEE D, 1992, J EXP BIOL, V172, P193; CIOFFI M, 1983, TISSUE CELL, V15, P781, DOI 10.1016/0040-8166(83)90050-2; DOW JAT, 1992, GENE, V122, P355, DOI 10.1016/0378-1119(92)90226-F; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GLUCK SL, 1992, J EXP BIOL, V172, P219; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GRINSTEIN S, 1992, J EXP BIOL, V172, P179; HARVEY BJ, 1992, J EXP BIOL, V172, P289; HARVEY WR, 1992, J EXP BIOL, V172, P1; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRATA R, 1993, J BIOL CHEM, V268, P961; HO MN, 1993, J BIOL CHEM, V268, P221; KLEIN U, 1992, J EXP BIOL, V172, P345; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LION T, 1990, ANAL BIOCHEM, V188, P335, DOI 10.1016/0003-2697(90)90616-H; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; NELSON N, 1992, J EXP BIOL, V172, P19; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; PEREZCASTINEIRA JR, 1990, BIOCHEM J, V271, P127, DOI 10.1042/bj2710127; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUSTER H, 1992, COMMENTS USB CORP, V19, P36; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; VANHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P37; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; WARD JM, 1992, PLANT PHYSIOL, V99, P925, DOI 10.1104/pp.99.3.925; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335; WIECZOREK H, 1989, J BIOL CHEM, V264, P11143; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608	39	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3767	3774						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106421				2022-12-25	WOS:A1994MV63100093
J	JAYARAM, B; HALEY, BE				JAYARAM, B; HALEY, BE			IDENTIFICATION OF PEPTIDES WITHIN THE BASE BINDING DOMAINS OF THE GTP-SPECIFIC AND ATP-SPECIFIC BINDING-SITES OF TUBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BETA-TUBULIN; GUANOSINE TRIPHOSPHATE; ALPHA-TUBULIN; PORCINE BRAIN; MICROTUBULES; POLYMERIZATION; LOCALIZATION; NUCLEOTIDES; MECHANISM	Using gamma-P-32-labeled 8-azidopurine nucleotide photoaffinity probes of GTP and ATP, the respective purine ring binding domain peptides of tubulin have been identified. First, the location of the GTP-specific binding site was shown to be on the beta-subunit, whereas the major ATP-specific binding site was on the alpha-subunit. Using a combination of anion-exclusion and immobilized Al3+ column chromatography, the respective photolabeled tryptic peptides of both nucleotide binding sites were isolated, further purified by reverse phase high performance liquid chromatography (HPLC) and sequenced. Chymotryptic peptides were also generated for the GTP binding site. High retention of the photoinserted radiolabel was observed with many of the peptides on reverse phase HPLC at low flow rates. The stability of the photoinserted radiolabel to HPLC varied with different peptides. However, certain peptides were easily distinguished as being within the base binding domains of the GTP and ATP binding sites of tubulin. Two beta-tubulin peptides containing the majority of photoinserted [gamma-P-32]8-azidoguanosine 5'-triphosphate corresponded to N-terminal beta-tubulin amino acid residues 3EIVHIQAGQCGNQIGAK19 and 20FWEVISDEHGIDP-TGS35. The peptide containing the majority of photoinserted [gamma-P-32]8-azidoadenosine 5'-triphosphate corresponded to the C-terminal alpha-tubulin sequence 431DYEEVGVDSVEGEGEEEGEE450.	UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,COLL PHARM,800 ROSE ST,LEXINGTON,KY 40536	University of Kentucky					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035766] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI T, 1977, J BIOCHEM-TOKYO, V82, P1063, DOI 10.1093/oxfordjournals.jbchem.a131777; BONNE BJ, 1982, BIOCHEMISTRY-US, V21, P1075; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; Chavan AJ, 1990, BIOCONJUGATE CHEM, V1, P337, DOI 10.1021/bc00005a007; Czarnecki J, 1979, Methods Enzymol, V56, P642; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; GEAHLEN RL, 1979, J BIOL CHEM, V254, P1982; GEAHLEN RL, 1977, P NATL ACAD SCI USA, V74, P4375, DOI 10.1073/pnas.74.10.4375; HALEY BE, 1983, H-S Z PHYSIOL CHEM, V364, P1137; HALLAK ME, 1977, FEBS LETT, V73, P147, DOI 10.1016/0014-5793(77)80968-X; HESSE J, 1987, J BIOL CHEM, V262, P15472; KHATOON S, 1989, ANN NEUROL, V26, P210, DOI 10.1002/ana.410260205; KIM H, 1991, BIOCONJUGATE CHEM, V2, P142, DOI 10.1021/bc00009a002; KIM H, 1987, FASEB J, V46, P2229; KING S, 1991, METHOD ENZYMOL, V191, P449; KOBYASHI T, 1975, J BIOCHEM-TOKYO, V77, P1193; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSE K, 1988, J BIOL CHEM, V263, P15205; LITTLE M, 1988, COMP BIOCHEM PHYS B, V90, P655, DOI 10.1016/0305-0491(88)90320-3; MEJILLANO MR, 1990, BIOCHEM BIOPH RES CO, V166, P653, DOI 10.1016/0006-291X(90)90859-L; MONASTERIO O, 1987, BIOCHEMISTRY-US, V26, P6091, DOI 10.1021/bi00393a022; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; PATURLELAFANECHERE L, 1991, BIOCHEMISTRY-US, V30, P10523, DOI 10.1021/bi00107a022; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; RAJAGOPALAN K, 1993, J BIOL CHEM, V268, P14230; RAYBIN D, 1977, BIOCHEMISTRY-US, V16, P2189, DOI 10.1021/bi00629a023; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; STONE KL, 1989, PRACTICAL GUIDE PROT; TIMASHEFF SN, 1980, ANNU REV BIOCHEM, V49, P565, DOI 10.1146/annurev.bi.49.070180.003025; TRAD CH, 1993, ARCH BIOCHEM BIOPHYS, V304, P58, DOI 10.1006/abbi.1993.1321; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; WEISENBERG RC, 1976, BIOCHEMISTRY-US, V15, P4248, DOI 10.1021/bi00664a018; ZABRECKY JR, 1983, ARCH BIOCHEM BIOPHYS, V225, P475, DOI 10.1016/0003-9861(83)90056-5; ZABRECKY JR, 1982, J BIOL CHEM, V257, P4633; ZABRECKY JR, 1982, NATURE, V296, P775, DOI 10.1038/296775a0	44	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3233	3242						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106359				2022-12-25	WOS:A1994MV63100020
J	OZAKI, K; TERAKITA, A; OZAKI, M; HARA, R; HARA, T; HARANISHIMURA, I; MORI, H; NISHIMURA, M				OZAKI, K; TERAKITA, A; OZAKI, M; HARA, R; HARA, T; HARANISHIMURA, I; MORI, H; NISHIMURA, M			MOLECULAR CHARACTERIZATION AND FUNCTIONAL EXPRESSION OF SQUID RETINAL-BINDING PROTEIN - A NOVEL SPECIES OF HYDROPHOBIC LIGAND-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIUM; BOVINE RETINA; VISUAL CELLS; RAT TISSUE; PHOTOISOMERASE; RETINOCHROME; SEQUENCE; EYES	The primary structure of squid retinal-binding protein (RALBP) was determined by cDNA and protein sequencing. Squid RALBP contains 342 amino acid residues in a single N-terminal-blocked chain with a molecular weight of 39,111. The N(alpha)-blocking group was identified as an acetyl moiety by mass spectrometry. The amino acid sequence revealed that the protein is highly hydrophilic and acidic, but it has several hydrophobic regions that are located mainly in the middle part of the polypeptide chain. It is also predicted that these hydrophobic regions form beta-sheet structures. The primary structure of RALBP is, however, quite distinct from those of other retinoid-binding proteins, showing that squid RALBP is a novel hydrophobic ligand-binding protein that functions in intracellular retinoid transport. Using the cloned cDNA, squid RALBP was expressed in vitro. By carrying out the translation at 20-degrees-C in reticulocyte lysates, the protein having retinol binding activity was produced.	NATL INST BASIC BIOL,DEPT CELL BIOL,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	OZAKI, K (corresponding author), OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.		; Ozaki, Koichi/O-2798-2015	Terakita, Akihisa/0000-0002-8379-8913; Ozaki, Koichi/0000-0001-7268-5377; Nishimura, Mikio/0000-0001-7960-9721				ADLER AJ, 1982, BIOCHEM BIOPH RES CO, V108, P1601, DOI 10.1016/S0006-291X(82)80091-0; BASHOR MM, 1973, P NATL ACAD SCI USA, V70, P3483, DOI 10.1073/pnas.70.12.3483; BRIDGES CDB, 1984, VISION RES, V24, P1581, DOI 10.1016/0042-6989(84)90316-X; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRABB JW, 1988, J BIOL CHEM, V263, P18678; FONG SL, 1988, VISION RES, V28, P563, DOI 10.1016/0042-6989(88)90106-X; FUTTERMAN S, 1977, J BIOL CHEM, V252, P3267; HARA R, 1987, RETINAL PROTEINS, P447; HARA T, 1991, PROGR RETINAL RES, V10, P1799; HARANISHIMURA I, 1990, FEBS LETT, V271, P106, DOI 10.1016/0014-5793(90)80383-T; HARANISHIMURA I, 1993, FEBS LETT, V317, P5, DOI 10.1016/0014-5793(93)81480-N; HELLER J, 1975, J BIOL CHEM, V250, P3613; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI YL, 1982, NATURE, V298, P848, DOI 10.1038/298848a0; LIN ZS, 1989, VISION RES, V29, P1699, DOI 10.1016/0042-6989(89)90152-1; Maniatis T., 1982, MOL CLONING; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907; ONG DE, 1975, J BIOL CHEM, V250, P6113; OZAKI K, 1987, VISION RES, V27, P1057, DOI 10.1016/0042-6989(87)90020-4; OZAKI K, 1991, BIOPHYSICS-USSR, V31, P129; PEPE IM, 1980, VISION RES, V20, P97, DOI 10.1016/0042-6989(80)90150-9; PEPE IM, 1992, J PHOTOCH PHOTOBIO B, V13, P5, DOI 10.1016/1011-1344(92)80035-T; RANDO RR, 1991, PROGR RETINAL RES, V10, P161; SAARI JC, 1982, J BIOL CHEM, V257, P13329; TAKAHASHI K, 1982, BIOCHEM BIOPH RES CO, V106, P1099, DOI 10.1016/0006-291X(82)91225-6; TERAKITA A, 1989, VISION RES, V29, P639, DOI 10.1016/0042-6989(89)90026-6; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ZIMMERMANN JG, 1988, TREND BIOCH SCI, V13, P64	31	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3838	3845						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106428				2022-12-25	WOS:A1994MV63100103
J	XU, QA; YU, LA; CHITNIS, VP; CHITNIS, PR				XU, QA; YU, LA; CHITNIS, VP; CHITNIS, PR			FUNCTION AND ORGANIZATION OF PHOTOSYSTEM-I IN A CYANOBACTERIAL MUTANT STRAIN THAT LACKS PSAF AND PSAJ SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; CHEMICAL CROSS-LINKING; TARGETED MUTAGENESIS; MOLECULAR-CLONING; 2 SUBUNITS; PLASTOCYANIN; IDENTIFICATION; POLYPEPTIDE; FERREDOXIN; TOPOLOGY	Photosystem I functions as a light-driven plastocyanin-ferredoxin oxidoreductase in the photosynthetic membranes of cyanobacteria and chloroplasts. A mutant strain of the cyanobacterium Synechocystis sp. PCC 6803 that contains a deletion of the psaF gene and a transcriptionally inactive psaJ gene has assembled photosystem I complexes that lack PsaF, a lumenal protein and PsaJ, a 4-kDa hydrophobic protein. The cells of the mutant and wild type strains have similar rates of photosynthetic electron transfer and P700+ rereduction under linear and cyclic electron transfer conditions. Analysis of flash-induced absorption transients -at 700 nm demonstrate that the absence of PsaF in purified mutant photosystem I did not affect the rate of P700 rereduction by cytochrome c553. Therefore, PsaF is not essential for docking of cytochrome c553. We also studied the organization of the proteins of mutant and wild type photosystem I by comparing their accessibility to digestion by thermolysin or to removal by 1 m NaI. The PsaA-PsaB subunits were more easily degraded by thermolysin in the mutant photosystem I. Thermolysin cleavage of PsaB yielded two major fragments that were immunoreactive with an antibody raised against the C terminus of PsaB. The N termini of these PsaB peptides mapped at Ile482 and Ile498 residues, thus identifying a surface-exposed domain of the core of photosystem I. The PsaE subunit could be removed by 1 m NaI and was rapidly digested by thermolysin in the mutant but not in the wild type photosystem I. Therefore, PsaF and PsaJ subunits of photosystem I have dispensable accessory roles in the function and organization of the complex.	KANSAS STATE UNIV AGR & APPL SCI, DIV BIOL, MANHATTAN, KS 66506 USA; UNIV NEBRASKA, DEPT BIOCHEM, LINCOLN, NE 68583 USA	Kansas State University; University of Nebraska System; University of Nebraska Lincoln								ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BENGIS C, 1977, J BIOL CHEM, V252, P4564; BOTTIN H, 1987, BIOCHIM BIOPHYS ACTA, V894, P39, DOI 10.1016/0005-2728(87)90210-6; BOTTIN H, 1985, BIOCHEMISTRY-US, V24, P6453, DOI 10.1021/bi00344a022; BRYANT DA, 1992, PHOTOSYSTEMS STRUCTU, P501; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; CHITNIS PR, 1992, PLANT PHYSIOL, V99, P239, DOI 10.1104/pp.99.1.239; CHITNIS PR, 1991, PHOTOSYNTHETIC APPAR, P178; CHITNIS PR, 1992, CHLOROPLAST BIOGENES, P277; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; HATANAKA H, 1993, BIOCHIM BIOPHYS ACTA, V1141, P45, DOI 10.1016/0005-2728(93)90187-K; HENRY RL, 1992, PLANT PHYSIOL BIOCH, V30, P357; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; HO KK, 1979, BIOCHIM BIOPHYS ACTA, V545, P236; IKEUCHI M, 1992, PLANT CELL PHYSIOL, V33, P1057; IKEUCHI M, 1991, FEBS LETT, V287, P5, DOI 10.1016/0014-5793(91)80003-L; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; LAGOUTTE B, 1992, EUR J BIOCHEM, V205, P1175, DOI 10.1111/j.1432-1033.1992.tb16888.x; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; NECHUSHTAI R, 1981, J BIOENERG BIOMEMBR, V13, P295, DOI 10.1007/BF00743207; REILLY P, 1988, J BIOL CHEM, V263, P17658; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMART LB, 1991, PLANT MOL BIOL, V17, P959, DOI 10.1007/BF00037136; SONOIKE K, 1993, BIOCHIM BIOPHYS ACTA, V1141, P52, DOI 10.1016/0005-2728(93)90188-L; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZHANG L, 1992, J BIOL CHEM, V267, P19054; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	41	103	108	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3205	3211						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106355				2022-12-25	WOS:A1994MV63100016
J	GLAVAS, N; AHMAD, S; BRAGG, PD; OLAUSSON, T; RYDSTROM, J				GLAVAS, N; AHMAD, S; BRAGG, PD; OLAUSSON, T; RYDSTROM, J			IDENTIFICATION OF N,N'-DICYCLOHEXYLCARBODIIMIDE-REACTIVE GLUTAMIC AND ASPARTIC-ACID RESIDUES IN ESCHERICHIA-COLI TRANSHYDROGENASE AND THE EXCHANGE OF THESE BY SITE-SPECIFIC MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE-NUCLEOTIDE TRANSHYDROGENASE; HEART MITOCHONDRIAL TRANSHYDROGENASE; ATP-DRIVEN TRANSHYDROGENASE; DICYCLOHEXYLCARBODIIMIDE; SEQUENCE; VESICLES; PROTEINS	Pyridine nucleotide transhydrogenase (EC 1.6.1.1) from Escherichia coli was investigated with respect to the role of glutamic and aspartic acid residues reactive to N,N'-dicyclohexylcarbodiimide (DCCD) and potentially involved in the proton-pumping mechanism of the enzyme. The E. coli transhydrogenase consists of an alpha (510 residues) and a beta (462 residues) subunit. DCCD reacts with the enzyme to inhibit catalytic activity and proton pumping. This reagent modifies Asp(alpha232), Glu(alpha238), and Glu(alpha240) as well as amino acid residue(s) in the beta subunit. Using the cloned and overexpressed E. coli transhydrogenase genes (Clarke, D. M., and Bragg, P. D. (1985) J. Bacteriol. 162, 367-373), Asp(alpha232) and Glu(alpha238) were replaced independently by site-specific mutagenesis. In addition, Asp(alpha232), Glu(alpha238), and Glu(alpha240) were replaced to generate triple mutants. The specific catalytic activities of the mutant transhydrogenases alphaD232N, alphaD232E, alphaD232K, alphaD232H, alphaE238K, and alphaE238Q as well as of the triple mutants alphaD232N,alphaE238Q,alphaE240Q and alphaD232H,alphaE238Q, alphaE240Q were in the range of 40-90% of the wild-type activity. Proton-pumping activity was present in all mutants. Examination of the extent of subunit modification by [C-14]DCCD revealed that the label was still incorporated into both alpha and beta subunits in the Asp(alpha232) mutants, but that the alpha subunit was not labeled in the triple mutants. Catalytic and proton-pumping activities were nearly insensitive to DCCD in the triple mutants. This suggests that loss of catalytic and proton pumping activities is associated with modification of the aspartic and glutamic acid residues of the a subunit. In the presence of the substrate NADPH, the rate of modification of the beta subunit by [C-14]DCCD was increased, and there was a greater extent of enzyme inactivation. By contrast, NADH and 3-acetylpyridine-NAD+ protected the catalytic activity of the transhydrogenase from inhibition by DCCD. The protection was particularly marked in the E238Q and E238K mutants. It is concluded that the Asp(alpha232), Glu(alpha238), and Glu(alpha240) residues are not essential for catalytic activity or proton pumping. The inactivation by DCCD is likely due to the introduction of a sterically hindering group that reacts with the identified acidic residues close to the NAD(H)-binding site.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM,2146 HLTH SCI MALL,VANCOUVER V6T 1Z3,BC,CANADA; CHALMERS UNIV TECHNOL,DEPT BIOCHEM & BIOPHYS,S-41296 GOTHENBURG,SWEDEN; ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,S-10044 STOCKHOLM 70,SWEDEN	University of British Columbia; Chalmers University of Technology; Royal Institute of Technology			Ahmad, Suhail/AAJ-5456-2021; Rydström, Jan/A-7683-2010					AHMAD S, 1992, J BIOL CHEM, V267, P7007; AHMAD S, 1992, EUR J BIOCHEM, V207, P733, DOI 10.1111/j.1432-1033.1992.tb17103.x; ANDERSON WM, 1978, ARCH BIOCHEM BIOPHYS, V187, P180, DOI 10.1016/0003-9861(78)90021-8; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CLARKE DM, 1985, J BACTERIOL, V162, P367, DOI 10.1128/JB.162.1.367-373.1985; CLARKE DM, 1985, EUR J BIOCHEM, V149, P517, DOI 10.1111/j.1432-1033.1985.tb08955.x; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; EARLE SR, 1980, BIOCHEMISTRY-US, V19, P561, DOI 10.1021/bi00544a026; EARLE SR, 1980, J BIOL CHEM, V255, P827; EYTAN GD, 1987, J BIOL CHEM, V262, P5015; EYTAN GD, 1987, J BIOL CHEM, V262, P5008; EYTAN GD, 1990, J BIOL CHEM, V265, P12949; FISHER RR, 1982, PYRIDINE NUCLEOTIDE, P280; HOJEBERG B, 1977, BIOCHEM BIOPH RES CO, V78, P1183, DOI 10.1016/0006-291X(77)91418-8; HU PS, 1992, BIOCHIM BIOPHYS ACTA, V1102, P19, DOI 10.1016/0167-4838(92)90494-X; JACKSON JB, 1991, J BIOENERG BIOMEMBR, V23, P715, DOI 10.1007/BF00785998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; OLSSON A, 1984, J BIOCHEM BIOPH METH, V10, P483; PENNINGTON RM, 1981, J BIOL CHEM, V256, P8963; PERSSON B, 1984, J BIOL CHEM, V259, P8626; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P6340, DOI 10.1021/bi00321a008; PHELPS DC, 1981, J BIOL CHEM, V256, P8217; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; Rydstrom J, 1979, Methods Enzymol, V55, P261; RYDSTROM J, 1977, BIOCHIM BIOPHYS ACTA, V463, P155, DOI 10.1016/0304-4173(77)90007-6; RYDSTROM J, 1987, PYRIDINE NUCLEOTID B, V2, P433; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TONG RCW, 1991, BIOCHIM BIOPHYS ACTA, V1080, P19, DOI 10.1016/0167-4838(91)90106-A; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P667; WU LNY, 1982, J BIOL CHEM, V257, P4052; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761	34	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14125	14130						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8100227				2022-12-25	WOS:A1993LJ82500052
J	DALLAS, SL; PARKSNYDER, S; MIYAZONO, K; TWARDZIK, D; MUNDY, GR; BONEWALD, LF				DALLAS, SL; PARKSNYDER, S; MIYAZONO, K; TWARDZIK, D; MUNDY, GR; BONEWALD, LF			CHARACTERIZATION AND AUTOREGULATION OF LATENT TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) COMPLEXES IN OSTEOBLAST-LIKE CELL-LINES - PRODUCTION OF A LATENT COMPLEX LACKING THE LATENT TGF-BETA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; MARFAN-SYNDROME; HUMAN-PLATELETS; BONE-FORMATION; MESSENGER-RNA; FACTOR-BETA-1; EXPRESSION; PRECURSOR; SEQUENCES; INVIVO	We have previously shown that bone organ cultures produce large amounts of latent transforming growth factor beta (TGF beta), which lacks latent TGF beta-binding protein (LTBP). In this study we used the known osteoblastlike cell lines UMR-106, ROS 17/2.8, and MG63 as models to further examine latent TGF beta expression in bone. We found that the osteosarcoma cell line UMR-106 secreted latent TGF beta almost exclusively as a 100-kDa complex lacking LTBP. ROS 17/2.8 cells produced both the 100-kDa complex and also a 290-kDa complex containing the fibroblastic (190 kDa) form of LTBP. MG63 cells (like human foreskin fibroblasts) expressed almost exclusively the 290-kDa complex. To investigate the regulation of latent TGF beta complexes in bone cells we assessed the effects of TGF beta 1 treatment on expression of active and latent TGF beta. TGF beta 1 induced secretion of latent but not active TGF beta in all cell types examined. In human foreskin fibroblast cells, TGF beta 1 and LTBP mRNA were expressed concomitantly. In contrast, in osteosarcoma cell lines autoinduction of TGF beta 1 mRNA was associated with either a delayed increase or no change in LTBP mRNA In UMR-106 cells LTBP message was virtually undetectable. We postulate that the expression of different latent TGF beta forms by osteoblast-like cells may reflect their maturation states and that different latent TGF beta complexes may have different functions, for example as secretory forms or as matrix storage forms.	LUDWIG INST CANC RES,UPPSALA,SWEDEN; BRISTOL MYERS SQUIBB,SEATTLE,WA 98121; UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284; AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284	Ludwig Institute for Cancer Research; Bristol-Myers Squibb; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	DALLAS, SL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL & METAB,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.		Bonewald, Lynda/Q-3638-2019		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE008569] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08569] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; BOYAN BD, 1989, J BIOL CHEM, V264, P11879; COLOSETTI P, 1993, FEBS LETT, V320, P140, DOI 10.1016/0014-5793(93)80079-A; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P7041; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MACKIE EJ, 1990, BONE, V11, P295, DOI 10.1016/8756-3282(90)90083-B; MARCELLI C, 1990, J BONE MINER RES, V5, P1087; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MILLER DM, 1992, MOL ENDOCRINOL, V6, P694, DOI 10.1210/me.6.5.694; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024; SEYEDIN SM, 1986, J BIOL CHEM, V261, P5693; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; TWARDZIK DR, 1990, ANN NY ACAD SCI, V593, P276, DOI 10.1111/j.1749-6632.1990.tb16119.x; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646	29	155	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6815	6822						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120044				2022-12-25	WOS:A1994MZ50300088
J	KIM, WK; RABIN, RA				KIM, WK; RABIN, RA			CHARACTERIZATION OF THE PURINERGIC P-2 RECEPTORS IN PC12 CELLS - EVIDENCE FOR A NOVEL SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAST-CELLS; TRANSFORMED MOUSE FIBROBLASTS; LIVER PLASMA-MEMBRANES; ADENOSINE 5'-TRIPHOSPHATE; EXTRACELLULAR ATP; SMOOTH-MUSCLE; ECTO-ENZYMES; CALCIUM; PERMEABILIZATION; CHANNELS	The properties of the purinergic receptors in the PC12 cells were studied. The rank order of potency to increase [Ca2+](i) was: adenosine 5'-O-(1-thiotriphosphate) > ATP > adenosine 5'-O-(3-thiotriphosphate) >>> 3'-O-(4-benzoylbenzoyl)ATP. ADP, AMP, GTP, UTP, alpha, beta- and beta,gamma-methylene adenosine 5'-triphosphates, 5'-adenylylimidodiphosphate, and adenosine analogues were ineffective. Although tetrabasic ATP(4-) was the form responsible for activation of the P-2 receptors, ATP(4-) did not cause cell membrane permeabilization. The binding of alpha-S-35-ATP to the intact cells showed a divalent cation dependency and a binding profile similar to the rank order of potency to increase [Ca2+](i). Scatchard plots of the equilibrium saturation binding data were nonlinear, and dissociation kinetics of the radioligand were best described using two kinetic rates. Different kinetic rates were, however, obtained when dissociation was initiated by the addition of excess ATP or by an 80-fold dilution. The present study describes a purinergic P-2 receptor on PC12 cells that does not fit the classification for the P(2)X, P(2)y, P(2)t, P(2)u, and P(2)z receptor subtypes.	SUNY BUFFALO,DEPT PHARMACOL & THERAPEUT,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006207] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06207] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ARAV R, 1985, BIOCHIM BIOPHYS ACTA, V820, P183, DOI 10.1016/0005-2736(85)90111-7; Bean B P, 1990, Ion Channels, V2, P169; BEAN BP, 1990, J NEUROSCI, V10, P1; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BURGER RM, 1975, BIOCHEMISTRY-US, V14, P2362, DOI 10.1021/bi00682a014; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; CARRAWAY CAC, 1980, BIOCHEM J, V191, P45, DOI 10.1042/bj1910045; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; COCKCROFT S, 1979, J PHYSIOL-LONDON, V296, P229, DOI 10.1113/jphysiol.1979.sp013002; DEPIERRE JW, 1974, J BIOL CHEM, V249, P7121; EVANS WH, 1973, BIOCHEM J, V133, P189, DOI 10.1042/bj1330189; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; FRIEL DD, 1988, J PHYSIOL-LONDON, V401, P361, DOI 10.1113/jphysiol.1988.sp017167; GONZALEZ FA, 1989, J CELL PHYSIOL, V139, P109, DOI 10.1002/jcp.1041390116; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GROHOVAZ F, 1991, J CELL BIOL, V113, P1341, DOI 10.1083/jcb.113.6.1341; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARLAN J, 1977, INFECT IMMUN, V15, P436, DOI 10.1128/IAI.15.2.436-443.1977; IGUSA Y, 1988, J PHYSIOL-LONDON, V405, P169, DOI 10.1113/jphysiol.1988.sp017327; IPATA PL, 1968, BIOCHEMISTRY-US, V7, P507, DOI 10.1021/bi00842a004; KELLEY LK, 1987, BIOCHEM BIOPH RES CO, V148, P126, DOI 10.1016/0006-291X(87)91085-0; KIM WK, 1993, MOL PHARMACOL, V44, P405; LIN SH, 1990, ANN NY ACAD SCI, V603, P394; MAJID MA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P283, DOI 10.1016/0167-4889(92)90118-U; MUNIZ O, 1984, ARTHRITIS RHEUM, V27, P184; MURRIN RJA, 1992, MOL PHARMACOL, V41, P561; NAKAZAWA K, 1991, J PHYSIOL-LONDON, V434, P647, DOI 10.1113/jphysiol.1991.sp018491; Pearson J.D., 1985, METHODS PHARM, V6, P83; PIEBER M, 1991, COMP BIOCHEM PHYS B, V100, P281, DOI 10.1016/0305-0491(91)90375-N; RATTO GM, 1988, J NEUROSCI, V8, P3240; SARKIS JJF, 1991, BRAIN RES BULL, V26, P871, DOI 10.1016/0361-9230(91)90251-E; SELA D, 1991, J BIOL CHEM, V266, P17990; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; STEINBERG TH, 1990, ANN NY ACAD SCI, V603, P120; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Tallarida RJ, 1981, MANUAL PHARM CALCULA; TATHAM PER, 1988, EUR J PHARMACOL, V147, P13, DOI 10.1016/0014-2999(88)90628-0; TORPPEDERSEN C, 1979, BIOCHIM BIOPHYS ACTA, V571, P94, DOI 10.1016/0005-2744(79)90229-8; TURNAY J, 1992, MOL CELL BIOCHEM, V117, P23; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152	42	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6471	6477						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119998				2022-12-25	WOS:A1994MZ50300034
J	PEPPERKOK, R; LORENZ, P; ANSORGE, W; PYERIN, W				PEPPERKOK, R; LORENZ, P; ANSORGE, W; PYERIN, W			CASEIN KINASE-II IS REQUIRED FOR TRANSITION OF G(0)/G(1), EARLY G(1), AND G(1)/S PHASES OF THE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; DNA-BINDING ACTIVITY; C-FOS GENE; BETA-SUBUNIT; CAPILLARY MICROINJECTION; PROTEIN-KINASES; GROWTH-FACTOR; PHOSPHORYLATION; TRANSCRIPTION; STIMULATION	Casein kinase II (CKII) is a ubiquitous serine/ threonine protein kinase with many cellular functions, including participation in mitogenic signaling by cytoplasmic nuclear translocation (Lorenz, P., Pepperkok, R., Ansorge, W., and Pyerin, W. (1993) J. Biol. Chem. 268, 2733-2739). To examine whether cell compartment-specific availability is a requirement for CKII function during cell cycle progression, antibodies against CKII beta, the regulatory subunit of CKII, were microinjected into the cytoplasm or the nucleus of G(0)-synchronized human primary fibroblasts (IMR-90) at the time of mitogenic stimulation or at various intervals thereafter. Significant inhibition of the stimulation was obtained with both cytoplasmic and nuclear injections. The inhibition was reversible, was not observed with control antibodies, and was abolished by co-injection of purified CKII holoenzyme. The inhibition differed, however, in extent, duration, and cell cycle phase between cytoplasmic and nuclear injections. After cytoplasmic injection, inhibition reached 45-50% and was effective at two intervals within the first 2 h and at 12-16 h post-stimulation, i.e. at G(0)/G(1) phase transition and at the G(1)/S phase boundary of the cell cycle. After injection into the nucleus, the inhibition was considerably stronger, reaching 80-85%, and was effective for the first 6 h post-stimulation, i.e. for the transition of G(0)/G(1) phase and the adjoining first part of G(1) phase. Cytoplasmic or nuclear injections within S phase affected neither DNA synthesis nor cell division. The data suggest that cell cycle transition from G(0) to S phase requires the presence of a certain functional level of CKII at defined times and at defined cellular locations as follows: for transition of G(0)/G(1) at both the nucleus and the cytoplasm, for transition of early G(1) at the nucleus, and for transition of G(1)/S at the cytoplasm.	GERMAN CANC RES CTR, W-6900 HEIDELBERG, GERMANY; EUROPEAN MOLEC BIOL LAB, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL)			Ansorge, Wilhelm/AAN-8780-2020	Lorenz, Peter A./0000-0001-7925-1002; Pepperkok, Rainer/0000-0002-9762-3583				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BODENBACH L, 1994, IN PRESS EUR J BIOCH; CARROLL D, 1989, J BIOL CHEM, V264, P7345; COCHET C, 1983, J BIOL CHEM, V258, P1403; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HUNTER T, 1988, COLD SPRING HARB SYM, V53, P131, DOI 10.1101/SQB.1988.053.01.019; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MANAK JR, 1993, ONCOGENE, V8, P703; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1993, EXP CELL RES, V204, P278, DOI 10.1006/excr.1993.1034; PEPPERKOK R, 1988, EXP CELL RES, V178, P369, DOI 10.1016/0014-4827(88)90406-5; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PYERIN W, 1987, BIOL CHEM H-S, V368, P215, DOI 10.1515/bchm3.1987.368.1.215; PYERIN W, 1992, ANN NY ACAD SCI, V660, P295, DOI 10.1111/j.1749-6632.1992.tb21091.x; PYERIN W, 1992, RECENT ADV CELL MOL, V4, P87; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBITZKI A, 1993, J BIOL CHEM, V268, P5694; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; VOSS H, 1991, J BIOL CHEM, V266, P13706; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	45	171	172	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6986	6991						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120061				2022-12-25	WOS:A1994MZ50300110
J	VANLAAR, T; STEEGENGA, WT; JOCHEMSEN, AG; TERLETH, C; VANDEREB, AJ				VANLAAR, T; STEEGENGA, WT; JOCHEMSEN, AG; TERLETH, C; VANDEREB, AJ			BLOOMS SYNDROME CELLS GM1492 LACK DETECTABLE P53 PROTEIN BUT EXHIBIT NORMAL G1 CELL-CYCLE ARREST AFTER UV IRRADIATION	ONCOGENE			English	Note							WILD-TYPE P53	The tumor suppressor gene p53 is thought to be a key factor in the onset of G1 cell-cycle arrest following DNA damage. However, here we describe cells derived from a patient with Bloom's syndrome, lacking any detectable p53 protein, that still shows a functional G1 cell-cycle checkpoint after irradiation with UV-C. Comparison with cells from other Bloom's patients showed that the absence of p53 protein is not a specific characteristic of Bloom's syndrome.	LEIDEN UNIV,SYLVIUS LAB,MOLEC CARCINOGENESIS LAB,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC								DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRIEDBERG EC, 1985, DNA REPAIR, P532; FRITSCHE M, 1993, ONCOGENE, V8, P307; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; TISHLER RB, 1993, CANCER RES, V53, P2212; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	21	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					981	983						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108144				2022-12-25	WOS:A1994MW55100038
J	BORG, C; LIM, CT; YEOMANS, DC; DIETER, JP; KOMIOTIS, D; ANDERSON, EG; LEBRETON, GC				BORG, C; LIM, CT; YEOMANS, DC; DIETER, JP; KOMIOTIS, D; ANDERSON, EG; LEBRETON, GC			PURIFICATION OF RAT-BRAIN, RABBIT AORTA, AND HUMAN PLATELET THROMBOXANE A(2) PROSTAGLANDIN H-2 RECEPTORS BY IMMUNOAFFINITY CHROMATOGRAPHY EMPLOYING ANTIPEPTIDE AND ANTIRECEPTOR ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BLOOD PLATELETS; 13-AZAPROSTANOIC ACID; POLYACRYLAMIDE GELS; A2 RECEPTOR; ANTAGONIST; PROTEINS; CELLS; AGGREGATION; BINDING; INVITRO	In the present study, a new polyclonal antibody (TxAb) was raised against native thromboxane A(2) (TXA(2))/prostaglandin H-2 (PGH(2)) receptor protein. Previously developed anti-peptide antibodies (P(1)Ab, P(2)Ab) and TxAb were then used to prepare immunoaffinity columns to purify TXA(2)/PGH(2) receptors from platelets, brain, and aorta. In platelets, SDS-polyacrylamide gel electrophoresis revealed the purification of a 55-kDa protein by each affinity column. Identification of this protein as the TXA(2)/PGH(2) receptor was based on: 1) an identical electrophoretic mobility to authentic receptor; 2) immunoblotting of TxAb against P(1)Ab and P(2)Ab-purified protein; 3) immunoblotting of P(1)Ab/P(2)Ab against TxAb-purified protein; and 4) specific [H-3]SQ29,548 binding to TxAb-purified protein. P(1)Ab/TxAb purification of receptors from brain revealed a major protein band at 55 kDa. Furthermore, the eluates from ligand affinity chromatography confirmed the presence of this 55-kDa protein in brain (which was immunoblotted with TxAb), and contained specific [H-3]SQ29,548 binding. In addition to the 55-kDa protein, P(1)Ab/TxAb also purified a minor protein in brain at 52 kDa, which when concentrated, cross-blotted with TxAb and P(1)Ab. This finding indicates sequence homology between the 55- and 52-kDa proteins. Independent identification of brain TXA(2)/PGH(2) receptors was provided by P(2)Ab/TxAb immunohistochemistry, which demonstrated specific labeling of discrete myelin-containing fiber tracts. P(2)Ab/TxAb purification of TXA(2)/PGH(2) receptors from aorta also revealed a major protein band at 55 kDa and a minor band at 52 kDa. These results represent the first purification of TXA(2)/PGH(2) receptors from either brain or aorta.	UNIV ILLINOIS,DEPT PHARMACOL MC 868,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Yeomans, David/0000-0002-9389-8539	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24530] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; ARMSTRONG RA, 1983, BRIT J PHARMACOL, V79, P953, DOI 10.1111/j.1476-5381.1983.tb10541.x; BORG C, 1993, BIOCHEM PHARMACOL, V45, P2071, DOI 10.1016/0006-2952(93)90018-R; BORG C, 1993, FASEB J, V7, P656; BORG C, 1992, BLOOD, V80, P57; BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185; BRACE LD, 1985, AM J PHYSIOL, V249, pH1, DOI 10.1152/ajpheart.1985.249.1.H1; HALUSHKA PV, 1987, FASEB J, V46, P149; HANASAKI K, 1988, BIOCHEM BIOPH RES CO, V151, P1352, DOI 10.1016/S0006-291X(88)80511-4; HORN PT, 1984, J CARDIOVASC PHARM, V6, P609, DOI 10.1097/00005344-198407000-00009; HUNG SC, 1983, BIOCHIM BIOPHYS ACTA, V728, P171, DOI 10.1016/0005-2736(83)90468-6; KIM SO, 1992, BIOCHEM PHARMACOL, V43, P313; KNEZEVIC I, 1992, J PHARMACOL EXP THER, V260, P947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1991, J PHARMACOL EXP THER, V259, P1371; LEBRETON GC, 1979, P NATL ACAD SCI USA, V76, P4097; LOHSE MJ, 1984, N-S ARCH PHARMACOL, V326, P69, DOI 10.1007/BF00518781; LUMLEY P, 1989, BRIT J PHARMACOL, V97, P783, DOI 10.1111/j.1476-5381.1989.tb12017.x; MAIS D, 1984, TETRAHEDRON LETT, V25, P4207, DOI 10.1016/S0040-4039(01)81396-4; MAYEUX PR, 1989, J PHARMACOL EXP THER, V250, P923; MONCADA S, 1976, PROSTAGLANDINS, V12, P715, DOI 10.1016/0090-6980(76)90048-4; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKAHATA N, 1990, EUR J PHARMACOL, V184, P233; NAKAHATA N, 1992, BRAIN RES, V583, P100, DOI 10.1016/S0006-8993(10)80013-7; NAKANO T, 1988, FEBS LETT, V234, P309, DOI 10.1016/0014-5793(88)80105-4; OGLETREE ML, 1987, FED PROC, V46, P133; OGLETREE ML, 1985, J PHARMACOL EXP THER, V234, P435; OWEN NE, 1981, AM J PHYSIOL, V241, pH613, DOI 10.1152/ajpheart.1981.241.4.H613; PARISE LV, 1982, J PHARMACOL EXP THER, V222, P276; PATSCHEKE H, 1984, THROMB RES, V33, P277, DOI 10.1016/0049-3848(84)90163-4; RYBICKI JP, 1983, BIOCHIM BIOPHYS ACTA, V751, P66, DOI 10.1016/0005-2760(83)90257-6; SWANSON ML, 1992, BIOL REPROD, V47, P105, DOI 10.1095/biolreprod47.1.105; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; WILKES BM, 1989, AM J PHYSIOL, V256, pF1111, DOI 10.1152/ajprenal.1989.256.6.F1111	35	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6109	6116						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119956				2022-12-25	WOS:A1994MY84000095
J	GRONEMEIER, M; CONDIE, A; PROSSER, J; STEINMEYER, K; JENTSCH, TJ; JOCKUSCH, H				GRONEMEIER, M; CONDIE, A; PROSSER, J; STEINMEYER, K; JENTSCH, TJ; JOCKUSCH, H			NONSENSE AND MISSENSE MUTATIONS IN THE MUSCULAR CHLORIDE CHANNEL GENE CLC-1 OF MYOTONIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYL-N-NITROSOUREA; SKELETAL-MUSCLE; MOUSE MUTANT; ETHYLNITROSOUREA; EXPRESSION; DISEASE; CLONING; LOCUS; ADR; P53	In mature vertebrate muscle, the chloride channel Clc-1 is necessary for the stabilization of the resting potential. Its functional defect leads to the disease myotonia. The ADR mouse (phenotype ADR, genotype adr/adr) is an animal model for human myotonias. The adr gene is a member of a family of non-complementing recessive autosomal mutations (''alleles'' of adr) that cause myotonia in the mouse. The standard allele adr has arisen by the insertion of a retroposon into the chloride channel gene Clc-1 (Steinmeyer, K., Klocke, R., Ortland, C., Gronemeier, M., Jockusch, H., Grunder, S., and Jentsch, T. J. (1991) Nature 354, 304-308). In order to study the nature of two other alleles, adr(mto) and adr(K), we have analyzed overlapping Clc-1 cDNA amplification products by the hydroxylamine and osmium tetroxide modification technique and direct sequencing. A comparison between ADR*MTO and C57BL/6 wild type showed six base pair substitutions, one of which resulted in a stop codon in position 47, whereas the five others are either silent or lead to amino acid substitutions in non-conserved regions of the Clc-1 sequence and were already present in the wild type inbred SWR/J strain from which adr(mto) was derived. The detection of the stop codon in the adr(mto) allele is further indication of the identity of the Clc-1 chloride channel with the adr myotonia gene in the mouse, because a chain termination close to the N terminus would necessarily destroy gene function. For the ethylnitrosourea-induced mutation adr(K), an Ile --> Thr exchange in codon 553 was identified. As this affects a conserved residue within a highly conserved region of the Clc-1 gene, a functional significance of this residue is suggested.	UNIV BIELEFELD,DEV BIOL UNIT,D-33501 BIELEFELD,GERMANY; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV HAMBURG,CTR MOLEC NEUROBIOL,D-20246 HAMBURG,GERMANY	University of Bielefeld; University of Edinburgh; University of Hamburg				Jentsch, Thomas/0000-0002-3509-2553				ABDALLA JA, 1992, AM J HUM GENET, V51, P579; ADKISON L, 1989, MOUSE NEWS LETT, V84, P89; ADRIAN RH, 1974, J PHYSIOL-LONDON, V240, P505, DOI 10.1113/jphysiol.1974.sp010620; BODE VC, 1984, GENETICS, V108, P457; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P367, DOI 10.1113/jphysiol.1971.sp009667; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHIOCCA SM, 1992, P NATL ACAD SCI USA, V89, P5331, DOI 10.1073/pnas.89.12.5331; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONDIE A, 1993, HUM MUTAT, V2, P58, DOI 10.1002/humu.1380020111; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DAVISSON MT, 1989, MOUSE NEWS LETT, V83, P167; ECKERT KA, 1988, MOL CARCINOGEN, V1, P50, DOI 10.1002/mc.2940010111; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HELLER AH, 1982, J NEUROSCI, V2, P924; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; JOCKUSCH H, 1988, GENET RES, V52, P203, DOI 10.1017/S001667230002766X; JOCKUSCH H, 1991, M MOUSE MOL GENETICS, P137; JOCKUSCH H, 1990, MOUSE GENOME, V86, P216; JOCKUSCH H, 1986, MOUSE NEWS LETT, V75, P19; JOCKUSCH H, 1990, MOUSE GENOME, V87, P72; KAWASAKI E, 1989, AMPLIFICATIONS FORUM, V3, P4; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KOLTGEN D, 1991, MUSCLE NERVE, V14, P775, DOI 10.1002/mus.880140813; LEHMANNHORN F, 1993, NEUROMUSCULAR DISORD, V3, P161, DOI 10.1016/0960-8966(93)90009-9; MEHRKE G, 1988, MUSCLE NERVE, V11, P440, DOI 10.1002/mus.880110505; MONTANDON AJ, 1989, NUCLEIC ACIDS RES, V17, P3347, DOI 10.1093/nar/17.9.3347; NEUMANN P, 1989, MOUSE NEWS LETT, V83, P157; POWELL JA, 1973, J CELL PHYSIOL, V82, P21, DOI 10.1002/jcp.1040820104; PROSSER J, 1990, ONCOGENE, V5, P1573; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; RIORDAN JR, 1989, SCIENCE, V245, P1066; RUDEL R, 1988, MUSCLE NERVE, V11, P202, DOI 10.1002/mus.880110303; RUSSELL LB, 1988, P NATL ACAD SCI USA, V85, P9167, DOI 10.1073/pnas.85.23.9167; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; Saleeba Jennifer A., 1992, Human Mutation, V1, P63, DOI 10.1002/humu.1380010110; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; WATKINS WJ, 1984, LAB ANIM, V18, P1, DOI 10.1258/002367784780865036; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; WISCHMEYER E, 1993, NEUROMUSCULAR DISORD, V3, P267, DOI 10.1016/0960-8966(93)90019-G	41	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5963	5967						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119941				2022-12-25	WOS:A1994MY84000075
J	HIASA, H; MARIANS, KJ				HIASA, H; MARIANS, KJ			PRIMASE COUPLES LEADING-STRAND AND LAGGING-STRAND DNA-SYNTHESIS FROM ORIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; OKAZAKI FRAGMENT SIZE; REPLICATION FORK; ENZYMATIC REPLICATION; K-12 CHROMOSOME; TERMINUS REGION; PBR322 DNA; ORIGIN; PROTEIN; SEQUENCE	Coupling of leading- and lagging-strand DNA synthesis at replication forks formed at Escherichia coli oriC has been studied in vitro using a replication system reconstituted with purified proteins. At low concentrations of primase (8 nM), the major replication products were multigenome-length molecules, generated by a rolling circle-type mechanism, and unit-length molecules Rolling circle DNA replication was inhibited at high concentrations of primase (80 nM) and the major replication products were half-unit-length leading strands and a distinct population of short Okazaki fragments. At low primase concentrations, an asymmetric mode of DNA synthesis occurred. Each strand was made independently and initiation could occur outside of oriC. At high primase concentrations, initiation occurred exclusively at oriC and two coupled replication forks proceeded bidirectionally around the plasmid. Presumably, at low concentrations of primase, DnaB (the replication fork helicase) unwound the plasmid DNA before replication forks could form, leading to initiation at sites other than oriC. On the other hand, high concentrations of primase resulted in successful capture of the helicase leading to the formation at oriC of coupled replication forks capable of coordinated leading- and lagging-strand synthesis.			HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BIRD RE, 1972, J MOL BIOL, V70, P549, DOI 10.1016/0022-2836(72)90559-1; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1988, J BACTERIOL, V170, P662, DOI 10.1128/jb.170.2.662-668.1988; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V74, P3927, DOI 10.1073/pnas.74.9.3927; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LOUARN J, 1979, MOL GEN GENET, V172, P7, DOI 10.1007/BF00276208; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MCMACKEN R, 1987, ESCHERICHIA COLI SAL, P564; MEIJER M, 1979, P NATL ACAD SCI USA, V76, P580, DOI 10.1073/pnas.76.2.580; MINDEN JS, 1986, J BIOL CHEM, V261, P1906; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; MOK M, 1987, J BIOL CHEM, V262, P2304; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PRESCOTT DM, 1972, P NATL ACAD SCI USA, V69, P2842, DOI 10.1073/pnas.69.10.2842; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	34	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6058	6063						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119951				2022-12-25	WOS:A1994MY84000088
J	FUKADA, Y; MATSUDA, T; KOKAME, K; TAKAO, T; SHIMONISHI, Y; AKINO, T; YOSHIZAWA, T				FUKADA, Y; MATSUDA, T; KOKAME, K; TAKAO, T; SHIMONISHI, Y; AKINO, T; YOSHIZAWA, T			EFFECTS OF CARBOXYL METHYLATION OF PHOTORECEPTOR G-PROTEIN GAMMA-SUBUNIT IN VISUAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL CYSTEINE; ROD OUTER SEGMENTS; BETA-GAMMA; ALPHA-SUBUNIT; MEMBRANE ATTACHMENT; BINDING PROTEIN; BOVINE BRAIN; GTP-BINDING; MYRISTOYLATION; ESTER	G protein gamma-subunits are isoprenylated and carboxyl-methylated at the C-terminal cysteine, which is indispensable for the function of photoreceptor G protein transducin (T alpha beta gamma). However, the physiological role of the methylation and its reversibility have been unclear, Here we isolated methylated and non-methylated forms of farnesylated T beta gamma, and demonstrated that the methylation remarkably facilitates not only the membrane association of T beta gamma but also the subunit interaction between T alpha and T beta gamma. Consequently, the functional coupling of transducin with light-activated receptor, metarhodopsin II, was stabilized by the methylation, resulting in acceleration of GTP gamma S (guanosine 5'-3-0-(thio) triphosphate) binding to T(alpha. An examination of the reversibility of the methylation suggested that T gamma is kept fully methylated in rod outer segments. These observations indicate that the methylation of T gamma plays an important role in the most efficient photon-signal transduction process in rod cells.	OSAKA UNIV,INST PROT RES,OSAKA 565,JAPAN	Osaka University	FUKADA, Y (corresponding author), UNIV TOKYO,COLL ARTS & SCI,DEPT PURE & APPL SCI,MEGURO KU,KOMABA 3-8-1,TOKYO 153,JAPAN.		吉孝, 深田/G-5090-2014	Kokame, Koichi/0000-0002-9654-6299				BASINGER S, 1976, J CELL BIOL, V69, P29, DOI 10.1083/jcb.69.1.29; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; BUTRYNSKI JE, 1992, BIOCHEMISTRY-US, V31, P8030, DOI 10.1021/bi00149a037; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FUKADA Y, 1989, J BIOL CHEM, V264, P5937; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUKADA Y, 1990, BIOCHEMISTRY-US, V29, P3133, DOI 10.1021/bi00464a033; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; Kuhn H., 1980, Neurochemistry International, V1, P269, DOI 10.1016/0197-0186(80)90066-2; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7672; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MORISHITA R, 1992, EUR J BIOCHEM, V210, P1061, DOI 10.1111/j.1432-1033.1992.tb17512.x; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; OHGURO H, 1990, BIOCHEM BIOPH RES CO, V167, P1235, DOI 10.1016/0006-291X(90)90656-8; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; OTA IM, 1989, J BIOL CHEM, V264, P12879; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STEPHENSON RC, 1992, J BIOL CHEM, V267, P1314; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; SWANSON RJ, 1983, J BIOL CHEM, V258, P599; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAN EW, 1992, BIOCHEMISTRY-US, V31, P5572, DOI 10.1021/bi00139a021; VOLKER C, 1991, J BIOL CHEM, V266, P21515; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	42	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5163	5170						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106497				2022-12-25	WOS:A1994MX57100074
J	HERSHKO, A; GANOTH, D; SUDAKIN, V; DAHAN, A; COHEN, LH; LUCA, FC; RUDERMAN, JV; EYTAN, E				HERSHKO, A; GANOTH, D; SUDAKIN, V; DAHAN, A; COHEN, LH; LUCA, FC; RUDERMAN, JV; EYTAN, E			COMPONENTS OF A SYSTEM THAT LIGATES CYCLIN TO UBIQUITIN AND THEIR REGULATION BY THE PROTEIN-KINASE CDC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PURIFICATION; AMPHIBIAN EGGS; CELL-CYCLES; CLAM EMBRYO; M-PHASE; DEGRADATION; DESTRUCTION; PATHWAY; RESOLUTION; EXTRACTS	Cyclin B, a positive regulatory subunit of the cdc2 protein kinase complex, is synthesized across the cell cycle and then rapidly degraded at the end of mitosis. Degradation of cyclin B is triggered by increased levels of active cdc2 and is required for exit from mitosis. It was shown previously that cyclin degradation is carried out by the ubiquitin system, but the components responsible for the specificity and regulation of cyclin-ubiquitin ligation have not been identified. The formation of ubiquitin-protein conjugates usually requires the sequential action of three enzymes: a ubiquitin-activating enzyme (E(1)), a ubiquitin-carrier protein (E(2)), and a ubiquitin-protein ligase (E(3)). In this work we employed a fractionation approach to identify the components of a clam oocyte system responsible for specific ubiquitination of cyclin and to determine which components are regulated by cdc2. Experimental conditions were established under which a fusion protein containing an amino-terminal fragment of cyclin B is ligated to ubiquitin only in extracts from M-phase but not from interphase cells. Fractionation of M-phase extracts by DEAE-cellulose and high speed centrifugation yielded three fractions that were all required for cell cycle stage-specific cyclin-ubiquitin ligation. Only one of these fractions could be replaced by a previously known enzyme of the ubiquitin system, E(1). A second fraction contained a novel species of E(2), termed E(2)-C, which acts in the ligation of ubiquitin to cyclin but not to other endogenous proteins. A third component is associated with particulate material. Whereas E(2)-C from either M-phase or interphase extracts is active, the particulate component is active only in M-phase. Incubation of the particulate fraction from interphase cells with the protein kinase cdc2 activates it for cyclin-ubiquitin ligation, after a lag of about 30 min. These findings suggest that the particulate fraction may contain an E(3) enzyme that acts on cyclin, as well as additional factors activated by cdc2.	TECHNION ISRAEL INST TECHNOL, RAPPAPORT FAMILY INST RES MED SCI, IL-31096 HAIFA, ISRAEL; FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Fox Chase Cancer Center; Harvard University; Harvard Medical School; Marine Biological Laboratory - Woods Hole	HERSHKO, A (corresponding author), TECHNION ISRAEL INST TECHNOL, B RAPPAPORT FAC MED, BIOCHEM UNIT, IL-31096 HAIFA, ISRAEL.				NICHD NIH HHS [HD-23696] Funding Source: Medline; NIDDK NIH HHS [DK-25614] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025614] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GIROD PA, 1993, J BIOL CHEM, V268, P955; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LEISS D, 1992, J CELL SCI, V102, P285; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1986, J BIOL CHEM, V261, P210; PINES J, 1992, Current Opinion in Cell Biology, V4, P144, DOI 10.1016/0955-0674(92)90024-7; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REISS Y, 1990, J BIOL CHEM, V265, P3685; ROSE IA, 1983, BIOCHEMISTRY-US, V22, P4234, DOI 10.1021/bi00287a012; RUDERMAN J, 1991, COLD SH Q B, V56, P495; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353	30	202	205	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4940	4946						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106468				2022-12-25	WOS:A1994MX57100040
J	O, IS; STITT, BL				O, IS; STITT, BL			8-AZIDO-ATP INACTIVATION OF ESCHERICHIA-COLI TRANSCRIPTION TERMINATION FACTOR-RHO - MODIFICATION OF ONE SUBUNIT INACTIVATES THE HEXAMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING DOMAIN; ATP-BINDING; ADENYLATE KINASE; PROTEIN-RHO; PHYSICAL-PROPERTIES; BETA-SUBUNIT; MUTANT-RHO; RNA; SITE	Escherichia coli transcription termination factor Rho (EC 3.6.1.3) releases nascent RNA from transcription complexes in a reaction which requires ATP hydrolysis. To understand the structure of the ATPase active site, we employed an analog of ATP, 8-azidoadenosine 5'-triphosphate (8-azido-ATP) as a photoaffinity labeling agent. 8-Azido-ATP interacts nearly normally with the active site of Rho. It binds to 3 sites per Rho hexamer with a 100 mu M K-D and is a substrate with a V-max 5% that of ATP and a K-m, of 18 mu M. Under UV irradiation, 8-azido-ATP makes covalent bonds with Rho, inactivating its ATPase. Rho is protected from this inactivation by the presence of ATP. We used [alpha-P-32]8-azido-ATP to label the active site and identify residues involved in ATP binding. Labeled tryptic peptides of the modified Rho were purified by Fe3+-iminodiacetic acid affinity chromatography and reverse-phase C-18 column high performance liquid chromatography. We identified a single peptide, Gly(174)-Lys(184), that is labeled by 8-azido-ATP and protected from labeling in the presence of ATP. The modified amino acid is Lys(181), whose conservative replacement by Gln(181) gives rise to a poorly active enzyme (Dombroski, A. J., Brennan, C. A., Spear, P., and Platt, T (1988a) J. Biol. Chem. 263, 18802-18809). Lys(181) probably participates in binding the phosphoryl groups of ATP. Incorporation of one 8-azido-ATP per Rho hexamer is sufficient to cause inactivation, a result that indicates that the active sites of Rho interact in RNA-dependent ATP hydrolysis.	TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; NYU, DEPT BIOL, NEW YORK, NY 10003 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; New York University				O-Sullivan, InSug/0000-0003-0161-2028				BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CARTWRIGHT IL, 1976, NUCLEIC ACIDS RES, V3, P2331, DOI 10.1093/nar/3.9.2331; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; Cleland W W, 1979, Methods Enzymol, V63, P103; Czarnecki J, 1979, Methods Enzymol, V56, P642; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; DREUSICKE D, 1986, FEBS LETT, V208, P301, DOI 10.1016/0014-5793(86)81037-7; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; ENGEL D, 1984, NUCLEIC ACIDS RES, V17, P7389; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P707, DOI 10.1021/bi00428a044; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P271; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GALLUPPI G, 1976, RNA POLYMERASE, P657; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GIESELMANN J, 1992, PROTEIN SCI, V1, P850; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; HALEY BE, 1974, P NATL ACAD SCI USA, V71, P3367, DOI 10.1073/pnas.71.9.3367; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KASHO VN, 1993, ARCH BIOCHEM BIOPHYS, V300, P293, DOI 10.1006/abbi.1993.1041; KING SM, 1991, METHOD ENZYMOL, V196, P449; LADINE J R, 1988, Journal of Cell Biology, V107, p854A; MORI H, 1989, J MOL BIOL, V210, P39, DOI 10.1016/0022-2836(89)90289-1; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; MUNEYAMA K, 1971, BIOCHEMISTRY-US, V10, P2390; ODA T, 1972, J MOL BIOL, V71, P799; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PALCZEWSKI K, 1987, BIOCHEMISTRY-US, V26, P3466, DOI 10.1021/bi00386a033; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; PLATT T, 1988, MOL BIOL RNA, V94, P325; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SATRE M, 1986, METHOD ENZYMOL, V126, P712; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; STEINMETZ EJ, 1990, J BIOL CHEM, V265, P18408; STITT BL, 1986, J BIOL CHEM, V261, P5906; STITT BL, 1988, J BIOL CHEM, V263; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	59	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5009	5015						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106476				2022-12-25	WOS:A1994MX57100050
J	GOPING, IS; SHORE, GC				GOPING, IS; SHORE, GC			INTERACTIONS BETWEEN REPRESSOR AND ANTI-REPRESSOR ELEMENTS IN THE CARBAMYL-PHOSPHATE SYNTHETASE-I PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXTINGUISHER; TRANSCRIPTION FACTOR-IIIA; C/EBP-RELATED PROTEINS; DNA-BINDING PROTEINS; GENE-EXPRESSION; ALBUMIN GENE; RAT-LIVER; INVITRO TRANSCRIPTION; HOMEODOMAIN PROTEIN; REGULATORY SUBUNIT	The proximal promoter of the rat carbamyl phosphate synthetase I gene contains four cis-acting regulatory regions, designated sites GAG, I, II, and III. The GAG site, which is located adjacent to the predicted TATA region, contains a direct repeat of the nonamer, GAGGAGGGG, and binds a factor which is unrelated to the other upstream binding site factors. Sites I-III, on the other hand, bind the same or similar factors, but with different affinities (site II > site III > site I). High affinity binding to site II requires the core octamer, GTTGCAAC. Sequential 5'-deletion of the promoter revealed that GAG is the predominant activating element in transient transfection analyses and, on its own, can sustain activity of a -67 promoter fragment. However, in the context of a -157 promoter in which the GTTGCAAC core of site II had been mutated, promoter activity was completely repressed, and this repression was due to sites I and III. Repression by sites I and III in the presence of mutated site II was relieved either by mutating sites I and III or by introducing a 76-bp random DNA fragment between GAG and site I. Our results suggest a model in which the carbamyl phosphate synthetase I promoter is controlled by a single activating element, GAG, and by two repressor elements, sites I and III. We conclude that the high affinity site II element binds an anti-repressor. Footprint analyses of the -157 promoter with and without a mutation of the GTTGCAAC element in site II suggest that the anti-repressor may interfere with the site I and site III repressors by quenching.	MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED SCI BLDG,MONTREAL H3G 1Y6,PQ,CANADA	McGill University								ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ADAMS TH, 1988, CELL, V54, P353, DOI 10.1016/0092-8674(88)90198-5; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; BEMIS LT, 1988, MOL CELL BIOL, V8, P2125, DOI 10.1128/MCB.8.5.2125; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOPING IS, 1992, GENE, V118, P283, DOI 10.1016/0378-1119(92)90201-Y; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; INOSTROZA JA, 1992, CELL, V70, P477; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; JONES ME, 1965, ANNU REV BIOCHEM, V34, P381; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LAGACE M, 1987, J BIOL CHEM, V262, P10415; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; PTASHNE M, 1980, CELL, V19, P1, DOI 10.1016/0092-8674(80)90383-9; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; ROZEN R, 1983, BIOCHIM BIOPHYS ACTA, V741, P47, DOI 10.1016/0167-4781(83)90008-8; RYALL J, 1985, EUR J BIOCHEM, V152, P287, DOI 10.1111/j.1432-1033.1985.tb09196.x; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; Sambrook J, 1989, MOL CLONING LABORATO; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; TANIGUCHI T, 1979, P NATL ACAD SCI USA, V76, P5090, DOI 10.1073/pnas.76.10.5090; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	67	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3891	3896						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106435				2022-12-25	WOS:A1994MV63100111
J	HOMOLYA, L; HOLLO, Z; GERMANN, UA; PASTAN, I; GOTTESMAN, MM; SARKADI, B				HOMOLYA, L; HOLLO, Z; GERMANN, UA; PASTAN, I; GOTTESMAN, MM; SARKADI, B			FLUORESCENT CELLULAR INDICATORS ARE EXTRUDED BY THE MULTIDRUG-RESISTANCE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							P-GLYCOPROTEIN; INSECT CELLS; TRANSPORTER; VINBLASTINE; EXPRESSION; CDNA; DYES	In this report we show that NIH-3T3 mouse fibroblasts stably expressing the human multidrug transporter (MDR1 or P-glycoprotein), in contrast to the control NIH-3T3 cells, actively extrude the hydrophobic acetoxymethyl ester (AM) derivatives used for cellular loading of various fluorescent calcium and pH indicators. This dye extrusion is blocked by competing substrates and inhibitors of the multidrug transporter, e.g. by verapamil, vincristine, sodium orthovanadate, oligomycin, and a monoclonal anti-MDR1 antibody. The hydrophilic free acid forms of the indicators are not exported by MDR1. We also demonstrate that in isolated cell membranes the MDR1-ATPase, similar to that by known substrates of the transporter, is stimulated by the AM derivatives of fluorescent dyes whereas the free acid forms of the dyes are without effect. Since (i) the AM derivatives of the fluorescent indicators rapidly permeate the cell membrane and are readily cleaved by high activity and large capacity cytoplasmic esterases and (ii) the free acid forms are not substrates for export by MDR1, the observations above suggest that dye extrusion by MDR1 may occur without a cytoplasmic appearance of the AM compounds. These data also call attention to the possible interaction of widely used hydrophobic fluorescent indicators with MDR1 and offer an efficient detection of MDR1-expressing tumor cells as well as a screening method for examining drug interactions with the multidrug transporter.	NATL INST HAEMATOL BLOOD TRANSFUS & IMMUNOL,DAROCZI U 24,H-1113 BUDAPEST,HUNGARY; NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019; Sarkadi, Balazs/I-5024-2013; Homolya, Laszlo/N-1154-2016	pastan, ira/0000-0002-9223-0270; Homolya, Laszlo/0000-0003-1639-8140				AMBDUKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN M, 1988, J BIOL CHEM, V263; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KESSEL D, 1991, CANCER RES, V51, P4665; KONEN PL, 1989, J HISTOCHEM CYTOCHEM, V37, P1141, DOI 10.1177/37.7.2567301; MECHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824, DOI 10.1073/pnas.89.13.5824; NEYFAKH AA, 1988, EXP CELL RES, V174, P168, DOI 10.1016/0014-4827(88)90152-8; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; SARKADI B, 1992, J BIOL CHEM, V267, P4854; STEIN WD, 1993, IN PRESS MOL PHARM; TSIEN RY, 1983, ANNU REV BIOPHYS BIO, V12, P91, DOI 10.1146/annurev.bb.12.060183.000515; TSURUO T, 1983, CANCER RES, V43, P2905; WALL DM, 1993, EUR J CANCER, V29A, P1024, DOI 10.1016/S0959-8049(05)80216-3; YOSHIMURA A, 1990, CANCER LETT, V50, P45, DOI 10.1016/0304-3835(90)90177-Y	24	457	471	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21493	21496						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104940				2022-12-25	WOS:A1993MC80900011
J	CORNWELL, MM; SMITH, DE				CORNWELL, MM; SMITH, DE			SP1 ACTIVATES THE MDR1 PROMOTER THROUGH ONE OF 2 DISTINCT G-RICH REGIONS THAT MODULATE PROMOTER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN; SECRETORY EPITHELIUM; NEGATIVE ELEMENT; DRUG-RESISTANCE; BINDING-SITE; RAT-LIVER; EXPRESSION; CELLS; TRANSCRIPTION	To define sequences in the human multidrug resistance (MDR1) promoter that influence transcription, we measured the activity of MDR1 promoter constructs using luciferase as a reporter gene. Deletion of promoter sequences to -121 (relative to the transcription initiation site) had very little effect on promoter activity in transiently transfected cells. Further deletion to -88 increased activity about 4-fold, while deletion to -51 decreased activity about 10-fold. The data indicated that between -121 and -88 and between -73 and -51 were sequences that modulated promoter activity. Because these two regions contain G-rich sequences, which are important for function in other promoters, the effect of mutation of the G-rich regions (-110 to -103 and -61 to -43) on MDR1 promoter activity was measured. Mutation of the -110 G-box (-110 to -103) resulted in a 6-fold increase in promoter activity and inhibited the formation of a specific nuclear protein complex, suggesting that this region functions as a transcriptional ''repressor'' binding site in cycling cells. In contrast, mutation of the -50 G-box (-61 to -43) reduced promoter activity 5-fold. DNase-I footprinting and electrophoretic mobility shift analysis indicated that specific but distinct protein-DNA complexes formed at each of these two G-rich regions. The -50 G-box contains overlapping sites to which both SP1 and EGR-1 bind specifically. Co-transfection of MDR1 promoter constructs with SP1 into cells that lack SP1 (Drosophila Schneider 2 cells) activated equivalently both the wild type MDR1 promoter and a synthetic promoter containing the MDR1 -50 GC box and MDR1 initiator element.			CORNWELL, MM (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV CLIN,MAIL STOP EP 310-N,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				NCI NIH HHS [CA51728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051728, R29CA051728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ARCECI RJ, 1990, MOL REPROD DEV, V25, P101, DOI 10.1002/mrd.1080250202; BAAS F, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P360; BATES SE, 1989, MOL CELL BIOL, V9, P4337, DOI 10.1128/MCB.9.10.4337; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CHIN KV, 1993, ADV CANCER RES, V60, P157; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FAISST S, 1991, NUCLEIC ACIDS RES, V20, P3; GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614; GERLACH JH, 1987, J CLIN ONCOL, V5, P1452, DOI 10.1200/JCO.1987.5.9.1452; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; HERZOG CE, 1993, J BIOL CHEM, V268, P2946; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HSU SIH, 1989, J BIOL CHEM, V264, P12053; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; KOIKA N, 1992, FEBS LETT, V301, P307; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; OGURA M, 1992, NUCLEIC ACIDS RES, V20, P5811, DOI 10.1093/nar/20.21.5811; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN DW, 1986, J BIOL CHEM, V261, P7762; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, J BIOL CHEM, V262, P17432; UEDA K, 1987, J BIOL CHEM, V262, P505; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANHUIJSDUIJNEN RAMH, 1992, BIOTECHNIQUES, V12, P830; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	44	137	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19505	19511						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103518				2022-12-25	WOS:A1993LW81900056
J	WALLIS, KT; AZHAR, S; RHO, MB; LEWIS, SA; COWAN, NJ; MURPHY, DB				WALLIS, KT; AZHAR, S; RHO, MB; LEWIS, SA; COWAN, NJ; MURPHY, DB			THE MECHANISM OF EQUILIBRIUM BINDING OF MICROTUBULE-ASSOCIATED PROTEIN-2 TO MICROTUBULES - BINDING IS A MULTI-PHASIC PROCESS AND EXHIBITS POSITIVE COOPERATIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULIN POLYMERIZATION INVITRO; TAU-PROTEIN; CHICKEN ERYTHROCYTES; BRAIN MICROTUBULES; LARGE LIGANDS; STEADY-STATE; MAP2; PHOSPHORYLATION; DYNAMICS; LATTICE	The mechanism of binding of microtubule-associated protein 2 (MAP2) to taxol-stabilized microtubules (MTs) was examined through Scatchard analysis of equilibrium binding and by immunoelectron microscopy. We demonstrate the following. 1) Binding is a cooperative process as indicated by sigmoidal binding curves, prominent humps in Scatchard plots, and an all-or-none response in binding during ligand titrations. At high tubulin/MAP2 ratios, the K(d) for noncontiguous binding (5-25 muM) is estimated to be 100-1500 times greater than that predicted for contiguous binding, suggesting a high degree of cooperativity. 2) Cooperativity is indicated independently by a highly clustered or patchy distribution of MAP2 on MTs as revealed by immunoelectron microscopy. 3) The binding of truncated constructs of mouse MAP2 protein suggests that a domain of MAP2 conferring cooperativity is located in or near the MT binding site near the carboxyl terminus. We speculate that in the cell, cooperativity may generate MTs with uniform biochemical properties and contribute to the segregation of MAPs in neuronal cell processes.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009989] Funding Source: NIH RePORTER; NIA NIH HHS [AG09989] Funding Source: Medline; NIGMS NIH HHS [GM33171] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS RG, 1984, EUR J BIOCHEM, V141, P609, DOI 10.1111/j.1432-1033.1984.tb08236.x; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CACERES A, 1992, NEURON, V9, P607, DOI 10.1016/0896-6273(92)90025-9; CAPLOW M, 1982, EUR J BIOCHEM, V127, P319, DOI 10.1111/j.1432-1033.1982.tb06873.x; DENTLER WL, 1975, J CELL BIOL, V65, P237, DOI 10.1083/jcb.65.1.237; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; FARRELL KW, 1987, J CELL BIOL, V104, P1035, DOI 10.1083/jcb.104.4.1035; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GOTTLIEB RA, 1983, J ULTRA MOL STRUCT R, V85, P175, DOI 10.1016/S0022-5320(83)90105-3; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JAMESON L, 1981, P NATL ACAD SCI-BIOL, V78, P3413, DOI 10.1073/pnas.78.6.3413; JOB D, 1985, J CELL BIOL, V101, P1680, DOI 10.1083/jcb.101.5.1680; KIM H, 1986, ANN NY ACAD SCI, V466, P218, DOI 10.1111/j.1749-6632.1986.tb38396.x; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1990, NATURE, V345, P674, DOI 10.1038/345674a0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; MATUS A, 1990, J PHYSIOL-PARIS, V84, P131; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MURPHY DB, 1987, J BIOL CHEM, V262, P14305; MURPHY DB, 1983, J BIOL CHEM, V258, P8357; MURTHY ASN, 1983, EUR J BIOCHEM, V137, P37, DOI 10.1111/j.1432-1033.1983.tb07792.x; OKABE S, 1989, P NATL ACAD SCI USA, V86, P4127, DOI 10.1073/pnas.86.11.4127; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; OLMSTED JB, 1989, J CELL BIOL, V109, P211, DOI 10.1083/jcb.109.1.211; ROTHWELL SW, 1986, ANN NY ACAD SCI, V466, P103, DOI 10.1111/j.1749-6632.1986.tb38387.x; SANDOVAL IV, 1981, J BIOL CHEM, V256, P8795; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHERSON T, 1984, J CELL BIOL, V99, P425, DOI 10.1083/jcb.99.2.425; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WICHE G, 1989, BIOCHEM J, V259, P1; WILLE H, 1992, J STRUCT BIOL, V108, P49, DOI 10.1016/1047-8477(92)90006-V	41	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15158	15167						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8100819				2022-12-25	WOS:A1993LL75900089
J	BRIGELIUS-FLOHE, R; AUMANN, KD; BLOCKER, H; GROSS, G; KIESS, M; KLOPPEL, KD; MAIORINO, M; ROVERI, A; SCHUCKELT, R; URSINI, F; WINGENDER, E; FLOHE, L				BRIGELIUS-FLOHE, R; AUMANN, KD; BLOCKER, H; GROSS, G; KIESS, M; KLOPPEL, KD; MAIORINO, M; ROVERI, A; SCHUCKELT, R; URSINI, F; WINGENDER, E; FLOHE, L			PHOSPHOLIPID-HYDROPEROXIDE GLUTATHIONE-PEROXIDASE - GENOMIC DNA, CDNA, AND DEDUCED AMINO-ACID-SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; RESPONSIVE ELEMENT; NUCLEAR-PROTEIN; BINDING-PROTEIN; GENE; SELENOCYSTEINE; HOMOLOGY; IDENTIFICATION; EXPRESSION; RECEPTOR	The complete amino acid sequence of the selenoprotein phospholipid hydroperoxide glutathione peroxidase (PHGPX) from pig heart has been deduced from the corresponding genomic DNA, the cDNA covering the coding region, and by sequencing the N terminus of the protein. The maximum length of the peptide chain derived from the cDNA amounts to 170 amino acid residues. By protein sequencing the N-terminal residues methionine and cysteine of the deduced sequence were found to be cleaved. The molecular mass of 19,671 Da obtained by laser desorption mass spectroscopy, however, significantly exceeds the mean molecular mass of 19,257.09 calculated for the sequence 3-170 of PHGPX, thus indicating posttranscriptional modification. In contrast to glutathione peroxidase (GPX) the coding area of the PHGPX gene is composed of seven exons. Only the amino acid sequences encoded by the third and fifth exon are highly homologous to GPX sequences. The amino acid residues selenocysteine, tryptophan, and glutamine forming the catalytic site in bovine GPX are conserved in homologous positions of PHGPX, whereas the arginine residues presumed to bind GSH in GPX are not. Gaps in the PHGPX sequence correspond to subunit interaction sites of the tetrameric GPX. The data suggest an identical catalytic mechanism of the selenoperoxidases, a less stringent substrate specificity of PHGPX, and explain the monomeric nature of PHGPX. As in other selenoproteins, the selenocysteine residue of PHGPX is encoded by UGA, The 3'-untranslated region (UTR) of the PHGPX shows a limited consensus with that of GPX and 5'-deiodinase, where it was shown to be responsible for the decoding of UGA as selenocysteine. The 3'-UTR of PHGPX can form a stem/loop as in other mammalian selenoprotein genes. The 5'-UTR and the first intron of the PHGPX gene contain a variety of putative regulatory elements indicating hormonal control.	GESELL BIOTECHNOL FORSCH MBH, D-38124 BRAUNSCHWEIG, GERMANY; UNIV PADUA, DEPT BIOL CHEM, I-35121 PADUA, ITALY; GRUNENTHAL GMBH, CTR RES, D-52078 AACHEN, GERMANY; UNIV UDINE, DEPT CHEM, I-33100 UDINE, ITALY	Gesellschaft fur Biotechnologische Forschung mbH; University of Padua; Grunenthal Group; University of Udine			Roveri, Antonella/AAF-3669-2019	Roveri, Antonella/0000-0002-3252-0559				AKASAKA M, 1989, NUCLEIC ACIDS RES, V17, P2136, DOI 10.1093/nar/17.5.2136; BEATO M, 1987, BIOCHIM BIOPHYS ACTA, V910, P95, DOI 10.1016/0167-4781(87)90060-1; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHU FF, 1993, J BIOL CHEM, V268, P2571; COOKSON E, 1992, P NATL ACAD SCI USA, V89, P5837, DOI 10.1073/pnas.89.13.5837; CRIQUI MC, 1992, PLANT MOL BIOL, V18, P623, DOI 10.1007/BF00040684; DEAR TN, 1991, BIOCHEMISTRY-US, V30, P10376, DOI 10.1021/bi00107a003; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; FLOHE L, 1993, ACTIVE OXYGENS, LIPID PEROXIDES, AND ANTIOXIDANTS, P299; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; FLOHE L, 1971, H-S Z PHYSIOL CHEM, V352, P159, DOI 10.1515/bchm2.1971.352.1.159; FLOHE L, 1989, HDB FREE RADICALS AN, V3, P281; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; FRIEDRICH MJ, 1986, J BACTERIOL, V167, P928, DOI 10.1128/jb.167.3.928-934.1986; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; GHYSELINCK NB, 1990, NUCLEIC ACIDS RES, V18, P7144, DOI 10.1093/nar/18.23.7144; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GUNZLER WA, 1984, H-S Z PHYSIOL CHEM, V365, P195, DOI 10.1515/bchm2.1984.365.1.195; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; HO YS, 1988, NUCLEIC ACIDS RES, V16, P5207, DOI 10.1093/nar/16.11.5207; ISHIDA K, 1987, NUCLEIC ACIDS RES, V15, P10051, DOI 10.1093/nar/15.23.10051; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; LEEGWATER PAJ, 1986, EMBO J, V5, P381, DOI 10.1002/j.1460-2075.1986.tb04223.x; LINCOLN D, 1989, GENMON VERSION 41 MA; MAIORINO M, 1994, BIOL OXIDANTS ANTIOX; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; ROVERI A, 1992, J BIOL CHEM, V267, P6142; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; WEITZEL F, 1990, BIOCHIM BIOPHYS ACTA, V1036, P88, DOI 10.1016/0304-4165(90)90018-R; WILLIAMS DL, 1992, MOL BIOCHEM PARASIT, V52, P127, DOI 10.1016/0166-6851(92)90042-I; YOSHIMURA S, 1991, J BIOCHEM-TOKYO, V109, P918, DOI 10.1093/oxfordjournals.jbchem.a123480; ZHANG LP, 1989, BIOCHIM BIOPHYS ACTA, V1006, P140, DOI 10.1016/0005-2760(89)90336-6; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	48	179	184	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7342	7348						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125951				2022-12-25	WOS:A1994NA03200050
J	DEWAARD, M; WITCHER, DR; CAMPBELL, KP				DEWAARD, M; WITCHER, DR; CAMPBELL, KP			FUNCTIONAL-PROPERTIES OF THE PURIFIED N-TYPE CA2+ CHANNEL FROM RABBIT BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; DEPENDENT PROTEIN-KINASE; EATON MYASTHENIC SYNDROME; CONOTOXIN GVIA RECEPTOR; CHICK SENSORY NEURONS; SKELETAL-MUSCLE; BETA-SUBUNIT; DIHYDROPYRIDINE RECEPTOR; CA-2+ CHANNELS; SMOOTH-MUSCLE	N-type Ca2+ channels control a variety of key neuronal functions including transmitter release at synaptic terminals. The purified omega-conotoxin receptor from rabbit brain is a multisubunit complex composed of alpha(1B), alpha 2 delta, beta 3, and 95-kDa subunits. Immunoadsorption experiments confirm that the purified preparation does not contain cn, subunits other than the omega-conotoxin-sensitive class B isoform. The functional properties of the purified channel have been analyzed further in lipid bilayers, and similarities to or differences from the native N-type Ca2+ channel have been outlined. Conserved properties include ion selectivity, open-time duration, and pharmacology (insensitivity to drugs affecting skeletal muscle L-type Ca2+ channels). Observed properties of the reconstituted channel which differ from the native channel include (a) sustained channel activity without Ca2+- or voltage-induced inactivation; (b) examples of extremely high open-state probability; (c) the absence of ''run-down''; and (d) voltage independence of the Ca2+ channel gating. In addition, the conductance of the purified receptor is comprised between 7 and 27 picosiemens. Our results suggest that cellular components may play critical roles in the regulation of several biophysical properties and neuronal function of the native N-type Ca2+ channel,	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa			De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Campbell, Kevin/0000-0003-2066-5889				AFFOLTER H, 1985, BIOPHYS J, V48, P341, DOI 10.1016/S0006-3495(85)83789-9; AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOHEIM G, 1985, MOL BASIS NERVE ACTI, P131; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CORONADO R, 1986, ION CHANNEL RECONSTI, P483; DELCOUR AH, 1993, SCIENCE, V259, P980, DOI 10.1126/science.8094902; DEWAARD M, 1991, EUR J NEUROSCI, V3, P771; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; FOX AP, 1987, J PHYSIOL-LONDON, V394, P173, DOI 10.1113/jphysiol.1987.sp016865; GROSS RA, 1989, J NEUROPHYSIOL, V61, P97, DOI 10.1152/jn.1989.61.1.97; HAMILTON SL, 1991, J BIOL CHEM, V266, P19528; HANKE W, 1984, BIOELECTROCH BIOENER, V12, P329, DOI 10.1016/0302-4598(84)87013-0; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HULIN R, 1992, EMBO J, V11, P885; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P4290, DOI 10.1073/pnas.85.12.4290; ITAGAKI K, 1992, FEBS LETT, V297, P221, DOI 10.1016/0014-5793(92)80542-O; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LOPEZ HS, 1991, NEURON, V7, P1061, DOI 10.1016/0896-6273(91)90350-9; MCCARRON JG, 1992, NATURE, V357, P74, DOI 10.1038/357074a0; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; PELZER D, 1988, CALCIUM CHANNEL STRU, P217; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; ROSENBERG RL, 1988, J GEN PHYSIOL, V92, P27, DOI 10.1085/jgp.92.1.27; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SCHINDLER H, 1984, P NATL ACAD SCI-BIOL, V81, P6222, DOI 10.1073/pnas.81.19.6222; SHER E, 1989, LANCET, V2, P640; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P; VALDIVIA HH, 1990, J GEN PHYSIOL, V95, P1, DOI 10.1085/jgp.95.1.1; WEI XY, 1991, J BIOL CHEM, V266, P21943; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P889; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887	50	15	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6716	6724						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120030				2022-12-25	WOS:A1994MZ50300073
J	INOUYE, CJ; SETO, E				INOUYE, CJ; SETO, E			RELIEF OF YY1-INDUCED TRANSCRIPTIONAL REPRESSION BY PROTEIN-PROTEIN INTERACTION WITH THE NUCLEOLAR PHOSPHOPROTEIN B23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; ADENOVIRUS E1A PROTEIN; SERUM RESPONSE FACTOR; EXPRESSION VECTOR; TUMOR-CELLS; YEAST; YY1; DNA; SEQUENCE; CLONING	Previous studies have shown that the transcription factor YY1 can both activate and repress transcription of many mammalian genes (reviewed by Hahn (Hahn, S. (1992) Curr. Biol. 2, 152-154)). Given the diverse effects of the YY1 protein, it seems likely that its function depends on interaction with other cellular factors. We have used the yeast two-hybrid system to isolate mouse cDNAs encoding proteins capable of directly binding to YY1. Sequence analysis of one clone revealed it had an open reading frame with the potential to code for a protein nearly identical to the previously published mouse nucleolar phosphoprotein B23. The YY1.B23 complex is specific, and occurs in vivo and in vitro. Overexpression of the B23 protein can reverse the transcriptional repression exerted by YY1. These results suggest a role for a nucleolar protein as a component in transcription and provide a possible mechanism for transcriptional regulation by YY1.	UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED INST BIOTECHNOL, DEPT CELLULAR & STRUCT BIOL, SAN ANTONIO, TX 78245 USA	University of Texas System; University of Texas Health San Antonio								BASU A, 1993, J BIOL CHEM, V268, P4188; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUSCH RK, 1984, LIFE SCI, V35, P1777, DOI 10.1016/0024-3205(84)90275-3; CHAN PK, 1989, CANCER RES, V49, P3271; CHAN PK, 1992, EXP CELL RES, V203, P174, DOI 10.1016/0014-4827(92)90053-B; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHAN PK, 1987, CANCER RES, V47, P3798; CHANG JH, 1989, J BIOL CHEM, V264, P11732; CHANG JH, 1990, J BIOL CHEM, V265, P18227; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LETO E, 1993, NATURE, V365, P462; LI XZ, 1989, BIOCHEM BIOPH RES CO, V163, P72, DOI 10.1016/0006-291X(89)92100-1; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NARAYANAN H, 1991, P NATL ACAD SCI USA, V88, P9799; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG DR, 1993, CELL MOL BIOL RES, V39, P33; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8	49	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6506	6510						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120001				2022-12-25	WOS:A1994MZ50300039
J	OKAZAKI, S; TANASE, S; CHOUDHURY, BK; SETOYAMA, K; MIURA, R; OGAWA, M; SETOYAMA, C				OKAZAKI, S; TANASE, S; CHOUDHURY, BK; SETOYAMA, K; MIURA, R; OGAWA, M; SETOYAMA, C			A NOVEL NUCLEAR-PROTEIN WITH ZINC FINGERS DOWN-REGULATED DURING EARLY MAMMALIAN-CELL DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERATOCARCINOMA STEM-CELLS; DNA-BINDING; RETINOIC ACID; TRANSCRIPTIONAL ACTIVATION; EXPRESSION; GENE; MOUSE; SEQUENCE; PARIETAL; ENDODERM	We introduced a promoter trap vector carrying a neo gene as a selectable marker into F9 cells and established several cell lines in which the expression of neo gene is under the control of an endogenous host gene that is active only in the undifferentiated F9 cells. Using one of these cell lines, G19, we isolated the integrated neo construct and its flanking host sequences by the plasmid rescue method, identified the host gene which contributes to the expression of neo gene, and named it the ZfP-57 gene. Two different Zfp-57 transcripts (1.8 and 3.2 kilobases) were identified in the undifferentiated F9 cells, and the levels of these transcripts were decreased significantly within a short time after induction of differentiation. We examined mouse organs for the pres ence of the ZfP-57 RNAs and found that the 1.8-kilobase RNA was detected only in the testis. The Zfp-57 cDNAs corresponding to the two different RNAs were isolated, and a comparison of the nucleotide sequences revealed that their coding regions were completely identical, but they differed both in length and in sequence of the 3'-untranslated region. The Zfp-57 cDNA encoded a protein consisting of 421 amino acids with an extremely high content of basic amino acid residues and multiple zinc finger moths. Immunocytochemical analysis revealed that this protein is localized in the nucleus. These findings suggest that the Zfp-57 protein is a DNA-binding protein.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT SURG 2,KUMAMOTO 860,JAPAN	Kumamoto University; Kumamoto University								CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOWDHURY K, 1988, NUCLEIC ACIDS RES, V16, P9995, DOI 10.1093/nar/16.21.9995; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; CUNLIFFE V, 1990, EMBO J, V9, P197, DOI 10.1002/j.1460-2075.1990.tb08096.x; ERNOULTLANGE M, 1990, MOL CELL BIOL, V10, P418, DOI 10.1128/MCB.10.1.418; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LEVINE RA, 1984, MOL CELL BIOL, V4, P2142, DOI 10.1128/MCB.4.10.2142; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAGAMINE CM, 1990, GENE DEV, V4, P63, DOI 10.1101/gad.4.1.63; NIETFELD W, 1989, J MOL BIOL, V208, P639, DOI 10.1016/0022-2836(89)90155-1; NOCE T, 1992, DEV BIOL, V155, P409; ROGERS MB, 1991, DEVELOPMENT, V113, P815; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SETOYAMA C, 1990, J BIOL CHEM, V26, P1293; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	32	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6900	6907						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120052				2022-12-25	WOS:A1994MZ50300099
J	ARIELI, B; SHAHAK, Y; TAGLICHT, D; HAUSKA, G; PADAN, E				ARIELI, B; SHAHAK, Y; TAGLICHT, D; HAUSKA, G; PADAN, E			PURIFICATION AND CHARACTERIZATION OF SULFIDE-QUINONE REDUCTASE, A NOVEL ENZYME DRIVING ANOXYGENIC PHOTOSYNTHESIS IN OSCILLATORIA-LIMNETICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ELECTRON-TRANSPORT; PROTEINS; THYLAKOIDS; OXIDOREDUCTASES; RECONSTITUTION; CYANOBACTERIA; CHLOROPLASTS; CHLOROBIUM; INDUCTION; COMPLEXES	An enzyme catalyzing sulfide quinone oxide-reduction (E.C.1.8.5.'.; SQR) has been purified in an active form, from thylakoids of the cyanobacterium Oscillatoria limnetica. It is composed of a single polypeptide of about 57 kDa. The catalytic activity of the purified enzyme is similar to the membrane-bound form in its kinetic parameters: apparent k(m) for sulfide equals 8 mu M; V(max)of 100-150 mu mol of plastoquinone-1 reduced/mg protein/h; quinone-substrate specificity; differential sensitivity to quinone analog inhibitors, the most potent of which being aurachin C (I-50 = 7 nm), and specific inducibility by sulfide. Taken together, they suggest that the purified SQR is the enzyme catalyzing anoxygenic photosynthesis in cyanobacteria. The UV and visible absorption and fluorescence spectra of the purified SQR are typical of a flavoprotein. Both the absorption and fluorescence intensities are reduced by sulfide. The SQR activity is inhibited by KCN, a flavoprotein inhibitor. We have sequenced so far 29 amino acid residues of the SQR NH2 terminus and found that from the second residue, this sequence contains the highly conserved fingerprint of the NAD/FAD binding domain of many NAD/FAD-binding enzymes (Wierenga, R. K., Terpstra, P., and Hol, W. G. S. (1986) J. Mol. Biol. 187, 101-107). This suggests that the SQR enzyme is a flavoprotein which contains binding sites for sulfide and quinone and that the electron transfer between the two is mediated by FAD.	HEBREW UNIV JERUSALEM,INST LIFE SCI,DIV MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL; AGR RES ORG,VOLCANI CTR,INST HORT,IL-50250 BET DAGAN,ISRAEL; UNIV REGENSBURG,LEHRSTUHL ZELLBIOL & PFLANZENPHYSIOL,W-8400 REGENSBURG,GERMANY	Hebrew University of Jerusalem; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; University of Regensburg								ARIELI B, 1991, J BIOL CHEM, V266, P104; ARIELI B, 1989, J BACTERIOL, V171, P699, DOI 10.1128/jb.171.2.699-702.1989; BELKIN S, 1982, ISRAEL J BOT, V31, P199; BELKIN S, 1978, FEBS LETT, V94, P291, DOI 10.1016/0014-5793(78)80959-4; BELKIN S, 1987, METHOD ENZYMOL, V167, P380; BRUNE DC, 1989, BIOCHIM BIOPHYS ACTA, V975, P189, DOI 10.1016/S0005-2728(89)80251-8; CLINE JD, 1969, LIMNOL OCEANOGR, V14, P454, DOI 10.4319/lo.1969.14.3.0454; COHEN Y, 1975, NATURE, V257, P489, DOI 10.1038/257489a0; COHEN Y, 1975, J BACTERIOL, V123, P858; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Ghisla S, 1980, Methods Enzymol, V66, P360; HAEHNEL W, 1982, J BIOENERG BIOMEMBR, V14, P181, DOI 10.1007/BF00745019; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HAUSKA G, 1986, METHOD ENZYMOL, V126, P271; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KUSAI A, 1973, BIOCHIM BIOPHYS ACTA, V304, P304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacKinney G, 1941, J BIOL CHEM, V140, P315; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OETTMEIER W, 1990, Z NATURFORSCH C, V45, P311; OREN A, 1978, J BACTERIOL, V133, P558, DOI 10.1128/JB.133.2.558-563.1978; OREN A, 1977, P NATL ACAD SCI USA, V74, P2152, DOI 10.1073/pnas.74.5.2152; PADAN E, 1979, ANNU REV PLANT PHYS, V30, P27, DOI 10.1146/annurev.pp.30.060179.000331; PICK U, 1979, J BIOL CHEM, V254, P2793; PICK U, 1982, BIOCHEMISTRY-US, V24, P6144; RICH PR, 1987, BIOCHIM BIOPHYS ACTA, V892, P138, DOI 10.1016/0005-2728(87)90256-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERRANO R, 1988, PLANT SCI, V56, P117, DOI 10.1016/0168-9452(88)90024-6; SHAHAK Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P605, DOI 10.1016/0003-9861(87)90527-3; SHAHAK Y, 1992, FEBS LETT, V299, P127, DOI 10.1016/0014-5793(92)80230-E; Shahak Y, 1992, RES PHOTOSYNTHESIS, VII, P483; SLOOTEN L, 1989, BIOCHIM BIOPHYS ACTA, V973, P272, DOI 10.1016/S0005-2728(89)80432-3; STEINMETZ MA, 1983, ARCH MICROBIOL, V135, P186, DOI 10.1007/BF00414477; SYBESMA C, 1987, PROG PHOTOSYN RES, V2, P633; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILLIAMS CH, 1976, ENZYMES            C, V13, P90; Yamanaka T, 1976, FLAVINS FLAVOPROTEIN, P292	39	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5705	5711						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119908				2022-12-25	WOS:A1994MY84000037
J	KUKULJAN, M; ROJAS, E; CATT, KJ; STOJILKOVIC, SS				KUKULJAN, M; ROJAS, E; CATT, KJ; STOJILKOVIC, SS			MEMBRANE-POTENTIAL REGULATES INOSITOL 1,4,5-TRISPHOSPHATE-CONTROLLED CYTOPLASMIC CA2+ OSCILLATIONS IN PITUITARY GONADOTROPHS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; CYTOSOLIC CALCIUM; XENOPUS OOCYTES; TRISPHOSPHATE; CHANNELS; RELEASE; ENTRY; MOBILIZATION; ACTIVATION; INFLUX	The influence of membrane potential (V-m) on cytoplasmic calcium ([Ca2+](i)) oscillations during the sustained extracellular Ca2+-dependent phase of the Ca2+ signaling response to gonadotropin-releasing hormone (GnRH) was analyzed in cultured pituitary gonadotrophs. In agonist- and inositol (1,4,5)-trisphosphate (Ins(1,4,5)P-3)-stimulated cells, sustained [Ca2+](i) oscillations were extinguished by hyperpolarization after 3-15 min despite the availability of Ca2+ in the extracellular medium. Single depolarizing pulses transiently restored the amplitude of the sustained spiking in a dihydropyridine- and extracellular Ca2+-sensitive manner. The responses to depolarization showed a marked dependence on V-m that was correlated with the steady state inward Ca2+ current. In addition, repetitive application of brief depolarizing pulses modulated the frequency of agonist- and Ins(1,4,5)Ps-controlled spiking; depolarization pulses at frequencies lower than the intrinsic rate of episodic Ca2+ release triggered large transients between the autonomous spikes, whereas higher frequencies of depolarizing pulses overcame the original Ca2+ spiking frequency. These extrinsically driven and extracellular Ca2+-dependent oscillations were sensitive to the Ca2+-ATPase blocker, thapsigargin, but not to ryanodine. On the other hand, spontaneous firing and application of depolarizing pulses to nonstimulated cells failed to induce thapsigargin-sensitive oscillations. These findings demonstrate that the pattern of Ca2+ signaling in gonadotrophs does not depend exclusively on the Ins(1,4,5)P-3 concentration, but also on the excitable status of the cell. Such modulation of the Ins(1,4,5)P-3-controlled Ca2+ signaling system by changes in V-m could provide a mechanism for the integration of multiple inputs that utilize diverse signal transduction pathways.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892; NIDDKD,CELL BIOL & GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BALLA T, 1991, J BIOL CHEM, V266, P24719; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CATT KJ, 1989, TRENDS ENDOCRIN MET, V1, P15, DOI 10.1016/1043-2760(89)90024-6; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; GUILLEMETTE G, 1987, P NATL ACAD SCI USA, V84, P8195, DOI 10.1073/pnas.84.23.8195; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; IZUMI SI, 1989, ARCH BIOCHEM BIOPHYS, V275, P410, DOI 10.1016/0003-9861(89)90388-3; KUKULJAN M, 1992, FEBS LETT, V301, P19, DOI 10.1016/0014-5793(92)80201-Q; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEONG DA, 1991, J BIOL CHEM, V266, P916; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MORGAN RO, 1987, J BIOL CHEM, V262, P116; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RAWLINGS SR, 1991, J BIOL CHEM, V266, P22755; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; STOJILKOVIC SS, 1990, SCIENCE, V248, P1663, DOI 10.1126/science.2163546; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STOJILKOVIC SS, 1991, J BIOL CHEM, V266, P10377; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; STOJILKOVIC SS, 1993, J BIOL CHEM, V268, P7713; STUTZIN A, 1989, AM J PHYSIOL, V257, pC865, DOI 10.1152/ajpcell.1989.257.5.C865; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TASAKA K, 1988, BIOCHEM BIOPH RES CO, V154, P398, DOI 10.1016/0006-291X(88)90699-7; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSE A, 1993, ENDOCRINOLOGY, V132, P1475, DOI 10.1210/en.132.4.1475; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WATRAS J, 1991, J NEUROSCI, V11, P3239; YAO Y, 1992, J PHYSIOL-LONDON, V458, P319, DOI 10.1113/jphysiol.1992.sp019420; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	45	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4860	4865						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106457				2022-12-25	WOS:A1994MX57100027
J	WENHAM, RM; LANDT, M; EASOM, RA				WENHAM, RM; LANDT, M; EASOM, RA			GLUCOSE ACTIVATES THE MULTIFUNCTIONAL CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE-II IN ISOLATED RAT PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; CA-2+-INDEPENDENT FORM; BETA-CELLS; CALMODULIN; CA-2+; PHOSPHORYLATION; INHIBITION; CHANNELS; CA2+; AUTOPHOSPHORYLATION	The influence of the insulin secretagogues, glucose and K+, to activate the multifunctional, Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) in isolated rat pancreatic islets has been examined. Glucose (28 mM) and K+ (40 mM) were demonstrated to induce a 1.89 +/- 0.19- and 1.75 +/- 0.15-fold increase, respectively, in phosphorylation of a subunit of CaM kinase II immunoprecipitated by an anti-CaM kinase II alpha antibody. In intact islets, glucose and K+ also induced the generation of an autonomous, Ca2+/calmodulin-independent protein kinase II activity characteristic of autophosphorylated enzyme. Maximal activation, 2.9 +/- 0.2- and 3.0 +/- 0.5-fold for glucose and K+, respectively, relative to basal glucose control, was achieved at 2.5-5 min followed by a decline to near basal levels by 20 min. Glucose induced the production of autonomous CaM kinase II activity that, in terms of -fold stimulation, correlated closely with the extent of insulin release over a glucose concentration range of 3-28 mM. This stimulated activity was completely prevented by an inhibitor of glucose metabolism, mannoheptulose. These data demonstrate that the exposure of islets to stimulatory glucose concentrations activates CaM kinase II. The close correlation of enzyme activation with insulin secretion is consistent with the hypothesis that CaM kinase II plays an important role in the regulation of insulin secretion or related beta-cell processes.	UNIV N TEXAS,HLTH SCI CTR FT WORTH,DEPT BIOCHEM & MOLEC BIOL,FT WORTH,TX 76107; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	University of North Texas System; University of North Texas Health Science Center; Washington University (WUSTL)								ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJ, 1970, BIOCHEM J, V118, P143, DOI 10.1042/bj1180143; ASHCROFT SJH, 1990, BIOCHEM SOC T, V18, P116, DOI 10.1042/bst0180116; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLCA JR, 1983, J BIOL CHEM, V258, P7260; COLCA JR, 1983, BIOCHEM J, V212, P819, DOI 10.1042/bj2120819; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; EASOM RA, 1990, J BIOL CHEM, V265, P14938; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; GORELICK FS, 1988, J BIOL CHEM, V263, P17209; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARRISON DE, 1982, BIOCHIM BIOPHYS ACTA, V714, P313, DOI 10.1016/0304-4165(82)90339-7; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HENQUIN JC, 1974, DIABETES, V23, P933, DOI 10.2337/diab.23.12.933; HENQUIN JC, 1980, DIABETOLOGIA, V18, P151, DOI 10.1007/BF00290493; HOWELL SL, 1984, EXPERIENTIA, V40, P1098, DOI 10.1007/BF01971457; HUGHES SJ, 1993, BIOCHEM J, V289, P795, DOI 10.1042/bj2890795; JEFFERSON AB, 1991, J BIOL CHEM, V266, P1484; JOHNSON JH, 1990, NEW ENGL J MED, V322, P653, DOI 10.1056/NEJM199003083221003; JONES PM, 1992, BIOCHEM J, V285, P973, DOI 10.1042/bj2850973; LANDT M, 1982, ARCH BIOCHEM BIOPHYS, V213, P148, DOI 10.1016/0003-9861(82)90449-0; LANDT M, 1992, DIABETES S1, V41, P103; LANZEN S, 1988, MOL PHARMACOL, V34, P395; LI GD, 1992, MOL PHARMACOL, V42, P489; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MCDANIEL ML, 1984, METHODS DIABETES R A, V1, P153; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NIKI I, 1993, BIOCHEM BIOPH RES CO, V191, P255, DOI 10.1006/bbrc.1993.1210; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SCHULMAN H, 1993, NEUROCHEM RES, V18, P65, DOI 10.1007/BF00966924; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; STUTCHFIELD J, 1984, FEBS LETT, V175, P393, DOI 10.1016/0014-5793(84)80775-9; TOBIMATSU T, 1989, J BIOL CHEM, V264; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; WANG JL, 1990, BIOCHEM BIOPH RES CO, V171, P424, DOI 10.1016/0006-291X(90)91410-T; WENHAM RM, 1992, BIOCHEM BIOPH RES CO, V189, P128, DOI 10.1016/0006-291X(92)91534-W; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; ZAWALICH W, 1983, BIOCHEM BIOPH RES CO, V117, P448, DOI 10.1016/0006-291X(83)91221-4	50	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4947	4952						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106469				2022-12-25	WOS:A1994MX57100041
J	ALTIERI, DC				ALTIERI, DC			MOLECULAR-CLONING OF EFFECTOR CELL PROTEASE RECEPTOR-1, A NOVEL CELL-SURFACE RECEPTOR FOR THE PROTEASE FACTOR-XA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; SERINE PROTEASE; COAGULATION; UROKINASE; MONOCYTES; THROMBIN; PHOSPHORYLATION; PROTHROMBIN; EXPRESSION	Cellular receptors for blood proteases regulate chemotaxis, extracellular proteolysis, and growth behavior of normal and malignant cells. Binding of the coagulation protease factor Xa to leukocytes is contributed by a recently identified molecule, denominated Effector cell Protease Receptor-1 (EPR-1). Monoclonal antibodies were generated against EPR-1+ MOLT13 lymphocytes and selected for reactivity with lymphocyte surface proteins by flow cytometry and with affinity-purified EPR-1 in Western blots. Antibody-based functional cloning of the cDNA for EPR-1 reveals the sequence of a novel molecule encoded by a prominent 1.9-kilobase mRNA. The cDNA predictes a glycoprotein of 337 amino acids, characterized by a unique cysteine-rich extracellular module, a single membrane-spanning domain, and a serine-rich (26%) cytoplasmic tail featuring at least 15 potential phosphorylation sites. Genetically engineered EPR-1 transfectants were recognized by monoclonal antibodies to EPR-1 and bound I-125-factor Xa in a specific and saturable manner (K(d) approximately 10-15 nM). In the absence of factor V/Va, EPR-1 transfectants promoted prothrombin activation in a factor Xa concentration-dependent reaction, inhibited by a monoclonal antibody to EPR-1. These findings define EPR-1 as a novel cell surface receptor for factor Xa potentially implicated in protease-dependent cellular effector functions.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	ALTIERI, DC (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, CVB-1, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL-43773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1990, J IMMUNOL, V145, P246; ALTIERI DC, 1989, J BIOL CHEM, V264, P2969; APPELLA E, 1987, J BIOL CHEM, V262, P4437; BARSHAVIT R, 1983, J CELL BIOL, V96, P282, DOI 10.1083/jcb.96.1.282; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GLENN KC, 1979, NATURE, V278, P711, DOI 10.1038/278711a0; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MCGEE MP, 1986, J EXP MED, V164, P1902, DOI 10.1084/jem.164.6.1902; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; PARIS S, 1984, J BIOL CHEM, V259, P989; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAPOPORT TA, 1986, CRC CR REV BIOCH MOL, V20, P73, DOI 10.3109/10409238609115901; REEVES WH, 1989, J CLIN INVEST, V84, P562, DOI 10.1172/JCI114199; RODGERS GM, 1983, P NATL ACAD SCI-BIOL, V80, P7001, DOI 10.1073/pnas.80.22.7001; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P349; TRACY PB, 1985, J BIOL CHEM, V260, P2119; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WORFOLK LA, 1992, BLOOD, V80, P1989	25	86	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3139	3142						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106347				2022-12-25	WOS:A1994MV63100005
J	ASTERMARK, J; HOGG, PJ; STENFLO, J				ASTERMARK, J; HOGG, PJ; STENFLO, J			THE GAMMA-CARBOXYGLUTAMIC ACID AND EPIDERMAL GROWTH FACTOR-LIKE MODULES OF FACTOR-IXA-BETA - EFFECTS ON THE SERINE-PROTEASE MODULE AND FACTOR-X ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL BINDING; BOVINE FACTOR-X; FACTOR-LIKE DOMAINS; CALCIUM-BINDING; STRUCTURAL REQUIREMENTS; BLOOD-COAGULATION; CA2+ BINDING; ENZYME COMPLEXES; CHRISTMAS FACTOR; PROTHROMBIN	Blood coagulation factors IX and X are two serine proteases with a similar modular structure. The noncatalytic part of each protein consists of a gamma-carboxyglutamic acid (Gla)-containing module and two modules homologous to the epidermal growth factor (EGF) precursor. We have now found that the NH2-terminal EGF-like module of both factors IX and X inhibits factor Xa formation in a Gla-independent manner, both in the presence and absence of phospholipid and the cofactor, factor VIIIa. In contrast, the COOH-terminal EGF-like module has no such effect. Our data indicate that the NH2-terminal EGF-like module of factor IXabeta interacts either with the corresponding module or with the serine protease module in the substrate, factor X, without affecting the hydrolysis of low molecular weight substrates. Using antibodies as structural probes, we found that Ca2+ binding to the Gla module of factor IXabeta induces a conformational transition in the serine protease module. No evidence was found for a direct interaction between the Gla module and factor VIIIa. We therefore propose that the Gla module in factor IXabeta is indirectly involved in the cofactor interaction, in that Ca2+ binding to sites in this module induces a conformation in the serine protease module that is commensurate with factor VIIIa interaction. In addition, the immunochemical approach revealed a Gla-independent Ca2+ binding site in the serine protease module (apparent K(d) of almost-equal-to 120 gm) that also might influence its conformation. Antibodies against the EGF-like modules of factor IX were used to probe Ca2+ binding to these modules in intact and in Gla-domainless factor IXabeta. The data indicate a Ca2+ binding site with an apparent K(d) of almost-equal-to 50 mum in the NH2-terminal EGF-like module of both factor IX species.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; PRINCE WALES HOSP,DEPT HAEMATOL,RANDWICK,NSW 2031,AUSTRALIA	Lund University				Hogg, Philip/0000-0001-6486-2863				ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; ASTERMARK J, 1991, J BIOL CHEM, V266, P2438; BAJAJ SP, 1982, J BIOL CHEM, V257, P3726; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CHEUNG WF, 1992, J BIOL CHEM, V267, P20529; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P2285; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIANNELLI F, 1993, NUCLEIC ACIDS RES, V21, P3075, DOI 10.1093/nar/21.13.3075; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; JACKSON CM, 1972, BIOCHEMISTRY-US, V11, P4873, DOI 10.1021/bi00776a001; Jesty J, 1976, Methods Enzymol, V45, P95; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; LIN SW, 1990, J BIOL CHEM, V265, P144; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MORITA T, 1985, J BIOL CHEM, V260, P2583; MORITA T, 1991, J BIOCHEM, V110, P990, DOI 10.1093/oxfordjournals.jbchem.a123701; MORITA T, 1988, J BIOCHEM, V104, P368, DOI 10.1093/oxfordjournals.jbchem.a122475; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORITA T, 1984, J BIOL CHEM, V259, P5698; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; OWEN WG, 1974, J BIOL CHEM, V249, P594; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PERSSON E, 1992, FEBS LETT, V314, P5, DOI 10.1016/0014-5793(92)81447-T; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PERSSON E, 1991, J BIOL CHEM, V266, P2453; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; RYAN J, 1989, J BIOL CHEM, V264, P20283; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SEGEL IH, 1990, ENZYME KINETICS, P100; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; STENFLO J, 1976, J BIOL CHEM, V251, P355; SUGO T, 1984, J BIOL CHEM, V259, P5705; TOOMEY JR, 1992, BIOCHEMISTRY-US, V31, P1806, DOI 10.1021/bi00121a031; VALCARCE C, 1993, J BIOL CHEM, V268, P26673	52	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3682	3689						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106413				2022-12-25	WOS:A1994MV63100081
J	CHAMBREY, R; PAILLARD, M; PODEVIN, RA				CHAMBREY, R; PAILLARD, M; PODEVIN, RA			ENZYMATIC AND FUNCTIONAL EVIDENCE FOR ADAPTATION OF THE VACUOLAR H+-ATPASE IN PROXIMAL TUBULE APICAL MEMBRANES FROM RATS WITH CHRONIC METABOLIC-ACIDOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; BRUSH-BORDER MEMBRANES; NEM-SENSITIVE ATPASE; ANTIPORTER ACTIVITY; NA+/H+ ANTIPORTER; GOLGI MEMBRANES; TURTLE BLADDER; VESICLES; ALKALOSIS; EXCHANGE	The present work examined the effects of chronic metabolic acidosis on the vacuolar proton-translocating adenosine triphosphatase (H+-ATPase) activity both in rat renal cortical homogenates and in their luminal membranes. Moreover, to assess the effect of acidosis on H+ transport by the apical H+-ATPase, we have developed a detergent-dilution procedure, resulting in the formation of sealed vesicles having this enzyme at their external surface. NH4Cl loading for 4 days had no effect on homogenates H+-ATPase activity, estimated with either N-ethylmaleimide or bafilomycin A1. In contrast, H+-ATPase activities were increased significantly by about 30% in both native apical membranes prepared by Ca2+ aggregation and detergent-treated luminal vesicles from acidotic animal. Kinetic analysis revealed that this stimulation was solely through changes in the V(max) for ATP. In membranes prepared by Mg2+ aggregation, acidosis also caused significant stimulation of the H+ATPase activity. In addition, the initial rate of ATP-induced intravesicular acidification was 25% higher in reoriented H+-ATPase vesicles from acidotic rats, whereas passive proton permeability was identical in both groups. Finally, both vesicle enrichments and yields of luminal markers and de-enrichments and yields of intracellular membrane markers were identical in the two groups. These results provide enzymatic and functional evidence suggesting that chronic acidosis induces an adaptative change in the rat brush border H+-ATPase.	CTR RECH BIOMED CORDELIERS,INSERM,U356,15 RUE ECOLE MED,F-75270 PARIS 06,FRANCE; HOP HOTEL DIEU,FAC MED BROUSSAIS,F-75181 PARIS 04,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite								AKIBA T, 1987, J CLIN INVEST, V80, P308, DOI 10.1172/JCI113074; ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; AUBRY H, 1986, BIOCHIM BIOPHYS ACTA, V856, P647; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BARBARAT B, 1986, J BIOL CHEM, V261, P4455; BASTANI B, 1991, J CLIN INVEST, V88, P126, DOI 10.1172/JCI115268; BLUMENTHAL SS, 1985, J LAB CLIN MED, V106, P17; BOUMENDILPODEVIN EF, 1981, AM J PHYSIOL, V240, pF185, DOI 10.1152/ajprenal.1981.240.3.F185; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN D, 1988, J CLIN INVEST, V82, P2114, DOI 10.1172/JCI113833; COHN DE, 1983, AM J PHYSIOL, V245, pF217, DOI 10.1152/ajprenal.1983.245.2.F217; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; FISHMAN WH, 1967, CLIN CHIM ACTA, V15, P435, DOI 10.1016/0009-8981(67)90008-3; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; Harper AE, 1965, METHODS ENZYMATIC AN, P788; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; KHADOURI C, 1992, AM J PHYSIOL, V262, pF583, DOI 10.1152/ajprenal.1992.262.4.F583; KINSELLA J, 1984, P NATL ACAD SCI-BIOL, V81, P630, DOI 10.1073/pnas.81.2.630; KINSELLA J, 1984, J BIOL CHEM, V259, P3224; KULANTHAIVEL P, 1990, BIOCHEMISTRY-US, V29, P10807, DOI 10.1021/bi00500a013; KURTZ I, 1987, J CLIN INVEST, V80, P928, DOI 10.1172/JCI113184; LEABACK DH, 1961, BIOCHEM J, V78, P151, DOI 10.1042/bj0780151; MANGANEL M, 1985, AM J PHYSIOL, V249, pF400, DOI 10.1152/ajprenal.1985.249.3.F400; MARTINEK RG, 1964, CLIN CHEM, V10, P1087; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NORTHRUP TE, 1988, AM J PHYSIOL, V255, pF237, DOI 10.1152/ajprenal.1988.255.2.F237; PORTEOUS JW, 1965, BIOCHEM J, V96, P159, DOI 10.1042/bj0960159; PREISIG PA, 1988, J CLIN INVEST, V82, P1445, DOI 10.1172/JCI113750; RACKER E, 1972, J MEMBRANE BIOL, V10, P221, DOI 10.1007/BF01867856; REESJONES R, 1984, BIOCHEMISTRY-US, V23, P2236, DOI 10.1021/bi00305a022; SABATINI S, 1990, AM J PHYSIOL, V258, pF297, DOI 10.1152/ajprenal.1990.258.2.F297; SABOLIC I, 1984, BIOCHIM BIOPHYS ACTA, V772, P140, DOI 10.1016/0005-2736(84)90037-3; SCHWARTZ GJ, 1985, J CLIN INVEST, V75, P1638, DOI 10.1172/JCI111871; SIMON BJ, 1990, J MEMBRANE BIOL, V117, P141, DOI 10.1007/BF01868681; STETSON DL, 1983, AM J PHYSIOL, V245, pC113, DOI 10.1152/ajpcell.1983.245.1.C113; TSAI CJ, 1984, AM J PHYSIOL, V247, pF339, DOI 10.1152/ajprenal.1984.247.2.F339; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; WERNER G, 1984, J ANTIBIOT, V37, P110, DOI 10.7164/antibiotics.37.110; YURKO MA, 1987, J BIOL CHEM, V262, P15770; ZIMOLO Z, 1992, J MEMBRANE BIOL, V126, P19	44	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3243	3250						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106360				2022-12-25	WOS:A1994MV63100021
J	COLAMONICI, OR; UYTTENDAELE, H; DOMANSKI, P; YAN, H; KROLEWSKI, JJ				COLAMONICI, OR; UYTTENDAELE, H; DOMANSKI, P; YAN, H; KROLEWSKI, JJ			P135(TYK2), AN INTERFERON-ALPHA-ACTIVATED TYROSINE KINASE, IS PHYSICALLY ASSOCIATED WITH AN INTERFERON-ALPHA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; SH3 DOMAINS; PHOSPHORYLATION; FAMILY; SYSTEM; CD4; PROTEINS; SUBUNIT	Recent genetic studies have linked the tyk2 gene, which encodes a novel type of non-receptor tyrosine kinase, to the interferon-alpha intracellular signaling pathway. In this report, biochemical evidence is presented which supports this proposed function for the tyk2 tyrosine kinase and further defines its role in the interferon-alpha signaling cascade. Specifically, the tyk2 gene is shown to encode a 135-kDa protein which is rapidly phosphorylated on tyrosine in response to interferon-alpha treatment. Indirect evidence suggests that the tyrosine phosphorylation of p135tyk2 is the result of autokinase activity, implying that the Tyk2 tyrosine kinase is activated by interferon-alpha treatment. Two complementary methods demonstrate a physical association between p135tyk2 and the alpha-subunit of the interferon-alpha receptor. First, immunoblots show that monoclonal antibodies against the alpha-subunit of the interferon-alpha receptor can coimmunoprecipitate p135tyk2. Second, interferon-alpha receptor proteins which have been labeled by affinity cross-linking with I-125-interferon-alpha2 can be coimmuno-precipitated using anti-tyk2 antisera. Taken together, these data suggest that an interferon-a receptor-p135tyk2 complex functions, in a manner analogous to the CD4-Ick tyrosine kinase complex, to initiate the interferon-alpha signaling cascade.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,ROOM P&S 14-451,630 W 168TH ST,NEW YORK,NY 10032; UNIV TENNESSEE CTR HLTH SCI,DEPT PATHOL,MEMPHIS,TN 38163; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032	Columbia University; University of Tennessee System; University of Tennessee Health Science Center; Columbia University					NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005395] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline; NCRR NIH HHS [2S07RR5395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENOIT P, 1993, J IMMUNOL, V150, P707; BERNARDS A, 1991, ONCOGENE, V6, P1185; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; EISEMAN E, 1992, NATURE, V355, P78; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HARPUR AG, 1992, ONCOGENE, V7, P1347; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P146; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VALAZQUEZ L, 1992, CELL, V70, P313; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	37	149	151	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3518	3522						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106393				2022-12-25	WOS:A1994MV63100060
J	RITCHIE, HH; HOU, H; VEIS, A; BUTLER, WT				RITCHIE, HH; HOU, H; VEIS, A; BUTLER, WT			CLONING AND SEQUENCE DETERMINATION OF RAT DENTIN SIALOPROTEIN, A NOVEL DENTIN PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE TEETH; INCISOR; PHOSPHOPROTEIN; PHOSPHOPHORYNS; LOCALIZATION; SPECIFICITY; RIBOSOMES; PEPTIDES; MATRIX; BONE	Dentin sialoprotein (DSP) is a 53-kDa protein isolated from rat dentin. It contains 29.6% carbohydrate (including 9% sialic acid) and has an overall composition similar to that of the bone sialoproteins osteopontin and bone sialoprotein (i.e. rich in Asp, Ser, Glu, and Gly). Using a monospecific anti-DSP polyclonal antibody to screen a rat incisor odontoblast cDNA library, a cDNA clone was isolated and sequenced. This approximately 750-base pair clone contained a DNA sequence corresponding to the NH2-terminal 9 amino acids of DSP. A second cDNA clone was isolated by using the first cDNA as a probe to rescreen the library. This second clone had the full-length DSP coding region. From the sequence, we deduced that the DSP cDNA coded for 366 amino acids, predominantly Asp, Ser, Glu, and Gly. The amino acid composition calculated for this sequence was very similar to that for purified DSP reported earlier; likewise the deduced molecular weight (53,045) was essentially identical to that determined by sedimentation equilibrium. Six potential N-linked glycosylation sites were present in the predicted DSP sequence. No Arg-Gly-Asp sequence was found, and the sequence for DSP was dissimilar to those of osteopontin and bone sialoprotein. Multiple transcripts near 4.6 and 1.5 kilobases were detected by Northern blot analysis in the incisor of 21-day-old rat and the tooth germ of the newborn rat. Consistent with previous immunohistochemical findings, no transcripts were detected in brain, salivary gland, heart, muscle, spleen, kidney, intestine, lung, liver, pancreas, tibia, calvaria, or osteoblast-like osteosarcoma (ROS 17/2.8) cells, indicating that DSP is specifically expressed by odontoblasts and related cells.	NORTHWESTERN UNIV, DEPT ORAL BIOL, CHICAGO, IL 60611 USA	Northwestern University	RITCHIE, HH (corresponding author), UNIV TEXAS, DENT BRANCH, DEPT BIOL CHEM, HOUSTON, TX 77030 USA.				NCI NIH HHS [CA 16672] Funding Source: Medline; NIDCR NIH HHS [R37 DE 05092] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE005092] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Bronckers A L, 1989, Connect Tissue Res, V22, P65; BRONCKERS ALJJ, 1987, BONE MINER, V2, P361; BRONCKERS ALJJ, 1993, CELL TISSUE RES, V272, P237, DOI 10.1007/BF00302729; Butler W T, 1991, J Biol Buccale, V19, P83; BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934-8832(11)80030-2; DEVRIES IG, 1986, ARCH ORAL BIOL, V31, P57, DOI 10.1016/0003-9969(86)90114-7; DIMUZIO MT, 1978, J BIOL CHEM, V253, P6845; DIMUZIO MT, 1985, CHEM BIOL MINERALIZE, P296; DSOUZA RN, 1992, J HISTOCHEM CYTOCHEM, V40, P359, DOI 10.1177/40.3.1552175; GEORGE A, 1992, INT CONGR SER, V1002, P203; GORSKI JP, 1992, CALCIFIED TISSUE INT, V50, P391, DOI 10.1007/BF00296767; Heinegard D, 1989, Connect Tissue Res, V21, P3, DOI 10.3109/03008208909049990; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JONTELL M, 1983, BIOCHEM J, V214, P769, DOI 10.1042/bj2140769; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LINDE A, 1989, ANAT REC, V224, P154, DOI 10.1002/ar.1092240206; MACDOUGALL M, 1985, BIOCHEM J, V232, P493, DOI 10.1042/bj2320493; Maniatis T., 1982, MOL CLONING; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; RABIE A M, 1991, Journal of Dental Research, V70, P380; RAHIMA M, 1988, J HISTOCHEM CYTOCHEM, V36, P153, DOI 10.1177/36.2.3335773; RITCHIE HH, 1990, NUCLEIC ACIDS RES, V18, P6857, DOI 10.1093/nar/18.23.6857; ROBEY PG, 1989, ENDOCRIN METAB CLIN, V18, P859, DOI 10.1016/S0889-8529(18)30347-5; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STETLERSTEVENSON WG, 1987, CALCIFIED TISSUE INT, V40, P97, DOI 10.1007/BF02555712; Veis A, 1985, CHEM BIOL MINERALIZE, P170; VEIS A, 1978, IONS MACROMOLECULAR, P259; WEINSTOCK M, 1973, J CELL BIOL, V56, P838, DOI 10.1083/jcb.56.3.838; WU CB, 1992, J BIOL CHEM, V267, P16588; YOUNG MF, 1992, CLIN ORTHOP RELAT R, P275	35	128	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3698	3702						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106414				2022-12-25	WOS:A1994MV63100083
J	DEPAIVA, A; POULAIN, B; LAWRENCE, GW; SHONE, CC; TAUC, L; DOLLY, JO				DEPAIVA, A; POULAIN, B; LAWRENCE, GW; SHONE, CC; TAUC, L; DOLLY, JO			A ROLE FOR THE INTERCHAIN DISULFIDE OR ITS PARTICIPATING THIOLS IN THE INTERNALIZATION OF BOTULINUM NEUROTOXIN-A REVEALED BY A TOXIN DERIVATIVE THAT BINDS TO ECTO-ACCEPTORS AND INHIBITS TRANSMITTER RELEASE INTRACELLULARLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDULLARY CHROMAFFIN CELLS; MOTOR-NERVE TERMINALS; CHOLERA-TOXIN; NEUROTRANSMITTER RELEASE; CLOSTRIDIUM-BOTULINUM; DIPHTHERIA-TOXIN; TETANUS TOXIN; LIGHT-CHAINS; CATECHOLAMINE SECRETION; APLYSIA NEURONS	Botulinum neurotoxin type A consists of a disulfide-linked light and heavy chain, with an intradisulfide present within the C-terminal half of the latter. The functional consequences of reducing these bonds and alkylating the thiols were investigated. Modification of free cysteine residues had no effect on the toxicity in mouse bioassays or on acetylcholine release in the mouse nerve-diaphragm and the buccal ganglion of Aplysia californica. However, reduction of the toxin prior to alkylation drastically decreased neuroparalytic potency; yet, this derivative inhibited transmitter release if injected directly into a presynaptic neuron in the Aplysia ganglion or added to bovine permeabilized adrenal chromaffin cells. Its antagonism of the action of botulinum neurotoxin A at mammalian motor nerve endings and Aplysia neurons indicates retention of the ability to bind to the toxin's productive ecto-acceptors. Thus, the abolition of the toxicity of extracellularly applied botulinum neurotoxin A by the cleavage of both disulfides, and the alkylation of the half-cystines involved, results from ineffective uptake. Modified forms of the isolated chains of botulinum neurotoxin A were utilized to determine which of the disulfides were necessary for internalization. Alkylation of the cysteines in the light and heavy chains, including those involved in the interchain bond but excluding those of the intact disulfide in the heavy chain, revealed that the intermolecular bond must be present, or the thiols concerned unmodified, for botulinum neurotoxin A to undergo membrane translocation into Aplysia neurons.	IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND; PUBL HLTH LAB SERV, SALISBURY SP4 0JG, WILTS, ENGLAND; CNRS, NEUROBIOL CELLULAIRE & MOLEC LAB, F-91198 GIF SUR YVETTE, FRANCE	Imperial College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Dolly, Oliver/G-1532-2012; Lawrence, Gary/F-3949-2012; Dolly, Oliver/ABH-6677-2020	Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320				AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; BANDYOPADHYAY S, 1987, J BIOL CHEM, V262, P2660; BARBIERI L, 1982, ARCH BIOCHEM BIOPHYS, V216, P380, DOI 10.1016/0003-9861(82)90224-7; BINZ T, 1990, J BIOL CHEM, V265, P9153; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BLACK JD, 1987, NEUROSCIENCE, V23, P767, DOI 10.1016/0306-4522(87)90094-7; BLACK JD, 1986, J CELL BIOL, V103, P521, DOI 10.1083/jcb.103.2.521; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; Dasgupta B.R., 1981, BIOMEDICAL ASPECTS B, P1; DAYANITHI G, 1990, NEUROSCIENCE, V39, P711, DOI 10.1016/0306-4522(90)90254-2; DEPAIVA A, 1990, FEBS LETT, V277, P171, DOI 10.1016/0014-5793(90)80836-8; DOLLY JO, 1988, E H S BIOT, P79; DOLLY JO, 1984, NATURE, V307, P457, DOI 10.1038/307457a0; DOLLY JO, 1992, BACTERIAL PROTEIN TO, P31; DUNN LA, 1983, J BIOL CHEM, V258, P4989; DWYER JD, 1982, BIOCHEMISTRY-US, V21, P3227, DOI 10.1021/bi00256a030; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gill D M, 1977, Adv Cyclic Nucleotide Res, V8, P85; KNOX JN, 1970, BIOCHIM BIOPHYS ACTA, V214, P350, DOI 10.1016/0005-2795(70)90012-7; KURAZONO H, 1992, J BIOL CHEM, V267, P14721; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; LOMNETH R, 1990, NEUROSCI LETT, V113, P211, DOI 10.1016/0304-3940(90)90305-S; LOMNETH R, 1991, J NEUROCHEM, V57, P1414; MAISEY EA, 1988, EUR J BIOCHEM, V177, P683, DOI 10.1111/j.1432-1033.1988.tb14423.x; MCINNES C, 1990, FEBS LETT, V261, P323, DOI 10.1016/0014-5793(90)80582-4; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; MOSS J, 1983, J BIOL CHEM, V258, P1879; POULAIN B, 1989, EUR J BIOCHEM, V185, P197, DOI 10.1111/j.1432-1033.1989.tb15102.x; POULAIN B, 1988, P NATL ACAD SCI USA, V85, P4090, DOI 10.1073/pnas.85.11.4090; POULAIN B, 1989, J BIOL CHEM, V264, P21928; POULAIN B, 1992, NEUROSCI LETT, V139, P289, DOI 10.1016/0304-3940(92)90573-P; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SHONE CC, 1985, EUR J BIOCHEM, V151, P75, DOI 10.1111/j.1432-1033.1985.tb09070.x; SIMPSON LL, 1981, PHARMACOL REV, V33, P155; SIMPSON LL, 1980, J PHARMACOL EXP THER, V212, P16; STECHER B, 1989, FEBS LETT, V248, P23, DOI 10.1016/0014-5793(89)80424-7; SUGIYAMA H, 1973, P SOC EXP BIOL MED, V143, P58; Tacket CO., 1989, BOTULINUM NEUROTOXIN, P351; TAUC L, 1974, NATURE, V250, P496, DOI 10.1038/250496a0; THOMPSON DE, 1990, EUR J BIOCHEM, V189, P73, DOI 10.1111/j.1432-1033.1990.tb15461.x; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TSE CK, 1982, EUR J BIOCHEM, V122, P493; VONEULER US, 1955, ACTA PHYSIOL SCAND, V33, P45; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0; WRIGHT HT, 1984, J BIOL CHEM, V259, P1649; WRIGHT HT, 1987, ARCH BIOCHEM BIOPHYS, V256, P280, DOI 10.1016/0003-9861(87)90447-4; [No title captured]; [No title captured]	52	70	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20838	20844						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8104936				2022-12-25	WOS:A1993MA28800033
J	BRUN, T; ROCHE, E; KIM, KH; PRENTKI, M				BRUN, T; ROCHE, E; KIM, KH; PRENTKI, M			GLUCOSE REGULATES ACETYL-COA CARBOXYLASE GENE-EXPRESSION IN A PANCREATIC BETA-CELL LINE (INS-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; CARBOHYDRATE RESPONSE ELEMENT; INDUCED INSULIN-SECRETION; PYRUVATE-KINASE GENE; MALONYL-COA; RAT-LIVER; S14 GENE; ISLETS; METABOLISM; PROMOTER	Acetyl-CoA carboxylase (ACC) catalyzes the production of malonyl-CoA which may act as a metabolic coupling factor in nutrient-induced insulin release. We have studied the long term regulation of ACC by nutrients using the cell line INS-1. Glucose, from 5 to 20 mm, elicited a 15-fold increase in ACC mRNA. The effect was detected after 4 h and reached a maximum by 24 h. ACC protein accumulation followed that of ACC mRNA, and glucose did not modify the half-life of the ACC transcript. Glucose caused a dose-dependent rise in the glucose 6-phosphate content of INS-1 cells. 2-Deoxyglucose, which is phosphorylated by glucokinase but is not further metabolized, induced ACC mRNA. The effect of glucose was blocked by the glucokinase inhibitors mannoheptulose and glucosamine and was not mimicked by the 3-O-methyl or 6-deoxy analogues of glucose, which are not phosphorylated. Activation of the Ca2+, cAMP, and C-kinase pathways with high K+, forskolin, and phorbol 12-myristate 13 acetate, respectively, caused insulin release but not ACC mRNA induction. Basal insulin release, at 5 mm glucose, correlated with the ACC protein content of INS-1 cells preincubated for 24 h at various glucose concentrations. In conclusion, glucose is a potent inducer of the ACC gene, and glucose 6-phosphate may mediate its effect. Different signaling systems mediate the action of glucose on insulin release and ACC gene expression. The data strengthen the view that ACC plays a pivotal role in nutrient-induced insulin release.	UNIV GENEVA, CMU, DIV BIOCHIM CLIN, 9 AV CHAMPEL, CH-1211 GENEVA 4, SWITZERLAND; PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	University of Geneva; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Roche, Enrique/V-5738-2017	Roche, Enrique/0000-0001-5128-1672; BRUN, Thierry/0000-0002-1659-4283				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BAI DH, 1986, J BIOL CHEM, V261, P2395; BEDOYA FJ, 1991, DIABETES, V40, P15, DOI 10.2337/diabetes.40.1.15; BERGMEYER HU, 1974, METHODS ENZYMATIC AN; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; BUSSO N, 1986, J BIOL CHEM, V261, P9309; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLART MA, 1989, ONCOGENE, V4, P237; COLLINS H, 1992, J BIOL CHEM, V267, P1357; COLLINS HW, 1990, P NATL ACAD SCI USA, V87, P5494, DOI 10.1073/pnas.87.14.5494; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; EVANS JL, 1988, ARCH BIOCHEM BIOPHYS, V264, P103, DOI 10.1016/0003-9861(88)90575-9; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FUKUDA H, 1992, J BIOCHEM-TOKYO, V111, P25, DOI 10.1093/oxfordjournals.jbchem.a123713; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JANJIC D, 1992, DIABETOLOGIA, V35, P482, DOI 10.1007/BF02342448; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KIM KH, 1983, CURR TOP CELL REGUL, V22, P143; KING DL, 1976, ENDOCRINOLOGY, V99, P1003, DOI 10.1210/endo-99-4-1003; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LIANG Y, 1991, DIABETES, V40, P327, DOI 10.2337/diabetes.40.3.327; LIANG Y, 1990, J BIOL CHEM, V265, P16863; LOPEZCASILLAS F, 1992, METABOLISM, V41, P201, DOI 10.1016/0026-0495(92)90154-3; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; MCDONALD MJ, 1991, J BIOL CHEM, V266, P1335; MCDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; PARK KR, 1991, J BIOL CHEM, V266, P12249; PHILIPPE J, 1991, ENDOCR REV, V12, P252, DOI 10.1210/edrv-12-3-252; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PRENTKI M, 1991, INT CONGR SER, V1000, P156; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; SALAS J, 1965, J BIOL CHEM, V240, P1014; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SWENNE I, 1980, DIABETES, V29, P686, DOI 10.2337/diab.29.9.686; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; WEIR G C, 1986, Diabetes Metabolism Reviews, V2, P125; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914	49	130	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18905	18911						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103051				2022-12-25	WOS:A1993LV65900079
J	HIXSON, JE; KAMMERER, CM; MOTT, GE; BRITTEN, ML; BIRNBAUM, S; POWERS, PK; VANDEBERG, JL				HIXSON, JE; KAMMERER, CM; MOTT, GE; BRITTEN, ML; BIRNBAUM, S; POWERS, PK; VANDEBERG, JL			BABOON APOLIPOPROTEIN-A-IV - IDENTIFICATION OF LYS(76)-] GLU THAT DISTINGUISHES 2 COMMON ISOFORMS AND DETECTION OF LENGTH POLYMORPHISMS AT THE CARBOXYL-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PROTEIN INTERACTIONS; PLASMA LIPOPROTEINS; SERUM-CHOLESTEROL; GENE; NUCLEOTIDE; FREQUENCY; CDNA; SUBSTITUTIONS; AMPLIFICATION; POPULATION	Various protein isoforms have been identified for human apolipoprotein A-IV (apoA-IV). However, investigations of their physiological effects have been limited because of low frequencies for many of the apoA-IV variants. Recent discovery of extensive variation in baboon apoA-IV using isoelectric focusing (IEF) makes this primate species an excellent model for genetic studies of apoA-IV. In this study, the molecular basis for net charge differences between two common apoA-IV isoforms (I and E) was determined by cloning and sequencing of intestinal cDNAs from homozygous baboons. An A --> G substitution was found in the third amphipathic repeat of the E isoform. This substitution causes a Lys --> Glu substitution at amino acid position 76 (Lys76 --> Glu), adding two negative charges to the E isoform compared to the I isoform, consistent with their relative mobilities on IEF gels. Restriction isotyping was used to identify the substitution in leukocyte DNA from 15 baboons that had been typed by IEF, thus verifying Lys76 --> Glu as the basis for the charge differences between the I and E isoforms. Physiological effects of the Lys76 --> Glu substitution on high density lipoprotein-C levels were investigated in 431 baboons carrying the E and I isoforms. These studies revealed that the I isoform was associated with higher levels of high density lipoprotein-C on a high cholesterol, saturated fat diet (p = 0.04). The cDNA sequences showed that the carboxyl terminus of baboon apoA-IV contains a region of hydrophilic repeats (Glu-Gln-X-Gln) that is the largest yet found in any species (nine repeats compared to three to five repeats in human, mouse, and rat). A common length polymorphism was identified that inserts a single amino acid to form a five amino acid repeat. This is the first report of this type of length variation (insertion of a single amino acid rather than insertion of an entire repeat) in this region. In addition, a rare variant was found that inserts an entire four-amino-acid repeat, similar to the human apoA-IV-0 isoform.	UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL, SAN ANTONIO, TX 78228 USA	University of Texas System; University of Texas Health San Antonio	HIXSON, JE (corresponding author), SW FDN BIOMED RES, DEPT GENET, POB 28147, SAN ANTONIO, TX 78228 USA.			Kammerer, Candace M/0000-0002-2841-4761; Hixson, James/0000-0002-0849-9315	NHLBI NIH HHS [HL-28972, HV-53030] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028972] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; BIGGIN MD, 1983, P NATL ACAD SCI USA, V380, P963; BLANGERO J, 1992, AM J PRIMATOL, V27, P119, DOI 10.1002/ajp.1350270207; BOERWINKLE E, 1986, ANN HUM GENET, V50, P181, DOI 10.1111/j.1469-1809.1986.tb01037.x; BOERWINKLE E, 1990, NUCLEIC ACIDS RES, V18, P4966, DOI 10.1093/nar/18.16.4966; BOGUSKI MS, 1984, P NATL ACAD SCI-BIOL, V81, P5021, DOI 10.1073/pnas.81.16.5021; DEKNIJFF P, 1988, J LIPID RES, V29, P1621; DVORIN E, 1986, J BIOL CHEM, V261, P5714; EICHNER JE, 1989, GENET EPIDEMIOL, V6, P493, DOI 10.1002/gepi.1370060404; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; FERRELL RE, 1990, J LIPID RES, V31, P131; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; HANIS CL, 1991, HUM GENET, V86, P323; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Hixson JE, 1988, GENOMICS, V2, P315, DOI 10.1016/0888-7543(88)90020-1; HIXSON JE, 1988, GENE, V64, P33, DOI 10.1016/0378-1119(88)90478-7; HIXSON JE, 1991, J LIPID RES, V32, P1529; HIXSON JE, 1990, J LIPID RES, V31, P545; HIXSON JE, 1988, GENE, V74, P483, DOI 10.1016/0378-1119(88)90181-3; HIXSON JE, 1989, ARTERIOSCLEROSIS, V9, P829, DOI 10.1161/01.ATV.9.6.829; KAISER ET, 1983, P NATL ACAD SCI USA, V80, P1137, DOI 10.1073/pnas.80.4.1137; KAMMERER CM, 1993, ATHEROSCLEROSIS, V98, P153, DOI 10.1016/0021-9150(93)90125-E; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KARATHANASIS SK, 1986, BIOCHEMISTRY-US, V25, P3962, DOI 10.1021/bi00361a034; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; LOHSE P, 1990, J BIOL CHEM, V265, P10061; LOHSE P, 1990, J BIOL CHEM, V265, P12734; LOHSE P, 1991, J BIOL CHEM, V266, P13513; MCGILL HC, 1988, ARTERIOSCLEROSIS, V8, P33, DOI 10.1161/01.ATV.8.1.33; MENZEL HJ, 1982, HUM GENET, V62, P349, DOI 10.1007/BF00304554; MENZEL HJ, 1990, HUM GENET, V84, P344; MENZEL HJ, 1988, HUM GENET, V79, P368; MORRISETT JD, 1977, BIOCHIM BIOPHYS ACTA, V472, P93, DOI 10.1016/0304-4157(77)90015-6; MOTT GE, 1982, ATHEROSCLEROSIS, V45, P191, DOI 10.1016/0021-9150(82)90138-1; PASTORCIC M, 1992, GENOMICS, V13, P368, DOI 10.1016/0888-7543(92)90255-Q; RAINWATER DL, 1992, ARTERIOSCLER THROMB, V12, P682, DOI 10.1161/01.ATV.12.6.682; REUE K, 1991, J BIOL CHEM, V266, P12715; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHERALDI CA, 1988, CIRCULATION S2, V78, P199; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; VISVIKIS S, 1990, CLIN GENET, V37, P435; VONECKARDSTEIN A, 1992, AM J HUM GENET, V50, P1115; WEINBERG RB, 1990, J BIOL CHEM, V265, P18372; WILLIAMS SC, 1986, MOL CELL BIOL, V6, P3807, DOI 10.1128/MCB.6.11.3807; WITTE DL, 1974, CLIN CHEM, V20, P1282; 1974, USDHEW NIH75628 PUBL	50	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15667	15673						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101842				2022-12-25	WOS:A1993LN30500053
J	DUHE, RJ; NIELSEN, MD; DITTMAN, AH; VILLACRES, EC; CHOI, EJ; STORM, DR				DUHE, RJ; NIELSEN, MD; DITTMAN, AH; VILLACRES, EC; CHOI, EJ; STORM, DR			OXIDATION OF CRITICAL CYSTEINE RESIDUES OF TYPE-I ADENYLYL-CYCLASE BY O-IODOSOBENZOATE OR NITRIC-OXIDE REVERSIBLY INHIBITS STIMULATION BY CALCIUM AND CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; ACID; EXPRESSION; PROTEINS; CLONING; IDENTIFICATION; FAMILY	The calmodulin binding domain of the type I adenylyl cyclase has recently been identified as an amino acid sequence (residues 495-522) that contains 2 cysteine residues. Therefore, we examined the effect of several sulfhydryl reagents on the calmodulin sensitivity of the enzyme. Treatment of membranes containing the type I adenylyl cyclase with N-ethylmaleimide rapidly inhibited basal, calcium/calmodulin-stimulated, and forskolin-stimulated adenylyl cyclase activity. When the enzyme was treated with limiting amounts of o-iodosobenzoate, which oxidizes vicinal sulfhydryls to disulfides, stimulation by Ca2+ and calmodulin was eliminated at concentrations which did not affect basal adenylyl cyclase activity. Calmodulin stimulation of the enzyme was restored by treatment with dithiothreitol or glutathione which reduce disulfides to free thiols. NO and sodium nitroprusside also reversible inhibited calmodulin stimulation of the enzyme. We propose that the loss in calmodulin sensitivity caused by these reagents may be due to the oxidation one or more sets of vicinal thiols present in the enzyme.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIDDK NIH HHS [DK07441-09] Funding Source: Medline; NINDS NIH HHS [NS08816-02, NS 20498] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008816, R01NS020498] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BRUNE B, 1989, J BIOL CHEM, V264, P8455; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FONTANA A, 1981, BIOCHEMISTRY-US, V20, P6997, DOI 10.1021/bi00527a034; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GARTHWAITE J, 1987, J NEUROCHEM, V48, P29, DOI 10.1111/j.1471-4159.1987.tb13123.x; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KIM DS, 1987, J BIOL CHEM, V262, P14250; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KRUPINSKI J, 1991, MOL CELL BIOCHEM, V104, P73; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; MAHONEY WC, 1981, BIOCHEMISTRY-US, V20, P443, DOI 10.1021/bi00505a033; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; MASURE HR, 1984, BIOCHEM J, V218, P691, DOI 10.1042/bj2180691; PARK JW, 1985, NEW ENGL J MED, V313, P1547; PEN J, 1989, NUCLEIC ACIDS RES, V17, P451, DOI 10.1093/nar/17.1.451; PIASCIK MT, 1980, J BIOL CHEM, V255, P4176; PROMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809; RADI R, 1991, J BIOL CHEM, V266, P4244; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAO YP, 1992, FEBS LETT, V314, P49, DOI 10.1016/0014-5793(92)81459-Y; Torchinsky Y, 1981, SULFUR PROTEINS; VALLEJOS RH, 1977, BIOCHIM BIOPHYS ACTA, V459, P20, DOI 10.1016/0005-2728(77)90004-4; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T	41	85	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7290	7296						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125943				2022-12-25	WOS:A1994NA03200042
J	LOMBARDO, A; COSTA, E; CHAO, WR; TOLL, L; HOBBS, PD; JONG, L; LEE, MO; PFAHL, M; ELY, KR; DAWSON, MI				LOMBARDO, A; COSTA, E; CHAO, WR; TOLL, L; HOBBS, PD; JONG, L; LEE, MO; PFAHL, M; ELY, KR; DAWSON, MI			RECOMBINANT HUMAN RETINOIC ACID RECEPTOR-BETA - BINDING OF SYNTHETIC RETINOIDS AND TRANSCRIPTIONAL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHARMACOLOGICAL ACTIVITY; NUCLEAR RECEPTORS; ESCHERICHIA-COLI; IDENTIFICATION; GAMMA; MOUSE; ALPHA; PROTEINS; PURIFICATION; ISOFORMS	All-trans-retinoic acid mediates cell growth and differentiation by binding to and then activating nuclear retinoid receptor proteins that regulate gene transcription. Recombinant human retinoic acid receptor beta was cloned and expressed in Escherichia coli as a fusion protein rMBP-RAR beta with maltose-binding protein to facilitate purification. After isolation from bacterial lysates, rMBP-RAR beta was used for binding with selected retinoids. Scatchard analysis with [11,12-H-3(2)]all-trans-retinoic acid gave a K-d of 0.34 nM. Competitive binding studies with a series of conformationally restricted aromatic retinoids indicated that the K-i values for binding to rMBP-RAR beta correlated with the logs of the EC(50) values for gene transcriptional activation (p less than or equal to 0.05) and with those for the relative activation compared to that of all-trans-retinoic acid (p less than or equal to 0.01). Inspection of binding-activation correlation diagrams indicates candidate structures for improved retinoid agonists or antagonists.	SRI INT,BIOORGAN CHEM LAB,MENLO PK,CA 94025; LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037; SRI INT,DEPT NEUROSCI,MENLO PK,CA 94025	SRI International; Sanford Burnham Prebys Medical Discovery Institute; SRI International					NATIONAL CANCER INSTITUTE [P01CA051993] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA51993] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; APFEL C, 1991, RETINOIDS : 10 YEARS ON, P110; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; APFEL C, 1992, RETINOIDS NORMAL DEV, P65; BEATO M, 1972, J BIOL CHEM, V247, P7890; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOURGUET W, 1992, BIOCHEM BIOPH RES CO, V187, P711, DOI 10.1016/0006-291X(92)91253-M; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAWSON MI, 1984, J MED CHEM, V27, P1516, DOI 10.1021/jm00377a022; DAWSON MI, 1983, J MED CHEM, V26, P1653, DOI 10.1021/jm00365a021; DAWSON MI, 1981, J MED CHEM, V24, P583, DOI 10.1021/jm00137a019; DAWSON MI, 1989, J MED CHEM, V32, P1504, DOI 10.1021/jm00127a018; DAWSON MI, 1993, RETINOIDS PROGR RES, P205; DAWSON MI, 1993, RETINOIDS BIOL CHEM, P5; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUKASAWA H, 1993, BIOL PHARM BULL, V16, P343; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUSMANN M, 1991, MOL CELL BIOL, V11, P4094; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KEIDEL S, 1992, EUR J BIOCHEM, V204, P1141, DOI 10.1111/j.1432-1033.1992.tb16739.x; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOELIGER P, 1980, EUR J MED CHEM, V15, P9; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; REDDY AP, 1992, BIOCHEM J, V287, P833, DOI 10.1042/bj2870833; Roberts A.B., 1984, RETINOIDS, V2, P210; RUBERTE E, 1990, DEVELOPMENT, V108, P213; SCHIFF LJ, 1990, CHEM BIOL SYNTHETIC, P308; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	49	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7297	7303						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125944				2022-12-25	WOS:A1994NA03200043
J	WILDE, A; DEMPSEY, C; BANTING, G				WILDE, A; DEMPSEY, C; BANTING, G			THE TYROSINE-CONTAINING INTERNALIZATION MOTIF IN THE CYTOPLASMIC DOMAIN OF TGN38/41 LIES WITHIN A NASCENT HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; LYSOSOMAL ACID-PHOSPHATASE; INTEGRAL MEMBRANE-PROTEIN; FACTOR-II RECEPTOR; SECONDARY STRUCTURE; PEPTIDE-FRAGMENTS; BREFELDIN-A; MEDIATED INTERNALIZATION; COMPLETE SEQUENCE; SIGNAL	TGN38 and TGN41 are isoforms of an integral membrane protein (TGN38/41) which is predominantly located in the trans-Golgi network of mammalian cells, but which constitutively recycles between the TGN and the plasma membrane. The cytoplasmic domain tetrapeptide sequence ''YQRL'' is responsible for the internalization of TGN38/41 from the plasma membrane. This sequence conforms to the tyrosine containing internal ization motif (''YXYhydro,'' where X is any amino acid and hydro is any large bulky hydrophobic amino acid) found in other integral membrane proteins which are internalized from the plasma membrane via clathrin-coated vesicles. Structural predictions have suggested that the YXXhydro motif might adopt a tight turn structure in solution, a prediction supported previously by nuclear magnetic resonance (NMR) studies on short synthetic peptides corresponding to variants of the generic YXXhydro motif. We have synthesized a 21-amino acid peptide which encompasses the TGN38/41 internalization motif and used it as template for two-dimensional NMR analysis. The data from these experiments demonstrate that the internalization motif in the cytoplasmic domain of TGN38/41 lies within a nascent helix, not a tight turn. This is the first study to show that tyrosine containing internalization motifs do not necessarily adopt a beta-turn conformation.	UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, ENGLAND; UNIV BRISTOL, SCH MED SCI, SCI & ENGN RES COUNCIL MOLEC RECOGNIT CTR, BRISTOL BS8 1TD, ENGLAND	University of Bristol; University of Bristol				Wilde, Andrew/0000-0002-9812-3847; Dempsey, Christopher/0000-0002-1933-7805; Banting, George/0000-0001-8249-1621				AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS AG, 1983, J AM CHEM SOC, V107, P2821; DYSON HJ, 1992, J MOL BIOL, V226, P819, DOI 10.1016/0022-2836(92)90634-V; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HONG WJ, 1993, BIOESSAYS, V15, P231, DOI 10.1002/bies.950150403; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KLEVIT RE, 1985, J MAGN RESON, V62, P551, DOI 10.1016/0022-2364(85)90227-6; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WAGNER G, 1986, J MOL BIOL, V187, P131, DOI 10.1016/0022-2836(86)90413-4; WILEMAN T, 1985, BIOCHEM J, V232, P1; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WONG SH, 1993, J BIOL CHEM, V268, P22853; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC	46	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7131	7136						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125922				2022-12-25	WOS:A1994NA03200017
J	PRASAD, K; HEUSER, J; EISENBERG, E; GREENE, L				PRASAD, K; HEUSER, J; EISENBERG, E; GREENE, L			COMPLEX-FORMATION BETWEEN CLATHRIN AND UNCOATING ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; HEAT-SHOCK; STRESS PROTEINS; TRANSLOCATION; DISSOCIATION; BINDING; HSP70; CAGES	The bovine brain uncoating ATPase, a constitutive 70-kDa heat shock protein, uncoats clathrin coated vesicles in an ATP dependent reaction. The uncoating ATPase-clathrin complex formed from the uncoating reaction was compared to the complex formed by directly binding free clathrin to uncoating ATPase. The amount of the latter complex shows a simple hyperbolic dependence on either free clathrin or free uncoating ATPase concentration, whichever is in excess, with a binding stoichiometry of one uncoating ATPase per clathrin heavy chain. ATP markedly increases the rates of formation and dissociation of this complex while ADP profoundly inhibits these rates. At low uncoating ATPase concentrations, much more complex is formed by uncoating than by directly binding clathrin to enzyme. However, during column chromatography or dilution for electron microscopy, both types of complex dissociate in ATP but not ADP, and electron microscopy of both types of complex diluted into ADP shows binding only to the vertex of the clathrin triskelion. We conclude that the uncoating ATPase forms only one type of complex with clathrin and has only one site for nucleotide; ADP at this site prevents either formation or dissociation of complex, whereas ATP at this site allows both processes to occur rapidly.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Washington University (WUSTL)								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHOCK SP, 1979, J BIOL CHEM, V254, P3229; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAO BC, 1991, J BIOL CHEM, V266, P19565; GAO BC, 1993, J BIOL CHEM, V268, P8507; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; NANDI PK, 1982, P NATL ACAD SCI USA, V107, P5885; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHMID SL, 1985, J BIOL CHEM, V260, P44; SCHMID SL, 1984, NATURE, V311, P228, DOI 10.1038/311228a0	25	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6931	6939						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120055				2022-12-25	WOS:A1994MZ50300103
J	CARE, A; MATTIA, G; MONTESORO, E; PAROLINI, I; RUSSO, G; COLOMBO, MP; PESCHLE, C				CARE, A; MATTIA, G; MONTESORO, E; PAROLINI, I; RUSSO, G; COLOMBO, MP; PESCHLE, C			C-FES EXPRESSION IN ONTOGENIC DEVELOPMENT AND HEMATOPOIETIC DIFFERENTIATION	ONCOGENE			English	Article							SERUM-FREE CULTURE; TYROSINE PHOSPHORYLATION; PROTO-ONCOGENE; BETA-SUBUNIT; GM-CSF; GROWTH; CDNA; PROGENITORS; RECEPTORS; EMBRYOS	The c-fes protein (NCP92) is a tyrosine-specific protein kinase, capable of both autophosphorylation and phosphorylation of other substrates. We have analysed c-fes RNA expression in human/murine ontogenetic development and in homogenous populations of embryonic and adult human hematopoietic cells. c-fes expression has been observed in rapidly proliferating embryonic-fetal tissues originating from different germinal layers, but not in adult non-hematopoietic tissues. In particular, a spatially and temporally regulated transcription was observed in the central nervous system and in developing cartilage. Expression in hematopoietic cells was evaluated in progenitors purified from embryonic-fetal liver and adult peripheral blood differentiating gradually and specifically along the erythroid or granulomonocytic lineage. In both embryonic and adult hematopoietic cells c-fes was abundantly expressed in undifferentiated progenitors of both lineages, as well as in differentiated granulomonocytic precursors, but not in erythroblasts. This expression pattern correlates with that of GM-CSF and in part IL-3 receptors (Testa et al., 1993 and our unpublished results). Altogether, these results suggest a possible role for c-fes in signal transduction, in both embryonic non-hematopoietic tissues and embryonic/ adult hematopoietic cells, following interaction of growth factors with their tyrosine-kinase negative receptors (i.e., GM-CSF and IL-3 receptors in adult hematopoietic cells and other hypothetical growth factor(s) receptors during embryonic development).	IST SUPER SANITA, DEPT HEMATOL ONCOL, I-00161 ROME, ITALY; OSPED AVELLINO, DIV OBSTET & GYNECOL, I-83100 AVELLINO, ITALY; IST NAZL STUDIO & CURA TUMORI, DIV EXPTL ONCOL D, I-20133 MILAN, ITALY; THOMAS JEFFERSON UNIV, THOMAS JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA	Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University			Colombo, Mario P./V-7166-2017; CARE', Alessandra/H-5090-2016; Mattia, Gianfranco/K-5194-2016; parolini, Isabella/J-9955-2016; felli, nadia/G-2088-2012	Colombo, Mario P./0000-0003-0042-7955; CARE', Alessandra/0000-0003-4106-3342; Mattia, Gianfranco/0000-0001-7047-6360; parolini, Isabella/0000-0001-9863-1051; felli, nadia/0000-0001-6763-3361				ALCALAY M, 1990, ONCOGENE, V5, P267; BISHOP JM, 1982, MRNA TUMOR VIRUSES M, P267; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; ELIASON JF, 1986, J CELL PHYSIOL, V128, P231, DOI 10.1002/jcp.1041280214; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HOGAN B, 1986, MOL CLONING LABORATO; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LANFRANCONE L, 1989, INT J CANCER, P35; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; MIGLIACCIO G, 1986, J CLIN INVEST, V78, P51, DOI 10.1172/JCI112572; Moore, 1982, DEV HUMAN; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; PLACZEK M, 1990, DEVELOPMENT, V110, P19; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Sambrook J, 1989, MOL CLONING LABORATO; SORENSEN PHB, 1989, BLOOD, V73, P406; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; TESTA U, 1993, BLOOD, V81, P1442; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VALTIERI M, 1989, BLOOD, V74, P460; YEE SP, 1989, P NATL ACAD SCI USA, V86, P5873, DOI 10.1073/pnas.86.15.5873	29	47	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					739	747						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108116				2022-12-25	WOS:A1994MW55100008
J	DAI, W; PAN, HQ; HASSANAIN, H; GUPTA, SL; MURPHY, MJ				DAI, W; PAN, HQ; HASSANAIN, H; GUPTA, SL; MURPHY, MJ			MOLECULAR-CLONING OF A NOVEL RECEPTOR TYROSINE KINASE, TIF, HIGHLY EXPRESSED IN HUMAN OVARY AND TESTIS	ONCOGENE			English	Note							HUMAN INTERFERON-GAMMA; LEUKEMIA-CELLS; GENE	Using a combination of polymerase chain reaction and conventional cDNA library screening approaches, we have cloned and characterized a putative receptor tyrosine kinase termed tif. The extracellular domain of tif has an immunoglobulin-like loop and a fibronectin type III structure. The intracellular domain contains a tyrosine kinase domain. Compared with ryk, a ubiquitously expressed receptor tyrosine kinase, tif expression is tissue-specific with human ovary and testis containing the highest amount of tif mRNA. Many other tested human tissues such as heart, liver, pancreas and thymus do not contain detectable levels of tif mRNA. The molecular cloning and characterization of tif cDNA will facilitate the identification of a potential ligand(s) for the putative receptor and the study of its biological role.	HIPPLE CANC RES CTR,BIOL RESPONSE MODIFIERS LAB,DAYTON,OH 45439; HIPPLE CANC RES CTR,BLOOD CELL GROWTH FACTOR LAB,DAYTON,OH 45439		DAI, W (corresponding author), HIPPLE CANC RES CTR,MOLEC BIOL LAB,4100 S KETTERING BLVD,DAYTON,OH 45439, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032483] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI32483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DAI W, 1990, BIOCHEM BIOPH RES CO, V168, P1, DOI 10.1016/0006-291X(90)91666-G; DAI W, 1993, BLOOD, V5, P1214; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; Sambrook J, 1989, MOL CLONING LABORATO; SIMONEAUX DK, 1992, J CELL BIOCHEM, V16, P101; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; TSIFTSOGLOU AS, 1991, EXP HEMATOL, V19, P928; TUY FPD, 1983, NATURE, V305, P435; ULLRICH A, 1990, CELL, V61, P201; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	20	62	63	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					975	979						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108143				2022-12-25	WOS:A1994MW55100037
J	LUKAS, J; PAGANO, M; STASKOVA, Z; DRAETTA, G; BARTEK, J				LUKAS, J; PAGANO, M; STASKOVA, Z; DRAETTA, G; BARTEK, J			CYCLIN D1 PROTEIN OSCILLATES AND IS ESSENTIAL FOR CELL-CYCLE PROGRESSION IN HUMAN TUMOR-CELL LINES	ONCOGENE			English	Article							CHROMOSOME 11Q13; SQUAMOUS-CELL; MESSENGER-RNA; S-PHASE; EXPRESSION; CLONING; KINASE; GENES; AMPLIFICATION; MITOSIS	Among the key cell cycle regulators, cyclin D1 has been implicated most strongly in oncogenesis. This G1 cyclin is a putative proto-oncogene whose clonal rearrangement and/or amplification and mRNA overexpression occurs in several types of human neoplasias. We have now raised a series of monoclonal antibodies to human cyclin D1 and analysed its regulation at the protein level in 40 human tumour cell lines. We found that 12 cell lines displayed low or undetectable cyclin D1 protein level, while the remaining lines accumulated the protein to a level comparable to, or moderately higher than, that of four normal diploid non-immortalized cell types. The cell cycle-dependent oscillation and subcellular localization of cyclin D1 were similar in both tumour and normal cells. The protein localized to the nucleus of G1 cells, and it was reduced to immunocytochemically undetectable level in DNA-replicating cells. At the functional level, microinjection and electroporation of anti-D1 antibodies revealed that in most tumour cell lines studied, including those with amplification at the cyclin D1 locus, this cyclin is essential for cell cycle progression in G1. Some tumours, however, seem to have evolved mechanism(s) that enable them to bypass the requirement for functional cyclin D1.	DANISH CANC SOC, DIV CANC BIOL, DK-2100 COPENHAGEN 0, DENMARK; EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, W-6900 HEIDELBERG, GERMANY; MITOTIX, CAMBRIDGE, MA 02139 USA	Danish Cancer Society; European Molecular Biology Laboratory (EMBL)			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; pagano, michele/0000-0003-3210-2442				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTEK J, 1993, STEM CELLS, V11, P51, DOI 10.1002/stem.5530110611; BERENSON JR, 1990, ONCOGENE, V5, P1343; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUMBERT C, 1992, J CELL SCI, V103, P97; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PALMERO I, 1993, ONCOGENE, V8, P1049; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PROCTOR AJ, 1991, ONCOGENE, V6, P789; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TOMMASINO M, 1993, ONCOGENE, V8, P195; TSAI LH, 1993, ONCOGENE, V8, P1593; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	63	300	306	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					707	718						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108113				2022-12-25	WOS:A1994MW55100005
J	MACLEAN, K; ROGAN, EM; WHITAKER, NJ; CHANG, ACM; ROWE, PB; DALLAPOZZA, L; SYMONDS, G; REDDEL, RR				MACLEAN, K; ROGAN, EM; WHITAKER, NJ; CHANG, ACM; ROWE, PB; DALLAPOZZA, L; SYMONDS, G; REDDEL, RR			IN-VITRO TRANSFORMATION OF LI-FRAUMENI SYNDROME FIBROBLASTS BY SV40 LARGE T-ANTIGEN MUTANTS	ONCOGENE			English	Article							HUMAN-DIPLOID FIBROBLASTS; CANCER-PRONE FAMILY; LARGE TUMOR-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; SIMIAN VIRUS-40; CELL-TRANSFORMATION; P53 GENE; IMMORTALIZATION; SPAN; EXPRESSION	Transfection of SV40 early region DNA into normal human diploid fibroblasts (NHDFs) increases their proliferative potential to a limited extent. We have investigated the roles of the SV40 large T antigen (LTAg) regions responsible for binding to the protein products of the retinoblastoma (Rb) and p53 genes in this temporary escape from senescence. Plasmids encoding LTAg mutants were transfected into NHDFs and into Li-Fraumeni syndrome (LFS) fibroblasts which are heterozygous wild-type (wt)/null-mutant for p53. A LTAg mutated in the p53-binding region (T402DE) had greatly reduced efficiency of focus formation, and a p110(Rb)-binding mutant was unable to induce any foci. T402DE-induced NHDF foci senesced at the same time as untransfected cells, but the equivalent LFS foci all had increased proliferative potentials, with the greatest increase being seen in clones that lost the wt p53 allele. One LFS clone expressed the T402DE mutant during focus formation, but later lost both the T402DE DNA and the wt p53 allele. We conclude that SV40-induced focus formation in NHDFs requires the LTAg p110(Rb)-binding region, and is enhanced by loss of normal p53 function. In contrast, increased proliferative potential is primarily due to loss of p53 function.	CHILDRENS MED RES INST,WESTMEAD,NSW 2145,AUSTRALIA; ROYAL ALEXANDRA HOSP CHILDREN,ONCOL UNIT,CAMPERDOWN,NSW 2050,AUSTRALIA	Children's Medical Research Institute - Australia			Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				BISCHOFF FZ, 1990, CANCER RES, V50, P7979; CHANG S E, 1986, Biochimica et Biophysica Acta, V823, P161, DOI 10.1016/0304-419X(86)90001-6; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERONDE A, 1989, VIROLOGY, V171, P160; DESILVA R, 1993, CELL MOL BIOL RES, V39, P101; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HAYFLICK L, 1965, EXP CELL RES, V37, P611; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; PEREIRASMITH OM, 1981, SOMAT CELL GENET, V7, P411, DOI 10.1007/BF01542986; SACK GH, 1981, IN VITRO CELL DEV B, V17, P1; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SOUDON J, 1991, LEUKEMIA, V5, P917; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRAUSS M, 1992, ONCOGENE, V7, P769; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WHITAKER NJ, 1992, J VIROL, V66, P1202, DOI 10.1128/JVI.66.2.1202-1206.1992; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	41	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					719	725						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108114				2022-12-25	WOS:A1994MW55100006
J	GEGG, CV; ETZLER, ME				GEGG, CV; ETZLER, ME			PHOTOAFFINITY-LABELING OF THE ADENINE BINDING-SITES OF 2 DOLICHOS-BIFLORUS LECTINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEED LECTIN; 3-DIMENSIONAL STRUCTURE; PHASEOLUS-LUNATUS; CONCANAVALIN-A; PROTEIN; CARBOHYDRATE; LEAVES; RESOLUTION; SUBUNITS; COMPLEX	Two differentially expressed lectins from the legume Dolichos biflorus, the seed lectin and a stem and leaf lectin (DB58), were photoaffinity-labeled at their adenine binding sites using the probe [2-H-3]8-azidoadenine. Both heteromeric subunits I and II of the seed lectin and alpha and beta of DB58 were specifically labeled. This result, combined with the adenine binding site stoichiometries of two identical sites/seed lectin tetramer or one site/DB58 dimer, indicates that the adenine binding site resides at a heterologous subunit interface. Three radiolabeled peaks from seed lectin and one from DB58 were isolated from chymotryptic digests of the labeled lectins by reverse phase chromatography at pH 7.0. From these four peaks, six unique peptide sequences were determined. When aligned with the concanavalin A sequence, four of these peptides map to three loops in the metal binding domain of concanavalin A. The remaining two sequences represent carboxyl-terminal peptides unique to the D. biflorus lectins which may extend to the putative binding site from adjacent, heterologous subunits. It thus appears that the adenine binding sites of these D. biflorus lectins are within the metal binding domain and adjacent to the carbohydrate binding site.	UNIV CALIF DAVIS, DEPT BIOCHEM & BIOPHYS, DAVIS, CA 95616 USA	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021882] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21882] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bayley H, 1977, Methods Enzymol, V46, P69; BECKER JW, 1983, CHEM TAXONOMY MOL BI, P31; BORREBAECK CAK, 1981, BIOCHEMISTRY-US, V20, P4119, DOI 10.1021/bi00517a026; BRINEGAR AC, 1988, P NATL ACAD SCI USA, V85, P5927, DOI 10.1073/pnas.85.16.5927; BUNKER TW, 1993, IN PRESS PLANTA; CARTER WG, 1975, J BIOL CHEM, V250, P2756; DELBAERE LTJ, 1990, CAN J CHEM, V68, P1116, DOI 10.1139/v90-172; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; ETZLER ME, 1984, PLANT PHYSIOL, V76, P871, DOI 10.1104/pp.76.4.871; ETZLER ME, 1981, J BIOL CHEM, V256, P2367; ETZLER ME, 1980, BIOCHEM BIOPH RES CO, V96, P92, DOI 10.1016/0006-291X(80)91185-7; ETZLER ME, 1992, GLYCOCONJUGATES COMP, P521; FOX JE, 1975, BIOCHEM BIOPH RES CO, V64, P694, DOI 10.1016/0006-291X(75)90376-9; FRIMER AA, 1983, OXY RADICALS THEIR S, P270; GEGG CV, 1992, BIOCHEMISTRY-US, V31, P6938, DOI 10.1021/bi00145a011; Goldstein I. J., 1986, LECTINS PROPERTIES F, P35; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HARADA JJ, 1990, J BIOL CHEM, V265, P4997; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; INOUE H, 1986, BIOCHEM BIOPH RES CO, V137, P372, DOI 10.1016/0006-291X(86)91220-9; JAYABASKARAN C, 1990, PLANT GROWTH REGUL, V9, P9, DOI 10.1007/BF00025274; KING SM, 1991, METHOD ENZYMOL, V196, P449; LESHEM YY, 1981, PHYSIOL PLANTARUM, V53, P9, DOI 10.1111/j.1399-3054.1981.tb05037.x; LESHEM YY, 1988, FREE RADICAL BIO MED, V5, P39, DOI 10.1016/0891-5849(88)90060-3; MALIARIK MJ, 1988, J BIOL CHEM, V263, P11274; MARTIN RL, 1991, ARCH BIOCHEM BIOPHYS, V284, P26, DOI 10.1016/0003-9861(91)90257-J; MOMOTANI E, 1992, PLANT CELL PHYSIOL, V33, P407; Moore T.C., 1989, BIOCH PHYSL PLANT HO, P158; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; QUINN JM, 1989, PLANT PHYSIOL, V91, P1382, DOI 10.1104/pp.91.4.1382; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; REEKE GN, 1975, J BIOL CHEM, V250, P1525; REEKE GN, 1986, SCIENCE, V234, P1108, DOI 10.1126/science.3775378; ROBERTS DD, 1986, PHYTOCHEMISTRY, V25, P589, DOI 10.1016/0031-9422(86)88004-9; ROBERTS DD, 1983, ARCH BIOCHEM BIOPHYS, V224, P479, DOI 10.1016/0003-9861(83)90235-7; ROBERTS DD, 1983, J BIOL CHEM, V258, P3820; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; RUOHO AE, 1973, P NATL ACAD SCI USA, V70, P2567, DOI 10.1073/pnas.70.9.2567; SAKAI S, 1992, BIOSCI BIOTECH BIOCH, V56, P504, DOI 10.1271/bbb.56.504; SCHNELL DJ, 1987, J BIOL CHEM, V262, P7220; SCHNELL DJ, 1988, J BIOL CHEM, V263, P14648; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; Sharon N., 1986, LECTINS PROPERTIES F, P294; TALBOT CF, 1978, BIOCHEMISTRY-US, V17, P1474, DOI 10.1021/bi00601a018	45	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5687	5692						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119905				2022-12-25	WOS:A1994MY84000034
J	GUIHARD, G; BOULANGER, P; BENEDETTI, H; LLOUBES, R; BESNARD, M; LETELLIER, L				GUIHARD, G; BOULANGER, P; BENEDETTI, H; LLOUBES, R; BESNARD, M; LETELLIER, L			COLICIN-A AND THE TOL PROTEINS INVOLVED IN ITS TRANSLOCATION ARE PREFERENTIALLY LOCATED IN THE CONTACT SITES BETWEEN THE INNER AND OUTER MEMBRANES OF ESCHERICHIA-COLI-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; INVIVO PROPERTIES; CROSS-RESISTANCE; CHANNEL ACTIVITY; ENVELOPE; K-12; RECEPTOR; ENTRY; BTUB; PORE	Colicin A is a bacterial toxin which forms channels in the cytoplasmic membrane of Escherichia coli. Its translocation through the envelope requires the participation of bacterial proteins encoded by the tolQ, -R, -A, and -B genes. Overproduction of the Tol proteins decreased the time needed for colicin A translocation and increased the number of channels formed in vivo. Cells overproducing radioactively labeled Tol proteins and containing or not colicin A were fractionated. The Tol proteins were mainly recovered in the inner membrane and in the contact sites between the two membranes. The presence of colicin A increased the specific radioactivity of the Tol proteins in the contact sites. Our data suggest that the Tol proteins form a complex of definite stoichiometry in the membranes and that colicin A is associated to this complex upon channel formation. We discuss the possibility that the channel activity determined in vivo is due to the colicin A-Tol proteins complex.	UNIV PARIS 11,BIOMEMBRANES LAB,CNRS,URA 1116,F-91405 ORSAY,FRANCE; LAB INGN & DYNAM SYST MEMBRANAIRES,UPR 9027,F-13402 MARSEILLE 9,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				LLOUBES, Roland/0000-0002-9520-1053				AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; BENEDETTI H, 1991, EMBO J, V10, P1989, DOI 10.1002/j.1460-2075.1991.tb07728.x; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BENEDETTI H, 1991, J MOL BIOL, V217, P429, DOI 10.1016/0022-2836(91)90747-T; BENEDETTI H, 1989, J GEN MICROBIOL, V135, P3413; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOURDINEAUD JP, 1989, J BACTERIOL, V171, P2458, DOI 10.1128/jb.171.5.2458-2465.1989; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; CAVARD D, 1981, FEMS MICROBIOL LETT, V12, P311; CHAI TJ, 1982, J BACTERIOL, V151, P983, DOI 10.1128/JB.151.2.983-988.1982; COLLARINI M, 1987, EUR BIOPHYS J BIOPHY, V14, P147, DOI 10.1007/BF00253839; DAVIES JK, 1975, J BACTERIOL, V123, P102, DOI 10.1128/JB.123.1.102-117.1975; DAVIES JK, 1975, J BACTERIOL, V123, P96, DOI 10.1128/JB.123.1.96-101.1975; FISCHER E, 1989, J BACTERIOL, V171, P5127, DOI 10.1128/jb.171.9.5127-5134.1989; FRENETTE M, 1991, J MOL BIOL, V217, P421, DOI 10.1016/0022-2836(91)90746-S; GELI V, 1992, BIOCHEMISTRY-US, V31, P11089, DOI 10.1021/bi00160a019; GUIHARD G, 1993, J BIOL CHEM, V268, P17775; GUIHARD G, 1992, J BIOL CHEM, V267, P3173; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; KAMPFERZEL K, 1993, BACTERIOLOGY, V175, P4485; KAMPFERZEL K, 1992, BACTERIOLOGY, V1174, P5485; KARLSSON M, 1993, MOL MICROBIOL, V8, P379, DOI 10.1111/j.1365-2958.1993.tb01581.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZDUNSKI CJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P445, DOI 10.1016/0304-4157(88)90003-2; LETELLIER L, 1992, BIOCHIM BIOPHYS ACTA, V1101, P218; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; LEVENGOODFREYERMUTH SK, 1993, J BACTERIOL, V175, P222, DOI 10.1128/JB.175.1.222-228.1993; LUPI N, 1989, MOL IMMUNOL, V26, P1027, DOI 10.1016/0161-5890(89)90067-9; Maniatis T., 1982, MOL CLONING; MEURY J, 1985, EUR J BIOCHEM, V151, P613, DOI 10.1111/j.1432-1033.1985.tb09148.x; PATTUS F, 1990, EXPERIENTIA, V46, P180; Pattus F., 1983, PHYSICAL CHEM TRANSM, P407; SABET SF, 1973, J BIOL CHEM, V248, P1797; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TILBY M, 1978, J BACTERIOL, V136, P1189, DOI 10.1128/JB.136.3.1189-1191.1978; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x	39	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5874	5880						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119930				2022-12-25	WOS:A1994MY84000061
J	DEBLAQUIERE, J; WALKER, F; MICHELANGELI, VP; FABRI, L; BURGESS, AW				DEBLAQUIERE, J; WALKER, F; MICHELANGELI, VP; FABRI, L; BURGESS, AW			PLATELET-DERIVED GROWTH-FACTOR STIMULATES THE RELEASE OF PROTEIN-KINASE-A FROM THE CELL-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; PHOSPHOLIPASE C-II; SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; SRC-FAMILY; SIGNAL TRANSDUCTION; EGF RECEPTOR; MAP KINASE; IDENTIFICATION	The mitogenic action of growth factors involves the stimulation of intracellular protein kinases. In this report we have characterized the major protein kinase released from Balb/c 3T3 and normal rat kidney plasma membranes by the action of platelet-derived growth factor (PDGF). PDGF appears to stimulate the release of approximately 10 proteins, at least one of which is a kinase capable of phosphorylating proteins on Ser or Thr (as determined by the lability of the phosphate to alkali treatment). More than 90% of the Ser/Thr kinase activity was inhibited by PKI5-22, a specific peptide inhibitor of the cAMP-dependent protein kinase (PKA). We used immunoblotting to confirm that the kinase released in response to PDGF was PRA. cAMP also stimulated the release of PKA, and the set of protein substrates phosphorylated was similar following PDGF or cAMP stimulation. Interestingly, in the presence of a cAMP analogue ((R(p))-cAMPS), cAMP could not induce dissociation of PKA from the membranes, whereas stimulation by PDGF increased the level of PKA activation. Furthermore, unlike Swiss 3T3 cells, neither Balb/c 3T3 fibroblasts nor normal rat kidney cells accumulate cAMP in response to PDGF, yet the level of PKA in the cytosol of these intact cells increases in response to PDGF. Thus, it appears as though PDGF activation of the membrane-associated form of the PKA holoenzyme occurs by a mechanism independent of an elevation in cAMP levels.	LUDWIG INST CANC RES,MELBOURNE TUMOR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT DIABET & ENDOCRINOL,MELBOURNE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital				fabri, louis/0000-0003-4033-3304				ABDELGHANY M, 1989, P NATL ACAD SCI USA, V86, P6072, DOI 10.1073/pnas.86.16.6072; AGOSTINIS P, 1992, J BIOL CHEM, V267, P9732; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BRAUN RK, 1991, ARCH BIOCHEM BIOPHYS, V289, P187, DOI 10.1016/0003-9861(91)90460-Z; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FISCHER TH, 1990, J BIOL CHEM, V265; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRAF T, 1976, VIROLOGY, V71, P423, DOI 10.1016/0042-6822(76)90370-6; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KERYER G, 1991, J CELL BIOL, V115, P284; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MICHELANGELI VP, 1984, BIOCHEM J, V224, P371, DOI 10.1042/bj2240371; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RADZIEJEWSKI C, 1989, BIOCHEMISTRY-US, V28, P9047, DOI 10.1021/bi00449a013; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMAS G, 1979, P NATL ACAD SCI USA, V76, P3952, DOI 10.1073/pnas.76.8.3952; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; USHIRO H, 1980, J BIOL CHEM, V255, P8363; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALKER F, 1991, J BIOL CHEM, V266, P2746; WALKER F, 1993, J BIOL CHEM, V268, P19552; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WOLFE L, 1992, J BIOL CHEM, V267, P9749; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	63	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4812	4818						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106451				2022-12-25	WOS:A1994MX57100020
J	OKADA, T; SAKUMA, L; FUKUI, Y; HAZEKI, O; UI, M				OKADA, T; SAKUMA, L; FUKUI, Y; HAZEKI, O; UI, M			BLOCKAGE OF CHEMOTACTIC PEPTIDE-INDUCED STIMULATION OF NEUTROPHILS BY WORTMANNIN AS A RESULT OF SELECTIVE-INHIBITION OF PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; SIGNAL TRANSDUCTION; ACTIVATED NEUTROPHILS; KINASE-ACTIVITY; HUMAN PLATELETS; RAT ADIPOCYTES; BOVINE BRAIN; THROMBIN; POLYPHOSPHOINOSITIDES; PHOSPHORYLATION	Wortmannin, a fungal metabolite, inhibited P-32 labeling of phosphatidylinositol trisphosphate, a product of phosphatidylinositol 3-kinase (PI 3-kinase), selectively in formyl peptide-stimulated P-32-loaded guinea pig neutrophils. The inhibition was of the same concentration dependence (with the half-maximal inhibition around 50 nM) as was observed for the simultaneous inhibition of formyl peptide-induced superoxide anion production. Wortmannin inhibited all three of the PI 3-kinase activities found in the cytosol fraction of guinea pig neutrophils, with a similar dose dependence (the half-maximal effects at 5 nM). Wortmannin was also effective on an immunologically purified preparation of the enzyme. The inhibition was of a noncompetitive type with regard to ATP and was observed consistently when PI, PI monophosphate, or PI bisphosphate was used as substrate. PI 4-kinase activity was not affected. It is concluded, therefore, that wortmannin abolished the formyl peptide-induced stimulation of neutrophils as a result of the inhibition of PI 3-kinase. An essential role of PI 3-kinase in receptor-mediated signaling in neutrophils thus evidenced with the use of wortmannin will be expanded to other cellular signaling systems.	INST PHYS & CHEM RES,UI LAB,HIROSAWA 2-1,WAKO 35101,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC AGR,DEPT AGR CHEM,BIOCHEM LAB,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; University of Tokyo; University of Tokyo			Fukui, Yasuhisa/E-8806-2010					AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DEWALD B, 1988, J BIOL CHEM, V263, P16179; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; EBERLE M, 1990, J BIOL CHEM, V265, P16725; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIPS DL, 1989, J BIOL CHEM, V264, P8759; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OKADA T, 1994, J BIOL CHEM, V269, P3568; OKAJIMA F, 1984, J BIOL CHEM, V259, P3863; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WIESINGE.D, 1974, EXPERIENTIA, V30, P135, DOI 10.1007/BF01927691; YATOMI Y, 1992, BIOCHEM J, V285, P745, DOI 10.1042/bj2850745; ZHANG J, 1992, J BIOL CHEM, V267, P4686	30	451	480	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3563	3567						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106399				2022-12-25	WOS:A1994MV63100067
J	RAHMATULLAH, M; ROBISHAW, JD				RAHMATULLAH, M; ROBISHAW, JD			DIRECT INTERACTION OF THE ALPHA-SUBUNIT AND GAMMA-SUBUNIT OF THE G-PROTEINS - PURIFICATION AND ANALYSIS BY LIMITED PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; TRANSDUCING G-PROTEINS; MUSCARINIC K+-CHANNEL; AMINO-TERMINAL REGION; ROD OUTER SEGMENTS; BETA-SUBUNIT; PHOSPHOLIPASE-C; MOLECULAR-CLONING; BRAIN; CDNA	The heterotrimeric G proteins are often regarded functionally as a heterodimer, consisting of a guanine nucleotide-binding alpha subunit and a betagamma subunit complex. Since the tightly associated betagamma subunit complex can be separated only under denaturing conditions, studies aimed at determining the individual contributions of the beta and gamma subunits in terms of binding to the various a subunits, interacting with receptors, and regulating effectors, have not been possible. To circumvent this problem, we have used baculovirus-infected cells to direct the individual expression of the beta1 and gamma2 subunits. Application of extracts from baculovirus-infected cells to an a subunit of G protein (G(o)alpha)-affinity matrix resulted in the selective retention and AMF-specific elution of the expressed gamma2 subunit, but not the expressed beta1 subunit. Overall, these and other data provide the first evidence of a direct association between the gamma and alpha subunits, which is dependent on prenylation of gamma. The apparent direct association between the gamma and alpha subunits was further probed by limited trypsin proteolysis. Upon addition of trypsin, the G(o)alpha subunit was rapidly cleaved to a 24-kDa fragment. However, in the presence of the purified gamma2 subunit, trypsin cleavage of the G(o)alpha subunit was completely prevented. This demonstration of a direct association between the gamma and alpha subunits is particularly intriguing in light of the increasingly large number of known alpha, beta, and gamma subunits, which raises important questions regarding the assembly of these subunits into functionally distinct G proteins. Thus, a direct association between the gamma and alpha subunits, which exhibit the greatest structural diversity, may provide the basis for the selective assembly of these subunits into G proteins with functional diversity.	GEISINGER MED CLIN,WEIS CTR RES,100 N ACAD AVE,DANVILLE,PA 17822	Geisinger Medical Center					NIGMS NIH HHS [GM39867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039867, R01GM039867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1986, FEBS LETT, V203, P135, DOI 10.1016/0014-5793(86)80729-3; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FOSTER KA, 1990, AM J PHYSIOL, V259, pH432, DOI 10.1152/ajpheart.1990.259.2.H432; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KATADA T, 1986, J BIOL CHEM, V261, P8182; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; ROBISHAW JD, 1989, ANNU REV PHYSIOL, V51, P229, DOI 10.1146/annurev.ph.51.030189.001305; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	51	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3574	3580						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106401				2022-12-25	WOS:A1994MV63100069
J	DSOUZA, B; BERDICHEVSKY, F; KYPRIANOU, N; TAYLORPAPADIMITRIOU, J				DSOUZA, B; BERDICHEVSKY, F; KYPRIANOU, N; TAYLORPAPADIMITRIOU, J			COLLAGEN-INDUCED MORPHOGENESIS AND EXPRESSION OF THE ALPHA-2-INTEGRIN SUBUNIT IS INHIBITED IN C-ERBB2-TRANSFECTED HUMAN MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article							MONOCLONAL-ANTIBODIES; C-ERBB-2 PROTEIN; BREAST; TUMORS; GLAND; GENE; ADENOCARCINOMA; AMPLIFICATION; KERATIN-19; DISTINCT	The c-erbB2 (or Her2) oncogene is amplified and/or overexpressed in a significant proportion of breast cancers. To assess the role of the c-erbB2 oncogene in mammary tumorigenesis, we have transfected the corresponding human c-erbB2 cDNA into an immortalized human mammary epithelial cell line, MTSV1-7, that was derived from luminal epithelial cells cultured from milk. Three transfectants expressing different levels of the c-erbB2 gene product have been isolated which form colonies in agar and produce tumours in nude mice with high efficiency. We have observed that MTSV1-7 cells form three-dimensional structures in collagen gels and that alpha2beta1-integrin plays a crucial role in the process of morphogenesis. We now find that the c-erbB2 transfectants exhibit an impaired ability to undergo morphogenesis in collagen gets as compared with the parental cell line or the control neomycin transfectant, and that the degree of impairment is related to the level of c-erbB2 expression. Moreover, overexpression of the c-erbB2 product was found to be correlated with a specific decrease in the expression of alpha2beta1-integrin subunit and in the alpha2-mRNA. The breast cancer cell line SKBr3, which carries multiple copies of the c-erbB2 gene and overexpresses the 185-kDa product, was also found to express very low levels of the alpha2-integrin protein and mRNA. Our results confirm the involvement of the alpha2beta1-integrin in collagen-induced morphogenesis of mammary epithelial cells and suggest that the c-erbB2 gene product may inhibit this morphogenesis by inhibiting the expression of the alpha2-integrin subunit.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; UNIV MARYLAND HOSP,DEPT SURG,DIV UROL,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Cancer Research UK; University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BARTEK J, 1986, EUR J CANCER CLIN ON, V22, P1441, DOI 10.1016/0277-5379(86)90077-5; BARTEK J, 1985, J CELL SCI, V75, P17; BARTEK J, 1985, INT J CANCER, V36, P299, DOI 10.1002/ijc.1985.36.3.299; BERDICHEVSKY F, 1991, EXP CELL RES, V194, P267, DOI 10.1016/0014-4827(91)90364-Z; BERDICHEVSKY F, 1992, J CELL SCI, V102, P437; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KYPRIANOU N, 1991, ONCOGENE, V7, P77; LONARDO F, 1990, New Biologist, V2, P992; Maniatis T., 1982, MOL CLONING; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHEARER M, 1992, INT J CANCER, V51, P602, DOI 10.1002/ijc.2910510417; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Taylor-Papadimitriou J., 1987, The mammary gland. Development, regulation, and function., P181; TAYLORPAPADIMIT.J, 1992, BREAST CANCER CELLUL, V3, P355; TAYLORPAPADIMIT.J, 1987, GROWTH DIFFERENTIATI, P1; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; VANLEEUWEN F, 1990, ONCOGENE, V5, P497; ZUTTER MM, 1990, AM J PATHOL, V137, P863	33	77	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1797	1806						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8099725				2022-12-25	WOS:A1993LG68200011
J	ALBERTY, RA				ALBERTY, RA			THERMODYNAMICS OF THE NITROGENASE REACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFIED PH; PMG	The thermodynamics of the nitrogenase reactions are discussed in terms of chemical equations and biochemical equations. Chemical equations balance all elements and electric charge. Biochemical equations represent changes at specified pH and specified free concentrations of metal ions that are bound by reactants, but they do not balance hydrogen or metal ions that have specified free concentrations. At a specified pH, it takes three separate biochemical equations to represent the changes catalyzed by nitrogenase. N-2(g) + 8 Fd(red) = 2 ammonia + 8 Fd(ox) + H-2(g) 2 Fd(red) = 2 Fd(ox) + H-2(g) ATP + H2O = ADP + P-i. The first two equations are required because the nitrogenase and hydrogenase activities of the enzyme have not been separated. The hydrolysis of ATP is necessary, but it is not coupled stoichiometrically to the first two equations. The function of the hydrolysis of ATP by nitrogenase may be to provide the 10 H+ required per mol of N-2 consumed. However, reactions cannot generally be coupled stoichiometrically through H+ because H+ is potentially available by dissociation of protein, buffer, and H2O. The standard Gibbs energies of formation of the reactant species are calculated for 25 degrees C, 1 bar, and ionic strengths of 0 and 0.25 M. The standard transformed Gibbs energies of formation of the reactants are calculated at 25 degrees C, 1 bar, pH 7, and ionic strengths of 0 and 0.25 M.			ALBERTY, RA (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.							ALBERTY RA, 1992, BIOPHYS CHEM, V42, P117, DOI 10.1016/0301-4622(92)85002-L; ALBERTY RA, 1992, BIOCHEMISTRY-US, V31, P10610, DOI 10.1021/bi00158a025; ALBERTY RA, 1992, BIOPHYS CHEM, V43, P239, DOI 10.1016/0301-4622(92)85024-X; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CLARKE HB, 1954, BIOCHEM J, V58, P146, DOI 10.1042/bj0580146; GOLDBERG RN, 1989, J PHYS CHEM REF DATA, V18, P809, DOI 10.1063/1.555831; HADFIELD KL, 1969, BIOCHEMISTRY-US, V8, P5103, DOI 10.1021/bi00840a064; HAGEMAN RV, 1980, BIOCHIM BIOPHYS ACTA, V591, P63, DOI 10.1016/0005-2728(80)90220-0; JENG DY, 1970, J BIOL CHEM, V245, P2809; LIANG JH, 1988, BIOCHEMISTRY-US, V27, P6726, DOI 10.1021/bi00418a013; SEIDEL A, 1919, SOLUBILITIES; SIMPSON FB, 1984, SCIENCE, V224, P1095, DOI 10.1126/science.6585956; STOMBAUGH NA, 1976, BIOCHEMISTRY-US, V15, P2633, DOI 10.1021/bi00657a024; TAGAWA K, 1968, BIOCHIM BIOPHYS ACTA, V153, P602, DOI 10.1016/0005-2728(68)90188-6; Wagman D. D., 1982, J PHYS CHEM REF D S2, V11; Webb E. C., 1992, ENZYME NOMENCLATURE; WINTER HC, 1968, J BIOL CHEM, V243, P940	17	40	40	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7099	7102						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125917				2022-12-25	WOS:A1994NA03200012
J	BEELER, T; GABLE, K; ZHAO, C; DUNN, T				BEELER, T; GABLE, K; ZHAO, C; DUNN, T			A NOVEL PROTEIN, CSG2P, IS REQUIRED FOR CA2+ REGULATION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR MEMBRANE; CELL-CYCLE; SUBUNIT-II; YEAST; CALCIUM; GENE; CALMODULIN; MUTANTS; CA-2+; DNA	Nineteen mutants that lost the ability to grow in 100 mM Ca2+ (but remained insensitive to 50 mM Sr2+) were identified in a screen of approximately 60,000 mutagenized yeast colonies. Cells carrying mutations in the CSG2 gene grow normally in low Ca2+ medium but have decreased growth rates when the Ca2+ concentration is above 10 mM. The csg2 mutant cells accumulate much higher levels of Ca2+ in a compartment that is exchangeable with extracellular Ca2+ but the nonexchangeable Ca2+ pool which predominates in wild-type cells is not influenced. Sr2+ influx is not increased in the csg2 mutant cells. Mg2+ decreases the amount of Ca2+ in the nonexchangeable pool without influencing the csg2-induced exchangeable Ca2+ pool. The data indicate that the csg2 mutation causes a selective increase in Ca2+ accumulation into a pool which is distinct from the vacuolar pool. The CSG2 protein consists of 410 amino acids, contains nine putative transmembrane segments, four potential sites for N-linked glycosylation, and a sequence with homology to the EF-hand Ca2+-binding site.	UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046495] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46495] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTL A, 1990, P NATL ACAD SCI USA, V87, P7824, DOI 10.1073/pnas.87.20.7824; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DAVIS TN, 1986, YEAST CELL BIOL, P477; DUNN T, 1994, J BIOL CHEM, V269, P7273; EILAM Y, 1982, MICROBIOS, V35, P99; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P561, DOI 10.1111/j.1432-1033.1988.tb14135.x; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; IIDA H, 1990, J BIOL CHEM, V265, P21216; IIDA H, 1990, J BIOL CHEM, V265, P13391; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LINDEGRE.G, 1965, CAN J GENET CYTOL, V7, P491, DOI 10.1139/g65-064; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; NEVES MJ, 1992, BIOCHEM J, V288, P859, DOI 10.1042/bj2880859; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P12784; OHYA Y, 1984, MOL GEN GENET, V193, P389, DOI 10.1007/BF00382073; OHYA Y, 1986, J GEN MICROBIOL, V132, P979; OHYA Y, 1986, J BACTERIOL, V165, P28, DOI 10.1128/jb.165.1.28-33.1986; OHYA Y, 1991, J BIOL CHEM, V266, P13971; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; Sherman F., 1974, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; [No title captured]	40	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7279	7284						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125941				2022-12-25	WOS:A1994NA03200040
J	GU, H; WALL, SC; RUDNICK, G				GU, H; WALL, SC; RUDNICK, G			STABLE EXPRESSION OF BIOGENIC-AMINE TRANSPORTERS REVEALS DIFFERENCES IN INHIBITOR SENSITIVITY, KINETICS, AND ION DEPENDENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET SEROTONIN TRANSPORT; PLASMA-MEMBRANE VESICLES; DOPAMINE TRANSPORTER; NORADRENALINE TRANSPORT; CHLORIDE DEPENDENCE; ACTIVE-TRANSPORT; NEURONAL UPTAKE; RAT-BRAIN; GBR 12783; CLONING	We have constructed stable cell lines expressing transporters for dopamine (DA), norepinephrine (NE), and serotonin (5-HT) by transfection with cloned cDNAs. The parental LLC-PK1 cell does not express any of these neurotransmitter transporters. Therefore, monoamine transport activities in each of these cell lines are due to the transfected DNA only, allowing comparison in the same background. Drug inhibition profiles for each cell line are distinct and as expected for each transporter. LLC-NET and LLC-DAT cells transported both NE and DA and both cell types exhibited a lower K-M for DA transport than for NE transport. Analysis of V-max data for LLC-NET cells suggests that substrate is bound to the NE transporter during the rate-limiting step(s) in transport, The cocaine analog 2-beta carbomethoxy-3 beta-(4-[I-125]iodophenyl)tropane binds to each cell type, and is displaced by transport substrate in each case. Binding and transport measurements on parallel cell cultures allowed estimation of turnover numbers for norepinephrine, dopamine, and serotonin transporters. All three transporters require external Na+ and Cl-. The Na+ concentration dependence suggests that a single Na+ ion is involved in transport catalyzed by norepinephrine and serotonin transporters while more than one Na+ ion participate in transport mediated by the dopamine transporter.			GU, H (corresponding author), YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510, USA.				NIDA NIH HHS [DA 7259, DA 8213] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008213, R01DA007259] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; AMEJDKICHAB N, 1992, J NEUROCHEM, V59, P1795, DOI 10.1111/j.1471-4159.1992.tb11012.x; AMEJDKICHAB N, 1992, J NEUROCHEM, V58, P793, DOI 10.1111/j.1471-4159.1992.tb09327.x; BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BOJA JW, 1992, SYNAPSE, V12, P27, DOI 10.1002/syn.890120104; CHO AK, 1990, SCIENCE, V249, P631, DOI 10.1126/science.249.4969.631; COOL DR, 1990, BIOCHEMISTRY-US, V29, P1818, DOI 10.1021/bi00459a022; COOL DR, 1990, AM J PHYSIOL, V259, pC196, DOI 10.1152/ajpcell.1990.259.2.C196; ENNA SJ, 1981, ANTIDEPRESSANTS NEUR; FRIEDRICH U, 1986, N-S ARCH PHARMACOL, V333, P246, DOI 10.1007/BF00512937; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1992, MOL PHARMACOL, V42, P383; HARDER R, 1985, J NEUROCHEM, V45, P1154, DOI 10.1111/j.1471-4159.1985.tb05536.x; HARDER R, 1984, BIOCHIM BIOPHYS ACTA, V775, P95, DOI 10.1016/0005-2736(84)90239-6; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HORN AS, 1970, MOL PHARMACOL, V7, P66; IVERSEN LL, 1965, ADV DRUG RES, V2, P5; IZENWASSER S, 1992, LIFE SCI, V50, P541, DOI 10.1016/0024-3205(92)90365-V; JOHNSON AM, 1992, INT CLIN PSYCHOPHARM, V6, P15, DOI 10.1097/00004850-199206004-00005; KEYES SR, 1982, J BIOL CHEM, V257, P1172; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; LINGJAERDE O, 1969, FEBS LETT, V3, P103, DOI 10.1016/0014-5793(69)80108-0; LOPEZIBOR JJ, 1992, INT CLIN PSYCHOPHARM, V7, P5, DOI 10.1097/00004850-199210002-00003; MCELVAIN JS, 1992, BIOCHEM PHARMACOL, V43, P2189, DOI 10.1016/0006-2952(92)90178-L; NELSON PJ, 1979, J BIOL CHEM, V254, P84; NELSON PJ, 1982, J BIOL CHEM, V257, P6151; NEUMEYER JL, 1991, J MED CHEM, V34, P3144, DOI 10.1021/jm00114a027; OHRBERG S, 1992, ACTA PSYCHIAT SCAND, V86, P437, DOI 10.1111/j.1600-0447.1992.tb03294.x; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1992, AM J PHYSIOL, V262, pC1189, DOI 10.1152/ajpcell.1992.262.5.C1189; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RUDNICK G, 1977, J BIOL CHEM, V252, P2170; RUDNICK G, 1986, SEROTONIN TRANSPORT, P119; Sambrook J, 1989, MOL CLONING LABORATO; SEIDEN LS, 1993, ANNU REV PHARMACOL, V33, P639, DOI 10.1146/annurev.pa.33.040193.003231; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SNEDDON JM, 1969, BRIT J PHARMACOL, V37, P680, DOI 10.1111/j.1476-5381.1969.tb08506.x; TALVENHEIMO J, 1979, J BIOL CHEM, V254, P4631; TALVENHEIMO J, 1983, J BIOL CHEM, V258, P6115; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; WALL SC, 1993, MOL PHARMACOL, V43, P264	47	291	313	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7124	7130						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125921				2022-12-25	WOS:A1994NA03200016
J	NAKANISHI, S; CATT, KJ; BALLA, T				NAKANISHI, S; CATT, KJ; BALLA, T			INHIBITION OF AGONIST-STIMULATED INOSITOL 1,4,5-TRISPHOSPHATE PRODUCTION AND CALCIUM SIGNALING BY THE MYOSIN LIGHT-CHAIN KINASE INHIBITOR, WORTMANNIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; PLASMA-MEMBRANE; ANGIOTENSIN-II; HUMAN NEUTROPHIL; PHOSPHOLIPASE-C; RECEPTOR; ACTIVATION; ENTRY; MECHANISM; RELEASE	The myosin light chain kinase inhibitor, wortmannin (WT), caused dose dependent inhibition of the sustained increases but not the initial spikes of inositol 1,4,5-trisphosphate (Ins-1,4,5-P-3) and cytoplasmic Ca2+ concentration ([Ca2+](i)) in angiotensin II (AII)-stimulated adrenal glomerulosa cells. In contrast, WT did not affect the [Ca2+](i) increases evoked by K+-induced depolarization or by depletion of intracellular Ca2+ stores with ionomycin or thapsigargin, suggesting that its inhibitory effects on Ins-1,4,5-P-3 and [Ca2+](i) responses are closely related. The inhibitory effect of WT on the lns-1,4,5-P-3 response was not secondary to its reduction of Ca2+ entry, since ionomycin induced elevation of [Ca2+](i) did not restore Ins-1,4,5-P-3 formation. Also, WT inhibited agonist- and GTP gamma S-stimulated Ins 1,4,5-P-3 formation in permeabilized cells maintained at fixed Ca2+ concentrations. Thus, inhibition of Ca2+ influx by WT is a consequence of reduced Ins-1,4,5-P-3 formation and could reflect the resultant refilling of the agonist-sensitive Ca2+ pool. Indeed, AII-depleted Ca2+ pools were found to refill by a thapsigargin-sensitive mechanism in WT-treated cells. Other structurally unrelated inhibitors of myosin light chain kinase (MS-347a, KT5926, and ML-9) also inhibited AII-induced inositol phosphate formation, albeit with lower potencies than WT. MS-347a, like WT, inhibited only the second phase of the inositol phosphate and [Ca2+](i) responses to AII. These findings demonstrate that WT is a potent inhibitor of the Ins-1,4,5-P-3-Ca2+ signaling pathway and acts primarily on a mechanism that promotes Ins-1,4,5-P-3 formation and is sensitive to inhibitors of myosin light chain kinase activity.	NIH,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA				Balla, Tamas/0000-0002-9077-3335				AMBROZ C, 1992, ENDOCRINOLOGY, V131, P408, DOI 10.1210/en.131.1.408; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BALLA T, 1991, J BIOL CHEM, V266, P24719; BALLA T, 1989, ARCH BIOCHEM BIOPHYS, V270, P398, DOI 10.1016/0003-9861(89)90043-X; BALLA T, 1988, J BIOL CHEM, V263, P4083; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; DEWALD B, 1988, J BIOL CHEM, V263, P16179; ELY JA, 1991, J BIOL CHEM, V266, P18635; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; GUILLEMETTE G, 1987, BIOCHEM BIOPH RES CO, V142, P15, DOI 10.1016/0006-291X(87)90445-1; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P17078; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KITANI S, 1992, BIOCHEM BIOPH RES CO, V183, P48, DOI 10.1016/0006-291X(92)91607-R; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NAKANISHI S, 1993, IN PRESS J ANTIBIOT; OHARAIMAIZUMI M, 1992, BIOCHEM BIOPH RES CO, V185, P1016, DOI 10.1016/0006-291X(92)91728-9; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SIMPLES JE, 1993, 75TH ANN M END SOC L, P360; YOSHIDA S, 1992, J PHYSIOL-LONDON, V458, P307, DOI 10.1113/jphysiol.1992.sp019419; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295; 1989, BIOCHEM J, V258, P1	43	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6528	6535						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120005				2022-12-25	WOS:A1994MZ50300043
J	SULPICE, JC; ZACHOWSKI, A; DEVAUX, PF; GIRAUD, F				SULPICE, JC; ZACHOWSKI, A; DEVAUX, PF; GIRAUD, F			REQUIREMENT FOR PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE IN THE CA2+-INDUCED PHOSPHOLIPID REDISTRIBUTION IN THE HUMAN ERYTHROCYTE-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; PLASMA-MEMBRANE; LIPID ASYMMETRY; AMINOPHOSPHOLIPID TRANSLOCASE; TRANSBILAYER DISTRIBUTION; DIVALENT-CATIONS; INDUCED FUSION; SHAPE CHANGES; POLYPHOSPHOINOSITIDES; PHOSPHATIDYLSERINE	In order to investigate how calcium on the cytosolic side of human erythrocytes induces the transmembrane redistribution of phospholipids, we studied the effect of this cation on the transmembrane movements of spin-labeled phospholipids (phosphatidylserine (PS) and phosphatidylcholine (PC)) incorporated into inside-out vesicles derived from human erythrocytes. We found that the extent of the Ca2+-induced lipid scrambling was dependent upon the level of phosphatidylinositol 4,5-bisphosphate (PIP2) contained in the external leaflet of inside out vesicles. The level of PIP2 in this leaflet, which normally accounts for 80% of the total membrane PIP2, was manipulated either by ATP depletion of the original erythrocytes or by incorporation of exogenous PIP2. Similarly loading the outer monolayer of the membrane of intact erythrocytes with exogenous PIP2 caused, in a dose-dependent way, the scrambling of spin-labeled phosphatidylethanolamine, sphingomyelin, PC, and PS and in parallel the stomatocytic conversion of the cells. Both scrambling and stomatocytosis were strictly dependent on the presence of divalent cations in the medium. Mg2+ could replace Ca2+ but required a 10 times higher concentration. The effect was specific for PIP2, the other phosphoinositides being unable to induce the lipid redistribution. The shape change, but not the scrambling, required a normal ATP level. These results show that Ca2+ or Mg2+ trigger the lipid redistribution either from the internal or the external side of the membrane, provided that enough PIP, is present on that side. Thus, no specific protein is required for this process. We infer that the ATP-dependent shape change of erythrocytes after incubation with PIP2 and Ca2+ results from the bilayer imbalance due to the activity of the aminophospholipid translocase which relocates PS and phosphatidylethanolamine to the inner monolayer without simultaneous outward diffusion of PC and sphingomyelin.	INST BIOL PHYSICOCHIM,CNRS,URA 526,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS)	SULPICE, JC (corresponding author), UNIV PARIS 11,BIOMEMBRANES & MESSAGERS CELLULAIRES LAB,CNRS,URA 1116,BAT 447,F-91405 ORSAY,FRANCE.		ZACHOWSKI, Alain/A-9029-2011					AIKEN NR, 1992, BIOCHIM BIOPHYS ACTA, V1136, P155, DOI 10.1016/0167-4889(92)90251-6; ALLAN D, 1978, BIOCHIM BIOPHYS ACTA, V508, P277, DOI 10.1016/0005-2736(78)90330-9; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BALDWIN JM, 1990, BIOCHIM BIOPHYS ACTA, V1028, P14, DOI 10.1016/0005-2736(90)90259-Q; BAZENET CE, 1990, J BIOL CHEM, V265, P7369; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BEVERS EM, 1989, BIOCHEMISTRY-US, V28, P2282; BITBOL M, 1987, BIOCHIM BIOPHYS ACTA, V904, P268, DOI 10.1016/0005-2736(87)90376-2; BUTIKOFER P, 1989, BLOOD, V73, P1699; BUTIKOFER P, 1990, J BIOL CHEM, V265, P16035; CHANDRA R, 1987, BIOCHIM BIOPHYS ACTA, V902, P253, DOI 10.1016/0005-2736(87)90303-8; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1990, BIOCHIM BIOPHYS ACTA, V1025, P82, DOI 10.1016/0005-2736(90)90193-R; DAWSON RMC, 1965, BIOCHEM J, V97, P134, DOI 10.1042/bj0970134; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2849, DOI 10.1021/bi00333a006; FERRELL JE, 1984, J CELL BIOL, V98, P1992, DOI 10.1083/jcb.98.6.1992; GADELLA TWJ, 1990, BIOCHEMISTRY-US, V29, P3389, DOI 10.1021/bi00465a035; GASCARD P, 1989, BIOCHEM J, V264, P547, DOI 10.1042/bj2640547; GASCARD P, 1991, BIOCHIM BIOPHYS ACTA, V1069, P27, DOI 10.1016/0005-2736(91)90100-M; GASCARD P, 1993, BIOCHEM SOC T, V21, P253, DOI 10.1042/bst0210253; GASCARD P, 1993, EUR J BIOCHEM, V211, P671, DOI 10.1111/j.1432-1033.1993.tb17595.x; GIRAUD F, 1984, BIOCHIM BIOPHYS ACTA, V778, P191, DOI 10.1016/0005-2736(84)90462-0; HENSELEIT U, 1990, BIOCHIM BIOPHYS ACTA, V1029, P127, DOI 10.1016/0005-2736(90)90445-T; JOINER CH, 1993, AM J PHYSIOL, V264, pC251, DOI 10.1152/ajpcell.1993.264.2.C251; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; KONISHI M, 1991, J GEN PHYSIOL, V97, P271, DOI 10.1085/jgp.97.2.271; MISSIAEN L, 1989, BIOCHEM J, V264, P609, DOI 10.1042/bj2640609; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; OBRIAN CA, 1987, FEBS LETT, V214, P339, DOI 10.1016/0014-5793(87)80083-2; RHODA MD, 1988, BIOCHEM J, V254, P161, DOI 10.1042/bj2540161; SARKADI B, 1980, BIOCHIM BIOPHYS ACTA, V598, P326, DOI 10.1016/0005-2736(80)90010-3; SCHEWE M, 1992, J BIOL CHEM, V267, P5910; SCHRIER SL, 1978, BLOOD CELLS, V4, P339; SCHRIER SL, 1986, BLOOD, V68, P1008; SCHRIER SL, 1992, BLOOD, V79, P782; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P3703, DOI 10.1021/bi00435a012; Steck T L, 1974, Methods Enzymol, V31, P172; TANAKA Y, 1983, J BIOL CHEM, V258, P1335; THOMPSON MG, 1987, CANCER RES, V47, P2799; TILLEY L, 1986, FEBS LETT, V194, P21, DOI 10.1016/0014-5793(86)80044-8; TONER M, 1988, BIOCHEMISTRY-US, V27, P7435, DOI 10.1021/bi00419a039; VANPARIDON PA, 1986, BIOCHIM BIOPHYS ACTA, V877, P216, DOI 10.1016/0005-2760(86)90137-2; VERHOVEN B, 1992, BIOCHIM BIOPHYS ACTA, V1104, P15, DOI 10.1016/0005-2736(92)90126-7; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WILLIAMSON P, 1985, J CELL PHYSIOL, V123, P209, DOI 10.1002/jcp.1041230209; ZACHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P2585, DOI 10.1021/bi00357a046; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	52	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6347	6354						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119984				2022-12-25	WOS:A1994MZ50300017
J	TANIGUCHI, T; MATSUI, T; ITO, M; MURAYAMA, T; TSUKAMOTO, T; KATAKAMI, Y; CHIBA, T; CHIHARA, K				TANIGUCHI, T; MATSUI, T; ITO, M; MURAYAMA, T; TSUKAMOTO, T; KATAKAMI, Y; CHIBA, T; CHIHARA, K			CHOLECYSTOKININ-B/GASTRIN RECEPTOR SIGNALING PATHWAY INVOLVES TYROSINE PHOSPHORYLATIONS OF P125(FAK) AND P42(MAP)	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE CELLS; SWISS 3T3 CELLS; GASTRIN RECEPTOR; MAP KINASES; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; PERTUSSIS TOXIN; PDGF RECEPTOR	The neuro-intestinal peptide hormone cholecystokinin (CCK)/gastrin has been suggested to have a trophic effect on gastro-intestinal tract in vivo as well as in vitro. In the present study, the human CCK-B/gastrin receptor was expressed in mouse NIH3T3 fibroblasts to investigate the molecular basis of signal transduction pathway of the guanine nucleotide regulatory protein (G protein)-coupled receptor. Human CCK-B/gastrin receptor expressed in NIH3T3 cells coupled efficiently to phosphoinositide hydrolysis and mobilization of intracellular Ca2+, and transduced mitogenic signals assessed by [H-3]thymidine incorporation in a dose-dependent manner. Moreover, CCK-8 or gastrin I alone promoted the cell growth in serum-free medium. CCK-8 induced tyrosine phosphorylation of several protein species. Among them, mitogen-activated protein (MAP) kinase was tyrosine phosphorylated and activated in response to CCK-8, as was induced by platelet-derived growth factor (PDGF). In contrast, tyrosine phosphorylation of p125(FAK) (focal adhesion kinase) was induced by CCK-8 but not by PDGF. CCK-8 as well as gastrin I induced the expression of early responsive genes such as c-fos and c-myc. These results suggest that CCK-B/gastrin receptors might transmit mitogenic signals by cross-talking with the tyrosine kinase cascades.	KOBE UNIV,SCH MED,DEPT MED,DIV 3,CHUO KU,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT GERONTOL,CHUO KU,KOBE 650,JAPAN	Kobe University; Kobe University			Matsui, Toshimitsu/E-8065-2010	Matsui, Toshimitsu/0000-0002-2536-7584				AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CREAN GP, 1969, GASTROENTEROLOGY, V57, P147; CROSS AJ, 1988, NEUROPEPTIDES, V11, P73, DOI 10.1016/0143-4179(88)90013-3; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HAKANSON R, 1986, SCAND J GASTROENTERO, V21, P18, DOI 10.3109/00365528609090883; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOOSEIN NM, 1988, CANCER RES, V48, P7179; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ISHIZUKA J, 1992, ANN SURG, V215, P528, DOI 10.1097/00000658-199205000-00016; ITO M, 1993, J BIOL CHEM, V268, P18300; JOHNSON LR, 1982, SCAND J GASTROENTERO, V17, P89; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE YM, 1993, J BIOL CHEM, V268, P8164; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; NAKATA H, 1992, BIOCHEM BIOPH RES CO, V187, P1151, DOI 10.1016/0006-291X(92)91317-J; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; POLACEK MA, 1966, SURGERY, V60, P606; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; RYBERG B, 1990, GASTROENTEROLOGY, V99, P935, DOI 10.1016/0016-5085(90)90610-D; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SETH A, 1991, J BIOL CHEM, V266, P23521; SETHI T, 1991, CANCER RES, V51, P3621; SMITH JP, 1991, REGUL PEPTIDES, V32, P341; SOLL AH, 1984, J CLIN INVEST, V73, P1434, DOI 10.1172/JCI111348; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; TSUKAMOTO T, 1991, J BIOL CHEM, V266, P10143; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZIMONJIC CB, 1993, IN PRESS CYTOGENET C	56	88	92	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					861	867						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108129				2022-12-25	WOS:A1994MW55100022
J	ADAMS, RM; YOAST, S; MAINZER, SE; MOON, K; PALOMBELLA, AL; ESTELL, DA; POWER, SD; SCHMIDT, BF				ADAMS, RM; YOAST, S; MAINZER, SE; MOON, K; PALOMBELLA, AL; ESTELL, DA; POWER, SD; SCHMIDT, BF			CHARACTERIZATION OF 2 COLD-SENSITIVE MUTANTS OF THE BETA-GALACTOSIDASE FROM LACTOBACILLUS-DELBRUCKII SUBSP BULGARICUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTANTS; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; DNA; DENATURATION; EFFICIENT; SECRETION; GLU-461; VECTORS; ACID	Methoxylamine mutagenesis of the beta-galactosidase gene from Lactobacillus delbruckii subsp. bulgaricus was used to generate cold-sensitive variants. Two variants, P429S and L317F, were characterized kinetically in order to determine the enzymatic consequences of these mutations. The kinetic parameters K-m and V-max on the synthetic substrate o-nitrophenyl-beta-D-galactopyranoside have been determined over a temperature range of 11-45 degrees C. Only the V-max of the two variants was significantly different than the wild-type enzyme over the temperature range studied. The V-max of the L317F variant is reduced proportionately at all temperatures compared to the wild-type enzyme while the value of V,, for the P429S mutant deviates from wild-type only at lower temperatures (in 2 mM Mg2+). This temperature-dependent effect on the V-max of P429S can be suppressed by increasing the Mg2+ concentration. The results suggest that the binding of this essential metal ion is altered in the P429S variant such that its dissociation is increased by lowering the temperature.	GENENCOR INT INC,S SAN FRANCISCO,CA 94080									BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRANDTS JF, 1964, J AM CHEM SOC, V86, P4291, DOI 10.1021/ja01074a013; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; EDWARDS RA, 1990, BIOCHEMISTRY-US, V29, P11001, DOI 10.1021/bi00501a019; EDWARDS RA, 1990, BIOCHEM BIOPH RES CO, V171, P33, DOI 10.1016/0006-291X(90)91352-S; ESTELL DA, 1985, J BIOL CHEM, V260, P6518; FINK A, 1975, BIOCHEM BIOPH RES CO, V62, P701; HUBER RE, 1976, BIOCHEMISTRY-US, V15, P1994, DOI 10.1021/bi00654a029; KADONAGA JT, 1985, NUCLEIC ACIDS RES, V13, P1733, DOI 10.1093/nar/13.5.1733; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARTINEZBILBAO M, 1991, J BIOL CHEM, V266, P4979; OKA T, 1985, P NATL ACAD SCI USA, V82, P7212, DOI 10.1073/pnas.82.21.7212; PORTZEHL H, 1964, BIOCHIM BIOPHYS ACTA, V79, P581, DOI 10.1016/0926-6577(64)90224-4; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; PRIVALOV PL, 1986, J MOL BIOL, V190, P487, DOI 10.1016/0022-2836(86)90017-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT BF, 1989, J BACTERIOL, V171, P625, DOI 10.1128/jb.171.2.625-635.1989; Segel I. H., 1975, ENZYME KINETICS, P931; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STROM R, 1971, EUR J BIOCHEM, V23, P118, DOI 10.1111/j.1432-1033.1971.tb01598.x; TENU JP, 1972, EUR J BIOCHEM, V26, P112, DOI 10.1111/j.1432-1033.1972.tb01746.x; ULLMANN A, 1969, BIOCHEM BIOPH RES CO, V35, P35, DOI 10.1016/0006-291X(69)90479-3; Wallenfels K., 1972, ENZYMES, V7, P617; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIPSER D, 1963, J MOL BIOL, V7, P113, DOI 10.1016/S0022-2836(63)80040-6; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	26	23	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5666	5672						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119903				2022-12-25	WOS:A1994MY84000031
J	PARK, K; CHOE, J; OSIFCHIN, NE; TEMPLETON, DJ; ROBBINS, PD; KIM, SJ				PARK, K; CHOE, J; OSIFCHIN, NE; TEMPLETON, DJ; ROBBINS, PD; KIM, SJ			HUMAN RETINOBLASTOMA SUSCEPTIBILITY GENE PROMOTER IS POSITIVELY AUTOREGULATED BY ITS OWN PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; CELL-CYCLE; BINDING PROTEIN; C-MYC; TRANSCRIPTION; EXPRESSION; IDENTIFICATION; CLONING; PHOSPHORYLATION; INACTIVATION	The product of the retinoblastoma susceptibility gene is a 1O5-kDa protein that has properties of a cell cycle regulatory factor. Previous reports indicated that two distinct DNA-binding factors, RBF-1 and ATF, play an important part in the transcription of the human retinoblastoma gene (Rb). Recently, we demonstrated that pRb activates expression of the human transforming growth factor-beta 2 gene through ATF-B Since the human Rb gene promoter also contains an ATF-a-like binding site, we examined whether pRb can regulate its own expression through ATF-2. Here we report that overexpression of Rb stimulates Rb promoter activity through the ATF binding site in a variety of different cell types. Mutation of the ATF binding site of the Rb promoter abolishes the Rb autoinduction. We have also determined that the carboxyl-terminal domain of pRb is responsible for the Rb autoinduction through ATF-2. Rb autoinduction may be important for maintaining the action of pRb during cell growth, and loss of autoinducibility may contribute to retinoblastoma.	NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261; CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Case Western Reserve University			Templeton, Dennis J/F-7695-2011		NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YK, 1987, SCIENCE, V236, P1675; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; OREILLY MA, 1992, J BIOL CHEM, V267, P19938; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578	40	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6083	6088						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119953				2022-12-25	WOS:A1994MY84000091
J	RUNQUIST, M; ERICSSON, J; THELIN, A; CHOJNACKI, T; DALLNER, G				RUNQUIST, M; ERICSSON, J; THELIN, A; CHOJNACKI, T; DALLNER, G			ISOPRENOID BIOSYNTHESIS IN RAT-LIVER MITOCHONDRIA - STUDIES ON FARNESYL PYROPHOSPHATE SYNTHASE AND TRANS-PRENYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLANESYL-DIPHOSPHATE SYNTHASE; UBIQUINONE BIOSYNTHESIS; CIS-PRENYLTRANSFERASE; PARA-HYDROXYBENZOATE; MOLECULAR-CLONING; CHAIN-LENGTH; PEROXISOMES; SYNTHETASE; REDUCTASE; DOLICHOL	Mevalonate pathway enzyme activities in rat liver mitochondria were investigated, and it was found that isopentenyl pyrophosphate can be utilized for the synthesis of all-trans-polyprenyl pyrophosphates in vitro. In this reaction sequence intermediate formation of farnesyl pyrophosphate (FPP) predominates, and the FPP synthase activity was studied in more detail. The mitochondrial activity constitutes 13% of the total hepatic capacity for FPP synthesis, exceeding the corresponding microsomal, nuclear, and peroxisomal activities by 10-fold. Mitochondrial FPP synthase exhibits trypsin sensitivity only after sonication of intact mitochondria and upon subfractionation the activity is found localized in the matrix. FPP synthase activities at different locations responded distinctly when rats were treated with a diet enriched in cholesterol or containing mevinolin or cholestyramine. With the high cholesterol diet, mitochondrial FPP synthase activity increased 2-fold, while the cytosolic activity was slightly decreased. Both mevinolin and cholestyramine treatment resulted in 3-fold increases in cytosolic FPP synthase activities, without altering the mitochondrial activity. FPP was utilized as substrate for trans-prenyltransferase activity in the inner mitochondrial membrane. The products formed in this reaction were identified as nona- and decaprenyl-PP, and the reaction was influenced by changes in both substrate and Mg2+ concentration, giving more decaprenyl-PP when the concentrations of these substances were increased. These results demonstrate that mitochondria utilize endogenously produced FPP for isoprenoid biosynthesis and that the biosynthetic steps in mitochondria are regulated independently from those occurring in other subcellular compartments.	KAROLINSKA INST,NOVUM,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN; POLISH ACAD SCI,INST BIOCHEM & BIOPHYS,PL-02532 WARSAW,POLAND	Karolinska Institutet; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	RUNQUIST, M (corresponding author), STOCKHOLM UNIV,ARRHENIUS LABS NAT SCI,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN.		Ericsson, Johan/AAA-6664-2020; Runquist, Marten/AAF-7613-2019	Ericsson, Johan/0000-0003-1186-6574; 				ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T; APPELKVIST EL, 1990, ARCH BIOCHEM BIOPHYS, V282, P318, DOI 10.1016/0003-9861(90)90123-G; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BROWN MS, 1980, J LIPID RES, V21, P505; CARSON DD, 1981, J BIOL CHEM, V256, P4679; CAUGHEY WS, 1975, J BIOL CHEM, V250, P7602; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; DALLNER G, 1966, J CELL BIOL, V30, P97, DOI 10.1083/jcb.30.1.97; DANILOV LL, 1989, CHEM PHYS LIPIDS, V51, P191, DOI 10.1016/0009-3084(89)90006-6; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; ERICSSON J, 1992, J BIOL CHEM, V267, P18708; ERICSSON J, 1992, J BIOL CHEM, V267, P19730; ERICSSON J, 1993, J BIOL CHEM, V268, P832; ERNSTER L, 1962, J CELL BIOL, V15, P563, DOI 10.1083/jcb.15.3.563; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRANICK S, 1978, METHOD ENZYMOL, V78, P33; HEMMING FW, 1981, BIOCH ISOPRENOID COM, P305; JONES MS, 1969, BIOCHEM J, V113, P507, DOI 10.1042/bj1130507; KALEN A, 1990, J BIOL CHEM, V265, P1158; KANG D, 1991, EUR J BIOCHEM, V198, P599, DOI 10.1111/j.1432-1033.1991.tb16056.x; KEENAN RW, 1975, ANAL BIOCHEM, V69, P504, DOI 10.1016/0003-2697(75)90153-0; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER RK, 1986, J BIOL CHEM, V261, P2053; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTKEBRINKHAUS F, 1984, EUR J BIOCHEM, V141, P537, DOI 10.1111/j.1432-1033.1984.tb08226.x; MOMOSE K, 1972, J BIOL CHEM, V247, P3930; NISHINO T, 1977, BIOCHEMISTRY-US, V16, P605, DOI 10.1021/bi00623a008; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; OHNUMA S, 1992, J BIOCHEM-TOKYO, V112, P743, DOI 10.1093/oxfordjournals.jbchem.a123969; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; Rilling H. C., 1985, STEROLS BILE ACIDS, P1; SAIKI K, 1993, BIOCHEM BIOPH RES CO, V186, P1491; SHIMIZU S, 1991, ARCH BIOCHEM BIOPHYS, V284, P35, DOI 10.1016/0003-9861(91)90259-L; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; Sottocasa G. L., 1967, METHOD ENZYMOL, V10, P448; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; SWIEZEWSKA E, 1992, BIOCHEM CELL BIOL, V70, P448; SWIEZEWSKA E, 1993, J BIOL CHEM, V268, P1494; TECLEBRHAN H, 1993, J BIOL CHEM, V268, P23081; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOLLBOM O, 1988, J BIOL CHEM, V263, P1347; TRUMPOWER BL, 1974, J BIOL CHEM, V249, P3041; Tzagoloff A, 1982, MITOCHONDRIA; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WEINSTEIN JD, 1986, ARCH BIOCHEM BIOPHYS, V245, P44, DOI 10.1016/0003-9861(86)90188-8; YAMAMOTO T, 1989, ARCH BIOCHEM BIOPHYS, V269, P86, DOI 10.1016/0003-9861(89)90089-1	52	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5804	5809						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119922				2022-12-25	WOS:A1994MY84000052
J	BENEVOLENSKY, SV; CLIFTON, D; FRAENKEL, DG				BENEVOLENSKY, SV; CLIFTON, D; FRAENKEL, DG			THE EFFECT OF INCREASED PHOSPHOGLUCOSE ISOMERASE ON GLUCOSE-METABOLISM IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED INTERCONVERSION; ISOTOPIC DISCRIMINATION; HEXOSE-PHOSPHATES; GLYCOLYSIS; YEAST; HYDROGEN; MUTANTS; CELLS	Comparison of microbial strains with normal and high content of single enzymes is coming into use for metabolic analysis and in vivo assessment of enzyme function. We present an example for phosphoglucose isomerase and glucose metabolism in the yeast Saccharomyces cerevisiae. We use cell suspensions in conditions of inhibited protein synthesis and respiration, with low assimilation, rapid and linear glucose utilization, fermentation almost quantitative, and high enough cell density for direct preparation of extracts for metabolite analysis. The mass action ratio and fitting of fructose-6-P and glucose-6-P concentrations and kinetic parameters of the enzyme are not inconsistent with near equilibrium of the reaction in the wild-type strain and small if any change in the high level strain. However, this conclusion would require that the V-max values underestimate the activity in the cell. On the other hand, the specific activities of glucose-6-P and fructose-1,6-P-2 during metabolism of [2-H-3]glucose are quite high which, together with knowledge of tritium exchange and isotope effects for the reaction in vitro, would point to the reaction in the wildtype strain being far from equilibrium; the specific activities are lower in the high level strain, indicating that extra enzyme is functional. One way to reconcile the latter results would be for tritium exchange to be considerably lower in vivo than known in vitro.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					PHS HHS [GB21098] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BABUL J, 1993, BIOCHEMISTRY-US, V32, P4685, DOI 10.1021/bi00068a029; BARWELL CJ, 1971, EUR J BIOCHEM, V18, P59, DOI 10.1111/j.1432-1033.1971.tb01214.x; BETZ A, 1965, ARCH BIOCHEM BIOPHYS, V109, P585, DOI 10.1016/0003-9861(65)90404-2; BRINDLE KM, 1988, BIOCHEMISTRY-US, V27, P6187, DOI 10.1021/bi00416a054; CLIFTON D, 1978, GENETICS, V88, P1; CORNISHBOWDEN A, 1993, EUR J BIOCHEM, V213, P87, DOI 10.1111/j.1432-1033.1993.tb17737.x; CRABTREE B, 1985, CURR TOP CELL REGUL, V25, P21; DAVIES SEC, 1992, BIOCHEMISTRY-US, V31, P4729, DOI 10.1021/bi00134a028; DENHOLLANDER JA, 1979, P NATL ACAD SCI USA, V76, P6096; DORRER HD, 1966, Z NATURFORSCH PT B, VB 21, P557, DOI 10.1515/znb-1966-0612; FRAENKEL DG, 1985, P NATL ACAD SCI USA, V82, P4740, DOI 10.1073/pnas.82.14.4740; FRAENKEL DG, 1992, ANNU REV GENET, V26, P159; GARFINKEL L, 1979, EUR J BIOCHEM, V96, P183, DOI 10.1111/j.1432-1033.1979.tb13028.x; Gunsalus I. C., 1961, BACTERIA, V2, P1; HARDEN A, 1923, ALCOHOLIC FERMENTATI; KATZ J, 1969, J BIOL CHEM, V244, P99; Katz J, 1976, Curr Top Cell Regul, V10, P237; KAWASAKI G, 1982, BIOCHEM BIOPH RES CO, V108, P1107, DOI 10.1016/0006-291X(82)92114-3; KELL DB, 1986, FEMS MICROBIOL LETT, V39, P305, DOI 10.1016/0378-1097(86)90020-0; KRETSCHMER M, 1992, FIT WINDOW CHEM SOFT; LANG JM, 1987, J BACTERIOL, V169, P2932, DOI 10.1128/jb.169.7.2932-2937.1987; LIEMANS V, 1989, BIOCHIM BIOPHYS ACTA, V998, P111, DOI 10.1016/0167-4838(89)90261-6; LIEMANS V, 1991, Medical Science Research, V19, P427; MALAISSE WJ, 1991, INT J BIOCHEM, V23, P1471, DOI 10.1016/0020-711X(91)90290-4; MALAISSELAGAE F, 1989, MOL CELL BIOCHEM, V89, P57; NAVAS MA, 1993, P NATL ACAD SCI USA, V90, P1290, DOI 10.1073/pnas.90.4.1290; Newsholme E. A., 1973, REGULATION METABOLIS; NOLTMANN EA, 1972, ENZYMES, V6, P271; Rose I.A., 1969, COMPR BIOCHEM, V17, P93; ROSE IA, 1961, J BIOL CHEM, V236, P3086; ROSE IA, 1964, J BIOL CHEM, V239, P12; ROSE IA, 1975, ADV ENZYMOL RAMB, V43, P491; SEEHOLZER SH, 1993, P NATL ACAD SCI USA, V90, P1237, DOI 10.1073/pnas.90.4.1237; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22934; SOLS A, 1981, CURR TOP CELL REGUL, V19, P77; SRIVASTAVA DK, 1986, CURR TOP CELL REGUL, V28, P1; WALSH RB, 1991, GENETICS, V128, P521; WRIGHT BE, 1981, CURR TOP CELL REGUL, V19, P103; WURSTER B, 1970, H-S Z PHYSIOL CHEM, V351, P961, DOI 10.1515/bchm2.1970.351.2.961	39	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4878	4882						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106459				2022-12-25	WOS:A1994MX57100030
J	RYU, S; GARGES, S				RYU, S; GARGES, S			PROMOTER SWITCH IN THE ESCHERICHIA-COLI PTS OPERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; CYCLIC-AMP; TRANSCRIPTION ACTIVATION; SALMONELLA-TYPHIMURIUM; POSITIVE REGULATION; RECEPTOR PROTEIN; MESSENGER-RNA; 2 PROMOTERS; CRR GENES; DNA	The ptsH operon of Escherichia coli is controlled by two promoters P0 and P1, each of which is regulated by cyclic AMP receptor protein (CRP) complexed with cAMP (CRP.cAMP). We have studied the in vitro as well as in vivo transcriptional regulation of these two promoters. Each promoter exhibits a switching mechanism in vitro, where, depending upon the presence or absence of CRP.cAMP, transcription is initiated from different start sites termed a and b.P0 (P0a) is affected by supercoliing: when the template is linear, transcription initiation is switched to a site 3 base pairs upstream (P0b) and becomes more CRP.cAMP dependent. Transcription from the P1 promoter (P1a) switches initiation sites to 7 base pairs downstream (P1b) in the presence of CRP.cAMP. Most transcription in vivo was from P1a, and P0b could not be detected in vivo. Glucose has independent positive effects on pts expression in vivo. The results indicate that the two different regulatory mechanisms (one through CRP.cAMP, the other through glucose) are working together for fine control of pts expression.			RYU, S (corresponding author), NCI, MOLEC BIOL LAB, BLDG 37, RM 2E06, BETHESDA, MD 20892 USA.							Adhya S, 1987, ESCHERICHIA COLI SAL, P1503; BLAKE VL, 1987, J BACTERIOL, V169, P4499; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BRAHMS JG, 1985, J MOL BIOL, V181, P455, DOI 10.1016/0022-2836(85)90419-X; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; CORDARO JC, 1972, J BACTERIOL, V112, P17, DOI 10.1128/JB.112.1.17-29.1972; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DEREUSE H, 1988, J BACTERIOL, V170, P3827, DOI 10.1128/jb.170.9.3827-3837.1988; DEREUSE H, 1992, J MOL BIOL, V226, P623, DOI 10.1016/0022-2836(92)90620-Y; DEREUSE H, 1991, J BACTERIOL, V173, P727, DOI 10.1128/jb.173.2.727-733.1991; DEREUSE H, 1985, GENE, V35, P199; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; EMORY SA, 1992, GENE DEV, V6, P135, DOI 10.1101/gad.6.1.135; FOX DK, 1992, P NATL ACAD SCI USA, V89, P7056, DOI 10.1073/pnas.89.15.7056; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; IRANI M, 1989, J BACTERIOL, V171, P1623, DOI 10.1128/jb.171.3.1623-1630.1989; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; LAU E, 1985, RECOMBINANT DNA TECH, V6, P21; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; PAGEL JM, 1992, J MOL BIOL, V224, P919, DOI 10.1016/0022-2836(92)90460-2; PLUMBRIDGE JA, 1990, J BACTERIOL, V172, P2728, DOI 10.1128/jb.172.5.2728-2735.1990; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; REPHAELI AW, 1980, J BACTERIOL, V141, P658, DOI 10.1128/JB.141.2.658-663.1980; ROSENBAUM V, 1993, J MOL BIOL, V229, P656, DOI 10.1006/jmbi.1993.1070; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAIER MH, 1993, J CELL BIOCHEM, V51, P62, DOI 10.1002/jcb.240510112; Sambrook J, 1989, MOL CLONING LABORATO; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; TRAVERS AA, 1992, CURR OPIN STRUC BIOL, V2, P71	32	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4767	4772						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106445				2022-12-25	WOS:A1994MX57100014
J	SCHIAVI, SC; WELLINGTON, CL; SHYU, AB; CHEN, CYA; GREENBERG, ME; BELASCO, JG				SCHIAVI, SC; WELLINGTON, CL; SHYU, AB; CHEN, CYA; GREENBERG, ME; BELASCO, JG			MULTIPLE ELEMENTS IN THE C-FOS PROTEIN-CODING REGION FACILITATE MESSENGER-RNA DEADENYLATION AND DECAY BY A MECHANISM COUPLED TO TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; SYNTHESIS INHIBITORS; SECONDARY STRUCTURE; GENE-EXPRESSION; XENOPUS-LAEVIS; MYC; DEGRADATION; STABILITY; SEQUENCE; INSTABILITY	The c-fos proto-oncogene transcript is one of the most labile mammalian mRNAs known. Rapid degradation of c-fos mRNA is mediated by both the c-fos protein-coding region and an AU-rich element in the 3'-untranslated region. Here we present evidence that the c-fos coding region contains multiple destabilizing elements that can function independently to facilitate both deadenylation and decay of mRNA. The ability of these coding region destabilizing elements to direct deadenylation and decay requires the assembly of ribosomes at the 5' end of this domain and, most likely, translation of the message.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School					NCI NIH HHS [CA43855] Funding Source: Medline; NIGMS NIH HHS [GM42720] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042720] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; ATWATER JA, 1990, ANNU REV GENET, V24, P19; BAER BW, 1980, P NATL ACAD SCI-BIOL, V77, P1890, DOI 10.1073/pnas.77.4.1890; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOUVET P, 1991, MOL CELL BIOL, V11, P3115, DOI 10.1128/MCB.11.6.3115; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GALILI G, 1988, J BIOL CHEM, V263, P5764; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KROWCZYNSKA A, 1985, J MOL BIOL, V181, P231, DOI 10.1016/0022-2836(85)90087-7; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; PARKER R, 1990, P NATL ACAD SCI USA, V87, P2780, DOI 10.1073/pnas.87.7.2780; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SEHGAL PB, 1978, P NATL ACAD SCI USA, V75, P5030, DOI 10.1073/pnas.75.10.5030; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WADA K, 1991, NUCLEIC ACIDS RES, V19, P1981, DOI 10.1093/nar/19.suppl.1981; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034; WHITTEMORE LA, 1990, MOL CELL BIOL, V10, P1329, DOI 10.1128/MCB.10.4.1329; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	48	118	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3441	3448						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106384				2022-12-25	WOS:A1994MV63100049
J	HAJEK, P; BEDWELL, DM				HAJEK, P; BEDWELL, DM			CHARACTERIZATION OF THE MITOCHONDRIAL BINDING AND IMPORT PROPERTIES OF PURIFIED YEAST F1-ATPASE BETA-SUBUNIT PRECURSOR - IMPORT REQUIRES EXTERNAL ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; OUTER-MEMBRANE; NUCLEOSIDE TRIPHOSPHATES; ESCHERICHIA-COLI; RECEPTOR COMPLEX; INNER MEMBRANE; TRANSLOCATION; IDENTIFICATION; RECOGNITION; PRESEQUENCE	To better understand the early events of the mitochondrial protein import process, we purified the precursor of the F-1-ATPase beta subunit (pre F-1 beta) and examined its import into isolated mitochondria. Import of purified urea-denatured pre-F-1 beta did not require cytosolic factors. However, the period of productive import was prolonged by the addition of reticulocyte lysate, suggesting that cytosolic factors such as molecular chaperones were acting to extend the period of import competence of pre-F-1 beta. Purified pre-F-1 beta bound extensively to both cardiolipin-containing liposomes and to intact mitochondria, indicating that a direct interaction between mitochondrial precursors and the mitochondrial outer membrane surface can occur. The ability to chase this surface-bound pre-F-1 beta into mitochondria suggests that precursors bound to the mitochondrial surface can be maintained in an import competent conformation. Finally, our defined mitochondrial import system was used to characterize the ATP requirements of pre-F-1 beta import in the absence of cytosol. We found a strong requirement for ATP on both sides of the mitochondrial inner membrane, suggesting that one or more previously undetected mitochondrial proteins outside the inner membrane utilize ATP to promote efficient pre-F-1 beta import.	UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham				Bedwell, David/0000-0002-6605-818X				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; BECKER K, 1992, J BIOL CHEM, V267, P5637; BEDWELL DM, 1989, MOL CELL BIOL, V9, P1014, DOI 10.1128/MCB.9.3.1014; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; IWAHASHI J, 1992, J BIOCHEM-TOKYO, V111, P451, DOI 10.1093/oxfordjournals.jbchem.a123778; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LOWRY OH, 1946, J BIOL CHEM, V162, P421; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; OHTA S, 1984, EMBO J, V3, P651, DOI 10.1002/j.1460-2075.1984.tb01862.x; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1990, J BIOL CHEM, V265, P16324; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1988, J BIOL CHEM, V263, P4509; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; ZWIZINSKI C, 1984, J BIOL CHEM, V259, P7850	45	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7192	7200						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125931				2022-12-25	WOS:A1994NA03200027
J	CHAPMAN, ER; JAHN, R				CHAPMAN, ER; JAHN, R			CALCIUM-DEPENDENT INTERACTION OF THE CYTOPLASMIC REGION OF SYNAPTOTAGMIN WITH MEMBRANES - AUTONOMOUS FUNCTION OF A SINGLE C-2-HOMOLOGOUS DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SYNAPTIC VESICLES; ACTIVE ZONES; BOVINE; P65; BINDING; RELEASE; CELLS; GAP; P38	The synaptic vesicle protein synaptotagmin has been implicated in the docking and subsequent calcium-regulated exocytosis of synaptic vesicles. We demonstrate that synaptotagmin is a major constituent of synaptic vesicle membranes, comprising 7-8% of the total vesicle protein. A proteolytic fragment of synaptotagmin, containing two repeats homologous to the C-2-domain of protein kinase C, bound to a variety of natural membranes in a calcium-dependent manner (EC(50) similar to 30 mu M calcium). Binding was insensitive to proteolysis of the acceptor membranes suggesting an interaction with the lipid constituents. This interaction was confirmed using a recom- binant fusion protein, containing both C-2-like domains of synaptotagmin, that bound to artificial liposomes in a calcium-dependent manner. Phospholipid binding properties were preserved in a 114-amino acid domain corresponding to the first C-2-like repeat of the protein and represents the shortest functional cassette yet reported. Furthermore, deletion of a highly conserved 9-amino acid moth, within this region, was sufficient to abolish the calcium-dependent phospholipid binding properties of this domain. This mutation may provide a means to selectively disrupt individual C-2-domains in order to assess their relative contributions to function.	YALE UNIV, SCH MED, BOYER CTR MOLEC MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	Yale University	CHAPMAN, ER (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA.			Chapman, Edwin/0000-0001-9787-8140; Jahn, Reinhard/0000-0003-1542-3498				BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FOHR KJ, 1994, IN PRESS METHODS ENZ; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GOELZ SE, 1981, P NATL ACAD SCI-BIOL, V78, P2130, DOI 10.1073/pnas.78.4.2130; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1987, ANN NY ACAD SCI, V493, P497, DOI 10.1111/j.1749-6632.1987.tb27235.x; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MOEHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TUGAL HB, 1991, BIOCHEM J, V279, P699, DOI 10.1042/bj2790699; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALCHSOOLIMENA C, 1993, IN PRESS NEUROSCIENC; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	33	194	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5735	5741						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119912				2022-12-25	WOS:A1994MY84000042
J	SHIRABE, K; FUJIMOTO, Y; YUBISUI, T; TAKESHITA, M				SHIRABE, K; FUJIMOTO, Y; YUBISUI, T; TAKESHITA, M			AN IN-FRAME DELETION OF CODON-298 OF THE NADH-CYTOCHROME B(5) REDUCTASE GENE RESULTS IN HEREDITARY METHEMOGLOBINEMIA TYPE-II (GENERALIZED TYPE) - A FUNCTIONAL IMPLICATION FOR THE ROLE OF THE COOH-TERMINAL REGION OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NADH-CYTOCHROME-B5 REDUCTASE; SITE-DIRECTED MUTAGENESIS; RAT-LIVER MICROSOMES; AMINO-ACID SEQUENCE; MENTAL-RETARDATION; NITRATE REDUCTASE; MESSENGER-RNA; BINDING SITE; B5; IDENTIFICATION	The nucleotide sequence was determined for the gene of NADH-cytochrome b(5) reductase of a patient of type II hereditary methemoglobinemia found in Yokohama, Japan. An in-frame deletion of 3 base pairs corresponding to codon 298 (TTC) was identified in the patient. The patient was homozygous for the mutation as shown by hybridization experiments using allele-specific oligonucleotides. The mutation causes deletion of Phe-298, which is the third to the COOH-terminal residue, indicating that in this mutant enzyme the sequence of this region has changed from -Cys-Phe-Val-Phe-COOH to -Cys-Val-Phe-COOH. The mutant enzyme, whose Phe-298 was deleted (F298 Delta), was prepared by means of a bacterial expression system and site-directed mutagenesis. The k(cat)/K-m value (NADH) of the enzyme was 5.7 s(-1) M(-1), which corresponds to 0.4% of that of the wild type. Moreover, the enzyme was much less thermostable than the wild type. To examine further the role of the COOH-terminal portion of the enzyme, various mutant enzymes were also prepared and characterized. The enzymatic properties of F298L, F300L, and F298L/F300L were essentially the same as that of the wild type. The kinetic properties of F298A, and F300A were not greatly affected, but the stability of the enzymes was somewhat impaired. Since Val-299 is naturally Ala in steer enzyme, no specific residues in the carboxyl-terminal region (298-300) are essential to the enzyme function. The instability of the F298A/F300A double mutant indicates that the hydrophobicity of the carboxyl-terminal region of the enzyme might be important to maintain the conformation of the enzyme. High impairment of the activity of the F298 Delta, F298stop, and F300stop mutants might be caused by the loss of the residue(s) in the carboxyl-terminal portion, These results indicate that the hydrophobicity, but not the specific amino acid residues, of the carboxyl-terminal portion of the enzyme is important for the stability of the enzyme.			SHIRABE, K (corresponding author), OITA MED UNIV, DEPT BIOCHEM, HASAMA, OITA 87955, JAPAN.							ADAMS JG, 1981, P NATL ACAD SCI-BIOL, V78, P469, DOI 10.1073/pnas.78.1.469; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P5425, DOI 10.1073/pnas.87.14.5425; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CAILLAUD C, 1991, J BIOL CHEM, V266, P9351; CASEY R, 1976, BRIT J HAEMATOL, V33, P143; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; CURIEL DT, 1989, J BIOL CHEM, V264, P13938; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; HIDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66; HYDE GE, 1991, J BIOL CHEM, V266, P23542; IYANAGI T, 1977, BIOCHEMISTRY-US, V16, P2725, DOI 10.1021/bi00631a021; JAFFE ER, 1989, METABOLIC BASIS INHE, P2267; JONES RT, 1966, SCIENCE, V154, P1024, DOI 10.1126/science.154.3752.1024; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KEYES SR, 1980, J BIOL CHEM, V255, P1357; KOBAYASHI Y, 1990, BLOOD, V75, P1408; LEROUX A, 1975, NATURE, V258, P619, DOI 10.1038/258619a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTCHER CL, 1976, BLOOD, V47, P99; MAEDAYORITA K, 1991, BIOCHEMISTRY-US, V30, P11788, DOI 10.1021/bi00115a008; MOOPENN WF, 1975, BIOCHEM BIOPH RES CO, V65, P8, DOI 10.1016/S0006-291X(75)80054-4; NAGAI T, 1993, BLOOD, V81, P808; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OZOLS J, 1985, J BIOL CHEM, V260, P1953; PARAD RB, 1990, P NATL ACAD SCI USA, V87, P6786, DOI 10.1073/pnas.87.17.6786; PIETRINI G, 1992, J CELL BIOL, V117, P975, DOI 10.1083/jcb.117.5.975; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENMAKERS JGG, 1968, NATURE, V220, P788; SCOTT EM, 1959, BIOCHIM BIOPHYS ACTA, V34, P584, DOI 10.1016/0006-3002(59)90324-5; SHIRABE K, 1989, BIOCHIM BIOPHYS ACTA, V1008, P189, DOI 10.1016/0167-4781(80)90007-X; SHIRABE K, 1992, J BIOL CHEM, V267, P20416; SHIRABE K, 1991, J BIOL CHEM, V266, P7531; STRITTMATTER P, 1965, J BIOL CHEM, V240, P4481; STRITTMATTER P, 1957, J BIOL CHEM, V228, P785; SUTTER TR, 1990, J BIOL CHEM, V265, P16428; TAKANO T, 1994, IN PRESS FLAVINS FLA; TAKESHITA M, 1982, J MED GENET, V19, P204, DOI 10.1136/jmg.19.3.204; TANISHIMA K, 1985, BLOOD, V66, P1288; TISCHLER ME, 1977, FEBS LETT, V76, P99, DOI 10.1016/0014-5793(77)80129-4; TOMATSU S, 1989, GENE, V80, P353; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; WAJCMAN H, 1973, BIOCHIM BIOPHYS ACTA, V295, P495, DOI 10.1016/0005-2795(73)90045-7; WILLIAMS GT, 1985, EXP CELL RES, V160, P419, DOI 10.1016/0014-4827(85)90189-2; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609; YUBISUI T, 1986, J BIOCHEM-TOKYO, V99, P407, DOI 10.1093/oxfordjournals.jbchem.a135495; YUBISUI T, 1991, J BIOL CHEM, V266, P66	52	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5952	5957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119939				2022-12-25	WOS:A1994MY84000073
J	KLEMAN, MI; POELLINGER, L; GUSTAFSSON, JA				KLEMAN, MI; POELLINGER, L; GUSTAFSSON, JA			REGULATION OF HUMAN DIOXIN RECEPTOR FUNCTION BY INDOLOCARBAZOLES, RECEPTOR LIGANDS OF DIETARY ORIGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON HYDROXYLASE; DNA-BINDING ACTIVITY; HEAT-SHOCK PROTEIN; AH-RECEPTOR; AROMATIC-HYDROCARBONS; NUCLEAR RECEPTORS; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; INDOLE-3-CARBINOL; INDUCTION; ELEMENTS	The intracellular basic helix-loop helix (bHLH) dioxin receptor mediates signal transduction by dioxin (2,3,7,8--tetrachlorodibenzo-p- dioxin). In analogy to nuclear receptors that are members of the steroid hormone receptor superfamily the dioxin receptor is a ligand-inducible transcriptional regulator that directly binds to response elements within regulated genes. The most commonly studied dioxin receptor ligands are dioxin itself and structurally related environmental contaminants. A physiological ligand has not yet been identified. Interestingly, however, indolo[3,2-b]carbazole, a compound formed from precursors in the diet, has been shown to bind the murine dioxin receptor with high affinity in vitro. In the present study we show that this compound and its methylated derivative 5,11-dimethylindolo[3,2-b]carbazole very potently activated transcription from a dioxin or xenobiotic response element (XRE)-driven reporter gene in both murine and human hepatoma cells. This effect was not observed in mutant, dioxin-resistant hepatoma cells which are either deficient in expression of dioxin receptor or the bHLH receptor partner factor Arnt. In vitro indolocarbazoles induced XRE binding activity by the human dioxin receptor-Arnt complex in a dose-dependent manner. Thus, both dioxin- and indolocarbazole-activated forms of dioxin receptor regulate target gene expression by the same mechanism involving recruitment of the bHLH factor Arnt and recognition of the XRE element. Finally, the indole [3,2-b]carbazole-activated human dioxin receptor appeared to generate more stable complexes with the XRE target sequence relative to those produced by the dioxin activated receptor form, indicating interesting mechanistic differences between different classes of dioxin receptor ligands in their abilities to modulate human dioxin receptor function.	KAROLINSKA INST, HUDDINGE UNIV HOSP F60, NOVUM, CTR NUTR & TOXICOL, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet	KLEMAN, MI (corresponding author), KAROLINSKA INST, HUDDINGE UNIV HOSP F60, NOVUM, DEPT MED NUTR, S-14186 HUDDINGE, SWEDEN.							BAILAR JC, 1991, NEW ENGL J MED, V324, P261; BERGHARD A, 1992, CARCINOGENESIS, V13, P651, DOI 10.1093/carcin/13.4.651; BERGMAN J, 1984, TETRAHEDRON LETT, V25, P1957, DOI 10.1016/S0040-4039(01)90086-3; BERGMAN J, 1970, TETRAHEDRON, V26, P3353, DOI 10.1016/S0040-4020(01)92913-8; BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CONNEY AH, 1982, CANCER RES, V42, P4875; CUTHILLS, 1991, MOL CELL BIOL, V11, P412; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GILLNER M, 1985, MOL PHARMACOL, V28, P357; GILLNER M, 1993, MOL PHARMACOL, V44, P336; GRADIN K, 1993, J BIOL CHEM, V268, P4061; GROSE KR, 1992, CHEM RES TOXICOL, V5, P188, DOI 10.1021/tx00026a007; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HARPER PA, 1992, MOL PHARMACOL, V42, P603; HARPER PA, 1991, ARCH BIOCHEM BIOPHYS, V290, P27, DOI 10.1016/0003-9861(91)90587-9; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUNIG S, 1976, LIEBIGS ANN CHEM, P1090; JELLINCK PH, 1993, BIOCHEM PHARMACOL, V45, P1129, DOI 10.1016/0006-2952(93)90258-X; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KLEMAN MI, 1992, CARCINOGENESIS, V13, P1619, DOI 10.1093/carcin/13.9.1619; LABRUZZO P, 1989, BIOCHEM PHARMACOL, V38, P2339, DOI 10.1016/0006-2952(89)90474-7; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; MANCHESTER DK, 1987, CANCER RES, V47, P4861; MASON GGF, 1994, IN PRESS J BIOL CHEM, V269; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, NUTR CANCER, V16, P209, DOI 10.1080/01635589109514159; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROBERTS EA, 1990, ARCH BIOCHEM BIOPHYS, V276, P442, DOI 10.1016/0003-9861(90)90743-I; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	39	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5137	5144						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106494				2022-12-25	WOS:A1994MX57100070
J	MILLERMARTINI, DM; CHIRGWIN, JM; HOROWITZ, PM				MILLERMARTINI, DM; CHIRGWIN, JM; HOROWITZ, PM			MUTATIONS OF NONCATALYTIC SULFHYDRYL-GROUPS INFLUENCE THE STABILITY, FOLDING, AND OXIDATIVE SUSCEPTIBILITY OF RHODANESE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; ENDOPLASMIC-RETICULUM; SPINACH FERREDOXIN; DISULFIDE BONDS; GROWTH-FACTOR; PROTEIN; THIOSULFATE; DNA; INACTIVATION; MUTAGENESIS	Mutants of rhodanese (EC 2.8.1.1) which substitute serine residues for each of the 4 cysteine residues have been studied to determine the roles of cysteines in the structure and function of the enzyme. The proteins compared in these studies were: the wild-type, C63S, C247S, C254S, C263S, C254S/C263S, and C63S/C254S/C263S. These current studies show that cysteine 247 is the only cysteine required for the activity of the enzyme. Although the other sulfhydryl groups do not participate in sulfur transfer, mutations of the noncatalytic cysteines result in the destabilization of the native structure of the enzyme. All the active proteins had similar kinetic parameters. Mutants substituting cysteine 254, compared with the other species, were: (a) more resistant than wild-type to inactivation by dithiothreitol, (b) more readily reactivated following oxidative inactivation, and (c) found to adopt conformations that show increased exposure of hydrophobic surfaces following removal of the transferable sulfur. On the other hand, cysteine to serine substitutions had very little effect on: (a) the rates of oxidative inactivation, (b) the increased fluorescence following the removal of transferable sulfur, or (c) the effectiveness of spontaneous refolding after urea denaturation. Forms of rhodanese that were formerly considered to be irreversibly oxidized can be reactivated if the protein is denatured in urea before reductants are used. It is proposed that these forms differ from reversibly oxidized states due to the inaccessibility of intramolecular disulfides to reductants and not to the formation of higher oxidation states of the protein.	UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	MILLERMARTINI, DM (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284, USA.				NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRO AF, 1972, EUR J BIOCHEM, V28, P83; Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BLUMENTHAL KM, 1971, J BIOL CHEM, V246, P2430; BONOMI F, 1977, FEBS LETT, V84, P149, DOI 10.1016/0014-5793(77)81076-4; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNELLA C, 1972, ITAL J BIOCHEM, V21, P1; CANNELLA C, 1974, FEBS LETT, V49, P22, DOI 10.1016/0014-5793(74)80622-8; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; FINAZZIAGRO A, 1971, FEBS LETT, V16, P172; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUIDO K, 1975, BIOCHEM BIOPH RES CO, V67, P670, DOI 10.1016/0006-291X(75)90864-5; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HEINRIKSON RL, 1983, FRONTIERS BIOCH BIOP, P163; Hol W G, 1985, Adv Biophys, V19, P133, DOI 10.1016/0065-227X(85)90053-X; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; HOROWITZ PM, 1987, J BIOL CHEM, V262, P8728; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HOROWITZ PM, 1992, BIOCATALYST DESIGN S, V516, P167; JAMBOU RC, 1988, P NATL ACAD SCI USA, V85, P9426, DOI 10.1073/pnas.85.24.9426; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lang K, 1933, BIOCHEM Z, V259, P243; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NISBET IT, 1985, GENE ANAL TECH, V2, P23, DOI 10.1016/0735-0651(85)90001-9; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OGATA K, 1989, J BIOL CHEM, V264, P2718; PAGANI S, 1982, BIOCHIM BIOPHYS ACTA, V700, P154, DOI 10.1016/0167-4838(82)90092-9; PAGANI S, 1986, BIOCHIM BIOPHYS ACTA, V870, P538, DOI 10.1016/0167-4838(86)90263-3; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PLOEGMAN JH, 1973, THESIS U GRONINGEN; RINAS U, 1992, BIO-TECHNOL, V10, P435, DOI 10.1038/nbt0492-435; SACHDEV D, 1992, ADV EXP MED BIOL, V306, P335; SCHLESINGER P, 1974, J BIOL CHEM, V249, P780; SORBO BH, 1955, METHOD ENZYMOL, V2, P3534; SZCZEPKOWSKI TW, 1967, BIOCHIM BIOPHYS ACTA, V139, P469, DOI 10.1016/0005-2744(67)90050-2; TANDON S, 1989, J BIOL CHEM, V264, P9859; ULLRICH A, 1984, EMBO J, V3, P361, DOI 10.1002/j.1460-2075.1984.tb01812.x; WASYLEWSKI Z, 1982, BIOCHIM BIOPHYS ACTA, V701, P12, DOI 10.1016/0167-4838(82)90305-3; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227; WENG L, 1978, J BIOL CHEM, V253, P8109; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327	44	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3423	3428						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106382				2022-12-25	WOS:A1994MV63100046
J	BURGERS, PMJ; YODER, BL				BURGERS, PMJ; YODER, BL			ATP-INDEPENDENT LOADING OF THE PROLIFERATING CELL NUCLEAR ANTIGEN REQUIRES DNA ENDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYMERASE-III HOLOENZYME; REPLICATION FACTOR-C; CEREVISIAE CDC2 GENE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BETA-SUBUNIT; CALF THYMUS; DELTA; INTERACTS; MECHANISM	The proliferating cell nuclear antigen (PCNA) is a processivity subunit for eukaryotic DNA polymerase delta. We present biochemical evidence that yeast PCNA likely adopts a toroidal structure containing an inside cavity through which double-stranded DNA slides. A comparative study of DNA replication reactions on circular versus linear model substrates shows that PCNA can only interact productively with DNA polymerase delta if the substrate is linear. This combined with the observation that a large molar excess of PCNA is required for maximal stimulatory activity is consistent with a model in which PCNA slips onto the end of the DNA in an ATP-independent manner.			BURGERS, PMJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BUDD M, 1987, P NATL ACAD SCI USA, V84, P2838, DOI 10.1073/pnas.84.9.2838; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; Sambrook J, 1989, MOL CLONING LABORATO; SITNEY KC, 1989, CELL, V56, P599, DOI 10.1016/0092-8674(89)90582-5; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; YODER BL, 1991, J BIOL CHEM, V266, P22689	18	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19923	19926						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104181				2022-12-25	WOS:A1993LY01900003
J	KONDO, T; YOSHIDA, K; URATA, Y; GOTO, S; GASA, S; TANIGUCHI, N				KONDO, T; YOSHIDA, K; URATA, Y; GOTO, S; GASA, S; TANIGUCHI, N			GAMMA-GLUTAMYLCYSTEINE SYNTHETASE AND ACTIVE-TRANSPORT OF GLUTATHIONE S-CONJUGATE ARE RESPONSIVE TO HEAT-SHOCK IN K562 ERYTHROID-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC ANHYDRASE-I; RAT; DISULFIDE; MEMBRANES; PROTEINS; TRANSFERASES; METABOLISM; INDUCTION; ATPASE; ASSAY	Effect of heat shock on a glutathione-synthesizing enzyme, gamma-glutamylcysteine synthetase (gamma-GCS), and ATP-dependent outward transport of glutathione S-conjugate was characterized using K562 erythroid cells. When K562 cells grown at 37-degrees-C were shifted to 42-degrees-C for 2 h, an approximate 1.7-fold increase in the activity of gamma-GCS was observed. Treatment of K562 cells with erythropoietin (EP) for 12 h resulted in a decrease in the activity of gamma-GCS to 64% of the control. However, responsiveness of this enzyme activity in the cells treated with EP to heat shock was similar to that in untreated cells. Changes in the immunological activity of gamma-GCS were also observed in parallel with those in the enzymatic activity. On Northern blot analysis of total RNAs isolated from the cells with human cDNA for gamma-GCS, a substantial induction of mRNA level was found by heat shock and a reduction by EP. These changes were modest but correlated to the mRNA expression of a heat shock protein, HSP 70. Heat shock also had an effect of 1.8-fold stimulation on glutathione S-conjugate transport in K562 cells previously incubated with 1-chloro-2,4-dinitrobenzene. Treatment of the cells with EP resulted in a decrease in this transport by 62%. Similarly, the levels of glutathione S-conjugate-stimulated Mg2+-ATPase, which enzyme is thought to be involved in the transport of glutathione S-conjugate, were responsive to heat shock and EP. These results suggest that glutathione synthesis and transport process of glutathione metabolites are responsive to heat shock and play a role in the defense system against stresses. It is also suggested that the regulatory site of the expression of these enzymes by heat shock is independent of that by EP.	HOKKAIDO UNIV,SCH MED,DEPT MED 1,SAPPORO,HOKKAIDO 060,JAPAN; SAPPORO MED COLL,DEPT CHEM,SAPPORO 064,JAPAN; OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	Hokkaido University; Sapporo Medical University; Osaka University	KONDO, T (corresponding author), NAGASAKI UNIV,SCH MED,INST ATOM DIS,DEPT PATHOL BIOCHEM,NAGASAKI 852,JAPAN.		Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; AWASTHI YC, 1983, BRIT J HAEMATOL, V55, P419, DOI 10.1111/j.1365-2141.1983.tb02156.x; BEUTLER E, 1986, CLIN CHIM ACTA, V158, P115, DOI 10.1016/0009-8981(86)90122-1; Beutler E, 1984, RED CELL METABOLISM, P122; Beutler E, 1984, RED CELL METABOLISM, P77; BOARD PG, 1981, FEBS LETT, V124, P163, DOI 10.1016/0014-5793(81)80127-5; CALTABIANO MM, 1986, J BIOL CHEM, V261, P3381; GOLDWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070; ISHIKAWA T, 1984, J BIOL CHEM, V259, P3838; KAPLOW LS, 1979, FLOW CYTOMETRY SORTI, P531; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KONDO T, 1989, BIOCHEM BIOPH RES CO, V162, P1, DOI 10.1016/0006-291X(89)91953-0; KONDO T, 1987, P NATL ACAD SCI USA, V84, P7373, DOI 10.1073/pnas.84.21.7373; KONDO T, 1982, EUR J BIOCHEM, V125, P551, DOI 10.1111/j.1432-1033.1982.tb06717.x; KONDO T, 1991, AM J HEMATOL, V38, P201, DOI 10.1002/ajh.2830380309; KONDO T, 1987, AM J HEMATOL, V26, P37, DOI 10.1002/ajh.2830260105; KRANZ SB, 1991, BLOOD, V177, P419; LABELLE EF, 1988, FEBS LETT, V228, P53, DOI 10.1016/0014-5793(88)80583-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU SC, 1991, J CLIN INVEST, V88, P260, DOI 10.1172/JCI115286; Mannervik B, 1981, Methods Enzymol, V77, P231; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MORIMOTO RI, 1990, STRESS PROTEINS BIOL, P212; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RIABOWOL KT, 1988, SCIENCE, V256, P500; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SAMBROOK J, 1989, MOL CLONING LAB MANU, P7; SHARMA R, 1990, TOXICOL APPL PHARM, V104, P421, DOI 10.1016/0041-008X(90)90164-P; VETTORE L, 1980, AM J HEMATOL, V8, P291, DOI 10.1002/ajh.2830080307; VILLEVAL JL, 1985, BLOOD, V66, P1162; WAHLLANDER A, 1979, EUR J BIOCHEM, V98, P441; WANG C, 1981, P NATL ACAD SCI-BIOL, V78, P3531, DOI 10.1073/pnas.78.6.3531; YAN N, 1990, J BIOL CHEM, V265, P1588; ZHANG W, 1992, BIOCHEM BIOPH RES CO, V183, P733, DOI 10.1016/0006-291X(92)90544-U	36	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20366	20372						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104187				2022-12-25	WOS:A1993LY01900067
J	USUI, T; TAKAGI, J; SAITO, Y				USUI, T; TAKAGI, J; SAITO, Y			PROPOLYPEPTIDE OF VONWILLEBRAND-FACTOR SERVES AS A SUBSTRATE FOR FACTOR-XIIIA AND IS CROSS-LINKED TO LAMININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIN-STABILIZING FACTOR; BASEMENT-MEMBRANE; ANTIGEN-II; ALPHA-2-PLASMIN INHIBITOR; TISSUE TRANSGLUTAMINASE; ENDOTHELIAL-CELLS; HUMAN-PLATELETS; LINKING; COLLAGEN; FIBRONECTIN	The propolypeptide of von Willebrand factor (pp-vWF) was found to serve as a substrate for Factor XIIIa (FXIIIa). FXIIIa catalyzed polymerization of pp-vWF as well as the incorporation of monodansyleadaverine and [C-14]putrescine into pp-vWF in a Ca2+- and time-dependent manner. The amount of putrescine incorporated into pp-vWF was increased as a function of putrescine concentration and reached a maximum of 3 mol/mol of pp-vWF, indicating that there are at least 3 glutamine residues in the pp-vWF molecule responsible for the reaction. I-125-pp-vWF was incubated with FXIIIa in the presence of various adhesive glycoproteins. Laminin, among the proteins tested, specifically formed a large molecular weight complex with I-125-pp-vWF in a Ca2+- and time-dependent manner. It was also found that FXIIIa catalyzed polymerization of laminin as well as the incorporation of monodansylcadaverine into laminin. The high molecular weight complexes of I-125-pp-vWF (or I-125-laminin) formed in the presence of laminin (or pp-vWF) were immunoprecipitated with anti-laminin (or anti-pp-vWF) antibodies. Taking all the data together it can be concluded that both pp-vWF and laminin have glutamine and lysine residues responsive to FXIIIa and make copolymers by virtue of FXIIIa.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT BIOLOG SCI,MEGURO KU,TOKYO 152,JAPAN	Tokyo Institute of Technology								AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; BOCKENSTEDT P, 1986, J CLIN INVEST, V78, P551, DOI 10.1172/JCI112608; BOHN H, 1978, MOL CELL BIOCHEM, V20, P67; BORTH W, 1991, J BIOL CHEM, V266, P18149; COHEN I, 1980, BIOCHIM BIOPHYS ACTA, V628, P365, DOI 10.1016/0304-4165(80)90386-4; COHEN I, 1979, ARCH BIOCHEM BIOPHYS, V192, P100, DOI 10.1016/0003-9861(79)90075-4; DOOLITTLE RF, 1971, BIOCHEM BIOPH RES CO, V44, P94, DOI 10.1016/S0006-291X(71)80163-8; FAY PJ, 1986, SCIENCE, V232, P995, DOI 10.1126/science.3486471; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FRANCIS RT, 1986, J BIOL CHEM, V261, P9787; FUJISAWA T, 1991, EUR J BIOCHEM, V196, P673, DOI 10.1111/j.1432-1033.1991.tb15864.x; GRINNELL F, 1980, CELL, V19, P517, DOI 10.1016/0092-8674(80)90526-7; HADA M, 1986, BLOOD, V68, P95; HASHIMOTO K, 1992, BIOCHIM BIOPHYS ACTA, V1165, P27, DOI 10.1016/0005-2760(92)90071-3; HASHIMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P1571, DOI 10.1016/0006-291X(91)90467-L; JELENSKA MM, 1980, BIOCHIM BIOPHYS ACTA, V616, P167, DOI 10.1016/0005-2744(80)90135-7; KIRBY EP, 1982, J LAB CLIN MED, V100, P963; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH GW, 1987, J BIOL CHEM, V262, P1772; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MCDONAGH J, 1976, BIOCHIM BIOPHYS ACTA, V446, P345, DOI 10.1016/0005-2795(76)90002-7; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; Mosher D F, 1978, Ann N Y Acad Sci, V312, P38, DOI 10.1111/j.1749-6632.1978.tb16791.x; MOSHER DF, 1980, J BIOL CHEM, V255, P1181; NACHMAN R, 1977, J CLIN INVEST, V60, P914, DOI 10.1172/JCI108846; PAYE M, 1986, J CELL SCI, V86, P95; PEERSCHKE EI, 1980, BLOOD, V55, P841; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; TAKAGI J, 1989, J BIOL CHEM, V264, P10425; TAKAGI J, 1989, J BIOL CHEM, V264, P6017; TAMAKI T, 1981, BIOCHIM BIOPHYS ACTA, V661, P280, DOI 10.1016/0005-2744(81)90016-4; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; TIMPL R, 1979, J BIOL CHEM, V254, P9933; USUI T, 1992, EUR J BIOCHEM, V205, P363, DOI 10.1111/j.1432-1033.1992.tb16788.x; WAGNER DD, 1987, P NATL ACAD SCI USA, V84, P1955, DOI 10.1073/pnas.84.7.1955; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	40	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12311	12316						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8099582				2022-12-25	WOS:A1993LG65800016
J	GALLIE, DR; TRAUGH, JA				GALLIE, DR; TRAUGH, JA			SERUM AND INSULIN REGULATE CAP FUNCTION IN 3T3-L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION-FACTORS; MESSENGER-RNA; PROTEIN-SYNTHESIS; TRANSLATIONAL CONTROL; RIBOSOMAL PROTEIN-S6; BINDING PROTEIN; PHORBOL ESTERS; FACTORS EIF-4F; POLY(A) TAIL; PHOSPHORYLATION	Serum starvation and readdition of serum, insulin, or mitogens result in changes in phosphorylation of several eukaryotic initiation factors that correlate with a decrease or stimulation in translation, respectively. We have introduced in vitro synthesized reporter mRNAs into exponentially growing and serum-deprived 3T3-L1 cells to examine whether serum deprivation affects capdependent translation. In serum-fed control cells, addition of a cap to poly(A)(-) or poly(A)(+) mRNA increased translational efficiency by 43- and 460-fold, respectively. In serum-deprived cells, the relative rate of translational efficiency of capped mRNA was reduced 2.6-fold relative from that observed in serum-fed cells with little change in the relative functional half-life. The effect of serum deprivation on translation was rapid and occurred within 90 min, and cap function was restored upon addition of serum or insulin to starved cells. Analysis of the dose dependence for reversal of the effects of serum starvation on cap dependent translation indi cated that 10 nm insulin was optimal. Little change in the function of the poly(A) tail was observed during serum starvation or hormone treatment. However, a decrease in the synergism between the cap and a poly(A) tail was observed upon starvation which was reversed by serum, and in part, by insulin.			GALLIE, DR (corresponding author), UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA.							BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUNCAN R, 1985, J BIOL CHEM, V260, P5486; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; EDERY I, 1983, J BIOL CHEM, V258, P1398; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; GALLIE DR, 1991, MOL GEN GENET, V228, P258, DOI 10.1007/BF00282474; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; KAEMPFER R, 1978, P NATL ACAD SCI USA, V75, P650, DOI 10.1073/pnas.75.2.650; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KEPES A, 1963, BIOCHIM BIOPHYS ACTA, V76, P293; LEVENSON RM, 1989, J BIOL CHEM, V264, P11904; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1993, IN PRESS BIOCHEMIE; PEDERSEN S, 1978, MOL GEN GENET, V166, P329, DOI 10.1007/BF00267626; PERISIC O, 1983, J BIOL CHEM, V258, P3998; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SMITH CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2641, DOI 10.1073/pnas.77.5.2641; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; TOWLE CA, 1984, BIOCHEM BIOPH RES CO, V121, P134, DOI 10.1016/0006-291X(84)90697-1; VANHEUGTEN HAA, 1991, J BIOL CHEM, V266, P7279; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	34	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7174	7179						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125928				2022-12-25	WOS:A1994NA03200024
J	GAO, GJ; FONDA, ML				GAO, GJ; FONDA, ML			KINETIC-ANALYSIS AND CHEMICAL MODIFICATION OF VITAMIN-B-6 PHOSPHATASE FROM HUMAN ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATIC-ACID-PHOSPHATASE; PYRIDOXAL 5'-PHOSPHATE; ALKALINE-PHOSPHATASE; RAT-LIVER; INORGANIC PYROPHOSPHATASE; PROTEIN PHOSPHATASE; COVALENT STRUCTURE; BINDING; SITE; INTERMEDIATE	The specificity and active site properties of vitamin B-6 phosphatase purified from human erythrocytes were studied by kinetic analyses with vitamin B-6 compounds and derivatives and chemical modification with group-specific reagents. The kinetic constants for pyridoxal phosphate (PLP), 4-pyridoxic acid phosphate, pyridoxine phosphate, and pyridoxamine phosphate were determined from pH 5 to 9. The values of V-max/K-m and pK(m) were highest for PLP and 4-pyridoxic acid phosphate and lowest for pryidoxamine phosphate. V-max/K-m and pK(m) for the four substrates were maximum between pH 6 and 8. Ionizable groups with pK alpha values about 6 and 8 affected substrate binding to the enzyme. V-max values for all the substrates gradually decreased with increasing pH. The enzyme also catalyzed the dephosphorylation of 4'-secondary amine derivatives of vitamin B-6-phosphate. The phosphatase had greatest catalytic efficiency with substrates that contained a negatively charged group on the 4'-position of the pyridine ring. It is concluded that there are one or two positively charged groups at the active site of the enzyme that interact with the substrate's phosphate ester and 4'-substituent. The phosphatase was inactivated by phenylglyoxal, and PLP protected the enzyme against this inactivation. Phenylglyoxal did not modify Lys or Cys residues or an ru-amino group since the enzyme's NH2 terminus is blocked, and it did not affect the quaternary structure of the phosphatase. The enzyme was inactivated by the incorporation of 1 mol of phenylglyoxal/ subunit. Diethylpyrocarbonate inactivated the enzyme by reacting with a group with a pK alpha of 6.7, and pyridoxine phosphate protected the enzyme against this inactivation. These data suggest that Arg and His residues are at or near the active site and may play roles in substrate binding and/or catalysis.	UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM,LOUISVILLE,KY 40292	University of Louisville					NIAAA NIH HHS [AA06861] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006861] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSON BB, 1980, GUT, V21, P192, DOI 10.1136/gut.21.3.192; Arnone A, 1985, TRANSAMINASES, P138; BOND MW, 1980, BIOCHEMISTRY-US, V19, P94, DOI 10.1021/bi00542a015; BORDERS CL, 1975, BIOCHEMISTRY-US, V14, P4699, DOI 10.1021/bi00692a021; CHEUNG ST, 1979, BIOCHEM BIOPH RES CO, V90, P940, DOI 10.1016/0006-291X(79)91918-1; CHOI JD, 1977, BIOCHEMISTRY-US, V20, P5722; Coburn SP, 1988, CLIN PHYSL APPLICATI, P65; DEPECOL ME, 1980, ANAL BIOCHEM, V101, P435, DOI 10.1016/0003-2697(80)90210-9; Ebadi M., 1986, VITAMIN B6 PYRIDOXAL, P449; FONDA ML, 1982, AM J CLIN NUTR, V35, P1391, DOI 10.1093/ajcn/35.6.1391; FONDA ML, 1991, ARCH BIOCHEM BIOPHYS, V288, P79, DOI 10.1016/0003-9861(91)90167-H; FONDA ML, 1992, J BIOL CHEM, V267, P15978; FONDA ML, 1989, ALCOHOL CLIN EXP RES, V3, P804; FUJIMOTO S, 1984, J BIOCHEM, V96, P1079, DOI 10.1093/oxfordjournals.jbchem.a134925; FUJIMOTO S, 1987, CHEM PHARM BULL, V35, P2011; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; HENDERSON JM, 1986, HEPATOLOGY, V6, P464, DOI 10.1002/hep.1840060324; HIRANO N, 1991, BIOCHEM J, V278, P595, DOI 10.1042/bj2780595; IGARASHI M, 1970, BIOCHIM BIOPHYS ACTA, V220, P85, DOI 10.1016/0005-2744(70)90231-7; JANSONIUS JN, 1985, TRANSAMINASES, P110; KALLEN RG, 1985, TRANSAMINASES, P37; KAZARINOFF MN, 1975, J BIOL CHEM, V250, P3436; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KYAW A, 1980, BIOCHEM MED METAB B, V24, P27, DOI 10.1016/0006-2944(80)90083-6; LUMENG L, 1975, J BIOL CHEM, V250, P8126; MCCORMICK D, 1961, J BIOL CHEM, V236, P2076; MCCORMICK D, 1961, J BIOL CHEM, V236, P2085; MCKEE JS, 1989, BIOCHEM J, V261, P301, DOI 10.1042/bj2610301; Miles E W, 1977, Methods Enzymol, V47, P431; MURAKAMI K, 1986, CHEM PHARM BULL, V34, P3320; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; RAIBAUD O, 1974, FEBS LETT, V40, P41, DOI 10.1016/0014-5793(74)80889-6; REYNOLDS RD, 1991, AM J CLIN NUTR, V53, P698, DOI 10.1093/ajcn/53.3.698; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; SARASWATHI S, 1963, J NEUROCHEM, V10, P127, DOI 10.1111/j.1471-4159.1963.tb11473.x; STOCK A, 1966, BIOCHEM Z, V344, P353; STONE KL, 1989, PRACTICAL GUIDE PROT, P37; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VANETTEN RL, 1977, ARCH BIOCHEM BIOPHYS, V183, P250, DOI 10.1016/0003-9861(77)90438-6; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; WADA H, 1961, J BIOL CHEM, V236, P2089; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WOODROOFE M N, 1978, Biochemical Society Transactions, V6, P562; ZHANG Z, 1991, P NATL ACAD SCI USA, V88, P10407, DOI 10.1073/pnas.88.23.10407; ZHANG ZY, 1992, BIOCHEMISTRY-US, V31, P1701, DOI 10.1021/bi00121a018	46	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7163	7168						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125926				2022-12-25	WOS:A1994NA03200022
J	SCHWIEBERT, EM; MILLS, JW; STANTON, BA				SCHWIEBERT, EM; MILLS, JW; STANTON, BA			ACTIN-BASED CYTOSKELETON REGULATES A CHLORIDE CHANNEL AND CELL-VOLUME IN A RENAL CORTICAL COLLECTING DUCT CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY EPITHELIAL-CELLS; CYCLIC-AMP ACCUMULATION; S49 LYMPHOMA-CELLS; ION CHANNELS; F-ACTIN; PROXIMAL TUBULE; CYTOCHALASIN-B; ACTIVATED CHANNELS; CYSTIC-FIBROSIS; MDCK CELLS	The regulatory volume decrease (RVD) of a renal cortical collecting duct cell line (RCCT-28A) exposed to a hypotonic solution was studied using electronic cell sizing to measure cell volume and the patch clamp technique to measure Cl- channel activity. Results demonstrate that RVD was mediated in part by KCl loss through separate K+ and Cl- channels. The Cl- channel had a conductance of 305 pS and was activated by cell swelling, membrane stretch, and disruption of F-actin by dihydrocytochalasins. In contrast, stabilizing F-actin with phalloidin prevented swelling and stretch activation of the Cl- channel and inhibited the RVD. Thus, the state of actin polymerization regulates the probability of the 305 pS Cl- channel being open. Short actin filaments activate whereas long actin filaments inactivate the channel. Taken together, our studies suggest that RVD in this renal collecting duct cell line cell is mediated in part by a 305 pS Cl- channel, which is activated, during cell swelling, by a signaling pathway that includes disruption of F-actin.	DARTMOUTH COLL, SCH MED, DEPT PHYSIOL, HANOVER, NH 03755 USA	Dartmouth College					NIDDK NIH HHS [DK-34533] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034533] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1989, METHOD ENZYMOL, V172, P49; AREND LJ, 1989, AM J PHYSIOL, V256, pF1067, DOI 10.1152/ajprenal.1989.256.6.F1067; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CIVAN MM, 1992, EXP EYE RES, V54, P181, DOI 10.1016/S0014-4835(05)80207-6; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CORNET M, 1987, PFLUG ARCH EUR J PHY, V410, P223, DOI 10.1007/BF00581921; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DIETL P, 1992, AM J PHYSIOL, V263, pF243, DOI 10.1152/ajprenal.1992.263.2.F243; DIETL P, 1992, AM J PHYSIOL, V262, pF578, DOI 10.1152/ajprenal.1992.262.4.F578; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; FALKE LC, 1989, P NATL ACAD SCI USA, V86, P3919, DOI 10.1073/pnas.86.10.3919; FILIPOVIC D, 1992, AM J PHYSIOL, V262, pF857, DOI 10.1152/ajprenal.1992.262.5.F857; FOSKETT JK, 1985, AM J PHYSIOL, V248, pC27, DOI 10.1152/ajpcell.1985.248.1.C27; GOGELEIN H, 1988, BIOCHIM BIOPHYS ACTA, V947, P521, DOI 10.1016/0304-4157(88)90006-8; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; HALLOWS KR, 1991, AM J PHYSIOL, V261, pC1154, DOI 10.1152/ajpcell.1991.261.6.C1154; HOFFMANN EK, 1987, CURR TOP MEMBR TRANS, V30, P125; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HUDSON RL, 1988, P NATL ACAD SCI USA, V85, P279, DOI 10.1073/pnas.85.1.279; HURST AM, 1990, J PHYSIOL-LONDON, V430, P13, DOI 10.1113/jphysiol.1990.sp018278; INSEL PA, 1982, J BIOL CHEM, V257, P9717; KELLY SM, 1991, AM J PHYSIOL, V260, pC652, DOI 10.1152/ajpcell.1991.260.3.C652; KENNEDY MS, 1979, MOL PHARMACOL, V16, P215; Kleinzeller A., 1990, Comparative Physiology, V4, P59; KOOB R, 1990, EUR J CELL BIOL, V53, P93; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LEWIS RS, 1990, ANNU REV PHYSIOL, V52, P415; LEWIS SA, 1990, NEWS PHYSIOL SCI, V5, P112; LIGHT DB, 1990, AM J PHYSIOL, V258, pF273, DOI 10.1152/ajprenal.1990.258.2.F273; LINSHAW MA, 1992, AM J PHYSIOL, V262, pF144, DOI 10.1152/ajprenal.1992.262.1.F144; LOPES AG, 1988, P NATL ACAD SCI USA, V85, P2873, DOI 10.1073/pnas.85.8.2873; LOW I, 1975, FEBS LETT, V54, P263, DOI 10.1016/0014-5793(75)80088-3; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; MEYERLEHNERT H, 1993, CLIN INVESTIGATOR, V71, P153; MILLS JW, 1987, CURR TOP MEMBR TRANS, V30, P75; MILLS JW, 1986, AM J PHYSIOL, V250, pC319, DOI 10.1152/ajpcell.1986.250.2.C319; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; SACHS F, 1991, MOL CELL BIOCHEM, V104, P57; SACKIN H, 1987, AM J PHYSIOL, V253, pF1253; SACKIN H, 1989, P NATL ACAD SCI USA, V86, P1731, DOI 10.1073/pnas.86.5.1731; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHWIEBERT E M, 1991, Journal of the American Society of Nephrology, V2, P750; SCHWIEBERT EM, 1992, P NATL ACAD SCI USA, V89, P10623, DOI 10.1073/pnas.89.22.10623; SCHWIEBERT EM, 1992, J CLIN INVEST, V89, P834, DOI 10.1172/JCI115662; SCHWIEBERT EM, 1991, FASEB J, V5, P739; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STANTON B A, 1991, Journal of the American Society of Nephrology, V2, P751; STANTON BA, 1990, J AM SOC NEPHROL, V1, P492; STRANGE K, 1991, AM J PHYSIOL, V260, pF225, DOI 10.1152/ajprenal.1991.260.2.F225; STRANGE K, 1988, AM J PHYSIOL, V255, pC612, DOI 10.1152/ajpcell.1988.255.5.C612; TANIGUCHI J, 1989, AM J PHYSIOL, V257, pF347, DOI 10.1152/ajprenal.1989.257.3.F347; TSENG GN, 1992, AM J PHYSIOL, V262, pC1056, DOI 10.1152/ajpcell.1992.262.4.C1056; VALE RD, 1992, MOL NEUROBIOL, P247; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WELLING PA, 1990, AM J PHYSIOL, V258, pF951, DOI 10.1152/ajprenal.1990.258.4.F951; YANTORNO RE, 1992, AM J PHYSIOL, V262, pC501, DOI 10.1152/ajpcell.1992.262.2.C501; YANTORNO RE, 1989, EXP EYE RES, V49, P423, DOI 10.1016/0014-4835(89)90051-1; ZIYADEH FN, 1992, AM J PHYSIOL, V262, pF468, DOI 10.1152/ajprenal.1992.262.3.F468	75	190	195	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7081	7089						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125915				2022-12-25	WOS:A1994NA03200009
J	KUROKAWA, H; MIKAMI, B; HIROSE, M				KUROKAWA, H; MIKAMI, B; HIROSE, M			CRUCIAL ROLE OF INTRALOBE PEPTIDE-PEPTIDE INTERACTIONS IN THE UPTAKE AND RELEASE OF IRON BY OVOTRANSFERRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL HALF; HUMAN LACTOFERRIN; SERUM TRANSFERRIN; X-RAY; BINDING; RESOLUTION; FRAGMENTS; MOLECULE; LACTOTRANSFERRIN; PYROPHOSPHATE	The mechanism for reversible iron binding in the N-terminal lobe of ovotransferrin was investigated by a protein fragmentation approach, The iron-saturated N-terminal half-molecule of ovotransferrin was proteo- lyzed into large 30-kDa (1-279) and small 6-kDa (280-332) fragments by a single cleavage with Achromobacter protease I, producing a stable nicked form. For the separation of the two fragments, denaturing conditions were required. The isolated large fragment contained all four iron-coordinating ligands and the anion-binding ligand, and according to spectroscopic titration analysis, it showed iron binding capacity. The iron-bound large fragment, however, showed a blue-shifted visible absorption spectrum and a much decreased iron stability compared with those of the intact half-molecule. Analyses by ion-exchange chromatography revealed that the large fragment reassociates with the small fragment, In order for reassociation to occur, iron must be bound to the large fragment; upon reassociation, the large fragment regained its stable iron binding capacity as well as a visible absorption spectrum almost indistinguishable from those of the intact half-molecule. These data are consistent with a two step sequential pathway for re- versible iron binding in the N-terminal lobe of ovotransferrin that includes an initial iron binding intermediate having a perturbed metal environment and its transformation into the stable iron-bound holoform by peptide-peptide interactions between the large coordinating and small noncoordinating segments.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University			Kurokawa, Hirofumi/A-7231-2010	Hirose, Masaaki/0000-0003-2672-4384				AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON BF, 1987, P NATL ACAD SCI USA, V84, P1769, DOI 10.1073/pnas.84.7.1769; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; AZARI PR, 1958, J BIOL CHEM, V232, P293; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BALI PK, 1989, J AM CHEM SOC, V111, P4457, DOI 10.1021/ja00194a047; COWART RE, 1982, J BIOL CHEM, V257, P7560; COWART RE, 1986, J BIOL CHEM, V261, P4607; DAY CL, 1992, J BIOL CHEM, V267, P13857; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; GROSSMANN JG, 1993, J MOL BIOL, V229, P585, DOI 10.1006/jmbi.1993.1063; GROSSMANN JG, 1992, J MOL BIOL, V225, P811, DOI 10.1016/0022-2836(92)90402-6; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P7643, DOI 10.1093/nar/15.18.7643; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRAND D, 1984, BIOCHIM BIOPHYS ACTA, V787, P90, DOI 10.1016/0167-4838(84)90111-0; LEGRAND D, 1990, BIOCHEM J, V266, P575; MAZURIER J, 1980, BIOCHIM BIOPHYS ACTA, V629, P399, DOI 10.1016/0304-4165(80)90112-9; OE H, 1989, J BIOCHEM-TOKYO, V106, P858, DOI 10.1093/oxfordjournals.jbchem.a122942; OE H, 1988, J BIOCHEM-TOKYO, V103, P1066, DOI 10.1093/oxfordjournals.jbchem.a122381; SANCHO J, 1992, J MOL BIOL, V224, P749, DOI 10.1016/0022-2836(92)90559-3; SARRA R, 1990, ACTA CRYSTALLOGR B, V46, P763, DOI 10.1107/S0108768190006450; TASAYCO ML, 1992, SCIENCE, V255, P594, DOI 10.1126/science.1736361; Wetlaufer D B, 1981, Adv Protein Chem, V34, P61, DOI 10.1016/S0065-3233(08)60518-5; WILLIAMS J, 1982, EUR J BIOCHEM, V122, P297, DOI 10.1111/j.1432-1033.1982.tb05880.x; WILLIAMS J, 1988, BIOCHEM J, V251, P849, DOI 10.1042/bj2510849; WOODWORTH RC, 1991, BIOCHEMISTRY-US, V30, P10824, DOI 10.1021/bi00109a002	29	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6671	6676						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120023				2022-12-25	WOS:A1994MZ50300066
J	NAKADE, S; RHEE, SK; HAMANAKA, H; MIKOSHIBA, K				NAKADE, S; RHEE, SK; HAMANAKA, H; MIKOSHIBA, K			CYCLIC-AMP-DEPENDENT PHOSPHORYLATION OF AN IMMUNOAFFINITY-PURIFIED HOMOTETRAMERIC INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR (TYPE-I) INCREASES CA2+ FLUX IN RECONSTITUTED LIPID VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE; INSP3 RECEPTOR; PROTEIN-KINASE; CA-2+ RELEASE; TRISPHOSPHATE RECEPTOR; ACETYLCHOLINE-RECEPTOR; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; MOUSE CEREBELLUM; PURKINJE-CELL	We established a novel method to isolate a single type of inositol 1,4,5-trisphosphate receptor (IP(3)R) among the heterogeneous population of receptors to study the regulatory mechanism of Ca2+ release. We raised in the rabbit a polyclonal antibody against synthetic peptide corresponding to amino acids 2736-2747 (pep 6) of type I IP(3)R (IP(3)R-I) that is most abundant in cerebellum. We purified IP(3)R-I from a 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid solubilized mouse cerebellar microsomal fraction by immunoaffinity chromatography on an anti-pep 6 antibody-Sepharose 4B column with specific elution by the pep 6 peptide (GHPPHMNVNPQQ) of the IP(3)R-I C terminus. Immunoaffinity-purified IP(3)R reconstituted into lipid vesicles formed a homotetramer structure. Monoclonal antibody 18A10, which partially blocks the Ca2+ release from cerebellar microsome, almost completely inhibited IP3-induced Ca-45(2+) influx into proteoliposomes, whereas monoclonal antibody that recognizes other regions did not inhibit Ca2+ influx. Both the rate and extent of Ca-45(2+) influx into proteoliposomes increased 20% after incubation with the catalytic subunit of cyclic AMP-dependent protein kinase, accompanied by stoichiometric phosphorylation of IP(3)R protein.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO,TOKYO 108,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC NEUROBIOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; RIKEN	NAKADE, S (corresponding author), ONO PHARMACEUT CO LTD,MINASE RES INST,BASIC RES LAB,3-1-1 SAKURAI,SHIMAMOTO,OSAKA 618,JAPAN.		Mikoshiba, Katsuhiko/N-7943-2015					BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CHOW SC, 1990, J BIOL CHEM, V265, P902; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; ENOUF J, 1987, BIOCHIM BIOPHYS ACTA, V928, P76, DOI 10.1016/0167-4889(87)90087-5; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1982, J BIOL CHEM, V257, P9372; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KAGAWA Y, 1973, J BIOL CHEM, V248, P676; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; KIEHM DJ, 1977, J BIOL CHEM, V252, P8524; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NAKANISHI S, 1991, J NEUROSCI, V11, P2075; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PIETRI F, 1990, J BIOL CHEM, V265, P17478; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; RICHARDSON CD, 1985, J VIROL, V54, P186, DOI 10.1128/JVI.54.1.186-193.1985; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SMITH JB, 1985, J BIOL CHEM, V260, P4413; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; VOLPE P, 1990, AM J PHYSIOL, V258, pC1086, DOI 10.1152/ajpcell.1990.258.6.C1086; WATRAS J, 1991, J NEUROSCI, V11, P3239; YAMAMOTO H, 1989, J NEUROCHEM, V53, P917, DOI 10.1111/j.1471-4159.1989.tb11792.x; YAMAMOTOHINO M, 1994, IN PRESS RECEPT CHAN; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613	53	148	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6735	6742						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120033				2022-12-25	WOS:A1994MZ50300076
J	SCHRADER, M; BECKERANDRE, M; CARLBERG, C				SCHRADER, M; BECKERANDRE, M; CARLBERG, C			THYROID-HORMONE RECEPTOR FUNCTIONS AS MONOMERIC LIGAND-INDUCED TRANSCRIPTION FACTOR ON OCTAMERIC HALF-SITES - CONSEQUENCES ALSO FOR DIMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; RESPONSE ELEMENTS; DNA-BINDING; NUCLEAR RECEPTORS; ACID RECEPTORS; RXR-ALPHA; HETERODIMERS; SUPERFAMILY; ORIENTATION; HOMODIMERS	The thyroid hormone (3,5,3'-triiodothyronine) receptor (T(3)R) belongs to the nuclear receptor superfamily of ligand-inducible transcription factors. T(3)Rs are known to bind as homodimers and heterodimers with retinoid X receptors (RXRs) to two hexameric half-sites in directly repeated, palindromic, and inverted palindromic orientations. The binding of T(3)R monomers to individual half-sites was often reported, but no clear ligand-induced transactivational activity has been shown. Here, we analyzed interactions of T(3)R monomers with individual half-sites of the sequence NNAGGTCA. We found that the two nucleotides 5' of the AGGTCA core half-site strongly influence T(3)R binding and transcriptional activity: octameric half sites of the consensus sequence (T/C)(A/G)AGGTCA were bound by T(3)Rs with the highest affinity. This suggests T(3)R functioning also as a monomeric transcription factor like the orphan nuclear receptors NGFI-B and FTZ-F1. Moreover, we observed that the function of T(3)R-RXR heterodimers on response elements composed of two half-sites in a directly repeated orientation spaced by 4 nucleotides is determined in major parts by the 5'-flanking sequence of the upstream half-site. Consequently, we noted that the affinity of T(3)R homodimers is influenced by both 5'-flanking sequences. Our findings suggest that the binding of dimerizing receptors like T(3)R and other nuclear receptors to their cognate response elements is determined not only by the half-site core sequence, orientation, and number of spacing nucleotides, but also by the nucleotide sequence preceding the half-sites.	HOP CANTONAL UNIV,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND; GLAXO INST MOLEC BIOL,CH-1228 PLAN LES OUATES,SWITZERLAND	University of Geneva; GlaxoSmithKline			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM J, V295, P343, DOI 10.1042/bj2950343; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MUSCAT GEO, 1993, CELL GROWTH DIFFER, V4, P269; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Yu Victor C., 1992, Current Opinion in Biotechnology, V3, P597, DOI 10.1016/0958-1669(92)90002-Z; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	41	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6444	6449						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119995				2022-12-25	WOS:A1994MZ50300031
J	TROPPMAIR, J; BRUDER, JT; MUNOZ, H; LLOYD, PA; KYRIAKIS, J; BANERJEE, P; AVRUCH, J; RAPP, UR				TROPPMAIR, J; BRUDER, JT; MUNOZ, H; LLOYD, PA; KYRIAKIS, J; BANERJEE, P; AVRUCH, J; RAPP, UR			MITOGEN-ACTIVATED PROTEIN-KINASE EXTRACELLULAR SIGNAL-REGULATED PROTEIN-KINASE ACTIVATION BY ONCOGENES, SERUM, AND 12-O-TETRADECANOYLPHORBOL-13-ACETATE REQUIRES RAF AND IS NECESSARY FOR TRANSFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; MAP KINASE; XENOPUS OOCYTES; A-RAF; V-RAF; GROWTH; PHOSPHORYLATION; RECEPTOR; TRANSDUCTION; ONCOPROTEIN	The protein kinase cascade Raf-MAPKK/MEK-MAPK/ERK connects protein tyrosine kinase receptors in the membrane with control of transcription factor activity in the nucleus. We have examined whether Raf is obligatory for activation of this cascade and whether this signaling pathway is relevant to transformation. By use of transient assays with epitope-tagged ERK-1 cDNA and a dominant inhibitory mutant of Raf-1 we found that serum and 12-O-tetradecanoylphorbol-13-acetate as well as representatives of three classes of oncogenes (protein tyrosine kinases abl/src, Ras, and protein serine/ threonine kinases mos/cot) were all Raf-dependent for stimulation of MAPK. All of the MAPK stimulating oncogenes were also activators of Raf kinase as judged by shift induction. It thus appears that there is little or no redundancy in pathways used by growth regulators for activation of MAPK/ERK. Furthermore, the ability to stimulate MAPK/ERK appears to be critical for transformation by oncogenic Raf-1 as ERK-1 and -2 synergized with v-raf in a focus induction assay on NIH3T3 cells and kinase dead mutants of ERK-2 were inhibitory. Raf/ERK synergism was also observed in transcriptional transactivation of the oncogene-response element in the polyoma enhancer. We conclude that this Raf signaling pathway, which connects to many upstream activators and downstream effecters, is essential for transformation by most oncogenes.	LAB VIRAL CARCINOGENESIS,VIRAL PATHOL SECT,FREDERICK,MD 21702; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital				Troppmair, Jakob/0000-0002-0611-3837				AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRUDER JT, 1992, GENE DEV, V6, P5454; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DORN P, 1990, J VIROL, V64, P1616, DOI 10.1128/JVI.64.4.1616-1624.1990; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, ONCOGENE, V8, P361; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEVIN DE, 1993, J NIH RES, V5, P49; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1993, IN PRESS CRITICAL RE; RAPP UR, 1988, HDB ONCOGENES, P213; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; ROBINSON DJ, 1993, J BIOL CHEM, V268, P5097; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SIEGEL JN, 1993, J IMMUNOL, V151, P4116; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	54	235	240	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					7030	7035						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120067				2022-12-25	WOS:A1994MZ50300117
J	WALKER, GJ; PALMER, JM; WALTERS, MK; NANCARROW, DJ; PARSONS, PG; HAYWARD, NK				WALKER, GJ; PALMER, JM; WALTERS, MK; NANCARROW, DJ; PARSONS, PG; HAYWARD, NK			REFINED LOCALIZATION OF THE MELANOMA (MLM) GENE ON CHROMOSOME 9P BY ANALYSIS OF ALLELIC DELETIONS	ONCOGENE			English	Article							LINKAGE MAP; POLYMORPHISMS; DNA	Various lines of evidence including linkage analysis, frequent homozygous and heterozygous deletions in melanoma DNAs, and the finding of a patient with multiple primary melanomas who harbours a 5p/9p translocation involving loss of several 9p markers, have indicated that the 9p22-p13 region harbours a gene important for the development of melanoma (MLM). We have used eight short tandem repeat polymorphism (STRP) markers mapping to this region to look for allelic losses in DNA from melanoma biopsies and cell lines. Heterozygous losses were found in 8/14 (57%) fresh melanoma biopsy DNAs with the smallest region of overlap (SRO) being between IFNA and D9S169. In addition, when DNA from 30 melanoma cell lines was studied, four cell lines (13%) were found to be homozygously deleted for various 9p markers. Two of these cell lines define the borders of overlapping homozygous deletions within a 4cM region of 9p21 between IFNA and D9S171. Moreover, a further 14 melanoma cell lines were hemizygous for the IFNA/ D9S171/D9S126 region. These data support the hypothesis that the MLM gene acts as a tumour suppressor, and provide a refinement of its localization on 9P.	QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,JOINT EXPTL ONCOL PROGRAM,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute			hayward, nick/AAV-8802-2020; hayward, nicholas k/C-1367-2015; Parsons, Peter G/H-8163-2015	hayward, nicholas k/0000-0003-4760-1033; Parsons, Peter G/0000-0002-0473-3346				CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; COWAN JN, 1988, J NATL CANCER I, V80, P201; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FOUNTAIN JW, 1993, HUM MOL GENET, V2, P823, DOI 10.1093/hmg/2.6.823-a; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; KWIATKOWSKI DJ, 1993, HUM MOL GENET, V8, P658; LIMON J, 1988, CANCER GENET CYTOGEN, V30, P201, DOI 10.1016/0165-4608(88)90186-0; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MCDANIEL DO, 1993, BIOTECHNIQUES, V15, P140; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; PEDERSEN MI, 1986, CANCER GENET CYTOGEN, V20, P11, DOI 10.1016/0165-4608(86)90103-2; PETTY EM, 1993, AM J HUM GENET, V53, P96; WEBER JL, 1991, GENOMICS, V11, P695, DOI 10.1016/0888-7543(91)90077-R; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILKIE PJ, 1992, GENOMICS, V12, P607, DOI 10.1016/0888-7543(92)90456-3	19	43	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					819	824						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108124				2022-12-25	WOS:A1994MW55100017
J	BREYER, RM; EMESON, RB; TARNG, JL; BREYER, MD; DAVIS, LS; ABROMSON, RM; FERRENBACH, SM				BREYER, RM; EMESON, RB; TARNG, JL; BREYER, MD; DAVIS, LS; ABROMSON, RM; FERRENBACH, SM			ALTERNATIVE SPLICING GENERATES MULTIPLE ISOFORMS OF A RABBIT PROSTAGLANDIN E(2) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY PROTEIN; BETA-ADRENERGIC-RECEPTOR; COLLECTING TUBULE CELLS; BOVINE ADRENAL-MEDULLA; PERTUSSIS TOXIN; MESSENGER-RNAS; GROWTH-FACTOR; ADENYLATE-CYCLASE; EXPRESSION; BINDING	Four cDNA clones homologous with a murine prostaglandin E(2) receptor have been isolated from a rabbit kidney cortex cDNA library. These cDNAs encode related proteins that differ only in their COOH-terminal sequences. Southern blot analysis of rabbit genomic DNA indicates that these receptor cDNAs represent alternatively spliced variants derived from a single gene. This was confirmed by isolation and sequence analysis of genomic clones containing common region exons and unique 3'-coding exons, which contained intron/exon boundaries at the predicted splice junctions. Transient expression of a novel full-length cDNA in COS1 cells confirmed the ligand binding profile typical of an EP3 receptor subtype. Ribonuclease protection assays indicate that the gene encoding these receptors is most highly expressed in kidney, adrenal, and stomach with lower but significant expression in uterus; lung, heart, ileum, spleen, and brain. Moreover, each of the cloned isoforms is expressed in the kidney. In situ hybridization analyses of rabbit kidney demonstrated that the level of expression is highest in the outer medulla with lesser expression in the cortex and no detectable expression in the inner medulla. The ligand binding profile and tissue distribution of these receptors is consistent with a functional role for this family of EP3 receptors in mediating the renal actions of prostaglandins as well as the effects of prostaglandins on gastric acid secretion and adrenal function.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,VET ADM MED CTR,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,NASHVILLE,TN 37232	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vanderbilt University; Vanderbilt University	BREYER, RM (corresponding author), VANDERBILT UNIV,DIV NEPHROL,NASHVILLE,TN 37232, USA.			Breyer, Matthew/0000-0003-1880-371X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, R01DK046205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-46205-01, DK-39261-05] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; ARMSTRONG RA, 1990, ADV PROSTAGLANDIN TH, V21, P375; ATWELL MM, 1988, BIOCHIM BIOPHYS ACTA, V971, P282; AUSEBEL F, 1990, CURRENT PROTOCOLS MO; BARR DB, 1988, J PHYSIOL-LONDON, V405, P39, DOI 10.1113/jphysiol.1988.sp017320; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BREYER M D, 1992, Journal of the American Society of Nephrology, V3, P452; BREYER MD, 1990, KIDNEY INT, V38, P618, DOI 10.1038/ki.1990.251; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; DUNN MJ, 1977, AM J PHYSIOL, V233, pF169, DOI 10.1152/ajprenal.1977.233.3.F169; EASON MG, 1992, J BIOL CHEM, V267, P11754; EDWARDS RH, 1986, NATURE, V319, P784, DOI 10.1038/319784a0; EDWARDS RM, 1985, AM J PHYSIOL, V248, pF779, DOI 10.1152/ajprenal.1985.248.6.F779; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARDINER PJ, 1990, ADV PROSTAG THROMB L, V20, P110; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; HAGA T, 1977, P NATL ACAD SCI USA, V74, P2016, DOI 10.1073/pnas.74.5.2016; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HEBERT RL, 1991, J CLIN INVEST, V87, P1992, DOI 10.1172/JCI115227; HEBERT RL, 1993, AM J PHYSIOL, V265, pF643, DOI 10.1152/ajprenal.1993.265.5.F643; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAWRENCE RA, 1992, BRIT J PHARMACOL, V105, P271, DOI 10.1111/j.1476-5381.1992.tb14245.x; LEFKOWITZ RJ, 1977, J BIOL CHEM, V252, P5295; LOUTTIT JB, 1992, 8TH P INT C PROST RE, P67; LOUTTIT JB, 1992, 8TH INT C PROST REL, P68; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAO A, 1989, AM J PHYSIOL, V256, pC652, DOI 10.1152/ajpcell.1989.256.3.C652; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; NEGISHI M, 1989, J BIOL CHEM, V264, P3916; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PELTON RW, 1989, DEVELOPMENT, V106, P759; RICHELSEN B, 1984, J LIPID RES, V26, P127; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; SONNENBURG WK, 1990, J BIOL CHEM, V265, P8479; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; WATANABE T, 1986, J BIOL CHEM, V261, P3430; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; [No title captured]	52	93	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6163	6169						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119961				2022-12-25	WOS:A1994MY84000102
J	HOWE, G; MERCHANT, S				HOWE, G; MERCHANT, S			ROLE OF HEME IN THE BIOSYNTHESIS OF CYTOCHROME C(6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROMES; CHLAMYDOMONAS-REINHARDTII; SACCHAROMYCES-CEREVISIAE; RHODOBACTER-SPHAEROIDES; APOCYTOCHROME-C; IMPORT; MITOCHONDRIA; LYASE; PROTEINS; COPPER	Cytochrome c(6), a nuclear-encoded protein, is synthesized in the cytoplasm in a precursor form (pre-apocytochrome c(6)). Time course radiolabeling experiments support the model that the pre-protein is the substrate for a lumen-targeting post-translational pathway which includes two proteolytic cleavage events and the covalent attachment of heme to cysteinyl thiols on the polypeptide. Cell fractionation studies indicate that the fully processed protein fractionates with other soluble proteins, whereas the precursor and intermediate forms appear to be membrane-associated. To determine whether either of the processing steps is influenced by heme attachment, the biosynthetic pathway was examined 1) in a Chlamydomonas reinhardtii mutant (B6) that is defective in the heme attachment step and 2) in wild-type cells treated with gabaculine, an inhibitor of heme synthesis. In vivo radiolabeling experiments with the B6 mutant showed that a defect in heme attachment affects neither the synthesis of the pre-apoprotein nor its processing to the mature apoform to any significant extent, supporting the notion that heme attachment and processing are not obligatorily coupled in this pathway. A similar conclusion is reached from examination of cytochrome c(6) synthesis in gabaculine-treated cells where inhibition of heme attachment did not prevent either of the two processing steps. The fully processed apoprotein is a suitable substrate for heme attachment in vivo, since the apoprotein was indeed converted to holoprotein in gabaculine-treated cells, albeit more slowly than in untreated cells. Despite the lack of effect of gabaculine treatment on the accumulation of cytochrome cg encoding messages, the amount of holocytochrome c6 precursors synthesized during a brief labeling period is 4-7-fold less than in untreated cells, suggesting that synthesis of the polypeptide may be coupled to home availability by a control mechanism operating at the translational level.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles					NIGMS NIH HHS [GM 00594] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K04GM000594] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CM, 1991, PLANT PHYSIOL, V96, P584, DOI 10.1104/pp.96.2.584; BECKMAN DL, 1992, GENE DEV, V6, P268, DOI 10.1101/gad.6.2.268; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRANDNER JP, 1991, J BACTERIOL, V173, P3958, DOI 10.1128/jb.173.13.3958-3965.1991; DAVIDSON E, 1987, BIOCHIM BIOPHYS ACTA, V890, P292, DOI 10.1016/0005-2728(87)90156-3; DUMONT MD, 1990, J BIOL CHEM, V265, P2733; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GAL A, 1990, CURRENT RES PHOTOSYN, V2, P779; GARRARD WT, 1972, J BIOL CHEM, V247, P5935; GOLDSCHMIDTCLERMONT M, 1989, PLANT PHYSIOL, V89, P15, DOI 10.1104/pp.89.1.15; GRANICK S, 1971, METABOLIC REGULATION, P74; GRAY JC, 1992, PHOTOSYNTH RES, V34, P359, DOI 10.1007/BF00029811; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAKVOORT TBM, 1990, P NATL ACAD SCI USA, V87, P4996, DOI 10.1073/pnas.87.13.4996; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HILL KL, 1991, J BIOL CHEM, V266, P15060; HILL KL, 1992, PLANT PHYSIOL, V100, P319, DOI 10.1104/pp.100.1.319; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; HOWE G, 1994, IN PRESS PHOTOSYN RE; JASPER F, 1991, J PHOTOCH PHOTOBIO B, V11, P139, DOI 10.1016/1011-1344(91)80256-H; JOHANNINGMEIER U, 1988, EUR J BIOCHEM, V177, P417, DOI 10.1111/j.1432-1033.1988.tb14391.x; JOHANNINGMEIER U, 1984, J BIOL CHEM, V259, P3541; KAHN A, 1987, CARLSBERG RES COMMUN, V52, P73, DOI 10.1007/BF02910429; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KRANZ RG, 1989, J BACTERIOL, V171, P456, DOI 10.1128/jb.171.1.456-464.1989; KUMAR CC, 1980, J BIOL CHEM, V255, P1130; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; LONDON IM, 1987, ENZYMES, V18, P360; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; OHASHI A, 1982, J BIOL CHEM, V257, P3042; PAGE MD, 1990, MOL MICROBIOL, V4, P1181, DOI 10.1111/j.1365-2958.1990.tb00693.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHILKE BA, 1992, J MOL BIOL, V226, P101, DOI 10.1016/0022-2836(92)90127-6; SCHILKE BA, 1992, J BIOL CHEM, V266, P12152; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; TANIUCHI H, 1983, J BIOL CHEM, V258, P963; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211, DOI 10.1146/annurev.pp.40.060189.001235; TOGASAKI RK, 1992, 5TH INT C CELL MOL B, P51; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x	49	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5824	5832						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119924				2022-12-25	WOS:A1994MY84000055
J	KITAMURA, M; KOJIMA, S; OGASAWARA, K; NAKAYA, T; SAGARA, T; NIKI, K; MIURA, K; AKUTSU, H; KUMAGAI, I				KITAMURA, M; KOJIMA, S; OGASAWARA, K; NAKAYA, T; SAGARA, T; NIKI, K; MIURA, K; AKUTSU, H; KUMAGAI, I			NOVEL FMN-BINDING PROTEIN FROM DESULFOVIBRIO-VULGARIS (MIYAZAKI-F) - CLONING AND EXPRESSION OF ITS GENE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; FLAVODOXIN GENE; OXIDIZED FLAVODOXIN; HILDENBOROUGH; RESOLUTION; GIGAS; RUBREDOXIN; FORM	A gene encoding a novel FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F) was cloned, and its expression system was constructed in Escherichia coli. The 1.4-kilobase pair DNA fragment isolated from D. vulgaris (Miyazaki F) by double digestion with KpnI and SmaI was found to express a protein binding FMN as a prosthetic group under control of the lac promoter in E. coli. This DNA fragment contained several putative open reading frames. The partial amino acid sequence of the polypeptide portion of the purified FMN-binding protein and its tryptic peptides were completely consistent with those deduced from the nucleotide sequence of the third open reading frame in the cloned SmaI-SmaI fragment of D. vulgaris (Miyazaki F) DNA, which may include promoter and regulatory sequences. The nucleotide sequence of FMN-binding protein indicated that the protein is composed of 122 amino acids including an initiator Met residue and lacks a signal peptide for secretion. The main redox potential of the FMN-binding protein was measured as -325 mV using direct current cyclic and differential pulse voltammetric techniques and an electroreflectance method, suggesting that this FMN-binding protein functions as a redox protein like other FMN-binding; proteins. Immunoblot analysis of the whole proteins from D. vulgaris (Miyazaki F) clearly indicated that this protein is expressed in this bacteria. However, the protein was found to have a primary structure distinct from those of other FWN-binding proteins and to be the smallest FMN-binding protein yet reported.	OSAKA CITY UNIV,FAC ENGN,DEPT BIOAPPL CHEM,SUMIYOSHI KU,OSAKA 558,JAPAN; GAKUSHUIN UNIV,INST BIOMOLEC SCI,TOSHIMA KU,TOKYO 171,JAPAN; YOKOHAMA NATL UNIV,FAC ENGN,DEPT BIOPHYS CHEM,HODOGAYA KU,YOKOHAMA 240,JAPAN; NAGASAKI UNIV,FAC ENGN,DEPT APPL CHEM,NAGASAKI 852,JAPAN	Osaka Metropolitan University; Gakushuin University; Yokohama National University; Nagasaki University	KITAMURA, M (corresponding author), UNIV TOKYO,FAC ENGN,DEPT IND CHEM,BUNKYO KU,TOKYO 113,JAPAN.			Akutsu, Hideo/0000-0001-7236-5285				BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; BURNETT RM, 1974, J BIOL CHEM, V249, P4383; CURLEY GP, 1988, FEMS MICROBIOL LETT, V49, P295; FREY M, 1987, J MOL BIOL, V197, P525, DOI 10.1016/0022-2836(87)90562-6; FUKUYAMA K, 1990, J BIOL CHEM, V265, P15804; HELMS LR, 1992, BIOCHIM BIOPHYS ACTA, V1131, P325, DOI 10.1016/0167-4781(92)90034-W; HELMS LR, 1991, BIOCHIM BIOPHYS ACTA, V1089, P417, DOI 10.1016/0167-4781(91)90190-W; HELMS LR, 1990, BIOCHEM BIOPH RES CO, V168, P809, DOI 10.1016/0006-291X(90)92393-E; HIGUCHI Y, 1984, J MOL BIOL, V172, P109, DOI 10.1016/0022-2836(84)90417-0; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; KISSINGER CR, 1989, FEBS LETT, V244, P447, DOI 10.1016/0014-5793(89)80580-0; Kitamura Masaya, 1993, Protein Sequences and Data Analysis, V5, P193; KNIGHT E, 1966, J BIOL CHEM, V241, P2752; KREY GD, 1988, J BIOL CHEM, V263, P15436; KSENZHEK OS, 1983, BIOELECTROCH BIOENER, V11, P105, DOI 10.1016/0302-4598(83)80086-5; KUMAGAI I, 1990, PROTEIN ENG, V3, P449, DOI 10.1093/protein/3.5.449; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQVIST Y, 1985, P NATL ACAD SCI USA, V82, P6855, DOI 10.1073/pnas.82.20.6855; Mayhew S.G., 1975, ENZYMES, V12, P57; MAYHEW SG, 1969, J BIOL CHEM, V244, P803; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P276, DOI 10.1016/0005-2744(71)90206-3; NAKAGAWA A, 1990, J BIOCHEM-TOKYO, V108, P701, DOI 10.1093/oxfordjournals.jbchem.a123267; POLLOCK WBR, 1991, J BACTERIOL, V173, P220, DOI 10.1128/jb.173.1.220-228.1991; Postgate JR, 1984, SULPHATE REDUCING BA, P32; PRICKRIL BC, 1991, BIOCHEMISTRY-US, V30, P11118, DOI 10.1021/bi00110a014; SAGARA T, 1991, LANGMUIR, V7, P1005, DOI 10.1021/la00053a032; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; SMITH WW, 1983, J MOL BIOL, V165, P737, DOI 10.1016/S0022-2836(83)80277-0; TAN J, 1991, BIOCHEMISTRY-US, V30, P9900, DOI 10.1021/bi00105a013; VANROOIJEN GJH, 1989, J BACTERIOL, V171, P3575, DOI 10.1128/jb.171.6.3575-3578.1989; VOORDOUW G, 1986, EUR J BIOCHEM, V159, P347, DOI 10.1111/j.1432-1033.1986.tb09874.x; VOORDOUW G, 1985, EUR J BIOCHEM, V148, P515, DOI 10.1111/j.1432-1033.1985.tb08869.x; WATT W, 1991, J MOL BIOL, V218, P195, DOI 10.1016/0022-2836(91)90884-9; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629	34	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5566	5573						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119891				2022-12-25	WOS:A1994MY84000018
J	KULMACZ, RJ; PENDLETON, RB; LANDS, WEM				KULMACZ, RJ; PENDLETON, RB; LANDS, WEM			INTERACTION BETWEEN PEROXIDASE AND CYCLOOXYGENASE ACTIVITIES IN PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE - INTERPRETATION OF REACTION-KINETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; H SYNTHASE; TYROSYL RADICALS; VESICULAR GLAND; BIOSYNTHESIS; HYDROPEROXIDES; CYANIDE; INACTIVATION; SIMILARITIES; SYNTHETASE	Prostaglandin-endoperoxide syntheses have two distinct enzymatic activities in the biosynthesis of prostanoids: a peroxidase and a fatty acid oxygenase. Hydroperoxides, such as the cyclooxygenase reaction product, prostaglandin G(2), act both as substrates for the synthase peroxidase and as obligatory initiators of the cyclooxygenase reaction itself. A mechanistic scheme was devised to describe the interactions between the two activities of the synthase. This mechanism was based on a heme-dependent peroxidase mechanism such as that observed with horseradish peroxidase and initiation of the cyclooxygenase reaction by intramolecular reaction with a peroxidase intermediate. Rate equations derived from the mechanism were numerically integrated by an interactive computer program that consolidated the diverse phenomena to provide quantitative predictions of the reaction kinetics of the synthase. The predictions agreed well with experimental observations of the purified ovine seminal vesicle enzyme under a wide variety of conditions, including inhibition by exogenous hydroperoxide scavenger and by cyanide, stimulation by exogenous hydroperoxide, and inhibition of eicosapentaenoic acid oxygenation under conditions where arachidonic acid reacts rapidly. The detailed analyses of reaction kinetics made possible with the computer simulation provide important insights into the interactions between the two catalytic activities of the synthase in the control of prostaglandin biosynthesis.	UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	KULMACZ, RJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,POB 20708,HOUSTON,TX 77225, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030509] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 34422] Funding Source: Medline; NIGMS NIH HHS [GM 30509] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; CULP BR, 1979, PROSTAG LEUKOTR ESS, V3, P269, DOI 10.1016/0161-4630(79)90068-5; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; ELING TE, 1991, J BIOL CHEM, V266, P12348; GRAFF G, 1982, METHOD ENZYMOL, V86, P376; GUNZLER WA, 1972, H-S Z PHYSIOL CHEM, V353, P1001; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HEMLER ME, 1979, ARCH BIOCHEM BIOPHYS, V193, P340, DOI 10.1016/0003-9861(79)90038-9; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HSUANYU YC, 1990, BIOCHEM CELL BIOL, V68, P965, DOI 10.1139/o90-142; HSUANYU YC, 1992, J BIOL CHEM, V267, P17649; HSUANYU YC, 1992, ARCH BIOCHEM BIOPHYS, V292, P213, DOI 10.1016/0003-9861(92)90070-D; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; KULMACZ RJ, 1990, METHOD ENZYMOL, V186, P431; KULMACZ RJ, 1983, ADV PROSTAG THROMB L, V11, P93; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LANDS W, 1971, ANN NY ACAD SCI, V180, P107, DOI 10.1111/j.1749-6632.1971.tb53190.x; LANDS WEM, 1973, ADV BIOSCI, V9, P15; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; LAWRENCE RA, 1974, EXP EYE RES, V18, P563, DOI 10.1016/0014-4835(74)90062-1; MACDONALD ID, 1989, J INORG BIOCHEM, V37, P35, DOI 10.1016/0162-0134(89)80027-3; MACDONALD ID, 1989, BIOCHEM CELL BIOL, V67, P301; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARSHALL PJ, 1985, ANAL BIOCHEM, V145, P192, DOI 10.1016/0003-2697(85)90347-1; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MARSHALL PJ, 1984, OXYGEN RADICALS CHEM, P299; MORENO SNJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P267, DOI 10.1016/0003-9861(88)90127-0; OHKI S, 1979, J BIOL CHEM, V254, P829; PENDELTON RB, 1990, THESIS U ILLINOIS UR; PENDLETON RB, 1991, EICOSANOIDS OTHER BI, P209; POTTER DW, 1987, J BIOL CHEM, V262, P974; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; TSAI AL, 1992, J BIOL CHEM, V267, P17753; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	46	114	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5527	5536						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119886				2022-12-25	WOS:A1994MY84000012
J	RAHA, A; WAGNER, C; MACDONALD, RG; BRESNICK, E				RAHA, A; WAGNER, C; MACDONALD, RG; BRESNICK, E			RAT-LIVER CYTOSOLIC 4-S POLYCYCLIC AROMATIC HYDROCARBON-BINDING PROTEIN IS GLYCINE N-METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; CYP1A1 GENE-EXPRESSION; AH-RECEPTOR; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; CYTOCHROME-P-450C GENE; NUCLEOTIDE-SEQUENCE; NUCLEAR UPTAKE; MOUSE-LIVER; CDNA CLONE; PURIFICATION	In the rat, cytochrome P-450IA1 gene expression, which is most closely associated with aryl hydrocarbon hydroxylase activity, is thought to be regulated by several trans-acting factors, including the 4 S polycyclic aromatic hydrocarbon (PAH)-binding protein. This protein has been purified to homogeneity from rat liver using ion exchange, gel permeation, hydrophobic interaction, and affinity chromatographies. Partial sequencing of the 33-kDa band indicated its identity as glycine N-methyltransferase (GNMT). Polyclonal antibodies to GNMT immunoprecipitated PAH-binding activity from rat liver cytosol. Methyltransferase and PAH-binding activities copurified during the course of protein purification. GNMT protein and PAH binding activity were co localized in various cytosolic fractions. These data all indicate that the 4 S PAH-binding protein and GNMT are one and the same protein or very similar proteins. Western blot analyses yielded a positive signal under denaturing (33 kDa) and nondenaturing (150 kDa, tetramer) conditions; the PAH-binding protein also was an oligomer, GNMT was detected by immunohistochemistry in nuclei from H4IIE rat hepatoma cells and rat liver. The localization of GNMT in liver nuclei is in accordance with a role in modulating cytochrome P-450IA1 gene expression.	DARTMOUTH COLL SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755; NORRIS COTTON CANC CTR,HANOVER,NH 03755; VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198	Dartmouth College; Norris Cotton Cancer Center; Vanderbilt University; University of Nebraska System; University of Nebraska Medical Center					NATIONAL CANCER INSTITUTE [R01CA036106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003980, T32ES007104] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36106] Funding Source: Medline; NIEHS NIH HHS [ES 03980, ES 07104] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARNOLD PS, 1987, BIOCHEM J, V242, P375, DOI 10.1042/bj2420375; BIGELOW SW, 1982, TOXICOL LETT, V10, P109, DOI 10.1016/0378-4274(82)90276-4; BLUMENSTEIN J, 1960, BIOCHEM BIOPH RES CO, V3, P259, DOI 10.1016/0006-291X(60)90235-7; BRESNICK E, 1988, CANCER METAST REV, V7, P51, DOI 10.1007/BF00048278; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; COLLINS S, 1984, MOL PHARMACOL, V26, P353; COLLINS S, 1985, BIOCHEM BIOPH RES CO, V129, P155, DOI 10.1016/0006-291X(85)91416-0; CONNEY AH, 1967, PHARMACOL REV, V19, P317; COOK RJ, 1981, ARCH BIOCHEM BIOPHYS, V208, P358, DOI 10.1016/0003-9861(81)90520-8; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOLDES RL, 1985, ARCH BIOCHEM BIOPHYS, V239, P137, DOI 10.1016/0003-9861(85)90820-3; GIBBONS JA, 1992, CHEM-BIOL INTERACT, V83, P203, DOI 10.1016/0009-2797(92)90098-6; GIBBONS JA, 1990, TOXICOLOGIST, V10, P193; GILLETTE JR, 1974, ANNU REV PHARMACOL, V14, P271, DOI 10.1146/annurev.pa.14.040174.001415; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROVES WE, 1968, ANAL BIOCHEM, V22, P195, DOI 10.1016/0003-2697(68)90307-2; GUENTHNER TM, 1977, J BIOL CHEM, V252, P8981; HAMILTON JW, 1988, BIOCHEM J, V255, P267; HEINTZ NH, 1981, CANCER RES, V41, P1794; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOLDER GM, 1981, CANCER RES, V41, P4408; HOUSER WH, 1986, ARCH BIOCHEM BIOPHYS, V251, P361, DOI 10.1016/0003-9861(86)90083-4; HOUSER WH, 1985, BIOCHEMISTRY-US, V24, P7839, DOI 10.1021/bi00347a050; HOUSER WH, 1992, MOL CARCINOGEN, V5, P232, DOI 10.1002/mc.2940050310; HOUSER WH, 1987, ARCH BIOCHEM BIOPHYS, V259, P215, DOI 10.1016/0003-9861(87)90488-7; KAMPS C, 1987, CANCER LETT, V36, P129; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KERR SJ, 1972, J BIOL CHEM, V247, P4248; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; NEBERT DW, 1988, GENES ENCODING DRUG, P45; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; OGAWA H, 1982, J BIOL CHEM, V257, P3447; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; PENNING TM, 1984, BIOCHEM J, V222, P601, DOI 10.1042/bj2220601; PENNING TM, 1991, J BIOL CHEM, V266, P8826; PISKORSKAPLISZCZYNSKA J, 1986, TOXICOL LETT, V34, P67, DOI 10.1016/0378-4274(86)90146-3; POLAND A, 1976, J BIOL CHEM, V251, P4936; RAHA A, 1990, J TOXICOL ENV HEALTH, V29, P339, DOI 10.1080/15287399009531397; RAHA A, 1991, TOXICOLOGY, V66, P175, DOI 10.1016/0300-483X(91)90217-O; RAVAL P, 1991, BIOCHEM PHARMACOL, V41, P1719, DOI 10.1016/0006-2952(91)90175-5; SMITHGALL TE, 1985, BIOCHEM PHARMACOL, V34, P831, DOI 10.1016/0006-2952(85)90763-4; SUZUKI N, 1980, ARCH BIOCHEM BIOPHYS, V199, P236, DOI 10.1016/0003-9861(80)90277-5; TIERNEY B, 1980, ARCH BIOCHEM BIOPHYS, V200, P513, DOI 10.1016/0003-9861(80)90383-5; TIERNEY B, 1983, ARCH BIOCHEM BIOPHYS, V225, P826, DOI 10.1016/0003-9861(83)90095-4; VOGEL K, 1980, J BIOL CHEM, V255, P9621; WEN LP, 1990, P NATL ACAD SCI USA, V87, P8545, DOI 10.1073/pnas.87.21.8545; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147; YEO EJ, 1994, IN PRESS P NATL ACAD; YUEN SW, 1989, BIOTECHNIQUES, V7, P74; ZYTKOVICZ TH, 1982, CANCER RES, V42, P4387	57	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5750	5756						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119914				2022-12-25	WOS:A1994MY84000044
J	YAMATO, I; KOTANI, M; OKA, Y; ANRAKU, Y				YAMATO, I; KOTANI, M; OKA, Y; ANRAKU, Y			SITE-SPECIFIC ALTERATION OF ARGININE-376, THE UNIQUE POSITIVELY CHARGED AMINO-ACID RESIDUE IN THE MID-MEMBRANE-SPANNING REGIONS OF THE PROLINE CARRIER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/PROLINE SYMPORT CARRIER; NUCLEOTIDE-SEQUENCE; LAC PERMEASE; GLUTAMATE TRANSPORTER; EXPRESSION CLONING; COTRANSPORT SYSTEM; CARBOXYL TERMINUS; ACTIVE-TRANSPORT; RAT-BRAIN; GENE	An alignment of 5 amino acids in the Escherichia coli proline carrier (G(328)-A(366)-L(371)-GR(376)) is common in the amino acid sequences of several Na+ symport carriers, and it has been proposed as the putative sodium binding motif (Deguchi, Y., Yamato, I., and Anraku, Y. (1990) J. Biol. Chem. 265, 21704-21708). To determine whether these amino acids are essential for Na+ symport activity as the Na+ binding site, one of the amino acids in this alignment, Arg-376, which is the only positively charged amino acid in the innermost part of the predicted membrane-spanning regions, was changed to either lysine, glutamine, or glutamic acid by oligonucleotide dependent site-specific mutagenesis. The transport and binding activities of the proline of the R376K mutant carrier were not detected at all. The activities of the other mutant carriers for uptake and binding of proline were as high as those of the wild-type carrier. These two mutant carriers were as sensitive to the proline analogue azetidine-2-carboxylate and to N-ethylmaleimide as the wildtype carrier, indicating that they have the same properties as the wild-type, The amounts of the carrier proteins expressed from these mutated putP genes were similar to that from the wild-type gene. These results imply that the Arg-376 in the proline carrier does not reside at the sodium binding site, suggesting that the similar alignment found in the amino acid sequences of several Na+ symport carriers is not essential for the transport or binding activities, although this similar alignment may have some relevance to the structure of the Na+ symporter. Furthermore, that the only Arg residue in the middle part of the predicted membrane-spanning regions is dispensable for the energy coupling activity indicates a unique difference of the coupling mechanism from the other secondary active transport systems, such as that of the lactose permease and the tetracycline/H+ antiporter.	UNIV TOKYO, FAC SCI, DEPT BIOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	YAMATO, I (corresponding author), SCI UNIV TOKYO, DEPT BIOL SCI & TECHNOL, 2641 YAMAZAKI, NODA, CHIBA 278, JAPAN.							CHEN CC, 1985, J MEMBRANE BIOL, V84, P157, DOI 10.1007/BF01872213; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; FRANK L, 1969, J BACTERIOL, V100, P329, DOI 10.1128/JB.100.1.329-336.1969; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HANADA K, 1985, FEBS LETT, V191, P278, DOI 10.1016/0014-5793(85)80024-7; HANADA K, 1988, J BIOL CHEM, V263, P7181; HANADA K, 1992, BIOCHIM BIOPHYS ACTA, V1105, P61, DOI 10.1016/0005-2736(92)90162-F; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HOSHINO T, 1990, MOL GEN GENET, V220, P461, DOI 10.1007/BF00391754; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KABACK HR, 1989, HARVEY LECT, V83, P77; KAMATA H, 1992, J BIOL CHEM, V267, P21650; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KOMEIJI Y, 1989, FEBS LETT, V256, P135, DOI 10.1016/0014-5793(89)81733-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEBLANC G, 1988, MOL BASIS BIOMEMBRAN, P53; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLEOD PR, 1992, MOL MICROBIOL, V6, P2673, DOI 10.1111/j.1365-2958.1992.tb01444.x; Maniatis T, 1989, MOL CLONING; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P6638, DOI 10.1021/bi00395a012; MILLER K, 1990, NUCLEIC ACIDS RES, V18, P3057, DOI 10.1093/nar/18.10.3057; MOGI T, 1986, MOL GEN GENET, V202, P35, DOI 10.1007/BF00330513; MOGI T, 1984, J BIOL CHEM, V259, P7797; MOTOJIMA K, 1979, P NATL ACAD SCI USA, V76, P6255, DOI 10.1073/pnas.76.12.6255; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; OHSAWA M, 1988, J BACTERIOL, V170, P5185, DOI 10.1128/jb.170.11.5185-5191.1988; PADAN E, 1992, ALKALI CATION TRANSP, P3; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PUTTNER IB, 1986, BIOCHEMISTRY-US, V25, P4483; SECKLER R, 1986, BIOCHEMISTRY-US, V25, P2403, DOI 10.1021/bi00357a016; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; WOOD JM, 1979, CAN J BIOCHEM CELL B, V57, P1191, DOI 10.1139/o79-155; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMATO I, 1990, J BIOL CHEM, V265, P2450; YAMATO I, 1975, J BIOCHEM, V77, P705, DOI 10.1093/oxfordjournals.jbchem.a130774; YAMATO I, 1992, FEBS LETT, V298, P1, DOI 10.1016/0014-5793(92)80008-5; YAMATO I, 1988, J BIOL CHEM, V263, P16055; YAMATO I, 1990, J MEMBRANE BIOL, V114, P143, DOI 10.1007/BF01869095; Yamato I., 1992, ALKALI CATION TRANSP, p[53, 76]; YAZYU H, 1984, J BIOL CHEM, V259, P4320	48	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5720	5724						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119910				2022-12-25	WOS:A1994MY84000039
J	SHOJI, W; YAMAMOTO, T; OBINATA, M				SHOJI, W; YAMAMOTO, T; OBINATA, M			THE HELIX-LOOP-HELIX PROTEIN ID INHIBITS DIFFERENTIATION OF MURINE ERYTHROLEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; DNA-BINDING; ERYTHROID-DIFFERENTIATION; GENE; EXPRESSION; ENHANCER; COMMITMENT; MYOD; SCL; REGULATOR	Id is considered to be a negative regulator of basic helix-loop-helix proteins, which play important roles in cell type-specific transcription and cell lineage commitment. The Id gene was first cloned in murine erythroleukemia (MEL) cells, which can be induced to differentiate toward erythrocytes with Me(2)SO, and its mRNA decreases after differentiation in various types of cells. In this report, we demonstrate that overexpression of Id interferes with MEL cell differentiation and that inhibition of differentiation is accompanied by reduction in expression of three erythroid-specific genes. While down-regulation of Id is an early event in the differentiation process of MEL cells, E-box binding activity of these cells increases only at a later stage of differentiation, and this late increase is reduced by the overexpression of Id in the early stage. Sequential changes in the activity of several basic helix-loop-helix proteins thus appeared to be involved in erythroid differentiation.	TOHOKU UNIV,INST DEV AGING & CANC,DEPT CELL BIOL,AOBA KU,SENDAI 980,JAPAN	Tohoku University			Yamamoto, Tohru/A-3801-2012	Yamamoto, Tohru/0000-0002-1652-0233				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P40; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRIDGES K, 1981, J CELL BIOL, V90, P542, DOI 10.1083/jcb.90.2.542; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOREN MV, 1991, DEVELOPMENT, V113, P245; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FALETTO DL, 1985, CELL, V43, P315, DOI 10.1016/0092-8674(85)90037-6; FALETTO DL, 1985, J BIOL CHEM, V260, P4884; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GREEN AR, 1991, ONCOGENE, V6, P475; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KARRIN M, 1984, CELL, V36, P371; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANNIGAN DA, 1985, J BIOL CHEM, V260, P7322; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MAGER D, 1978, J CELL PHYSIOL, V94, P275, DOI 10.1002/jcp.1040940305; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OMORI Y, 1993, ONCOGENE, V8, P379; ONCLERCQ R, 1989, ONCOGENE RES, V4, P293; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; Sambrook J, 1989, MOL CLONING LABORATO; SHOJI W, 1993, JPN J CANCER RES, V84, P885, DOI 10.1111/j.1349-7006.1993.tb02062.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VISVADER J, 1991, ONCOGENE, V6, P187; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	43	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5078	5084						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106486				2022-12-25	WOS:A1994MX57100061
J	WOOD, DR; POULLET, P; WILSON, BA; KHALIL, M; TANAKA, K; CANNON, JF; TAMANOI, F				WOOD, DR; POULLET, P; WILSON, BA; KHALIL, M; TANAKA, K; CANNON, JF; TAMANOI, F			BIOCHEMICAL-CHARACTERIZATION OF YEAST RAS2 MUTANTS REVEALS A NEW REGION OF RAS PROTEIN INVOLVED IN THE INTERACTION WITH GTPASE-ACTIVATING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GUANINE-NUCLEOTIDE; GENE-PRODUCT; CATALYTIC DOMAIN; BINDING DOMAIN; GAP; P21; REQUIREMENT; SENSITIVITY; MUTATION	We report biochemical characterization of two recently identified mutants of yeast RAS2, RAS2-E99K and RAS2-E130K. These mutants exhibit dominant activating phenotypes in yeast. Characterization of their intrinsic GTPase and GDP dissociation as well as their ability to stimulate adenylate cyclase showed that these activities of RAS2-E99K mutant protein were similar to those of the wild type protein. RAS2-E130K protein, on the other hand, differed from the wild type protein with a fast GDP dissociation rate and 2-fold higher activation of adenylate cyclase. When the sensitivity to GTPase-activating protein (GAP) was examined, we found that the RAS2-E99K protein was approximately 1200-fold less sensitive to NF1-GAP activity. In addition, the affinity for NF1 as revealed by competition binding experiments was reduced more than 150-fold with RAS2-E99K protein. Thus, the RAS2-E99K mutation affects interaction with GAP proteins. This mutation is particularly interesting because it is the first mutation identified in the alpha 3 region of ras protein that affects GAP interaction. The alpha 3 region appears to be directly involved in interaction with NF1, since peptides containing the sequence encompassing residue 99 of RAS2 inhibit NF1-GAP activity. These results suggest that the interaction between ras and GAP involves a larger region within ras than previously recognized.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV MISSOURI, DEPT MOLEC MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA; KOBE UNIV, DEPT BIOCHEM, KOBE, HYOGO 650, JAPAN	University of California System; University of California Los Angeles; University of Missouri System; University of Missouri Columbia; Kobe University	WOOD, DR (corresponding author), UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA.			Cannon, John/0000-0001-6698-176X	NINDS NIH HHS [NS30054] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030054] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CRECHET JB, 1986, EUR J BIOCHEM, V161, P647, DOI 10.1111/j.1432-1033.1986.tb10489.x; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; HU JS, 1993, BIOCHEMISTRY-US, V32, P6763, DOI 10.1021/bi00077a031; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MARSHALL MS, 1993, ONCOGENE, V8, P425; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TAMANOI F, 1984, P NATL ACAD SCI-BIOL, V81, P6924, DOI 10.1073/pnas.81.22.6924; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1992, MOL CELL BIOL, V12, P631, DOI 10.1128/MCB.12.2.631; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILSON BA, 1993, ONCOGENE, V8, P3441; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934	32	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5322	5327						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106517				2022-12-25	WOS:A1994MX57100094
J	HUBBARD, SC; WALLS, L; RULEY, HE; MUCHMORE, EA				HUBBARD, SC; WALLS, L; RULEY, HE; MUCHMORE, EA			GENERATION OF CHINESE-HAMSTER OVARY CELL GLYCOSYLATION MUTANTS BY RETROVIRAL INSERTIONAL MUTAGENESIS - INTEGRATION INTO A DISCRETE LOCUS GENERATES MUTANTS EXPRESSING HIGH-LEVELS OF N-GLYCOLYLNEURAMINIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; GOLGI VESICLE MEMBRANES; MOUSE-LIVER CYTOSOL; ACETYLNEURAMINIC ACID; ANIMAL-CELLS; SIALIC-ACID; PROMOTER TRAP; GLOBIN GENES; HUMAN-COLON; HYDROXYLATION	Retroviral insertional mutagenesis can both generate somatic cell mutants and pinpoint the genomic locus associated with a mutant phenotype. In the present study, this approach was applied to Chinese hamster ovary cells (CHO) made susceptible to Moloney murine leukemia virus (MoMuLV) infection by stable expression of an ecotropic retrovirus receptor. These CHO cells were infected with a replication incompetent MoMuLV construct with a promoterless hygromycin phosphotransferase (hygro) gene inserted into the U3 region of the long terminal repeat and a second selectable marker, neomycin phosphotransferase (neo), expressed from an internal promoter. CHO clones containing integrated proviruses were selected with hygromycin or G418, and the subset of these with reduced cell surface Neu5Ac were then selected with wheat germ agglutinin (WGA). The majority of the resulting clones had a phenotype not previously described for WGA-resistant CHO mutants arising spontaneously or from chemical mutagenesis: Neu5Ac was almost completely replaced by Neu5Gc. We have provisionally termed these clones SAP mutants, for sialic acid phenotype. Southern analysis of HindIII digested DNA from four SAP mutants revealed that the MoMuLV provirus is present in a 10.4-kilobase (kb) fragment. Probing with a flanking CHO sequence resulted in equivalent hybridization to a 4.6-kb fragment and the 10.4-kb provirus-containing fragment in all four cases, while uninfected parental cells and non-SAP glycosylation mutants generated in the same retrovirus insertional mutagenesis experiments yielded only the 4.6-kb fragment. Sequencing of the 3'-flanking DNA revealed that each of the four SAP mutants had a unique provirus integration site falling within a 796 bp region of the CHO genome. The frequency with which SAP mutants arise suggests that this may be a preferred site for retrovirus integration.	VET ADM MED CTR, DEPT MED, DIV HEMATOL ONCOL, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA; UCSD, CTR CANC, SAN DIEGO, CA 92161 USA; MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; Massachusetts Institute of Technology (MIT)					NCI NIH HHS [R01-CA40602] Funding Source: Medline; NHGRI NIH HHS [R01 HG00684] Funding Source: Medline; NIGMS NIH HHS [R29-GM43165] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040602] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043165] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; CHANG W, 1993, VIROLOGY, V193, P737, DOI 10.1006/viro.1993.1182; CHEN J, IN PRESS METHODS MOL, V4; DENNIS JW, 1986, CANCER RES, V46, P4594; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DIAZ S, 1985, ANAL BIOCHEM, V150, P32, DOI 10.1016/0003-2697(85)90438-5; FUJII Y, 1982, MOL IMMUNOL, V19, P87, DOI 10.1016/0161-5890(82)90250-4; GAHM SJ, 1991, P NATL ACAD SCI USA, V88, P10267, DOI 10.1073/pnas.88.22.10267; GOFF SP, 1987, METHOD ENZYMOL, V152, P469; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P251; HUBBARD SC, 1988, J BIOL CHEM, V263, P19303; HUBBARD SC, 1987, J BIOL CHEM, V262, P16403; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; KILPATRICK MW, 1984, J BIOL CHEM, V259, P7268; KOZUTSUMI Y, 1991, J BIOCHEM, V110, P429, DOI 10.1093/oxfordjournals.jbchem.a123598; KOZUTSUMI Y, 1990, J BIOCHEM, V108, P704, DOI 10.1093/oxfordjournals.jbchem.a123268; MAGETDANA R, 1981, EUR J BIOCHEM, V114, P11; MERRICK JM, 1978, INT ARCH ALLER A IMM, V57, P477, DOI 10.1159/000232140; MUCHMORE EA, 1987, FASEB J, V1, P229, DOI 10.1096/fasebj.1.3.3623000; MUCHMORE EA, 1989, J BIOL CHEM, V264, P20216; MUCHMORE EA, 1992, GLYCOBIOLOGY, V2, P337, DOI 10.1093/glycob/2.4.337; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OLEE TW, 1992, J EXP MED, V175, P831, DOI 10.1084/jem.175.3.831; Sambrook J, 1989, MOL CLONING LABORATO; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHAUER R, 1982, CELL BIOL MONOGR, V10, P374; SHAW L, 1991, GLYCOCONJUGATE J, V8, P434, DOI 10.1007/BF00731295; SHAW L, 1988, BIOL CHEM H-S, V369, P477, DOI 10.1515/bchm3.1988.369.1.477; SHEN SH, 1981, CELL, V26, P191, DOI 10.1016/0092-8674(81)90302-0; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SIMINOVITCH L, 1985, MOL CELL GENETICS, P869; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; STANLEY P, 1985, MOL CELL BIOL, V5, P1204, DOI 10.1128/MCB.5.6.1204; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STANLEY P, 1975, SOMAT CELL GENET, V1, P3, DOI 10.1007/BF01538729; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; STANLEY P, 1985, MOL CELL BIOL, V5, P923, DOI 10.1128/MCB.5.5.923; STANLEY P, 1985, MOL CELL GENETICS CH, P745; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARMUS HE, 1981, CELL, V25, P23, DOI 10.1016/0092-8674(81)90228-2; VONMELCHNER H, 1989, J VIROL, V63, P3227, DOI 10.1128/JVI.63.8.3227-3233.1989; VONMELCHNER H, 1990, P NATL ACAD SCI USA, V87, P3733, DOI 10.1073/pnas.87.10.3733; WEICKERT MJ, 1989, USB EDITORIAL COMMEN, V16, P5	51	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3717	3724						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106417				2022-12-25	WOS:A1994MV63100086
J	TEAL, SB; HSU, VW; PETERS, PJ; KLAUSNER, RD; DONALDSON, JG				TEAL, SB; HSU, VW; PETERS, PJ; KLAUSNER, RD; DONALDSON, JG			AN ACTIVATING MUTATION IN ARF1 STABILIZES COATOMER BINDING TO GOLGI MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADP-RIBOSYLATION FACTOR; SENSITIVE G-PROTEIN; BREFELDIN-A; GUANINE-NUCLEOTIDE; COATED VESICLES; BETA-COP; GTP; EXPRESSION; CISTERNAE; TRANSPORT	The Ras-related protein ADP-ribosylation factor 1 (ARF1) is a low molecular weight GTP binding protein, which in its GTP state supports the binding of coatomer, a cytosolic coat protein complex, to Golgi membranes. To create an ''active'' ARF, we constructed a point mutation in ARF1, Q71I, which was predicted to slow the rate of GTP hydrolysis. We demonstrate that Q71I, in contrast to wild type ARF1, exhibits a 2-3-fold increase in the half-life of ARF-GTP and is able to promote stable coatomer binding to Golgi membranes in the presence of GTP in vitro. Additionally, Q71I is able to support the binding of a significant amount of coatomer to membranes in the absence of added nucleotides, effectively bypassing the brefeldin A (BFA)-sensitive exchange activity. Furthermore, transfection of cells with Q71I, but not ARF1, renders the Golgi association of coatomer resistant to the effects of BFA in vivo. These observations provide compelling evidence that ARF1 is a necessary GTP binding protein that regulates the reversible binding of coat proteins to Golgi membranes and that the effects of BFA on this process in living cells must be a consequence of BFA's inhibition of guanine nucleotide exchange onto ARF1.	NICHHD,CELL BIOL & METAB BRANCH,BLDG 18T-101,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Teal, Stephanie/A-3097-2019	Teal, Stephanie/0000-0002-0167-1071				BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; ORCI L, 1991, CELL, V64, P1183; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PATEL G, 1992, ONCOGENE, V7, P283; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; SERAFINI T, 1992, METHOD ENZYMOL, V219, P286; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WEISS O, 1989, J BIOL CHEM, V264, P21066	24	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3135	3138						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106346				2022-12-25	WOS:A1994MV63100004
J	COFFEY, ET; SIHRA, TS; NICHOLLS, DG				COFFEY, ET; SIHRA, TS; NICHOLLS, DG			PROTEIN-KINASE-C AND THE REGULATION OF GLUTAMATE EXOCYTOSIS FROM CEREBROCORTICAL SYNAPTOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED NERVE-TERMINALS; RAT CORTICAL SYNAPTOSOMES; ADRENAL CHROMAFFIN CELLS; GAMMA-AMINOBUTYRIC-ACID; SUBSTRATE B-50 GAP-43; CYTOSOLIC FREE CA-2+; PHORBOL ESTER; NEUROTRANSMITTER RELEASE; NORADRENALINE RELEASE; RECEPTOR STIMULATION	The role of protein kinase C (PKC) in the regulation of transmitter glutamate release from rat cerebral cortical synaptosomes is investigated. Two depolarization protocols are used: first, elevated KCl, which produces a clamped depolarization, and second, 4-aminopyridine, which evokes spontaneous ''action potentials'' allowing any potential modulation of Na+ or K+ channels to influence release. Although the PKC inhibitor Ro 31-8220 prevents both the depolarization-evoked and phorbol dibutyrate (PDBu)-evoked phosphorylation of the major presynaptic PKC substrate, myristoylated alanine-rich C kinase substrate, it is without effect on KCl-evoked Ca2+-dependent glutamate release. Ro 31-8220 totally inhibits the Ca2+-dependent 4-aminopyridine-evoked release of glutamate in the presence and absence of PDBu and again decreases the phosphorylation of myristoylated alanine-rich C kinase substrate. Ro 31-8220 strongly inhibits the 4-aminopyridine-evoked increase in [Ca2+] both in the presence and absence of PDBu and antagonizes the PDBu enhancement of depolarization. This indicates that PKC isoforms activatable by PDBu and sensitive to Ro 31-8220 play no discernable role in Ca2+-secretion coupling per se in cerebral cortical glutamatergic nerve terminals, but that the kinase plays a major role in regulating the depolarization of the terminal.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Sihra, Talvinder S/A-4581-2009; NICHOLLS, DAVID G/K-4300-2012	Coffey, Eleanor/0000-0002-9717-5610				ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; ALLGAIER C, 1991, J PHARMACOL EXP THER, V258, P143; AUGUSTINE GJ, 1990, J PHYSIOL-LONDON, V431, P343, DOI 10.1113/jphysiol.1990.sp018333; BARRIE AP, 1991, J NEUROCHEM, V57, P1398, DOI 10.1111/j.1471-4159.1991.tb08306.x; BARRIE AP, 1993, J NEUROCHEM, V60, P1081; BARTMANN P, 1989, N-S ARCH PHARMACOL, V339, P302; BERNSTEIN BW, 1989, NEURON, V3, P257, DOI 10.1016/0896-6273(89)90039-1; BITTNER MA, 1990, J NEUROCHEM, V54, P205, DOI 10.1111/j.1471-4159.1990.tb13302.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; BURGOYNE RD, 1989, CELL SIGNAL, V1, P323, DOI 10.1016/0898-6568(89)90051-X; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; COGGINS PJ, 1990, J NEUROCHEM, V54, P274, DOI 10.1111/j.1471-4159.1990.tb13311.x; COHEN LB, 1974, J MEMBRANE BIOL, V19, P1, DOI 10.1007/BF01869968; DEGRAAN PNE, 1990, J NEUROCHEM, V55, P2139; DEKKER LV, 1990, J NEUROCHEM, V54, P1645, DOI 10.1111/j.1471-4159.1990.tb01217.x; DEKKER LV, 1991, J NEUROCHEM, V56, P1146, DOI 10.1111/j.1471-4159.1991.tb11404.x; DIVIRGILIO F, 1986, J BIOL CHEM, V261, P32; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; FAZELI MS, 1992, TRENDS NEUROSCI, V15, P115, DOI 10.1016/0166-2236(92)90350-H; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; HERRERO I, 1992, J NEUROCHEM, V59, P1574, DOI 10.1111/j.1471-4159.1992.tb08478.x; HUANG HY, 1989, EUR J PHARMACOL, V169, P115; HUANG HY, 1988, EUR J PHARMACOL, V153, P175; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KAUPPINEN RA, 1988, NEUROSCIENCE, V27, P175, DOI 10.1016/0306-4522(88)90228-X; KNIGHT DE, 1983, FEBS LETT, V160, P98, DOI 10.1016/0014-5793(83)80944-2; LINDEN DJ, 1992, J NEUROSCI, V12, P3601; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; MURPHY CT, 1992, BIOCHEM J, V283, P159, DOI 10.1042/bj2830159; NEUMANN R, 1991, SCIENCE, V254, P115; NICHOLLS DG, 1992, NATURE, V360, P106, DOI 10.1038/360106a0; NICHOLS RA, 1987, J NEUROCHEM, V48, P615, DOI 10.1111/j.1471-4159.1987.tb04137.x; POCOCK JM, 1992, EUR J PHARM-MOLEC PH, V226, P343, DOI 10.1016/0922-4106(92)90052-W; RAMDINE R, 1989, SYNAPSE, V3, P173, DOI 10.1002/syn.890030302; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; SCHROEDER JE, 1990, J NEUROSCI, V10, P947; SHEARMAN MS, 1991, J NEUROCHEM, V56, P1255, DOI 10.1111/j.1471-4159.1991.tb11419.x; TANAKA C, 1986, FEBS LETT, V195, P129, DOI 10.1016/0014-5793(86)80146-6; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; TIBBS GR, 1989, J NEUROCHEM, V52, P201, DOI 10.1111/j.1471-4159.1989.tb10917.x; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; VERSTEEG DHG, 1987, BRAIN RES, V416, P343, DOI 10.1016/0006-8993(87)90916-4; VITALE ML, 1992, NEUROSCIENCE, V51, P463, DOI 10.1016/0306-4522(92)90330-5; WANG JKT, 1988, J NEUROSCI, V8, P281; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; ZURGIL N, 1986, NEUROSCIENCE, V19, P1255, DOI 10.1016/0306-4522(86)90140-5	51	101	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21060	21065						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8104937				2022-12-25	WOS:A1993MA28800065
J	MACBEATH, JRE; SHACKLETON, DR; HULMES, DJS				MACBEATH, JRE; SHACKLETON, DR; HULMES, DJS			TYROSINE-RICH ACIDIC MATRIX PROTEIN (TRAMP) ACCELERATES COLLAGEN FIBRIL FORMATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-ASSEMBLY INVITRO; LYSYL OXIDASE; I COLLAGEN; ARTICULAR-CARTILAGE; LIGHT-SCATTERING; FIBER FORMATION; FIBRILLOGENESIS; PROTEOGLYCANS; SKIN; FIBRONECTIN	Tyrosine-rich acidic matrix protein (TRAMP) is a recently discovered protein that co-purifies with porcine skin lysyl oxidase and is equivalent to the M(r) 22,000 extracellular matrix protein from bovine skin that co-purifies with dermatan sulfate proteoglycans (Cronshaw, A. D., MacBeath, J. R. E., Shackleton, D. R., Collins, J. F., Fothergill-Gilmore, L. A., and Hulmes, D. J. S. (1993) Matrix 13, 255-266; Neame, P. J., Choi, H. U., and Rosenberg, L. C. (1989) J. Biol. Chem. 264, 5474-5479). The effect of TRAMP on collagen fibril formation was studied in vitro by reconstitution of fibrils from lathyritic rat skin collagen I. Fibril formation was initiated by the warm start procedure, in which acidic collagen solutions and double strength neutral buffer, both preincubated separately at 34-degrees-C, were mixed. When monitored by turbidimetry, TRAMP was found to accelerate collagen fibril formation. Acceleration occurred at sub-stoichiometric molar ratios of TRAMP to collagen, and the presence of TRAMP stabilized the fibrils against low temperature dissociation. It was confirmed by centrifugation that the amount of fibrillar collagen formed in the presence of TRAMP was greater than in its absence. By SDS-polyacrylamide gel electrophoresis and scanning densitometry, binding of TRAMP to collagen was detected that approached saturation with a molar ratio of TRAMP to collagen of approximately 1:2. Fibrils formed in the presence of TRAMP were normal when observed by electron microscopy, although fibril diameters were smaller than the controls. TRAMP was found to partially reverse the inhibitory effects of urea and increased ionic strength on the kinetics of fibril formation, although inhibition by glucose was unaffected. TRAMP also accelerated the assembly of pepsin-treated collagen, where the non-helical, telopeptide regions were partially removed. Acceleration of collagen fibril formation by TRAMP is discussed in the light of the known effects of other extracellular matrix components on this process.	UNIV EDINBURGH,DEPT BIOCHEM,HUGH ROBSON BLDG,GEORGE SQ,EDINBURGH EH8 9XD,SCOTLAND	University of Edinburgh				Hulmes, David/0000-0002-0651-1317	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADELMANN B, 1966, BIOCHEM Z, V346, P282; AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; ANDERSON JC, 1977, BIOCHEM J, V168, P345; ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BERNENGO JC, 1983, J BIOL CHEM, V258, P1001; BIRK DE, 1981, BIOCHIM BIOPHYS ACTA, V670, P362, DOI 10.1016/0005-2795(81)90108-2; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; BRENNAN M, 1980, BIOPOLYMERS, V19, P1861, DOI 10.1002/bip.1980.360191013; BROKAW JL, 1985, INT J BIOL MACROMOL, V7, P135, DOI 10.1016/0141-8130(85)90015-7; CARR ME, 1978, MACROMOLECULES, V11, P46, DOI 10.1021/ma60061a009; CHANDRAKASAN G, 1976, J BIOL CHEM, V251, P6062; Chapman JA, 1984, ULTRASTRUCTURE CONNE; CHOI HU, 1989, J BIOL CHEM, V264, P2876; COCKINGJOHNSON D, 1983, BIOCHIM BIOPHYS ACTA, V742, P49, DOI 10.1016/0167-4838(83)90357-6; COMPER WD, 1977, BIOPOLYMERS, V16, P2133, DOI 10.1002/bip.1977.360161005; CRONLUND AL, 1985, CONNECT TISSUE RES, V14, P109, DOI 10.3109/03008208509015017; CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; DOMBI GW, 1985, BIOCHEM J, V228, P551, DOI 10.1042/bj2280551; DRAKE MP, 1966, BIOCHEMISTRY-US, V5, P301, DOI 10.1021/bi00865a039; FESSLER JH, 1975, J SUPRAMOL STR CELL, V3, P17, DOI 10.1002/jss.400030103; GARG AK, 1989, BIOMATERIALS, V10, P413, DOI 10.1016/0142-9612(89)90133-6; GAVRIEL P, 1988, BIOCHEMISTRY-US, V27, P2811, DOI 10.1021/bi00408a022; GELMAN RA, 1979, J BIOL CHEM, V254, P1741; HAY ED, 1991, CELL BIOL EXTRACELLU, P1; HAYASHI T, 1972, J BIOCHEM-TOKYO, V72, P749, DOI 10.1093/oxfordjournals.jbchem.a129953; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HOLMES DF, 1986, INT J BIOL MACROMOL, V8, P161, DOI 10.1016/0141-8130(86)90020-6; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; KADLER KE, 1986, ANN NY ACAD SCI, V460, P456; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KARVONEN RL, 1992, CONNECT TISSUE RES, V27, P235, DOI 10.3109/03008209209006999; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEINMAN HK, 1981, BIOCHEMISTRY-US, V20, P2325, DOI 10.1021/bi00511a039; KUIJER R, 1988, CONNECT TISSUE RES, V17, P83, DOI 10.3109/03008208809015022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWANDOWSKA K, 1991, J CELL SCI, V99, P657; LIEN YH, 1984, SCIENCE, V225, P1489, DOI 10.1126/science.6147899; MATHEWS MB, 1968, BIOCHEM J, V109, P517, DOI 10.1042/bj1090517; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MILLER EJ, 1971, BIOCHEMISTRY-US, V10, P1652, DOI 10.1021/bi00785a024; NEAME PJ, 1989, J BIOL CHEM, V264, P5474; OBRINK B, 1973, EUR J BIOCHEM, V34, P129, DOI 10.1111/j.1432-1033.1973.tb02739.x; OEGEMA TR, 1975, ARCH BIOCHEM BIOPHYS, V170, P698, DOI 10.1016/0003-9861(75)90167-8; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; OLDBERG A, 1990, BIOCHEM SOC T, V18, P789, DOI 10.1042/bst0180789; PAYNE KJ, 1986, BIOPOLYMERS, V25, P1185, DOI 10.1002/bip.360250703; RATHI AN, 1989, BIOCHEM MED METAB B, V42, P209, DOI 10.1016/0885-4505(89)90057-1; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SCOTT JE, 1991, INT J BIOL MACROMOL, V13, P157, DOI 10.1016/0141-8130(91)90041-R; SHACKLETON DR, 1990, ANAL BIOCHEM, V185, P359, DOI 10.1016/0003-2697(90)90308-V; SHACKLETON DR, 1990, BIOCHEM J, V266, P917; SIEGEL RC, 1974, P NATL ACAD SCI USA, V71, P4826, DOI 10.1073/pnas.71.12.4826; SILVER FH, 1979, BIOPOLYMERS, V18, P2523, DOI 10.1002/bip.1979.360181011; SNOWDEN JM, 1979, BIOCHIM BIOPHYS ACTA, V580, P372, DOI 10.1016/0005-2795(79)90149-1; SNOWDEN JM, 1980, BIOPOLYMERS, V19, P767, DOI 10.1002/bip.1980.360190405; SPERANZA ML, 1987, COLLAGEN REL RES, V7, P115; TANG SS, 1983, J BIOL CHEM, V258, P4331; TOOLE BP, 1968, ARCH BIOCHEM BIOPHYS, V128, P567, DOI 10.1016/0003-9861(68)90064-7; TOOLE BP, 1969, NATURE, V222, P872, DOI 10.1038/222872a0; TOOLE BP, 1968, BIOCHEM J, V109, P857, DOI 10.1042/bj1090857; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Veis A, 1988, COLLAGEN, V1, P113; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WARD NP, 1986, J MOL BIOL, V190, P107, DOI 10.1016/0022-2836(86)90079-3; WILLIAMS BR, 1978, J BIOL CHEM, V253, P6578; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; WOOD GC, 1960, BIOCHEM J, V75, P605, DOI 10.1042/bj0750605	67	57	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19826	19832						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103522				2022-12-25	WOS:A1993LW81900100
J	OMKUMAR, RV; DARNAY, BG; RODWELL, VW				OMKUMAR, RV; DARNAY, BG; RODWELL, VW			MODULATION OF SYRIAN-HAMSTER 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE-ACTIVITY BY PHOSPHORYLATION - ROLE OF SERINE-871	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COENZYME-A REDUCTASE; HMG-COA REDUCTASE; RAT-LIVER; ISOCITRATE DEHYDROGENASE; ENZYMIC ACTIVITY; SITE; INACTIVATION; INVITRO; DEPHOSPHORYLATION	Attenuation of Syrian hamster 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMG-CoA reductase, EC 1.1.1.34) activity by in vitro phosphorylation was studied using AMP-activated protein kinase and wild type and mutant forms of HMG-CoA reductase. The only residue of the wild-type enzyme phosphorylated was Sers?l. Substrates protected against kinase mediated attenuation of activity, consistent with substrate-induced conformational changes at the C-terminal region. Although close to the catalytic histidine His(865), Ser(871) appears to play no direct role in catalysis or substrate recognition. Mu tent enzymes S871A, S871H, S871N, and S871Q exhibited from 62-106% of wild-type activity and had wild-type K-M values for HMG-CoA and NADPH. Replacement of Ser(871) by aspartate or glutamate, but not by glutamine, asparagine, histidine, or tyrosine, severely attenuated activity, Attenuation of catalytic activity that accompanies phosphorylation thus appears to result primarily from the introduction of negative charge, not merely steric hindrance. Other than the wild-type enzyme, only mutant enzyme S871T was phosphorylated, and phosphorylation was accompanied by attenuation of activity. The AMP-activated kinase thus can also phosphorylate threonyl residues.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NHLBI NIH HHS [HL 47113] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BARFORD D, 1991, BIOCHIM BIOPHYS ACTA, V1133, P55, DOI 10.1016/0167-4889(91)90241-O; BEG ZH, 1987, J BIOL CHEM, V262, P13228; BEG ZH, 1985, J BIOL CHEM, V260, P1682; BEG ZH, 1980, J BIOL CHEM, V255, P8541; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CLARKE PR, 1990, FEBS LETT, V269, P213, DOI 10.1016/0014-5793(90)81157-J; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; DARNAY BG, 1993, J BIOL CHEM, V268, P8429; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DEAN AM, 1989, J BIOL CHEM, V264, P20482; FRIMPONG K, 1993, PROTEIN EXPRES PURIF, V4, P337, DOI 10.1006/prep.1993.1044; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; HUNTER CF, 1980, J LIPID RES, V21, P399; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17913; KEITH ML, 1983, J PROTEIN CHEM, V2, P209, DOI 10.1007/BF01025355; KEITH ML, 1979, BIOCHEM BIOPH RES CO, V90, P969, DOI 10.1016/0006-291X(79)91922-3; KENNELLY PJ, 1983, BIOCHEMISTRY-US, V22, P2784, DOI 10.1021/bi00281a002; KENNELLY PJ, 1985, J LIPID RES, V26, P903; LAWRENCE CM, 1994, UNPUB SCIENCE; MACKINTOSH RW, 1992, EUR J BIOCHEM, V209, P923, DOI 10.1111/j.1432-1033.1992.tb17364.x; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; Omkumari R. V, 1991, BIOCHIM BIOPHYS ACTA, V1078, P219; PARKER RA, 1989, J BIOL CHEM, V264, P4877; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROITELMAN J, 1989, J LIPID RES, V30, P97; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; WANG YL, 1990, J BIOL CHEM, V265, P21634; 1991, PROTOCOLS APPLICATIO, P109; 1983, OLIGONUCLEOTIDE DIRE, P1	41	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6810	6814						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120043				2022-12-25	WOS:A1994MZ50300087
J	CHANG, CC; ZHANG, JD; LOMBARDI, L; NERI, A; DALLAFAVERA, R				CHANG, CC; ZHANG, JD; LOMBARDI, L; NERI, A; DALLAFAVERA, R			MECHANISM OF EXPRESSION AND ROLE IN TRANSCRIPTIONAL CONTROL OF THE PROTOONCOGENE NFKB-2/LYT-10	ONCOGENE			English	Article							NF-KAPPA-B; CELL-CYCLE CONTROL; DNA-BINDING; P65 SUBUNIT; GENE-PRODUCT; REL; HOMOLOGY; CLONING; P50; ACTIVATION	The NFKB-2 gene (previously LYT-10, NF-kappa Bp100 or NF-kappa Bp97) codes for a NF-kappa B/rel related protein which is highly homologous to NFKB-1 (previously NF-kappa Bp105) within its rel, poly-glycine and ankyrin domains. The NFKB-2 gene is a candidate proto-oncogene since it is involved in lymphoma-associated chromosomal aberrations. In order to gain insight into the physiological function and role in tumorigenesis of NFKB-2, we have analysed its mechanism of expression and role in transcriptional regulation. We report that, contrary to previous studies, a single 3.2 kb mRNA species and its 100 kD (p100) primary translation product is detectable in all cell types tested. A second NFKB-2 protein, p52, corresponding to the amino-terminal half (rel domain) of NFKB-2 p100, is detectable in the same cell types and derives from the post-translational processing of p100. While p100 is constitutively localized in the cytoplasm, NF-kappa B induction by TPA treatment of Hela cells is associated with cytoplasmic/nuclear translocation of NFKB-2 p52 and its appearance within DNA-binding NF-kappa B complexes. NFKB-2 p52 differs from NFKB-1p50 in its differential affinity for kappa B sequences: by itself it binds H2/HLA-kappa B sites more efficiently than HIV/ IgK-kappa B sites, while it can bind both sites efficiently,when complexed with Rel-A(p65). Transient co-transfection of expression and reporter plasmids in cells devoid of endogenous NF-kappa B activity showed that p52 has no intrinsic transcriptional activation capabilities: it can stimulate Rel-A(p65)-driven transcription by formation of p65/p52 heterodimers, whereas, overexpressed, it down-regulates p65-dependent transcription by formation of inactive p52/p52 homodimers. These results indicate that the NFKB-2 gene codes for an inducible NF-kappa B transcription factor with the capability of differentially regulating NF-kappa B transcription depending on its abundance in,the nucleus.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; UNIV MILAN,OSPED MAGGIORE,IRCCS,IST SCI MED,SERV EMATOL,MILAN,ITALY	Columbia University; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan			Neri, Antonino/I-9690-2014	Neri, Antonino/0000-0001-9047-5912	NCI NIH HHS [CA 44029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUERLE PA, 1988, SCIENCE, V242, P540; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V344, P36; BROWNELL E, 1989, ONCOGENE, V4, P935; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GRILLI M, 1992, INT REV CYTOL, V48, P1; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MERCURIO F, 1993, GENE DEV, V7, P75; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAKSELA K, UNPUB; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	41	51	52	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					923	933						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108136				2022-12-25	WOS:A1994MW55100029
J	JAYADEV, S; LINARDIC, CM; HANNUN, Y				JAYADEV, S; LINARDIC, CM; HANNUN, Y			IDENTIFICATION OF ARACHIDONIC-ACID AS A MEDIATOR OF SPHINGOMYELIN HYDROLYSIS IN RESPONSE TO TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIFFERENTIATION; FATTY-ACIDS; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; PROTEIN; CERAMIDE; RELEASE; PHOSPHATIDYLCHOLINE; STIMULATION; SPHINGOSINE	A sphingomyelin (SM)-signaling cycle has been described in human leukemia-derived HL-60 cells (Okazaki, T., Bell, R. M., and Hannun, Y. A. (1989) J. Biol. Chem. 264, 19076-19080). Activation of the cycle by tumor necrosis factor alpha (TNF alpha) occurs rapidly, with peak levels of approximately 30% SM hydrolysis observed within 45-60 min. The mechanisms by which TNF alpha induces this SM turnover remain largely unexplored. In this study, arachidonic acid (AA) was investigated as a potential mediator of TNF alpha effects on SM turnover. In HL-60 cells, 30 nM TNF alpha stimulated the release of AA within 5-10 min. In turn, AA stimulated SM hydrolysis and concomitant ceramide generation within 20 min of addition to cells, Other fatty acids, notably oleate, mimicked the effects of AA on SM hydrolysis, but the methyl ester and alcohol analogs of fatty acids were inactive. Diacylglycerol, a candidate mediator of TNF alpha responses, failed to stimulate SM hydrolysis even at con centrations as high as 300 mu M. Moreover, in an in vitro assay, AA activated a cytosolic sphingomyelinase dose dependently, with 10-100 mu M AA inducing 3-4-fold activation, thus suggesting a direct effect of AA on sphingomyelinase. Melittin, a potent phospholipase Az activator, induced SM hydrolysis at concentrations as low as 35 nM. However, unlike AA, melittin was unable to stimulate sphingomyelinase activation in an in vitro assay system. Finally, exogenous addition of AA also produced antiproliferative effects reminiscent of ceramide effects. Thus, a role for the phospholipase A(2)/AA pathway in mediating TNF alpha induction of the SM cycle is supported by multiple lines of evidence. These studies begin to elucidate a mechanism of TNF alpha signaling and identify a close rela tionship between glycerophospholipid and sphingolipid signaling. AA, therefore, may be pivotal to understanding the sphingomyelin-signaling cascade.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON YH, 1990, IMMUNOLOGY, V70, P82; BEGIN ME, 1986, PROG LIPID RES, V25, P573, DOI 10.1016/0163-7827(86)90116-5; BEGIN ME, 1985, PROSTA LEUKOTR MED, V19, P177, DOI 10.1016/0262-1746(85)90084-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CLARK MA, 1987, J BIOL CHEM, V262, P4402; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FOLCH J, 1957, J BIOL CHEM, V226, P497; GODFREY RW, 1987, BIOCHEM BIOPH RES CO, V142, P235, DOI 10.1016/0006-291X(87)90476-1; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GRANDISON L, 1984, ENDOCRINOLOGY, V114, P1; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAPUANO BE, 1991, BIOCHIM BIOPHYS ACTA, V1091, P374, DOI 10.1016/0167-4889(91)90203-A; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SIEGEL I, 1987, J NATL CANCER I, V78, P271; STOFFEL W, 1971, H-S Z PHYSIOL CHEM, V352, P1058, DOI 10.1515/bchm2.1971.352.2.1058; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; YANAGA F, 1992, J BIOL CHEM, V267, P5114	29	320	323	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5757	5763						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119915				2022-12-25	WOS:A1994MY84000045
J	AKIYAMA, Y; OGURA, T; ITO, K				AKIYAMA, Y; OGURA, T; ITO, K			INVOLVEMENT OF FTSH IN PROTEIN ASSEMBLY INTO AND THROUGH THE MEMBRANE .1. MUTATIONS THAT REDUCE RETENTION EFFICIENCY OF A CYTOPLASMIC REPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ALKALINE-PHOSPHATASE FUSIONS; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; GENETIC-ANALYSIS; EXPORT; SECY; TRANSLOCATION; INSERTION; TOPOLOGY	To identify cellular factors that assist in membrane protein biogenesis, we looked for mutants affected in the ''stop transfer'' anchoring process. Using a SecY-PhoA fusion protein in which alkaline phosphatase (PhoA) mature sequence is attached to the last cytoplasmic domain following the 1Oth transmembrane segment of SecY, we isolated a mutation (std101) that allowed significant export of the PhoA moiety across the membrane. The mutation did not cause nonspecific leakage of cytoplasmic proteins. The mutation was identified as a single base change in the ftsH gene, causing an amino acid substitution in the proposed periplasmic region of FtsH, a putative membrane-bound ATPase. In addition, the ftsH1 temperature-sensitive mutation caused a similar phenotype. Disruption of the chromosomal ftsH in combination with a lac promoter-controlled copy of ftsH on a plasmid rendered the cell viability dependent on lac induction. Repression of this system resulted in a strong Std phenotype as well as significant export defects of beta-lactamase and OmpA Thus, the loss of ftsH function enhances translocation of normally anchored protein segments and retards that of normally translocated proteins. These results suggest that FtsH participates in assembly of proteins into and through the membrane. It is needed for the cell to assure efficient stop-transfer of some transmembrane proteins.	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,KUMAMOTO 862,JAPAN	Kumamoto University	AKIYAMA, Y (corresponding author), KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN.			Ogura, Teru/0000-0003-3784-0970				AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; ANDERSON DJ, 1982, J CELL BIOL, V93, P501, DOI 10.1083/jcb.93.2.501; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BEGG KJ, 1992, J BACTERIOL, V174, P2416, DOI 10.1128/JB.174.7.2416-2417.1992; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; Boyd D, 1987, PHOSPHATE METABOLISM, P89; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Davis R., 1980, ADV BACTERIAL GENETI; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; ITO K, 1992, MOL MICROBIOL, V6, P2423; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KLECKNER N, 1978, GENETICS, V90, P427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JI, 1992, J BIOL CHEM, V267, P938; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; Miller J.H., 1972, EXPT MOL GENETICS; NAKAI M, 1993, J BIOL CHEM, V268, P24262; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; OGURA T, 1991, RES MICROBIOL, V142, P279, DOI 10.1016/0923-2508(91)90041-8; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; PUZISS JW, 1992, J BACTERIOL, V174, P92, DOI 10.1128/jb.174.1.92-101.1992; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SHIMOIKE T, 1992, MOL MICROBIOL, V6, P1205, DOI 10.1111/j.1365-2958.1992.tb01559.x; SINGER M, 1989, MICROBIOL REV, V53, P1; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; SPIESS M, 1989, J BIOL CHEM, V264, P19117; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; YOST CS, 1983, CELL, V34, P756	54	137	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5218	5224						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106504				2022-12-25	WOS:A1994MX57100081
J	MIDDLEMAS, DS; MEISENHELDER, J; HUNTER, T				MIDDLEMAS, DS; MEISENHELDER, J; HUNTER, T			IDENTIFICATION OF TRKB AUTOPHOSPHORYLATION SITES AND EVIDENCE THAT PHOSPHOLIPASE C-GAMMA-1 IS A SUBSTRATE OF THE TRKB RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; INSULIN-RECEPTOR; NEUROTROPHIC FACTOR; C-GAMMA; PC12 CELLS; SIGNAL TRANSDUCTION; EGF RECEPTOR; DOMAIN AUTOPHOSPHORYLATION	The TrkB receptor protein-tyrosine kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. In response to brain-derived neurotrophic factor and neurotrophin-3 treatment, TrkB expressed exogenously in Rat-2 cells is rapidly phosphorylated on tyrosine residues. At least 2 regions of TrkB contain phosphorylated tyrosines. The major sites of autophosphorylation are in the region containing Tyr-670, Tyr-674, and Tyr-675, which lies in the kinase domain and corresponds by sequence homology to the Tyr-416 autophosphorylation site in p60(c-Src). Tyr-785, which lies just to the COOH-terminal side of the kinase domain in a relatively short tail characteristic of the Trk family of protein-tyrosine kinase receptors, is also phosphorylated in response to neurotrophin-3 treatment. The sequence around Tyr-785 fits a consensus sequence for binding phospholipase C-gamma 1. The simplest interpretation of these results is that, in response to neurotrophin binding, at least two and perhaps all three of the tyrosines in the Tyr-670/674/675 region are autophosphorylated independently and Tyr-785 is autophosphorylated in vivo. Following activation of TrkB, phospholipase C-gamma 1 is phosphorylated on Tyr-783, Tyr-771, and Tyr-1254. Phospholipase C-gamma 1 also forms a complex with TrkB in response to neurotrophin-3 treatment, consistent with the possibility that one of the TrkB autophosphorylation sites provides a binding site for the phospholipase C-gamma 1 SH2 domains, as is the case for other receptor protein-tyrosine kinases. We conclude that phospholipase C-gamma 1 is directly phosphorylated by TrkB. Since phosphorylation of Tyr-783 and Tyr-1254 results in activation of phospholipase C-gamma 1, we predict that neurotrophin-3 leads to activation of phospholipase C-gamma 1 following binding to TrkB in Rat-2 cells.			MIDDLEMAS, DS (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, SAN DIEGO, CA 92186 USA.				NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008123] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA14195] Funding Source: Medline; NINDS NIH HHS [2F32NS08123-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; ALTIN JG, 1990, J NEUROCHEM, V54, P1666, DOI 10.1111/j.1471-4159.1990.tb01220.x; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DUGICHDJORDJEVIC MM, 1992, NEURON, V8, P1127, DOI 10.1016/0896-6273(92)90133-X; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KLEIN R, 1992, CELL, V8, P947; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MEISENHELDER J, 1991, METHOD ENZYMOL, V197, P288; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIDDLEMAS DS, 1993, METHODS NEUROSCI, V12, P139; MITRA G, 1991, ONCOGENE, V6, P2237; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OHMICHI M, 1992, J BIOL CHEM, V267, P21601; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PAWSON T, 1988, ONCOGENE, V3, P491; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUH PG, 1988, J BIOL CHEM, V263, P14497; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	103	91	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5458	5466						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106527				2022-12-25	WOS:A1994MX57100112
J	DAHMS, NM; WICK, DA; BRZYCKIWESSELL, MA				DAHMS, NM; WICK, DA; BRZYCKIWESSELL, MA			THE BOVINE MANNOSE 6-PHOSPHATE INSULIN-LIKE GROWTH FACTOR-II RECEPTOR - LOCALIZATION OF THE INSULIN-LIKE GROWTH FACTOR-II BINDING-SITE TO DOMAINS 5-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-II; MANNOSE-6-PHOSPHATE RECEPTOR; BETA-GALACTOSIDASE; SERUM; PROTEINS; AFFINITY; CHICKEN; LIGAND; REGION; CELLS	The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF-II receptor) binds two distinct ligands, mannose 6-phosphate (Man-6-P) and insulin-like growth factor II (IGF-II). The extracytoplasmic region of the receptor is composed of 15 homologous repeating domains and domains 1-3 and 7-9 have been shown to contain the two Man-6-P binding sites. To determine the location of the single IGF-II binding site, truncated forms of the M6P/IGF-II receptor were expressed transiently in COS-1 cells and assayed for their ability to bind iodinated human recombinant IGF-II. The binding of [I-125]IGF-II to the receptors in the presence or absence of excess unlabeled IGF-II, IGF-I, or insulin was determined by incubation with homobifunctional cross-linking agents followed by SDS-polyacrylamide gel electrophoresis. These binding studies demonstrated that a construct encoding domains 5-11 bound 0.9 mol of IGF-II/mol of receptor, whereas a construct encoding domains 5-10 exhibited no detectable binding to IGF-II. These results indicate that the IGF-II binding site of the M6P/IGF-II receptor is contained within domains 5-11 and that residues in domain 11 play an important role in IGF-II binding.			DAHMS, NM (corresponding author), MED COLL WISCONSIN,DEPT BIOCHEM,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.				NIDDK NIH HHS [DK42667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042667, R01DK042667, R56DK042667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH LA, 1993, J BIOL CHEM, V268, P9246; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BRINKMAN A, 1991, FEBS LETT, V291, P264, DOI 10.1016/0014-5793(91)81298-M; BRZYCKI M, 1909, MOL BIOL CELL, V3, pA297; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CANFIELD WM, 1989, J BIOL CHEM, V264, P7100; CAUSIN C, 1988, BIOCHEM J, V252, P795, DOI 10.1042/bj2520795; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CLAIRMONT KB, 1989, J BIOL CHEM, V264, P16390; DAHMS NM, 1993, ENDOCRINOLOGY, V133, P440, DOI 10.1210/en.133.2.440; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; GELATO MC, 1989, ENDOCRINOLOGY, V124, P2935, DOI 10.1210/endo-124-6-2935; GELATO MC, 1988, J CLIN ENDOCR METAB, V67, P669, DOI 10.1210/jcem-67-4-669; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KIESS W, 1988, J BIOL CHEM, V263, P9339; KIESS W, 1991, MOL ENDOCRINOL, V5, P281, DOI 10.1210/mend-5-2-281; KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432-1033.1990.tb15547.x; KIESS W, 1989, J BIOL CHEM, V264, P4710; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; Nolan C M, 1987, Adv Exp Med Biol, V225, P199; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; OKA Y, 1985, J BIOL CHEM, V260, P9435; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROTH RA, 1987, BIOCHEM BIOPH RES CO, V149, P600, DOI 10.1016/0006-291X(87)90410-4; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; TAIT JF, 1981, J BIOL CHEM, V256, P1086; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; YANG YWH, 1991, ENDOCRINOLOGY, V128, P1177, DOI 10.1210/endo-128-2-1177	46	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3802	3809						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106425				2022-12-25	WOS:A1994MV63100098
J	MOL, CD; MUIR, AKS; LEE, JS; ANDERSON, WF				MOL, CD; MUIR, AKS; LEE, JS; ANDERSON, WF			STRUCTURE OF AN IMMUNOGLOBULIN FAB FRAGMENT SPECIFIC FOR POLY(DG)CENTER-DOT-POLY(DC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR REPLACEMENT METHOD; MULTIWIRE AREA DETECTOR; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; TRANSLATION-FUNCTION; NUCLEIC-ACIDS; STRANDED-DNA; ANTIBODY; COMPLEX; BINDING	Jel 72 is a murine monoclonal antibody that is highly specific for the right-handed DNA duplex formed by poly(dG).poly(dC). The three-dimensional structure of the antigen-binding fragment (Fab) of Jel 72 has been determined by x-ray crystallographic methods and refined to 2.7-angstrom resolution. The structure has been determined using a combination of molecular replacement and multiple isomorphous replacement techniques. Crystals of Jel 72 contain two Fab fragments/asymmetric unit. The orientation of each of the four separate constant and variable domain pairs was determined from rotation function searches against appropriately oriented model Fab fragments. The rotated Fab domain pairs were placed within the unit cell using a phased translation search procedure with low resolution phases calculated from three derivatives. The two crystallographically independent Fab fragments possess ''elbow'' angles (relating the variable and constant domain pairs) that differ by 14-degrees (146-degrees versus 132-degrees). The shape and electrostatic surface potential of the combining site suggest a possible model for the recognition of double helical DNA. The model proposes that residues in the third hypervariable region of the heavy chain interact with the DNA bases via the major groove of poly(dG).poly(dC). This model may be applicable to the recognition of double-stranded DNA by autoimmune antibodies that occur in systemic lupus erythematosus.	VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; NATL RES COUNCIL CANADA,DIV BIOL SCI,OTTAWA K1A 0R6,ONTARIO,CANADA; UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA	Vanderbilt University; National Research Council Canada; University of Saskatchewan					NIDDK NIH HHS [DK42502] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ARNOTT S, 1974, J MOL BIOL, V88, P551, DOI 10.1016/0022-2836(74)90502-6; BALLARD DW, 1985, J IMMUNOL, V135, P3372; BARRY MM, 1994, J BIOL CHEM, V269, P3623; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BOODHOO A, 1988, J BIOL CHEM, V263, P18578; BRAM S, 1971, NATURE-NEW BIOL, V233, P161, DOI 10.1038/newbio233161a0; BRAUN RP, 1986, NUCLEIC ACIDS RES, V14, P5049, DOI 10.1093/nar/14.12.5049; BRAUN RP, 1987, J IMMUNOL, V139, P175; BRAUN RP, 1988, J IMMUNOL, V141, P2084; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; CYGLER M, 1988, ACTA CRYSTALLOGR A, V44, P38, DOI 10.1107/S0108767387008365; CYGLER M, 1987, J BIOL CHEM, V262, P643; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; EILAT D, 1991, J IMMUNOL, V147, P361; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; LANGE A, 1978, CLIN EXP IMMUNOL, V31, P472; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE JS, 1982, BIOCHEMISTRY-US, V21, P4940, DOI 10.1021/bi00263a017; LEE JS, 1984, BIOCHEMISTRY-US, V23, P3277, DOI 10.1021/bi00309a024; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCCALL M, 1985, J MOL BIOL, V183, P385, DOI 10.1016/0022-2836(85)90009-9; MOL CD, 1994, J BIOL CHEM, V269, P3615; NAVIA MA, 1979, P NATL ACAD SCI USA, V76, P4071, DOI 10.1073/pnas.76.8.4071; PADLAN E, 1973, NATURE, V145, P165; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RADIC MZ, 1993, J IMMUNOL, V150, P4966; RADIC MZ, 1989, COLD SPRING HARB SYM, V54, P933; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; READ RJ, 1988, J APPL CRYSTALLOGR, V21, P490, DOI 10.1107/S002188988800562X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STOLLAR BD, 1986, CRC CR REV BIOCH MOL, V20, P1, DOI 10.3109/10409238609115899; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3739, DOI 10.1021/bi00229a022; TORMO J, 1992, PROTEIN SCI, V1, P1154, DOI 10.1002/pro.5560010909; TULIP WR, 1992, J MOL BIOL, V227, P122, DOI 10.1016/0022-2836(92)90687-F; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105	52	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3605	3614						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106405				2022-12-25	WOS:A1994MV63100073
J	QIN, N; BAEHR, W				QIN, N; BAEHR, W			EXPRESSION AND MUTAGENESIS OF MOUSE ROD PHOTORECEPTOR CGMP PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; DROSOPHILA DUNCE+ GENE; BETA-SUBUNIT GENE; ALPHA-SUBUNIT; CAMP PHOSPHODIESTERASE; GAMMA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; RETINAL DEGENERATION; MOLECULAR-CLONING; MEMBRANE-BINDING	Using recombinant baculovirus vectors, the three sub. units of mouse rod photoreceptor cGMP phosphodiesterase (PDE) (alphabetagamma2) have been expressed in insect cells. The recombinant alpha,beta subunits accumulate to 5 mg/liter culture, but most (98%) of the expressed polypeptides are insoluble. In the soluble fraction, individually expressed a and 13 subunits showed insignificant PDE activity, but coexpression (by coinfection) of alphabeta subunits elevated PDE activity 7-fold and coexpression of alphabetagamma up to 15-fold. The soluble expressed holoenzyme associated with ROS membranes under isotonic, but not hypotonic, conditions. The K(m) of the soluble holoenzyme was 11-16 muM both for coexpressed alphabeta subunits and for alphabetagamma subunits, similar to the K(m) (6-80 muM) of native PDE. Site-directed mutagenesis of cysteine to serine in the C-terminal CAAX box of both alpha and beta subunits substantially decreased the protein expression level, abolished post-translational isoprenylation, and prevented subunit binding to the rod outer segment (ROS) membranes. The mutant holoenzyme, however, showed a cGMP hydrolytic activity comparable with that of the normal recombinant enzyme. These results suggest that both alpha and beta subunits are required for the formation of a functional enzyme and that isoprenylation of the subunits is essential for membrane association and stability of PDE.	BAYLOR COLL MED, DEPT OPHTHALMOL, 6501 FANNIN ST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine					NATIONAL EYE INSTITUTE [R01EY008123] Funding Source: NIH RePORTER; NEI NIH HHS [EY08123] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AKESON AL, 1989, J CELL BIOCHEM, V39, P217, DOI 10.1002/jcb.240390302; ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ANANT JS, 1992, J BIOL CHEM, V267, P687; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAEHR W, 1991, FEBS LETT, V278, P107, DOI 10.1016/0014-5793(91)80095-K; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILLESPIE PG, 1993, ADV SEC MESS PHOSPH, P163; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; JANSEN JJM, 1991, BIOCHIM BIOPHYS ACTA, V1089, P68, DOI 10.1016/0167-4781(91)90086-2; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KLOC M, 1991, J BIOL CHEM, V266, P8206; KOCH KW, 1991, J BIOL CHEM, V266, P8634; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEM J, 1992, P NATL ACAD SCI USA, V89, P4422, DOI 10.1073/pnas.89.10.4422; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OHGURO H, 1990, BIOCHEM BIOPH RES CO, V167, P1235, DOI 10.1016/0006-291X(90)90656-8; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PITTLER SJ, 1991, PROG CLIN BIOL RES, V362, P33; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; QIN N, 1992, J BIOL CHEM, V267, P8458; QIN N, 1993, FEBS LETT, V321, P6, DOI 10.1016/0014-5793(93)80609-X; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; STROOP SD, 1992, ADV SEC MESS PHOSPH, V25, P55; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; TANG WJ, 1991, J BIOL CHEM, V266, P8595; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; WASHBURN T, 1992, GENETICS, V130, P585; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; ZUSMAN DR, 1978, ANAL BIOCHEM, V84, P551, DOI 10.1016/0003-2697(78)90074-X	64	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3265	3271						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106363				2022-12-25	WOS:A1994MV63100024
J	DUKE, RC; WITTER, RZ; NASH, PB; YOUNG, JDE; OJCIUS, DM				DUKE, RC; WITTER, RZ; NASH, PB; YOUNG, JDE; OJCIUS, DM			CYTOLYSIS MEDIATED BY IONOPHORES AND PORE-FORMING AGENTS - ROLE OF INTRACELLULAR CALCIUM IN APOPTOSIS	FASEB JOURNAL			English	Article						CELL DEATH; ENDONUCLEASE; IONOPHORES; TOXINS	PROGRAMMED CELL-DEATH; TOXIC LYMPHOCYTES-T; DNA FRAGMENTATION; IMMUNE-SYSTEM; TARGET-CELLS; GLUCOCORTICOIDS ACTIVATE; ENDONUCLEASE ACTIVATION; IMMATURE THYMOCYTES; SUICIDE PROCESS; LEUKEMIA-CELLS	Apoptosis is a term used to describe certain forms of physiological cell death that occur during embryogenesis, differentiation, and normal cell turnover. Previous reports concerning the effects of calcium ionophores on rodent thymocytes and the pore-forming proteins perforin and staphylococcal alpha-toxin on murine tumor cells led to the suggestion that simply raising intracellular calcium causes apoptotic cell death. This hypothesis was tested using two ionophores, A23187 and valinomycin, and two pore-forming agents, melittin and staphylococcal alpha-toxin, on four murine tumor cell lines. Although treatment with these agents could raise intracellular calcium, and in some instances cause DNA fragmentation, only valinomycin caused apoptosis. In contrast to previous reports, our results suggest that raising intracellular calcium and inducing internucleosomal DNA fragmentation is not sufficient to elicit apoptotic cell death in all cell types.	UNIV COLORADO, SCH MED, DEPT MICROBIOL & IMMUNOL, DENVER, CO 80262 USA; ROCKEFELLER UNIV, MOLEC IMMUNOL & CELL BIOL LAB, NEW YORK, NY 10021 USA; INSERM, U277, UNITE BIOL MOLEC GENE, F-75724 PARIS 15, FRANCE	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Rockefeller University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	DUKE, RC (corresponding author), UNIV COLORADO, SCH MED,DEPT MED,DIV MED ONCOL,CAMPUS BOX B-171, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NCI NIH HHS [CA47307] Funding Source: Medline; NIAID NIH HHS [AI29953, AI07035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R55AI029953, T32AI007035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLBRITTON NL, 1988, J EXP MED, V167, P514, DOI 10.1084/jem.167.2.514; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; BELLOMO G, 1992, CANCER RES, V52, P1342; BERNHEIMER AW, 1986, BIOCHIM BIOPHYS ACTA, V864, P123, DOI 10.1016/0304-4157(86)90018-3; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; CHOI OH, 1992, J PHARMACOL EXP THER, V260, P369; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COHEN JJ, 1985, ADV EXP MED BIOL, V184, P493; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUKE RC, 1988, J IMMUNOL, V141, P2191; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUKE RC, 1992, CURRENT PROTOCOLS IM; DUKE RC, 1992, IN PRESS SEMIN IMMUN; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; FRUMAN DA, 1992, EUR J IMMUNOL, V22, P2513, DOI 10.1002/eji.1830221008; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; Green D R, 1992, Semin Immunol, V4, P355; GROMKOWSKI SH, 1988, J IMMUNOL, V141, P774; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMEED A, 1989, J EXP MED, V169, P765, DOI 10.1084/jem.169.3.765; HEISLER S, 1989, CAN J PHYSIOL PHARM, V67, P411, DOI 10.1139/y89-065; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; ISEKI R, 1991, J IMMUNOL, V147, P4286; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; JOSEPH R, 1993, MOL BRAIN RES, V17, P70, DOI 10.1016/0169-328X(93)90074-Y; KAISER N, 1977, P NATL ACAD SCI USA, V74, P638, DOI 10.1073/pnas.74.2.638; KATSU T, 1989, BIOCHIM BIOPHYS ACTA, V983, P135, DOI 10.1016/0005-2736(89)90226-5; KELLEY LL, 1992, J CELL PHYSIOL, V151, P487, DOI 10.1002/jcp.1041510307; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LENNON SV, 1992, CLIN EXP IMMUNOL, V87, P465; LING YH, 1993, CANCER RES, V53, P1845; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MCCONKEY DJ, 1990, FASEB J, V4, P2661, DOI 10.1096/fasebj.4.9.2347464; METZ SA, 1986, BIOCHEM PHARMACOL, V35, P3371, DOI 10.1016/0006-2952(86)90438-7; OJCIUS DM, 1991, EXP CELL RES, V197, P43, DOI 10.1016/0014-4827(91)90477-C; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SELLINS KS, 1991, RADIAT RES, V126, P88, DOI 10.2307/3578175; SHARMA SV, 1993, ONCOGENE, V8, P939; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; STARKE PE, 1986, J BIOL CHEM, V261, P3006; STORY MD, 1992, INT J RADIAT BIOL, V61, P243, DOI 10.1080/09553009214550871; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545	59	108	109	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1994	8	2					237	246		10.1096/fasebj.8.2.8119494	http://dx.doi.org/10.1096/fasebj.8.2.8119494			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119494				2022-12-25	WOS:A1994MY29900031
J	FITZGERALD, M; KEAST, D				FITZGERALD, M; KEAST, D			FAB FRAGMENTS FROM THE MONOCLONAL-ANTIBODY ML30 BIND TO TREATED HUMAN MYELOID-LEUKEMIA CELLS	FASEB JOURNAL			English	Article						ML30; SURFACE EXPRESSION; HSP60; MYELOID LEUKEMIA; GLUTAMINE ANALOGS	HEAT-SHOCK; EXPRESSION; HSP60	Traditionally, heat-shock proteins were believed to be located intracellularly; however, recent studies have demonstrated that under certain circumstances these proteins can be located at the cell surface. Murine ascites developed from the anti-mycobacterial hsp65 hybridoma ML30 have been shown to contain an antibody that binds to the surface of a range of stimulated myelomonocytic cell lines; however, as the purified ML30 monoclonal antibody produced in vitro did not bind to these cell lines, the results were not considered conclusive evidence of cell-surface expression of the hsp60 homologue of the mycobacterial hsp 65 on human cells. In an effort to clarify this situation, we have confirmed that the ascites derived from the ML30 hybridoma bound to the surface of human myeloid leukemia cell lines and myeloid blast cells purified from freshly diagnosed leukemic patients, but that the in vitro-derived ML30 antibody did not. In addition, we have isolated Fab fragments from the ascites derived from the ML30 hybridoma and demonstrated that these fragments bound to the surface of human myeloid leukemia cells after their treatment with the glutamine analog 6-diazo-5-oxo-L-norleucine (DON) for various times up to four days. Evidence has been presented in the literature that the ML30 monoclonal antibody recognizes a molecule corresponding to the human hsp60 homologue of the mycobacterial hsp65; therefore our results from the binding of Fab fragment preparations from ascites imply that when human myeloid leukemic cells are treated with DON, they express a human hsp60 homologue on their surface.	UNIV WESTERN AUSTRALIA, QUEEN ELIZABETH II MED CTR, DEPT MICROBIOL, NEDLANDS, WA 6009, AUSTRALIA	University of Western Australia			Fitzgerald, Melinda/C-4235-2011	Fitzgerald, Melinda/0000-0002-4823-8179				CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; FERM MT, 1992, INT IMMUNOL, V4, P305, DOI 10.1093/intimm/4.3.305; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; JARJOUR W, 1989, Arthritis and Rheumatism, V32, pS44; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KIESSLING R, 1991, IMMUNOL REV, V121, P91, DOI 10.1111/j.1600-065X.1991.tb00824.x; SRIVASTAVA PK, 1991, CURR TOP MICROBIOL, V167, P109; WANDWURTTENBERGER A, 1991, EUR J IMMUNOL, V21, P1089, DOI 10.1002/eji.1830210437	8	9	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1994	8	2					259	261		10.1096/fasebj.8.2.8119496	http://dx.doi.org/10.1096/fasebj.8.2.8119496			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119496				2022-12-25	WOS:A1994MY29900034
J	LEE, JI; HWANG, PP; WILSON, TH				LEE, JI; HWANG, PP; WILSON, TH			LYSINE-319 INTERACTS WITH BOTH GLUTAMIC ACID-269 AND ASPARTIC ACID-240 IN THE LACTOSE CARRIER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; SALT BRIDGES; BACTERIORHODOPSIN; TRANSPORT; MEMBRANE; RESIDUES; PERMEASE; PROTEIN; MUTANTS; GENE	It is believed that there are several charged amino acid residues in membrane-spanning alpha-helices of the lactose carrier of Escherichia coli. Evidence has previously been presented for two different salt bridges in membrane-spanning regions of the lactose carrier. One of these involves an interaction between Asp-237 and Lys-358; another involves interaction between Asp-240 and Lys-319. Additional studies of Lys-319 suggest that it may intereact with Glu-269 as well as Asp-240. A cell containing the LacY gene with the mutation Lys-319 --> Asn failed to ferment melibiose and after several days melibiose-positive mutants arose on indicator plates. These revertants showed second site mutations which replaced Asp-240 by neutral amino acids (Val or Gly). In addition, a second site mutation showed Glu-269 changed to Asn. Cells containing the mutation Lys-319 --> Leu also failed to ferment melibiose and melibiose-positive revertants showed Asp-240 --> Ala and Asp-240 --> Tyr as well as Tyr-236 --> Phe and His-322 --> Arg. Second site revertants were also sought from the mutant Glu-269 --> Asn which grew poorly on melibiose minimal plates. Melibiose-positive revertants included the double mutant Gln-269/Asn-319. All of the Glu-269 --> Asn mutants were extremely defective in transport. It was concluded thet Lys-319 interacts with Glu-269 and Asp-240 probably as salt bridges.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Hwang, Pung-Pung/AAH-1538-2022; Hwang, Pung-Pung/AEQ-4633-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005736, R01DK005736] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK05736] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASLANIDIS C, 1989, J BACTERIOL, V171, P6753, DOI 10.1128/jb.171.12.6753-6763.1989; BOCKMANN J, 1992, MOL GEN GENET, V235, P22, DOI 10.1007/BF00286177; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BROOKER RJ, 1985, J BIOL CHEM, V260, P6181; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COHEN G N, 1956, Ann Inst Pasteur (Paris), V91, P693; GARTY H, 1988, J BIOL CHEM, V263, P5550; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; HOBSON AC, 1977, J BACTERIOL, V131, P830, DOI 10.1128/JB.131.3.830-838.1977; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; KARLISH SJD, 1985, SODIUM PUMP, P487; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KING SC, 1989, J BIOL CHEM, V264, P7390; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KLINGENBERG M, 1988, BIOCHEMISTRY-US, V27, P781, DOI 10.1021/bi00402a044; LEE JI, 1992, J BIOL CHEM, V267, P20758; LOLKEMA JS, 1988, BIOCHEMISTRY-US, V27, P8307, DOI 10.1021/bi00422a003; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MACARA IG, 1981, BIOCHEMISTRY-US, V20, P5695, DOI 10.1021/bi00523a009; MCMORROW I, 1988, BIOCHIM BIOPHYS ACTA, V945, P315, DOI 10.1016/0005-2736(88)90494-4; PERSSON B, 1992, BIOCHEMISTRY-US, V31, P8892, DOI 10.1021/bi00152a028; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; STERN LJ, 1989, J BIOL CHEM, V264, P14202; SUBRAMANIAM S, 1992, J BIOL CHEM, V267, P25730; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P655, DOI 10.1016/0006-291X(70)90063-X; WILSON DM, 1986, METHOD ENZYMOL, V125, P377	31	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20007	20015						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	8104184				2022-12-25	WOS:A1993LY01900017
J	CARMEL, G; LEICHUS, B; CHENG, XD; PATTERSON, SD; MIRZA, U; CHAIT, BT; KURET, J				CARMEL, G; LEICHUS, B; CHENG, XD; PATTERSON, SD; MIRZA, U; CHAIT, BT; KURET, J			EXPRESSION, PURIFICATION, CRYSTALLIZATION, AND PRELIMINARY-X-RAY ANALYSIS OF CASEIN KINASE-1 FROM SCHIZOSACCHAROMYCES-POMBE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; PHOSPHATE; DETERMINANTS; MUTAGENESIS; SEQUENCES; AFFINITY; RESIDUES	The catalytic domain of Schizosaccharomyces pombe casein kinase-1 (the product of the cki1 gene) has been overexpressed in Escherichia coli, purified by chromatographic methods, characterized in vitro, and crystallized in the presence and absence of nucleotide substrate. The best crystals belong to the trigonal space group P3(1)21 or its enantiomorph, have unit cell parameters a = b = 79 Angstrom, c = 121 Angstrom, and diffract x-rays to 2.0-Angstrom resolution. Kinetic characterization of the purified catalytic domain and other C-terminal deletion mutants of Cki1 suggests that it is subject to two forms of regulation. One mechanism involves autophosphorylation, and results in a 4-fold decrease in the affinity for protein substrate. In contrast, truncation of intact Cki1 results in a 3-fold activation in its catalytic rate. This activation may arise from the removal of an inhibitory domain present in the intact enzyme.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Cold Spring Harbor Laboratory; Rockefeller University			Patterson, Scott/A-7404-2009		NIGMS NIH HHS [GM 44806, GM 48216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R13GM048216, R01GM044806] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILAR CF, 1993, ACTA CRYSTALLOGR A, V49, P306, DOI 10.1107/S010876739200847X; ALLEN G, 1981, SEQUENCING PROTEINS, P64; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; CARMEL G, 1992, ANAL BIOCHEM, V203, P274, DOI 10.1016/0003-2697(92)90313-V; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; EGHTEDARZADEH MK, 1986, NUCLEIC ACIDS RES, V14, P5115, DOI 10.1093/nar/14.12.5115; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURET J, 1988, J BIOL CHEM, V263, P9149; KURET J, 1991, BIOCHEMISTRY-US, V30, P10595, DOI 10.1021/bi00107a031; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MEGGIO F, 1990, EUR J BIOCHEM, V187, P89, DOI 10.1111/j.1432-1033.1990.tb15280.x; MEGGIO F, 1991, FEBS LETT, V283, P303, DOI 10.1016/0014-5793(91)80614-9; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; VANCURA A, 1993, ARCH BIOCHEM BIOPHYS, V305, P47, DOI 10.1006/abbi.1993.1391; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	39	57	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7304	7309						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125945				2022-12-25	WOS:A1994NA03200044
J	CRAMM, R; SIDDIQUI, RA; FRIEDRICH, B				CRAMM, R; SIDDIQUI, RA; FRIEDRICH, B			PRIMARY SEQUENCE AND EVIDENCE FOR A PHYSIOLOGICAL-FUNCTION OF THE FLAVOHEMOPROTEIN OF ALCALIGENES-EUTROPHUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-BINDING FLAVOHEMOPROTEIN; MEMBRANE-BOUND HYDROGENASE; ESCHERICHIA-COLI; GENE-EXPRESSION; NITRIC-OXIDE; HETEROLOGOUS EXPRESSION; BACTERIAL HEMOGLOBIN; NUCLEOTIDE-SEQUENCES; PSEUDOMONAS-STUTZERI; REDUCTASE	The flavohemoprotein (FHP) encoding gene of the strictly respiratory Gram-negative bacterium Alcaligenes eutrophus was isolated from a megaplasmid library by using FHP-specific antibodies and oligonucleotide probes based on the amino-terminal polypeptide sequence of FHP, determined previously (Zhu, H., and Riggs, A. F. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5015-5019). The fhp gene codes for a monomeric polypeptide of 403 amino acids (M(r) 44,796) whose structure is highly homologous to the proteins of the two-domain flavohemoglobin family comprising the hemoproteins from Escherichia coli and Saccharomyces cerevisiae. FHP consists of an amino-terminal-located O-2-binding hemoglobin domain and a carboxyl-terminal-located redox active domain with potential binding sites for NAD(P)H and FAD. Two potential binding motifs for NARL and FNR upstream of fhp suggest a role of FHP in the anaerobic metabolism of A. eutrophus. Isogenic Fhp-negative mutants showed no significant delay in aerobic or anaerobic growth. Compared with the wild type, however, the mutant did not accumulate nitrous oxide during denitrification with nitrite as electron acceptor. This property was restored by complementation. The result suggests that FHP interacts directly or indirectly with the gas metabolism during denitrification in A. eutrophus.	FREE UNIV BERLIN,INST PFLANZENPHYSIOL & MIKROBIOL,D-14195 BERLIN,GERMANY	Free University of Berlin								APPLEBY CA, 1988, PLANT CELL ENVIRON, V11, P359, DOI 10.1111/j.1365-3040.1988.tb01360.x; Aragno M., 1981, PROKARYOTES HDB HABI, P865, DOI [10.1007/978-3-662-13187-9_70, DOI 10.1007/978-3-662-13187-9_70]; BOLIVAR F, 1978, GENE, V4, P121, DOI 10.1016/0378-1119(78)90025-2; BONNEFOY V, 1992, MOL MICROBIOL, V6, P3595; BOWIEN B, 1981, ANNU REV MICROBIOL, V35, P405, DOI 10.1146/annurev.mi.35.100181.002201; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CARR GJ, 1990, BIOCHEM J, V269, P423, DOI 10.1042/bj2690423; CATALDO DA, 1975, COMMUN SOIL SCI PLAN, V6, P71, DOI 10.1080/00103627509366547; DIKSHIT KL, 1990, NUCLEIC ACIDS RES, V18, P4149, DOI 10.1093/nar/18.14.4149; EITINGER T, 1991, J BIOL CHEM, V266, P3222; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; HEISS B, 1989, J BACTERIOL, V171, P3288, DOI 10.1128/jb.171.6.3288-3297.1989; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KHOSLA C, 1989, J BACTERIOL, V171, P5995, DOI 10.1128/jb.171.11.5995-6004.1989; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; KORTLUKE C, 1992, J BACTERIOL, V174, P6290; KORTLUKE C, 1992, J BACTERIOL, V174, P6277; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI J, 1992, J BACTERIOL, V174, P4935, DOI 10.1128/JB.174.15.4935-4942.1992; LI SF, 1988, J BIOL CHEM, V263, P13700; LOWE RH, 1964, BIOCHIM BIOPHYS ACTA, V85, P377, DOI 10.1016/0926-6569(64)90301-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEIDLE EL, 1991, J BACTERIOL, V173, P5385, DOI 10.1128/jb.173.17.5385-5395.1991; OSHINO R, 1973, EUR J BIOCHEM, V35, P23, DOI 10.1111/j.1432-1033.1973.tb02805.x; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PERUTZ MF, 1965, J MOL BIOL, V13, P669, DOI 10.1016/S0022-2836(65)80134-6; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; PROBST I, 1976, BIOCHIM BIOPHYS ACTA, V440, P412, DOI 10.1016/0005-2728(76)90075-X; RIGGS AF, 1991, AM ZOOL, V31, P535; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEGEL HG, 1961, ARCH MIKROBIOL, V38, P209, DOI 10.1007/BF00422356; SIDDIQUI RA, 1993, J BACTERIOL, V175, P5867, DOI 10.1128/JB.175.18.5867-5876.1993; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRANBETCKE A, 1990, J BACTERIOL, V172, P2920, DOI 10.1128/jb.172.6.2920-2929.1990; TYREE B, 1978, J BIOL CHEM, V253, P6988; UNDEN G, 1990, FORUM MIKROBIOLOGIE, V4, P211; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; WEIHS V, 1989, ARCH MICROBIOL, V151, P546, DOI 10.1007/BF00454873; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015; ZUMFT WG, 1993, ARCH MICROBIOL, V160, P253, DOI 10.1007/BF00292074; ZUMFT WG, 1992, EUR J BIOCHEM, V208, P31, DOI 10.1111/j.1432-1033.1992.tb17156.x	49	106	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7349	7354						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125952				2022-12-25	WOS:A1994NA03200051
J	PAPADOPOULOU, B; ROY, G; MOURAD, W; LEBLANC, E; OUELLETTE, M				PAPADOPOULOU, B; ROY, G; MOURAD, W; LEBLANC, E; OUELLETTE, M			CHANGES IN FOLATE AND PTERIN METABOLISM AFTER DISRUPTION OF THE LEISHMANIA-H LOCUS SHORT-CHAIN DEHYDROGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DIHYDROPTERIDINE REDUCTASE; P-GLYCOPROTEIN GENE; TRYPANOSOMA-BRUCEI; DIHYDROFOLATE-REDUCTASE; CRITHIDIA-FASCICULATA; TETRAHYDROBIOPTERIN BIOSYNTHESIS; HOMOLOGOUS RECOMBINATION; REGION AMPLIFICATION; DRUG-RESISTANCE; TUBULIN GENE	The short chain dehydrogenase gene ltdh, which is derived from the H locus of Leishmania, confers high level resistance to the dihydrofolate reductase inhibitor methotrexate via a novel mechanism. Resistance is correlated with LTDH overproduction. High level resistance of ltdh transfectants was observed even in poor media where reduced folates are essential for the synthesis of thymidylate precursors. The ltdh transfectants were also capable of growing for several passages, at slightly reduced rates, in unsupplemented folate-deficient medium (fdDME-L), unlike the wild-type cells that could grow only in fdDME-L if supplemented with various folates or pterins. An homozygous ltdh mutant was obtained by gene targeting. This mutant became hypersensitive to methotrexate, but unlike wild-type cells, methotrexate toxicity could not be circumvented by the addition of thymidine. Although the homozygous mutant was capable of growing in fdDME-L supplemented with folate derivatives, it lost its ability to thrive in fdDME-L supplemented with pterins. Our results support the model in which LTDH is a key enzyme responsible for the conversion of a pterin derivative into an essential cofactor. This essential cofactor can also be converted into reduced folates at sufficient levels for growth when LTDH is overproduced, rendering dihydrofolate reductase dispensable. The novelty and uniqueness of LTDH opens the possibility of developing parasite specific inhibitors.	CHU LAVAL, CTR RECH, SERV INFECTIOL, ST FOY G1V 4G2, PQ, CANADA; UNIV LAVAL, FAC MED, DEPT MICROBIOL, ST FOY G1V 4G2, PQ, CANADA	Laval University; Laval University			Ouellette, Marc/K-8694-2017	Ouellette, Marc/0000-0002-6743-9646; Mourad, Walid/0000-0002-1859-9387				AMYES SGB, 1990, J MED MICROBIOL, V31, P1, DOI 10.1099/00222615-31-1-1; BAKER ME, 1991, STEROIDS, V56, P354, DOI 10.1016/0039-128X(91)90067-6; BECK JT, 1991, MOL BIOCHEM PARASIT, V49, P21, DOI 10.1016/0166-6851(91)90126-Q; BECK JT, 1990, MOL BIOCHEM PARASIT, V43, P221, DOI 10.1016/0166-6851(90)90147-E; BERMAN JD, 1988, REV INFECT DIS, V10, P560; Blau N., 1993, PTERIDINES, V4, P1; Brown G. M., 1987, ESCHERICHIA COLI SAL, V1, P521; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; CHUNG HMM, 1993, MOL CELL BIOL, V13, P3734, DOI 10.1128/MCB.13.6.3734; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; COOPER R, 1993, J CELL BIOL, V122, P149, DOI 10.1083/jcb.122.1.149; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DAHL HHM, 1987, NUCLEIC ACIDS RES, V15, P1921, DOI 10.1093/nar/15.5.1921; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; DEWES H, 1986, MOL BIOCHEM PARASIT, V19, P149, DOI 10.1016/0166-6851(86)90120-9; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P10053; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15960; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P13501; HAMMALVAREZ SF, 1990, J BIOL CHEM, V265, P9850; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGHTOWER RC, 1988, J BIOL CHEM, V263, P16970; ICHINOSE H, 1991, BIOCHEM BIOPH RES CO, V179, P183, DOI 10.1016/0006-291X(91)91352-D; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KAUR K, 1988, J BIOL CHEM, V263, P7020; KIDDER GW, 1972, J PROTOZOOL, V19, P93, DOI 10.1111/j.1550-7408.1972.tb03420.x; KIDDER GW, 1973, BIOCHEM BIOPH RES CO, V53, P929, DOI 10.1016/0006-291X(73)90181-2; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LEE MGS, 1991, GENE, V105, P255, DOI 10.1016/0378-1119(91)90159-9; LOCKYER J, 1987, P NATL ACAD SCI USA, V84, P3329, DOI 10.1073/pnas.84.10.3329; MOERTENSEN RM, 1992, MOL CELL BIOL, V12, P2391; OE H, 1984, AGR BIOL CHEM TOKYO, V48, P505; OUELLETTE M, 1991, RES MICROBIOL, V142, P737, DOI 10.1016/0923-2508(91)90089-S; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; OUELLETTE M, 1993, PARASITOL TODAY, V9, P150, DOI 10.1016/0169-4758(93)90135-3; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PAPADOPOULOU B, 1993, NUCLEIC ACIDS RES, V21, P4305, DOI 10.1093/nar/21.18.4305; PAPADOPOULOU B, 1993, ADV EXP MED BIOL, V338, P559; PARK YS, 1991, BIOCHEM BIOPH RES CO, V175, P738, DOI 10.1016/0006-291X(91)91628-P; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; PETRILLOPEIXOTO ML, 1988, MOL CELL BIOL, V8, P5188, DOI 10.1128/MCB.8.12.5188; PETRILLOPEIXOTO MP, 1987, ANTIMICROB AGENTS CH, V31, P1575; SCOTT DA, 1987, MOL BIOCHEM PARASIT, V23, P139, DOI 10.1016/0166-6851(87)90149-6; SHABBAZ M, 1987, J BIOL CHEM, V262, P16412; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; TOBIN JF, 1992, J BIOL CHEM, V267, P4752; WHITE TC, 1988, J BIOL CHEM, V263, P16977; WHITELEY JM, 1993, CHEM BIOL PTERIDINES	49	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7310	7315						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125946				2022-12-25	WOS:A1994NA03200045
J	DEMARIA, S; SCHWAB, R; GOTTESMAN, SRS; BUSHKIN, Y				DEMARIA, S; SCHWAB, R; GOTTESMAN, SRS; BUSHKIN, Y			SOLUBLE BETA(2)-MICROGLOBULIN-FREE CLASS-I HEAVY-CHAINS ARE RELEASED FROM THE SURFACE OF ACTIVATED AND LEUKEMIA-CELLS BY A METALLOPROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTOCOMPATIBILITY COMPLEX-MOLECULES; T-CELL; HUMAN LYMPHOCYTES; ALPHA-3 DOMAIN; MHC; PEPTIDE; ANTIGEN; BETA-2-MICROGLOBULIN; ASSOCIATION; EXPRESSION	Regulation of the expression of major histocompatibility complex (MHC) class I heavy chains not associated with beta(2)-microglobulin (beta(2)m) on freshly isolated and in vitro cultured human B and T leukemia cells was analyzed. These beta(2)m-free class I heavy chains originate from surface beta(2)m-associated MHC class I molecules and are expressed as integral membrane glycoproteins on activated, but not resting, cells. We found that the levels of beta(2)m-free class I heavy chains can be regulated by proteolytic cleavage and release into the medium of soluble molecules containing the extracellular domains. The release is mediated by a Zn2+ dependent, membrane-bound metalloprotease that does not cleave HLA-DR, CD4, and CD71 surface receptors and can be activated by phorbol myristate acetate. Specific cleavage by the metalloprotease occurs at a site close to the papain cleavage site in the alpha 3 domain of class I heavy chains. This site is not accessible to the metalloprotease in beta(2)m-associated MHC class I molecules. The dissociation of beta(2)m-associated MHC class I molecules and subsequent cleavage of beta(2)m-free class I heavy chains may be partially responsible for controlling the levels of MHC class I molecules on the surface of activated cells.	PUBL HLTH RES INST CITY NEW YORK INC,MOLEC IMMUNOL LAB,NEW YORK,NY 10016; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021; NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	Cornell University; New York University; New York University			Demaria, Sandra/AAA-5816-2020; Demaria, Sandra/A-8959-2008	Demaria, Sandra/0000-0003-4426-0499; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008092] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI 07382] Funding Source: Medline; NIA NIH HHS [AG 08092] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AOSAI F, 1991, EUR J IMMUNOL, V21, P2767, DOI 10.1002/eji.1830211118; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; BENJAMIN RJ, 1992, IMMUNOGENETICS, V37, P73; BIX M, 1992, J EXP MED, V176, P829, DOI 10.1084/jem.176.3.829; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BUSHKIN Y, 1986, J EXP MED, V164, P458, DOI 10.1084/jem.164.2.458; BUSHKIN Y, 1988, P NATL ACAD SCI USA, V85, P3985, DOI 10.1073/pnas.85.11.3985; CARBONE E, 1993, EUR J IMMUNOL, V23, P1752, DOI 10.1002/eji.1830230803; CHAKRABARTI A, 1992, BIOCHEMISTRY-US, V31, P7182, DOI 10.1021/bi00146a022; CSERMELY P, 1987, BIOCHEM BIOPH RES CO, V144, P863, DOI 10.1016/S0006-291X(87)80044-X; CSERMELY P, 1988, J BIOL CHEM, V263, P6487; DEMARIA S, 1993, INT J CLIN LAB RES, V23, P61, DOI 10.1007/BF02592285; DEMARIA S, 1992, CELL IMMUNOL, V142, P103, DOI 10.1016/0008-8749(92)90272-Q; DOBBE LME, 1988, IMMUNOGENETICS, V27, P203, DOI 10.1007/BF00346587; DUE C, 1986, P NATL ACAD SCI USA, V83, P6007, DOI 10.1073/pnas.83.16.6007; ELLIOTT T, 1991, IMMUNOL TODAY, V12, P386; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; ERDOS EG, 1989, J BIOL CHEM, V264, P14519; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; GEPPERT TD, 1988, J IMMUNOL, V140, P2155; GILLILAND LK, 1989, HUM IMMUNOL, V25, P269, DOI 10.1016/0198-8859(89)90089-X; GLAS R, 1992, P NATL ACAD SCI USA, V89, P1138; GRASSI F, 1991, J EXP MED, V174, P53, DOI 10.1084/jem.174.1.53; HARRISON D, 1991, J IMMUNOL, V147, P3459; HOXIE JA, 1986, J IMMUNOL, V137, P1194; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; MADRIGAL JA, 1991, J EXP MED, V174, P1085, DOI 10.1084/jem.174.5.1085; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; MAY WS, 1984, P NATL ACAD SCI-BIOL, V81, P2016, DOI 10.1073/pnas.81.7.2016; MCCUNE JM, 1975, P NATL ACAD SCI USA, V72, P3206, DOI 10.1073/pnas.72.8.3206; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; ORR HT, 1979, BIOCHEMISTRY-US, V18, P5711, DOI 10.1021/bi00592a030; OTTEN GR, 1992, J IMMUNOL, V148, P3723; PICKL WF, 1993, J IMMUNOL, V151, P2613; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Powers J.C., 1986, PROTEINASE INHIBITOR, P219; QUARANTA V, 1981, IMMUNOGENETICS, V13, P285, DOI 10.1007/BF00364494; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROMAGNOLI P, 1991, EMBO J, V10, P1303, DOI 10.1002/j.1460-2075.1991.tb07648.x; SAMBHARA SR, 1991, SCIENCE, V252, P1424; SCHNABL E, 1990, J EXP MED, V171, P1431, DOI 10.1084/jem.171.5.1431; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SMITH JD, 1992, J EXP MED, V175, P191, DOI 10.1084/jem.175.1.191; SPIER CM, 1986, HUM PATHOL, V17, P1126, DOI 10.1016/S0046-8177(86)80418-X; SPRINGER TA, 1976, P NATL ACAD SCI USA, V73, P2481, DOI 10.1073/pnas.73.7.2481; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STAM NJ, 1986, J IMMUNOL, V137, P2299; TANABE M, 1992, J IMMUNOL, V148, P3202; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WU Q, 1991, P NATL ACAD SCI USA, V88, P676, DOI 10.1073/pnas.88.2.676	55	82	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6689	6694						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120026				2022-12-25	WOS:A1994MZ50300069
J	FOLEY, M; DEADY, LW; NG, K; COWMAN, AF; TILLEY, L				FOLEY, M; DEADY, LW; NG, K; COWMAN, AF; TILLEY, L			PHOTOAFFINITY-LABELING OF CHLOROQUINE-BINDING PROTEINS IN PLASMODIUM-FALCIPARUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; HUMAN MALARIA PARASITES; ANTIMALARIAL SCHIZONTOCIDES; MECHANISM; PH; IDENTIFICATION; PROTEASE; INVITRO	A photoreactive analog of chloroquine, N-(4-(4-diethylamino-1 -methylbutylamino) quinolin-6-yl)-4-azido-2-hydroxybenzamide (referred to as ASA-Q), has been synthesized and shown to mimic the action of chloroquine in possessing substantial antimalarial activity against a chloroquine-sensitive strain of Plasmodium falciparum. As for chloroquine, ASA-Q is less effective at killing drug-resistant strains of malaria, and the resistance can be modulated using the reagent verapamil. ASA-Q has been radiolabeled with (NaI)-I-125 and used as a photoaffinity probe for labeling chloroquine-binding proteins in malaria-infected erythrocytes. Two proteins have been identified with apparent molecular masses of 42 and 33 kDa in both chloroquine-sensitive and chloroquine-resistant strains of malaria. Photoaffinity labeling of the two proteins by iodo-ASA-Q and was competitively inhibited by an excess of unlabeled chloroquine. The structurally related antimalarials amodiaquine and quinine also inhibited labeling of the two proteins, while verapamil and doxycyclin had no effect. We suggest that the two labeled proteins are the macromolecular targets of chloroquine action in malaria parasites.	LA TROBE UNIV, DEPT BIOCHEM, BUNDOORA, VIC 3083, AUSTRALIA; LA TROBE UNIV, DEPT CHEM, BUNDOORA, VIC 3083, AUSTRALIA; UNIV MELBOURNE, SCH BOT, PLANT CELL BIOL RES CTR, PARKVILLE, VIC 3052, AUSTRALIA; WALTER & ELIZA HALL INST MED RES, IMMUNOPARASITOL UNIT, MELBOURNE, VIC 3052, AUSTRALIA	La Trobe University; La Trobe University; University of Melbourne; Walter & Eliza Hall Institute			Ng, Ken/L-5370-2015; Cowman, Alan F/C-7642-2013	Ng, Ken/0000-0002-1843-0506; Cowman, Alan F/0000-0001-5145-9004; Foley, Michael/0000-0003-1349-4698	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEY SB, 1986, PARASITOLOGY, V92, P511, DOI 10.1017/S0031182000065410; BAKER RH, 1946, J AM CHEM SOC, V68, P1267, DOI 10.1021/ja01211a039; BARNES DA, 1992, EMBO J, V11, P3067, DOI 10.1002/j.1460-2075.1992.tb05378.x; Bayley H, 1977, Methods Enzymol, V46, P69; CHARET P, 1980, COMP BIOCHEM PHYS B, V65, P519, DOI 10.1016/0305-0491(80)90305-3; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; EKONG RM, 1993, PARASITOLOGY, V106, P107, DOI 10.1017/S0031182000074904; FITCH CD, 1972, P HELM SOC WASH, V39, P265; FITCH CD, 1986, PARASITOL TODAY, V2, P330, DOI 10.1016/0169-4758(86)90051-7; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GEARY TG, 1990, BIOCHEM PHARMACOL, V40, P685, DOI 10.1016/0006-2952(90)90302-2; GINSBURG H, 1987, BIOCHEM PHARMACOL, V36, P1567, DOI 10.1016/0006-2952(87)90038-4; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; GYANG FN, 1982, MOL BIOCHEM PARASIT, V5, P263, DOI 10.1016/0166-6851(82)90034-2; HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0; HUSAIN SN, 1983, CARBOHYD RES, V118, P57, DOI 10.1016/0008-6215(83)88035-5; JI I, 1985, ANAL BIOCHEM, V151, P348, DOI 10.1016/0003-2697(85)90186-1; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; PETERS W, 1970, CHEMOTHERAPY DRUG RE, P540; RIEGEL B, 1946, J AM CHEM SOC, V68, P1264, DOI 10.1021/ja01211a038; SHERMAN IW, 1983, MOL BIOCHEM PARASIT, V8, P207, DOI 10.1016/0166-6851(83)90044-0; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERJAGT DI, 1986, MOL BIOCHEM PARASIT, V18, P389, DOI 10.1016/0166-6851(86)90095-2; VANDERJAGT DL, 1987, BIOCHEM PHARMACOL, V36, P3285, DOI 10.1016/0006-2952(87)90646-0; VANDERJAGT DL, 1992, BIOCHIM BIOPHYS ACTA, V1122, P256, DOI 10.1016/0167-4838(92)90401-X; WARHURST DC, 1986, PARASITOL TODAY, V2, P331, DOI 10.1016/0169-4758(86)90052-9; YA Z, 1986, J PARASITOL, V72, P830, DOI 10.2307/3281830; YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784	34	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6955	6961						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120058				2022-12-25	WOS:A1994MZ50300106
J	HERELD, D; VAUGHAN, R; KIM, JY; BORLEIS, J; DEVREOTES, P				HERELD, D; VAUGHAN, R; KIM, JY; BORLEIS, J; DEVREOTES, P			LOCALIZATION OF LIGAND-INDUCED PHOSPHORYLATION SITES TO SERINE CLUSTERS IN THE C-TERMINAL DOMAIN OF THE DICTYOSTELIUM CAMP RECEPTOR, CAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC 3',5'-AMP RELAY; CELL-CELL INTERACTIONS; RHODOPSIN KINASE; CHEMOTACTIC RECEPTOR; GUANINE-NUCLEOTIDES; SIGNALING RESPONSE; ADENYLATE-CYCLASE; AMP RECEPTOR; DISCOIDEUM; ADAPTATION	When Dictyostelium cells are stimulated with cyclic adenosine 3',5'-monophosphate (cAMP), the major surface cAMP receptor expressed in early development, cAR1, undergoes a rapid phosphorylation and parallel decrease in electrophoretic mobility which may serve to regulate the activity of this G protein-coupled receptor. Biochemical analyses indicate the electrophoretic mobility shift is caused by phosphorylation of serine residues within the C-terminal cytoplasmic domain. The 18 serines of this domain are grouped in four clusters, designated 1 to 4 (in N- to C-terminal order). Two approaches were taken to determine the distribution of phosphorylation sites among the serine clusters. First, a proteolytic analysis of the C-terminal domain was performed. Second, mutants lacking various combinations of the serine clusters were created by site-directed mutagenesis and their abilities to undergo ligand-induced modification were determined. Both approaches yielded corroborative results consistent with the following model: the stimulus induces the addition of approximately two phosphates to cluster 1 and one to cluster 2; basal phosphorylation occurs predominantly in cluster 3 and to a lesser extent in cluster 2; and cluster 4 is not phosphorylated. The phosphorylation-deficient receptor mutants should be useful for establishing the role of ligand-induced phosphorylation of cAR1 in chemotaxis, cell-cell signaling, and gene expression.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University					NIGMS NIH HHS [GM34933] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHEN CY, 1993, J BIOL CHEM, V268, P7825; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DINAUER MC, 1980, J CELL BIOL, V86, P545, DOI 10.1083/jcb.86.2.545; DINAUER MC, 1980, J CELL BIOL, V86, P554, DOI 10.1083/jcb.86.2.554; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; FIRTEL RA, 1991, TRENDS GENET, V7, P381, DOI 10.1016/0168-9525(91)90260-W; JOHNSON RL, 1992, COLD SPRING HARB SYM, V57, P169, DOI 10.1101/SQB.1992.057.01.022; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; KLEIN P, 1987, J BIOL CHEM, V262, P352; KLEIN P, 1985, COLD SPRING HARB SYM, V50, P787, DOI 10.1101/SQB.1985.050.01.097; KLEIN P, 1987, J BIOL CHEM, V262, P358; KLEIN P, 1985, J BIOL CHEM, V260, P1757; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MEIER K, 1988, P NATL ACAD SCI USA, V85, P2181, DOI 10.1073/pnas.85.7.2181; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; SAXE CL, 1993, GENE DEV, V7, P262, DOI 10.1101/gad.7.2.262; SAXE CL, 1991, DEV GENET, V12, P6, DOI 10.1002/dvg.1020120104; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TAO YP, 1990, J BIOL CHEM, V265, P15584; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; VANHAASTERT PJM, 1983, J CELL BIOL, V96, P1559, DOI 10.1083/jcb.96.6.1559; VANHAASTERT PJM, 1987, EUR J BIOCHEM, V162, P251; VANHAASTERT PJM, 1992, MOL BIOL CELL, V3, P603, DOI 10.1091/mbc.3.6.603; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538	40	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					7036	7044						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120068				2022-12-25	WOS:A1994MZ50300118
J	KALOUSEK, MB; TRUB, T; SCHUERMANN, M; KLEMENZ, R				KALOUSEK, MB; TRUB, T; SCHUERMANN, M; KLEMENZ, R			T1 IS A C-FOS-RESPONSIVE AND FOSB-RESPONSIVE GENE WHICH IS INDUCED BY GROWTH-FACTORS THROUGH MULTIPLE SIGNAL-TRANSDUCTION PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SWISS 3T3 CELLS; CYCLIC-AMP; HEAT-SHOCK; TRANSCRIPTIONAL ACTIVATION; CARCINOEMBRYONIC ANTIGEN; G0-TO-G1 TRANSITION; MITOGENIC RESPONSE; MOLECULAR-CLONING; MOUSE FIBROBLASTS	Stimulation of quiescent cells with growth factors triggers changes in gene expression through multiple signal transduction pathways. One of these changes in Swiss 3T3 cells is the strong accumulation of T1 mRNA which encodes a secreted glycoprotein of the immunoglobulin superfamily. Proliferating cells continued to express T1 mRNA at a lower level, whereas growth arrest induced either by serum deprivation or by contact inhibition was paralleled by the disappearance of the T1 mRNA. T1 mRNA synthesis in response to serum and platelet-derived growth factor stimulation is mediated through protein kinase C-dependent and protein kinase C-independent pathways. Activation of protein kinase A also led to T1 gene expression. Ongoing protein synthesis is a prerequisite for TI gene induction by growth factors which defines T1 as a delayed early serum re sponsive gene. The ability of the immediate early transcription factors c-Fos and FosB to directly induce the T1 gene was demonstrated in a conditional expression system in the absence of protein synthesis. Furthermore, all known inducers of the T1 gene also lead to c-fos gene activation. Thus we show that the T1 gene is regulated by signals which are transduced through multiple pathways and provide evidence that the Fos proteins play an important role in the integration of these pathways.	UNIV HOSP ZURICH,DEPT PATHOL,DIV CANC RES,CH-8091 ZURICH,SWITZERLAND; IMT,D-35037 MARBURG,GERMANY	University of Zurich; University Zurich Hospital								ABATE C, 1991, ONCOGENE, V6, P2179; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; AUWERX J, 1992, ONCOGENE, V7, P2271; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; Bravo R, 1990, Semin Cancer Biol, V1, P37; BUTLERGRALLA E, 1981, J CELL PHYSIOL, V107, P59, DOI 10.1002/jcp.1041070108; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOTTA F, 1990, BIOCHEM BIOPH RES CO, V168, P1013, DOI 10.1016/0006-291X(90)91130-K; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Foulkes, 1991, HORMONAL CONTROL REG, P257; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GINZBURG I, 1980, NUCLEIC ACIDS RES, V8, P3553, DOI 10.1093/nar/8.16.3553; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PETES TD, 1978, J BACTERIOL, V134, P295, DOI 10.1128/JB.134.1.295-305.1978; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANO M, 1990, J NEUROCHEM, V55, P427, DOI 10.1111/j.1471-4159.1990.tb04154.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; STUBER D, 1991, IMMUNOL METHODS, P121; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TRUB T, 1994, IN PRESS P NATL ACAD; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WOODGETT JR, 1989, BRIT MED BULL, V45, P529, DOI 10.1093/oxfordjournals.bmb.a072340; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	61	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6866	6873						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120048				2022-12-25	WOS:A1994MZ50300094
J	WARTMANN, M; DAVIS, RJ				WARTMANN, M; DAVIS, RJ			THE NATIVE STRUCTURE OF THE ACTIVATED RAF PROTEIN-KINASE IS A MEMBRANE-BOUND MULTISUBUNIT COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; REGULATED EIF-2-ALPHA KINASE; ROUS-SARCOMA VIRUS; GLUCOCORTICOID RECEPTOR; MAP KINASE; SIGNAL TRANSDUCTION; CELLS; EXPRESSION; SEQUENCE; GROWTH	Raf is a mitogen-stimulated protein kinase that functions as a component of the signaling cascade that leads to the stimulation of mitogen-activated protein kinase. Here we show that the native structure of Raf is a large multi-subunit protein complex with an apparent mass of 300-500 kDa that interacts with Res and the mitogen-activated protein kinase kinase Mek. Analysis of the structure of the Raf complex demonstrates that it contains a single Raf protein kinase together with the molecular chaperones hsp90 and p50. The Raf-hsp90-p50 complex was observed in starved cells and in cells activated with serum or phorbol ester. Thus, changes in complex formation with hsp90 and p50 are not required for activation of the Raf protein kinase, However, Raf activation caused by Res was associated with the translocation of the cytoplasmic Raf-hsp90-p50 complex to the cell membrane. Significantly, it is only the membrane-bound complex that exhibits increased protein kinase activity. Thus, the Has-activated Raf protein kinase functions as a membrane-bound multi-subunit complex,	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA58396] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BORNER C, 1989, J BIOL CHEM, V264, P13902; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENIS M, 1987, J BIOL CHEM, V262, P11803; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; ITOH T, 1993, J BIOL CHEM, V268, P3025; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIH TY, 1984, CANCER INVEST, V2, P109, DOI 10.3109/07357908409020294; SOZERI O, 1992, ONCOGENE, V7, P3345; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	60	251	253	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6695	6701						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120027				2022-12-25	WOS:A1994MZ50300070
J	ZGOMBICKNIGHT, M; SATRE, MA; DUESTER, G				ZGOMBICKNIGHT, M; SATRE, MA; DUESTER, G			DIFFERENTIAL ACTIVITY OF THE PROMOTER FOR THE HUMAN ALCOHOL-DEHYDROGENASE (RETINOL DEHYDROGENASE) GENE ADH3 IN NEURAL-TUBE OF TRANSGENIC MOUSE EMBRYOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RESPONSE ELEMENT; CHICK LIMB BUD; BINDING-PROTEIN; POLARIZING ACTIVITY; ETHANOL INHIBITION; HENSEN NODE; HUMAN LIVER; VITAMIN-A; IDENTIFICATION; FAMILY	Mammalian alcohol dehydrogenase (ADH) has previously been shown to function in vitro as a retinol dehydrogenase as well as an ethanol dehydrogenase. Thus, ADH participates in the conversion of retinol (vitamin A alcohol) to retinoic acid, a regulatory ligand for the retinoic acid receptor class of transcription factors. Human ADH exists as a family of isozymes encoded by seven genes, which are differentially expressed in adult liver and extrahepatic tissues, being found preferentially in the epithelial cells which are retinoid target tissues. However, human ADH expression patterns have not been analyzed in early embryonic tissues, which are known to synthesize and respond to retinoic acid such as the neural tube and limb buds. To estimate the embryonic expression pattern for one member of the human ADH family, we have constructed transgenic mouse lines carrying the human ADH3 promoter fused to the lacZ gene. ADH3-lacZ transgene expression was first noted at embryonic day 9.5 and was active in the neural tube extending from the midbrain to the spinal cord, as well as the heart and proximal regions of the forelimb buds. In day 12.5 and 13.5 embryos, ADH3 transgene expression remained in the neural tube and heart and was also observed in more distal regions of the forelimb and hindlimb buds as well as the kidney. Expression in the neural tube was highest in the ventral midline including the floor plate and showed a ventral to dorsal gradient of decreasing expression. These findings indicate that at least one human ADH isozyme may exist in the correct tissues to act as an embryonic retinol dehydrogenase catalyzing the synthesis of retinoic acid.	LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NIAAA NIH HHS [AA07261] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007261] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; BALKAN W, 1992, P NATL ACAD SCI USA, V89, P3347, DOI 10.1073/pnas.89.8.3347; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; BUHLER R, 1983, PHARMACOL BIOCHEM BE, V18, P55, DOI 10.1016/0091-3057(83)90147-8; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10056, DOI 10.1073/pnas.89.21.10056; CLARREN SK, 1978, NEW ENGL J MED, V298, P1063, DOI 10.1056/NEJM197805112981906; DENCKER L, 1987, DEV PHARMACOL THERAP, V10, P212, DOI 10.1159/000457746; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DUESTER G, 1986, J BIOL CHEM, V261, P2027; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Duester G., 1991, LIVER PATHOLOGY ALCO, P375; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HALEVY O, 1993, J CELL PHYSIOL, V154, P566, DOI 10.1002/jcp.1041540315; HENEHAN GTM, 1993, BIOCHEMISTRY-US, V32, P736, DOI 10.1021/bi00054a001; HOGAN B, 1986, MANIPULATING MOUSE E; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; HUNTER K, 1991, P NATL ACAD SCI USA, V88, P3666, DOI 10.1073/pnas.88.9.3666; IWAMOTO M, 1993, EXP CELL RES, V205, P213, DOI 10.1006/excr.1993.1079; JONES KL, 1973, LANCET, V2, P999; JULIA P, 1983, BIOCHEM J, V213, P547, DOI 10.1042/bj2130547; KIM CI, 1992, ARCH BIOCHEM BIOPHYS, V294, P388, DOI 10.1016/0003-9861(92)90700-7; KOCHHAR DM, 1967, ACTA PATHOL MIC SC, V70, P398; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; MEZEY E, 1971, EXP MOL PATHOL, V15, P148, DOI 10.1016/0014-4800(71)90095-5; MURRAY RF, 1971, SCIENCE, V171, P71, DOI 10.1126/science.171.3966.71; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; PARES X, 1992, FEBS LETT, V303, P69, DOI 10.1016/0014-5793(92)80479-Z; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIETRUSZKO R, 1979, BIOCH PHARMACOLOGY E, V1, P87; POCKER Y, 1993, ADV EXP MED BIOL, V328, P411; POCKER Y, 1987, ADV BIOMEDICAL ALCOH, P181; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUGH R, 1990, MOUSE ITS REPRODUCTI; SMITH M, 1971, ANN HUM GENET, V34, P251, DOI 10.1111/j.1469-1809.1971.tb00238.x; STEWART MJ, 1990, GENE, V90, P271, DOI 10.1016/0378-1119(90)90190-3; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; VANTHIEL DH, 1974, SCIENCE, V186, P941, DOI 10.1126/science.186.4167.941; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WAGNER M, 1992, DEVELOPMENT, V116, P55; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873; Yang Z. N., 1993, Alcoholism Clinical and Experimental Research, V17, P496; YIN SJ, 1993, ALCOHOL CLIN EXP RES, V17, P376, DOI 10.1111/j.1530-0277.1993.tb00779.x; ZACHMAN RD, 1961, J BIOL CHEM, V236, P2309	51	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6790	6795						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120040				2022-12-25	WOS:A1994MZ50300084
J	CAMANI, C; BACHMANN, F; KRUITHOF, EKO				CAMANI, C; BACHMANN, F; KRUITHOF, EKO			THE ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN THE CLEARANCE OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY RAT HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; T-PA; UROKINASE RECEPTOR; COMPLEXES; LIVER; BINDING; IDENTIFICATION; INTERNALIZES; DEGRADATION	The role of plasminogen activator inhibitor type 1 (PAI-1) in the clearance of tissue-type plasminogen activator (t-PA) by hepatocyte like cells was studied. Rat (Novikoff) hepatoma cells were able to bind and degrade t-PA in a PAI-1 independent fashion, but PAI-I markedly increased the rate of degradation and t-PA/PAI-1 was a more efficient inhibitor of I-125-t-PA or of I-125-t-PA/PAI-1 degradation than free t-PA. Competition studies revealed that the effect of PAI-1 is unlikely to involve determinants located on the PAI-1 part of the complex: 1) an excess of fi ee PAI had no effect on the rate of degradation of I-125-t-PA/PAI-1. 2) Complexes of PAI-1 with urokinase-type PA or with a t-PA mutant lacking the finger and growth factor domains were unable to compete for the binding and degradation of free or PAI-l-complexed I-125-t-PA.3) t-PA KHRR296-299AAAA, a mutant which reacts 2 orders of magnitude slower with PAI-1 than wild type t-PA, behaved similar to wild type t-PA. The clearance via both the PAI-1-dependent and the PAI-1-independent mechanisms was inhibited by the receptor-associated protein, a general inhibitor of clearance mediated by the LDL receptor-related protein. We conclude that t-PA can be cleared by rat hepatoma cells in a PAI-1 independent fashion, but after complex formation with PAI-1, binding of BPA to the cells is increased and clearance accelerated. Both mechanisms seem to involve the same receptor.	CHU VAUDOIS,DEPT INTERNAL MED,DIV HEMATOL,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Kruithof, Egbert/AGR-4755-2022					ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BASSELDUBY R, 1992, J BIOL CHEM, V267, P9668; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; EINARSSON M, 1988, THROMB HAEMOSTASIS, V59, P474; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KUIPER J, 1988, J BIOL CHEM, V263, P18220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1990, J BIOL CHEM, V265, P5677; MORTON PA, 1990, J BIOL CHEM, V265, P14093; MORTON PA, 1989, J BIOL CHEM, V264, P7228; NGUYEN G, 1992, J BIOL CHEM, V267, P6249; NGUYEN G, 1992, BIOCHEM J, V287, P911, DOI 10.1042/bj2870911; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; PAONI NF, 1993, THROMB HAEMOSTASIS, V70, P307; SEYDEL W, 1991, DRUG RES, V41, P182; SMEDSROD B, 1990, THROMB HAEMOSTASIS, V63, P60; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WING LR, 1991, FEBS LETT, V278, P95, DOI 10.1016/0014-5793(91)80092-H; WING LR, 1991, J LAB CLIN MED, V117, P109	34	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5770	5775						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119917				2022-12-25	WOS:A1994MY84000047
J	WELHAM, MJ; DURONIO, V; SCHRADER, JW				WELHAM, MJ; DURONIO, V; SCHRADER, JW			INTERLEUKIN-4-DEPENDENT PROLIFERATION DISSOCIATES P44(ERK-1), P42(ERK-2) AND P21(RAS) ACTIVATION FROM CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MAP KINASE-KINASE; INDUCED TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE; XENOPUS OOCYTES; RECEPTOR; P21RAS; EXPRESSION; INSULIN	The activation of erk/mitogen-activated protein kinases and p21(ras) is strongly associated with progression through the cell cycle. Cell growth induced by the cytokine interleukin-4 (IL-4) effectively dissociates the activation of p44(erk-1) and p42(erk-2) mitogen-activated protein kinases and p21(ras) from cell proliferation. In two cell lines of T lymphocyte and myeloid origin that were dependent upon IL-4 for continuous growth, IL-4 failed to detectably activate or induce tyrosine phosphorylation of p44(erk-1) and p42(erk-2). The activation of p21(ras) was also not detectably affected by IL-4 treatment of these cells. Treatment of the same cells with other growth factors (colony-stimulating factor-1 and Steel factor) or phorbol esters induced the tyrosine phosphorylation and activation of p44(erk-1) and p42(erk-2) and stimulated p21(ras) activity. The presence of IL-4 neither diminished nor enhanced the activation of p44(erk-1) and p42(erk-2) by colony-stimulating factor 1, Steel factor, or 12-O-tetradecanoylphorbol-13-acetate. Furthermore, IL-4 also failed to activate p44(erk-1), p42(erk-2), and p21(ras) in normal T lymphocytes and mast cells derived from spleen and bone marrow, respectively. Significantly, these findings demonstrate that IL-4-induced cell growth may be dissociated from the activation of p44(erk-1), p42(erk-2), and p21(ras), suggesting that their activation may not be an absolute requirement for growth factor-stimulated mitogenesis.			WELHAM, MJ (corresponding author), UNIV BRITISH COLUMBIA, BIOMED RES CTR, 2222 HLTH SCI MALL, VANCOUVER V6T 1Z3, BC, CANADA.							AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BECKMANN MP, 1992, CHEM IMMUNOL, V51, P107; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CALLARD RE, 1990, IMMUNOL TODAY, V11, P200, DOI 10.1016/0167-5699(90)90082-K; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GOLD MR, 1992, BIOCHEM J, V287, P269, DOI 10.1042/bj2870269; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HULI J, 1989, J IMMUNOL, V142, P800; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NEL AE, 1990, J IMMUNOL, V144, P2683; OKUDA K, 1992, BLOOD, V79, P2880; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAUL WE, 1991, BLOOD, V77, P1859; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAINES MA, 1992, BLOOD, V79, P3350; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RENNICK DM, 1992, IL4 STRUCTURE FUNCTI, P51; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	53	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5865	5873						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119929				2022-12-25	WOS:A1994MY84000060
J	LUI, JX; LEE, WK; JIANG, C; KELLER, EB				LUI, JX; LEE, WK; JIANG, C; KELLER, EB			START SITE SELECTION BY SP1 IN THE TATA-LESS HUMAN HA-RAS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; BLADDER-CARCINOMA ONCOGENE; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; INITIATOR; BINDING; ELEMENT; REQUIREMENT; INVITRO; PROTEIN	Th promoter of the human Ha-ras gene is very GC-rich, has four Sp1-binding sites and no TATA element. Transcription initiates at multiple start sites spread over a 90-base pair region, with a major cluster between +1 and +11. We detected the binding of a HeLa nuclear protein to the region from +6 to +20, a region which overlaps the major cluster and includes nine start sites within its boundaries. When part of this region was mutated, the nine start sites were abolished, so the region may be an initiator. The regulatory elements of the promoter have no differential effect on start site usage. But Sp1 bound to GCIV located at -38 acts as a start site selector, increasing the activity of the start sites from +1 downstream but not the upstream sites at -31, -21, and -10. When spacers of increasing length were inserted 3' to GCIV, the major cluster dwindled, and the upstream sites became strong sites, first the one at -10 and then the one at -21. Thus start sites were strongest when put into an Sp1-selected locus 36 to 53 base pairs downstream from GCIV and weak when outside this locus. The start sites with these properties may be due to initiators.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; AMC,CANC RES CTR,DENVER,CO 80214; MYONGJI UNIV,DEPT BIOL,KYUNGGI DO 449728,SOUTH KOREA	Cornell University; AMC Cancer Research Center; Myongji University				Lu, Junxuan/0000-0002-2354-7186	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010791] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM10791] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BASU A, 1993, J BIOL CHEM, V268, P4188; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CICHUTEK K, 1986, P NATL ACAD SCI USA, V83, P2340, DOI 10.1073/pnas.83.8.2340; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DAMANTE G, 1987, P NATL ACAD SCI USA, V84, P774, DOI 10.1073/pnas.84.3.774; Favaloro J, 1980, Methods Enzymol, V65, P718; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; LEE W, 1991, TRANSCRIPTIONAL REGU; LEE WK, 1991, J MOL BIOL, V220, P599, DOI 10.1016/0022-2836(91)90103-D; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Sambrook J, 1989, MOL CLONING LABORATO; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIELAND S, 1990, NUCLEIC ACIDS RES, V18, P5113, DOI 10.1093/nar/18.17.5113	37	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5391	5402						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106522				2022-12-25	WOS:A1994MX57100104
J	NOESKEJUNGBLUT, C; KRATZSCHMAR, J; HAENDLER, B; ALAGON, A; POSSANI, L; VERHALLEN, P; DONNER, P; SCHLEUNING, WD				NOESKEJUNGBLUT, C; KRATZSCHMAR, J; HAENDLER, B; ALAGON, A; POSSANI, L; VERHALLEN, P; DONNER, P; SCHLEUNING, WD			AN INHIBITOR OF COLLAGEN-INDUCED PLATELET-AGGREGATION FROM THE SALIVA OF TRIATOMA-PALLIDIPENNIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAEMENTERIA-OFFICINALIS LEECH; IDENTIFICATION; ADHESION; GLANDS; ACTIVATION; PROTEINS; RECEPTOR; PEPTIDE; BLOOD	The saliva of Triatoma pallidipennis, a blood-sucking triatomine bug (Hemiptera, family Reduviidae, subfamily Triatominae) was found to contain a factor that specifically inhibits collagen-induced platelet aggregation. The 19-kDa protein was purified to homogeneity and named pallidipin. Collagen-mediated aggregation of platelets in plasma and of washed platelets was inhibited with the same efficacy. No inhibition of aggregation stimulated by other effecters (ADP, thrombin, thromboxane A(2) mimetic U46619, phorbol ester) was detected. Pallidipin had no effect on platelet adhesion to collagen but inhibited ATP release from platelets. It interacted reversibly with platelets and may share with collagen a common target on them. The protein exhibits a unique primary structure (predicted from cDNA clones) with no significant similarity to other previously described sequences. The protein produced in recombinant baby hamster kidney cells had antiaggregatory effects similar to those of native pallidipin. Availability of recombinant pallidipin will allow further investigation of the precise mechanism of action.	UNIV NACL AUTONOMA MEXICO, INST BIOTECNOL, CUERNAVACA 62271, MORELOS, MEXICO	Universidad Nacional Autonoma de Mexico	NOESKEJUNGBLUT, C (corresponding author), SCHERING AG, RES LABS, D-13342 BERLIN, GERMANY.		Possani, Lourival D/J-2397-2013					BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLER BS, 1989, BLOOD, V74, P182; CONNOLLY TM, 1992, J BIOL CHEM, V267, P6893; HARLOW E, 1988, ANTIBODIES LAB MANUA, P508; KELLER PM, 1993, J BIOL CHEM, V268, P5450; KELLER PM, 1992, J BIOL CHEM, V267, P6899; KRATZSCHMAR J, 1992, GENE, V116, P281, DOI 10.1016/0378-1119(92)90526-U; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Peitsch M C, 1990, New Biol, V2, P197; RIBEIRO JMC, 1989, SCIENCE, V243, P212, DOI 10.1126/science.2783496; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TARR GE, 1986, METHODS PROTEIN MICR, P162; WAXMAN L, 1993, J BIOL CHEM, V268, P5445; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; WIRTH M, 1988, GENE, V73, P419, DOI 10.1016/0378-1119(88)90506-9; ZUCKER MB, 1989, METHOD ENZYMOL, V169, P117	22	87	91	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5050	5053						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106481				2022-12-25	WOS:A1994MX57100056
J	WANG, X; FOLK, WR				WANG, X; FOLK, WR			TERMINATION OF TRANSCRIPTION BY RNA-POLYMERASE-III FROM WHEAT-GERM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO TRANSCRIPTION; BINDING PROTEIN; PAUSE SITE; DNA; ELONGATION; SEQUENCES; PURIFICATION; INITIATION; EFFICIENCY; COMPLEXES	A novel system has been established to study transcription by RNA polymerase III. Purified wheat germ RNA polymerase III will initiate transcription on SV40 DNA templates amplified by polymerase chain reaction. Transcription initiates primarily at a thymidine 3 residues from a PvuII terminus at nucleotide 272 and terminates at a downstream A(8):T-8 sequence at nucleotides 21-28. Termination is enhanced if the RNA polymerase is caused to pause downstream of the A(8):T-8 sequence, but termination is unaffected by upstream sequences. Transcription of heteroduplex DNA templates with mismatches in the A(8):T-8 sequence indicates that termination is dependent upon the integrity of the A(8) sequence in the template strand and is only slightly affected by changes in the T-8 sequence of the non-template strand. However, templates containing 2'-deoxyuridine or 5'-bromo-2'-deoxyuridine in place of thymidine in the nontemplate strand reduce termination efficiency, as does incorporation of 5'-bromouracil into RNA. There is no obvious correlation between DNA bending and termination efficiency.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia				Folk, William/0000-0003-2216-3233				BARTSCH I, 1988, MOL CELL BIOL, V8, P3891, DOI 10.1128/MCB.8.9.3891; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BROWN RD, 1976, J MOL BIOL, V102, P1, DOI 10.1016/0022-2836(76)90070-X; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CHAMBERLIN M, 1963, J MOL BIOL, V7, P334, DOI 10.1016/S0022-2836(63)80028-5; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHENG SWC, 1991, SCIENCE, V254, P1205, DOI 10.1126/science.1835546; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; DIEKMANN S, 1992, J MOL BIOL, V225, P729, DOI 10.1016/0022-2836(92)90397-3; ENRIQUEZHARRIS P, 1991, EMBO J, V10, P1833, DOI 10.1002/j.1460-2075.1991.tb07709.x; FISHER RF, 1985, J MOL BIOL, V182, P397, DOI 10.1016/0022-2836(85)90199-8; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; GRUMMT I, 1986, CELL, V45, P837, DOI 10.1016/0092-8674(86)90558-1; JAMES P, 1990, GENETICS, V125, P293; JENDRISAK J, 1981, PLANT PHYSIOL, V67, P438, DOI 10.1104/pp.67.3.438; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LEDNICKY J, 1992, J VIROL, V66, P6379, DOI 10.1128/JVI.66.11.6379-6390.1992; MATSUMOTO K, 1989, J BIOL CHEM, V264, P1124; MCSTAY B, 1990, MOL CELL BIOL, V10, P2793, DOI 10.1128/MCB.10.6.2793; PAULY M, 1992, NUCLEIC ACIDS RES, V20, P975, DOI 10.1093/nar/20.5.975; PENNINGROTH SM, 1980, J BIOL CHEM, V255, P9545; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WATSON JB, 1984, NUCLEIC ACIDS RES, V12, P5369, DOI 10.1093/nar/12.13.5369; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009	42	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4993	5004						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106475				2022-12-25	WOS:A1994MX57100048
J	CRAIG, L; JOHNSON, JE; CORNELL, RB				CRAIG, L; JOHNSON, JE; CORNELL, RB			IDENTIFICATION OF THE MEMBRANE-BINDING DOMAIN OF RAT-LIVER CTP - PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE USING CHYMOTRYPSIN PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; HAMSTER OVARY CELLS; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE SYNTHESIS; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE-C; FATTY-ACIDS; TRANSLOCATION; CYTOSOL	Limited chymotrypsin proteolysis of CTP:phosphocholine cytidylyltransferase (CT; EC 2.7.7.15) produced several distinct fragments which were mapped to the N terminus of CT using antibodies directed against the N and C terminus and the conserved central domain. A time course of chymotrypsin proteolysis showed a progression in digestion as follows: 42 --> 39 --> 35 --> 30 --> 28 --> 26 kDa. The binding of CT and of the chymotrypsin fragments to lipid vesicles was assessed by floatation analysis. The ability of the fragments to bind to activating lipid vesicles correlated with the presence of a putative amphipathic alpha-helix, helix-1, between residues 236 and 293. Fragments lacking this helix could, however, bind to phosphatidylcholine/sphingosine vesicles, which inhibit CT activity, and were capable of dimer formation. The degree of resistance to chymotrypsin degradation increased when CT was bound to the strongly activating lipid vesicles phosphatidylcholine/oleic acid (1:1) and phosphatidylcholine/phosphatidylglycerol (1:1). Conversion of the 39- and 35-kDa fragments, which contain the intact helix-1, to the 30-, 28-, and 26-kDa bands, which lack helix-1, required longer proteolysis times, suggesting that this helical domain is more shielded from solvent upon membrane binding. These results support the theory that CT has a bipartite tertiary structure composed of a globular N-terminal domain and an extended C-terminal domain and that CT interacts with membranes via its putative amphipathic helix which intercalates into the membrane bilayer of activating phospholipids.	SIMON FRASER UNIV,DEPT CHEM BIOCHEM,BURNABY V5A 1S6,BC,CANADA; SIMON FRASER UNIV,INST MOLEC BIOL & BIOCHEM,BURNABY V5A 1S6,BC,CANADA	Simon Fraser University; Simon Fraser University				Craig, Lisa/0000-0001-8515-9915				BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARLTON LA, 1992, J BIOL CHEM, V267, P8840; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; EDELSTEIN C, 1979, J LIPID RES, V20, P143; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; HATCH GM, 1992, J BIOL CHEM, V267, P15751; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; JOHNSON JE, 1994, IN PRESS BIOCHEMISTR; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KAY R, 1991, Methods in Molecular and Cellular Biology, V2, P254; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; KUMAR N, 1981, J BIOL CHEM, V256, P5886; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTY I, 1992, BIOCHEMISTRY-US, V31, P4058, DOI 10.1021/bi00131a023; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; MYHER JJ, 1979, CAN J BIOCHEM CELL B, V57, P117, DOI 10.1139/o79-015; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; STERN W, 1976, BIOCHIM BIOPHYS ACTA, V441, P280, DOI 10.1016/0005-2760(76)90171-5; TERCE F, 1992, BIOCHEM J, V282, P333, DOI 10.1042/bj2820333; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; WANG YL, 1993, J BIOL CHEM, V268, P5512; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; YAO ZM, 1990, J BIOL CHEM, V265, P4326; ZWERLING SJ, 1991, J BIOL CHEM, V266, P4574; [No title captured]	37	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3311	3317						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106370				2022-12-25	WOS:A1994MV63100031
J	TANG, SQ; MIKALA, G; BAHINSKI, A; YATANI, A; VARADI, G; SCHWARTZ, A				TANG, SQ; MIKALA, G; BAHINSKI, A; YATANI, A; VARADI, G; SCHWARTZ, A			MOLECULAR LOCALIZATION OF ION SELECTIVITY SITES WITHIN THE PORE OF A HUMAN L-TYPE CARDIAC CALCIUM-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SODIUM-CHANNEL; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; K+ CHANNELS; GUINEA-PIG; PERMEATION; CELLS	A highly conserved position of negatively charged amino acids is present in the SS2 segments of the S5-S6 linker regions among calcium channels. We report here that replacing Glu residues at this position alters the ion selectivity of the human cardiac calcium channel. Substituting Glu334 in motif I or Glu1086 in motif III with Lys produced mutant calcium channels that permeated sodium ions 10-fold more effectively than barium ions. More conservative changes such as substitution of Glu1086 with Gln or substitution of Glu1387 with Ala also increased sodium permeation through the mutant calcium channels. Sodium currents through the mutant calcium channels could be modulated by dihydropyridines and blocked by external divalent cations. These results suggest that Glu334, Glu1086, and Glu1387 are part of a ring of glutamate residues formed in the pore-lining SS1-SS2 region and are critical in determining ion selectivity and permeability of a human cardiac calcium channel.	UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, 231 BETHESDA AVE, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, T32HL007382, R37HL043231] Funding Source: NIH RePORTER; NHLBI NIH HHS [5R37 HL43231-04, T32 HL07382-16, P01 HL22619-15] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Erlich H.A., 1989, PCR TECHNOLOGY; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hille B, 1992, IONIC CHANNELS EXCIT, P362; KOSTYUK PG, 1983, J MEMBRANE BIOL, V76, P83, DOI 10.1007/BF01871455; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE KS, 1984, J PHYSIOL-LONDON, V354, P253, DOI 10.1113/jphysiol.1984.sp015374; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATSUDA H, 1986, PFLUG ARCH EUR J PHY, V407, P465, DOI 10.1007/BF00657502; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHULTZ D, 1993, IN PRESS P NATL ACAD; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	25	161	166	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13026	13029						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8099908				2022-12-25	WOS:A1993LH55300005
J	LEVEQUE, C; ELFAR, O; MARTINMOUTOT, N; SATO, K; KATO, R; TAKAHASHI, M; SEAGAR, MJ				LEVEQUE, C; ELFAR, O; MARTINMOUTOT, N; SATO, K; KATO, R; TAKAHASHI, M; SEAGAR, MJ			PURIFICATION OF THE N-TYPE CALCIUM-CHANNEL ASSOCIATED WITH SYNTAXIN AND SYNAPTOTAGMIN - A COMPLEX IMPLICATED IN SYNAPTIC VESICLE EXOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONOTOXIN GVIA RECEPTOR; PROTEIN-KINASE-C; SKELETAL-MUSCLE; NEUROTRANSMITTER RELEASE; FUNCTIONAL EXPRESSION; MONOCLONAL-ANTIBODY; CA-2+ CHANNELS; CA2+ CHANNELS; ACTIVE ZONES; BETA-SUBUNIT	omega-Conotoxin-sensitive N-type calcium channels control neurotransmitter release at the nerve terminal and interact with proteins implicated in secretion. Solubilized omega-conotoxin receptors from rat brain synaptic membranes were immunoprecipitated by antibodies against calcium channel alpha 1 subunits, syntaxin, and a 105-kDa plasma membrane protein. A multimeric complex, composed of calcium channel subunits, and synaptic proteins that showed varying degrees of association, was purified by a procedure involving anti-syntaxin immunoaffinity chromatography. A 250-kDa N-type alpha 1 subunit, containing cAMP-dependent phosphorylation site(s), was identified by photoaffinity labelling with I-125-azidonitrobenzoyl omega-conotoxin and immunoblotting with sequence-directed antibodies. An immunologically related 210-kDa form of the alpha 1 subunit was detected that displayed different pharmacological and regulatory properties. Protein bands of 140, 70, 58, and 35 kDa comigrated with purified alpha 1 subunits upon sucrose gradient centrifugation, whereas the 105-kDa protein was removed. The 58- and 35-kDa bands contained, respectively, the synaptic vesicle protein synaptotagmin and syntaxin, a plasma membrane protein that binds synaptic vesicle proteins. Purified omega-conotoxin receptors were quantitatively immunoprecipitated by anti-syntaxin antibodies. These proteins may constitute an isolated exo-cytotic complex in which the N-type calcium channel tightly interacts with a synaptic vesicle docking site.	FAC MED MARSEILLE,INST JEAN ROCHE,INST NATL SANTE & RECH MED,U374,SECTEUR NORD,F-13916 MARSEILLE 20,FRANCE; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			leveque, christian/GVU-3567-2022; Far, Oussama El/D-4225-2017; EL FAR, Oussama/P-9915-2019	leveque, christian/0000-0003-2583-2148; Far, Oussama El/0000-0002-7473-8345; EL FAR, Oussama/0000-0002-7473-8345				ABE T, 1987, J BIOL CHEM, V262, P9877; AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; BARHANIN J, 1988, BIOCHEM BIOPH RES CO, V150, P1051, DOI 10.1016/0006-291X(88)90736-X; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MALOUF NN, 1992, NEURON, V8, P899, DOI 10.1016/0896-6273(92)90204-Q; MARQUEZE B, 1988, MOL PHARMACOL, V34, P87; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MORITA T, 1992, BIOMED RES-TOKYO, V13, P357, DOI 10.2220/biomedres.13.357; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; SAISU H, 1991, BIOCHEM BIOPH RES CO, V181, P59, DOI 10.1016/S0006-291X(05)81381-6; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHMID A, 1986, BIOCHEMISTRY-US, V25, P3492, DOI 10.1021/bi00360a002; SCOTT RH, 1991, PROG NEUROBIOL, V36, P485, DOI 10.1016/0301-0082(91)90014-R; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; TAKAHASHI M, 1989, BIOCHEM BIOPH RES CO, V163, P1182, DOI 10.1016/0006-291X(89)92345-0; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; TAKAHASHI M, 1987, SCIENCE, V236, P88, DOI 10.1126/science.2436296; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; Walch-Solimena C, 1993, Curr Opin Neurobiol, V3, P329, DOI 10.1016/0959-4388(93)90125-I; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P	46	186	191	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6306	6312						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119979				2022-12-25	WOS:A1994MZ50300011
J	MEERABUX, JM; COTTER, FE; KEARNEY, L; NIZETIC, D; DHUT, S; GIBBONS, B; LISTER, TA; YOUNG, BD				MEERABUX, JM; COTTER, FE; KEARNEY, L; NIZETIC, D; DHUT, S; GIBBONS, B; LISTER, TA; YOUNG, BD			MOLECULAR-CLONING OF A NOVEL 11Q23 BREAKPOINT ASSOCIATED WITH NON-HODGKINS-LYMPHOMA	ONCOGENE			English	Article							B-CELL LYMPHOMA; ACUTE LEUKEMIAS; CHROMOSOME-TRANSLOCATION; DROSOPHILA-TRITHORAX; INSITU HYBRIDIZATION; GENE; ABNORMALITIES; T(4-11); IDENTIFICATION; DISTINCT	Chromosomal analysis of a non-Hodgkin's lymphoma revealed a t(11;14)(q23;q32) translocation amongst other abnormalities. To investigate the molecular basis of this translocation, a cosmid library was constructed from the tumour DNA and the rearranged IGH locus was isolated in a single cosmid. Fluorescence in situ hybridization confirmed that the cloned region contained sequences from chromosome 11q23 fused to chromosome 14q32. Sequence analysis identified the breakpoint as a fusion between a region from the switch segment of the C gamma 4 gene of the IGH locus and an unknown sequence on chromosome 11. The chromosome 11 sequence maps proximal to the CD3 gene cluster and is therefore distinct from both the HTRX1 gene (rearranged in acute leukaemias) and the RCK gene (rearranged in a cell line derived from a histiocytic B-cell lymphoma). This newly identified region contains a cluster of rare cutting restriction enzyme sites located within 200 bases of the breakpoint, suggestive of a CpG island. Although this t(11;14)(q23;q32) translocation and that in the RC-K8 cell line affect different regions on chromosome 11, the breakpoints on chromosome 14 were found to have occurred at equivalent positions of S gamma 2 and S gamma 4 segments.	ST BARTHOLOMEWS HOSP,DEPT MED ONCOL,IMPERIAL CANC RES FUND,LONDON EC1A 7BE,ENGLAND; INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND; IMPERIAL CANC RES FUND,GENOME ANAL LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; University of London; Queen Mary University London; University of London; University College London; Cancer Research UK; The Genome Analysis Centre (TGAC)			Nizetic, Dean/F-9509-2015	Nizetic, Dean/0000-0001-5486-5761				AKAO Y, 1991, CANCER RES, V51, P1574; AKAO Y, 1992, CANCER RES, V52, P6083; AKAO Y, 1990, CANCER RES, V50, P4856; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; CABANILLAS F, 1988, BLOOD, V71, P1615; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COTTER FE, 1990, GENOMICS, V7, P257, DOI 10.1016/0888-7543(90)90548-9; DAS S, 1992, GENE CHROMOSOME CANC, V5, P244, DOI 10.1002/gcc.2870050312; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIBSON TJ, 1987, GENE, V53, P275, DOI 10.1016/0378-1119(87)90016-3; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; KEARNEY L, 1992, BLOOD, V80, P1659; KIEVITS T, 1990, CYTOGENET CELL GENET, V53, P134, DOI 10.1159/000132913; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LEVINE EG, 1985, BLOOD, V66, P1414; MCKEITHAN TW, 1990, GENE CHROMOSOME CANC, V1, P247, DOI 10.1002/gcc.2870010310; MILLS FC, 1990, NUCLEIC ACIDS RES, V18, P7305, DOI 10.1093/nar/18.24.7305; MOLLER P, 1986, VIRCHOWS ARCH A, V409, P79, DOI 10.1007/BF00705408; NISHIDA Y, 1982, P NATL ACAD SCI-BIOL, V79, P3833, DOI 10.1073/pnas.79.12.3833; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; PARRY P, 1993, P NATL ACAD SCI USA, V90, P4738, DOI 10.1073/pnas.90.10.4738; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; RADICE P, 1992, GENE CHROMOSOME CANC, V5, P50, DOI 10.1002/gcc.2870050108; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARPA A, 1987, VIRCHOWS ARCH A, V412, P17, DOI 10.1007/BF00750725; SCARPA A, 1991, BLOOD, V78, P780; TAKAHASHI N, 1980, NUCLEIC ACIDS RES, V8, P5983, DOI 10.1093/nar/8.24.5983; TAKAHASHI N, 1982, CELL, V29, P671, DOI 10.1016/0092-8674(82)90183-0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	34	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					893	898						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108133				2022-12-25	WOS:A1994MW55100026
J	CHAO, CP; LAULEDERKIND, SJF; BALLOU, LR				CHAO, CP; LAULEDERKIND, SJF; BALLOU, LR			SPHINGOSINE-MEDIATED PHOSPHATIDYLINOSITOL METABOLISM AND CALCIUM MOBILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FACTOR RECEPTOR PHOSPHORYLATION; EPIDERMOID CARCINOMA-CELLS; NECROSIS-FACTOR-ALPHA; PAROTID ACINAR-CELLS; HUMAN-FIBROBLASTS; PROSTAGLANDIN-E2 PRODUCTION; SPHINGOMYELIN TURNOVER; CELLULAR PROLIFERATION; INOSITOL TRISPHOSPHATE	The cytokine mediated stimulation of sphingomyelin (SM) metabolism is emerging as an important signal transduction pathway via the generation of ceramide and sphingosine, products which have been shown to affect a wide variety of biological processes. Because SM-mediated signal transduction is initiated via the hydrolysis of an integral membrane phospholipid by a phospholipase C-like enzyme (sphingomyelinase) to yield lipids which modulate protein kinase C activity, the SM and phosphatidylinositol (PI) signaling pathways share certain similarities. The present study was undertaken to examine the potential for interplay between SM and PI turnover by testing the effects of sphingosine, sphingosine-1-phosphate, and ceramide on PI turnover. In dermal fibroblasts, sphingosine stimulated a rapid dose-dependent hydrolysis of PI, yielding inositol 1,4,5-triphosphate, followed by increased levels of intracellular calcium, Sphingosine-induced inositol phosphate (IF) accumulation was observed between 5 and 30 mu M sphingosine with a maximal accumulation of 2.7-fold over control levels. Enhanced IP formation was measured as early as 5 s following sphingosine treatment and IP levels remained elevated for more than 60 min. Intracellular calcium mobilization accompanied the dose dependent accumulation of IPs in response to sphingosine, although this effect was not apparent until after a 30-40 s lag period. Interestingly sphingosine-1-phosphate stimulated a more rapid release of intracellular Ca2+ than sphingosine, but it had no effect on PI turnover. DL-threo-Dihydrosphingosine, a competitive inhibitor of sphingosine kinase, stimulates both PI turnover and Ca2+ flux, but does not block the action of sphingosine relative to those two processes. Ceramide (added as C-2-ceramide), N-stearylamine, and stearoyl-D-sphingosine did not affect PI turnover or Ca2+ mobilization. Pretreatment of intact cells with pertussis toxin partially inhibited sphingosine-mediated IP accumulation, suggesting a role for guanine nucleotide binding protein(s) (G protein) in sphingosine-stimulated PI turnover. Furthermore, guanosine 5'-O-(3-thiotriphosphate) stimulated, whereas guanosine 5'-O-(2-thiodiphosphate) inhibited, sphingosine-induced IP accumulation in permeabilized cells. Collectively, these data suggest that sphingosine enhances PI turnover by stimulating phospholipase C activity, and the activation of this process may be modulated by G protein interactions. Thus, the regulation of PI turnover and Ca2+ mobilization by sphingosine may represent another mechanism by which sphingosine modulates cell function and that these effects can be distinguished from those of ceramide.	UNIV TENNESSEE,DEPT MED,DIV CONNECT TISSUE DIS,MEMPHIS,TN 38163; UNIV TENNESSEE,DEPT PEDIAT,MEMPHIS,TN 38163; UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38163; DEPT VET AFFAIRS,MEMPHIS,TN	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center			Laulederkind, Stanley/GLQ-8970-2022		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026034, P50AR039166] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR26034, AR39166] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOLD RS, 1991, BIOCHEMISTRY-US, V30, P7747, DOI 10.1021/bi00245a011; BALLOU LR, 1992, IMMUNOL TODAY, V13, P339, DOI 10.1016/0167-5699(92)90167-6; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BALLOU LR, 1990, J IMMUNOL, V145, P4245; BALLOU LR, 1991, J CLIN INVEST, V89, P299; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CANDELA M, 1991, J EXP MED, V174, P1363, DOI 10.1084/jem.174.6.1363; COCKCROFT S, 1992, BIOCHEM J, V288, P1; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FINE J, 1989, BIOCHEM J, V263, P371, DOI 10.1042/bj2630371; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HASHIZUME T, 1992, BIOCHEM J, V282, P243, DOI 10.1042/bj2820243; HUANG CL, 1989, J BIOL CHEM, V264, P4391; JENNINGS LK, 1989, BLOOD, V74, P2674; KIM MY, 1991, J BIOL CHEM, V266, P484; KISS Z, 1990, J BIOL CHEM, V265, P7345; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LITOSCH I, 1987, BIOCHEM J, V244, P35, DOI 10.1042/bj2440035; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PAWELCZYK T, 1992, ARCH BIOCHEM BIOPHYS, V297, P328, DOI 10.1016/0003-9861(92)90680-U; PUSHKAREVA MY, 1992, J BIOL CHEM, V267; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; SUGIYA H, 1990, CELL CALCIUM, V11, P469, DOI 10.1016/0143-4160(90)90079-A; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	44	85	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5849	5856						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119927				2022-12-25	WOS:A1994MY84000058
J	CHICHEPORTICHE, Y; VASSALLI, P				CHICHEPORTICHE, Y; VASSALLI, P			CLONING AND EXPRESSION OF A MOUSE MACROPHAGE CDNA CODING FOR A MEMBRANE GLYCOPROTEIN OF THE SCAVENGER RECEPTOR CYSTEINE-RICH DOMAIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIN GENE; ANCHOR ATTACHMENT; MESSENGER-RNA; MAC-2 ANTIGEN; PROTEIN; CELLS; IDENTIFICATION; SEQUENCE; BINDING; LECTIN	We have cloned from murine macrophages a cDNA coding for a new protein of the scavenger receptor family whose mRNA is increased very strongly by adherence and moderately by exposure to tumor necrosis factor and interferon-gamma. The nucleotidic sequence extends for 2168 bases and encodes a protein of 559 amino acids with six potential glycosylation sites. The first 100 NH2-terminal amino acids represent a single scavenger receptor cysteine-rich domain, whereas the COOH-terminal end of the molecule is compatible either with a transmembrane hydrophobic peptide followed by a very short intracytoplasmic sequence or a signal sequence for an anchoring via a glycophosphatidylinositol. The protein is highly homologous to most of the very recently identified human MAC-2-binding protein and murine cyclophilin C-associated protein.	CTR MED UNIV GENEVA,DEPT PATHOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva								ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DANGOTT LJ, 1989, P NATL ACAD SCI USA, V86, P2128, DOI 10.1073/pnas.86.7.2128; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERLANGER BF, 1992, IMMUNOL TODAY, V13, P487, DOI 10.1016/0167-5699(92)90023-Z; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FRIEDMAN J, 1993, P NATL ACAD SCI USA, V90, P6815, DOI 10.1073/pnas.90.14.6815; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GOLBBERGER G, 1987, J BIOL CHEM, V262, P10065; GRUBER DF, 1977, EXP HEMATOL, V5, P392; HO MK, 1982, J IMMUNOL, V128, P1221; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; KOTHS K, 1993, J BIOL CHEM, V268, P14245; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LINSLEY PS, 1986, BIOCHEMISTRY-US, V25, P2978, DOI 10.1021/bi00358a037; LUSSOW AR, 1990, P NATL ACAD SCI USA, V87, P2960, DOI 10.1073/pnas.87.8.2960; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; MORAN P, 1991, J CELL BIOL, V115, P1595, DOI 10.1083/jcb.115.6.1595; MORAN P, 1991, J BIOL CHEM, V266, P1250; NATALI PG, 1982, CANCER RES, V42, P583; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; ODA Y, 1991, GENE, V99, P279; PAUL P, 1984, EXP HEMATOL, V12, P825; PENNMAN M, 1991, J BIOL CHEM, V266, P23985; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RICH IN, 1982, J RETICULOENDOTH SOC, V31, P17; RICH IN, 1982, BLOOD, V60, P1007; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; Strauss W. M., 1990, CURRENT PROTOCOLS MO; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TURNER AJ, 1991, CELL BIOL INT REP, V15, P1083, DOI 10.1016/0309-1651(91)90057-P; WIJNGAARD PLJ, 1992, J IMMUNOL, V149, P3273; WOO HJ, 1990, J BIOL CHEM, V265, P7097	39	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5512	5517						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119883				2022-12-25	WOS:A1994MY84000009
J	RUPPRECHT, HD; DRUMMOND, IA; MADDEN, SL; RAUSCHER, FJ; SUKHATME, VP				RUPPRECHT, HD; DRUMMOND, IA; MADDEN, SL; RAUSCHER, FJ; SUKHATME, VP			THE WILMS-TUMOR SUPPRESSOR GENE WT1 IS NEGATIVELY AUTOREGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; GROWTH-FACTOR; HUMAN CHROMOSOME-11; AUTO-REGULATION; BINDING-SITE; KIDNEY-CELLS; DNA; EXPRESSION; DELETION; LOCUS	The Wilms' tumor suppressor gene WT1 encodes a zinc-finger DNA-binding protein that functions as a transcriptional repressor. WT1 is expressed in a dramatic spatial and temporal pattern during kidney development and is thought to be critical during mesenchymal-epithelial conversion. The WT1 protein bound multiple sites in the WT1 promoter and functioned as a powerful transcriptional repressor of its gene in vivo (>50-fold). The WT1 protein carrying an NH2-terminal 17-amino acid insertion and a 3-amino acid insertion (KTS) between zinc fingers 3 and 4, arising from the most abundant of four alternatively spliced transcripts, was the most powerful repressor. Of importance, a subset of WT1-binding sites differs from the Egr-1 consensus sequence, which has been shown to bind one splice variant of the WT1 protein (WT1(-KTS)). We characterized two of these sites and show that they bind bath -KTS and +KTS forms of the WT1 zinc-finger protein and can confer repression on a heterologous promoter construct. Our data demonstrate that WT1, in addition to its known effects on insulin-like growth factor II, platelet-derived growth factor A, and Pax-2 transcription, is a powerful repressor of its own gene. These observations emphasize its critical role as a transcriptional regulatory protein during normal kidney development.	BETH ISRAEL HOSP,DIV RENAL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19107	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; The Wistar Institute			Sukhatme, Vikas/W-2776-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045617, R01DK044921] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44921, DK 45617] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; BURNSTEIN KL, 1991, STEROIDS, V56, P52, DOI 10.1016/0039-128X(91)90124-E; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAVENEE W, 1989, RECESSIVE ONCOGENES; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; COWELL JK, 1991, ONCOGENE, V6, P595; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FRAIZER GE, 1987, J CELL PHYSIOL, V133, P169, DOI 10.1002/jcp.1041330122; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GASHLER AL, 1992, P NATL ACAD SCI US, V89; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1989, AM J HUM GENET, V44, P486; GLASER T, 1986, NATURE, V321, P882, DOI 10.1038/321882a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUFF V, 1991, AM J HUM GENET, V48, P997; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MORRIS JF, 1991, ONCOGENE, V6, P2339; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; RIO DC, 1983, CELL, V32, P1227, DOI 10.1016/0092-8674(83)90305-7; Sambrook J, 1989, MOL CLONING LABORATO; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	45	129	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6198	6206						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119964				2022-12-25	WOS:A1994MY84000107
J	TSUJITA, T; OKUDA, H				TSUJITA, T; OKUDA, H			FATTY-ACID ETHYL ESTER-SYNTHESIZING ACTIVITY OF LIPOPROTEIN-LIPASE FROM RAT POSTHEPARIN PLASMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYLESTER LIPASE; ETHANOL-METABOLISM; KINETIC-PROPERTIES; LIPID INTERFACE; SYNTHASE; PURIFICATION; EXCHANGE	Lipoprotein lipase (LPL) was obtained from rat postheparin plasma by chromatographies on heparin-Sepharose and hydroxyapatite. The enzyme was associated with fatty acid ethyl ester synthase (FAEE synthase) as judged by their co-elution profiles and identical profiles of inhibition by diisopropyl fluorophosphate. Only one polypeptide of molecular weight 57,000 in purified LPL fraction was labeled by affinity labeling with [H-3]-diisopropyl fluorophosphate. The FAEE synthase activity of LPL was not affected by addition of apolipoprotein C-II. Digestion of the enzyme with trypsin resulted in almost complete loss of the triolein-hydrolyzing activity without change in FAEE synthase activity. The tributyrin-hydrolyzing activity of LPL was also not affected by addition of apolipoprotein C-II or trypsin digestion. On addition at progressively higher concentrations, bovine serum albumin increased FAEE synthesis to a maximum at 2 mg/ml and at higher concentrations inhibited its activity. On incubation of purified LPL with chylomicrons in an ethanol/water mixture, FAEE was formed in the presence of a high concentration of bovine serum albumin. The specific activity of FAEE synthesis from chylomicrons was about 65 times that from oleic acid. Triolein/gum arabic emulsion was used for identification of reaction products. We propose the following mechanism of FAEE formation from chylomicrons by LPL. The enzyme attacks chylomicrons forming an acyl-enzyme intermediate, and during the deacylation process, ethanol binds to fatty acids as an acceptor. These results suggest that LPL contributes to nonoxidative ethanol metabolism (FAEE formation) through degradation of triglyceride-rich lipoproteins such as chylomicrons.			TSUJITA, T (corresponding author), EHIME UNIV,SCH MED,DEPT MED BIOCHEM,SHIGENOBU,EHIME 79102,JAPAN.							BELFRAGE P, 1969, J LIPID RES, V10, P341; BENGTSSON G, 1981, EUR J BIOCHEM, V113, P547, DOI 10.1111/j.1432-1033.1981.tb05097.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brockman HL, 1984, LIPASES, P1; CHEN RF, 1967, J BIOL CHEM, V242, P173; DUGI KA, 1992, J BIOL CHEM, V267, P25086; HIDE WA, 1992, J LIPID RES, V33, P167; KOBAYASHI J, 1989, EUR J CLIN INVEST, V19, P424, DOI 10.1111/j.1365-2362.1989.tb00254.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE LG, 1983, J CLIN INVEST, V72, P724, DOI 10.1172/JCI111022; LANGE LG, 1982, P NATL ACAD SCI-BIOL, V79, P3954, DOI 10.1073/pnas.79.13.3954; LAPOSATA EA, 1990, J BIOL CHEM, V265, P9688; LAPOSATA EA, 1986, SCIENCE, V231, P476; MOGELSON S, 1984, BIOCHEMISTRY-US, V23, P4075, DOI 10.1021/bi00313a010; MUDERHWA JM, 1992, BIOCHEMISTRY-US, V31, P141, DOI 10.1021/bi00116a021; OLIVECRONA T, 1977, PROTIDES BIOL FLUIDS, V25, P201; RILEY DJS, 1990, BIOCHEMISTRY-US, V29, P3848, DOI 10.1021/bi00468a007; ROJAS C, 1989, BIOCHEMISTRY-US, V28, P4475, DOI 10.1021/bi00436a053; SHIRAI K, 1984, BIOCHIM BIOPHYS ACTA, V795, P1; Smith L.C., 1984, P263; TSUJITA T, 1987, BIOCHEMISTRY-US, V26, P8423, DOI 10.1021/bi00399a059; TSUJITA T, 1990, PROG CLIN BIOL RES, V344, P915; TSUJITA T, 1992, J BIOL CHEM, V267, P23489; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290	26	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5884	5889						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119932				2022-12-25	WOS:A1994MY84000063
J	WAKABAYASHI, S; BERTRAND, B; SHIGEKAWA, M; FAFOURNOUX, P; POUYSSEGUR, J				WAKABAYASHI, S; BERTRAND, B; SHIGEKAWA, M; FAFOURNOUX, P; POUYSSEGUR, J			GROWTH-FACTOR ACTIVATION AND H+-SENSING OF THE NA+/H+ EXCHANGER ISOFORM-1 (NHE1) - EVIDENCE FOR AN ADDITIONAL MECHANISM NOT REQUIRING DIRECT PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; INDEPENDENT MECHANISM; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; PROTEIN-KINASE; ALPHA-THROMBIN; CYTOPLASMIC PH; OKADAIC ACID; ANTIPORTER; FIBROBLASTS	Growth factors stimulate the Na+/H+ exchange activity (NHE1 human isoform) and at the same time increase the phosphorylation state of the exchanger at serine residues. To determine the role of NHE1 phosphorylation, a set of deletion and point mutants has been generated. Functional characterization of deletion mutants expressed in fibroblastic cells revealed that the cytoplasmic region between amino acids 567 and 635 is required for both growth factor-induced cytoplasmic alkalinization and maintenance of high intracellular pH (pH(i)) sensitivity. In contrast to the loss of growth factor activation and pH(i) sensitivity caused by the deletion of amino acids 567-635, the same deletion had no apparent effect on the pattern of growth factor-induced phosphorylation. In addition, individual replacement of any of the serine residues between amino acids 567 and 635 with alanine also had no effect on growth factor activation of the exchange activity. Comparison of phosphopeptide maps for the wild type with those for the internal deletion mutant exchangers and the expressed cytoplasmic domain revealed that all major in vivo phosphorylation sites including growth factor-sensitive ones map to the cytoplasmic tail (amino acids 636-815). Deletion of these sites preserves high pH(i) sensitivity and reduces by only 50% growth factor-induced cytoplasmic alkalinization. Taken together, these data support the existence of a mechanism not requiring direct phosphorylation of NHE1, by which growth factor signals transmit to the ''H+-sensor'' and control the set point value of the exchanger. We propose that a regulatory factor(s) controls NHE1, presumably through its interaction with the critical cytoplasmic region prior to amino acid 635.	UNIV NICE,CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE 2,FRANCE; NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 565,JAPAN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; National Cerebral & Cardiovascular Center - Japan								ARONSON P, 1986, NA PLUS H PLUS EXCHA; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; Battey, 1986, BASIC METHODS MOL BI; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; CASSEL D, 1986, J BIOL CHEM, V261, P5460; FAFOURNOUX P, 1991, BIOCHEMISTRY-US, V30, P9510, DOI 10.1021/bi00103a018; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1988, NA PLUS H PLUS; GRINSTEIN S, 1993, IN PRESS EMBO J; HELMEKOB C, 1993, IN PRESS EUR J PHYSL; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LALLEMAIN G, 1985, J BIOL CHEM, V260, P4877; MALY K, 1989, J BIOL CHEM, V264, P11839; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PARIS S, 1984, J BIOL CHEM, V259, P989; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TSE C M, 1991, Gastroenterology, V100, pA258; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; WEINMAN EJ, 1990, AM J PHYSIOL, V258, pF1254; ZIEGELSTEIN RC, 1992, SCIENCE, V258, P656, DOI 10.1126/science.1329207	37	172	172	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5583	5588						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119893				2022-12-25	WOS:A1994MY84000020
J	KISHINO, J; OHARA, O; NOMURA, K; KRAMER, RM; ARITA, H				KISHINO, J; OHARA, O; NOMURA, K; KRAMER, RM; ARITA, H			PANCREATIC-TYPE PHOSPHOLIPASE A(2) INDUCES GROUP-II PHOSPHOLIPASE A(2) EXPRESSION AND PROSTAGLANDIN BIOSYNTHESIS IN RAT MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; FORSKOLIN-INDUCED SYNTHESIS; BINDING-SITES; PURIFICATION; PROTEIN; CLONING; RELEASE; LUNG; RNA	The effect of pancreatic group I phospholipase Az (PLA(2)-I) on receptor-mediated expression of arthritic group II phospholipase A(2) (PLA(2)-II) and its correlation with prostaglandin E(2) (PGE(2)) synthesis were examined in cultured rat mesangial cells. Scatchard analysis using I-125-PLA(2)-I revealed the existence of a single class of specific binding sites for PLA(2)-I in rat mesangial cells with an equilibrium dissociation constant (K-d) of 1.6 nM and a maximum binding capacity of 10.1 fmol/10(6) cells. The mammalian mature type of PLA(2)-I specifically recognized this binding site, whereas its inactive zymogen and mammalian PLA(2)-II showed much lower affinities. PLA(2)-I markedly increased PLA(2)-II mRNA levels as well as PLA(2)-II secretion from the cells in a time- and dose-dependent manner that was closely correlated with PGE(2) production. Both PLA(2)-II expression and PGE(2) synthesis were completely suppressed by pretreatment of the cells with actinomycin D, cycloheximide, or dexamethasone. These results strongly suggest that there may be crosstalk between PLA(2)-I and PLA(2)-II via the specific PLA(2)-I receptor that elicits PGE(2) synthesis.	SHIONOGI & CO LTD,SHIONOGI RES LABS,FUKUSHIMA KU,OSAKA,OSAKA 553,JAPAN; ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285	Shionogi & Company Limited; Eli Lilly			Ohara, Osamu/A-9119-2012; Ohara, Osamu/G-5448-2015	Ohara, Osamu/0000-0002-3328-9571				ARITA H, 1991, J BIOL CHEM, V266, P19139; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; HARPER PA, 1984, KIDNEY INT, V26, P875, DOI 10.1038/ki.1984.231; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; ISHIZAKI J, 1989, BIOCHEM BIOPH RES CO, V162, P1030, DOI 10.1016/0006-291X(89)90777-8; KANEMASA T, 1992, FEBS LETT, V303, P217, DOI 10.1016/0014-5793(92)80523-J; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; KISHINO J, 1992, BIOCHEM BIOPH RES CO, V186, P1025, DOI 10.1016/0006-291X(92)90849-G; KORTESUO PT, 1993, INT J PANCREATOL, V13, P111; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN LL, 1992, J BIOL CHEM, V267, P23451; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; NAKANO T, 1990, J BIOL CHEM, V265, P1274; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; NISHIJIMA J, 1983, J BIOCHEM, V94, P137, DOI 10.1093/oxfordjournals.jbchem.a134322; PFEILSCHIFTER J, 1989, BIOCHEM BIOPH RES CO, V159, P385, DOI 10.1016/0006-291X(89)90003-X; RADEKE HH, 1992, CLIN INVESTIGATOR, V70, P825; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SHARP JD, 1991, J BIOL CHEM, V266, P14850; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; TOJO H, 1988, J BIOL CHEM, V263, P5724; TOPLEY N, 1989, J IMMUNOL, V143, P1989; YASUDA T, 1990, BIOCHIM BIOPHYS ACTA, V1046, P18	31	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5092	5098						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106488				2022-12-25	WOS:A1994MX57100063
J	TENNEY, DJ; HURLBURT, WW; MICHELETTI, PA; BIFANO, M; HAMATAKE, RK				TENNEY, DJ; HURLBURT, WW; MICHELETTI, PA; BIFANO, M; HAMATAKE, RK			THE UL8 COMPONENT OF THE HERPES-SIMPLEX VIRUS HELICASE-PRIMASE COMPLEX STIMULATES PRIMER SYNTHESIS BY A SUBASSEMBLY OF THE UL5 AND UL52 COMPONENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE; GENE-PRODUCTS; INSECT CELLS; TYPE-1; PROTEIN; REPLICATION; BACTERIOPHAGE-T7; IDENTIFICATION; LOCALIZATION; ASSOCIATION	The herpes simplex virus type 1 (HSV) UL5, UL8, and UL52 proteins form a helicase-primase complex in infected cells, Several laboratories have demonstrated that helicase and nucleoside triphosphatase activities of the heterotrimer (UL5/8/52) are indistinguishable from that of a subassembly of UL5 and UL52 (UL5/52). Although the UL5/52 subassembly functions in coupled primase-polymerase assays on homopolymeric templates, its activity on natural DNA templates has been reported to require UL8. To determine the role of UL8 in primase assays, the activity of the UL5/52 subassembly was compared to that of the heterotrimer reconstituted by adding UL8 to UL5/52. We detected significant activity of the UL5/52 subassembly in coupled primase-polymerase and oligoribonucleotide primer synthesis assays on phi X174 and M13 virion DNAs. However the addition of UL8 to UL5/52 stimulated this activity in a dose-dependent manner. We demonstrate that stimulation occurred at the level of primer synthesis. UL8 did not affect the amount or size of primers annealed to template, their utilization by DNA polymerase, or the use of specific initiation sites within the template. In kinetic studies, the rate of primer synthesis was increased by UL8 but the K-m for phi X174 DNA template was unchanged. These results suggest that a function of the UL8 component of the HSV helicase-primase complex is to increase the efficiency of primer synthesis by UL5/52.			TENNEY, DJ (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT VIROL,PRINCETON,NJ 08543, USA.							CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CALDER JM, 1992, J GEN VIROL, V73, P531, DOI 10.1099/0022-1317-73-3-531; CARMICHAEL EP, 1989, J VIROL, V63, P591, DOI 10.1128/JVI.63.2.591-599.1989; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; GAO M, 1992, MOL CELL BIOL, V12, P1330, DOI 10.1128/MCB.12.3.1330; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDSTEIN DJ, 1988, J VIROL, V62, P2970, DOI 10.1128/JVI.62.8.2970-2977.1988; HAMATAKE RK, 1993, J GEN VIROL, V74, P2181, DOI 10.1099/0022-1317-74-10-2181; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; HINTON DM, 1987, J BIOL CHEM, V262, P10873; KORNBERG A, 1992, DNA REPLICATION, P275; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; PATEL SS, 1992, J BIOL CHEM, V267, P15013; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; STOW ND, 1992, J GEN VIROL, V73, P313, DOI 10.1099/0022-1317-73-2-313; TENEY DJ, 1993, J VIROL, V67, P543; TENNEY DJ, 1993, J VIROL, V67, P1959, DOI 10.1128/JVI.67.4.1959-1966.1993; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WELLER SK, 1991, HERPESVIRUS TRANSCRI, P105; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; ZHU L, 1992, J VIROL, V66, P458, DOI 10.1128/JVI.66.1.458-468.1992	31	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5030	5035						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106478				2022-12-25	WOS:A1994MX57100053
J	BROWN, WC; CAMPBELL, JL				BROWN, WC; CAMPBELL, JL			INTERACTION OF PROLIFERATING CELL NUCLEAR ANTIGEN WITH YEAST DNA POLYMERASE-DELTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION INVITRO; CALF THYMUS; III HOLOENZYME; MECHANISM; PROTEIN; ACTIVATOR-1; SUBUNIT; CYCLIN; ALPHA; CLAMP	Previously, we described the purification of the catalytic core subunit of yeast DNA polymerase delta from Escherichia coli carrying the yeast POL3 gene cloned in a vector that allowed efficient expression. The basic catalytic properties of the single subunit enzyme are virtually identical to the heterodimeric core enzyme purified from yeast cells (Brown, W. C., Duncan, J. A., and Campbell, J. L. (1993) J. Biol. Chem. 268, 982-990). In this work, we investigate the ability of yeast proliferating cell nuclear antigen (PCNA) to stimulate processive synthesis by the bacterially produced, single-subunit DNA polymerase delta. Yeast PCNA was found to stimulate the full-length single-subunit yeast DNA polymerase delta and to increase its processivity. A truncated version of DNA polymerase delta, from which the NH2-terminal 220 amino acids had been removed, was prepared and similarly investigated. While the catalytic properties of the truncated protein were nearly identical to those of the full-length enzyme, neither the extent of synthesis nor processivity was increased in the presence of PCNA. Thus, we conclude that the single-subunit DNA polymerase can associate productively with PCNA in the absence of other proteins and that the NH2-terminal domain of the catalytic subunit must be intact for this interaction.	CALTECH,BRAUN LABS,147-75CH,PASADENA,CA 91125	California Institute of Technology					NCI NIH HHS [NRSA CA-08692] Funding Source: Medline; NIGMS NIH HHS [GM25508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAVO R, 1980, J CELL BIOL, V84, P795, DOI 10.1083/jcb.84.3.795; BROWN WC, 1993, GENE, V127, P99, DOI 10.1016/0378-1119(93)90622-A; BROWN WC, 1993, J BIOL CHEM, V268, P982; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CAMPBELL JL, 1991, MOL CELLULAR BIOL YE, P85; DEMORENO MR, 1985, ANAL BIOCHEM, V151, P466, DOI 10.1016/0003-2697(85)90206-4; DIGARD P, 1990, J BIOL CHEM, V265, P17393; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; MIYACHI K, 1978, J IMMUNOL, V121, P2228; NG L, 1991, J BIOL CHEM, V266, P11699; ODONNELL M, 1992, BIOESSAYS, V14, P105, DOI 10.1002/bies.950140206; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002	24	32	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21706	21710						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104944				2022-12-25	WOS:A1993MC80900044
J	LOFTS, FJ; HURST, HC; STERNBERG, MJE; GULLICK, WJ				LOFTS, FJ; HURST, HC; STERNBERG, MJE; GULLICK, WJ			SPECIFIC SHORT TRANSMEMBRANE SEQUENCES CAN INHIBIT TRANSFORMATION BY THE MUTANT NEU GROWTH-FACTOR RECEPTOR IN-VITRO AND IN-VIVO	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; ONCOGENIC ACTIVATION; SIGNAL TRANSDUCTION; TRUNCATED RECEPTOR; POINT MUTATION; EGF RECEPTOR; PROTEIN; DOMAIN; DIMERIZATION; EXPRESSION	The neu oncogene is activated by a point mutation within its transmembrane domain that results in the substitution of glutamic acid for valine at position 664, and is associated with constitutive activation of the tyrosine kinase. It has been proposed that the mutation allows for stabilization of homodimers of the receptor that are necessary for transduction of the mitogenic signal. To investigate the role of the alpha-helical transmembrane sequence in the function of neu, we constructed an expression vector to produce a variety of short transmembrane neu proteins, lacking ligand binding or intracellular kinase domains. Such sequences should interact with full-length receptors and prevent receptor dimerization and thus act as specific inhibitors of function. These small proteins all included a pentapeptide from position 661-665, which has been proposed to be necessary for packing. We show that the short transmembrane molecules are expressed at the cell surface and can retard the growth of neu-transformed cells in monolayers, as colonies in soft agar and as tumours in animals. As predicted by molecular modelling, the magnitude of inhibition depended on the nature of the packing surface, suggesting that the neu transmembrane domain is directly involved in neu protein dimerization.	HAMMERSMITH HOSP,ICRF,ONCOL GRP,MOLEC ONCOL LAB,DU CANE RD,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,ICRF,ONCOL GRP,GENE TRANSCRIPT LAB,LONDON W12 0HS,ENGLAND; ICRF,BIOMOLEC MODELLING LAB,LONDON WC2A 3PX,ENGLAND	Imperial College London; Imperial College London				Sternberg, Michael/0000-0002-1884-5445				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BARGMANN CI, 1986, CELL, V45, P469; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2921; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1992, J BIOL CHEM, V267, P20489; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Gullick W J, 1988, Methods Mol Biol, V3, P341, DOI 10.1385/0-89603-126-8:341; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	43	70	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2813	2820						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8104327				2022-12-25	WOS:A1993LX34300023
J	HARVEY, M; SANDS, AT; WEISS, RS; HEGI, ME; WISEMAN, RW; PANTAZIS, P; GIOVANELLA, BC; TAINSKY, MA; BRADLEY, A; DONEHOWER, LA				HARVEY, M; SANDS, AT; WEISS, RS; HEGI, ME; WISEMAN, RW; PANTAZIS, P; GIOVANELLA, BC; TAINSKY, MA; BRADLEY, A; DONEHOWER, LA			IN-VITRO GROWTH-CHARACTERISTICS OF EMBRYO FIBROBLASTS ISOLATED FROM P53-DEFICIENT MICE	ONCOGENE			English	Article							WILD-TYPE P53; TUMOR-ANTIGEN; GENE-PRODUCT; T-ANTIGEN; DNA; CELLS; PROTEIN; IMMORTALIZATION; TRANSFORMATION; EXPRESSION	Fibroblast cultures were derived from mouse embryos containing either one (p53+/-) or two (p53-/-) inactivated p53 alleles and compared to normal embryo fibroblasts for a number of growth parameters. Early passage p53-deficient embryo fibroblasts (p53-/-) divided faster than normal embryo fibroblasts, achieved higher confluent densities, and had a higher fraction of division-competent cells under conditions of low cell density. Flow cytometry studies of early passage embryo fibroblasts showed that the percent of p53-deficient cells in G0/G1 was lower than in normal cells, consistent with the argument that p53 mediates a GI block. When p53-deficient and normal cells were passaged for long periods of time, the homozygote (p53-/-) fibroblasts grew at a high rate for over 50 passages and never entered a non-growing senescent phase characteristic of the heterozygote (p53+/-) and normal (p53+/+) cells. The p53-deficient fibroblasts were genetically unstable during passaging, with the p53-/- cells showing a high degree of aneuploidy and the p53+/- cells displaying a moderate level of chromosomal abnormalities by passage 25. Surprisingly, the heterozygote cells lost their single wild type allele very early during culturing and in spite of this loss most heterozygote lines entered into senescence. We conclude that the loss of p53 by itself is insufficient to confer immortality on a cell, but does confer a growth advantage. Taken together, the findings confirm that the absence of p53 promotes genomic instability, which in turn may result in genetic alterations which directly produce immortality.	BAYLOR COLL MED,DEPT MOLEC VIROL,HOUSTON,TX 77030; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; STEHLIN FDN CANC RES,HOUSTON,TX 77002; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; UNIV TEXAS,M D ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center			Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495; Tainsky, Michael/0000-0002-0261-831X; Bradley, Allan/0000-0002-2349-8839	NATIONAL CANCER INSTITUTE [R01CA054897] Funding Source: NIH RePORTER; NCI NIH HHS [CA54897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFFIE A, IN PRESS; DIETRICH W, 1992, GENETICS, V131, P423; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; Newbold R F, 1985, Carcinog Compr Surv, V9, P17; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RITTLING SR, 1992, ONCOGENE, V7, P935; ROVINSKI B, 1988, ONCOGENE, V2, P445; Sambrook J, 1989, MOL CLONING LABORATO; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; ULLRICH E, 1992, GENE DEV, V6, P876; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WARE LM, 1972, VIROLOGY, V50, P339, DOI 10.1016/0042-6822(72)90385-6	46	479	486	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2457	2467						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8103211				2022-12-25	WOS:A1993LT36800017
J	SAUTER, SL; RUTHERFURD, SM; WAGENER, C; SHIVELY, JE; HEFTA, SA				SAUTER, SL; RUTHERFURD, SM; WAGENER, C; SHIVELY, JE; HEFTA, SA			IDENTIFICATION OF THE SPECIFIC OLIGOSACCHARIDE SITES RECOGNIZED BY TYPE-1 FIMBRIAE FROM ESCHERICHIA-COLI ON NONSPECIFIC CROSS-REACTING ANTIGEN, A CD66 CLUSTER GRANULOCYTE GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CEA GENE FAMILY; CARCINOEMBRYONIC ANTIGEN; CROSSREACTING ANTIGEN; MONOCLONAL-ANTIBODIES; BILIARY GLYCOPROTEIN; HUMAN-NEUTROPHILS; CARCINOMA-CELLS; DE-GRANULATION; CDNA CLONE	Nonspecific cross-reacting antigen (NCA), a CD66 cluster antigen, is a well characterized glycoprotein on granulocytes, macrophages, and lung epithelium. Structural studies at the protein and genomic levels have revealed that NCA is a member of the immunoglobulin (Ig) supergene family and contains a domain structure similar to Ig with an amino-terminal variable-like domain followed by disulfide loop-containing constant-like domains. Previous work by this laboratory and others has demonstrated that NCA is a receptor for binding of bacteria expressing type 1 fimbriae (pili). This binding is mediated by interaction between lectins on the bacteria fimbriae and carbohydrate chains on NCA. In the present work we further characterize the specificity for bacterial binding by NCA using endoglycosidases and site-directed mutagenesis. Results of these studies demonstrate that Escherichia coli expressing type 1 fimbriae binds to high mannose oligosaccharide structures on NCA and that the functionally relevant sites are located in the variable-like domain of NCA.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010; UNIV HAMBURG,KRANKENHAUS EPPENDORF,DEPT CLIN CHEM,MED CLIN,W-2000 HAMBURG 20,GERMANY	City of Hope; Beckman Research Institute of City of Hope; University of Hamburg			Rutherfurd, Shane M/D-8254-2011		NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SN, 1987, J BACTERIOL, V169, P5530, DOI 10.1128/jb.169.12.5530-5536.1987; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARAKAWA F, 1990, BIOCHEM BIOPH RES CO, V166, P1063, DOI 10.1016/0006-291X(90)90975-S; AUDETTE M, 1987, MOL IMMUNOL, V24, P1177, DOI 10.1016/0161-5890(87)90164-7; BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BERLING B, 1990, CANCER RES, V50, P6534; BLUMENSTOCK E, 1982, INFECT IMMUN, V35, P264, DOI 10.1128/IAI.35.1.264-269.1982; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; BUCHEGGER F, 1984, INT J CANCER, V33, P643, DOI 10.1002/ijc.2910330515; BURTIN P, 1975, NATURE, V255, P714, DOI 10.1038/255714a0; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DRZENIEK Z, 1991, CANCER LETT, V56, P173, DOI 10.1016/0304-3835(91)90093-W; EISENSTEINBI, 1988, REV INFECT DIS, V10, pS341; ESHDAT Y, 1981, J BACTERIOL, V148, P308, DOI 10.1128/JB.148.1.308-314.1981; FIRON N, 1983, CARBOHYD RES, V120, P235, DOI 10.1016/0008-6215(83)88019-7; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; GBARAH A, 1989, BIOCHEM BIOPH RES CO, V165, P1243, DOI 10.1016/0006-291X(89)92735-6; GOETZ MB, 1989, J INFECT DIS, V159, P533, DOI 10.1093/infdis/159.3.533; GOETZ MB, 1987, INFECT IMMUN, V55, P534, DOI 10.1128/IAI.55.3.534-540.1987; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEFTA LJF, 1992, CANCER RES, V52, P5647; HEFTA SA, 1990, J BIOL CHEM, V265, P8618; HINODA Y, 1989, P NATL ACAD SCI USA, V86, P1668; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HOFFSTEIN ST, 1982, J CELL BIOL, V95, P234, DOI 10.1083/jcb.95.1.234; KANTOR J, 1989, CANCER RES, V49, P2651; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; KORHONEN TK, 1982, INFECT IMMUN, V37, P286, DOI 10.1128/IAI.37.1.286-291.1982; KUROKI M, 1992, J LEUKOCYTE BIOL, V52, P551, DOI 10.1002/jlb.52.5.551; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEUSCH HG, 1990, FEBS LETT, V261, P405, DOI 10.1016/0014-5793(90)80603-G; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NEUMAIER M, 1988, J BIOL CHEM, V263, P3202; OFEK I, 1988, INFECT IMMUN, V56, P539, DOI 10.1128/IAI.56.3.539-547.1988; PERRY A, 1983, INFECT IMMUN, V39, P1334, DOI 10.1128/IAI.39.3.1334-1345.1983; RODRIGUEZORTEGA M, 1987, INFECT IMMUN, V55, P968, DOI 10.1128/IAI.55.4.968-973.1987; RUDERT F, 1989, J MOL EVOL, V29, P126, DOI 10.1007/BF02100111; SAUTER SL, 1991, INFECT IMMUN, V59, P2485, DOI 10.1128/IAI.59.7.2485-2493.1991; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; SILVERBLATT FJ, 1979, INFECT IMMUN, V24, P218, DOI 10.1128/IAI.24.1.218-223.1979; SPITZNAGEL JK, 1983, REV INFECT DIS, V5, pS806; STEADMAN R, 1988, INFECT IMMUN, V56, P815, DOI 10.1128/IAI.56.4.815-822.1988; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P63; von Kleist S, 1972, Proc Natl Acad Sci U S A, V69, P2492; WAGENER C, 1983, J IMMUNOL, V130, P2308	47	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15510	15516						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101840				2022-12-25	WOS:A1993LN30500031
J	FISHER, MT				FISHER, MT			ON THE ASSEMBLY OF DODECAMERIC GLUTAMINE-SYNTHETASE FROM STABLE CHAPERONIN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; AGGREGATION; RECONSTITUTION; DEHYDROGENASE; PROTEINS; STATE	For many in vitro protein-folding reactions, the fraction of correctly folded product declines as the initial protein concentration increases due primarily to misfolding and aggregation reactions. Under optimal conditions and in the presence of ATP, chaperonins (groEL and groES) enhanced the renaturation of dodecameric glutamine synthetase (GS) with yields of active enzyme between 75 and 85% of the original activity (Fisher, M. T. (1992) Biochemistry 31, 3955-3963). In spite of this enhancement, a concentration-dependent decline in recoverable activity was observed when increasing concentrations of unfolded GS were rapidly mixed with renaturation buffer containing a 2-fold molar excess (GS subunits:groEL oligomer) of chaperonins. When a stable groEL-GS complex, formed under optimal conditions, was concentrated 4-fold by centrifugal ultrafiltration prior to ATP addition, the amount of total active GS (percent of the original activity) recovered remained at optimal levels and no longer showed a concentration-dependent decline. The GS subunits that are initially bound and then released from groEL by ATP are assembly-competent. It is proposed that the subunits are no longer able to kinetically equilibrate with folding intermediates that misfold or aggregate. If a stable groEL-protein substrate complex can be amassed without loss of activity, this will facilitate studies on molecular aspects of chaperonin release mechanisms and oligomeric protein assembly.			FISHER, MT (corresponding author), UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160, USA.							BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; FISHER MT, 1992, J BIOL CHEM, V267, P1872; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; Garel Jean-Renaud, 1992, P405; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRIMM R, 1993, J BIOL CHEM, V268, P5220; JAENICKE R, 1990, PROTEIN STRUCTURE PR, P191; KEPES A, 1966, BIOCHIM BIOPHYS ACTA, V123, P546, DOI 10.1016/0005-2787(66)90222-X; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MAURIZI MR, 1982, J BIOL CHEM, V257, P7246; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MITAKI A, 1989, BIOTECHNOLOGY, V7, P690; STADTMAN ER, 1979, ANAL BIOCHEM, V95, P275, DOI 10.1016/0003-2697(79)90217-3; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P792, DOI 10.1021/bi00781a011; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	19	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13777	13779						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8100224				2022-12-25	WOS:A1993LJ82500004
J	DUNN, T; GABLE, K; BEELER, T				DUNN, T; GABLE, K; BEELER, T			REGULATION OF CELLULAR CA2+ BY YEAST VACUOLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; NUCLEAR MAGNETIC-RESONANCE; PROTON MOTIVE FORCE; SACCHAROMYCES-CEREVISIAE; MEMBRANE-VESICLES; TRANSPORT; CALCIUM; MUTANTS; GENE; POLYPHOSPHATE	The role of vacuolar Ca2+ transport systems in regulating cellular Ca2+ was investigated by measuring the vacuolar Ca2+ transport rate, the free energy available to drive vacuolar Ca2+ transport, the ability of the vacuole to buffer lumenal Ca2+, and the vacuolar Ca2+ efflux rate. The magnitude of the Ca2+ gradient generated by the vacuolar H+ gradient best supports a 1 Ca2+:2 H+ coupling ratio for the vacuolar Ca2+/H+ exchanger. This coupling ratio along with a cytosolic Ca2+ concentration of 125 nM would give a vacuolar free Ca2+ concentration of similar to 30 mu M. The total vacuolar Ca2+ concentration is similar to 2 mM due to Ca2+ binding to vacuolar polyphosphate. The Ca2+ efflux rate from the vacuole is less than the growth rate indicating that the steady-state Ca2+ loading level of the vacuole is dependent mainly on the Ca2+ transport rate and the rate that vacuolar Ca2+ is diluted by growth. Based on the kinetic parameters of vacuolar Ca2+ accumulation in vitro, the maximum rate of Ca2+ accumulation in vivo is expected to be similar to 0.2 nmol of Ca2+ min(-1) mg protein(-1), a rate that is similar to the cellular Ca2+ accumulation rate. The cytosolic Ca2+ concentration increases from 0.1 mu M to 1-2 mu M as the extracellular Ca2+ concentration is raised from 0.3 mM to 50 mM. The rise in cytosolic Ca2+ concentration increases cellular Ca2+ from 10 to 300 nmol Ca2+/mg by increasing the rate of vacuolar Ca2+ accumulation but does not significantly alter the cellular growth rate.			DUNN, T (corresponding author), UNIFORMED SERV UNIV HLTH SCI, DEPT BIOCHEM, 4301 JONES BRIDGE RD, BETHESDA, MD 20814 USA.				NIGMS NIH HHS [GM 46495] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; CARAFOLI E, 1970, BIOCHIM BIOPHYS ACTA, V205, P18, DOI 10.1016/0005-2728(70)90057-5; CLARK JE, 1986, J BACTERIOL, V168, P1212, DOI 10.1128/jb.168.3.1212-1219.1986; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DAVIS TN, 1986, YEAST CELL BIOL, P477; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; HALACHMI D, 1993, FEBS LETT, V316, P73, DOI 10.1016/0014-5793(93)81739-M; HIRATA R, 1990, J BIOL CHEM, V265, P6726; IIDA H, 1990, J BIOL CHEM, V265, P13391; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KITAMOTO K, 1988, J BACTERIOL, V170, P2687, DOI 10.1128/jb.170.6.2687-2691.1988; LOMANDER L, 1965, PHYSIOL PLANTARUM, V18, P968, DOI 10.1111/j.1399-3054.1965.tb06993.x; LOMANDER L, 1965, PHYSIOL PLANTARUM, V18, P153, DOI 10.1111/j.1399-3054.1965.tb06878.x; Morris EO, 1958, CHEM BIOL YEASTS, P251; NAVON G, 1979, BIOCHEMISTRY-US, V18, P4487, DOI 10.1021/bi00588a006; NICOLAY K, 1982, ARCH MICROBIOL, V133, P83, DOI 10.1007/BF00413516; NOVICK P, 1989, GENETICS, V121, P659; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1986, J GEN MICROBIOL, V132, P979; OHYA Y, 1991, J BIOL CHEM, V266, P13971; OKOROKOV LA, 1985, FEBS LETT, V192, P303, DOI 10.1016/0014-5793(85)80130-7; OLSON BH, 1949, J BACTERIOL, V57, P235, DOI 10.1128/JB.57.2.235-246.1949; RUBIN GM, 1973, J BIOL CHEM, V248, P3860; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; URECH K, 1978, ARCH MICROBIOL, V116, P275, DOI 10.1007/BF00417851	28	160	165	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7273	7278						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125940				2022-12-25	WOS:A1994NA03200039
J	SPIVACK, J; LEIB, TK; LOBOS, JH				SPIVACK, J; LEIB, TK; LOBOS, JH			NOVEL PATHWAY FOR BACTERIAL METABOLISM OF BISPHENOL-A - REARRANGEMENTS AND STILBENE CLEAVAGE IN BISPHENOL-A METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ROT FUNGUS; HYDROXYLATION; LIGNIN	Bisphenol A (BPA) is metabolized by a Gram-negative aerobic bacterium via a novel pathway involving oxidative skeletal rearrangement of the BPA. Oxidation of the aliphatic methyl group of BPA leads to coproduction of the methyl-hydroxylated 2,2-bis(4-hydroxyphenyl)-1-propanol and a skeletally rearranged triol 1,2-bis(4-hydroxyphenyl)-2-propanol. The major route of metabolism (>80%) is through the rearrangement. The 1,2-bis(4-hydroxyphenyl)-2-propanol is dehydrated to 4,4'-dihydroxy-alpha-methylstilbene, which is rapidly cleaved by oxidation to 4-hydroxybenzaldehyde and 4-hydroxyacetophenone. 4-Hydroxybenzaldehyde is oxidized to 4-hydroxybenzoic acid. Both 4-hydroxybenzoic acid and 4-hydroxyacetophenone are mineralized. The minor product of BPA hydroxylation, 2,2-bis(4-hydroxyphenyl)-1-propanol, is further oxidized to form both 2,2-bis(4-hydroxyphenyl)propanoic acid and a skeletally rearranged tetraol, 2,3-bis(4-hydroxyphenyl)-1,2-propanediol. As is the case in the hydroxylation of BPA, the major product is skeletally rearranged. 2,3-Bis(4-hydroxyphenyl)-1,2-propanediol is slowly transformed to 4-hydroxyphenacyl alcohol.			SPIVACK, J (corresponding author), GE CO, CORP RES & DEV, SCHENECTADY, NY 12301 USA.							ALEXANDER HC, 1988, ENVIRON TOXICOL CHEM, V7, P19, DOI 10.1002/etc.5620070104; Barbour, 1984, MICROBIAL DEGRADATIO, P253; BAYLY RC, 1966, BIOCHEM J, V101, P293, DOI 10.1042/bj1010293; DAGLEY S, 1957, BIOCHEM J, V66, P227, DOI 10.1042/bj0660227; Dodds EC, 1944, PROC R SOC SER B-BIO, V132, P83, DOI 10.1098/rspb.1944.0005; DORN PB, 1987, CHEMOSPHERE, V16, P1501, DOI 10.1016/0045-6535(87)90090-7; GIBSON DT, 1984, MICROBIAL DEGRADATIO, P193; HOPPER DJ, 1976, BIOCHEM BIOPH RES CO, V69, P462, DOI 10.1016/0006-291X(76)90544-1; KIRK TK, 1970, ACTA CHEM SCAND, V24, P1470, DOI 10.3891/acta.chem.scand.24-1470; KIRK TK, 1975, HOLZFORSCHUNG, V29, P99, DOI 10.1515/hfsg.1975.29.3.99; KIRK TK, 1970, ACTA CHEM SCAND, V24, P3379, DOI 10.3891/acta.chem.scand.24-3379; LOBOS JH, 1992, APPL ENVIRON MICROB, V58, P1823, DOI 10.1128/AEM.58.6.1823-1831.1992; MIAO VPW, 1991, MOL GEN GENET, V226, P214, DOI 10.1007/BF00273606; MUNJKO I, 1980, VODOPRIVREDA, V12, P167; PASCZYNSKI A, 1977, MICROBIOS, V18, P111; SANDELL J, 1988, BISPHENOL A CEH PROD; SMITH RV, 1974, ARCH BIOCHEM BIOPHYS, V161, P551, DOI 10.1016/0003-9861(74)90338-5; ZAHEER SH, 1954, J CHEM SOC, P3360, DOI 10.1039/jr9540003360	18	170	186	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7323	7329						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125948				2022-12-25	WOS:A1994NA03200047
J	EAKLE, KA; KABALIN, MA; WANG, SG; FARLEY, RA				EAKLE, KA; KABALIN, MA; WANG, SG; FARLEY, RA			THE INFLUENCE OF BETA-SUBUNIT STRUCTURE ON THE STABILITY OF NA+/K+-ATPASE COMPLEXES AND INTERACTION WITH K+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; NA,K-ATPASE; H,K-ATPASE; BINDING; YEAST; CELLS; NA,K-PUMP; CLONING	Heterologous expression of the beta subunit of H+/K+-ATPase (HK beta) with alpha subunits of Na+/K+-ATPase (NK alpha) in yeast leads to the formation of ouabain binding complexes, indicating assembly of the two subunits into active ion pumps (Eakle, K. A., Kim, K. S., Kabalin, M. A., and Farley, R. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2834-2838). Complexes of NK alpha and HK beta are less sensitive to inhibition of ouabain binding by K+, suggesting that HK beta lowers the affinity of K+ binding sites. This effect is particularly pronounced when HK beta is combined with the alpha 3 isoform of NK alpha. In this case, titration with K+ yields a biphasic curve, suggesting that there are two nonequivalent sites for K+ binding. Attempts at purifying complexes formed with either alpha 1 + HK beta or alpha 3 + HK beta using SDS extraction of microsomal membranes resulted in the loss of ouabain binding. Controls show that alpha 1 + beta 1 and alpha 3 + beta 1 complexes still retain ouabain binding after SDS extraction under the same conditions. This suggests that the HK beta subunit forms a less stable complex with NK alpha subunits. We have created chimeric beta subunits comprised of the amino-terminal cytoplasmic and transmembrane regions of HK beta combined with the carboxyl-terminal extracellular region of Na+/K+-ATPase beta 1 (HN beta 1) and the complementary chimera with amino-terminal cytoplasmic and transmembrane regions of beta 1 combined with the carboxyl-terminal extracellular region of HK beta (NH beta 1). When NH beta 1 is combined with either alpha 1 or alpha 3, the complexes show profiles of K+ inhibition of ouabain binding that are very similar to HK beta combined with either alpha 1 or alpha 3. The data suggest that the extracellular region of HK beta is primarily responsible for the effect on apparent K+ affinity. When the HN beta 1 subunit is expressed with the alpha 3 subunit, less than 5% of the amount of ouabain binding complexes are formed compared with HN beta 1 + alpha 1. This observation suggests that the HN beta 1 subunit either assembles poorly or forms an unstable complex with alpha 3. After SDS extraction, complexes of alpha 1 + NH beta 1 and alpha 3 + NH beta 1 retain ouabain binding, while alpha 1 + HN beta 1 complexes are sensitive to SDS extraction. Together, these data indicate that the cytoplasmic/transmembrane region of beta 1 is important for the assembly and stability of alpha + beta Na+/K+-ATPase complexes.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033	University of Southern California	EAKLE, KA (corresponding author), UNIV SO CALIF,SCH MED,DEPT PHYSIOL & BIOPHYS,LOS ANGELES,CA 90033, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028673] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39295] Funding Source: Medline; NIGMS NIH HHS [GM28673] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1993, IN PRESS 7TH P INT C; EAKLE KA, 1991, SODIUM PUMP RECENT D, P125; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HOROWITZ B, 1988, NA PLUS K PLUS PUM B, P85; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; NOGUCHI S, 1992, BIOCHEM BIOPH RES CO, V182, P659, DOI 10.1016/0006-291X(92)91783-M; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; SHERMAN F, 1979, METHODS YEAST GENETI, P164; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SKOU JC, 1960, BIOCHIM BIOPHYS ACTA, V42, P6, DOI 10.1016/0006-3002(60)90746-0; WANG K, 1992, J BIOL CHEM, V267, P3577; YODA S, 1986, J BIOL CHEM, V261, P1147	28	103	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6550	6557						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120007				2022-12-25	WOS:A1994MZ50300046
J	ALBERT, T; URLBAUER, B; KOHLHUBER, F; EICK, D; HAMMERSEN, B				ALBERT, T; URLBAUER, B; KOHLHUBER, F; EICK, D; HAMMERSEN, B			ONGOING MUTATIONS IN THE N-TERMINAL DOMAIN OF C-MYC AFFECT TRANSACTIVATION IN BURKITTS-LYMPHOMA CELL-LINES	ONCOGENE			English	Article							NUCLEOTIDE-SEQUENCE; PROTEIN-KINASE; SWITCH REGION; EXPRESSION; GENE; PHOSPHORYLATION; TRANSFORMATION; FIBROBLASTS; APOPTOSIS; ONCOGENE	A panel of 18 Burkitt's lymphoma (BL) and nine other cell Lines was examined for mutations in the N-terminal transactivation domain of c-Myc. Mutations leading to exchange of amino acids were detected in 13 BL but in none of the control cell lines. Mutations in c-Mye clustered between amino acid positions 57 and 62. Thr-58 and Ser-62 are known phosphorylation sites of c-Myc in vivo. BL cell lines derived from the same tumour revealed different mutations. Mutant cDNAs of the BL cell line Raji differed at 14 positions indicating ongoing mutation of the translocated c-myc during long-term propagation in cell culture. The effect of mutations on transactivation by c-Mye was tested by expression of GAL4/c-Myc fusion proteins in the BL cell line Raji. Mutants with an amino acid exchange at positions 58 or 60 transactivated a reporter gene two- to fivefold weaker than wildtype c-Myc, Thr-58 and Ser-62 were replaced by aspartic acid to mimic constitutively phosphorylated forms of c-Myc. These mutants transactivated two- to three-fold weaker than wildtype c-Mye indicating that a negative charge at positions 58 and/or 62 per se does not enhance transactivation. We propose that mutations in the N-terminal domain of c-Mye correlate with reduced transactivation and provide a growth advantage for BL cells.	GSF MUNICH,UMWELT & GESUNDHEIT FORSCHUNGSZENTRUM,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health				Albert, Thomas Karl/0000-0002-2488-0706				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; APEL TW, 1992, ONCOGENE, V7, P1267; ASKEW DS, 1991, ONCOGENE, V6, P1915; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EICK D, 1990, ONCOGENE, V5, P1397; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FALK MH, 1993, INT J CANCER, V55, P1; FRYKBERG L, 1987, ONCOGENE, V1, P415; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HENRIKSSONM, 1993, ONCOGENE, V8, P3199; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; LILLIE JW, 1989, NATURE, V341, P179; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SETH A, 1992, J BIOL CHEM, V267, P24796; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SYMONDS G, 1989, ONCOGENE, V4, P285; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; YANO T, 1993, ONCOGENE, V8, P2741; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	36	62	63	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					759	763						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108117				2022-12-25	WOS:A1994MW55100010
J	KERPPOLA, TK; CURRAN, T				KERPPOLA, TK; CURRAN, T			MAF AND NRL CAN BIND TO AP-1 SITES AND FORM HETERODIMERS WITH FOS AND JUN	ONCOGENE			English	Article							DNA-BINDING; LEUCINE ZIPPER; TRANSCRIPTION FACTORS; YEAST GCN4; GENE; INVITRO; PROTEINS; TRANSFORMATION; ONCOGENE; ENCODES	The c-maf proto-oncogene and the neural retina specific gene nrl encode members of a new bZIP protein subfamily. We have examined the dimerization and DNA binding properties of this new protein family using polypeptides encompassing the leucine zipper and basic regions. Purified polypeptides bound specifically to the AP-1 and CRE sites as well as to variants of the AP-1 site. Maf and Nrl were also able to form heterodimers with Fos and Jun in vitro. All pairwise combinations of Maf, Nrl, Fos and Jun could be co-immunoprecipitated by antisera directed against either subunit. Heterodimers among these proteins bound to the AP-1 site, although with different affinities. Mutations in the leucine zipper dimerization interface or in the basic DNA contact region inhibited heterodimer formation and binding to the AP-1 site. These results indicate that Maf and Nrl together with Fos and Jun family proteins form a bZIP protein superfamily whose members can form an array of heterodimers that have overlapping DNA binding specificities.			KERPPOLA, TK (corresponding author), ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110, USA.		Kerppola, Tom/AAG-4457-2022; Curran, Tom/D-7515-2011; Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Kerppola, Tom/AFK-6155-2022; Curran, Tom/C-1164-2008	Kerppola, Tom/0000-0002-0611-9446; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Curran, Tom/0000-0003-1444-7551				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1987, ONCOGENE, V2, P79; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OKUNO H, 1991, ONCOGENE, V6, P1491; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	37	169	172	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					675	684						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108109				2022-12-25	WOS:A1994MW55100001
J	JOSEPH, SK				JOSEPH, SK			BIOSYNTHESIS OF THE INOSITOL TRISPHOSPHATE RECEPTOR IN WB RAT-LIVER EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; 1,4,5-TRISPHOSPHATE RECEPTOR; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; INSP3 RECEPTOR; FUNCTIONAL EXPRESSION; LOCALIZATION; PURIFICATION; PROTEIN; LYMPHOCYTES	We have studied the biosynthesis and turnover of the inositol 1,4,5-trisphosphate receptor (IP,R) in WB cells, a rat liver epithelial cell line. In detergent extracts of S-35-labeled WB cells, an affinity-purified antibody directed at the C terminus of the IP(3)R immunoprecipitated two labeled polypeptides, a major band at 233 kDa and a minor band at 222 kDa. The major band was shown to correspond to the IP(3)R by immunoblotting. The minor band was not a proteolytic clip of the IP(3)R because, unlike the IP(3)R, the 222-kDa band was not a glycoprotein or a substrate for protein kinase A and was-not recognized by three different IP(3)R antibodies on immunoblots. The identity and function of this co-immunoprecipitating protein is unknown. The IP(3)R in WB cells was 5 kDa smaller than the rat cerebellar IP(3)R. Significant changes in the molecular weight of the IP(3)R were not observed in pulse-chase experiments, indicating that extensive proteolytic or carbohydrate processing events do not occur during biosynthesis of the receptor. From the analysis of such experiments in confluent WB cells, it was determined that the half-life of the IP(3)R protein was 11 h. Chromatography of the S-35-labeled extracts on Sephacryl S-400 columns revealed rapid oligomerization of newly synthesized protein with >95% of newly synthesized protein forming tetramers during a short (10 min) pulse labeling period. However, significant amounts of mature IP(3)R were found as incompletely oligomerized forms. Mature IP(3)R was bound by concanavalin A-Sepharose beads, and binding was greatly reduced by endoglycosidase H treatment of the receptor. Endoglycosidase H sensitivity, absence of binding to wheat germ agglutinin-Sepharose, and insensitivity of biosynthesis or oligomerization to brefeldin A suggest that processing of the WB IP(3)R does not involve transit through the Golgi apparatus.			JOSEPH, SK (corresponding author), THOMAS JEFFERSON UNIV, SCH MED, DEPT PATHOL & CELL BIOL, RM 230AJAH, 1020 LOCUST ST, PHILADELPHIA, PA 19107 USA.				NIAAA NIH HHS [AA-07186] Funding Source: Medline; NIDDK NIH HHS [R01-DK-34804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; CORREIA MA, 1991, METHOD ENZYMOL, V206, P315; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HARLOW E, 1988, ANTIBODIES LABORATOR; HINGORANI SR, 1992, METHOD ENZYMOL, V207, P573; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1992, ANNU REP MED CHEM, P261; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MATTER N, 1993, J BIOL CHEM, V268, P732; Meldolesi Jacopo, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P187; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETER F, 1992, J BIOL CHEM, V267, P10631; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKEI K, 1992, J NEUROSCI, V12, P489; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; VAN PN, 1989, J BIOL CHEM, V264, P17494; WOJCIKIEWICZ RJH, 1992, J NEUROCHEM, V59, P383, DOI 10.1111/j.1471-4159.1992.tb08916.x; ZAMMIT V, 1901, BIOCHEM J, V279, P377	46	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5673	5679						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119904				2022-12-25	WOS:A1994MY84000032
J	KURABAYASHI, M; JEYASEELAN, R; KEDES, L				KURABAYASHI, M; JEYASEELAN, R; KEDES, L			DOXORUBICIN REPRESSES THE FUNCTION OF THE MYOGENIC HELIX-LOOP-HELIX TRANSCRIPTION FACTOR MYOD - INVOLVEMENT OF ID GENE INDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIFFERENTIATION PROGRAM; ALPHA-ACTIN PROMOTER; DNA-BINDING; ENHANCER-BINDING; CARDIAC-MUSCLE; C-JUN; EXPRESSION; PROTEINS; ACTIVATION; CELLS	We have shown recently that Doxorubicin (Hox, Adriamycin), a potent broad spectrum chemotherapeutic agent with a major side effect of cardiomyopathy, completely prevents myoblast fusion and accumulation of muscle-specific transcripts in the mouse C2 skeletal muscle cell line. Here we use mouse embryonic fibroblast 10T1/2 cells to demonstrate that Hox represses muscle-specific gene expression by interfering with MyoD activity. As assayed by transient cotransfection, Hox inhibits the ability of MyoD to trans-activate muscle-specific reporter genes. A stable cell system was developed in which MyoD is constitutively expressed in 10T1/2 cells (M10 cells). Dox-treated M10 cells express MyoD from a long terminal repeat-driven vector but fail to activate endogenous MyoD and myogenin loci. Dox did not effect E2A gene transcript levels, but Id mRNA levels are significantly increased in Dox-treated M10 cells. Interestingly, overexpression of E2-5, which forms inactive heterodimers with Id, can overcome the Dox-induced suppression of the trans activation function of MyoD in 10T1/2 cells, Furthermore, we demonstrate that the 5'-flanking region of the Id2 gene mediates its Dox-inducible transcriptional expression. These findings support a model in which Dox inhibits muscle specific gene expression by interfering with the function of MyoD protein through, at least in part, induction of Id gene expression. The implications of our results for the molecular mechanisms underlying the myofibrillar loss observed in Dox-induced cardiomyopathy are discussed.	UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,INST GENET MED,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University of Southern California; University of Southern California								ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOROSHOW JH, 1985, AM J PATHOL, V118, P288; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GAHLMANN R, 1990, J BIOL CHEM, V265, P12520; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREENE RF, 1983, CANCER RES, V43, P3417; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUSTAFSON TA, 1989, MOL CELL BIOL, V9, P3269, DOI 10.1128/MCB.9.8.3269; HAQ MM, 1985, CANCER-AM CANCER SOC, V56, P1361, DOI 10.1002/1097-0142(19850915)56:6<1361::AID-CNCR2820560624>3.0.CO;2-S; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HERRLICH P, 1986, ADV ENZYME REGUL, V25, P485, DOI 10.1016/0065-2571(86)90030-0; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KURABAYASHI M, 1993, J BIOL CHEM, V268, P5524; KURABAYASHI M, 1988, J BIOL CHEM, V263, P13930; KURABAYASHI M, 1994, IN PRESS GENE AMST; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEWIS W, 1986, LAB INVEST, V54, P416; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	55	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6031	6039						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119948				2022-12-25	WOS:A1994MY84000084
J	KUSKE, CR; TICKNOR, LO; GUZMAN, E; GURLEY, LR; VALDEZ, JG; THOMPSON, ME; JACKSON, PJ				KUSKE, CR; TICKNOR, LO; GUZMAN, E; GURLEY, LR; VALDEZ, JG; THOMPSON, ME; JACKSON, PJ			PURIFICATION AND CHARACTERIZATION OF O-ACETYLSERINE SULFHYDRYLASE ISOENZYMES FROM DATURA-INNOXIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SERINE SULFHYDRYLASE; CYSTEINE SYNTHASE; GLUTATHIONE; METABOLISM; CADMIUM; LEAVES; O-ACETYLSERINE(THIOL)LYASE; MECHANISM; PROTEINS; OLERACEA	Three isoenzyme forms (designated A, B, and C) of O-acetylserine sulfhydrylase were purified from Datura innoxia suspension cultures. Isoenzyme A is the most abundant form, comprising 45-60% of the total activity. Isoenzymes C and B comprise 35-40% and 10-20% of the activity, respectively. The specific activities of the purified isoenzymes are similar (870-893 mu mol of cysteine/min/mg of protein). Molecular masses for isoenzymes A, B, and C, estimated by analytical size exclusion high performance Liquid chromatography, are 63, 86, and 63 kDa, respectively. Isoenzymes A and B are homodimers; isoenzyme C is a heterodimer. Spectral analysis indicates that these isoenzymes possess a pyridoxal 5'-phosphate cofactor that binds the O-acetylserine substrate. Binding is reversible by addition of the sulfide substrate. The O-acetylserine sulfhydrylase isoenzymes are active over a broad temperature range, with maximum activity between 42 and 58 degrees C. They are active only between pH 7 and 8, with optimal activity at pH 7.6. Kinetic analysis indicates these enzymes are allosterically regulated and exhibit positive cooperativity with respect to both substrates. They are inhibited by sulfide concentrations above 200 mu M. The kinetic analysis together with the physical and spectrophotometric characteristics indicate that the O-acetylserine sulfhydrylase enzymes have two active sites.	LOS ALAMOS NATL LAB, DIV ANAL & ASSESSMENT, STAT GRP, LOS ALAMOS, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	KUSKE, CR (corresponding author), LOS ALAMOS NATL LAB, DIV LIFE SCI, LOS ALAMOS, NM 87545 USA.							ASCANO A, 1977, PHYTOCHEMISTRY, V16, P889, DOI 10.1016/S0031-9422(00)86686-8; BECKER MA, 1969, J BIOL CHEM, V244, P2418; BERTAGNOLLI BL, 1977, PLANT PHYSIOL, V60, P115, DOI 10.1104/pp.60.1.115; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BORONAT A, 1984, J GEN MICROBIOL, V130, P673; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN SA, 1989, PICO TAG METHOD MANU, P1; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; COOK PF, 1976, J BIOL CHEM, V251, P2023; DELHAIZE E, 1989, PLANT PHYSIOL, V89, P700, DOI 10.1104/pp.89.2.700; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; DROUX M, 1992, ARCH BIOCHEM BIOPHYS, V295, P379, DOI 10.1016/0003-9861(92)90531-Z; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; FERSHT A, 1985, ENZYME STRUCTURE MEC, P263; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; Hill R, 1926, P R SOC LOND B-CONTA, V100, P419, DOI 10.1098/rspb.1926.0064; IKEGAMI F, 1988, PHYTOCHEMISTRY, V27, P697, DOI 10.1016/0031-9422(88)84078-0; IKEGAMI F, 1987, PHYTOCHEMISTRY, V26, P2699, DOI 10.1016/S0031-9422(00)83575-X; Jackson Paul J., 1993, P157; JACKSON PJ, 1987, P NATL ACAD SCI USA, V84, P6619, DOI 10.1073/pnas.84.19.6619; JACKSON PJ, 1992, PLANT SOIL, V146, P281, DOI 10.1007/BF00012022; JACKSON PJ, 1984, PLANT PHYSIOL, V75, P914, DOI 10.1104/pp.75.4.914; KALLEN RG, 1985, TRANSAMINASES, P37; KAPLAN MM, 1966, J BIOL CHEM, V241, P5781; KENNEDY WJ, 1980, STATISTICAL COMPUTIN, P480; KREDICH NM, 1969, J BIOL CHEM, V244, P2428; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; KUSKE CR, 1992, J CELL BIOCHEM, V16, P122; LEON J, 1987, PLANT SCI, V53, P93, DOI 10.1016/0168-9452(87)90118-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNN JE, 1990, PLANT PHYSIOL, V94, P1345, DOI 10.1104/pp.94.3.1345; MASADA M, 1975, J BIOCHEM, V77, P1107, DOI 10.1093/oxfordjournals.jbchem.a130811; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MORGAN PH, 1975, P NATL ACAD SCI USA, V72, P4327, DOI 10.1073/pnas.72.11.4327; MURAKOSHI I, 1985, PHYTOCHEMISTRY, V24, P1907, DOI 10.1016/S0031-9422(00)83090-3; NAKAMURA K, 1989, AGR BIOL CHEM TOKYO, V53, P2537, DOI 10.1080/00021369.1989.10869671; NIETOSOTELO J, 1986, PLANT PHYSIOL, V82, P1031, DOI 10.1104/pp.82.4.1031; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ratkowsky D.A., 1983, NONLINEAR REGRESSION, P61; RATKOWSKY DA, 1986, BIOCHEM J, V240, P357, DOI 10.1042/bj2400357; Ratkowsky DD, 1990, HDB NONLINEAR REGRES, P128; RAUSER WE, 1990, ANNU REV BIOCHEM, V59, P61, DOI 10.1146/annurev.bi.59.070190.000425; REED D J, 1984, Pharmacological Reviews, V36, p25S; Roberts D.V., 1977, ENZYME KINETICS; ROBINSON NJ, 1988, PLANT SCI, V56, P197, DOI 10.1016/0168-9452(88)90098-2; ROLLAND N, 1992, PLANT PHYSIOL, V98, P927, DOI 10.1104/pp.98.3.927; SCHMIDT A, 1992, ANNU REV PLANT PHYS, V43, P325, DOI 10.1146/annurev.pp.43.060192.001545; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P3557, DOI 10.1021/bi00583a019; SMITH IK, 1971, BIOCHIM BIOPHYS ACTA, V227, P288, DOI 10.1016/0005-2744(71)90061-1; TAMURA G, 1976, AGR BIOL CHEM TOKYO, V40, P637, DOI 10.1080/00021369.1976.10862100; Tierney L., 1990, LISP STAT OBJECT ORI; WILSON DA, 1965, J BIOL CHEM, V240, P4801; ZEFFREN E, 1973, STUDY ENZYME MECHANI, P133	55	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6223	6232						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119966				2022-12-25	WOS:A1994MY84000110
J	LI, YL; VALAITIS, AP; LATSHAW, SP; KWIATKOWSKA, D; TRIPATHI, RL; CAMPBELL, MC; KEMP, RG				LI, YL; VALAITIS, AP; LATSHAW, SP; KWIATKOWSKA, D; TRIPATHI, RL; CAMPBELL, MC; KEMP, RG			STRUCTURE AND EXPRESSION OF THE CDNA FOR THE C ISOZYME OF PHOSPHOFRUCTO-1-KINASE FROM RABBIT BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; LIVER-TYPE PHOSPHOFRUCTOKINASE; MUSCLE PHOSPHOFRUCTOKINASE; MESSENGER-RNA; PROTEIN; PHOSPHORYLATION; ISOENZYMES; SEQUENCE; GENE; SITE	Rabbit brain contains three phosphofructo-1-kinase (PFK) isozymic subunits designated A, B, and C. The primary structures of the first of these two isozyme types have been determined previously. The isozyme C of rabbit brain was isolated by immunoaffinity chromatography and subjected to proteolytic and chemical digestion. A large number of peptides were sequenced, the total number of amino acids identified being equal to about 80% of the total structure. The sequence of the cDNA derived from brain mRNA for C isozyme was determined from polymerase chain reaction fragments synthesized using oligonucleotides designed on the basis of the peptide sequences. The deduced size of the C isozyme was 86,371 Da, slightly larger than PFKs described previously. The amino acid sequence identity with the rabbit A isozyme was 68.9% and a range of identity to other sequenced mammalian PFKs was 67-69%. Using these data plus previously published data on chemical modification, assignments of the 6 organic ligand binding sites of PFK were inferred. The full-length cDNA was cloned into and expressed in Escherichia coli. Phosphofructokinase C was purified to homogeneity from the bacterial extracts.	UNIV HLTH SCI CHICAGO MED SCH, DEPT BIOL CHEM, N CHICAGO, IL 60064 USA	Chicago Medical School					NIDDK NIH HHS [DK19912] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019912] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTTREAU D, 1979, BIOCHIM BIOPHYS ACTA, V568, P183, DOI 10.1016/0005-2744(79)90285-7; DEFARIA JD, 1978, DEV BIOL, V65, P75; DUNAWAY GA, 1988, BRAIN RES, V456, P310, DOI 10.1016/0006-8993(88)90233-8; DUNAWAY GA, 1985, J BIOL CHEM, V260, P4180; DUNAWAY GA, 1987, BIOCHEM J, V242, P667, DOI 10.1042/bj2420667; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FOE LG, 1984, ARCH BIOCHEM BIOPHYS, V228, P503, DOI 10.1016/0003-9861(84)90016-X; FOE LG, 1985, J BIOL CHEM, V260, P726; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEHNRICH SC, 1988, J BIOL CHEM, V263, P11755; GEKAKIS N, 1989, J BIOL CHEM, V264, P3658; GONZALEZ F, 1975, COMP BIOCHEM PHYS B, V52, P315, DOI 10.1016/0305-0491(75)90071-1; HELLINGA HW, 1985, EUR J BIOCHEM, V149, P363, DOI 10.1111/j.1432-1033.1985.tb08934.x; HOTTA K, 1991, EUR J BIOCHEM, V202, P293, DOI 10.1111/j.1432-1033.1991.tb16375.x; KEMP RG, 1987, BIOCHEMISTRY-US, V26, P3443, DOI 10.1021/bi00386a029; KEMP RG, 1981, J BIOL CHEM, V256, P7282; KEMP RG, 1990, FRUCTOSE 2 6 BISPHOS, P17; KHAN A, 1979, HUM GENET, V48, P93; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU FTK, 1989, BIOCHEMISTRY-US, V28, P6841, DOI 10.1021/bi00443a010; LEE CP, 1987, J BIOL CHEM, V262, P4195; LEVANON D, 1989, DNA-J MOLEC CELL BIO, V8, P733, DOI 10.1089/dna.1989.8.733; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA PM, 1989, GENE, V77, P177, DOI 10.1016/0378-1119(89)90372-7; SIMPSON CJ, 1991, BIOCHEM BIOPH RES CO, V180, P197, DOI 10.1016/S0006-291X(05)81276-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSAI MY, 1974, J BIOL CHEM, V249, P6590; TSAI MY, 1973, J BIOL CHEM, V248, P785; VALAITIS AP, 1988, BIOCHIM BIOPHYS ACTA, V956, P232, DOI 10.1016/0167-4838(88)90140-9; VALAITIS AP, 1989, BIOCHIM BIOPHYS ACTA, V995, P187, DOI 10.1016/0167-4838(89)90079-4; VORA S, 1981, BLOOD, V57, P724; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	36	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5781	5787						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119919				2022-12-25	WOS:A1994MY84000049
J	MOUSTAID, N; BEYER, RS; SUL, HS				MOUSTAID, N; BEYER, RS; SUL, HS			IDENTIFICATION OF AN INSULIN-RESPONSE ELEMENT IN THE FATTY-ACID SYNTHASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONAL-REGULATION; 3T3-L1 CELLS; GENE; PROTEIN; TRANSCRIPTION; EXPRESSION; LIVER; TRIIODOTHYRONINE; RESPONSIVENESS; GLUCAGON	We have previously reported that insulin increases fatty acid synthase (FAS) gene transcription, and that sequences responsible for positive regulation are located within the first 332 base pairs of the FAS promoter. To define minimal sequences required for insulin regulation within this region, chimeric constructs containing serial 5' deletions starting at -318 and extending through position +67 of the rat FAS gene ligated to the luciferase reporter gene were transfected into 3T3-L1 adipocytes. Insulin treatment at 10 nm increased luciferase activity 2-3-fold in 3T3-L1 adipocytes transfected with constructs containing progressive deletions from -318 to -67. This stimulation of the FAS promoter activity by insulin was dose-dependent. However, no effect of insulin was observed when fusion constructs containing FAS promoter sequences spanning from -25 or from -19 to +67 were transfected into adipocytes. These results suggest that the insulin response sequences of the FAS gene may be located in the region from -67 to -25. DNase I footprinting using liver nuclear extracts revealed a protected region spanning -71 and -50 in addition to a region near the putative TATA box. Gel mobility shift assays using the sequence from -71 to -50 as a probe revealed nuclear factor(s) from mouse liver and 3T3-L1 adipocytes that specifically complexed with this sequence. Mutational analysis of this region showed that sequences between -68 and -60 are essential for recognition and interaction with a trans-acting factor(s). Moreover, when three tandem repeats of the sequences spanning -68 to -52 were linked to the SV40 promoter and used for transfection, luciferase activity increased 3.6-fold in response to insulin treatment. Thus, we have identified novel cis-acting DNA sequences responsible for insulin regulation of the FAS gene, which interact with nuclear protein(s) from liver and adipocytes and which are found to share limited homology to insulin response sequences present in other genes.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health			Han, Zaiqi/AAI-2233-2019; Moustaid-Moussa, Naima/B-9067-2014	Moustaid-Moussa, Naima/0000-0002-7508-8030	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008814, R01DK036264] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36264, F2 DK 08814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; LAKSHMAN MR, 1989, J PHARMACOL EXP THER, V248, P62; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKIM JM, 1991, LIPIDS, V26, P521, DOI 10.1007/BF02536597; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OSBORN L, 1988, J BIOL CHEM, V263, P16519; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PRAGER D, 1990, J CLIN INVEST, V85, P1680, DOI 10.1172/JCI114620; RONGNOPARUT P, 1991, J BIOL CHEM, V266, P8086; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541	31	130	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5629	5634						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119899				2022-12-25	WOS:A1994MY84000026
J	WALKEY, CJ; KALMAR, GB; CORNELL, RB				WALKEY, CJ; KALMAR, GB; CORNELL, RB			OVEREXPRESSION OF RAT-LIVER CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE ACCELERATES PHOSPHATIDYLCHOLINE SYNTHESIS AND DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-C; HELA-CELLS; DIACYLGLYCEROL PRODUCTION; ENDOPLASMIC-RETICULUM; SIGNAL TRANSDUCTION; INDUCED INHIBITION; CULTURED-CELLS; CDP-CHOLINE; HEPATOCYTES	Two rat liver cDNAs encoding CTP:phosphocholine cytidylyltransferase (CT-1 and CT2) were expressed in COS cells. The specific activity of CT in the microsomes increased approximately 20- or 100-fold after transfection with CT-1 or CT-2, respectively, but there was only a 3-5-fold increase in the rate of [H-3]choline or [H-3]glycerol incorporation into phosphatidylcholine (PC). The phosphocholine pool decreased similar to 40% in keeping with a stimulation of the CT-catalyzed reaction. The CDP-choline pool increased 12-fold suggesting that the conversion of CDP choline to PC, catalyzed by cholinephosphotransferase, could not keep pace with the CT-catalyzed reaction. This could account for the discrepancy between the increases in the amount of active (membrane-bound) CT and the rate of PC synthesis. Incubation of CT-transfected cells with sodium oleate to increase the supply of cellular diacylglycerol resulted in a further 2-fold increase in the rate of PC synthesis. This suggests that the diacylglycerol supply may be a Limiting factor in the degree of stimulation of PC synthesis in CT-transfected COS cells. Despite the increased rate of PC synthesis, the total cellular PC mass increased only 17%, due to a 3-fold acceleration of the PC degradation rate. To determine which degradative pathway far PC was accelerated in the CT-transfected cells, we measured the pool sizes of several catabolites. Neither diacylglycerol nor phosphatidic acid mass was altered. The pool of glycerophosphocholine (GPC) was increased similar to 4-fold, and there was elevated release of GPC from the CT-transfected cells. The turnover of choline in GPC and lyse-PC was very slow compared with that of choline, phosphocholine, or CDP-choline, suggesting that GPC and lyso-PC were derived from slowly degraded choline-labeled PC. The metabolism of GPC and lyse-PC was stimulated in the cells overexpressing CT. These data suggest that PC synthesis and degradation are coordinated and that PC catabolism involving PC --> lyso-PC --> GPC is accelerated in COS cells overexpressing CT.	SIMON FRASER UNIV,INST MOLEC BIOL & BIOCHEM,BURNABY V5A 1S6,BC,CANADA; SIMON FRASER UNIV,DEPT CHEM,BURNABY V5A 1S6,BC,CANADA	Simon Fraser University; Simon Fraser University								ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P23147; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; CRAIG L, 1994, J BIOL CHEM, V269, P3311; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLORINCHRISTENSEN J, 1992, J BIOL CHEM, V267, P14783; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; HAMMARSKJOLD ML, 1986, GENE, V43, P41, DOI 10.1016/0378-1119(86)90006-5; HATCH GM, 1992, J BIOL CHEM, V267, P15751; HOFFMAN JM, 1991, BIOCHEMISTRY-US, V30, P3315, DOI 10.1021/bi00227a021; HUANG CF, 1990, J BIOL CHEM, V265, P14858; HUI GS, 1991, J BIOL CHEM, V266, P20238; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KANOH H, 1973, BIOCHIM BIOPHYS ACTA, V326, P17, DOI 10.1016/0005-2760(73)90023-4; KAY R, 1991, Methods in Molecular and Cellular Biology, V2, P254; KOLESNICK RN, 1987, J BIOL CHEM, V262, P14525; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LIM P, 1986, BIOCHEM CELL BIOL, V64, P692, DOI 10.1139/o86-095; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; MORASH SC, 1989, BIOCHIM BIOPHYS ACTA, V1004, P221, DOI 10.1016/0005-2760(89)90271-3; MORASH SC, 1988, BIOCHIM BIOPHYS ACTA, V961, P194, DOI 10.1016/0005-2760(88)90114-2; PAI JK, 1988, J BIOL CHEM, V263, P12472; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TERCE F, 1991, BIOCHIM BIOPHYS ACTA, V1084, P69, DOI 10.1016/0005-2760(91)90057-O; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TIJBURG LBM, 1991, BIOCHIM BIOPHYS ACTA, V1085, P167, DOI 10.1016/0005-2760(91)90091-U; TIJBURG LBM, 1989, BIOCHEM J, V257, P645, DOI 10.1042/bj2570645; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANCE DE, 1984, TRENDS BIOCHEM SCI, V9, P17, DOI 10.1016/0968-0004(84)90041-0; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P3345	50	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5742	5749						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119913				2022-12-25	WOS:A1994MY84000043
J	HIRAIZUMI, S; SPOHR, U; SPIRO, RG				HIRAIZUMI, S; SPOHR, U; SPIRO, RG			LIGAND AFFINITY CHROMATOGRAPHIC PURIFICATION OF RAT-LIVER GOLGI ENDOMANNOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-D-MANNOSIDASE; N-LINKED OLIGOSACCHARIDES; GLUCOSIDASE-II-DEFICIENT; PATHWAY; CELLS; GLYCOPROTEINS; MEMBRANES; PROTEINS	In order to achieve isolation of endo-alpha-D-mannosidase, a GoIgi-located processing enzyme that accomplishes deglucosylation of glycoproteins with N-linked carbohydrate units by cleaving the linkage between the glucose-substituted mannose residue and the remainder of the oligosaccharide, we have prepared an affinity matrix (Glc alpha 1-->3Man-O-(CH2)8CONH-Affi-Gel 102) containing the derivative of the characteristic disaccharide product of this enzyme. Chromatography of a Triton extract of rat liver Golgi membranes on a column of this gel in the presence of castanospermine to prevent binding of alpha-glucosidases permitted a rapid purification of the endomannosidase (70,000-fold over the homogenate) with a 12% yield. This purified enzyme was free of other processing glycosidases and was completely inhibited by Glc alpha 1-->3(1-deoxy)mannojirimycin. Examination of the endomannosidase by SDS-polyacrylamide gel electrophoresis revealed a doublet (M(r) 60,000 and 56,000) with the bands being of approximately equal density. Gel permeation high performance liquid chromatography indicated that in its native form the enzyme has an oligomeric structure (M(r) similar to 560,000) consisting of eight to ten subunits.	JOSLIN DIABET CTR,ELLIOTT P JOSLIN RES LAB,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,AB,CANADA; CHEMBIOMED LTD,EDMONTON T6G 2G2,AB,CANADA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Alberta					NIDDK NIH HHS [DK 17477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4076, DOI 10.1021/ja00847a035; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4056, DOI 10.1021/ja00847a032; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINTO BM, 1983, CARBOHYD RES, V124, P313, DOI 10.1016/0008-6215(83)88466-3; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; SAXENA S, 1987, BIOCHEM J, V247, P563, DOI 10.1042/bj2470563; SRIVASTAVA OP, 1987, CARBOHYD RES, V161, P195, DOI 10.1016/S0008-6215(00)90077-6; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227	22	18	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4697	4700						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106437				2022-12-25	WOS:A1994MX57100002
J	TSAI, AL; HSI, LC; KULMACZ, RJ; PALMER, G; SMITH, WL				TSAI, AL; HSI, LC; KULMACZ, RJ; PALMER, G; SMITH, WL			CHARACTERIZATION OF THE TYROSYL RADICALS IN OVINE PROSTAGLANDIN-H SYNTHASE-1 BY ISOTOPE REPLACEMENT AND SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HIGHER OXIDATION-STATES; SHEEP VESICULAR GLAND; HEME-BINDING; COMPOUND ES; YEAST; TRANSLOCATION; BIOSYNTHESIS; KINETICS; ACID	Several free radical species, attributed to tyrosyl radicals, have been previously observed by electron paramagnetic resonance (EPR) spectroscopy during reaction of pure ovine prostaglandin H synthase-1 (PGHS-1) with hydroperoxide or fatty acid substrates. The identity and location of amino acid residue(s) involved in formation of these radicals has been investigated using wild type and mutant PGHS-1 expressed in transfected COS-1 cells. Upon reaction with hydroperoxide, detergent extracts from microsomes of cells expressing wild type ovine PGHS-1 rapidly produced EPR signals made up of a broad component, resembling either either the wide doublet or the wide singlet seen in reactions of the purified ovine enzyme, mixed with a variable proportion of a narrow component. Isotope replacement with perdeuterated tyrosine and phenylalanine in wild type PGHS-1 caused no change in enzymatic activity or capability to form a peroxide-induced radical, but the radical was an isotropic singlet without any wide features. This loss of splitting in the deuterated enzyme establishes that the wide radical signal in PGHS-1 is indeed a tyrosyl radical, validating the earlier assignment based on spectral similarities with a tyrosyl radical in ribonucleotide reductase. A Y385F mutation abolished cyclooxygenase but not peroxidase activity, and the peroxide-induced EPR was narrowed to a singlet essentially identical with that obtained with indomethacin-treated ovine enzyme. Isotopic replacement with perdeuterated tyrosine and phenylalanine in the Y385F mutant led to further narrowing of the peroxide-induced EPR to an isotropic singlet, establishing that this radical also involved a tyrosine residue. A Y355F mutant exhibited some decrease in cyclooxygenase activity, but the peroxidase activity and the peroxide-induced radical characteristics were not significantly different from those of the wild type enzyme, indicating that Tyr(355) is not involved in tyrosyl radical formation in PGHS-1. An interpretation consistent with the results is that the peroxide-induced radical is formed on Tyr(385) in wild type PGHS-1, but cyclooxygenase inactivation by a Y385F mutation or by indomethacin results in radical formation on an alternate tyrosine residue.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Michigan State University; Rice University	TSAI, AL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042509, R01DK022042, R37DK022042] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07404] Funding Source: Medline; NIDDK NIH HHS [DK 42509, DK 22042] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRY BA, 1990, J BIOL CHEM, V265, P20139; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DREZTEN D, 1981, ANAL BIOCHEM, V112, P295; GRAFF G, 1982, METHOD ENZYMOL, V86, P386; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; HORI H, 1985, J BIOL CHEM, V260, P349; HSI LC, 1993, J LIPID MEDIATOR, V6, P131; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASSMANN G, 1991, J BIOL CHEM, V266, P2004; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NELSON MJ, 1993, FASEB J, V7, pA1059; PRINCE RC, 1988, TRENDS BIOCHEM SCI, V13, P286, DOI 10.1016/0968-0004(88)90119-3; RUAN KH, 1993, J IMMUNOL METHODS, V162, P23, DOI 10.1016/0022-1759(93)90403-T; Sambrook J., 1989, MOL CLONING LAB MANU, P916; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P2007; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH WL, 1990, ADV PROSTAG THROMB L, V20, P14; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; TSAI AL, 1992, J BIOL CHEM, V267, P17753; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WILKS A, 1992, J BIOL CHEM, V267, P8827	35	93	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5085	5091						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106487				2022-12-25	WOS:A1994MX57100062
J	HEBERT, CA; CHUNTHARAPAI, A; SMITH, M; COLBY, T; KIM, J; HORUK, R				HEBERT, CA; CHUNTHARAPAI, A; SMITH, M; COLBY, T; KIM, J; HORUK, R			PARTIAL FUNCTIONAL MAPPING OF THE HUMAN INTERLEUKIN-8 TYPE-A RECEPTOR - IDENTIFICATION OF A MAJOR LIGAND-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL CHEMOTACTIC FACTOR; ACTIVATING FACTOR; PURIFICATION; MUTAGENESIS; MONOCYTES; RESIDUES; SKIN; IL-8	We have previously demonstrated that a basic amino acid residue of interleukin (IL)-8, namely Arg-6, is critical for the binding of IL-8 to its receptor. We reasoned that this residue is likely to be poised to directly interact with a counterpart acidic residue on the receptor. To identify this key residue, we systematically mutated to Ala all acidic residues present on the ligand accessible surface of IL-8 receptor type A. Using this strategy, we demonstrate that two residues which are present in extracellular loop 3 of the receptor, namely Glu-275 and Arg-80, are critical for ligand binding. In addition, we show that although Asp-11 is critical for ligand binding, a conservative mutation of Asp-11 to Glu or a substitution of Asp-11 with Lys (the residue found at position 11 in IL-8 receptor type B) does not affect the K(d) of the receptor/ligand interaction. These data suggest that Lys-11 recruits a new and favorable interaction with IL-8 (analogous to that of IL-8 receptor type B with IL-8) or that the cavity created by mutating Asp-11 to Ala is particularly deleterious. Finally, we discuss fluorescence-activated cell sorter staining data which support the hypothesis that the N-terminal region and the extracellular loop 3 of the receptor may lie in close proximity of one another and constitute a major binding domain for IL-8.	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech	HEBERT, CA (corresponding author), GENENTECH INC,DEPT IMMUNOL,S SAN FRANCISCO,CA 94080, USA.							BROADDUS VC, 1992, IN PRESS AM REV RESP; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COLDITZ I, 1989, AM J PATHOL, V134, P755; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; GREGORY H, 1988, BIOCHEM BIOPH RES CO, V151, P883, DOI 10.1016/S0006-291X(88)80364-4; GROTZINGER J, 1991, PROTEIN ENG, V4, P767, DOI 10.1093/protein/4.7.767; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KOCH AE, 1991, J IMMUNOL, V147, P2187; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PACAUD JP, 1990, BIOCHEM BIOPH RES CO, V166, P187; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAMPART M, 1989, AM J PATHOL, V135, P21; RICHMANEISENSTA.JB, 1993, IN PRESS AM J PHYSL; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; TERKELTAUB R, 1991, ARTHRITIS RHEUM, V34, P894, DOI 10.1002/art.1780340716; VANDAMME J, 1988, J EXP MED, V167, P1364, DOI 10.1084/jem.167.4.1364; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1987, J IMMUNOL, V139, P788	23	134	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18549	18553						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103045				2022-12-25	WOS:A1993LV65900029
J	PARK, K; KIM, KH				PARK, K; KIM, KH			THE SITE OF CAMP ACTION IN THE INSULIN INDUCTION OF GENE-EXPRESSION OF ACETYL-COA CARBOXYLASE IS AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; DEPENDENT PROTEIN-KINASE; TUMOR NECROSIS FACTOR; FATTY-ACID SYNTHESIS; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; MESSENGER-RNA; CYCLIC-AMP; HOUSEKEEPING GENE; 5' END	Insulin induction of acetyl-CoA carboxylase (ACC) and differentiation of 30A5 preadipocytes into adipocytes requires a brief exposure of the cells to cAMP. Using the techniques of DNase I footprinting, DNA band shift, and analysis of the point and deletion mutations, a region from -113 to -95 has been identified as the site through which cAMP sensitizes the cell for the response to insulin. One sequence-specific DNA-protein complex, b3, is formed in the DNA-mobility shift assay when nuclear extract from 30A5 cells is mixed with the oligonucleotide representing this region. Purified human AP-2 also generates the complex corresponding to b3 with the same ACC PII probe or with the AP-2 consensus sequence probe from SV40 promoter. Substitution of A for G in the sequence GGGGCTGGG abolishes the formation of b3 sequence-specific complex. Stably transfected 30A5 cells with the same mutations in the plasmid no longer respond to insulin in spite of their exposure to cAMP. These results establish that the 21 base pair region in ACC promoter II and the binding of AP-2 protein to this sequence are required for cAMP action. cAMP-dependent protein kinase phosphorylates AP-2 both in vitro and in vivo and the phosphorylation of AP-2 does not affect its binding activity.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA 46882] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAI DH, 1986, J BIOL CHEM, V261, P2395; BATENBURG JJ, 1989, BIOCHIM BIOPHYS ACTA, V1006, P329, DOI 10.1016/0005-2760(89)90020-9; BOYER TG, 1989, J BIOL CHEM, V264, P5177; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON CA, 1974, ARCH BIOCHEM BIOPHYS, V164, P490, DOI 10.1016/0003-9861(74)90059-9; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P19; HAYSTEAD TAJ, 1990, EUR J BIOCHEM, V187, P199, DOI 10.1111/j.1432-1033.1990.tb15295.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; Lane M D, 1974, Curr Top Cell Regul, V8, P139; LOPEZCASILLAS F, 1987, ARCH BIOCHEM BIOPHYS, V257, P63, DOI 10.1016/0003-9861(87)90543-1; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Numa S, 1984, FATTY ACID METABOLIS, P1; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PAPE ME, 1989, THESIS PURDUE U; PARK KR, 1991, J BIOL CHEM, V266, P12249; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAI T, 1988, ARCH BIOCHEM BIOPHYS, V266, P313, DOI 10.1016/0003-9861(88)90263-9; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VOLPE JJ, 1973, ANNU REV BIOCHEM, V42, P21, DOI 10.1146/annurev.bi.42.070173.000321; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WHITEHOUSE S, 1982, J BIOL CHEM, V257, P6028; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WITTERS LA, 1985, MOL BASIS INSULIN AC, P315; ZHU Z, 1989, J BIOL CHEM, V264, P6550	42	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17811	17819						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	8102369				2022-12-25	WOS:A1993LT74300029
J	TANAKA, K; YANOSHITA, R; KONISHI, M; OSHIMURA, M; MAEDA, Y; MORI, T; MIYAKI, M				TANAKA, K; YANOSHITA, R; KONISHI, M; OSHIMURA, M; MAEDA, Y; MORI, T; MIYAKI, M			SUPPRESSION OF TUMORIGENICITY IN HUMAN COLON-CARCINOMA CELLS BY INTRODUCTION OF NORMAL CHROMOSOME 1P36 REGION	ONCOGENE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; ENDOCRINE NEOPLASIA; COLORECTAL TUMORS; HIGH-FREQUENCY; WILMS-TUMOR; SHORT ARM; TUMORIGENICITY; DNA; SEQUENCE; GENE	Development of colon carcinomas appears to be associated with inactivation of multiple tumour suppressor genes. Cytogenetic and DNA analyses of colon carcinomas have detected a high frequency of chromosome 1p deletion, which suggests the presence of a tumour suppressor gene. We therefore introduced normal human chromosome 1 into colon carcinoma COKFu cells, through microcell hybridization. Six clones of hybrid cells containing normal chromosome 1 were obtained, four of which had a small fragment of the introduced chromosome 1, including 1p36-34. The morphology of hybrid cells with chromosome 1 markedly altered to a flat shape. The cloning efficiency of all six hybrid cells in soft agar was significantly reduced, and the tumourigenicity in athymic nude mice was completely suppressed. Hybrid cells containing only the region of 1p36-34, as well as those containing intact chromosome 1, showed suppressed transformed phenotype. Furthermore, several tumourigenic revertant cells were obtained from the hybrid cells. These revertant cells had a morphology similar to that of COKFu cells, and were found to have lost the 1p36 region from the introduced chromosome 1. These results indicate that a normal chromosome 1p36 carries a tumour suppressor gene for colon carcinogenesis.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,3-18-22 HONKOMAGOME,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT CHEMOTHERAPY & SURG,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tottori University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital								BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BENEDICT WF, 1984, CANCER RES, V44, P3471; COUTURIERTURPIN MH, 1992, HUM GENET, V88, P431, DOI 10.1007/BF00215678; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DRACOPOLI N C, 1988, Genomics, V3, P124, DOI 10.1016/0888-7543(88)90142-5; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KLEIN G, 1971, J CELL SCI, V8, P659; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MIYAKI M, 1990, CANCER RES, V50, P7166; MOLEY JF, 1992, CANCER RES, V52, P770; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P9367, DOI 10.1093/nar/16.19.9367; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P9368, DOI 10.1093/nar/16.19.9368; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P9622, DOI 10.1093/nar/15.22.9622; NEGRINI M, 1992, CANCER RES, V52, P1297; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; PARASKEVA C, 1988, INT J CANCER, V41, P908; PARASKEVA C, 1989, CANCER RES, V49, P1282; REICHMANN A, 1984, CANCER GENET CYTOGEN, V12, P295, DOI 10.1016/0165-4608(84)90062-1; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHIMIZU M, 1990, ONCOGENE, V5, P185; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VANNI R, 1990, GENE CHROMOSOME CANC, V2, P255, DOI 10.1002/gcc.2870020316; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISS MJ, 1987, NUCLEIC ACIDS RES, V15, P860, DOI 10.1093/nar/15.2.860; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WILLIAMS AC, 1990, CANCER RES, V50, P4724; YANOSHITA R, 1992, CANCER RES, V52, P3965	45	91	101	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2253	2258						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8101648				2022-12-25	WOS:A1993LP17100027
J	BULLIS, BL; LEMIRE, BD				BULLIS, BL; LEMIRE, BD			ISOLATION AND CHARACTERIZATION OF THE SACCHAROMYCES-CEREVISIAE SDH4 GENE ENCODING A MEMBRANE ANCHOR SUBUNIT OF SUCCINATE-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUMARATE REDUCTASE; FLAVOPROTEIN SUBUNIT; NUCLEOTIDE-SEQUENCE; UBIQUINONE REDUCTASE; PROTEINS; IMPORT; ELECTROPHORESIS; MITOCHONDRIA; HELICES	Succinate dehydrogenase (EC 1.3.99.1) is an intrinsic bacterial or inner mitochondrial membrane protein that catalyses the oxidation of succinate and donates electrons to the respiratory chain via quinone accepters. It is a heterotetramer composed of a flavoprotein, an iron-sulfur, and two hydrophobic subunits. We purified succinate dehydrogenase by blue native gel electrophoresis, determined the amino-terminal sequence of the Sdh4p subunit and used this information to clone the SDH4 gene. It encodes a precursor protein of 181 amino acids that is converted to the 150-amino acid mature Sdh4p protein with a mass of 16,638 Da. Hydrophobicity analysis predicts that Sdh4p forms three transmembrane alpha-helices. We have constructed an SDH4 mutant by targeted gene disruption; it retains the ability to grow on rich glycerol medium. Western blot analysis of SDH4 disruption mutant membrane fractions indicates that membrane attachment of the flavoprotein and iron-sulfur subunits is impaired but not abolished, This membrane-bound enzyme is able to reduce ubiquinone, although less efficiently than the wild-type enzyme. These findings indicate that Sdh4p contributes both to the membrane attachment of the catalytic flavoprotein and iron-sulfur subunits and to electron transfer to ubiquinone.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2H7, AB, CANADA	University of Alberta								Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; CHAPMAN KB, 1992, GENE, V118, P131, DOI 10.1016/0378-1119(92)90260-V; COLE ST, 1987, EUR J BIOCHEM, V167, P481, DOI 10.1111/j.1432-1033.1987.tb13362.x; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GRUNDSTROM T, 1982, P NATL ACAD SCI-BIOL, V79, P1111, DOI 10.1073/pnas.79.4.1111; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; KITA K, 1989, J BIOL CHEM, V264, P2672; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATOUR DJ, 1987, J GEN MICROBIOL, V133, P597; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; OWEN P, 1982, TECHN LIPID MEMBR B, V407, P1; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHILLING RJ, 1982, FED PROC, V41, P896; SCHULKE N, 1992, P NATL ACAD SCI USA, V89, P8011, DOI 10.1073/pnas.89.17.8011; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; WEINER JH, 1984, J CELL BIOCHEM, V24, P207, DOI 10.1002/jcb.240240303; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; XU Y, 1987, BIOCHEM BIOPH RES CO, V144, P315, DOI 10.1016/S0006-291X(87)80512-0; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YU CA, 1982, J BIOL CHEM, V257, P6127; YU L, 1987, J BIOL CHEM, V262, P1137; YU L, 1992, J BIOL CHEM, V267, P24508	35	59	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6543	6549						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120006				2022-12-25	WOS:A1994MZ50300045
J	DONG, ZG; THOMA, RS; CRIMMINS, DL; MCCOURT, DW; TULEY, EA; SADLER, JE				DONG, ZG; THOMA, RS; CRIMMINS, DL; MCCOURT, DW; TULEY, EA; SADLER, JE			DISULFIDE BONDS REQUIRED TO ASSEMBLE FUNCTIONAL VON-WILLEBRAND-FACTOR MULTIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN VONWILLEBRAND-FACTOR; PLATELET GLYCOPROTEIN-IB; AMINO-ACID RESIDUES; FACTOR-VIII BINDING; FIBRILLAR COLLAGEN; FACTOR VWF; DOMAIN; HEPARIN; IDENTIFICATION; CHROMATOGRAPHY	The hemostatic functions of human von Willebrand Factor (VWF) depend on the normal assembly of disulfide-linked multimers from similar to 250-kDa subunits. Subunits initially form dimers through disulfide bonds near the COOH terminus. Dimers then form multimers through disulfide bonds near the NH2 terminus of each subunit. Previous studies of plasma vWF and recombinant vWF fragments indicate that 1 or more of the Cys residues at position 459, 462, and 464 form intersubunit disulfide bonds. No evidence has been reported that vWF multimer formation involves additional intersubunit bonds. To probe the disulfide bond requirements for multimer formation, mutant vWF proteins were expressed in which all 3 Cys residues at positions 459, 462, and 464 were changed to either Gly or Ala. Surprisingly, none of these cysteines appears to be necessary for efficient multimer assembly. Furthermore, recombinant vWF with Gly or Ala at all three positions induces platelet aggregation in the presence of ristocetin and binds to platelet glycoprotein Ib, factor VIII, and collagen in a manner similar to wild-type recombinant vWF. These results suggest that other intersubunit disulfide bonds must exist. Direct evidence for such a bond was obtained by characterization of tryptic fragments of vWF. By Edman degradation, amino acid composition, and mass spectrometry, a disulfide bond was demonstrated between Cys(379) residues of adjacent vWF subunits, Thus, intersubunit disulfide bonds involving Cys(379) and 1 or more of the Cys residues at positions 459, 462, and 464 connect the NH2-terminal ends of the vWF subunits in a parallel orientation.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X				ADAMS GA, 1985, MOL CELL BIOL, V5, P1442, DOI 10.1128/MCB.5.6.1442; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; AZUMA H, 1993, J BIOL CHEM, V268, P2821; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BURKE RL, 1986, J BIOL CHEM, V261, P2574; CRIMMINS DL, 1989, ANAL BIOCHEM, V176, P255, DOI 10.1016/0003-2697(89)90305-9; DOUCETDEBRUINE MHM, 1978, J LAB CLIN MED, V92, P96; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; FUJIMURA Y, 1987, BLOOD, V70, P985; GIRMA JP, 1986, BIOCHEMISTRY-US, V25, P3156, DOI 10.1021/bi00359a013; GRALNICK HR, 1981, BLOOD, V58, P387; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUBERT AJ, 1963, HELV CHIM ACTA, V46, P1429, DOI 10.1002/hlca.19630460439; KALAFATIS M, 1987, BLOOD, V70, P1577; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEGAZ ME, 1973, J BIOL CHEM, V248, P3946; LYONS SE, 1992, J BIOL CHEM, V267, P4424; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MAZURIER C, 1991, VOX SANG, V61, P61; MOHRI H, 1989, J BIOL CHEM, V264, P17361; PARETI FI, 1987, J BIOL CHEM, V262, P13835; RAINES G, 1990, THROMB RES, V60, P201, DOI 10.1016/0049-3848(90)90181-B; RANDI AM, 1992, J BIOL CHEM, V267, P21187; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SANTORO SA, 1983, BIOCHIM BIOPHYS ACTA, V756, P123, DOI 10.1016/0304-4165(83)90032-6; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VERWEIJ CL, 1987, EMBO J, V6, P2885, DOI 10.1002/j.1460-2075.1987.tb02591.x; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9	39	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6753	6758						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120035				2022-12-25	WOS:A1994MZ50300078
J	MAGHAZACHI, AA; ALAOUKATY, A				MAGHAZACHI, AA; ALAOUKATY, A			G(S) IS THE MAJOR G-PROTEIN INVOLVED IN INTERLEUKIN-2-ACTIVATED NATURAL-KILLER (IANK) CELL-MEDIATED CYTOTOXICITY - SUCCESSFUL INTRODUCTION OF ANTI-G PROTEIN ANTIBODIES INSIDE STREPTOLYSIN O-PERMEABILIZED IANK CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; GTP-BINDING PROTEINS; ALPHA-SUBUNITS; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; CHOLERA-TOXIN; ADENYLYL CYCLASE; ACTIVATION; RECEPTOR; PURIFICATION	In the present work, anti-G protein antibodies were introduced inside streptolysin permeabilized 0 interleukin-2-activated natural killer (IANK) cells. Successful entry of the antibodies was determined by flow cytometry and fluorescence microscopy. Permeabilized cells showed typical large granular lymphocyte morphology and remained functional, significantly lysing both NK-sensitive K562 cells and NK-resistant/IANK-sensitive RAJI target cells. This method was utilized to study the effect of anti-G protein antibodies on the functional ac tivities of IANK cells. Anti-G, antibody inhibited IANK cell killing of RAJI but not of K562 target cells. Further analysis showed that K562 and RAJI cells enhance the binding of guanosine 5'-O-(thiotriphosphate) to IANK cell membranes, and increase the hydrolysis of [P-32]GTP in these membranes. Immunoblot analysis showed that K562 and RAJI cells induce the release of cu,, but not cui, alpha(s), or alpha(q)11 from IANK cell membranes. Cumulatively, these data indicate that putative receptors recognizing H562 or RAJI target cells are coupled to G(o) in IANK cells, however, only G, seems to be coupled to receptors recognizing RAJI target cells. Our results point out the importance of G, protein as a mediator of cellular cytotoxicity of the anti-tumor effector cells.	LAURENTIAN UNIV, DEPT CHEM BIOCHEM, SUDBURY P3E 5J1, ON, CANADA; UNIV OTTAWA, FAC MED, DEPT MED, OTTAWA K1N 6N5, ON, CANADA; UNIV OTTAWA, FAC MED, DEPT MICROBIOL & IMMUNOL, OTTAWA K1N 6N5, ON, CANADA	Laurentian University; University of Ottawa; University of Ottawa	MAGHAZACHI, AA (corresponding author), NE ONTARIO REG CANC CTR, SUDBURY, ON, CANADA.			Maghazachi, Azzam/0000-0002-3310-678X				ABOOD ME, 1982, J BIOL CHEM, V257, P540; AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; BADER MF, 1986, J BIOL CHEM, V261, P5777; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDFARB RH, 1981, J IMMUNOL, V126, P2129; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; LOTZOVA E, 1989, CURR OPIN IMMUNOL, V1, P904, DOI 10.1016/0952-7915(89)90069-1; MAGHAZACHI A A, 1988, Journal of Immunology, V140, P2846; MAGHAZACHI AA, 1988, J IMMUNOL, V141, P4039; MAGHAZACHI AA, 1993, INT IMMUNOL, V5, P825, DOI 10.1093/intimm/5.8.825; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MILLIGAN G, 1992, NEUROMETHODS, P1; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; NAGLER A, 1990, J EXP MED, V171, P1527, DOI 10.1084/jem.171.5.1527; ORTALDO JR, 1988, J NATL CANCER I, V80, P999, DOI 10.1093/jnci/80.13.999; PANG IH, 1990, J BIOL CHEM, V265, P18707; PROSS HF, 1981, J CLIN IMMUNOL, V1, P51, DOI 10.1007/BF00915477; RABINOWICH H, 1992, J IMMUNOL, V149, P340; SCHWARZ RE, 1989, CANCER RES, V49, P1441; SEBOK K, 1993, J IMMUNOL, V150, P1524; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TING AT, 1992, J BIOL CHEM, V267, P23957; WHALEN MM, 1990, BIOCHEM J, V272, P327, DOI 10.1042/bj2720327; WINDEBANK KP, 1988, J IMMUNOL, V141, P3951; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	45	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6796	6802						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120041				2022-12-25	WOS:A1994MZ50300085
J	EZOE, K; LEE, ST; STRUNK, KM; SPRITZ, RA				EZOE, K; LEE, ST; STRUNK, KM; SPRITZ, RA			PTK1, A NOVEL PROTEIN-KINASE REQUIRED FOR PROLIFERATION OF HUMAN MELANOCYTES	ONCOGENE			English	Note							CELL-LINE; SEQUENCE; DOMAINS	We have identified and characterized PTK1, a novel human non-receptor protein kinase. Partial PTK1 cDNA was initially isolated by RT-PCR from mRNA of normal human melanocytes. Northern blot hybridization detected a 3.8-kb PTK1 mRNA in ah tissues and cell types studied. Nucleotide sequence analysis of a full-length PTK1 cDNA showed it to encode an 847-amino acid polypeptide with an amino-terminal SH3 domain, a kinase catalytic domain, a leucine zipper-like domain, and a carboxyl proline-rich domain. The PTK1 kinase domain contains motifs generally considered diagnostic of serine/threonine kinases but also contains amino acids highly conserved among the tyrosine kinases. This suggests that PTK1 is a serine/threonine kinase, but one very closely related to the tyrosine kinase superfamily. When normal human melanocytes were exposed to antisense PTK1 oligonucleotide, cell growth was inhibited, whereas a corresponding sense oligonucleotide had no inhibitory effect. These data indicate that PTK1 plays an important role in the proliferation of normal human melanocytes.	UNIV WISCONSIN,DEPT MED GENET,MADISON,WI 53706; UNIV WISCONSIN,DEPT PEDIAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Lee, Seung-Taek/0000-0001-7300-9784	NIAMS NIH HHS [AR39892] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039892] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BOLEN JB, 1993, ONCOGENE, V8, P2025; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; FENG XH, 1993, BIOCHIM BIOPHYS ACTA, V1172, P200, DOI 10.1016/0167-4781(93)90295-O; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE ST, 1993, ONCOGENE, V8, P3403; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TVEIT KM, 1980, BRIT J CANCER, V41, P724, DOI 10.1038/bjc.1980.134	14	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					935	938						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108137				2022-12-25	WOS:A1994MW55100030
J	MOASSER, MM; DEBLASIO, A; DMITROVSKY, E				MOASSER, MM; DEBLASIO, A; DMITROVSKY, E			RESPONSE AND RESISTANCE TO RETINOIC ACID ARE MEDIATED THROUGH THE RETINOIC ACID NUCLEAR RECEPTOR-GAMMA IN HUMAN TERATOCARCINOMAS	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; RIBONUCLEIC-ACID; X-RECEPTOR; BETA-GENE; DIFFERENTIATION; ALPHA; EXPRESSION; CLONING; LINE; EFFICIENCY	All-trans-retinoic acid (RA) treatment of the multipotent human teratocarcinoma (TC) cell line NTERA-2 clone D1 (abbreviated NT2/D1) induces a neuronal phenotype. Compared to untreated NT2/D1 cells, RA treated cells have reduced proliferative potential. To identify which retinoic acid receptor (RAR) is directly linked to RA response in these cells, nine RA resistant subclones were derived and characterized. Unlike parental NT2/D1 cells, all these subclones and a de novo RA resistant human TC cell line, N2102Ep clone 2AG (abbreviated N2102ep), exhibited reduced RAR gamma expression. The RAR gamma gene was studied within NT2/D1 cells and a representative RA resistant NT2/D1 subclone called NT2/D1-R1 by Southern analysis and by the transcriptional properties of cloned RAR gamma cDNAs. No structural or functional differences between these RAR gamma species were found suggesting that RA resistance is due to reduced levels of RAR gamma expressed in NT2/D1-R1 cells. To explore this possibility an RAR gamma cDNA was stably transfected into NT2/D1-R1 cells. Expression of this cDNA partially restored the response to RA in NT2/D1-R1 cells. The role of RAR gamma in parental NT2/D1 cells was studied in transient transfection assays using an FGF4 promoter-enhancer reporter construct that is transcriptionally active in undifferentiated but not in differentiated TC cells. The dose dependent co-transfection of an expressed RAR gamma cDNA with this reporter more efficiently repressed its transcriptional activity in the presence of RA than transfection of the reporter without expressed RAR gamma. Co-transfection also decreased reporter activity in the absence of exogenously added ligand, Together, these findings reveal that RAR gamma expression is tightly coupled to RA response and resistance in human TC cells. These data implicate an important role for RAR gamma in the RA-mediated differentiation of these TCs.	MEM SLOAN KETTERING CANC CTR,RECEPTOR BIOL LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MOLEC MED LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA01712, 1R01-CA54494-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001712, R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1980, INT J CANCER, V26, P269, DOI 10.1002/ijc.2910260304; ANDREWS PW, 1984, LAB INVEST, V50, P147; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KLIEWER SA, 1992, NATURE, V355, P441; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KURIE JM, 1993, DIFFERENTIATION, V54, P123; KURIE JM, 1993, DIFFERENTIATION, V54, P115; KURIE JM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P203, DOI 10.1016/0167-4889(93)90142-C; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Maniatis T, 1989, DECONTAMINATION DILU; MCCUE PA, 1983, DEV BIOL, V96, P416, DOI 10.1016/0012-1606(83)90179-3; MILLER WH, IN PRESS DIFFERENTIA; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WONG SY, 1984, J BIOL CHEM, V259, P5899; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	34	68	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					833	840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108126				2022-12-25	WOS:A1994MW55100019
J	DESNOYERS, L; MANJUNATH, P				DESNOYERS, L; MANJUNATH, P			MAJOR PROTEINS OF BOVINE SEMINAL FLUID BIND TO INSULIN-LIKE GROWTH FACTOR-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; AMINO-ACID SEQUENCE; MOLECULAR-CLONING; PLASMA; EXPRESSION; IDENTIFICATION; FIBRONECTIN; CELLS; CDNA; POLYPEPTIDES	Bovine seminal plasma (BSP) contains a family of four closely related proteins previously designated as BSP-A1, BSP-A2, BSP-A3, and BSP-30-kDa (collectively called BSP proteins). They are secreted by seminal vesicles and they bind to the choline phospholipids composing the sperm plasma membrane upon ejaculation. These proteins contain two homologous domains that are similar to the type II structure present in the putative insulinlike growth factor II (IGF-II) binding domain of the IGF-II receptor. Thus, it was of interest to verify the interaction between the IGF-II and these proteins. The interaction between the IGF-II and BSP proteins was demonstrated by solid phase assay, analytical gel filtration, affinity cross-linking, and gel overlay binding technique. Ah techniques showed that I-125-IGF-II interacted specifically with BSP proteins and that the binding could be inhibited with an excess of unlabeled IGF-II. No structural homology has been found between BSP proteins and any IGF-binding proteins (IGFBP) identified to date, and therefore, they represent a new family of IGFBP. Since BSP cross-reacting proteins are ubiquitous, we propose that the specific binding of these proteins to IGF-II could modulate the activity of this growth factor.	HOP MAISON NEUVE ROSEMONT, RES CTR, ENDOCRINE LAB, MONTREAL H1T 2M4, PQ, CANADA; UNIV MONTREAL, DEPT MED, MONTREAL H1T 2M4, PQ, CANADA	Universite de Montreal; Universite de Montreal								Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAXTER RC, 1991, ACTA PAEDIATR SCAND, P107; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BREWER MT, 1988, BIOCHEM BIOPH RES CO, V152, P1289, DOI 10.1016/S0006-291X(88)80425-X; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; CHANDONNET L, 1990, MOL REPROD DEV, V26, P313, DOI 10.1002/mrd.1080260404; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DESNOYERS L, 1993, ARCH BIOCHEM BIOPHYS, V305, P341, DOI 10.1006/abbi.1993.1431; DESNOYERS L, 1992, J BIOL CHEM, V267, P10149; ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584; ESCH FS, 1983, BIOCHEM BIOPH RES CO, V113, P861, DOI 10.1016/0006-291X(83)91078-1; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GLENNEY JR, 1983, METHOD ENZYMOL, V102, P204; GUYDA HJ, 1981, PHYSL PEPTIDES NEW T, P173; HSU D, 1992, J BIOL CHEM, V267, P25576; KEMME M, 1988, DNA-J MOLEC CELL BIO, V7, P595, DOI 10.1089/dna.1988.7.595; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLOND E, 1993, MOL REPROD DEV, V34, P443, DOI 10.1002/mrd.1080340414; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MANJUNATH P, 1987, BIOSCIENCE REP, V7, P231, DOI 10.1007/BF01124794; MANJUNATH P, 1982, J BIOL CHEM, V257, P7109; MANJUNATH P, 1989, J BIOL CHEM, V264, P16853; MANJUNATH P, 1993, J REPROD FERTIL, V97, P75, DOI 10.1530/jrf.0.0970075; MANJUNATH P, 1987, BIOCHEM J, V241, P685, DOI 10.1042/bj2410685; Manjunath P, 1984, GONADAL PROTEINS PEP, P49; Manjunath P, 1988, MOL BIOL BRAIN ENDOC, P259; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; ROSENFELD RG, 1990, J CLIN ENDOCR METAB, V70, P551, DOI 10.1210/jcem-70-2-551; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SEIDAH NG, 1987, BIOCHEM J, V243, P195, DOI 10.1042/bj2430195; SEPPALA M, 1985, ANN NY ACAD SCI, V442, P212, DOI 10.1111/j.1749-6632.1985.tb37522.x; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176	42	12	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5776	5780						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119918				2022-12-25	WOS:A1994MY84000048
J	THOMA, B; BIRD, TA; FRIEND, DJ; GEARING, DP; DOWER, SK				THOMA, B; BIRD, TA; FRIEND, DJ; GEARING, DP; DOWER, SK			ONCOSTATIN-M AND LEUKEMIA INHIBITORY FACTOR TRIGGER OVERLAPPING AND DIFFERENT SIGNALS THROUGH PARTIALLY SHARED RECEPTOR COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; GROWTH-FACTOR; MAP KINASE; TYROSINE PHOSPHORYLATION; STIMULATING FACTOR; CELLS; PROTEIN; IDENTIFICATION; TRANSDUCER; ACTIVATION	Leukemia inhibitory factor (LIF) and oncostatin M (OSM) both bind to the same receptor with high affinity and thus mediate an overlapping spectrum of biological activities, the signal transduction mechanisms for which are unclear. We show that mitogen-activated protein kinases are involved in both the LIF and OSM signal transduction pathways. However, we found that OSM is a much more potent inducer of both mitogen-activated protein kinase activity and biological response, both of which correlate with the expression of a second OSM receptor that does not bind LIF. In addition, different patterns of tyrosine-phosphorylated proteins were stimulated by OSM and LIF. We therefore suggest that the two receptors for OSM can be coupled to different signal transduction events.	IMMUNEX CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101	Immunex Corporation	THOMA, B (corresponding author), IMMUNEX CORP,DEPT BIOCHEM,SEATTLE,WA 98101, USA.			dower, steve/0000-0002-4675-4225				AHN NG, 1990, J BIOL CHEM, V265, P11487; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAUMANN H, 1992, CIBA F SYMP, V167, P100; BENJAMIN D, 1990, BLOOD, V75, P2017; BIRD TA, 1992, CYTOKINE, V4, P429, DOI 10.1016/1043-4666(92)90003-A; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROWN TJ, 1991, J IMMUNOL, V147, P2175; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; EISENBERG SP, 1990, NATURE, V343, P342; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; KRONHEIM SR, 1986, BIO-TECHNOL, V4, P1078, DOI 10.1038/nbt1286-1078; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; LIU JW, 1992, J BIOL CHEM, V267, P16763; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SLACK J, 1993, J BIOL CHEM, V268, P2513; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VANLINT J, 1992, J BIOL CHEM, V267, P25916; WANG XY, 1993, J BIOL CHEM, V268, P3573; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	47	169	173	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6215	6222						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119965				2022-12-25	WOS:A1994MY84000109
J	BOLDYREFF, B; MEGGIO, F; PINNA, LA; ISSINGER, OG				BOLDYREFF, B; MEGGIO, F; PINNA, LA; ISSINGER, OG			EFFICIENT AUTOPHOSPHORYLATION AND PHOSPHORYLATION OF THE BETA-SUBUNIT BY CASEIN KINASE-2 REQUIRE THE INTEGRITY OF AN ACIDIC CLUSTER 50 RESIDUES DOWNSTREAM FROM THE PHOSPHOACCEPTOR SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA; EXPRESSION	Various beta-mutants were investigated either as subunits or as substrates for casein kinase 2 (CK-2), in the absence or presence of polylysine. A total of 21 beta-mutants were characterized for their susceptibility to au- tophosphorylation, by combining them in equimolar amounts with the recombinant cy-subunit. Six mutants, i.e. beta A(5,6), beta A(59-61,63,64), beta A(55,57), beta A(55-57), beta Delta 171-215, and beta Delta 150-215 exhibited a >70% reduction in autophosphorylation. This strongly suggests that in addition to amino acid residues 5,6, distant amino acid residues within the sequence 55-64 are also involved in the process of autophosphorylation, possibly by means of a loop formation. The results obtained with the COOH-terminal-deleted mutants support the view that reconstitution of a functional holoenzyme must occur to allow efficient autophosphorylation. Polylysine prevents the autophosphorylation of beta(wt) (86% inhibition) inducing a parallel increase of the alpha-subunit autophosphorylation. The autophosphorylation of all mutants, with the exception of beta A(55-57) and beta A(59-61,63,64), is also inhibited by polylysine (>64%). The alpha-subunit autophosphorylation is increased with all mutants reconstituting a tetrameric holoenzyme. Only with the three largest COOH-terminal deletion mutants beta Delta 150-215, beta Delta 171-215, and beta Delta 181-215 is no significant alpha-subunit autophosphorylation observed. The phosphorylation of the beta-subunit mutants added in large molar excess to CK-2 holoenzyme (either native or recombinant) is also severly impaired by Ala for Glu/Asp substitutions at position 5,6 and in the 55-64 region and by the deletion of the COOH-terminal segments 150-215 and 171-215. Such a phosphorylation is inhibited by polylysine, with the exception of mutants beta Delta 171-215 and beta Delta 150-215, whose phosphorylation is conversely stimulated by polylysine. The decreased phosphorylation efficiency of those mutants that are poor substrates is invariably accounted for by lower V-max values, whereas the affinity for CK-2 is actually increased (K-m values lower than that of beta(wt)).	UNIV SAARLAND, INST HUMANGENET, D-66421 HOMBURG, GERMANY; UNIV PADUA, DEPT BIOL CHEM, I-35121 PADUA, ITALY	Saarland University; University of Padua								ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; AGOSTINIS P, 1987, BIOCHEM J, V248, P785, DOI 10.1042/bj2480785; BIDWAI AP, 1993, ARCH BIOCHEM BIOPHYS, V300, P256; BIRNBAUM MJ, 1992, PROTEIN EXPRES PURIF, V3, P142, DOI 10.1016/S1046-5928(05)80098-1; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; BOLDYREFF B, 1993, IN PRESS BIOCHEMISTR; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; ISSINGER OG, 1992, BIOCHEMISTRY-US, V31, P6098, DOI 10.1021/bi00141a020; JAKOBI R, 1992, J BIOL CHEM, V267, P23894; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1981, J BIOL CHEM, V256, P1958; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEGGIO F, 1993, BIOCHIM BIOPHYS ACTA, V1164, P223, DOI 10.1016/0167-4838(93)90252-M; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123	18	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4827	4831						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106453				2022-12-25	WOS:A1994MX57100022
J	HENICS, T; SANFRIDSON, A; HAMILTON, BJ; NAGY, E; RIGBY, WFC				HENICS, T; SANFRIDSON, A; HAMILTON, BJ; NAGY, E; RIGBY, WFC			ENHANCED STABILITY OF INTERLEUKIN-2 MESSENGER-RNA IN MLA-144 CELLS - POSSIBLE ROLE OF CYTOPLASMIC AU-RICH SEQUENCE-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; T-CELLS; GENE; CYTOKINE; IDENTIFICATION; ACCUMULATION; RECOGNIZES; LYMPHOKINE; TURNOVER	The MLA 144 gibbon T cell line is infected with a type C retrovirus and constitutively expresses interleukin-2 (IL-2) and granulocyte macrophage colony-stimulating factor (GM-CSF). IL-2 mRNA levels are 10-fold more abundant than GM-CSF in these cells. Comparable transcriptional rates for these lymphokines suggested the involvement of post-transcriptional mechanisms in selective IL-2 mRNA accumulation, IL-2 mRNA is exceptionally stable in MLA cells with a t(1/2) of more than 8 h. The presence of reiterated AUUUA sequences in the 3'-untranslated region (UTR) has been shown to confer mRNA lability. The provirally altered MLA IL-2 allele encodes an mRNA in which three AUUUA motifs have been deleted. Six major cytoplasmic proteins bound in vitro transcribed RNA probes containing sequences from the 3'-UTR of normal human IL-2 (3'-IL-2), GM-CSF (Delta 2R1), and the virally altered MLA IL-2 (3'-IL-2 PV) mRNA. Increased binding of these proteins to 3'-IL-2 PV was observed relative to 3'-IL-2 or Delta 2R1. Northwestern blotting demonstrated similar differential ability of a 36- and 43-kDa protein to bind, as well as showed that these proteins colocalized by immunoblotting as hnRNP Al and C, respectively. These findings suggest a direct correlation between differential binding of cytoplasmic proteins to AU-rich 3'-UTRs in vitro and lymphokine mRNA stability in vivo.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,LEBANON,NH 03766; DARTMOUTH COLL SCH MED,DEPT MED & MICROBIOL,LEBANON,NH 03766	Dartmouth College; Dartmouth College	HENICS, T (corresponding author), VET ADM MED CTR,RES LABS,RES BLDG 44,WHITE RIVER JCT,VT 05009, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000910] Funding Source: NIH RePORTER; NIAID NIH HHS [R0 1 AI2438, KO4 AI00910] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BICKEL M, 1990, J IMMUNOL, V145, P840; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHEN SJ, 1985, P NATL ACAD SCI USA, V82, P7284, DOI 10.1073/pnas.82.21.7284; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILLIS P, 1991, J BIOL CHEM, V266, P3172; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HOLBROOK NJ, 1987, VIROLOGY, V159, P178, DOI 10.1016/0042-6822(87)90364-3; IWAI Y, 1991, J BIOL CHEM, V266, P17959; KAWAKAMI TG, 1972, NATURE-NEW BIOL, V235, P170, DOI 10.1038/newbio235170a0; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RABIN H, 1981, J IMMUNOL, V127, P1852; ROSS HJ, 1991, BLOOD, V77, P1787; ROSS J, 1988, MOL BIOL MED, V5, P1; SCHIAVI SC, 1985, BIOCHIM BIOPHYS ACTA, V1114, P589; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355	32	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5377	5383						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106521				2022-12-25	WOS:A1994MX57100101
J	HULFORD, A; HAZELL, L; MOULD, RM; ROBINSON, C				HULFORD, A; HAZELL, L; MOULD, RM; ROBINSON, C			2 DISTINCT MECHANISMS FOR THE TRANSLOCATION OF PROTEINS ACROSS THE THYLAKOID MEMBRANE, ONE REQUIRING THE PRESENCE OF A STROMAL PROTEIN FACTOR AND NUCLEOTIDE TRIPHOSPHATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; PRECURSOR PROTEIN; ESCHERICHIA-COLI; PROCESSING PEPTIDASE; CHROMOPHYTIC ALGA; TRANSIT PEPTIDE; CHLOROPLASTS; TRANSPORT; SEQUENCE; IMPORT	Cytosolically synthesized thylakoid lumen proteins are normally transported across the thylakoid membrane of chloroplasts as intermediate forms following cleavage Of the full PreCursor polypeptides by a stromal peptidase. We have examined the mechanisms by which two lumenal proteins, the 33- and 23-kDa components of the oxygen-evolving complex, are translocated across the thylakoid membrane using an in vitro import assay and synthetic engineered intermediate forms of the two proteins as substrates. Efficient transport of the 23-kDa protein is observed in both the presence and absence of stromal extracts, but efficient import of the 33-kDa protein into thylakoids is completely dependent on the presence of stroma. The required stromal factor is heat-sensitive, macromolecular, and trypsin-sensitive. These findings thus represent the first evidence for the active participation of one or more stromal proteins in thylakoidal protein transport. We also show that import into thylakoids of the 33-kDa protein, but not of the 23-kDa protein, is absolutely dependent on the presence of nucleotide triphosphates. The data therefore indicate that at least two distinct mechanisms exist for the translocation of Iumenal proteins across the thylakoid membrane.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick								BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BAUERLE C, 1991, J BIOL CHEM, V266, P5876; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1986, J BIOL CHEM, V261, P4804; FLACHMANN R, 1993, J BIOL CHEM, V268, P7514; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; JAMES HE, 1991, PLANT MOL BIOL, V17, P179, DOI 10.1007/BF00036827; JAMES HE, 1989, J BIOL CHEM, V264, P19573; JANSEN T, 1987, FEBS LETT, V216, P234, DOI 10.1016/0014-5793(87)80696-8; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KIRWIN PM, 1989, EMBO J, V8, P3917; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KNOETZEL J, 1993, PLANT MOL BIOL, V22, P337, DOI 10.1007/BF00014940; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; MEADOWS JW, 1991, PLANT MOL BIOL, V16, P1085, DOI 10.1007/BF00016082; MOULD RM, 1991, J BIOL CHEM, V266, P17286; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; SCARAMUZZI CD, 1992, FEBS LETT, V304, P119, DOI 10.1016/0014-5793(92)80601-C; SCARAMUZZI CD, 1992, CURR GENET, V22, P421, DOI 10.1007/BF00352444; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; TYAGI A, 1987, MOL GEN GENET, V207, P288, DOI 10.1007/BF00331591; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; YALOVSKY S, 1992, P NATL ACAD SCI USA, V89, P5616, DOI 10.1073/pnas.89.12.5616	27	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3251	3256						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106361				2022-12-25	WOS:A1994MV63100022
J	TAKAHASHI, K; TSUCHIDA, K; TANABE, Y; MASU, M; NAKANISHI, S				TAKAHASHI, K; TSUCHIDA, K; TANABE, Y; MASU, M; NAKANISHI, S			ROLE OF THE LARGE EXTRACELLULAR DOMAIN OF METABOTROPIC GLUTAMATE RECEPTORS IN AGONIST SELECTIVITY DETERMINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-ADRENERGIC RECEPTORS; SIGNAL TRANSDUCTION; SUBTYPE SPECIFICITY; LUTROPIN RECEPTOR; ALPHA-SUBUNITS; HIGH-AFFINITY; BINDING; CHORIOGONADOTROPIN; DELINEATION; EXPRESSION	Metabotropic glutamate receptors consist of at least six different subtypes termed mGluR1-mGluR6. They belong to the family of G protein-coupled receptors and commonly possess an unusually large extracellular domain preceding the seven transmembrane segments. mGluR1 and mGluR2 show similar affinities for L-glutamate but distinct patterns in their responsiveness to quisqualate and trans-1-amino-1,3-cyclopentane-dicarboxylate (tACPD). To assign structural determinants for the different agonist selectivities, we constructed a series of chimeric receptors at the extracellular domains of mGluR1 and mGluR2 and determined their agonist selectivities by measuring their electro-physiological responses to L-glutamate, quisqualate, and tACPD in Xenopus oocytes. Replacement of the extracellular domain up to about one-half of the amino-terminal extracellular domain of mGluR1 with the corresponding portion of mGluR2 generated a pattern of the agonist selectivity characteristic of mGluR2. The acquirement of this property in agonist selectivity was further indicated by the selective responses of these chimeric receptors to an mGluR2-specific agonist, (2S,1'R,2'R,3'R)-2-(2,3-dicarboxycyclopropyl) glycine. This investigation demonstrates that the extracellular domain of mGluR is critical in determining agonist selectivity and that the mode of determination of agonist selectivity of mGluR is different from that of other G protein-coupled receptors for small molecule transmitters.	KYOTO UNIV,FAC MED,INST IMMUNOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Tsuchida, Kunihiro/A-4501-2012	Tsuchida, Kunihiro/0000-0002-3983-5756				ABE T, 1992, J BIOL CHEM, V267, P13361; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; HAYASHI Y, 1992, BRIT J PHARMACOL, V107, P539, DOI 10.1111/j.1476-5381.1992.tb12780.x; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; JI I, 1991, J BIOL CHEM, V266, P13076; JI IH, 1991, J BIOL CHEM, V266, P14953; KAKIZUKA A, 1990, J BIOL CHEM, V265, P10102; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; NAKAMURA K, 1992, NEUROSCI RES       S, V17, pS85; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHFUNE Y, 1993, BIOORG MED CHEM LETT, V3, P15, DOI 10.1016/S0960-894X(00)80083-9; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANABE Y, 1993, J NEUROSCI, V13, P1372; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	28	139	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19341	19345						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103516				2022-12-25	WOS:A1993LW81900031
J	PAN, Y; SHENOUDA, NS; WILSON, GE; SCHAEFER, J				PAN, Y; SHENOUDA, NS; WILSON, GE; SCHAEFER, J			CROSS-LINKS IN CELL-WALLS OF BACILLUS-SUBTILIS BY ROTATIONAL-ECHO DOUBLE-RESONANCE N-15 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERATOMIC DISTANCE; HELICAL PEPTIDE; GAFFKYA-HOMARI; REDOR NMR; PEPTIDOGLYCAN; SPECTROSCOPY	The cross-link index of peptidoglycan of intact cell walls of Bacillus subtilis grown in media containing L-[2-C-13, N-15]aspartic acid has been determined by rotational-echo double-resonance N-15 NMR. A cross-link index of 72% decreased to 47% when the bacteria were exposed to the antibiotic cephalosporin C. The fraction of N-15 label routed from aspartic acid in the media to glutamic acid in the peptidoglycan peptide stems more than doubled for the cephalosporin-exposed cells, indicating interference with general cell wall nitrogen metabolism by the antibiotic.	WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130; UNIV AKRON,DEPT CHEM,AKRON,OH 44325	Washington University (WUSTL); University System of Ohio; University of Akron								CHRISTENSEN AM, 1991, J AM CHEM SOC, V113, P6799, DOI 10.1021/ja00018a013; CHRISTENSEN AM, 1993, BIOCHEMISTRY-US, V32, P2868, DOI 10.1021/bi00062a018; FORREST TM, 1991, J BIOL CHEM, V266, P24485; GULLION T, 1989, J MAGN RESON, V81, P196, DOI 10.1016/0022-2364(89)90280-1; GULLION T, 1991, J MAGN RESON, V92, P439, DOI 10.1016/0022-2364(91)90286-3; GULLION T, 1989, ADV MAGN RESON, V13, P57; HING AW, 1993, IN PRESS BIOCHEMISTR; HOLL SM, 1993, ARCH BIOCHEM BIOPHYS, V302, P255, DOI 10.1006/abbi.1993.1207; HOLL SM, 1992, J AM CHEM SOC, V114, P4830, DOI 10.1021/ja00038a056; MARSHALL GR, 1990, J AM CHEM SOC, V112, P963, DOI 10.1021/ja00159a009; ROGERS HJ, 1980, MICROBIAL CELL WALLS, P200; SINHA RK, 1991, ANTIMICROB AGENTS CH, V35, P1753, DOI 10.1128/AAC.35.9.1753; WILSON GE, 1985, BIOCHEM BIOPH RES CO, V126, P1006, DOI 10.1016/0006-291X(85)90285-2; WORTH AD, 1971, BIOCHEMISTRY-US, V10, P4349	14	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18692	18695						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103049				2022-12-25	WOS:A1993LV65900052
J	BOCK, K; SCHUSTERKOLBE, J; ALTMAN, E; ALLMAIER, G; STAHL, B; CHRISTIAN, R; SLEYTR, UB; MESSNER, P				BOCK, K; SCHUSTERKOLBE, J; ALTMAN, E; ALLMAIER, G; STAHL, B; CHRISTIAN, R; SLEYTR, UB; MESSNER, P			PRIMARY STRUCTURE OF THE O-GLYCOSIDICALLY LINKED GLYCAN CHAIN OF THE CRYSTALLINE SURFACE-LAYER GLYCOPROTEIN OF THERMOANAEROBACTER-THERMOHYDROSULFURICUS L111-69 - GALACTOSYL TYROSINE AS A NOVEL LINKAGE UNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; ASSISTED LASER DESORPTION; CARBOHYDRATE CHAINS; CLOSTRIDIUM-THERMOCELLUM; REGULAR ARRAYS; CELL-WALLS; OLIGOSACCHARIDES; ACID; MATRIX; GLYCOSYLATION	The products of Pronase digestion of the crystalline surface layer (S-layer) glycoproteins of Thermoanaerobacter thermohydrosulfuricus strains L111-69 and L110-69 were isolated by gel permeation chromatography, cation exchange chromatography, chromatofocusing, and reversed phase high performance liquid chromatography. Four compounds were obtained which were analyzed by monosaccharide analysis, one- and two-dimensional 500 and 600 MHz H-1 and C-13 NMR spectroscopy, methylation analysis, gas-liquid chromatography/mass spectrometry, and matrix-assisted laser desorption ionization mass spectrometry. For all glycopeptides we propose the following glycan structure with galactose as the linkage sugar. 3-OMeLRhap alpha 1-[4DManp alpha 1-3LRhap alpha 1](n similar to 27) -4DManp alpha 1- 3LRhap alpha 1-3LRhap alpha 1-3LRhap alpha 1-3DGalp beta 1-OTyr STRUCTURE 1 The isolated glycopeptides resulted from Pronase cleavage at the glycosylated tyrosine residues. Tyrosine was found as the linkage amino acid in all fractions but the remaining amino acid sequences varied, indicating the presence of different glycosylation sites in the intact S-layer glycoprotein.	UNIV WIEN, ZENTRUM ULTRASTRUKTURFORSCH, A-1180 VIENNA, AUSTRIA; UNIV WIEN, LUDWIG BOLTZMANN INST MOLEK NANOTECHNOL, A-1180 VIENNA, AUSTRIA; CARLSBERG LAB, DEPT CHEM, DK-2500 VALBY, DENMARK; NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA K1A 0R6, ON, CANADA; UNIV MUNSTER, INST MED PHYS & BIOPHYS, D-48149 MUNSTER, GERMANY; SCI SOFTWARE CO, A-1140 VIENNA, AUSTRIA	University of Vienna; Ludwig Boltzmann Institute; University of Vienna; National Research Council Canada; University of Munster			Allmaier, Guenter/F-2604-2012; Messner, Paul/Q-5345-2017	Messner, Paul/0000-0002-3246-5801; Schuster, Judith/0000-0002-5637-3688				ALTMAN E, 1988, CARBOHYD RES, V179, P245, DOI 10.1016/0008-6215(88)84122-3; ALTMAN E, 1992, BIOCHIM BIOPHYS ACTA, V1117, P71, DOI 10.1016/0304-4165(92)90164-P; AON MA, 1985, BIOCHEM J, V299, P269; BOCK K, 1990, CARBOHYD RES, V200, P33, DOI 10.1016/0008-6215(90)84180-3; BOCK K, 1991, CARBOHYD RES, V211, P219, DOI 10.1016/0008-6215(91)80093-3; CHRISTIAN R, 1988, CARBOHYD RES, V176, P160, DOI 10.1016/0008-6215(88)84069-2; CHRISTIAN R, 1993, J BACTERIOL, V175, P1250, DOI 10.1128/JB.175.5.1250-1256.1993; CUMMINGS RD, 1992, GLYCOCONJUGATES COMP, P333; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; FEIGL P, 1983, INT J MASS SPECTROM, V47, P15, DOI 10.1016/0020-7381(83)87125-3; GERWIG GJ, 1989, J BIOL CHEM, V264, P1027; GERWIG GJ, 1991, EUR J BIOCHEM, V196, P115, DOI 10.1111/j.1432-1033.1991.tb15793.x; GORIN PAJ, 1965, CAN J CHEMISTRY, V43, P2978, DOI 10.1139/v65-412; GUNNER SW, 1961, CAN J CHEM, V39, P1892, DOI 10.1139/v61-254; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HARTMANN E, 1989, ARCH MICROBIOL, V151, P274, DOI 10.1007/BF00413142; HARTMANN E, 1993, J BACTERIOL, V175, P4515, DOI 10.1128/JB.175.14.4515-4519.1993; HASELBECK A, 1990, GLYCOCONJUGATE J, V7, P63, DOI 10.1007/BF01050403; ISOBE M, 1981, AGR BIOL CHEM TOKYO, V45, P687, DOI 10.1080/00021369.1981.10864566; KARCHER U, 1993, J BIOL CHEM, V268, P26821; Kochetkov N K, 1966, Adv Carbohydr Chem Biochem, V21, P39; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUPCU Z, 1984, FEBS LETT, V173, P185, DOI 10.1016/0014-5793(84)81043-1; LECHNER J, 1989, ANNU REV BIOCHEM, V58, P173, DOI 10.1146/annurev.bi.58.070189.001133; LEE YE, 1993, INT J SYST BACTERIOL, V43, P41, DOI 10.1099/00207713-43-1-41; LU PW, 1982, INSECT BIOCHEM, V12, P377, DOI 10.1016/0020-1790(82)90034-8; MATTEUZZI D, 1978, INT J SYST BACTERIOL, V28, P528, DOI 10.1099/00207713-28-4-528; MESSNER P, 1984, INT J SYST BACTERIOL, V34, P202, DOI 10.1099/00207713-34-2-202; MESSNER P, 1992, J BACTERIOL, V174, P2236, DOI 10.1128/JB.174.7.2236-2240.1992; MESSNER P, 1992, ADV MICROB PHYSIOL, V33, P213, DOI 10.1016/S0065-2911(08)60218-0; MESSNER P, 1993, NATO ADV SCI INST SE, V252, P95; MESSNER P, 1988, BACTERIAL CELL SURFA, P97; MICHON F, 1989, CARBOHYD RES, V194, P321, DOI 10.1016/0008-6215(89)85033-5; MOCK KK, 1991, BIOCHEM BIOPH RES CO, V177, P644, DOI 10.1016/0006-291X(91)91837-3; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OGATA S, 1982, ANAL BIOCHEM, V119, P351, DOI 10.1016/0003-2697(82)90597-8; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; SARA M, 1989, ARCH MICROBIOL, V151, P416, DOI 10.1007/BF00416600; SCHOMBURG D, 1991, ENZYME HDB CLASS 3 H, V4; Sleytr U B, 1978, Int Rev Cytol, V53, P1, DOI 10.1016/S0074-7696(08)62240-8; SLEYTR UB, 1976, J BACTERIOL, V126, P377, DOI 10.1128/JB.126.1.377-383.1976; SLEYTR UB, 1976, J BACTERIOL, V126, P869, DOI 10.1128/JB.126.2.869-882.1976; SLEYTR UB, 1983, ANNU REV MICROBIOL, V37, P311, DOI 10.1146/annurev.mi.37.100183.001523; STAHL B, 1991, ANAL CHEM, V63, P1463, DOI 10.1021/ac00014a022; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; STRUPAT K, 1991, INT J MASS SPECTROM, V111, P89, DOI 10.1016/0168-1176(91)85050-V; SVENSON SB, 1979, J VIROL, V32, P583, DOI 10.1128/JVI.32.2.583-592.1979; TEESCH LM, 1992, ORG MASS SPECTROM, V27, P931, DOI 10.1002/oms.1210270902; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; 1988, CHROMATOFOCUSING POL	52	81	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7137	7144						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125923				2022-12-25	WOS:A1994NA03200018
J	DEVERAUX, Q; USTRELL, V; PICKART, C; RECHSTEINER, M				DEVERAUX, Q; USTRELL, V; PICKART, C; RECHSTEINER, M			A 26-S PROTEASE SUBUNIT THAT BINDS UBIQUITIN CONJUGATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RABBIT RETICULOCYTE LYSATE; ATP-DEPENDENT PROTEASES; IDENTIFICATION; PURIFICATION; DEGRADATION; CYCLIN; ENZYME; CELLS	Ubiquitin-mediated proteolysis provides an important mechanism for regulating a variety of cellular processes. Ubiquitin-conjugated proteins are degraded by a 26 S protease that contains more than 30 different subunits. Of these, a single 50-kDa polypeptide, subunit 5, specifically binds ubiquitin-lysozyme conjugates. Binding is inhibited by short polymeric chains of ubiquitin but not by ubiquitin monomers or by lysozyme. In addition, subunit 5 binds free ubiquitin chains with efficient association requiring at least four ubiquitins. Thus, proteins conjugated to polymers of ubiquitin may be selected for degradation by a single subunit of the 26 S protease complex.	SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	DEVERAUX, Q (corresponding author), UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; COOK WJ, 1992, J BIOL CHEM, V267, P16467; COOK WJ, 1994, IN PRESS J MOL BIOL; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HOUGH R, 1986, J BIOL CHEM, V261, P2391; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; PICKART CM, 1992, J BIOL CHEM, V267, P14418; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359	24	596	605	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7059	7061						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125911				2022-12-25	WOS:A1994NA03200004
J	NATHAN, B; HSU, CC; BAO, J; WU, R; WU, JY				NATHAN, B; HSU, CC; BAO, J; WU, R; WU, JY			PURIFICATION AND CHARACTERIZATION OF A NOVEL FORM OF BRAIN L-GLUTAMATE DECARBOXYLASE A CA2+-DEPENDENT PERIPHERAL MEMBRANE-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; ACID DECARBOXYLASE	L-Glutamic acid decarboxylase (GAD) catalyzes the one-step biosynthesis of gamma-aminobutyric acid (GABA), which is widely accepted as the major inhibitory neurotransmitter in the mammalian brain. In this paper, we report the identification and purification of a new and novel form of peripheral membrane GAD (MGAD) referred to as MGADIII, using a combination of chromatography on DE52, AcA 34, hydroxylapatite and Sephadex G-200, and native gel electrophoresis. The purified MGADIII migrated as a single protein band on a native 5-25% gradient polyacrylamide gel electrophoresis and sodium dodecyl sulfate-polyacrylamide gel electrophoresis with an apparent molecular mass of 118 +/- 6 and 60 +/- 4 kDa, respectively, suggesting that it is a homodimer of 60 kDa. MGADIII was established as a Ca2+-dependent peripheral membrane protein based on Triton X-114 phase partitioning assay, liposome binding experiment, and membrane extraction studies. Several lines of evidence are presented to show that the association of MGADIII with membranes occurs during depolarization of nerve terminal and that this is a reversible process. Based on these results and previous findings that GAD associates with synaptic vesicles and is regulated by phosphorylation, a model for regulation of GAD in the nerve terminal is proposed.	UNIV KANSAS,DEPT PHYSIOL & CELL BIOL,LAWRENCE,KS 66045	University of Kansas			WU, JANG-YEN/I-6424-2013					ANGEL I, 1983, NEUROCHEM INT, V5, P697, DOI 10.1016/0197-0186(83)90095-5; Bao J., 1992, Society for Neuroscience Abstracts, V18, P1384; Bao Jun, 1993, Society for Neuroscience Abstracts, V19, P1385; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHANG YC, 1988, J NEUROSCI, V8, P2123; CHRISTGAU S, 1992, J CELL BIOL, V118, P309, DOI 10.1083/jcb.118.2.309; COVARRUBIAS M, 1980, J NEUROCHEM, V34, P1682, DOI 10.1111/j.1471-4159.1980.tb11261.x; DENNER LA, 1987, P NATL ACAD SCI USA, V84, P668, DOI 10.1073/pnas.84.3.668; ERLANDER MG, 1991, NEUROCHEM RES, V16, P215, DOI 10.1007/BF00966084; FINDLAY JBC, 1990, MOL CELL BIOL MEMBRA, P21; GOHEEN SC, 1984, J CHROMATOGR, V317, P55, DOI 10.1016/S0021-9673(01)91647-4; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P206; MARTIN DL, 1982, J NEUROCHEM, V39, P1001, DOI 10.1111/j.1471-4159.1982.tb11489.x; MCLAUGHLIN BJ, 1975, BRAIN RES, V85, P355, DOI 10.1016/0006-8993(75)90813-6; Nathan B., 1992, Society for Neuroscience Abstracts, V18, P1384; NATHAN B, 1994, IN PRESS P NATL ACAD; NATHAN B, IN PRESS BRAIN RES; Roberts E, 1975, NERVOUS SYSTEM, V1, P541; WU JY, 1973, J BIOL CHEM, V248, P3029; WU JY, 1986, BRAIN RES, V373, P1, DOI 10.1016/0006-8993(86)90309-4; WU JY, 1991, NEUROCHEM RES, V16, P227, DOI 10.1007/BF00966085	21	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7249	7254						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125937				2022-12-25	WOS:A1994NA03200035
J	GOVARDHAN, CP; OPRIAN, DD				GOVARDHAN, CP; OPRIAN, DD			ACTIVE-SITE-DIRECTED INACTIVATION OF CONSTITUTIVELY ACTIVE MUTANTS OF RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIFF-BASE COUNTERION; POINT-CHARGE MODEL; BOVINE RHODOPSIN; TRANSDUCIN ACTIVATION; WAVELENGTH REGULATION; VISUAL PIGMENTS; G-PROTEIN; CHROMOPHORE; ATTACHMENT; EXPRESSION	Recently, mutations of the active site Lys(296) residue in rhodopsin (Lys(296) --> Glu and Lys(296) --> Met) have been found as the cause of disease in some patients with autosomal dominant retinitis pigmentosa. In vitro, these mutations result in constitutive activation of the protein. In an effort to develop a potential therapeutic agent for treatment of the disease, we have examined various amine derivatives of 11-cis- and 9-cis-retinal for ability to irreversibly inactivate a related constitutively active mutant, K296G. Three amines were prepared by reductive amination of retinal: 11-cis-retinylpropylamine, 11-cis-retinylamine, and 9-cis-retinylamine. All three compounds inactivated K296G, and the inactivation could not be reversed upon exposure to light. None of the compounds inactivated the wild-type protein. Although the amines were not effective on the naturally occurring retinitis pigmentosa mutants, presumably because of unfavorable steric interactions with the bulky Glu and Met side chains at position 296, the success with K296G makes it highly encouraging that this approach will evolve related compounds that are capable of inactivating the naturally occurring mutants as well.	BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University					NEI NIH HHS [R01 EY007965, EY07965] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007965] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKITA H, 1980, J AM CHEM SOC, V102, P6370, DOI 10.1021/ja00540a047; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BLATZ PE, 1972, BIOCHEMISTRY-US, V11, P848, DOI 10.1021/bi00755a026; BOWNDS D, 1967, NATURE, V216, P1178, DOI 10.1038/2161178a0; CALHOON RD, 1985, BIOCHEMISTRY-US, V24, P6446, DOI 10.1021/bi00344a021; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DEGRIP WJ, 1990, EUR J BIOCHEM, V191, P211; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HONIG B, 1979, J AM CHEM SOC, V101, P7084, DOI 10.1021/ja00517a060; HUBBARD R, 1956, J AM CHEM SOC, V78, P4662, DOI 10.1021/ja01599a037; ITO M, 1982, CHEM PHARM BULL, V30, P1913; KEEN TJ, 1991, GENOMICS, V11, P199, DOI 10.1016/0888-7543(91)90119-Y; KHORANA HG, 1992, J BIOL CHEM, V267, P1; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; MORTON RA, 1955, BIOCHEM J, V59, P128, DOI 10.1042/bj0590128; NAKANISHI K, 1980, J AM CHEM SOC, V102, P7945, DOI 10.1021/ja00547a028; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OSEROFF AR, 1974, BIOCHEMISTRY-US, V13, P4243, DOI 10.1021/bi00717a027; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; RAO VR, 1994, IN PRESS NATURE; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SIEVING PA, 1992, INVEST OPHTH VIS SCI, V33, P1397; SULLIVAN JM, 1993, INVEST OPHTH VIS SCI, V34, P1149; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; [No title captured]	36	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6524	6527						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120004				2022-12-25	WOS:A1994MZ50300042
J	MAKINGS, LR; TSIEN, RY				MAKINGS, LR; TSIEN, RY			CAGED NITRIC-OXIDE - STABLE ORGANIC-MOLECULES FROM WHICH NITRIC-OXIDE CAN BE PHOTORELEASED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RELEASE; CALCIUM; PHARMACOLOGY; DISSOCIATION; INHIBITION; COMPLEXES; PLATELETS; CHELATORS; NO	We report the synthesis and testing of a series of ''caged'' nitric oxide compounds that are stable indefinitely in oxygen-containing solutions until photolyzed by ultraviolet irradiation, whereupon they release nitric oxide (NO) with quantum yields of Delta 5% for 3a (CNO-1) and Delta 2% for compounds 3b-e (CNO2-5). After a flash, NO release is complete within 5 ms, so that precise temporal control of NO release is possible. NO donor 3d (CNO-4) includes two carboxylate negative charges at physiological pH, which reduce membrane permeability and enable photolytic generation of NO to be selectively confined to either extracellular or intracellular compartments. Esterification of these carboxyls with acetoxymethyl groups produces 3e (CNO-5), which is membrane-permeant and intracellularly hydrolyzable. Therefore, large populations of intact cells can be conveniently intracellularly loaded with ''caged'' NO donor 3d by incubation with 3e (CNO-5). The biological efficacy of these NO donors and their absolute dependence on UV-irradiation was demonstrated by inhibition of thrombin-stimulated platelet aggregation. Extracellular hemoglobin blocked the effects of NO generated outside but not inside platelets, verifying the sidedness of the NO donors and the limited spatial range of NO action. These molecules should permit precise spatial, temporal, and concentration control of NO release for investigation of its important biological functions.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177, R37NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; ADAMS SR, 1993, ANNU REV PHYSIOL, V55, P755, DOI 10.1146/annurev.ph.55.030193.003543; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTON CL, 1993, J PHYSIOL-LONDON, V467, pP181; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CARTER TD, 1993, J PHYSIOL-LONDON, V467, pP165; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; CHAMULITRAT W, 1993, J BIOL CHEM, V268, P11520; Di Iorio E E, 1981, Methods Enzymol, V76, P57; DOYLE MP, 1984, J AM CHEM SOC, V106, P3678, DOI 10.1021/ja00324a049; DRAGO RS, 1960, J AM CHEM SOC, V82, P96, DOI 10.1021/ja01486a021; DRAGO RS, 1961, J AM CHEM SOC, V83, P1819, DOI 10.1021/ja01469a012; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; FLITNEY FW, 1993, J PHYSIOL-LONDON, V459, pP89; FLITNEY FW, 1993, J PHYSIOL-LONDON, V459, pP90; FLITNEY FW, 1992, BRIT J PHARMACOL, V107, P842, DOI 10.1111/j.1476-5381.1992.tb14534.x; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HALLAM TJ, 1984, BIOCHEM J, V218, P819, DOI 10.1042/bj2180819; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; IVANOVA K, 1993, EUR J PHARM-MOLEC PH, V244, P37, DOI 10.1016/0922-4106(93)90057-G; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MCCALL T, 1992, TRENDS PHARMACOL SCI, V13, P1, DOI 10.1016/0165-6147(92)90002-N; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.biophys.18.1.239; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLER JG, 1990, INORG CHEM, V29, P2185, DOI 10.1021/ic00336a032; NOACK E, 1992, NEUROPROTOCOLS DETEC, P133; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P181, DOI 10.1111/j.1476-5381.1987.tb11310.x; ROSE EJ, 1983, J AM CHEM SOC, V105, P2866, DOI 10.1021/ja00347a056; SAAVEDRA JE, 1992, J ORG CHEM, V57, P6134, DOI 10.1021/jo00049a017; SALVEMINI D, 1990, BRIT J PHARMACOL, V101, P991, DOI 10.1111/j.1476-5381.1990.tb14194.x; SHARMA VS, 1983, BIOCHEMISTRY-US, V22, P3897, DOI 10.1021/bi00285a026; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SMITH RP, 1990, BIOL REACT INTERMED, V4, P365; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TRACEY WR, 1992, NEUROPROTOCOLS DETEC, P125; TSIEN RY, 1986, BIOPHYS J, V50, P843, DOI 10.1016/S0006-3495(86)83525-1; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; WILCOX M, 1990, J ORG CHEM, V55, P1585, DOI 10.1021/jo00292a038; WILLIAMS JH, 1993, J PHYSIOL-LONDON, V467, pP166	42	110	114	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6282	6285						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119976				2022-12-25	WOS:A1994MZ50300007
J	KHARITONOV, VG; SUNDQUIST, AR; SHARMA, VS				KHARITONOV, VG; SUNDQUIST, AR; SHARMA, VS			KINETICS OF NITRIC-OXIDE AUTOXIDATION IN AQUEOUS-SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN MONOXIDE; OXYGEN; OXIDATION	A kinetic study of the reaction of NO with O-2 in aqueous solution has been carried out using a colorimetric method based on a pH indicator and a stopped-flow spectrophotometer. The reaction is second order in NO concentration and first order in O-2 concentration; the overall third order rate constant is 6.3 (+/- 0.4) x 10(6) (M(-1))(2) s(-1). Model calculations for the reaction at estimated physiological concentrations of NO and O-2 indicate that the simple autoxidation of NO will not limit its diffusion from the site of production in endothelial cells to a spatially removed target molecule such as guanylate cyclase in myocytes and platelets.			KHARITONOV, VG (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093, USA.				NHLBI NIH HHS [HL48014, HL1358] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; CHALLIS BC, 1979, J CHEM SOC PERK T 1, P299, DOI 10.1039/p19790000299; EGUCHI W, 1989, KAGAKU KOGAKU RONBUN, V15, P1115, DOI 10.1252/kakoronbunshu.15.1115; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MCCALL T, 1992, TRENDS PHARMACOL SCI, V13, P1, DOI 10.1016/0165-6147(92)90002-N; MONCADA S, 1991, PHARMACOL REV, V43, P109; OLBREGTS J, 1985, INT J CHEM KINET, V17, P835, DOI 10.1002/kin.550170805; Olson J S, 1981, Methods Enzymol, V76, P652; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; TAHA Z, 1992, BIOCHEM BIOPH RES CO, V188, P734, DOI 10.1016/0006-291X(92)91117-9; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857	17	194	196	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5881	5883						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119931				2022-12-25	WOS:A1994MY84000062
J	TAKATA, Y; KONISHI, K; GOMI, T; FUJIOKA, M				TAKATA, Y; KONISHI, K; GOMI, T; FUJIOKA, M			RAT GUANIDINOACETATE METHYLTRANSFERASE - EFFECT OF SITE-DIRECTED ALTERATION OF AN ASPARTIC-ACID RESIDUE THAT IS CONSERVED ACROSS MOST MAMMALIAN S-ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ESCHERICHIA-COLI; GLYCINE METHYLTRANSFERASE; N-METHYLTRANSFERASE; NUCLEOTIDE-SEQUENCE; O-METHYLTRANSFERASE; SULFHYDRYL-GROUPS; LIVER; CDNA; MUTAGENESIS	Most mammalian S-adenosylmethionine (AdoMet)dependent methyltransferases have a conserved aspartate residue in a sequence oDso (o denotes a hydrophobic amino acid and s denotes a small neutral amino acid). Rat guanidinoacetate methyltransferase has two aspartate residues (Asp-129 and Asp-134) conforming to the motif in close proximity to Tyr-136 that is photoaffinity-labeled by AdoMet (Takata, Y., and Fujioka, M. (1992) Biochemistry 31, 4369-4374). In order to investigate the role of these residues, we prepared variant forms of the enzyme by oligonucleotide-directed mutagenesis. Conversion of Asp-129 to asparagine or alanine resulted in a functional enzyme. Alteration of Asp-134 to glutamate (D134E) and asparagine (D134N) decreased activity, and replacement with alanine (D134A) led to inactivation. Decreases of 3- and 120-fold were found for k(cat) values of D134E and D134N, respectively. The K-m values of D134E for AdoMet and those for guanidinoacetate were increased about 160- and 80-fold over the respective values of wild type. The corresponding increases in D134N were 800- and 50-fold, respectively. Conservative changes of the residues flanking Asp-134 had little effect on activity. Guanidinoacetate methyltransferase obeys an ordered Bi Bi mechanism in which AdoMet binds first. Thus, the large decreases in k(cat)/K-m values for AdoMet indicate that Asp-134 is crucial for binding AdoMet. Spectroscopic studies indicated that the amino acid substitutions of Asp-134 resulted in no significant changes in the secondary and tertiary structures, and urea denaturation experiments showed that the altered enzymes were not destabilized.	TOYAMA MED & PHARMACEUT UNIV,FAC MED,DEPT BIOCHEM,TOYAMA,TOYAMA 93001,JAPAN	University of Toyama								BAETGE EE, 1986, P NATL ACAD SCI USA, V83, P5454, DOI 10.1073/pnas.83.15.5454; DARBRE A, 1986, PRACTICAL PROTEIN CH, P227; FUJIOKA M, 1986, J BIOL CHEM, V261, P6346; FUJIOKA M, 1991, ARCH BIOCHEM BIOPHYS, V285, P181, DOI 10.1016/0003-9861(91)90347-L; FUJIOKA M, 1988, BIOCHEMISTRY-US, V27, P7658, DOI 10.1021/bi00420a013; GOMI T, 1992, INT J BIOCHEM, V24, P1639; GOMI T, 1989, J BIOL CHEM, V264, P16138; HENZEL WJ, 1989, J BIOL CHEM, V264, P15905; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; ISHIDA I, 1987, J BIOL CHEM, V262, P2895; KONISHI K, 1991, ARCH BIOCHEM BIOPHYS, V289, P90, DOI 10.1016/0003-9861(91)90446-P; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; OGAWA H, 1988, P NATL ACAD SCI USA, V85, P694, DOI 10.1073/pnas.85.3.694; OGAWA H, 1983, ARCH BIOCHEM BIOPHYS, V226, P265, DOI 10.1016/0003-9861(83)90293-X; Pace C N, 1986, Methods Enzymol, V131, P266; SALMINEN M, 1990, GENE, V93, P241, DOI 10.1016/0378-1119(90)90231-F; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKATA Y, 1992, BIOCHEMISTRY-US, V31, P4369, DOI 10.1021/bi00132a030; TAKATA Y, 1990, INT J BIOCHEM, V22, P1333; TAKATA Y, 1991, BIOCHEM J, V277, P399, DOI 10.1042/bj2770399; TAKEMURA M, 1992, J BIOL CHEM, V267, P15687; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	25	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5537	5542						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119887				2022-12-25	WOS:A1994MY84000013
J	BEDALOV, A; BREAULT, DT; SOKOLOV, BP; LICHTLER, AC; BEDALOV, I; CLARK, SH; MACK, K; KHILLAN, JS; WOODY, CO; KREAM, BE; ROWE, DW				BEDALOV, A; BREAULT, DT; SOKOLOV, BP; LICHTLER, AC; BEDALOV, I; CLARK, SH; MACK, K; KHILLAN, JS; WOODY, CO; KREAM, BE; ROWE, DW			REGULATION OF THE ALPHA-1(I) COLLAGEN PROMOTER IN VASCULAR SMOOTH-MUSCLE CELLS - COMPARISON WITH OTHER ALPHA-1(I) COLLAGEN-PRODUCING CELLS IN TRANSGENIC ANIMALS AND CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1ST INTRON CONTRIBUTE; MESSENGER-RNA LEVELS; MAMMALIAN-CELLS; TRANSCRIPTIONAL CONTROL; GENE-EXPRESSION; MICE; ATHEROSCLEROSIS; ELASTIN; AORTA; DNA	We have previously reported that the expression of the ColCAT3.6 transgene containing 3.5 kilobases (kb) of alpha 1(I) collagen (COL1A1) promoter sequence fused to the chloramphenicol acetyltransferase (CAT) reporter gene paralleled the expression of the endogenous gene in several connective tissues. We report here that the activity of the reporter gene in aorta from 7-day-old transgenic mice is 10-64-fold lower than in tendon or bone, whereas the endogenous gene is highly expressed in all three tissues. In contrast, the COL1A1 minigene containing 2.3 kb of upstream sequence, the first five exon/intron units, the last six exon/intron units, and 2 kb of 3'-flanking sequence showed high CAT activity in aorta. These results suggest that cia sequences found in ColCAT3.6 mediate high levels of COL1A1 expression in bone and tendon, but not in vascular smooth muscle cells (VSMC), whereas sequences located within the minigene, but not found in ColCAT3.6, mediate VSMC-specific expression. Analysis of promoter activity in cultured cells derived from transgenic tissues further suggests the presence of VSMC-specific regulatory domains. Transient transfection studies, however, failed to shows differential regulation. These differences stress the importance of not relying exclusively on transient transfection data when mapping tissue-specific regulatory domains.	UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06032; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; DEPT VET AFFAIRS MED CTR,NEWINGTON,CT 06111; UNIV CONNECTICUT,DEPT ANIM SCI,STORRS,CT 06269; UNIV ZAGREB,SCH MED,41000 ZAGREB,CROATIA; UNIV ZAGREB,SCH DENT MED,41000 ZAGREB,CROATIA	University of Connecticut; University of Connecticut; Jefferson University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Connecticut; University of Zagreb; University of Zagreb; University of Zagreb, School of Dental Medicine			Breault, David/HDN-6048-2022		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR029983] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR29983] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANG AH, 1990, BIOCHEM J, V265, P461, DOI 10.1042/bj2650461; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BAKER CC, 1990, RECOMBINANT SYSTEMS IN PROTEIN EXPRESSION, P75; BARNES MJ, 1988, COLLAGEN, P275; BOAST S, 1990, J BIOL CHEM, V265; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BRASIER AR, 1989, BIOTECHNIQUES, V7, P116; BRINSTER RL, 1981, CELL, V27, P233; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DEYL Z, 1987, BLOOD VESSELS, V24, P313; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Higgins CF, 1991, CURR OPIN CELL BIOL, V3, P1013, DOI 10.1016/0955-0674(91)90122-F; HOGAN B, 1986, MANIPULATING MOUSE E; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KREAM BE, 1980, P NATL ACAD SCI-BIOL, V77, P5654, DOI 10.1073/pnas.77.10.5654; LEUSHNER JRA, 1986, PATHOL BIOL, V34, P14; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; MECHAM RP, 1987, SCIENCE, V237, P423, DOI 10.1126/science.3603030; MORTON LF, 1982, ATHEROSCLEROSIS, V42, P41, DOI 10.1016/0021-9150(82)90124-1; OAKES BW, 1982, EUR J CELL BIOL, V27, P34; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; Sambrook J, 1989, MOL CLONING LABORATO; SHERWOOD AL, 1990, GENE, V89, P239, DOI 10.1016/0378-1119(90)90011-F; SJOLUND M, 1986, DIFFERENTIATION, V32, P173, DOI 10.1111/j.1432-0436.1986.tb00570.x; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WINSTON HW, 1992, J BIOL CHEM, V267	44	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4903	4909						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106463				2022-12-25	WOS:A1994MX57100034
J	KAST, C; STIEGER, B; WINTERHALTER, KH; MEIER, PJ				KAST, C; STIEGER, B; WINTERHALTER, KH; MEIER, PJ			HEPATOCELLULAR TRANSPORT OF BILE-ACIDS - EVIDENCE FOR DISTINCT SUBCELLULAR LOCALIZATIONS OF ELECTROGENIC AND ATP-DEPENDENT TAUROCHOLATE TRANSPORT IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANALICULAR MEMBRANE-VESICLES; PLASMA-MEMBRANE; SALT TRANSPORT; GOLGI-APPARATUS; LIVER-CELLS; SYSTEM; MECHANISMS; PROTEINS; GLYCOPROTEIN; SECRETION	To investigate whether electrogenic and ATP-dependent taurocholate transport activities are both mediated by the same bile acid-transporting polypeptide in rat liver, we further purified isolated canalicular membrane vesicles by free flow electrophoresis. Removal of most of the contaminating endoplasmic reticulum resulted in a complete loss of electrogenic taurocholate transport from an ecto-ATPase-enriched canalicular membrane subfraction. In contrast, ATP-dependent taurocholate transport remained associated with both an ecto-ATPase enriched and an ecto-ATPase-free canalicular membrane subfraction. Microsomes containing 64% of total endoplasmic reticulum exhibited saturable electrogenic (K-m approximate to 270 mu M), but no ATP-dependent taurocholate uptake. Golgi membrane vesicles were devoid of any taurocholate transport activity. These results indicate that electrogenic taurocholate transport resides entirely in the endoplasmic reticulum, whereas ATP-dependent bile acid transport is an intrinsic function of the canalicular membrane as well as of a so far unidentified intracellular membrane bound compartment. Hence, the two transport activities are most probably mediated by two different bile acid transporting poly peptides. Furthermore, the finding of ATP-dependent taurocholate transport in virtually ecto-ATPase-free vesicles argues against the concept of primary active bile acid transport being exclusively mediated by the canalicular ecto-ATPase.	UNIV HOSP ZURICH,DEPT MED,DIV CLIN PHARMACOL & TOXICOL,CH-8091 ZURICH,SWITZERLAND; ETH ZURICH,BIOCHEM LAB,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich			Stieger, Bruno/U-6323-2017	Stieger, Bruno/0000-0002-7190-5785				ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ARIAS IM, 1990, HEPATOLOGY, V12, P159, DOI 10.1002/hep.1840120125; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BOSSARD R, 1993, J CLIN INVEST, V91, P2714, DOI 10.1172/JCI116511; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; BOYER JL, 1993, P NATL ACAD SCI USA, V90, P435, DOI 10.1073/pnas.90.2.435; BOYWER JL, 1990, MEHTODS ENZYMOL, V192, P517; BRUCK R, 1992, AM J PHYSIOL, V262, pG806, DOI 10.1152/ajpgi.1992.262.5.G806; CASSANO G, 1984, PFLUG ARCH EUR J PHY, V400, P309, DOI 10.1007/BF00581565; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CRAWFORD JM, 1991, AM J PHYSIOL, V260, pG119, DOI 10.1152/ajpgi.1991.260.1.G119; Fitz Greg, 1993, P281; FRICKER G, 1987, BIOL CHEM H-S, V368, P1143, DOI 10.1515/bchm3.1987.368.2.1143; FRIMMER M, 1988, BIOCHIM BIOPHYS ACTA, V947, P75, DOI 10.1016/0304-4157(88)90020-2; HAASE W, 1978, BIOCHEM J, V172, P57, DOI 10.1042/bj1720057; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAUSSINGER D, 1993, BIOCHEM J, V291, P355; INOUE M, 1984, J CLIN INVEST, V73, P659, DOI 10.1172/JCI111257; KEEFFE EB, 1979, J CLIN INVEST, V64, P1590, DOI 10.1172/JCI109620; LAMRI Y, 1988, J CLIN INVEST, V82, P1173, DOI 10.1172/JCI113714; LEVY D, 1991, HEPATOLOGY, V14, pA136; LEVY D, 1991, HEPATOLOGY, V14, P356; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; Meier Peter J., 1993, P587; MEIER PJ, 1990, METHOD ENZYMOL, V192, P534; MEIER PJ, 1984, J BIOL CHEM, V259, P614; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; MICHAL G, 1993, METHOD ENZYMAT AN, V1, P197; MULLER M, 1991, J BIOL CHEM, V266, P18920; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NEVILLE DM, 1976, BIOCH ANAL MEMBRANES, P27; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, HEPATOLOGY, V16, pA149; REUBEN A, 1988, GASTROENTEROLOGY, V94, pA584; REUBEN A, 1990, Gastroenterology, V98, pA624; REYNIER MO, 1992, GASTROENTEROLOGY, V102, P2024, DOI 10.1016/0016-5085(92)90328-V; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; RUETZ S, 1987, J BIOL CHEM, V262, P11324; RUETZ S, 1988, P NATL ACAD SCI USA, V85, P6147, DOI 10.1073/pnas.85.16.6147; SCALERA V, 1980, BIOCHEM J, V186, P177, DOI 10.1042/bj1860177; SCHAFFNER F, 1969, LANCET, V2, P355; SIMION FA, 1984, BIOCHEMISTRY-US, V23, P6459, DOI 10.1021/bi00321a028; SIMION FA, 1984, J BIOL CHEM, V259, P814; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STIEGER B, 1986, J MEMBRANE BIOL, V91, P19, DOI 10.1007/BF01870211; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; STOLZ A, 1989, ANNU REV PHYSIOL, V51, P161, DOI 10.1146/annurev.ph.51.030189.001113; SUCHY FJ, 1983, AM J PHYSIOL, V245, pG681, DOI 10.1152/ajpgi.1983.245.5.G681; VEITH CM, 1992, BIOCHIM BIOPHYS ACTA, V1103, P51, DOI 10.1016/0005-2736(92)90056-R; VERDON B, 1983, METHOD ENZYMAT AN, V3, P374; WEINMAN SA, 1989, AM J PHYSIOL, V256, pG826, DOI 10.1152/ajpgi.1989.256.5.G826; YEH HI, 1991, HEPATOLOGY, V13, P523, DOI 10.1016/0270-9139(91)90307-H	59	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5179	5186						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106499				2022-12-25	WOS:A1994MX57100076
J	SPRINGHORN, JP; SINGH, K; KELLY, RA; SMITH, TW				SPRINGHORN, JP; SINGH, K; KELLY, RA; SMITH, TW			POSTTRANSCRIPTIONAL REGULATION OF ID1 ACTIVITY IN CARDIAC-MUSCLE - ALTERNATIVE SPLICING OF NOVEL ID1 TRANSCRIPT PERMITS HOMODIMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; PREPROENKEPHALIN MESSENGER-RNA; DNA-BINDING PROTEINS; NEGATIVE REGULATOR; RAT-HEART; GENE; EXPRESSION; DOMAIN; CELL; DIFFERENTIATION	The transcriptional regulatory protein Id, a negatively trans-acting protein with a helix-loop-helix moth that is expressed in many proliferating tissues early in development, continues to be expressed in postmitotic adult cardiac myocytes and vascular smooth muscle. Following the observation of a ''doublet'' band of 1.1 and 1.25 kilobases on Northern hybridizations of Id1 cDNA with mRNA isolated hom both cardiac muscle and vascular smooth muscle cells, we identified and sequenced an alternatively spliced Id1 gene product containing an insert of 214 base pairs within the coding domain of the original Id1 cDNA. A protein with a molecular mass corresponding to that predicted by the Id1.25-kilobase mRNA sequence could be identified on immunoblots of cell lysates from neonatal and adult rat ventricular myocytes. The insert appears to be a ''coding intron,'' based on the presence of intron-exon consensus sequences at the insert boundaries and the presence of the originally described Id1 carboxyl-terminal coding sequence immediately downstream from, and out of frame with, this insert. In contrast to Id1 and Id2, which do not form homodimers, the carboxyl-terminal sequence of this alternatively spliced Id1 transcript, termed Id1.25, permits homodimerization. Thus, alternative splicing of Id1 may allow for tissue-specific expression of Id1, while formation of homodimers could provide a post-translational mechanism to regulate the ability of Id1.25 to bind and inactivate E2A gene products.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036141] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL-36141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CLAYCOMB WC, 1980, DEV BIOL, V80, P466, DOI 10.1016/0012-1606(80)90419-4; DEED RW, 1993, ONCOGENE, V8, P599; DIBELLO PR, 1991, GENETICS, V129, P385; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; EVANS SM, 1993, CIRC RES, V73, P569, DOI 10.1161/01.RES.73.3.569; FINKEL T, 1993, J BIOL CHEM, V268, P5; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; KEMP PR, 1991, BIOCHEM J, V277, P285, DOI 10.1042/bj2770285; KOMURO I, 1990, CIRC RES, V66, P979, DOI 10.1161/01.RES.66.4.979; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LI XY, 1992, J BIOL CHEM, V267, P8984; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OGATA T, 1991, BIOCHEM BIOPH RES CO, V180, P1194, DOI 10.1016/S0006-291X(05)81322-1; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SPRINGHORN JP, 1992, AM J PHYSIOL, V263, pH1560, DOI 10.1152/ajpheart.1992.263.5.H1560; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	40	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5132	5136						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106493				2022-12-25	WOS:A1994MX57100069
J	NIRANJANAKUMARI, S; GOPINATHAN, KP				NIRANJANAKUMARI, S; GOPINATHAN, KP			ISOLATION AND CHARACTERIZATION OF DNA POLYMERASE-EPSILON FROM THE SILK GLANDS OF BOMBYX-MORI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; CALF THYMUS; SACCHAROMYCES-CEREVISIAE; HUMAN-FIBROBLASTS; REPAIR SYNTHESIS; HELA-CELLS; DELTA; ALPHA; PURIFICATION; REPLICATION	The silk gland of Bombyx mori, an endomitotically replicative tissue shows high levels of DNA polymerases alpha, delta, and epsilon activities. The ratio of polymerase alpha to that of delta plus epsilon is maintained at 1.1 to 1.3 in both the posterior and middle silk glands for the entire duration of late larval development. The three activities copurify in the initial stages of fractionation through phosphocellulose and DE52 but polymerase alpha gets resolved from the others on hydroxylapatite column. Separation between polymerase delta and epsilon is achieved by chromatography on QAE-Sephadex. DNA polymerase epsilon is a heterodimer comprising of 215- and 42-kDa subunits. The activity is maximum at pH 6.5 and the K(m) values for dNTPs vary between 3-9 muM. The enzyme possesses an intrinsically associated exonuclease activity which functions in the mismatch repair during DNA synthesis. Both polymerase and 3' --> 5' exonuclease activities are associated with the 215-kDa subunit. By itself, DNA polymerase epsilon is processive and the catalytic activity is not enhanced by externally added bPCNA (Bombyx-proliferating cell nuclear antigen, an auxiliary protein for DNA polymerase delta). The enzyme resembles polymerase delta in having the exonuclease activity and in its response to aphidicolin or substrate analogs, but could be distinguished from the latter by its lack of response to the bPCNA and sensitivity to dimethyl sulfoxide. The two enzymes show partial immunological cross-reactivity with each other but no immunological relatedness to polymerase alpha. The absence of the repair enzyme DNA polymerase beta and the presence of substantial levels of polymerase epsilon in the silk glands suggest a possible role for the latter in DNA repair in that tissue.	INDIAN INST SCI,DEPT MICROBIOL & CELL BIOL,BANGALORE 560012,KARNATAKA,INDIA; INDIAN INST SCI,CTR GENET ENGN,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore								BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; CRUTE JJ, 1986, BIOCHEMISTRY-US, V25, P26, DOI 10.1021/bi00349a005; FOCHER F, 1989, NUCLEIC ACIDS RES, V17, P1805, DOI 10.1093/nar/17.5.1805; FOCHER F, 1988, NUCLEIC ACIDS RES, V16, P6279, DOI 10.1093/nar/16.14.6279; GAGE LP, 1974, CHROMOSOMA, V45, P27; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; KEENEY S, 1990, MUTAT RES, V236, P239, DOI 10.1016/0921-8777(90)90008-S; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; LEE MYWT, 1987, BIOCHEMISTRY-US, V26, P1076, DOI 10.1021/bi00378a014; LEE SH, 1991, J BIOL CHEM, V266, P22707; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NIRANJANAKUMARI S, 1992, J BIOL CHEM, V267, P17531; NIRANJANAKUMARI S, 1991, EUR J BIOCHEM, V201, P431, DOI 10.1111/j.1432-1033.1991.tb16301.x; NIRANJANAKUMARI S, 1993, INSECT BIOCHEM MOLEC, V23, P345, DOI 10.1016/0965-1748(93)90018-N; NISHIDA C, 1988, J BIOL CHEM, V263, P501; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2998, DOI 10.1021/bi00408a050; SUGINO A, 1990, CELL, V62, P1561; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TURCHI JJ, 1992, BIOCHEMISTRY-US, V31, P9008, DOI 10.1021/bi00152a043; WAHL AF, 1986, BIOCHEMISTRY-US, V25, P7821, DOI 10.1021/bi00372a006; WANG TSF, 1991, ANN REV BIOCH, V60, P477; WONG SW, 1989, J BIOL CHEM, V264, P5924; YODER BL, 1991, J BIOL CHEM, V266, P22689	27	15	15	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15557	15564						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101841				2022-12-25	WOS:A1993LN30500038
J	FERREIRA, GC; FRANCO, R; LLOYD, SG; PEREIRA, AS; MOURA, I; MOURA, JJG; HUYNH, BH				FERREIRA, GC; FRANCO, R; LLOYD, SG; PEREIRA, AS; MOURA, I; MOURA, JJG; HUYNH, BH			MAMMALIAN FERROCHELATASE, A NEW ADDITION TO THE METALLOENZYME FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ELEMENT BINDING-PROTEIN; DESULFOVIBRIO-GIGAS; MOLECULAR-CLONING; MOSSBAUER-SPECTRA; PURIFICATION; PROTOPORPHYRIA; MITOCHONDRIA; FERREDOXIN; LIVER; ACID	A [2Fe-2S] cluster has been detected in mammalian ferrochelatase, the terminal enzyme of the heme biosynthetic pathway. Natural ferrochelatase, purified from mouse livers, and recombinant ferrochelatase, purified from an overproducing strain of Escherichia coli, were investigated by electron paramagnetic resonance (EPR) and Mossbauer spectroscopy. In their reduced forms, both the natural and recombinant ferrochelatases exhibited an identical EPR signal with g values (g = 2.00, 1.93, and 1.90) and relaxation properties typical of [2Fe-2S](+) cluster. Mossbauer spectra of the recombinant ferrochelatase, purified from a strain of E. coli cells transformed with a plasmid encoding murine liver ferrochelatase and grown in Fe-57-enriched medium, demonstrated unambiguously that the cluster is a [2Fe-2S] cluster. No change in the cluster oxidation state was observed during catalysis, The putative protein binding site for the Fe-S cluster in mammalian ferrochelatases is absent from the sequences of the bacterial and yeast enzymes, suggesting a possible role of the [2Fe-2S] center in regulation of mammalian ferrochelatases.	UNIV S FLORIDA, H LEE MOFFITT CANC CTR & RES INST, TAMPA, FL 33612 USA; UNIV NOVA LISBOA, FAC CIENCIAS & TECNOL, DEPT QUIM, P-2825 MONTE DE CAPARICA, PORTUGAL; EMORY UNIV, DEPT PHYS, ATLANTA, GA 30322 USA; UNIV NOVA LISBOA, INST TECNOL QUIM & BIOL, P-2780 OEIRAS, PORTUGAL	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Universidade Nova de Lisboa; Emory University; Universidade Nova de Lisboa	FERREIRA, GC (corresponding author), UNIV S FLORIDA, COLL MED, INST BIOMOLEC SCI, DEPT BIOCHEM & MOLEC BIOL, TAMPA, FL 33612 USA.		Ferreira, Gloria C/A-4709-2012; Franco, Ricardo/C-5247-2008; Pereira, Alice S/D-7779-2013; Moura, José J G/D-6426-2013; Moura, Isabel/D-6339-2013	Ferreira, Gloria C/0000-0001-9279-2217; Franco, Ricardo/0000-0002-5139-2871; Pereira, Alice S/0000-0001-5567-6073; Moura, José J G/0000-0002-4726-2388; Moura, Isabel/0000-0003-0971-4977	NIGMS NIH HHS [GM 47295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARATA BAS, 1992, EUR J BIOCHEM, V204, P773, DOI 10.1111/j.1432-1033.1992.tb16693.x; BRENNER DA, 1992, AM J HUM GENET, V50, P1203; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1986, METHOD ENZYMOL, V123, P401; FERREIRA GC, 1994, J BIOL CHEM, V269, P4396; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; GRABOWSKI R, 1991, EUR J BIOCHEM, V199, P89, DOI 10.1111/j.1432-1033.1991.tb16095.x; GRABOWSKI R, 1993, TRENDS BIOCHEM SCI, V18, P297, DOI 10.1016/0968-0004(93)90040-T; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HAMPSEY DM, 1986, J BIOL CHEM, V261, P3259; HARBIN BM, 1985, BIOCHEMISTRY-US, V24, P366, DOI 10.1021/bi00323a019; Huynh B H, 1984, Adv Inorg Biochem, V6, P163; HUYNH BH, 1980, J BIOL CHEM, V255, P3242; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; Labbe-Bois Rosine, 1994, V11, P413; LONDON IM, 1987, ENZYMES, V18, P359; MIDDLETON P, 1980, EUR J BIOCHEM, V104, P289, DOI 10.1111/j.1432-1033.1980.tb04427.x; MIDDLETON P, 1978, EUR J BIOCHEM, V88, P135, DOI 10.1111/j.1432-1033.1978.tb12430.x; MUNCK E, 1972, BIOCHEMISTRY-US, V11, P855; NAKAHASHI Y, 1990, BIOCHIM BIOPHYS ACTA, V1037, P321, DOI 10.1016/0167-4838(90)90032-B; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; ORMEJOHNSON WH, 1982, IRON SULFUR PROTEINS, V4, P67; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA1; SANDS RH, 1974, Q REV BIOPHYS, V7, P443, DOI 10.1017/S0033583500001517; Schulz C., 1976, J PHYS C SOLID STATE, V37, DOI DOI 10.1051/JPHYSCOL:1976633; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; THORSON JS, 1993, J AM CHEM SOC, V115, P7539, DOI 10.1021/ja00069a078; WHITCOMBE DM, 1991, GENOMICS, V11, P1152, DOI 10.1016/0888-7543(91)90044-F; ZHANG L, 1993, P NATL ACAD SCI USA, V90, P2851, DOI 10.1073/pnas.90.7.2851	34	76	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7062	7065						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125912				2022-12-25	WOS:A1994NA03200005
J	SCHUBERT, H; KROON, BMA; MATTHIJS, HCP				SCHUBERT, H; KROON, BMA; MATTHIJS, HCP			IN-VIVO MANIPULATION OF THE XANTHOPHYLL CYCLE AND THE ROLE OF ZEAXANTHIN IN THE PROTECTION AGAINST PHOTODAMAGE IN THE GREEN-ALGA CHLORELLA-PYRENOIDOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; CHLOROPHYLL; PHYTOPLANKTON; VIOLAXANTHIN; PLANTS; ENERGY	Chlorella pyrenoidosa was grown in steady state continuous cultures in either high or low light. Samples of these cultures were incubated in darkness (violaxanthin state) or in saturating light (zeaxanthin state). These samples were kept in the respective preadapted states throughout the entire photodamage treatment. Photodamage involved exposure to single-turnover flashes fired at a low (non-actinic) frequency. The damage caused by the light stress thus applied was monitored by changes in photosynthetic properties and pigment composition. Cells preadapted in the light resisted photodamage better than those kept in darkness. The low light grown cells were more vulnerable to photodamage than the high light grown cells. Our experimental approach permitted the equilibria between the components that participate in the xanthophyll cycle to be set without addition of inhibitors. Regardless of the total amount of violaxanthin being present, its conversion to anthera- and zeaxanthin is a prerequisite for protection. The protection is most effective for photosystem II. It appeared that antheraxanthin accumulates as a result of photodamaging flashes provided that these are fired in the presence of background light, i.e. with zeaxanthin present. From this, it is newly derived that the xanthophyll cycle operates in full in the light, including epoxidation of zeaxanthin. The latter conversion was also demonstrated in vitro, via nonenzymatic oxygen-dependent turnover of zeaxanthin into violaxanthin.	UNIV AMSTERDAM,AMSTERDAM RES INST SUBSTANCES ECOSYST,MICROBIOL LAB,1018 WS AMSTERDAM,NETHERLANDS; UNIV ROSTOCK,FACHBEREICH BIOL,D-18051 ROSTOCK,GERMANY	University of Amsterdam; University of Rostock	SCHUBERT, H (corresponding author), UNIV AMSTERDAM,EC SLATER INST,NIEWE ACHTERGRACHI 127,1018 WS AMSTERDAM,NETHERLANDS.		Matthijs, Hans/B-4503-2009					Allen J. F., 1986, Photosynthesis: energy transduction: a practical approach, P103; ALLEN JF, 1986, FEBS LETT, V202, P175, DOI 10.1016/0014-5793(86)80682-2; BLASS U, 1959, PLANT PHYSIOL, V34, P329, DOI 10.1104/pp.34.3.329; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DUBINSKY Z, 1987, J PLANKTON RES, V9, P607, DOI 10.1093/plankt/9.4.607; GILMORE AM, 1993, PHOTOSYNTH RES, V35, P67, DOI 10.1007/BF02185412; HAGER A, 1981, ARCH MIKROBIOL, P57; JEFFREY SW, 1975, BIOCHEM PHYSIOL PFL, V167, P191, DOI 10.1016/s0015-3796(17)30778-3; Krinsky N. I., 1971, CAROTENOIDS, P669; LIEBLER DC, 1992, METHOD ENZYMOL, V213, P472; MANTOURA RFC, 1983, ANAL CHIM ACTA, V151, P297, DOI 10.1016/S0003-2670(00)80092-6; Mills J. D., 1986, Photosynthesis: energy transduction: a practical approach, P143; MULLINEAUX CW, 1990, BIOCHIM BIOPHYS ACTA, V1015, P231, DOI 10.1016/0005-2728(90)90025-Y; OWENS TG, 1987, J PHYCOL, V23, P79; Owens TG, 1992, RES PHOTOSYNTHESIS, VI, P179; PFUNDEL EE, 1993, PLANT PHYSIOL, V101, P65, DOI 10.1104/pp.101.1.65; REES D, 1989, FEBS LETT, V256, P85, DOI 10.1016/0014-5793(89)81723-5; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROWELL P, 1986, BIOCH ALGAE CYANOBAC, P201; SAPOZHNIKOV DI, 1957, DOKL AKAD NAUK SSSR+, V113, P465; SAPOZHNIKOV DJ, 1972, CAROTENOIDS OTHER VI; SCHREIBER U, 1986, PHOTOSYNTH RES, V10, P51, DOI 10.1007/BF00024185; THAYER SS, 1990, PHOTOSYNTH RES, V23, P331, DOI 10.1007/BF00034864; THOMAS DM, 1965, J PHYCOL, V1, P118, DOI 10.1111/j.1529-8817.1965.tb04568.x; van Liere L, 1978, MITT INT VER LIMNOL, V21, P158; VANDERSTAAY GWM, 1992, BIOCHIM BIOPHYS ACTA, V1102, P220, DOI 10.1016/0167-4838(92)90513-D; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7; YAMAMOTO HY, 1972, BIOCHIM BIOPHYS ACTA, V267, P538, DOI 10.1016/0005-2728(72)90182-X	28	46	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7267	7272						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125939				2022-12-25	WOS:A1994NA03200038
J	ALTSCHULER, Y; GALILI, G				ALTSCHULER, Y; GALILI, G			ROLE OF CONSERVED CYSTEINES OF A WHEAT GLIADIN IN ITS TRANSPORT AND ASSEMBLY INTO PROTEIN BODIES IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE PROTEINS; ENDOPLASMIC-RETICULUM; DEVELOPING ENDOSPERM; GOLGI-APPARATUS; MESSENGER-RNAS; ACCUMULATION; EVOLUTION; ROUTE	Following sequestration into the endoplasmic reticulum, wheat gliadin storage proteins may either be retained and packaged into protein bodies inside the or ganelle or be transported via the Golgi apparatus to vacuoles and condense into protein bodies at a post-endoplasmic reticulum location. To unravel the mechanism of this complex process of deposition, we expressed wild-type and mutant forms of two closely related gamma and aggregated gliadins in Xenopus oocytes. Although a considerable amount of the gamma-gliadin was secreted to the medium, its closely related aggregated gliadin was entirely retained within the oocytes. This differential secretion was largely due to structural variations in the C-terminal regions of the proteins. Retention of the wild-type aggregated and gamma-gliadins within the endo plasmic reticulum could not be explained by rapid assembly into insoluble deposits inasmuch as both proteins could diffuse rather efficiently within the organelle for several hours. To address more closely the role of the C-terminal region in the transport and assembly of the gamma-gliadin within the endoplasmic reticulum, 3 cysteine codons in this region were mutated, one at a time, to serine codons. The cysteine-replacement mutants improperly aggregated within the endoplasmic reticulum forming denser deposits compared with the wild-type protein.	WEIZMANN INST SCI, DEPT PLANT GENET, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								ALTSCHULER Y, 1993, PLANT CELL, V5, P443; BECHTEL DB, 1986, CEREAL CHEM, V63, P232; CAMPBELL WP, 1981, AUST J PLANT PHYSIOL, V8, P5, DOI 10.1071/PP9810005; CERIOTTI A, 1988, EMBO J, V7, P633, DOI 10.1002/j.1460-2075.1988.tb02857.x; DRUMMOND DR, 1985, J CELL BIOL, V100, P1148, DOI 10.1083/jcb.100.4.1148; KIM WT, 1988, PLANTA, V176, P173, DOI 10.1007/BF00392442; Kreis M., 1985, Oxford Surveys of Plant Molecular and Cell Biology, V2, P253; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEVANONY H, 1992, J CELL BIOL, V119, P1117, DOI 10.1083/jcb.119.5.1117; OKITA TW, 1985, J BIOL CHEM, V260, P8203; PARKER ML, 1982, PLANT CELL ENVIRON, V5, P37; PARKER ML, 1982, PLANTA, V154, P277, DOI 10.1007/BF00387875; PAYNE PI, 1987, ANNU REV PLANT PHYS, V38, P141, DOI 10.1146/annurev.pp.38.060187.001041; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; RUBIN R, 1992, PLANT PHYSIOL, V99, P718, DOI 10.1104/pp.99.2.718; SHEWRY PR, 1990, BIOCHEM J, V267, P1; SHOTWELL MA, 1989, BIOCH PLANTS COMPREH, V15, P297; SIMON R, 1990, PLANT CELL, V2, P941, DOI 10.1105/tpc.2.9.941; SUGIYAMA T, 1986, PLANT SCI, V44, P205, DOI 10.1016/0168-9452(86)90092-0; TATHAM AS, 1985, J CEREAL SCI, V3, P103, DOI 10.1016/S0733-5210(85)80021-7; WALLACE JC, 1988, SCIENCE, V240, P662, DOI 10.1126/science.2834822	21	27	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6677	6682						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120024				2022-12-25	WOS:A1994MZ50300067
J	AMARA, FM; CHEN, FY; WRIGHT, JA				AMARA, FM; CHEN, FY; WRIGHT, JA			PHORBOL ESTER MODULATION OF A NOVEL CYTOPLASMIC PROTEIN-BINDING ACTIVITY AT THE 3'-UNTRANSLATED REGION OF MAMMALIAN RIBONUCLEOTIDE REDUCTASE R2 MESSENGER-RNA AND ROLE IN MESSAGE STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; BALB/C 3T3 FIBROBLASTS; UNTRANSLATED REGION; DNA-SYNTHESIS; CELLS; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; EXPRESSION; MECHANISMS; SEQUENCE; SUBUNIT	The R2 gene of ribonucleotide reductase is elevated in BALB/c 3T3 fibroblasts treated with the tumor prometer, 12-O-tetradecanoylphorbol-13-acetate (TPA). TPA treatment increased the half-life of the R2 message by 3-fold, showing that TPA regulates R2 gene expression by a post-transcriptional mechanism(s). A 20-nucleotide (nt) TPA-responsive region was found within the R2 mRNA 3'-untranslated region (3'UTR), Ultraviolet crosslinking detected a novel 45-kDa protein-R2 mRNA complex migration band that bound selectively to the 20-nt fragment and did not bind to the 5'UTR or the coding region of the R2 message, or to the 3'UTRs of mRNAfrom several other genes, or to the homopolymer poly(A) se quence. The-45 KDa protein-R2 mRNA binding activity observed in unstimulated cells was markedly down regulated after TPA treatment. Deletion of a 20-nt region, containing the 20-nt sequence, from the 3'UTR caused stabilization of hybrid chloramphenicol acetyltransferase mRNA in the absence of TPA treatment. Furthermore, in vitro decay reaction mixtures supplemented with the 20-nt sense RNA transcript resulted in stabilization of R2 message. A model is presented of R2 message regulation in which a vis-element within the 20-nt sequence of the 3'UTR interacts with a cytosolic protein to form a 45-kDa protein mRNA binding complex. The TPA-induced alteration of R2 message stability is at least in part due to the down regulation of the 45-kDa protein-mRNA binding activity which is linked to a reduction in the rate of R2 mRNA degradation.	UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG R3E 0V9,MB,CANADA; UNIV MANITOBA,DEPT BIOCHEM & MOLEC BIOL,WINNIPEG R3E 0V9,MB,CANADA	University of Manitoba; University of Manitoba								AMARA FM, 1993, NUCLEIC ACIDS RES, V21, P4803, DOI 10.1093/nar/21.20.4803; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BLOSMANIS R, 1987, CANCER RES, V47, P1273; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CARTER BZ, 1991, LAB INVEST, V65, P610; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOY BK, 1989, BIOCHEM BIOPH RES CO, V162, P1417, DOI 10.1016/0006-291X(89)90832-2; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FIGGE J, 1988, CELL, V52, P713, DOI 10.1016/0092-8674(88)90409-6; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; HURTA RAR, 1992, BIOCHEM CELL BIOL, V70, P1081, DOI 10.1139/o92-153; HURTA RAR, 1991, J BIOL CHEM, V266, P24097; IWAI Y, 1991, J BIOL CHEM, V266, P17959; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEWIS WH, 1978, J CELL PHYSIOL, V94, P287, DOI 10.1002/jcp.1040940306; LIANG HM, 1991, NUCLEIC ACIDS RES, V19, P2289, DOI 10.1093/nar/19.9.2289; MANZELLA JM, 1992, J BIOL CHEM, V267, P7077; MCCLARTY GA, 1988, BIOCHEMISTRY-US, V27, P7524, DOI 10.1021/bi00419a052; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SACEDA M, 1991, J BIOL CHEM, V266, P17809; SLAGA TJ, 1983, ENVIRON HEALTH PERSP, V50, P3, DOI 10.2307/3429529; SMITH KB, 1983, J CELL PHYSIOL, V117, P91, DOI 10.1002/jcp.1041170113; WEBER G, 1983, CANCER RES, V43, P3466; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; WRIGHT JA, 1989, INT ENCY PHARM THERA, V128, P89; YUSPA SH, 1976, CANCER RES, V36, P4062	33	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6709	6715						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120029				2022-12-25	WOS:A1994MZ50300072
J	KAPPELER, F; ITIN, C; SCHINDLER, R; HAURI, HP				KAPPELER, F; ITIN, C; SCHINDLER, R; HAURI, HP			A DUAL ROLE FOR COOH-TERMINAL LYSINE RESIDUES IN PRE-GOLGI RETENTION AND ENDOCYTOSIS OF ERGIC-53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOPLASMIC-RETICULUM; CYTOPLASMIC DOMAIN; MDCK CELLS; RETROGRADE TRANSPORT; PROTEIN-TRANSPORT; EPITHELIAL-CELLS; BREFELDIN-A; RECEPTOR; IDENTIFICATION; COMPARTMENT	ERGIC-53 (former designation, p53) is a 53-kDa non-glycosylated, dimeric, and hexameric type I membrane protein that has been established as a marker protein for a tubulovesicular intermediate compartment in which protein transport from the endoplasmic reticulum to the Golgi apparatus is blocked at 15 degrees C. Although ERGIC-53 is not a resident protein of the rough endoplasmic reticulum its cDNA sequence carries a double lysine endoplasmic reticulum retention motif at the cytoplasmically exposed COOH terminus. Here we report that overexpression of ERGIC-53 in COS cells saturates its intracellular retention system leading to the appearance of ERGIC-53 at the cell surface. Cell surface ERGIC-53 is efficiently endocytosed by a mechanism that is disturbed when the two critical lysines of the endoplasmic reticulum retention motif are replaced by serines. The results suggest a mechanistic similarity of pre-Golgi retention by the double lysine motif and lysine based. endocytosis.	UNIV BASEL,BIOZENTRUM,DEPT PHARMACOL,CH-4056 BASEL,SWITZERLAND	University of Basel								BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CULLEN BR, 1987, METHOD ENZYMOL, V152, P692; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; MATTER K, 1990, J BIOL CHEM, V265, P3503; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185	31	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6279	6281						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119975				2022-12-25	WOS:A1994MZ50300006
J	MONTESANORODITIS, L; GLITZ, DG				MONTESANORODITIS, L; GLITZ, DG			TRACING THE PATH OF MESSENGER-RNA ON THE ESCHERICHIA-COLI SMALL RIBOSOMAL-SUBUNIT - IMMUNE ELECTRON-MICROSCOPY USING DEFINED OLIGODEOXYNUCLEOTIDE ANALOGS OF MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPLATE POLYNUCLEOTIDES; PROTEIN-SYNTHESIS; ELONGATION CYCLE; DECODING REGION; 30-S SUBUNIT; LOCALIZATION; TRANSLATION; SITE; INITIATION; BINDING	Oligodeoxynucleotide models of mRNA were used to determine the ribosomal site of specific nucleotides 3' to the initiation codon. Each mRNA analog had a 5'-terminal 9-base Shine-Dalgarno sequence, a 7-nucleotide spacer, and an ATG initiation signal, followed by up to 31 nucleotides, one of which carried an antibody-recognizable marker. All probes bound efficiently to activated Escherichia coli 30 S ribosomal subunits. Complexes were formed using ribosomal subunits, initiator tRNA, an oligodeoxynucleotide probe, and antibodies. Electron microscopy was then used to place specific positions in the mRNA analog on the subunit and thus to trace the pathway of the messenger. As viewed from the cytoplasmic side of the subunit, the 5' segment of the mRNA lies on the left, along the inner surface of the platform. The initiation codon and the next 9 nucleotides are located in the cleft between the subunit platform and body; within this segment the mRNA makes a U turn and emerges from the cleft at the left of the neck that separates the subunit head and body. The mRNA then loops around the neck to the right, along the cytoplasmic surface of the subunit and toward the site of the 7-methylguanosine residue of the 16 S ribosomal RNA.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BACKENDORF C, 1980, EUR J BIOCHEM, V110, P599, DOI 10.1111/j.1432-1033.1980.tb04904.x; BAKIN AV, 1991, J MOL BIOL, V221, P441, DOI 10.1016/0022-2836(91)80065-3; BRETSCHER MS, 1969, J MOL BIOL, V42, P595, DOI 10.1016/0022-2836(69)90247-2; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BROUDE NE, 1983, EUR J BIOCHEM, V132, P139, DOI 10.1111/j.1432-1033.1983.tb07338.x; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CZWORKOWSKI J, 1991, BIOCHEMISTRY-US, V30, P4821, DOI 10.1021/bi00233a026; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; EVSTAFIEVA AG, 1983, EMBO J, V2, P799, DOI 10.1002/j.1460-2075.1983.tb01503.x; FIERS W, 1975, NATURE, V256, P273, DOI 10.1038/256273a0; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GOODWIN GH, 1982, GEL ELECTROPHORESIS, P199; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; HARTZ D, 1990, RIBOSOME, P275; HARTZ D, 1991, J MOL BIOL, V218, P83, DOI 10.1016/0022-2836(91)90875-7; HOLLAND JJ, 1964, P NATL ACAD SCI USA, V52, P1554, DOI 10.1073/pnas.52.6.1554; LAKE JA, 1977, P NATL ACAD SCI USA, V74, P1903, DOI 10.1073/pnas.74.5.1903; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LAKE JA, 1978, ADV TECHNIQUES BIOL, V2, P173; LASATER LS, 1988, BIOCHEMISTRY-US, V27, P4687, DOI 10.1021/bi00413a016; LASATER LS, 1990, NUCLEIC ACIDS RES, V18, P477, DOI 10.1093/nar/18.3.477; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; MILSTONE DS, 1978, NUCLEIC ACIDS RES, V5, P3439, DOI 10.1093/nar/5.9.3439; MOAZED D, 1986, J MOL BIOL, V191, P483, DOI 10.1016/0022-2836(86)90143-9; MONTESANORODITIS L, 1993, J BIOL CHEM, V268, P18701; MORGAN AR, 1967, J MOL BIOL, V26, P477, DOI 10.1016/0022-2836(67)90316-6; MURAKAWA GJ, 1989, BIOCHEMISTRY-US, V28, P8067, DOI 10.1021/bi00446a015; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OAKES MI, 1986, P NATL ACAD SCI USA, V83, P275, DOI 10.1073/pnas.83.2.275; OFENGAND J, 1986, STRUCTURE FUNCTION G, P473; OLSON HM, 1979, P NATL ACAD SCI USA, V76, P3769, DOI 10.1073/pnas.76.8.3769; OLSON HM, 1988, J BIOL CHEM, V263, P15196; PEACOCK AC, 1967, BIOCHEMISTRY-US, V6, P1818, DOI 10.1021/bi00858a033; RICKER RD, 1991, NUCLEIC ACIDS RES, V19, P6573, DOI 10.1093/nar/19.23.6573; RINKEAPPEL J, 1993, NUCLEIC ACIDS RES, V21, P2853, DOI 10.1093/nar/21.12.2853; SCHEINMAN A, 1992, BIOCHIMIE, V74, P307, DOI 10.1016/0300-9084(92)90108-Q; SHABAROVA ZA, 1991, NUCLEIC ACIDS RES, V19, P4247, DOI 10.1093/nar/19.15.4247; SHATSKY IN, 1991, BIOCHIMIE, V73, P937, DOI 10.1016/0300-9084(91)90135-N; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SPIRIN AS, 1989, BIOL CELL, V66, P215, DOI 10.1016/0248-4900(89)90174-3; STEITZ JA, 1975, P NATL ACAD SCI USA, V72, P4734, DOI 10.1073/pnas.72.12.4734; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; TREMPE MR, 1982, J BIOL CHEM, V257, P9822; WALLECZEK J, 1990, J BIOL CHEM, V265, P11338; WOWER J, 1991, BIOCHIMIE, V73, P961, DOI 10.1016/0300-9084(91)90137-P; ZAMIR A, 1971, J MOL BIOL, V60, P347, DOI 10.1016/0022-2836(71)90299-3	48	14	14	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6458	6470						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119997				2022-12-25	WOS:A1994MZ50300033
J	HASHIMOTO, Y; MATUOKA, K; TAKENAWA, T; MUROYA, K; HATTORI, S; NAKAMURA, S				HASHIMOTO, Y; MATUOKA, K; TAKENAWA, T; MUROYA, K; HATTORI, S; NAKAMURA, S			DIFFERENT INTERACTIONS OF GRB2/ASH MOLECULE WITH THE NGF AND EGF RECEPTORS IN RAT PHEOCHROMOCYTOMA PC12 CELLS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; SH3 DOMAINS; SIGNAL TRANSDUCTION; TRK PROTOONCOGENE; PROTEIN-KINASE; SRC; ACTIVATION; ACCUMULATION; ASSOCIATION	We have previously shown that nerve growth factor (NGF) induces a rapid and relatively continuous activation of pas in rat pheochromocytoma PC12 cells while epidermal growth factor (EGF) activates Ras transiently, and that tyrosine kinase activity of the NGF receptor is essential for the activation of pas (Muroya et al., Oncogene, 7, 277-281, 1992). In order to explore the signaling mechanism from tyrosine kinase to Ras activation in more detail, interactions between two adaptor molecules, She and Grb2/Ash, which contain Src homology regions, and their interactions with the NGF and EGF receptors were examined. Both NGF and EGF induced rapid tyrosine phosphorylation of She and its association with both the receptors and with Grb2/Ash. When cells were stimulated with EGF at 4 degrees C, the activation of pas proceeded slowly and MAP kinase activation was quite low. Under such restricted conditions, tyrosine-phosphorylated She formed a complex with Grb2/Ash, suggesting that the complex formation may be one of the immediate early responses. In contrast to She, Grb2/Ash bound to EGF receptor but did not form a stable complex with the NGF receptor. These results suggest that there may be an alternative pathway for the activation of Ras in PC12 cells.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO,TOKYO 173,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,MINATO KU,TOKYO,TOKYO 108,JAPAN	National Center for Neurology & Psychiatry - Japan; Tokyo Metropolitan Institute of Gerontology; University of Tokyo								BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1994, IN PRESS P NATL ACAD; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P277; MUROYA K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P353, DOI 10.1016/0167-4889(92)90243-5; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409	39	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					869	875						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108130				2022-12-25	WOS:A1994MW55100023
J	LAI, C; LEMKE, G				LAI, C; LEMKE, G			STRUCTURE AND EXPRESSION OF THE TYRO-10 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; TRK PROTOONCOGENE PRODUCT; NEUROTROPHIC FACTOR; PROTEIN-KINASE; VISUAL CENTERS; FACTOR FAMILY; FACTOR-VIII; DOMAINS; SEQUENCE; MOLECULE	We have isolated cDNA clones encoding Tyro 10, a novel receptor protein-tyrosine kinase (PTK) whose catalytic domain exhibits significant similarity to the Trk family of neurotrophin receptors (Lai and Lemke, 1991). We find that the Tyro 10 gene is widely expressed, both within and outside the nervous system, and in both developing and mature neural tissue. The primary structure of Tyro 10, deduced from cDNA sequence, defines a new sub-family of receptor PTKs. Although the Tyro 10 kinase domain is more closely related to the equivalent domains of Trk, TrkB and TrkC than to the catalytic domains of other receptor PTKs, it is less closely related to these Trk domains than they are to each other. More significantly, the Tyro 10 extracellular (ligand binding) domain is not structurally related to the extracellular domains of the Trk receptors, but instead bears homology to cell surface mediators of protein-protein interactions, including blood coagulation Factors V and VIII, and the neuronal recognition protein A5. These appear to be structural features of a distinct receptor PTK sub-family, in that they are also found in the recently-described discoidin domain receptor (DDR).	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Salk Institute; Scripps Research Institute								BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERKEMEIER LR, 1992, SOMAT CELL MOLEC GEN, V18, P233, DOI 10.1007/BF01233860; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FUJISAWA H, 1989, DEV BIOL, V135, P231, DOI 10.1016/0012-1606(89)90175-9; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1990, N HORIZ TH, P119; HUNTER T, 1993, IN PRESS FRONTIERS B; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RODRIGUEZTEBAR A, 1991, PHILOS T ROY SOC B, V331, P255, DOI 10.1098/rstb.1991.0013; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	60	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					877	883						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108131				2022-12-25	WOS:A1994MW55100024
J	WU, C; AKIYAMA, Y; IMAI, K; MIYAKE, S; NAGASAKI, H; OTO, M; OKABE, S; IWAMA, T; MITAMURA, K; MASUMITSU, H; NOMIZU, T; BABA, S; MARUYAMA, K; YUASA, Y				WU, C; AKIYAMA, Y; IMAI, K; MIYAKE, S; NAGASAKI, H; OTO, M; OKABE, S; IWAMA, T; MITAMURA, K; MASUMITSU, H; NOMIZU, T; BABA, S; MARUYAMA, K; YUASA, Y			DNA ALTERATIONS IN CELLS FROM HEREDITARY NONPOLYPOSIS COLORECTAL-CANCER PATIENTS	ONCOGENE			English	Note							GENE; IDENTIFICATION; MUTATIONS; CHROMOSOME-5Q21; LOCUS; SUSCEPTIBILITY; CARCINOMA; PRODUCTS; FAP	To determine if the MCC, DCC or p53 gene is associated with susceptibility to hereditary non-polyposis colorectal cancer (HNPCC), these genes in normal cells from 12 HNPCC patients were analysed by polymerase chain reaction-single strand conformation polymorphism analysis. No changes which may alter the amino acid sequences of these genes were detected, suggesting that these genes are not associated with the susceptibility to HNPCC. Only one of nine HNPCC cancers showed mutations in the MCC and p53 genes on the same analysis. Loss of heterozygosity in chromosomes 5q, 17p, 18q and 22 was detected in four of the nine cancers, all of them being positive as to metastasis to lymph nodes. Abnormalities of the (CA)n repeat were found in six cancers, including all four without metastasis. These data indicate that tumor suppressor genes in chromosomes 5q, 17p, 18q and 22 are associated with the late stage of colorectal tumorigenesis in HNPCC, whereas the (CA)n repeat abnormalities are an early event of tumorigenesis and more essential to HNPCC.	TOKYO MED & DENT UNIV, SCH MED, DEPT HYG & ONCOL, TOKYO, TOKYO 113, JAPAN; TOKYO MED & DENT UNIV, SCH MED, DEPT SURG, TOKYO, TOKYO 113, JAPAN; SHOWA UNIV, SCH MED, DEPT INTERNAL MED, TOKYO, TOKYO 142, JAPAN; TOKYO METROPOLITAN PUBL HLTH PROMOT FDN, TAMA CANC DETECT CTR, TOKYO, TOKYO 183, JAPAN; HOSHI GEN HOSP, DEPT SURG, FUKUSHIMA, FUKUSHIMA 963, JAPAN; HAMAMATSU UNIV SCH MED, DEPT SURG, HAMAMATSU, SHIZUOKA 43131, JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Showa University; Hamamatsu University School of Medicine								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JINNAI D, 1983, JPN J SURG, V13, P557; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LYNCH HT, 1985, CANCER, V56, P939, DOI 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5705, DOI 10.1093/nar/16.12.5705; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1991, CANCER RES, V51, P4135; PELTOMAKI P, 1992, CANCER RES, V52, P4530; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA, P3	22	43	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					991	994						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108146				2022-12-25	WOS:A1994MW55100040
J	FABRE, S; MANIN, M; PAILHOUX, E; VEYSSIERE, G; JEAN, C				FABRE, S; MANIN, M; PAILHOUX, E; VEYSSIERE, G; JEAN, C			IDENTIFICATION OF A FUNCTIONAL ANDROGEN RESPONSE ELEMENT IN THE PROMOTER OF THE GENE FOR THE ANDROGEN-REGULATED ALDOSE REDUCTASE-LIKE PROTEIN-SPECIFIC TO THE MOUSE VAS-DEFERENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; PROSTATIC BINDING-PROTEIN; MESSENGER-RNA EXPRESSION; GLUCOCORTICOID RECEPTOR; ORNITHINE DECARBOXYLASE; TRANSCRIPTION FACTORS; GENOMIC ORGANIZATION; MEDIATES INDUCTION; STEROID-HORMONES; MAJOR PROTEIN	Mouse vas deferens protein (MVDP), a member of the aldo-keto reductase superfamily, is exclusively produced in the epithelial cells of the deferent duct under androgenic regulation. To better understand androgen-regulated MVDP gene expression, the location and sequences of androgen response elements (AREs) in the 5'-flanking DNA were determined. Sequence analysis revealed two putative AREs as follows: one between positions -1186 and -1171 (distal ARE) and the other between -111 and -97 (proximal ARE). To study hormonal regulation, fragments of the MVDP promoter region, extending from residue -1804 to +41, were linked to the chloramphenicol acetyltransferase (CAT) reporter gene and cotransfected with a human androgen receptor expression vector into T47D cells in a transient expression assay. A minimal region (-121 to +41) was identified as being sufficient for androgen-regulated gene expression. A mutation in proximal ARE almost completely abolished androgen induction of CAT. One copy of the sequence TGAAGT tcc TGTTCT, cloned in the opposite orientation in front of the thymidine kinase promoter, confers androgen responsiveness to the CAT reporter gene. Androgen transcriptional activity was not detected with the distal ARE. The data provide strong evidence that transcriptional regulation of the MVDP gene occurs via the sequence TGAAGT tcc TGTTCT.			FABRE, S (corresponding author), UNIV CLERMONT FERRAND,PHYSIOL COMPAREE & ENDOCRINOL LAB,CNRS,UA 360,F-63177 CLERMONT FERRAND,FRANCE.							ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BONDY CA, 1989, MOL ENDOCRINOL, V3, P1409, DOI 10.1210/mend-3-9-1409; BONDY CA, 1989, MOL ENDOCRINOL, V3, P1417, DOI 10.1210/mend-3-9-1417; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; CLAESSENS F, 1990, MOL CELL ENDOCRINOL, V74, P203, DOI 10.1016/0303-7207(90)90225-W; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; CROZAT A, 1992, ENDOCRINOLOGY, V130, P1131, DOI 10.1210/en.130.3.1131; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DASSOULI A, 1994, IN PRESS J STEROID B; DENISON SH, 1989, ENDOCRINOLOGY, V124, P1091, DOI 10.1210/endo-124-2-1091; EISENBERG LM, 1989, NUCLEIC ACIDS RES, V17, P2359, DOI 10.1093/nar/17.6.2359; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GHYSELINCK NB, 1993, MOL ENDOCRINOL, V7, P258, DOI 10.1210/me.7.2.258; GRAHAM A, 1991, J BIOL CHEM, V266, P6872; GRAHAM C, 1991, GENE, V107, P259, DOI 10.1016/0378-1119(91)90326-7; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; IWATA N, 1990, ARCH BIOCHEM BIOPHYS, V282, P70, DOI 10.1016/0003-9861(90)90088-G; JEFFERY J, 1983, P NATL ACAD SCI-BIOL, V80, P901, DOI 10.1073/pnas.80.4.901; KINOSHITA JH, 1981, JAMA-J AM MED ASSOC, V246, P257, DOI 10.1001/jama.246.3.257; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUND SD, 1991, MOL CELL BIOL, V11, P5426, DOI 10.1128/MCB.11.11.5426; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANIN M, 1992, ENDOCRINOLOGY, V131, P2378, DOI 10.1210/en.131.5.2378; MANN T, 1964, BIOCH SEMEN MALE REP, P237; MARTINEZ A, 1989, J ENDOCRINOL, V120, P67, DOI 10.1677/joe.0.1200067; MARTINEZ A, 1991, MOL CELL ENDOCRINOL, V76, P191, DOI 10.1016/0303-7207(91)90273-U; MARTINEZ A, 1990, MOL CELL ENDOCRINOL, V72, P201, DOI 10.1016/0303-7207(90)90144-W; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1966; PAILHOUX E, 1992, J STEROID BIOCHEM, V42, P561, DOI 10.1016/0960-0760(92)90445-O; PAILHOUX EA, 1990, J BIOL CHEM, V265, P19932; PARKER MG, 1987, J CELL BIOCHEM, V35, P285, DOI 10.1002/jcb.240350403; PETRASH JM, 1992, BIOCHEM BIOPH RES CO, V187, P201, DOI 10.1016/S0006-291X(05)81479-2; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; RUSHMERE NK, 1987, MOL CELL ENDOCRINOL, V51, P259, DOI 10.1016/0303-7207(87)90036-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; STAVENHAGEN JB, 1988, CELL, V55, P247, DOI 10.1016/0092-8674(88)90047-5; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAN JA, 1992, J BIOL CHEM, V267, P4456; TARAGNAT C, 1988, J REPROD FERTIL, V83, P835, DOI 10.1530/jrf.0.0830835; TARAGNAT C, 1990, J ANDROL, V11, P279; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZHANG HY, 1991, J BIOL CHEM, V266, P24332	63	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5857	5864						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119928				2022-12-25	WOS:A1994MY84000059
J	HANSSON, L; EDLUND, M; EDLUND, A; JOHANSSON, T; MARKLUND, SL; FROMM, S; STROMQVIST, M; TORNELL, J				HANSSON, L; EDLUND, M; EDLUND, A; JOHANSSON, T; MARKLUND, SL; FROMM, S; STROMQVIST, M; TORNELL, J			EXPRESSION AND CHARACTERIZATION OF BIOLOGICALLY-ACTIVE HUMAN EXTRACELLULAR-SUPEROXIDE DISMUTASE IN MILK OF TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CELL-LINES; BETA-LACTOGLOBULIN; FREE-RADICALS; REPERFUSION; RAT; BINDING; ISOENZYMES; SEQUENCE; ISCHEMIA; PROTEINS	We have targeted the expression of recombinant human extracellular superoxide dismutase, a glycosylated tetrameric metalloprotein, to the mammary gland of transgenic mice. This was achieved by using regulatory elements from either the murine whey acidic protein gene or the ovine beta-lactoglobulin gene to control expression of human extracellular superoxide dismutase cDNA. Whey acidic protein regulatory sequences directed high level mammary gland-specific expression of the recombinant gene and secretion of biologically active extracellular superoxide dismutase into the milk. The produced recombinant protein was fully active, it was in tetrameric form, it showed heparin affinity, and its mass was similar to that of the native enzyme. In addition, the in vivo plasma clearance in a rabbit model was similar to the previously studied native and recombinant forms. To our knowledge, this is the first example of efficient production of a tetrameric, protease-susceptible metalloprotein in milk of transgenic animals. Production at equivalent levels in transgenic farm animals would yield sufficient extracellular superoxide dismutase for therapeutic purposes.	UMEA UNIV HOSP, DEPT CLIN CHEM, S-90185 UMEA, SWEDEN; UNIV OSLO, MOLEC EMBRYOL LAB, N-0316 OSLO 3, NORWAY; UNIV GOTEBORG, DEPT PHYSIOL, S-41390 GOTHENBURG, SWEDEN	Umea University; University of Oslo; University of Gothenburg	HANSSON, L (corresponding author), SYMBICOM AB, POB 1451, S-90124 UMEA, SWEDEN.							ABRAHAMSSON T, 1992, CIRC RES, V70, P264, DOI 10.1161/01.RES.70.2.264; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, pCH2; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; ERLANSSON M, 1990, FREE RADICAL BIO MED, V9, P59, DOI 10.1016/0891-5849(90)90050-S; FERRARI R, 1989, PHARMACOL RES, V21, P57, DOI 10.1016/S1043-6618(89)80018-0; HARRIS S, 1988, NUCLEIC ACIDS RES, V16, P10379, DOI 10.1093/nar/16.21.10379; HATORI N, 1992, FREE RADICAL BIO MED, V13, P221, DOI 10.1016/0891-5849(92)90018-C; HATORI N, 1992, FREE RADICAL BIO MED, V13, P137, DOI 10.1016/0891-5849(92)90075-R; HENNIGHAUSEN L, 1990, Protein Expression and Purification, V1, P3, DOI 10.1016/1046-5928(90)90037-Y; Hennighausen L, 1990, Curr Opin Biotechnol, V1, P74, DOI 10.1016/0958-1669(90)90013-B; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; HOGAN B, 1986, MANIPULATING MOUSE E, P153; JOHANSSON MH, 1990, CARDIOVASC RES, V24, P500, DOI 10.1093/cvr/24.6.500; KARLSSON K, 1988, BIOCHEM J, V255, P223; KARLSSON K, 1993, BIOCHEM J, V290, P623, DOI 10.1042/bj2900623; KARLSSON K, 1988, BIOCHEM J, V256, P29, DOI 10.1042/bj2560029; KARLSSON K, 1987, BIOCHEM J, V242, P55, DOI 10.1042/bj2420055; KARLSSON K, 1988, J CLIN INVEST, V82, P762, DOI 10.1172/JCI113676; KARLSSON K, 1993, FREE RADICAL BIO MED, V14, P185, DOI 10.1016/0891-5849(93)90009-J; KARLSSON K, 1989, LAB INVEST, V60, P659; KEELE BB, 1970, J BIOL CHEM, V245, P6176; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKLUND S, 1976, J BIOL CHEM, V251, P7504; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1990, BIOCHEM J, V266, P213, DOI 10.1042/bj2660213; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MARKLUND SL, 1982, CLIN CHIM ACTA, V126, P41, DOI 10.1016/0009-8981(82)90360-6; MARKLUND SL, 1986, ANN RHEUM DIS, V45, P847, DOI 10.1136/ard.45.10.847; MARKLUND SL, 1985, CRC HDB METHODS OXYG, P249; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOSS DW, 1985, ENZYME, V34, P212, DOI 10.1159/000469387; Omar B A, 1992, Adv Pharmacol, V23, P109, DOI 10.1016/S1054-3589(08)60964-3; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SANDSTROM J, 1993, BIOCHEM J, V294, P853, DOI 10.1042/bj2940853; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; SANFEY H, 1984, ANN SURG, V200, P405, DOI 10.1097/00000658-198410000-00003; SCHOENBERG MH, 1990, CHEM-BIOL INTERACT, V76, P141, DOI 10.1016/0009-2797(90)90085-2; SIMONS JP, 1987, NATURE, V328, P530, DOI 10.1038/328530a0; SJOQUIST PO, 1991, J CARDIOVASC PHARM, V17, P678; SJOQUIST PO, 1992, J CARDIOVASC PHARM, V26, P347; STROMQVIST M, 1991, J CHROMATOGR, V548, P293, DOI 10.1016/S0021-9673(01)88611-8; STROMQVIST M, 1992, BIOTECHNIQUES, V13, P744; TIBELL L, 1987, P NATL ACAD SCI USA, V84, P6634, DOI 10.1073/pnas.84.19.6634; WAHLUND G, 1992, FREE RADICAL RES COM, V17, P41, DOI 10.3109/10715769209061087; WALL RJ, 1991, P NATL ACAD SCI USA, V88, P1696, DOI 10.1073/pnas.88.5.1696; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WILMUT I, 1991, EXPERIENTIA, V47, P905, DOI 10.1007/BF01929881	52	21	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5358	5363						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106520				2022-12-25	WOS:A1994MX57100098
J	KULIAWAT, R; ARVAN, P				KULIAWAT, R; ARVAN, P			INTRACELLULAR IODINATION OF THYROGLOBULIN IN FILTER-POLARIZED THYROCYTES LEADS TO THE SYNTHESIS AND BASOLATERAL SECRETION OF THYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL PLASMA-MEMBRANE; EPITHELIAL-CELLS; FOLLICLE CELLS; THYROTROPIN REGULATION; CARBOHYDRATE UNITS; IODIDE TRANSPORT; PRIMARY CULTURE; GOLGI-COMPLEX; THYROXINE; PROTEIN	Thyroid follicles perform several functions that depend upon epithelial polarity: secretion of thyroglobulin (Tg) to the apical lumen, uptake of iodide for Tg iodination, and the manufacture of thyroid hormone for delivery to the bloodstream. In this report we examine Tg processing by thyroid epithelial monolayers cultured on porous filters. Basolateral I-125 uptake resulted in thyrotropin-dependent radiolabeling of Tg in cells and apical medium. Polarized thyrocytes iodinated exogenous gamma globulins (IgG), demonstrating labeling in the apical extracellular space. Apical catalase addition inhibited the appearance of apical, [I-125]IgG and [I-125]Tg, but had no effect on cell-associated [I-125]Tg, indicating additional iodination of Tg in an intracellular compartment. A similar conclusion was drawn from radioiodination experiments at 20 degrees C. Intracellular iodination was selective for Tg forms receiving prior Golgi carbohydrate modifications. During a 2-h chase, [I-125]Tg was exported from cells to apical medium, while modest amounts of thyroxine were secreted with a majority to the basolateral medium. Neither radioiodination at 20 degrees C nor apical catalase addition blocked formation or secretion of [I-125]thyroxine during the chase. Thus in filter-grown thyroid epithelial cells, prior to apical extracellular iodination, intracellular iodination of Tg begins the process leading to formation of thyroxine.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV ENDOCRINOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, CELL & DEV BIOL PROGRAM, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School				Kuliawat, Regina/0000-0001-8386-2279	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK107516, T32DK007516, R01DK040344, R29DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07516, DK40344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLUCHONGERARD MJ, 1979, ARCH ANAT MICROSC MO, V68, P43; ARIMA T, 1972, J BIOL CHEM, V247, P1825; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BARRIERE H, 1986, CELL TISSUE RES, V245, P159; BJORKMAN U, 1988, ENDOCRINOLOGY, V122, P488; CHAMBARD M, 1990, J MOL ENDOCRINOL, V4, P193, DOI 10.1677/jme.0.0040193; CHAMBARD M, 1983, J CELL BIOL, V96, P1172, DOI 10.1083/jcb.96.4.1172; CROFT CJ, 1970, BIOCHEM J, V118, P311, DOI 10.1042/bj1180311; DAMANTE G, 1989, ENDOCRINOLOGY, V124, P2889, DOI 10.1210/endo-124-6-2889; DOCTER R, 1987, J CLIN ENDOCR METAB, V65, P624, DOI 10.1210/jcem-65-4-624; DUMONT JE, 1989, METABOLIC BASIS INHE, P1843; DUNN JT, 1981, J BIOL CHEM, V256, P942; DUNN JT, 1992, WERNER INGBARS THYRO, P98; EKHOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141, DOI 10.1016/0303-7207(81)90056-3; ENGLER H, 1983, ENDOCRINOLOGY, V112, P86, DOI 10.1210/endo-112-1-86; ERICSON LE, 1979, J ULTRA MOL STRUCT R, V69, P297, DOI 10.1016/S0022-5320(79)90118-7; ERICSON LE, 1981, MOL CELL ENDOCRINOL, V22, P1, DOI 10.1016/0303-7207(81)90098-8; FRANCON J, 1989, J NEUROCHEM, V53, P1456, DOI 10.1111/j.1471-4159.1989.tb08538.x; GALTON VA, 1986, ENDOCRINOLOGY, V118, P1918, DOI 10.1210/endo-118-5-1918; GERARD C, 1985, EUR J CELL BIOL, V38, P134; GERARD CM, 1988, MOL CELL ENDOCRINOL, V60, P239, DOI 10.1016/0303-7207(88)90184-0; GONCALVES E, 1990, MOL CELL ENDOCRINOL, V69, P157, DOI 10.1016/0303-7207(90)90009-W; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GROLLMAN EF, 1992, J CLIN ENDOCR METAB, V74, P43, DOI 10.1210/jc.74.1.43; GRUFFAT D, 1991, J ENDOCRINOL, V128, P51, DOI 10.1677/joe.0.1280051; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; HERZOG V, 1992, J CELL BIOL, V118, P1071, DOI 10.1083/jcb.118.5.1071; HERZOG V, 1986, EUR J CELL BIOL, V39, P399; KASTELLAKIS A, 1989, MOL CELL ENDOCRINOL, V67, P231; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1993, AM J PHYSIOL, V265, pC704, DOI 10.1152/ajpcell.1993.265.3.C704; KIM PS, 1993, J BIOL CHEM, V268, P4873; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KOHN LD, 1985, THYROGLOBULIN PROTHY, P171; LAKSHMANAN M, 1990, ENDOCRINOLOGY, V126, P3245, DOI 10.1210/endo-126-6-3245; LAURBERG P, 1986, ENDOCRINOLOGY, V118, P895, DOI 10.1210/endo-118-3-895; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P2137, DOI 10.1210/endo-103-6-2137; MAGNUSSON RP, 1987, J BIOL CHEM, V262, P13885; MAGNUSSON RP, 1985, ENDOCRINOLOGY, V116, P1493, DOI 10.1210/endo-116-4-1493; MALTHIERY Y, 1989, BIOCHIMIE, V71, P195, DOI 10.1016/0300-9084(89)90057-6; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MAUCHAMP J, 1979, CELL TISSUE RES, V204, P417, DOI 10.1007/BF00233653; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MONACO F, 1975, ENDOCRINOLOGY, V97, P347, DOI 10.1210/endo-97-2-347; NAKAMURA Y, 1990, J ENDOCRINOL, V126, P275, DOI 10.1677/joe.0.1260275; NEVE P, 1970, Z ZELLFORSCH MIK ANA, V103, P61, DOI 10.1007/BF00335401; NILSSON M, 1987, CELL TISSUE RES, V250, P295, DOI 10.1007/BF00219074; NILSSON M, 1992, ACTA ENDOCRINOL-COP, V126, P67, DOI 10.1530/acta.0.1260067; NILSSON M, 1990, EUR J CELL BIOL, V52, P270; OSTY J, 1990, J CLIN ENDOCR METAB, V71, P1589, DOI 10.1210/jcem-71-6-1589; PALUMBO G, 1990, J BIOL CHEM, V265, P8887; PENEL C, 1989, PFLUG ARCH EUR J PHY, V414, P509, DOI 10.1007/BF00580985; PRABAKARAN D, 1993, J BIOL CHEM, V268, P9041; RAO GS, 1983, J ENDOCRINOL, V97, P277, DOI 10.1677/joe.0.0970277; REMY L, 1986, BIOL CELL, V56, P97, DOI 10.1111/j.1768-322X.1986.tb00446.x; RING P, 1987, CELL TISSUE RES, V247, P505, DOI 10.1007/BF00215743; ROLLAND M, 1976, BIOCHIM BIOPHYS ACTA, V427, P696, DOI 10.1016/0005-2795(76)90213-0; ROUSSET B, 1991, MOL CELL ENDOCRINOL, V78, pC89, DOI 10.1016/0303-7207(91)90176-S; ROUSSET B, 1991, PROGRESS IN THYROID RESEARCH, P495; SCHNEIDER AB, 1988, ENDOCRINOLOGY, V122, P2428, DOI 10.1210/endo-122-6-2428; SHEPARD TH, 1968, GEN COMP ENDOCR, V10, P174, DOI 10.1016/0016-6480(68)90024-5; STRUM J M, 1970, Journal of Cell Biology, V44, P655, DOI 10.1083/jcb.44.3.655; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249	64	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4922	4927						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106466				2022-12-25	WOS:A1994MX57100037
J	SADASIVAN, E; CEDENO, MM; ROTHENBERG, SP				SADASIVAN, E; CEDENO, MM; ROTHENBERG, SP			CHARACTERIZATION OF THE GENE ENCODING A FOLATE-BINDING PROTEIN EXPRESSED IN HUMAN PLACENTA - IDENTIFICATION OF PROMOTER ACTIVITY IN A G-RICH SP1 SITE LINKED WITH THE TANDEMLY REPEATED GGAAG MOTIF FOR THE ETS ENCODED GA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CULTURED KB-CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRANSCRIPTION FACTORS; GENOMIC ORGANIZATION; DNA; MEMBRANE; MILK; CDNA; RECEPTORS	The gene encoding a folate-binding protein (FBP) expressed in human placenta has been cloned by screening a genomic library with the KB cell FBP complementary DNA. This gene, contained in a 10-kilobase EcoRI fragment of this genomic clone, has 5 exons, 4 introns, the AATAA polyadenylation signal in the 3'-untranslated region, and a 5'-flanking sequence which contains the promoter elements, all of which span approximately 5 kilobases. Transcription initiation was mapped by RNase protection to a site 73 base pairs downstream from a G-rich sequence linked to a tandemly repeated GGAAG sequence which is a motif that the ets oncogene encoded GA-binding protein (GABP) transcription factor binds, Gel shift and supershift mobility assays indicate that the G-rich sequence and the ets motif bind specifically to SP1 and GABP, respectively. These cis regulatory elements in tandem drive expression of the chloramphenicol acetyltransferase reporter gene in transiently transfected mouse 3T3 cells. The location of these elements upstream of transcription initiation in this gene, which lacks an appropriately located TATA box promoter, indicates that this SP1-GA binding region most probably regulates expression of this placental FBP. The gene encoding this placental FBP has been assigned the FBP/PL-1 gene because it is a member of a multigene family that includes a gene encoding a FBP expressed in both EE cells and placenta and its unprocessed pseudogene.	SUNY HLTH SCI CTR BROOKLYN,DEPT MED,DIV HEMATOL ONCOL,BROOKLYN,NY 11209; VET AFFAIRS MED CTR,BROOKLYN,NY 11209	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007289] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA032369] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA32369] Funding Source: Medline; NIADDK NIH HHS [5T32-AM-07289] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONY AC, 1992, BLOOD, V79, P2807; ANTONY AC, 1982, J BIOL CHEM, V257, P81; ANTONY AC, 1989, J BIOL CHEM, V264, P1911; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CARTER RS, 1992, J BIOL CHEM, V267, P23418; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; LUHRS CA, 1991, BLOOD, V77, P1171; LUHRS CA, 1986, ARCH BIOCHEM BIOPHYS, V250, P94, DOI 10.1016/0003-9861(86)90705-8; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PAGE ST, 1993, J MOL BIOL, V229, P1175, DOI 10.1006/jmbi.1993.1116; RAGOUSSIS J, 1992, GENOMICS, V14, P423, DOI 10.1016/S0888-7543(05)80236-8; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; ROTHENBERG SP, 1971, J CLIN INVEST, V50, P719, DOI 10.1172/JCI106542; ROTHENBERG SP, 1976, CLIN HAEMATOL, V5, P569; SABINA RL, 1990, J BIOL CHEM, V265, P9423; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1992, BIOCHIM BIOPHYS ACTA, V1131, P91, DOI 10.1016/0167-4781(92)90103-7; SADASIVAN E, 1990, J BIOL CHEM, V265, P1821; SADASIVAN E, 1987, BIOCHIM BIOPHYS ACTA, V925, P36, DOI 10.1016/0304-4165(87)90145-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SVENDSEN IB, 1982, CARLSBERG RES COMMUN, V47, P371, DOI 10.1007/BF02907775; SVENDSEN IB, 1984, CARLSBERG RES COMMUN, V49, P123, DOI 10.1007/BF02913971; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; UDENFRIEND S, 1991, CELL BIOL INT REP, V15, P739, DOI 10.1016/0309-1651(91)90030-M; VERMA RS, 1992, J BIOL CHEM, V267, P4119; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1988, BIOCHIM BIOPHYS ACTA, V951, P17, DOI 10.1016/0167-4781(88)90021-8	39	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4725	4735						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106441				2022-12-25	WOS:A1994MX57100009
J	JACOB, GA; KITZMILLER, JA; LUSE, DS				JACOB, GA; KITZMILLER, JA; LUSE, DS			RNA POLYMERASE-II PROMOTER STRENGTH IN-VITRO MAY BE REDUCED BY DEFECTS AT INITIATION OR PROMOTER CLEARANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; PREINITIATION COMPLEX; ELONGATION COMPLEXES; ABORTIVE INITIATION; TRANSCRIPTION; ELEMENTS; BINDING; TATA	We have measured the ability of three TATA box promoters, adenovirus 2 major late (Ad 2 ML), Ad 2 ML with a point mutation in the TATA box, and mouse P-globin, to support abortive and productive RNA synthesis in vitro. We have also measured the ability of these promoters to direct the assembly of preinitiation complexes using a nuclease protection assay. The relative strengths in productive transcription, determined from the synthesis of RNAs 10 nucleotides or longer, were 12:6:1 for Ad 2 ML, mouse beta-globin, and the TATA mutant of Ad 2 ML. However, the TATA mutant was reduced only 4-fold in its ability to assemble preinitiation complexes, compared to Ad 2 ML. Complexes formed on the Ad 2 ML TATA mutant may therefore also be reduced in their ability to initiate transcription. The mouse beta-globin promoter directed assembly and initiation as well as Ad 2 ML, but the beta-globin transcription complexes were less able to clear the promoter, resulting in an increase in aborted transcripts at the expense of productive RNA synthesis. We have thus shown that the transcriptional strength of eukaryotic promoters may be determined not only at the step of transcription complex assembly but also at the level of promoter clearance and possibly at transcription initiation as well.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati				Jacob, George/0000-0003-4120-7334	NHLBI NIH HHS [HL 15996] Funding Source: Medline; NIGMS NIH HHS [GM 29487] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CAI H, 1987, MOL CELL BIOL, V7, P3371, DOI 10.1128/MCB.7.10.3371; CHOY HE, 1993, P NATL ACAD SCI USA, V90, P472, DOI 10.1073/pnas.90.2.472; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; JACOB GA, 1991, J BIOL CHEM, V266, P22537; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; NUEZ B, 1992, P NATL ACAD SCI USA, V89, P11401, DOI 10.1073/pnas.89.23.11401; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; REINBERG D, 1993, PROG NUCL ACID RES M, V44, P67; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	20	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3655	3663						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106410				2022-12-25	WOS:A1994MV63100078
J	ACHYUTHAN, KE; SLAUGHTER, TF; SANTIAGO, MA; ENGHILD, JJ; GREENBERG, CS				ACHYUTHAN, KE; SLAUGHTER, TF; SANTIAGO, MA; ENGHILD, JJ; GREENBERG, CS			FACTOR-XIIIA-DERIVED PEPTIDES INHIBIT TRANSGLUTAMINASE ACTIVITY - LOCALIZATION OF SUBSTRATE RECOGNITION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XIII; AMINO-ACID-SEQUENCE; PIG LIVER TRANSGLUTAMINASE; FIBRIN-STABILIZING FACTOR; CROSS-LINKING; TISSUE TRANSGLUTAMINASE; ALPHA-CHAIN; MOLECULAR RECOGNITION; GAMMA-CHAIN; BINDING	Factor XIIIa is a transglutaminase that catalyzes intermolecular gamma-glutamyl-epsilon-lysyl bonds between fibrin and other proteins involved in hemostasis. We synthesized 25 peptides from various regions of factor XIIIa and studied their effects on cross-linking fibrin, N,N'-dimethylcasein, or fibronectin. We found that two peptides, Asn72-Asp97 (peptide-4) and Asp190-Phe230 (peptide- 7), inhibited factor XIIIa cross-linking of these substrates. The other peptides did not inhibit factor XIIIa activity. The inhibition of cross-linking was reversed by excess substrate, indicating that the peptides were interacting with fibrin and not factor XIIIa. The peptides were not pseudosubstrates since they were not cross-linked to fibrin. The peptides did not modify the primary amine binding site as increasing the primary amine concentration did not reverse inhibition. Peptides-4 and -7 also had no effect on exposure of the active site of factor XIIIa and no synergistic inhibitory effects were detected. Peptides-4 and -7 had no effect on factor XIIIa binding to fibrin suggesting that the binding sites and the substrate recognition sites were distinct. Synthetic peptides containing shorter amino acid sequences of peptide-4 were inactive. In contrast, the amino-terminal (Asp190-Lys199, Tyr194-Tyr204) and the carboxyl-terminal (Lys211-Phe230) portions of peptide-7 were 20-60-fold less inhibitory compared to intact peptide-7. Peptides-4 and -7 also inhibited guinea pig liver tissue transglutaminase from cross-linking fibrinogen, N,N'-dimethylcasein, and fibronectin. In conclusion, we have identified two regions outside the active site pocket which are important for substrate recognition in factor XIIIa and tissue transglutaminase.	DUKE UNIV,MED CTR,DEPT MED,BOX 3031,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT ANESTHESIOL,DURHAM,NC 27710	Duke University; Duke University; Duke University				Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL028391, R01HL038245, P50HL026309] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26309, HL-28391, HL-38245] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHYUTHAN KE, 1986, BIOCHIM BIOPHYS ACTA, V872, P261, DOI 10.1016/0167-4838(86)90279-7; ACHYUTHAN KE, 1988, J BIOL CHEM, V263, P14296; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; ALTIERI DC, 1991, SCIENCE, V254, P1200, DOI 10.1126/science.1957171; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BALE MD, 1986, BIOCHEMISTRY-US, V25, P5667, DOI 10.1021/bi00367a048; BINNIE CG, 1991, THROMB HAEMOSTASIS, V65, P165; BOCKENSTEDT P, 1986, J CLIN INVEST, V78, P551, DOI 10.1172/JCI112608; CHATTOPADHYAY A, 1989, J BIOL CHEM, V264, P11035; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CONNELLAN JM, 1971, J BIOL CHEM, V246, P1093; COTTRELL BA, 1979, BIOCHEMISTRY-US, V18, P5405, DOI 10.1021/bi00591a023; COUSSONS PJ, 1992, BIOCHEM J, V282, P929, DOI 10.1042/bj2820929; FICKENSCHER K, 1991, THROMB HAEMOSTASIS, V65, P535; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FRANCIS RT, 1986, J BIOL CHEM, V261, P9787; FUKUE H, 1992, BLOOD, V79, P64; GENTILE V, 1991, J BIOL CHEM, V266, P478; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1973, J BIOL CHEM, V248, P1301; GREENBERG CS, 1985, BLOOD, V66, P1028; GREENBERG CS, 1987, BLOOD, V70, P702; GREENBERG CS, 1988, ARCH BIOCHEM BIOPHYS, V262, P142, DOI 10.1016/0003-9861(88)90176-2; GREENBERG CS, 1988, BIOCHEM J, V256, P1013, DOI 10.1042/bj2561013; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HOEPRICH PD, 1983, BIOCHEMISTRY-US, V22, P2049, DOI 10.1021/bi00278a003; HORNYAK TJ, 1992, BIOCHEMISTRY-US, V31, P423, DOI 10.1021/bi00117a017; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; LAI TS, 1991, BLOOD S1, V78, pA391; LEE KN, 1992, BIOCHIM BIOPHYS ACTA, V1136, P12, DOI 10.1016/0167-4889(92)90078-P; LORAND L, 1964, ARCH BIOCHEM BIOPHYS, V105, P58, DOI 10.1016/0003-9861(64)90235-8; Lorand L, 1980, Prog Hemost Thromb, V5, P245; MARTINEZ J, 1989, J BIOL CHEM, V264, P20502; MARY A, 1988, ARCH BIOCHEM BIOPHYS, V261, P112, DOI 10.1016/0003-9861(88)90110-5; McDonagh J, 1987, HEMOSTASIS THROMBOSI, P289; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; MIRAGLIA CC, 1985, ANAL BIOCHEM, V144, P165, DOI 10.1016/0003-2697(85)90099-5; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; MOSHER DF, 1979, J CLIN INVEST, V64, P781, DOI 10.1172/JCI109524; MUSZBEK L, 1985, CLIN CHEM, V31, P35; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; ROSENBERG JB, 1993, THROMB HAEMOSTASIS, V69, P217; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; Segel I. H., 1975, ENZYME KINETICS, P203; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W	54	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21284	21292						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8104938				2022-12-25	WOS:A1993MA28800094
J	FLEURY, V; LIJNEN, HR; ANGLESCANO, E				FLEURY, V; LIJNEN, HR; ANGLESCANO, E			MECHANISM OF THE ENHANCED INTRINSIC ACTIVITY OF SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR DURING ONGOING FIBRINOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOSE SYNERGISTIC COMBINATIONS; ACUTE MYOCARDIAL-INFARCTION; SITE-SPECIFIC MUTAGENESIS; HUMAN-PLASMA; PRO-UROKINASE; MONOCLONAL-ANTIBODY; CLOT LYSIS; CORONARY THROMBOLYSIS; 2-CHAIN UROKINASE; SARCOMA-CELLS	The activation of plasminogen at the surface of fibrin by single-chain urokinase-type plasminogen activator (scu-PA) was investigated using recombinant forms of a plasmin-resistant mutant of scu-PA, rscu-PA-Glu158, and an inactive catalytic site mutant of human plasminogen, rPg-Ala741. Conversion of cleavable I-125-labeled single-chain proteins to their two-chain forms, was quantitated by radioisotope counting of protein bands on reduced SDS-polyacrylamide gels. The efficiency of the activation (moles of plasmin generated per mol of plasminogen activator) of native Glu-plasminogen bound to degraded fibrin was comparable for scu-PA and its two-chain form (tcu-PA) and approximately 4-fold lower for rscu-PA-Glu158. The corresponding values with rPg-Ala741 were 4-fold or 9-fold lower for scu-PA or rscu-PA-Glu158, as compared to tcu-PA. In contrast, in solution in the absence of fibrin, the efficiency of scu-PA for activation of rPg-Ala741 was 100-fold lower than that of tcu-PA. Initial activation rates of rPg-Ala741 (32.7 fmol/well containing 50 mul of solution) with 4 nm tcu-PA were comparable in solution and bound to degraded fibrin (v(o) = 1.01 and 1.16 fmol/min, respectively). In contrast, with 4 nm scu-PA the corresponding values when rPg-Ala741 was bound to degraded fibrin were 20-fold higher as compared to the soluble phase (v(o) = 0.23 and 0.012 fmol/min, respectively). Comparable results were obtained when using Glu- or Lys-forms of rPg-Ala741. Furthermore, in the presence of normal human plasma, activation of Glu-plasminogen bound to degraded fibrin was found to be about 2.5-fold more efficient with scu-PA than with tcu-PA. These findings indicate that the fibrin specificity of scu-PA does not require its conversion to tcu-PA, nor conversion of Glu- to Lys-plasminogen, but appears to be due to the additional binding of plasminogen to partially digested fibrin; scu-PA may thus represent a physiological functional form of u-PA in plasma.	HOP BICETRE,IPC,INSERM,U143,F-94275 LE KREMLIN BICETR,FRANCE; CATHOLIC UNIV LEUVEN,CTR MOLEC & VASC BIOL,B-3000 LOUVAIN,BELGIUM	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); KU Leuven			Lijnen, Roger/AAA-4085-2020; ANGLES-CANO, Eduardo/ABA-1739-2020; ANGLES-CANO, Eduardo/G-2311-2012	ANGLES-CANO, Eduardo/0000-0001-7891-3975; ANGLES-CANO, Eduardo/0000-0001-7891-3975				ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; ANGLESCANO E, 1990, FIBRINOLYSIS, V4, P127, DOI 10.1016/0268-9499(90)90386-X; ANGLESCANO E, 1986, ANAL BIOCHEM, V153, P201, DOI 10.1016/0003-2697(86)90082-5; ANGLESCANO E, 1984, J IMMUNOL METHODS, V69, P115, DOI 10.1016/0022-1759(84)90283-7; ANGLESCANO E, 1992, BIOCHIM BIOPHYS ACTA, V1156, P34, DOI 10.1016/0304-4165(92)90092-9; BINNEMA DJ, 1986, THROMB RES, V43, P569, DOI 10.1016/0049-3848(86)90077-0; Blomback B., 1956, ARK KEMI, V10, P415; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CHASE T, 1970, METHOD ENZYMOL, V19, P20; COLLEN D, 1987, AM J CARDIOL, V60, P431, DOI 10.1016/0002-9149(87)90280-3; COLLEN D, 1989, J VASC MED BIOL, V1, P46; DECLERCK PJ, 1990, BLOOD, V75, P1794; DECLERCK PJ, 1991, THROMB HAEMOSTASIS, V65, P394; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEVEER AMTJ, 1991, BIOCHEMISTRY-US, V30, P10034, DOI 10.1021/bi00105a031; ELLIS V, 1987, J BIOL CHEM, V262, P14998; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; FLEURY V, 1993, FIBRINOLYSIS, V7, P87, DOI 10.1016/0268-9499(93)90028-T; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GUREWICH V, 1988, J CLIN INVEST, V82, P1956, DOI 10.1172/JCI113815; GUREWICH V, 1984, J CLIN INVEST, V73, P1731, DOI 10.1172/JCI111381; HUSAIN SS, 1983, ARCH BIOCHEM BIOPHYS, V220, P31, DOI 10.1016/0003-9861(83)90383-1; HUSAIN SS, 1991, BIOCHEMISTRY-US, V30, P5797, DOI 10.1021/bi00237a024; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KIRSHENBAUM JM, 1991, AM J CARDIOL, V68, P1564, DOI 10.1016/0002-9149(91)90310-H; KOPPERT PW, 1986, BLOOD, V68, P437; KOPPERT PW, 1985, BLOOD, V66, P503; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; LIJNEN HR, 1989, BLOOD, V73, P1864; LIJNEN HR, 1986, J BIOL CHEM, V261, P1253; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MASSON C, 1988, BIOCHEM J, V256, P237, DOI 10.1042/bj2560237; NELLES L, 1987, J BIOL CHEM, V262, P5682; PANNELL R, 1986, BLOOD, V67, P1215; PANNELL R, 1987, BLOOD, V69, P22; PANNELL R, 1990, THROMB HAEMOSTASIS, V64, P556; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PONTING CP, 1992, BIOCHIM BIOPHYS ACTA, V1159, P155, DOI 10.1016/0167-4838(92)90020-E; SCULLY MF, 1991, BRIT J HAEMATOL, V79, P537, DOI 10.1111/j.1365-2141.1991.tb08078.x; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; TISSOT JD, 1982, J CLIN INVEST, V70, P1320, DOI 10.1172/JCI110733; TRANQUI L, 1979, BIOL CELLULAIRE, V34, P39; VANDEWERF F, 1986, ANN INTERN MED, V104, P345, DOI 10.7326/0003-4819-104-3-345; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; WALLEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P122, DOI 10.1016/0005-2795(72)90261-9; WIMAN B, 1973, EUR J BIOCHEM, V36, P25, DOI 10.1111/j.1432-1033.1973.tb02880.x; WUN TC, 1982, J BIOL CHEM, V257, P3276; ZAMARRON C, 1984, THROMB HAEMOSTASIS, V52, P19; 1989, LANCET, P863	52	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18554	18559						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103046				2022-12-25	WOS:A1993LV65900030
J	SEGATTO, O; PELICCI, G; GIULI, S; DIGIESI, G; DIFIORE, PP; MCGLADE, J; PAWSON, T; PELICCI, PG				SEGATTO, O; PELICCI, G; GIULI, S; DIGIESI, G; DIFIORE, PP; MCGLADE, J; PAWSON, T; PELICCI, PG			SHC PRODUCTS ARE SUBSTRATES OF ERBB-2 KINASE	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; AUTOPHOSPHORYLATION SITES; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; EGF RECEPTOR; NEU ONCOGENE; HUMAN-BREAST; PROTEIN; PHOSPHORYLATION	The shc gene encodes three widely expressed proteins of 46, 52 and 66 kDa. Overexpression of p46shc and p52shc in NIH3T3 fibroblasts induces a tumorigenic phenotype. Shc products are phosphorylated on tyrosine by the activated epidermal growth factor receptor (EGFR) and become physically associated with EGFR via their SH2 domain. Thus Shc oncoproteins may play a role in mitogenic signal transduction. Here we report that Shc products are substrates also of the erbB-2 kinase and form complexes with the erbB-2 product in intact cells. In vitro, the bacterially expressed Shc SH2 domain is sufficient to reconstitute the high affinity Shc/erbB-2 interaction. The erbB-2 region required for Shc binding was narrowed down to the most COOH-terminal 179 residues of gp185erbB-2; within this region, phosphorylation of one or more of the erbB-2 autophosphorylation sites is required for Shc/gp185erbB-2 complex formation as well as optimal phosphorylation of Shc products by the erbB-2 kinase. Thus, Shc proteins may play a role in signal transduction by gp185erbB-2.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED 1, I-06100 PERUGIA, ITALY	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Perugia	SEGATTO, O (corresponding author), IST REGINA ELENA, CTR RIC SPERIMENTALE, IMMUNOL LAB, VIA MESSI ORO 156, I-00158 ROME, ITALY.		Pawson, Tony J/E-4578-2013; Pelicci, Giuliana/AAA-8921-2022; Di Fiore, Pier Paolo/K-2130-2012; Pelicci, Pier Giuseppe/AAL-6572-2020	Pelicci, Giuliana/0000-0003-0986-8255; Di Fiore, Pier Paolo/0000-0002-2252-0950; Segatto, Oreste/0000-0003-2561-1142				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JANCHILL JL, 1969, J VIROL, V4, P549; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOCH CA, 1991, SCIENCE, V252, P669; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHAVASHAIO H, 1989, EMBO J, V8, P159; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1992, ONCOGENE, V7, P1339; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	45	130	133	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2105	2112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8101647				2022-12-25	WOS:A1993LP17100010
J	WEGLOHNER, W; SUBRAMANIAN, AR				WEGLOHNER, W; SUBRAMANIAN, AR			MULTICOPY GTPASE CENTER PROTEIN L12 OF ARABIDOPSIS CHLOROPLAST RIBOSOME IS ENCODED BY A CLUSTERED NUCLEAR GENE FAMILY WITH THE EXPRESSED MEMBERS CLOSELY LINKED TO TRNA(PRO) GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; CDNA CLONES; SEQUENCE; SPINACH; HOMOLOGY; TRANSIT; CLONING; PLANT; RNA	A conserved architectural feature of ribosomes is a protuberance (the stalk) in the large subunit, essential for ribosomal interactions with translational factors and GTP hydrolysis and generated by two dimers of L12, the only multicopy protein in ribosomes. In higher plants, the rpl12 gene for chloroplast L12 is located in the nucleus. We report here the cloning and sequencing of this nuclear gene from Arabidopsis thaliana, revealing the first gene family for a chloroplast ribosomal protein (RP). A single cluster/haploid genome of three rpl12 genes is located in the sequenced 9.1-kilobase region of the Arabidopsis genome. Two of the rpl12 genes encode identical mature proteins, and the third encodes a 25% divergent RP, although the chloroplast-targeting transit peptide in each is distinct. The rpl12 genes encoding identical RPs are closely linked at their 5' ends to identical cytosolic tRNA(Pro) genes with a <250-base pair spacer. Reverse transcriptase polymerase chain reaction experiments with total RNA isolated from Arabidopsis (and characterization of several L12 cDNA clones) show that only the tRNA-linked rpl12 genes are expressed. We also show (by polymerase chain reaction experiments with isolated total DNA) that this tRNA(Pro) rpl12 gene linkage is conserved in spinach (inferred to contain a single gene copy) indicating its importance. The previously described enhanced translation of spinach L12 mRNA from its two tandem AUG codons and the two functional rpl12 genes in Arabidopsis probably provide two mechanisms for generating the four copies of L12/chloroplast ribosome, qualitatively different from those attempted in eubacteria.	MAX PLANCK INST MOLEC GENET,D-14195 BERLIN,GERMANY	Max Planck Society								Ausubel FM., 2006, ENZYMATIC MANIPULATI; AXELOS M, 1989, MOL GEN GENET, V219, P106, DOI 10.1007/BF00261164; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BARTSCH M, 1982, P NATL ACAD SCI-BIOL, V79, P6871, DOI 10.1073/pnas.79.22.6871; BISANZSEYER C, 1992, PLANT MOL BIOL, V18, P337, DOI 10.1007/BF00034960; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; DOWNING WL, 1987, J MOL BIOL, V194, P609, DOI 10.1016/0022-2836(87)90238-5; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; ELHAG GA, 1992, NUCLEIC ACIDS RES, V20, P689, DOI 10.1093/nar/20.4.689; FRANZETTI B, 1992, NUCLEIC ACIDS RES, V20, P4153, DOI 10.1093/nar/20.16.4153; GANTT JS, 1991, EMBO J, V10, P3073, DOI 10.1002/j.1460-2075.1991.tb07859.x; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GIESE K, 1990, BIOCHEMISTRY-US, V29, P10562, DOI 10.1021/bi00498a020; GIESE K, 1989, BIOCHEMISTRY-US, V28, P3525, DOI 10.1021/bi00434a056; GIESE K, 1990, THESIS FREE U BERLIN; GREEN GA, 1989, PLANT MOL BIOL, V13, P727, DOI 10.1007/BF00016029; Hallick RB, 1983, PLANT MOL BIOL REPOR, V1, P38, DOI [10.1007/BF02712675, DOI 10.1007/BF02712675]; HEIN J, 1989, MOL BIOL EVOL, V6, P649; HEIN J, 1989, MOL BIOL EVOL, V6, P669; ITOH T, 1978, FEBS LETT, V96, P392, DOI 10.1016/0014-5793(78)80445-1; KANG HA, 1992, MOL GEN GENET, V233, P487, DOI 10.1007/BF00265449; KEEGSTRA K, 1988, BIOESSAYS, V9, P15, DOI 10.1002/bies.950090105; LAGRANGE T, 1993, MOL CELL BIOL, V13, P2614, DOI 10.1128/MCB.13.4.2614; LARKIN JC, 1989, GENE DEV, V3, P500, DOI 10.1101/gad.3.4.500; LEIJONMARCK M, 1984, BIOCHEM INT, V8, P69; LI YQ, 1992, FEBS LETT, V300, P199, DOI 10.1016/0014-5793(92)80845-8; Liljas A, 1986, STRUCTURE FUNCTION G, P379; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MACHE R, 1991, TRANSLATIONAL APPARA; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MARQUIS D, 1978, J MOL BIOL, V119, P557, DOI 10.1016/0022-2836(78)90202-4; MARTINGALLARDO A, 1992, NAT GENET, V1, P34, DOI 10.1038/ng0492-34; Meyerowitz E. M., 1992, Methods in Arabidopsis research., P100; Moller W., 1986, STRUCTURE FUNCTION G, P309; MONK RJ, 1981, CELL, V24, P301, DOI 10.1016/0092-8674(81)90319-6; REMACHA M, 1990, CURR GENET, V17, P535, DOI 10.1007/BF00313084; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT J, 1993, J BIOL CHEM, V268, P27447; SCHMIDT J, 1993, NUCLEIC ACIDS RES, V21, P2519, DOI 10.1093/nar/21.10.2519; SCHMIDT J, 1993, TRANSLATIONAL APPARATUS, P555; SCHMIDT M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P349, DOI 10.1016/0167-4781(93)90230-B; SIBOLD C, 1990, BIOCHIM BIOPHYS ACTA, V1050, P61, DOI 10.1016/0167-4781(90)90142-O; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; SMOOKER PM, 1990, J BIOL CHEM, V265, P16699; STEWARD KL, 1991, J MOL BIOL, V218, P23, DOI 10.1016/0022-2836(91)90870-C; Stewart WN., 1983, PALEOBOTANY EVOLUTIO; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; SUBRAMANIAN AR, 1993, TRENDS BIOCHEM SCI, V18, P177, DOI 10.1016/0968-0004(93)90110-9; SUBRAMANIAN AR, 1991, TRANSLATIONAL APPARA, P95; SUGIURA M, 1992, PLANT MOL BIOL, V19, P149, DOI 10.1007/BF00015612; TERHORST C, 1973, EUR J BIOCHEM, V34, P138, DOI 10.1111/j.1432-1033.1973.tb02740.x; THOMPSON MD, 1992, PLANT MOL BIOL, V18, P931, DOI 10.1007/BF00019207; WITTMANN HG, 1983, ANNU REV BIOCHEM, V52, P35, DOI 10.1146/annurev.bi.52.070183.000343; WOOL IG, 1990, RIBOSOME, P203; ZHOU DX, 1992, J BIOL CHEM, V267, P23515	55	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7330	7336						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125949				2022-12-25	WOS:A1994NA03200048
J	ZAK, O; TRINDER, D; AISEN, P				ZAK, O; TRINDER, D; AISEN, P			PRIMARY RECEPTOR-RECOGNITION SITE OF HUMAN TRANSFERRIN IS IN THE C-TERMINAL LOBE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM TRANSFERRIN; EMBRYO RED-CELLS; IRON RELEASE; CHICK RETICULOCYTES; HUMAN LACTOFERRIN; RAT TRANSFERRIN; HALF-MOLECULES; BINDING SITES; OVOTRANSFERRIN; FRAGMENTS	The role of the transferrin receptor in capturing and conveying transferrin through the cell during the iron-donating cycle of receptor-mediated endocytosis has been studied extensively. Nevertheless, almost nothing is known of how human transferrin binds to its receptor. In an initial approach toward delineating the receptor-recognition site(s) of human transferrin, we have studied the interactions of proteolytically-cleaved, single-sited fragments of transferrin, representing the N- and C-lobes of the molecule respectively, with cells expressing the transferrin receptor on their plasma membranes. Only the C-fragment was found capable of donating iron to hepatoma-derived HuH-7 cells or of binding to surface receptors of HuH-7 and leukemic K562 cells. Although no association of N- and C-fragments could be demonstrated by gel chromatography, the presence of excess N-fragment strengthened the binding of C-fragment by an order of magnitude. An explanation of these observations is that the primary receptor recognition site of human transferrin is on the C-lobe of the protein, but that prior binding of this lobe to receptor enables the N-lobe to respond to receptor as well, either directly or by interaction with the bound C-lobe.	ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NIDDK NIH HHS [DK15056, DK37927] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015056, R01DK037927] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AISEN P, 1968, BIOCHEM BIOPH RES CO, V32, P220, DOI 10.1016/0006-291X(68)90372-0; AISEN P, 1989, IRON CARRIERS IRON P, P353; ALCANTARA J, 1993, MOL MICROBIOL, V8, P1135, DOI 10.1111/j.1365-2958.1993.tb01658.x; ANDERSON BF, 1987, P NATL ACAD SCI USA, V84, P1769, DOI 10.1073/pnas.84.7.1769; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BALI PK, 1992, BIOCHEMISTRY-US, V31, P3963, DOI 10.1021/bi00131a011; BROWNMASON A, 1987, BIOCHEM J, V245, P103, DOI 10.1042/bj2450103; BROWNMASON A, 1984, J BIOL CHEM, V259, P1866; DAY CL, 1992, J BIOL CHEM, V267, P13857; EGAN TJ, 1993, BIOCHEMISTRY-US, V32, P8162, DOI 10.1021/bi00083a016; ESPARZA I, 1980, BIOCHIM BIOPHYS ACTA, V624, P479, DOI 10.1016/0005-2795(80)90089-6; FEENEY RE, 1966, STRUCT BOND, V1, P149; GARRICK MD, 1993, J BIOL CHEM, V268, P14867; Harris D., 1989, IRON CARRIERS IRON P, P239; HEMMAPLARDH D, 1976, INT J APPL RADIAT IS, V27, P89, DOI 10.1016/0020-708X(76)90182-4; JAMROZ RC, 1993, P NATL ACAD SCI USA, V90, P1320, DOI 10.1073/pnas.90.4.1320; KEUNG WM, 1982, J BIOL CHEM, V257, P1184; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KLOTZ IM, 1971, BIOCHEMISTRY-US, V10, P3065, DOI 10.1021/bi00792a013; KUHN LC, 1989, SCHWEIZ MED WSCHR, V119, P1319; LINEBACKZINS J, 1980, J BIOL CHEM, V255, P708; MACGILLIVRAY RTA, 1983, J BIOL CHEM, V258, P3543; MASON AB, 1993, BIOCHEMISTRY-US, V32, P5472, DOI 10.1021/bi00071a025; MASON AB, 1987, J BIOL CHEM, V262, P9011; MASON AB, 1987, BIOCHEM J, V247, P417, DOI 10.1042/bj2470417; OE H, 1988, J BIOCHEM-TOKYO, V103, P1066, DOI 10.1093/oxfordjournals.jbchem.a122381; ORATORE A, 1989, BIOCHEM J, V257, P301, DOI 10.1042/bj2570301; PARK I, 1985, P NATL ACAD SCI USA, V82, P3149, DOI 10.1073/pnas.82.10.3149; SASAKI K, 1993, AM J HEMATOL, V42, P74, DOI 10.1002/ajh.2830420115; SIPE DM, 1991, J BIOL CHEM, V266, P8002; TRINDER D, 1988, BIOCHIM BIOPHYS ACTA, V943, P440, DOI 10.1016/0005-2736(88)90375-6; YOUNG SP, 1982, BIOCHIM BIOPHYS ACTA, V718, P35, DOI 10.1016/0304-4165(82)90006-X; ZAK O, 1990, BIOCHIM BIOPHYS ACTA, V1052, P24, DOI 10.1016/0167-4889(90)90052-F; ZAK O, 1983, BIOCHIM BIOPHYS ACTA, V742, P490, DOI 10.1016/0167-4838(83)90266-2; ZAK O, 1985, BIOCHIM BIOPHYS ACTA, V829, P348, DOI 10.1016/0167-4838(85)90243-2; ZAPOLSKI EJ, 1976, BIOCHIM BIOPHYS ACTA, V421, P80, DOI 10.1016/0304-4165(76)90171-9	40	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7110	7114						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125919				2022-12-25	WOS:A1994NA03200014
J	CAIRO, G; PIETRANGELO, A				CAIRO, G; PIETRANGELO, A			TRANSFERRIN RECEPTOR GENE-EXPRESSION DURING RAT-LIVER REGENERATION - EVIDENCE FOR POSTTRANSCRIPTIONAL REGULATION BY IRON REGULATORY FACTOR(B), A 2ND IRON-RESPONSIVE ELEMENT-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; CELL-GROWTH; DIFFERENTIAL REGULATION; HEAVY-SUBUNIT; LIGHT-SUBUNIT; FERRITIN; SEQUENCE; PROMOTER; INVITRO	Transferrin receptor (TfR) expression is regulated by iron at the level of mRNA stability through a factor (IRF/ IRE-BP) which binds to specific iron-responsive elements (IRE). On the other hand, growth-dependent regulation of TfR expression is generally believed to be transcriptionally controlled. We analyzed the molecular mechanisms that control TfR gene expression at the onset of cell proliferation in vivo during liver regeneration after partial hepatectomy. The amount of TfR mRNA increased considerably after partial hepatectomy while run-on assays did not show significant changes in TfR gene transcription. RNA band-shift assays documented a significant activation of IRF/IRE-BP specific for the faster migrating IRE-protein complex (IRF(B)). These changes occurred in the absence of modifications of total liver iron concentration but together with a significant decrease of ferritin content. Moreover, when extreme variations of liver iron content were achieved by either chronic iron overload or severe iron deficiency, liver regeneration was unable to influence IRE-binding activity. We conclude that IRF/IRE-BP-mediated post-transcriptional control can fully account for TfR mRNA induction during liver cell proliferation in vivo. IRF/ IRE-RE activation in the absence of changes in total tissue iron content might depend either on a drop of iron levels into the regulatory pool or on a relatively iron-independent mechanism specific for the faster migrating complex.	UNIV MODENA,MED GEN & TERAPIA MED CLIN 3,MODENA,ITALY	Universita di Modena e Reggio Emilia	CAIRO, G (corresponding author), UNIV MILAN,IST PATOL GEN,CNR,CTR PATOL CELLULARE,VIA MANGIAGALLI 31,I-20133 MILAN,ITALY.		Pietrangelo, Antonello/K-1517-2016; Cairo, Gaetano/M-5104-2016	Pietrangelo, Antonello/0000-0002-7411-935X; Cairo, Gaetano/0000-0002-8147-4720				BEARD P, 1991, NUCLEIC ACIDS RES, V19, P7117, DOI 10.1093/nar/19.25.7117; BRIDGES KR, 1987, J BIOL CHEM, V262, P14773; CAIRO G, 1993, EXP CELL RES, V206, P255, DOI 10.1006/excr.1993.1145; CAIRO G, 1989, BIOCHEM J, V264, P925, DOI 10.1042/bj2640925; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHAN LNL, 1992, J BIOL CHEM, V267, P8254; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; FRIEDMAN JM, 1984, J MOL BIOL, V179, P37, DOI 10.1016/0022-2836(84)90305-X; GUO B, 1993, FASEB J, V7, pA1084; HARFORD JB, 1991, INTRACELLULAR TRAFFI, P302; HENDERSON BC, 1993, IN PRESS J BIOL CHEM, V268; HIGGINS GM, 1931, ARCH PATHOL, V12, P281; HIROSEKUMAGAI A, 1989, BIOCHEM BIOPH RES CO, V164, P1105, DOI 10.1016/0006-291X(89)91783-X; HIROSEKUMAGAI A, 1984, INT J BIOCHEM, V16, P601; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kuhn L., 1990, IRON TRANSPORT STORA, P149; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; KUHN LC, 1991, BRIT J HAEMATOL, V79, P1, DOI 10.1111/j.1365-2141.1991.tb07998.x; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1984, J BIOL CHEM, V259, P4327; LESLEY JF, 1985, MOL CELL BIOL, V5, P1814, DOI 10.1128/MCB.5.8.1814; MAKINO R, 1984, NATURE, V310, P687; MAKINO Y, 1983, STRUCTURE FUNCTION I, P367; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MISKIMINS WK, 1986, J CELL BIOL, V103, P1781, DOI 10.1083/jcb.103.5.1781; MISKIMINS WK, 1990, IRON TRANSPORT STORA, P119; MORELLO D, 1990, ONCOGENE, V5, P1511; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NECKERS LM, 1991, PATHOBIOLOGY, V59, P11, DOI 10.1159/000163610; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; SARGENT TD, 1981, P NATL ACAD SCI-BIOL, V78, P243, DOI 10.1073/pnas.78.1.243; SCHIAFFONATI L, 1990, J CELL PHYSIOL, V143, P79, DOI 10.1002/jcp.1041430110; SEISER C, 1993, J BIOL CHEM, V268, P13074; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEARNE PA, 1985, J IMMUNOL, V134, P3474; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; TESTA U, 1991, J BIOL CHEM, V266, P13925; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TROWBRIDGE IS, 1982, P NATL ACAD SCI-BIOL, V79, P1175, DOI 10.1073/pnas.79.4.1175; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485	45	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6405	6409						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119990				2022-12-25	WOS:A1994MZ50300025
J	DUCHE, D; PARKER, MW; GONZALEZMANAS, JM; PATTUS, F; BATY, D				DUCHE, D; PARKER, MW; GONZALEZMANAS, JM; PATTUS, F; BATY, D			UNCOUPLED STEPS OF THE COLICIN-A PORE FORMATION DEMONSTRATED BY DISULFIDE BOND ENGINEERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-DEPENDENT CHANNEL; SITE-DIRECTED MUTAGENESIS; PLANAR LIPID BILAYERS; MEMBRANE-INSERTION; FORMING DOMAIN; ESCHERICHIA-COLI; PROTEIN STABILITY; SENSORY RECEPTOR; ION SELECTIVITY; CROSS-LINKING	Four disulfide bonds were engineered into the pore-forming domain of colicin A to probe the conformational changes associated with its membrane insertion and channel formation. The soluble pore-forming domain consists of 10 alpha-helices with two outer layers (helices 1, 2, and 3-7, respectively) sandwiching a middle layer of three helices (8-10). Helices 8 and 9 form a hairpin which is completely buried and consists of hydrophobic and neutral residues only. This helical hairpin has been hypothesized to be the membrane anchor. Each double-cysteine mutant possessing an individual disulfide bond, cross-linking either helices 1 to 9 (H1/H9), 5 to 6 (H5/H6), 7 to 8 (H7/H8), or 9 to 10 (H9/H10), respectively, is unable to promote K+ efflux from sensitive Escherichia coli cells. Activity can be restored by addition of a reducing agent. In vitro studies with brominated lipid vesicles and planar lipid bilayers show that the disulfide bond which connects the helices 1 to 9 prevents colicin A membrane insertion, whereas the other disulfide bond mutants insert readily into lipid vesicles. All of the engineered bridges prevented the formation of a conducting channel in the presence of a membrane potential. This novel approach indicates that membrane insertion and channel formation are two separate steps. Moreover, the effects of the distance constraints introduced by the different disulfide bonds on colicin A activity indicate that the helical pair 1 and 2 moves away from the other helices upon membrane insertion, Helices 3-10 remain associated together. As a consequence, the results imply that the helical hairpin lies parallel to the membrane surface. In contrast, induction of the colicin channel by the membrane potential requires a profound reorganization of the helices association. These results are discussed in light of several proposed models of the membrane-bound colicin and channel structures.	CTR BIOCHEM & BIOL MOLEC,INGN & DYNAM SYST MEMBRANAIRES LAB,F-13402 MARSEILLE 20,FRANCE; ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	St. Vincent's Institute of Medical Research; European Molecular Biology Laboratory (EMBL)			Parker, Michael W/F-9069-2013	Parker, Michael W/0000-0002-3101-1138; GONZALEZ MANAS, JUAN MANUEL/0000-0002-1833-6982; Duche, Denis/0000-0002-4208-6661; Baty, Daniel/0000-0001-8443-4444	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; BATY D, 1987, P NATL ACAD SCI USA, V84, P1152, DOI 10.1073/pnas.84.5.1152; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; BULLOCK JO, 1992, J MEMBRANE BIOL, V128, P1; COLLARINI M, 1987, EUR BIOPHYS J BIOPHY, V14, P147, DOI 10.1007/BF00253839; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; GELI V, 1992, BIOCHEMISTRY-US, V31, P11089, DOI 10.1021/bi00160a019; GONZALEZMANAS JM, 1993, EUR J BIOCHEM, V211, P625, DOI 10.1111/j.1432-1033.1993.tb17590.x; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; JACOBSON BL, 1991, J BIOL CHEM, V266, P5220; JAKES KS, 1990, J BIOL CHEM, V265, P6984; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LAKEY JH, 1992, FEBS LETT, V307, P26, DOI 10.1016/0014-5793(92)80895-N; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LLOUBES R, 1986, NUCLEIC ACIDS RES, V14, P2621, DOI 10.1093/nar/14.6.2621; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MARTINEZ MC, 1983, EMBO J, V2, P1501, DOI 10.1002/j.1460-2075.1983.tb01614.x; MASSOTTE D, 1991, COLICINE A INSERTION; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; MITCHINSON C, 1989, BIOCHEMISTRY-US, V28, P4807, DOI 10.1021/bi00437a043; NISHIKAWA S, 1990, PROTEIN ENG, V3, P443, DOI 10.1093/protein/3.5.443; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; Pattus F., 1983, PHYSICAL CHEM TRANSM, P407; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; RAYMOND L, 1986, J MEMBRANE BIOL, V92, P255, DOI 10.1007/BF01869394; SCHEIN SJ, 1978, NATURE, V276, P159, DOI 10.1038/276159a0; SCHINDLER H, 1976, BIOPHYS J, V16, P1109, DOI 10.1016/S0006-3495(76)85759-1; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; SLATIN SL, 1986, J MEMBRANE BIOL, V92, P247, DOI 10.1007/BF01869393; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VILLAFRANCA JE, 1983, SCIENCE, V222, P782, DOI 10.1126/science.6356360; WETZEL R, 1988, P NATL ACAD SCI USA, V85, P401, DOI 10.1073/pnas.85.2.401; WILMSEN HU, 1990, EUR BIOPHYS J, V18, P149, DOI 10.1007/BF02427374; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215	47	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6332	6339						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119982				2022-12-25	WOS:A1994MZ50300015
J	HARE, JF; HOLOCHER, A				HARE, JF; HOLOCHER, A			SOLUBILITY IN NONIONIC DETERGENTS DISTINGUISHES BETWEEN SLOWLY AND RAPIDLY DEGRADED PLASMA-MEMBRANE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE PHOTOBLEACHING RECOVERY; LATERAL MOBILITY; ANCHORED PROTEINS; CELL-SURFACE; SKELETON; DEGRADATION; ENDOCYTOSIS; RECEPTOR; CYTOSKELETON; MECHANISMS	Four cell surface-exposed, integral membrane proteins from H4-II-E-3 hepatoma monolayer cultures, derivatized by the membrane-impermeant reagent sulfosuccinimidyl 2-(biotin-amido)ethyl-1,3-dithioproprionate, were resistant to extraction with Triton X-100 at 0 degrees C. Thirty-three other similarly derivatized proteins were solubilized under these same conditions. Antisera were prepared that reacted only with Triton X-100-insoluble proteins. All four Triton X-100-insoluble proteins precipitated with the antibody were slowly degraded (t(1/2) > 100 h). By contrast, all but four Triton X-100-soluble proteins were rapidly degraded (t(1/2) = 24 h). The detergent-insoluble proteins did not possess glycosylphosphatidylinositol anchors nor were they solubilized by Triton X-100 after disruption of the cytoskeleton. In addition, they were insoluble in Triton X-100 in isolated membrane preparations but soluble when isolated on streptavidin-agarose and removed from other membrane proteins. We conclude that protein-protein interactions within the membrane itself result in insolubility in non-ionic detergents for a small cohort of plasma membrane proteins and that this may be directly related to the increased metabolic stability for this class of proteins.			HARE, JF (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201, USA.							ALEXANDER RR, 1985, BASIC BIOCH METHODS, P117; APGAR JR, 1985, J CELL BIOL, V100, P1369, DOI 10.1083/jcb.100.5.1369; ASH JF, 1977, P NATL ACAD SCI USA, V74, P5584, DOI 10.1073/pnas.74.12.5584; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cabral F, 1979, Methods Enzymol, V56, P602; CHANG CH, 1981, J BIOCHEM-TOKYO, V90, P997, DOI 10.1093/oxfordjournals.jbchem.a133586; DELBECCO R, 1954, J EXP MED, V99, P167; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DOERING TL, 1990, J BIOL CHEM, V265; FABER JL, 1981, ARCH BIOCHEM BIOPHYS, V211, P312; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; GOLAN DE, 1980, P NATL ACAD SCI-BIOL, V77, P2537, DOI 10.1073/pnas.77.5.2537; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; HARE JF, 1985, EXP CELL RES, V161, P331, DOI 10.1016/0014-4827(85)90090-4; HARE JF, 1991, P NATL ACAD SCI USA, V88, P5902, DOI 10.1073/pnas.88.13.5902; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; JEMMERSON R, 1987, BIOCHEMISTRY-US, V26, P5703, DOI 10.1021/bi00392a019; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MAIZEL JV, 1969, FUNDAMENTAL TECHNIQU, P334; MAO SY, 1992, P NATL ACAD SCI USA, V89, P222, DOI 10.1073/pnas.89.1.222; MEIRI KF, 1990, J NEUROSCI, V10, P256; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; PETELL JK, 1987, LYSOSOMES THEIR ROLE, P519; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; SHEETZ MP, 1980, NATURE, V285, P510, DOI 10.1038/285510a0; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATTS C, 1992, J CELL SCI, V103, P1; WIEGANT FAC, 1988, J CELL BIOL, V103, P387; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308; ZAMBETTI G, 1990, EXP CELL RES, V191, P246, DOI 10.1016/0014-4827(90)90011-X	38	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5981	5988						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119944				2022-12-25	WOS:A1994MY84000078
J	KOBAYASHI, T; TAO, T; GERGELY, J; COLLINS, JH				KOBAYASHI, T; TAO, T; GERGELY, J; COLLINS, JH			STRUCTURE OF THE TROPONIN COMPLEX - IMPLICATIONS OF PHOTOCROSS-LINKING OF TROPONIN-I TO TROPONIN-C THIOL MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; NUCLEAR-MAGNETIC-RESONANCE; CALCIUM-BINDING SITES; X-RAY-SCATTERING; INHIBITORY REGION; PROTEOLYTIC FRAGMENTS; REGULATORY DOMAIN; PEPTIDE COMPLEX; CROSS-LINKING; CALMODULIN	Ca2+ regulation of vertebrate-striated muscle contraction is initiated by conformational changes in the Ca2+-binding protein troponin C (TnC) and subsequent changes in the interaction of TnC with the inhibitory protein TnI. We have constructed mutants of rabbit skeletal muscle TnC in which natural Cys-98 was replaced by Leu, and a single Cys residue was introduced at position 12 (TnC12) or 89 (TnC89). Cys residues of mutant TnCs were derivatized with 4-maleimidobenzophenone and photocross-linked to TnI in binary TnC.TnI complexes. After digestion with CNBr or proteases, crosslinked peptides were purified and sequenced. TnC12 cross-linked at or near TnI Met-134 in a region known to be sensitive not only to occupancy of the regulatory Ca2+-binding sites of TnC but also to the contractile state of the thin filament. TnC89 cross-linked to TnI(108-113) in the inhibitory region. Taken together with earlier findings, these results indicate that in the Tnc TnI complex, both domains of TnC, as well as the linker region between them, make contact with the inhibitory region of TnI. Our data also indicate that the N- and C-terminal domains of TnC interact with opposite ends of the TnI inhibitory region.	UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA; UNIV MARYLAND, CTR MED BIOTECHNOL, INST BIOTECHNOL, BALTIMORE, MD 21201 USA; BOSTON BIOMED RES INST, DEPT MUSCLE RES, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, NEUROL SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL005949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR021673, R37AR021673] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL05949] Funding Source: Medline; NIAMS NIH HHS [AR-21673] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CHEN Q, 1988, FEBS LETT, V228, P22, DOI 10.1016/0014-5793(88)80576-3; CHEUNG HC, 1989, BIOPHYS J, V55; CHONG PCS, 1982, J BIOL CHEM, V257, P2549; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; COLLINS JH, 1973, FEBS LETT, V36, P268, DOI 10.1016/0014-5793(73)80388-6; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FUJISAWA T, 1987, J APPL CRYSTALLOGR, V20, P349, DOI 10.1107/S0021889887086497; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GREASER ML, 1973, J BIOL CHEM, V248, P2125; GREENE LE, 1986, J BIOL CHEM, V261, P1279; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KATAYAMA E, 1982, J BIOCHEM-TOKYO, V91, P1449, DOI 10.1093/oxfordjournals.jbchem.a133835; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NOZAKI S, 1980, CHEM LETT, P345, DOI 10.1246/cl.1980.345; OGAWA Y, 1985, J BIOCHEM-TOKYO, V97, P1011, DOI 10.1093/oxfordjournals.jbchem.a135143; OHTUSKI I, 1986, ADV PROTEIN CHEM, V38, P1; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SIN IL, 1978, BIOCHEM BIOPH RES CO, V82, P1132, DOI 10.1016/0006-291X(78)90304-2; SLUPSKY CM, 1992, PROTEIN SCI, V1, P1595, DOI 10.1002/pro.5560011207; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017	39	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5725	5729						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119911				2022-12-25	WOS:A1994MY84000040
J	NAKAMURA, S; SAKURAI, T; NONOMURA, Y				NAKAMURA, S; SAKURAI, T; NONOMURA, Y			DIFFERENTIAL EXPRESSION OF BOVINE ADSEVERIN IN ADRENAL-GLAND REVEALED BY IN-SITU HYBRIDIZATION - CLONING OF A CDNA FOR ADSEVERIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT-SEVERING PROTEIN; ACTIN-BINDING PROTEINS; CHROMAFFIN CELLS; 74-KDA PROTEIN; GELSOLIN; SEQUENCE; DOMAIN; VILLIN; IDENTIFICATION; TRANSFORMATION	Adseverin is a Ca2+-dependent actin filament-severing protein that is presumed to have a regulatory function in exocytosis by affecting the organization of the microfilament network underneath the plasma membrane. As the first step to investigate whether adseverin has the expected function in vivo, we have cloned a cDNA for bovine adseverin. Analysis of the nucleotide sequence revealed the following points. 1) Adseverin consisted of 715 amino acid residues, and its predicted molecular mass was 80.5 kDa. 2) Adseverin belonged to the gelsolin family of proteins, which consists of six homologous segments. 3) Adseverin had two putative polyphosphoinositide binding sequences, very similar to but distinct from those in gelsolin. Adseverin was produced in Escherichia coli and purified to homogeneity. The adseverin reacted with adseverin-specific antibody and showed Ca2+-dependent actin filament severing activity like authentic adseverin. In situ hybridization demonstrated that adseverin mRNA was differentially expressed in the bovine adrenal gland; it was expressed in the adrenal medulla but not in most parts of the adrenal cortex, although both have a secretory function. The observation strongly suggested that adseverin is not involved in secretory processes in general but is specifically involved in exocytosis.	UNIV TOKYO, FAC MED, DEPT PHARMACOL, TOKYO 113, JAPAN	University of Tokyo								ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; BURGOYNE RD, 1984, BIOCHIM BIOPHYS ACTA, V779, P201, DOI 10.1016/0304-4157(84)90009-1; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CLACKSON T, 1902, PCR PRACTICAL APPROA, P187; DELCASTILLO AR, 1990, EMBO J, V9, P43, DOI 10.1002/j.1460-2075.1990.tb08078.x; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KNIGHT DE, 1987, ANN NY ACAD SCI, V493, P504, DOI 10.1111/j.1749-6632.1987.tb27237.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; MADIN SH, 1958, P SOC EXP BIOL MED, V98, P574, DOI 10.3181/00379727-98-24111; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; SAKURAI T, 1990, NEUROSCIENCE, V38, P743, DOI 10.1016/0306-4522(90)90067-E; SAKURAI T, 1991, J BIOL CHEM, V266, P15979; SAKURAI T, 1991, J BIOL CHEM, V266, P4581; SAKURAI T, 1981, BIOMED RES S2, V12, P179; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YU FX, 1992, J BIOL CHEM, V267, P14616; [No title captured]	34	16	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5890	5896						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119933				2022-12-25	WOS:A1994MY84000064
J	CHERNIACK, AD; KLARLUND, JK; CZECH, MP				CHERNIACK, AD; KLARLUND, JK; CZECH, MP			PHOSPHORYLATION OF THE RAS NUCLEOTIDE EXCHANGE FACTOR SON OF SEVENLESS BY MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; SUBSTRATE RECOGNITION; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; CDC25 GENE; MAP KINASE; TYROSINE; P21RAS	Son of sevenless-1 and -2 (Sos-1 and -2) are guanosine nucleotide exchange factors implicated in the activation of Pas by both the insulin and epidermal growth factor signal transduction pathways. Pas appears to function by initiating the activation of cellular protein kinases including mitogen-activated protein (MAP) kinases. Sos proteins contain numerous sequences in their carboxylterminal regions which correspond to consensus sites for MAP kinase phosphorylation. To examine whether these sites are substrates for MAP kinases, the cDNA encoding Drosophila Sos (dSos) was tagged with sequences encoding the major antigenic epitope of the influenza virus hemagglutinin (HA) to create a dSosHA fusion construct. dSosHA was transiently expressed in COS-1 cells and immunoprecipitated with anti-HA antibodies. When immune complexes were incubated with purified MAP kinase and [gamma-P-32]ATP, a phosphorylated band of 180 kDa was observed when analyzed by SDS-polyacrylamide gel electrophoresis. This band was not present in immunoprecipitations from cells transfected with vector alone. No phosphorylation of the 180 kDa band was seen when immunoprecipitates were incubated with [gamma(32)P]ATP in the absence of MAP kinase. Two dimensional analysis of tryptic peptides from dSosHA phosphorylated by MAP kinase in vitro revealed two major phosphorylated species that were also found in dSosHA isolated from COS-1 cells labeled with P-32(i). These results are consistent with the hypothesis that a feedback loop exits wherein growth factor-activated MAP kinases phosphorylate and regulate Sos proteins.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	CHERNIACK, AD (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.		Cherniack, Andrew D./AAY-8132-2020	Cherniack, Andrew D./0000-0003-0470-0111	NIDDK NIH HHS [DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LINLING L, 1993, CELL, V72, P269; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SETH A, 1992, J BIOL CHEM, V267, P24796; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THOMAS SM, 1992, CELL, V68, P1032; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	46	82	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4717	4720						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106439				2022-12-25	WOS:A1994MX57100007
J	LOKUTA, AJ; COOPER, C; GAA, ST; WANG, HE; ROGERS, TB				LOKUTA, AJ; COOPER, C; GAA, ST; WANG, HE; ROGERS, TB			ANGIOTENSIN-II STIMULATES THE RELEASE OF PHOSPHOLIPID-DERIVED 2ND MESSENGERS THROUGH MULTIPLE RECEPTOR SUBTYPES IN HEART-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC-FREE CALCIUM; PROTEIN-KINASE-C; ARACHIDONIC-ACID; RAT-HEART; PITUITARY-CELLS; HUMAN-LUNG; MYOCYTES; ACTIVATE; IDENTIFICATION; BIOSYNTHESIS	The octapeptide angiotensin II (Ang-II) induces both acute functional changes and longer lasting molecular changes in cultured mammalian heart myocytes, yet the underlying molecular mechanisms are poorly understood. In this study, Ang-II was found to stimulate a sustained release (>30 min) of arachidonic acid (ARA) from cultured neonatal rat cardiac myocytes, with a half-maximal response observed at 0.1 nM. Mass spectroscopy analysis showed that Ang-II stimulated a specific release equivalent to 104 fmol of ARA/mu g of protein in 10 min. Only Ang-II type 1 (AT(1)) receptor-specific antagonists were potent inhibitors of hormone-evoked [H-3]inositol phosphate accumulation (DuP 753 IC50 approximate to 7 nM compared to CGP 42112A IC50 > 1 mu M). In contrast, only AT(2) receptor-specific antagonists were potent inhibitors of [H-3]ARA release (CGP 42112A IC50 approximate to 7 nM) EXP 3880 IC50 approximate to 2 nM and PD 123177 IC50 approximate to 10 nM). Further studies with phospholipase inhibitors (p-amylcinnamoylanthranilic acid and U73122) revealed that the production of [H-3]inositol phosphates and [H-3]ARA occurs through parallel and independent pathways involving phospholipase C and phospholipase Az, respectively. Ang-II also increased the level of lysophosphatidylcholine by 49%, direct evidence that this peptide activated phospholipase Az. Thus, Ang-II stimulates distinct phospholipases in parallel through AT(1) and AT(2) receptors. These results reveal coordinate signaling roles for multiple Ang-II receptor subtypes in heart.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BIOMED RES FACIL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT SURG,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NHLBI NIH HHS [HL-28138] Funding Source: Medline; NIGMS NIH HHS [GM-08414, GM-08181] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008414, T32GM008181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELLATIF MM, 1991, CIRC RES, V69, P800, DOI 10.1161/01.RES.69.3.800; ALLEN IS, 1988, CIRC RES, V62, P524, DOI 10.1161/01.RES.62.3.524; BAKER KM, 1989, J PHARMACOL EXP THER, V251, P578; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; CATT K, 1991, TRENDS PHARMACOL SCI, V12, P279, DOI 10.1016/0165-6147(91)90573-B; CHAREST R, 1985, BIOCHEM J, V227, P79, DOI 10.1042/bj2270079; CRANE JK, 1982, J BIOL CHEM, V257, P4959; DAMRON DS, 1993, CIRC RES, V72, P376, DOI 10.1161/01.RES.72.2.376; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; ENGELS W, 1990, AM J PHYSIOL, V258, pH1865, DOI 10.1152/ajpheart.1990.258.6.H1865; ERNSBERGER P, 1992, AM J PHYSIOL, V263, pF411, DOI 10.1152/ajprenal.1992.263.3.F411; FREYSSBEGUIN M, 1989, AM J PHYSIOL, V257, pH444, DOI 10.1152/ajpheart.1989.257.2.H444; GONG MC, 1992, J BIOL CHEM, V267, P21492; GROSS RW, 1992, TRENDS CARDIOVAS MED, V2, P115, DOI 10.1016/1050-1738(92)90016-L; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; HUBBARD WC, 1989, CANCER RES, V49, P826; HUBBARD WC, 1986, PROSTAGLANDINS, V32, P889, DOI 10.1016/0090-6980(86)90097-3; JASWAL N, 1991, HYPERTENSION, V17, P1115; JI H, 1991, MOL PHARMACOL, V39, P120; KEM DC, 1991, AM J PHYSIOL, V261, pC77, DOI 10.1152/ajpcell.1991.261.1.C77; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KOHOUT TA, 1993, AM J PHYSIOL, V264, pC1350, DOI 10.1152/ajpcell.1993.264.5.C1350; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KONRAD RJ, 1992, BIOCHIM BIOPHYS ACTA, V1135, P216; KOZAWA O, 1992, PROSTAG LEUKOTR ESS, V47, P215, DOI 10.1016/0952-3278(92)90242-B; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LOKUTA AJ, 1994, IN PRESS J CARDIOVAS; LONG CS, 1990, J HYPERTENS, V8, pS219; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; NAGANO M, 1992, HYPERTENSION, V19, P708, DOI 10.1161/01.HYP.19.6.708; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PONZONI M, 1992, FEBS LETT, V310, P17, DOI 10.1016/0014-5793(92)81136-A; ROGG H, 1990, BIOCHEM BIOPH RES CO, V173, P416, DOI 10.1016/S0006-291X(05)81074-5; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SANFELIU C, 1990, BRAIN RES, V526, P241, DOI 10.1016/0006-8993(90)91228-9; SCHMID PC, 1981, J LIPID RES, V22, P882; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SCOTT AL, 1992, J PHARMACOL EXP THER, V261, P931; SECHI LA, 1992, CIRC RES, V71, P1482, DOI 10.1161/01.RES.71.6.1482; SMALLRIDGE RC, 1992, ENDOCRINOLOGY, V131, P1883, DOI 10.1210/en.131.4.1883; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; TAKUWA N, 1991, J BIOL CHEM, V266, P14237; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TIMMERMANS PBMWM, 1992, AM J HYPERTENS, V5, P406, DOI 10.1093/ajh/5.6.406; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; VANOVERVELD FJ, 1992, PROSTAGLANDINS, V44, P101, DOI 10.1016/0090-6980(92)90071-Z; WALLUKAT G, 1991, MOL CELL BIOCHEM, V102, P35	58	119	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4832	4838						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106454				2022-12-25	WOS:A1994MX57100023
J	SEKINE, N; CIRULLI, V; REGAZZI, R; BROWN, LJ; GINE, E; TAMARITRODRIGUEZ, J; GIROTTI, M; MARIE, S; MACDONALD, MJ; WOLLHEIM, CB; RUTTER, GA				SEKINE, N; CIRULLI, V; REGAZZI, R; BROWN, LJ; GINE, E; TAMARITRODRIGUEZ, J; GIROTTI, M; MARIE, S; MACDONALD, MJ; WOLLHEIM, CB; RUTTER, GA			LOW LACTATE-DEHYDROGENASE AND HIGH MITOCHONDRIAL GLYCEROL PHOSPHATE DEHYDROGENASE IN PANCREATIC BETA-CELLS - POTENTIAL ROLE IN NUTRIENT SENSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN RELEASE; LINKED ISOCITRATE DEHYDROGENASE; GLUCOSE-METABOLISM; GLUCOKINASE GENE; COUPLING MECHANISMS; ADENINE-NUCLEOTIDES; CALCIUM-IONS; LINE RINM5F; RAT ISLETS; HIT CELLS	Nutrient metabolism was examined with regard to insulin secretion in purified rat islet beta- and non-beta-cells, beta-cell lines, and hepatocytes. Lactate dehydrogenase (LDH) activity (nanomoles.min(-1).mg protein(-1)) was remarkably low in the glucose-sensitive INS-1 cell line (15.7) and in beta-cells (22.3), Thus, beta-cell LDH was respectively 8-, 122-, 17-, and 136-fold lower than in islet non-beta-, liver, HIT-T15, and RINm5F cells. plasma membrane lactate transport activity was 3-10-fold lower in beta- or INS-1 cells than in the other cell types. Conversely, mitochondrial glycerol phosphate dehydrogenase was strongly expressed only in beta- and INS-1 cells. The significance of these findings to nutrient recognition was explored using INS-1 cells as a model of native beta-cells. Glucose-stimulated lactate output and glucose utilization were, respectively, 12- and 5 fold lower in INS-1 than in RINm5F cells. Each process was entirely blocked by respiratory chain inhibitors in INS-1 cells, whereas glucose utilization was barely affected and lactate output stimulated in RINm5F cells. Glucose oxidation represented 73% of total utilization in INS-1 cells, but only 9% in RINm5F cells. Absolute rates of glucose oxidation, and the extent of mitochondrial NAD(P) reduction, were similar in the two cell types, and glucose stimulated insulin secretion 1.9-fold in INS-1 and 1.4-fold in RINm5F cells. The mitochondrial substrates, monomethyl succinate, pyruvate, and leucine, each triggered secretion in INS-1 cells. The balance of LDH, plasma membrane lactate transport, and mitochondrial glycerol phosphate dehydrogenase activities therefore appear to be important in beta- and INS-1 cell glucose recognition to ensure that mitochondrial oxidation is the principle fate of pyruvate and NADH produced by glycolysis. The resultant close coupling of glycolysis with mitochondrial oxidation explains the absence in beta-cells of Crabtree and Pasteur effects.	UNIV GENEVA, DEPT MED, DIV BIOCHIM CLIN, CH-1211 GENEVA 4, SWITZERLAND; UNIV GENEVA, LAB RECH LOUIS JEANTET, CH-1211 GENEVA 4, SWITZERLAND; UNIV WISCONSIN, DEPT PAEDIAT DIABET & ENDOCRINOL, MADISON, WI 53706 USA; UNIV COMPLUTENSE MADRID, FAC MED, DEPT BIOQUIM, E-28040 MADRID, SPAIN	University of Geneva; University of Geneva; University of Wisconsin System; University of Wisconsin Madison; Complutense University of Madrid			Gine, Elena/I-3205-2012; Dominguez, Elena Giné/ABF-9419-2020	Gine, Elena/0000-0001-6305-6237; Dominguez, Elena Giné/0000-0001-6305-6237; Rutter, Guy/0000-0001-6360-0343	NIDDK NIH HHS [DK 28348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028348, R55DK028348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BAETENS D, 1979, SCIENCE, V206, P1323, DOI 10.1126/science.390711; BEGGS M, 1990, FEBS LETT, V267, P217, DOI 10.1016/0014-5793(90)80928-C; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; BEST L, 1991, BIOCHEM PHARMACOL, V41, P405, DOI 10.1016/0006-2952(91)90537-F; BEST L, 1992, MOL CELL ENDOCRINOL, V86, P49, DOI 10.1016/0303-7207(92)90174-5; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BRUN T, 1993, J BIOL CHEM, V268, P18905; DENTON RM, 1978, BIOCHEM J, V176, P899, DOI 10.1042/bj1760899; DIXIT PK, 1964, METABOLISM, V13, P285, DOI 10.1016/0026-0495(64)90107-6; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GIROIX MH, 1991, DIABETES, V40, P227, DOI 10.2337/diabetes.40.2.227; HALBAN PA, 1983, BIOCHEM J, V212, P439, DOI 10.1042/bj2120439; HALBAN PA, 1980, BIOCHEM PHARMACOL, V29, P2625, DOI 10.1016/0006-2952(80)90077-5; Hay RJ, 1986, ANIMAL CELL CULTURE, P71; HEDESKOV CJ, 1978, REGULATORY MECHANISM, V42, P237; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HELLMAN B, 1975, DIABETOLOGIA, V11, P495, DOI 10.1007/BF01222098; HELLMAN B, 1967, ENDOCRINOLOGY, V81, P125, DOI 10.1210/endo-81-1-125; HUTTON JC, 1980, ENDOCRINOLOGY, V106, P203, DOI 10.1210/endo-106-1-203; INGLEDEW WJ, 1977, BIOCHEM J, V164, P617, DOI 10.1042/bj1640617; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1989, J BIOL CHEM, V264; JAIN K, 1978, BIOCHEM J, V176, P31, DOI 10.1042/bj1760031; JANJIC D, 1992, DIABETOLOGIA, V35, P482, DOI 10.1007/BF02342448; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; KISSANE JM, 1964, STRUCTURE METABOLISM, P281; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1988, DIABETES, V37, P997, DOI 10.2337/diabetes.37.7.997; MALAISSE WJ, 1979, ARCH BIOCHEM BIOPHYS, V194, P49, DOI 10.1016/0003-9861(79)90594-0; MALAISSE WJ, 1974, EUR J BIOCHEM, V47, P365, DOI 10.1111/j.1432-1033.1974.tb03701.x; MALAISSE WJ, 1988, DIABETES RES CLIN EX, V7, P53; MARIE S, 1993, J BIOL CHEM, V268, P23881; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MCCORMACK JG, 1989, METHOD ENZYMOL, V174, P95; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1987, DIABETES, V36, P477, DOI 10.2337/diabetes.36.4.477; MEGLASSON MD, 1989, AM J PHYSIOL, V256, pE173, DOI 10.1152/ajpendo.1989.256.1.E173; Newsholme E. A., 1973, REGULATION METABOLIS; NICHOLLS D, 1982, BIOENERGETICS INTRO, P119; OHTA M, 1990, J BIOL CHEM, V265, P17525; OSTENSON CG, 1993, DIABETOLOGIA, V36, P722, DOI 10.1007/BF00401142; PANTEN U, 1982, ENDOCRINOLOGY, V111, P1595, DOI 10.1210/endo-111-5-1595; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; Reed LJ, 1987, ENZYMES, P77; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; ROUILLER DG, 1990, EXP CELL RES, V191, P305, DOI 10.1016/0014-4827(90)90019-7; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; RUTTER GA, 1989, BIOCHEM J, V263, P445, DOI 10.1042/bj2630445; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SENER A, 1978, BIOCHEM J, V176, P218; SENER A, 1988, J BIOL CHEM, V2634, P88; STRYER L, 1988, BIOCHEMISTRY-US, P495; TAMARITRODRIGUEZ J, 1992, DIABETOLOGIA, V35, pA125; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; VISCHER U, 1987, BIOCHEM J, V241, P249, DOI 10.1042/bj2410249; ZAWALICH WS, 1993, DIABETES, V42, P843, DOI 10.2337/diabetes.42.6.843; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44; ZIVKOVIC RV, 1975, EXPERIENTIA, V31, P1258	71	363	365	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4895	4902						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106462				2022-12-25	WOS:A1994MX57100033
J	SA, G; FOX, PL				SA, G; FOX, PL			BASIC FIBROBLAST GROWTH FACTOR-STIMULATED ENDOTHELIAL-CELL MOVEMENT IS MEDIATED BY A PERTUSSIS-TOXIN-SENSITIVE PATHWAY REGULATING PHOSPHOLIPASE-A(2) ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SIGNALING PATHWAYS; G-PROTEINS; FACTOR RECEPTOR; DNA-SYNTHESIS; PLASMINOGEN-ACTIVATOR; POSSIBLE INVOLVEMENT; GUANINE-NUCLEOTIDES; HUMAN-NEUTROPHILS; TYROSINE KINASES; BINDING PROTEINS	Basic fibroblast growth factor (bFGF) stimulates migration and proliferation of vascular endothelial cells (EC). Fibroblast growth factor (FGF) receptors have an intrinsic tyrosine kinase activity involved in FGF-mediated proliferation, but the signal transduction path-, way(s) responsible for movement is not known. We, compared the role of signal-transducing G-proteins in migratory and proliferative responses of bovine aortic EC in vitro. Pertussis toxin, which ADP-ribosylates susceptible G-proteins, reduced bFGF-stimulated EC migration by 80%. The toxin did not block serum-stimulated movement, indicating that structural components required for motility were not impaired. The toxin did not inhibit bFGF-stimulated EC proliferation, showing that distinct intracellular signaling mechanisms are involved in the migratory and proliferative responses to bFGF. Three experimental approaches indicated that promigratory responses were due to release of arachidonic acid: (i) of the second messengers induced by G-protein-coupled effectors, only arachidonic acid overcame the pertussis toxin block, (ii) bFGF stimulated arachidonic acid release from EC in a pertussis toxin-sensitive manner, and (iii) phospholipase A2 inhibitors blocked the EC migration in response to bFGF. These data provide evidence that the migratory response of vascular EC to bFGF may be mediated by a G-protein-coupled phospholipase A2 activity.	CLEVELAND CLIN, RES INST, DEPT CELL BIOL, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040352, R01HL041178] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40352, HL41178] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BELL L, 1992, J CLIN INVEST, V89, P315, DOI 10.1172/JCI115578; BICKNELL R, 1989, P NATL ACAD SCI USA, V86, P1573, DOI 10.1073/pnas.86.5.1573; BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651; BOUTHERINFALSON O, 1990, BIOCHEM BIOPH RES CO, V172, P306, DOI 10.1016/S0006-291X(05)80210-4; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHURCH JG, 1988, J BIOL CHEM, V263, P4242; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COCKCROFT S, 1991, BIOCHEM SOC T, V19, P333, DOI 10.1042/bst0190333; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; FOX PL, 1992, LAB INVEST, V66, P467; GAUDRY M, 1992, J LEUKOCYTE BIOL, V51, P103, DOI 10.1002/jlb.51.2.103; GOSPODAROWICZ D, 1991, ANN NY ACAD SCI, V638, P1, DOI 10.1111/j.1749-6632.1991.tb49012.x; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HASSELAAR P, 1992, J CELL BIOCHEM, V49, P272, DOI 10.1002/jcb.240490310; HOWE PH, 1990, BIOCHEM J, V266, P537, DOI 10.1042/bj2660537; IM MJ, 1990, J BIOL CHEM, V265, P18944; JARVIS MF, 1992, J PHARMACOL EXP THER, V263, P253; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KELVIN DJ, 1989, J CELL BIOL, V108, P169, DOI 10.1083/jcb.108.1.169; KITAGAWA K, 1987, BIOCHIM BIOPHYS ACTA, V931, P110, DOI 10.1016/0167-4889(87)90056-5; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LESTER BR, 1991, INT J CANCER, V48, P113; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LINDNER V, 1990, J CLIN INVEST, V85, P2004, DOI 10.1172/JCI114665; LOGAN A, 1991, CELL SIGNAL, V3, P215, DOI 10.1016/0898-6568(91)90047-X; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MONTESANO R, 1988, J CELL PHYSIOL, V134, P460, DOI 10.1002/jcp.1041340318; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V148, P403, DOI 10.1016/0006-291X(87)91125-9; PATTE C, 1992, CELL MOL BIOL, V38, P429; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; ROSENTHAL MD, 1989, BIOCHIM BIOPHYS ACTA, V1001, P1, DOI 10.1016/0005-2760(89)90299-3; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SCHENK PW, 1991, DEV BIOL, V145, P110, DOI 10.1016/0012-1606(91)90217-Q; SELDEN SC, 1981, J CELL PHYSIOL, V108, P195, DOI 10.1002/jcp.1041080210; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRACKE ML, 1987, BIOCHEM BIOPH RES CO, V146, P339, DOI 10.1016/0006-291X(87)90730-3; TERRANOVA VP, 1985, J CELL BIOL, V101, P2330, DOI 10.1083/jcb.101.6.2330; THYBERG J, 1984, EXP CELL RES, V155, P1, DOI 10.1016/0014-4827(84)90761-4; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; UI M, 1990, ADV SEC MESS PHOSPH, V24, P63; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WAKELAM MJO, 1992, SIGNAL TRANSDUCTION, P153; XING MZ, 1992, J BIOL CHEM, V267, P25966	58	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3219	3225						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106357				2022-12-25	WOS:A1994MV63100018
J	KUBO, T; MIZOBATA, T; KAWATA, Y				KUBO, T; MIZOBATA, T; KAWATA, Y			REFOLDING OF YEAST ENOLASE IN THE PRESENCE OF THE CHAPERONIN GROE - THE NUCLEOTIDE SPECIFICITY OF GROE AND THE ROLE OF GROES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE-DENATURED RHODANESE; ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE CARBOXYLASE; MOLECULAR CHAPERONE; ATP HYDROLYSIS; PROTEIN; COOPERATIVITY; PURIFICATION; DETERGENT; SURFACE	GroE, a chaperonin protein from Escherichia coli, facilitates the folding of numerous proteins by binding to protein-folding intermediates and suppressing aggregation (Gething, M., and Sambrook, J. (1992) Nature 355, 33-45). The specific mechanism of GroE-facilitated folding involves numerous interactions between GroEL, GroES, the refolding protein, and ATP. In the present study, we have probed the molecular characteristics of the refolding reaction of yeast enolase in the presence of GroE. We have found that (a) GroEL interacts specifically with enolase during the folding reaction, resulting in folding arrest; (b) the release of partially folded molecules of enolase from the GroE complex may be mediated by the addition of nucleotides other than ATP (ADP, CTP, and UTP); and (c) GroES is required for enolase to be released from GroEL in the presence of ADP, CTP, and UTP but not required in the presence of ATP. The nucleotide binding mechanism of GroEL and the specific role of GroES during the refolding reaction are discussed in detail.	TOTTORI UNIV,FAC ENGN,DEPT BIOTECHNOL,TOTTORI 680,JAPAN; KYOTO UNIV,FAC SCI,DEPT CHEM,KYOTO 60601,JAPAN	Tottori University; Kyoto University			Mizobata, Tomohiro/V-6672-2019; Kawata, Yasushi/ABA-9608-2021	Mizobata, Tomohiro/0000-0002-7808-2099; Kawata, Yasushi/0000-0002-2744-1506				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BORDERS CL, 1978, BIOCHEM BIOPH RES CO, V82, P901, DOI 10.1016/0006-291X(78)90868-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHIN CCQ, 1981, J BIOL CHEM, V256, P1377; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1987, J BIOL CHEM, V262, P4486; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; Wold F., 1971, ENZYMES, P499	34	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19346	19351						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	8103517				2022-12-25	WOS:A1993LW81900032
J	CHAO, TSO; FOSTER, DA; RAPP, UR; ROSNER, MR				CHAO, TSO; FOSTER, DA; RAPP, UR; ROSNER, MR			DIFFERENTIAL RAF REQUIREMENT FOR ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE BY GROWTH-FACTORS, PHORBOL ESTERS, AND CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNALING PATHWAYS; MURINE FIBROBLASTS; CELLS; MEMBRANE; PHOSPHORYLATION; THAPSIGARGIN; STIMULATION; 3T3-CELLS; BINDING	Although a pathway that requires sequential activation of Ras, Raf, and MAP kinase kinase has been proposed as the major mechanism for stimulation of mitogen-activated protein kinase (MAP kinase), alternative pathways also exist. A wide variety of extracellular stimuli have been shown to activate MAP kinase; however, the precise mechanisms by which these stimuli mediate the signaling events have not been elucidated. Using a Balb/c-derived cell line expressing a dominant-negative mutant of Raf, we determined whether Raf is required for the activation of MAP kinase by growth factors, phorbol esters, and calcium. Insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), and phorbol 12,13-dibutyrate activated Ras in both mutant and control cells. However, stimulation of MAP kinase by IGF-I was nearly abolished in the dominant-negative Raf mutant. Stimulation of MAP kinase by the Ca2+ mobilizer thapsigargin was also inhibited in the presence of the Raf mutant. In contrast, EGF and phorbol 12,13-dibutyrate remained potent stimulators of MAP kinase in the dominant-negative Raf cells. The activation of MAP kinase by these stimuli can be further distinguished by differential requirements for Ca2+ and protein kinase C. These results suggest that Raf is required for the activation of MAP kinase by IGF-I and calcium, whereas EGF and possibly phorbol eaters may employ alternative Raf-independent pathways for MAP kinase activation.	UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL,CHICAGO,IL 60637; CUNY HUNTER COLL,DEPT BIOL SCI,NEW YORK,NY 10021; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702	University of Chicago; University of Chicago; City University of New York (CUNY) System; Hunter College (CUNY); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [CA35541, CA46677] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035541, R29CA046677, R01CA046677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRAY GM, 1988, J BIOL CHEM, V263, P10714; GRISWOLDPRENNER I, 1993, J BIOL CHEM, V268, P13050; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QURESHI SA, 1991, ONCOGENE, V6, P995; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TUCKER MS, 1993, J NEUROCHEM, V61, P1376, DOI 10.1111/j.1471-4159.1993.tb13631.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	39	134	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7337	7341						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125950				2022-12-25	WOS:A1994NA03200049
J	HELL, JW; APPLEYARD, SM; YOKOYAMA, CT; WARNER, C; CATTERALL, WA				HELL, JW; APPLEYARD, SM; YOKOYAMA, CT; WARNER, C; CATTERALL, WA			DIFFERENTIAL PHOSPHORYLATION OF 2 SIZE FORMS OF THE N-TYPE CALCIUM-CHANNEL ALPHA-L SUBUNIT WHICH HAVE DIFFERENT COOH TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; OMEGA-CONOTOXIN GVIA; SKELETAL-MUSCLE; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CA2+ CHANNELS; DIHYDROPYRIDINE RECEPTOR; PERIPHERAL NEURONS; CATALYTIC SUBUNIT	Two size forms of the class B N-type calcium channel alpha 1 subunit were recently identified with CNB1, an anti-peptide antibody directed against an intracellular loop of this channel (Westenbroek, R. E., Hell, J. W., Warner, C., Dubel, S. J., Snutch, T. P., and Catterall, W.A, (1992) Neuron 9, 1099-1115). To investigate the biochemical differences between these two size forms, the antibodies CNB3 and CNB4 were raised against peptides with sequences corresponding to the COOH-terminal end of the full-length form. Immunoblot experiments demonstrated that both antibodies specifically recognize the longer form of 250 kDa, indicating that the COOH-terminal regions of the two size forms of the class B N-type channel alpha 1 subunit are different. Phosphorylation experiments with immunopurified calcium channels and different second messenger activated protein kinases revealed that both the 220- and 250-kDa forms of the class B N-type calcium channel alpha 1 subunit are substrates for cAMP-dependent protein kinase, cGMP-dependent protein kinase, and protein kinase C. These three kinases incorporated approximately 1 mol of phosphate/mol of binding sites for omega-conotoxin (omega-CgTx) GVIA, a ligand specific for the N-type calcium channel, and may regulate the activity of both forms in vivo. In contrast, calcium- and calmodulin dependent protein kinase II (CaM kinase II) phosphorylated only the long form of the class B N-type calcium channel alpha 1 subunit, with a stoichiometry of 0.5 mol of phosphate/mol of total omega-CgTx GVIA binding sites. Specific phosphorylation of the long form of the class B alpha 1 subunit by CaM kinase II may differentially regulate the function of N-type calcium channels containing different size forms of their alpha 1 subunits in vivo.	UNIV WASHINGTON, GRAD PROGRAM NEUROBIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	HELL, JW (corresponding author), UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA.		Hell, Johannes W./P-5085-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022625] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS22625] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BERNHEIM L, 1991, NEURON, V6, P859, DOI 10.1016/0896-6273(91)90226-P; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CHIN H, 1991, GENOMICS, V11, P914, DOI 10.1016/0888-7543(91)90014-6; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; Dado R., 1993, Society for Neuroscience Abstracts, V19, P1330; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; DOERNER D, 1990, J NEUROSCI, V10, P1699; DOLPHIN AC, 1990, ANNU REV PHYSIOL, V52, P243; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FLOCKERZI V, 1986, EUR J BIOCHEM, V161, P217, DOI 10.1111/j.1432-1033.1986.tb10145.x; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; GLOSSMANN H, 1990, REV PHYSIOL BIOCH P, V114, P1; GROSS RA, 1988, NEUROSCI LETT, V88, P50, DOI 10.1016/0304-3940(88)90314-X; GROSS RA, 1989, J NEUROPHYSIOL, V61, P97, DOI 10.1152/jn.1989.61.1.97; GROSS RA, 1990, J PHYSIOL-LONDON, V429, P483, DOI 10.1113/jphysiol.1990.sp018268; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HELL JW, 1993, J BIOL CHEM, V268, P19451; HELL JW, 1994, IN PRESS ANN NY ACAD; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P4290, DOI 10.1073/pnas.85.12.4290; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; JAY SD, 1991, J BIOL CHEM, V266, P3287; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; LAI Y, 1990, J BIOL CHEM, V265, P20839; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MUNDINAWEILENMANN C, 1991, J BIOL CHEM, V266, P4067; NASTAINCZYK W, 1987, EUR J BIOCHEM, V169, P137, DOI 10.1111/j.1432-1033.1987.tb13590.x; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; OCALLAHAN CM, 1988, BIOCHEMISTRY-US, V27, P6071, DOI 10.1021/bi00416a036; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TAKAHASHI M, 1987, SCIENCE, V236, P88, DOI 10.1126/science.2436296; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1991, J BIOL CHEM, V266, P21943; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P	78	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7390	7396						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125957				2022-12-25	WOS:A1994NA03200057
J	TRIEBER, CA; ROTHERY, RA; WEINER, JH				TRIEBER, CA; ROTHERY, RA; WEINER, JH			MULTIPLE PATHWAYS OF ELECTRON-TRANSFER IN DIMETHYL-SULFOXIDE REDUCTASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; IRON-SULFUR MOLYBDOENZYME; NUCLEOTIDE-SEQUENCE; FORMATE DEHYDROGENASE; FUMARATE REDUCTASE; DIMETHYLSULFOXIDE REDUCTASE; METHANOBACTERIUM-FORMICICUM; WOLINELLA-SUCCINOGENES; NITRATE REDUCTASE; CLONING	The catalytic subunit of dimethyl sulfoxide (Me(2)SO) reductase, DmsA, contains six blocks of sequence that are homologous to other members of the superfamily of prokaryotic molybdoenzymes. The amino-terminal block contains 5 conserved residues (Cys(38), Cys(42), Cys(75) Lys(28), and Arg(77)). Site-directed mutagenesis of these residues did not alter membrane localization but in some cases less enzyme accumulated. The activity of Me(2)SO reductase was monitored by measuring Me(2)SO-dependent anaerobic growth, benzyl viologen, or dimethylnaphthoquinol oxidase activity, and using a quinol pool-coupling assay. Only Cys(75) and Lys(28) mutant enzymes were able to support anaerobic growth with Me(2)SO suggesting a critical role for Cys(38), Cys(42), and Arg(77). Benzyl viologen oxidase activity was retained in the mutants although with reduced efficiency in Cys(42)-Ser. Electron transport with dimethylnaphthoquinol was reduced in Cys(38)-Ser, Cys(42)-Ser, and Cys(75)-Ser and almost totally eliminated in the Arg(77)-Ser mutant. Cys(38)-Ser, Cys(42)-Ser, and Arg(77)-Ser were unable to support quinol oxidation although electron transfer from the quinol pool to the [Fe-S] centers in DmsB was normal. These results indicate that the amino-terminal region is involved in functional electron transfer from the quinol pool to Me(2)SO and that electrons from benzyl viologen, dimethylnaphthoquinol, and menaquinol may follow different paths within the catalytic subunit.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA; UNIV ALBERTA,MED RES COUNCIL PROGRAM MOLEC BIOL MEMBRANES,EDMONTON T6G 2H7,AB,CANADA	University of Alberta; University of Alberta				Trieber, Catharine/0000-0002-1336-1126; Rothery, Richard/0000-0003-3265-1783				BERG BL, 1991, J BIOL CHEM, V266, P22380; BILOUS PT, 1988, J BACTERIOL, V170, P1511, DOI 10.1128/jb.170.4.1511-1518.1988; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; BOKRANZ M, 1991, ARCH MICROBIOL, V156, P119, DOI 10.1007/BF00290984; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CAMMACK R, 1990, BIOCHEMISTRY-US, V29, P8410, DOI 10.1021/bi00488a030; Gibson T.J., 1984, THESIS CAMBRIDGE U U; JOHNSON MK, 1988, J BIOL CHEM, V263, P14732; KRAFFT T, 1992, EUR J BIOCHEM, V206, P503, DOI 10.1111/j.1432-1033.1992.tb16953.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; PIERSON DE, 1990, J BACTERIOL, V172, P2194, DOI 10.1128/jb.172.4.2194-2198.1990; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; SAMBASIVARAO D, 1991, CURR MICROBIOL, V23, P105, DOI 10.1007/BF02092258; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; SAMBASIVARAO D, 1990, J BACTERIOL, V172, P5938, DOI 10.1128/jb.172.10.5938-5948.1990; Sambrook J, 1989, MOL CLONING LABORATO; SAUTER M, 1992, MOL MICROBIOL, V6, P1523, DOI 10.1111/j.1365-2958.1992.tb00873.x; SHUBER AP, 1986, J BIOL CHEM, V261, P2942; TARTOF KD, 1987, FOCUS, V9, P12; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; WEINER JH, 1986, P NATL ACAD SCI USA, V83, P2056, DOI 10.1073/pnas.83.7.2056; WEINER JH, 1988, J BACTERIOL, V170, P1505, DOI 10.1128/jb.170.4.1505-1510.1988; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; WHITE WB, 1992, J BACTERIOL, V174, P4997, DOI 10.1128/JB.174.15.4997-5004.1992; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; YAMATO I, 1975, J BIOCHEM, V77, P705, DOI 10.1093/oxfordjournals.jbchem.a130774; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	33	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7103	7109						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125918				2022-12-25	WOS:A1994NA03200013
J	GAIKWAD, AS; CUMSKY, MG				GAIKWAD, AS; CUMSKY, MG			THE USE OF CHEMICAL CROSS-LINKING TO IDENTIFY PROTEINS THAT INTERACT WITH A MITOCHONDRIAL PRESEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; SOLID-PHASE SYNTHESIS; INNER MEMBRANE; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; DIHYDROFOLATE-REDUCTASE; PEPTIDE-SYNTHESIS; IMPORT MACHINERY; 45-KDA PROTEIN; IDENTIFICATION	Previous work has shown that when yeast mitochondria are incubated in the presence of the presequence peptide pL4(1-22), the peptide is imported and accumulates within the mitochondrial membranes, presumably at the import sites. If the extramitochondrial concentration of peptide is sufficiently high, enough peptide accumulates within the import sites to prevent the uptake of authentic precursor proteins. We have used chemical cross-linking to probe the interaction of this peptide with yeast mitochondrial proteins. We found that radiolabeled pL4(1-22) could be reproducibly cross-linked to a number of polypeptides. Interestingly, nearly all were membrane proteins. Several of the cross-linked proteins were located in the outer membrane, while others were located in the inner membrane, The interaction between the peptide and many of the cross-linked products was shown to be specific by two independent criteria, First, an excess of unlabeled peptide acted as a competitor in the cross-linking reaction, and, second, treatment of the peptide with the alkylating agent N-ethylmaleimide dramatically reduced its ability to form cross-links. Two of the cross-linked species corresponded to the outer membrane proteins, Mas70p and ISP42. Significantly, both of these proteins have previously been shown to play critical roles in mitochondrial protein import. While the role of the other cross-linked proteins in the import process remains to be determined, the results of this study demonstrate that our experimental approach may be useful in identifying components of the import machinery as well as proteins that interact with mitochondrial presequences.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine					NIGMS NIH HHS [GM 36675] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036675] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHERTON E, 1981, J CHEM SOC PERK T 1, P538, DOI 10.1039/p19810000538; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; DIHANICH M, 1990, EXPERIENTIA, V46, P146, DOI 10.1007/BF02027310; DRYLAND A, 1986, J CHEM SOC PERK T 1, P125, DOI 10.1039/p19860000125; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; GILLESPIE LL, 1987, J BIOL CHEM, V262, P7939; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; GLASER SM, 1990, MOL CELL BIOL, V10, P1873, DOI 10.1128/MCB.10.5.1873; GLICK B, 1991, ANNU REV GENET, V25, P21; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HINES V, 1993, J BIOL CHEM, V268, P449; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; JENSEN RE, 1988, EMBO J, V7, P3868; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MEYER DI, 1990, NATURE, V347, P424, DOI 10.1038/347424a0; MILLER BR, 1993, J CELL BIOL, V121, P1021, DOI 10.1083/jcb.121.5.1021; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; MURAKAMI H, 1990, NATURE, V347, P488, DOI 10.1038/347488a0; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI H, 1993, P NATL ACAD SCI USA, V90, P3358, DOI 10.1073/pnas.90.8.3358; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PFALLER R, 1990, EXPERIENTIA, V46, P153, DOI 10.1007/BF02027311; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1988, EUR J BIOCHEM, V175, P205, DOI 10.1111/j.1432-1033.1988.tb14185.x; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; ROISE D, 1988, J BIOL CHEM, V263, P4509; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; YAFFE MP, 1989, J BIOL CHEM, V264, P21091	45	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6437	6443						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119994				2022-12-25	WOS:A1994MZ50300030
J	PATRICK, DR; OLIFF, A; HEIMBROOK, DC				PATRICK, DR; OLIFF, A; HEIMBROOK, DC			IDENTIFICATION OF A NOVEL RETINOBLASTOMA GENE-PRODUCT BINDING-SITE ON HUMAN PAPILLOMAVIRUS TYPE-16 E7 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F TRANSCRIPTION FACTOR; LARGE T-ANTIGEN; CARCINOMA CELL-LINES; DNA-BINDING; SUPPRESSOR PROTEIN; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; 2 DISTINCT; HIGH-RISK; CYCLIN-A	Transformation of mammalian cells by human papil lomavirus type 16 appears to require binding of the viral E7 protein to the cellular retinoblastoma growth suppresser gene product (pRB). Binding of E7 protein to pRB inhibits several of pRB's biochemical properties, including association with the transcription factor E2F. Fragments of E7 protein derived from its conserved region 2 (CR2) domain bind to pRB and are sufficient to inhibit binding of full-length E7 protein to pRB. However, these CR2 fragments exhibit reduced affinity for pRB compared to the full-length protein and do not inhibit formation of the pRB E2F complex. These observations suggest the existence of additional contact sites between the E7 protein and pRB. In the current study we have identified a region of E7, distinct from the CR2 domain, which is sufficient to bind pRB. This new pRB binding motif encompasses the zinc-binding conserved region 3 (CR3) domain of E7. Studies with a series of pRB deletion mutants suggest that pRB residues between amino acids 803 and 841 are necessary for binding to the E7 CR3 domain. An E7 CR3 peptide inhibits binding of E2F to pRB, indicating that E2F and E7(31-98) bind to pRB at the same or overlapping sites. These results are consistent with a model in which optimal binding of E7 to pRB requires at least two distinct contact sites: the previously identified high affinity interaction between the E7 CR2 domain and the pRB ''pocket'' region, and a second interaction between the E7 CR3 domain and the COOH-terminal region of pRB. The latter interaction is sufficient for E7's inhibition of E2F binding to pRB.	MERCK SHARP & DOHME LTD,RES LABS,DEPT CANC RES,W POINT,PA 19486	Merck & Company								BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; EDWARDS GM, 1992, J BIOL CHEM, V267, P7971; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3325; JEFFERSON JR, 1990, BIOCHEMISTRY-US, V29, P6687, DOI 10.1021/bi00480a019; JONES RE, 1992, J BIOL CHEM, V267, P908; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P853; KANDA T, 1988, J VIROL, V62, P610, DOI 10.1128/JVI.62.2.610-613.1988; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1992, CANCER SURV, V12, P197; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; NEVINS JR, 1992, SCIENCE, V258, P424; PATRICK DR, 1992, J BIOL CHEM, V267, P6910; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RAWLS JA, 1990, J VIROL, V64, P6121, DOI 10.1128/JVI.64.12.6121-6129.1990; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RILEY TEW, 1990, MOL CELL BIOL, V10, P6664, DOI 10.1128/MCB.10.12.6664; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SANG BC, 1992, P NATL ACAD SCI USA, V89, P8063, DOI 10.1073/pnas.89.17.8063; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STAMMERS DK, 1991, FEBS LETT, V283, P298, DOI 10.1016/0014-5793(91)80613-8; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; STOREY A, 1990, J GEN VIROL, V71, P965, DOI 10.1099/0022-1317-71-4-965; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE C, 1985, AM J PATHOL, V119, P363; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	63	80	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6842	6850						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120046				2022-12-25	WOS:A1994MZ50300091
J	HAINZL, T; BOEHM, T				HAINZL, T; BOEHM, T			A VERSATILE EXPRESSION VECTOR FOR THE IN-VITRO STUDY OF PROTEIN-PROTEIN INTERACTIONS - CHARACTERIZATION OF E47 MUTANT PROTEINS	ONCOGENE			English	Article							GLUTATHIONE-S-TRANSFERASE; HELIX ZIPPER PROTEIN; DNA-BINDING; ESCHERICHIA-COLI; ENHANCER-BINDING; TRANSLOCATION; CLONING; MYC; PURIFICATION; DIMERIZATION	Several mutants of the E47 protein, a member of the family of basic/helix-loop-helix (b-HLH) transcriptional regulators, were examined for their ability to homo- and heterodimerize with the protein product of the T-cell oncogene tal-1/SCL. For this purpose, a novel bacterial expression system was developed in which proteins are expressed as fusions appended to glutathione-S-transferase via a thrombin cleavage site and either one or four protein kinase recognition sites embedded in a glycine-rich domain. Since the interaction domain can be purified away from the glutathione-S-transferase moiety and the radioactive label is located in a flexible N-terminal tag, protein folding should occur normally. Our studies with E47 proteins prepared in this system indicate that the ratio between E47 homodimers and E47/tal-1 heterodimers can dramatically shift upon subtle mutations in the loop region and the second helix of the E47 protein. This unexpected result suggests a novel mechanism to alter the equilibrium between different transactivating protein complexes of the b-HLH class.	UNIV FREIBURG, DEPT MED 1, MOLEC MED GRP, D-79106 FREIBURG, GERMANY	University of Freiburg								BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GREEN AR, 1992, ONCOGENE, V7, P653; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEHLS M, 1993, TRENDS GENET, V9, P336, DOI 10.1016/0168-9525(93)90024-C; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RABBITTS TH, 1994, IN PRESS NATURE; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; SACCHETTA P, 1993, EUR J BIOCHEM, V215, P741, DOI 10.1111/j.1432-1033.1993.tb18087.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUJN XH, 1991, MOL CELL BIOL, V11, P5603; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722	30	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					885	891						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108132				2022-12-25	WOS:A1994MW55100025
J	STONGE, L; BASTIN, M				STONGE, L; BASTIN, M			TRANSCRIPTION ACTIVATION MEDIATED BY CHROMOSOMAL INVERSION IN RAT-CELLS	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION; INTRACHROMOSOMAL RECOMBINATION; GENE-AMPLIFICATION; DNA METHYLATION; MAMMALIAN-CELLS; STEM-CELLS; POLYOMAVIRUS; VIRUS; TRANSFORMATION; FIBROBLASTS	To investigate the relationship between the local configuration of a gene and its level of expression, we constructed a rat cell line, Hy5, carrying a mutant polyomavirus middle T oncogene (pmt) whose overexpression converted the cells to the transformed state. The structure of the transgene was such that pmt was able to undergo chromosomal inversion at a relatively high rate by a cross-over in flanking pBR322 sequences. Hy5 cells became spontaneously transformed at a rate of 10(-5) per cell generation and all of the transformants analysed had sustained pmt inversion. CpG sequences were partially methylated in the Hy5 insert but appeared demethylated in transformants. In two subclones derived from untransformed Hy5 cells, the pmt insert was densely methylated, transcriptionally inactive and unable to undergo homologous recombination. Our results suggest that DNA repair associated with recombinational events leads to a heritable hypomethylation of the locus which is responsible for its activation.	UNIV SHERBROOKE,DEPT BIOCHEM,SHERBROOKE J1H 5N4,PQ,CANADA	University of Sherbrooke								ALT FW, 1978, J BIOL CHEM, V253, P1357; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ASSELIN C, 1986, J VIROL, V57, P165, DOI 10.1128/JVI.57.1.165-172.1986; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird A.J., 1980, CATALYSIS ORGANIC SY, P61; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BOUCHARD L, 1987, J VIROL, V61, P2448, DOI 10.1128/JVI.61.8.2448-2453.1987; BOUCHARD L, 1987, ONCOGENE, V2, P379; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Croce C M, 1986, Horiz Biochem Biophys, V8, P545; CROCE CM, 1985, BLOOD, V65, P1; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; GELINAS C, 1985, VIROLOGY, V146, P233, DOI 10.1016/0042-6822(85)90007-8; GREEN AR, 1986, EMBO J, V5, P707, DOI 10.1002/j.1460-2075.1986.tb04271.x; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; JAT P, 1982, NUCLEIC ACIDS RES, V10, P871, DOI 10.1093/nar/10.3.871; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; KASTAN MB, 1982, CELL, V30, P509, DOI 10.1016/0092-8674(82)90248-3; KEIL RL, 1984, CELL, V39, P377, DOI 10.1016/0092-8674(84)90016-3; LAROSE A, 1990, VIROLOGY, V176, P98, DOI 10.1016/0042-6822(90)90234-I; Luria SE, 1943, GENETICS, V28, P491; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHEYPREVOT B, 1984, J VIROL, V50, P325, DOI 10.1128/JVI.50.2.325-334.1984; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NICKOLOFF JA, 1990, MOL CELL BIOL, V10, P4837, DOI 10.1128/MCB.10.9.4837; NICKOLOFF JA, 1992, MOL CELL BIOL, V12, P5311, DOI 10.1128/MCB.12.12.5311; NOTTENBURG C, 1987, J VIROL, V61, P1828, DOI 10.1128/JVI.61.6.1828-1833.1987; PALL ML, 1981, P NATL ACAD SCI-BIOL, V78, P2465, DOI 10.1073/pnas.78.4.2465; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RENZO A, 1989, ONCOGENE, V4, P1469; ROGINSKI RS, 1983, CELL, V35, P149, DOI 10.1016/0092-8674(83)90217-9; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SHAD D, 1986, SCIENCE, V233, P478; SHENKAR R, 1991, MOL CELL BIOL, V11, P1813, DOI 10.1128/MCB.11.4.1813; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONGE L, 1990, J VIROL, V64, P2958, DOI 10.1128/JVI.64.6.2958-2966.1990; STONGE L, 1993, J VIROL, V67, P1788, DOI 10.1128/JVI.67.4.1788-1795.1993; STONGE L, 1991, NUCLEIC ACIDS RES, V19, P6619, DOI 10.1093/nar/19.23.6619; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; VARSHAVSKY A, 1981, CELL, V25, P561, DOI 10.1016/0092-8674(81)90074-X; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	47	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					781	789						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108120				2022-12-25	WOS:A1994MW55100013
J	PAN, BT; CHEN, CT; LIN, SM				PAN, BT; CHEN, CT; LIN, SM			ONCOGENIC RAS BLOCKS CELL-CYCLE PROGRESSION AND INHIBITS P34(CDC2) KINASE IN ACTIVATED XENOPUS EGG EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P34CDC2 PROTEIN-KINASE; FISSION YEAST; TYROSINE PHOSPHORYLATION; CDC25 PROTEIN; SARCOMA-VIRUS; M-PHASE; MITOSIS; DEPHOSPHORYLATION; GENE; PHOSPHATASE	The effect of purified, bacterially expressed human Ras(H) proteins on embryonic cell cycle progression in activated Xenopus egg extracts was studied. Bacterially expressed human oncogenic Ras(H) protein is able to block the progression of the Xenopus embryonic cell cycle into M-phase. In contrast, the corresponding normal human Ras protein is relatively ineffective when assayed in a like manner. The observed arresting activity can be blocked by the addition of Y13-259 anti-Ras monoclonal antibody but not by nonspecific IgG. Oncogenic Ras also induces unique morphological changes in the reconstituted nuclei; the nuclei appear to be enlarged, and the chromatin partially condenses into fiber-like structures. This induced arrest is associated with suppression of p34(cdc2) kinase activity, indicating that the oncogenic Ras protein induces the arrest by inactivating p34(cdc2). This inactivation by oncogenic Ras protein does not result from inhibition of the synthesis of cyclin B or of the binding of the newly synthesized cyclin B to the p34(cdc2).	UNIV KENTUCKY,MED CTR,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,DEPT SURG,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky	PAN, BT (corresponding author), UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,RM 310,COMBS BLDG,LEXINGTON,KY 40536, USA.			CHEN, CHIN-TIN/0000-0002-7439-8774				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BIRSCHMEIER CD, 1985, CELL, V43, P615; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DURKIN JP, 1987, MOL CELL BIOL, V7, P444, DOI 10.1128/MCB.7.1.444; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KIRSCHNER M, 1985, TRENDS GENET, V1, P41, DOI 10.1016/0168-9525(85)90021-6; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0	58	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5968	5975						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119942				2022-12-25	WOS:A1994MY84000076
J	SHAW, SK; CEPEK, KL; MURPHY, EA; RUSSELL, GJ; BRENNER, MB; PARKER, CM				SHAW, SK; CEPEK, KL; MURPHY, EA; RUSSELL, GJ; BRENNER, MB; PARKER, CM			MOLECULAR-CLONING OF THE HUMAN MUCOSAL LYMPHOCYTE INTEGRIN ALPHA(E) SUBUNIT - UNUSUAL STRUCTURE AND RESTRICTED RNA DISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY HML-1; AMINO-ACID-SEQUENCE; HAIRY-CELL LEUKEMIA; LEUKOCYTE ADHESION GLYCOPROTEIN; MESSENGER-RNAS; INTESTINAL LYMPHOCYTES; BETA-7 SUBUNIT; CHEMICAL MODIFICATION; CLEAVAGE SITES; T-CELLS	The human mucosal lymphocyte-1 (HML-1) antigen is expressed on a subclass of T-lymphocytes known as intra epithelial lymphocytes which are located between mucosal epithelial cells. The HML-1 complex is known to mediate adhesion of intra-epithelial T-lymphocytes to epithelial cell monolayers in vitro. We and others have shown that the HBL-1 antigen is an integrin composed of the beta(7) subunit in association with a novel alpha subunit, alpha(E). Here we report the cloning of the alpha(E) cDNA and its primary amino acid sequence. alpha(E) contained an inserted or I domain and was more homologous to the other I domain containing integrins than to the cleaved group of integrin alpha subunits. However, alpha(E) contained a unique extra domain of 55 amino acids located just NH2-terminal 60 the I domain without counterpart in other integrins. This extra domain contained a stretch of 18 consecutive charged residues and included a proteolytic cleavage site. Thus alpha(E) is the only I domain containing integrin a subunit that is also cleaved, and the cleavage site is distinct from that of members of the cleaved group of integrin alpha subunits. These structural features mark alpha(E) as an unusual member of the integrin family. High levels of alpha(E) and beta(7) mRNA were restricted to mucosal lymphocytes supporting the hypothesis that alpha(E) beta(7) plays a role in the localization or site-specific functions of intra-epithelial T-lymphocytes.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Massachusetts General Hospital	SHAW, SK (corresponding author), BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL IMMUNOL,DIV MED SCI,LYMPHOCYTE BIOL SECT,RM 507,SGMB,BOSTON,MA 02115, USA.			Shaw, Sunil/0000-0001-9701-6065	NIAMS NIH HHS [AR 36308] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEDNARCZYK JL, 1992, CLIN EXP METASTAS, V10, P281; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; BRAY PF, 1990, J BIOL CHEM, V265, P9587; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CALVETE JJ, 1990, FEBS LETT, V272, P37, DOI 10.1016/0014-5793(90)80443-M; CEPEK KL, 1993, J IMMUNOL, V150, P3459; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CERFBENSUSSAN N, 1986, J IMMUNOL, V136, P76; CERFBENSUSSAN N, 1992, EUR J IMMUNOL, V22, P273, DOI 10.1002/eji.1830220140; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; CORBI AL, 1990, J BIOL CHEM, V265, P2782; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FLEMING JC, 1993, J IMMUNOL, V150, P480; GEORGES E, 1987, EUR J BIOCHEM, V165, P281, DOI 10.1111/j.1432-1033.1987.tb11439.x; HANSEN JA, 1984, LEUKOCYTE TYPING HUM, P195; HARLOW E, 1988, ANTIBODIES LABORATOR; HAURY M, 1993, J IMMUNOL, V23, P313; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HOCHSTENBACH F, 1988, J EXP MED, V168, P761, DOI 10.1084/jem.168.2.761; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HOGG N, 1989, IMMUNOL TODAY, V10, P111, DOI 10.1016/0167-5699(89)90238-7; HOLZMANN B, 1989, IMMUNOL REV, V108, P45, DOI 10.1111/j.1600-065X.1989.tb00012.x; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KILSHAW PJ, 1990, EUR J IMMUNOL, V20, P2201, DOI 10.1002/eji.1830201008; KIMLT, 1992, J CELLSCI, V103, P743; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRISSANSEN GW, 1992, FEBS LETT, V296, P25, DOI 10.1016/0014-5793(92)80395-W; KRUSCHWITZ M, 1991, J CLIN PATHOL, V44, P636, DOI 10.1136/jcp.44.8.636; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; MATAGNE A, 1991, BIOCHEM J, V280, P553, DOI 10.1042/bj2800553; MICKLEM KJ, 1991, AM J PATHOL, V139, P1297; MOLLER P, 1990, AM J PATHOL, V136, P509; NEUMAN E, 1992, J IMMUNOL, V148, P3520; PALLESEN G, 1990, LANCET, V335, P537, DOI 10.1016/0140-6736(90)90768-Z; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; ROBERTS AI, 1993, CANCER RES, V53, P1608; ROBERTS K, 1993, EUR J IMMUNOL, V23, P1630, DOI 10.1002/eji.1830230735; RUBIO M, 1992, EUR J IMMUNOL, V22, P1099, DOI 10.1002/eji.1830220434; Sambrook J, 1989, MOL CLONING LABORATO; SCHIEFERDECKER HL, 1990, J IMMUNOL, V144, P2541; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SONNENBERG A, 1990, J CELL SCI, V96, P207; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; STASHENKO P, 1980, J IMMUNOL, V125, P1678; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VANVOORHIS WC, 1983, J EXP MED, V158, P126, DOI 10.1084/jem.158.1.126; VISSER L, 1989, BLOOD, V74, P320; VISSER L, 1990, BRIT J HAEMATOL, V75, P359, DOI 10.1111/j.1365-2141.1990.tb04349.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; YUAN Q, 1992, J BIOL CHEM, V267, P7352; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	75	102	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6016	6025						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119947				2022-12-25	WOS:A1994MY84000082
J	WILLIAMS, FMR; MURRAY, RC; UNDERHILL, TM; FLINTOFF, WF				WILLIAMS, FMR; MURRAY, RC; UNDERHILL, TM; FLINTOFF, WF			ISOLATION OF A HAMSTER CDNA CLONE CODING FOR A FUNCTION INVOLVED IN METHOTREXATE UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE-BINDING-PROTEIN; HUMAN KB CELLS; MEDIATED GENE-TRANSFER; L1210 LEUKEMIA-CELLS; OVARY CELLS; TRANSPORT-SYSTEM; TUMOR-CELLS; TETRAHYDROFOLATE COFACTOR; MEMBRANE-TRANSPORT; MOLECULAR-CLONING	A clone has been isolated from a Chinese hamster ovary cell cDNA expression library that complements mutant cells defective in the uptake of the folate analogue methotrexate. When transfected with this clone, the mutant cells regain the ability to bind and transport the drug and, as a consequence, become sensitive to its cytotoxic action. The clone is 2314 base pairs long and has an open reading frame of 1557 base pairs that codes for a putative protein of 58 kDa. This novel putative protein has a high content of hydrophobic residues and has a large part of its predicted secondary structure in the form of P-sheets. In the wild-type cell Line and in one of the mutant cell lines, this clone detects an mRNA of 2.5 kilobases, while in another mutant cell line, this message is absent. The data are consistent with this clone encoding either the reduced folate transporter or an auxiliary function that interacts with this transporter. This is the first report of a cDNA coding for a function, other than folate-binding protein, that is involved in the transport of methotrexate.	UNIV WESTERN ONTARIO,DEPT MICROBIOL & IMMUNOL,LONDON N6A 5C1,ON,CANADA	Western University (University of Western Ontario)								ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANTONY AC, 1985, J BIOL CHEM, V260, P4911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHUNG KN, 1992, J CLIN INVEST, V91, P1289; CONEY LR, 1991, CANCER RES, V51, P6125; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DIXON KH, 1992, J BIOL CHEM, V267, P24140; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FAN JG, 1991, J BIOL CHEM, V266, P14862; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLINTOFF WF, 1976, IN VITRO CELL DEV B, V12, P749, DOI 10.1007/BF02835450; FLINTOFF WF, 1976, SOMAT CELL GENET, V2, P245, DOI 10.1007/BF01538963; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FLINTOFF WF, 1989, DRUG RESISTANCE MAMM, V1, P1; GALIVAN J, 1979, CANCER RES, V39, P735; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V202, P144, DOI 10.1016/0003-9861(80)90416-6; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; HENDERSON GB, 1986, FOLATES PTERINS, V3, P208; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HSUEH CT, 1992, ONCOL RES, V4, P497; JANSEN G, 1989, CANCER RES, V49, P1959; JANSEN G, 1990, J BIOL CHEM, V265, P18272; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KANE MA, 1989, LAB INVEST, V60, P737; KANE MA, 1986, J BIOL CHEM, V261, P44; KANE MA, 1986, J BIOL CHEM, V261, P5625; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MATHERLY LH, 1991, CANCER RES, V51, P3420; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P7853, DOI 10.1021/bi00420a040; ROSOWSKY A, 1985, CANCER RES, V45, P1815; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SAIKAWA Y, 1993, J BIOL CHEM, V268, P5293; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; SIROTNAK FM, 1981, CANCER RES, V41, P966; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1981, CANCER RES, V41, P447; UNDERHILL TM, 1989, MOL CELL BIOL, V9, P1754, DOI 10.1128/MCB.9.4.1754; UNDERHILL TM, 1989, SOMAT CELL MOLEC GEN, V15, P49, DOI 10.1007/BF01534669; UNDERHILL TM, 1992, SOMAT CELL MOLEC GEN, V18, P337, DOI 10.1007/BF01235757; WEITMAN SD, 1992, CANCER RES, V52, P3396; WESTERHOF GR, 1991, CANCER RES, V51, P5507; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067; 1991, PROGRAM MANUAL GCG P	59	118	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5810	5816						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119923				2022-12-25	WOS:A1994MY84000053
J	FALLER, DV; MUNDSCHAU, LJ; FORMAN, LW; QUINONES, MA				FALLER, DV; MUNDSCHAU, LJ; FORMAN, LW; QUINONES, MA			V-MOS SUPPRESSES PLATELET-DERIVED GROWTH-FACTOR (PDGF) TYPE-BETA RECEPTOR AUTOPHOSPHORYLATION AND INHIBITS PDGF-BB-MEDIATED SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EJ-RAS ONCOGENE; PHOSPHOLIPASE-C-GAMMA; GLUCOCORTICOID RECEPTOR; CELL-CYCLE; TYROSINE PHOSPHORYLATION; TRANSFORMING ACTIVITY; MEIOTIC MATURATION; XENOPUS OOCYTES; KINASE-ACTIVITY; CDNA CLONING	The function of mos protein in somatic cells, the mechanisms underlying its ability to transform cells, and its relationship to growth factor autonomy and growth factor-mediated signal transduction are not well defined. This report demonstrates that the expression of transforming mos (v-mos) can block the stimulation of growth-related gene expression mediated by the platelet-derived growth factor (PDGF-BB). This blockade by v-mos of PDGF-BB signal transduction occurs very early in the signalling pathway at the level of PDGF type-beta receptor autophosphorylation. Although the expression of PDGF type-beta receptor, as detected by Western blot with anti-PDGF type-beta receptor antibody, was not diminished in v-mos transformed BALB/c-3T3 murine fibroblasts, the autophosphorylation of PDGF-beta receptor in response to ligand (recombinant PDGF-BB homodimer) stimulation was profoundly suppressed. This same phenomenon of v-mos-mediated PDGF type-beta receptor autophosphorylation inhibition was also demonstrated in NIH-3T3 fibroblasts. A v-mos mutant gene, which was incapable of binding ATP and was kinase-defective, did not block ligand-mediated receptor autophosphorylation. Factor(s) present in v-mos expressing fibroblasts, and found in the membrane fractions of these cells, dominantly inhibit the autophosphorylation of the PDGF type-beta receptor obtained from normal fibroblasts. This trans-acting factor does not appear to be a protein-tyrosine phosphatase. These findings suggest a role for mos, or a similar serine/threonine kinase, as a control mechanism in one of the earliest steps of the PDGF signal transduction pathway, and may provide a model for the functional interaction of mos with growth factor receptors.			FALLER, DV (corresponding author), BOSTON UNIV,SCH MED,CANC RES CTR,80 E CONCORD ST,E-124,BOSTON,MA 02118, USA.			Kasman, Laura/0000-0002-8661-2918				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BAI WL, 1992, ONCOGENE, V7, P1757; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COHEN S, 1980, J BIOL CHEM, V255, P4834; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DOPPLER W, 1987, GENE, V54, P147, DOI 10.1016/0378-1119(87)90357-X; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; ESCOBEDO JA, 1988, SCIENCE, V240, P1532, DOI 10.1126/science.2836953; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO J, 1985, CANCER CELLS GROWTH, V3; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HUNT T, 1992, NATURE, V355, P587, DOI 10.1038/355587a0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFFERMANN MK, 1989, MOL CELL BIOL, V9, P1969, DOI 10.1128/MCB.9.5.1969; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIEFERT RA, 1989, J BIOL CHEM, V264, P8771; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TOURAY M, 1991, ONCOGENE, V6, P211; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; WOOD TG, 1983, J VIROL, V46, P726, DOI 10.1128/JVI.46.3.726-736.1983; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHOU R, 1992, SCIENCE, V251, P671; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	64	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5022	5029						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106477				2022-12-25	WOS:A1994MX57100052
J	KIRK, K; HORNER, HA; ELFORD, BC; ELLORY, JC; NEWBOLD, CI				KIRK, K; HORNER, HA; ELFORD, BC; ELLORY, JC; NEWBOLD, CI			TRANSPORT OF DIVERSE SUBSTRATES INTO MALARIA-INFECTED ERYTHROCYTES VIA A PATHWAY SHOWING FUNCTIONAL-CHARACTERISTICS OF A CHLORIDE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; CA2+-ACTIVATED K+ CHANNEL; PLASMODIUM-FALCIPARUM; MEMBRANE-TRANSPORT; HOST ERYTHROCYTE; MAMMALIAN ERYTHROCYTES; ACTIVATED CHANNEL; EPITHELIAL-CELLS; PERMEABILITY; PARASITE	Following infection by the malaria parasite, Plasmodium falciparum, human erythrocytes show increased permeability to a variety of low molecular weight,solutes. In this study a number of anion transport blockers were identified as potent inhibitors of the transport of a wide range of solutes into human erythrocytes infected in vitro with P. falciparum. 5-Nitro-2-(3-phenyl-propylamino)benzoic acid (NPPB), furosemide, and niflumate blocked the malaria-induced transport of monovalent cations, neutral amino acids, sugars, nucleosides, and monovalent anions. For all of the substrates tested the order of potency of these three inhibitors was the same (NPPB > furosemide > niflumate) and dose-response curves for the effect of these inhibitors on malaria-induced choline transport were similar to those for malaria-induced thymidine transport. The data suggest that much, if not all, of the high capacity (non-saturable) transport of low molecular weight solutes into P. falciparum-infected erythrocytes is via a single type of pathway. The broad specificity of the pathway, its non-saturability in the physiological concentration range, and its failure to distinguish between stereoisomers (L- and D-alanine) are consistent with its being a type of pore or channel. For those substrates for which quantitative influx measurements were made the magnitude of the malaria-induced (inhibitor-sensitive) transport was in the order: Cl- > lactate > thymidine, adenosine > carnitine > choline > K+. The pathway is therefore anion-selective. The pharmacological and substrate-selectivity properties of the pathway show marked similarities to those of chloride channels in other cell types; this raises the possibility that the high capacity transport of small organic solutes may be an important and, as yet, largely unrecognized role for such channels in other tissues.	JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND	University of Oxford	KIRK, K (corresponding author), UNIV OXFORD, PHYSIOL LAB, PARKS RD, OXFORD OX1 3PT, ENGLAND.		Kirk, Kiaran/C-8299-2009	Kirk, Kiaran/0000-0002-5613-2622; Newbold, Chris/0000-0002-9274-3789	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AABIN B, 1986, ACTA PHYSIOL SCAND, V128, pA42; BANDERALI U, 1992, AM J PHYSIOL, V263, pC1200, DOI 10.1152/ajpcell.1992.263.6.C1200; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BODAMMER JE, 1973, LAB INVEST, V28, P708; BOOKCHIN RM, 1980, J PHYSL, V312, pP65; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CABANTCHIK ZI, 1990, BLOOD CELLS, V16, P421; CABANTCHIK ZI, 1989, BLOOD, V74, P1464; CABANTCHIK ZI, 1990, UCLA SYM BI, V118, P267; DEUTICKE B, 1978, BIOCHIM BIOPHYS ACTA, V507, P137, DOI 10.1016/0005-2736(78)90381-4; Elford B.C., 1991, P377; ELFORD BC, 1990, BLOOD CELLS, V16, P433; ELFORD BC, 1985, MOL BIOCHEM PARASIT, V16, P43, DOI 10.1016/0166-6851(85)90048-9; ELFORD BC, 1990, J PHYSIOL-LONDON, V426, pP100; ELFORD BC, 1992, BIOCHEM SOC T, V20, P790, DOI 10.1042/bst0200790; ELLORY JC, 1988, PARASITOLOGY, V96, pS5, DOI 10.1017/S0031182000085942; ELLORY JC, 1992, FEBS LETT, V296, P219, DOI 10.1016/0014-5793(92)80383-R; EVANS MG, 1986, PFLUG ARCH EUR J PHY, V406, P65, DOI 10.1007/BF00582955; FINCHAM DA, 1987, J MEMBRANE BIOL, V96, P45, DOI 10.1007/BF01869333; FRANCIOLINI F, 1992, BIOCHIM BIOPHYS ACTA, V1113, P1, DOI 10.1016/0304-4157(92)90031-5; FRANCIOLINI F, 1987, J GEN PHYSIOL, V90, P453, DOI 10.1085/jgp.90.4.453; FRANCIOLINI F, 1990, BIOCHIM BIOPHYS ACTA, V1031, P247, DOI 10.1016/0304-4157(90)90009-2; FRIZZELL R A, 1992, Current Biology, V2, P285, DOI 10.1016/0960-9822(92)90862-5; FUJIOKA H, 1993, EXP PARASITOL, V76, P302, DOI 10.1006/expr.1993.1036; GATI WP, 1990, BIOCHEM J, V272, P277, DOI 10.1042/bj2720277; Gero A.M., 1991, P387; GERO AM, 1988, MOL BIOCHEM PARASIT, V27, P159, DOI 10.1016/0166-6851(88)90035-7; GERO AM, 1991, MOL BIOCHEM PARASIT, V44, P195, DOI 10.1016/0166-6851(91)90005-Q; GERO AM, 1992, PARASITOL TODAY, V8, P283, DOI 10.1016/0169-4758(92)90147-T; GINSBERG H, 1990, COMP BIOCHEM PHYS A, V95, P31, DOI 10.1016/0300-9629(90)90006-E; GINSBURG H, 1987, BIOSCIENCE REP, V7, P455, DOI 10.1007/BF01116501; GINSBURG H, 1988, P188; GINSBURG H, 1983, MOL BIOCHEM PARASIT, V8, P177, DOI 10.1016/0166-6851(83)90008-7; GINSBURG H, 1985, MOL BIOCHEM PARASIT, V14, P313, DOI 10.1016/0166-6851(85)90059-3; GINSBURG H, 1987, J MEMBRANE BIOL, V96, P1, DOI 10.1007/BF01869329; GREGER R, 1990, METHOD ENZYMOL, V191, P793; HALDAR K, 1992, MOL BIOCHEM PARASIT, V50, P161, DOI 10.1016/0166-6851(92)90253-G; HALM DR, 1992, J GEN PHYSIOL, V99, P339, DOI 10.1085/jgp.99.3.339; JARVIS SM, 1982, BIOCHEM J, V208, P83, DOI 10.1042/bj2080083; JOSHI P, 1987, BIOCHEM J, V246, P103, DOI 10.1042/bj2460103; KANAANI J, 1991, J CELL PHYSIOL, V149, P469, DOI 10.1002/jcp.1041490316; KIRK K, 1991, BIOCHEM J, V278, P521, DOI 10.1042/bj2780521; KIRK K, 1992, J PHYSIOL-LONDON, V452, pP342; KIRK K, 1992, J BIOL CHEM, V267, P23475; KIRK K, 1991, BIOCHIM BIOPHYS ACTA, V1061, P305, DOI 10.1016/0005-2736(91)90296-K; KIRK K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P8, DOI 10.1016/0167-4889(92)90159-9; KUTNER S, 1983, J CELL PHYSIOL, V114, P245, DOI 10.1002/jcp.1041140215; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LOYEVSKY M, 1993, J CLIN INVEST, V91, P218, DOI 10.1172/JCI116174; MANNING SD, 1989, J MEMBRANE BIOL, V109, P113, DOI 10.1007/BF01870850; NAGEL W, 1985, PFLUG ARCH EUR J PHY, V403, P337, DOI 10.1007/BF00589243; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; POLLARD CE, 1991, J MEMBRANE BIOL, V124, P275, DOI 10.1007/BF01994360; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; POPE AJ, 1991, BIOCHIM BIOPHYS ACTA, V1067, P51, DOI 10.1016/0005-2736(91)90025-4; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; RASOLA A, 1992, BIOCHIM BIOPHYS ACTA, V1139, P319, DOI 10.1016/0925-4439(92)90108-Y; ROY G, 1992, J MEMBRANE BIOL, V130, P83; SARKADI B, 1985, AM J PHYSIOL, V248, pC480, DOI 10.1152/ajpcell.1985.248.5.C480; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SHERMAN IW, 1992, PARASITOL TODAY, V8, P2, DOI 10.1016/0169-4758(92)90294-C; SHERMAN IW, 1988, PARASITOLOGY, V96, pS57, DOI 10.1017/S003118200008598X; Stein W., 1990, CHANNELS CARRIERS PU; TARASCHI TF, 1986, SCIENCE, V232, P102, DOI 10.1126/science.3006251; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WANGEMANN P, 1986, PFLUG ARCH EUR J PHY, V407, pS128, DOI 10.1007/BF00584942; WHITE MM, 1990, MOL PHARMACOL, V37, P720; YOUNG GPH, 1984, P NATL ACAD SCI-BIOL, V81, P5155, DOI 10.1073/pnas.81.16.5155; ZARCHIN S, 1986, BIOCHEM PHARMACOL, V35, P2435, DOI 10.1016/0006-2952(86)90473-9	70	205	210	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3339	3347						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106373				2022-12-25	WOS:A1994MV63100035
J	MATTIE, M; BROOKER, G; SPIEGEL, S				MATTIE, M; BROOKER, G; SPIEGEL, S			SPHINGOSINE-1-PHOSPHATE, A PUTATIVE 2ND MESSENGER, MOBILIZES CALCIUM FROM INTERNAL STORES VIA AN INOSITOL TRISPHOSPHATE-INDEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDIC-ACID LEVELS; PAROTID ACINAR-CELLS; CELLULAR PROLIFERATION; ENDOGENOUS GANGLIOSIDE; LYSOPHOSPHATIDIC ACID; HUMAN-NEUTROPHILS; 3T3 FIBROBLASTS; PHOSPHOLIPASE-D; TUMOR PROMOTER	Sphingosine-1-phosphate, a metabolite of sphingolipids which has previously been shown to stimulate DNA synthesis and cell division in quiescent cultures of Swiss 3T3 fibroblasts (Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) J. Cell Biol. 114, 155-167), induced a transient increase in intracellular free calcium independent of extracellular calcium. The increase in calcium was completely abolished when intracellular calcium pools were depleted with thapsigargin, an inhibitor of the endoplasmic reticulum Ca2+-ATPase. The dose-response for calcium release induced by sphingosine-1-phosphate correlated closely with the concentration required for stimulation of DNA synthesis. The magnitude of the calcium response decreased with successive challenges, although sphingosine-1-phosphate did not attenuate the responses to either bradykinin or ionomycin. Conversely, prior stimulation of the cells with bradykinin had no effect on the sphingosine-1-phosphate-induced calcium signal. Although sphingosine-1-phosphate increased inositol (1,4,5)-trisphosphate levels, complete inhibition of inositol phosphate formation by pretreament with 12-0-tetradecanoylphorbol-13-acetate did not block sphingosine-1-phosphate-mediated calcium responses. Moreover, in permeabilized cells, heparin, an inositol (1,4,5)-trisphosphate antagonist, blocked Ca2+ release induced by inositol (1,4,5)-trisphosphate, but did not significantly alter the Ca2+ release induced by sphingosine-1-phosphate. Sphingosine-1-phosphate did not stimulate the release of arachidonic acid, another signaling molecule known to elevate [Ca2+]i without inositol lipid turnover or calcium influx. Our data suggest that sphingosine-1-phosphate mobilizes Ca+ from internal stores primarily through a mechanism independent of inositol lipid hydrolysis and arachidonic acid release and that sphingolipid metabolism may be important in calcium homeostasis.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,357 BASIC SCI BLDG,3900 RESERVOIR RD,WASHINGTON,DC 20007	Georgetown University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039718, R01GM043880] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28940] Funding Source: Medline; NIGMS NIH HHS [1R29 GM 39718, 1RO1 GM43880] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; CHOW SC, 1990, J BIOL CHEM, V265, P902; DEERAUSQUIN GA, 1990, P NATL ACAD SCI USA, V87, P8017, DOI 10.1073/pnas.87.20.8017; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JALINK K, 1990, J BIOL CHEM, V265, P12232; KIM MY, 1991, J BIOL CHEM, V266, P484; KISS Z, 1990, J BIOL CHEM, V265, P7345; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; OLIVERA A, 1992, GLYCOCONJUGATE J, V9, P109; POWIS G, 1990, J BIOL CHEM, V265, P10266; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; RITCHIE T, 1992, BIOCHEM BIOPH RES CO, V186, P790, DOI 10.1016/0006-291X(92)90815-3; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SPIEGEL S, 1989, J BIOL CHEM, V264, P16512; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; SPIEGEL S, 1988, EXP CELL RES, V177, P414, DOI 10.1016/0014-4827(88)90474-0; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS AP, 1988, J BIOL CHEM, V263, P2704; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; WILSON E, 1986, J BIOL CHEM, V261, P2616; YAMASHITA T, 1987, J BIOL CHEM, V262, P5536; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	46	255	262	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3181	3188						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106352				2022-12-25	WOS:A1994MV63100013
J	ZHANG, XL; MATHEWS, CK				ZHANG, XL; MATHEWS, CK			EFFECT OF DNA CYTOSINE METHYLATION UPON DEAMINATION-INDUCED MUTAGENESIS IN A NATURAL TARGET SEQUENCE IN DUPLEX DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-INDUCED DEAMINATION; VERTEBRATE GENOMES; CPG DINUCLEOTIDE; METHYLTRANSFERASE; RESIDUES; 5-METHYLCYTOSINE; MUTATION; REPAIR; CELLS; REPLICATION	Are 5-methylcytosine residues in DNA hot spots for transition mutagenesis? Numerous studies identify 1) structural changes induced by DNA methylation, 2) high percentages of human mutations that result from GC to AT transition pathways, and 3) differences between G.C and G.mC base pairs in susceptibility to nonenzymatic deamination. However, investigations of chemical stability necessarily involve non-physiological conditions for chemical analysis of deamination. Here we describe an experiment that compares rates of deamination-induced mutagenesis between a G.C and G.mC base pair, when both are present in duplex DNA, incubated at 37 degrees C and pH 7.4, within identical sequence contexts, in a natural mutational target (the Escherichia coli lacZ alpha gene) that selects for mutagenesis at the specific site under investigation. Under these conditions the rate of spontaneous deamination at G.mC exceeds that at G.C by more than 21-fold. Our data implicate differences in chemical stability toward deamination as a major causal factor relating DNA cytosine methylation to spontaneous mutagenesis.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	Oregon State University								BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COOPER DN, 1989, HUM GENET, V83, P181, DOI 10.1007/BF00286715; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; EHRLICH M, 1986, BIOSCIENCE REP, V6, P387, DOI 10.1007/BF01116426; EVANS BE, 1975, BIOCHEMISTRY-US, V14, P621, DOI 10.1021/bi00674a024; FREDERICO LA, 1993, BIOCHEMISTRY-US, V32, P6523, DOI 10.1021/bi00077a005; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; HODGESGARCIA Y, 1992, BIOCHEMISTRY-US, V31, P7595, DOI 10.1021/bi00148a022; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KRICKER MC, 1992, P NATL ACAD SCI USA, V89, P1075, DOI 10.1073/pnas.89.3.1075; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P362; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; Sambrook J, 1989, MOL CLONING LABORATO; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; Shapiro R, 1981, CHROMOSOME DAMAGE RE, P3; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SHENOY S, 1987, J MOL BIOL, V197, P617, DOI 10.1016/0022-2836(87)90468-2; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; SOBER HA, 1968, HDB BIOCH SELECTED D, pG12; SOWERS LC, 1989, MUTAT RES, V215, P131, DOI 10.1016/0027-5107(89)90225-X; SOWERS LC, 1987, MUTAT RES, V177, P201, DOI 10.1016/0027-5107(87)90003-0; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V697, P371, DOI 10.1016/0167-4781(82)90101-4; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; WU JC, 1987, J BIOL CHEM, V262, P4778	41	45	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7066	7069						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125913				2022-12-25	WOS:A1994NA03200006
J	LUCHT, JM; DERSCH, P; KEMPF, B; BREMER, E				LUCHT, JM; DERSCH, P; KEMPF, B; BREMER, E			INTERACTIONS OF THE NUCLEOID-ASSOCIATED DNA-BINDING PROTEIN H-NS WITH THE REGULATORY REGION OF THE OSMOTICALLY CONTROLLED PROU OPERON OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-LIKE PROTEINS; SALMONELLA-TYPHIMURIUM; GENE-EXPRESSION; CURVED DNA; PROLINE TRANSPORT; STRUCTURAL GENE; BENT DNA; IDENTIFICATION; SEQUENCES; MUTATIONS	The Escherichia coli hns gene encodes the abundant nucleoid-associated DNA-binding protein H-NS. Mutations in hns alter the expression of many genes with unrelated functions and result in a derepression of the proU operon (proVWX) without abolishing the osmotic control of its transcription. We have investigated the interactions of H-NS with the proU regulatory region by deletion analysis of cis-acting sequences, competitive gel retardation assays, and DNase I footprinting. The negative effect of H-NS on proU transcription was mediated by cis-acting sequences within proV but did not depend on the presence of a curved DNA segment upstream of the proU -35 region previously characterized as a target for H-NS binding in vitro. We detected a 46-base pair high affinity H-NS binding region downstream of the proU promoter at the 5' end of the proV gene and a complex array of additional H-NS binding sites which suggest the presence of an extended H-NS nucleoprotein complex. Most of the H-NS binding sites were highly A + T-rich and carried stretches of 5 or more consecutive A-T base pairs. The implications of our results for the osmotic regulation of proU transcription are discussed.	MAX PLANCK INST TERR MIKROBIOL, D-35043 MARBURG, GERMANY; UNIV KONSTANZ, DEPT BIOL, D-78434 CONSTANCE, GERMANY	Max Planck Society; University of Konstanz				Lucht, Jan/0000-0002-4722-1244; Dersch, Petra/0000-0001-8177-3280				BARRON A, 1986, J BACTERIOL, V167, P433, DOI 10.1128/jb.167.2.433-438.1986; BERTIN P, 1990, BIOCHIMIE, V72, P889, DOI 10.1016/0300-9084(90)90008-5; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DATTANANDA CS, 1991, J BACTERIOL, V173, P7481, DOI 10.1128/jb.173.23.7481-7490.1991; DERSCH P, 1993, MOL MICROBIOL, V8, P875, DOI 10.1111/j.1365-2958.1993.tb01634.x; DORMAN CJ, 1990, NATURE, V344, P789, DOI 10.1038/344789a0; DRI AM, 1992, GENE, V120, P11, DOI 10.1016/0378-1119(92)90003-8; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; DUNLAP VJ, 1985, J BACTERIOL, V163, P296, DOI 10.1128/JB.163.1.296-304.1985; DURRENBERGER M, 1991, RES MICROBIOL, V142, P373, DOI 10.1016/0923-2508(91)90106-K; FALCONI M, 1988, MOL MICROBIOL, V2, P323, DOI 10.1111/j.1365-2958.1988.tb00035.x; FALCONI M, 1991, NEW BIOL, V3, P615; FORSMAN K, 1992, P NATL ACAD SCI USA, V89, P9880, DOI 10.1073/pnas.89.20.9880; FRIEDRICH K, 1988, FEBS LETT, V229, P197, DOI 10.1016/0014-5793(88)80826-3; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; GOWRISHANKAR J, 1989, J BACTERIOL, V171, P1923, DOI 10.1128/jb.171.4.1923-1931.1989; GOWRISHANKAR J, 1985, J BACTERIOL, V164, P434, DOI 10.1128/JB.164.1.434-445.1985; GRAEMECOOK KA, 1989, MOL MICROBIOL, V3, P1287, DOI 10.1111/j.1365-2958.1989.tb00279.x; GUTIERREZ C, 1991, J MOL BIOL, V220, P959, DOI 10.1016/0022-2836(91)90366-E; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HIGGINS CF, 1992, NUCLEIC ACIDS MOL BI, V6, P67; HINTON JCD, 1992, MOL MICROBIOL, V6, P2327, DOI 10.1111/j.1365-2958.1992.tb01408.x; HROMOCKYJ AE, 1992, MOL MICROBIOL, V6, P2113, DOI 10.1111/j.1365-2958.1992.tb01385.x; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; JORDI BJAM, 1992, EMBO J, V11, P2627, DOI 10.1002/j.1460-2075.1992.tb05328.x; JOVANOVICH SB, 1989, J BIOL CHEM, V264, P7821; KANO Y, 1993, GENE, V126, P93; KAWULA TH, 1991, J BACTERIOL, V173, P4116, DOI 10.1128/jb.173.13.4116-4123.1991; LATEANA A, 1989, FEBS LETT, V244, P34, DOI 10.1016/0014-5793(89)81156-1; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; LEJEUNE P, 1990, P NATL ACAD SCI USA, V87, P360, DOI 10.1073/pnas.87.1.360; LIU QY, 1993, P NATL ACAD SCI USA, V90, P1761, DOI 10.1073/pnas.90.5.1761; LUCHT JM, 1991, J BACTERIOL, V173, P801, DOI 10.1128/jb.173.2.801-809.1991; MARSH M, 1990, NUCLEIC ACIDS RES, V18, P3397, DOI 10.1093/nar/18.11.3397; MAY G, 1990, MOL GEN GENET, V224, P81, DOI 10.1007/BF00259454; MAY G, 1986, MOL GEN GENET, V205, P225, DOI 10.1007/BF00430432; MAY G, 1989, MOL MICROBIOL, V3, P1521, DOI 10.1111/j.1365-2958.1989.tb00138.x; Miller J.H., 1972, EXPT MOL GENETICS; MINTON NP, 1984, GENE, V31, P269, DOI 10.1016/0378-1119(84)90220-8; MIZUNO T, 1987, NUCLEIC ACIDS RES, V15, P6827, DOI 10.1093/nar/15.17.6827; MORSCHHAUSER J, 1993, MOL GEN GENET, V238, P97; OHYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1617, DOI 10.1093/nar/20.7.1617; OLSEN A, 1993, MOL MICROBIOL, V7, P523, DOI 10.1111/j.1365-2958.1993.tb01143.x; OVERDIER DG, 1989, J BACTERIOL, V171, P4694, DOI 10.1128/jb.171.9.4694-4706.1989; OVERDIER DG, 1992, P NATL ACAD SCI USA, V89, P3140, DOI 10.1073/pnas.89.7.3140; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; PRINCE WS, 1990, J BIOL CHEM, V265, P17673; RIMSKY S, 1990, BIOCHEMISTRY-US, V29, P3765, DOI 10.1021/bi00467a024; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SERRANO M, 1993, TRENDS BIOCHEM SCI, V18, P202, DOI 10.1016/0968-0004(93)90187-R; SHI XL, 1993, J BACTERIOL, V175, P1182, DOI 10.1128/JB.175.4.1182-1186.1993; Silhavy T.J., 1984, EXPT GENE FUSIONS; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; SPEARS PA, 1986, J BACTERIOL, V168, P179, DOI 10.1128/jb.168.1.179-185.1986; SPURIO R, 1992, MOL GEN GENET, V231, P201, DOI 10.1007/BF00279792; TANAKA K, 1991, MOL GEN GENET, V226, P367, DOI 10.1007/BF00260648; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; UEGUCHI C, 1993, MOL GEN GENET, V236, P171, DOI 10.1007/BF00277109; VARSHAVSKY AJ, 1977, NUCLEIC ACIDS RES, V4, P2725, DOI 10.1093/nar/4.8.2725; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; YAMADA H, 1991, MOL GEN GENET, V230, P332, DOI 10.1007/BF00290685; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	69	169	172	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6578	6586						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120010				2022-12-25	WOS:A1994MZ50300050
J	MURPHY, G; NGUYEN, Q; COCKETT, MI; ATKINSON, SJ; ALLAN, JA; KNIGHT, CG; WILLENBROCK, F; DOCHERTY, AJP				MURPHY, G; NGUYEN, Q; COCKETT, MI; ATKINSON, SJ; ALLAN, JA; KNIGHT, CG; WILLENBROCK, F; DOCHERTY, AJP			ASSESSMENT OF THE ROLE OF THE FIBRONECTIN-LIKE DOMAIN OF GELATINASE-A BY ANALYSIS OF A DELETION MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 72-KDA GELATINASE; C-TERMINAL DOMAIN; TISSUE INHIBITOR; IV COLLAGENASE; MATRIX METALLOPROTEINASES; ACTIVATION; BINDING; PURIFICATION; STROMELYSIN; IDENTIFICATION	The properties of a deletion mutant Delta(V191-Q364) of gelatinase A, which represents the removal of the fibronectin like type II repeats defined by exons 5-7, were compared with those of full length gelatinase A. Both enzymes underwent self-activation over a similar time course in the presence of 4-aminophenylmercuric acetate. The fully active enzymes had similar k(cat)/K-m values for the cleavage of an octapeptide substrate, but the deletion mutant had 50% of the activity of wild type gelatinase A against beta-casein and 10% of the activity against gelatin. The cleavage pattern for gelatin was similar for both enzymes but differed for type IV collagen. Comparison of the rates of association of the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 and their N-terminal domains to both forms of gelatinase indicated that the fibronectin-like domain plays little role in TIMP binding. The deletion mutant failed to bind to collagen, while the wild type gelatinase bound tightly, indicating that the fibronectin-like domain is the sole site of collagen binding. Both gelatinases could be activated by concanavalin A-activated fibroblasts, suggesting that the fibronectin-like domain is not required for the membrane-mediated activation process.	UNIV LONDON,QUEEN MARY & WESTFIELD COLL,DEPT BIOCHEM,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London	MURPHY, G (corresponding author), STRANGEWAYS RES LAB,WORTS CAUSEWAY,CAMBRIDGE CB1 4RN,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Bos E S, 1981, J Immunoassay, V2, P187, DOI 10.1080/15321818108056977; CAWSTON TE, 1981, BIOCHIM BIOPHYS ACTA, V657, P73, DOI 10.1016/0005-2744(81)90131-5; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; FESSLER LI, 1984, J BIOL CHEM, V259, P9783; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HIPPS DS, 1991, BIOL CHEM H-S, V372, P287, DOI 10.1515/bchm3.1991.372.1.287; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1981, BIOCHEM J, V199, P807, DOI 10.1042/bj1990807; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023	29	176	180	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6632	6636						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120015				2022-12-25	WOS:A1994MZ50300058
J	ROTHMAN, A; WOLNER, B; BUTTON, D; TAYLOR, P				ROTHMAN, A; WOLNER, B; BUTTON, D; TAYLOR, P			IMMEDIATE-EARLY GENE-EXPRESSION IN RESPONSE TO HYPERTROPHIC AND PROLIFERATIVE STIMULI IN PULMONARY ARTERIAL SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SPONTANEOUSLY HYPERTENSIVE RATS; FOS MESSENGER-RNA; GROWTH-FACTOR; ANGIOTENSIN-II; CELLULAR HYPERTROPHY; RESISTANCE VESSELS; VASCULAR-DISEASE; JUN PROTEINS; SHORT FORM	Remodeling of the pulmonary vascular tree in pulmonary hypertension is associated with hypertrophy and proliferation of smooth muscle cells. Since the stimuli and signaling pathways for these processes are not well understood, we used a rat pulmonary arterial smooth muscle cell line (PAC1) to examine the effects of thrombin and platelet-derived growth factor (PDGF) on cellular growth and immediate-early gene expression, Over 72 h, thrombin (1 unit/ml) caused hypertrophy as reflected by a 102 +/- 12% increase in protein synthesis and a 49 +/- 11% increase in protein content per cell, but no change in cell number. PDGF (2.5 ng/ml) stimulated proliferation as evidenced by an increase in cell number (doubling in 5 days), but no significant change in protein content per cell. Immediate-early gene expression was examined by Northern blotting: both thrombin and PDGF induced egr(-1), c-fos, c-jun,junB, and fra-1 mRNAs within 15 min; the response was maximal at 30-60 min (increases ranging from 2.9- to 9.3-fold over control serum-deprived cells) and returned to base-line levels within 2-4 h. Neither agent affected junD mRNA levels. However, thrombin, but not PDGF, caused an increase in fosB mRNA levels (7.7 +/- 4.0-fold higher than control, n = 12, p < 0.0005). The immediate-early gene response to both agonists was generally dependent on extracellular Ca2+, Na+/H+ exchange, and protein kinase C activation, but not on cAMP. The exception was c-jun mRNA, the levels of which were not affected by inhibition of protein kinase C, but decreased significantly by prevention of cAMP formation. Thapsigargin-sensitive intracellular Ca2+ stores were necessary for the response to thrombin, but not to PDGF. These results demonstrate that thrombin is a hypertrophic agent and that PDGF is a proliferative agent in PAC1 cells. These two agonists stimulate increases in a variety of immediate-early gene mRNAs, but only thrombin induces fosB mRNA.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	ROTHMAN, A (corresponding author), UCSD, MED CTR,DEPT PEDIAT,DIV PEDIAT CARDIOL,8445, 200 W ARBOR DR, SAN DIEGO, CA 92103 USA.		Wolner, Branden/A-9615-2015	Wolner, Branden/0000-0003-0021-2073				BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BENDHACK LM, 1992, HYPERTENSION, V19, P142; BERK BC, 1990, J BIOL CHEM, V265, P19632; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1990, J BIOL CHEM, V265, P17334; BERK BC, 1991, BIOCHEM J, V274, P799, DOI 10.1042/bj2740799; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIALECKI RA, 1991, J CLIN INVEST, V88, P1894, DOI 10.1172/JCI115512; BOSWELL CA, 1992, MICROVASC RES, V43, P178, DOI 10.1016/0026-2862(92)90015-H; BRAVO R, 1989, GROWTH FACTORS DIFFE, P324; BUTTON D, 1994, J BIOL CHEM, V269, P6390; CAMPBELL JH, 1991, BASIC RES CARDIOL, V86, P3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EISENBERG PR, 1990, CIRCULATION, V82, P841, DOI 10.1161/01.CIR.82.3.841; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GRIENDLING KK, 1987, HYPERTENSION, V9, P181; HALL SM, 1992, J PATHOL, V166, P183, DOI 10.1002/path.1711660216; HAWORTH SG, 1977, AM J CARDIOL, V40, P781, DOI 10.1016/0002-9149(77)90197-7; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HOFFMAN JIE, 1981, CIRCULATION, V64, P873, DOI 10.1161/01.CIR.64.5.873; HORGAN MJ, 1987, J APPL PHYSIOL, V63, P1993, DOI 10.1152/jappl.1987.63.5.1993; HUANG CL, 1989, J BIOL CHEM, V264, P4391; ILKIW R, 1989, CIRC RES, V64, P814, DOI 10.1161/01.RES.64.4.814; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KOVARY K, 1991, NEW BIOL, V3, P870; KULIK TJ, 1991, BIOCHEM BIOPH RES CO, V180, P982, DOI 10.1016/S0006-291X(05)81162-3; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V158, P105, DOI 10.1016/S0006-291X(89)80183-4; MEYRICK B, 1983, CLIN CHEST MED, V4, P199; MEYRICK B, 1979, AM J PATHOL, V96, P51; MULVANY MJ, 1978, CIRC RES, V43, P854, DOI 10.1161/01.RES.43.6.854; MULVANY MJ, 1985, CIRC RES, V57, P794, DOI 10.1161/01.RES.57.5.794; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NABEL EG, 1988, CIRC RES, V62, P486, DOI 10.1161/01.RES.62.3.486; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; RABINOVITCH M, 1980, HUM PATHOL, V11, P499; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAO GN, 1990, J BIOL CHEM, V265, P19393; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1990, ONCOGENE, V5, P1091; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TREJO J, 1991, J BIOL CHEM, V266, P7876; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	64	88	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6399	6404						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119989				2022-12-25	WOS:A1994MZ50300024
J	KUPKE, T; KEMPTER, C; GNAU, V; JUNG, G; GOTZ, F				KUPKE, T; KEMPTER, C; GNAU, V; JUNG, G; GOTZ, F			MASS SPECTROSCOPIC ANALYSIS OF A NOVEL ENZYMATIC-REACTION - OXIDATIVE DECARBOXYLATION OF THE LANTIBIOTIC PRECURSOR PEPTIDE EPIA CATALYZED BY THE FLAVOPROTEIN EPID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMIN; BIOSYNTHESIS; PREPEPTIDE; SEQUENCE; GENES; ACIDS	The epidermin biosynthetic reaction between the flavoprotein EpiD and the precursor peptide EpiA was investigated by reversed-phase chromatography and ion spray mass spectrometry. Several products with molecular masses 46 and 104 Da less than that of EpiA were observed; these results were confirmed by using an MBP-EpiD fusion protein as enzyme and the mutant peptides EpiAR-1Q and K-EpiA as substrates. The reaction was inhibited by Zn2+ ions. Modifications were localized in the C-terminal fragment of EpiA as shown by factor Xa cleavage of the products followed by mass spectrometry analysis. In addition, EpiD reacted with the precursor peptides and with proepidermin, indicating that the leader peptide is not necessary for the recognition of EpiA by EpiD. Sequence analysis of modified proepidermin revealed that at least the amino acids Ile(+1)-Tyr(+20) are unmodified. The observed decrease in mass of 46 Da and the modification at the C terminus of EpiA is in agreement with the proposed enzymatic function of EpiD, the oxidative decarboxylation of the precursor peptide. In addition, the increased absorbance at 260 nm of the modified peptides indicates the presence of a thioenol group in the C-terminal proepidermin.	UNIV TUBINGEN,INST ORGAN CHEM,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen	KUPKE, T (corresponding author), UNIV TUBINGEN,WALDHAUSERSTR 70-8,D-72076 TUBINGEN,GERMANY.			Kupke, Thomas/0000-0003-2341-1710				ALLGAIER H, 1985, ANGEW CHEM INT EDIT, V24, P1051, DOI 10.1002/anie.198510511; AUGUSTIN J, 1992, EUR J BIOCHEM, V204, P1149, DOI 10.1111/j.1432-1033.1992.tb16740.x; AUGUSTIN J, 1991, NISIN NOVEL LANTIBIO, P277; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; GOTZ F, 1990, PATHOGENESIS OF WOUND AND BIOMATERIAL-ASSOCIATED INFECTIONS, P285; HAWKE D, 1987, APPLIED BIOSYSTEMS U, V28, P1; JANSON JC, 1989, PROTEIN PURIFICATION; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; JUNG G, 1991, ANGEW CHEM INT EDIT, V30, P1051, DOI 10.1002/anie.199110513; KLEIN C, 1993, APPL ENVIRON MICROB, V59, P296, DOI 10.1128/AEM.59.1.296-303.1993; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; KUPKE T, 1993, FEMS MICROBIOL LETT, V112, P43, DOI 10.1016/0378-1097(93)90535-A; KUPKE T, 1992, J BACTERIOL, V174, P5354, DOI 10.1128/JB.174.16.5354-5361.1992; PESCHEL A, 1993, MOL MICROBIOL, V9, P31, DOI 10.1111/j.1365-2958.1993.tb01666.x; REIS M, 1991, NISIN NOVEL LANTIBIO, P320; RIGGS P, 1990, CURRENT PROTOCOLS MO; Sahl H. G., 1991, NISIN NOVEL LANTIBIO, P347; SAHL HG, 1991, NISIN NOVEL LANTIBIO, P332; SCHNELL N, 1992, EUR J BIOCHEM, V204, P57, DOI 10.1111/j.1432-1033.1992.tb16605.x; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SUROVOY A, 1992, PEPTIDES 1992, P563; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; WEIL HP, 1990, EUR J BIOCHEM, V194, P217, DOI 10.1111/j.1432-1033.1990.tb19446.x	26	78	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5653	5659						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119901				2022-12-25	WOS:A1994MY84000029
J	KURODA, S; OTAKA, S; FUJISAWA, Y				KURODA, S; OTAKA, S; FUJISAWA, Y			FERMENTABLE AND NONFERMENTABLE CARBON-SOURCES SUSTAIN CONSTITUTIVE LEVELS OF EXPRESSION OF YEAST TRIOSEPHOSPHATE DEHYDROGENASE-3 GENE FROM DISTINCT PROMOTER ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS SURFACE-ANTIGEN; DNA-BINDING PROTEIN; UPSTREAM ACTIVATING SEQUENCES; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCES; EFFICIENT EXPRESSION; ENOLASE GENES; GCR1; TRANSCRIPTION; ENCODES	The triosephosphate dehydrogenase 3 gene (TDH3) is a glycolytic enzyme gene and is abundantly transcribed in Saccharomyces cerevisiae. The promoter region of the TDH3 gene is known to exhibit high transcriptional activity regardless of the fermentability of the carbon source and has been widely utilized to synthesize heterologous gene products in S. cerevisiae. To clarify the mechanism of constitutive transcription by the promoter, we constructed mutant promoters and analyzed the in vivo transcriptional activity of these promoters. The majority of the transcriptional potential is contained within a DNA fragment extending from nucleotides -524 to -255 (-524/-255; relative to the translation initiation codon), which consists of three cia-acting elements: a fermentable carbon source-dependent upstream activation sequence (UAS) 1 (-524/-426), a fermentable carbon source-dependent upstream repression sequence (URS) (-426/-393), and a nonfermentable carbon source-dependent UAS2 (-305/-255). This result indicates that the promoter involves two apparent promoter elements. One is fermentable carbon source-dependent, and another is nonfermentable carbon source-dependent. Southwestern analyses indicated that a novel 20-kDa protein is induced in yeast cells by shifting from a fermentable to nonfermentable carbon source. The protein interacts with two UAS1 13-base pair elements and one URS 18-base pair element, one of which had been previously designated GPE (general regulatory factor 1 (GRF1) binding site potentiator element) (Bitter, G. A., Chang, K. K. H., and Egan, K. M. (1991) Mol. Gen. Genet. 231, 22-32). We therefore termed the 20-kDa protein GPEB (GRF1-binding site potentiator element-binding protein). In addition, mutational analyses strongly suggested that UAS 1, URS, and UAS2 interact with GRF1 and GPEB, GPEB, and the GCR1 (glycolysis regulation 1) gene product, respectively. We therefore concluded that constitutive transcription by the TDH3 promoter is sustained by two promoter elements and that the switch between them might be controlled by the nonfermentable carbon source-inducible GPEB.			KURODA, S (corresponding author), TAKEDA CHEM IND LTD,PHARMACEUT GRP,DIV DISCOVERY RES,DISCOVERY RES LABS 2 DEPT 5,YODOGAWA KU,OSAKA 532,JAPAN.							BAKER HV, 1986, MOL CELL BIOL, V6, P3774, DOI 10.1128/MCB.6.11.3774; BAKER HV, 1991, P NATL ACAD SCI USA, V88, P9443, DOI 10.1073/pnas.88.21.9443; BITTER GA, 1991, MOL GEN GENET, V231, P22, DOI 10.1007/BF00293817; BRINDLE PK, 1990, MOL CELL BIOL, V10, P4872, DOI 10.1128/MCB.10.9.4872; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUCHMAN AR, 1986, MOL CELL BIOL, V8, P5079; CHAMBER A, 1988, MOL CELL BIOL, V9, P5516; CHAMBER A, 1988, NUCLEIC ACIDS RES, V16, P8254; CLIFTON D, 1981, J BIOL CHEM, V256, P3074; COHEN R, 1987, MOL CELL BIOL, V7, P2753, DOI 10.1128/MCB.7.8.2753; DELVIN C, 1991, MOL CELL BIOL, V11, P3624; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; HESS B, 1986, ADV ENZYME REGUL, V7, P149; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HOLLAND JP, 1979, J BIOL CHEM, V254, P9839; HOLLAND JP, 1980, J BIOL CHEM, V255, P2596; HOLLAND JP, 1983, J BIOL CHEM, V258, P5291; HOLLAND MJ, 1981, J BIOL CHEM, V256, P1385; HOLLAND MJ, 1987, MOL CELL BIOL, V7, P813, DOI 10.1128/MCB.7.2.813; HOLLAND MJ, 1976, J BIOL CHEM, V254, P5466; HUET J, 1987, P NATL ACAD SCI USA, V84, P3648, DOI 10.1073/pnas.84.11.3648; HUET J, 1985, EMBO J, V4, P3539, DOI 10.1002/j.1460-2075.1985.tb04114.x; HUIE MA, 1992, MOL CELL BIOL, V12, P2690, DOI 10.1128/MCB.12.6.2690; ITOH Y, 1986, BIOCHEM BIOPH RES CO, V138, P268, DOI 10.1016/0006-291X(86)90275-5; JAYARAM M, 1983, CELL, V34, P95, DOI 10.1016/0092-8674(83)90139-3; KAISHO Y, 1989, YEAST, V5, P91, DOI 10.1002/yea.320050204; KITANO K, 1987, BIO-TECHNOL, V5, P281, DOI 10.1038/nbt0387-281; KNISKERN PJ, 1986, GENE, V46, P135, DOI 10.1016/0378-1119(86)90177-0; KREBS EG, 1953, J BIOL CHEM, V200, P471; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURODA S, 1992, J BIOL CHEM, V267, P1953; KURODA S, 1989, GENE, V78, P297; MARSCHALL M, 1989, GENE, V81, P109, DOI 10.1016/0378-1119(89)90341-7; MCALISTER L, 1985, J BIOL CHEM, V260, P5013; MCALISTER L, 1985, J BIOL CHEM, V260, P5019; NISHIZAWA M, 1989, MOL CELL BIOL, V9, P442, DOI 10.1128/MCB.9.2.442; OGDEN JE, 1986, MOL CELL BIOL, V6, P4335, DOI 10.1128/MCB.6.12.4335; PAVLOVIC B, 1988, MOL CELL BIOL, V8, P5513, DOI 10.1128/MCB.8.12.5513; SANTANGELO GM, 1990, MOL CELL BIOL, V10, P859, DOI 10.1128/MCB.10.2.859; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; STANWAY C, 1987, NUCLEIC ACIDS RES, V15, P6855, DOI 10.1093/nar/15.17.6855; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; WILLETT CE, 1993, MOL CELL BIOL, V13, P2623, DOI 10.1128/MCB.13.4.2623; WOUDT LP, 1986, EMBO J, V5, P1037, DOI 10.1002/j.1460-2075.1986.tb04319.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0	47	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6153	6162						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119960				2022-12-25	WOS:A1994MY84000101
J	LING, JS; SAHLIN, M; SJOBERG, BM; LOEHR, TM; SANDERSLOEHR, J				LING, JS; SAHLIN, M; SJOBERG, BM; LOEHR, TM; SANDERSLOEHR, J			DIOXYGEN IS THE SOURCE OF THE MU-OXO BRIDGE IN IRON RIBONUCLEOTIDE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; ESCHERICHIA-COLI; HORSERADISH-PEROXIDASE; METHANE MONOOXYGENASE; ACTIVE-SITES; PROTEINS; ACTIVATION; MECHANISM; SUBUNIT; ENZYME	The formation of the iron-radical cofactor in the R2 subunit of ribonucleotide reductase has been monitored by resonance Raman spectroscopy. The diferrous cluster in reduced R2 functions as a tyrosine oxidase; it uses O-2 to oxidize Tyr-122 to a stable radical and results in an ore-bridged diferric cluster. The Phe-122 mutant produces an identical dinuclear iron center and provides a simplified model for O-2 activation. Oxidation with O-18(2) results in quantitative incorporation of O-18 into the diferric cluster as evidenced by the 13-cm(-1) downshift in the Fe-O-Fe stretching vibration at 500 cm(-1). Thus, O-2 must be coordinated to the diiron center during O-O bond cleavage. When the Phe-208 adjacent to the diferrous cluster is mutated to Tyr, reaction with O-2 results in its oxidation to dihydroxyphenylalanine (DOPA-208) and subsequent coordination to Fe as a catecholate ligand. The Fe-O/(catecholate) stretching modes at 512 and 592 cm(-1) shift by -13 and -8 cm(-1), respectively, when the oxidation is performed in (H2O)-O-18, These isotope shifts indicate that the second oxygen atom of DOPA-208 originates from H2O rather than O-2. Taken together, our re suits are consistent with a mu-1,1-peroxide and a high valent iron-ore species as reaction intermediates. A common pathway for oxygen activation by the related iron-ore enzymes methane monooxygenase and fatty acid desaturase is proposed.	OREGON GRAD INST SCI & TECHNOL, DEPT CHEM BIOCHEM & MOLEC BIOL, PORTLAND, OR 97291 USA; UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN	Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360	NIGMS NIH HHS [GM-18865] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018865] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERG A, 1993, BIOCHEMISTRY-US, V32, P9845; ABERG A, 1993, THESIS U STOCKHOLM; ANDERSSON KK, 1988, J BIOL CHEM, V263, P18621; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; ATTA M, 1992, J BIOL CHEM, V267, P20682; BACKES G, 1989, BIOCHEMISTRY-US, V28, P1923, DOI 10.1021/bi00430a074; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1993, J INORG BIOCHEM, V51, P6; BUIST PH, 1992, J AM CHEM SOC, V114, P5073, DOI 10.1021/ja00039a018; CHUANG WJ, 1989, J BIOL CHEM, V264, P14209; COX DD, 1988, J AM CHEM SOC, V110, P2026, DOI 10.1021/ja00215a002; DALTON H, 1980, ADV APPL MICROBIOL, V26, P71; DEMONTELLANO PRO, 1987, J BIOL CHEM, V262, P11641; DEROSE VJ, 1993, J AM CHEM SOC, V115, P6440, DOI 10.1021/ja00067a081; DORDICK JS, 1986, BIOCHEMISTRY-US, V25, P2946, DOI 10.1021/bi00358a032; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1990, BIOCHEM BIOPH RES CO, V168, P659, DOI 10.1016/0006-291X(90)92371-6; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HENDRA PJ, 1968, CHEM IND-LONDON, P718; HESTER RE, 1964, INORG CHEM, V3, P513, DOI 10.1021/ic50014a012; HOLMES MA, 1991, J MOL BIOL, V218, P583, DOI 10.1016/0022-2836(91)90703-9; KARLIN KD, 1988, J AM CHEM SOC, V110, P6769, DOI 10.1021/ja00228a027; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; LOEHR TM, 1993, METHOD ENZYMOL, V226, P431; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; NORDLUND P, 1992, FEBS LETT, V307, P257, DOI 10.1016/0014-5793(92)80690-I; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMO M, 1992, J BIOL CHEM, V267, P8711; PEDERSEN JZ, 1993, FEBS LETT, V325, P53, DOI 10.1016/0014-5793(93)81412-S; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; PYRZ JW, 1985, J AM CHEM SOC, V107, P614, DOI 10.1021/ja00289a013; QUE L, 1991, SCIENCE, V253, P273, DOI 10.1126/science.1857963; RARDIN RL, 1991, NEW J CHEM, V15, P417; RAVI N, 1993, BIOCHEMISTRY-US, V32, P8487, DOI 10.1021/bi00084a013; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SALAMA S, 1978, BIOCHEMISTRY-US, V17, P3781, DOI 10.1021/bi00611a017; SANDERSLOEHR J, 1989, IRON CARRIERS IRON P, P373; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1987, BIOCHEMISTRY-US, V26, P4242; SOLOMON EI, 1992, ACCOUNTS CHEM RES, V25, P343, DOI 10.1021/ar00020a004; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991; STENKAMP RE, 1992, AM CRYST ASS ABSTR, V20, P140; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; THEWALT U, 1967, J AM CHEM SOC, V89, P6364, DOI 10.1021/ja01000a074; THOMANN H, 1993, J AM CHEM SOC, V115, P8881, DOI 10.1021/ja00072a068; THOMPSON DC, 1993, CHEM-BIOL INTERACT, V86, P129, DOI 10.1016/0009-2797(93)90117-H; TOLMAN WB, 1991, J AM CHEM SOC, V113, P152, DOI 10.1021/ja00001a023; VALENTINE JS, 1994, IN PRESS ACTIVATION; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; VOLBEDA A, 1989, J MOL BIOL, V206, P531, DOI 10.1016/0022-2836(89)90499-3; Wagner H.-U., 1974, CHEM QUINONOID COMPO, P1145	64	91	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5595	5601						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119895				2022-12-25	WOS:A1994MY84000022
J	STRAUSFELD, U; FERNANDEZ, A; CAPONY, JP; GIRARD, F; LAUTREDOU, N; DERANCOURT, J; LABBE, JC; LAMB, NJC				STRAUSFELD, U; FERNANDEZ, A; CAPONY, JP; GIRARD, F; LAUTREDOU, N; DERANCOURT, J; LABBE, JC; LAMB, NJC			ACTIVATION OF P34(CDC2) PROTEIN-KINASE BY MICROINJECTION OF HUMAN CDC25C INTO MAMMALIAN-CELLS - REQUIREMENT FOR PRIOR PHOSPHORYLATION OF CDC25C BY P34(CDC2) AT MITOSIS ON SITES PHOSPHORYLATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P80CDC25 MITOTIC INDUCER; FISSION YEAST CDC25; TYROSINE PHOSPHORYLATION; DNA-REPLICATION; P34CDC2 KINASE; STARFISH OOCYTES; CYCLE CONTROL; PHOSPHATASE; MPF; XENOPUS	Human cdc25C protein, a specific tyrosine phosphatase that activates the p34(cdc2) protein kinase at mitosis, is itself a phosphoprotein that shows increased phosphorylation during the G(2)-M transition. In vitro, cdc25C protein is substantially phosphorylated by purified p34(cdc2)-cyclin B protein kinase. Of seven putative phosphorylation sites for p34(cdc2) protein kinase present in human cdc25C, five are phosphorylated by p34(cdc2) protein kinase in vitro, as assessed by tryptic phosphopeptide mapping and peptide sequencing. These same sites are also phosphorylated in vivo during the G(2)-M transition in normal mammalian fibroblasts and have been precisely mapped. The cdc25C phosphorylated in vitro by p34(cdc2) protein kinase exhibits a 2-3-fold higher activity than the nonphosphorylated cdc25C, as assayed by activation of inactive cdca prokinase. Microinjection of purified cdc25C proteins into living fibroblasts reveals that only the phosphorylated form of cdc25 is highly effective in activating G(2) cells into premature prophase in a manner similar to microinjection of purified active p34(cdc2) protein kinase. Together these data show that multisite phosphorylation of cdc25C by p34(cdc2)-cyclin B protein kinase occurs at the G(2)-M transition and is sufficient to induce the autoamplification of cdc2/M-phase promoting factor necessary to drive somatic mammalian cells into mitosis.	CTR RECH BIOCHIM MACROMOLEC, DEPT CELL BIOL, CNRS, INSERM, F-34033 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			labbe, jean-claude/B-2277-2009	Girard, Franck/0000-0003-2587-4495				AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GIRARD F, 1992, J CELL BIOL, V118, P785, DOI 10.1083/jcb.118.4.785; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, COLD SPRING HARB SYM, V56, P585; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1992, BIOCHEM SOC T, V20, P239, DOI 10.1042/bst0200239; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0	44	133	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5989	6000						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119945				2022-12-25	WOS:A1994MY84000079
J	TSUKAMOTO, T; HATA, S; YOKOTA, S; MIURA, S; FUJIKI, Y; HIJIKATA, M; MIYAZAWA, S; HASHIMOTO, T; OSUMI, T				TSUKAMOTO, T; HATA, S; YOKOTA, S; MIURA, S; FUJIKI, Y; HIJIKATA, M; MIYAZAWA, S; HASHIMOTO, T; OSUMI, T			CHARACTERIZATION OF THE SIGNAL PEPTIDE AT THE AMINO-TERMINUS OF THE RAT PEROXISOMAL 3-KETOACYL-COA THIOLASE PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-TRANSFER PROTEIN; COENZYME-A OXIDASE; 3-KETOACYL-COA THIOLASE; TARGETING SIGNAL; 3-OXOACYL-COA THIOLASE; EXPRESSION VECTORS; LIVER PEROXISOMES; CARBOXY TERMINUS; MAMMALIAN-CELLS; BETA-OXIDATION	The amino-terminal presequences of rat peroxisomal 3-ketoacyl-CoA thiolase precursors (types A and B) were reported to be cleavable signal peptides for peroxisomal protein translocation. In the present study, this was proven by immunoelectron microscopy of the cultured Chinese hamster ovary cells stably expressing fusion proteins of the amino-terminal sequences of the thiolase precursor and Escherichia coli dihydrofolate reductase. The fusion proteins were processed into mature forms of the apparently correct sizes. Site-directed mutagenesis studies of the charged residues in the B-type presequence (26 amino acid residues) revealed that arginine at position -24 and histidine at position -17 were both indispensable. Even replacement of these residues with other basic amino acids abolished the import activity. Both Arg(-24) and His(-17) were also required in a longer presequence (36 amino acid residues) of the thiolase A, thereby suggesting that the signal can function in an internal position. When glutamic acid at position -11 was changed to amino acids other than aspartic acid, the signal peptide became apparently effective in both peroxisomal and mitochondrial targeting. All of these data indicate that the thiolase signal peptide is a newly defined type of peroxisomal targeting signal recognized by a mechanism presumably different from that for a known peroxisomal signal, the carboxyl-terminal Ser-Lys-Leu-COOH motif.	HIMEJI INST TECHNOL,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN; YAMANASKI MED COLL,DEPT ANAT,TAMAHO,YAMANASHI 40938,JAPAN; MEIJI INST HLTH SCI,MOLEC CELL BIOL LAB,ODAWARA,KANAGAWA 250,JAPAN; SHINSHU UNIV,SCH MED,DEPT BIOCHEM,MATSUMOTO,NAGANO 390,JAPAN	University of Hyogo; University of Yamanashi; Shinshu University								BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; BENDAYAN M, 1982, J HISTOCHEM CYTOCHEM, V30, P81, DOI 10.1177/30.1.6172469; BLATTNER J, 1992, J CELL BIOL, V119, P1129, DOI 10.1083/jcb.119.5.1129; BODNAR AG, 1990, GENE, V91, P193, DOI 10.1016/0378-1119(90)90088-9; BOUT A, 1988, NUCLEIC ACIDS RES, V16, P10369, DOI 10.1093/nar/16.21.10369; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEROE C, 1987, J HISTOCHEM CYTOCHEM, V35, P1191, DOI 10.1177/35.11.3655323; FAIRBAIRN LJ, 1989, NUCLEIC ACIDS RES, V17, P3588, DOI 10.1093/nar/17.9.3588; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUNG K, 1991, MOL BIOCHEM PARASIT, V45, P261, DOI 10.1016/0166-6851(91)90093-L; GIETL C, 1990, P NATL ACAD SCI USA, V87, P5773, DOI 10.1073/pnas.87.15.5773; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; IWAKURA M, 1992, J BIOCHEM-TOKYO, V111, P31, DOI 10.1093/oxfordjournals.jbchem.a123714; KAMIRYO T, 1989, AGR BIOL CHEM TOKYO, V53, P179, DOI 10.1080/00021369.1989.10869248; KRAGLER F, 1993, J CELL BIOL, V120, P665, DOI 10.1083/jcb.120.3.665; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MIURA S, 1984, J BIOL CHEM, V259, P6397; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1980, EUR J BIOCHEM, V103, P589, DOI 10.1111/j.1432-1033.1980.tb05984.x; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; OSSENDORP BC, 1991, EUR J BIOCHEM, V201, P233, DOI 10.1111/j.1432-1033.1991.tb16279.x; OSUMI T, 1990, BIOESSAYS, V12, P217, DOI 10.1002/bies.950120505; OSUMI T, 1992, BIOCHEM BIOPH RES CO, V186, P811, DOI 10.1016/0006-291X(92)90818-6; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Roth J, 1982, TECHNIQUES IMMUNOCYT, V1, P108; Sambrook J, 1989, MOL CLONING LABORATO; SINGH KK, 1992, MOL CELL BIOL, V12, P5593, DOI 10.1128/MCB.12.12.5593; SMALL GM, 1988, EMBO J, V7, P1167, DOI 10.1002/j.1460-2075.1988.tb02927.x; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170	45	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6001	6010						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119946				2022-12-25	WOS:A1994MY84000080
J	HUTCHISON, KA; DITTMAR, KD; CZAR, MJ; PRATT, WB				HUTCHISON, KA; DITTMAR, KD; CZAR, MJ; PRATT, WB			PROOF THAT HSP70 IS REQUIRED FOR ASSEMBLY OF THE GLUCOCORTICOID RECEPTOR INTO A HETEROCOMPLEX WITH HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STEROID-BINDING DOMAIN; PROGESTERONE-RECEPTOR; COMPLEX; 90-KDA; RECONSTITUTION; ASSOCIATION; CYTOSOL; CELL; MR	Incubation of immunopurified glucocorticoid receptor with rabbit reticulocyte lysate forms a complex between the receptor and hsp90, with simultaneous conversion of the receptor from a non-steroid binding but DNA binding state typical of the transformed receptor back to the steroid binding, non-DNA binding state typical of the untransformed receptor (Scherrer, L. C., Dalman, F. C., Masse, E., Meshinchi, S., and Pratt, W. B. (1990) J. Biol. Chem. 265, 21397-21400). The receptor heterocomplex formed by the lysate also contains hsp70 and is formed in an ATP-dependent and cation-selective manner (Hutchison, K. A., Czar, M. J., Scherrer, L. C., and Pratt, W. B. (1992) J. Biol. Chem. 267, 14047-14053). In this work, we selectively depleted reticulocyte lysate of hsp70 by passing it through a column of ATP-agarose. The hsp70-depleted lysate contains hsp90, but it cannot form a receptor-hsp90 heterocomplex. hsp70 purified from mouse L cells binds to immunopurified glucocorticoid receptor but does not convert it to the steroid binding state. Addition of purified hsp70 to the hsp70-depleted lysate reactivates the heterocomplex assembly system, permitting formation of a receptor-hsp90-hsp70 complex, with the receptor being returned to the high affinity steroid-binding conformation. These data are consistent with a model in which the protein-unfolding activity of hsp70 is required for hsp90 binding to the hormone binding domain of the glucocorticoid receptor. The hsp56 immunophilin component of the native receptor heterocomplex is also present in the reconstituted receptor heterocomplex in an hsp70-dependent manner. In addition to hsp70, other as yet unidentified factors in reticulocyte lysate are required for receptor heterocomplex assembly.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXIS MN, 1992, EUR J BIOCHEM, V204, P75, DOI 10.1111/j.1432-1033.1992.tb16607.x; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, J BIOL CHEM, V263, P18520; ERHART JC, 1988, ONCOGENE, V3, P595; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1988, J BIOL CHEM, V263, P267; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; REXIN M, 1991, J BIOL CHEM, V266, P24601; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436	33	163	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5043	5049						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106480				2022-12-25	WOS:A1994MX57100055
J	MARSZALEK, J; KAGUNI, JM				MARSZALEK, J; KAGUNI, JM			DNAA PROTEIN DIRECTS THE BINDING OF DNAB PROTEIN IN INITIATION OF DNA-REPLICATION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIALIZED NUCLEOPROTEIN STRUCTURES; P1 PLASMID REPLICATION; LAMBDA-O-PROTEIN; MINI-F PLASMID; BACTERIOPHAGE-LAMBDA; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; PHYSICAL-PROPERTIES; AUTONOMOUS REPLICATION; ENCODED PROTEINS	DnaA protein of Escherichia coli acts in the initiation of chromosomal replication to bind to sequences in the chromosomal origin. On binding, it promotes the assembly of other replication proteins that serve to prime DNA replication and assemble the replication apparatus for bidirectional replication fork movement. A collection of monoclonal antibodies to DnaA protein have been produced, one of which is described here, that interferes with the action of DnaA protein in promoting formation of a prepriming complex. On the analysis of this process, the antibody appears to interfere with the physical interaction between DnaA and DnaB protein in the DnaB.DnaC complex. Cross-linking studies confirm that DnaA and DnaB proteins interact directly These results provide the first direct evidence that one of the roles of DnaA protein is to act as a site for binding of DnaB protein to the DNA and perhaps orients DnaB helicase to account for the directionality of replication fork movement.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; UNIV GDANSK, DEPT MOLEC BIOL, PL-80822 GDANSK, POLAND	Michigan State University; Fahrenheit Universities; University of Gdansk			Marszalek, Jaroslaw/F-5824-2011	Kaguni, Jon/0000-0002-3096-4447; Marszalek, Jaroslaw/0000-0002-6978-1189	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM033992, GM33992] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; ABELES AL, 1989, J BACTERIOL, V171, P43, DOI 10.1128/jb.171.1.43-52.1989; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5247; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CHURCHWARD G, 1983, NUCLEIC ACIDS RES, V11, P5645, DOI 10.1093/nar/11.16.5645; DIAZ R, 1982, J BACTERIOL, V150, P1077, DOI 10.1128/JB.150.3.1077-1084.1982; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1989, J BIOL CHEM, V264, P10719; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FELTON J, 1979, MOL GEN GENET, V175, P231, DOI 10.1007/BF00425541; FILUTOWICZ M, 1986, J MOL BIOL, V187, P225, DOI 10.1016/0022-2836(86)90230-5; FREY J, 1979, MOL GEN GENET, V174, P117, DOI 10.1007/BF00268349; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1986, CELL, V38, P5616; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; FURTH ME, 1978, J MOL BIOL, V126, P195, DOI 10.1016/0022-2836(78)90359-5; GAYLO PJ, 1987, J BACTERIOL, V169, P4703, DOI 10.1128/jb.169.10.4703-4709.1987; GERMINO J, 1983, CELL, V32, P131, DOI 10.1016/0092-8674(83)90503-2; HANSEN EB, 1986, P NATL ACAD SCI USA, V83, P4423, DOI 10.1073/pnas.83.12.4423; HARING V, 1989, PROMISCUOUS PLASMIDS, P95; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HWANG DS, 1992, J BIOL CHEM, V267, P23087; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KLEIN A, 1980, EUR J BIOCHEM, V105, P1, DOI 10.1111/j.1432-1033.1980.tb04467.x; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; KOLTER R, 1982, J MOL BIOL, V161, P45, DOI 10.1016/0022-2836(82)90277-7; LANKA E, 1978, P NATL ACAD SCI USA, V75, P799, DOI 10.1073/pnas.75.2.799; LANKA E, 1983, NUCLEIC ACIDS RES, V11, P987, DOI 10.1093/nar/11.4.987; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; MACALLISTER TW, 1991, J BIOL CHEM, V266, P16056; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; MARSZALEK J, 1992, J BIOL CHEM, V267, P19334; MASAI H, 1990, J BIOL CHEM, V265, P15134; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; MASSON L, 1986, NUCLEIC ACIDS RES, V14, P5693, DOI 10.1093/nar/14.14.5693; MEIJER M, 1979, P NATL ACAD SCI USA, V76, P580, DOI 10.1073/pnas.76.2.580; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MUROTSU T, 1981, GENE, V15, P257, DOI 10.1016/0378-1119(81)90135-9; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; OHTSUBO E, 1977, PLASMID, V1, P8, DOI 10.1016/0147-619X(77)90004-X; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; ORTEGA S, 1986, NUCLEIC ACIDS RES, V14, P4865, DOI 10.1093/nar/14.12.4865; ORTEGAJIMENEZ S, 1992, NUCLEIC ACIDS RES, V20, P2547, DOI 10.1093/nar/20.10.2547; PARDA CA, 1991, J BIOL CHEM, V266, P18895; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RYDER T, 1981, ICN UCLA S MOL CELL, V22, P91; SCHOLZ P, 1985, PLASMIDS BACTERIA, P243; SCLAFANI RA, 1981, J BACTERIOL, V146, P418, DOI 10.1128/JB.146.1.418-421.1981; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEUFERT W, 1988, J BIOL CHEM, V263, P2719; STALKER DM, 1979, P NATL ACAD SCI USA, V76, P1150, DOI 10.1073/pnas.76.3.1150; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; STENZEL TT, 1991, GENE DEV, V5, P1453, DOI 10.1101/gad.5.8.1453; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TANG XB, 1989, J BACTERIOL, V171, P5290, DOI 10.1128/jb.171.10.5290-5295.1989; TOKINO T, 1986, P NATL ACAD SCI USA, V83, P4109, DOI 10.1073/pnas.83.12.4109; TSURIMOTO T, 1991, NUCLEIC ACIDS RES, V9, P1789; VOCKE C, 1983, CELL, V35, P495, DOI 10.1016/0092-8674(83)90183-6; VOCKE C, 1983, P NATL ACAD SCI USA, V80, P580; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER SH, 1979, COLD SPRING HARB SYM, V43, P303, DOI 10.1101/SQB.1979.043.01.037; WICKNER SH, 1986, J BIOL CHEM, V261, P7537; WICKNER SH, 1987, P NATL ACAD SCI USA, V84, P3668, DOI 10.1073/pnas.84.11.3668; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; YAMAGUCHI K, 1984, GENE, V29, P311; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1984, MOL GEN GENET, V196, P401, DOI 10.1007/BF00436186	80	176	177	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4883	4890						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106460				2022-12-25	WOS:A1994MX57100031
J	GOMBAU, L; SCHLEEF, RR				GOMBAU, L; SCHLEEF, RR			PROCESSING OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) INTO THE REGULATED SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; HUMAN-PLATELETS; ATT-20 CELLS; P-SELECTIN; PROTEIN; GRANULES; PLASMA; PROPOLYPEPTIDE; VITRONECTIN; TRYPSINOGEN	To understand the processing of type 1 plasminogen activator inhibitor (PAI-1) into the storage granules of platelets, we utilized a eukaryotic expression vector (pRC/CMV) to transfer the human cDNA for PAI-1 into AtT-20 cells, a mouse pituitary cell line known to sort proteins in a regulated fashion. Immunofluorescence staining of PAI-1-transfected AtT-20 clones revealed colocalization of PAI-1 with an endogenously produced and stored hormone (i.e. adrenocorticotropic hormone, ACTH). Stimulation of PAI-1-transfected AtT-20 cells with a secretagogue resulted in the release of both active PAI-1 and the latent form. In comparison, PAI-1-transfected Chinese hamster ovary cells (i.e. a nonpackaging cell line) did not release PAI-1 in response to a secretagogue and exhibited immunoreactivity for PAI-1 primarily confined to the Golgi region. Percoll density gradient fractionation of AtT-20 cells revealed a codistribution of PAI-1 and ACTH in cellular compartments of the same density.The half-life of PAI-1 activity at 37-degrees-C was prolonged in intact granules (t1/2, 5 h) in comparison with its half-life in lysed granules (t1/2, 2 h). These studies demonstrate the presence of a new functional property associated with the PAI-1 molecule that directs this inhibitor into the storage secretory pathway.	Scripps Res Inst, DEPT VASC BIOL, CVB-3, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL 45954] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BITHELL TC, 1993, CLIN HEMATOLOGY, P511; BOOTH NA, 1985, J CLIN PATHOL, V38, P825, DOI 10.1136/jcp.38.7.825; BOOTH NA, 1988, BRIT J HAEMATOL, V70, P327, DOI 10.1111/j.1365-2141.1988.tb02490.x; BOOTH NA, 1990, FIBRINOLYSIS, V4, P138, DOI 10.1016/0268-9499(90)90391-V; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGESS TL, 1987, J CELL BIOL, V105, P659, DOI 10.1083/jcb.105.2.659; DECLERCK PJ, 1988, BLOOD, V71, P220; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; KONKLE BA, 1993, ARTERIOSCLER THROMB, V13, P669, DOI 10.1161/01.ATV.13.5.669; KRUITHOF EKO, 1987, BLOOD, V70, P1645; KRUITHOF EKO, 1986, THROMB HAEMOSTASIS, V55, P201; LANG IM, 1993, CIRCULATION, V87, P1990, DOI 10.1161/01.CIR.87.6.1990; LANG IM, 1992, BLOOD, V80, P2269; LEVI M, 1992, CIRCULATION, V85, P305, DOI 10.1161/01.CIR.85.1.305; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1989, BLOOD, V74, P1989; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; SCHLEEF RR, 1991, J CELL BIOL, V113, P1413, DOI 10.1083/jcb.113.6.1413; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; SCHLEEF RR, 1985, J LAB CLIN MED, V106, P408; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; SIMPSON AJ, 1990, BRIT J HAEMATOL, V75, P543, DOI 10.1111/j.1365-2141.1990.tb07796.x; SPRENGERS ED, 1986, THROMB HAEMOSTASIS, V55, P325; SPRENGERS ED, 1987, BLOOD, V69, P381; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I	40	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3875	3880						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106433				2022-12-25	WOS:A1994MV63100108
J	OKADA, T; KAWANO, Y; SAKAKIBARA, T; HAZEKI, O; UI, M				OKADA, T; KAWANO, Y; SAKAKIBARA, T; HAZEKI, O; UI, M			ESSENTIAL ROLE OF PHOSPHATIDYLINOSITOL 3-KINASE IN INSULIN-INDUCED GLUCOSE-TRANSPORT AND ANTILIPOLYSIS IN RAT ADIPOCYTES - STUDIES WITH A SELECTIVE INHIBITOR WORTMANNIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SIGNAL TRANSDUCTION; INSULINOMIMETIC AGENTS; INTACT-CELLS; FAT-CELLS; PROTEIN; PHOSPHORYLATION; STIMULATION; ACTIVATION; SUBSTRATE	Significant activity of phosphatidylinositol 3-kinase (PI 3-kinase) was detected in the membrane fractions, or in the immunoprecipitates prepared with anti-phosphotyrosine antibodies, from rat adipocytes that had been incubated with insulin for 20 min. The PI 3-kinase activity in these preparations as well as in the whole cell lysates of adipocytes not treated with insulin was inhibited by the addition of wortmannin, a fungal metabolite, to the enzyme assay mixture. The inhibition was dependent on the inhibitor concentration with IC50 being less than 10 nm and perfect inhibition at 100 nM. The effect of insulin to induce membrane PI 3-kinase activity was mostly abolished, but its effects to tyrosine-phosphorylate the beta-subunit of the insulin receptor or other cellular substrate proteins including insulin-receptor-substrate-1 were not at all antagonized, by wortmannin added to the cell incubation medium. Insulin stimulation of cellular 2-deoxyglucose uptake and inhibition of isoproterenol-induced lipolysis observable in adipocytes under the same conditions were also antagonized by wortmannin added in the same concentration range as used for the inhibition of insulin-susceptible PI 3-kinase. It is concluded, therefore, that activation of wort-mannin-sensitive PI 3-kinase plays a pivotal role in the intracellular signaling pathways arising from the insulin receptor autophosphorylation and leading to certain metabolic responses.	INST PHYS & CHEM RES,UI LAB,HIROSAWA 2-1,WAKO 35101,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; University of Tokyo								ABLER A, 1992, J BIOL CHEM, V267, P3946; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; Cuatrecasas P, 1974, Methods Enzymol, V34, P653; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; DESBOIS C, 1992, J BIOL CHEM, V267, P13488; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; GLIEMANN J, 1972, BIOCHIM BIOPHYS ACTA, V286, P1, DOI 10.1016/0304-4165(72)90082-7; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; INOUE G, 1993, J BIOL CHEM, V268, P5272; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P736; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KONO T, 1973, J BIOL CHEM, V248, P7417; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OKADA T, 1994, J BIOL CHEM, V269, P3563; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHECHTER Y, 1989, EMBO J, V8, P1671, DOI 10.1002/j.1460-2075.1989.tb03558.x; SHISHEVA A, 1992, FEBS LETT, V300, P93, DOI 10.1016/0014-5793(92)80171-C; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; SHISHEVA A, 1992, BIOCHEMISTRY-US, V31, P8059, DOI 10.1021/bi00149a041; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846	43	923	958	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3568	3573						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106400				2022-12-25	WOS:A1994MV63100068
J	LOLLO, BA; CHAN, KWH; HANSON, EM; MOY, VT; BRIAN, AA				LOLLO, BA; CHAN, KWH; HANSON, EM; MOY, VT; BRIAN, AA			DIRECT EVIDENCE FOR 2 AFFINITY STATES FOR LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 ON ACTIVATED T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; MONOCLONAL-ANTIBODY; BETA-SUBUNIT; INDUCED PHOSPHORYLATION; COMPLEMENT RECEPTORS; CYTOPLASMIC DOMAIN; LIGAND-BINDING; CROSS-LINKING; B-CELLS; LFA-1	Lymphocytes activated by antigen receptor cross-linking or phorbol esters adhere avidly to surfaces bearing intercellular adhesion molecule 1 (ICAM-1) through the adhesion receptor lymphocyte function-associated antigen 1 (LFA-1). It is not known whether avid adhesion by stimulated lymphocytes is due to higher affinity binding of ICAM-1 or due solely to post-receptor mechanisms. We have used a recombinant, soluble form of the ICAM-1 molecule to measure the affinity of binding to LFA-1 on unstimulated T cells and T cells stimulated with phorbol esters. The affinity was found to be too low for direct measurements, requiring instead the use of competition protocols in which ICAM-1 competes for binding with radiolabeled Fab from a monoclonal antibody specific for LFA-1. By analysis of the equilibrium and kinetics of competitive binding, we found that the affinity on unstimulated T cells is very low, about 100 muM. Activation of the T cells by phorbol esters caused a small increase in average binding affinity. Further analysis suggested that the change in average affinity reflected the conversion of a fraction of LFA-1 molecules to a state with a 200-fold higher affinity.	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048054] Funding Source: NIH RePORTER; NCI NIH HHS [CA01974] Funding Source: Medline; NIGMS NIH HHS [GM48054, GM07313] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; BUYON JP, 1990, J IMMUNOL, V144, P191; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; CONTRERAS ML, 1986, J PHARMACOL EXP THER, V239, P136; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DAVIGNON D, 1981, J IMMUNOL, V127, P590; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIMINNO G, 1983, BLOOD, V61, P140; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FINE JS, 1991, J IMMUNOL, V147, P2852; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GULINO D, 1990, J BIOL CHEM, V265, P9575; HAMANN A, 1988, J IMMUNOL, V140, P693; HAVERSTICK DM, 1992, AM J PHYSIOL, V262, pC916, DOI 10.1152/ajpcell.1992.262.4.C916; HEDMAN H, 1992, J IMMUNOL, V149, P2295; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; KANE KP, 1989, MOL IMMUNOL, V26, P759, DOI 10.1016/0161-5890(89)90036-9; KELLEHER D, 1990, EUR J IMMUNOL, V20, P2351, DOI 10.1002/eji.1830201028; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MOINGEON PE, 1991, EUR J IMMUNOL, V21, P605, DOI 10.1002/eji.1830210311; MOTULSKY HJ, 1984, MOL PHARMACOL, V25, P1; MOY VT, 1992, J EXP MED, V175, P1, DOI 10.1084/jem.175.1.1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; PALS ST, 1988, J IMMUNOL, V140, P1851; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PRESS WH, 1988, NUMERICAL RECIPES C, P305; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; SAYRE PH, 1989, J EXP MED, V169, P995, DOI 10.1084/jem.169.3.995; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SHIMIZU Y, 1992, J EXP MED, V175, P577, DOI 10.1084/jem.175.2.577; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SINGER KH, 1990, J LEUKOCYTE BIOL, V48, P367, DOI 10.1002/jlb.48.4.367; SIU G, 1989, J IMMUNOL, V143, P3813; TEDDER TF, 1986, EUR J IMMUNOL, V16, P1539, DOI 10.1002/eji.1830161212; TOHMA S, 1991, J IMMUNOL, V146, P492; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WRIGHT SD, 1986, J IMMUNOL, V136, P1759	51	199	200	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21693	21700						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104943				2022-12-25	WOS:A1993MC80900042
J	BORNANCIN, F; AUDIGIER, Y; CHABRE, M				BORNANCIN, F; AUDIGIER, Y; CHABRE, M			ADP-RIBOSYLATION OF G(S) BY CHOLERA-TOXIN IS POTENTIATED BY AGONIST ACTIVATION OF BETA-ADRENERGIC RECEPTORS IN THE ABSENCE OF GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; ADENYLATE-CYCLASE; PHOTOEXCITED RHODOPSIN; REGULATORY COMPONENT; ALPHA-SUBUNIT; HL-60 CELLS; GS-ALPHA; TRANSDUCIN; MEMBRANES; SITE	Purified G(s) is a substrate for ADP-ribosylation catalyzed by cholera toxin (CTx). In S49 cyc- membranes complemented with in vitro translated G(s)alpha, the beta-adrenergic agonist isoproterenol enhanced the ADP-ribosylation rate. This effect was maximal if all guanyl nucleotides were suppressed but was blocked by the beta-adrenergic antagonist alprenolol. Enhancement was partially diminished if addition of GDP followed that of isoproterenol. When added in the absence of agonist, the GTP analogues guanosine 5'-O-(gamma-thiotriphosphate) and guanosine 5'-(beta,gamma-imido)triphosphate potentiated CTx-catalyzed ADP-ribosylation of G(s)alpha consistent with their activating ADP-ribosylation factors. However, this effect was lessened when the same nucleotides were tested in the presence of agonist. Taken altogether, these results indicate that like G(t) and G(i), G(s) is an optimal substrate for CTx when coupled to an agonist-activated receptor and depleted of nucleotide. Therefore, coupling to the receptor and subsequent departure of the GDP turn out to be the common features underlying the sensitivity of all GTP-binding proteins to CTx-catalyzed ADP-ribosylation.	INST PHARMACOL MOLEC & CELLULAIRE, CNRS, SOPHIA ANTIPOLIS, F-06560 VALBONNE, FRANCE; UNIV TOULOUSE 3, CTR BIOL DEV, CNRS, UMR 9925, F-31062 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier								ABOOD ME, 1982, J BIOL CHEM, V257, P540; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; BORNANCIN F, 1991, FEBS LETT, V291, P273, DOI 10.1016/0014-5793(91)81300-W; BORNANCIN F, 1992, EUR J BIOCHEM, V210, P33, DOI 10.1111/j.1432-1033.1992.tb17387.x; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; BRUCKERT F, 1992, BIOPHYS J, V63, P616, DOI 10.1016/S0006-3495(92)81650-8; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; ENOMOTO K, 1980, J BIOL CHEM, V255, P1252; GIERSCHIK P, 1987, FEBS LETT, V224, P219, DOI 10.1016/0014-5793(87)80451-9; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1992, HDB EXPT PHARM, V102, P807; GILL DM, 1991, METHOD ENZYMOL, V195, P267; GILL DM, 1987, BIOCHEMISTRY-US, V26, P6364, DOI 10.1021/bi00394a009; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; IIRI T, 1989, J BIOL CHEM, V264, P21394; JOHNSON GL, 1978, J BIOL CHEM, V253, P7120; JOURNOT L, 1989, FEBS LETT, V251, P230, DOI 10.1016/0014-5793(89)81460-7; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KAHN RA, 1984, J BIOL CHEM, V259, P6235; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1990, G PROTEINS, P201; KLINZ FJ, 1989, BIOCHEM BIOPH RES CO, V165, P554, DOI 10.1016/S0006-291X(89)80002-6; MILLIGAN G, 1988, BIOCHEM J, V252, P369, DOI 10.1042/bj2520369; MOSS J, 1991, METHOD ENZYMOL, V195, P243; NAVON SE, 1984, J BIOL CHEM, V259, P6686; NORTHUP JK, 1980, P NATL ACAD SCI-BIOL, V77, P6516, DOI 10.1073/pnas.77.11.6516; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0	31	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17026	17029						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8102365				2022-12-25	WOS:A1993LQ98800024
J	SOARES, H; GALEGO, L; COIAS, R; RODRIGUESPOUSADA, C				SOARES, H; GALEGO, L; COIAS, R; RODRIGUESPOUSADA, C			THE MECHANISMS OF TUBULIN MESSENGER REGULATION DURING TETRAHYMENA-PYRIFORMIS RECILIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; BETA-TUBULIN; AUTOREGULATORY CONTROL; RNA STABILITY; STARVED TETRAHYMENA; PROTEIN-SYNTHESIS; GENE-EXPRESSION; ALPHA-TUBULIN; REGENERATION; THERMOPHILA	The reciliation of Tetrahymena pyriformis cells is accompanied in the first minutes by a transient induction of stress mRNAs, i.e. hsp70 and ubiquitin. At the same time an accentuated and coordinate reduction in the amount of alpha- and beta-tubulin mRNAs is observed as analyzed by Northern blot hybridization using the homologous genomic tubulin probes. Between 60 and 120 min after the onset of reciliation, tubulin transcripts in the cytoplasm reach higher values than in exponentially growing cells. Run-on transcription assays reveal that the decrease in tubulin mRNA levels is not caused by a decrease in transcription of tubulin genes. The results obtained show that the apparent tubulin gene transcription rate is increased in reciliating cells from 15 min up to 90 min. The block of transcription using actinomycin D shows that hsps are not implicated in the destabilization of tubulin mRNA during the first minutes of reciliation. The effects of the inhibitors of protein synthesis, cycloheximide and pactamycin, on tubulin mRNA levels suggest that the translational apparatus plays a role in the stability of tubulin mRNA in cells reciliating for 15 and 30 min. Experiments using the microtubule-polymerizing drug taxol also show that tubulin mRNA destabilization is not a simple consequence of a temporary increase in free tubulin subunit pools resulting from cilia resorption.	INST GULBENKIAN CIENCIAS,GENET MOLEC LAB,APARTADO 14,P-2781 OEIRAS,PORTUGAL	Instituto Gulbenkian de Ciencia			Antunes Soares, Maria Helena/G-3065-2010	Antunes Soares, Maria Helena/0000-0001-6180-7041; Galego, Lisete/0000-0002-8832-7651; Rodrigues-Pousada, Claudina/0000-0002-5075-3639				AMARAL M, 1993, IN PRESS BIOCH BIOPH; AMARAL MD, 1988, EUR J BIOCHEM, V171, P463, DOI 10.1111/j.1432-1033.1988.tb13812.x; BAKER EJ, 1986, MOL CELL BIOL, V6, P54, DOI 10.1128/MCB.6.1.54; BARAHONA I, 1985, FEBS LETT, V188, P227, DOI 10.1016/0014-5793(85)80377-X; BARAHONA I, 1988, J MOL BIOL, V202, P365, DOI 10.1016/0022-2836(88)90271-9; BRODL MR, 1990, PLANT PHYSIOL, V92, P1133, DOI 10.1104/pp.92.4.1133; CARON JM, 1985, NATURE, V317, P618; CLEVELAND DW, 1983, J CELL BIOL, V97, P919, DOI 10.1083/jcb.97.3.919; CLEVELAND DW, 1981, CELL, V25, P537, DOI 10.1016/0092-8674(81)90072-6; COIAS R, 1988, EUR J BIOCHEM, V175, P467, DOI 10.1111/j.1432-1033.1988.tb14218.x; GALEGO L, 1985, EUR J BIOCHEM, V149, P571, DOI 10.1111/j.1432-1033.1985.tb08963.x; GALEGO L, 1984, EUR J BIOCHEM, V139, P163, DOI 10.1111/j.1432-1033.1984.tb07990.x; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GAY DA, 1987, CELL, V50, P671, DOI 10.1016/0092-8674(87)90325-4; GONG ZY, 1987, MOL CELL BIOL, V7, P4238, DOI 10.1128/MCB.7.12.4238; GUTTMAN SD, 1980, CELL, V22, P299, DOI 10.1016/0092-8674(80)90177-4; GUTTMAN SD, 1979, CELL, V17, P307, DOI 10.1016/0092-8674(79)90156-9; HALLBERG RL, 1984, MOL CELL BIOL, V4, P2170, DOI 10.1128/MCB.4.10.2170; HALLBERG RL, 1985, MOL CELL BIOL, V5, P2061, DOI 10.1128/MCB.5.8.2061; HEIDEMANN SR, 1980, DEV BIOL, V80, P489, DOI 10.1016/0012-1606(80)90421-2; HOFFMAN EP, 1984, MOL CELL BIOL, V4, P2883, DOI 10.1128/MCB.4.12.2883; JULIANI MH, 1990, J BIOL CHEM, V265, P9077; KLEMENZ R, 1985, EMBO J, V4, P2053, DOI 10.1002/j.1460-2075.1985.tb03891.x; LEFEBVRE PA, 1986, ANNU REV CELL BIOL, V2, P517, DOI 10.1146/annurev.cb.02.110186.002505; LOVE HD, 1988, MOL CELL BIOL, V8, P427, DOI 10.1128/MCB.8.1.427; Maniatis T., 1982, MOL CLONING; MAY GS, 1980, J CELL BIOL, V87, P272; NEVES AM, 1988, GENE, V73, P87, DOI 10.1016/0378-1119(88)90315-0; NEVES AM, 1991, MOL GEN GENET, V230, P186, DOI 10.1007/BF00290667; NEVES AM, 1991, J DNA SEQUENCING MAP, V2, P173; NOVER L, 1991, HEAT SHOCK RESPONSE, P299; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PENQUE D, 1991, EUR J BIOCHEM, V195, P487, DOI 10.1111/j.1432-1033.1991.tb15729.x; PITTENGER MF, 1985, J CELL BIOL, V101, P1941, DOI 10.1083/jcb.101.5.1941; RANNESTA.J, 1974, J CELL BIOL, V63, P1009, DOI 10.1083/jcb.63.3.1009; RODRIGUESPOUSAD.C, 1975, EUR J BIOCHEM, V56, P117; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SOARES H, 1991, EUR J BIOCHEM, V197, P291, DOI 10.1111/j.1432-1033.1991.tb15910.x; VAZQUEZ D, 1979, INHIBITORS PROTEIN S, P36; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; ZEFF RA, 1987, FOCUS, V9, P1	42	17	17	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16623	16630						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	8102139				2022-12-25	WOS:A1993LQ33600078
J	HUNTER, J; JEPSON, MA; TSURUO, T; SIMMONS, NL; HIRST, BH				HUNTER, J; JEPSON, MA; TSURUO, T; SIMMONS, NL; HIRST, BH			FUNCTIONAL EXPRESSION OF P-GLYCOPROTEIN IN APICAL MEMBRANES OF HUMAN INTESTINAL CACO-2 CELLS - KINETICS OF VINBLASTINE SECRETION AND INTERACTION WITH MODULATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COLON-CARCINOMA; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODY; CALCIUM CHANNELS; DRUG-RESISTANCE; TUMOR-CELLS; TRANSPORT; GENE; VERAPAMIL; TISSUES	The functional expression of P-glycoprotein has been studied in confluent epithelial layers of human Caco-2 cells, a polarized, highly differentiated cell line demonstrating an intestinal absorptive cell phenotype. Expression of P-glycoprotein was localized, by indirect immunofluorescence with monoclonal antibody MRK16, to the apical brush-border, approximately 20 mum above the base of the cells. Functional, high capacity expression of P-glycoprotein in Caco-2 cell layers was demonstrated by the saturable secretion of vinblastine, a typical substrate, from basolateral to apical surfaces: K(m) 18.99 +/- 5.55 mum, V(max) 1285.9 +/- 281.2 pmol.cm-2 h-1. The direct correlation of apical P-glycoprotein expression with vinblastine net secretory flux was demonstrated by the reduction of this flux after treatment with MRK16 antibodies. Vinblastine secretory flux was also reduced by treatment with verapamil (R- and S-isomers with equal affinity), nifedipine, taxotere, and 1,9-dideoxyforskolin. Kinetic analyses suggest that the inhibition of vinblastine secretory flux by verapamil and nifedipine was competitive, while that by dideoxyforskolin was non-competitive, in nature. The polarized expression and activity of P-glycoprotein in Caco-2 cells is direct evidence for its secretory detoxifying function in the intestine, subserving at least one role of the gastrointestinal epithelial barrier.	UNIV NEWCASTLE UPON TYNE,SCH MED,GASTROINTESTINAL DRUG DELIVERY RES CTR,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PHYSIOL SCI,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK; Newcastle University - UK								AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; Beck W T, 1991, Cancer Treat Res, V57, P151; BROXTERMAN HJ, 1989, INT J CANCER, V43, P340, DOI 10.1002/ijc.2910430229; CABRAL F, 1989, FASEB J, V3, P1593, DOI 10.1096/fasebj.3.5.2646163; CHANTRET I, 1988, CANCER RES, V48, P1936; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; DIX CJ, 1990, GASTROENTEROLOGY, V98, P1272, DOI 10.1016/0016-5085(90)90344-Z; FERRY DR, 1985, BRIT J PHARMACOL, V84, P811, DOI 10.1111/j.1476-5381.1985.tb17375.x; FORD JM, 1990, PHARMACOL REV, V42, P155; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOLDSTEIN LJ, 1992, CRIT REV ONCOL HEMAT, V12, P243, DOI 10.1016/1040-8428(92)90057-W; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HORIO M, 1989, J BIOL CHEM, V264, P14880; HORIO M, 1990, BIOCHIM BIOPHYS ACTA, V1027, P116, DOI 10.1016/0005-2736(90)90074-X; HORIO M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P106, DOI 10.1016/0005-2736(91)90274-C; HUET S, 1988, INT J CANCER, V41, P283, DOI 10.1002/ijc.2910410220; HUNTER J, 1991, BRIT J CANCER, V64, P437, DOI 10.1038/bjc.1991.328; HUNTER J, 1991, BIOCHEM BIOPH RES CO, V181, P671, DOI 10.1016/0006-291X(91)91243-6; HUNTER J, 1992, J PHYSIOL-LONDON, V446, pP32; MEYERS MB, 1991, CANCER COMMUN, V3, P159, DOI 10.3727/095535491820873335; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; PEARSON JW, 1991, J NATL CANCER I, V83, P1386, DOI 10.1093/jnci/83.19.1386; PETERS WHM, 1992, CANCER RES, V52, P1886; PLUMB JA, 1990, BIOCHEM PHARMACOL, V39, P787, DOI 10.1016/0006-2952(90)90160-M; RILEY SA, 1991, BIOCHIM BIOPHYS ACTA, V1066, P175, DOI 10.1016/0005-2736(91)90184-A; RINGEL I, 1991, J NATL CANCER I, V83, P288, DOI 10.1093/jnci/83.4.288; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SUGAWARA I, 1988, CANCER RES, V48, P1926; TATSUTA T, 1992, J BIOL CHEM, V267, P20383; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THWAITES DT, 1993, J BIOL CHEM, V268, P7640; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; WEINSTEIN RS, 1991, CANCER RES, V51, P2720; WOODCOCK S, 1991, J CELL SCI, V98, P323	39	338	347	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14991	14997						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8100817				2022-12-25	WOS:A1993LL75900068
J	LENTING, PJ; DONATH, MJSH; VANMOURIK, JA; MERTENS, K				LENTING, PJ; DONATH, MJSH; VANMOURIK, JA; MERTENS, K			IDENTIFICATION OF A BINDING-SITE FOR BLOOD-COAGULATION FACTOR IXA ON THE LIGHT-CHAIN OF HUMAN FACTOR-VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PORCINE FACTOR-VIII; VON-WILLEBRAND FACTOR; VONWILLEBRAND-FACTOR; FACTOR-XA; MONOCLONAL-ANTIBODIES; FACTOR-VA; CATALYZED INACTIVATION; PHOSPHOLIPID-VESICLES; A1/A3-C1-C2 DIMER	The interaction between human factor IXa and factor VIII or its constituent units was investigated. Equilibrium binding studies were performed employing factor VIII light chain that was immobilized on a monoclonal antibody. Factor VIII light chain was observed to bind factor IXa with high affinity (K-d = 14.8 +/- 3.2 nM) and approximately 1:1 stoichiometry. Optimal interaction required NaCl concentrations below 0.2 M and the presence of Ca2+ ions. Factor VIII light chain in solution effectively inhibited binding of factor IXa to the immobilized light chain (K-i = 10.9 +/- 1.9 nM). The isolated factor VIII light chain and the factor VIII heterodimer were equally effective in factor IXa binding, demonstrating that this interaction did not require the factor VIII heavy chain. Factor Xa and activated Protein C were found to be inefficient (K-i greater than or equal to 1.2 mu M) in competing with factor IXa, indicating that the high affinity for factor VII light chain was unique for factor IXa. The factor IXa-factor VIII light chain interaction was inhibited by von Willebrand factor, but this effect was abolished by cleavage of the factor VIII light chain by thrombin. An antibody that inhibits von Willebrand factor-factor VIII complex formation did not compete for factor IXa binding. In contrast, association of factor IXa with the factor VIII light chain was inhibited by an antibody directed against the factor VIII region Gln(1778)-Asp(1840). We propose that this sequence provides a factor IXa binding site and that its exposure requires dissociation of the factor VIII-von Willebrand factor complex.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT BLOOD COAGULAT,1066 CX AMSTERDAM,NETHERLANDS				Lenting, Peter/AAH-5663-2019; Lenting, Peter/F-8269-2013	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429				ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; ANNAMALAI AE, 1987, BLOOD, V70, P139; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BERTINA RM, 1984, BIOCHEM BIOPH RES CO, V125, P177, DOI 10.1016/S0006-291X(84)80351-4; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1989, BIOCHIM BIOPHYS ACTA, V994, P142, DOI 10.1016/0167-4838(89)90153-2; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LEYTE A, 1991, BIOCHEM J, V274, P257, DOI 10.1042/bj2740257; LEYTE A, 1989, BIOCHEM J, V263, P187, DOI 10.1042/bj2630187; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; MANN KG, 1990, BLOOD, V76, P1; MERTENS K, 1982, THROMB HAEMOSTASIS, V47, P96; MERTENS K, 1984, BIOCHEM J, V223, P599, DOI 10.1042/bj2230599; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; PRECUP JW, 1991, BLOOD, V77, P1929; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; ROTBLAT F, 1985, BIOCHEMISTRY-US, V24, P4294, DOI 10.1021/bi00337a007; SADLER JE, 1987, MOL BASIS BLOOD DISE, P575; STEL HV, 1983, THROMB HAEMOSTASIS, V50, P860; STEL HV, 1984, THESIS U AMSTERDAM, P51; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; VEERMAN ECI, 1983, THROMB RES, V33, P89; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P322, DOI 10.1016/0003-9861(87)90037-3; WALKER FJ, 1990, J BIOL CHEM, V265, P1484	46	148	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7150	7155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125924				2022-12-25	WOS:A1994NA03200020
J	VYAS, TB; MOOERS, SU; NARAYAN, SR; SIEGMAN, MJ; BUTLER, TM				VYAS, TB; MOOERS, SU; NARAYAN, SR; SIEGMAN, MJ; BUTLER, TM			CROSS-BRIDGE CYCLING AT REST AND DURING ACTIVATION - TURNOVER OF MYOSIN-BOUND ADP IN PERMEABILIZED SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN PHOSPHORYLATION; HEAVY-MEROMYOSIN; TENSION; MECHANISM; BINDING; CALCIUM; STRESS; ACTIN; CA-2+	Single turnover experiments were performed on myosin-bound ADP by measuring the time course of incorporation of [H-3]ADP following rapid formation of [H-3]ATP by photolysis of caged [H-3]ATP. Permeabilized rabbit portal veins were incubated in a solution at 20 degrees C with 1 mM MgATP, 20 mM phosphocreatine, 1 mg/ml creatine phosphokinase, and containing [C-14]ATP and high specific activity caged [H-3]ATP. At variable times following a UV flash, the muscle was frozen, nucleotides were extracted, and the ratio H-3:C-14 in ADP was compared to that in ATP. At rest, the exchange of bound ADP occurred with a rate constant of 0.004 s(-1). When the myosin light chain was about 80% thiophosphorylated, and the muscle was generating maximum isometric force, there appeared a fast phase of ADP exchange (44% of the total) which had a rate constant of 0.2 s(-1). The change in rate of ADP exchange on myosin is sufficient to explain the measured increase in ATPase activity upon thiophosphorylation of the myosin light chain. A simple analysis of the data suggests that there is a 50-fold increase in the cycling rate of cross-bridges in the muscle upon phosphorylation under isometric conditions. The fraction of ADP exchanged at 10 s following photolytic release of [H-3]ATP was found to be approximately linearly related to the degree of thiophosphorylation of the myosin light chain. This supports the idea that phosphorylation of the light chain causes the transition of myosin from the resting (slow ATPase) cycle into the activated (fast ATPase) cycle, and that the fraction of myosin in the fast cycle is directly determined by the degree of light chain phosphorylation. The data are also consistent with the cooperativity model described previously by Vyas ct al. (Vyas, T. B., Mooers, S. U., Narayan, S. R., Witherell, J. C., Siegman, M. J., and Butler, T. M. (1992) Am. J. Physiol. 263, C210-C219).			VYAS, TB (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PHYSIOL,PHILADELPHIA,PA 19107, USA.				NHLBI NIH HHS [T35 HL07599, HL15835] Funding Source: Medline; NIDDK NIH HHS [DK37598] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL015835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037598] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTLER TM, 1983, AM J PHYSIOL, V244, pC234, DOI 10.1152/ajpcell.1983.244.3.C234; BUTLER TM, 1989, AM J PHYSIOL, V256, pC59, DOI 10.1152/ajpcell.1989.256.1.C59; BUTLER TM, 1990, AM J PHYSIOL, V258, pC1092, DOI 10.1152/ajpcell.1990.258.6.C1092; BUTLER TM, 1986, AM J PHYSIOL, V251, pC945, DOI 10.1152/ajpcell.1986.251.6.C945; CASSIDY P, 1979, J BIOL CHEM, V254, P1148; GERTHOFFER WT, 1987, J PHARMACOL EXP THER, V240, P8; GREENE LE, 1987, J BIOL CHEM, V262, P4177; HAEBERLE JR, 1985, J MUSCLE RES CELL M, V6, P347, DOI 10.1007/BF00713174; HAEBERLE JR, 1985, PFLUG ARCH EUR J PHY, V403, P215, DOI 10.1007/BF00584103; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; JIANG MJ, 1989, PFLUG ARCH EUR J PHY, V413, P637, DOI 10.1007/BF00581814; KUSHMERICK MJ, 1987, CARDIAC ENERGETICS, P17; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MORELAND S, 1987, AM J PHYSIOL, V252, pH1049, DOI 10.1152/ajpheart.1987.252.6.H1049; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; RATZ PH, 1987, CIRC RES, V60, P410, DOI 10.1161/01.RES.60.3.410; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SIEGMAN MJ, 1984, PFLUG ARCH EUR J PHY, V401, P385, DOI 10.1007/BF00584340; TANSEY MG, 1990, FEBS LETT, V270, P219, DOI 10.1016/0014-5793(90)81272-P; TAYLOR EW, 1992, HEART CARDIOVASCULAR, P1281; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; VYAS TB, 1992, AM J PHYSIOL, V263, pC210, DOI 10.1152/ajpcell.1992.263.1.C210; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036	26	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7316	7322						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125947				2022-12-25	WOS:A1994NA03200046
J	NISHI, K; YOSHIDA, M; FUJIWARA, D; NISHIKAWA, M; HORINOUCHI, S; BEPPU, T				NISHI, K; YOSHIDA, M; FUJIWARA, D; NISHIKAWA, M; HORINOUCHI, S; BEPPU, T			LEPTOMYCIN-B TARGETS A REGULATORY CASCADE OF CRM1, A FISSION YEAST NUCLEAR-PROTEIN, INVOLVED IN CONTROL OF HIGHER-ORDER CHROMOSOME STRUCTURE AND GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-FUNGAL ANTIBIOTICS; SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; ANTITUMOR-ACTIVITY; TRICHOSTATIN-A; KAZUSAMYCIN; FIBROBLASTS; INHIBITION; CHROMATIN; EXPOSURE	The molecular action of leptomycin B (LMB), an agent inducing arrest of the eukaryotic cell cycle at G1 and G2 phases, was investigated by analyzing an LMB resistance gene of Schizosaccharomyces pombe. A genomic library of ah LMB-resistant mutant was screened for LMB resistance, and a DNA fragment containing an open reading frame (ORF) of 1078 amino acids was cloned on a multicopy vector. The plasmid was found to confer drug resistance specifically to LMB. Nucleotide sequencing revealed that the ORF was a mutant gene for the essential nuclear protein crm1, which had been reported to complement a cold-sensitive mutation causing deformed nuclear morphology. The gene product named crm1-N1 had two amino acid replacements (Gly-503 to Asp and Met-546 to Ile). Two allelic mutants of crm1 (crm1-809 and crm1-119) were found to be hypersensitive and resistant, respectively, to LMB. Nuclear morphology of the cold-sensitive crm1-809 mutant at the restrictive temperature was almost the same as that of the wild-type cells treated with LMB. Furthermore, a low concentration of LMB induced the intracellular accumulation of a 25-kDa protein in the wild-type cells, which was immunologically identical to the protein accumulating in the crm1-809 mutant cells. These results strongly suggest that LMB primarily inhibits the function of the crm1 gene which is required for maintaining higher order chromosome structures, correct gene expression, and cell growth in the fission yeast.	UNIV TOKYO, FAC AGR, DEPT AGR CHEM, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, BIOTECHNOL RES CTR, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; University of Tokyo			Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				ABE K, 1993, J ANTIBIOT, V46, P728, DOI 10.7164/antibiotics.46.728; ABE K, 1993, J ANTIBIOT, V46, P735, DOI 10.7164/antibiotics.46.735; ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; BEACH D, 1982, MOL GEN GENET, V187, P326, DOI 10.1007/BF00331138; CRISSMAN HA, 1988, CANCER RES, V48, P5742; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; Gutz H., 1974, HDB GENETICS, V1, P395; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646; HAMAMOTO T, 1985, J ANTIBIOT, V38, P1573, DOI 10.7164/antibiotics.38.1573; HAYAKAWA Y, 1987, J ANTIBIOT, V40, P1349, DOI 10.7164/antibiotics.40.1349; ISHIDA R, 1991, CANCER RES, V51, P4909; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOMIYAMA K, 1985, J ANTIBIOT, V38, P220, DOI 10.7164/antibiotics.38.220; KOMIYAMA K, 1985, J ANTIBIOT, V38, P427, DOI 10.7164/antibiotics.38.427; KOMIYAMA K, 1985, J ANTIBIOT, V38, P224, DOI 10.7164/antibiotics.38.224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKS KW, 1990, CANCER RES, V50, P4776; LARNO S, 1984, J CELL PHYSIOL, V120, P384, DOI 10.1002/jcp.1041200317; Maniatis T., 1982, MOL CLONING LABORATO; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NISHI K, 1992, MOL MICROBIOL, V6, P761, DOI 10.1111/j.1365-2958.1992.tb01526.x; REEVES R, 1984, BIOCHIM BIOPHYS ACTA, V782, P343, DOI 10.1016/0167-4781(84)90044-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1992, RADIAT RES, V129, P163, DOI 10.2307/3578153; TODA T, 1981, J CELL SCI, V52, P271; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	32	394	402	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6320	6324						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119981				2022-12-25	WOS:A1994MZ50300013
J	SATOH, H; NAGAE, Y; IMMENSCHUH, S; SATOH, T; MULLEREBERHARD, U				SATOH, H; NAGAE, Y; IMMENSCHUH, S; SATOH, T; MULLEREBERHARD, U			IDENTIFICATION OF A LIVER PREFERENCE ENHANCER ELEMENT OF THE RAT HEMOPEXIN GENE AND ITS INTERACTION WITH NUCLEAR FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; APOLIPOPROTEIN-A-I; TRANSCRIPTION FACTOR BINDS; ACID RESPONSE PATHWAYS; 9-CIS RETINOIC ACID; THYROID-HORMONE; OVALBUMIN GENE; ORPHAN RECEPTORS; DNA-BINDING; COUP-TF	Transcription of hemopexin (Hx) occurs predominantly in the liver. To investigate the contribution of the cis-acting enhancer element to the hepatocyte preferential expression, we performed chloramphenicol acetyltransferase (CAT) assays in HepG2 cells. A strong enhancer element was identified by successive truncation to reside in the region -157/-104 from the cap site. The Hx region -145/-125 interacts with rat liver nuclear pro teins, as shown by standard DNA-protein binding assays. The nucleotide sequence -(141)AGACTTTGACCT-(130) includes, in reverse orientation, a direct repeat of the imperfect AGGTCA sequence, one of the recognition motifs of the steroid-thyroid hormone receptor superfamily. That this AGGTCA repeat is an enhancer core of the Hx element was affirmed by mutational analyses, In electrophoretic mobility shift assays, oligonucleotides, corresponding to binding regions of chicken ovalbumin upstream promoter transcription factor (COUP-TF) and apolipoprotein AI regulatory protein 1 (ARP 1) but not of hepatocyte nuclear factor-4 (HNF-4), competed with the Hx element for binding sites. Co-transfection analyses indicated that HNF-4 does not affect CAT expression whereas ARP-I and COUP-TF repress it. Antibody supershift analyses suggested that HNF-4 and COUP-TF may not be major factors binding to the Hx element.	CORNELL UNIV, COLL MED, DEPT PEDIAT, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA	Cornell University; Cornell University; Cornell University			Immenschuh, Stephan/AAM-9181-2020	Immenschuh, Stephan/0000-0003-3722-5791	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030203] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-30203] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTRUDA F, 1988, J MOL EVOL, V27, P102, DOI 10.1007/BF02138368; BAGCHI MK, 1992, ENDOCR REV, V13, P525, DOI 10.1210/er.13.3.525; BARNARD ML, 1993, BIOCHEM BIOPH RES CO, V192, P82, DOI 10.1006/bbrc.1993.1384; BAUMANN H, 1987, BIOCHEM BIOPH RES CO, V146, P1218, DOI 10.1016/0006-291X(87)90778-9; BRUNEL F, 1988, J BIOL CHEM, V263, P10180; COONEY AJ, 1991, J VIROL, V65, P2853, DOI 10.1128/JVI.65.6.2853-2860.1991; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V2, P743; CRABTREE GR, 1992, TRANSCRIPTIONAL REGU, V2, P1063; DAVIES DM, 1979, BIOCHEM BIOPH RES CO, V91, P1504, DOI 10.1016/0006-291X(79)91235-X; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; ING NH, 1992, J BIOL CHEM, V267, P17617; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; KARATHANASIS SK, 1992, HIGH DENSITY LIPOPRO, V3, P21; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KNOLL BJ, 1983, NUCLEIC ACIDS RES, V11, P6733, DOI 10.1093/nar/11.19.6733; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LIU YH, 1991, J BIOL CHEM, V266, P21880; MANGELSDORF DJ, 1992, TRANSCRIPTIONAL REGU, V2, P1137; METZGER S, 1993, J BIOL CHEM, V268, P16831; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; Muller- Eberhard U, 1974, STRUCTURE FUNCTION P, V1, ppp; MULLEREBERHARD U, 1988, METHOD ENZYMOL, V163, P536; MULLEREBERHARD U, 1993, AM J HEMATOL, V42, P59, DOI 10.1002/ajh.2830420112; NAGAE Y, 1992, BIOCHEM BIOPH RES CO, V185, P420, DOI 10.1016/S0006-291X(05)81002-2; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NIKKILA H, 1991, BIOCHEMISTRY-US, V30, P823, DOI 10.1021/bi00217a036; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; POLI V, 1989, NUCLEIC ACIDS RES, V17, P9351; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1992, TRENDS PHARMACOL SCI, V13, P318, DOI 10.1016/0165-6147(92)90099-R; RITCHIE HH, 1990, NUCLEIC ACIDS RES, V18, P6857, DOI 10.1093/nar/18.23.6857; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; Sambrook J, 1989, MOL CLONING LABORATO; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMITH A, 1981, J BIOL CHEM, V256, P902; SWERTS JP, 1992, J BIOL CHEM, V267, P10596; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	72	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6851	6858						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120047				2022-12-25	WOS:A1994MZ50300092
J	COFFER, P; DEJONGE, M; METTOUCHI, A; BINETRUY, B; GHYSDAEL, J; KRUIJER, W				COFFER, P; DEJONGE, M; METTOUCHI, A; BINETRUY, B; GHYSDAEL, J; KRUIJER, W			JUNB PROMOTER REGULATION - RAS MEDIATED TRANSACTIVATION BY C-ETS-1 AND C-ETS-2	ONCOGENE			English	Review							GUANINE NUCLEOTIDE-BINDING; EMBRYONAL CARCINOMA-CELLS; ACTIVATED PROTEIN-KINASE; LONG TERMINAL REPEAT; MURINE SARCOMA-VIRUS; NIH 3T3 CELLS; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; DNA-BINDING; MAP KINASE	The Jun gene family encode components of the AP-1 transcription factor complex that regulate a variety of TRE-containing target promoters. Expression of family members is induced by a wide variety of extracellular stimuli and thought to be important in mediating cellular proliferation and differentiation. We have localized cis-acting; DNA sequences in the murine junB promoter capable of mediating transcriptional activation by the proto-oncogene products c-Ets-l and c-Ets-2. We show by promoter deletion analysis that multiple elements located between - 848 and - 574, and between - 196 and - 91 can mediate transactivation by ETS-family members in different cell types. In vitro DNA binding assays indicate that the elements identified can specifically interact with c-Ets-1 protein. Furthermore, we show that ETS-transactivation of a variety of reporter constructs is dramatically enhanced by introduction of oncogenic Ha-ras. The activation of Pas by extracellular stimuli invokes a phosphorylation cascade that includes the downstream mitogen-activated protein (MAP) kinase p44(ERK-1). W,further show that addition of activated p44(ERK-1) MAP kinase can also enhance ETStransactivation of junB promoter reporter constructs. Here we propose that ETS-family members play a role in the activation of junB transcription by a Ras-stimulated signal transducing pathway that includes MAP kinase(s).	CTR UNIV ORSAY,INST CURIE,F-91405 ORSAY,FRANCE; UNIV GRONINGEN,DEPT GENET,9850 AA GRONINGEN,NETHERLANDS	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; University of Groningen	COFFER, P (corresponding author), HUBRECHT LAB,UPPSALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Binetruy, Bernard/A-6465-2009; Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020; Binetruy, Bernard/AFL-7188-2022; GHYSDAEL, Jacques/F-3377-2013; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/S-2062-2019	Binetruy, Bernard/0000-0001-8012-7092				ADLER V, 1992, J BIOL CHEM, V267, P17001; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V8, P148; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMPH WW, 1988, NATURE, V334, P592; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEUNG S, 1993, ONCOGENE, V8, P989; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MEDEMA RH, 1991, MOL CELL BIOL, V12, P3245; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SETH A, 1990, ONCOGENE, V5, P1761; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TYMMS M, 1993, J CELL BIOCH A S, V17, P210; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	102	122	123	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					911	921						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108135				2022-12-25	WOS:A1994MW55100028
J	WAGNER, F; GIMONA, M; AHORN, H; PESCHEK, GA; FALKNER, G				WAGNER, F; GIMONA, M; AHORN, H; PESCHEK, GA; FALKNER, G			ISOLATION AND FUNCTIONAL RECONSTITUTION OF A PHOSPHATE-BINDING PROTEIN OF THE CYANOBACTERIUM ANACYSTIS-NIDULANS INDUCED DURING PHOSPHATE-LIMITED GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSPORT PROTEIN	Adaptation of the blue-green algae Anacystis nidulans to phosphate-deficient growth leads to the expression of two membrane proteins, which appear as major constituents after separation by gel electrophoresis. One of these proteins, referred to as high affinity phosphate binding protein, has been isolated and its function reconstituted in liposomes. Partial sequencing showed no significant homologies to other proteins. The binding capacity of the proteoliposomes could be inhibited by arsenate but not by sulfhydryl reagents. Scatchard plot analyses of phosphate binding to reconstituted proteoliposomes suggested the existence of two different binding sites, one with a dissociation constant below micromolar and the other in the micromolar range.	AUSTRIAN ACAD SCI, INST MOLEC BIOL, A-5020 SALZBURG, AUSTRIA; UNIV VIENNA, INST PHYS CHEM, A-1090 VIENNA, AUSTRIA; BENDER & CO, A-1120 VIENNA, AUSTRIA	Austrian Academy of Sciences; University of Vienna								BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; FALKNER G, 1989, ARCH MICROBIOL, V152, P353, DOI 10.1007/BF00425173; Helenius A, 1979, Methods Enzymol, V56, P734; KRATZ WA, 1955, AM J BOT, V42, P282, DOI 10.2307/2438564; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MEDVECZKY N, 1970, BIOCHIM BIOPHYS ACTA, V211, P158, DOI 10.1016/0005-2736(70)90090-8; MOLITOR V, 1987, CURR MICROBIOL, V14, P263, DOI 10.1007/BF01568134; PLANAS D, 1978, J PHYCOL, V14, P337, DOI 10.1111/j.1529-8817.1978.tb00309.x; RIGLER FH, 1956, ECOLOGY, V37, P550, DOI 10.2307/1930179; Rosenberg H., 1987, ION TRANSPORT PROKAR, P205; SATO N, 1988, METHOD ENZYMOL, V167, P251; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; VANDEKERCKHOVE J, 1987, METHODS PROTEIN SEQU, P261; WAGNER F, 1992, J PLANT PHYSIOL, V140, P163, DOI 10.1016/S0176-1617(11)80928-4; WEIDEMAN.MJ, 1970, EUR J BIOCHEM, V16, P313, DOI 10.1111/j.1432-1033.1970.tb01086.x; WOHLRAB H, 1980, J BIOL CHEM, V255, P8170; ZIERLER K, 1989, TRENDS BIOCHEM SCI, V14, P314, DOI 10.1016/0968-0004(89)90157-6	21	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5509	5511						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119882				2022-12-25	WOS:A1994MY84000008
J	LOCATI, M; ZHOU, D; LUINI, W; EVANGELISTA, V; MANTOVANI, A; SOZZANI, S				LOCATI, M; ZHOU, D; LUINI, W; EVANGELISTA, V; MANTOVANI, A; SOZZANI, S			RAPID INDUCTION OF ARACHIDONIC-ACID RELEASE BY MONOCYTE CHEMOTACTIC PROTEIN-1 AND RELATED CHEMOKINES - ROLE OF CA2+ INFLUX, SYNERGISM WITH PLATELET-ACTIVATING-FACTOR AND SIGNIFICANCE FOR CHEMOTAXIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; PHOSPHOLIPASE-A2 ACTIVATION; VENOM PHOSPHOLIPASE-A2; INTRACELLULAR CALCIUM; POTASSIUM CHANNELS; CYTOKINE FAMILY; FATTY-ACIDS; KINASE-C; MEMBRANE	Monocyte Chemotactic Protein-1 (MCP-1), a member of the Cys-Cys branch of the chemokine superfamily, induced a mepacrine- and manoalide-sensitive increase in the release of [H-3]arachidonic acid from prelabeled human monocytes and monocytic THP-1 leukemic cells. The effect was rapid (<30 s), reached maximum at optimal chemotactic concentrations, and was completely blocked by pretreatment of monocytes with Bordetella pertussis toxin. A specific antiserum and heat inactivation blocked the induction of arachidonic release by MCP-1. No [H-3]arachidonic acid release was observed in the absence of Ca2+ influx (5 mM EGTA or 5 mM Ni2+) or in monocytes loaded with a Ca2+-buffering agent. However, using ionophore-permeabilized monocytes and controlled intracellular Ca2+ concentration it was possible to dissociate MCP-1-induced Ca2+ influx from [H-3]arachidonic acid release. Thus, the MCP-1-induced increase in [Ca2+](i) is necessary but not sufficient for arachidonic acid accumulation. Phospholipase A(2) inhibitors (mepacrine, p-bromophenacyl bromide, and manoalide) blocked monocyte polarization and chemotaxis induced by MCP-1. The related Cys-Cys chemokines RANTES and LD78/MIP1(alpha) also induced a rapid release of [H-3]arachidonic acid, and their chemotactic activity was blocked by phospholipase A(2) inhibitors. Brief (5 min) pretreatment of monocytes with platelet-activating factor amplified MCP-1-induced arachidonic acid release and, at MCP-1 suboptimal concentrations, synergized in inducing monocyte migration. Since MCP-1 and platelet-activating factor are induced concomitantly by inflammatory cytokines in monocytes and endothelial cells, we speculate that the observed synergism may have in vivo relevance, The results presented here show that the Cgs-Cys chemokines MCP-1, LD78/MIP1(alpha), and RANTES cause rapid release of arachidonic acid in monocytes and that this may be important in inducing monocyte chemotaxis.	IST RIC FARMACOL MARIO NEGRI,I-20157 MILAN,ITALY; IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,I-66030 SANTA MARIA IMBAR,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Locati, Massimo/H-8404-2015; Locati, Massimo/ABF-6807-2021; Sozzani, Silvano/C-1447-2009; Mantovani, Alberto/HCI-7449-2022	Locati, Massimo/0000-0003-3077-590X; Sozzani, Silvano/0000-0002-3144-8743; Mantovani, Alberto/0000-0001-5578-236X				ADEREM AA, 1986, J EXP MED, V163, P139, DOI 10.1084/jem.163.1.139; AEPFELBACHER M, 1992, J IMMUNOL, V148, P2186; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BALSINDE J, 1990, J IMMUNOL, V144, P4298; BATES EJ, 1993, J LEUKOCYTE BIOL, V53, P420, DOI 10.1002/jlb.53.4.420; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; COLOTTA F, 1984, J IMMUNOL, V132, P936; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; DISE CA, 1982, J BIOL CHEM, V257, P4701; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GLASER KB, 1986, BIOCHEM PHARMACOL, V35, P449, DOI 10.1016/0006-2952(86)90218-2; GOLDYNE ME, 1984, J BIOL CHEM, V259, P8815; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALENDA SP, 1987, BIOCHEM J, V248, P471, DOI 10.1042/bj2480471; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; HIRATA F, 1979, P NATL ACAD SCI USA, V76, P2640, DOI 10.1073/pnas.76.6.2640; HOFFMAN T, 1991, J IMMUNOL, V146, P692; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KUIJPERS TW, 1992, J IMMUNOL, V148, P72; KUIJPERS TW, 1991, J IMMUNOL, V147, P1369; KUNA P, 1992, J IMMUNOL, V149, P636; LEFKOWITH JB, 1991, J BIOL CHEM, V266, P1071; LEFKOWITH JB, 1992, J IMMUNOL, V149, P1729; LOMBARDO D, 1985, J BIOL CHEM, V260, P7234; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MANTOVANI A, 1989, IMMUNOL TODAY, V10, P370, DOI 10.1016/0167-5699(89)90270-3; MANTOVANI A, 1992, TODAY, V13, P265; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MCPHAIL LC, 1993, NATURAL IMMUNE SYSTE, P63; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; REHFELDT W, 1991, BIOCHEM J, V276, P631, DOI 10.1042/bj2760631; ROLLINS BJ, 1991, BLOOD, V78, P1112; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SICA A, 1990, J IMMUNOL, V144, P3034; SOZZANI S, 1993, J IMMUNOL, V150, P1544; SOZZANI S, 1991, J IMMUNOL, V147, P2215; TAKUWA N, 1991, J BIOL CHEM, V266, P14237; VALONE FH, 1988, J IMMUNOL, V141, P3945; VANDAMME J, 1989, EUR J IMMUNOL, V19, P2367; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; WANG JM, 1986, J IMMUNOL, V137, P2726; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; YORIO T, 1978, NATURE, V271, P79, DOI 10.1038/271079a0; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; ZACHARIAE COC, 1990, J EXP MED, V171, P2177, DOI 10.1084/jem.171.6.2177	56	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4746	4753						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106442				2022-12-25	WOS:A1994MX57100011
J	NADAL, M; COUDERC, E; DUGUET, M; JAXEL, C				NADAL, M; COUDERC, E; DUGUET, M; JAXEL, C			PURIFICATION AND CHARACTERIZATION OF REVERSE GYRASE FROM SULFOLOBUS-SHIBATAE - ITS PROTEOLYTIC PRODUCT APPEARS AS AN ATP-INDEPENDENT TOPOISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLE; COLI PROTEIN-OMEGA; DNA TOPOISOMERASE; DESULFUROCOCCUS-AMYLOLYTICUS; SUPERHELICAL TURNS; HIGH-TEMPERATURE; SUPERCOILED DNA; I TOPOISOMERASE; ARCHAEBACTERIUM; ACIDOCALDARIUS	Sulfolobus shibatae B12 is a thermophilic archaebacterium that contains an inducible virus named SSV1. The viral DNA has been shown to be positively supercoiled before encapsidation. We have previously purified an archaebacterial DNA topoisomerase from Sulfolobus acidocaldarius DSM 639, reverse gyrase, likely responsible for this positive supercoiling reaction. In order to study an homogeneous system containing both reverse gyrase and one of its preferential substrate, SSV1 DNA, we have purified this enzyme from S. shibatae. During the course of the purification, we have detected another topoisomerase activity. In order to separate and purify these two topoisomerases, we have devised a new purification procedure. Purified S. shibatae reverse gyrase is a 124-kDa monomer, with a Stokes radius of 43 Angstrom and a sedimentation coefficient of 6.2 S. It is able to perform a DNA reverse gyration per se at 10 mM NaCl in a Mg- and ATP-dependent manner. The other topoisomerase is a monomer of about 40 kDa, with a Stokes radius of 25 Angstrom and a sedimentation coefficient of 4 S. This additional topoisomerase activity is Mg-dependent and ATP-independent and catalyzes only a relaxation reaction of negatively supercoiled DNA at 150 mM NaCl. This new ATP-independent topoisomerase activity seems to be a proteolysis product of reverse gyrase.	UNIV PARIS 11,INST GENET MICROBIOL,ENZYMOL ACIDES NUCL LAB,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay				NADAL, Marc/0000-0001-9637-7694				BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; CHAMPOUX JJ, 1972, P NATL ACAD SCI USA, V69, P143, DOI 10.1073/pnas.69.1.143; CHARBONNIER F, 1992, J BACTERIOL, V174, P6103, DOI 10.1128/JB.174.19.6103-6108.1992; COLLIN RG, 1988, FEMS MICROBIOL LETT, V55, P235, DOI 10.1111/j.1574-6968.1988.tb13940.x; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; DELATOUR CB, 1993, BIOCHIM BIOPHYS ACTA, V1216, P213, DOI 10.1016/0167-4781(93)90147-6; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; DELATOUR CB, 1991, J BACTERIOL, V173, P3921, DOI 10.1128/JB.173.12.3921-3923.1991; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DRLICA K, 1984, MICROBIOL REV, V48, P273, DOI 10.1128/MMBR.48.4.273-289.1984; DUGUET M, 1983, NUCLEIC ACIDS RES, V11, P1059, DOI 10.1093/nar/11.4.1059; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GROGAN D, 1990, ARCH MICROBIOL, V154, P594; Hames B.D., 1981, GEL ELECTROPHORESIS, P71; JAXEL C, 1989, EMBO J, V8, P3135, DOI 10.1002/j.1460-2075.1989.tb08466.x; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; MARTIN A, 1984, EMBO J, V3, P2165, DOI 10.1002/j.1460-2075.1984.tb02107.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MENZEL R, 1983, CELL, V34, P105, DOI 10.1016/0092-8674(83)90140-X; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MIRAMBEAU G, 1984, J MOL BIOL, V179, P559, DOI 10.1016/0022-2836(84)90080-9; NADAL M, 1988, BIOCHEMISTRY-US, V27, P9102, DOI 10.1021/bi00426a006; NADAL M, 1986, NATURE, V321, P256, DOI 10.1038/321256a0; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SLESAREV AI, 1991, J BIOL CHEM, V266, P12321; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; SRIVENUGOPAL KS, 1985, BIOCHEMISTRY-US, V24, P4766, DOI 10.1021/bi00339a009; SVOBODA M, 1985, ANAL BIOCHEM, V151, P16, DOI 10.1016/0003-2697(85)90046-6; UPTON C, 1990, VIROLOGY, V176, P439, DOI 10.1016/0042-6822(90)90013-H; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YEATS S, 1982, EMBO J, V1, P1035, DOI 10.1002/j.1460-2075.1982.tb01292.x	40	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5255	5263						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106509				2022-12-25	WOS:A1994MX57100086
J	VOYNOYASENETSKAYA, T; CONKLIN, BR; GILBERT, RL; HOOLEY, R; BOURNE, HR; BARBER, DL				VOYNOYASENETSKAYA, T; CONKLIN, BR; GILBERT, RL; HOOLEY, R; BOURNE, HR; BARBER, DL			G-ALPHA-13 STIMULATES NA-H EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; CYCLIC-AMP ACCUMULATION; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; INTRACELLULAR PH; NA+/H+ EXCHANGE; PERTUSSIS TOXIN; ADENYLYL CYCLASE; PHOSPHOLIPASE-C; CYTOPLASMIC PH	Activity of the ubiquitous Na-H exchanger (NHE1) is regulated by a number of receptors with tyrosine kinase activity as well as by several classes of receptors coupled to heterotrimeric GTP-binding proteins. We previously demonstrated that the beta(2)-adrenergic receptor and other receptors that stimulate adenylyl cyclase by activating G(s) stimulate NHE1 by a guanine nucleotide-dependent mechanism that is independent of receptor coupling to G(s). Now we report that a recently identified G alpha subunit, alpha 13, activates the exchanger. Transient expression of mutationally activated alpha 13 constitutively stimulates Na-H exchange; moreover, an alpha 13/alpha(z) chimera, designed to respond to stimulation by G(i)-coupled receptors, mediates stimulation of Na-H exchange by one such receptor, the dopamine(2), receptor. Mutationally activated alpha 13, however, does not stimulate adenylyl cyclase activity or phosphoinositide hydrolysis, indicating that its action on NHE1 occurs independently of these two effector pathways. These findings reveal the first known signaling function of alpha 13 and identify a new G protein involved in the regulation of NHE1.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061	NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413, R37GM027800, R01GM027800] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54427] Funding Source: Medline; NIGMS NIH HHS [GM 27800, GM 47413] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; CLARK JD, 1991, AM J PHYSIOL, V261, pC945, DOI 10.1152/ajpcell.1991.261.6.C945; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GANZ MB, 1988, AM J PHYSIOL, V254, pF737; GRINSTEIN S, 1986, BIOCHIM BIOPHYS ACTA, V889, P301, DOI 10.1016/0167-4889(86)90192-8; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAZAV P, 1989, CANCER RES, V49, P72; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HUANG CL, 1987, J BIOL CHEM, V262, P14134; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; RAO GN, 1991, J BIOL CHEM, V266, P1385; RESNICK RJ, 1986, CANCER RES, V46, P1800; SARDET C, 1991, J BIOL CHEM, V266, P19166; SIFFERT W, 1987, THROMB RES, V44, P235; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRATHMANN M, 1989, P NATL ACAD SCI USA, V88, P5582; SWEATT JD, 1985, J BIOL CHEM, V260, P2910; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VARIO G, 1990, J BIOL CHEM, V265, P16929; VIGNE P, 1988, J BIOL CHEM, V263, P18023; VOLPI M, 1985, P NATL ACAD SCI USA, V82, P2708, DOI 10.1073/pnas.82.9.2708; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1992, J BIOL CHEM, V267, P1811	40	155	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4721	4724						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106440				2022-12-25	WOS:A1994MX57100008
J	HAGIWARA, H; YORIFUJI, H; SATOYOSHITAKE, R; HIROKAWA, N				HAGIWARA, H; YORIFUJI, H; SATOYOSHITAKE, R; HIROKAWA, N			COMPETITION BETWEEN MOTOR MOLECULES (KINESIN AND CYTOPLASMIC DYNEIN) AND FIBROUS MICROTUBULE-ASSOCIATED PROTEINS IN BINDING TO MICROTUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; MEMBRANOUS ORGANELLES INVIVO; CARBOXYL-TERMINAL DOMAIN; IMMUNOELECTRON MICROSCOPY; TAU PROTEINS; SYNTHETIC PEPTIDES; REGULATORY DOMAIN; QUICK-FREEZE; DEEP-ETCH; TUBULIN	In neuronal cells, microtubule-associated proteins (MAPs) can be classified into two distinct groups. One consists of force-producing MAPs, the main components of which are kinesin and cytoplasmic dynein. The other is composed of fibrous MAPs, which include tau and MAP2. Many studies have been performed on the respective groups to understand their structures and functions. However, the problem of how the groups interact with each other on microtubules is still unresolved. To elucidate the interaction between kinesin or cytoplasmic dynein and tau or MAP2, we performed three experiments: competition, motility assay, and cosedimentation. To distinguish whether the binding competition is caused by steric hindrance of the projection domains of MAPs or by the competition of the binding sites on microtubules, we used microtubule binding domains of tau and MAP2 as well as native proteins. Our results revealed that kinesin or cytoplasmic dynein and tau or MAP2 compete for almost the same binding domains located on the carboxyl-terminal side of alpha- and the amino-terminal side of beta-tubulin from the site of subtilisin cleavage. Furthermore, the projection of tau, and probably of MAP2, might inhibit the binding of kinesin or cytoplasmic dynein to microtubules by steric hindrance. These findings will provide a useful step toward understanding the regulation system of intracellular organelle transport.	UNIV TOKYO, SCH MED, DEPT ANAT & CELL BIOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								AMOS LA, 1989, J CELL SCI, V93, P19; BERNHARDT R, 1982, J CELL BIOL, V92, P589, DOI 10.1083/jcb.92.2.589; BLOOM GS, 1984, J CELL BIOL, V98, P320, DOI 10.1083/jcb.98.1.320; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; GARNER CC, 1988, J NEUROCHEM, V50, P609, DOI 10.1111/j.1471-4159.1988.tb02954.x; GILBERT SP, 1986, J CELL BIOL, V103, P947, DOI 10.1083/jcb.103.3.947; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; HEINS S, 1991, J CELL SCI, P121; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIROKAWA N, 1988, J NEUROSCI, V8, P2769; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1985, J CELL BIOL, V101, P277; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; LOPEZ LA, 1993, CELL MOTIL CYTOSKEL, V24, P1, DOI 10.1002/cm.970240102; LYE RJ, 1987, CELL, V51, P309, DOI 10.1016/0092-8674(87)90157-7; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MACCIONI RB, 1986, EUR J BIOCHEM, V156, P375, DOI 10.1111/j.1432-1033.1986.tb09593.x; MASSOW A, 1989, CELL MOTIL CYTOSKEL, V14, P562; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; NUNEZ J, 1988, TRENDS NEUROSCI, V11, P477, DOI 10.1016/0166-2236(88)90004-5; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PENNINGROTH SM, 1987, FEBS LETT, V222, P204, DOI 10.1016/0014-5793(87)80220-X; PORTER ME, 1987, J BIOL CHEM, V262, P2794; RIVAS CI, 1988, P NATL ACAD SCI USA, V85, P6092, DOI 10.1073/pnas.85.16.6092; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; SACKETT DL, 1985, J BIOL CHEM, V260, P43; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SHIOMURA Y, 1987, J CELL BIOL, V104, P1575, DOI 10.1083/jcb.104.6.1575; SHIOMURA Y, 1987, J NEUROSCI, V7, P1461; UMEYAMA T, 1993, J CELL BIOL, V120, P451, DOI 10.1083/jcb.120.2.451; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; Vallee R, 1991, Trends Cell Biol, V1, P25, DOI 10.1016/0962-8924(91)90066-I; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P1342, DOI 10.1073/pnas.80.5.1342; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; VINA S, 1988, BIOCHEMISTRY-US, V27, P5352; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; YOUNG JT, 1988, P NATL ACAD SCI USA, V85, P1864	67	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3581	3589						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106402				2022-12-25	WOS:A1994MV63100070
J	HSIEH, JT; LIN, SH				HSIEH, JT; LIN, SH			ANDROGEN REGULATION OF CELL-ADHESION MOLECULE GENE-EXPRESSION IN RAT PROSTATE DURING ORGAN DEGENERATION - C-CAM BELONGS TO A CLASS OF ANDROGEN-REPRESSED GENES ASSOCIATED WITH ENRICHED STEM AMPLIFYING CELL-POPULATION AFTER PROLONGED CASTRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-BETA; VENTRAL PROSTATE; E-CADHERIN; CARCINOEMBRYONIC ANTIGEN; SURFACE GLYCOPROTEIN; CANCER; TISSUES; DEATH; BASAL; IDENTIFICATION	Androgen is required for maintaining the differentiated state of prostatic epithelium, and that cell adhesion molecules play active roles in controlling the development of epithelial cells. However, little is known about the regulation of cell adhesion molecules during prostate development. In this study, we demonstrated that the expression of an epithelial cell adhesion molecule, C-CAM, in rat ventral prostatic epithelium are repressed by androgen. A similar regulatory pattern was also observed in the seminal vesicle but not in other androgen-dependent organs (the coagulating gland and the dorsolateral prostate), or other organs (the liver and kidney). These observations suggest that regulation of C-CAM expression by androgen is tissue-specific. Unlike the other androgen-repressed genes associated with apoptosis, which have transient expression patterns, the elevated level of C-CAM in the ventral prostate persisted for more than 30 days postcastration, suggesting that C-CAM belongs to a class of androgen-repressed genes which are not associated with apoptosis. Immunohistochemical study detected C-CAM on the apical surface of secretory epithelium in control rats; castration resulted in an altered localization of C-CAM expression from columnar epithelium to cuboidal basal epithelium. Taken together, the up-regulation and altered expression pattern of C-CAM in ventral prostatic epithelium by androgen deprivation may be associated with the enriched epithelial stem/amplifying cell population in degenerated ventral prostate. These observations suggest that C-CAM may play an active role in the process of prostatic epithelial differentiation.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOLEC PATHOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	HSIEH, JT (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT UROL, HOUSTON, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA059939] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043189] Funding Source: NIH RePORTER; NCI NIH HHS [CA59939] Funding Source: Medline; NIGMS NIH HHS [GM43189] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABAJKO S, 1993, P NATL ACAD SCI USA, V90, P272, DOI 10.1073/pnas.90.1.272; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY DS, 1990, UROL CLIN N AM, V17, P461; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; DEKLERK DP, 1975, BENIGN PROSTATIC HYP, P43; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1984, P NATL ACAD SCI-BIOL, V81, P1460, DOI 10.1073/pnas.81.5.1460; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GETZENBERG RH, 1990, MOL ENDOCRINOL, V4, P1336, DOI 10.1210/mend-4-9-1336; GLEAVE M, 1991, CANCER RES, V51, P3753; HIXSON DC, 1989, CANCER RES, V49, P6788; HSIEH JT, 1992, J BIOL CHEM, V267, P2303; ISAACS JT, 1989, PROSTATE, P33; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Lee C., 1987, GENITAL SYSTEM, P239; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LESSER B, 1974, BIOCHEM J, V142, P429, DOI 10.1042/bj1420429; LIAO S, 1977, BIOCHEM ACTION HORM, V4, P351; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; MATSUURA K, 1992, BRIT J CANCER, V66, P1122, DOI 10.1038/bjc.1992.421; MCCORMICK BA, 1992, PHARMACOL THERAPEUT, V53, P239, DOI 10.1016/0163-7258(92)90011-N; MOWERY J, 1991, HEPATOLOGY, V13, P47; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; ODIN P, 1988, J HISTOCHEM CYTOCHEM, V36, P729, DOI 10.1177/36.7.3290331; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; RAYNAUD JP, 1988, AM J CLIN ONCOL-CANC, V11, pS132, DOI 10.1097/00000421-198801102-00034; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; SALTZMAN AG, 1987, J BIOL CHEM, V262, P432; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; THOMPSON NL, 1993, CELL GROWTH DIFFER, V4, P257; TINGSTROM A, 1990, J CELL SCI, V96, P17; UMBAS R, 1992, CANCER RES, V52, P5104; VERHAGEN APM, 1988, PROSTATE, V13, P25, DOI 10.1002/pros.2990130104; VISKOCHIL DH, 1983, J BIOL CHEM, V258, P8861	46	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3711	3716						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106416				2022-12-25	WOS:A1994MV63100085
J	KADOWAKI, M; VENERANDO, R; MIOTTO, G; MORTIMORE, GE				KADOWAKI, M; VENERANDO, R; MIOTTO, G; MORTIMORE, GE			DE-NOVO AUTOPHAGIC VACUOLE FORMATION IN HEPATOCYTES PERMEABILIZED BY STAPHYLOCOCCUS-AUREUS ALPHA-TOXIN - INHIBITION BY NONHYDROLYZABLE GTP ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID CONTROL; ISOLATED RAT HEPATOCYTES; BINDING PROTEINS; COLLOIDAL SILICA; PLASMA-MEMBRANE; INTRACELLULAR DEGRADATION; HEPATIC PROTEOLYSIS; LIVER LYSOSOMES; CELLS; TRANSPORT	The role of GTP-binding proteins in autophagic vacuole formation was investigated in isolated rat hepatocytes permeabilized by alpha-toxin from Staphylococcus aureus, an agent which creates stable plasma membrane channels allowing exchange of small (less-than-or-equal-to 1000 Da) molecules. Vacuole formation was monitored from the uptake of I-125-tyramine-cellobiitol ((ITC)-I-125) into osmotically sensitive vacuoles isolated on colloidal silica density gradients. Separation was based on an established observation that autophagic vacuoles are retained in a heavy midgradient band when samples are layered, but are selectively shifted to dense fractions when they are previously dispersed in the gradient material. The vacuolar uptake of (ITC)-I-125 was concentration-dependent and required exogenous ATP: 94% was directly mediated by sequestration; 6% was acquired by fluid-phase endocytosis as monitored by [carboxyl-C-14]dextran-carboxyl. Although the amino acid control of proteolysis was lost, addition of the nonhydrolyzable GTP analog GTPgammaS (as well as GMP-PNP) decreased fractional rates of direct vacuolar (ITC)-I-125 uptake and long-lived proteolysis by similar amounts (1.02-1.03% h-1), substantiating the notion that the effects were the direct result of autophagic inhibition. These and associated findings, supported by quantitative electron microscopy, indicate the presence of ongoing macro- and microautophagy in alpha-toxin-permeabilized cells and suggest that one or more GTP-binding proteins is required in macroautophagic vacuole formation.	UNIV PADUA, DIPARTIMENTO CHIM BIOL, I-35121 PADUA, ITALY	University of Padua	KADOWAKI, M (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, COLL MED, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA.		Miotto, Giovanni/S-1903-2016	Miotto, Giovanni/0000-0002-4278-4873	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021624] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21624] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARION WJ, 1980, J BIOL CHEM, V255, P387; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GORDON PB, 1988, BIOCHEM BIOPH RES CO, V151, P40, DOI 10.1016/0006-291X(88)90556-6; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARSHMAN S, 1988, METHOD ENZYMOL, V165, P3; HENDIL KB, 1980, J CELL PHYSIOL, V105, P449, DOI 10.1002/jcp.1041050309; HIRSIMAKI P, 1983, PATHOBIOLOGY CELL ME, V3, P201; HOHMAN RJ, 1988, P NATL ACAD SCI USA, V85, P1624, DOI 10.1073/pnas.85.5.1624; KADOWAKI M, 1992, J BIOL CHEM, V267, P22060; KINDBERG GM, 1987, J BIOL CHEM, V262, P7066; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; MCEWEN BF, 1985, J CELL BIOL, V100, P1922, DOI 10.1083/jcb.100.6.1922; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MIOTTO G, 1992, J BIOL CHEM, V267, P22066; MORTIMORE GE, 1988, J BIOL CHEM, V263, P2506; MORTIMORE GE, 1991, J BIOL CHEM, V266, P1021; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; MORTIMORE GE, 1994, IN PRESS CELLULAR PR; OSE L, 1980, EXP CELL RES, V126, P109, DOI 10.1016/0014-4827(80)90475-9; Pittman R C, 1986, Methods Enzymol, V129, P612; PLOMP PJAM, 1989, J BIOL CHEM, V264, P6699; SCHWARTZ AL, 1992, AM J PHYSIOL, V262, pC1031, DOI 10.1152/ajpcell.1992.262.4.C1031; SCHWORER CM, 1981, J BIOL CHEM, V256, P7652; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SEGLEN PO, 1984, J CELL BIOL, V99, P435, DOI 10.1083/jcb.99.2.435; SEGLEN PO, 1986, EXP CELL RES, V162, P273, DOI 10.1016/0014-4827(86)90446-5; SEGLEN PO, 1987, LYSOSOMES THEIR ROLE, P371; SURMACZ CA, 1983, AM J PHYSIOL, V245, pC52, DOI 10.1152/ajpcell.1983.245.1.C52; SURMACZ CA, 1983, AM J PHYSIOL, V245, pC61, DOI 10.1152/ajpcell.1983.245.1.C61; SURMACZ CA, 1987, BIOCHEM J, V242, P453, DOI 10.1042/bj2420453; SURMACZ CA, 1982, BIOCHEM BIOPH RES CO, V107, P1425, DOI 10.1016/S0006-291X(82)80158-7; THELESTAM M, 1983, BIOCHIM BIOPHYS ACTA, V762, P481, DOI 10.1016/0167-4889(83)90050-2; TOOZE J, 1990, J CELL BIOL, V111, P329, DOI 10.1083/jcb.111.2.329; VENERANDO R, 1991, FASEB J, V5, pA1178	43	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3703	3710						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106415				2022-12-25	WOS:A1994MV63100084
J	SCHROEDER, JJ; CRANE, HM; XIA, J; LIOTTA, DC; MERRILL, AH				SCHROEDER, JJ; CRANE, HM; XIA, J; LIOTTA, DC; MERRILL, AH			DISRUPTION OF SPHINGOLIPID METABOLISM AND STIMULATION OF DNA-SYNTHESIS BY FUMONISIN-B(1) - A MOLECULAR MECHANISM FOR CARCINOGENESIS ASSOCIATED WITH FUSARIUM-MONILIFORME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HAMSTER OVARY CELLS; GROWTH-FACTOR RECEPTOR; PHOSPHATIDATE PHOSPHOHYDROLASE; EQUINE LEUKOENCEPHALOMALACIA; SPHINGOMYELIN TURNOVER; CELLULAR PROLIFERATION; COMPLEX SPHINGOLIPIDS; SPHINGOSINE; INHIBITION	Consumption of grains contaminated with Fusarium moniliforme (Sheldon) causes liver cancer in rats and has been correlated with esophageal cancer in humans. The causative agents are believed to be a family of compounds known as fumonisins, which bear remarkable structural resemblances to sphingosine and sphinganine, the long-chain (sphingoid) base backbones of sphingolipids. Recently, fumonisin B1 has been shown to block de novo synthesis of sphingolipids by inhibiting sphingosine (sphinganine) N-acyltransferase, which leads to accumulation of sphingoid bases. Because the exogenous addition of sphingosine and sphingosine 1-phosphate to Swiss 3T3 cells has been shown to stimulate DNA synthesis (Zhang, H., Buckley, N. E., Gibson, K., and Spiegel, S. (1990) J. Biol. Chem. 265,76-81; Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) J. Cell Biol. 114,155-167), we hypothesized that fumonisins might stimulate DNA synthesis by disrupting sphingolipid metabolism. Fumonisin B1 caused accumulation of sphinganine and sphingosine in Swiss 3T3 fibroblasts and, as occurred when these sphingoid bases were added exogenously, stimulated thymidine incorporation into DNA and augmented the mitogenic effect of insulin in a concentration-dependent manner. The mechanism underlying the mitogenic effect of fumonisin B1 was further investigated by using beta-fluoroalanine to block the initial step of sphingolipid biosynthesis catalyzed by serine palmitoyltransferase. beta-Fluoroalanine reduced sphingoid base accumulation in fumonisin B1-treated fibroblasts and inhibited fumonisin B1-stimulated DNA synthesis, but had no effect on mitogenesis when added alone. Fumonisin B1 did not cause accumulation of sphinganine 1-phosphate; therefore, it appears that sphingoid bases per se can stimulate DNA synthesis. To prove that the 1-phosphate is not obligatory, a 1-deoxysphinganine was synthesized, and it was as potent as sphinganine in stimulating DNA synthesis. These results establish that fumonisin B1 is mitogenic via accumulation of sphingoid bases rather than inhibition of complex sphingolipid biosynthesis per se. Because mitogens can often affect cell transformation, this provides a plausible molecular mechanism to explain the carcinogenicity of fumonisins.	EMORY UNIV,SCH MED,DEPT BIOCHEM,4113 ROLLINS RES CTR,ATLANTA,GA 30322; EMORY UNIV,DEPT CHEM,ATLANTA,GA 30322	Emory University; Emory University				Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM14733, GM46368, GM33369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014733, R01GM033369, R01GM046368] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BEZUIDENHOUT CS, 1988, J CHEM SOC CHEM COMM, P743; BREMER EG, 1984, J BIOL CHEM, V259, P6818; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; Gelderblom W C, 1991, Mycotoxin Res, V7, P46, DOI 10.1007/BF03192165; GELDERBLOM WCA, 1988, APPL ENVIRON MICROB, V54, P1806, DOI 10.1128/AEM.54.7.1806-1811.1988; GELDERBLOM WCA, 1992, CARCINOGENESIS, V13, P433, DOI 10.1093/carcin/13.3.433; GELDERBLOM WCA, 1992, MYCOPATHOLOGIA, V117, P11, DOI 10.1007/BF00497273; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; Harrison L R, 1990, J Vet Diagn Invest, V2, P217; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KELLERMAN T S, 1972, Onderstepoort Journal of Veterinary Research, V39, P205; KIM MY, 1991, J BIOL CHEM, V266, P484; KRIEK NPJ, 1981, ONDERSTEPOORT J VET, V48, P129; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LIN M, 1980, GENETIC ENV FACTORS, P139; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marasas W. F. O., 1982, CANCER ESOPHAGUS, V1, P29; MARASAS WFO, 1984, INT J CANCER, V34, P383, DOI 10.1002/ijc.2910340315; MARASAS WFO, 1988, ONDERSTEPOORT J VET, V55, P197; MARASAS WFO, 1984, TOXIGENIC FUSARIUM S; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1993, ADV LIPID RES, V26, P215; MERRILL AH, 1993, ADV LIPID RES, V25, P1; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1985, J LIPID RES, V26, P617; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MESSMER TO, 1989, J NUTR, V119, P534, DOI 10.1093/jn/119.4.534; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; NORED WP, 1992, FOOD CHEM TOXICOL, V30, P233; NORRED WP, 1992, MYCOPATHOLOGIA, V117, P73, DOI 10.1007/BF00497281; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OGURA K, 1992, EXP CELL RES, V199, P169, DOI 10.1016/0014-4827(92)90475-N; OISHI K, 1990, J BIOL CHEM, V265, P70; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; RAMEL C, 1988, MUTAT RES, V205, P13, DOI 10.1016/0165-1218(88)90004-3; RILEY RT, 1993, TOXICOL APPL PHARM, V118, P105, DOI 10.1006/taap.1993.1015; ROSS PF, 1990, APPL ENVIRON MICROB, V56, P3225, DOI 10.1128/AEM.56.10.3225-3226.1990; SPIEGEL S, 1987, P NATL ACAD SCI USA, V84, P141, DOI 10.1073/pnas.84.1.141; SPIEGEL S, 1988, EXP CELL RES, V177, P414, DOI 10.1016/0014-4827(88)90474-0; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; SYDENHAM EW, 1990, J AGR FOOD CHEM, V38, P285, DOI 10.1021/jf00091a064; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; VOSS KA, 1990, MYCOPATHOLOGIA, V112, P81, DOI 10.1007/BF00436503; VOSS KA, 1989, FOOD CHEM TOXICOL, V27, P89, DOI 10.1016/0278-6915(89)90002-1; WANG E, 1992, J NUTR, V122, P1706, DOI 10.1093/jn/122.8.1706; WANG E, 1991, J BIOL CHEM, V266, P14486; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; YANG CS, 1980, CANCER RES, V40, P2633; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	61	145	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3475	3481						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106389				2022-12-25	WOS:A1994MV63100054
J	SIMBOLICAMPBELL, M; GAGNON, A; FRANKS, DJ; WELSH, J				SIMBOLICAMPBELL, M; GAGNON, A; FRANKS, DJ; WELSH, J			1,25-DIHYDROXYVITAMIN-D3 TRANSLOCATES PROTEIN KINASE-C-BETA TO NUCLEUS AND ENHANCES PLASMA-MEMBRANE ASSOCIATION OF PROTEIN KINASE-C-ALPHA IN RENAL EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; VITAMIN-D RECEPTOR; PHORBOL ESTERS; HL-60 CELLS; MDBK CELLS; RAT; INVOLVEMENT; EXPRESSION; ZETA; PHOSPHORYLATION	1,25-Dihydroxycholecalciferol (1,25-(OH)2-D3) increases membrane-associated protein kinase C (PKC) activity and immunoreactivity in renal epithelial (Madin Darby bovine kidney, MDBK) cells (Simboli-Campbell, M., Franks, D. J., and Welsh, J. E. (1992) Cell Signalling 4, 99-109). We have now characterized the effects of 1,25-(OH)2-Ds on the subcellular localization of three individual isozymes by immunofluorescence and immunoblotting. Although the total amount of PKCalpha, PKCbeta, and PKCzeta are unaffected by 1,25-(OH)2-D3, this steroid hormone induces subcellular redistribution of both PKCalpha and PKCbeta. Treatment with 1,25-(OH)2-D3 (100 nM, 24 h) enhances plasma membrane association of PKCalpha and induces translocation of PKCbeta to the nuclear membrane. The effects of 1,25-(OH)2-D3 appear to be limited to the calcium-dependent PKC isozymes, since 1,25-(OH)2-D3 has no effect on the calcium independent isozyme, PKCzeta. In contrast to rapid transient PKC translocation seen in response to agents which interact with membrane receptors to induce phospholipid hydrolysis, modulation of PKCalpha and PKCbeta is observed after 24 h treatment with 1,25-(OH)2-D3. In MDBK cells, the phorbol ester 12-0-tetradecanoylphorbol-13-acetate (TPA) (100 nM, 24 h) down-regulates PKCalpha and, to a lesser extent, PKCzeta, without altering their subcellular distribution. TPA also induces translocation of PKCbeta to the nuclear membrane. MDBK cells treated with 1,25-(OH)2-D3, but not TPA, exhibit enhanced phosphorylation of endogenous nuclear proteins. In addition to the distinct effects of 1,25-(OH)2-D3 and TPA on PKC isozyme patterns, 1,25-(OH)2-Ds up-regulates both the vitamin D receptor and calbindin D-28K, whereas TPA down-regulates the expression of both proteins. These data support the involvement of PKC in the mechanism of action of 1,25-(OH)2-Ds and specifically implicate PKCbeta in 1,25-(OH)2-Ds-mediated nuclear events.	UNIV OTTAWA,DEPT BIOCHEM,451 SMYTH RD,OTTAWA K1H 8M5,ONTARIO,CANADA	University of Ottawa				Gagnon, AnneMarie/0000-0002-6522-4879				BELLIDO T, 1991, VITAMIN D, P409; BINDELS RJM, 1991, AM J PHYSIOL, V261, pF799, DOI 10.1152/ajprenal.1991.261.5.F799; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN TA, 1990, J BIOL CHEM, V265, P10025; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; COHEN P, 1977, METHOD ENZYMOL, V47, P208; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; FRANKS DJ, 1984, J CELL PHYSIOL, V119, P41, DOI 10.1002/jcp.1041190108; GAGNON AM, 1994, IN PRESS KIDNEY INT; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HENRICH CJ, 1992, FOCUS, V13, P133; HENRY HL, 1989, ENDOCRINOLOGY, V124, P2228, DOI 10.1210/endo-124-5-2228; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; KOSAKA Y, 1988, BIOCHEM BIOPH RES CO, V151, P973, DOI 10.1016/S0006-291X(88)80461-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1988, J BIOL CHEM, V263, P13223; MADIN SH, 1958, P SOC EXP BIOL MED, V98, P574, DOI 10.3181/00379727-98-24111; MANDLA S, 1990, ENDOCRINOLOGY, V127, P2639, DOI 10.1210/endo-127-6-2639; MARTELL RE, 1992, J BIOL CHEM, V267, P7511; MILLER BE, 1983, METHOD ENZYMOL, V102, P291; MULER RE, 1983, J BIOL CHEM, V258, P9227; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; OBEID LM, 1990, J BIOL CHEM, V265, P2370; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; SIMBOLICAMPBELL M, 1992, CELL SIGNAL, V4, P99, DOI 10.1016/0898-6568(92)90011-V; SIMBOLICAMPBELL M, 1992, MOL CELL ENDOCRINOL, V83, P143, DOI 10.1016/0303-7207(92)90155-Y; SIMBOLICAMPBELL M, 1993, FOCUS, V15, P12; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SOLOMON DH, 1991, CELL GROWTH DIFFER, V2, P187; STANDAERT ML, 1993, ENDOCRINOLOGY, V132, P689, DOI 10.1210/en.132.2.689; TAYLOR AN, 1982, KIDNEY INT, V21, P765, DOI 10.1038/ki.1982.95; TORNQUIST K, 1989, ENDOCRINOLOGY, V124, P2765, DOI 10.1210/endo-124-6-2765; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WEAVER VM, 1992, CELL SIGNAL, V4, P293, DOI 10.1016/0898-6568(92)90069-K; WELSH J, 1991, BIOCHEM CELL BIOL, V69, P768, DOI 10.1139/o91-118; WETSEL CM, 1991, J CELL BIOL, V117, P121; WIESE RJ, 1992, J BIOL CHEM, V267, P20082	45	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3257	3264						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106362				2022-12-25	WOS:A1994MV63100023
J	SINDHWANI, R; ISMAILBEIGI, F; LEINWAND, LA				SINDHWANI, R; ISMAILBEIGI, F; LEINWAND, LA			POSTTRANSCRIPTIONAL REGULATION OF RAT ALPHA-CARDIAC MYOSIN HEAVY-CHAIN GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; FULL LENGTH CDNA; MESSENGER-RNA; THYROID-HORMONE; GROWTH-HORMONE; HEART; BOUNDARIES; ISOFORMS; POLY(A); TAIL	The cardiac myosin heavy chain genes, alpha and beta, have been shown to change their patterns of expression rapidly and dramatically in response to a variety of stimuli. A major means of achieving these changes in gene expression is transcriptional control; however, the role of post-transcriptional regulation in cardiac myosin gene expression has not been investigated. We have identified two post-transcriptional events in rat a cardiac myosin heavy chain (alpha-MHC) gene expression and investigated their regulatory significance in different developmental and thyroid hormone states. The polyadenylation of alpha-MHC mRNA occurs at three different sites: 12, 18, and 23 bases downstream from a single polyadenylation signal. Hyperthyroid hearts did not demonstrate any change in the proportion of the three alpha-MHC mRNA subspecies. Hypothyroid hearts (which have a decreased amount of total alpha-MHC mRNA) showed a significant increase in the proportion of the longest subspecies and a decrease in the shortest subspecies. The second post-transcriptional event in alpha-MHC gene expression which was demonstrated was the inclusion or exclusion of a codon, CAG, encoding glutamine at position 1931, resulting from alternate splicing of the alpha-MHC transcript. The ratio of CAG+ and CAG- forms of mRNA in the adult euthyroid hearts is 40:60% which was unchanged in hypo- and hyperthyroid states. This is the first example of alternate splicing in a vertebrate sarcomeric myosin heavy chain gene. We conclude that the rat alpha-MHC gene transcript is post-transcriptionally modified.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, RM 416, FORCHHEIMER BLDG, BRONX, NY 10461 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA	Yeshiva University; Albert Einstein College of Medicine; Columbia University				LEINWAND, LESLIE/0000-0003-1470-4810	NHLBI NIH HHS [R01HL50560, 1T32HL07675, P01HL37412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050560, P01HL037412, T32HL007675] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BERNSTEIN SI, 1986, MOL CELL BIOL, V6, P2511, DOI 10.1128/MCB.6.7.2511; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOHELER KR, 1992, J BIOL CHEM, V267, P12979; BOUVAGNET P, 1987, CIRC RES, V61, P329, DOI 10.1161/01.RES.61.3.329; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHESNE CA, 1987, DEV BIOL, V123, P169, DOI 10.1016/0012-1606(87)90439-8; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; EVERETT AW, 1984, BIOCHEMISTRY-US, V23, P1596, DOI 10.1021/bi00303a002; HIGGS DR, 1983, NATURE, V306, P398, DOI 10.1038/306398a0; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; KUROO M, 1989, J BIOL CHEM, V264, P18272; LOMPRE AM, 1981, DEV BIOL, V84, P286, DOI 10.1016/0012-1606(81)90396-1; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MANLEY JL, 1989, GENE DEV, V3, P2218, DOI 10.1101/gad.3.12b.2218; MAURER RA, 1981, J BIOL CHEM, V256, P524; MCNALLY EM, 1989, NUCLEIC ACIDS RES, V17, P7527, DOI 10.1093/nar/17.18.7527; MORKIN E, 1983, PROG CARDIOVASC DIS, V25, P435, DOI 10.1016/0033-0620(83)90004-X; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; WALLIS M, 1980, NATURE, V284, P512, DOI 10.1038/284512a0; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	30	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3272	3276						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106364				2022-12-25	WOS:A1994MV63100025
J	HANSEN, JE; GAFNI, A				HANSEN, JE; GAFNI, A			THERMAL SWITCHING BETWEEN ENHANCED AND ARRESTED REACTIVATION OF BACTERIAL GLUCOSE-6-PHOSPHATE-DEHYDROGENASE ASSISTED BY GROEL IN THE ABSENCE OF ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HOST PROTEIN; LEUCONOSTOC-MESENTEROIDES; CHAPERONIN; IDENTIFICATION; GENE; PURIFICATION; PRECURSOR; PRODUCT; INVITRO	Facilitation of protein folding by GroEL usually requires involvement of GroES and ATP. In their absence nascent proteins tend to be arrested on GroEL or, if released, fail to show enhancement of reactivation yield relative to that observed without the chaperonin. In contrast, the yield of reactivation of glucose-6-phosphate dehydrogenase (Glu-6-PDH) from Leuconostoc mesenteroides at 20-degrees-C is increased 2-3-fold (to over 80%) by GroEL alone. ATP greatly enhances the rate of GroEL-assisted reactivation and slightly increases its yield to 90%. The efficiency of the GroEL-assisted reactivation of Glu-6-PDH is strongly dependent on temperature. A switch from enhanced to fully arrested reactivation occurs over a narrow temperature range from 25 to 30-degrees-C in the presence of GroEL when ATP is absent. At physiological temperature therefore, reactivation is fully arrested by GroEL if ATP is absent and in its presence the protein is released in a form not committed to correct folding. The data shows that the committing step in Glu-6-PDH refolding occurs while the nascent protein is bound to GroEL, a step which is temperature-sensitive. The extreme temperature sensitivity of this step indicates a sharp structural transition in GroEL.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE ON AGING [R01AG009761] Funding Source: NIH RePORTER; NIA NIH HHS [AG09761] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GEORGOPOULOS CP, 1978, P NATL ACAD SCI USA, V75, P131, DOI 10.1073/pnas.75.1.131; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEE WT, 1991, J BIOL CHEM, V266, P13028; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; PLOMER JJ, 1992, BIOCHIM BIOPHYS ACTA, V1122, P234, DOI 10.1016/0167-4838(92)90398-W; PLOMER JJ, 1993, BIOCHIM BIOPHYS ACTA, V1163, P89, DOI 10.1016/0167-4838(93)90283-W; SAIBIL H, 1993, CURR OPIN STRUC BIOL, V3, P207, DOI 10.1016/S0959-440X(05)80154-X; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WICKNER W, 1989, TRENDS BIOCHEM SCI, V14, P280, DOI 10.1016/0968-0004(89)90064-9	25	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21632	21636						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104942				2022-12-25	WOS:A1993MC80900033
J	LI, M; KEDDIE, JS; SMITH, LJ; CLARK, DC; MURPHY, DJ				LI, M; KEDDIE, JS; SMITH, LJ; CLARK, DC; MURPHY, DJ			EXPRESSION AND CHARACTERIZATION OF THE N-TERMINAL DOMAIN OF AN OLEOSIN PROTEIN FROM SUNFLOWER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BODY MEMBRANE-PROTEIN; SODIUM DODECYL-SULFATE; CIRCULAR-DICHROISM; ESCHERICHIA-COLI; BRASSICA-NAPUS; IMMUNOGOLD-LOCALIZATION; SECONDARY STRUCTURE; RNA-POLYMERASE; SIGMA-SUBUNIT; LIPID BODIES	Oil bodies of plant seeds contain a triacylglycerol matrix surrounded by a monolayer of phospholipids embedded with alkaline proteins termed oleosins. Although oleosins are amphipathic proteins, they are unlike bilayer membrane proteins since they are associated with a single lipid:water interface at the oil body surface. Oleosins are unusual proteins because they contain a 70-80-residue uninterrupted nonpolar domain, flanked by relative polar C- and N-terminal domains. In the present study, we report the expression of the N-terminal domain of the 18-kDa oleosin isoform from sunflower as a recombinant fusion protein in Escherichia coli and the determination of its secondary structure using CD and Fourier transform infrared spectroscopy either as a purified but partially denatured peptide or reconstituted into liposomes. The structure derived from physical studies was then compared and assigned with those predicted from analysis of the primary sequence of the N-terminal domain. Based on data derived from CD spectroscopy analysis of purified and partially renatured N-terminal polypeptide, it contains about 10% alpha-helical structure, 20-30% beta-strand structure, approximately 8% beta-turn structure, and 60% random coil structure. However, analysis of the polypeptide reconstituted into liposomes showed an increased content of alpha-helical structure to about 20% and an increased beta-strand structure content to about 30-40%. Data derived from Fourier transform infrared spectroscopy studies and compared with the data predicted from the primary sequence showed the peptide is well structured with some antiparallel beta-strand structure from residues 2-9, parallel beta-strand structure from residues 30-37 and/or 42-49, and alpha-helical structure from residues 10-23 and/or 43-49. There is potential amphipathic alpha-helix from residues 10-23. Based on these results, the following model for the secondary structure of the N-terminal domain of sunflower oleosin can be proposed. Residues 2-9 would produce amphipathic antiparallel beta-strand structure. Residues 10-23 would produce an amphipathic alpha-helical structure. Residues 30-37 and/or 42-49 would give parallel beta-strand structure, or residues 42-49 could form a nonpolar alpha-helical structure that would insert into the oil matrix.	JOHN INNES CTR PLANT SCI RES,DEPT BRASSICA & OILSEEDS RES,NORWICH NR4 7UH,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Murphy, Denis J/ABC-1734-2020	Murphy, Denis J/0000-0002-5291-2445				BARANY G, 1980, PEPTIDES, P1; BROWN KL, 1992, MOL MICROBIOL, V6, P1133, DOI 10.1111/j.1365-2958.1992.tb01551.x; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHANG LH, 1990, BIOCHEMISTRY-US, V29, P744, DOI 10.1021/bi00455a022; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARK DC, 1989, J AGR FOOD CHEM, V37, P627, DOI 10.1021/jf00087a011; CUMMINS I, 1992, PLANT MOL BIOL, V19, P873, DOI 10.1007/BF00027084; FERNANDEZ DE, 1988, PLANT PHYSIOL, V86, P270, DOI 10.1104/pp.86.1.270; FTZEN JTC, 1992, J BIOL CHEM, V267, P15626; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GREIGHTON TE, 1991, NATURE, V352, P17; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HERMAN EM, 1987, PLANTA, V172, P336, DOI 10.1007/BF00398662; KEDDIE JS, 1992, PLANT MOL BIOL, V19, P1079, DOI 10.1007/BF00040541; KNNO T, 1975, ANAL BIOCHEM, V67, P226; Koening J. K., 1980, ANAL APPLICATIONS FT, P241; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI M, 1992, J BIOL CHEM, V267, P8245; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MURPHY DJ, 1990, PROG LIPID RES, V29, P299; MURPHY DJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P86, DOI 10.1016/0167-4781(91)90156-G; MURPHY DJ, 1989, J PLANT PHYSIOL, V135, P63, DOI 10.1016/S0176-1617(89)80225-1; MURPHY DJ, 1989, J SCI FOOD AGR, V48, P209, DOI 10.1002/jsfa.2740480208; MURPHY DJ, 1989, PLANT SCI, V60, P47, DOI 10.1016/0168-9452(89)90042-3; MURPHY DJ, 1989, BIOCHEM J, V258, P285, DOI 10.1042/bj2580285; MURPHY DJ, 1981, PHYTOCHEMISTRY OXF, V28, P2063; ORBAN J, 1992, BIOCHEMISTRY-US, V31, P3604, DOI 10.1021/bi00129a008; PARKER FS, 1983, APPLICATION IR RAMAN; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RENUGOPALAKRISH.V, BIOCHEM BIOPH RES CO, V126, P1029; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIZER PJH, 1987, BIOCHEMISTRY-US, V26, P5106, DOI 10.1021/bi00390a032; SMITH DB, 1988, MOL BIOCHEM PARASIT, V27, P249, DOI 10.1016/0166-6851(88)90044-8; Takakuwa T, 1985, ANAL SCI, V1, P215, DOI DOI 10.2116/ANALSCI.1.215; VANCE VB, 1987, J BIOL CHEM, V262, P11275; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZHENG Z, 1992, BIOCHEMISTRY-US, V31, P4426, DOI 10.1021/bi00133a006	46	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17504	17512						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8102367				2022-12-25	WOS:A1993LQ98800090
J	KLOCKNER, U; STORCK, T; CONRADT, M; STOFFEL, W				KLOCKNER, U; STORCK, T; CONRADT, M; STOFFEL, W			ELECTROGENIC L-GLUTAMATE UPTAKE IN XENOPUS-LAEVIS OOCYTES EXPRESSING A CLONED RAT-BRAIN L-GLUTAMATE L-ASPARTATE TRANSPORTER (GLAST-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLIAL-CELLS; NERVOUS-SYSTEM; SYNAPTOSOMES; MEMBRANE; RETINA	The transport of L-glutamate into Xenopus laevis oocytes expressing the cloned L-glutamate/L-aspartate transporter (GLAST-1) from rat brain was studied using the voltage clamp technique. At a holding potential of -90 mV, a bath application of 100 muM L-glutamate induced an inward current (I(GLAST)) with an amplitude ranging from -5 to -30 nA. I(GLAST) did not require extracellular Ca2+, Mg2+, or Cl-, was larger at negative potentials, and did not reverse up to +80 mV. The current was dependent on external L-glutamate and Na+ with half-maximal amplitudes at 11 muM L-glutamate and 41 mM Na+. I(GLAST) saturated at 100 muM L-glutamate and 80 mM Na+. The Hill coefficient for Na+ and L-glutamate was 3.3 and 1.3, respectively, suggesting that 3 Na+ accompany the transport of 1 L-glutamate molecule. At low [Na+]o, I(GLAST) was enhanced by reducing [K+]o, an indication for the countertransport of K+. Reducing external pH from 7.4 to 6.0 did not change the amplitude of I(GLAST). This argues against a glutamate/proton cotransport. The results provide evidence for GLAST-1 carrying out a high affinity, sodium-dependent L-glutamate transport with a proposed stoichiometry of 3 Na+, 1 L-glutamate-/1 K+.	UNIV COLOGNE, FAC MED, INST BIOCHEM, JOSEPH STELZMANN STR 52, W-5000 COLOGNE 41, GERMANY; UNIV COLOGNE, DEPT PHYSIOL, W-5000 COLOGNE, GERMANY	University of Cologne; University of Cologne								BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BENNETT JP, 1973, J NEUROCHEM, V21, P1533, DOI 10.1111/j.1471-4159.1973.tb06037.x; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FLOTT B, 1991, GLIA, V4, P293, DOI 10.1002/glia.440040307; GAZZOLA GC, 1981, J BIOL CHEM, V256, P6064; GORDON RD, 1983, J NEUROCHEM, V40, P1090, DOI 10.1111/j.1471-4159.1983.tb08097.x; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V114, P62; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; WANIEWSKI RA, 1984, J NEUROSCI, V4, P2237	20	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14594	14596						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8100815				2022-12-25	WOS:A1993LL75900012
J	ALILECHE, A; PLAISANCE, S; HAN, DS; RUBINSTEIN, E; MINGARI, C; BELLOMO, R; JASMIN, C; AZZARONE, B				ALILECHE, A; PLAISANCE, S; HAN, DS; RUBINSTEIN, E; MINGARI, C; BELLOMO, R; JASMIN, C; AZZARONE, B			HUMAN-MELANOMA CELL-LINE M14 SECRETES A FUNCTIONAL INTERLEUKIN-2	ONCOGENE			English	Article							T-CELL; LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; ACTIVE INTERLEUKIN-2; HUMAN-PLACENTA; EXPRESSION; RECEPTOR; GENE; PROLIFERATION; PROMOTER	Interleukin 2 (IL2) is an important regulator of the immune system. In this report, we have analysed five human melanoma cell lines expressing the IL2R for their ability to secrete IL2. In the M14 melanoma cell line, we observed the appearance of the 0.9 kb transcript specific for the IL2 gene, 72 h after subculture, and the secretion of a biologically active IL2 which specifically sustains the proliferation of the IL2 dependent murine lymphoid cell tine CTLL2. In M14 cells, IL2 gene activation is transient as in lymphoid cells but is not inhibited by the immunosuppressive drugs cyclosporine-A and FK506 which are effective on PHA-blasts. In M14 cells, recombinant IL2 (36 pM) induces the down modulation of ICAM-1 expression at the surface of M14 cells. Overnight incubation of these cells with polyclonal anti-IL2 antibodies leads to an increased expression of ICAM-1 and a decreased membrane detection of the IL2Ralpha, suggesting the existence of an autocrine/paracrine loop involved in the surface expression of these antigens. A decreased expression of the ICAM-1 protein could help some melanoma cells to escape from cytolytic recognition and therefore favour their metastasis.	HOP PAUL BROUSSE,INSERM,UNITE 268,14 AV PAUL VAILLANT COUTURIER,F-94800 VILLEJUIF,FRANCE; IST,GENOA,ITALY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Rubinstein, Eric/B-4650-2019; Azzarone, Bruno/AAH-9251-2019; Plaisance, Stephane/B-3488-2009; Plaisance, Stephane/ABI-6307-2020	Rubinstein, Eric/0000-0001-7623-9665; Azzarone, Bruno/0000-0002-5962-3849; Plaisance, Stephane/0000-0002-1651-241X; Plaisance, Stephane/0000-0002-1651-241X				ARYA SK, 1984, BIOCHEMISTRY-US, V23, P6686; BENVENISTE EN, 1988, J NEUROIMMUNOL, V17, P301, DOI 10.1016/0165-5728(88)90121-X; BOEHM KD, 1989, P NATL ACAD SCI USA, V86, P656, DOI 10.1073/pnas.86.2.656; CARLONI G, 1989, ONCOGENE, V4, P873; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CILLO C, 1984, INT J CANCER, V34, P11, DOI 10.1002/ijc.2910340104; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DOMZIG W, 1983, J IMMUNOL, V130, P1970; DRENO B, 1986, J INVEST DERMATOL, V86, P359, DOI 10.1111/1523-1747.ep12285581; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; EFRAT S, 1984, P NATL ACAD SCI-BIOL, V81, P2601, DOI 10.1073/pnas.81.9.2601; EFRAT S, 1982, NATURE, V297, P236, DOI 10.1038/297236a0; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; FARRAR JJ, 1982, IMMUNOL REV, V63, P129, DOI 10.1111/j.1600-065X.1982.tb00414.x; FARRAR WL, 1981, J IMMUNOL, V126, P1120; FLOMENBERG N, 1983, J IMMUNOL, V130, P2635; FRAZIERSCOTT K, 1988, J CLIN INVEST, V82, P1877; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; GRIMM EA, 1983, J EXP MED, V157, P884, DOI 10.1084/jem.157.3.884; HENNEY CS, 1982, TRANSPLANT P, V14, P565; HERLYN M, 1990, CLIN EXP METASTAS, V8, P9; Hicks C, 1991, Growth Factors, V5, P201, DOI 10.3109/08977199109000284; JANKOVIC DL, 1990, J IMMUNOL, V145, P4136; JOHNSON JP, 1981, EUR J IMMUNOL, V11, P825, DOI 10.1002/eji.1830111015; JONJIC N, 1992, EUR J IMMUNOL, V22, P2255, DOI 10.1002/eji.1830220912; LANTZ O, 1991, J IMMUNOL METHODS, V137, P121, DOI 10.1016/0022-1759(91)90401-Z; LEIBSON HJ, 1981, J EXP MED, V154, P1681, DOI 10.1084/jem.154.5.1681; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; NABEL GJ, 1988, P NATL ACAD SCI USA, V85, P2934, DOI 10.1073/pnas.85.9.2934; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PLAISANCE S, 1992, INT IMMUNOL, V4, P739, DOI 10.1093/intimm/4.7.739; PLAISANCE S, 1993, NATO ASI SERIES H, V67, P103; SANETO RP, 1986, P NATL ACAD SCI USA, V83, P9221, DOI 10.1073/pnas.83.23.9221; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SMITH KA, 1988, ADV IMMUNOL, V42, P165, DOI 10.1016/S0065-2776(08)60844-5; SOUBIRAN P, 1987, J REPROD IMMUNOL, V12, P225, DOI 10.1016/0165-0378(87)90026-X; SWAIN SL, 1981, P NATL ACAD SCI-BIOL, V78, P2517, DOI 10.1073/pnas.78.4.2517; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WALKER E, 1988, J IMMUNOL, V140, P859; WEIDMANN E, 1992, CANCER RES, V52, P5963; WILLIAMS TM, 1988, J IMMUNOL, V141, P662; YAMADA G, 1992, PROGR IMMUNOLOGY, V6, P469	45	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1791	1796						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8099724				2022-12-25	WOS:A1993LG68200010
J	KIDO, H; KAMOSHITA, K; FUKUTOMI, A; KATUNUMA, N				KIDO, H; KAMOSHITA, K; FUKUTOMI, A; KATUNUMA, N			PROCESSING PROTEASE FOR GP160 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I ENVELOPE GLYCOPROTEIN PRECURSOR IN HUMAN T4+ LYMPHOCYTES - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CELL-LINES; ENDOPROTEOLYTIC CLEAVAGE; PROHORMONE; ENZYME; RETROVIRUS; RECEPTOR; HIV-1; ACID; SITE; IDENTIFICATION	A processing protease for the human immunodeficiency virus type I (HIV-I) envelope glycoprotein gp160 precursor has been purified to homogeneity from the post-nuclear membrane fraction of a human T4+ lymphocyte clone. Most of the processing activity was found to be present in the fractions of endoplasmic reticulum and Golgi apparatus of the cells. The purified enzyme has a monomeric structure with a molecular mass of 26 +/- 3 kDa, as judged by gel-permeation liquid chromatography and sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing and nonreducing conditions. The purified enzyme converted gp160 to gp120 and gp41, showing a pH optimum of 6.5-7.0. Direct amino acid sequencing of the amino terminus of the product gp41 revealed that the cleavage site of gp160 was between Arg511 and Ala512. The enzyme activity was inhibited by trypsin-type protease inhibitors, but was not affected by CaCl2, MgCl2 or chelating agents. The properties of the purified enzyme are clearly distinct from those of processing proteases reported previously. Although the significance of the enzyme in vivo is not currently certain, judging from its cleavage specificity and subcellular localization, this endopeptidase appears to be a processing enzyme for the human immunodeficiency virus type I gp160 precursor protein in human T cells.			KIDO, H (corresponding author), UNIV TOKUSHIMA, INST ENZYME RES, DIV ENZYME CHEM, TOKUSHIMA 770, JAPAN.							BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEDGOOD RM, 1992, J BIOL CHEM, V267, P7060; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BRENNAN SO, 1990, J BIOL CHEM, V265, P21494; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; CROMLISH JA, 1986, J BIOL CHEM, V261, P850; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; ESTIVARIZ FE, 1992, J BIOL CHEM, V267, P7456; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GUO HG, 1990, VIROLOGY, V174, P217, DOI 10.1016/0042-6822(90)90070-8; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KIDO H, 1990, J BIOL CHEM, V265, P21979; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KIKUKAWA R, 1986, J VIROL, V57, P1159, DOI 10.1128/JVI.57.3.1159-1162.1986; KIM WS, 1990, J BIOL CHEM, V265, P5930; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOGA Y, 1990, J IMMUNOL, V144, P94; KOGA Y, 1990, J VIROL, V64, P4661, DOI 10.1128/JVI.64.10.4661-4671.1990; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNMARK A, 1976, J CELL BIOL, V71, P606, DOI 10.1083/jcb.71.2.606; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MILSOM DW, 1972, BIOCHEM J, V128, P331, DOI 10.1042/bj1280331; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MORRE DJ, 1971, METHOD ENZYMOL, V22, P130; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; PEREZ LG, 1987, J VIROL, V61, P1609, DOI 10.1128/JVI.61.5.1609-1614.1987; SHINAGAWA T, 1990, P NATL ACAD SCI USA, V87, P1927, DOI 10.1073/pnas.87.5.1927; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEIN BS, 1990, J BIOL CHEM, V265, P2640; Strobel H W, 1978, Methods Enzymol, V52, P89; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; Wharton DC., 1967, METHOD ENZYMOL, P245; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230	41	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13406	13413						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8099909				2022-12-25	WOS:A1993LH55300057
J	MISSIAEN, L; DESMEDT, H; PARYS, JB; CASTEELS, R				MISSIAEN, L; DESMEDT, H; PARYS, JB; CASTEELS, R			COACTIVATION OF INOSITOL TRISPHOSPHATE-INDUCED CA2+ RELEASE BY CYTOSOLIC CA2+ IS LOADING-DEPENDENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; 1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM OSCILLATIONS; LUMINAL CA2+; SYMPATHETIC NEURONS; ACINAR-CELLS; STORES; CHANNELS; MODEL; ENTRY	Luminal and cytosolic Ca2+ control the sensitivity of the intracellular Ca2+ stores to inositol 1,4,5-trisphosphate (InsP(3)). In this work, we have characterized how luminal Ca2+ interfered with the stimulation of the InsP(3) receptor by cytosolic Ca2+ in permeabilized A7r5 smooth muscle cells. InsP(3)-induced Ca2+ release from stores containing 34 pmol of Ca2+/10(6) cells absolutely depended on a simultaneous rise in cytosolic Ca2+ concentration in the submicromolar range. This stimulation by cytosolic Ca2+ was more pronounced when the stores were preincubated with Ca2+. In contrast, fully loaded stores containing 3400 pmol of Ca2+/10(6) cells already responded to InsP(3) in the absence of cytosolic Ca2+ and the release from these stores was much less stimulated by increasing the cytosolic Ca2+ concentration. The loading dependence of the release was not due to a higher cytosolic Ca2+ concentration around more loaded stores sensitizing the InsP(3) receptor by binding at a cytoplasmic site. Luminal Ca2+ was therefore found to functionally substitute for cytosolic Ca2+ in triggering Ca2+ release in the presence of a constant InsP(3) concentration. These findings are relevant for explaining base line Ca2+ spiking in non-excitable cells.			MISSIAEN, L (corresponding author), KATHOLIEKE UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG, HERESTR 49, B-3000 LOUVAIN, BELGIUM.			Parys, Jan/0000-0002-3591-4967				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GILL DL, 1989, NATURE, V342, P16, DOI 10.1038/342016a0; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1993, J BIOL CHEM, V268, P25206; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TREGEAR RT, 1991, P ROY SOC B-BIOL SCI, V243, P263, DOI 10.1098/rspb.1991.0040; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHAO H, 1990, J BIOL CHEM, V265, P20856	50	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7238	7242						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125936				2022-12-25	WOS:A1994NA03200033
J	ELBENNA, J; RUEDI, JM; BABIOR, BM				ELBENNA, J; RUEDI, JM; BABIOR, BM			CYTOSOLIC GUANINE-NUCLEOTIDE-BINDING PROTEIN RAC2 OPERATES IN-VIVO AS A COMPONENT OF THE NEUTROPHIL RESPIRATORY BURST OXIDASE - TRANSFER OF RAC2 AND THE CYTOSOLIC OXIDASE COMPONENTS P47(PHOX) AND P67(PHOX) TO THE SUBMEMBRANOUS ACTIN CYTOSKELETON DURING OXIDASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; NADPH OXIDASE; PLASMA-MEMBRANE; CYTOCHROME-B; PHOSPHORYLATION; GTP; ASSOCIATION; ELECTROPHORESIS; IDENTIFICATION	The respiratory burst oxidase is responsible for O-2(-) production in stimulated neutrophils and B lymphocytes. Components of this oxidase include cytochrome b(558), a membrane-bound flavohemoprotein; the cytosolic polypeptides p47(phox) and p67(phox); and one or more small G proteins including Rad1 Rac2, and/or Rap1A. We found that when normal neutrophils were activated, small percentages of each of the cytosolic proteins p47(phox) p67(phox), and Rac2 were transferred to the membrane cytoskeleton. However, Rac2 was not transferred to the membrane during activation of p47(phox)-deficient neutrophils. In normal cells, some p47(phox) also became associated with the non-cytoskeletal portion of the plasma membrane, but p67(Phox), Rac2, and O-2(-)-forming activity were restricted to the cytoskeleton. Neutrophil activation also causes the phosphorylation of multiple serines in p47(phox), The most heavily phosphorylated forms of p47(phox) were found solely in the membrane cytoskeleton. These results suggest that 1) the membrane cytoskeleton participates in respiratory burst oxidase activation, 2) the fully phosphorylated p47(phox) is located in the active oxidase, which resides in the membrane cytoskeleton, and 3) Rac2 acts like a dedicated component of the respiratory burst oxidase.			ELBENNA, J (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NIAID NIH HHS [AI-24227, AI-28479, AI-30742] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI130742, R01AI028479, R01AI030742, R37AI024227, R01AI024227] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AHARONI I, 1990, J LEUKOCYTE BIOL, V48, P107, DOI 10.1002/jlb.48.2.107; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROWLEY CA, 1980, NEW ENGL J MED, V302, P1163, DOI 10.1056/NEJM198005223022102; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; FOX JEB, 1985, J BIOL CHEM, V260, P1970; HARPER AM, 1984, BIOCHEM J, V219, P519, DOI 10.1042/bj2190519; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OKAMURA N, 1988, BLOOD, V72, P811; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1985, J BIOL CHEM, V260, P6541; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; SCHWARZ HP, 1985, BLOOD, V66, P1452; SENGELOV H, 1992, J BIOL CHEM, V267, P14912; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	44	166	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6729	6734						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120032				2022-12-25	WOS:A1994MZ50300075
J	BARTHOLOMEW, C; CLARK, AM				BARTHOLOMEW, C; CLARK, AM			INDUCTION OF 2 ALTERNATIVELY SPLICED EVI-1 PROTOONCOGENE TRANSCRIPTS BY CAMP IN KIDNEY-CELLS	ONCOGENE			English	Note							MYELOID TRANSFORMING GENE; MOUSE MYELOBLASTIC LEUKEMIAS; ZINC FINGER PROTEIN; RETROVIRAL INSERTIONS; EXPRESSION; SITE; IDENTIFICATION; TRANSLOCATIONS; ACTIVATION; KILOBASES	The evi-1 proto-oncogene is normally predominantly expressed in the kidney. We report here that evi-1 transcripts are also abundant in foetal kidney and expression is retained in primary kidney cell cultures. However available kidney cell lines express low or no evi-1 mRNA. In the human renal cell carcinoma cell line, A704, evi-1 is inducible approximately 16-fold by elevating intra-cellular cAMP levels with either forskolin or dibutyryl cAMP. TPA down-regulates evi-1 mRNA production and blocks forskolin mediated induction. Similar effects are seen in NIH3T3 cells and primary kidney cell cultures. Induction of evi-1 gene expression by forskolin does not alter the ratio of full length and an alternatively spliced transcript which encodes a protein lacking two repeats of the zinc finger motif. Potential regulation of evi-1 expression in kidney by hormones which modulate intra-cellular cAMP levels suggest that h can respond to environmental cues which might be important to the normal physiological role of this protein in kidney differentiation, development and function.			BARTHOLOMEW, C (corresponding author), BEATSON INST CANC RES,CANC RES CAMPAIGN BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND.							BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; BORDEREAUX D, 1990, ONCOGENE, V5, P925; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; FICHELSON S, 1992, LEUKEMIA, V6, P93; HOLLAND PWH, 1988, DEVELOPMENT, V102, P159; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NGUYEN VC, 1989, HUM GENET, V81, P257; NIBBS RJB, 1993, MOL CELL BIOL, V13, P5582, DOI 10.1128/MCB.13.9.5582; PERKINS AS, 1991, DEVELOPMENT, V111, P479; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Saxen L., 1987, ORGANOGENESIS KIDNEY; TAUB M, 1979, P NATL ACAD SCI USA, V76, P3338, DOI 10.1073/pnas.76.7.3338; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	26	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					939	942						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108138				2022-12-25	WOS:A1994MW55100031
J	LANG, FF; MILLER, DC; PISHARODY, S; KOSLOW, M; NEWCOMB, EW				LANG, FF; MILLER, DC; PISHARODY, S; KOSLOW, M; NEWCOMB, EW			HIGH-FREQUENCY OF P53 PROTEIN ACCUMULATION WITHOUT P53 GENE MUTATION IN HUMAN JUVENILE PILOCYTIC, LOW-GRADE AND ANAPLASTIC ASTROCYTOMAS	ONCOGENE			English	Note							17P ALLELIC LOSS; ACTIVATING MUTATIONS; BREAST-CANCER; EXPRESSION; HETEROZYGOSITY; OVEREXPRESSION; FORMS; CHROMOSOME-17; CARCINOMA; ONCOGENE	We analysed 31 non-glioblastoma astrocytomas for alterations in p53 protein expression and for mutations in the p53 gene. Immunohistochemistry detected p53 protein accumulation in 71% (five of seven) of juvenile pilocytic astrocytomas (WHO grade I), 63% (five of eight) of astrocytomas (WHO grade II), and 63% (10 of 16) of anaplastic astrocytomas (WHO grade III). The single strand conformation polymorphism (SSCP) assay of exons 2-11 of the p53 gene and direct DNA sequencing identified p53 mutations in 14% (one of seven) of grade I, 25% (two of eight) of grade II, and 19% (three of 16) of grade III astrocytomas. This is the first report of a p53 mutation in grade I juvenile pilocytic astrocytomas. Immunohistochemistry and SSCP analyses gave concordant results in 55% (17 of the 31) of the tumors. A total of 14 tumors, 60-80% within each grade, showed p53 protein accumulation in the absence of detectable mutations of the p53 gene. No mdm-2 gene amplification was found in these tumors. The similar frequency of p53 alterations in tumors of grades I-III suggests that the p53 gene plays a significant role early in the formation of astrocytomas rather than late in tumor progression to higher grade. The data suggest that mechanisms other than p53 gene inactivation by mutation or mdm-2 complex formation result in the accumulation of P53 protein in > 70% of non-glioblastoma astrocytomas.	NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU MED CTR,DEPT NEUROSURG,NEW YORK,NY 10016; KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016	New York University; New York University					NCI NIH HHS [CA 40533] Funding Source: Medline; PHS HHS [P30-16087] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040533, R23CA040533, R29CA040533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1991, ONCOGENE, V6, P1699; BENNETT WP, 1992, CANCER RES, V52, P6092; BRUNER JM, 1991, MODERN PATHOL, V4, P671; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CAMPO E, 1991, CANCER RES, V51, P4436; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULTS D, 1992, CANCER RES, V52, P674; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KLEIHUES P, 1993, HISTOLOGIC TYPING TU; KOHLER MF, 1992, CANCER RES, V52, P1622; KORNBLITH PL, 1987, NEUROLOGIC ONCOLOGY, P35; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASSAM NJ, 1993, CANCER RES, V53, P2235; LAWS ER, 1984, J NEUROSURG, V61, P665, DOI 10.3171/jns.1984.61.4.0665; LEACH FS, 1993, CANCER RES, V53, P2231; LOUIS DN, 1993, J NEUROPATH EXP NEUR, V52, P31, DOI 10.1097/00005072-199301000-00005; MARKS JR, 1991, CANCER RES, V51, P2979; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MCCORMACK BM, 1992, NEUROSURGERY, V31, P636; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEWCOMB EW, 1993, BRAIN PATHOL, V3, P229, DOI 10.1111/j.1750-3639.1993.tb00749.x; NEWCOMB EW, 1993, GROWTH CONTROL NEOPL, P53; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; OKAZAKI H, 1989, FUNDAMENTALS NEUROPA, P205; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RUBIO MP, 1993, CANCER RES, V53, P3465; SAXENA A, 1992, CANCER RES, V52, P6716; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; STRETCH JR, 1991, CANCER RES, V51, P5976; SZENASY J, 1983, CHILD BRAIN, V10, P39; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WAGATA T, 1993, CANCER RES, V53, P846; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303	45	127	130	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					949	954						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108140				2022-12-25	WOS:A1994MW55100033
J	BERGLER, H; WALLNER, P; EBELING, A; LEITINGER, B; FUCHSBICHLER, S; ASCHAUER, H; KOLLENZ, G; HOGENAUER, G; TURNOWSKY, F				BERGLER, H; WALLNER, P; EBELING, A; LEITINGER, B; FUCHSBICHLER, S; ASCHAUER, H; KOLLENZ, G; HOGENAUER, G; TURNOWSKY, F			PROTEIN ENVM IS THE NADH-DEPENDENT ENOYL-ACP REDUCTASE (FABI) OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SEQUENCE; GENE	The EnvM protein was purified from an overproducing Escherichia coli strain. It showed NADH-dependent enoyl-acyl carrier protein (ACP) reductase activity using both crotonyl-ACP and crotonyl-CoA as substrates. The protein bound a radioactive diazaborine derivative in the presence of NAD(+) and radioactive NAD(+) in the presence of the drug. Based on these data, it is concluded that EnvM is the NADH-dependent enoyl-ACP reductase (EC 1.3.1.9) of E. coli and we propose to rename the corresponding gene fabI.	GRAZ UNIV,INST MIKROBIOL,A-8010 GRAZ,AUSTRIA; GRAZ UNIV,INST ORGAN CHEM,A-8010 GRAZ,AUSTRIA; SANDOZ GMBH,FORSCHUNGSINST,A-1235 VIENNA,AUSTRIA	University of Graz; University of Graz; Novartis; Sandoz			Aschauer, Harald/G-8850-2016	Aschauer, Harald/0000-0002-4449-372X; Bergler, Helmut/0000-0002-7724-309X				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; Borsche W, 1926, LIEBIGS ANN CHEM, V450, P75; BROWN HC, 1958, J AM CHEM SOC, V80, P5377, DOI 10.1021/ja01553a014; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; EGAN AF, 1973, GENET RES, V21, P139, DOI 10.1017/S001667230001332X; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GRASSBERGER MA, 1984, J MED CHEM, V27, P947, DOI 10.1021/jm00374a003; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; KATER MM, 1991, PLANT MOL BIOL, V17, P895, DOI 10.1007/BF00037070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MULLER BW, 1978, HELV CHIM ACTA, V61, P325, DOI 10.1002/hlca.19780610128; SCHMID H, 1954, HELV CHIM ACTA, V37, P1706; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; Shapiro R. H, 1976, ORG REACTIONS, V23, P405; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; WEEKS G, 1968, J BIOL CHEM, V243, P1180	19	141	171	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5493	5496						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119879				2022-12-25	WOS:A1994MY84000004
J	CALA, SE; JONES, LR				CALA, SE; JONES, LR			GRP94 RESIDES WITHIN CARDIAC SARCOPLASMIC-RETICULUM VESICLES AND IS PHOSPHORYLATED BY CASEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING GLYCOPROTEIN; MOLECULAR-WEIGHT PROTEINS; GLUCOSE-REGULATED PROTEIN; ENDOPLASMIC-RETICULUM; SKELETAL-MUSCLE; RYANODINE RECEPTOR; CALSEQUESTRIN; PURIFICATION; CLONING; SITE	Cardiac sarcoplasmic reticulum (SR) plays a dominant role in cellular Ca2+ homeostasis by storing and releasing Ca2+. SDS-polyacrylamide gel electrophoresis and Stains Ah staining reveals that at feast six Ca2+-binding proteins are contained in cardiac SR vesicles, five of which have now been identified. These five SR proteins comprise a set of high capacity Ca2+-binding proteins, localized to the SR lumen, that exhibit properties expected for physiological Ca2+ stores. In this study, we have purified and isolated cDNA clones for the sixth major Stains All blue-staining protein of dog cardiac SR and identified it as GRP94 (glucose-regulated protein, M(r) = 94,000). Previously, this prominent Ca2+-binding component has only been described in non-muscle endoplasmic reticulum. Cardiac GRP94 co-sedimented with cardiac SR vesicles and all previously described SR markers and was completely contained within the SR lumen. GRP94, like several other SR Ca2+-binding proteins, was a substrate for casein kinase II and was phosphorylated at two or more sites located near the two ends of the molecule. A low level of endogenous casein kinase II activity was found in crude preparations of cardiac SR but did not co-purify with SR vesicles after calcium oxalate loading, suggesting that casein kinase II phosphorylation in vivo occurs at a site other than the SB	INDIANA UNIV, SCH MED, KRANNERT INST CARDIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	CALA, SE (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556, R01HL049428, R37HL049428] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49428, HL28556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Cala S E, 1990, Semin Cell Biol, V1, P265; CALA SE, 1983, J BIOL CHEM, V258, P1932; CALA SE, 1993, J BIOL CHEM, V268, P2969; CALA SE, 1992, BIOCHIM BIOPHYS ACTA, V1118, P277, DOI 10.1016/0167-4838(92)90285-L; CALA SE, 1991, J BIOL CHEM, V266, P391; CALA SE, 1993, BIOPHYS J, V64, pA194; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1197; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FLIEGEL L, 1990, J BIOL CHEM, V265, P15496; HOFMANN SL, 1989, J BIOL CHEM, V264, P18083; JONES LR, 1993, J BIOL CHEM, V268, P11486; JONES LR, 1979, J BIOL CHEM, V254, P530; JONES LR, 1981, J BIOL CHEM, V256, P1809; JONES LR, 1988, METHOD ENZYMOL, V157, P85; KANG HS, 1991, J BIOL CHEM, V266, P5643; KOCH G, 1986, J CELL SCI, V86, P217; KOCH GLE, 1987, J CELL SCI, V87, P491; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KULOMAA MS, 1986, BIOCHEMISTRY-US, V25, P6244, DOI 10.1021/bi00368a061; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1989, P NATL ACAD SCI USA, V86, P6047, DOI 10.1073/pnas.86.16.6047; LEBERER E, 1990, J BIOL CHEM, V265, P10118; LEE A, 1987, TRENDS BIOCHEM SCI, V23, P20; LEWIS MJ, 1985, J BIOL CHEM, V260, P6926; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1992, HEART CARDIOVASCULAR, P1203; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MAHONY L, 1986, J BIOL CHEM, V261, P5257; Maniatis T., 1982, MOL CLONING; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RARDON DP, 1989, CIRC RES, V64, P779, DOI 10.1161/01.RES.64.4.779; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SEILER S, 1984, J BIOL CHEM, V259, P8550; SLUPSKY JR, 1987, BIOCHEMISTRY-US, V26, P6539, DOI 10.1021/bi00394a038; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; SUKO J, 1976, EUR J BIOCHEM, V64, P123, DOI 10.1111/j.1432-1033.1976.tb10280.x; VOLPE P, 1992, P NATL ACAD SCI USA, V89, P6142, DOI 10.1073/pnas.89.13.6142; VOLPE P, 1991, FEBS LETT, V278, P274, DOI 10.1016/0014-5793(91)80134-O; WADA I, 1991, J BIOL CHEM, V266, P19599; WITCHER DR, 1992, J BIOL CHEM, V267, P4963; WITCHER DR, 1991, J BIOL CHEM, V266, P11144	57	65	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5926	5931						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119936				2022-12-25	WOS:A1994MY84000069
J	LEI, BF; CHO, KW; TU, SC				LEI, BF; CHO, KW; TU, SC			MECHANISM OF ALDEHYDE INHIBITION OF VIBRIO-HARVEYI LUCIFERASE - IDENTIFICATION OF 2 ALDEHYDE SITES AND RELATIONSHIP BETWEEN ALDEHYDE AND FLAVIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL LUCIFERASE; DIRECTED MUTATION; SUBSTRATE	Vibrio harveyi luciferase is sensitive to aldehyde substrate inhibition, and two kinetic schemes have been previously postulated to account for such an inhibition, One scheme depicts a sequential binding of 2 aldehyde molecules, yielding an active enzyme-aldehyde binary complex and subsequently an inactive enzyme-(aldehyde)(2) ternary complex (Holzman, T. F., and Baldwin, T. O. (1983) Biochemistry 22, 2838-2846). This two-aldehyde model was later withdrawn, and recently, a different scheme was proposed, following which the prior binding of one aldehyde to the native luciferase farms an inactive dead-end complex (Abu-Soud, H. M., Clark, A. C., Francisco, W. A, Baldwin, T. O., and Raushel, F.M. (1993) J. Biol. Chem. 268, 7699-7706). In this work, kinetic and equilibrium studies were carried out to elucidate further the mechanism of aldehyde inhibition. Two, presumably independent, aldehyde-binding sites were detected, with a higher affinity site for the aldehyde substrate and a weaker affinity site for the aldehyde inhibitor. Binding to and dissociation from the inhibitor site by decanal were revealed by chemical relaxation analysis to be slow processes. Furthermore, whereas the binding of the decanal substrate enhances the affinity of the reduced riboflavin 5'-phosphate (FMNH(2)) site, the binding of decanal to the inhibitor site competes against FMNH(2) binding, thus resulting in inhibition of luciferase activity. These findings are not compatible with either of the two earlier schemes mentioned above. A new kinetic model is formulated for the mechanism of aldehyde inhibition. Theoretical kinetic behaviors predicted on the basis of this model are in excellent agreement with experimental observations. A particularly reactive cysteine (residue 106) on the alpha subunit has been previously demonstrated to be at or near an aldehyde site (Fried, A., and Tu, S.-C. (1984) J. Biol. Chem. 259, 10754-10759). Evidence is presented to indicate that this residue is at or near the aldehyde inhibitor site. Relative locations of this residue and binding sites for FMNH(2), the aldehyde substrate, and the aldehyde inhibitor are proposed.	UNIV HOUSTON,DEPT BIOCHEM & BIOPHYS SCI,HOUSTON,TX 77204; UNIV HOUSTON,DEPT CHEM,HOUSTON,TX 77204	University of Houston System; University of Houston; University of Houston System; University of Houston				Lei, Benfang Lei/0000-0001-8133-6021	NIGMS NIH HHS [GM25953] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025953] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, J BIOL CHEM, V268, P7699; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P40, DOI 10.1002/bio.1170040111; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; FRIED A, 1984, J BIOL CHEM, V259, P754; GAJIWALA KS, 1988, THESIS U TEXAS EL PA; GIBSON QH, 1962, BIOCHEM J, V83, P368, DOI 10.1042/bj0830368; HASTINGS JW, 1969, BIOCHEMISTRY-US, V8, P4681, DOI 10.1021/bi00840a004; HASTINGS JW, 1963, J OPT SOC AM, V53, P1410, DOI 10.1364/JOSA.53.001410; HASTINGS JW, 1963, J BIOL CHEM, V238, P2537; Hastings JW., 1978, METHOD ENZYMOL, V57, P135; HEMMERICH P, 1963, EXPERIENTIA, V19, P488, DOI 10.1007/BF02150666; HOLZMAN TF, 1981, BIOCHEMISTRY-US, V20, P5524, DOI 10.1021/bi00522a027; HOLZMAN TF, 1983, BIOCHEMISTRY-US, V22, P2838, DOI 10.1021/bi00281a011; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P532; Job P, 1928, ANN CHIM FRANCE, V9, P113; LEI BF, 1991, PHOTOCHEM PHOTOBIOL, V54, P473, DOI 10.1111/j.1751-1097.1991.tb02043.x; MEIGHEN EA, 1973, BIOCHEMISTRY-US, V12, P1482, DOI 10.1021/bi00732a003; NICOLI MZ, 1974, J BIOL CHEM, V249, P2385; PAQUATTE O, 1989, PHOTOCHEM PHOTOBIOL, V50, P817, DOI 10.1111/j.1751-1097.1989.tb02913.x; RAUSHEL FM, 1991, FLAVINS FLAVOPROTEIN, P281; SUNDBERG L, 1974, J CHROMATOGR, V90, P87, DOI 10.1016/S0021-9673(01)94777-6; TU SC, 1994, IN PRESS CRC HDB ORG; TU SC, 1991, ADV OXYGENATED PROCE, V3, P115; XI L, 1991, J BACTERIOL, V173, P1399, DOI 10.1128/jb.173.4.1399-1405.1991; XI L, 1990, J BIOL CHEM, V265, P4200; XIN X, 1991, BIOCHEMISTRY-US, V30, P11255, DOI 10.1021/bi00111a010	26	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5612	5618						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119897				2022-12-25	WOS:A1994MY84000024
J	MARUYAMA, K; MIYATA, K; YOSHIMURA, A				MARUYAMA, K; MIYATA, K; YOSHIMURA, A			PROLIFERATION AND ERYTHROID-DIFFERENTIATION THROUGH THE CYTOPLASMIC DOMAIN OF THE ERYTHROPOIETIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; SIGNAL TRANSDUCTION; LIGAND-BINDING; ACTIVATION; PHOSPHORYLATION; SUPERFAMILY; HORMONE; COMPLEX; PROTEIN	Interaction of erythropoietin (EPO) and its membrane receptor induces the proliferation and differentiation of erythroid progenitors. The molecular mechanism of the EPO receptor-mediated signal transduction remains unclear because the cloned EPO receptor does not contain any enzyme-related or nucleotide-binding consensus sequences in its cytoplasmic domain. We have previously shown that epidermal growth factor (EGF) induces dimerization of a chimeric receptor carrying the extracellular domain of the EGF receptor linked to the cytoplasmic domain of the EPO receptor, resulting in producing proliferation signals in interleukin-3-dependent cells. Here we show that this chimeric receptor transmits an EGF-dependent erythroid differentiation signal in the EPO-responsive erythroleukemia cell line, TSA8. EGF as well as EPO had little effect on the proliferation of TSA8 cells expressing the chimeric receptor, but both of them induced globin synthesis in these cells. Moreover, a truncated chimeric receptor carrying the membrane proximal 127 amino acids of the cytoplasmic domain of the EPO receptor linked to the extracellular domain of the EGF receptor conferred EGF-dependent proliferation on Ba/F3 cells and globin induction on TSA8 cells. These findings indicate that the membrane proximal region of the cytoplasmic domain of the EPO receptor is sufficient to produce both proliferation and differentiation signals if it is properly activated by receptor dimerization.	KAGOSHIMA UNIV, FAC MED, INST CANC RES, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, FAC MED, DEPT PEDIAT, KAGOSHIMA 890, JAPAN	Kagoshima University; Kagoshima University			Yoshimura, Akihiko/K-5515-2013					BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUH G, 1992, SCIENCE, V256, P1677; FUKUMOTO H, 1989, DEVELOPMENT, V105, P109; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; JUBINSKY PT, 1993, BLOOD, V81, P587; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRANTZ SB, 1991, BLOOD, V77, P419; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; OHASHI H, 1993, IN PRESS P NATL ACAD; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	26	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5976	5980						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119943				2022-12-25	WOS:A1994MY84000077
J	REILLY, A; MORGAN, P; DAVIS, K; KELLY, SM; GREENE, J; ROWE, AJ; HARDING, SE; PRICE, NC; COGGINS, JR; KLEANTHOUS, C				REILLY, A; MORGAN, P; DAVIS, K; KELLY, SM; GREENE, J; ROWE, AJ; HARDING, SE; PRICE, NC; COGGINS, JR; KLEANTHOUS, C			PRODUCT-INDUCED STABILIZATION OF TERTIARY AND QUATERNARY STRUCTURE IN ESCHERICHIA-COLI DEHYDROQUINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The effects of irreversibly attaching product at the active site of type I dehydroquinase from Escherichia coli have been investigated at the level of the secondary, tertiary, and quaternary structure of the protein by spectroscopic and hydrodynamic techniques. The results agree with the previously identified stabilization of the enzyme but show for the first time that the protein dimer is also stabilized and suggest that the E. coli dehydroquinase subunit may be bilobal.	UNIV E ANGLIA, SCH BIOL SCI, NORWICH NR4 7TJ, NORFOLK, ENGLAND; UNIV NOTTINGHAM, DEPT APPL BIOCHEM & FOOD SCI, SUTTON LE12 5RD, LEICS, ENGLAND; UNIV STIRLING, DEPT BIOL & MOLEC SCI, STIRLING FK9 4LA, SCOTLAND; UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, ENGLAND; UNIV GLASGOW, DEPT BIOCHEM, GLASGOW G12 8QQ, SCOTLAND	University of East Anglia; University of Nottingham; University of Stirling; University of Leicester; University of Glasgow				Harding, Stephen E./0000-0002-7798-9692; Kelly, Sharon/0000-0002-3516-1387				BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; BOYS CWG, 1992, J MOL BIOL, V227, P352, DOI 10.1016/0022-2836(92)90704-N; CHAUDHURI S, 1987, METHOD ENZYMOL, V142, P320; CHAUDHURI S, 1991, BIOCHEM J, V275, P1; GILES NH, 1985, MICROBIOL REV, V49, P338, DOI 10.1128/MMBR.49.3.338-358.1985; HANSON KR, 1963, P NATL ACAD SCI USA, V50, P981, DOI 10.1073/pnas.50.5.981; HARRIS J, 1993, J CHEM SOC CHEM COMM, P1080, DOI 10.1039/c39930001080; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10929; KLEANTHOUS C, 1992, BIOCHEM J, V282, P687, DOI 10.1042/bj2820687; KLEANTHOUS C, 1991, J BIOL CHEM, V266, P10893; REILLY A, 1993, BIOORG MED CHEM LETT, V3, P1429, DOI 10.1016/S0960-894X(01)80424-8; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SHNEIER A, 1991, J AM CHEM SOC, V113, P9416, DOI 10.1021/ja00024a085; SHNEIER A, 1993, BIOORG MED CHEM LETT, V3, P1399, DOI 10.1016/S0960-894X(01)80419-4; VANHOLDE KE, 1985, PHYSICAL BIOCH, P117	15	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5523	5526						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119885				2022-12-25	WOS:A1994MY84000011
J	SCHRADER, M; MULLER, KM; CARLBERG, C				SCHRADER, M; MULLER, KM; CARLBERG, C			SPECIFICITY AND FLEXIBILITY OF VITAMIN-D SIGNALING - MODULATION OF THE ACTIVATION OF NATURAL VITAMIN-D RESPONSE ELEMENTS BY THYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RETINOIC ACID; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; OSTEOCALCIN GENE; DNA-BINDING; SUPERFAMILY	Cellular responsiveness to 1,25-dihydroxyvitamin D-3 (VD) is conferred by its intracellular receptor (VDR), which belongs to the nuclear receptor superfamily of ligand-inducible transcription factors. VDRs are known to bind to specific response elements in the promoter region of VD-regulated genes. Two types of natural VD response elements (VDREs) have been identified so far. One is bound by VDR homodimers and is found in the human osteocalcin gene promoter (DR6-type), and the other is bound by heterodimers of VDR with retinoid X receptors (RXRs) as in the mouse osteopontin promoter (DR3-type). Here, we demonstrate that VDRs directly interact in solution not only with RXR but also with retinoid acid receptors (RARs) and, interestingly, with thyroid hormone receptors (T(3)Rs). All three heterodimeric partners were able to enhance the in vitro DNA binding affinity of MDR as compared to VDR homodimers, but they showed different affinities for the two types of VDREs, as determined by Scatchard analysis. Moreover, functional assays showed that VDR-T(3)R heterodimers act differently on the two types of VDREs; on the DR3-type we observed highest induction by thyroid hormone (3,5,3'-triiodothyronine, T-3) alone, whereas on a DRG-type VDRE VD and T-3 together provided maximal gene activity. Our data suggest that the expression levels of VDRs, RXRs, RARs, and T(3)Rs and their specific ligands regulate the transcription of VD-responsive genes and illustrates the complexity of this interactive network of nuclear receptors.	HOP CANTONAL UNIV,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				ALLAIN TJ, 1993, J ENDOCRINOL, V139, P9, DOI 10.1677/joe.0.1390009; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; DEGROOT LJ, 1993, ENDOCRINOLOGY, V133, P963, DOI 10.1210/en.133.3.963; DELUCA HF, 1990, KIDNEY INT, V38, pS2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; ROSS DS, 1991, J ENDOCRINOL INVEST, V14, P763, DOI 10.1007/BF03347911; ROSS TK, 1992, P NATL ACAD SCI USA, V89, P256, DOI 10.1073/pnas.89.1.256; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	28	111	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5501	5504						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119880				2022-12-25	WOS:A1994MY84000006
J	DEANS, DA; KASAMATSU, H				DEANS, DA; KASAMATSU, H			SIGNAL-DEPENDENT AND ENERGY-DEPENDENT NUCLEAR TRANSPORT OF SV40 VP3 BY ISOLATED-NUCLEI - ESTABLISHMENT OF A FILTRATION ASSAY FOR NUCLEAR-PROTEIN IMPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; PORE COMPLEX; T-ANTIGEN; NUCLEOCYTOPLASMIC TRANSPORT; ENVELOPE VESICLES; 2 STEPS; BINDING; TRANSLOCATION; INVITRO; CYTOPLASM	Nuclear transport signal (NTS)-containing proteins are transported into the nucleus through the nuclear pore complex by a mechanism that is not well understood. To better characterize the mechanisms of transport, we have established an homologous in vitro system using an NTS-containing structural protein of simian virus 40 (SV40) and isolated nuclei from cultured cells of its natural host. Isolated nuclei accumulated either fluorescently labeled SV40 Vp3-NTS peptide-BSA conjugates (NTSwt-BSA), as assayed cytochemically, or I-125-NTSwt-BSA, as assayed by filtration, in a signal- and ATP-dependent manner. Nuclear accumulation required nuclear membrane integrity and was inhibited by the lectin wheat germ agglutinin but not concanavalin A. Unlike several other systems, this system is not dependent on cytoplasmic extracts for the transport of SV40 proteins. NTSwt-BSA was transported with an apparent K-m of 0.8 mu m and V-max of 0.8 nmol/min/10(8) nuclei. Thin section autoradiography confirmed the transport. This system faithfully reproduced what occurs in vivo: nuclear import of the SV40 capsid protein Vp3 was dependent on the presence of its functional NTS. Full-length Vp3, expressed as a glutathione S-transferase fusion protein, and a deletion mutant which retains its NTS, Vp3 Delta C13, were transported by the nuclei but Vp3 Delta C35, which lacks the NTS, and an NTS mutant, VP3(202E/204T), were not transported.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	DEANS, DA (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [R01CA050574] Funding Source: NIH RePORTER; NCI NIH HHS [CA50574, CA09148] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CLEVER J, 1993, J BIOL CHEM, V268, P20877; CLEVER J, 1991, P NATL ACAD SCI USA, V88, P7333, DOI 10.1073/pnas.88.16.7333; CLEVER J, 1991, VIROLOGY, V181, P78, DOI 10.1016/0042-6822(91)90472-N; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GHARAKHANIAN E, 1987, VIROLOGY, V157, P440, DOI 10.1016/0042-6822(87)90286-8; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; IMAMOTOSONOBE N, 1988, P NATL ACAD SCI USA, V85, P3426, DOI 10.1073/pnas.85.10.3426; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MARKLAND W, 1987, MOL CELL BIOL, V7, P4255, DOI 10.1128/MCB.7.12.4255; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIEDEL N, 1987, BIOCHEM J, V241, P213, DOI 10.1042/bj2410213; RIEDEL N, 1987, BIOCHEM J, V241, P203, DOI 10.1042/bj2410203; SEGARINI PR, 1983, J CELL PHYSIOL, V116, P311, DOI 10.1002/jcp.1041160308; TOOZE J, 1980, MOL BIOL TUMOR VIRUS; Worthington CC, 1988, WORTHINGTON MANUAL; YAMADA M, 1993, J VIROL, V67, P119, DOI 10.1128/JVI.67.1.119-130.1993	41	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4910	4916						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106464				2022-12-25	WOS:A1994MX57100035
J	KIM, SJ; PARK, K; RUDKIN, BB; DEY, BR; SPORN, MB; ROBERTS, AB				KIM, SJ; PARK, K; RUDKIN, BB; DEY, BR; SPORN, MB; ROBERTS, AB			NERVE GROWTH-FACTOR INDUCES TRANSCRIPTION OF TRANSFORMING GROWTH-FACTOR-BETA-1 THROUGH A SPECIFIC PROMOTER ELEMENT IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; FACTOR-BETA; TRANSACTIVATION; DIFFERENTIATION; IDENTIFICATION; REPRESSION; E1A; FOS; WT1	Nerve growth factor (NGF) stimulates the differentiation of PC12 pheochromocytoma cells to those resembling sympathetic neurons. We have investigated whether NGF regulates transforming growth factor (TGF)-beta gene expression and protein secretion in PC12 cells. These cells constitutively express TGF-beta1 mRNA, whereas TGF-beta2 and -beta3 mRNAs are expressed at very low levels. TGF-beta1 gene expression was stimulated greater than 10-fold when PC12 cells were treated with NGF. Sequences between -119 and -98 in the TGF-beta1 promoter, homologous to an Egr-1 binding site, were shown to be important for both basal and NGF-induced promoter activity. We also found that a factor(s) present in nuclear extracts from PC12 cells interacted with the sequences between -119 and -98 and that expression of this factor was induced by NGF treatment. Moreover, specific binding to TGF-beta1 promoter fragments between -119 and -98 was seen using the bacterially expressed transcription factor Egr-1. These results indicate that activation of TGF-beta1 expression is one of the cellular responses of PC12 cells to NGF and suggest that TGF-beta may play a role in the differentiation of sympathetic neurons.	NICHHD,GROWTH FACTORS SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	KIM, SJ (corresponding author), NCI,CHEMOPREVENT LAB,BLDG 41,RM C629,BETHESDA,MD 20892, USA.			RUDKIN, Brian B./0000-0003-3700-1982				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; Denhez F, 1990, GROWTH FACTORS, V3, P139, DOI 10.3109/08977199009108276; DICKSON G, 1986, EMBO J, V5, P3449, DOI 10.1002/j.1460-2075.1986.tb04668.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FEIGE JJ, 1987, J BIOL CHEM, V262, P13491; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; GILARDI P, 1984, NUCLEIC ACIDS RES, V12, P7877, DOI 10.1093/nar/12.20.7877; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HOTTA M, 1986, P NATL ACAD SCI USA, V83, P7795, DOI 10.1073/pnas.83.20.7795; KIM SJ, 1992, J BIOL CHEM, V267, P13702; KIM SJ, 1989, J BIOL CHEM, V264, P402; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; LEVI-MONTALCINI RITA, 1966, HARVEY LECT, V60, P217; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; OREILLY MA, 1992, J BIOL CHEM, V267, P19938; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SING GK, 1990, CELL GROWTH DIFFER, V1, P511; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WU BY, 1989, J BIOL CHEM, V264, P9000	35	87	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3739	3744						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106419				2022-12-25	WOS:A1994MV63100089
J	NIELSEN, VS; MANT, A; KNOETZEL, J; MOLLER, BL; ROBINSON, C				NIELSEN, VS; MANT, A; KNOETZEL, J; MOLLER, BL; ROBINSON, C			IMPORT OF BARLEY PHOTOSYSTEM-I SUBUNIT-N INTO THE THYLAKOID LUMEN IS MEDIATED BY A BIPARTITE PRESEQUENCE LACKING AN INTERMEDIATE PROCESSING SITE - ROLE OF THE DELTA-PH IN TRANSLOCATION ACROSS THE THYLAKOID MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; ESCHERICHIA-COLI; PRECURSOR PROTEIN; PEA-CHLOROPLASTS; PROTON GRADIENT; TRANSIT PEPTIDE; FULL PRECURSOR; TRANSPORT; REQUIREMENTS; PLASTOCYANIN	Translocation across the thylakoid membrane of the recently identified photosystem I polypeptide, PSI-N, has been analyzed in pea (Pisum sativum) and barley (Hordeum vulgare). PSI-N from barley is synthesized in the cytosol with a bipartite presequence similar in structural terms to those of other cytosolically synthesized proteins routed to the thylakoid lumen. In vitro reconstitution assays demonstrate that translocation into thylakoids is absolutely dependent on the trans-thylakoidal DELTApH, but that nucleotide triphosphates are not required; the translocation mechanism is thus similar in these respects to those utilized by the 23- and 16-kDa proteins of the oxygen-evolving complex. The translocation of PSI-N is unique in that the presequence of PSI-N does not contain an intermediate cleavage site for the stromal processing peptidase; import experiments using intact chloroplasts depleted of a DELTApH by nigericin treatment demonstrate the accumulation of the full precursor protein in the stroma. Translocation across the thylakoid membrane can take place in the absence of stromal factors, although the presence of stromal extracts leads to a consistent but slight enhancement of translocation efficiency. We also show that efficient translocation of the 33-kDa protein of the oxygen-evolving complex can take place in the complete absence of DELTApH, in apparent contradiction with earlier findings; the translocation of this protein is thus similar in several respects to that of plastocyanin. The data indicate the operation of two very different types of translocation mechanism, with PSI-N exhibiting additional separate characteristics.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND; UNIV BREMEN,INST CELL BIOL BIOCHEM & BIOTECHNOL,W-2833 BREMEN,GERMANY	University of Warwick; University of Bremen	NIELSEN, VS (corresponding author), ROYAL VET & AGR UNIV,DEPT PLANT BIOL,PLANT BIOCHEM LAB,40 THORVALDSENSVEJ,DK-1871 FREDERIKSBERG C,DENMARK.		Møller, Birger Lindberg/H-2657-2014; Møller, Birger Lindberg/GQI-1792-2022	Møller, Birger Lindberg/0000-0002-3252-3119; Møller, Birger Lindberg/0000-0002-3252-3119; Mant, Alexandra/0000-0001-7169-209X				BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BAUERLE C, 1991, J BIOL CHEM, V266, P5876; CLARK SE, 1991, J CELL BIOL, V114, P681, DOI 10.1083/jcb.114.4.681; CLINE K, 1992, J BIOL CHEM, V267, P2688; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KIRWIN PM, 1989, EMBO J, V8, P3917; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KNOETZEL J, 1993, PLANT MOL BIOL, V22, P337, DOI 10.1007/BF00014940; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KONISHI T, 1993, PLANT CELL PHYSIOL, V34, P315; KUWABARA T, 1987, P NATL ACAD SCI USA, V84, P8230, DOI 10.1073/pnas.84.23.8230; MEADOWS JW, 1991, PLANT MOL BIOL, V17, P1241, DOI 10.1007/BF00028739; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; ROBERTS LM, 1991, FEBS LETT, V293, P134, DOI 10.1016/0014-5793(91)81169-9; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SHACKLETON JB, 1991, J BIOL CHEM, V266, P12152; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; THEG SM, 1989, J BIOL CHEM, V264, P6730; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	28	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3762	3766						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106420				2022-12-25	WOS:A1994MV63100092
J	BALSARI, AL; MORELLI, D; MENARD, S; VERONESI, U; COLNAGHI, MI				BALSARI, AL; MORELLI, D; MENARD, S; VERONESI, U; COLNAGHI, MI			PROTECTION AGAINST DOXORUBICIN-INDUCED ALOPECIA IN RATS BY LIPOSOME-ENTRAPPED MONOCLONAL-ANTIBODIES	FASEB JOURNAL			English	Article						DOXORUBICIN; ALOPECIA; MONOCLONAL ANTIBODIES; LIPOSOMES	CHEMOTHERAPY-INDUCED ALOPECIA; INTERLEUKIN-1 PROTECTS; INVIVO; DRUG; MODEL; CELLS; GENE	Alopecia is a common side effect of several anti-cancer drugs, including doxorubicin. Based on our recent observation that a monoclonal antibody (MADl1) directed against this anthracycline inhibits the systemic toxic effect of the drug in mice, we investigated the possibility that MAD11 administered topically might protect against doxorubicin-induced alopecia. In 31 of 45 young rats treated intraperitoneally with doxorubicin, alopecia was completely prevented by topical treatment of the skin with liposome-incorporated anti-doxorubicin monoclonal antibody. This type of treatment might find relevance in preventing anthracycline-induced alopecia in cancer patients. Our findings also provide the first demonstration that liposome-entrapped monoclonal antibodies are capable of penetrating the stratum corneum of the skin without losing their function.	IST NAZL TUMORI,DIV EXPTL ONCOL E,I-20133 MILAN,ITALY; UNIV MILAN,FAC MED,MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan			Morelli, Daniele/I-4113-2017; balsari, andrea/M-5657-2016	Morelli, Daniele/0000-0002-1823-3764; balsari, andrea/0000-0002-3250-2668				ALINO SF, 1992, LAB INVEST, V66, P671; BALSARI A, 1988, INT J CANCER, V42, P798, DOI 10.1002/ijc.2910420528; BALSARI A, 1991, INT J CANCER, V47, P889, DOI 10.1002/ijc.2910470617; Baxley K O, 1984, Cancer Nurs, V7, P499; BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; CHEN HSG, 1979, CANCER CHEMOTH PHARM, V2, P85; Cline B W, 1984, Cancer Nurs, V7, P221; CROUNSE RG, 1960, J INVEST DERMATOL, V35, P83, DOI 10.1038/jid.1960.88; HUNTER MM, 1982, J IMMUNOL, V129, P1165; HUSSEIN AM, 1990, SCIENCE, V249, P1564, DOI 10.1126/science.2218498; JIMENEZ JJ, 1992, CANCER RES, V52, P5123; JIMENEZ JJ, 1992, CANCER INVEST, V10, P271, DOI 10.3109/07357909209032751; JIMENEZ JJ, 1991, FASEB J, V5, P2456, DOI 10.1096/fasebj.5.10.2065892; JIMENEZ JJ, 1992, FASEB J, V6, P911, DOI 10.1096/fasebj.6.3.1740239; KORTING HC, 1991, J AM ACAD DERMATOL, V25, P1068, DOI 10.1016/0190-9622(91)70309-P; OBRIEN R, 1970, NEW ENGL J MED, V283, P1469; SCHAFERKORTING M, 1989, J AM ACAD DERMATOL, V21, P1271, DOI 10.1016/S0190-9622(89)70342-X; SEIPP CA, 1983, ONCOLOGY NURSING FOR, V10, P12; SORIANO P, 1983, P NATL ACAD SCI-BIOL, V80, P7128, DOI 10.1073/pnas.80.23.7128; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; WITMAN G, 1981, CANCER TREAT REP, V65, P507	22	50	52	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					226	230		10.1096/fasebj.8.2.8119493	http://dx.doi.org/10.1096/fasebj.8.2.8119493			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119493				2022-12-25	WOS:A1994MY29900029
J	LI, R; NORTAMO, P; KANTOR, C; KOVANEN, P; TIMONEN, T; GAHMBERG, CG				LI, R; NORTAMO, P; KANTOR, C; KOVANEN, P; TIMONEN, T; GAHMBERG, CG			A LEUKOCYTE INTEGRIN BINDING PEPTIDE FROM INTERCELLULAR-ADHESION MOLECULE-2 STIMULATES T-CELL ADHESION AND NATURAL-KILLER-CELL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FUNCTION-ASSOCIATED ANTIGEN-1; LARGE GRANULAR LYMPHOCYTES; MONOCLONAL-ANTIBODY; COUNTER-RECEPTOR; PHORBOL ESTER; COSTIMULATORY SIGNAL; BETA-SUBUNIT; CD11 CD18; LFA-1; ICAM-1	Adhesion is of pivotal importance for a number of leukocyte functions. Little is known about the binding between leukocyte integrins and the intercellular adhesion molecules (ICAMs). Normally integrins are nonadhesive, and require a stimulus to become active. We have now identified a peptide from ICAM-2, which binds to leukocyte integrins and activates adhesion. Furthermore, the peptide strongly increased the binding and cytotoxicity of natural killer cells. These findings show that adhesion-dependent leukocyte functions can be activated by ligand-derived peptides, and therefore provide evidence that the avidity of leukocyte integrins is up-regulated by integrin-ligand interactions.	UNIV HELSINKI,DEPT BIOCHEM,POB 5,UNIONINKATU 35,SF-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT PATHOL,SF-00014 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki			Gahmberg, Carl/AAE-1876-2019	Gahmberg, Carl/0000-0001-9892-9296				ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BUYON JP, 1990, J IMMUNOL, V144, P1916; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; DAMLE NK, 1992, J IMMUNOL, V148, P665; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; HEDMAN H, 1992, J IMMUNOL, V149, P2295; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; JAASKELAINEN J, 1992, J IMMUNOL, V149, P260; KOOPMAN G, 1992, EUR J IMMUNOL, V22, P1851, DOI 10.1002/eji.1830220726; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LI R, 1993, J BIOL CHEM, V268, P17513; NORTAMO P, 1988, SCAND J IMMUNOL, V28, P537, DOI 10.1111/j.1365-3083.1988.tb01485.x; NORTAMO P, 1991, J IMMUNOL, V146, P2530; PATARROYO M, 1990, IMMUNOL REV, V114, P67, DOI 10.1111/j.1600-065X.1990.tb00562.x; PATARROYO M, 1985, SCAND J IMMUNOL, V22, P171, DOI 10.1111/j.1365-3083.1985.tb01869.x; PATARROYO M, 1987, FEBS LETT, V210, P127, DOI 10.1016/0014-5793(87)81321-2; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TIMONEN T, 1981, J EXP MED, V153, P569, DOI 10.1084/jem.153.3.569; TIMONEN T, 1990, INT J CANCER, V46, P1035, DOI 10.1002/ijc.2910460615; TIMONEN T, 1988, J IMMUNOL, V141, P1041; VALMU L, 1991, EUR J IMMUNOL, V21, P2857, DOI 10.1002/eji.1830211130; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; WALLIS WJ, 1986, BLOOD, V67, P1007; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	40	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21474	21477						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	8104939				2022-12-25	WOS:A1993MC80900006
J	COLLER, BS; SPRINGER, KT; SCUDDER, LE; KUTOK, JL; CERUSO, M; PRESTWICH, GD				COLLER, BS; SPRINGER, KT; SCUDDER, LE; KUTOK, JL; CERUSO, M; PRESTWICH, GD			SUBSTITUTING ISOSERINE FOR SERINE IN THE THROMBIN RECEPTOR ACTIVATION PEPTIDE SFLLRN CONFERS RESISTANCE TO AMINOPEPTIDASE-M-INDUCED CLEAVAGE AND INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AGONIST PEPTIDES; PH-DEPENDENCE; MECHANISM	Peptides containing sequences derived from the new NH2 terminus of the seven-transmembrane domain thrombin receptor after thrombin cleavage can activate platelets directly. We recently demonstrated that such peptides are readily cleaved and inactivated by plasma, serum, and endothelial cell-associated aminopeptidase M. The rapid degradation and inactivation of the peptides makes it difficult to assess dose-response relationships precisely or to conduct long term incubations with cells in the presence of plasma or serum. To overcome these problems, we first substituted D-serine for the NH2-terminal L-serine in an active peptide ligand (SFLLRNPNDKY). The D-serine derivative resisted degradation in plasma, but it is less than 1% as active as the L-serine peptide. Substituting a racemic mixture of the beta-amino acid isoserine for serine in a related peptide ligand (SFLLRN) produced an active peptide ((iso-S)FLLRN) that is approximately 15-20% as potent as SFLLRN as judged by platelet aggregation. To assess the stability of the peptides in plasma, SFLLRN (1 mM) was incubated with 50% plasma for various periods of time; after 15 min, 65% of the peptide remained intact, and after 2 h only 4% remained intact. Loss of aggregating activity paralleled the loss of intact peptide. In contrast, even after 2 h of incubation with plasma, 83% of the (iso-S)FLLRN remained intact and the aggregating activity was essentially unchanged. Qualitative differences in the patterns of platelet aggregation produced by the peptides were also observed. Thus, the distinct pattern of aggregation followed by rapid disaggregation observed with submaximal aggregating doses of SFLLRN was less evident with (iso-S)FLLRN, and inhibition of aminopeptidase M by amastatin enhanced aggregation in platelet-rich plasma induced by SFLLRN but not (iso-S)FLLRN. The (iso-S)FLLRN peptide should permit improved analysis of the effects of constant levels of peptide-induced thrombin receptor stimulation in the presence of plasma or serum, or when testing the effects of the peptide on cells that contain surface-associated aminopeptidase M.	SUNY,DEPT CHEM,STONY BROOK,NY 11794; SUNY,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College	COLLER, BS (corresponding author), SUNY,DEPT MED,DIV HAEMATOL,STONY BROOK,NY 11794, USA.		CERUSO, MARCO/C-5164-2009; Ceruso, Marco/AAL-9179-2020		NCRR NIH HHS [RR65547A] Funding Source: Medline; PHS HHS [45791, 19278] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; COLLER BS, 1976, BLOOD, V47, P841; COLLER BS, 1992, BIOCHEMISTRY-US, V31, P11713, DOI 10.1021/bi00162a007; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; PALMIERI FE, 1989, BIOCHEM PHARMACOL, V38, P173, DOI 10.1016/0006-2952(89)90165-2; SABO T, 1992, BIOCHEM BIOPH RES CO, V188, P604, DOI 10.1016/0006-291X(92)91099-C; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	11	31	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20741	20743						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	8104935				2022-12-25	WOS:A1993MA28800016
J	MANIE, S; SCHMIDALLIANA, A; KUBAR, J; FERRUA, B; ROSSI, B				MANIE, S; SCHMIDALLIANA, A; KUBAR, J; FERRUA, B; ROSSI, B			DISRUPTION OF MICROTUBULE NETWORK IN HUMAN MONOCYTES INDUCES EXPRESSION OF INTERLEUKIN-1 BUT NOT THAT OF INTERLEUKIN-6 NOR TUMOR-NECROSIS-FACTOR-ALPHA - INVOLVEMENT OF PROTEIN KINASE-A STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; RAT 3Y1 CELLS; DNA-SYNTHESIS; ADENYLATE-CYCLASE; HUMAN IL-1-ALPHA; TAXOL; MACROPHAGES; IL-1-BETA; INITIATION; INHIBITION	We have reported recently that colchicine and other microtubule-disrupting agents stimulated interleukin-1 (IL-1) alpha and beta synthesis in human monocytes. In this study we found that unexpectedly colchicine failed to stimulate the expression of two other potent immune mediators, namely tumor necrosis factor-alpha and interleukin-6. Remarkably, taxol which induces stable microtubule bundles, antagonized the colchicine but not the LPS-induced IL-1 synthesis. These results suggested that the colchicine- mediated IL-1 induction was generated by microtubule disassembly. We next demonstrated that microtubule disruption triggered an elevation of intracellular levels of cAMP and a subsequent stimulation of protein kinase A. The use of different protein kinase inhibitors supported a role of the PKA, but not the PKC, in the colchicine-induced IL-1 production. Furthermore, elevation of intracellular cAMP levels by 8-bromo-cAMP, forskolin, or cholera toxin potentiated the effect of suboptimal concentration of colchicine on IL-1 synthesis. However, these agents alone were unable to induce IL-1 synthesis. Therefore, our data indicate that the cAMP/protein kinase A-signaling pathway is necessary but not sufficient to generate IL-1 synthesis by microtubule disruption. Thus, microtubule-disrupting drugs appear as useful tools to further characterize the molecular events which regulate IL-1 production in human monocytes.	FAC MED NICE, INSERM, U364, AVE VALOMBROSE, F-06107 NICE 02, FRANCE; FAC MED NICE, PHARMACOL LAB, F-06107 NICE 02, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur			Manie, Serge/ABC-8331-2021; SCHMID-ALLIANA, Annie/P-4366-2016	SCHMID-ALLIANA, Annie/0000-0003-2321-7408				AVILA J, 1990, FASEB J, V4, P3284, DOI 10.1096/fasebj.4.15.2253844; BAKOUCHE O, 1992, J IMMUNOL, V148, P84; BIRCHMEIER W, 1984, TRENDS BIOCHEM SCI, V9, P478; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BOZOU JC, 1986, MOL PHARMACOL, V29, P489; BROWN DL, 1985, EUR J CELL BIOL, V37, P130; CARTER KC, 1989, J BIOL CHEM, V264, P515; CAVAILLON JM, 1990, CYTOKINE, V2, P1; CLEVELAND DW, 1990, CELL, V60, P701, DOI 10.1016/0092-8674(90)90083-Q; CROSSIN KL, 1981, CELL, V23, P61, DOI 10.1016/0092-8674(81)90270-1; CROSSIN KL, 1981, CELL, V27, P341, DOI 10.1016/0092-8674(81)90417-7; DINARELLO CA, 1991, BLOOD, V77, P1627; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; DING AH, 1990, J EXP MED, V171, P715, DOI 10.1084/jem.171.3.715; FERRUA B, 1990, CELL IMMUNOL, V131, P391, DOI 10.1016/0008-8749(90)90263-Q; FERRUA B, 1988, J IMMUNOL METHODS, V114, P41, DOI 10.1016/0022-1759(88)90151-2; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HURME M, 1990, BLOOD, V76, P2198; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOVACS EJ, 1988, J IMMUNOL, V141, P3101; KRONKE M, 1990, CELL SIGNAL, V2, P1, DOI 10.1016/0898-6568(90)90027-8; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MANIE S, 1993, EUR CYTOKINE NETW, V4, P51; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; RAVINDRA R, 1991, FASEB J, V5, pA1498; RUDOLPH SA, 1977, P NATL ACAD SCI USA, V74, P3403; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCOTT CW, 1989, BIOCHEM J, V263, P207, DOI 10.1042/bj2630207; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P5732, DOI 10.1073/pnas.82.17.5732; SERRANO L, 1989, EXP CELL RES, V181, P263, DOI 10.1016/0014-4827(89)90200-0; SHINOHARA Y, 1989, EUR J BIOCHEM, V183, P275, DOI 10.1111/j.1432-1033.1989.tb14924.x; SHINOHARAGOTOH Y, 1991, EXP CELL RES, V193, P161, DOI 10.1016/0014-4827(91)90551-5; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SUNG SSJ, 1991, J CLIN INVEST, V88, P1915, DOI 10.1172/JCI115515; TURNER M, 1989, J IMMUNOL, V143, P3556; VALLANO ML, 1985, P NATL ACAD SCI USA, V83, P3203; VALLEE RB, 1981, J CELL BIOL, V90, P568, DOI 10.1083/jcb.90.3.568; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WANG N, 1991, BIOCHEMISTRY-US, V30, P10957, DOI 10.1021/bi00109a021; WANG N, 1990, J BIOL CHEM, V265, P1239	41	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13675	13681						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8099911				2022-12-25	WOS:A1993LH55300092
J	BARAK, D; KRONMAN, C; ORDENTLICH, A; ARIEL, N; BROMBERG, A; MARCUS, D; LAZAR, A; VELAN, B; SHAFFERMAN, A				BARAK, D; KRONMAN, C; ORDENTLICH, A; ARIEL, N; BROMBERG, A; MARCUS, D; LAZAR, A; VELAN, B; SHAFFERMAN, A			ACETYLCHOLINESTERASE PERIPHERAL ANIONIC SITE DEGENERACY CONFERRED BY AMINO-ACID ARRAYS SHARING A COMMON CORE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; TORPEDO-CALIFORNICA; BINDING-SITES; ACTIVE-CENTER; DERIVATIVES; HYDROLYSIS; INHIBITION; CATALYSIS; SECRETION; PROPIDIUM	Several of the residues constituting the peripheral anionic site (PAS) in human acetylcholinesterase (HuAChE) were identified by a combination of kinetic studies with 19 single and multiple HuAChE mutants, fluorescence binding studies with the Trp-286 mutant, and by molecular modelling. Mutants were analyzed with three structurally distinct positively charged PAS ligands, propidium, decamethonium, and di(p-allyl-N-dimethylaminophenyl)pentane-3-one (BW284C51), as well as with selective active center inhibitors, hexamethonium and edrophonium. Single mutations of residues Tyr-72, Tyr-124, Glu-285, Trp-286, and Tyr-341 resulted in up to 10-fold increase in inhibition constants for PAS ligands, whereas for multiple mutants up to 400-fold increase was observed. The 6th PAS element residue Asp-74 is unique in its ability to affect conformation of both the active site and the PAS (Shafferman, A., Velan, B., Ordentlich, A., Kronman, C., Grosfeld, H., Leitner, M., Flashner, Y., Cohen, S., Barak, D., and Ariel, N. (1992) EMBO J. 11, 3561-3568) as demonstrated by the several hundred-fold increase in K-i for D74N inhibition by the bisquaternary ligands decamethonium and BW284C51. Based on these studies, singular molecular models for the various HuAChE inhibitor complexes were defined. Yet, for the decamethonium complex two distinct conformations were generated, accommodating the quaternary ammonium group by interactions with either Trp-286 or with Tyr-341. We propose that the PAS consists of a number of binding sites, close to the entrance of the active site gorge, sharing residues Asp-74 and Trp-286 as a common core. Binding of ligands to these residues may be the key to the allosteric modulation of HuAChE catalytic activity. This functional degeneracy is a result of the ability of the Trp-286 indole moiety to interact either via stacking, aromatic-aromatic, or via pi-cation attractions and the involvement of the carboxylate of Asp-74 in charge-charge or H-bond interactions.	ISRAEL INST BIOL RES, DEPT BIOCHEM, IL-70450 NESS ZIONA, ISRAEL; ISRAEL INST BIOL RES, DEPT ORGAN CHEM, IL-70450 NESS ZIONA, ISRAEL; ISRAEL INST BIOL RES, DEPT PHYS CHEM, IL-70450 NESS ZIONA, ISRAEL; ISRAEL INST BIOL RES, DEPT BIOTECHNOL, IL-70450 NESS ZIONA, ISRAEL									BARAK D, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P195; BARNETT P, 1977, J BIOL CHEM, V252, P7200; BERMAN HA, 1981, BIOCHEMISTRY-US, V20, P4803, DOI 10.1021/bi00519a043; BERMAN HA, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P149; BERMAN HA, 1986, BIOCHIM BIOPHYS ACTA, V872, P125, DOI 10.1016/0167-4838(86)90155-X; BERMAN HA, 1987, MOL PHARMACOL, V31, P610; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; CYGLER M, 1993, PROTEIN SCI, V2, P366; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GIACOBINI R, 1988, CURRENT RES ALZHEIME, P113; HAAS R, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P131; HAN SY, 1992, EUR J MED CHEM, V27, P673, DOI 10.1016/0223-5234(92)90087-H; HODGE AS, 1992, MOL PHARMACOL, V41, P937; HUCHO F, 1991, TRENDS PHARMACOL SCI, V12, P422; KAY MI, 1971, ACTA CRYSTALL B-STRU, VB 27, P26, DOI 10.1107/S0567740871001663; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; KRUPKA RM, 1966, BIOCHEMISTRY-US, V5, P1988, DOI 10.1021/bi00870a029; LAZAR A, 1993, ANIMAL CELL TECHNOLO; LULLMANN H, 1971, BIOCHEM PHARMACOL, V20, P2579, DOI 10.1016/0006-2952(71)90166-3; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCCURDY A, 1992, J AM CHEM SOC, V114, P10314, DOI 10.1021/ja00052a031; MOOSER G, 1972, BIOCHEMISTRY-US, V11, P1595, DOI 10.1021/bi00759a008; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1991, MOL PHARMACOL, V39, P98; ROSENBERRY TL, 1972, BIOCHEMISTRY-US, V11, P4308, DOI 10.1021/bi00773a018; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; ROUFOGALIS BD, 1972, MOL PHARMACOL, V8, P41; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SHAFFERMAN A, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P165; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; SUSSMAN JL, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P95; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; TAYLOR P, 1974, MOL PHARMACOL, V10, P703; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x; WILSON IB, 1958, ARCH BIOCHEM BIOPHYS, V73, P131, DOI 10.1016/0003-9861(58)90248-0	44	152	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6296	6305						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119978				2022-12-25	WOS:A1994MZ50300010
J	HU, LM; BODWELL, J; HUO, JM; ORTI, E; MUNCK, A				HU, LM; BODWELL, J; HUO, JM; ORTI, E; MUNCK, A			GLUCOCORTICOID RECEPTORS IN ATP-DEPLETED CELLS - DEPHOSPHORYLATION, LOSS OF HORMONE-BINDING, HSP90 DISSOCIATION, AND ATP-DEPENDENT CYCLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; SITE-SPECIFIC MUTAGENESIS; RAT THYMUS-CELLS; PROGESTERONE-RECEPTOR; PHENOTYPIC SELECTION; NUCLEAR MATRIX; INTACT-CELLS; PHOSPHORYLATION; COMPLEXES; MODEL	Dependence of hormone binding to glucocorticoid receptors (GRs) on cellular ATP levels suggested that GRs traverse an ATP-dependent cycle, and without ATP accumulate in forms that cannot bind hormone. Such ''null'' receptors (NRs) were identified in ATP-depleted WEHI-7 cells, where they are tightly associated with the nuclear fraction and partly dephosphorylated. With WCL2 cells (Chinese hamster ovary cells with overexpressed GRs) depleted of ATP with azide, we have now identified dephosphorylated sites on NRs, studied possible roles of phosphorylation using GR mutants, and measured association with the 90-kDa heat shock protein (hsp90). Most NRs in WCL2 cells are dephosphorylated at serines 220 and 234, but G;Rs with those serines mutated to alanines do not resemble NRs since they bind hormone. They do not associate strongly with nuclei. On azide treatment, however, mutated GRs lose hormone binding capacity faster than normal GRs. Association of hsp90 (and presumably other heat shock proteins) with cytosolic GRs is drastically reduced by azide treatment, sufficient to account for decreased hormone binding. We conclude that: (a) dephosphorylation of GRs does not yield NRs, but may weaken association with hsp90. (b) The postulated ATP-dependent GR cycle can be accounted for by dissociation, and ATP-dependent reconstitution, of GR.hsp90 complexes. (c) ATP depletion blocks reconstitution of complexes. Uncomplexed GRs may accumulate as one form of NR; they are probably also the precursors for other forms of NR.	DARTMOUTH COLL SCH MED, DEPT PHYSIOL, LEBANON, NH 03756 USA	Dartmouth College					FIC NIH HHS [1FOS TWO3923-01] Funding Source: Medline; NCI NIH HHS [CA 23108] Funding Source: Medline; NIDDK NIH HHS [DK 03535] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003535] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL PA, 1973, BIOCHEM J, V136, P97, DOI 10.1042/bj1360097; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CIDLOWSKI JA, 1980, J STEROID BIOCHEM, V13, P105, DOI 10.1016/0022-4731(80)90180-6; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DANIELSEN M, 1989, CANCER RES, V49, pS2286; DISTELHORST CW, 1989, J BIOL CHEM, V264, P13080; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HOCK W, 1989, J STEROID BIOCHEM, V34, P71, DOI 10.1016/0022-4731(89)90067-8; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; HUTCHISON KA, 1992, J BIOL CHEM, V267, P3190; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; Kaufmann S H, 1986, Methods Achiev Exp Pathol, V12, P141; KAUFMANN SH, 1986, J BIOL CHEM, V261, P1962; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MENDEL DB, 1990, PROG CLIN BIOL RES, V322, P97; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; MENDEL DB, 1987, J BIOL CHEM, V262, P5644; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MENDEL DB, 1986, NATURE, V324, P478, DOI 10.1038/324478a0; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; MUNCK A, 1968, J BIOL CHEM, V243, P5556; MUNCK A, 1984, J BIOL CHEM, V259, P820; MUNCK A, 1972, J STEROID BIOCHEMIST, V3, P567, DOI 10.1016/0022-4731(72)90103-3; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; ORTI E, 1989, J BIOL CHEM, V264, P9728; ORTI E, 1989, J STEROID BIOCHEM, V34, P85, DOI 10.1016/0022-4731(89)90069-1; ORTI E, 1993, J BIOL CHEM, V268, P7779; RAAKA BM, 1983, J BIOL CHEM, V258, P417; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; WERB Z, 1978, J EXP MED, V147, P1684, DOI 10.1084/jem.147.6.1684	40	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6571	6577						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120009				2022-12-25	WOS:A1994MZ50300049
J	REGNSTROM, K; ABERG, A; ORMO, M; SAHLIN, M; SJOBERG, BM				REGNSTROM, K; ABERG, A; ORMO, M; SAHLIN, M; SJOBERG, BM			THE CONSERVED SERINE-211 IS ESSENTIAL FOR REDUCTION OF THE DINUCLEAR IRON CENTER IN PROTEIN R2 OF ESCHERICHIA-COLI RIBONUCLEOTIDE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; SMALL SUBUNIT; PHENOTYPIC SELECTION; CRYSTAL-STRUCTURE; B2 PROTEIN; SPECTROSCOPY; ACTIVATION; MOSSBAUER; FORMS; AID	The R2 protein family of class I ribonucleotide reductases contains a highly conserved serine residue close to the essential tyrosyl radical and the dinuclear iron center. In order to test its physiological importance, we have engineered the Ser-211 of Escherichia coli R2 to an alanine and a cysteine residue. The three-dimensional structure of R2 S211A solved to 2.4-Angstrom resolution is virtually identical to the wild-type structure apart from the substituted residue. Both mutant proteins contain oxidized dinuclear iron and tyrosyl radical, and their specific enzyme activity per radical are comparable to that of the wild-type protein. In R2 S211A the stability of the tyrosyl radical is substantially decreased, probably caused by movement of Gln-80 into hydrogen bonding distance of Tyr-122. The major defect in R2 S211A, however, is the inability of its iron center to be reduced by enzymic or chemical means, a characteristic not found in R2 S211C. We propose that Ser-211 is needed as a proton donor/transporter during reduction of the iron center of R2, a reaction which in vivo precedes reconstitution of the tyrosyl radical. This offers a physiological explanation for the high conservation of a serine residue at this position in the R2 family.	STOCKHOLM UNIV,DEPT MOLEC BIOL,S-10891 STOCKHOLM,SWEDEN	Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1993, NATURE, V361, P276, DOI 10.1038/361276a0; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; ATTA M, 1992, J BIOL CHEM, V267, P20682; BACKES G, 1989, BIOCHEMISTRY-US, V28, P1923, DOI 10.1021/bi00430a074; Bernitz U, 1993, NYA KONKURRENSLAGEN; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P285; BOURSNELL M, 1991, VIROLOGY, V184, P411, DOI 10.1016/0042-6822(91)90860-E; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARLSON J, 1984, P NATL ACAD SCI-BIOL, V81, P4294, DOI 10.1073/pnas.81.14.4294; CLIMENT I, 1992, P NATL ACAD SCI USA, V31, P4801; Creighton T. E., 1993, PROTEINS STRUCTURES, P6; ELGREN TE, 1991, J BIOL CHEM, V266, P19265; ELIASSON R, 1986, P NATL ACAD SCI USA, V83, P2373, DOI 10.1073/pnas.83.8.2373; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1989, J BIOL CHEM, V264, P9164; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; GEREZ C, 1992, BIOCHEMISTRY-US, V31, P780, DOI 10.1021/bi00118a020; GEREZ C, 1991, ANGEW CHEM INT EDIT, V80, P1135; GREENE PJ, 1974, METHODS MOLECULAR BI, V7, P87; HENDRICH MP, 1991, BIOCHEM BIOPH RES CO, V176, P705, DOI 10.1016/S0006-291X(05)80241-4; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; Maniatis T., 1982, MOL CLONING; NORDLUND P, 1992, FEBS LETT, V307, P257, DOI 10.1016/0014-5793(92)80690-I; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; ORMO M, 1993, UNPUB; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; RARDIN RL, 1991, NEW J CHEM, V15, P417; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; Thelander L, 1978, Methods Enzymol, V51, P227; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; WATSON JD, MOL BIOL GENE, P339	50	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6355	6361						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119985				2022-12-25	WOS:A1994MZ50300018
J	REY, I; TAYLORHARRIS, P; VANERP, H; HALL, A				REY, I; TAYLORHARRIS, P; VANERP, H; HALL, A			R-RAS INTERACTS WITH RASGAP, NEUROFIBROMIN AND C-RAF BUT DOES NOT REGULATE CELL-GROWTH OR DIFFERENTIATION	ONCOGENE			English	Article							TYPE-1 GENE TRANSCRIPTS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; PROTEIN GAP; P21; IDENTIFICATION; EXPRESSION; PRODUCT; DOMAIN; GTPASE	Within the superfamily of ras-related GTP-binding proteins, only ras itself has been shown to act as an oncogene. Seven other proteins, however, have greater than 50% amino acid identity to ras and one of them, rap1A, has been shown to interact with the ras GTPase activating protein, ras-GAP, and to inhibit ras function when overexpressed. In this paper, we have examined the biological and biochemical activities of another close relative of ras, R-ras. We show that in vitro, R-ras shares a number of activities with ras; it interacts with the catalytic domain of ras-GAP, with the GAP-related domain of neurofibromin and with the ser/thr kinase, c-raf. Furthermore, R-ras stimulates the expression of c-fos when microinjected into Swiss 3T3 cells. However, unlike ras, R-ras does not include DNA synthesis or membrane ruining in quiescent fibroblasts, nor does it induce maturation of Xenopus oocytes or differentiation of PC12 cells. In addition, we show that unlike rap1A, R-ras does not interfere with ras-stimulated gene transcription. We conclude from these experiments that although R-ras and ras share some biochemical activities, they control distinct biological processes.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOLLAG G, 1992, CANCER BIOL, V3, P199; BOS JL, 1989, CANCER RES, V49, P4682; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1986, J BIOL CHEM, V261, P963; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHI T, 1991, ONCOGENE, V6, P1555; PIZON V, 1988, ONCOGENE, V3, P201; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAKODA T, 1992, ONCOGENE, V7, P1705; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SELF AJ, 1993, ONCOGENE, V8, P655; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P955, DOI 10.1016/0006-291X(91)92029-J; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UCHIDA T, 1992, BIOCHEM BIOPH RES CO, V187, P332, DOI 10.1016/S0006-291X(05)81497-4; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	52	64	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					685	692						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108110				2022-12-25	WOS:A1994MW55100002
J	YOON, HY; BOETTIGER, D				YOON, HY; BOETTIGER, D			EXPRESSION OF V-SRC ALTERS THE EXPRESSION OF MYOGENIC REGULATORY FACTOR GENES	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; CONTRACTILE PROTEIN-SYNTHESIS; MUSCLE-SPECIFIC GENES; DIFFERENTIATION PROGRAM; MYOBLAST DIFFERENTIATION; SKELETAL-MUSCLE; CELLS; MYOD1; FIBROBLASTS; ACTIVATION	Inactivation of v-src in transformed chicken myoblasts induced changes in expression of the myogenic regulatory factors (MRF's), MyoD, myogenin and Myf5. Both MyoD and Myf5 were expressed in the transformed cells. The inactivation of v-src by a temperature up-shift resulted in the loss of Myf5 expression, a transient increase in MyoD, followed by a rise in myogenin mRNA levels. The increase in transcripts for the later muscle proteins, myosin heavy and light chains, alpha-actin and troponin T followed the sequence of changes in MRF expression suggesting that their induction was the result of altered MRF expression. Thus, v-src appears to operate through effects on MRF's and not directly on the expression of the late muscle-specific proteins. When v-src was reactivated in mature myotubes by a temperature down-shift, the pattern of expression was quite different, the late muscle-specific transcripts decreased before the loss of myogenin transcripts and before the rise of Myf5 transcripts.	UNIV PENN,DEPT MICROBIOL,PHILADELPHIA,PA 19104	University of Pennsylvania					NCI NIH HHS [CA 49866, CA 16502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049866, R01CA016502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ANESKIEVICH BJ, 1991, ONCOGENE, V6, P1381; BILLETER R, 1988, MOL CELL BIOL, V8, P1361, DOI 10.1128/MCB.8.3.1361; BISCHOFF R, 1968, J CELL BIOL, V36, P111, DOI 10.1083/jcb.36.1.111; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BRAN T, 1989, EMBO J, V8, P2617; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; DEVLIN RB, 1978, CELL, V13, P599, DOI 10.1016/0092-8674(78)90211-8; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELDRIDGE J, 1985, GENE, V36, P55, DOI 10.1016/0378-1119(85)90069-1; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1984, EMBO J, V3, P1327, DOI 10.1002/j.1460-2075.1984.tb01971.x; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; GROSSI M, 1991, ONCOGENE, V6, P1767; HASTINGS KEM, 1985, J BIOL CHEM, V260, P3699; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; HUMPHRIES EH, 1972, J VIROL, V10, P82, DOI 10.1128/JVI.10.1.82-87.1972; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MANGIACAPRA FJ, 1992, MOL ENDOCRINOL, V6, P2038, DOI 10.1210/me.6.12.2038; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; OTT MO, 1991, DEVELOPMENT, V111, P1097; PAYETTE RF, 1988, DEV BIOL, V125, P341, DOI 10.1016/0012-1606(88)90217-5; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SU HY, 1991, ONCOGENE, V6, P1759; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEST CM, 1983, CANCER RES, V43, P2042; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WYKE JA, 1973, VIROLOGY, V54, P152; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	46	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					801	807						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108122				2022-12-25	WOS:A1994MW55100015
J	OKAZAKI, K; NIKI, I; IINO, S; KOBAYASHI, S; HIDAKA, H				OKAZAKI, K; NIKI, I; IINO, S; KOBAYASHI, S; HIDAKA, H			A ROLE OF CALCYCLIN, A CA2+-BINDING PROTEIN, ON THE CA2+-DEPENDENT INSULIN RELEASE FROM THE PANCREATIC BETA-CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; KINASE-C; SECRETION; CALMODULIN; EXPRESSION; STIMULUS; GROWTH; IDENTIFICATION; PARTICIPATION; EXOCYTOSIS	Exocytosis is an important example of cell activation. Ca2+ and calcium-binding proteins are considered to modulate signal transduction in exocytosis. We examined the role of calcyclin, calcium-binding protein, in the stimulus-secretion coupling in pancreatic beta cells. The presence of calcyclin in these cells was demonstrated immunologically. We permeabilized rat pancreatic islets with streptolysin-O and examined the effects of calcyclin on insulin release. The Ca2+-stimulated insulin release was enhanced by calcyclin, in a dose-dependent manner, whereas this calcium-binding protein had no effect on insulin release from islets in low Ca2+ buffer or from the islets not subjected to the streptolysin-O treatment. Calgizzarin, another member of the S-100 protein family had no apparent effect on the Ca2+ stimulated secretion under parallel conditions. An anticalcyclin antibody suppressed the increase in insulin release induced by calcyclin. We propose that calcyclin may be involved in signal transduction of the Ca2+-induced release of insulin.	NAGOYA UNIV, SCH MED, DEPT PHARMACOL, SHOWA KU, NAGOYA 466, JAPAN; NAGOYA UNIV, SCH MED, DEPT GERIATR, SHOWA KU, NAGOYA 466, JAPAN; NAGOYA UNIV, SCH MED, DEPT ANAT, SHOWA KU, NAGOYA 466, JAPAN; NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 3, SHOWA KU, NAGOYA 466, JAPAN	Nagoya University; Nagoya University; Nagoya University; Nagoya University								ADLER EM, 1991, J NEUROSCI, V11, P1496; ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; BIESIADA E, 1988, CELL BIOL INT REP, V12, P483, DOI 10.1016/0309-1651(88)90140-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; BUFFA R, 1989, HISTOCHEMISTRY, V91, P107, DOI 10.1007/BF00492384; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; DOUBELL AF, 1991, HYPERTENSION, V18, P648, DOI 10.1161/01.HYP.18.5.648; FILIPEK A, 1991, EUR J BIOCHEM, V195, P795, DOI 10.1111/j.1432-1033.1991.tb15768.x; FOREMAN JC, 1973, NATURE, V245, P249, DOI 10.1038/245249a0; GAGLIARDINO JJ, 1980, BIOCHEM J, V192, P919, DOI 10.1042/bj1920919; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HUTTON JC, 1986, CELL CALCIUM, V7, P339, DOI 10.1016/0143-4160(86)90037-0; KRAUSZ Y, 1987, ACTA ENDOCRINOL-COP, V116, P241, DOI 10.1530/acta.0.1160241; KUZNICKI J, 1992, EXP CELL RES, V200, P425, DOI 10.1016/0014-4827(92)90191-A; LINDAU M, 1991, BIOCHIM BIOPHYS ACTA, V1071, P429, DOI 10.1016/0304-4157(91)90006-I; NICAISE G, 1992, BIOL CELL, V75, P89, DOI 10.1016/0248-4900(92)90128-N; NIKI I, 1993, BIOCHEM BIOPH RES CO, V191, P255, DOI 10.1006/bbrc.1993.1210; ONAYA T, 1987, ENDOCRINOL JAPON, V34, P89; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SUGDEN MC, 1979, FEBS LETT, V105, P95, DOI 10.1016/0014-5793(79)80894-7; TAMAGAWA T, 1985, FEBS LETT, V183, P433, DOI 10.1016/0014-5793(85)80825-5; THORDARSON G, 1991, ENDOCRINOLOGY, V129, P1257, DOI 10.1210/endo-129-3-1257; TODOROKI H, 1991, J BIOL CHEM, V266, P18668; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TOKUMITSU H, 1991, ARCH BIOCHEM BIOPHYS, V288, P202, DOI 10.1016/0003-9861(91)90184-K; UCHIDA T, 1989, CELL TISSUE RES, V255, P379; WETERMAN MAJ, 1992, CANCER RES, V52, P1291; WOOD L, 1991, J INVEST DERMATOL, V96, P383, DOI 10.1111/1523-1747.ep12466230	31	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6149	6152						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119959				2022-12-25	WOS:A1994MY84000100
J	JACKOWSKI, S				JACKOWSKI, S			COORDINATION OF MEMBRANE PHOSPHOLIPID-SYNTHESIS WITH THE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; HAMSTER OVARY CELLS; PROTEIN-KINASE-C; CULTURED RAT HEPATOCYTES; GH3 PITUITARY-CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; FACTOR-I; GROWTH-FACTOR; DIACYLGLYCEROL LEVELS	The formation of membrane phospholipid is coordinated with the cell cycle in a colony-stimulating factor 1-dependent macrophage cell line. Net phospholipid accumulation occurs as cells enter S phase and results from an interaction between cell cycle-dependent oscillations in the rates of phosphatidylcholine (PtdCho) biosynthesis and degradation. CTP-phosphocholine cytidylyltransferase (CT) is the rate-controlling step in PtdCho biosynthesis, and its activity is inhibited by cell cycle-dependent phosphorylation. CT phosphorylation is low in early G1, begins to rise in late G1, increases steadily through S and G2/M, and then declines precipitously as cells exit mitosis and reenter G1. CT activity increases in early G1 and then decreases steadily as the cells progress through late G1, S, and G2/M, reflecting the elevated phosphorylation state of the protein. Membrane phospholipid degradation is also periodic: the rate is rapid in G1, slows significantly during S phase, and accelerates again as cells reenter G1. The data support the hypothesis that CT dephosphorylation accelerates PtdCho synthesis in response to the increased membrane phospholipid degradation to maintain membrane phospholipid mass during G1 and that the periodic cessation of phospholipid degradation during S phase accounts for the transition to net membrane phospholipid accumulation. Inactivation of CT associated with hyper-phosphorylation of the protein during G2/M likely plays a determining role in the cessation of net membrane accumulation prior to cell division.	UNIV TENNESSEE CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	JACKOWSKI, S (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.		Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOUDHURY GG, 1991, FEBS LETT, V282, P351, DOI 10.1016/0014-5793(91)80511-Z; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; COTTRELL SF, 1981, J BIOL CHEM, V256, P973; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ESKO JD, 1981, J BIOL CHEM, V256, P7388; EXTON JH, 1990, J BIOL CHEM, V265, P1; GALLAGHER S, 1988, CURRENT PROTOCOLS MO; GROSS G, 1988, BIOCHIM BIOPHYS ACTA, V962, P220, DOI 10.1016/0005-2760(88)90163-4; HABENICHT AJR, 1985, J BIOL CHEM, V260, P1370; HATCH GM, 1992, J BIOL CHEM, V267, P15751; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; JACKOWSKI S, 1990, J BIOL CHEM, V265, P6611; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JONES GA, 1992, ARCH BIOCHEM BIOPHYS, V288, P331; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KOFF A, 1992, EMBO J, V11, P961; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KOLESNICK RN, 1990, BIOCHEM J, V267, P17, DOI 10.1042/bj2670017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; MATOZAKI T, 1991, J BIOL CHEM, V266, P22246; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORAND JN, 1989, J BIOL CHEM, V264, P13785; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; OKUDA T, 1992, ONCOGENE, V7, P2249; ONEILL EA, 1987, J BACTERIOL, V169, P2618, DOI 10.1128/jb.169.6.2618-2623.1987; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P447, DOI 10.1016/0005-2760(84)90171-1; PELECH SL, 1982, J BIOL CHEM, V257, P4198; PELECH SL, 1981, J BIOL CHEM, V256, P8283; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PRIESS J, 1986, J BIOL CHEM, V261, P8597; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; STANLEY ER, 1978, NATURE, V274, P168, DOI 10.1038/274168a0; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TUSHINISKI RJ, 1985, J CLEL PHYSL, V122, P71; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE DE, 1984, TRENDS BIOCHEM SCI, V9, P17, DOI 10.1016/0968-0004(84)90041-0; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; VARIO G, 1991, IMMUNOL TODAY, V12, P362; VEIS N, 1991, J CELL PHYSIOL, V147, P298, DOI 10.1002/jcp.1041470215; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YAO ZM, 1990, J BIOL CHEM, V265, P4326	78	244	248	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3858	3867						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106431				2022-12-25	WOS:A1994MV63100106
J	MATZARIS, M; JACKSON, SP; LAXMINARAYAN, KM; SPEED, CJ; MITCHELL, CA				MATZARIS, M; JACKSON, SP; LAXMINARAYAN, KM; SPEED, CJ; MITCHELL, CA			IDENTIFICATION AND CHARACTERIZATION OF THE PHOSPHATIDYLINOSITOL-(4,5)-BISPHOSPHATE 5-PHOSPHATASE IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; INOSITOL POLYPHOSPHATE-5-PHOSPHATASE; HUMAN-ERYTHROCYTES; PHOSPHOLIPASE-C; RAT-BRAIN; 4,5-BISPHOSPHATE; PURIFICATION; PHOSPHOMONOESTERASE; 4-PHOSPHATE; PHOSPHATE	Phosphatidylinositol (4,5)-bisphosphate (PtdIns(4,5)P2) is the precursor of several second messenger molecules. In unstimulated cells PtdIns(4,5)P2 is hydrolyzed by a PtdIns(4,5)P2 5-phosphatase to form phosphatidylinositol 4-phosphate (PtdIns(4)P) which is subsequently recycled to phosphatidylinositol. PtdIns(4,5)P2 5-phosphatase activity was detected in platelet cytosolic and particulate fractions. The platelet Ptdins(4,5)P2 5-phosphatase activity was magnesium but not calcium dependent. The elution profile of platelet cytosolic PtdIns(4,5)P2 5-phosphatase from anion exchange resins, exactly matched that of the 75-kDa inositol-polyphosphate 5-phosphatase (Ins(1,4,5)P3 5-phosphatase). The latter is a signal terminating enzyme responsible for the hydrolysis of inositol (1,4,5)-trisphosphate (Ins(1,4,5)Ps) to inositol (1,4)-bisphosphate (Mitchell, C. A., Connolly, T. M., and Majerus, P. W. (1989) J. Biol. Chem. 264, 8873-8877). Polyclonal antibodies raised against recombinant 75-kDa Ins(1,4,5)P3 5-phosphatase specifically immunoprecipitated all PtdIns(4,5)P2 5-phosphatase activity from both the platelet membrane and cytosolic fractions. Purified 75-kDa Ins(1,4,5)Ps 5-phosphatase hydrolyzed PtdIns(4,5)P2 forming PtdIns(4)P (K(m) = 250 muM). By contrast, purified membrane-associated 43-kDa Ins(1,4,5)P3 5-phosphatase did not hydrolyze Ptdins(4,5)P2. In the unstimulated platelet, recycling of PtdIns(4,5)P2 to PtdIns(4)P is mediated by the 75-kDa Ins(1,4,5)P3 5-phosphatase.	BOX HILL HOSP,MONASH MED SCH,DEPT MED,NELSON RD,MELBOURNE 3128,AUSTRALIA	Box Hill Hospital; Monash University				Mitchell, Christina A/0000-0001-9372-3192; Jackson, Shaun/0000-0002-4750-1991				ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; Baenziger N L, 1974, Methods Enzymol, V31, P149; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V341, P194; BROCKERHOFF H, 1962, J BIOL CHEM, V237, P1764; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CONNOLLY TM, 1986, J BIOL CHEM, V261, P122; COOPER PH, 1975, BIOCHEM J, V150, P537, DOI 10.1042/bj1500537; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HOKIN LE, 1961, NATURE, V189, P836, DOI 10.1038/189836a0; JAMNEY PA, 1989, J BIOL CHEM, V264, P4825; JAMNEY PA, 1992, J BIOL CHEM, V267, P11818; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; KING CE, 1989, BIOCHEM J, V259, P893, DOI 10.1042/bj2590893; KING CE, 1987, BIOCHEM J, V244, P209, DOI 10.1042/bj2440209; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; MACK SE, 1984, J LIPID RES, V25, P75; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MULLER E, 1986, BIOCHEM J, V235, P775; NIJJAR MS, 1977, BIOCHIM BIOPHYS ACTA, V480, P390, DOI 10.1016/0005-2744(77)90032-8; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PALMER FBS, 1990, BIOCHEM CELL BIOL, V68, P800; PALMER FBS, 1994, J BIOL CHEM, V269, P3403; PALMER FBSC, 1976, BIOCHIM BIOPHYS ACTA, V441, P477, DOI 10.1016/0005-2760(76)90244-7; ROACH PD, 1981, BIOCHIM BIOPHYS ACTA, V661, P323, DOI 10.1016/0005-2744(81)90021-8; ROSS TS, 1991, J BIOL CHEM, V266, P20283; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; STREB H, 1985, J BIOL CHEM, V260, P7309; SUN GY, 1990, METHODS INOSITIDE RE, P153; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; VEDIA LMM, 1986, J BIOL CHEM, V261, P10493	41	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3397	3402						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106379				2022-12-25	WOS:A1994MV63100042
J	VANDERMEER, JR; ROLLEMA, HS; SIEZEN, RJ; BEERTHUYZEN, MM; KUIPERS, OP; DEVOS, WM				VANDERMEER, JR; ROLLEMA, HS; SIEZEN, RJ; BEERTHUYZEN, MM; KUIPERS, OP; DEVOS, WM			INFLUENCE OF AMINO-ACID SUBSTITUTIONS IN THE NISIN LEADER PEPTIDE ON BIOSYNTHESIS AND SECRETION OF NISIN BY LACTOCOCCUS-LACTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPEPTIDE SEQUENCE; LANTIBIOTIC NISIN; ANTIBIOTIC NISIN; GENE; PROTEIN; CLONING; EXPRESSION; PRECURSOR; PEP5	Structural genes for small lanthionine-containing antimicrobial peptides, known as lantibiotics, encode N-terminal leader sequences which are not present in the mature peptide, but are cleaved off at some stage in the maturation process. Leader sequences of the different lantibiotics share a number of identical amino acid residues, but they are clearly different from sec-dependent protein export signal sequences. We studied the role of the leader sequence of the lantibiotic nisin, which is produced and secreted by Lactococcus lactis, by creating site-directed mutations at various positions in the leader peptide sequence. Mutations at Arg-1 and Ala-4, but not at the conserved Pro-2, strongly affected the processing of the leader sequence and resulted in the extracellular accumulation of a biologically inactive precursor peptide. Amino acid analysis and H-1 NMR studies indicated that the precursor peptide with an Ala-4 --> Asp mutation contained a modified nisin structural part with the (mutated) unmodified leader sequence still attached to it. The Ala-4 --> Asp precursor peptide could be activated in vitro by enzymatic cleavage with trypsin, liberating nisin. These results confirmed that cleavage of the leader peptide is the last step in nisin maturation and is necessary to generate a biologically active peptide. Several mutations, i.e. Pro-2 --> Gly, Pro-2 --> Val, Asp-7 --> Ala, Lys-9 --> Leu, Ser-10 --> Ala/Ser-12 --> Ala and Val-11 --> Asp/Val-13 --> Glu in the leader peptide did not have any detectable effect on nisin production and secretion, although some of them affected highly conserved residues. When mutations were created in the -18 to -15 region of the nisin leader peptide (i.e. Phe-18 --> Leu, Leu-16 --> Lys, Asp-15 --> Ala), no secretion or intracellular accumulation could be detected of nisin or its precursors. This suggested that these conserved residues are involved in the maturation process and may interact with lantibiotic-specific modifying enzymes.	NIZO, DEPT BIOPHYS CHEM, POB 20, 6710 BA EDE, NETHERLANDS	NIZO Food Research			Siezen, Roland J/P-5745-2015; van der Meer, Jan Roelof/G-6610-2012; Kuipers, Oscar/B-6752-2009	van der Meer, Jan Roelof/0000-0003-1485-3082; Kuipers, Oscar/0000-0001-5596-7735				BANERJEE S, 1988, J BIOL CHEM, V263, P9508; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHAN WC, 1989, FEBS LETT, V252, P29, DOI 10.1016/0014-5793(89)80884-1; DEVOS WM, 1993, APPL ENVIRON MICROB, V59, P213, DOI 10.1128/AEM.59.1.213-218.1993; DEVUYST L, 1992, J GEN MICROBIOL, V138, P571, DOI 10.1099/00221287-138-3-571; DODD HM, 1990, J GEN MICROBIOL, V136, P555, DOI 10.1099/00221287-136-3-555; ENGELKE G, 1992, APPL ENVIRON MICROB, V58, P3730, DOI 10.1128/AEM.58.11.3730-3743.1992; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; JUNG G, 1991, ANGEW CHEM, V103, P1067, DOI DOI 10.1002/ANGE.19911030904; KALETTA C, 1989, J BACTERIOL, V171, P1597, DOI 10.1128/jb.171.3.1597-1601.1989; KALETTA C, 1989, ARCH MICROBIOL, V152, P16, DOI 10.1007/BF00447005; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; KUIPERS OP, 1993, FEBS LETT, V330, P23, DOI 10.1016/0014-5793(93)80911-D; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; MULDERS JWM, 1991, EUR J BIOCHEM, V201, P581, DOI 10.1111/j.1432-1033.1991.tb16317.x; RAUCH PJG, 1992, J BACTERIOL, V174, P1280, DOI 10.1128/jb.174.4.1280-1287.1992; Sambrook J, 1989, MOL CLONING LAB MANU, V1 and 3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SIEZEN RJ, 1993, IN PRESS SUBTILISIN; STEEN MT, 1991, APPL ENVIRON MICROB, V57, P1181, DOI 10.1128/AEM.57.4.1181-1188.1991; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; VANROOIJEN RJ, 1990, J BIOL CHEM, V265, P18499; WEIL HP, 1990, EUR J BIOCHEM, V194, P217, DOI 10.1111/j.1432-1033.1990.tb19446.x	27	135	139	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3555	3562						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106398				2022-12-25	WOS:A1994MV63100066
J	PUPA, SM; MENARD, S; MORELLI, D; POZZI, B; DEPALO, G; COLNAGHI, MI				PUPA, SM; MENARD, S; MORELLI, D; POZZI, B; DEPALO, G; COLNAGHI, MI			THE EXTRACELLULAR DOMAIN OF THE C-ERBB-2 ONCOPROTEIN IS RELEASED FROM TUMOR-CELLS BY PROTEOLYTIC CLEAVAGE	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; HUMAN-BREAST-CARCINOMA; PLASMINOGEN-ACTIVATOR ACTIVITY; EGF RECEPTOR; MONOCLONAL-ANTIBODIES; PROTO-ONCOGENE; TRUNCATED RECEPTOR; MAMMARY-TUMOR; CATHEPSIN-B	A molecule that is immunologically related to the c-erbB-2 oncogene product (p185HER2/neu) was detected in the conditioned culture medium from neu-overexpressing tumor cell lines and in sera of advanced-stage breast carcinoma patients. Using a sensitive (in the range of 0.5 ng ml-1) double-determinant radioimmunoassay (DDIRMA) with two monoclonal antibodies (MAbs) directed against the neu extracellular domain (ECD), soluble oncoproteins were detected in supernatants from several neu-positive tumor cell lines, independent of the levels of membrane p185HER2 expression. The molecule detected did not react with a MAb directed against an intracytoplasmic epitope of the p185HER2. Western blot analysis of the concentrated supernatant revealed a protein of approximately 110 kDa molecular mass, which closely matches the predicted size of the glycosylated p185HER2 ECD. Immunoprecipitation of culture supernatant from cell surface-radioiodinated cells confirmed the 110 kDa molecular mass of the glycosylated shed protein, which migrated to 86 kDa after deglycosylation. Proteolytic cleavage of the p185HER2 molecule was demonstrated in release assays carried out with protease inhibitors. The combined use of leupeptin and EDTA completely inhibited release of the molecule. Analysis of sera from breast carcinoma patients and healthy donors by DDIRMA revealed the presence of soluble neu in 15% of pathologic sera but none of the normal sera. A good correlation was found between neu-overexpression in the primary tumor and the soluble marker in serum of patients with advanced disease; sera of early-stage patients were always negative, independent of neu-overexpression in the tumor. These results suggest the usefulness of soluble neu as an indicator of tumor aggressiveness but not as a diagnostic marker of breast cancer.	IST NAZL TUMORI,DIV DIAGNOST SURG,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	PUPA, SM (corresponding author), IST NAZL TUMORI,DIV EXPTL ONCOL E,VIA G VENEZIAN 1,I-20133 MILAN,ITALY.		Pupa, Serenella/K-6388-2016; Morelli, Daniele/I-4113-2017; menard, sylvie mm/C-7940-2011	Pupa, Serenella/0000-0002-4592-6830; Morelli, Daniele/0000-0002-1823-3764; 				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ALPER O, 1990, CELL GROWTH DIFFER, V1, P591; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; CARNEY W P, 1991, Journal of Tumor Marker Oncology, V6, P53; CENTIS F, 1992, HYBRIDOMA, V11, P267, DOI 10.1089/hyb.1992.11.267; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Diotti A, 1987, Int J Biol Markers, V2, P161; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EISEMANN A, 1991, ONCOGENE, V6, P1195; ETO I, 1992, BIOCHEM J, V283, P209, DOI 10.1042/bj2830209; EVERS JL, 1982, CANCER RES, V42, P219; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; KAMITANI H, 1992, Neurological Research, V14, P236; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGTON BC, 1991, CANCER RES, V51, P2593; LEITZEL K, 1992, J CLIN ONCOL, V10, P1436, DOI 10.1200/JCO.1992.10.9.1436; LIN YZJ, 1991, ONCOGENE, V6, P639; MAIER LA, 1991, CANCER RES, V51, P5361; MARIANICOSTANTINI R, 1984, VIRCHOWS ARCH A, V402, P389, DOI 10.1007/BF00734636; MENARD S, 1983, CANCER RES, V43, P1295; MORI S, 1990, JPN J CANCER RES, V81, P489, DOI 10.1111/j.1349-7006.1990.tb02596.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NYGREN PA, 1988, J MOL RECOG, V1, P540; PARK JB, 1989, CANCER RES, V49, P6605; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; POOLE AR, 1978, NATURE, V273, P545, DOI 10.1038/273545a0; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RECKLIES AD, 1982, BIOCHEM J, V207, P633, DOI 10.1042/bj2070633; RECKLIES AD, 1980, CANCER RES, V40, P550; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SAINSBURY JRC, 1987, LANCET, V1, P1398; SHI ZR, 1983, CANCER RES, V43, P4045; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUTHERLAND DJA, 1980, JNCI-J NATL CANCER I, V64, P3; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; THORSEN T, 1982, EUR J CANCER CLIN ON, V18, P129, DOI 10.1016/0277-5379(82)90055-4; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WALDMANN TA, 1985, CANCER RES, V45, P4559; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	53	138	147	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2917	2923						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8105438				2022-12-25	WOS:A1993MC09300004
J	WATANABE, T; KOBORI, K; MIYASHITA, K; FUJII, T; SAKAI, H; UCHIDA, M; TANAKA, H				WATANABE, T; KOBORI, K; MIYASHITA, K; FUJII, T; SAKAI, H; UCHIDA, M; TANAKA, H			IDENTIFICATION OF GLUTAMIC ACID-204 AND ASPARTIC ACID-200 IN CHITINASE-A1 OF BACILLUS-CIRCULANS WL-12 AS ESSENTIAL RESIDUES FOR CHITINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; LYSOZYME CHITINASE; STREPTOMYCES; GENES; HOMOLOGY; ENZYME; SITE; PURIFICATION; MUTAGENESIS; MEMBRANE	Prokaryotic chitinases, class III plant chitinases, yeast chitinases, and endo-beta-N-acetylglucosaminidases share weak amino acid sequence similarities at the certain region of each enzyme. These regions have been assumed to be important for catalytic activities of the enzymes. To verify this assumption, three amino acid residues (Ser-160, Asp-200, Glu-204) in chitinase A1 of Bacillus circulans WL-12 were chosen, based on the amino acid sequence alignment of the regions sharing sequence similarity, and were replaced by site-directed mutagenesis. Kinetic parameters for 4-methylumbelliferyl-N,N',N''-triacetylchitotriose hydrolysis were determined with wild-type and seven mutant chitinases. Chitinases with Glu-204 --> Gln mutation and Glu-204 --> Asp mutation were essentially inactive and k(cat) values of these chitinases were approximately 1/5,000 and 1/17,000 of that of wild-type chitinase, respectively. Asp-200 --> Asn mutation decreased the k(cat) value to approximately 1/350 of that of the wild-type enzyme, while the K(m) value decreased only slightly. On the other hand, neither the k(cat) value nor the K(m) value was affected by Asp-200 --> Glu mutation. Thus, it appeared that Glu-204 and Asp-200 are directly involved in the catalytic events of chitinase A1. The role of the carboxyl group of Asp-200 can be fully substituted by that of Glu residue. The Ser-160 --> Ala mutant retained 10% activity of the wild-type chitinase indicating that the hydroxyl group of Ser-160 is not absolutely required for the catalytic activity. These results indicate a lysozyme-type catalytic mechanism of the chitinase.	NATL INST AGROENVIRONM SCI,TSUKUBA 305,JAPAN; UNIV TOKYO,FAC AGR,DEPT AGR CHEM,BUNKYO KU,TOKYO 113,JAPAN	National Institute for Agro-Environmental Sciences (NIAES) Japan; University of Tokyo	WATANABE, T (corresponding author), NIIGATA UNIV,FAC AGR,DEPT APPL BIOL CHEM,8050 IKARASHI 2,NIIGATA 95021,JAPAN.							ABELES FB, 1970, PLANT PHYSIOL, V47, P129; AMES GFL, 1974, J BIOL CHEM, V249, P634; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; Boller T, 1985, CELLULAR MOL BIOL PL, P247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; HARPSTER MH, 1989, NUCLEIC ACIDS RES, V17, P5396; HENRISSAT B, 1990, Protein Sequences and Data Analysis, V3, P523; IMOTO T, 1971, AGR BIOL CHEM TOKYO, V35, P1154, DOI 10.1080/00021369.1971.10860050; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; Jeuniaux C., 1966, METHOD ENZYMOL, V8, P644, DOI [DOI 10.1016/0076-6879(66)08117-5, 10.1016/0076-6879(66)08117-5]; JONES JDG, 1986, EMBO J, V5, P467, DOI 10.1002/j.1460-2075.1986.tb04235.x; KAMEI K, 1989, J BIOCHEM-TOKYO, V105, P979, DOI 10.1093/oxfordjournals.jbchem.a122791; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWYTON K, 1992, PLANT MOL BIOL, V19, P735; LIN TY, 1969, J BIOL CHEM, V244, P505; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; METRAUX JP, 1989, P NATL ACAD SCI USA, V86, P896, DOI 10.1073/pnas.86.3.896; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; PRICE JS, 1975, J BACTERIOL, V124, P1574, DOI 10.1128/JB.124.3.1574-1585.1975; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; SAMAC DA, 1990, PLANT PHYSIOL, V93, P907, DOI 10.1104/pp.93.3.907; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINSHI H, 1990, PLANT MOL BIOL, V14, P357, DOI 10.1007/BF00028772; STARK MJR, 1990, YEAST, V6, P1, DOI 10.1002/yea.320060102; TAKEGAWA K, 1991, EUR J BIOCHEM, V202, P175, DOI 10.1111/j.1432-1033.1991.tb16359.x; TSUJIBO H, 1993, J BACTERIOL, V175, P176, DOI 10.1128/JB.175.1.176-181.1993; VERBURG JG, 1992, J BIOL CHEM, V267, P3886; WATANABE T, 1992, J BACTERIOL, V174, P408, DOI 10.1128/jb.174.2.408-414.1992; WATANABE T, 1990, J BACTERIOL, V172, P4017, DOI 10.1128/jb.172.7.4017-4022.1990; WATANABE T, 1990, J BIOL CHEM, V265, P15659; YAMADA H, 1981, CARBOHYD RES, V92, P160, DOI 10.1016/S0008-6215(00)85993-5; YANAI K, 1992, J BACTERIOL, V174, P7398, DOI 10.1128/jb.174.22.7398-7406.1992	36	329	351	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18567	18572						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	8103047				2022-12-25	WOS:A1993LV65900032
J	ZHANG, JT; DUTHIE, M; LING, V				ZHANG, JT; DUTHIE, M; LING, V			MEMBRANE TOPOLOGY OF THE N-TERMINAL HALF OF THE HAMSTER P-GLYCOPROTEIN MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MULTIDRUG RESISTANCE; HOMOLOGY; ORIENTATION; GENE	P-glycoprotein (Pgp) is a tandemly duplicated plasma membrane protein containing 12 predicted transmembrane (TM) segments and two cytoplasmic ATP-binding domains. Pgp appears to be responsible for multidrug resistance in cancer cells. A detailed knowledge of the topological structure of Pgp will be required for understanding its mechanism of action. Previously, we have investigated the membrane orientation of Pgp using a cell free translation/translocation system supplemented with canine pancreatic microsomal membranes. We observed unexpectedly that the C-terminal half of the Pgp molecules was present in two different topological orientations (Zhang, J.-T., and Ling, V. (1991) J. Biol. Chem. 266, 18224-18232). In the present study, using a similar approach, we have investigated in detail the topological structure of the N-terminal half of the Pgp molecule. Again, two orientations were observed. One has all six predicted TM segments in the membrane bilayer, the other has only four TM segments in the bilayer with predicted TM3 and TM5 in a cytoplasmic and extracellular location, respectively. Although the primary sequence of Pgp appears to be a tandem duplication, the new topological structure of N-terminal half is not a simple tandem duplication of that in the C-terminal half. Thus it appears that the insertion and orientation of Pgp TM segments are dictated by specific localized sequences. These results, together with our previous findings, raise the possibility that Pgp in the native membrane may be present in different topological orientations and this feature may be important for its function.	UNIV TORONTO, DEPT MED BIOPHYS,ONTARIO CANC INST, DIV MOLEC & STRUCT BIOL,500 SHERBOURNE ST, TORONTO M4X 1K9, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto			Zhang, Jian-Ting/L-8334-2015		NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37130] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BRANDOLIN G, 1989, BIOCHEMISTRY-US, V28, P1093, DOI 10.1021/bi00429a025; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Stein W., 1990, CHANNELS CARRIERS PU; Vignais P. V., 1985, STRUCTURE PROPERTIES, V2, P139; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	18	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15101	15110						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8100818				2022-12-25	WOS:A1993LL75900082
J	MAENAKA, K; KAWAI, G; WATANABE, K; SUNADA, F; KUMAGAI, I				MAENAKA, K; KAWAI, G; WATANABE, K; SUNADA, F; KUMAGAI, I			FUNCTIONAL AND STRUCTURAL ROLE OF A TRYPTOPHAN GENERALLY OBSERVED IN PROTEIN-CARBOHYDRATE INTERACTION - TRP-62 OF HEN EGG-WHITE LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-1-NMR SPECTRA; BINDING; RESOLUTION; SPECTROSCOPY; SUBSTRATE; RESIDUES; COMPLEX; SITE	In order to elucidate the role of the aromatic ring in recognition of the sugar ring, Trp-62 of hen egg white lysozyme, which is proposed on the basis of x-ray crystallography data to make contact with a sugar ring through van der Waals interaction, was replaced with aliphatic amino acids (Leu, Ile, Val, and Ala) and Gly by site-directed mutagenesis. In spite of the loss of the aromatic effect, these mutant lysozymes, except for the Trp-62 --> Gly mutant, showed higher bacteriolytic activity than the wild-type lysozyme. Furthermore, the Trp-62 --> Gly mutant still retained appreciable bacteriolytic activity. On the other hand, by these replacements, the enzymatic activities toward non-charged substrates were markedly reduced. Additionally, the side-chain structure of position 62 was found to be largely responsible for recognition of a saccharide ring in its active site cleft. NMR analysis of the Trp-62 --> Leu and Trp-62 -->, Gly mutants indicated that the structural effects of Trp-62 replacements were localized in the loop region around position 62 and the part of the beta-sheet containing the hydrogen bonding network important for enzymatic activity. Thus, we conclude that Trp-62 not only interacts with oligosaccharide through van der Waals contact, but also maintains the local structural conformation to produce the lysozyme-oligosaccharide interaction.	UNIV TOKYO, FAC ENGN, DEPT IND CHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								ARCHER DB, 1990, BIO-TECHNOL, V8, P741, DOI 10.1038/nbt0890-741; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BLAKE CCF, 1981, J MOL BIOL, V147, P73, DOI 10.1016/0022-2836(81)90080-2; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; CHEETHAM JC, 1992, J MOL BIOL, V224, P613, DOI 10.1016/0022-2836(92)90548-X; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FUKAMIZO T, 1992, EUR J BIOCHEM, V210, P351, DOI 10.1111/j.1432-1033.1992.tb17428.x; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HAYASHI K, 1965, J BIOCHEM-TOKYO, V58, P227, DOI 10.1093/oxfordjournals.jbchem.a128190; IMOTO T, 1971, AGR BIOL CHEM TOKYO, V35, P1154, DOI 10.1080/00021369.1971.10860050; Imoto T., 1972, ENZYMES, V7, P665; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; JOLLES P, 1984, MOL CELL BIOCHEM, V63, P165; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAGAI I, 1989, J BIOCHEM-TOKYO, V105, P946, DOI 10.1093/oxfordjournals.jbchem.a122784; KUMAGAI I, 1992, J BIOL CHEM, V267, P4608; KUMAGAI I, 1993, EUR J BIOCHEM, V212, P151, DOI 10.1111/j.1432-1033.1993.tb17645.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER GL, 1950, ARCH BIOCHEM, V29, P420; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; NANJO F, 1988, J BIOCHEM-TOKYO, V104, P255, DOI 10.1093/oxfordjournals.jbchem.a122453; PARRY RM, 1965, P SOC EXP BIOL MED, V119, P384; QUIOCHO FA, 1988, CURR TOP MICROBIOL, V139, P135; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REDFIELD C, 1988, BIOCHEMISTRY-US, V27, P122, DOI 10.1021/bi00401a020; SMITH LJ, 1993, J MOL BIOL, V229, P930, DOI 10.1006/jmbi.1993.1097; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; UEDA T, 1990, J BIOCHEM-TOKYO, V108, P886, DOI 10.1093/oxfordjournals.jbchem.a123297; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YAMADA H, 1985, ANAL BIOCHEM, V146, P71, DOI 10.1016/0003-2697(85)90397-5; YAMASAKI N, 1976, J BIOCHEM-TOKYO, V80, P409, DOI 10.1093/oxfordjournals.jbchem.a131292	35	55	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7070	7075						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125914				2022-12-25	WOS:A1994NA03200007
J	SCHWABE, M; ZHAO, J; KUNG, HF				SCHWABE, M; ZHAO, J; KUNG, HF			DIFFERENTIAL EXPRESSION AND LIGAND-INDUCED MODULATION OF THE HUMAN INTERLEUKIN-6 RECEPTOR ON INTERLEUKIN-6-RESPONSIVE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-6 SIGNAL TRANSDUCER; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR; INTERFERON RECEPTOR; BREAST-CARCINOMA; MULTIPLE-MYELOMA; RAT HEPATOCYTES; DOWN-REGULATION; GAMMA-RECEPTOR; IFN-GAMMA	The human interleukin-6 receptor (IL-6) was differentially expressed on IL-6-dependent (U266 and SKO-007) and -independent (RPMI8226) myeloma cells as well as melanoma cells (A375-C6) that are growth-inhibited by IL-6. U266 and SKO-007 cells expressed four distinct IL-6R complexes (molecular masses of 100, 120, 145, and 165 kDa) as revealed by affinity cross-linking of iodinated IL-6. RPMI8226 and A375-C6 cells primarily expressed the 165-kDa complex relative to the others. Immunoprecipitation and antibody competition studies showed that the 100- and 120-kDa complexes contained the gp80 subunit, whereas the 145- and 165-kDa complexes contained the gp130 subunit of the IL-6R. Assay solubilized U266 plasma membrane proteins by affinity cross-linking or ligand blotting revealed that only gp80 bound IL-6 specifically. Induction of an IL-6 response was associated with ligand-induced down-regulation of gp130 and was inhibited by neutralizing antin-IL-6 antibodies. Furthermore, the relative ratios of gp80 to gp130 determined the binding kinetics of the IL-6R, yielding high- and low affinity binding sites by Scatchard plots. Our data imply that distinct IL-6 bioactivities are based upon the differential expression and regulation by IL-6 of its ligand binding (gp80) and signal-transducing (gp130) receptor subunits.			SCHWABE, M (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,BIOCHEM PHYSIOL LAB,BIOL RESPONSE MODIFIERS PROGRAM,BLDG 560,FREDERICK,MD 21701, USA.							Aarden L, 1985, LYMPHOKINES, V10, P175; BAUER J, 1989, J EXP MED, V170, P1537, DOI 10.1084/jem.170.5.1537; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRANCA AA, 1986, J INTERFERON RES, V6, P305, DOI 10.1089/jir.1986.6.305; BRANCA AA, 1982, J BIOL CHEM, V257, P13197; CHEN L, 1988, P NATL ACAD SCI USA, V85, P8037, DOI 10.1073/pnas.85.21.8037; COULIE PG, 1987, EUR J IMMUNOL, V17, P1435, DOI 10.1002/eji.1830171008; DALESSANDRO F, 1993, J BIOL CHEM, V268, P2149; FALTYNEK CR, 1990, J INTERFERON RES, V10, P55, DOI 10.1089/jir.1990.10.55; FALTYNEK CR, 1986, J IMMUNOL, V136, P4134; FALTYNEK CR, 1986, J INTERFERON RES, V6, P639, DOI 10.1089/jir.1986.6.639; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HIRATA Y, 1989, J IMMUNOL, V143, P2900; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LEVY Y, 1991, J CLIN INVEST, V88, P696, DOI 10.1172/JCI115355; LIU JW, 1992, J BIOL CHEM, V267, P16763; LOKESHWAR VB, 1989, J BIOL CHEM, V264, P19318; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; MAY LT, 1991, J BIOL CHEM, V266, P9950; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NESBITT JE, 1992, MOL BIOL CELL, V3, P103, DOI 10.1091/mbc.3.1.103; NESBITT JE, 1992, J BIOL CHEM, V267, P5739; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; PIETZKO D, 1993, J BIOL CHEM, V268, P4250; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; SANCEAU J, 1991, J IMMUNOL, V147, P2630; SCHWAB G, 1991, BLOOD, V77, P587; SCHWABE M, 1988, EUR J IMMUNOL, V18, P2009, DOI 10.1002/eji.1830181221; SEHGAL PB, 1990, J INVEST DERMATOL, V94, pS2, DOI 10.1111/1523-1747.ep12874963; SHALABY MR, 1989, CELL IMMUNOL, V121, P372, DOI 10.1016/0008-8749(89)90036-1; SIDELL N, 1991, J IMMUNOL, V146, P3809; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAMM I, 1991, P NATL ACAD SCI USA, V88, P4414, DOI 10.1073/pnas.88.10.4414; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WONG GG, 1988, IMMUNOL TODAY, V9, P137, DOI 10.1016/0167-5699(88)91200-5; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XG, 1989, BLOOD, V74, P11	54	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7201	7209						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125932				2022-12-25	WOS:A1994NA03200028
J	COOK, JR; EMANUEL, SL; DONNELLY, RJ; SOH, JM; MARIANO, TM; SCHWARTZ, B; RHEE, SJ; PESTKA, S				COOK, JR; EMANUEL, SL; DONNELLY, RJ; SOH, JM; MARIANO, TM; SCHWARTZ, B; RHEE, SJ; PESTKA, S			SUBLOCALIZATION OF THE HUMAN INTERFERON-GAMMA RECEPTOR ACCESSORY FACTOR GENE AND CHARACTERIZATION OF ACCESSORY FACTOR ACTIVITY BY YEAST ARTIFICIAL CHROMOSOMAL FRAGMENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DINUCLEOTIDE REPEAT POLYMORPHISMS; HUMAN FIBROBLAST INTERFERON; HUMAN IMMUNE INTERFERON; MOLECULAR CHARACTERIZATION; TYROSINE PHOSPHORYLATION; HAMSTER-CELLS; EXPRESSION; ALPHA; TRANSCRIPTION; PURIFICATION	A chromosomal fragmentation procedure was employed to produce a deletion set of yeast artificial chromosomes (YACs) from a parental YAC, CART D142H8, known to map to human chromosome 21q and to encode the human interferon-gamma receptor (Hu-IFN-gamma R) accessory factor gene as well as the phosphoribosylglycinamide formyltransferase (CART) gene. When expressed in Chinese hamster ovary cells, these deleted YACs retain accessory factor activity, as judged by major histocompatibility complex class I antigen inducibility, until the deletions from the acentric end exceed 390 kilobases (kb). Therefore, the accessory factor (AF-1) gene can be localized to a 150-kb region at the left (centric) end of the parental 540-kb GART YAC. Cells containing functional YACs are also able to induce the ISGF3 gamma and gamma-activated factor (GAF) transcription factors, but were not protected against encephalomyocarditis virus (EMCV) upon treatment with Hu-IFN-gamma. Therefore, the Hu-IFN-gamma R and the AF-1 are sufficient for some, but not all, of the actions of Hu-IFN-gamma. We postulate that an additional accessory factor (AF-2) required for antiviral activity against EMCV is encoded on chromosome 21q.			COOK, JR (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854, USA.				NATIONAL CANCER INSTITUTE [R01CA046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007403] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA46465] Funding Source: Medline; NIAID NIH HHS [T32 AI07403] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; CHENG S, 1993, MAMM GENOME, V4, P338, DOI 10.1007/BF00357094; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; COOK JR, 1994, IN PRESS GENET ANAL; DONALDSON DH, 1992, HUM MOL GENET, V1, P651, DOI 10.1093/hmg/1.8.651; Donnelly Robert J., 1992, Journal of Interferon Research, V12, pS216; Familletti P C, 1981, Methods Enzymol, V78, P387; FRIESEN HJ, 1981, ARCH BIOCHEM BIOPHYS, V206, P432, DOI 10.1016/0003-9861(81)90111-9; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11141; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1990, J BIOL CHEM, V265, P1827; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; JUNG V, 1991, THESIS RUTGERS U PIS; KALINA U, 1993, J VIROL, V67, P1702, DOI 10.1128/JVI.67.3.1702-1706.1993; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; KUNG HF, 1986, METHOD ENZYMOL, V119, P204; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P321; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEWIS BC, 1992, GENET ANAL-BIOMOL E, V9, P86, DOI 10.1016/1050-3862(92)90003-N; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; MARIANO TM, 1987, J BIOL CHEM, V262, P5812; MOSCHERA JA, 1986, METHOD ENZYMOL, V119, P177; PAVAN WJ, 1990, P NATL ACAD SCI USA, V87, P1300, DOI 10.1073/pnas.87.4.1300; PAVAN WJ, 1991, GENE, V106, P125, DOI 10.1016/0378-1119(91)90576-W; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; REHBERG E, 1982, J BIOL CHEM, V257, P1497; ROSEN DR, 1992, HUM MOL GENET, V1, P547, DOI 10.1093/hmg/1.7.547; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANCAMP G, 1990, SOMAT CELL MOLEC GEN, V16, P241	40	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					7013	7018						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120065				2022-12-25	WOS:A1994MZ50300114
J	DE, SK; MARSH, JW				DE, SK; MARSH, JW			HIV-1 NEF INHIBITS A COMMON ACTIVATION PATHWAY IN NIH-3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PHOSPHOLIPASE-C; MESSENGER-RNA; CALCIUM POOLS; T-CELLS; TYPE-1; EXPRESSION; GENE; INDUCTION	The human immunodeficiency virus type 1 (HlV-1) Nef is a myristylated 27-kDa, cytoplasmic protein. It is attributed to have suppressive effects on LTR-based expression and T cell activation. Additionally, SIV nef has been shown to possess an essential in vivo function in the development of immunodeficiency. To define the bio chemical activity of HIV-1 Nef in a signal transduction pathway, we have transduced murine NIH-3T3 cells with a retroviral nef expression system, In nef-expressing cells, but not in controls, the proliferative response to bombesin and platelet-derived growth factor (PDGF) was eliminated. Analysis of an early signal pathway metabolite, inositol l,4,5-trisphosphate following bombesin and PDGF treatment to quiscent cells, revealed that both control and nef-transformed cells displayed similar kinetics of signal formation. Normally, inositol 1,4,5-trisphosphate mediates increase in the cytosolic free Ca2+ ([Ca2+](i)). Upon stimulation with bombesin or PDGF, control cells displayed a 2-4-fold increase of [Ca2+](i) over the basal level, while the [Ca2+](i) response in nef-expressing NIH-3T3 cells was lacking or highly diminished. However, the release of [Ca2+](i) from the intracellular store of the nef-expressing cells by an endomembrane Ca2+ ATPase inhibitor, thapsigargin, revealed that these cells contained normal Ca2+ stores. These results suggest a specific, definable biochemical activity for the HIV-1 Nef protein in the context of a well characterized cellular activation pathway. Our results thus define, for the first time, a unique function of Nef that is not limited to an alteration of T cell function or of expression of a T cell surface antigen.			DE, SK (corresponding author), NIMH,MOLEC BIOL LAB,BLDG 36,RM 1B08,BETHESDA,MD 20892, USA.							AHMED N, 1988, SCIENCE, V241, P1481; AKESON M, 1992, J MEMBRANE BIOL, V125, P81; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIDEN TJ, 1986, J BIOL CHEM, V261, P7223; BLUMBERG BM, 1992, J VIROL, V66, P5256, DOI 10.1128/JVI.66.9.5256-5264.1992; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DE SK, 1990, J BIOL CHEM, V265, P15267; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GARCIA JV, 1993, J VIROL, V67, P1511, DOI 10.1128/JVI.67.3.1511-1516.1993; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; KLOTMAN ME, 1991, P NATL ACAD SCI USA, V88, P5011, DOI 10.1073/pnas.88.11.5011; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MAITRA RK, 1991, VIROLOGY, V182, P522, DOI 10.1016/0042-6822(91)90593-Z; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; RENARD DC, 1992, BIOCHEM J, V281, P775, DOI 10.1042/bj2810775; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F	38	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6656	6660						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120020				2022-12-25	WOS:A1994MZ50300063
J	OTSU, M; OMURA, F; YOSHIMORI, T; KIKUCHI, M				OTSU, M; OMURA, F; YOSHIMORI, T; KIKUCHI, M			PROTEIN DISULFIDE-ISOMERASE ASSOCIATES WITH MISFOLDED HUMAN LYSOZYME IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; PRE-GOLGI; DEGRADATION; SECRETION; COMPONENT; CLEAVAGE; COMPLEX; FAMILY; BONDS	Wild-type human lysozyme (hLZM) is quantitatively secreted into the media when expressed in mouse fibroblast cells, but some misfolded hLZMs are retained and rapidly degraded in a pre-Golgi compartment (Omura, F., Otsu, M., Yoshimori, T., Tashiro, Y., and Kikuchi, M. (1992) Eur. J. Biochem. 210, 591-599). To detect the association with misfolded hLZMs of cellular proteins involved in their folding, retention, and pre-Golgi degradation, a co-precipitation experiment was carried out using anti-hLZM antibody and metabolically labeled cell lysates, which were treated with a membrane-permeable cross-linking reagent. Here we report that protein disulfide isomerase associated in vivo with misfolded hLZMs, but not with the wild-type protein, and discuss the possible role of protein disulfide isomerase in the quality control of newly synthesized proteins in the endoplasmic reticulum.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; KANSAI MED UNIV,DEPT PHYSIOL,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University								AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHAUDHURI MM, 1992, BIOCHEM J, V281, P645, DOI 10.1042/bj2810645; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAYANO T, 1993, FEBS LETT, V328, P203, DOI 10.1016/0014-5793(93)80993-5; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INAKA K, 1991, J BIOL CHEM, V266, P12599; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LE AQ, 1992, J BIOL CHEM, V267, P1072; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OMURA F, 1991, EUR J BIOCHEM, V198, P477, DOI 10.1111/j.1432-1033.1991.tb16038.x; OMURA F, 1992, EUR J BIOCHEM, V205, P551, DOI 10.1111/j.1432-1033.1992.tb16812.x; OMURA F, 1992, EUR J BIOCHEM, V210, P591, DOI 10.1111/j.1432-1033.1992.tb17459.x; PERSSON R, 1991, J CELL BIOL, V112, P257, DOI 10.1083/jcb.112.2.257; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; URADE R, 1992, J BIOL CHEM, V267, P15152; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800	31	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6874	6877						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120049				2022-12-25	WOS:A1994MZ50300095
J	WEINACKER, A; CHEN, A; AGREZ, M; CONE, RI; NISHIMURA, S; WAYNER, E; PYTELA, R; SHEPPARD, D				WEINACKER, A; CHEN, A; AGREZ, M; CONE, RI; NISHIMURA, S; WAYNER, E; PYTELA, R; SHEPPARD, D			ROLE OF THE INTEGRIN ALPHA-V-BETA-6 IN CELL ATTACHMENT TO FIBRONECTIN - HETEROLOGOUS EXPRESSION OF INTACT AND SECRETED FORMS OF THE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-V SUBUNIT; BETA-1 SUBUNIT; MONOCLONAL-ANTIBODIES; VITRONECTIN RECEPTOR; EPITHELIAL-CELLS; SURFACE-ANTIGENS; ADHESION; BINDING; DOMAINS; INTEGRIN-ALPHA-V-BETA-5	The integrin alpha v beta 6 has been shown to be a fibronectin binding protein. To determine whether the cytoplasmic and transmembrane domains of alpha v beta 6 are necessary for binding to fibronectin, a truncated, secreted form of the integrin lacking these domains was engineered and expressed in Chinese hamster ovary cells. Fibronectin affinity chromatography demonstrated that the secreted integrin, like its full-length counterpart, was capable of binding fibronectin. Monoclonal antibodies were made to secreted alpha v beta 6 and to beta 6-transfected NIH 3T3 cells. In experiments designed to determine whether alpha v beta 6 can mediate cell attachment to fibronectin, full-length human beta 6 was expressed in Chinese hamster ovary cells and in the human colon carcinoma cell line SW480. beta 6-expressing cells were identified by alpha v beta 6-specific antibodies, and the beta 6-transfectants were used in cell-adhesion assays, In Chinese hamster ovary cells, human beta 6 associated with hamster alpha v but was incapable of mediating cell attachment to fibronectin. However, expression of beta 6 in these cells had the dominant negative effect of decreasing alpha v beta 5-dependent adhesion to vitronectin. In SW480 cells, beta 6 expression conferred the ability to bind to fibronectin even in the presence of inhibitory antibodies against beta 1 integrins. In such cells, fibronectin binding ability could be blocked by an antibody to alpha v integrins. These results constitute the first direct evidence that alpha v beta 6 mediates cell attachment to fibronectin.	UNIV CALIF SAN FRANCISCO,CTR OCCUPAT & ENVIRONM HLTH,CTR LUNG BIOL,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV NEWCASTLE,CANC RES UNIT,NEWCASTLE,NSW 2300,AUSTRALIA; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Newcastle; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047412, P01HL025816] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47412, HL25816, HL/A133259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; BROWN PJ, 1988, EXP CELL RES, V177, P303, DOI 10.1016/0014-4827(88)90464-8; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHUNTHARAPAI A, 1993, EXP CELL RES, V205, P345, DOI 10.1006/excr.1993.1096; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; DITTEL BN, 1993, BLOOD, V81, P2272; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FRACHET P, 1992, BIOCHEMISTRY-US, V31, P2408, DOI 10.1021/bi00123a028; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; MCDONALD JA, 1989, AM J PHYSIOL, V257, pL331, DOI 10.1152/ajplung.1989.257.6.L331; REAL FX, 1985, CANCER RES, V45, P4401; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	30	230	241	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6940	6948						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120056				2022-12-25	WOS:A1994MZ50300104
J	SAVATIER, P; HUANG, S; SZEKELY, L; WIMAN, KG; SAMARUT, J				SAVATIER, P; HUANG, S; SZEKELY, L; WIMAN, KG; SAMARUT, J			CONTRASTING PATTERNS OF RETINOBLASTOMA PROTEIN EXPRESSION IN MOUSE EMBRYONIC STEM-CELLS AND EMBRYONIC FIBROBLASTS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; SV40 LARGE-T; GENE-PRODUCT; SUSCEPTIBILITY GENE; MOLECULAR-CLONING; RB GENE; E1A-LIKE ACTIVITY; CARCINOMA-CELLS; BINDING PROTEIN; CELLULAR GENES	The expression of the retinoblastoma susceptibility (RB-1) gene was investigated in highly proliferating mouse embryonic stem (ES) cells and in slowly proliferating mouse embryonic fibroblasts. The RIB protein was expressed at the same level in these two cell types. Mainly hyperphosphorylated RB was detected in exponentially-growing ES cells. Embryonic fibroblasts and embryonic stem cells were synchronized by colcemid block followed by mitotic shake-off. In embryonic fibroblasts, DNA replication started 10-15 h after exit from mitosis and RB was transiently dephosphorylated during the G1 phase as previously described. In ES cells, DNA replication started 2h after release from the colcemid block but virtually no hypophosphorylated RB was observed after the release. Instead, there was a dramatic decrease in the total RB protein level between exit from mitosis and entry into S phase, These observations were made by using two different monoclonal antibodies, both in immunoblotting and immunoprecipitation experiments. Absence of hypophosphorylated RB and cell cycle-dependent change in total RB protein level may be relevant to the high proliferation rate and to the tumorigenic nature of mouse embryonic stem tells.	KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet	SAVATIER, P (corresponding author), ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.		Szekely, Laszlo/B-1268-2009; Wiman, Klas/AAB-8399-2021; SAVATIER, Pierre/J-4663-2014; Samarut, Jacques/AAD-2587-2019	Wiman, Klas/0000-0002-7113-524X; 				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BEDDINGTON RSP, 1983, J EMBRYOL EXP MORPH, V75, P189; BERG RW, 1990, DEV BIOL, V138, P123, DOI 10.1016/0012-1606(90)90182-I; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DAMJANOV I, 1971, ROUX ARCH DEV BIOL, V167, P288, DOI 10.1007/BF00584254; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLINGSWORTH RE, 1993, CURRENT OPINION CELL, V5, P1194; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; ILES SA, 1977, J EMBRYOL EXP MORPH, V38, P63; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MACAULEY A, 1993, DEVELOPMENT, V117, P873; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MCCORMICK PJ, 1990, EXP CELL RES, V189, P183, DOI 10.1016/0014-4827(90)90234-2; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MURRAY EJ, 1991, MOL CELL BIOL, V11, P5534, DOI 10.1128/MCB.11.11.5534; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENSTRAUS MJ, 1982, DEV BIOL, V89, P516, DOI 10.1016/0012-1606(82)90340-2; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SLACK RS, 1993, ONCOGENE, V8, P1585; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; STOKKE T, 1993, EXP CELL RES, V204, P147, DOI 10.1006/excr.1993.1019; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	63	212	215	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					809	818						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108123				2022-12-25	WOS:A1994MW55100016
J	VALENTINIS, B; PORCU, P; QUINN, K; BASERGA, R				VALENTINIS, B; PORCU, P; QUINN, K; BASERGA, R			THE ROLE OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR IN THE TRANSFORMATION BY SIMIAN-VIRUS-40 T-ANTIGEN	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; CELLULAR DNA-SYNTHESIS; MESSENGER-RNA LEVELS; SV40-TRANSFORMED CELLS; PERMISSIVE CELLS; SOMATOMEDIN-C; A REGULATION; PROTEIN; BINDING; PHOSPHORYLATION	Balb/c 3T3 cells transformed by the tsA58 temperature-sensitive (ts) mutant of SV40 large T antigen, BalbA58 cells, grow in 1% serum at the permissive temperature of 34 degrees C but fail to grow at the restrictive temperature of 39.6 degrees C. Although incapable of growing, BalbA58 cells, in low serum at 39.6 degrees C, stilt synthesize DNA and tend to accumulate in the G(2) phase of the cell cycle. Growth in 1% serum at 39.6 degrees C resumes if BalbA58 cells are treated with insulin-like growth factor I (IGF-I). By using cells overexpressing the IGF-I receptor, and cells with a targeted disruption of the IGF-I receptor genes, we show that: 1) the activation of the IGP-I receptor by its ligand(s) plays a major role in the ability of the SV40 large T antigen to promote growth in low serum; and 2) the IGF-I receptor plays a role in the progression of cells not only through G(1), but also through the S and G(2) phases of the cell cycle. These findings, together with other recent findings from the literature, suggest that one of the mechanisms by which oncogenes and tumor suppresser genes regulate cell growth is through the modulation of growth factors and their receptors.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107; NCI,DCPC,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NCI NIH HHS [CA56309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; CAMPISI J, 1984, MOL CELL BIOL, V4, P1807, DOI 10.1128/MCB.4.9.1807; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CRISTOFALO VJ, 1989, J GERONTOL, V44, P55, DOI 10.1093/geronj/44.6.55; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1991, ONCOGENE, V6, P1931; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FERBER A, 1993, J BIOL CHEM, V268, P17883; FOYT HL, 1991, INSULIN LIKE GROWTH, P1; Gai X X, 1988, Oncogene Res, V3, P377; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HISCOTT JB, 1979, J VIROL, V30, P590, DOI 10.1128/JVI.30.2.590-599.1979; HISCOTT JB, 1981, J VIROL, V37, P802, DOI 10.1128/JVI.37.2.802-812.1981; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251; NIELSEN FC, 1993, MOL CELL ENDOCRINOL, V93, P87, DOI 10.1016/0303-7207(93)90143-8; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; OTTAVIO L, 1990, MOL CELL BIOL, V10, P303, DOI 10.1128/MCB.10.1.303; PERDUE JF, 1991, ENDOCRINOLOGY, V129, P3101, DOI 10.1210/endo-129-6-3101; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RUSSELL WE, 1984, P NATL ACAD SCI-BIOL, V81, P2389, DOI 10.1073/pnas.81.8.2389; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, IN PRESS P NATL ACAD; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TRAVALI S, 1991, ONCOGENE, V6, P887; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WERNER H, 1991, INSULIN LIKE GROWTH, P17; YAMORI T, 1991, CANCER RES, V51, P5859; YOSHINOUCHI M, 1993, CELL PROLIFERAT, V26, P139, DOI 10.1111/j.1365-2184.1993.tb00014.x	49	55	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					825	831						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108125				2022-12-25	WOS:A1994MW55100018
J	LANG, V; ZANCHIN, NIT; LUNSDORF, H; TUITE, M; MCCARTHY, JEG				LANG, V; ZANCHIN, NIT; LUNSDORF, H; TUITE, M; MCCARTHY, JEG			INITIATION-FACTOR EIF-4E OF SACCHAROMYCES-CEREVISIAE - DISTRIBUTION WITHIN THE CELL, BINDING TO MESSENGER-RNA, AND CONSEQUENCES OF ITS OVERPRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTEIN-SYNTHESIS; SECONDARY STRUCTURE; CAP RECOGNITION; DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; CROSS-LINKING; YEAST; TRANSLATION; TRANSCRIPTION	The eukaryotic translational initiation factor 4E (eIF-4E) is an essential protein that binds the 5' cap structure with high specificity and affinity. Yeast eIF-4E is homologous to eIF-4E of higher eukaryotes, but interacts with a different set of cap-binding complex proteins. In the present study the distribution of yeast eIF-4E in Saccharomyces cerevisiae was found to be similar to that observed in higher cells, whereby the yeast factor was more concentrated in the nucleus than in the cytoplasm. Overexpression of yeast eIF-4E in S. cerevisiae exerted at most a minimal effect on growth in liquid minimal medium and was not found to influence the translation of reporter gene mRNAs bearing secondary structure in their leader regions. In a new method to study mRNA-protein interactions, biotinylated mRNAs were synthesized in vitro for use in studies of the binding of eIF-4E in yeast extracts. Streptavidin was used to adsorb the biotinylated mRNAs plus bound initiation factors. Stem-loop structures in the leader region did not influence the binding of eIF-4E or, in comparative experiments, of eIF-4A Thus yeast eIF-4E shows both similarities and differences with respect to the distribution and function of its counterparts in higher eukaryotes.	GESELL BIOTECHNOL FORSCH MBH,DEPT GENE EXPRESS,D-38124 BRAUNSCHWEIG,GERMANY; GESELL BIOTECHNOL FORSCH MBH,DEPT MICROBIOL,D-38124 BRAUNSCHWEIG,GERMANY; UNIV KENT,BIOL LAB,CANTERBURY,KENT,ENGLAND	Gesellschaft fur Biotechnologische Forschung mbH; Gesellschaft fur Biotechnologische Forschung mbH; University of Kent			Tuite, Mick/ABC-7909-2020; Zanchin, Nilson Ivo Tonin/AAB-4907-2019	Tuite, Mick/0000-0002-5214-540X; Zanchin, Nilson Ivo Tonin/0000-0002-1153-0694				ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ALTMANN M, 1988, J BIOL CHEM, V263, P17229; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; GERSTEL B, 1992, MOL MICROBIOL, V6, P2339, DOI 10.1111/j.1365-2958.1992.tb01409.x; GOYER C, 1989, J BIOL CHEM, V264, P7603; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; JOBLING SA, 1988, NUCLEIC ACIDS RES, V16, P4483, DOI 10.1093/nar/16.10.4483; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LANKER S, 1992, J BIOL CHEM, V267, P21167; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEE KAW, 1983, J BIOL CHEM, V258, P707; LEIBKOMICZH F, 1992, P NATL ACAD SCI USA, V89, P9612; LUNSDORF H, 1991, J BACTERIOL, V173, P978; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PELLETIER J, 1985, MOL CELL BIOL, V5, P3222, DOI 10.1128/MCB.5.11.3222; RAY BK, 1985, J BIOL CHEM, V260, P7651; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; Tuite M F, 1986, Yeast, V2, P35, DOI 10.1002/yea.320020103; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	37	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6117	6123						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119957				2022-12-25	WOS:A1994MY84000096
J	REHAKRANTZ, LJ; NONAY, RL				REHAKRANTZ, LJ; NONAY, RL			MOTIF-A OF BACTERIOPHAGE-T4 DNA-POLYMERASE - ROLE IN PRIMER EXTENSION AND DNA-REPLICATION FIDELITY - ISOLATION OF NEW ANTIMUTATOR AND MUTATOR DNA-POLYMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; ESCHERICHIA-COLI; REVERSE-TRANSCRIPTASE; WILD-TYPE; ACCESSORY PROTEINS; BIOCHEMICAL BASIS; MUTANT; ACID; GENE; TRIPHOSPHOHYDROLASE	Polymerases in general share only a few regions of amino acid similarity. One of the most conserved regions, called motif A, has the sequence DXXSLYPSII or a similar sequence in many eukaryotic and viral DNA polymerases and in bacteriophage T4 DNA polymerase. We designed genetic techniques to isolate mutant T4 DNA polymerases with amino acid substitutions in this highly conserved motif. The mutant DNA polymerases differed from wild type T4 DNA polymerase in several ways. For one mutant DNA polymerase, the pyrophosphate analog, phosphonoacetic acid, was a potent inhibitor of DNA replication, and this mutant DNA polymerase replicated DNA with reduced fidelity. Another mutant DNA polymerase replicated DNA with increased accuracy, but this mutant DNA polymerase was less processive in primer extension reactions, and DNA replication required high concentrations of deoxynucleoside triphosphates. We provide evidence that indicates that all of these changes to DNA polymerase function are due to differences in how the mutant DNA polymerases partition between states active for DNA replication or exonucleolytic proofreading. These studies also provide further support for the hypothesis that the accuracy of DNA replication observed for DNA polymerases depends on the interplay between polymerase and 3' --> 5' exonuclease activities (Muzyczka, N., Poland, R. L., and Bessman, M. J. (1972) J. Biol. Chem. 247, 7116-7122).			REHAKRANTZ, LJ (corresponding author), UNIV ALBERTA,DEPT GENET,EDMONTON T6G 2E9,AB,CANADA.		Reha-Krantz, Linda/A-3748-2014	Reha-Krantz, Linda/0000-0003-4497-423X				ALLEN EF, 1970, GENETICS, V65, P187; BEAUCHAMP BB, 1988, P NATL ACAD SCI USA, V85, P2563, DOI 10.1073/pnas.85.8.2563; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BESSMAN MJ, 1974, J MOL BIOL, V88, P409, DOI 10.1016/0022-2836(74)90491-4; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DRAKE JW, 1969, NATURE, V221, P1128, DOI 10.1038/2211128a0; ERIKSSON B, 1982, BIOCHIM BIOPHYS ACTA, V696, P115, DOI 10.1016/0167-4781(82)90018-5; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; GAUSS P, 1983, P NATL ACAD SCI-BIOL, V80, P1669, DOI 10.1073/pnas.80.6.1669; GIBBS JS, 1988, P NATL ACAD SCI USA, V85, P6672, DOI 10.1073/pnas.85.18.6672; GILLIN FD, 1976, J BIOL CHEM, V251, P5219; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HALL JD, 1985, P NATL ACAD SCI USA, V82, P3889, DOI 10.1073/pnas.82.11.3889; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; Joyce CM, 1991, CURR OPIN STRUC BIOL, V1, P123, DOI 10.1016/0959-440X(91)90020-T; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; LEINBACH SS, 1976, BIOCHEMISTRY-US, V15, P426, DOI 10.1021/bi00647a029; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MAO JCH, 1975, J VIROL, V15, P1281, DOI 10.1128/JVI.15.5.1281-1283.1975; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; OLESON AE, 1964, J BIOL CHEM, V239, P2935; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1986, J MOL BIOL, V189, P261, DOI 10.1016/0022-2836(86)90508-5; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1985, J MOL BIOL, V186, P505, DOI 10.1016/0022-2836(85)90125-1; REHAKRANTZ LJ, 1989, J VIROL, V63, P4762, DOI 10.1128/JVI.63.11.4762-4766.1989; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; ROZOVSKAYA T A, 1981, Molekulyarnaya Biologiya (Moscow), V15, P1205; SETO D, 1988, J BIOL CHEM, V263, P1494; SPICER EK, 1988, J BIOL CHEM, V263, P7478; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WURGLER SM, 1990, P NATL ACAD SCI USA, V87, P2740, DOI 10.1073/pnas.87.7.2740; YU H, 1992, J BIOL CHEM, V267, P10888	47	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5635	5643						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119900				2022-12-25	WOS:A1994MY84000027
J	COHENFIX, O; LIVNEH, Z				COHENFIX, O; LIVNEH, Z			IN-VITRO UV MUTAGENESIS ASSOCIATED WITH NUCLEOTIDE EXCISION-REPAIR GAPS IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; ALPHA-SUBUNIT; BETA-SUBUNIT; BACTERIOPHAGE-LAMBDA; ULTRAVIOLET-LIGHT; COLI; HOLOENZYME; REPLICATION; GENE; PURIFICATION	Using a cell-free system for UV mutagenesis we have recently shown that extracts prepared from Escherichia coli cells promote a W mutagenesis pathway that depends on the uvrABC repair genes independent of DNA replication (type II UV mutagenesis; Cohen-Fix, O., and Livneh, Z. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3300-3304). Type II W mutagenesis was defective also in extracts prepared from a uvrD strain. These deficiencies were complemented by adding purified UvrA, UvrB, UvrC, or UvrD proteins to the respective cell extracts. The Uvr proteins act at an early stage in the process, probably preparing a premutagenic single-stranded DNA gap, which subsequently serves as a substrate for the mutagenic reaction. Type II UV mutagenesis was not dependent on DNA polymerases I or on DNA polymerase II, but it was dependent on DNA polymerase III. Thus, similar to the in vivo situation, only DNA polymerase III is essential for UV mutagenesis. Antibodies against the beta subunit of DNA polymerase III holoenzyme inhibited DNA replication but not W mutagenesis. Thus, the processivity subunit of the holoenzyme is not required for type II W mutagenesis, in agreement with a mechanism involving filling-in of short single-stranded DNA gaps.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								[Anonymous], 1985, DNA REPAIR; BATES H, 1989, J BACTERIOL, V171, P2480, DOI 10.1128/jb.171.5.2480-2484.1989; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BRESLER SE, 1975, MUTAT RES, V29, P467, DOI 10.1016/0027-5107(75)90065-2; BRIDGES BA, 1971, MUTAT RES, V13, P1, DOI 10.1016/0027-5107(71)90120-5; BRIDGES BA, 1976, MOL GEN GENET, V144, P53, DOI 10.1007/BF00277304; BRIDGES BA, 1990, MUTAGENESIS, V5, P35, DOI 10.1093/mutage/5.1.35; BRIDGES BA, 1992, MUTAT RES, V270, P135, DOI 10.1016/0027-5107(92)90124-K; BROTCORNELANNOYE A, 1985, MOL GEN GENET, V199, P64, DOI 10.1007/BF00327511; BRYAN SK, 1990, MUTAT RES, V243, P313, DOI 10.1016/0165-7992(90)90149-E; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; COHENFIX O, 1992, P NATL ACAD SCI USA, V89, P3300, DOI 10.1073/pnas.89.8.3300; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; FAY PJ, 1981, J BIOL CHEM, V256, P976; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; HAGENSEE ME, 1987, P NATL ACAD SCI USA, V84, P4195, DOI 10.1073/pnas.84.12.4195; IWASAKI H, 1990, J BACTERIOL, V172, P6268, DOI 10.1128/jb.172.11.6268-6273.1990; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; KATO T, 1977, MOL GEN GENET, V156, P121, DOI 10.1007/BF00283484; KENYON CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2819, DOI 10.1073/pnas.77.5.2819; KITAGAWA Y, 1985, P NATL ACAD SCI USA, V82, P4336, DOI 10.1073/pnas.82.13.4336; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1991, DNA REPLICATION; KOW YW, 1993, J BACTERIOL, V175, P561, DOI 10.1128/JB.175.2.561-564.1993; LAM LH, 1987, MUTAT RES, V178, P167, DOI 10.1016/0027-5107(87)90266-1; LIVNEH Z, 1993, IN PRESS CRC CRIT RE; MAKI H, 1989, J BACTERIOL, V171, P3139, DOI 10.1128/jb.171.6.3139-3143.1989; MAKI H, 1985, J BIOL CHEM, V260, P2982; MAKI H, 1985, J BIOL CHEM, V260, P2987; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Miller J.H., 1972, EXPT MOL GENETICS; MOK M, 1987, J BIOL CHEM, V262, P16644; NISHIOKA H, 1970, MUTAT RES, V9, P349, DOI 10.1016/0027-5107(70)90017-5; NISHIOKA H, 1969, MUTAT RES, V8, P215, DOI 10.1016/0027-5107(69)90001-3; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; PERRY KL, 1985, P NATL ACAD SCI USA, V82, P4331, DOI 10.1073/pnas.82.13.4331; PERRY KL, 1982, NATURE, V300, P278, DOI 10.1038/300278a0; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SHAVITT O, 1989, J BIOL CHEM, V264, P11275; SHAVITT O, 1989, J BACTERIOL, V171, P3530, DOI 10.1128/jb.171.6.3530-3538.1989; SHWARTZ H, 1988, J BIOL CHEM, V263, P18277; SKALITER R, 1992, MUTAT RES, V267, P139, DOI 10.1016/0027-5107(92)90118-L; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; SWEASY JB, 1990, J BACTERIOL, V172, P303; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; TAIT RC, 1974, P NATL ACAD SCI USA, V71, P675, DOI 10.1073/pnas.71.3.675; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WASHBURN BK, 1991, J BACTERIOL, V173, P2569, DOI 10.1128/jb.173.8.2569-2575.1991; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YOUNGS DA, 1973, NATURE-NEW BIOL, V244, P240, DOI 10.1038/newbio244240a0	58	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4953	4958						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106470				2022-12-25	WOS:A1994MX57100042
J	JETTON, TL; LIANG, Y; PETTEPHER, CC; ZIMMERMAN, EC; COX, FG; HORVATH, K; MATSCHINSKY, FM; MAGNUSON, MA				JETTON, TL; LIANG, Y; PETTEPHER, CC; ZIMMERMAN, EC; COX, FG; HORVATH, K; MATSCHINSKY, FM; MAGNUSON, MA			ANALYSIS OF UPSTREAM GLUCOKINASE PROMOTER ACTIVITY IN TRANSGENIC MICE AND IDENTIFICATION OF GLUCOKINASE IN RARE NEUROENDOCRINE CELLS IN THE BRAIN AND GUT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; FACILITATIVE GLUCOSE TRANSPORTER; DEPENDENT DIABETES-MELLITUS; HUMAN GROWTH-HORMONE; HYPOTHALAMIC NEURONS; INSITU HYBRIDIZATION; CHOROID-PLEXUS; ISLET CELLS; K+ CHANNELS; PEPTIDE-I	A transgene consisting of an upstream glucokinase (GK) promoter fragment linked to coding sequences of the human growth hormone gene was expressed in certain neuroendocrine cells of the pancreas, pituitary, brain, gut, thyroid, and lungs of mice. In pancreas, the transgene was expressed in a nonuniform manner among beta cells and in a variable but substantial fraction of the other islet cell types. In pituitary, it was expressed in corticotropes, and in brain, it was expressed in cells of the medial hypothalamus. Within the gut transgene expression was detected in a subset of enteroendocrine cells of the stomach and duodenal epithelium, some of which also exhibited glucagon-like polypeptide-1 immunoreactivity. In thyroid, transgene expression was observed in C cells of neonatal animals, whereas in the lung, it was expressed among rare endocrine cells of the bronchopulmonary mucosa. RNA polymerase chain reaction analysis of human growth hormone mRNA corroborated the tissue-specific transgene expression pattern. Prompted by the finding of transgene expression in specific neuroendocrine cells, we sought to determine whether GK mRNA and GK itself was also expressed in the brain and gut, tissues not previously associated with the expression of this enzyme. Using rat tissues, GK mRNA was detected by RNA polymerase chain reaction in both the brain and intestine and was localized to specific cells in the hypothalamus and enteric mucosa by in situ hybridization. A high K(m) glucose phosphorylating activity was detected from isolated rat jejunal enterocytes that displayed a chromatographic elution profile identical to hepatic GK. GK immunoreactivity was detected in cells of the medial hypothalamus with many of the same cells also displaying GLUT2 immunoreactivity. Together, these studies provide evidence for upstream GK promoter activity, GK mRNA, and GK itself in certain neuroendocrine cells outside the pancreatic islet and lead us to suggest that GK may play a broader role in glucose sensing by neuroendocrine cells than was thought previously.	VANDERBILT UNIV, MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS, 702 LIGHT HALL, NASHVILLE, TN 37232 USA; UNIV PENN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA; UNIV PENN, DIABET RES CTR, PHILADELPHIA, PA 19104 USA; HAHNEMANN UNIV, DEPT PEDIAT, PHILADELPHIA, PA 19102 USA	Vanderbilt University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Drexel University			Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07563, DK42612, DK42502] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ANGERER LM, 1987, IN SITU HYBRIDIZATIO, P42; ASHFORD MLJ, 1990, PFLUG ARCH EUR J PHY, V415, P479, DOI 10.1007/BF00373626; BEDOYA FJ, 1985, ANAL BIOCHEM, V144, P504, DOI 10.1016/0003-2697(85)90147-2; BRANT AM, 1993, BIOCHEM BIOPH RES CO, V192, P1297, DOI 10.1006/bbrc.1993.1557; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVAGNINO J, 1980, J BIOL CHEM, V255, P2633; DEANE R, 1985, J PHYSIOL-LONDON, V362, P245, DOI 10.1113/jphysiol.1985.sp015674; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; EISSELE R, 1992, EUR J CLIN INVEST, V22, P283, DOI 10.1111/j.1365-2362.1992.tb01464.x; FARRELL CL, 1992, J HISTOCHEM CYTOCHEM, V40, P193, DOI 10.1177/40.2.1552163; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GEFEL D, 1990, ENDOCRINOLOGY, V126, P2164, DOI 10.1210/endo-126-4-2164; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HACKER HJ, 1991, HISTOCHEMISTRY, V96, P435, DOI 10.1007/BF00316001; HOGAN B, 1986, MANIPULATING MOUSE E; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; IYNEDJIAN PB, 1986, P NATL ACAD SCI USA, V83, P1998, DOI 10.1073/pnas.83.7.1998; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; Le Douarin N.M., 1982, NEURAL CREST; LIANG Y, 1991, J BIOL CHEM, V266, P6999; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON MD, 1983, P NATL ACAD SCI-BIOL, V80, P85, DOI 10.1073/pnas.80.1.85; MEI N, 1978, J PHYSIOL-LONDON, V282, P485, DOI 10.1113/jphysiol.1978.sp012477; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; MOBBS CV, 1990, REV BIOL RES AGING, V4, P201; MOJSOV S, 1990, J BIOL CHEM, V265, P8001; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; OOMURA Y, 1992, AM J CLIN NUTR, V55, P278; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; PICTET R, 1972, HDB PHYSL ENDOCRINOL, V7, P25; PRASAD AS, 1972, J LAB CLIN MED, V80, P598; PRELLER A, 1992, ARCH BIOCHEM BIOPHYS, V294, P482, DOI 10.1016/0003-9861(92)90715-9; PRICE JM, 1950, CANCER RES, V10, P18; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; SALAS J, 1965, J BIOL CHEM, V240, P1014; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; SHIMIZU N, 1983, BRAIN RES, V265, P49, DOI 10.1016/0006-8993(83)91332-X; STEWART TA, 1993, TRENDS ENDOCRIN MET, V4, P136, DOI 10.1016/1043-2760(93)90038-G; SUZUE K, 1989, NUCLEIC ACIDS RES, V17, P10099, DOI 10.1093/nar/17.23.10099; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TREHERNE JM, 1992, P ROY SOC B-BIOL SCI, V247, P121, DOI 10.1098/rspb.1992.0017; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; UNGER RH, 1969, ARCH INTERN MED, V123, P261, DOI 10.1001/archinte.123.3.261; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; WEISER MM, 1971, J BIOL CHEM, V246, P2331; YIN L, 1992, DIABETES, V41, P792	55	262	269	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3641	3654						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106409				2022-12-25	WOS:A1994MV63100077
J	MILLER, CC; HALE, P; PENTLAND, AP				MILLER, CC; HALE, P; PENTLAND, AP			ULTRAVIOLET-B INJURY INCREASES PROSTAGLANDIN SYNTHESIS THROUGH A TYROSINE KINASE-DEPENDENT PATHWAY - EVIDENCE FOR UVB-INDUCED EPIDERMAL GROWTH-FACTOR RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; MAMMALIAN-CELLS; FACTOR BINDING; HUMAN-SKIN; PHOSPHOLIPASE-A2; IRRADIATION; INHIBITION; KERATINOCYTES; LIGHT; FIBROBLASTS	To study the signal transduction mechanisms by which unltraviolet B (UVB) leads to increased prostaglandin E2 (PGE2) Synthesis, human epidermal cultures were irradiated with 30 mJ/cm2 UVB and assayed for 6-h cumulative PGE2. Supernatants from irradiated cultures showed a 4-fold increase in PGE2 synthesis (113.6 +/- 26.8 pg/mg protein) when compared to supernatants from sham-irradiated cultures (25.6 +/- 3.9 pg/mg protein). Pretreatment of irradiated cultures with genistein (10 pg/ml) or tyrphostin-23 (50 muM), inhibitors of tyrosine kinases, blocked UVB-stimulated PGE2 synthesis. Treatment of nonirradiated cultures with epidermal growth factor (EGF), which acts through the receptor tyrosine kinase EGF-R, produced a 4-fold increase in PGE2 Synthesis. However, addition of EGF to irradiated cultures did not further enhance their PGE2 synthesis, indicating irradiation rendered them refractory to EGF stimulation. In contrast, irradiated cultures could still significantly increase their PGE2 synthesis in response to the calcium ionophore A23187 or the protein kinase C activator 12-0-tetradecanoylphorbol-13-acetate, suggesting that the lack of response to EGF was selective. Furthermore, anti-phosphotyrosine immunoblot analysis revealed UVB-induced phosphorylation of tyrosine residues of EGF-R, an indicator of receptor activation. Phosphorylation was maximal 30-60 min after irradiation and was blocked by the tyrosine kinase inhibitors, genistein and tyrphostin. The antioxidant N-acetylcysteine decreased UVB-induced EGF-R tyrosine phosphorylation and PGE2 Synthesis to near-basal levels. Conversely, treatment of unirradiated cultures with the potent oxidant tert-butyl-hydroperoxide (100 muM) increased both PGE2 synthesis and EGF-R phosphorylation. Collectively, these data suggest that antioxidant depletion induced by UV results in tyrosine phosphorylation and activation of the EGF-R. This activation may subsequently activate epidermal phospholipase at early time points after UVB exposure.	WASHINGTON UNIV, SCH MED,DEPT MED,DIV DERMATOL,660 S EUCLID AVE, CAMPUS BOX 8123, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIAMS NIH HHS [K04 AR01849, AR40574] Funding Source: Medline; NIDDK NIH HHS [DK38111] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040574, K04AR001849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038111] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; ANDERSON RR, 1981, J INVEST DERMATOL, V77, P13, DOI 10.1111/1523-1747.ep12479191; BLACK AK, 1978, BRIT J CLIN PHARMACO, V5, P431, DOI 10.1111/j.1365-2125.1978.tb01650.x; BLACK AK, 1980, BRIT J CLIN PHARMACO, V10, P453, DOI 10.1111/j.1365-2125.1980.tb01788.x; BROOKS G, 1990, CARCINOGENESIS, V11, P1223, DOI 10.1093/carcin/11.7.1223; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; COYNE DW, 1990, BIOCHEM BIOPH RES CO, V173, P718, DOI 10.1016/S0006-291X(05)80094-4; DELEO VA, 1985, PHOTOCHEM PHOTOBIOL, V41, P51; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FUCHS J, 1989, J INVEST DERMATOL, V93, P769, DOI 10.1111/1523-1747.ep12284412; FUCHS J, 1989, PHOTOCHEM PHOTOBIOL, V50, P739, DOI 10.1111/j.1751-1097.1989.tb02904.x; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; GOLDMAN R, 1992, FEBS LETT, V309, P190, DOI 10.1016/0014-5793(92)81092-Z; GUPTA N, 1973, BRIT J PHARMACOL, V47, P240, DOI 10.1111/j.1476-5381.1973.tb08321.x; HACK N, 1991, BIOCHEM J, V275, P563, DOI 10.1042/bj2750563; HAWK JLM, 1983, PHOTOIMMUNOLOGY, P219; HELIN K, 1991, ONCOGENE, V6, P825; HRUZA LL, 1993, J INVEST DERMATOL, V100, pS35, DOI 10.1111/1523-1747.ep12355240; KANGROTONDO CH, 1993, AM J PHYSIOL, V264, pC396, DOI 10.1152/ajpcell.1993.264.2.C396; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MATSUI MS, 1989, J INVEST DERMATOL, V92, P617, DOI 10.1111/1523-1747.ep12712158; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; NISHI J, 1991, J INVEST DERMATOL, V97, P115, DOI 10.1111/1523-1747.ep12478534; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; PENTLAND AP, 1992, J BIOL CHEM, V267, P15578; PENTLAND AP, 1991, AM J PHYSIOL, V261, pR543, DOI 10.1152/ajpregu.1991.261.3.R543; PUNNONEN K, 1992, J INVEST DERMATOL, V99, P221, DOI 10.1111/1523-1747.ep12650445; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SNYDER DS, 1974, J INVEST DERMATOL, V62, P47, DOI 10.1111/1523-1747.ep12676722; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233	40	138	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3529	3533						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106395				2022-12-25	WOS:A1994MV63100062
J	MUKHERJEE, SK; REDDY, MK; KUMAR, D; TEWARI, KK				MUKHERJEE, SK; REDDY, MK; KUMAR, D; TEWARI, KK			PURIFICATION AND CHARACTERIZATION OF A EUKARYOTIC TYPE-1 TOPOISOMERASE FROM PEA CHLOROPLAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASES; REPLICATION; CEREVISIAE; INVITRO; TRANSCRIPTION; PROTEIN; LINKAGE; ORIGIN; CELLS	A 69-kDa protein with topoisomerase I activity has been homogeneously purified from the chloroplasts of pea leaves. The topoisomerase properties are detected in crude lysate of pea chloroplasts using the technique of transferring P-32 radioactivity from the P-32-labeled DNA to the protein. The purified enzyme relaxes both positive and negative supercoils in topological steps of unity without requiring magnesium ions. The enzyme is sensitive to topoisomerase I-specific inhibitors like camptothecin and berenil, and unaffected by reagents like novobiocin and doxorubicin at the topoisomerase II-inhibitory dosage. In the presence of the enzyme, supercoiled DNA is nicked, and the 3'-phosphoryl end of the nick becomes covalently linked with the enzyme. A tyrosine residue of the enzyme is responsible for the covalent linkage. Rabbit antiserum raised against the 16-mer peptide spanning the active residues of hu an topoisomerase I recognizes the 69-kDa protein within the crude lysate of pea chloroplasts as does the antiserum to the purified 69-kDa protein. From the enzymatic characteristics, the protein has been classified as a eukaryotic type I topoisomerase.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine	MUKHERJEE, SK (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, NII CAMPUS, ARUNA ASAF ALI MARG, NEW DELHI 110067, INDIA.							BOGORAD L, 1991, MOL BIOL PLASTIDS, P39; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; CHIU WL, 1992, MOL GEN GENET, V232, P33, DOI 10.1007/BF00299134; CHOW K-C, 1985, Biotechniques, V3, P290; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; COLE AD, 1992, PLANT MOL BIOL, V19, P265, DOI 10.1007/BF00027348; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; FUKATA H, 1991, J BIOCHEM-TOKYO, V109, P127, DOI 10.1093/oxfordjournals.jbchem.a123332; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; IKEDA JE, 1979, J BIOL CHEM, V254, P9416; KAGUNI JM, 1984, J BIOL CHEM, V259, P8578; KOLODNER RD, 1975, NATURE, V256, P708, DOI 10.1038/256708a0; LAKHANI S, 1992, BIOCHEM J, V286, P833, DOI 10.1042/bj2860833; LAM E, 1987, PLANT MOL BIOL, V8, P415, DOI 10.1007/BF00015819; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MINDEN JS, 1986, J BIOL CHEM, V261, P1906; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; NIELSEN BL, 1988, PLANT MOL BIOL, V11, P3, DOI 10.1007/BF00016009; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PYKE KA, 1989, FEBS LETT, V242, P305, DOI 10.1016/0014-5793(89)80490-9; ROBINSON C, 1988, PLANT MOL BIOL PRACT, P67; ROSS CF, 1983, BIOCHIM BIOPHYS ACTA, V741, P230, DOI 10.1016/0167-4781(83)90063-5; ROWE TC, 1984, J BIOL CHEM, V259, P9177; ROWE TC, 1981, J BIOL CHEM, V256, P354; Sambrook J, 1989, MOL CLONING LABORATO; SIEDLECKI J, 1983, NUCLEIC ACIDS RES, V11, P1523, DOI 10.1093/nar/11.5.1523; SLESAREV AI, 1993, NATURE, V364, P735, DOI 10.1038/364735a0; Sternglanz R, 1989, CURR OPIN CELL BIOL, V1, P533, DOI 10.1016/0955-0674(89)90016-1; STEWART AF, 1987, CELL, V50, P1109, DOI 10.1016/0092-8674(87)90177-2; SUN E, 1986, PLANT MOL BIOL, V6, P429, DOI 10.1007/BF00027135; TAKEDA Y, 1992, MOL GEN GENET, V232, P191, DOI 10.1007/BF00279996; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x; TSE YC, 1980, J BIOL CHEM, V255, P5560; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	39	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3793	3801						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106424				2022-12-25	WOS:A1994MV63100097
J	ZHANG, L; CASTELLINO, FJ				ZHANG, L; CASTELLINO, FJ			THE BINDING-ENERGY OF HUMAN COAGULATION PROTEIN-C TO ACIDIC PHOSPHOLIPID-VESICLES CONTAINS A MAJOR CONTRIBUTION FROM LEUCINE-5 IN THE GAMMA-CARBOXYGLUTAMIC ACID DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOTTING FACTOR-X; BOVINE FACTOR-IX; CONFORMATION-SPECIFIC ANTIBODIES; INVITRO ANTICOAGULANT ACTIVITY; THROMBIN-CATALYZED ACTIVATION; K-DEPENDENT PROTEINS; PROTHROMBIN FRAGMENT-1; MEMBRANE-BINDING; FACTOR-VIII; METAL-IONS	A mutant cDNA of recombinant (r)-human protein C (PC) encoding a Leu5 --> Gln substitution ([Leu5 --> Gln]r-PC) has been constructed and expressed in human 293 cells. A subpopulation of molecules was then purified that contained fully gamma-carboxylated [Leu5 --> Gln]r-PC. Intrinsic fluorescence quenching studies with this mutant protein revealed a C50 for Ca2+ binding (0.24 mM) that was essentially the same as that of wild-type (wt) r-PC (0.35 mM). Additionally, the C50 for the Ca2+ dependence of binding of a Ca2+-specific monoclonal antibody to [Leu5 --> Gln]r-PC, of 5.4 mm-6.5 nM, was similar to that of wtr-PC (4.5 mM). On the other hand, the anticoagulant activity of the activated form of this mutant ([Leu5 --> Gln]r-APC) was only 2% of that of activated wtr-PC (wtr-APC), and the inactivation rate of human factor Va catalyzed by this same mutant enzyme was approximately 10% of that of wtr-APC, at maximal levels of Ca2+. This substantial loss of activity was reconciled with the apparent retention of the integrity of the Ca2+-dependent conformation of this mutant by the finding that this Ca2+-dependent conformation of [Leu5 --> Gln]r-PC interacted poorly with mixed (60:40, w/w) phosphatidylcholine/phosphatidylserine (PL) vesicles. These results suggest that Leu5, a residue strictly conserved in vitamin K-dependent proteins, is required for functional binding of PC to PL vesicles. These findings lend support to recent observations that have shown the importance of hydrophobic interactions in the binding of coagulation factors to PL vesicles. This current work further implicates Leu5 as a possible key participant in this hydrophobic binding energy.	UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA	University of Notre Dame					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19982] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1978, J BIOL CHEM, V253, P6774; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ATKINS JS, 1992, MOL CELL BIOCHEM, V112, P61; BAJAJ SP, 1977, J BIOL CHEM, V252, P4758; BAJAJ SP, 1976, J BIOL CHEM, V251, P6294; BEALS JM, 1986, BIOCHEM J, V236, P861, DOI 10.1042/bj2360861; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; CHIBBER BAK, 1990, INT J PEPT PROT RES, V35, P73; CHURCH WR, 1989, BLOOD, V74, P2418; COLPITTS TL, 1993, INT J PEPT PROT RES, V41, P567; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON NL, 1982, J BIOL CHEM, V257, P859; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; KEYT B, 1982, J BIOL CHEM, V257, P8687; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KUSTER H, 1992, J BIOL CHEM, V267, P12782; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LOWRY OH, 1946, J BIOL CHEM, V162, P421; MANN KG, 1990, BLOOD, V76, P1; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STRICKLAND DK, 1980, ARCH BIOCHEM BIOPHYS, V199, P61, DOI 10.1016/0003-9861(80)90256-8; SUGO T, 1985, J BIOL CHEM, V260, P453; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WAKABAYASHI K, 1986, J BIOL CHEM, V261, P1097; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1993, J BIOL CHEM, V268, P12040; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	39	65	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3590	3595						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106403				2022-12-25	WOS:A1994MV63100071
J	DAVID, F; BERNARD, AM; PIERRES, M; MARGUET, D				DAVID, F; BERNARD, AM; PIERRES, M; MARGUET, D			IDENTIFICATION OF SERINE-624, ASPARTIC ACID-702, AND HISTIDINE-734 AS THE CATALYTIC TRIAD RESIDUES OF MOUSE DIPEPTIDYLPEPTIDASE-IV (CD26) - A MEMBER OF A NOVEL FAMILY OF NONCLASSICAL SERINE HYDROLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMOCYTE-ACTIVATING MOLECULE; PROLYL OLIGOPEPTIDASE FAMILY; ACTIVE-SITE RESIDUES; T-CELL ACTIVATION; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY; SECONDARY STRUCTURE; CDNA CLONING; SUBSTANCE-P; SEQUENCE	Dipeptidyl-peptidase IV (DPP IV, CD26, EC 3.4.14.5), a multifunctional ectoenzyme, is involved not only in the proteolytic cleavage of X-Pro from the NH2 terminus of a variety of biologically active peptides, but also in activation signal transduction and cell matrix adherence processes. We recently characterized mouse DPP IV cDNA and identified the serine protease Gly-X-Ser-X-Gly consensus motif in its extracellular domain. Mouse DPP IV does not exhibit sequence similarity with any of the classical members of this enzyme family (e.g. chymotrypsin and subtilisin) but shares a conserved structural domain of approximately 200 amino acids with several nonclassical serine hydrolases. In this study, analysis of the similarity of secondary structures and amino acid sequences between these enzymes led us to identify several conserved residues likely to be involved in the catalytic site of these DPP IV-related enzymes. These amino acids (Ser624, Asp702, and His734) were found to be arranged in a novel sequential order as compared with that of archetypal serine proteases (e.g. nucleophile (Ser)-acid-His versus His-acid-nucleophile (Ser), respectively). To directly explore the involvement of these residues in the catalytic function of these enzymes, we performed in vitro site-directed mutagenesis on mouse DPP IV cDNA. Our results indicate that although conservative or non-conservative permutations at these positions do not significantly alter the surface expression and biochemical properties of the mutant molecules, they completely impair their DPP IV enzymatic function. In contrast, mutagenesis of two other aspartic residues (Asp599 and Asp657), also conserved between these DPP IV-related enzymes, did not affect the enzymatic properties of the mouse enzyme. These data provide evidence that DPP IV and its related enzymes belong to a novel family that displays a catalytic triad distinct from that of the classical serine proteases.	CNRS MARSEILLE LUMINY,INSERM,CTR IMMUNOL,CASE 906,F-13288 MARSEILLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Marguet, Didier/B-9946-2008; Marguet, Didier/AGO-5421-2022	Marguet, Didier/0000-0003-3198-5095				ABBS MT, 1983, CLIN SCI, V65, P551, DOI 10.1042/cs0650551; AHMAD S, 1992, J PHARMACOL EXP THER, V260, P1257; BARRETT AJ, 1992, BIOL CHEM H-S, V373, P353, DOI 10.1515/bchm3.1992.373.2.353; BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRISTOL LA, 1992, J IMMUNOL, V148, P332; CHEVALLIER S, 1992, J BIOL CHEM, V267, P8192; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DELAESCALERA S, 1990, EMBO J, V9, P3593, DOI 10.1002/j.1460-2075.1990.tb07570.x; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DUGI KA, 1992, J BIOL CHEM, V267, P25086; FLEISCHER B, 1987, J IMMUNOL, V138, P1346; FOX DA, 1984, J IMMUNOL, V133, P1250; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; FUJIWARA T, 1992, BIOCHEM BIOPH RES CO, V185, P776, DOI 10.1016/0006-291X(92)91693-K; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GORRELL MD, 1991, CELL IMMUNOL, V134, P205, DOI 10.1016/0008-8749(91)90343-A; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; HARTEL S, 1988, HISTOCHEMISTRY, V89, P151, DOI 10.1007/BF00489918; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KANATANI A, 1991, J BIOCHEM-TOKYO, V110, P315, DOI 10.1093/oxfordjournals.jbchem.a123577; KENNY AJ, 1976, BIOCHEM J, V155, P169; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; LIAO DI, 1990, J BIOL CHEM, V265, P6528; MARGUET D, 1992, J BIOL CHEM, V267, P2200; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MITTA M, 1989, J BIOCHEM-TOKYO, V106, P548, DOI 10.1093/oxfordjournals.jbchem.a122891; NAQUET P, 1988, J IMMUNOL, V141, P4101; NAUSCH I, 1985, J NEUROCHEM, V44, P1354, DOI 10.1111/j.1471-4159.1985.tb08769.x; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; OGATA S, 1992, BIOCHEMISTRY-US, V31, P2582, DOI 10.1021/bi00124a019; OGATA S, 1989, J BIOL CHEM, V264, P3596; OLSON PF, 1990, EMBO J, V9, P1219, DOI 10.1002/j.1460-2075.1990.tb08229.x; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P7729, DOI 10.1021/bi00148a038; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCALONI A, 1992, J BIOL CHEM, V267, P3811; SCHRAG JD, 1992, J BIOL CHEM, V267, P4300; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; Shaw E., 1970, ENZYMES, V1, P91; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; SWILLENS S, 1986, BIOCH RES COMMUN, V1347, P142; TSUJI E, 1992, BIOCHEMISTRY-US, V31, P11921, DOI 10.1021/bi00162a035; VIVIER I, 1991, J IMMUNOL, V147, P447; WADA K, 1992, P NATL ACAD SCI USA, V89, P197, DOI 10.1073/pnas.89.1.197	58	78	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17247	17252						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8102366				2022-12-25	WOS:A1993LQ98800057
J	HEITZ, T; GEOFFROY, P; STINTZI, A; FRITIG, B; LEGRAND, M				HEITZ, T; GEOFFROY, P; STINTZI, A; FRITIG, B; LEGRAND, M			CDNA CLONING AND GENE-EXPRESSION ANALYSIS OF THE MICROBIAL PROTEINASE-INHIBITOR OF TOBACCO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEINS; NICOTIANA-SYLVESTRIS; ACQUIRED-RESISTANCE; BIOLOGICAL FUNCTION; SALICYLIC-ACID; TOMATO LEAVES; DNA; CHITINASE; VIRUS; BETA-1,3-GLUCANASE	Tobacco mosaic virus-infected tobacco (Nicotiana tabacum var. Samsun NN) leaves produce a serine proteinase inhibitor that has evolved a specificity for microbial proteinases. We have isolated two closely related cDNAs that were shown to encode two active inhibitors. Southern analysis of genomic DNA, comparison of deduced amino acid sequences, and characterization of the two separated proteins suggest that the two genes of tobacco are homeologues originating from each parent. Amino acid sequences deduced from the cDNAs exhibit a glutamic residue at the P1 position of the active site, known to determine the specificity of this type of inhibitors. Nevertheless, the V8 proteinase from Staphylococcus aureus, an enzyme that cleaves polypeptides after glutamic acid residues, was found to be unaffected by the tobacco inhibitor. We demonstrate strong accumulation of the two mRNAs and proteins during the hypersensitive reaction of tobacco to tobacco mosaic virus. Messengers and products of the two genes are present in a 3:2 ratio, in infected leaves as well as in upper uninfected leaves, the induction being markedly lower at distance from the infection site. The transcripts were also found in sepals and petals of healthy plants, indicating that these genes are also developmentally regulated. Unlike the tomato and potato I inhibitors, the tobacco inhibitor was only weakly induced by wounding, but was expressed upon salicylic acid or ethephon treatment, as many pathogenesis-related proteins.	UNIV STRASBOURG 1, CNRS,INST BIOL MOLEC PLANTES,PHYTOPATHOL LAB, 12 RUE GEN ZIMMER, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Geoffroy, Pierre Alexis/D-9743-2011	Geoffroy, Pierre Alexis/0000-0001-9121-209X; Stintzi, Annick/0000-0002-6479-8184				BINGHAM PM, 1981, CELL, V25, P693, DOI 10.1016/0092-8674(81)90176-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; CERVONE F, 1989, PLANT PHYSIOL, V90, P542, DOI 10.1104/pp.90.2.542; CRIQUI MC, 1992, MECH DEVELOP, V38, P121, DOI 10.1016/0925-4773(92)90004-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOW JM, 1990, APPL ENVIRON MICROB, V56, P2994, DOI 10.1128/AEM.56.10.2994-2998.1990; ECKER JR, 1987, P NATL ACAD SCI USA, V84, P5202, DOI 10.1073/pnas.84.15.5202; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELIX G, 1987, PLANTA, V172, P386, DOI 10.1007/BF00398668; GEOFFROY P, 1990, MOL PLANT MICROBE IN, V3, P327, DOI 10.1094/MPMI-3-327; GRAHAM JS, 1985, J BIOL CHEM, V260, P6555; GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776; GURUSIDDAIAH S, 1972, PLANT PHYSIOL, V50, P627, DOI 10.1104/pp.50.5.627; HENDRIKS T, 1991, PLANT MOL BIOL, V17, P385, DOI 10.1007/BF00040633; HERGET T, 1990, MOL GEN GENET, V224, P469, DOI 10.1007/BF00262442; JONGSMA MA, 1993, DEV PLANT PATHOL, V2, P364; KAUFFMANN S, 1987, EMBO J, V6, P3209, DOI 10.1002/j.1460-2075.1987.tb02637.x; KNIGHT ME, 1992, PLANT MOL BIOL, V19, P793, DOI 10.1007/BF00027075; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEE KY, 1988, EMBO J, V7, P1241, DOI 10.1002/j.1460-2075.1988.tb02937.x; LEE SY, 1990, BIOTECHNIQUES, V9, P676; LEGRAND M, 1987, P NATL ACAD SCI USA, V84, P6750, DOI 10.1073/pnas.84.19.6750; LOTAN T, 1989, PLANT CELL, V1, P881, DOI 10.1105/tpc.1.9.881; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MARGOSSIAN LJ, 1988, P NATL ACAD SCI USA, V85, P8012, DOI 10.1073/pnas.85.21.8012; MAUCH F, 1988, PLANT PHYSIOL, V88, P936, DOI 10.1104/pp.88.3.936; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; MORIHARA K, 1974, ADV ENZYMOL RAMB, V41, P179; NEALE AD, 1990, PLANT CELL, V2, P673, DOI 10.1105/tpc.2.7.673; OKAMURO JK, 1985, MOL GEN GENET, V198, P290, DOI 10.1007/BF00383009; PAUTOT V, 1991, MOL PLANT MICROBE IN, V4, P284, DOI 10.1094/MPMI-4-284; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; RICHARDSON M, 1974, FEBS LETT, V45, P11, DOI 10.1016/0014-5793(74)80798-2; ROBY D, 1987, PHYSIOL MOL PLANT P, V30, P453, DOI 10.1016/0885-5765(87)90024-5; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; STONE KL, 1989, PRACTICAL GUIDE PROT, P37; Strauss WM, 1987, CURRENT PROTOCOLS MO, P631; VANBUUREN M, 1992, MOL GEN GENET, V232, P460, DOI 10.1007/BF00266251; VANHUIJSDUIJNEN RAMH, 1985, EMBO J, V4, P2167, DOI 10.1002/j.1460-2075.1985.tb03911.x; VIGERS AJ, 1992, PLANT SCI, V83, P155, DOI 10.1016/0168-9452(92)90074-V; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WINGATE VPM, 1989, J BIOL CHEM, V264, P17734; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809	46	19	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16987	16992						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	8102364				2022-12-25	WOS:A1993LQ98800019
J	SHYNG, SL; HUBER, MT; HARRIS, DA				SHYNG, SL; HUBER, MT; HARRIS, DA			A PRION PROTEIN CYCLES BETWEEN THE CELL-SURFACE AND AN ENDOCYTIC COMPARTMENT IN CULTURED NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-ASSOCIATED FORM; BREFELDIN-A; TRANSFERRIN RECEPTOR; CYTOPLASMIC DOMAIN; MEMBRANE; PRP; INTERNALIZATION; TRANSPORT; LYSOSOMES; KINETICS	The prion protein (PrP(C)) is a glycolipid-anchored, cell surface protein of unknown function, a posttranslationally modified isoform of which has been implicated in the pathogenesis of spongiform encephalopathies in man and animals. We report here the novel observation that chPrP, the chicken homologue of mammalian PrP(C), constitutively cycles between the cell surface and an endocytic compartment with a transit time of approximately 60 min, as demonstrated by surface iodination and immunofluorescence microscopy. Most (>95%) of the internalized protein is returned to the cell surface intact, and the remainder is proteolytically cleaved within a highly conserved region in the NH2-terminal half of the molecule. Pulse-chase labeling experiments indicate that while this cleavage is slow, with a rate of approximately 1%/h, the COOH-terminal fragment produced is stable and accumulates on the cell surface for as long as 24 h. The cleavage is likely to take place in an acidified endocytic compartment, since it is reduced by lysosomotropic amines and inhibitors of lysosomal proteases. Our results raise the possibility that chPrP, and perhaps other PrP(C)s, function as cell surface receptors, and they suggest cellular pathways that might be involved in the generation of the pathogenic isoform.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,660 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)				Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS030137] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30137] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BAMEZAI A, 1992, EUR J IMMUNOL, V22, P15, DOI 10.1002/eji.1830220104; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BLUM JS, 1991, J BIOL CHEM, V266, P22091; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; CLOUGH G, 1991, PROG BIOPHYS MOL BIO, V55, P47, DOI 10.1016/0079-6107(91)90011-G; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; GABRIEL JM, 1992, P NATL ACAD SCI USA, V89, P9097, DOI 10.1073/pnas.89.19.9097; GAJDUSEK DC, 1990, VIROLOGY, P2289; HARRIS DA, 1993, P NATL ACAD SCI USA, V90, P4309, DOI 10.1073/pnas.90.9.4309; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; MANSON J, 1992, DEVELOPMENT, V115, P117; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; VANDENBOSCH RA, 1988, EMBO J, V7, P3345, DOI 10.1002/j.1460-2075.1988.tb03206.x	45	260	265	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15922	15928						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8101844				2022-12-25	WOS:A1993LN30500085
J	BRUSILOW, WSA; MONTICELLO, RA				BRUSILOW, WSA; MONTICELLO, RA			SYNTHESIS AND ASSEMBLY OF THE F-0 PROTON CHANNEL FROM F-0 GENES CLONED INTO BACTERIOPHAGE-LAMBDA AND INTEGRATED INTO THE ESCHERICHIA-COLI CHROMOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ATPASE; F1F0 ATPASE; H+-ATPASE; EXPRESSION; SUBUNITS; OPERON; UNC; DNA; F1F0-ATPASE; SYNTHASE	The promoter region and the first four genes of the Escherichia coli proton-translocating ATPase (unc) operon, uncIBEF, were cloned into bacteriophage lambda, enabling this region to be recombined into an unc-deleted E. coli chromosome at the lambda att site. The resultant E. coli strain, carrying single-copy F-0 genes, was tested for synthesis and assembly of functional F-0 proton channels. Membranes isolated from this strain contained all three F-0 subunits and were capable of binding purified F-1 and reconstituting F1F0-dependent energy coupling activities. The presence of these F-0 sectors did not affect cell growth or membrane proton permeability assayed by fluorescence quenching. When compared with wild type membranes, membranes from the single-copy F-0 strain contained less a and b subunits. When the single-copy lambda F-0 strain was transformed with an F-1 plasmid, the cells became phenotypically and biochemically Unc(+) with membrane-bound ATPase and ATP synthase activities that were 50-60% of wild type. The results demonstrate that F-0 produced from single-copy genes in the absence of F-1 is membrane-bound and functional (i.e. reconstitutable) but not freely permeable to protons. The presence of F-1 genes and/or subunits during F-0 synthesis and assembly both increases the relative amounts of membrane-bound a and b subunits and produces an F-0 sector more like that found in wild type cells than is produced from the single-copy F-0 genes alone.			BRUSILOW, WSA (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,SCOTT HALL,540 E CANFIELD AVE,DETROIT,MI 48201, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000882] Funding Source: NIH RePORTER; NIAID NIH HHS [KO4-AI00882] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGOV E, 1991, J BACTERIOL, V173, P407, DOI 10.1128/jb.173.1.407-411.1991; ANGOV E, 1988, J BACTERIOL, V170, P459, DOI 10.1128/jb.170.1.459-462.1988; ARIS JP, 1985, J BIOL CHEM, V260, P1207; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRUSILOW WSA, 1993, MOL MICROBIOL, V9, P419, DOI 10.1111/j.1365-2958.1993.tb01703.x; BRUSILOW WSA, 1987, J BACTERIOL, V169, P4984, DOI 10.1128/jb.169.11.4984-4990.1987; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COX GB, 1987, CURR TOP BIOENERG, V15, P163; COX GB, 1981, J BACTERIOL, V148, P30, DOI 10.1128/JB.148.1.30-42.1981; FILLINGAME RH, 1986, J BACTERIOL, V165, P244, DOI 10.1128/jb.165.1.244-251.1986; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GROVE CL, 1987, J BACTERIOL, V169, P2158, DOI 10.1128/jb.169.5.2158-2164.1987; GUNSALUS RP, 1982, P NATL ACAD SCI-BIOL, V79, P320, DOI 10.1073/pnas.79.2.320; MONTICELLO RA, 1992, J BACTERIOL, V174, P3370, DOI 10.1128/jb.174.10.3370-3376.1992; NIEUWENHUIS FJR, BIOCHIM BIOPHYS ACTA, V325, P62; OSTROW KS, 1986, J BACTERIOL, V168, P1165, DOI 10.1128/jb.168.3.1165-1171.1986; PATI S, 1989, J BIOL CHEM, V264, P2640; PATI S, 1991, BIOCHEMISTRY-US, V30, P4710, DOI 10.1021/bi00233a011; SCARPETTA MA, 1991, J BIOL CHEM, V266; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SOLOMON KA, 1988, J BACTERIOL, V171, P3039; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799	22	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7285	7289						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125942				2022-12-25	WOS:A1994NA03200041
J	HAWEL, L; TJANDRAWINATA, RR; FUKUMOTO, GH; BYUS, CV				HAWEL, L; TJANDRAWINATA, RR; FUKUMOTO, GH; BYUS, CV			BIOSYNTHESIS AND SELECTIVE EXPORT OF 1,5-DIAMINOPENTANE (CADAVERINE) IN MYCOPLASMA-FREE CULTURED-MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SPERMINE N1-ACETYLTRANSFERASE ACTIVITY; ORNITHINE DECARBOXYLASE; ALPHA-DIFLUOROMETHYLORNITHINE; LIQUID-CHROMATOGRAPHY; POLYAMINE METABOLISM; HEPATOMA-CELLS; EXCRETION; GROWTH; ACCUMULATION	Macrophage-like RAW 264 and H35 hepatoma cells grown under serum-free conditions exported putrescine and an unidentified diamine into the culture medium. Unlike putrescine, the unknown compound could be detected only extracellularly. Analyses of dansylated polyamine standards and mass spectroscopy confirmed that the unknown compound was cadaverine (1,5-diaminopentane). The cells were free of mycoplasma as evidenced by a negative result using a probe specific for prokaryotic rRNA. After prophylactic treatments with two different mycoplasmacidal agents, the cells continued to export cadaverine. Attempts to ''infect'' a noncadaverine-exporting cell line with culture medium and cell-free lysates proved unsuccessful, establishing that cadaverine was in fact a bona fide product of these mammalian cells. Cadaverine export by RAW 264 and H35 cells was stimulated by lipopolysaccharide and insulin, respectively. However, administration of exogenous ornithine caused cadaverine export to decrease significantly with concomitant increases in putrescine export. alpha-Difluoromethylornithine, a selective inhibitor of ornithine decarboxylase, inhibited both cadaverine and putrescine export. When cells were labeled with [H-3]lysine, the great majority of the radioactivity recovered in exported polyamines was found in cadaverine. The cumulative data suggested that cadaverine formation may be caused by the action of intracellular ornithine decarboxylase upon lysine to produce cadaverine, which is then effluxed from the cell with a high degree of efficiency.	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside			Tjandrawinata, Raymond R/F-1889-2013	Tjandrawinata, Raymond R/0000-0003-0461-9874	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006128] Funding Source: NIH RePORTER; NIEHS NIH HHS [ESO6128] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALHONENHONGISTO L, 1982, BIOCHEM J, V202, P267, DOI 10.1042/bj2020267; ALHONENHONGISTO L, 1982, BIOCHEM BIOPH RES CO, V106, P291, DOI 10.1016/0006-291X(82)91108-1; ALHONENHONGISTO L, 1987, BIOCHEM J, V247, P651, DOI 10.1042/bj2470651; BACHRACH U, 1985, CANCER RES, V45, P2159; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYUS CV, 1991, J CELL PHYSIOL, V149, P9, DOI 10.1002/jcp.1041490103; DAVIS RH, 1989, ARCH BIOCHEM BIOPHYS, V271, P315, DOI 10.1016/0003-9861(89)90281-6; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; FOTHERGILL JC, 1977, J GEN MICROBIOL, V99, P139, DOI 10.1099/00221287-99-1-139; GILBERT RS, 1991, ANAL BIOCHEM, V199, P86, DOI 10.1016/0003-2697(91)90273-V; GONZALEZ GG, 1991, CANCER RES, V51, P2932; HOLTTA E, 1983, BIOCHEM J, V210, P945; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1979, BIOCHIM BIOPHYS ACTA, V568, P416, DOI 10.1016/0005-2744(79)90310-3; PEGG AE, 1990, BIOCHEM J, V267, P331, DOI 10.1042/bj2670331; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PEGG AE, 1988, CANCER RES, V48, P2678; PEGG AE, 1988, ISI ATLAS-BIOCHEM, P11; PERSSON L, 1977, ACTA PHYSIOL SCAND, V100, P424, DOI 10.1111/j.1748-1716.1977.tb05966.x; POHJANPELTO P, 1985, J BIOL CHEM, V260, P8532; PORTER CW, 1991, CANCER RES, V51, P3715; Segel I.H., 1975, ENZYME KINETICS; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; TAFFET SM, 1985, J CELL PHYSIOL, V122, P215, DOI 10.1002/jcp.1041220209; TAKIGAWA M, 1983, CANCER RES, V43, P3723; WALLACE HM, 1986, FEBS LETT, V194, P60, DOI 10.1016/0014-5793(86)80051-5; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028; WU VS, 1984, BIOCHIM BIOPHYS ACTA, V804, P89, DOI 10.1016/0167-4889(84)90102-2	30	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7412	7418						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125959				2022-12-25	WOS:A1994NA03200060
J	BRADFUTE, DL; SIMONI, RD				BRADFUTE, DL; SIMONI, RD			NONSTEROL COMPOUNDS THAT REGULATE CHOLESTEROGENESIS - ANALOGS OF FARNESYL PYROPHOSPHATE REDUCE 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; MEVALONATE-DERIVED PRODUCT; HAMSTER OVARY CELLS; HMG COA REDUCTASE; ENDOPLASMIC-RETICULUM; MEMBRANE DOMAIN; MESSENGER-RNA; DEGRADATION; SQUALENE; ENZYME	Farnesyl acetate and ethyl farnesyl ether, two analogues of farnesyl pyrophosphate, stimulate post-transcriptional down-regulation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the biosynthesis of cholesterol and isoprenoids. Farnesyl acetate and ethyl farnesyl ether reduce translation of HMG-CoA reductase mRNA and enhance degradation of the enzyme, the same regulatory effects attributed to the putative non-sterol regulatory metabolite (Goldstein, J. L., and frown, M. S. (1990) Nature 343, 425-430). HMGal, a fusion protein consisting of the membrane domain of HMG-CoA reductase linked to Escherichia coli beta-galactosidase, is subject to the same regulated degradation as HMG-CoA reductase (Skalnik, D. G., Narita, H., Kent, C,, and Simoni, R. D. (1988) J. Biol. Chem. 263, 6836-6841). At 10 mu g/ml (37.8 mu M), farnesyl acetate and ethyl farnesyl ether trigger a 50-80% reduction in HMGal activity. Farnesyl acetate reduces the synthesis of HMG-CoA reductase and HMGal by 60-80%, but neither farnesyl compound affects HMG-CoA reductase mRNA levels. Farnesyl acetate and ethyl farnesyl ether stimulated the degradation of HMG-CoA reductase and HMGal, reducing the half-lives of the enzymes by 40-70%. In addition to their regulatory ef fects on HMG-CoA reductase, these farnesyl compounds also directly disrupt sterol synthesis.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NHLBI NIH HHS [HL26502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTOLINO A, 1978, BIOCHIM BIOPHYS ACTA, V530, P17, DOI 10.1016/0005-2760(78)90122-4; BILLER SA, 1988, J MED CHEM, V31, P1869, DOI 10.1021/jm00118a001; BRADFUTE DL, 1992, J BIOL CHEM, V267, P18308; BROWN MS, 1980, J LIPID RES, V21, P505; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; COREY EJ, 1976, J AM CHEM SOC, V98, P1291, DOI 10.1021/ja00421a056; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DEMONTELLANO PRO, 1977, BIOCHEMISTRY-US, V16, P2680; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARDEMAN EC, 1983, P NATL ACAD SCI-BIOL, V80, P1516, DOI 10.1073/pnas.80.6.1516; INOUE S, 1991, J BIOL CHEM, V266, P13311; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PANINI SR, 1989, J BIOL CHEM, V264, P11044; PARKER RA, 1993, J BIOL CHEM, V268, P11230; PEARCE BC, 1992, J MED CHEM, V35, P3595, DOI 10.1021/jm00098a002; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHARMA RC, 1993, BIOTECHNIQUES, V14, P176; SIMENSKY M, 1982, J BIOL CHEM, V257, P7284; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836	29	96	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6645	6650						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120018				2022-12-25	WOS:A1994MZ50300061
J	GUO, IC; TSAI, HM; CHUNG, BC				GUO, IC; TSAI, HM; CHUNG, BC			ACTIONS OF 2 DIFFERENT CAMP-RESPONSIVE SEQUENCES AND AN ENHANCER OF THE HUMAN CYP11A1 (P450SCC) GENE IN ADRENAL Y1 AND PLACENTAL JEG-3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; STEROIDOGENIC ENZYMES; REGULATORY ELEMENTS; ADRENOCORTICAL EXPRESSION; PROMOTER REGION; P-450SCC GENE; TUMOR-CELLS; CYCLIC-AMP; PROTEIN; TRANSCRIPTION	We have characterized three cis-acting elements of the human CYP11A1 gene. A proximal cAMP-responsive sequence (P-CRS) functioned in both adrenal Y1 and placental JEG-3 cells. An upstream cAMP-responsive sequence (U-CRS) and an enhancer, localized by transfections of deleted gene segments linked to a reporter gene to bases -1621 to -1503 and -1931 to -1822, respectively, functioned in Y1 but not JEG-3 cells. Both regions bind proteins only from Y1 cells as identified by footprinting analysis. U-CRS contains the TCAAGGTCA sequence that binds the nuclear receptor family of proteins. The cAMP dependent transcription mediated by U-CRS, but not by P-CRS, was abolished in a cell line deficient in cAMP-dependent protein kinase. Therefore, P-CRS and U-CRS use different effecters to mediate cAMP response. Gel mobility shift, competition, and antibody supershift experiments showed that nucleotides -117 to -94, which contributed to P-CRS activity in transfection experiments, bound weakly to Sp1-like proteins. This feature is shared by many proximal regulatory elements of steroidogenic genes. Therefore, steroidogenic genes could be coordinately regulated through common regulatory elements such as P-CRS, U-CRS, and cell type-selective enhancers.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN; NATL TAIWAN UNIV, DEPT ANIM SCI, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan; National Taiwan University				Chung, Bon-chu/0000-0002-8612-0219				AHLGREN R, 1990, J BIOL CHEM, V265, P3313; BOGERD AM, 1990, MOL ENDOCRINOL, V4, P845, DOI 10.1210/mend-4-6-845; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; CHEN JY, 1992, BIOCHEMISTRY-US, V31, P2400, DOI 10.1021/bi00123a027; CHUNG BC, 1989, BIOCHEM BIOPH RES CO, V160, P276, DOI 10.1016/0006-291X(89)91652-5; FISHER RJ, 1991, ONCOGENE, V6, P2249; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GOLOS TG, 1987, J CLIN INVEST, V80, P896, DOI 10.1172/JCI113149; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P132; GUO IC, 1993, DNA CELL BIOL, V12, P849, DOI 10.1089/dna.1993.12.849; HALES DB, 1990, ENDOCRINOLOGY, V126, P2800, DOI 10.1210/endo-126-6-2800; HANUKOGLU I, 1990, J BIOL CHEM, V265, P20602, DOI 10.1016/S0021-9258(17)30545-8; HANUKOGLU I, 1989, SERONO S REV, V23, P233; HONDA S, 1993, J BIOL CHEM, V268, P7494; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; HU MC, 1991, BIOCHEM J, V274, P813, DOI 10.1042/bj2740813; HUM DW, 1993, ENDOCRINOLOGY, V132, P546, DOI 10.1210/en.132.2.546; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KAGAWA N, 1991, J BIOL CHEM, V266, P11199; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KRAMER RE, 1984, J BIOL CHEM, V259, P707; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maxam A M, 1980, Methods Enzymol, V65, P499; MELLON SH, 1989, P NATL ACAD SCI USA, V86, P7775, DOI 10.1073/pnas.86.20.7775; MILLER WL, 1989, ENDOCR RES, V15, P1; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OONK RB, 1990, J BIOL CHEM, V265, P22392; ORMEJOHNSON NR, 1990, BIOCHIM BIOPHYS ACTA, V1020, P213, DOI 10.1016/0005-2728(90)90151-S; PARISSENTI AM, 1993, MOL ENDOCRINOL, V7, P283, DOI 10.1210/me.7.2.283; PAYNE AH, 1991, 1ST INT S MOL VIEW S, P47; PICADOLEONARD J, 1988, J BIOL CHEM, V263, P3240; RICE DA, 1990, J BIOL CHEM, V265, P8052; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; RICE DA, 1990, J BIOL CHEM, V265, P11713; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WONG M, 1989, J BIOL CHEM, V264, P12867	47	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6362	6369						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8119986				2022-12-25	WOS:A1994MZ50300019
J	HAYASHI, JI; OHTA, S; KAGAWA, Y; KONDO, H; KANEDA, H; YONEKAWA, H; TAKAI, D; MIYABAYASHI, S				HAYASHI, JI; OHTA, S; KAGAWA, Y; KONDO, H; KANEDA, H; YONEKAWA, H; TAKAI, D; MIYABAYASHI, S			NUCLEAR BUT NOT MITOCHONDRIAL GENOME INVOLVEMENT IN HUMAN AGE-RELATED MITOCHONDRIAL DYSFUNCTION - FUNCTIONAL INTEGRITY OF MITOCHONDRIAL-DNA FROM AGED SUBJECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROKE-LIKE EPISODES; NORMAL HUMAN-CELLS; PROTEIN-SYNTHESIS; HUMAN FIBROBLAST; LACTIC-ACIDOSIS; HUMAN-TISSUES; HUMAN BRAIN; HELA-CELLS; MUTATION; DELETION	The role of mtDNA and nuclear genome in human aging was examined by their intercellular transfer using skin fibroblasts and mtDNA-less HeLa cells (rho(0)-HeLa cells). We found in vivo age-related reductions in the activity of cytochrome c oxidase in human skin fibroblasts obtained from 16 donors of various ages (0-97 years). The abnormality in mitochondria of the aged donors was not attributable to either decrease in the copy number of mtDNA molecules or increase in the copy number of deletion mutant mtDNA molecules, but to significant decrease in overall polypeptide synthesis in the mitochondria. However, intercellular mtDNA transfer experiments showed that fibroblast mtDNA from elderly donors is functionally intact. By contrast, intercellular transfer of HeLa nuclei to fibroblasts from aged donors restored cytochrome c oxidase activity, suggesting that the age related phenotype was nuclear recessive. However, during subsequent cultivation of these hybrids, the activity gradually reduced again, associated with gradual chromosome loss. These observations support the idea that accumulation of nuclear recessive somatic mutations, but not mtDNA mutations, is responsible for the in vivo age-related mitochondrial dysfunction observed in human skin fibroblasts.	SAITAMA CANC CTR,RES INST,DEPT BIOCHEM,INA,SAITAMA 362,JAPAN; JICHI MED SCH,DEPT BIOCHEM,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOL,TOKYO,TOKYO 103,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT LAB ANIM SCI,TOKYO,TOKYO 113,JAPAN; TOHOKU UNIV,SCH MED,DEPT PEDIAT,SENDAI,MIYAGI 980,JAPAN	Jichi Medical University; Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Medical Science; Tohoku University	HAYASHI, JI (corresponding author), UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN.							ALLEN JA, 1980, NATURE, V287, P244, DOI 10.1038/287244a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATTARDI G, 1991, PROG NEUROPATH, V7, P75; BACKER JM, 1980, SCIENCE, V209, P297, DOI 10.1126/science.6770466; BODENTEICH A, 1991, GENE, V108, P305, DOI 10.1016/0378-1119(91)90451-G; BROWN WM, 1980, P NATL ACAD SCI-BIOL, V77, P3605, DOI 10.1073/pnas.77.6.3605; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x; GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H; GOLDSTEIN S, 1982, J CELL PHYSIOL, V112, P419, DOI 10.1002/jcp.1041120316; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P1023, DOI 10.1016/0006-291X(91)91921-X; HAYASHI JI, 1986, CANCER RES, V46, P4001; HAYASHI JI, 1989, CANCER RES, V49, P4715; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1991, PROG NEUROPATH, V7, P93; HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159; HAYASHI JI, 1987, EXP CELL RES, V172, P218, DOI 10.1016/0014-4827(87)90108-X; HAYASHI JI, 1984, CANCER RES, V44, P3957; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; LINNANE AW, 1992, MUTAT RES, V275, P195, DOI 10.1016/0921-8734(92)90023-I; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MARIOTTINI P, 1986, P NATL ACAD SCI USA, V83, P1563, DOI 10.1073/pnas.83.6.1563; MIQUEL J, 1991, ARCH GERONTOL GERIAT, V12, P99, DOI 10.1016/0167-4943(91)90022-I; MITA S, 1988, CANCER RES, V48, P4578; MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6; MONNAT RJ, 1986, GENE, V43, P205, DOI 10.1016/0378-1119(86)90208-8; MONNAT RJ, 1985, P NATL ACAD SCI USA, V82, P2895, DOI 10.1073/pnas.82.9.2895; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167; MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H; NIRANJAN BG, 1982, SCIENCE, V215, P73, DOI 10.1126/science.6797067; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; REIS RJS, 1983, J BIOL CHEM, V258, P9078; ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; SOONG NW, 1992, NAT GENET, V2, P318; SUGIYAMA S, 1991, BIOCHEM BIOPH RES CO, V180, P894, DOI 10.1016/S0006-291X(05)81149-0; SUN AS, 1975, ARCH BIOCHEM BIOPHYS, V170, P1, DOI 10.1016/0003-9861(75)90092-2; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0; ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7	58	111	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6878	6883						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120050				2022-12-25	WOS:A1994MZ50300096
J	KRIEF, S; FEVE, B; BAUDE, B; ZILBERFARB, V; STROSBERG, AD; PAIRAULT, J; EMORINE, LJ				KRIEF, S; FEVE, B; BAUDE, B; ZILBERFARB, V; STROSBERG, AD; PAIRAULT, J; EMORINE, LJ			TRANSCRIPTIONAL MODULATION BY N-BUTYRIC ACID OF BETA-1-ADRENERGIC, BETA-2-ADRENERGIC, AND BETA-3-ADRENERGIC RECEPTOR BALANCE IN 3T3-P442A ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLATILE FATTY-ACIDS; CANCER CELL-LINES; SODIUM-BUTYRATE; 3T3-F442A ADIPOCYTES; HELA-CELLS; ADRENERGIC RECEPTORS; MOLECULAR-CLONING; GENE-EXPRESSION; MESSENGER-RNA; 3T3-L1 PREADIPOCYTES	3T3-F442A adipocytes, which express major beta 3-adrenergic receptors (beta 3-AR) (90%) and minor beta 1-AR (<10%) and beta 2-AR (<1%) populations, were used to investigate regulation by n-butyric acid of beta-AR subtype expression. Following butyrate treatment, EC(50), values of beta 1- and beta 2-selective agonists, dobutamine and fenoterol, were decreased, whereas that of the beta 3-selective agonist BRL37344 was increased. Direct binding and competition of (-)-[I-125]iodocyanopindolol binding by selective beta 1- and beta 2-AR antagonists, CGP20712A and ICI118551, and by the beta 3-AR agonist, BRL37344, revealed that both beta 1- and beta 2-AR were increased in butyrate-treated adipocytes, whereas beta 3-AR almost totally disappeared. In control adipocytes, beta 1-, beta 2-, and beta 3-AR transcripts (quantitated by a polymerase chain reaction assay) represented 6.5, 0.5, and 93% of total beta-AR mRNA, respectively. In butyrate exposed cells, proportions of beta-AR proteins and mRNAs were, respectively, 87 and 94% for beta 1 and 9 and 1% for beta 2-AR. beta 3-ARs were barely detectable in binding assays and accounted for 4.5% of beta-AR transcripts. Variations of beta-AR protein and mRNA levels were accompanied by parallel changes in the transcription rates of the corresponding genes. The differential regulation of the three beta-ARs by n-butyric acid, a dietary factor produced from colonic fermentation, may have significant nutritional and energetic consequences.	CNRS,UNITE PROPRE RECH 0415,F-75014 PARIS,FRANCE; UNIV PARIS 07,INST COCHIN GENET MOLEC,F-75014 PARIS,FRANCE; HOP HENRI MONDOR,INSERM,U282,F-94010 CRETEIL,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)				Feve, Bruno/0000-0001-6577-9009; Krief, Stephane/0000-0002-5543-731X				ANDREWS GK, 1987, NUCLEIC ACIDS RES, V15, P5461, DOI 10.1093/nar/15.13.5461; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; ANTRAS J, 1991, MOL CELL ENDOCRINOL, V82, P183, DOI 10.1016/0303-7207(91)90030-V; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BOFFA LC, 1981, J BIOL CHEM, V256, P9612; BOHAN CA, 1989, VIROLOGY, V172, P573, DOI 10.1016/0042-6822(89)90200-6; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; DANKERT J, 1981, CLIN CHIM ACTA, V110, P301, DOI 10.1016/0009-8981(81)90359-4; DEFAZIO A, 1992, J BIOL CHEM, V267, P18008; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EMORINE LJ, 1991, BIOCHEM PHARMACOL, V41, P853, DOI 10.1016/0006-2952(91)90188-B; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FEVE B, 1991, J BIOL CHEM, V266, P20329; FEVE B, 1990, J BIOL CHEM, V265, P16343; FEVE B, 1992, J BIOL CHEM, V267, P15909; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; GRAHAM KA, 1988, J CELL PHYSIOL, V136, P63, DOI 10.1002/jcp.1041360108; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; HENNEBERRY RC, 1977, NATURE, V268, P252, DOI 10.1038/268252a0; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; KASSIS S, 1984, J BIOL CHEM, V259, P4910; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; LAI E, 1982, J BIOL CHEM, V257, P6691; LEVITT MD, 1968, ANN NY ACAD SCI, V150, P75, DOI 10.1111/j.1749-6632.1968.tb19033.x; LEVYWILSON B, 1981, P NATL ACAD SCI-BIOL, V78, P2189, DOI 10.1073/pnas.78.4.2189; LIN MC, 1979, J BIOL CHEM, V254, P4684; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NAMBI P, 1986, BIOCHEM PHARMACOL, V35, P3813, DOI 10.1016/0006-2952(86)90669-6; ORMANDY CJ, 1992, ENDOCRINOLOGY, V131, P982, DOI 10.1210/en.131.2.982; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; REMESY C, 1976, Annales de Recherches Veterinaires, V7, P39; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SAMUELS HH, 1980, J BIOL CHEM, V255, P2499; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P650; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STADEL JM, 1987, EUR J PHARMACOL, V143, P35, DOI 10.1016/0014-2999(87)90732-1; STORER GB, 1983, NUTR RES, V3, P519, DOI 10.1016/S0271-5317(83)80013-X; TALLMAN JF, 1977, P NATL ACAD SCI USA, V74, P873, DOI 10.1073/pnas.74.3.873; THOMAS RF, 1992, P NATL ACAD SCI USA, V89, P4490, DOI 10.1073/pnas.89.10.4490; TOSCANI A, 1990, J BIOL CHEM, V265, P5722; TOSCANI A, 1988, ONCOGENE RES, V3, P233; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; VIDALI G, 1978, P NATL ACAD SCI USA, V75, P2239, DOI 10.1073/pnas.75.5.2239	52	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6664	6670						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	8120022				2022-12-25	WOS:A1994MZ50300065
J	SUGIMOTO, H; YAMASHITA, S				SUGIMOTO, H; YAMASHITA, S			PURIFICATION, CHARACTERIZATION, AND INHIBITION BY PHOSPHATIDIC-ACID OF LYSOPHOSPHOLIPASE TRANSACYLASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CANINE KIDNEY-CELLS; LYMPHOCYTE-T ACTIVATION; SIGNAL TRANSDUCTION; KINETIC-ANALYSIS; MIXED MICELLES; POTENTIAL ROLE; BEEF LIVER; LYSOPHOSPHATIDYLCHOLINE; PHOSPHOLIPASE-A2	Lysophospholipase transacylase was purified 214,360-fold to homogeneity from the rat Liver 100,000 x g supernatant. After DEAE chromatography, total activity increased 12.9-fold, due to the removal of endogenous inhibitors. The inhibitors were isolated and identified as phosphatidic acid and fatty acid The final preparation showed a single band on SDS-polyacrylamide electrophoresis with an M(r) of 60,000. Gel filtration through Sephacryl S-200 gave a similar value, suggesting that the enzyme exists as a monomer. Activity was highest at pH 6.0 and was not affected by Ca2+, Mg2+, and EDTA. The enzyme produced glycerophosphocholine (GPC), palmitic acid, and dipalmitoyl-GPC on incubation with 1-palmitoyl GPC, indicating that the enzyme catalyzed both deacylation and transacylation. The relative rates of deacylation and transacylation were 1:0.3 under standard assay conditions. K-m for 1-palmitoyl-GPC and V-max of hydrolase activity were 91 mu M and 12.9 mu mol/min/mg, respectively. The enzyme was selective for choline lysophospholipid. Ethanolamine, inositol, and serine lysophospholipids were not good substrates of the enzyme. Phosphatidic acid was a potent, competitive inhibitor of the enzyme with K-i of about 10 mu M as determined with 1-stearoyl-2-arachidonoyl glycerophosphate. Although less potent, lysophosphatidic said, palmitoyl-L-carnitine, and fatty acid were also inhibitory to the enzyme.	GUNMA UNIV,SCH MED,DEPT BIOCHEM,MAEBASHI,GUNMA 371,JAPAN	Gunma University								AARSMAN AJ, 1991, EUR J BIOCHEM, V200, P187, DOI 10.1111/j.1432-1033.1991.tb21066.x; ASAOKA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1378, DOI 10.1016/0006-291X(91)91046-F; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUMLEY G, 1977, J LIPID RES, V18, P523; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DEJONG JGN, 1974, BIOCHIM BIOPHYS ACTA, V369, P50, DOI 10.1016/0005-2760(74)90191-X; DOMIN J, 1993, J BIOL CHEM, V268, P8927; DUAN RD, 1993, BIOCHIM BIOPHYS ACTA, V1167, P326, DOI 10.1016/0005-2760(93)90236-3; ERBLAND JF, 1964, BIOCHIM BIOPHYS ACTA, V106, P128; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GARSETTI D, 1992, BIOCHEM J, V288, P831, DOI 10.1042/bj2880831; GARSETTI DE, 1992, BIOCHIM BIOPHYS ACTA, V1165, P229, DOI 10.1016/0005-2760(92)90191-W; GROSS RW, 1982, CIRC RES, V51, P27, DOI 10.1161/01.RES.51.1.27; GROSS RW, 1983, J BIOL CHEM, V258, P5221; GROSS RW, 1983, J BIOL CHEM, V258, P5165; HABERLAND ME, 1975, J BIOL CHEM, V250, P6636; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P14858; HUGGINS C, 1947, J BIOL CHEM, V170, P467; IKUTA S, 1977, J BIOCHEM-TOKYO, V82, P157, DOI 10.1093/oxfordjournals.jbchem.a131664; JARVIS AA, 1984, J BIOL CHEM, V259, P5188; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P136, DOI 10.1016/0005-2744(80)90049-2; MARQUARDT DL, 1991, J ALLERGY CLIN IMMUN, V88, P721, DOI 10.1016/0091-6749(91)90178-Q; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OISHI K, 1988, J BIOL CHEM, V263, P6865; PARKER J, 1987, J BIOL CHEM, V262, P5385; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Rudd E.A., 1984, P185; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; THIBONNIER M, 1991, ENDOCRINOLOGY, V129, P2845, DOI 10.1210/endo-129-6-2845; VANDENBOSCH H, 1975, BIOCHIM BIOPHYS ACTA, V398, P244, DOI 10.1016/0005-2760(75)90140-X; VANDENBOSCH H, 1973, BIOCHIM BIOPHYS ACTA, V296, P94, DOI 10.1016/0005-2760(73)90048-9; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WELLER PF, 1984, J BIOL CHEM, V259, P5100; XIA T, 1992, BIOCHIM BIOPHYS ACTA, V1126, P327, DOI 10.1016/0005-2760(92)90248-T; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	46	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6252	6258						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	8119970				2022-12-25	WOS:A1994MY84000114
J	KIM, YT; RICHARDSON, CC				KIM, YT; RICHARDSON, CC			ACIDIC CARBOXYL-TERMINAL DOMAIN OF GENE-2.5 PROTEIN OF BACTERIOPHAGE-T7 IS ESSENTIAL FOR PROTEIN-PROTEIN INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEINS; HELIX-DESTABILIZING PROTEIN; ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; POLYMERASE ACTIVITY; 32 PROTEIN; PHYSICOCHEMICAL PROPERTIES; LIMITED PROTEOLYSIS; SECONDARY-STRUCTURE; UNWINDING PROTEIN	The product of gene 2.5 protein of bacteriophage T7, a single-stranded DNA-binding protein, physically interacts with phage encoded DNA polymerase and primase/helicase proteins. A truncated gene 2.5 protein (GP2.5-Delta 21C) was constructed by in vitro mutagenesis and lacks the 21 carboxyl-terminal amino acids found in wild-type gene 2.5 protein, 15 of which are acidic. GP2.5-Delta 21C cannot substitute for wild-type gene 2.5 protein in vivo; the phage are not viable and exhibit less than 1% of the DNA synthesis observed in wild-type phage-infected cells. GP2.5-Delta 21C has been purified to apparent homogeneity from cells overexpressing its cloned gene and has a conformation that differs from that of the wild-type gene 2.5 protein as judged by its circular dichroism spectra. Purified GP2.5-Delta 21C retains its ability to bind to single-stranded DNA; the association constant of the protein for single-stranded DNA, determined by nitrocellulose filter binding, is 3.2 x 10(6)M(-1) and is identical to that determined for wild-type gene 2.5 protein. However, GP2.5-Delta 21C is a monomer in solution, whereas the wildtype protein exists as a dimer. GP2.5-Delta 21C does not physically interact with T7 DNA polymerase as measured by affinity chromatography and fluorescent emission anisotropy. The mutant protein cannot stimulate T7 DNA polymerase activity on primed single-stranded DNA templates.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P907, DOI 10.1021/bi00676a006; ARAKI H, 1981, MOL GEN GENET, V183, P66, DOI 10.1007/BF00270140; ARAKI H, 1981, VIROLOGY, V111, P509, DOI 10.1016/0042-6822(81)90353-6; ARGOS P, 1986, VIROLOGY, V149, P208, DOI 10.1016/0042-6822(86)90122-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CARROLL RB, 1975, J MOL BIOL, V91, P275, DOI 10.1016/0022-2836(75)90380-0; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CASASFINET JR, 1989, FEBS LETT, V2249, P396; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; DOHERTY DH, 1982, MOL GEN GENET, V188, P77, DOI 10.1007/BF00332998; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HAUGLAND RP, 1989, HDB FLUORESCENT PROB, P20; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HOSODA J, 1978, J BIOL CHEM, V253, P7547; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBERMAN JA, 1971, J MOL BIOL, V62, P39, DOI 10.1016/0022-2836(71)90129-X; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1988, J BIOL CHEM, V263, P13712; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lohman TM., 1990, BIOL NONSPECIFIC DNA, P131; LONBERG N, 1981, J MOL BIOL, V145, P122; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NAKAI H, 1988, J BIOL CHEM, V263, P9818; Nakai H., 1988, DNA REPLICATION MUTA, P85; NOSSAL NG, 1979, J BIOL CHEM, V254, P6032; PRASAD BVV, 1987, J MOL BIOL, V193, P579; QUIRK S, 1991, J BACTERIOL, V173, P6665, DOI 10.1128/jb.173.21.6665-6669.1991; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SHAMOO Y, 1989, BIOCHEMISTRY-US, V28, P7409, DOI 10.1021/bi00444a039; STUDIER FW, 1975, J MOL BIOL, V94, P283, DOI 10.1016/0022-2836(75)90083-2; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1989, J BIOL CHEM, V264, P6447; TABOR S, 1990, CURRENT PROTOCOLS MO; WILLIAMS KR, 1981, J BIOL CHEM, V256, P1754; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346	63	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5270	5278						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106511				2022-12-25	WOS:A1994MX57100088
J	SHIN, SU; FRIDEN, P; MORAN, M; MORRISON, SL				SHIN, SU; FRIDEN, P; MORAN, M; MORRISON, SL			FUNCTIONAL-PROPERTIES OF ANTIBODY INSULIN-LIKE GROWTH-FACTOR FUSION PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; SERUM BINDING-PROTEINS; AFFINITY FC RECEPTOR; FACTOR-I; PSEUDOMONAS EXOTOXIN; HUMAN-IGG; ELECTRICAL-RESISTANCE; DIPHTHERIA-TOXIN; CH2 DOMAIN; CELL-LINE	Genetic engineering and expression techniques have been used to produce antibody growth factor fusion proteins. Insulin-like growth factors (IGFs) 1 and 2 have been fused to mouse human chimeric IgG3 at the end of C(H)1, immediately after the hinge, and at the end of C(H)3. Fusion heavy chains of the expected molecular weight were expressed, assembled with a co-expressed light chain, and secreted. The resulting molecules continued to bind antigen; they also bound the growth factor receptors, albeit with decreased affinity. The molecule with IGF1 attached after C(H)3 (CH3-IGF1) had reduced ability to carry out complement-mediated cytolysis. In contrast the molecule with IGFS attached after C(H)3 (C(H)3-IGF2) showed an approximately 50-fold increase in its ability to effect complement-mediated cytolysis and so should be an effective cytolytic agent. Both C(H)3-IGF1 and C(H)3-IGF2 bound Fc gamma RI with affinity similar to that of IgG3. The growth factor fusion proteins showed small but significant uptake into the brain parenchyma.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; ALKERMES INC, CAMBRIDGE, MA 02139 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Alkermes					NATIONAL CANCER INSTITUTE [R01CA016858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029470, R37AI029470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16858] Funding Source: Medline; NIAID NIH HHS [AI 29470] Funding Source: Medline; NINDS NIH HHS [1T32-NSO7356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON CL, 1980, J IMMUNOL, V125, P2735; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BALLARD FJ, 1986, BIOCHEM J, V233, P223, DOI 10.1042/bj2330223; BATRA JK, 1991, MOL CELL BIOL, V11, P2200, DOI 10.1128/MCB.11.4.2200; BATRA JK, 1990, J BIOL CHEM, V265, P15198; BAYNE ML, 1988, J BIOL CHEM, V263, P6233; BULLARD DE, 1984, J NEUROSURG, V61, P901, DOI 10.3171/jns.1984.61.5.0901; BUTT AM, 1990, J PHYSIOL-LONDON, V429, P47, DOI 10.1113/jphysiol.1990.sp018243; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; CASCIERI MA, 1988, ENDOCRINOLOGY, V123, P373, DOI 10.1210/endo-123-1-373; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P9491, DOI 10.1073/pnas.87.23.9491; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CRONE C, 1982, BRAIN RES, V241, P49, DOI 10.1016/0006-8993(82)91227-6; CZECH MP, 1977, ANNU REV BIOCHEM, V46, P359, DOI 10.1146/annurev.bi.46.070177.002043; CZECH MP, 1982, CELL, V31, P8, DOI 10.1016/0092-8674(82)90399-3; DAUGHADAY WH, 1982, J CLIN ENDOCR METAB, V55, P916, DOI 10.1210/jcem-55-5-916; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; DUFFY KR, 1987, BRAIN RES, V420, P32, DOI 10.1016/0006-8993(87)90236-8; DUFFY KR, 1988, METABOLISM, V37, P136, DOI 10.1016/S0026-0495(98)90007-5; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; FISHMAN JB, 1987, J NEUROSCI RES, V18, P299, DOI 10.1002/jnr.490180206; FRIDEN PM, 1993, SCIENCE, V259, P373, DOI 10.1126/science.8420006; FRIDEN PM, 1991, P NATL ACAD SCI USA, V88, P4771, DOI 10.1073/pnas.88.11.4771; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GILLIES SD, 1991, J IMMUNOL, V146, P1067; HAN VKM, 1987, SCIENCE, V236, P193, DOI 10.1126/science.3563497; JOHANSSON BB, 1990, FERNS FOUND SERIES, V14, P145; KUMMER U, 1986, METHOD ENZYMOL, V121, P670; LARRICK JW, 1980, J IMMUNOL, V125, P6; MISRA P, 1986, J CLIN ENDOCR METAB, V63, P1400, DOI 10.1210/jcem-63-6-1400; MORRISON SL, 1988, CLIN CHEM, V34, P1668; NEUWELT EA, 1984, FED PROC, V43, P214; OI VT, 1986, BIOTECHNIQUES, V4, P214; Pardridge W. M., 1991, PEPTIDE DRUG DELIVER, P123; PARDRIDGE WM, 1986, ENDOCR REV, V7, P314, DOI 10.1210/edrv-7-3-314; PRIOR TI, 1991, CANCER RES, V51, P174; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; ROSENFELD RG, 1982, DIABETES, V31, P375, DOI 10.2337/diabetes.31.5.375; SHIN SU, 1989, METHOD ENZYMOL, V178, P459; SHIN SU, 1990, P NATL ACAD SCI USA, V87, P5322, DOI 10.1073/pnas.87.14.5322; SZABO L, 1988, BIOCHEM BIOPH RES CO, V151, P207, DOI 10.1016/0006-291X(88)90580-3; TAO MH, 1993, J EXP MED, V178, P661, DOI 10.1084/jem.178.2.661; TAO MH, 1989, J IMMUNOL, V143, P2595; TAO MH, 1991, J EXP MED, V173, P1025, DOI 10.1084/jem.173.4.1025; WALTON PE, 1989, COMP BIOCHEM PHYS B, V92, P561, DOI 10.1016/0305-0491(89)90132-6	47	15	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4979	4985						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	8106473				2022-12-25	WOS:A1994MX57100046
J	FUHRER, C; GEFFEN, I; HUGGEL, K; SPIESS, M				FUHRER, C; GEFFEN, I; HUGGEL, K; SPIESS, M			THE 2 SUBUNITS OF THE ASIALOGLYCOPROTEIN RECEPTOR CONTAIN DIFFERENT SORTING INFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; HUMAN TRANSFERRIN RECEPTOR; HUMAN HEPATOMA-CELLS; CANINE KIDNEY-CELLS; FACTOR-II RECEPTOR; AMINO-ACID CHANGE; CYTOPLASMIC TAIL; COATED PITS; MDCK CELLS; RAPID INTERNALIZATION	The human asialoglycoprotein receptor, an endocytic transport receptor of the basolateral surface of hepatocytes, is a hetero-oligomer of two homologous subunits Hl and H2. The cytoplasmic domain of H1 has been shown previously to contain a tyrosine-based signal tor endocytosis and basolateral sorting. Here, we have investigated sorting determinants within subunit H2 and their contribution to the targeting of the hetero-oligomeric receptor complex. Despite extensive sequence homology, H2 expressed separately in fibroblast cells was endocytosed poorly, and mutation of phenylalanine 5 (corresponding to the critical tyrosine in Hl) did not further reduce internalization. Consistent with this observation, ligand uptake by receptors composed of H1 lacking tyrosine 5 and H2 was inefficient. With respect to polarized transport in Madin-Darby canine kidney cells, H2 could not be analyzed separately, because in the absence of Hl subunit H2 was completely degraded intracellularly. Coexpression of both subunits yielded ligand-binding receptors located specifically on the basolateral surface. The mutant Hl(5A) (tyrosine 5 replaced by alanine) is approximately 55% apical in the absence of H2. In cells expressing Hl(5A) together with H2, however, subunit H2 directed receptor complexes exclusively to the basolateral domain. Phenylalanine 5 is not essential for basolateral transport. Thus, whereas the endocytosis signal of the hetero-oligomeric asialoglycoprotein receptor resides exclusively in subunit Hl, polarized transport to the basolateral domain of Madin-Darby canine kidney cells may involve two signals, only one of which is active for endocytosis.	UNIV BASEL, BIOCTR, DEPT BIOCHEM, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND	University of Basel				Spiess, Martin/0000-0001-7139-0550; Fuhrer, Christian/0000-0001-8216-8883				ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GRAEVE L, 1990, J BIOL CHEM, V265, P1216; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; II M, 1990, J BIOL CHEM, V265, P11295; JADOT M, 1992, J BIOL CHEM, V267, P11069; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; OZAKI K, 1992, J BIOL CHEM, V267, P9229; OZAKI K, 1993, J BIOCHEM-TOKYO, V113, P271, DOI 10.1093/oxfordjournals.jbchem.a124038; PAIETTA E, 1992, HEPATOLOGY, V15, P395, DOI 10.1002/hep.1840150307; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RICE KG, 1990, J BIOL CHEM, V265, P18429; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; VERREY F, 1990, CELL REGUL, V1, P471, DOI 10.1091/mbc.1.6.471; WESSELS HP, 1989, J BIOL CHEM, V264, P17	46	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3277	3282						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	8106365				2022-12-25	WOS:A1994MV63100026
J	SAFFITZ, JE; NASH, JA; GREEN, KG; LUKE, RA; RANSNAS, LA; INSEL, PA				SAFFITZ, JE; NASH, JA; GREEN, KG; LUKE, RA; RANSNAS, LA; INSEL, PA			IMMUNOELECTRON MICROSCOPIC IDENTIFICATION OF CYTOPLASMIC AND NUCLEAR G(S-ALPHA) IN S49 LYMPHOMA-CELLS	FASEB JOURNAL			English	Article						IMMUNOELECTRON MICROSCOPY; G(S-ALPHA); S49 CELLS; CONFOCAL MICROSCOPY	GTP-BINDING PROTEIN; ISLET-ACTIVATING PROTEIN; PERTUSSIS TOXIN; ALPHA-SUBUNIT; PLASMA-MEMBRANE; GS-ALPHA; RECEPTOR; PATHWAYS; G(S); ASIALOGLYCOPROTEIN	The subcellular distribution of G(s alpha) was characterized in S49 lymphoma cells with two polyclonal antisera directed against specific COOH- and NH2-terminal epitopes. Nonspecific binding was determined in each subcellular compartment by incubating cyc(-) S49 cells, known to be deficient in G(s alpha) and its mRNA, with primary and secondary antisera. Small proportions of total specific binding sites were localized to the plasmalemma as well as the nuclear envelope. Because of their small size, these compartments contained a high concentration of G(s alpha). However, most of the specific binding sites were found in nonstructured cytoplasm and within the nucleus. Specific binding was abolished or significantly reduced by preincubating primary antisera with their peptide immunogens but not with an irrelevant peptide. Intracellular G(s alpha) immunoreactive binding sites did not colocalize with gold-conjugated transferrin in cells preincubated with this ligand to mark a classical endocytotic pathway. The intracellular and intranuclear location of G(s alpha) was confirmed with confocal microscopy of S49 cells immunostained with specific primary and fluorescently labeled secondary antibodies. G(s alpha) was also detected with immunoblots of proteins extracted from purified S49 cell. nuclei. Thus, G(s alpha) is abundantly distributed in intracellular and intranuclear sites in S49 cells and occurs in loci distinct from organelles of the transferrin pathway. The substantial intracellular distribution of G(s alpha) suggests that G(s) may subserve intracellular and, perhaps, intranuclear functions that may be important in proliferating cells.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,SAN DIEGO,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92093	Washington University (WUSTL); University of California System; University of California San Diego; University of California System; University of California San Diego	SAFFITZ, JE (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,BOX 8118,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL-17646, HL-17682] Funding Source: Medline; NIGMS NIH HHS [GM40781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017646, P50HL017682, P60HL017646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040781] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI N, 1989, BIOCHEM J, V261, P905, DOI 10.1042/bj2610905; BERRYMAN M A, 1988, Journal of Cell Biology, V107, p111A; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FUGINAGA Y, 1989, FEBS LETT, V245, P117; GERARDYSCHAN R, 1989, J BIOL CHEM, V266, P6942; GEUZE HJ, 1983, EUR J CELL BIOL, V32, P38; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; ROTH DA, 1992, FEBS LETT, V296, P46, DOI 10.1016/0014-5793(92)80400-B; ROTROSEN D, 1988, J BIOL CHEM, V263, P10958; RUBINS JB, 1990, P NATL ACAD SCI USA, V87, P7080, DOI 10.1073/pnas.87.18.7080; SCHERER NM, 1987, ARCH BIOCHEM BIOPHYS, V259, P431, DOI 10.1016/0003-9861(87)90509-1; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SEYDEL U, 1991, J BIOL CHEM, V266, P7602; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; STIRLING JW, 1990, J HISTOCHEM CYTOCHEM, V38, P145, DOI 10.1177/38.2.2405054; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; TOHKIN M, 1989, FEBS LETT, V255, P187, DOI 10.1016/0014-5793(89)81088-9; VEDIA LMY, 1989, P NATL ACAD SCI USA, V86, P868, DOI 10.1073/pnas.86.3.868; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WANG N, 1990, J BIOL CHEM, V265, P1239	32	33	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					252	258		10.1096/fasebj.8.2.8119495	http://dx.doi.org/10.1096/fasebj.8.2.8119495			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	8119495				2022-12-25	WOS:A1994MY29900033
J	SORKIN, A; DIFIORE, PP; CARPENTER, G				SORKIN, A; DIFIORE, PP; CARPENTER, G			THE CARBOXYL-TERMINUS OF EPIDERMAL GROWTH-FACTOR RECEPTOR/ERBB-2 CHIMERAE IS INTERNALIZATION IMPAIRED	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; EGF RECEPTOR; DOWN-REGULATION; A431 CELLS; HUMAN-FIBROBLASTS; ENDOCYTIC SYSTEM; CARCINOMA-CELLS; NEU ONCOGENE; GENE; PROTEIN	The endocytosis of gp185erbB-2 was studied using chimeric receptors in which the intracellular domain of erbB-2, or subdomains thereof, was substituted for the corresponding regions of the epidermal growth factor (EGF) receptor. Chimeric and wild-type EGF or erbB-2 receptors were expressed in mouse NIH3T3 or NR6 fibroblasts and in a human mammary adenocarcinoma cell line, MDAMB-134. The rate of EGF-induced internalization for the chimera consisting of the extracellular EGF receptor domain and intracellular erbB-2 domain was reduced three- to fourfold compared with the wild-type EGF receptor. The low rate of internalization of the chimeric receptor resulted in impaired down-regulation and degradation of the receptor. Substitution of the carboxyl terminus of erhB-2 for the corresponding region of the EGF receptor caused a similar decrease of receptor endocytosis, whereas substitution of the erhB-2 tyrosine kinase domain did not affect internalization and down-regulation. Since the tyrosine kinase of the internalization-defective chimeric receptors could be activated by EGF, kinase activity and autophosphorylation of erhB-2 do not appear to be sufficient for a maximum rapid internalization of the chimeric receptors. These results suggest that the carboxyl terminus of erhB-2 either does not possess all the signals required for the rapid internalization or contains an inhibitory signal for rapid internalization.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SORKIN, A (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA.		Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Sorkin, Alexander/0000-0002-4446-1920	NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER; NCI NIH HHS [CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIFIORE PP, 1992, GENES ONCOGENES HORM, P139; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HELIN K, 1991, J BIOL CHEM, V266, P8363; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LONARDO F, 1990, New Biologist, V2, P992; LOTTI LV, 1990, NEW BIOL, V2, P992; LUND KA, 1990, J BIOL CHEM, V265, P15713; MAIER LA, 1991, CANCER RES, V51, P5361; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEGATTO O, 1992, ONCOGENE, V7, P1339; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; STOSCHECK CM, 1984, J CELL PHYSIOL, V120, P296, DOI 10.1002/jcp.1041200306; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	47	95	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3021	3028						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8105439				2022-12-25	WOS:A1993MC09300016
J	OLMSTED, EA; OBRIEN, L; HENSHAW, EC; PANNIERS, R				OLMSTED, EA; OBRIEN, L; HENSHAW, EC; PANNIERS, R			PURIFICATION AND CHARACTERIZATION OF EUKARYOTIC INITIATION-FACTOR (EIF)-2-ALPHA KINASES FROM EHRLICH ASCITES TUMOR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN INITIATION; NUCLEOTIDE-EXCHANGE FACTOR; DOUBLE-STRANDED-RNA; PROTEIN-SYNTHESIS INITIATION; FACTOR-II; TRANSLATIONAL INHIBITOR; RABBIT RETICULOCYTE; PHYSIOLOGICAL STRESSES; ALPHA-SUBUNIT; PHOSPHORYLATION	A major mechanism of regulation of mammalian protein synthesis initiation is accomplished by the phosphorylation of the alpha subunit of eukaryotic initiation factor (eIF) 2 . This modification inhibits the activity of another initiation factor, guanine nucleotide exchange factor, preventing conversion of eIF-2.GDP to eIF-2.GTP and hence binding of initiator tRNA and formation of ternary complex (eIF-2.GTP.Met-tRNA(f)). Inhibition of protein synthesis and phosphorylation of eIF-2 occurs in Ehrlich cells when they are amino acid- or serum-deprived or heat-shocked as well as in other nucleated cells under similar conditions. This paper describes the purification of two eIF-2alpha kinases from Ehrlich cells. Unlike the two well characterized eIF-2alpha kinases, HRI (heme-regulated inhibitor from reticulocytes) and P68 (double-stranded RNA-dependent kinase found in interferon-treated cells), the Ehrlich cell kinases do not appear to auto-phosphorylate. The two kinases chromatograph differently on DEAE-cellulose and Mono Q. Furthermore, their Michaelis constants (K(m) values) for ATP are different. Both kinases can inhibit purified guanine nucleotide exchange factor (GEF) from stimulating ternary complex formation. However, only one kinase inhibits reticulocyte lysate cell free protein synthesis. The other kinase co-purifies with a factor that suppresses inhibition of protein synthesis in reticulocyte lysates by eIF-2alpha kinases. This suppressing activity is probably guanine nucleotide exchange factor.	NIH,DIV RES GRANTS,RM 2A17,WESTWOOD BLDG,5333 WESTBARD AVE,BETHESDA,MD 20892; UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	National Institutes of Health (NIH) - USA; University of Rochester; University of Rochester					NCI NIH HHS [R01 CA21663] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021663] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALACAZAR A, 1986, INT J DEV NEUROSCI, V4, P525; DELAUNAY J, 1977, P NATL ACAD SCI USA, V74, P2264, DOI 10.1073/pnas.74.6.2264; FARRELL PJ, 1977, CELL, V11, P182; GROSS M, 1980, J BIOL CHEM, V255, P6270; HUNT T, 1985, BIOCHIM BIOPHYS ACTA, V826, P224; HUNTER T, 1975, J BIOL CHEM, V250, P409; JEDLICKA P, 1991, J BIOL CHEM, V266, P15663; KRAMER G, 1976, P NATL ACAD SCI USA, V73, P3078, DOI 10.1073/pnas.73.9.3078; KUDLICKI W, 1987, J BIOL CHEM, V262, P9695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LEBLEU B, 1976, P NATL ACAD SCI USA, V73, P3107, DOI 10.1073/pnas.73.9.3107; LEVIN DH, 1976, P NATL ACAD SCI USA, V73, P3112, DOI 10.1073/pnas.73.9.3112; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PANNIERS LRV, 1981, J CELL SCI, V48, P259; PANNIERS R, 1988, J BIOL CHEM, V263, P5519; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; Ranu R S, 1979, Methods Enzymol, V60, P459; RANU RS, 1980, BIOCHEM BIOPH RES CO, V97, P1124, DOI 10.1016/0006-291X(80)91492-8; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; SAFER B, 1980, J BIOL CHEM, V255, P6913; SARRE TF, 1989, EUR J BIOCHEM, V183, P137, DOI 10.1111/j.1432-1033.1989.tb14905.x; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SIEKIERKA J, 1982, P NATL ACAD SCI-BIOL, V79, P2537, DOI 10.1073/pnas.79.8.2537; SIEKIERKA J, 1983, P NATL ACAD SCI-BIOL, V80, P1232, DOI 10.1073/pnas.80.5.1232; SIEKIERKA J, 1981, P NATL ACAD SCI-BIOL, V78, P220, DOI 10.1073/pnas.78.1.220; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; WEST DK, 1979, EUR J BIOCHEM, V101, P461, DOI 10.1111/j.1432-1033.1979.tb19740.x; 1985, FPLC ION EXCHANGE CH	38	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12552	12559						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8099583				2022-12-25	WOS:A1993LG65800050
